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A RANDOMISED OPEN-LABEL COMPARISON OF THE EF-
FICACY, TOLERABILITY, AND HORMONAL EFFECTS OF
SODIUM VALPROATE AND LAMOTRIGINE MONOTHERAPY
IN NEWLY-DIAGNOSED EPILEPSY
G. Sills, L. Stephen, E. Butler, P. Parker, K. Kelly, E. Wilson, and
M. Brodie (Epilepsy Unit, University Division of Cardiovascular & Med-
ical Sciences, Western Infirmary, Glasgow, Scotland)
Purpose: This study was designed to compare monotherapy with
sodium valproate (VPA) and lamotrigine (LTG) in patients with newly
diagnosed epilepsy.
Method: A total of 226 untreated patients (116 male) with a recent di-
agnosis of epilepsy (60 idiopathic generalised epilepsy, 149 localisation-
related epilepsy, 17 unclassified) were randomised to receive either
VPA or LTG as monotherapy. Median age was 35 years (range 13–80
years). Patients were followed-up at six-weekly intervals and remained
in the study until reaching a predetermined end point (12 month seizure-
freedom; intolerable side-effects including idiosyncratic reaction; lack
of efficacy despite adequate dosing).
Results: Twenty-nine patients were excluded from the analysis (24
lost to follow-up, 3 withdrawn consent, 1 protocol violator, 1 non-
epileptic attack). A total of 197 patients reached an end point, with
126 (63%) becoming seizure-free for a minimum period of 12 months
on initial monotherapy. Of these, 64 took VPA (67% of VPA com-
pleters; median dose = 1000 mg, range 600–3000 mg) and 62 took
LTG (60% of LTG completers; median dose = 200 mg, range 100–
700 mg). Thirty-eight patients (24 VPA, 14 LTG) experienced intoler-
able side effects, while a further 33 (18 VPA, 15 LTG) failed to report
acceptable efficacy despite adequate dosing. There were no significant
changes in mean (±SEM) serum concentrations of testosterone (p =
0.225), SHBG (p = 0.201), or androstenedione (p = 0.394) in either
patient group at 6 months after initiation of therapy.
Conclusion: These findings suggest that there is little (if any) dif-
ference in the efficacy, tolerability, or hormonal effects of VPA or LTG
monotherapy in the treatment of newly diagnosed epilepsy.
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MULTICENTRE RANDOMISED CONTROLLED TRIAL COM-
PARING STANDARD AND NEW ANTIEPILEPTIC DRUGS
(SANAD)
1A. Marson, 1C. Tudur Smith, 1P. Williamson, 2D. Smith, 1A. Jacoby,
and 1D. Chadwick (1University of Liverpool, Liverpool, UK, 2The Wal-
ton Centre, Liverpool, UK)
Purpose: There is a paucity of randomised controlled trials (RCTs)
that inform a choice among antiepileptic drugs, and existing trials have
largely failed to examine longer term effectiveness. SANAD assesses
these longer term outcomes.
Method: SANAD is a multicentre, UK based, unblinded RCT re-
cruiting patients over the age of 5 years, requiring antiepileptic drug
monotherapy. SANAD has 2 arms. Patients for whom carbamazepine
was the standard drug (arm A) were randomised to carbamazepine,
gabapentin, lamotrigine, oxcarbazepine or topiramate. Patients for whom
valproate was the standard drug (arm B) were randomised to valproate,
lamotrigine or topiramate. Recruitment commenced in 1999, ended
2005, and follow up ended in 2005. Outcomes included time to the fol-
lowing events: withdrawal of allocated treatment, 12 month remission
from seizures, first seizure, as well as adverse events, quality of life and
cost effectiveness.
Results: 2443 patients were recruited, for whom we have 7799 patient
years follow up, 95% of the maximum possible. 1721 patients entered
arm A, 378 were allocated carbamazepine, 377 gabapentin, 378 lamot-
rigine, 210 oxcarbazepine and 378 topiramate. The mean age was 38.3
yrs, 55% were male and 89% were classified as having a partial epilepsy
syndrome. 716 patients entered arm B, 238 were allocated valproate,
239 lamotrigine and 239 topiramate. The mean age was 25.5 yrs, 60%
were male, and 62% were classified as having an idiopathic generalised
epilepsy syndrome. Full clinical results will be presented.
Conclusion: Large multicentre studies examining the longer term ef-
fects of antiepileptic drugs, such as SANAD, are required to inform
clinical practice.
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AN INTERNATIONAL MULTICENTER DOUBLE-BLIND
DOUBLE-DUMMY RANDOMISED TRIAL COMPARING
LAMOTRIGINE AND SLOW-RELEASE CARBAMAZEPINE
FOR TREATING NEWLY DIAGNOSED EPILEPSY IN THE
ELDERLY
1E. Saetre, 2E. Perucca, 3J. Isoja¨rvi, and 4L. Gjerstad (1Ullevaal Uni-
versity Hospital, Oslo, Norway 2University of Pavia, Pavia, Italy,
3University of Oulu, Oulu, Finland / Jazz Pharmaceuticals, Palo Alto,
Ca, USA, 4University of Oslo, Oslo, Norway)
Purpose: To compare lamotrigine (LTG) and slow-release carba-
mazepine (CBZ) in the treatment of newly diagnosed epilepsy in the
elderly.
Method: Patients aged >65 years with a history of two or more un-
provoked partial and/or tonic–clonic seizures received LTG (n = 93) or
CBZ (n = 91) in a randomised double-blind 40-week trial. Target dose
was 100 mg/day for LTG and 400 mg/day for CBZ; dose escalation was
4 weeks and dose adjustments according to response were permitted.
Results: In the LTG group, 68 patients (73%) completed the trial
compared with 61 (67%) in the CBZ group (not significant). Time to
withdrawal from any cause did not differ between groups (p = 0.34).
The number of subjects who completed the study and were seizure-free
during weeks 4–40 was 37 (40%) in the LTG group and 46 (50%) in the
CBZ group. Adverse events leading to withdrawal occurred in 26 (28%)
CBZ-treated subjects and 15 LTG-treated subjects (16%). The Liverpool
Adverse Event Profile (AEP) score showed a non-significant advantage
for LTG.
Conclusion: LTG and CBZ showed comparable effectiveness, with
a trend for higher seizure-free rates for CBZ and better tolerability for
LTG. Acknowledgment: Supported by GlaxoSmithKline.
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EFFICACY OF LEVETIRACETAM MONOTHERAPY: RAN-
DOMISED DOUBLE-BLIND HEAD-TO-HEAD COMPARISON
WITH CARBAMAZEPINE-CR IN NEWLY DIAGNOSED
EPILEPSY PATIENTS WITH PARTIAL ONSET OR GENER-
ALISED TONIC–CLONIC SEIZURES
1M. Brodie, 2E. Ben-Menachem, 3E. Perucca, and N1061 Study Group
(1Epilepsy Unit, Western Infirmary, Glasgow, UK, 2Department of Clin-
ical Neuroscience, Sahlgrenska University Hospital, Go¨teborg, Sweden,
3Clinical Pharmacology Unit, University of Pavia, Italy)
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Purpose: Sustained seizure freedom (SF) without side effects remains
the epilepsy treatment goal. New broad spectrum, well tolerated AEDs
at least comparably effective to older AEDs in newly diagnosed patients
are still required. This study aimed to demonstrate the noninferiority of
levetiracetam (LEV) vs carbamazepine controlled-release (CBZ-CR) in
achieving 6 month SF in newly diagnosed partial onset or generalised
tonic-clonic seizure (GTCS) patients, excluding idiopathic generalised
epilepsy (IGE).
Method: Phase III, randomised, double-blind, noninferiority design
(non-inferiority limit −15%). Newly or recently diagnosed epilepsy pa-
tients (confirmed/suspected localisation-related), ≥2 seizures in preced-
ing year (≥1 in preceding 3 months), no epilepsy treatment for 6 months,
received LEV 1000 mg/day or CBZ-CR 400 mg/day following 3 weeks
uptitration. Doses were maintained for 6 months evaluation or until
next seizure (doses increased to LEV 2000 mg/CBZ-CR 800 mg/day; if
needed, to LEV 3000 mg/CBZ-CR 1200 mg/day). Six months SF was
followed by 6 months maintenance treatment.
Results: ITT and PP populations included 576 (285 LEV; 291 CBZ-
CR) and 472 (237 LEV; 235 CBZ-CR) patients respectively. Six months
SF (PP) was achieved in: LEV 73.0% vs CBZ-CR 72.8%; absolute treat-
ment differences 0.2% (95% 2-sided CI: −7.8–8.2%). Twelve months SF
rates; LEV 56.6%; CBZ-CR 58.5% (95% 2-sided CI of the difference:
−10.8 –7.2%). Fewer LEV patients reported adverse events causing drug
discontinuation or dose change (16.1% LEV vs 23.0% CBZ-CR; p =
0.046).
Conclusion: LEV was effective as first-line monotherapy in newly
diagnosed patients with partial onset seizures or GTCS with similar
SF rates at 6 and 12 months to CBZ-CR with better tolerability. UCB
supported.
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CONSEQUENCES OF WITHDRAWAL OF ANTIEPILEPTIC
MEDICATION ON SEIZURE RELAPSE AND COGNITIVE
FUNCTION: A RANDOMISED, PLACEBO CONTROLLED,
DOUBLE BLINDED STUDY (THE AKERSHUS WITHDRAWAL
STUDY)
1,2,3M. Lossius, 2,3E. Hessen, 4P. Mowinckel, 2P. Gulbrandsen, and 4L.
Gjerstad (1National Centre For Epilepsy, 2Helse Øst Health Services
Research Centre, Akershus University Hospital, 3Neurological Depart-
ment, Akershus University Hospital, Norway, 4Department of Paedi-
atrics, Div. Woman And Child. Ulleva˚l University Hospital, Norway,
5Department of Neurology, Rikshospitalet, University of Oslo, Norway)
Purpose: The aim of this study was to assess the possibility and
consequences of withdrawal of antiepileptic drugs (AEDs) in a double
blind design in a selected group of patients who had been seizure free
for more than two years.
Method: The study was prospective, randomised, placebo controlled
and double blinded. Epilepsy patients (18–67 yrs) on monotherapy were
included. Exclusion criteria were: juvenile myoclonus epilepsy (JME),
poly pharmacy, paroxysmal epileptiform activity in patients with pri-
marily generalised epilepsy, two prior withdrawal attempts, pregnant or
seeking pregnancy, mental retardation, progressive neurological disease,
co-medication (except post menopausal hormone substitution, ASA and
thyroxin) or other serious disease which may influence the health sta-
tus of the patient in the study period. Each patient was followed for 12
months or until seizure relapse. Seizure relapse or acute diseases were
criteria for breaking the code. The patients went through a set of inves-
tigations prior to and after intervention (withdrawal/not withdrawal).
Results: One hundred sixty-nine patients were included in the study.
One hundred fifty were randomised and were included in the final anal-
ysis. In the withdrawal group (placebo group) 10 patients experienced
seizures while 5 patients did so in the group continuing medication (p =
0.14). The percentage of patients scoring normal on all subscales in the
neuropsychological test battery increased from 12% to 29% in the with-
drawal group and this improvement was significantly better compared
to the nonwithdrawal group (p = 0.005).
Conclusion: The vast majority of selected seizure free epilepsy pa-
tients remain seizure free one year after discontinuation of medication.
The neuropsychological scores improved significantly in the withdrawal
group.
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UNCONTROLLED SEIZURES AFTER DISCONTINUATION OF
ANTIEPILEPTIC DRUG TREATMENT IN SEIZURE-FREE PA-
TIENTS WITH CHILDHOOD-ONSET EPILEPSY: A LONG-
TERM POPULATION-BASED STUDY
1D. Schmidt, and 2M. Sillanpa¨a¨ (1Epilepsy Research Group, Berlin,
Germany, 2Departments of Public Health And Child Neurology, Uni-
versity of Turku, Turku, Finland)
Purpose: The long-term outcome of seizure recurrence after planned
discontinuation of antiepileptic drugs (AEDs) in seizure-free patients is
not well known. We studied seizure recurrence and its outcome following
reinstituted treatment.
Method: We carried out a prospective long-term population-based
study of 242 patients.
Results: Seizure recurrence after AED discontinuation was seen in
43 (36%) of 120 patients. Thirty-two of the 43 patients with a relapse
elected not to restart AEDs. Reinstitution of AEDs after recurrence was
implemented in 11 of 43 patients leading to 5-year terminal remission
(5YTR) in 3 patients, only 10–19 years after restarting treatment. In
the other 8 patients, 5YTR was never achieved, and 5 of the 8 did not
enter a 5-year remission. Factors associated with failure to reach 5YTR
after treatment of recurrence were symptomatic aetiology, and partial
epilepsy.
Conclusion: Discontinuation of AEDs in seizure-free patients is as-
sociated with seizure recurrence(s) in 1 of 3 patients, and development
of drug resistant epilepsy following treatment of recurrence in 8 of 11
patients or delayed control in a further 3 patients, mostly in those with
symptomatic and/or partial epilepsy. These risks need to be considered,
although there is no evidence that discontinuation was responsible for
poor treatment outcome of recurrence.
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FACIAL DISPLAY OF EMOTIONS DURING EPILEPTIC
SEIZURES
1E. Gardella, 1F. Rondelli, 1M. Stanzani Maserati, 1G. Rubboli, 2S. Fran-
cione, 2L. Tassi, 3R. Caterina, 3M. Costa, 2G. Lo Russo, 3P. Ricci Bitti,
and 1C. Tassinari (1Dept. of Neuroscience, Bellaria Hospital, University
of Bologna, Italy, 2Center of Epilepsy Surgery “C. Munari,” Niguarda
Hospital, Milan, Italy, 3Dept. of Psychology, University of Bologna,
Italy)
Purpose: To investigate the emergence of emotional display during
temporal versus frontal lobe seizures (TLS, FLS).
Method: Three independent observers reviewed presurgical video-
EEG recordings of 477 seizures, in 84 patients with drug-resistant
epilepsy (45 temporal/39 frontal), analysing the topography of the ic-
tal discharge and the ictal modifications of facial expression, suggesting
emotions (FEE). The pattern of facial activation underwent FACS (fa-
cial action coding system) analysis. The presence of coherent emotional
motor/acoustic behaviour and of a subjective feeling has been alsobreak
investigated.
Results: All the six fundamental emotions were observed, with the
same muscular pattern of facial activation during FLS and TLS. Nega-
tive emotions, particularly fear, were most represented. The prevalence
of FEE was similar in FLS (68%) versus TLS (67%); right-sided ic-
tal discharge was observed more frequently (59%). Association of FEE
with emotional motor/acoustic behaviours occurred in 21% of seizures
and in 13% an emotional experience was referred. Despite the similar
prevalence of ictal FEE in both genders, there was male predominance in
facial display of rage and a female predominance in referring a subjec-
tive emotional feeling and/or in manifesting coherent motor behaviours
related to FEE, especially in case of ictal fear.
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Conclusion: A coherent pattern of FEE and emotional behaviour can
equally emerge during FLS and TLS, with a slight right prevalence of
the ictal discharge, confirming the hemispheric right specialisation for
emotion. Gender dimorphism expressing and/or referring fear and rage,
could reflect either inborn or socio-behavioural differences.
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THE CONTRIBUTION OF HIPPOCAMPAL DEVELOPMEN-
TAL MALFORMATION TO EPILEPTOGENICITY: AN IN-
TRACRANIAL SEEG STUDY
1M. Holtkamp, 2D. Kinay, 2E. Kobayashi, 2N. Bernasconi, 2F.
Andermann, 2A. Olivier, 2A. Bernasconi, 2J. Gotman, and 2F. Dubeau
(1Department of Neurology, Charite´–Universita¨tsmedizin Berlin,
Germany, 2Montre´al Neurological Hospital and Institute, McGill Uni-
versity, Montre´al, Canada)
Purpose: To assess the epileptogenicity of hippocampal forma-
tions (HF) with developmental changes (Baulac et al., Ann Neurol
1998;44:223) through SEEG.
Method: Seventy-three patients with focal epilepsy who underwent at
least bilateral temporal lobe SEEG evaluation between 1995–2005 were
studied, and divided in 3 groups based on MRI findings: Group 1 (n = 17
patients) with malformed HFs (n = 27), Group 2 (n = 25) with atrophic
hippocampus (n = 34) and Group 3 (n = 31) with normal hippocampi.
To assess the epileptogenicity of the malformed HF, we compared the
interictal (IEA) and ictal epileptiform activity in limbic structures. We
also analysed epileptogenicity of other temporal and extratemporal (n =
39 patients) structures.
Results: In the limbic and extratemporal neocortical structures, IEA
was recorded equally in all groups. All patients with malformed HF
(Group 1) showed neocortical temporal IEA, but fewer in Group 2 (76%,
p = 0.034) and Group 3 (58%, p = 0.001). Limbic seizure onsets were
more frequent in malformed HF and atrophic hippocampi compared to
normal hippocampi (63 and 82 vs 37%, p = 0.021 and p < 0.0001).
Regional temporal seizure onsets occurred more often in Group 1 (65%)
than Group 3 (32%, p = 0.031) but not differently from Group 2 (44%).
Extratemporal seizure onsets were equal in all groups. Temporal lobe
resection only led to unfavourable outcome (Engel’s class III–IV) in
Groups 1 (6/9 patients) and 3 (12/18) compared to Group 2 (4/18, p =
0.019 and p = 0.009).
Conclusion: This study demonstrates that malformed HFs generate
epileptic activity, but in association with widespread epileptogenicity,
as most patients show neocortical temporal or extratemporal epileptic
discharges and poor outcome only after temporal lobe surgery.
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DISTRIBUTION OF TEMPORAL LOBE EPILEPTIC SEIZURES
OVER THE DAY DURING VIDEO-EEG
C. Bentes, M. Couto, R. Peralta, I. Henriques, and T. Paiva
(Hospital de Santa Maria. Faculdade de Medicina de Lisboa,
Portugal)
Purpose: Some epileptic seizures have a characteristic temporal dis-
tribution, occurring mainly in a specific day/night pattern or period of
the sleep–wake cycle. Our aim was to determine the patterns in seizure
frequency among patients with temporal lobe epilepsy (TLE) during
video-EEG.
Method: From 190 video-EEGs, we selected patients with temporal
lobe seizures (TLS) and retrospectively analysed the time when seizures
occurred. Each seizure was classified according to the time of occur-
rence and grouped into 3 × 8 hour ‘‘bins,’’ which we called “afternoon”
(12 to 8 p.m.),“night” (8 p.m. to 4 a.m.) and “morning” (4 a.m. to 12
p.m.).
Results: There were 95 reports with TLS and in 75 of these the time
of occurrence was registered. We analysed 323 seizures. Each patient
had an average of 4.3 seizures (1–17). 148 seizures (48.8%) occurred in
the afternoon, 77 (23.8%) at night and 98 (30.3%) in the morning. On
average each patient had 2.0 seizures in the afternoon, 1.0 at night and 1.3
in the morning. The difference night/afternoon and morning/afternoon
was significant (p < .05). We also noticed that, from the 38 patients that
had more than 2 seizures in one of the considered periods, 22 of them
(57.9%) had them in the afternoon.
Conclusion: The distribution of seizures during the day/night period
was clearly unequal. It was during the afternoon that most seizures oc-
curred and that most patients had multiple seizures. This observation
suggests the existence of a circadian mechanism regulating the occur-
rence of TLE seizures.
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UNILATERAL CEREBRAL POLYMICROGYRIA WITH IPSI-
LATERAL CEREBRAL HEMIATROPHY
1G. Kuchukhidze, 1B. Frauscher, 1I. Unterberger, 1G. Walser, 1N. Em-
bacher, 1J. Dobesberger, 1A. Auckenthaler, 1G. Luef, 2T. Gotwald, 2S.
Felber, 1G. Bauer, and 1E. Trinka (1University Hospital For Neurol-
ogy, Innsbruck, Austria 2University Hospital For Radiology, Innsbruck,
Austria)
Purpose: There are sporadic reports on unilateral polymicrogyria with
ipsilateral hemiatrophia cerebri. Hayakawa et al. (2002) reported on 6
children with this condition associated with epilepsy, spastic hemiparesis
and mental retardation. The authors suggested the disorder could con-
stitute a new clinical entity calling it “hemimicrocephaly.” The aim of
the study was to delineate clinical, electrophysiological, neuropsycho-
logical and imaging features of unilateral cerebral polymicrogyria with
ipsilateral cerebral hemiatrophy.
Method: Four patients (2 m/2 w) aged from 23 to 31 years (mean 27.5)
were evaluated at the Epilepsy outpatient clinic of the Innsbruck Uni-
versity Hospital for Neurology. All subjects underwent clinical, electro-
physiological, neuropsychological and high resolution MRI assessment.
Results: All patients were born full term without any significant peri-
natal event and exposure to intrauterine infection. None suffered from
birth asphyxia or ischemic injury. Two patients had closely related par-
ents; 2 had a positive family history of epilepsy. All had delayed devel-
opmental milestones and were mentally retarded. All patients suffered
from congenital nonprogressive spastic hemiparesis, more prominent in
upper extremity. All had epilepsy with seizure onset ranging from 3 to
17 years (mean 7.5), two had intractable seizures. Two patients had local
epileptogenic activity on interictal EEG. All patients showed unilateral,
right side cerebral polymicrogyria associated with ipsilateral hemiat-
rophia cerebri. Polymicrogyria involved frontal, temporal and parietal
lobes; the occipital region was relatively spared. Sylvian fissure was
hypoplastic in all subjects.
Conclusion: The evaluated patients showed homogenous clinical and
neuroimaging characteristics. We support the idea that the disorder could
constitute a new clinical entity. It might have an underlying genetic cause.
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EPILEPSY AND SCHIZENCEPHALY
1J. Kruja, 1S. Mijo, 2G. Vreto, and 3E. Shehu (1UHC Mother Theresa,
Service of Neurology, Tirana, Albania, 2UHC Mother Theresa, Service
of Neuroradiology, Tirana, Albania, 3Durres Hospital, Albania)
Purpose: Four patients affected by schizencephaly were analysed to
show the relationship between anatomic brain malformation, electroen-
cephalographic and clinical findings.
Method: The schizencephaly was diagnosed by means of MRI (3
cases) or CT scan (1 case). These patients were selected from 589 patients
(out-inpatients) who had been seen and registered at Epilepsy Center of
our Service of Neurology, last year (January–December 2005). The 4
patients (3 male and 1 female) were aged 18–42 years. In these patients
we evaluated disease history, age and modality of seizure onset, clinical
course of epilepsy and electroclinical and neuroradiological features.
MRI scans were performed in 3 cases and CT scan in 1 case. Interictal
EEGs during wakefulness according to the 10–20 International System
was recorded for all patients.
Results: One patient had a convulsion in hyperthermia at age 24
months, and 2 patients had convulsions without hyperthermia during
childhood. One patient has moderate spastic hemiparesis; more invalid
the upper limb, contra lateral to the cleft. Two patients have moderate
psychomotor delay and the other 2 only a mild delay. All these patients
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have simple or complex partial seizures followed by secondary gener-
alisation. The interictal EEG recordings show focal abnormalities, slow
wave, consistent with the cleft location in 2 patients; bilateral frontal
discharges of spike-wave complexes D > S in 1 patient and left anterior
isolated spikes in the last patient. They are treated with AED in poly-
therapy, and all of them have shown drug resistance. Three patients have
right temporoparietal, open clefts. One patient has also an arachnoideal
cyst in the posterior fossa.
Conclusion: Schizencephaly causes neurological impairment, drug
resistant secondary generalised seizures and mainly focal discharges on
EEG records.
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DIFFERENCES BETWEEN FEMALE PATIENTS WHO DO AND
DO NOT REPORT SEXUAL ABUSE IN A POPULATION OF PA-
TIENTS WITH PSYCHOGENIC NONEPILEPTIC SEIZURES
1M. Selkirk, 2A. Pelosi, 1M. Oto, and 1R. Duncan (1West of Scotland
Regional Epilepsy Service, Glasgow, Scotland, 2Department of Psychi-
atgry, Hairmyres Hospital, East Kilbride, Scotland)
Purpose: To investigate differences between female patients with
PNES who do and do not report antecedent sexual abuse.
Method: In a consecutive series of 177 patients seen at a PNES clinic.
Results: In a consecutive series of 131 female patients seen at a PNES
clinic, 60 reported sexual abuse. Female patients reporting sexual abuse
had a higher rate of depression (p < .001), self harm (p = .001, suicide
attempt (p < .001), personality disorder (p = .001) and previous mental
health service referral (p < .001). They were more likely to have flash-
backs during attacks (p < .001) and urinary incontinence during attacks
(p = .001). Reported nocturnal attacks and injury were more common
in the abused group (p = 0.012 and 0.020, respectively).
Conclusion: We found some striking differences between abused and
nonabused female patients with PNES. These differences may have im-
plications for our understanding of causation of PNES, and for treatment.
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FRAMELESS STEREOTACTIC ROBOT-GUIDED PLACE-
MENT OF DEPTH ELECTRODES FOR STEREOELECTROEN-
CEPHALOGRAPHY IN PRESURGICAL ASSESSMENT OF
CHILDREN WITH REFRACTORY PARTIAL EPILEPSY
G. Dorfmu¨ller, C. Bulteau, M. Fohlen, C. Jalin, and O. Delalande
(Fondation A. de Rothschild, Paris, France)
Purpose: To present our experience with frameless stereotactically
placed depth electrodes in presurgical evaluation of children with drug-
resistant partial seizures.
Method: A total of 738 multilead electrodes were placed with the aid
of a Robot-guided MRI-based stereotactic system (Schaerer-Mayfield
Neuromate) in 83 children (2.8 to 18 years, mean 9.4). Each monitoring
included 6 to 14 electrodes (mean 9) for a period of 2 to 17 days (mean
7).
Results: Twelve children underwent monitoring of a single lobe, 43 of
2, 26 of 3, and 2 children of 4 lobes; 6 had a bilateral recording. MRI was
negative in 8 patients (10%). Further studies (PET, SPECT, fMRI, WADA
testing, foramen ovale recording) were performed prior to the stereoelec-
troencephalography (S-EEG) in several cases. We performed electrode
stimulations in order to map motor and/or language cortex, and in order
to induce seizures. Beside 3 electrode breaks during removal, there were
no other surgery-related complications. Having identified the epilepto-
genic zone, we proposed tailored resection in 69 cases, 1 child had a
hemispherotomy instead. In 13 children (16%), SEEG results precluded
resective surgery. To date, 57 children underwent surgery; histopathology
revealed cortical developmental malformation in 29, glioneural tumour
in 13, hippocampal sclerosis in 7 (+ neocortical dysplasia in 5), ischemic
alteration in 3, and was negative in 5 cases.
Conclusion: Depth recording remains essential in evaluating the in-
dication and extension of focal resection, particularly in children. Our
frameless technique is safe and well tolerated, with no related morbidity
in this large series.
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SURGICAL TREATMENT OF OCCIPITAL LOBE EPILEPSY
1M. Von Lehe, 1D. Binder, 1T. Kral, 2C. Bien, 3H. Urbach, 1J. Schramm,
and 1H. Clusmann (1Department of Neurosurgery, University of Bonn,
Germany, 2Department of Epileptology, University of Bonn, Germany,
3Department of Radiology, University of Bonn, Germany)
Purpose: Occipital lobe epilepsy (OLE) accounts for a small percent-
age of extratemporal epilepsies and few large series have been reported.
Preoperative findings, surgical strategies, pathologic basis and postop-
erative outcome for OLE remain to be elucidated.
Method: From a prospective epilepsy surgery database established in
1990, a group of 44 patients with occipital lobe involvement were found.
Charts, surgical reports, MRI and pathology data were reviewed, and
patients with temporal or parietal involvement were excluded. Seizure
outcome was classified according to Engel’s score (I–IV).
Results: Twenty-nine patients with pure OLE were found, compris-
ing 9.9% of 292 patients undergoing operation for extratemporal epilep-
sies. Most (83%) had complex partial seizures, and 69% had generalised
seizures. All patients revealed a lesion on MRI and underwent occipital
lesionectomies, 6 patients with additional MST. Histopathology revealed
9 gliotic scars (31%), 7 gangliogliomas (24%), 7 vascular malformations
(24%), 5 dysplasias (17%) and one low-grade ependymoma (3%). Vi-
sual field deficits were present in 11 patients preoperatively (38%), and 6
patients (21%) showed new and 3 patients (10%) aggravated visual field
deficits after surgery. After a mean follow-up of 38 months, 21 patients
became seizure-free (72% Engel I), 2 had rare seizures (7% Engel II), 3
improved more than 75% (10.5% Engel III), and 3 had no worthwhile
improvement (10.5% Engel IV).
Conclusion: Pure OLE is a rare but significant cause of extratempo-
ral epilepsy. Satisfactory results (Engel I or II) were obtained in 79%
of patients in our series. Postoperative visual field deficits occur in a
significant proportion of patients.
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MULTIPLE SUBPIAL TRANSECTIONS: SAFETY AND EVOLU-
TION OF 30 PATIENTS
1K. van Rijckevorsel, 1M. de Tourtchaninoff, 2Y. Van Raay, 1G. Vaz, and
1C. Raftopoulos (1Reference Center For Refractory Epilepsy, Belgium,
2Neurosurgery Unit, Belgium)
Purpose: Multiple subpial transections (MST) are an effective surgi-
cal option for some refractory epilepsy patients. This technique is often
considered as palliative, with high risk of sequelae if done in functional
areas. We analysed safety and short term seizure outcome of 30 patients
operated since January 2003.
Method: 30 patients, 19 male, 11 months to 56 years old at the time
of surgery, have a 14 years mean time of epilepsy duration. 11 suffer
from cryptogenic focal epilepsy, 3 from CSWS, 9 from tumour or dys-
plasia in functional areas, 3 from post-traumatic or infectious lesions
and 4 from various aetiologies. When possible, cortectomy, lobectomy
or lesionectomy were completed with MST to get better seizure control.
Results: Only temporary deficits have been reported in 11 patients.
None have a permanent deficit related to MST. Three have been re-
operated for intracranial collection. Acute postsurgery seizures occured
in 2 patients, concomittant to unexplained antiepileptic drugs plasma
levels decreased. All patients have improved at least for behaviour and/or
cognition. Eight patients became seizure free with a variable cognitive
improvement, but 2 relapsed when AEDs were stopped abruptly. Six
remained seizure free for a few months but relapsed with less severe
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seizures. Seizures were less severe and/or less numerous in the remaining
patients.
Conclusion: MST is a valid and effective option in very difficult to
treat patients discarded for classic surgical treatment. MST is a useful
complementary treatment when the lesion is near or in a functional zone,
to improve seizure control after resection.
016
GAMMA KNIFE CALLOSOTOMY: A SAFE AND EFFICIENT
ALTERNATIVE TO OPEN SURGERY
1M. Feichtinger, 2O. Schroettner, 2H. Eder, 3H. Holthausen, 3T. Pieper,
1E. Koerner, 1F. Fazekas, and 1E. Ott (1Dept. of Neurology, Medical Uni-
versity Graz, Austria, 2Dept. of Neurosurgery, Medical University Graz,
Austria, 3Dept. of Neuropediatrics and Neurorehabilitation, Vogtareuth,
Germany)
Purpose: Beside open surgery, a radiosurgical callosal disconnection
using the Gamma Knife (GK) for the treatment of generalised epilepsies
with drop attacks (DA) is possible. The purpose of this retrospective
analysis was to assess long term results of gamma knife callosotomy
concerning tolerability and efficacy.
Method: Eight patients (3 female, 5 male, age range from 5 to 69
years) suffering from severe generalised epilepsy associated with dis-
abling drop attacks underwent GK callosotomy between 1993 and 2004.
In 6 patients the anterior third of the corpus callosum was radiosurgically
disconnected. In 1 patient a second procedure with GK treatment of the
middle third of the corpus callosum was added 17 months later. In 2 pa-
tients posterior GK callosotomy had followed partial hemispherotomy.
Results: Drop attacks (DA) were completely abolished in 3 patients
and 2 patients had a marked DA seizure reduction of 60%. Two out
of 4 patients with additional generalised tonic–clonic seizures showed
a reduction of 100% and the remaining a 50% and 60% decrease, re-
spectively. Other seizure types responded less well to the radiosurgical
treatment. In both patients with posterior GK callosotomy after hemi-
spherotomy partial seizures decreased. Beside transient headache in 2
patients no immediate or long term postradiosurgical side effects were
observed.
Conclusion: Radiosurgical callosotomy is an efficient noninvasive
alternative to the open procedure as results are comparable. It can be
viewed as a safe procedure without severe postradiosurgical side effects.
017
ELECTRICAL STIMULATION OF THE HIPPOCAMPUS IN
EPILEPSY PATIENTS
1C. Boex, 1S. Vulliemoz, 1L. Spinelli, 2G. Foletti, 2C. Pollo, and 1M.
Seeck (1Hoˆpitaux Universitaires De Gene`ve, Switzerland, 2Centre Hos-
pitalier Universitaire Vaudois, Switzerland)
Purpose: Optimal intracranial stimulation parameters in epilepsy pa-
tients are still not defined. In the present study, we try to elucidate the
efficiency of high or low stimulation frequencies with respect to interictal
EEG and seizure frequency.
Method: Two patients were implanted with depth electrodes includ-
ing the mesial temporal lobe structures bilaterally. Noninvasive (EEG,
MRI, PET and SPECT) and later invasive monitoring suggested in pa-
tient S1 nonlesional partial epilepsy, in patient S2 nonlesional bitemporal
epilepsy with left sided predominance. Stimulation was applied using
bipolar biphasic 5 Hz and 130 Hz pulses (450 μs/phase, 1V) on two
consecutive days, for 3 hours in S1 and 6 hours in S2. Stimulation sites
included right hippocampus in S1 and left hippocampus in S2. Occur-
rence of seizures and interictal EEG discharges were quantified before,
during and after each stimulation period.
Results: The low rate stimulation increased the epileptogenic activity
in the mesial temporal structures bilaterally (p < 0.001) in both patients,
compared to baseline. Two (S1) and three (S2) clinical seizures were
noted as well corresponding to the habitual seizure frequency. In con-
trast, the high rate stimulation significantly decreased the epileptogenic
activity in both hippocampi for both patients (p < 0.005). During the high
rate stimulation and the period thereafter, no seizures were recorded in
either patient.
Conclusion: These results suggest that high, but not low rate electri-
cal intracranial stimulation of the hippocampus is efficient in reducing
epileptogenic activity in man. The antiepileptogenic effect was observed
during and after stimulation.
018
DEEP BRAIN STIMULATION FOR REFRACTORY TEMPO-
RAL LOBE EPILEPSY
K. Vonck, V. De Herdt, A. Van Dycke, I. De Waele, L. Goossens, M.
Van Zandijcke, T. De Smedt, L. Waterschoot, T. Wijckhys, F. De Waele,
D. Van Roost, W. Wadman, and P. Boon (Ghent University Hospital,
Reference Center For Refractory Epilepsy, Ghent, Brussels, Belgium)
Purpose: Deep brain stimulation (DBS) is under investigation as a
treatment for patients with medically refractory epilepsy. The purpose
of the present study is to prospectively evaluate the efficacy of long-term
DBS in medial temporal lobe (MTL) structures in patients with MTL
epilepsy.
Method: Ten consecutive patients with refractory complex partial
seizures with and without secondary generalisation (CPS ± SG) were
implanted with bilateral amygdalohippocampal (AH) electrodes and/or
subdural strips and/or grids for ictal onset localisation and subsequent
stimulation of the ictal onset zone. Side effects and changes in seizure
frequency were carefully monitored.
Results: After a mean follow-up of 31 months (range: 12–52 months)
1/10 patient is seizure free (>1 year), 1/10 patient has a >90% reduction
in seizure frequency; 5/10 patients have a seizure frequency reduction of
≥50%; 2/10 patients have a seizure frequency reduction of 30–49%; 1/10
patient is a nonresponder. None of the patients reported side effects. In 1
patient MRI showed asymptomatic intracranial hemorrhages along the
trajectory of the DBS electrodes. None of the patients showed changes
in clinical neurological testing.
Conclusion: This open study demonstrates the efficacy of long-term
DBS in MTL structures.
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019
ESTIMATES OF MORTALITY AND MORBIDITY ASSOCI-
ATED WITH CHILDHOOD STATUS EPILEPTICUS ARE DE-
PENDENT ON STUDY QUALITY
1,2,3M. Raspall-Chaure, 1,2,3R. Chin, 1,2,3B. Neville, and 1,2,3R. Scott
(1Neurosciences Unit, Institute of Child Health, London, UK, 2Epilepsy
Unit, Great Ormond Street Hospital for Children NHS Trust, London,
UK, 3The National Centre for Young People with Epilepsy, Lingfield,
UK)
Purpose: It is widely accepted that convulsive status epilepticus (CSE)
in childhood is associated with significant morbidity and mortality, but
there is a wide range of estimates of adverse outcome with CSE. Although
the variation in estimates may have a biological cause, we investigated
whether this variation is also a function of the quality of the studies.
Method: A systematic review methodology search for studies re-
garding outcome of paediatric CSE was conducted. Each study’s
methodological quality was evaluated using a scoring system that in-
cluded scores for study design, type of study, duration of follow-up,
aetiology, standardisation of rates, ascertainment adjustment, therapeu-
tic algorithm and definition of outcome parameters. Maximum possible
score was 50.
Results: Fifty-nine studies were identified. Median quality score was
25 (range 10–41). Mean score was higher in prospective studies than in
retrospective studies (33.5 vs 22, p < 0.005). Population-based studies
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scored better than hospital-based studies (30.6 vs 24.2, p = 0.006). These
differences are not attributable to the scoring system itself. Morbidity
and mortality estimates each ranged from <1% to >40%. A correlation
was found between higher scores (i.e. better study quality) and lower
mortality (Rho Spearman = −0.38, p = 0.009) and morbidity (Rho
Spearman = −0.539, p = 0.004), but not between scores and subsequent
epilepsy or CSE recurrence.
Conclusion: Lack of homogeneity and accuracy in methodological
designs account for the heterogeneous results observed between studies
and impede meaningful comparisons. The best scored studies suggest an
overall short-term mortality of 3% and morbidity <15%, values that are
likely to be closest to “reality.”
020
AETIOLOGY, COURSE AND OUTCOME OF CHILDREN AD-
MITTED TO PAEDIATRIC INTENSIVE CARE WITH CONVUL-
SIVE STATUS EPILEPTICUS: A FIVE-YEAR EXPERIENCE:
‘ZERO MORTALITY AND LOW MORBIDITY’
1N. Hussain, 2R. Appleton, and 2K. Thorburn (1Leicester Royal Infir-
mary, Leicester, UK, 2Royal Liverpool Children’s Hospital NHS Trust,
Liverpool, UK)
Purpose: Convulsive status epilepticus (CSE) is the most common
neurological emergency in childhood (1) and is a life-threatening condi-
tion with serious risk of neurological sequelae. (2) Mortality and morbid-
ity due to CSE have declined during the last two decades when compared
to previous decades. (3) The purpose of this retrospective study was to
explore the role of age, sex, previous neurological disorders, aetiology,
duration and treatment on the outcome of CSE.
Method: A retrospective study of the aetiology, course and prognosis
of children in convulsive status epilepticus (CSE) admitted to a large
paediatric intensive care unit (PICU) between January 1999 and April
2004. Status epilepticus was defined as a prolonged (>30 mins) tonic–
clonic seizure irrespective of whether the seizure had stopped prior to
admission to PICU.
Results: One hundred thirty-seven (74 male) children aged 1 month to
15 years were admitted to PICU with 147 episodes of status epilepticus.
Forty-seven children (34%) were admitted following a prolonged febrile
seizure. Fifty-three children (39%) had a remote symptomatic cause for
the CSE (cerebral palsy in 34 of the 53). Twenty-four children (18%)
were admitted for an acute symptomatic cause. Six children had a pro-
gressive encephalopathy and no cause was identified in the remaining
seven of the 137 children (5%). Forty-nine children (36%) had preex-
isting epilepsy. The mean duration of CSE was 44 minutes (range, 30
to 120) minutes. Forty nine (36%) children admitted to PICU required
treatment to terminate the presenting episode of CSE. Forty-two and
7 of these children were treated with thiopentone anaesthesia and mi-
dazolam infusions respectively, successfully terminating the episode of
status in all. No child died on PICU as a result of either the CSE or
its cause. Of the 70 children considered to be previously neurologically
and developmentally normal prior to admission, 64 demonstrated normal
neurological or developmental findings on discharge from the PICU. The
majority (95%) of the 47 children with febrile CSE demonstrated normal
neurodevelopmental findings at a median period of 1.3 years following
discharge from PICU.
Conclusion: The most common cause of CSE in children admitted
to a large children’s hospital PICU was epilepsy. Thiopentone was the
most commonly used drug to terminate persisting status on PICU that
had proved resistant to first line treatment using a benzodiazepine and
phenytoin or phenobarbitone. No child died as a direct result of CSE.
Only 1 (0.01%) of the previously neurologically and developmentally
normal children demonstrated any abnormality at the time of their latest
follow up.
021
SOCIOECONOMIC DEPRIVATION INDEPENDENT OF ETH-
NICITY INCREASES THE RISK OF CONVULSIVE STATUS
EPILEPTICUS IN CHILDHOOD
R. Chin, B. Neville, C. Peckham, H. Bedford, A. Wade, and R. Scott
(Institute of Child Health, UCL Medical School, London, UK)
Purpose: The incidence of convulsive status epilepticus (CSE) is
higher amongst nonwhite compared to white patients. However, eth-
nicity effects may be related to socioeconomic factors. The study with
the highest reported incidence of CSE worldwide was conducted in a
predominantly black, economically deprived population. Thus, we hy-
pothesised that the incidence previously reported in nonwhite patients
may in part reflect the effect of socioeconomic deprivation.
Method: Subjects were enrolled as part of a two year prospective
population based study. Excluding neonates, children aged < 16 years
with CSE were identified using a multitiered notification system. Home
post-codes of children were used to determine their Index of Multi-
ple Deprivation 2004 (IMD2004) score of socioeconomic deprivation.
Poisson multiple regression analysis was used to investigate the rela-
tionships between incidence of CSE, socioeconomic deprivation and
ethnicity.
Results: 176 children were enrolled. Ascertainment-adjusted inci-
dence = 19 (95% CI 17–23) per 100,000 children/yr. Nonwhite chil-
dren were 1.8 times more likely (p = 0.03) to have CSE compared
to white children. Asian children were 2.1 times more likely (p <
0.0005) but black children were as likely (or 1.3, p = 0.2) to have CSE
compared to white children. For each one point increase in IMD2004
(worsening socioeconomic deprivation) there is a 3% cumulative in-
creased risk of CSE irrespective of ethnicity (p = 0.003). There were
no differences in IMD2004 scores and aetiology or IMD2004 scores
and the interval between CSE onset and arrival of emergency medical
services.
Conclusion: The relationship between ethnicity and CSE is complex
and is likely to be influenced by socioeconomic and genetic factors.
022
CONVULSIVE STATUS EPILEPTICUS AS INITIAL SEIZURE
IN CHILDREN: TYPE OF LATER EPILEPSY
P. Haapala, L. Pekkarinen, A. Kuusela, T. Kera¨nen, and K. Eriksson
(Tampere University Hospital and Medical School of Tampere Univer-
sity, Finland)
Purpose: Epilepsy is one of the most common sequelae in patients
with convulsive status epilepticus. Whether the seizure prolongation is
an independent risk factor for later epilepsy is uncertain and little is
known about the type of it. We reviewed data of a set of children treated
for prolonged convulsive seizure to determine whether the duration of
the initial episode has an effect on the incidence and the type of later
epilepsy.
Method: We retrospectively reviewed data of all children (aged 1
month to 16 years) who had been admitted to the Paediatric Emergency
Department of Tampere University Hospital from 1993 to 1999, due to
an acute convulsive disorder lasting over 5 minutes (n = 186). Of those,
children with no previous epilepsy were included in the retrospective
analysis on the initial seizure episode and clinical follow-up.
Results: There were 159 children included in the analysis and they
were divided into two groups based on the initial seizure duration (5–29
min and 30 min or more). The groups did not differ significantly by aeti-
ological or other background factors. 75.5% were neurologically normal
prior to the initial seizure episode. The mean age was 3.5 years (range 2
mo–14.7 y), the mean follow-up time 15.9 months. There were 94 chil-
dren with initial seizure duration over 30 min, of which 26 (27.7%) were
diagnosed with epilepsy during follow-up. The risk for later epilepsy
associated significantly with the aetiology; the risk was 50–55% in id-
iopathic or remote symptomatic aetiology groups compared to 13.3% in
febrile or other aetiologies (p < .001). The type of later epilepsy was sig-
nificantly more often focal (84.6%) than generalised (15.4%, p < .001).
In 65 children the duration of initial seizure episode was 5–29 minutes
and 14 (21.5%) were diagnosed with epilepsy during follow-up. Almost
all (92.9%) of those epilepsies were focal.
Conclusion: Onset of epilepsy after prolonged initial seizure episode
occurred in every fourth child. Children with longer (over 30 minutes)
initial seizure episode had a 1.3-fold risk for later epilepsy compared
to children with a shorter initial seizure. The type of later epilepsy was
focal in most patients.
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023
STATUS EPILEPTICUS IN CHILDREN WITH PROGRESSIVE
MYOCLONUS EPILEPSIES
1R. Kravljanac, 1M. Djordjevic, 2N. Jovic, 1M. Djuric, and 3T. Pekme-
zovic (1Institute For Mother And Child Health of Serbia, Belgrade, Ser-
bia and Montenegro, 2Clinic of Child Neurology and Psychiatry, Bel-
grade, Serbia and Montegro, 3Institute For Epidemiology, School of
Medicine, Belgrade, Serbia and Montenegro)
Purpose: To evaluate clinical and neurophysiologic characteristics,
precipitating factors, response to treatment and outcome of status epilep-
ticus (SE) in children with progressive myoclonus epilepsies (PME).
Method: We analysed 20 episodes of SE in 7 patients (mean age
9 ± 4.6 years) with PME. Molecular biology and/or microscopic analysis
were used to confirm aetiology of PME. The follow up duration ranged
1–7 years (4.3 ± 1.6).
Results: Aetiology of PME was estimated: ceroidlipofuscinoses
(CLF) (3), Lafora disease (LD) (3) and MERRF (1). The most frequent
type of SE was myoclonic (12), secondary generalised tonic–clonic (6)
and complex partial SE in 2 episodes. Duration of SE ranged from 30min-
7 days (mean duration 850 min). Infection provoked 8 episodes, intro-
duction of lamotrigine aggravated SE in 1 patient with LD and topiramate
in 1 patient with CLF. Ten episodes occurred without acute provocation.
In control of SE, midazolam was effective in 16, thiopental in 1, pheno-
barbital in 2 and clonazepam in 1 episode. A patient with MERRF died
due to respiratory impairment, and the others returned to the baseline
neurological status in a period of 7–20 days after SE.
Conclusion: More than 2/3 episodes of SE in children with PME
were long lasting and resistant to appropriate treatment. Most frequent
type was myoclonic SE, aggravated by infection and the introduction of
some drugs. The most effective drug for control of SE was midazolam
administered in continuous intravenous infusion. Duration of recovery
and return to the baseline neurological status after an episode of SE was
prolonged and correlated to the treatment duration.
024
CHILDREN PRESENTING WITH A FIRST TONIC–CLONIC
SEIZURE: THE ROLE OF A “FIRST-FITTER” CLINIC
R. Appleton, K. Williams, J. Daly, and D. O’Hagan (Royal Liverpool
Children’s Hospital (Alder Hey), UK)
Purpose: A “first-fitter” clinic (FFC) was established to address the
concerns of families whose children had attended the Emergency De-
partment (ED) with a first tonic–clonic seizure. The study reports the
results of the first 2 years of this FFC held within the ED of a large
Children’s Hospital.
Method: The study included all children attending the ED after a
first tonic–clonic seizure not requiring admission and who were offered
an appointment for the FFC. Children were seen by an advanced nurse-
practitioner with support from a Consultant in Emergency Medicine after
which they were discharged back to their general practitioner or referred
to the neurology clinic in the same hospital. The study was retrospective
using the child’s ED and FFC medical notes.
Results: One hundred twenty-one children (68 boys), aged 2–15
(mean, 9.4 years) attended the ED with a reported first tonic–clonic
seizure. One hundred and seventeen of these 121 (97%) attended the
FFC clinic, 92 (79%) within 4 weeks of the seizure. After FFC review,
diagnoses in the 117 included tonic–clonic seizures (82), reflex anoxic
seizures (15), vaso-vagal syncope (13), febrile seizures (3), breath-
holding (2) and ‘unclear’ (2). Forty eight children were referred to the
neurology clinic with 90% being assessed within 4 weeks of referral.
Conclusion: Almost one-third of the 117 children had not experi-
enced a tonic–clonic seizure as first diagnosed when they attended the
ED. Consequently the FFC could reassure many families but also “fast-
track” those children who were considered to have had multiple seizures
(epilepsy).
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SILENT PERIOD MEASUREMENTS IN UNTREATED PA-
TIENTS WITH IDIOPATHIC GENERALISED EPILEPSY
1V. Kimiskidis, 1D. Kazis, 1S. Papagiannopoulos, 1G. Vasiliadis, 1F.
Zara, 2X. Fitsioris, 2G. Georgiadis, and 1A. Kazis (1III Neurological
Department, Aristotle University of Thessaloniki, Greece, 2Neurological
Department, “Papageorgiou” Hospital, Thessaloniki, Greece)
Purpose: Transcranial magnetic stimulation (TMS) studies reflecting
cortical and spinal inhibitory mechanisms. Previous studies of SP in
epilepsy have generally provided divergent results. The objective of the
present study is to investigate SP in untreated patients with idiopathic
generalised epilepsy (IGE) using a novel methodological approach.
Method: Fourteen patients with IGE (9 females, median age 19 yrs,
range: 16–22) entered the study. Seven patients suffered from juvenile
myoclonic epilepsy (JME), 4 patients from idiopathic epilepsy with gen-
eralised tonic–clonic seizures on awakening and the rest from other id-
iopathic generalised epilepsy syndromes not better defined. All elec-
trophysiological examinations were performed at least 48 hours after
the occurrence of an epileptic seizure so as to account for the con-
founding factor of postictal changes. Results were compared with those
of a control group comprising 13 healthy, age-matched subjects. SPs
were investigated as recently described [Kimiskidis et al. Exp Brain Res
2005;163:21–31]. First, SPs were elicited using a wide range of stimu-
lus intensities (SIs) (from 5 to 100% maximum SI at 5% increments).
At each SI, 4 SPs were obtained and the average value of SP duration
was used to construct a stimulus/response (S/R) curve of SI vs SP. The
resulting S/R curves were then fitted to a Boltzman function, the best-fit
values of which were statistically compared between the patient and the
control group.
Results: The SP S/R curve of the patients was significantly different
compared to the controls (p > 0.0001, F-test and AIC). In particular, the
Max value of the patient’s curve was 257.5 ± 3.98 ms vs 221.4 ± 2.89
ms in the controls (p < 0.0001) and V50 was 46.95 ± 0.71 vs 51.03 ±
0.57 (p < 0.0001) whereas slope was not significantly different (9.94 ±
0.58 vs 10.09 ± 0.46, p > 0.05).
Conclusion: SP, a GABAB receptor mediated event, is prolonged in
IGE. Basic neurophysiology experiments prove that GABAB IPSPs are
more efficiently activated in the presence of GABAA receptor antago-
nists. Therefore, it could be hypothesised that a hypofunction of GABAA
receptors in patients with IGE results in increased GABAB IPSPs re-
flected in prolonged SPs.
026
PROPOSAL OF AN EEG TIME INDEX VARIATION OF SPIKES
(ETIVS) DURING ENDOSCOPIC DISCONNECTION IN IN-
TRACTABLE EPILEPSY ASSOCIATED WITH HYPOTHALA-
MIC HAMARTOMA (HH)
1D. Debatisse, 1E. Pralong, 1J. Villlemure, 2M. Maeder, 3E. Roulet,
1O. Delalande, 1M. Tetreault, and 1C. Pollo (1Neurosurgery-UNN
CHUV Lausanne, Switzerland, 2Neurology Department CHUV Lau-
sanne, Switzerland, 3Neuropediatric Department CHUV Lausanne,
Switzerland)
Purpose: Intractable epilepsy associated with hypothalamic hamar-
toma (HH) can be controlled by microsurgical resection of the lesion;
excision of deep-seated lesions is often associated with morbidity and
mortality. Endoscopic disconnection is less invasive and seems to be well
suited for this indication. Hypothalamic hamartoma are often associ-
ated to a progressive epileptic encephalopathy. Surgery clinical outcome
data indicates that destruction or isolation of the hamartoma may stop
seizures. We present data of 1 patient with endoscopic disconnection for
the treatment of intractable epilepsy. On-line EEG recording was car-
ried out during the surgery. By this surgery technical approach, Epilepsy
improved theoretically in the literature in 60% of patients with minimal
morbidity. In our knowledge this case report is first one in the liter-
ature where the opportunity of EEG neuromonitoring during epilepsy
endoscopic surgery is discussed. The authors (a) discuss the interest of
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EEG neuromonitoring during endoscopic-assisted surgery in the man-
agement of HH-induced seizures; (b) propose an EEG neuromonitoring
approach with calculation of an EEG time index variation of spikes
(ETIVS) during endoscopic epilepsy surgery (c) give an online “EEG
predictive value” (EPV) of post operative outcome.
Method: One patient suffering from intractable epilepsy with a HH
lesion. (age 2 years old BD: 07-07-2002). Intractable epilepsy with 10
or 20 Gelastic crisis per day and a strong bad psychomotor deficit
(mentally retarded). Endoscopic surgery was proposed in this case by a
left approach for the disconnection of the left side of HH, using neuron-
avigation technique. On-line scalp EEG recording was performed (Fp2-
Fp1-C3-C4, T3-T4,O1-O2) during the length of surgery (EEG signals
were recorded using a Micromed (Italy) 32 channels system at 512 Hz,
low passed filtered at 128 Hz and high passed filtered at 1 Hz. The signal
was visualised using a monopolar montage or an averaged reference).
An off line analysis was performed using linear and temporal techniques
(wavelet and FFT) with EEmagine software from ANT (Germany) to
calculate the number of left and right hemisphere epileptic discharges.
A time index of variation (duration, amplitude and number) of discharges
was calculated and compared between the two hemispheres (using for
the analysis FP1 and FP2 electrodes).
Results and Conclusion: We calculated ETIVS spike discharges for
both hemispheres. By comparison we observed 1791 spikes on the right
Fp2 electrode and 3177 spikes on the Fp1 electrodes during the total
recording time (148 min). On the right hemisphere we observed a statis-
tical significance decrease of the number of discharges at time 78 to 127
minutes during the surgery approach. During this period, we observed
also a change of the EEG pattern spikes recognition in term of re-
duction of spike numbers, duration and amplitude but with an increase
of small multi spike discharges. At 128 min on the left hemisphere corre-
lated with the surgery location, we observed an increase of spike numbers
without modification in duration and amplitude in comparison with the
beginning of surgery. Epilepsy surgery in children requires a multidis-
ciplinary approach. This original case report examines the role of scalp
EEG monitoring during surgical endoscopic surgery in 1 case with a HH.
An illustrative case demonstrates (1) the interest of EEG neuromonitor-
ing during endoscopic approach in intractable epilepsy and (2) can be
used as an on-line tool to determine and predict the EEG or epilepsy
outcome of the patient; (3) we developed an EEG time index variation
of spikes (ETIVS) of epileptic discharges during endoscopic surgery. In
conclusion, using EEG neuromonitoring with an ETIVS during endo-
scopic surgery, we expect that this neurophysiological approach can be
a help in the comprehension of mechanisms in epilepsy network in mul-
tifocal intractable epilepsy. These first and encouraging results should
be confirmed by prospective studies.
027
DIFFERENCES IN EEG INTERICTAL SPIKE PROPAGATION
BETWEEN RIGHT AND LEFT TEMPORAL LOBE EPILEPSY
G. Lantz, C. Sottas, M. Seeck, and C. Michel (Department of Neurology,
University Hospital, Geneva, Switzerland)
Purpose: Previous studies revealed structural, metabolic, and neu-
ropsychological differences between right and left temporal epilepsy
and suggested that right temporal lobe epilepsy (RTLE) might be a more
diffuse or generalised disease than left temporal epilepsy (LTLE). Based
on these studies we hypothesised that a more widespread propagation of
the epileptiform activity in RTLE patients might underlie these differ-
ences.
Method: We analysed spikes of 57 patients with temporal lobe
epilepsy (30 left, 27 right), recorded from 29 electrodes. A distributed
linear inverse solution (LAURA) was used in combination with statistical
parametrical mapping to determine those areas of the brain that showed
a significantly different activation in the two patient groups during dif-
ferent phases of the spike-wave complex.
Results: LTLE patients showed significantly stronger ipsilateral tem-
poral activation than RTLE patients, while RTLE patients showed signif-
icantly stronger contralateral temporal activation throughout the whole
spike-wave complex. Early ipsilateral frontal propagation was seen in
both patient groups, but this propagation had a more anterior distribu-
tion in the LTLE patients. Later propagation to contralateral frontal areas
was more pronounced in RTLE patients.
Conclusion: With the current technique it has been possible to deter-
mine statistical differences in the propagation patterns between RTLE
and LTLE patients. The stronger contralateral temporal activation and
the more extensive frontal propagation in RTLE is in line with the notion
of a more diffuse or generalised disease in these cases.
028
INTERICTAL TO ICTAL TRANSITION IN HUMAN TLE: IN-
SIGHTS FROM COMPUTATIONAL MODELLING OF INTRAC-
EREBRAL EEG
1F. Wendling, 1A. Hernandez, 2F. Bartolomei, and 2P. Chauvel (1Inserm–
University of Rennes, France, 2Inserm–University of Mediterranee,
France)
Purpose: In human partial epilepsies, the role of inhibition and the
relationship between the inhibition and excitation and epileptogene-
sis has long been questioned. Pathophysiological mechanisms can be
approached by direct recording of brain electrical activity in human
epilepsy performed during presurgical evaluation. In this study, we re-
late electrophysiological patterns typically observed during the transition
from interictal to ictal activity in human mesial temporal lobe epilepsy
(MTLE) to mechanisms involved in seizure generation through a com-
putational model of EEG activity.
Method: Intracerebral EEG signals recorded from the hippocampus
in patients with MTLE during interictal activity, during seizure onset and
during ictal activity were used to identify the three main parameters of a
model of hippocampus EEG activity (related to excitation, slow dendritic
inhibition and fast somatic inhibition). The identification procedure used
optimisation algorithms to minimise a spectral distance between real and
simulated signals.
Results: Results demonstrated that the model generates very realistic
signals for automatically identified parameters. They also showed that
the transition from interictal to ictal activity cannot be simply explained
by an increase in excitation and a decrease in inhibition but rather by
time-varying ensemble interactions between pyramidal cells and local
interneurons projecting to either their dendritic or perisomatic region
(with slow and fast GABAA kinetics). Particularly, fast onset oscillations
(25 Hz) are explained by the model feedback loop between pyramidal
cells and interneurons targeting their perisomatic region.
Conclusion: This model-based approach is able to reveal physiolog-
ical changes that take place inside recorded brain structures during the
transition from interictal to seizure activity.
029
ENHANCING THE LOCALISING VALUE OF ICTAL SCALP
EEG BY APPLYING THE NEW BSS-CCA METHOD TO RE-
MOVE MUSCLE ARTIFACTS
1A. Vergult, 1W. De Clecq, 1B. Vanrumste, 1S. Van Huffel, 2A. Palmini,
and 2W. Van Paesschen (1Katholieke Universiteit Leuven, Leuven,
Belgium, 2University Hospital Gasthuisberg, Leuven, Belgium)
Purpose: The influence on the localising value of ictal EEGs on mus-
cle artifact suppression by blind source separation-canonical correlation
analysis (BSS-CCA) was investigated.
Method: All patients with refractory partial epilepsy having a reliably
defined epileptogenic zone based on multimodal studies were selected.
One ictal EEG of all 37 patients was presented to a clinical neurophysi-
ologist (AP) who was blind to all other clinical and localising data. The
ictal EEG was rated twice: first after applying a tunable band pass filter,
then after eliminating the muscle artifacts using BSS-CCA in combi-
nation with a band-pass filter (0.3–35 Hz). Assigned localisations and
lateralisations were compared between the two readings and with the
other localising data.
Results: In 2 out of 37 ictal EEGs no seizure could be identified. In
one case a seizure could only be determined and correctly localised after
applying BSS-CCA+filter. Of the remaining 34 EEGs 21 (62%) were
lateralised correctly after band-pass filtering, 26 (76%) after applying
BSS-CCA+filter. Correct localisation increased from 23 (67%) using
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band-pass filters to 29 (85%) using BSS-CCA+filter. Improvements in
lateralisation and localisation were both reached for temporal (2 out of
25 cases, resp. 3 out of 25 [0]cases) and extratemporal cases (3 out of 9
cases, resp. 4 out of 9 cases).
Conclusion: The new BSS-CCA algorithm to eliminate muscle arti-
facts from scalp EEGs enhances the localising value of ictal EEGs from
62% correct lateralisations to 76[0]% and from 67% correct localisations
to 85% compared to band-pass filtering.
This work was supported by European network of excellence BIOPAT-
TERN (FP6-2002-IST-508803) and Fund for Scientific Research Flan-
ders FWO research project nr G.0360.05. Bart Vanrumste is funded by
the “Programmatorische Federale Overheidsdienst Wetenschapsbeleid”
of the Belgian Government.
030
A NEW SIMULTANEOUSLY OBJECTIVE AND PATIENT-
SPECIFIC SPIKE AND WAVE DETECTION ALGORITHM
BASED ON TEMPLATE MATCHING
1A. Nonclercq, 1D. Verheulpen, 2C. De Cock, 1P. Mathys, and 2M.
Foulon (1Universite´ Libre De Bruxelles, Belgium, 2Centre Hospitalier
Universitaire De Charleroi, Charleroi, Belgium)
Purpose: Automatic spike and wave detection is useful to enhance
objectivity and reduce human work. Template matching algorithms are
computationally simple–hence quick–but it is difficult to find a template
that is suitable for all cases. The EEG expert can be asked to score a
few spikes and waves to generate a patient-specific template before the
automatic detection gives better performance, but is not always suitable
because of the time it requires (the amount of data is sometimes huge)
and because it reduces the objectivity. We present a new, simultaneously
objective and patient-specific, spike and wave detection algorithm. A first
spike and wave detection is made with a patient-independent template,
showing an average performance. Out of that detection, a patient-specific
template is created. Thanks to it, a patient-specific detection is made,
showing high performance.
Method: The algorithm was tested against the scoring of three EEG
experts over 30 minutes of EEG samples from three different subjects,
suffering form the syndrome of continuous spike and wave discharges
during slow sleep (CSWSS).
Results: The algorithm showed an average specificity of 81% and an
average false positive rate of 11%, compared to the average specificity
(90%) and false positive alarm rate (12%) when we compare the three
EEG experts.
Conclusion: The algorithm developed shows high performance, is
easy to use and is fast. It can be useful to increase the level of objectivity
and to decrease the amount of diagnostic work.
Monday July 3, 2006
12:00–13:30
Hall 3D
Platform Session
Basic Science I: Molecules and Networks for Epilepto-
genesis
031
NEUROGENESIS IN EPILEPTIC BRAIN: AFFERENT
SYNAPSES TO NEWBORN CELLS ATTENUATE NETWORK
EXCITABILITY
M. Kokaia (Wallenberg Neuroscience Center, Lund University Hospital,
Sweden)
Purpose: Neural stem cells in the adult mammalian brain (including
humans) continue to produce new functional granule cells in the dentate
gyrus subgranular zone and new olfactory bulb neurons in the subven-
tricular zone during an entire life. In the hippocampus, neurogenesis has
been proposed to play a role in learning and memory and mood reg-
ulation. The new cells develop electrophysiological characteristics and
synaptic inputs very similar to those of the rest of the cell population.
The purpose of the study was to explore whether tissue environment in
an epileptic brain influences properties of afferent synapses formed on
newborn granule cells.
Method: Rats were exposed to either a physiological stimulus, i.e.,
running, or status epilepticus, which gives rise to neuronal death, in-
flammation, increased network excitability and recurrent spontaneous
seizures. Both treatments increase neurogenesis in the dentate gyrus.
We labelled newborn cells by GFP-retroviral vector injections right after
these treatments to identify the cells and apply whole-cell patch-clamp
recordings in live hippocampal slices.
Results: Granule cells formed after running and status epilepticus
exhibited similar intrinsic membrane properties. However, new neu-
rons born into the epileptic environment differed with respect to tonic
drive and short-term plasticity of both excitatory and inhibitory afferent
synapses. The new granule cells formed after status epilepticus exhib-
ited functional connectivity consistent with reduced synaptic network
excitability of the dentate gyrus, i.e., decreased excitatory and increased
inhibitory input activity.
Conclusion: We demonstrate for the first time a high degree of plas-
ticity in synaptic inputs to the new neurons, which could mitigate patho-
logical activity in the epileptic brain.
032
PERTURBED EXPRESSION OF THE K-Cl COTRANSPORTER
KCC2 AND GABAERGIC SIGNALLING IN HUMAN TEMPO-
RAL LOBE EPILEPSY
1,2,3G. Huberfeld, 1L. Wittner, 1,2S. Cle´menceau, 1,2M. Baulac, 1R.
Miles, 4K. Kaila, and 4C. Rivera (1INSERM U 739 ‘Cortex & Epilep-
sie,’ CHU Pitie´-Salpeˆtrie`re, Paris, France, 2Epilepsy Unit, Hoˆpital
Pitie´-Salpeˆtrie`re, Paris, France, 3Laboratoire de Neurophysiologie,
Faculte´ de Me´decine Pitie´-Salpeˆtrie`re, Paris, France, 4Department
of Biological and Environmental Sciences, University of Helsinki,
Finland)
Purpose: An interictal-like activity is spontaneously generated in the
subiculum of slices obtained from patients with temporal lobe epilepsies
and hippocampal sclerosis. This activity is associated with depolarising
responses to GABA in a minority of subicular pyramidal cells, probably
related to a perturbation of neuronal Cl homeostasis. We therefore studied
relations between Cl homeostasis and GABAergic signalling in human
epileptic tissue, focusing on the K-Cl transporter KCC2, which is known
to be responsible for the generation of hyperpolarising GABA responses
in central neurons.
Method: Slices of human temporal lobe tissue with hippocampal
sclerosis containing the subiculum were prepared after surgery. Field
potentials and unit activity were recorded with extracellular electrodes.
Intracellular pipettes contained biocytin so that recorded cells could be
anatomically identified. KCC2 expression was studied with in situ hy-
bridisation and immunochemistry.
Results: Morphological characteristics or intrinsic parameters did not
differ in the ∼20% of pyramidal cells depolarised by GABA. GABAA re-
sponse reversal potentials were asymmetrically distributed with a mode
near −70 mV and most depolarised values up to −50 mV. Their driv-
ing force was positive with respect to resting potential in 20% of pyra-
midal cells. In situ hybridisation showed that KCC2 mRNA was not
detectable in ∼30% of subicular pyramidal cells. Combined biocytin
labelling and immunohistochemistry for KCC2 showed that 6/6 cells
with hyperpolarising responses to GABA were positive, while only 3/7
cells that discharged with epileptiform bursts were immunopositive for
KCC2.
Conclusion: A perturbation of KCC2 expression in a minor-
ity of subicular pyramidal cells may contribute to human interictal
epileptogenesis.
033
ASTROCYTIC-NEURONAL INTERACTIONS DURING
EPILEPTOGENESIS IN THE RAT NEOCORTEX
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1S. Ivens, 1I. Bechmann, 2D. Kaufer, 1U. Heinemann, and 1,3A. Fried-
man (1Charite´ University Medicine, Berlin, Germany, 2Department of
Integrative Biology, Berkeley, CA, USA, 3Ben-Gurion University, Beer-
Sheva, Israel)
Purpose: Focal cortical epilepsy is common following different brain
insults such as trauma, ischemia and infectious diseases. In many of
these insults the blood-brain barrier (BBB) is disrupted. We have re-
cently shown that prolonged cortical BBB opening is associated with
high amplitude, slow electroencephalographic activity in humans (Korn
et al., 2004) and hypersynchronised epileptiform activity in the rat cortex
(Seiffert et al., 2004). However, the mechanisms underlying epileptoge-
nesis after BBB disruption are not known.
Method: We used a rat model to disrupt the BBB by application of
the bile salt deoxycholic acid or exposed the rat cortex to serum albumin
in vivo.
Results: Here we show that astrocytic activation occurred within the
first 24 hours after treatment, while neuronal epileptiform activity was
noted from day 4. Extracellular recordings in vitro using ion-sensitive
microelectrodes showed that astrocytic activation was associated with
reduced K+ buffering due to a decrease in Ba2+ sensitive potassium
current, suggesting decreased inward rectifying K+ current. PCR anal-
yses and immunostainings confirmed the down regulation of KIR4.1
channels. Reduced K+ buffering lead to potassium accumulation dur-
ing neuronal activity, subsequently causing NMDA-receptor dependent
neuronal hyperexcitability. Serum albumin is rapidly and specifically
transported into astrocytes suggesting that it may be a signal for as-
trocytic activation. Albumin transport into astrocytes was found to be
receptor mediated, and could be blocked by antibodies against TGF-
beta receptors. Blocking albumin uptake in vivo significantly reduced
the likelihood of epileptogenesis.
Conclusion: Our results stress the importance of interactions between
the brain’s blood vessels, astrocytes and neurons in the pathogenesis of
focal neocortical epilepsy.
034
DYNAMIC CHANGES OF PROTEASES AND PROTEASE IN-
HIBITORS REVEALED BY MICROARRAY ANALYSIS IN CA3
AND TEMPORAL LOBE DURING EPILEPTOGENESIS IN THE
RAT
1,3J. Gorter, 1,3E. Van Vliet, 2H. Rauwerda, 4E. Aronica, 1F. Lopes
daSilva, and 1W. Wadman (1Center for Neuroscience, SILS, The Nether-
lands, 2Micro-Array Department, SILS, The Netherlands, 3Stichting
Epilepsie Instellingen Nederland, 4Neuropathology, AMC, University
of Amsterdam, The Netherlands)
Purpose: In order to find genes that could be potential targets to
intervene with epileptogenesis we investigated gene expression in a rat
model for temporal lobe epilepsy.
Method: RNA was obtained from three different brain regions (CA3,
entorhinal cortex and cerebellum) at three different time points (1 day
= acute phase; and 1 week = latent period; 3–4 months = chronic
epileptic) after electrically induced status epilepticus (SE); a group that
was stimulated but that had not developed epilepsy was also included.
Gene expression analysis was performed using the Affymetrics Gene
Chip System (230A). We used GENMAPP and gene ontology to identify
global biological trends in gene expression data. In this study we focused
on the proteolytic process.
Results: Proteolysis occurred mainly in the acute and latent phase.
We found noticeable differences in dynamics of the changes of several
protease genes such as cathepsins, caspases, matrix metalloproteinases
and plasminogen activators. Most genes were acutely upregulated while
others were mainly activated during the latent phase. Interestingly sev-
eral proteolytic genes were still elevated in the chronic epileptic phase.
Various protease inhibitors followed a similar time course.
Conclusion: The identification of activated genes involved in proteol-
ysis at critical phases during epileptogenesis could point to potential time
specific targets for intervention. The fact that several proteolytic genes
were still activated in the chronic epileptic phase makes them interesting
candidates to modify and slow down seizure progression.
035
COMMON TRAITS IN ALTERATIONS OF PATTERNS OF
GENE EXPRESSION ACROSS DIFFERENT ANIMAL MODELS
OF EPILEPTOGENESIS
1K. Lukasiuk, 1M. Dabrowski, 1A. Adach, and 2A. Pitka¨nen (1The
Nencki Institute of Experimental Biology, Polish Academy of Sciences,
Warsaw, Poland, 2A.I.Virtanen Institute For Molecular Sciences, Uni-
versity of Kuopio, Kuopio, Finland)
Purpose: The main goal of this study was to identify common fea-
tures in the molecular response to epileptogenic stimuli across different
animal models of epileptogenesis. We were searching for highly rep-
resented functional gene classes (GO terms) within the data sets, and
individual genes that appeared in several data sets, and therefore, could
be of particular importance for epileptogenesis.
Method: Fifteen papers describing alterations in the transcription
following status epilepticus or traumatic brain injury were selected
for analysis. To detect overrepresented GO terms we used GOstat
(http://gostat.wehi.edu.au). To find a particular gene with altered expres-
sion, all data were re-annotated using a purpose-built relational database
and comparisons were performed with SQL queries embedded in a script-
ing language. The analysis was performed at different time windows
following the insult: 30 min to 9 h; 1–4 d; and ≥14 days.
Results: Our analysis revealed that epileptogenic insults induce sig-
nificant changes in gene expression within a subset of predefined GO
terms. We also found individual genes for which expression changed
across different models of epileptogenesis. Alterations in gene expres-
sion appear time-specific and underlie a number of processes that are
linked with epileptogenesis, such as cell death and survival, neuronal
plasticity, or immune response. Supporting information containing sum-
mary of genes with altered expression and results of analysis of GO terms
can be viewed at http://www.nencki.gov.pl/labs/epg.htm.
Conclusion: Application of bioinformatic tools to compare the avail-
able literature on global analysis of gene expression following epilepto-
genic insults highlights most prominent phenomena that underlie reor-
ganisation of the epileptogenic circuitry in the brain.
036
INVESTIGATION OF ACUTE HIPPOCAMPAL INJURY FOL-
LOWING STATUS EPILEPTICUS USING MRI AND PRO-
TEOME ANALYSIS
M. Choy (UCL Institute of Child Health, London, UK)
Purpose: Status epilepticus (SE), in humans, may be associated with
hippocampal injury, epileptogenesis and development of temporal lobe
epilepsy. The purpose of this MRI and proteomics study is to investi-
gate the mechanisms underlying these relationships using the lithium-
pilocarpine model.
Method: Pilocarpine (n = 5) or saline (n = 5) was administered to
adult Sprague-Dawley rats. MRI measurements of CBF and T2 were
performed before injections, immediately after, 1 day and 2 days after
SE. On day 2, animals were sacrificed for proteome analysis using 2D
gels. Statistical analyses were performed using 2-way repeated measures
ANOVA.
Results: Significant interactions between treatment and time were
observed for both T2 (F = 3.86, p = 0.05) and CBF (F = 7.01, p
= 0.003) in the hippocampus. Proteome analysis on day 2 indicated
that there was at least a five-fold upregulation of heat shock protein
27 (HSP27) and dihydropyrimidinase related protein-2 (DRP-2) when
compared to controls.
Conclusion: We demonstrated that 2 days following SE, both T2
and CBF increased in the hippocampus with concomitant upregulation
of HSP27 and DRP-2. Over-expression of HSP27 has been shown to
be neuroprotective following SE (Akbar MT et al. J Biol Chem 2003;
278(22):19956–65.) and DRP-2 has been identified as a marker of new-
born neurons (Minturn JE et al. J Comp Neurol 1995; 355(3):369–79).
The parallel changes observed in both MRI and proteomics at 2 days
suggest that these proteins may have functional consequences in the hip-
pocampus following SE. Further studies are required to elucidate the
contribution of these proteins in epileptogenesis.
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037
ELECTROCLINICAL FEATURES OF A FAMILY WITH SCN1A
LOSS-OF-FUNCTION MUTATION ASSOCIATED WITH SIM-
PLE FEBRILE SEIZURES
1,3A. Gambardella, 2M. Mantegazza, 1,3A. Labate, 1E. Colosimo, 2R.
Rusconi, 4E. Schiavon, 3F. Annesi, 4R. Cassulini, 3S. Carrideo, 5R.
Chifari, 5M. Canevini, 5R. Canger, 2S. Franceschetti, 3G. Annesi,
4E. Wanke, and 1,3A. Quattrone (1Institute of Neurology, University
Magna Græcia, Italy, 2Department of Neurophysiopathology, Istituto
Neurologico C. Besta, Milano, Italy, 3Institute of Neurological Sciences,
National Research Council, Mangone, Cosenza, Italy, 4Department of
Biotechnologies and Biosciences, University of Milano Bicocca, Mi-
lano, Italy, 5Regional Centre of Epilepsy, San Paolo Hospital, Milano,
Italy)
Purpose: To report in detail electroclinical features of a large family
in which we recently identified a missense mutation (M145T) of SCN1A
gene.
Method: We studied a family comprising 35 members spread over 4
generations. Among 14 affected individuals, 13 living members (7 males,
mean age 36.6 ± 20.4) underwent a complete electroclinical evaluation.
Peripheral blood samples were obtained for DNA extraction from 23
members of the family.
Results: The neurologic and psychiatric status of all 13 affected sub-
jects was normal. All 13 affected family members had febrile seizures
(FS). In details, 9 had FS only, 3 had FS and temporal lobe epilepsy (TLE)
and 1 had post-traumatic epilepsy. None had febrile seizures beyond the
age of six. Only 2 out of 9 patients with FS have had rare complex febrile
seizures. In 2 of the 3 patients with FC-TLE the MRI study revealed a
mesial temporal sclerosis. All affected members had a M145T within the
S1 segment of domain I (DIS1) of the SCN1A causing a loss of function.
Conclusion: Our findings illustrate that SCN1A mutations can cause
simple FS associated with TLE, which differ from the characteristic
clinical spectrum of GEFS+. It is questionable if this unusual phenotype
might be at least in part related to the fact that M145T is the first missense
mutation found in DIS1 of SCN1A.
038
MICRODELETIONS OF THE SCN1A GENE MAY BE COMMON
IN “SCN1A-MUTATION-NEGATIVE” SMEI PATIENTS
1L. Claes, 1A. Suls, 1,2K. Claeys, 1D. Goossens, 3R. van Luijk,
3S. Scheers, 1L. Deprez, 1D. Audenaert, 1T. Van Dyck, 3S. Beeck-
mans, 1,2I. Smouts, 2,4B. Ceulemans, 4,5L. Lagae, 5G. Buyse, 6N.
Barisic, 7J. Misson, 1J. Del-Favero, 3J. Wauters, and 1.2P. De
Jonghe (1Flanders Interuniversity Institute For Biotechnology (VIB8),
Antwerp, Belgium, 2University Hospital Antwerp, Antwperp, Belgium,
3University of Antwerp, Antwerp, Belgium, 4Epilepsy Center For Chil-
dren And Youth, Pulderbos, Belgium, 5University Hospital Gasthuis-
berg, Leuven, Belgium, 6University Medical School, Zagreb, Croatia,
7University of Liege, Liege, Belgium)
Purpose: Severe myoclonic epilepsy of infancy (SMEI) or Dravet
syndrome is a severe epilepsy syndrome that has an onset in the first
year of life and usually starts with febrile generalised or unilateral
clonic seizures. Later in life, other types of seizures, retardation of the
psychomotor development and other progressive neurological deficits
are observed. In 30–70% of SMEI patients, truncating and missense
mutations in the neuronal voltage-gated sodium-channel -subunit gene
(SCN1A) have been identified. About 50% of patients have truncating
mutations which predict be loss-of-function alleles. Because mutation
detection studies use PCR sequencing or conformation sensitive gel
electrophoresis, microdeletions, which are also predicted to be loss-of-
function alleles, can easily escape detection.
Method: We selected 11 SMEI patients without a SCN1A mutation
on sequencing analysis. In addition, none of these patients were het-
erozygous for any of the single nucleotide polymorphisms (SNPs) in
SCN1A indicating that they were either homozygous for all SNPs or
hemizygous due to a microdeletion of the gene. We subsequently stud-
ied these patients with quantitative multiplex PCR for the identification
of microdeletions in SCN1A.
Results: We observed 3 patients missing one copy of the SCN1A gene.
All 3 microdeletions were confirmed by fluorescence in situ hybridisa-
tion (FISH).
Conclusion: These findings demonstrate that a substantial percent-
age of “SCN1A-mutation-negative” SMEI patients carry a chromosomal
microdeletion comprising the SCN1A gene and that haploinsufficiency
of the SCN1A gene is a major cause of SMEI.
039
NOVEL SCN2A MUTATION ASSOCIATED WITH BENIGN FA-
MILIAL NEONATAL INFANTILE SEIZURES IN A BULGARIAN
FAMILY
1L. Deprez, 1,2A. Jordanova, 3D. Christova, 1L. Claes, 2R. Ra-
jnova, 2I. Kremensky, 1,4K. Claeys, 1A. Suls, and 1,4P. De Jonghe
(1Department of Molecular Genetics, Neurogenetics Research Group,
Flanders Interuniversity Institute of Biotechnology, University Antwerp,
Antwerp, Belgium, 2Laboratory of Molecular Pathology, Sofia Medical
University, Sofia, Bulgaria, 3Department of Pediatrics, Sofia Medical
University, Sofia, Bulgaria, 4Division of Neurology, University Hospital
Antwerp, Antwerp, Belgium)
Purpose: Mutations in voltage–gated sodium channel genes are
known to be responsible for inherited idiopathic epilepsy syndromes.
Missense mutations in SCN2A were identified as a cause for benign fa-
milial neonatal-infantile seizures (BFNIS). BFNIS is characterised by
afebrile secondarily generalised partial seizures with an age of onset
from the first days of life to 7 months. The outcome is usually good with
a remission by 12 months. In addition, a SCN2A mutation was found in a
small Japanese family with phenotypes of febrile and afebrile seizures,
where it was difficult to apply a clear syndrome classification.
Method: SCN2A was analysed in 24 unrelated patients. These pa-
tients were diagnosed as BFNIS, the related syndromes benign familial
neonatal convulsions (BFNC) and benign familial infantile convulsions
(BFIC), or GEFS+.
Results: One SCN2A mutation was detected in a Bulgarian patient
with BFNIS. This missense mutation causes a substitution of methionine
with valine at position 252 (p.M252V), located within segment S5 of
the first transmembrane domain in the protein. Further analysis of the
three-generation family revealed cosegregation of this mutation with the
disease phenotype. The patients in the family experienced several clusters
of generalised tonic and/or clonic seizures within the first year of life.
The outcome was good in all patients, none of them had psychomotor
retardation or required long-term anticonvulsant treatment.
Conclusion: Here we report one novel SCN2A mutation in a family
with a classical BFNIS phenotype. The absence of SCN2A mutations
in patients with other phenotypes confirms the specificity of SCN2A
mutations for BFNIS.
040
ASSOCIATION BETWEEN THE SYNAPTIC VESICLE PRO-
TEIN SV2A AND MESIAL TEMPORAL LOBE EPILEPSY
A. Heils and C. Elger (Clinic of Epileptology, University Clinic of
Bonn, Germany)
Purpose: The novel antiepileptic drug levetiracetam confers its ther-
apeutic effects by a binding interaction with the synaptic vesicle protein
SV2a. The gene encoding SV2a therefore defines a novel candidate for
genetically determined epilepsies. In this study we tested the hypothesis
that genetic variation in SV2a is associated with increased susceptibility
to mesial temporal lobe epilepsy (mTLE) in cases with familial risk.
Method: We resequenced the SV2a gene to search for a genetic vari-
ation. We tested these in two independent study samples comprising a
total of 296 mTLE patients who report a family history of epilepsy with
at least 1 affected first and/or second degree relative. Statistical analysis
was done by chi-square statistics. A two-tailed type I error rate of 5%
was chosen as the significance level.
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Results: We identified a novel common polymorphism (IVS6-60G/A)
which is significantly associated with mTLE at familial risk. Geno-
type, and allele frequencies showed an overrepresentation of the A-allele
(p = 0.0001, df = 1, OR = 1.74) and the GA/AA genotypes (p = .0003,
df = 1, OR = 1.78) among patients compared with 515 ethnically
matched genomic controls.
Conclusion: Our data strongly suggest a role of SV2a in mTLE.
The mechanisms by which the intronic polymorphism leads to this
observation are still under investigation. It either confers functional prop-
erties or is in linkage disequilibrium with another as yet unidentified
sequence variant.
041
NEW SUSCEPTIBILITY LOCUS AT 13Q13.2 FOR EPILEPSY-
RELATED PHOTOSENSITIVITY IN A COMBINED EUROPEAN
GENOMEWIDE LINKAGE SCAN
1D. Pinto, 2U. Tauer, 3,4S. Lorenz, 2H. Muhle, 5B. Neubauer,
6S. Waltz, 3,4K. Lenzen, 7G. Rudolf, 8G. de Haan, 1D. Lind-
hout, 1B. Koeleman, 3,4T. Sander, 1D. Kasteleijn-Nolst Trenite´, and
2U. Stephani (1Complex Genetics Section, DBG-Dept. Medical Ge-
netics, University Medical Center Utrecht, Utrecht, The Netherlands,
2Clinic for Neuropediatrics, Kiel University, Germany, 3Gene Map-
ping Center, Max-Delbru¨ck-Center, Berlin, Germany, 4Dept. Neurol-
ogy, Charite´ University Medicine, Berlin, Germany, 5Clinic for Neuro-
pediatrics, University Giessen, Germany, 6Children’s Hospital, Cologne,
Germany, 7Strasbourg University, Strasbourg, France, 8Stichting Epilep-
sie Instellingen Nederland, Heemstede, The Netherlands)
Purpose: Photosensitivity or photoparoxysmal response (PPR) is an
heritable EEG trait highly prevalent in idiopathic generalised epilepsies
(IGEs). It is characterised by an abnormal cortical response to visual
stimuli and can be evoked by standardised intermittent photic stimulation
in the EEG laboratory. Given the strong association with IGEs, PPR
can be regarded as a potential endophenotype for IGEs. Recently two
independent genomewide scans on PPR identified four susceptibility loci
in the chromosomal regions 7q32, 16p13 and 6p21, 13q31, varying on
the familial background of epilepsy syndromes.
Method: To search for risk factors that are independent of familial
epilepsy background we pooled genotype data from all 75 multiplex fam-
ilies and performed a combined nonparametric linkage (NPL) analysis.
To account for genetic heterogeneity, family members were classified
under a broad (all PPR types I-IV n = 205 affected) and a narrow (only
PPR types III and IV; n = 106 affected) trait definition.
Results: We found evidence for a novel, shared locus on 13q13.2 at
D13S1493 under broad (PNPL = 3.64 × 10−4) and narrow (PNPL = 6.81
× 10−5) trait definitions, achieving empirical genomewide significance
for the narrow model (Pgw = 0.0132). Accentuated linkage under the
narrow trait definition (generalised PPRs) suggests an increase in pheno-
typic homogeneity, emphasising the close genetic relationship between
generalised PPRs (PPR types III and IV) and IGEs.
Conclusion: These findings suggest that the locus on 13q13.2 rep-
resent a common genetic component for visually induced and sponta-
neously occurring generalised spike and wave EEG discharges underly-
ing generalised PPR in IGE patients.
042
FEBRILE SEIZURES AND IDIOPATHIC EPILEPSY: A CLINI-
CAL AND GENETIC STUDY IN A FINNISH FAMILY
1,2,4A. Sire´n, 3A. Nuutila, 1A. Anttonen, 4S. Abboud, 2M.
Koivikko, 4M. Pandolfo, and 1A. Lehesjoki (1Neuroscience Center
and Folkhalsan Institute of Genetics, University of Helsinki, Helsinki,
Finland, 2Department of Pediatrics, Tampere University Hospital, Tam-
pere, Finland, 3Department of Pediatrics, Central Hospital of South Oe-
strobothnia, Seina¨joki, Finland, 4Department of Neurology, Erasme Hos-
pital, Brussels, Belgium)
Purpose: We describe a three-generation family with febrile seizures
(FS), childhood absence epilepsy (CAE) and generalised epilepsy with
focal abnormalities in EEG. We report the results of a genome-wide scan.
Method: Detailed clinical description of FS and epilepsy was col-
lected from medical files and by interviewing patients and their parents
during a field trip. DNA was extracted from venous blood with stan-
dard methods. The genome-wide scan was carried out in the Finnish
Genome Center with 382 microsatellite markers using an ABI 3730 cap-
illary sequencer. Two-point lod scores were calculated with the MLINK
programme assuming autosomal dominant inheritance with reduced
penetrance.
Results: Out of 9 affected individuals 4 had experienced one to four
common FS between the ages of 1 and 4.5 years. Three patients had
CAE; 1 also had one preceding FS. One boy, on two occasions, had a
seizure starting with an absence and evolving to a generalised tonic–
clonic seizure. He had an EEG with 3 Hz spike-wave discharges and
focal abnormality in the right mid-temporal region. One boy had status
epilepticus once and no other seizures. MLINK analysis of the genome-
wide data revealed the highest lod score of 1.76 at two markers: D2S305
and D16S423.
Conclusion: Several individuals in the family are affected with FS or
epilepsy. Initial analysis of the genome scan data did not reveal a single
locus when autosomal dominant inheritance was assumed. Fine mapping
combined with linkage analysis using different inheritance patterns is
needed to identify a putative major epilepsy susceptibility locus in this
family.
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COMPETING RISKS OF ANTIEPILEPTIC DRUG FAILURE:
IMPORTANCE, MEASUREMENT AND ANALYSIS
1P. Williamson, 1C. Tudur Smith, 2J. Sander, and 1A. Marson
(1University of Liverpool, Liverpool, UK 2University College London,
UK)
Purpose: Retention time (time to treatment failure) is a commonly
used outcome in antiepileptic drug studies. In this paper we present the
issues involved and demonstrate the importance of a full investigation
of this outcome.
Method: Fifteen antiepileptic drug monotherapy trials and an add-on
therapy clinic cohort are used to illustrate both design and analysis is-
sues. Cumulative incidence analysis is described and applied to a dataset
comparing lamotrigine and topiramate. The results are compared to the
more common approach using standard survival analysis methods.
Results: A nonsignificant difference in overall retention between lam-
otrigine and topiramate (logrank test statistic = 2.58, 1 degree of free-
dom, p = 0.108) masked highly significant differences in opposite direc-
tions between the drugs with respect to withdrawals due to side effects
(Gray’s test statistic = 12.26, 1 degree of freedom, p = 0.0005) and
poor seizure control (Gray’s test statistic = 34.58, 1 degree of freedom,
p < 0.0001).
Conclusion: Retention time can be measured reliably but care is
needed to collect sufficient information on reasons for drug withdrawal
to allow a competing risks analysis. Important differences between the
profiles of antiepileptic drugs may be missed unless appropriate statis-
tical methods are used to fully investigate retention time. Cumulative
incidence rather than logrank analysis is likely to be a more powerful
approach for comparison of standard and new antiepileptic drugs.
044
MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY TRIAL
INVESTIGATING SAFETY, TOLERABILITY AND PHARMA-
COKINETICS OF INTRAVENOUS SPM 927 IN SUBJECTS
WITH PARTIAL SEIZURES
1V. Biton, 2W. Rosenfeld, 3R. Mameniskiene, 4N. Vaiciene, 5J.
Whitesides, 6B. Schiltmeyer, and 7K. Sommerville (1Arkansas
Epilepsy Clinic, Little Rock, USA, 2The Comprehensive
Epilepsy Care Center for Children and Adults, St. Louis,
MO, USA, 3Vilnius University Hospital, Vilnius, Lithua-
nia, 4Kaunas Medical University Hospital, Kaunas, Lithuania,
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5Schwarz Biosciences, Inc., RTP, USA, 6Schwarz Biosciences, GmbH.,
Monheim, Germany, 7Schwarz Biosciences, Inc., RTP, USA)
Purpose: SP616 was a double-blind, double-dummy investigation
of the pharmacokinetics, safety and tolerability of intravenous (iv) la-
cosamide (LCM) as a replacement of adjunctive oral LCM in adults with
partial-onset seizures.
Method: Subjects (n = 60) currently receiving adjunctive, stable,
twice daily (bid) doses (200 to 600 mg/day) of oral LCM were ran-
domised 2:1 to receive iv LCM plus oral placebo (PBO) bid or iv PBO
plus oral LCM bid for two consecutive days. Subjects (n = 30) in Cohort
A received 60-minute infusions. Cohort B subjects (n = 30) received
30-minute infusions. Serial ECGs and vital signs data were collected.
Pharmacokinetic sampling was performed for the morning dose on day
2 for both cohorts at predose and hours 0.5, 1, 1.5, 2, 4, 8, and 12.
Results: Fifty-nine subjects completed the trial. No clear differences
in AE reports, ECG intervals, blood pressure, or heart rate were observed
for iv versus oral dosing.
60- and 30-minute LCM infusions resulted in similar plasma concen-
tration time curves and pharmacokinetic parameters compared with oral
administration after normalisation for body weight and dose. The tmax
most commonly occurred at the end of LCM infusion (eg, 30 min for
Group B) and later for oral LCM dosing (eg, 1.5 to 4 hr for 55% of
subjects in Group B).
Conclusion: The safety profile following 60- and 30-minute LCM
infusions was comparable to oral LCM. In addition, both LCM infu-
sion rates resulted in similar pharmacokinetics to oral dosing. Funding
supported by: Schwarz Biosciences, Inc.
045
INCREASED APPARENT ORAL CLEARANCE OF VALPROIC
ACID DURING INTAKE OF COMBINED CONTRACEPTIVE
STEROIDS IN WOMEN WITH EPILEPSY
1C. Galimberti, 2I. Mazzucchelli, 1C. Arbasino, 3V. Chiesa, 2C. Fattore,
and 1,2E. Perucca (1IRCCS Institute of Neurology “C. Mondino” Foun-
dation, Pavia, Italy, 2Clinical Pharmacology Unit, Department of Inter-
nal Medicine And Therapeutics, University of Pavia, Italy, 3Regional
Epilepsy Center, S. Paolo Hospital, University of Milan, Italy)
Purpose: Combined contraceptive steroids (CS) stimulate the glu-
curonidation of paracetamol, some benzodiazepines, and lamotrigine. As
a result of this, the serum levels of lamotrigine are considerably higher
at the end of a 7-day CS-free interval than during CS intake (Epilepsia
2004;45(suppl 7:330). Valproic acid (VPA) undergoes extensive glu-
curonide conjugation, and a case report suggested that VPA clearance
is also increased by CS (Epilepsia 2005;46:970–1). We assessed serum
VPA concentration in women with epilepsy in relation to a CS intake
cycle.
Method: Nine women aged 18–45 years and stabilised on VPA (500–
1500 mg/day) in combination with oral or transdermal CS, without asso-
ciated antiepileptic drugs, were assessed on two randomised occasions:
(i) on the last day of CS intake, and (ii) on day 4 to 7 of the CS-free
interval. Serum VPA levels were determined by immunoassay.
Results: Mean total VPA concentrations were 21% higher during the
CS-free interval than during CS intake (425 ± 184 vs 350 ± 145 (μmol/L
respectively, means ± SD, p = 0.002). Unbound, pharmacologically
active, VPA levels increased in parallel by 41%, from 39 ± 25 to 55 ±
37 (μmol/L (p = 0.005).
Conclusion: Serum VPA concentrations increase during the interval
of interruption of CS intake. This is consistent with a stimulating effect
of CS on the enzymes responsible for VPA metabolism, presumably
due to induction of glucuronosyltransferases by ethinyloestradiol. The
magnitude of interaction varies across patients, and may be clinically
significant in some cases.
046
PROPHYLACTIC EFFECT OF FOLIC ACID SUPPLEMEN-
TATION ON SPONTANEOUS ABORTION IN WOMEN WITH
EPILEPSY UNDERGOING ANTIEPILEPTIC THERAPY
1S. Pittschieler, 2C. Brezinka, 1E. Trinka, 3B. Jahn, 1I. Unterberger, 1J.
Dobesberger, 1G. Walser, 1A. Auckenthaler, 1N. Embacher, 1G. Bauer,
and 1G. Luef (1Department of Neurology, Innsbruck Medical Univer-
sity, Austria, 2Department of Gynecology, Innsbruck Medical Univer-
sity, Austria, 3Department For Medical Statistics, Informatics and Health
Economics, Innsbruck Medical University, Austria)
Purpose: Antiepileptic drugs (AEDs) like phenytoin (PHT), carba-
mazepine (CBZ), barbiturates and valproic acid (VPA) interfere with
folic acid absorption and metabolism, and consequently can elevate risk
for adverse pregnancy outcome. Our objective was to study the prophy-
lactic effect of folic acid supplementation with regard to spontaneous
abortion in pregnant women receiving AED therapy and compare bene-
fits of most common dosage and pre- and postconceptional commence-
ment.
Method: Retrospective analysis of data from our epilepsy data bank
completed with medical records and patients interviews and in some
cases prospective examination of 388 pregnancies in 244 patients of the
Department of Neurology of Innsbruck University Hospital from 1971
to 2004.
Results: Pregnancies with folic acid supplementation showed a sig-
nificantly reduced rate of spontaneous abortions. In women without folic
acid supplementation spontaneous abortion occurred in 14.5% compared
to 6.3% when folic acid had been taken during pregnancy (odds ratio:2.6,
95% CI:1.2–5.3, p = 0.007). Supplementation with 5 mg/d had no ad-
vantage over 0.4 mg/d. Preconception commencement of supplementa-
tion showed no larger benefit. Folate benefits were higher in pregnan-
cies under AED monotherapy than under polytherapy. With regard to
monotherapies, only women in the group taking VPA supplementation
had a significant benefit. Other examined monotherapies (CBZ, PHT,
PB, LTG, and OXC) showed no significant results.
Conclusion: This study confirms the prophylactic effect of folic acid
supplementation on spontaneous abortion. Data did not show clear ad-
vantage for dosage of 5 mg/day or preconception commencement, but
underlined the particular profit for women under AED monotherapy,
especially for those who are taking VPA.
047
DRUG INTERACTION BETWEEN PHENPROCOUMON AND
VALPROATE: CLINICALLY RELEVANT INCREASE OF INR IN
PATIENTS WITH ISCHEMIC STROKE AND SYMPTOMATIC
SEIZURES
B. Tettenborn, A. Felbecker, and B. Weder (Dept. of Neurology, Kan-
tonsspital St. Gallen, Switzerland)
Purpose: Cotreatment with the oral anticoagulant phenprocoumon
and valproate is common, especially in patients suffering from cardioem-
bolic stroke and symptomatic seizures. There are no reports of clinically
relevant interactions between these drugs.
Method: We reviewed the data of all patients of our neurological
department within the last 38 months. Two groups of patients were iden-
tified: group 1 was treated with valproate in addition to established phen-
procoumon therapy, whereas in group 2 phenprocoumon was started ei-
ther at the same time or in addition to valproate. For group 1, the latest
available International Normalized Ratio (INR) values were achieved,
mean values calculated and correlated to the maximum INR values
shortly after the initiation of valproate. Patients were excluded if the
dosage of the drugs during the relevant time was unknown or compli-
ance was insufficient.
Results: 18 patients received a combined treatment with valproate and
phenprocoumon. Three patients met exclusion criteria, the remaining pa-
tients were divided into group 1 (11 patients) and group 2 (4 patients).
Means of INR values in group 1 before treatment with valproate ranged
between 1.6 and 3.2 (SD 0.05–1.22) and raised significantly after initi-
ation of valproate (mean +77%, range from +45 to +138%). In group
2, the intended INR values were achieved with unexpectedly low doses
of phenprocoumon.
Conclusion: There is a clinically relevant interaction between val-
proate and phenprocoumon. Patients on valproate need unusually low
doses of phenprocoumon for active anticoagulation. In patients receiv-
ing valproate with preexisting phenprocoumon a potentially hazardous
rise of INR has to be observed.
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048
fMRI REVEALS DECLINED PREFRONTAL CORTEX ACTIVA-
TION IN EPILEPSY PATIENTS ON TOPIRAMATE THERAPY
1,2J. Jansen, 1,3A. Aldenkamp, 1,3H. Majoie, 1,3R. Reijs, 1M. de Krom,
1P. Hofman, 1,2M. Kooi, 1,2K. Nicolay, and 1,2W. Backes (1Maastricht
University Hospital Maastricht University Hospital, Maastricht, The
Netherlands, 2Eindhoven University of Technology, Eindhoven, The
Netherlands, 3Epilepsy Centre Kempenhaeghe, Heeze, The Netherlands)
Purpose: Topiramate treatment for patients with epilepsy is frequently
associated with cognitive side effects, which can be the major reason
for drug discontinuation, even when the drug has a favourable effect on
seizure frequency. In this study, the functional neuroanatomy of language
was visualised in patients with epilepsy on topiramate therapy.
Method: A group of 5 patients with epilepsy on topiramate therapy,
and a control group of 10 epilepsy patients, not on topiramate therapy,
were examined using neuropsychological testing and functional mag-
netic resonance imaging of covert word generation, to examine brain
activation abnormalities associated with topiramate-induced cognitive
impairment.
Results: The control epilepsy patients showed a typical distribution of
language-activation involving the left inferior prefrontal cortex (IPC) and
the medial prefrontal cortex (MPC), whereas the patients on topiramate
therapy showed significantly less activation in these language-mediating
cortical regions (p = 0.01) together with significantly lower neuropsy-
chological language scores (p = 0.002). Furthermore, the IPC and MPC
display a higher relat;oive sensitivity to TPM treatment than other brain
regions.
Conclusion: These findings suggest that topiramate has a crit-
ical effect on the cerebral neural systems that mediate expressive
language.
Tuesday July 4, 2006
12:00–13:30
Hall 5A
Platform Session
Adult Epileptology II
049
NEGATIVE MYOCLONUS NOT ATAXIA IS THE MAIN REA-
SON FOR LOCOMOTION DISABILITY IN PATIENTS SUFFER-
ING FROM UNVERRICHT-LUNDBORG DISEASE
H. Vogt, T. Baisch, and I. Mothersill (Swiss Epilepsy Center, Zurich,
Switzerland)
Purpose: Unverricht-Lundborg disease or EPM1 is one type of the
progressive myoclonus epilepsies. It is generally accepted that locomo-
tion disablement is due to cerebellar ataxia. We observed that in the
course of the disease negative myoclonias are one of the most striking
symptoms and hypothesised that they were the main reason for locomo-
tor disability.
Method: Negative myoclonias are very difficult to recognise without
ictal polygraphic recordings in freely moving patients. We performed
ictal polygraphic video-EEG-recordings (16 channel EEG, 8 channel
surface EMG) in 14 patients with EPM1 (Unverricht-Lundborg Disease),
all proven by mutation of the CSTB Gene. Two or more recordings were
performed in 9 EPM1 patients with a mean interval of 12 years.
Results: All 14 patients had documented negative myoclonias in their
polygraphic recordings when standing or walking. The duration of the
atonia was between 100 and 200 ms. Except 4 patients with EPM1 all
where wheelchair bound after a mean disease duration of 19 (10–31)
years, mainly due to fear of falls, caused by the frequent negative my-
oclonias.
Conclusion: We have shown, using simultaneous EEG/EMG record-
ings in freely moving patients, that the locomotor disability is in fact
mainly due to negative myoclonus in voluntary innervated muscles.
050
EPILEPSY AND DRIVING: REPORT OF A EUROPEAN WORK-
ING GROUP
E. Schmedding, G. Wetherall, E. Beghi, J. Burcet Darde, B. Gappmaier,
J. Kirker, G. Kraemer, M. Ojala, A. Sundqvist, E. Valde`s, H. Vespigniani,
and J. Worm-Petersen (Second Working Group on Epilepsy and Driving
to the Driving Licence Committee of the European Union)
Purpose: Following an earlier workshop, organised by the ILAE/IBE
in 1995/1996, national legislation was adapted to an important degree
in several European countries, but remained unchanged in others. This
situation led to a renewed call for harmonisation and the installation
of the working group on epilepsy and driving by the Driving Licence
Committee of the European Union. Later, some members of the ILAE
and the IBE were added to the working group. The purpose was to give an
overview of the literature and to devise recommendations for European
Law in the hope of harmonising regulations all over Europe.
Method: In order to do so, we had to find a criterion for acceptable risk,
find the temporal relationship between the period of seizure-freedom
and risk decrease in different situations and link this risk to the period of
seizure-freedom via a general theory of risk. The risk for the population
(attributable risk) is low, theoretically and on calculation. The criterion
for acceptable relative risk should mainly be decided on the basis of the
risk for the driver. In comparison with other accepted risk variations in
the population (e.g. relative risk [RR] for someone older than 75 years
of age is 3 or higher) the criterion for individual risk was expressed as a
RR of 2 to 3 and used to set the duration of seizure-free periods in dif-
ferent epileptological situations (first seizure, epilepsy, etc). Where data
were scant, consensus was applied. Attention was given to the existing
regulations in Member States.
Results: The criteria, thus devised are internally consistent. They are
conceived as minimum criteria, because the national legislation of the
Member States can be more strict, but not more lenient.
Conclusion: New medical criteria for driving and epilepsy were de-
vised for use in the European Union. A short review of the procedure
and the resulting criteria will be given and problems addressed.
051
TREATMENT OF STATUS EPILEPTICUS: A RETROSPECTIVE
ANALYSIS
1E. Trinka, 1J. Dobesberger, 1G. Bro¨ssner, 1G. Walser, 1N. Embacher,
1I. Unterberger, 1S. Pittschieler, 1G. Luef, 2E. Haberlandt, 1A. Aucken-
thalre, 1E. Schmutzhard, and 1G. Bauer (1Universita¨tsklinik Fu¨r Neu-
rologie, Innsbruck, Austria, 2Universita¨tsklinik Fu¨r Kinder-Und Jugend-
heilkunde, Innsbruck, Austria)
Purpose: Status epilepticus (SE) is a neurological emergency. So far,
IV benzodiazepines and phenytoin are recommended as the first-line
antiepileptic drugs for SE. IV valproate is widely used, but RCTs com-
paring PHE and VPA are not available. This study aimed to investigate
the overall success rates with various AEDs in a large series of 248
patients.
Method: Retrospective analysis of all patients with SE, admitted to a
university medical centre serving as the only neurology and emergency
department in that area, between 2001 and 2004. SE was defined as repet-
itive or ongoing epileptic seizures lasting at least 10 minutes. Coma with
severe hypoxic or traumatic brain injury and “status-like EEG patterns”
was not included in this series. Clinical variables (type, duration and ae-
tiology of SE) as well as AED treatment were noted. Responsiveness to
AED treatment, adverse events and neurological outcome was assessed
by chart review.
Results: 248 pts (110w/138m) with SE were analysed (mean age
56yrs, sd23, range 1–94). SE was convulsive in 194 (78%, (69 fo-
cal motor, 125 GTC-SE) and nonconvulsive in 54 (22%). Preexisting
epilepsy was found in 50% (43% focal, 7% generalised). Aetiology was
acute symptomatic in 46%, cryptogenic in 4%. Overall SE was stopped
in 92% [95% CI 89–95.6]. Success rates were 56% [95% CI 49.5–61.8]
with the 1st drug, 19% [95% CI 13.7–23.4] with the 2nd and 10% [95%
CI 6.7–14.3] with the 3rd AED. IV VPA was used in 72 (29%) pts. Suc-
cess rates with VPA were 69% [95% CI55.4–82.4], with BDZ 63% [95%
CI56.2–70], with PHE 51% [95% CI36.8–65.4], with barbiturates 77%
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[95% CI64.5–88.7] and with TPM 62% [95% CI29–96]. VPA induced
encephalopathy occurred in 2 (3%) pts.
Conclusion: VPA is well tolerated in the management of SE. Success
rates are comparable to BDZ and PHE, however, large RCTs are needed
to detect differences between the treatment options.
052
LAFORA DISEASE: A GENETIC AND PHENOTYPIC STUDY
OF A LARGE CASE SERIES
C. Gomez Abad, P. Go´mez-Garre, E. Gutie´rrez-Delicado, and J.
Serratosa (Fundacio´n Jime´nez Dı´az, Madrid, Spain)
Purpose: To perform a clinical and genetic study of a large series of
Lafora disease patients.
Method: We performed a clinical and mutational analysis of 104
patients, belonging to 82 unrelated families, with a clinical diagnosis of
Lafora disease. Statistical analysis was performed using SPSS software
for Windows (version 11.5).
Results: A similar male/female ratio was found. Progression from age
at onset to complete deterioration of mental status was shorter in males.
Brain MR was available in 37 cases: in 34 cases it was normal and in
3 cerebellar atrophy was observed. Photosensitivity was present in 27
out of 36 patients tested. Age at onset ranged from 4 to 22 years and
progression of the disease from 5 to 9 years. We identified 72 different
mutations in EPM2A and EPM2B. The R241X in EPM2A is the predom-
inant mutation. In patients with EPM2B mutations time of progression of
the disease is increased, and age at which patients die and onset of gait
disturbance occur several years later. Simple partial occipital seizures
are more common in EPM2A patients.
Conclusion: A slightly milder clinical course associated with EPM2B
mutations is confirmed. Males present a shorter progression from age
at onset to complete deterioration of mental status. Photosensitivity and
normal brain MRs are common in Lafora disease.
053
EYELID POSITIONS DURING EPILEPTIC VERSUS PSY-
CHOGENIC SEIZURES
1,2F. Donati, 2M. Kollar, 2H. Pihan, 1,3G. Vatti, and 2H. Mathis
(1Department of Neurology, Spitalzentrum Biel, Biel-Bienne, Switzer-
land, 2Department of Neurology, Uinversity Hospital Inselspital, Bern,
Switzerland, 3Department of Neurology, Policlinico le Scotte, Univer-
sity of Siena, Italy)
Purpose: Aim of this study was to evaluate whether the position of
the eyelids (open or closed) helps to differentiate epileptic versus psy-
chogenic seizures.
Method: Forty adults with epileptic seizures (20 with frontal, 20 with
temporal epilepsy) and 40 patients with psychogenic seizures were in-
cluded in the study. We analysed retrospectively by video analysis the
position of the eyelids before the clinical beginning of the seizure and
during the first 30 seconds after seizure onset. A multivariate variance
analysis was performed using the duration of open eyes within the anal-
ysis time window after seizure onset as the dependent variable (ranked
values). Seizure type (temporal, frontal, psychogenic), gender (male,
female) and eyelid position before seizure onset (opened, closed) con-
stituted the independent variables.
Results: A highly significant effect of seizure type was found indicat-
ing that eyelids were closed significantly longer (p < .001) within the first
30 seconds of psychogenic seizures (20.85s, 69.5% of the time), com-
pared to epileptic seizures of temporal (1.95s, 6.5%) or frontal (9.25s,
30.8%) origin. This difference was more pronounced in male patients
with psychogenic seizures yielding a significant interaction between
seizure type and gender. In addition, a significant interaction between
seizure type and eyelid position before seizure onset indicated that eyes
were mostly kept closed after onset of psychogenic seizures whereas
eyes were opened early in epileptic seizures.
Conclusion: Our results suggest that keeping the eyes closed or clos-
ing them within the first 30 seconds after seizure onset is highly sugges-
tive of a psychogenic nature of a seizure.
054
CAUSES OF LATE SEIZURE RECURRENCE IN PATIENTS
WITH JUVENILE MYOCLONIC EPILEPSY AFTER A LONG
PERIOD OF REMISSION
A. Sindjelic, A. Ristic, N. Vojvodic, S. Jankovic, and D. Sokic (Institute
of Neurology, Clinical Center of Serbia, Serbia and Montenegro)
Purpose: To determine causes of late seizure recurrence in patients
with juvenile myoclonic epilepsy (JME) after a long period of remission.
Method: From approximately 2500 patients from our epilepsy clinic,
we retrospectively identified 105 patients (female 62, mean age 19.8 ±
7.7 years) with established diagnosis of JME. All patients were treated
with antiepileptic drugs (AED) and during a period of at least 1 year, no
seizure of any type occurred.
Results: Median period of follow-up was 4 (range 1–17) years. Ther-
apy included valproate in 87.6% of patients (median dose 500 mg, range
250–2750 mg), lamotrigine, benzodiazepines, topiramate or combina-
tions. Seizures of any type recurred in 76 patients (72.4%) after median
time of 1 (0.5–17) year. Twenty-five patients (32.9%) presented with
myoclonic jerks after 1 (0.58) year, 13 (17.1%) with generalised tonic–
clonic (GTC) seizures after 2 (0.5–12) years, and 38 (50%) with the
combination of both seizure types. The majority of patients had a single
seizure as a recurrence (84.8%), while a series of seizures (13.9%) or pro-
longed deterioration of seizure control (1.4%) occurred rarely. Cause of
seizure recurrence was not obvious in the majority of patients. However,
it was associated with sleep deprivation in 46% and AED withdrawal
in 15.9% of patients, and less frequently, with alcohol or drug abuse,
photic stimulation, or menses. No causative or provoking factors were
identified in 31.8% of patients.
Conclusion: Late recurrences of seizures (mainly of GTC type), after
a long period of remission are not rare in patients with JME despite best-
known therapy. Seizures are probably provoked by sleep deprivation or
some other poorly recognised factors.
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055
SURGICAL TREATMENT OF PARIETAL LOBE EPILEPSY
1M. Podlogar, 1D. Binder, 1H. Clusmann, 2C. Bien, 3H. Urbach, 1J.
Schramm, and 1T. Kral (1Department of Neurosurgery, University of
Bonn, Germany, 2Department of Epileptology, University of Bonn, Ger-
many, 3Department of Radiology, University of Bonn, Germany)
Purpose: Surgical treatment and outcome of parietal lobe epilepsy
(PLE) is poorly understood. The aim of this study was to analyse presur-
gical characteristics, pathologic basis, surgical procedures and postop-
erative outcome in a large group of PLE patients.
Method: A prospective database containing all patients undergoing
epilepsy surgery at the University of Bonn since 1990 was screened for
PLE. Charts, preoperative MRI, surgical reports, and neuropathological
findings were reviewed. Seizure outcome was classified according to
Engel’s score (I–IV).
Results: Forty-one patients with PLE were identified. Twelve patients
had a history complicated by trauma, meningitis/encephalitis or preterm
birth. Preoperative MRI abnormalities were identified in 98%. Lesionec-
tomy of the dominant (n = 20) or nondominant (n = 21) parietal lobe
and additional MST of the motor cortex (n = 11) was performed. Two
patients suffered from surgical and 10 from neurological complications,
including temporary partial Gerstmann syndrome in most cases (n =
8). There was no mortality. Histopathology revealed 17 low grade tu-
mours, 13 cortical dysplasias, 2 cavernous vascular malformations, 7
gliotic scars and 2 others. After a mean follow-up of 43 months, 27 pa-
tients (66%) became seizure-free or had rare seizures (Engel I: 56%;
Engel II: 10%; Engel III: 29%; Engel IV: 5%). Of the 12 patients with an
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unsatisfactory outcome (Engel class III/IV), 9 (75%) had a complicated
history.
Conclusion: PLE is rare but can be safely and effectively treated sur-
gically. A temporary partial Gerstmann syndrome occurs postoperatively
in a significant proportion of patients. Complicating factors in the history
such as trauma or infection portend a poor prognosis for postoperative
seizure outcome.
056
EPILEPSY SURGERY IN THE POSTERIOR PART OF
THE BRAIN: DIAGNOSTIC PROCEDURES AND SURGICAL
OUTCOME
S. Francione, I. Sartori, L. Castana, R. Mai, L. Nobili, M. Cossu, F. Car-
dinale, G. Lo Russo, and L. Tassi (“Claudio Munari” Epilepsy Surgery
Centre, Ospedale Niguarda Ca’ Granda, Milano, Italy)
Purpose: Surgical treatment for epilepsies localised in the posterior
cortex is performed with increasing frequency, nonetheless literature data
are less numerous than in other cerebral localisations. The purpose of
this study is to report our experience with a series of 91 patients operated
on in our Centre from May 1996 to October 2004 in the parietooccipito-
temporal region.
Method: The studied patients were 53 males and 38 females with:
mean age at surgery 24.8 ± 13 years (1–54), mean epilepsy onset 6.9 ±
5.2 years (birth–26), mean epilepsy duration 17.9 ± 11.6 years (1–46).
Seizures were several per month in 13 cases (14.3%), per week in 40
(43.9%) per day in 38 (41.8%). Neurological examination was abnormal
in 33 patients (36.2%). MRI was negative in 14 cases (15.4%) and posi-
tive in 77 (84.6%). Presurgical diagnostic work-up included video-EEG
monitoring in 75 patients and stereo-EEG recordings in 69.
Results: Surgery was limited to parietal lobe in 30 cases (32.9%),
and occipital lobe in 5 (5.5%), being multilobar in 56 (61.6%). Neuro-
pathology accounted for dysplastic lesions in 43 cases, neoplastic in 28,
scars in 8 and ulegyria in 4, resulting cryptogenic in 8 patients. After a
mean follow-up of 49.6 ± 25.1 months, 57 patients are in Engel’s Class
I (62.6%), 15 in class II (16.5%), 5 in class III (5.5%) and 14 in class IV
(15.4%).
Conclusion: Our series shows that epilepsy surgery in the posterior
brain: is not episodically performed (17.7% of the 514 patients operated
on during the same period), often requires invasive recordings (75.8%),
frequently is multilobar (61.6%), and allows the achievement of good
post-operative results.
057
HETEROTOPIA: NEUROPATHOLOGICAL STUDY OF PA-
TIENTS OPERATED FOR DRUG RESISTANT EPILEPSY
1R. Spreafico, 2E. Bramerio, 3L. Tassi, 3M. Cossu, 3G. Lo Russo, 4A.
Citterio, 1G. Magnaghi, 1A. Meroni, and 2C. Galli (1Istituto Neurologico
“C. Besta,” Milano, Italy, 2Neuropatologia, Ospedale Niguarda, Milano,
Italy, 3Centro Chirurgia Dell’Epilessia “C. Munari,” Ospedale Niguarda,
Milano, Italy, 4Neuroradiologia, Ospedale Niguarda, Milano, Italy)
Purpose: To describe the neuropathological characteristics of dif-
ferent types of heterotopia in patients operated on for drug-resistant
epilepsy.
Method: 24 patients out of 583, operated on for intractable epilepsy
from June 1996 to December 2005 at the “C. Munari” Epilepsy Surgery
Centre, were selected on the basis of MRI and neuropathological diagno-
sis presenting different types of heterotopia. Specimens were evaluated
by routine neuropathological methods and immunocytochemistry.
Results: According to current classification, 4 cases were classified as
laminar heterotopia (LH) and 20 as nodular heterotopia (NH). Among the
patients with NH, 13 had MRI characteristics of periventricular nodular
heterotopia (PNH); in 2 of them PNH was associated with complex corti-
cal malformations. Isolated nodules were observed in 7 patients. Within
this group, nodules were associated with other lesions in 6 patients. Ar-
chitectural dysplasia (type 1A) was present in the overlying cortex in 1
case of LH and 12 cases of PNH. Microscopic organisation was different
in PNH and isolated nodules. LH was organised as a ribbon of unlayered
grey matter; numerous isolated neurons were present between the cortex
and LH. Follow up of at least 12 months was available for all patients
and 80% are in class I.
Conclusion: Neuropathological and immunocytochemical data show
that the intrinsic organisation of nodules are different in PNH and in
isolated nodules. PNH are frequently associated with dysplasia of the
overlaying cortex. Good clinical outcome is expected particularly for
patients with unilateral PNH and for those with isolated nodules associ-
ated with other lesions.
058
PERICOLLATERAL CORTICAL DYSPLASIA: AETIOLOGY
FOR REFRACTORY TEMPORAL LOBE EPILEPSY
1,2A. Cukiert, 1,2J. Burattini, 1L. Seda, 1R. Camara, 1,2P. Mariani, 1,2C.
Baldauf, 1,2M. Argentoni-Baldochi, 1,2C. Baise-Zung, 1,2C. Forster, and
1V. Mello (1Epilepsy Surgery Program, Hospital Brigadeiro, Sao Paulo,
Brazil, 2Clinica De Epilepsia De Sao Paulo, Sao Paulo, Brazil)
Purpose: Cortical dysplasia is an important aetiology of refractory
epilepsy, especially in the paediatric population. We describe a distinct
type of focal cortical dysplasia which is centered on the collateral fissure
and associated to refractory temporal lobe epilepsy.
Method: Five patients with refractory temporal lobe epilepsy were
studied. Age ranged from 3 to 25 years (mean = 18 years), age at the
beginning of seizures from 2 to 14 years (mean = 8 years) and seizure
frequency from 3 to 10/week (mean = 5 seizures/week). All patients
had simple (vegetative in 4 and cephalic in one) and complex partial
seizures. Interictal EEG showed unilateral temporal lobe spiking in 4
and bilateral discharges in 1 patient. No patient was submitted to video-
EEG monitoring. MRI disclosed dysplastic lesions in all patients. These
lesions were spread around the collateral fissure, occupying both the
parahippocampal and fusiform gyri. In 4 patients, imaging findings sug-
gestive of ipsolateral mesial temporal sclerosis were also noted. In 1
patient, the hippocampus looked normal (visual analysis). All patients
were submitted to a cortico-amygdalo-hippocampectomy at the side of
the MRI-defined lesion.
Results: All patients were rendered seizure-free after surgery. Patho-
logical examination showed cortical dysplasia and mesial temporal scle-
rosis in all patients, including the patient with a normal looking hip-
pocampus on MRI.
Conclusion: Pericollateral cortical dysplasia seems to be a very spe-
cific aetiology of refractory temporal lobe epilepsy with many features
of classical mesial temporal epilepsy. It is usually associated to mesial
temporal sclerosis and surgical outcome is probably similar (or better)
to that obtained in patients with mesial temporal sclerosis alone.
059
PRESURGICAL DIFFERENTIATION BETWEEN FOCAL COR-
TICAL DYSPLASIAS TYPE I AND II
1P. Krsek, 2T. Pieper, 3M. Hildebrandt, 4D. Kolodziejczyk, 5P. Winkler,
2A. Karlmeier, 3I. Blu¨mcke, and 2H. Holthausen (1Department of Pedi-
atric Neurology, Charles University, 2nd Medical School, Prague, Czech
Republic, 2Neuropediatric Clinic and Clinic for Neurorehabilitation, Be-
handlungszenstrum Vogtareuth, Germany, 3Department of Neuropathol-
ogy and Neuropathological Reference Center for Epilepsy Surgery, Er-
langen, Germany, 4Clinic for Neurosurgery and Neuroradiology, Be-
handlungszenstrum Vogtareuth, Germany, 5Department of Radiology,
Olgahospital Stuttgart, Germany)
Purpose: Focal cortical dysplasia (FCD) is being recognised as a
frequent cause of epilepsy in childhood. It is pathologically noted in
about 50% of the children operated on because of drug resistant seizures.
According to the current classification, two major pathological subtypes
(FCD type I and II) are distinguished. The study was undertaken in order
to find clinical, EEG, imaging and surgical outcome differences between
the two groups.
Method: We retrospectively analysed a series of 40 children with
FCD who had been investigated at the Behandlungszenstrum Vogtareuth,
Germany. FCD type I was histologically proven in 24 patients and FCD
type II in 16 patients.
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Results: Perinatal adverse events as well as different CNS comorbid-
ity were more commonly encountered in FCD I group. Children with
FCD type I had lower intelligence quotient scores, worse maladaptive
behaviour level scores and more frequent social/emotional behaviour
disturbances. Continuous EEG slowing was also more common among
FCD I patients. Typical MRI findings in FCD type II were increased
cortical thickness, grey-white matter junction blurring, FLAIR and PD
grey matter signal changes and T1w and PD white matter signal changes.
The MRI pathology more typical for FCD type I was regional reduction
of the white matter volume. Surgical outcomes were significantly worse
in FCD I group (Engel I outcome had 73% of patients from FCD II group
but only 22% from FCD I group).
Conclusion: Clinically important differences, which can be of a key
value in the management of patients, were found between patients with
different pathological FCD subtypes. Supported by Grant IGA NR/8843–
4.
060
DIRECT COSTS IN EPILEPSY SURGERY
1,2P. Putkonen, 3L. Jutila, 4M. Granstro¨m, 4E. Gaily, and 3R. Ka¨lvia¨inen
(1Helsinki University of Technology, Laboratory of Biomedical Engi-
neering, Espoo, Finland, 2University of Kuopio, The Department of
Health Policy And Management, Kuopio, Finland, 3Kuopio Univer-
sity Hospital (KUH), The Department of Neurology, Kuopio, Finland,
4Hospital For Children And Adolescents, Helsinki University Hospital
(HUCH), Helsinki, Finland)
Purpose: Approximately 20% of all epilepsy patients are drug resis-
tant and may benefit from surgical treatment. Direct treatment costs and
quality of life (QOL) are measured both retrospectively and prospec-
tively for Finnish patients with epilepsy who are evaluated for surgical
treatment.
Method: Group I contains 141 adult TLE-epilepsy patients from
KUH operated from 1988–1999 and 118 children, adolescents and adults
from HUCH operated from 1991–2002. Patients have been enrolled to
prospective group II from April 2004 including all patients referred for
surgical evaluation. Until January 2006, over 70 prospective patients have
been enrolled. Direct treatment costs from treatments related to epilepsy
in primary and special health care (outpatient visits and hospital admis-
sions) are taken into the cost-effectiveness analysis (CE). Count-period
covers at least 2 years before and 2 years after surgery. QOL–score is
measured three times with 15D and disease specific QOLIE-31 instru-
ment; before, 6 months and 1 year after epilepsy surgery in patient group
II, and at once in group I.
Results: Preliminary cost estimation in the retrospective research
groups suggests significant decrease in postsurgical costs, especially
in outpatient visits, of both children and adults. Results are based to
the evaluation of patient data. Final calculations will have HILMO (the
Finnish register for treatment announcements) data, which may change
results.
Conclusion: Good outcome in epilepsy surgery may predict posi-
tive changes in several dimensions, including direct treatment costs and
QOL-values. Surgical therapy is a cost-effective treatment even without
indirect costs being taken into consideration.
Tuesday July 4, 2006
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061
PROGNOSIS FOLLOWING CLINICAL NEONATAL SEIZURES:
RESULTS FROM A POPULATION-BASED COHORT 14 YEARS
LATER
1G. Ronen, 2,3D. Buckley, 3S. Penney, and 4D. Streiner (1McMaster Uni-
versity, Hamilton, Canada, 2Memorial University, St. John’s, Canada,
3Janeway Child Health Center, St. John’s, Canada, 4University of
Toronto, Toronto, Canada)
Purpose: To prospectively evaluate survival and neurodevelopmen-
tal outcome following neonatal seizures (NSz). Most recent population
based data are from 1959–1962 and may not be generalisable to current
neonatal populations.
Method: We collected prospective data on all neonates (<44 weeks
gestation) with clinical NSz ( = paroxysmal behaviours with high speci-
ficity for “epileptic” seizures) from 1990–1995, targeting all live births in
Newfoundland. Uniform video assisted training for standardised seizure
recognition preceded the study (J Pediatr 1999;134:71). Follow-up data
were analysed 10–14 years later.
Results: Data were analysed for 87/90 children (61 term and 26
preterm). At follow-up 30 children (34%) were considered to be function-
ing normally (including 44% of the term infants and 12% of the preterm
group). 21 children (24%) had died (including16% of term infants and
42% of preterm children). Disabilities were apparent in 36 (41%) (of
whom 24 (39%) were term infants and 12 (46%) were preterm). Among
the 66 survivors, 17/65 (26%) still had epilepsy, 15/66 (23%) had cerebral
palsy, 13/65 (20%) were intellectually retarded, and 16/65 (25%) were
considered to have learning disabilities. Details of the probable aetiolo-
gies of the seizure problems have been identified and will be provided
in the full presentation.
Conclusion: Preterm infants with seizures are at higher risk for death
and impairment compared to term infants. The 12% normal outcome for
preterm is lower than in most studies, possibly reflecting their outborn
nature. The lower frequency of normal outcome compared to 47% from
1959–1962 may primarily be due to reduction in hypocalcemic seizures.
Cognitive deficits are present in 45% of survivors.
062
IRRITATIVE ZONE IN PAEDIATRIC FOCAL EPILEPSIES
ANALYSED BY 3-TESLA EEG-fMRI RECORDINGS AND EEG
MULTIPLE SOURCE ANALYSIS
1R. Boor, 2J. Jacobs, 3S. Wolff, 2U. Stephani, and 2M. Siniatchkin
(1North German Epilepsy Centre for Children and Juveniles, Kiel-
Raisdorf, Germany, 2Department of Pediatric Neurology, University-
Children’s Hospital Kiel, Germany, 3Department of Neuroradiology,
University Hospital Kiel, Germany)
Purpose: EEG-related fMRI (EEG-fMRI) and EEG multiple source
analysis (MSA) are promising functional neuroimaging techniques to
analyse the irritative zone in focal epilepsies noninvasively. However,
there is scarce functional neuroimaging data studying the irritative net-
work in paediatric focal epilepsies. The present study applies the com-
bined EEG-fMRI and MSA techniques to paediatric focal epilepsies and
subdivides the irritative zone noninvasively by discriminating the spike
onset zone from propagated source activity.
Method: Six children with focal epilepsies were studied by simultane-
ous recordings of EEG (Brain Vision@ MR-compatible EEG amplifier,
32 channels, 20 min. recording time) and fMRI (3-T Achieva Philips
scanner, TE = 64 ms, TR = 1240 ms, 24 × 24 matrics, 250 scans) dur-
ing medically induced sleep. After EEG artifact reduction, the event ( =
spike)-related design was used to analyse the BOLD responses (SPM-
2, standard HRF), which were co-registered to T1-weighted anatomical
images. Additionally, interictal EEG spikes were averaged and localised
using MSA (BESA 2000), and source locations were displayed in the
anatomical 3D-MRI.
Results: In all cases the BOLD responses corresponded to the EEG
localisation of the interictal discharges. Using the combination of EEG-
fMRI and MSA we were able to discriminate the spike onset zone from
propagated source activity.
Conclusion: The irritative zone in children with focal epilepsies
can be successfully studied by EEG-fMRI recordings in 3-T scanners.
The results of EEG-fMRI and MSA can be combined to distinguish
the spike onset zone from propagated activity, using the spatial reso-
lution of the EEG-fMRI technique and the temporal resolution of the
MSA.
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063
LANGUAGE LATERALISATION IN CHILDREN WITH LEFT
HEMISPHERAL EPILEPTOGENIC LESIONS OF PRE- OR
POSTNATAL ORIGIN: A fMRI STUDY
1J. Hadac, 1K. Brozova, 2P. Krsek, and 3J. Tintera (1Faculty Thomayer’s
Hospital, Prague, Czech Republic, 22nd Faculty of Medicine, Charles’
University Prague, Czech Republic, 3Institute for Clinical and Experi-
mental Medicine, Prague, Czech Republic)
Purpose: The aim of the study was to assess the correlation of lan-
guage lateralisation with the time of lesion formation, age at onset and
duration of epilepsy in children with left hemispheral epileptogenic
lesions.
Method: We studied 34 children and adolescents from 7 to18 years of
age (mean 13 years) suffering from epilepsy due to left hemispheral le-
sion of pre- (n = 18) or postnatal (n = 16) origin. All the patients except 3
were right-handed. Hemispheric dominance for language was evaluated
by fMRI using a silent word generation paradigm for all patients.
Results: Significant coactivation of the right hemisphere was present
in 11 patients (32%); a complete language shift to this hemisphere was
detected in the other 4 subjects (11.8%). The average age of these 15
patients was 12.9 years with the mean age at epilepsy onset 5.7 years
and epilepsy duration 7.2 years. Only 5 (33.3%) had a prenatal aetiol-
ogy of epilepsy. However, 3 out of 4 patients with a complete shift were
those with a prenatal aetiology. Nineteen children (55.9%), including
3 left-handed individuals, exhibited pronounced left-hemispheric lan-
guage dominance. They averaged 13.3 years of age; their epilepsy started
at the age of 9.2 years and lasted for 4.2 years. Thirteen of them (68%)
had a prenatal lesion.
Conclusion: Language dominance shift was significantly more fre-
quent in children with epilepsy manifestation before the age of 6 years
and a persistence of seizures of more than 4 years. Surprisingly, pre-
natal lesions had a lesser tendency to alter localisation of cortical lan-
guage centres than those of postnatal origin. However, language shift
caused by prenatal lesions, when such a shift occurs, tends to be more
complete. The study was supported by grant IGA MZ CR NR/7808-3
OK 06.
064
INTRACTABLE EPILEPSY IN CHILDHOOD OWING TO DNET
1M. Topcu, 1D. Yalnizoglu, 2B. Bilginer, 1G. Turanli, 4D. Acikgo¨z, 1F.
Soylemezoglu, 3I. Saatci, and 2N. Akalan (1Hacettepe University, School
of Medicine, Department of Neurology, Hacettepe, Turkey, 2Hacettepe
University, School of Medicine, Department of Neurosurgery, Hacettepe,
Turkey 3Hacettepe University, School of Medicine, Department of
Pathology, Hacettepe, Turkey)
Purpose: Dysembryoplastic neuroepithelial tumour (DNET) is recog-
nised as one of the most frequent reasons for medically intractable
epilepsy. Patients with DNET present with partial onset refractory
seizures following normal development.
Method: Children who underwent surgery for epilepsy from 1994–
2005 at Hacettepe University Children’s Hospital were analysed and 42
were diagnosed with DNET. We reviewed the charts retrospectively for
age at the time of surgery, age at seizure onset, presenting features, loca-
tion, EEG, MRI, surgical and adjuvant treatment, and seizure outcome.
Results: Male/female ratio was 17/25. Age at the time of evalua-
tion ranged between 5–25 years, age at seizure onset ranged between
7 months–17 years, age at the time of surgery ranged between 4–
24 years. 33 patients (78.5%) had complex partial seizures and 9 had
simple partial seizures. Follow-up duration was 6 months–6.5 years.
In 12 patients interictal EEG before surgery showed no epileptiform
discharges. In 27 patients EEG showed lateralising epileptiform dis-
charges with the lesion on MRI. In 3 patients EEG showed localising
features. MRI showed a temporal lesion in 31 (73%) patients, and ex-
tratemporal in the remaining 11 patients. Three patients had a recur-
rence of seizures after surgery and underwent a second operation to re-
move the residual mass. Forty patients had Class IA and 2 had Class IB
outcome.
Conclusion: The aim of epilepsy surgery in children with medically
intractable partial seizures is to control seizures, and thus improve learn-
ing and behaviour. Complete resection of the lesion is necessary for a
favourable outcome in patients with developmental tumours including
DNET.
065
THE VALUE OF MEASURING GLUCOSE AND BLOOD
KETONES WHEN ADJUSTING A CLASSICAL KETOGENIC
DIET
1L. Brendstrup, 2G. Rerup, and 1M. Nikanorova (1The Danish Epilepsy
Center, Dianalund, Denmark, 2Consultant Clinical Dietician, Hornbaek,
Denmark)
Purpose: Dysembryoplastic neuroepithelial tumour (DNET) is recog-
nised as one of the most frequent reasons for medically intractable
epilepsy. Patients with DNET present with partial onset refractory
seizures following normal development.
Method: Children who underwent surgery for epilepsy from 1994–
2005 at Hacettepe University Children’s Hospital were analysed and 42
were diagnosed with DNET. We reviewed the charts retrospectively for
age at the time of surgery, age at seizure onset, presenting features, loca-
tion, EEG, MRI, surgical and adjuvant treatment, and seizure outcome.
Results: Male/female ratio was 17/25. Age at the time of evalua-
tion ranged between 5–25 years, age at seizure onset ranged between 7
months–17 years, age at the time of surgery ranged between 4–24 years.
33 patients (78.5%) had complex partial seizures and 9 had simple par-
tial seizures. Follow-up duration was 6 months–6.5 years. In 12 patients
interictal EEG before surgery showed no epileptiform discharges. In 27
patients EEG showed lateralising epileptiform discharges with the lesion
on MRI. In 3 patients EEG showed localising features. MRI showed a
temporal lesion in 31 (73%) patients, and extratemporal in the remain-
ing 11 patients. Three patients had a recurrence of seizures after surgery
and underwent a second operation to remove the residual mass. Forty
patients had Class IA and 2 had Class IB outcome.
Conclusion: The aim of epilepsy surgery in children with medically
intractable partial seizures is to control seizures, and thus improve learn-
ing and behaviour. Complete resection of the lesion is necessary for a
favourable outcome in patients with developmental tumours including
DNET.
066
SECONDARY (SYMPTOMATIC) GENERALISED EPILEPSY
(SGE): A 20-YEAR FOLLOW-UP OF A POPULATION-BASED
COHORT
C. Camfield and P. Camfield (IWK Health Centre and Dalhousie Uni-
versity, Dalhousie, Canada)
Purpose: Secondary generalised epilepsies (SGE) are often the most
resistant of childhood epilepsies with an unsatisfactory outcome. SGEs
may be poorly defined in clinical practice and are relatively uncommon.
We carefully defined the 11 syndromes that make up most of this group
of epilepsies and describe their response to treatment over long-term
follow up.
Method: Children were identified from the Nova Scotia population-
based epilepsy study (n = 693). Onset of epilepsy was from 1977–85 and
follow-up was in 2003. Secondary generalised epilepsies were defined
as having a mixture of >1 generalised seizure type including one of
myoclonus, akinetic/atonic, drop attacks, tonic, atypical absence plus an
interictal EEG with generalised spike-wave (irregular or slow) and/or
multifocal spikes.
Results: SGE represents 11% (75/693) of all childhood epilepsy.
Nearly 40% of patients do not fit into one of the currently accepted syn-
dromes (such as Lennox-Gastaut, myoclonic-astatic or West). 63% have
seizure onset in the first year of life and only 9% are free of intellectual
or physical handicap. 65% (11/17) with Lennox Gastaut had preceding
West Syndrome. During a median follow up of 20 years, mortality was
24% and 51% had persistently intractable seizures. Surprisingly one-
third had >48 months terminal remission (West 37%, Lennox-Gastaut
0%, myoclonic-astatic 63%, undefined 37%).
Conclusion: Many children with SGE have ill-defined epilepsy syn-
dromes. SGE is characterised by early age of onset, high rates of
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handicap, intractability and death; although one third achieve complete
seizure control with a long terminal remission.
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Clinical Neurophysiology II
067
EARLY CONTINUOUS VIDEO-EEG MONITORING AND
PREDICTION OF NEURODEVELOPMENTAL OUTCOME
IN MODERATE NEONATAL HYPOXIC-ISCHAEMIC
ENCEPHALOPATHY
1D. Murray, 1G. Boylan, 1C. Ryan, and 2S. Connolly (1Department
of Paediatrics and Child Health, University College Cork, Ireland,
2Department of Clinical Neurophysiology, St Vincent’s University Hos-
pital, Dublin, Ireland)
Purpose: Whilst EEG gives excellent prediction of outcome in mild
and severe hypoxic-ischaemic encephalopathy, the outcome in infants
with moderate EEG abnormalities is unclear, with 20–40% proceeding to
neurodisability. We have used early continuous EEG in infants to identify
features within the moderate group which could predict outcome.
Method: Infants with evidence of perinatal asphyxia were recruited
at birth. Continuous video-EEG monitoring for 24–72 hours was per-
formed from within 6 hours of birth. EEG abnormalities were graded as
mild, moderate, severe or inactive. Developmental assessment (Griffiths
scales) was performed at 6 and 12 months.
Results: Forty-eight infants had early continuous EEG and completed
follow-up. Initial EEG showed abnormalities classified as mild in 23/48,
moderate in 17/48, severe in 4/48, and inactive in 4/48. All 23 infants with
mildly abnormal EEGs had normal GQ scores at follow up. In the group
with severe abnormalities 2 have died and 2 have significant global delay.
Of the 4 infants with inactive EEGs 2 have died and 2 have severe spastic
quadriplegia. In the infants with moderate EEG abnormalities, 5/17 had
abnormal GQ scores or significant motor deficits. A further 3 infants had
isolated deficits in Griffiths subgroups. Electrographic seizures occurred
in 8/17. Abnormal outcome was seen in 3/8 infants with seizures. In ad-
dition to the seizure burden, low amplitude on initial EEG (<50 μv), and
delayed return of sleep cycling were associated with a poor neurological
outcome.
Conclusion: By identifying high risk features, early continuous EEG
can be used to predict abnormal outcome in infants with moderate
hypoxic-ischaemic encephalopathy.
068
INFLUENCE OF FOCUS LOCALISATION ON PROPAGA-
TION AND CLINICAL MANIFESTATION OF ICTAL ACTIV-
ITY IN PATIENTS WITH FRONTAL AND TEMPORAL LOBE
EPILEPSY
A. Schulze-Bonhage, K. Go¨tz-Trabert, C. Hauck, and K. Wagner
(Epilepsy Centre, University Hospital Freiburg, Germany)
Purpose: Recently, the implementation of online-seizure detection
systems for warning of patients and closed-loop-intervention systems
has attained increased interest. Latencies between electrographic seizure
onset time, propagation of ictal activity, and occurrence of clinical symp-
toms are of critical importance for the applicability of detection-based
intervention systems. This study evaluates intracranial EEG-recordings
for determination of spread of ictal activity and its dependence on focus
localisation.
Method: Video-EEG recordings of 215 seizures from 43 patients
(mean age 28.8 y, 24 female) with pharmacoresistant focal epilepsy
were evaluated. Seizure onset zone was temporomesial in 15, temporal-
neocortical in 15, and frontal in 13. The first five seizures recorded by
intracranial EEG and video were analysed regarding latencies between
seizure onset, propagation for a distance of at least 2cm, and clinical
seizure onset.
Results: Median latencies between electrographic seizure onset and
early propagation were 5s in mesiotemporal epilepsy, 3s in temporolat-
eral epilepsy, and 1s in frontal lobe epilepsy. Median latencies between
electrographic seizure onset and onset of clinical symptoms were 18s
in mesiotemporal epilepsy, 11s in temporolateral epilepsy, and 4s in
frontal lobe epilepsy. Latencies were significantly longer in temporome-
sial epilepsy as compared to frontal lobe epilepsy (p < .05).
Conclusion: There are significant differences with regard to the speed
of propagation of ictal activity and onset of seizure semiology depending
on focus localisation. This may have implications for the applicability of
closed-loop intervention systems based on automated seizure detection
algorithms. Mesiotemporal epilepsies may offer best chances for warning
and intervention systems based on seizure detection.
069
FRONTAL SEIZURES DURING SLEEP WITH SUBTLE RESPI-
RATORY CHANGES MAY MIMIC AROUSALS BUT SHOW DIS-
TINCT PATTERNS ON POLYSOMNOGRAPHY
A. Bauerfeind, I. Mothersill, T. Grunwald, and G. Kraemer (Swiss
Epilepsy-Center, Zurich, Switzerland)
Purpose: Respiratory parameters during sleep, as monitored by
polysomnography, exhibit characteristic changes not only during gen-
uine respiratory events such as apneas, but also following arousals, for
which an increase in respiratory rate is characteristic. Aside from any
overt clinical signs, frontal seizures may also show an increased res-
piratory rate for the duration of the discharges. Before assuming that
tachypnoea in itself may be considered ictal semiology, this specific
polysomnographic pattern must be established and the delineation to
arousal made possible.
Method: Respiratory tracings of 16 Patients in whom nocturnal frontal
epileptiform discharges were concomitant with tachypnoea were re-
viewed for spontaneous (nonrespiratory) and induced arousal. Respi-
ratory rate was calculated using either thoracic strain gauge or oro-nasal
flow parameters (polysomnography). A minimum of 2 full breathing cy-
cles of a sinusoidal curve was used when calculating frequency changes.
Results: Respiratory changes after arousal were generally in accor-
dance with the observations made by Carley et al., Sleep 1996;19(10
Suppl):S189–92, consisting of a moderate increase in respiratory rate
for 3 to 5 seconds following the stimulus with a gradual slowing (ta-
pering) to the original respiratory rate after this time. Discharge related
increases in respiratory rate, on the other hand, was characterised by an
increased and stable frequency for the duration of the discharges, often
lasting as long as 8 to 10 seconds.
Conclusion: Tachypnoea during frontal epileptiform discharges in
sleep may be regarded as ictal semiology and can be distinguished
polysomnographically from an arousal response. Although subtle, these
respiratory changes may be the only manifestation of certain nocturnal
frontal seizures.
070
ICTAL MANIFESTATIONS OF EMOTIONS: A VIDEO-EEG
ANALYSIS
A. Marinas, I. Garcı´a-Morales, A. Jime´nez-Huete, and A. Gil-Nagel
(Hospital Ruber Internacional, Madrid, Spain)
Purpose: To analyse manifestations with emotional content during
ictal recordings in patients with epilepsy.
Method: From 134 patients with ictal recordings, those with seizures
showing manifestations commonly found in association with emotions
were selected.
Results: Focal epilepsy was diagnosed in 111/134 (83%) patients,
while generalised epilepsies were diagnosed in 23/134 (17%). 34/111
(30%) patients with focal epilepsy had emotional manifestations dur-
ing their seizures, compared with none of 23 patients with generalised
epilepsy (p = 0.0010; X2). Patients with focal epilepsy expressed 41
different emotional manifestations during their seizures. The most com-
mon manifestations were: restlessness in 14/41 (34%) and fear in 9/41
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(22%). Other manifestations were: laughter, groaning, shouting, crying,
anguish, agitation, and kissing. The localisation was temporal in 25/34
(74%), frontal in 4/34 (12%), non localising in 4/34 (12%), and fronto-
temporal in one. 19/34 (56%) originated from the right hemisphere,
14/34 (41%) from the left, and one were not lateralised. 25/61 (41%)
patients with temporal lobe epilepsy showed emotional manifestations
which included fear, anxiety, groaning, agitation, kissing, and shouting;
4/21 patients with frontal lobe epilepsy (19%) showed cry and anguish.
Conclusion: Emotional expressions are common ictal manifestations
in partial epilepsy, mostly in temporal and frontal lobe seizures, but
are not present in generalised epilepsies. Anxiety and fear are the most
common manifestations expressed during seizures, probably in relation
to activation of the limbic system.
071
EXCITATORY AND INHIBITORY MECHANISMS OF
PHOTOSENSITIVITY
1M. Siniatchkin, 1S. Groppa, 1B. Jerosch, 1H. Muhle, 2A. Shepherd, 3H.
Siebner, and 1U. Stephani (1Neuropediatric Department, University of
Kiel, Germany, 2School of Psychology, Birkbeck College, London, UK,
3Neurology Clinic, University of Kiel, Germany)
Purpose: Photosensitivity or photoparoxysmal response (PPR) is a
highly heritable electroencephalographic trait characterised by an ab-
normal EEG reaction to intermittent photic stimulation (IPS), consisting
of spikes, spike-waves, and intermittent slow waves. The knowledge con-
cerning the pathophysiology of human photosensitivity is still limited.
Method: Threshold of phosphenes induced by a paired-pulse tran-
scranial magnetic stimulation (TMS, Magstim 200), stimulus-response
curves for phosphenes, suppression of visual perception by a single-pulse
TMS (40–180 stimulus onset asynchrony, 75% of stimulator output, per-
ception of letter trigrams), visual evoked potentials (2 Hz stimulation
rate, 8 c.p.d., N135, habituation paradigm), and duration of the motion
aftereffect were studied in healthy subjects with (N = 17, age 25.2 ±
12.2 years) and without (N = 18, age 26.5 ± 7.3 years) PPR.
Results: Subjects with PPR propagation were characterised by a lower
phosphene threshold than subjects without PPR and with occipital spikes
(F(2.32) = 3.73; p = 0.035). Stimulus-response curves of subjects with
PPR propagation were steeper than those of other groups (intensity x
group F(9.297) = 4.58; p < 0.001). Amplitudes of VEP were signif-
icantly larger in the group with PPR propagation and showed a more
pronounced habituation (block of recording x group F(28.406) = 2.01;
p = 0.02). The PPR group demonstrated a shorter motion aftereffect
(F(1.26) = 5.1; p = 0.03) and (5) a more pronounced visual suppression
by a single-pulse TMS (interaction SOA x group: F(14.224) = 2.34;
p = 0.005).
Conclusion: This study provides evidence for both increased cortical
excitability and intracortical inhibition in the occipital cortex in subjects
with PPR propagation. PPR with propagation and with only occipital
spikes seem to represent different phenotypic expressions.
072
PHOTOSENSITIVITY IN THE MYOCLONIC EPILEPSIES OF
CHILDHOOD
1,2S. Patil, 2K. Dwyer-St Pier, 2S. Boyd, 2S. White, 2M. Pitt, and 1,2H.
Cross (1Institute of Child Health, London, UK, 2Great Ormond Street
Hospital For Children NHS Trust, London, UK)
Purpose: Photosensitivity is seen in a proportion of children with
myoclonic epilepsy. This would suggest an idiopathic aetiology, includ-
ing severe myoclonic epilepsy of infancy (SMEI), and may imply an
unsatisfactory outcome. The true range of the group with photosensi-
tivity, however, remains unknown. We aimed to review children with
myoclonic epilepsy associated with photosensitivity.
Method: Retrospective study of EEG records of children with a his-
tory of myoclonic epilepsy aged less than 10 years at onset, with normal
brain imaging and development, presenting for EEG at Great Ormond
Street Hospital for Children from 1992–2005. Children with known pro-
gressive disorders, structural lesions and abnormal neurodevelopment
before the onset of epilepsy were excluded.
Results: The EEG records of 150 patients were studied. Of these, 45
had a single EEG and the remaining 105 had 2–9 recordings. 39 children
(26%) had a grade 3–4 photoparoxysmal response. The mean age at
onset was 24.7 months; 34 (87.2%) presenting before the age of 5 years.
Diagnostic categories were SMEI, myoclonic astatic epilepsy, epilepsy
with myoclonic absences and stimulus sensitive epilepsy. Nearly 46% of
children were unclassifiable. Of the 5 children with an onset after the age
of 5 years, photosensitivity was the most prominent historical feature in
2 children, while another 2 had deterioration of EEG with time.
Conclusion: Photosensitivity was seen in one-quarter of our patients
with childhood myoclonic epilepsies. The presence of photosensitivity
did not assist the other EEG features in making a clear syndromic diag-
nosis in almost half the children.
Tuesday July 4, 2006
12:00–13:30
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073
VASCULAR REMODELLING AND ANGIOGENIC PROCESSES
IN TEMPORAL LOBE EPILEPSY
1M. Lerner-Natoli, 1,2V. Rigau, 1M. Morin, 1,3A. Crespel, and 1J. Bock-
aert (1Institute of Functional Genomics, CNRS-INSERM, Montpellier,
France, 2Lab of Pathological Anatomy And Cytology, CHU, Montpel-
lier, France, 3Epileptology Unit, CHU, Montpellier, France)
Purpose: We previously described inflammatory processes and pro-
liferation of neural progenitors in the chronic focus of patients with
temporal lobe epilepsy (TLE). We noted an increased vascularisation of
the focus, compared to non epileptic hippocampi. Here we hypothesized
that vascular remodeling is associated with neuroglial reorganisation
and we attempted to evidence angiogenic processes in the adult epileptic
hippocampus.
Method: We collected hippocampi from 30 patients who underwent
surgery for intractable TLE and from 4 non epileptic, autopsied pa-
tients (NE). By immunohistochemistry or immunoblotting, we checked:
i) microvessel density, ii) markers of immature endothelial cells, iii) an-
giogenic factors and their receptors. We performed similar studies on
epileptic rats (lithium-pilocarpine model) to study the kinetic of neovas-
cularisation.
Results: In TLE, we observed clusters of immature endothelial cells
in the neurogenic areas. In CA1 and dentate gyrus, microvessel density
was higher in epileptic than in NE patients, particularly in case of hip-
pocampal sclerosis. Angiogenic factors and their receptors were detected
in different types of cells. In rats, the degree of vascularisation seems
to be related to the intensity of seizures and lesions. A rapid and strong
neuronal expression of VEGF was obvious after seizures, whereas its
receptor appeared later.
Conclusion: A neovascularisation contributes to epileptic tissue re-
modeling and likely depends on the severity of epilepsy. The persistence
of angiogenic factors in the chronic phase of epilepsy suggests that an-
giogenesis is recurrently stimulated by spontaneous seizures. The con-
sequences of neovascularisation may concern inflammation, blood brain
barrier permeability and haemodynamics.
074
LONG-LASTING INCREASED PERMEABILITY OF THE
BLOOD-BRAIN BARRIER DURING PROGRESSION OF
EPILEPSY
1,2E. van Vliet, 1S. da Costa Arau´jo, 3S. Redeker, 3E. Aronica, and
1,2J. Gorter (1Swammerdam Institute For Life Sciences, Center for
Neuroscience, University of Amsterdam, Amsterdam, The Netherlands,
2Epilepsy Institute of the Netherlands (SEIN), Heemstede, The Nether-
lands, 3Academic Medical Center, Department of (Neuro) Pathology,
University of Amsterdam, Amsterdam, The Netherlands)
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Purpose: To get more insight into the role of the blood-brain barrier
(BBB) in epileptogenesis, we determined BBB permeability in epileptic
rats and humans with epilepsy and studied the possible consequences of
a compromised BBB for the subsequent progression of epilepsy.
Method: BBB permeability was investigated at different time points
after electrically induced SE using various tracers that bind to albu-
min. The cellular localisation of albumin was further investigated using
immunocytochemistry in rat and human epileptic brain specimens. In
addition, we investigated whether BBB opening was related to seizure
progression.
Results: In rats, the BBB was most affected 1 day after SE in lim-
bic brain regions and partly restored in the latent period. However, the
BBB was still permeable in the chronic epileptic phase. Tracer (albu-
min) was found in microglia, astrocytes and neurons. Similarly, albumin
extravasation in humans was most prominent directly after SE in astro-
cytes and neurons and to a lesser extent in the hippocampi of temporal
lobe epilepsy patients. In chronic epileptic rats, seizure frequency was
correlated to BBB permeability. BBB opening by mannitol significantly
increased seizure frequency more than 2-fold. Interestingly, mannitol
induced the expression of the multidrug transporter P-glycoprotein in
control brains.
Conclusion: These results show that albumin still enters the brain in
the chronic epileptic phase and colocalises with neuronal and glial cells.
The fact that the seizure frequency was correlated to BBB permeabil-
ity, suggests that BBB leakage may be involved in the progression of
epilepsy. Moreover, opening of the BBB induced compensatory mecha-
nisms that could affect drug transport and contribute to pharmacoresis-
tance.
075
MECHANISMS OF GENERATION OF FAST ACTIVITY AT IC-
TAL ONSET IN THE ENTORHINAL CORTEX OF THE ISO-
LATED GUINEA PIG BRAIN PREPARATION IN VITRO.
M. De Curtis, V. Gnatkovsky, and L. Uva (Unit of Clinical Epileptology
And Experimental Neurophysiology, Istituto Nazionale Neurologico,
Milano, Italy)
Purpose: One of the ictal onset patterns commonly observed in the
temporal lobe of humans suffering from temporal lobe epilepsy and in
experimental models of temporal epilepsy is characterised by recruiting
fast activity. Such a pattern has been observed also in extratemporal
cortical foci during presurgical stereo-EEG recordings in patients with
drug-resistant epilepsy. The mechanisms involved in the generation of
fast ictal-onset activity are still largely unknown.
Method: We developed a model of acute ictogenesis determined by
transient disinhibition of the in vitro isolated brain of young guinea
pigs by means of brief (3 minutes) arterial perfusion of the GABAa
receptor antagonist, bicuculline (50 μM). Interictal and ictal discharges
were induced with this protocol in the olfactory and limbic cortices that
include the hippocampus and the entorhinal cortex (Uva et al. Epilepsia
46: 1914, 2005).
Results: Ictal onset in the medial entorhinal cortex was typically char-
acterised by fast activity at 25–35 Hz, followed by ictal burst discharges
of increasing amplitude. Bursting activity was always preceded by fast
activity. In the present study we performed simultaneous intracellular
recordings and extracellular laminar profiles in the medial entorhinal
cortex, together with extracellular recordings from the CA1 region dur-
ing the transition between interictal and ictal discharge in this model.
Intracellular recordings in superficial neurons demonstrated that the fast
activity was associated with IPSPs of decreasing amplitude, coupled
with slow membrane depolarisation. No firing of principal neurons was
observed in these conditions. Such activity was followed by cellular
burst discharges in coincidence with the bursting ictal phase. Prelimi-
nary recordings from putative interneurons demonstrated the presence
of sustained firing during ictal onset fast activity. Deep neurons are rel-
atively quiescent during fast onset activity.
Conclusion: The present findings demonstrate that in the entorhinal
cortex fast activity at ictal onset in an acute model of ictogenesis is
characterised by a prominent interneuronal activation. The study was
partially sponsored by Mariani Foundation grant (R-06-50).
076
VASOREACTIVITY TO CO2 AS MEASURED BY FUNCTIONAL
MAGNETIC RESONANCE IMAGING IS ENHANCED IN
EPILEPTIC REGIONS IN THE GENETIC ABSENCE EPILEPSY
RAT FROM STRASBOURG (GAERS)
1,3O. David, 2,3I. Guillemain, 1,3A. Krainik, 2,3C. Deransart, 1,3C. Sege-
barth, and 2,3A. Depaulis (1Inserm, U594, Grenoble, France, 2Inserm,
U704, Grenoble, France, 3Universite´ Joseph Fourier, Grenoble, France)
Purpose: To evaluate whether neurovascular coupling is modified in
brain regions implicated in absence epilepsy in a genetic rat model using
hypercapnia challenges in functional MRI (fMRI).
Method: FMRI was performed at 2.35T in male and female GAERS
and their non epileptic controls (NEC) anaesthetised with 1.2% isoflu-
rane. During functional scans, the rate of inhaled CO2 was varied from 0
to 10% during two periods of 3 min followed by rest periods of the same
duration. Functional images were acquired using Echo Planar Imaging
(FOV = 35 mm, matrix size = 48∗48, 15 contiguous slices 1.5 mm
thick covering the whole brain). fMRI responses to CO2 were compared
between GAERS and NEC after image normalisation, with the atlas of
Paxinos and Watson as the reference.
Results: Significant increases of the fMRI response to hypercapnia
(p < 0.05) were found in GAERS as compared to NEC in the anteroven-
tral thalamus, the primary somatosensory cortex (barrel field), the retros-
plenial granular cortex and the most anterior part of the secondary motor
cortex. Most of these structures are known from intracerebral EEG to be
involved in the generation of spike-and-wave discharges in the GAERS.
Conclusion: FMRI shows enhanced responses to hypercapnia in
epileptic regions in a rat model of absence epilepsy. These results sug-
gest that fMRI of vasoreactivity to CO2 might be of great interest to
non-invasively localising epileptic regions in patients.
077
MOLECULAR AND FUNCTIONAL INTERACTIONS BE-
TWEEN TNF-ALPHA AND GLUTAMATE IN THE MOUSE HIP-
POCAMPUS: IMPLICATIONS FOR NEURONAL EXCITABIL-
ITY AND SEIZURE SUSCEPTIBILITY
1S. Balosso, 1T. Ravizza, 1E. Calcagno, 1A. Mariotto, 2L. Bernardino,
2J. Malva, 1R. Invernizzi, and 1A. Vezzani (1Mario Negri Institute for
Pharmacological Research, Milano, Italy, 2Center for Neuroscience and
Cell Biology, Institute of Biochemistry, University of Coimbra, Portugal)
Purpose: TNF-alpha is produced by glia during seizures. Its p55 and
p75 receptor (R) subtypes mediate opposite effects on seizures. After
intrahippocampal kainate, p55R knock-out (KO) mice show decreased
EEG seizures while p75R KO mice show enhanced seizures. p75R medi-
ates the anticonvulsant effects of TNF-alpha in wild-type (WT) mice. We
investigated whether TNF-alpha receptor-mediated changes in seizure
susceptibility involve functional interactions with glutamatergic system.
Method: We used p55R and p75R KO mice and their C57BL6 WT.
Membrane-bound AMPA (GLUR1,2,3), kainate (GLUR6/7) and NMDA
(NR1,NR2A/B) receptor subunits were measured in hippocampal ho-
mogenates by western blot. Extracellular glutamate was measured in
freely-moving mouse hippocampus by microdialysis. TNF-alpha recep-
tors expression was assessed by immunohistochemistry.
Results: In p55R KO mice (less susceptible to seizures), GluR3
(AMPA) and NR1 (NMDA) subunits were decreased in the hippocam-
pus, while all other subunits were unchanged vs WT mice. In p75R KO
mice (more susceptible to seizures) GluR2,3 (AMPA), GLUR6/7 (KA)
and NR2A/B (NMDA) subunits were increased, while the other subunits
did not change. Spontaneous glutamate release was significantly reduced
in p55R KO vs WT mice but unchanged in p75R KO; depolarisation-
induced glutamate release was unchanged in either KO vs WT mice. In
WT mice, p75R was expressed in hippocampal neurons while p55R was
below detection limit. Ninety-24 h after seizure onset, both receptors
were upregulated in astrocytes.
Conclusion: Functional glioneuronal communications between TNF-
alpha and glutamate systems may contribute to changes in seizure sus-
ceptibility, thus highlighting a novel mechanism to control neuronal ex-
citability. Supported by Fondazione Mariani Onlus.
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ROLE OF INTERLEUKIN I AND TNF DURING EPILEPTOGE-
NESIS IN EPILEPTIC MUTANT EL MICE
Y. Murashima, J. Suzuki, and M. Yoshii (Division of Psychobiology
Tokyo Instituye of Psychiatry, Tokyo, Japan)
Purpose: Epileptic mutant EL mice show secondarily generalised
seizures. Seizure discharges initiate in the parietal cortex and gener-
alise through the hippocampus. We recently provided evidence for an
altered equilibrium between pro-apoptotic Bax and anti-apoptotic Bcl-2
in association with a DNA fragmentation without cell loss. The level
of neurotrophic factors in the hippocampus showed a significant in-
crease in earlier developmental stages before exhibiting frequent seizures
(Murashima et al., Epilepsia 2005;48(suppl 5):10–16). It has also been
known that limbic seizures may induce pro-inflammatory cytokines to
control seizures (Vezzari A et al., Epilepsia 2002;43(suppl 5):30-5). In
the present study, we examined how interleukins and tumour necrosis
factor (TNF) are involved in transition from the interictal to ictal state
during development.
Method: EL mice and the control animal, DDY mice of 4, 6, 8, 10,
12, 15, 19, 23 weeks of age were used. Western blotting was employed to
assess developmental changes of interleukins and TNF in the hippocam-
puses of these mice during development.
Results: Western blot analysis demonstrated significant increases in
the levels of interleukin and TNF in EL mice compared to the control
DDY. In EL, the levels of interleukin were increased predominantly after
experienced frequent seizures.
Conclusion: It is concluded that in EL mice, experience of frequent
seizures promotes expressions of proinflammatory cytokines, which may
facilitate the shift from the interictal to the ictal state. Inflammatory
cytokines and neurotrophic factors may work together in the process of
epileptogenesis during development.
Tuesday July 4, 2006
12:00–13:30
Ballroom 1
Platform Session
Psychiatric and Social Issues
079
DEPRESSION AND ANXIETY IN WOMEN WITH EPILEPSY
1M. Pfaefflin, 1T. May, 2I. Coban, and 2B. Schmitz (1Epilepsy Cen-
ter Bethel, Bielefeld, Germany, 2Clinic for Neurology, Charite´, Berlin,
Germany)
Purpose: To identify predictors and risk factors for depression and
anxiety in women with epilepsy.
Method: Prospective, cross-sectional study using questionnaires. In
total, 420 women (aged from 16 to 60 years) with epilepsy and on
antiepileptic drug treatment were included. Epilepsy specific data (e.g.
seizure frequency, side effects of drugs) and demographic data were as-
sessed. Restrictions and limitations due to epilepsy and quality of life
were assessed with the PESOS-Scales; depression and anxiety with the
Hospital Anxiety and Depression Scale (HADS). Statistical evaluation:
logistic regression analysis.
Results: Depression and especially anxiety were increased compared
to the German population (cp. Hinz et al. PPmP 2001; 51: 193–200):
anxiety and depression values were in 32% and in 18% of the women,
respectively, above the age adjusted 90%-percentile in general popu-
lation. Depression and anxiety correlated significantly with perceived
restrictions due to epilepsy (r = 0.56; r = 0.49; p < 0.01) and with the
global quality of life (r = −0.66; r = −0.57; p < 0.01). Multivariate
analysis revealed important predictors for depression and anxiety, e.g.
tolerability and efficacy of antiepileptic drug therapy, financial situation
and education of the women and being registered as handicapped.
Conclusion: Our data indicate that women with epilepsy are at a
higher risk for depression and particularly for anxiety. Perceived restric-
tions due to epilepsy and due to antiepileptic drug therapy as well as the
financial situation are significant predictors of anxiety and depression. A
comprehensive treatment of women with epilepsy should pay attention
to anxiety and depression.
080
SCREENING FOR SYMPTOMS OF ANXIETY AND DEPRES-
SION IN ADOLESCENTS WITH EPILEPSY AND IN THE
GENERAL POPULATION
Z. Martinovic (Institute of Mental Health, Belgrade, Serbia and
Montenegro)
Purpose: To assess the symptoms of anxiety and depression among
adolescents with epilepsy and in the general population.
Method: A sample of adolescents with epilepsy and a control group
of age- and sex-matched healthy adolescents from the general population
were screened for symptoms of anxiety and depression with Beck anxiety
inventory (BAI) and Beck depression inventory (BDI). All subjects were
tested in short 7 to 15 day intervals to determine the retest reliability. In
addition, adolescents with epilepsy were tested during a 2 year treatment
period. Pearson correlations were used to analyse dependence between
variables, and Student’s t-test was used to compare mean values between
test scores.
Results: Each group consisted of 104 subjects, age range 13–19 years
(median 17 years), 46% males. Females reported more anxiety symptoms
(t-test, p = 0.002) and depressive symptoms (t-test, p = 0.04) than males.
BAI and BDI scores showed a very high positive correlation (Pearson r
= 0.76). Adolescents with epilepsy had higher BDI scores (mean ± SD,
9.48 ± 6.52) than controls (8.21 ± 5.6) (p < 0.05), but the difference was
not statistically significant except for subgroups of those with increased
risk for depression and lack of seizure control (p < 0.05). BAI scores
of patients with newly diagnosed epilepsy (14.06 ± 9.30) were signif-
icantly higher than controls (9.54 ± 4.82) (p < 0.05) whereas the sub-
groups of patients with complete seizure control were no different from
controls.
Conclusion: The BDI and BAI showed discriminative power to char-
acterise demographic and epilepsy variables associated with increased
anxiety and depressive symptoms in adolescents with epilepsy.
081
INCIDENCE OF EPILEPSY OR SEIZURE DISORDER IN A POP-
ULATION AGED 15 YEARS AND OLDER AFTER TRAUMATIC
BRAIN INJURY
E. Pickelsimer (Medical University of South Carolina, Charleston, USA)
Purpose: To estimate the incidence of epilepsy or seizure disorder
(ESD) before and after traumatic brain injury (TBI) in a statewide rep-
resentative sample of 2118 individuals with new TBI.
Method: South Carolina, USA, currently has a follow-up registry that
captures a stratified random sample (55%) of individuals aged 15 years
and older discharged alive from inpatient hospitalisation after TBI, and
collects more in-depth information, including ESD, through chart review
and telephone interview. Registry data from the first year post-TBI were
used to estimate ESD.
Results: of participants, 5.5% said they had been told by a doctor
before their injury that they had ESD. 2.0% had no prior ESD, but said
they had had ESD in the four weeks prior to interview or had been told by
a doctor they that had developed ESD since the index TBI. Individuals
reporting preexisting ESD were more likely to have ‘fall’ listed as the
aetiology of their index TBI than individuals without preexisting ESD
(OR = 2.17, 95% CI 1.47, 3.20).
Conclusion: A higher prevalence of ESD was noted before injury
(57.8 per 1000 age-adjusted to US 1980 standard population) than is
usually reported in the literature for the general population. Increased
efforts to control ESD, and to protect individuals with uncontrollable
ESD, should result in decreased incidence of TBI in this vulnerable
group.
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082
DISSOCIATION AND SELF-REPORTED SYMPTOMS OF
AROUSAL IN DISSOCIATIVE (NONEPILEPTIC SEIZURES
1L. Goldstein, 2I. Lichter, and 2J. Mellers (1Department of Psychology,
PO77, Institute of Psychiatry, London, UK, 2Neuropsychiatry Depart-
ment, Maudsley Hospital, London, UK)
Purpose: We have demonstrated that, in addition to scores on the
Dissociative Experiences Scale (DES), the numbers of symptoms of
autonomic arousal that are experienced during dissociative seizures (DS)
help distinguish such patients from those with partial epilepsy. Currently
we investigated whether a general tendency to dissociate might be related
to particular constellations of autonomic and cognitive symptoms that
patients report during their DS, and whether general levels of anxiety
and depression contribute further to such relationships.
Method: Thirty-six patients with DS completed the DES, the Hos-
pital Anxiety and Depression Scale and the Attack Symptoms Ques-
tionnaire, which subdivides self-reported DS-related symptoms into five
categories. Mood and seizure-related symptoms that showed unadjusted
significant relationships with DES total scores (and an index of patho-
logical dissociation: DES-T) were regressed onto DES-related scores,
with seizure related symptoms in the first block and mood related scores
in the second.
Results: Whilst Total DES scores were predicted by all categories of
DS symptoms and by anxiety and depression, DES total scores were best
predicted by cognitive symptoms occurring during DS (p < 0.001, adj
R2 = 0.32). All DS symptom-types individually predicted DES-T scores
(as did depression scores); the best predictor of DES-T after adjusting for
other variables was the number of seizure related cognitive symptoms
(p < 0.001, adj R2 = 0.27).
Conclusion: Results suggest that autonomic and particularly cogni-
tive symptoms reflecting high arousal levels during DS bear a strong
relationship to more general self-reported dissociative tendencies, sug-
gesting that in DS patients, the DES may be measuring arousal-related
state dissociative experiences rather than a trait-like vulnerability to dis-
sociation.
083
LEVEL AND CONTENTS OF ICTAL CONSCIOUSNESS IN
TEMPORAL LOBE EPILEPSY
1F. Monaco, 1M. Mula, 1L. Collimedaglia, 1D. Barbagli, 1G. Tota, 1R.
Cantello, 2P. O’Callaghan, and 1,3A. Cavanna (1Department of Neurol-
ogy, Neuropsychiatry Research Group, Amedeo Avogadro University,
Novara, Italy, 2School of Psychology, Brunel University, London, UK,
3Institute of Neurology, Queen Square, London, UK)
Purpose: To develop a systematic approach for the combined assess-
ment of the level and the contents of consciousness during epileptic
seizures of temporal lobe origin, and to identify putative psychopatho-
logical correlations.
Method: 33 consecutive patients with temporal lobe epilepsy (TLE)
referred to our Epilepsy Unit were evaluated. Accurate descriptions of
ictal semiology and subjective experiences were collected by means of
clinical interviews with patients and reliable witnesses. All subjects un-
derwent quantitative assessment using the Beck Depression Inventory
(BDI), the State-Trait Anxiety Inventory (STAI), and the ICI (Ictal Con-
sciousness Inventory), a new 20-item questionnaire specifically devel-
oped to assess (1) the level of general awareness/responsiveness and (2)
the “vividness” of ictal experiential phenomena.
Results: We evaluated 41 seizure descriptions and plotted them into
a biaxial diagram according to the level vs contents of ictal conscious-
ness (Monaco et al., Epilepsy Behav 2005;7:150–160). ICI subscores for
level (L) and contents (C) showed a positive correlation (p < 0.05). L
and C dimensions were not associated with age at onset, duration of dis-
ease, seizure frequency, or localisation of EEG focus. Only C subscores
correlated significantly with affective psychopathology (p < 0.01).
Conclusion: Our quantification of both objective and subjective ictal
features in patients with TLE shows that 1) the vast majority (>80%)
of seizures involving altered conscious experiences are accompanied by
a degree of responsiveness and/or retained awareness of the surround-
ings; 2) the presence of emotionally vivid experiential phenomena is
selectively associated with comorbid affective psychopathology.
084
PRESENTATION OF EPILEPSY IN POLISH NEWSPAPERS
M. Sieminski, J. Kunikowska, and W. Nyka (Medical University of
Gdansk, Dept. of Adults’ Neurology, Gdansk, Poland)
Purpose: The aim of this study was to examine how epilepsy is pre-
sented in Polish newspapers and to assess the relevance and reliability of
information on epilepsy found in Polish articles. We also wanted to check
how newspapers can influence the prejudices and stigma connected with
epilepsy.
Method: We searched the electronic archives of the largest Polish
newspapers issued all over the country. We analysed all articles pub-
lished from 1 January 2002 to 31 December 2005, containing words
“epilepsy” or “seizure.” We divided articles into the following topical
groups: aetiology, clinical symptoms, living with epilepsy, first aid in
case of seizure, employment of patients, attitude, antiepileptic drugs,
therapy, pregnancy, erroneous articles, noninformative articles.
Results: The largest Polish newspapers published 302,299 articles
during the analysed period, out of which 262 contained one of the
searched words (0.08%). 59.6% of the articles contained no information
about the disease or the patients. The following percentage of articles
fit each of the topical groups: aetiology 6.1%; clinical symptoms, 2.3%;
living with epilepsy, 10.7%; employment, 2.3%; pregnancy, 0.7%; atti-
tude to epilepsy, 3%; AEDs, 8.4%; therapy, 1.4%; 5.3% of the articles
contained errors, in 3% of the articles epilepsy was called a “psychiatric
disease.” There were no articles about first aid in case of seizure.
Conclusion: Epilepsy is not well presented in Polish newspapers.
There is not enough information on epilepsy, especially on first aid for
seizures. The errors found in articles may lead to reinforcement of prej-
udices connected with epilepsy.
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085
FRONTAL LOBE RESECTIONS: SEIZURE OUTCOME AND
PATHOANATOMICAL DIAGNOSES—DATA FROM THE
SWEDISH NATIONAL EPILEPSY SURGERY REGISTER
1990–1999
1C. Sundal, 1K. Malmgren, 2R. Flink, and 1B. Rydenhag (1Epilepsy
Research Group, Insitute of Neuroscience and Physiology, Sahlgrenska
Academy, Go¨teborg, Sweden, 2Department of Neuroscience, Section for
Clinical Neurophysiology, Uppsala, Sweden)
Purpose: Frontal lobe resection (FLR) is the second most common
epilepsy resection but constitutes only 10–20% of surgical series. FLR
are challenging, since the epilepsy is often devastating while seizure
outcome is not as good as for temporal lobectomies. This is a report of
the outcome of FLR on a national basis.
Method: The Swedish National Epilepsy Surgery Register, which
includes data on all epilepsy surgery procedures in Sweden, was analysed
with respect to FLR and pathoanatomical diagnoses 1990–1999.
Results: 448 patients underwent resective surgery 1990–1999 and
completed a two-year follow-up. 61 of these underwent FLR. Two years
after surgery 44% (n = 27) were seizure-free, and 11% (n = 7) had
>75% reduction of seizure frequency. Of 13 patients with lesions (gan-
gliogliomas, astrocytomas or cavernomas) 78% were seizure-free, and
one had >75% reduction of seizure frequency. Of 13 patients with corti-
cal malformations 54% (n = 7) were seizure-free, and 2 (15%) had >75%
reduction of seizure frequency. Of the 23 patients who had gliosis only,
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22% (N = 5) were seizure-free, and 18% (n = 4) had >75% reduction
of seizure frequency.
Conclusion: In the Swedish national population-based epilepsy
surgery series 1990–1999 14% of the patients underwent FLR. Seizure
outcome in patients with lesions equalled that after temporal lesionec-
tomies. Resections of frontal cortical malformations also led to seizure
outcomes comparable to those after surgery for malformations else-
where. Even in patients with gliosis only, 38% obtained significant im-
provement (seizure-free or >75% reduction of seizure frequency). Pa-
tients with frontal lobe epilepsy may have a desolate situation and partial
seizure relief can be valuable.
086
PREDICTORS OF OUTCOME AFTER EPILEPSY SURGERY
FOR NONLESIONAL TEMPORAL LOBE EPILEPSY
1U. Wieshmann, 2C. Denby, 2N. Roberts, 1T. Varma, and 1P. Eldridge
(1The Walton Centre for Neurology and Neurosurgery, Liverpool, UK,
2Magnetic Resonance and Image Analysis Research Centre, University
of Liverpool, UK)
Purpose: To identify predictors of outcome after epilepsy surgery in
patients with nonlesional temporal lobe epilepsy (TLE).
Method: Nonlesional TLE patients with anterior temporal lobe re-
sections were included. (Patients with vascular lesions or tumours were
excluded; patients with normal magnetic resonance imaging (MRI)
or hippocampal sclerosis on MRI were included). All patients had a
standardised presurgical workup including Wada test and quantitative
MRI. Outcome 1 year after surgery was classified as good (Engel I
and II) or poor (Engel III and IV). Gender, age at onset and dura-
tion of epilepsy, history of febrile convulsions, the presence of auras,
the frequency of secondary generalisation, right or left sided TLE,
the memory ipsilateral to seizure onset on Wada testing, and a se-
ries of quantitative MRI parameters including hippocampal asymme-
try and volume, amygdala, temporal lobe and hemispheral volume and
hippocampal T2 relaxation time were tested for an association with
outcome.
Results: 67% had a good outcome. Only a history of febrile con-
vulsions, the presence of auras and hippocampal asymmetry/ipsilateral
volume reduction on quantitative MRI were significantly associated with
a good seizure outcome. The absence of these parameters did not neces-
sarily exclude a good outcome. About 50% of all patients without febrile
convulsions, auras or hippocampal asymmetry still had a good outcome.
Conclusion: Febrile convulsions, auras and hippocampal asymmetry
were predictors of outcome after epilepsy surgery in non-lesional TLE.
Extrahippocampal structural abnormalities, although frequently present,
were not associated with outcome.
087
SELECTIVE AMOBARBITAL TEST IN THE ANTERIOR
CHOROIDAL ARTERY: IS IT PREDICTIVE OF POSTOPERA-
TIVE MEMORY?
1S. Vulliemoz, 2J. Annoni, 3J. Willi, 2T. Landis, 4H. Yilmaz, 2A. Pegna,
and 1M. Seeck (1Presurgical Epilepsy Evaluation Unit, Neurology, Uni-
versity Hospital, Geneva, Switzerland, 2Neurology, University Hospital,
Geneva, Switzerland, 3Nuclear Medicine, University Hospital, Geneva,
Switzerland, 4Neuro-Radiology, University Hospital, Geneva, Switzer-
land)
Purpose: Surgical resection is a common treatment of pharmacoresis-
tant temporal lobe epilepsy (TLE), with postoperative memory decline
as a feared complication. Selective intraarterial amobarbital tests, e.g.
with injection in the anterior choroidal artery (IACAT), aim at predicting
postoperative memory. However, their predictive value is debated. We
compare the results of recognition memory during IACAT with interic-
tal, postictal and postoperative recall memory as well as the amobarbital
perfusion pattern.
Method: Sixteen patients with pharmacoresistant TLE underwent IA-
CAT because of concerns of postoperative verbal memory dysfunction.
After the amobarbital injection, verbal and visuo-spatial items were pre-
sented and their recognition tested. Seven patients had an additional
injection of ECD-SPECT tracer in the anterior choroidal artery to iden-
tify the anaesthetised territory. Interictal and postictal memory was deter-
mined during noninvasive workup; postoperative memory was examined
3–6 months after the intervention.
Results: Of the 7 operated patients, only 1 suffered moderate decrease
of verbal memory. This patient had the worst IACAT performance (15%).
In all other patients, IACAT performance was not correlated with the
postoperative outcome. Also, no significant correlation between preop-
erative interictal, postictal and postoperative performances was found.
IACAT coupled with intra-arterial SPECT revealed major variability of
the territory affected by amobarbital.
Conclusion: Only a severe decrease of verbal memory during IACAT,
compared to interictal scores, predicted a significant postoperative mem-
ory decline. Variation in the anaesthetised areas might explain the lack
of correlation between IACAT results and postoperative memory. Pos-
tictal memory function did not reliably predict IACAT performance or
postoperative memory.
088
LONG-TERM MEMORY PERFORMANCE AFTER SURGICAL
TREATMENT OF UNILATERAL TEMPORAL LOBE EPILEPSY
(TLE)
1,5L. Jutila, 2H. Hurskainen, 1M. ¨Aikia¨, 5,6A. Ylinen, 2A. Immo-
nen, 3E. Mervaala, 4I. Alafuzoff, 2M. Vapalahti, and 1,5R. Ka¨lvia¨inen
(1Department of Neurology, Kuopio Epilepsy Center, Kuopio Univer-
sity Hospital, Kuopio, Finland, 2Department of Neurosurgery, Kuo-
pio Epilepsy Center, Kuopio University Hospital, Kuopio, Finland,
3Department of Clinical Neurophysiology, Kuopio Epilepsy Center,
Kuopio University Hospital, Kuopio, Finland, 4Department of Clinical
Pathology, Kuopio Epilepsy Center, Kuopio University Hospital, Kuo-
pio, Finland, 5Department of Neuroscience and Neurology, University
of Kuopio, Kuopio, Finland, 6Department of Neurology, Neurosurgery
and Rehabilitation, Tampere University Hospital, Tampere, Finland)
Purpose: To assess long-term memory performance after surgical
treatment of TLE.
Method: Altogether 128 adult patients with unilateral TLE were op-
erated on at KUH 1988–2002. Complete neuropsychological evaluation
(preoperatively, one year postoperatively, and two or three years postop-
eratively) was available for 107 patients, with 98 patients eligible for the
study. Engel I–II outcome was achieved in 71% of operations. Immediate
and delayed verbal memory was evaluated using Wechsler Memory Scale
Logical Prose Subtest and Paired Associate Learning. Visual memory
was estimated using WMS visual reproduction test and Rey-Osterrieth
Complex Figure.
Results: MANOVA for repeated measures showed a significant de-
crease in the immediate and delayed recall of paired associates among
both left and right TLE groups (p < 0.001). The delayed recall of paired
associates deteriorated especially between one year and long term follow-
up (p < 0.001). There was no significant change in learning and delayed
recall of logical prose. The copying of Rey Figure also decreased among
both TLE groups (p < 0.001), but there was no significant change in
the delayed recall of Rey Figure. Immediate recall in the WMS visual
reproduction test improved slightly in both TLE groups (p < 0.05) pos-
sibly reflecting practice effect, but delayed recall showed no significant
change.
Conclusion: Surgical treatment of TLE can have adverse effects on
postoperative verbal memory performance irrespective of side of surgery.
In this study the delayed recall of paired associates deteriorated especially
between one year and long-term follow-up, highlighting the importance
of long-term follow-up of operated patients.
089
COGNITIVE OUTCOME IN CHILDREN WITH REFRACTORY
EPILEPSY AFTER EARLY SURGICAL TREATMENT
1D. Battaglia, 1D. Lettori, 1D. Chieffo, 1A. Sacco, 1P. De Rose, 1D.
Martinelli, 1G. Vasco, 2G. Tamburrini, 1L. Massimi, 2C. Di Rocco, and
2F. Guzzetta (1Neuropsichiatria Infantile, Universita` Cattolica Sacro
Cuore- Rome, Italy, 2Neurochirurgia Infantile, Universita` Cattolica
Sacro Cuore- Rome, Italy)
Purpose: The aim of our study was to investigate cognitive changes
after surgery performed before school-age and possibly to study the
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cognitive profile in order to evaluate functional reorganisation after early
surgical treatment.
Method: Forty five children affected by resistant epilepsy, operated
on before 7 years of age and with a postsurgical follow-up (≥1 year)
were included. Twenty-five children were affected by cortical malfor-
mations, 12 by low grade tumours, 3 by Sturge-Weber syndrome, 4
by porencephalic cysts and one by Rasmussen encephalitis. Presurgi-
cal evaluation included clinical examination, seizure semiology, video-
EEG monitoring, MRI and neuropsychological assessment. Mean age at
surgery was 2.2 years (range 4 months–6 years 9 months). Postsurgical
follow-up included neurological examination, seizure outcome, MRI,
EEG and neuropsychological assessment. Mean duration of follow-up
was 3 years (range 1 year- 8.5 years).
Patients were assessed postoperatively at 6 weeks, 6 months, 1 year
and every year.
Results: Nineteen patients underwent a hemispherectomy, 9 a mul-
tilobar resection and 17 a focal resection (9 temporal, 4 frontal and 4
parieto/occipital). Thirty-one children were seizure-free (class Ia or Ib
of Engel), 8 presented with rare seizures (class II) and 5 presented a 50%
seizure reduction. Only 13 children had a normal mental development
before surgery. After surgery: in the group with multilobar resection or
hemispherectomy 6/19 patients improved, in the group with focal resec-
tion 3/17 patients showed an improvement and 4 a further impairment
of cognitive functions. Neuropsychological profile revealed an improve-
ment of verbal competences in patients treated with parieto/occipital
resection or hemispherectomy, irrespective of the side of surgery.
Conclusion: Early surgical treatment in children with symptomatic
resistant epilepsy may sometimes improve cognitive functions. Reorgan-
isation of neuropsychological functions, particularly regarding verbal
competences, was observed especially in patients with extensive resec-
tions.
090
HEALTH-RELATED QUALITY OF LIFE IN ADULT EPILEPSY
SURGERY CANDIDATES: A SWEDISH NATIONAL, PROSPEC-
TIVE, LONGITUDINAL STUDY
1E. Sager Magnusson, 1G. Ekstedt, 2C. Taft, and 1K. Malmgren
(1Epilepsy Research Group, Institute of Neuroscience and Physiol-
ogy, Sahlgrenska Academy at Go¨teborg University, Go¨teborg, Swe-
den, 2Health Care Research Unit, Institute of Medicine, Sahlgrenska
Academy at Go¨teborg University, Go¨teborg, Sweden)
Purpose: To prospectively assess and compare the health-related qual-
ity of life (HRQL) of adults evaluated for epilepsy surgery: 1) in operated
versus nonoperated patients, 2) in operated seizure-free versus seizure-
persistent patients, and 3) with population norms.
Method: 141 adult epilepsy surgery candidates (median age = 33;
45% men) completed the SF-36 health survey and a questionnaire in-
cluding epilepsy-related questions at initial evaluation and two years
postoperatively (n = 96) or after having been declined surgery (n =
45). A sex and age-matched reference sample (n = 987) was randomly
drawn from the Swedish SF-36 normative database. Data analysis was
nonparametric.
Results: 53 (55%) of the operated patients (OP) were seizure-free
(SzFree) after 2 years, versus 5 (11%) of the nonoperated patients
(NonOP). At baseline, both OP and NonOP had significantly worse
scores than referents in all SF-36 domains, except bodily pain for OP.
OP scored better than NonOP in only 1/8 domains, versus 5/8 domains
at follow-up. Between baseline and follow-up, SzFree improved signifi-
cantly in 7/8 domains, while neither operated seizure-persistent patients
(SzPrst) nor NonOP changed significantly in any domain. At follow-
up, SzFree scored better than NonOP in all SF-36 domains and than
SzPrst in 5/8 domains. SzFree differed from referents only in social
functioning.
Conclusion: Patients rendered seizure-free after epilepsy surgery
significantly improved in HRQL to levels largely comparable with
those of their counterparts in the population, emphasising benefits of
surgery beyond seizure eradication. Conversely, the lack of HRQL
decrements in patients with persistent seizures postoperatively sug-
gests that suboptimal surgical outcome may not worsen their health
status.
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091
PROGNOSTIC FACTORS IN PATIENTS WITH MESIAL TEM-
PORAL LOBE EPILEPSY (MTLE): A PRELIMINARY STUDY
1P. Tinuper, 1F. Bisulli, 1F. Pittau, 1I. Naldi, 1P. Avoni, 1A. Parmeg-
giani, 1L. Licchetta, 2R. Mai, 2L. Tassi, 3A. Gambardella, 3A. Labate,
3A. Quattrone, and 1A. Baruzzi (1Epilepsy Center for Adults and Chil-
dren, Department of Neurological Sciences, University of Bologna, Italy,
2Center for Epilepsy Surgery, Niguarda Hospital, Milan, Italy, 3Epilepsy
Center, Department of Neurological Sciences, University of Catanzaro,
Italy)
Purpose: To disclose familial, clinical, anamnestic, electrophysiolog-
ical and neuroradiological factors correlated to prognosis in patients with
mesial temporal lobe epilepsy (MTLE).
Method: 170 MTLE patients were studied for family history, clinical
findings, neuropsychological and instrumental data (EEG, video-EEG,
neuroimaging) and outcome. This population was then divided into le-
sional (LES: 74 pts, 43.5%) and non-lesional (N-LES: 96 pts, 56.5%)
groups.
Results: Among LES pts 38 (51%) were drug-resistant (DR) and 36
(49%) responsive (N-DR). Mesial temporal sclerosis (MTS) was present
in 58% of N-DR and in 71% of DR patients. Among 48 pts with MTS
33% had presented with febrile convulsions (FC) during childhood in the
N-DR group versus 39% in the DR group. Familial and sporadic cases
were equally present in DR and N-DR groups. Among N-LES pts 18%
had had FC: 34% were DR and 66% N-DR. CF antecedents were 40%
and 6% respectively. Familial cases were 3% in DR group and 41% in
N-DR group.
Conclusion: MTLE is a heterogeneous syndrome. Establishing the
factors responsible for and associated with drug resistance is important
for therapeutic purposes, as prompt diagnosis of drug resistance must
lead to an early surgical approach. This preliminary study shows that
MTS is not a negative prognostic factor. A positive family history of
epilepsy is a favourable prognostic factor in N-LES and LES pts. FC are
associated with MTS, but do not constitute a negative factor.
092
PREDICTIVE FACTORS FOR PHARMACORESISTANT
EPILEPSY
N. Hitiris, R. Mohanraj, and M. Brodie (Epilepsy Unit, University Divi-
sion of Cardiovascular And Medical Sciences, Western Infirmary, Glas-
gow, Scotland, UK)
Purpose: Uncontrolled epilepsy can result in cognitive deterioration,
psychosocial dysfunction, and increased morbidity and mortality. Clin-
ical differences between responders and nonresponders to antiepileptic
drugs (AED) were analysed for factors that could help predict refractory
epilepsy.
Method: Subjects with suspected seizures were referred to the
epilepsy clinic of the Western Infirmary, Glasgow, between July 1982
and May 2001. Patients with newly diagnosed epilepsy were divided
into 3 groups: responders were patients who went into remission, non-
responders were patients who were pharmacoresistant de novo and re-
lapsers were patients whose intractable seizures returned after at least
one year of seizure freedom.
Results: Follow up data were available for 780 (88%) patients from
a total of 890 with newly diagnosed epilepsy. We identified 462 (59%)
responders, 42 (5%) relapsers and 276 (35%) nonresponders. Median
numbers of pretreatment seizures were 4 for responders and 8 for
nonresponders (Mann-Whitney test, p < 0.0001). Median numbers
of seizures reported during the 3 months prior to starting treatment
were 2 for responders and 4 for nonresponders (Mann-Whitney test,
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p < 0.0001). In comparison to responders, nonresponders were more
likely to have a family history of epilepsy [OR 2.22 (95% CI 1.42–
3.48), p = 0.001], traumatic brain injury [OR 3.11 (95% CI 1.92–5.03),
p < 0.001], psychiatric comorbidity [OR 2.29 (95% CI 1.51–3.48), p
< 0.001] and febrile convulsions [OR 2.62 (95% CI 1.24–5.52), p =
0.012].
Conclusion: The numbers of pretreatment seizures were greater in pa-
tients who developed refractory epilepsy than those entering remission.
Traumatic brain injury, febrile convulsions, psychiatric co-morbidity and
family history were all predictive of uncontrolled epilepsy.
093
DOES THE MECHANISM OF ACTION OF INITIAL
ANTIEPILEPTIC DRUG INFLUENCE THE DEVELOP-
MENT OF PHARMACORESISTANCY IN NEWLY DIAGNOSED
EPILEPSY?
1A. Kantanen, 1M. ¨Aikia¨, 1,3L. Jutila, 2E. Mervaala, and 1,3R. Ka¨lvia¨inen
(1Department of Neurology, Kuopio Epilepsy Center, Kuopio University
Hospital, Kuopio, Finland, 2Department of Clinical Neurophysiology,
Kuopio Epilepsy Center, Kuopio University Hospital, Kuopio, Finland,
3Department of Neuroscience and Neurology, University of Kuopio,
Kuopio, Finland)
Purpose: We aimed to evaluate whether the mechanism of action of the
initial antiepileptic drug (AED) treatment influences the rate of pharma-
coresistancy by randomising newly diagnosed patients with adult-onset
focal epilepsy to initial treatment with either sodium-channel blocker
carbamazepine or GABAergic AED (vigabatrin/tiagabine).
Method: From the population of Kuopio University Hospital District
(pop. 250,000) in Finland patients with newly diagnosed focal epilepsy
(over 15 years and with normal intelligence (IQ >85) during time period
from 1988 to 1999 were enrolled. Patients with progressive neurological
disorder, severe psychiatric or other medical condition or substance abuse
were excluded.
Results: Altogether 220 patients were randomised and followed for
five years. Altogether 111 patients were randomised to treatment with
sodium channel blocker and 109 patients to GABAergic AED (56 to
vigabatrin and 53 to tiagabine). The baseline demographic variables
did not differ between the groups. After 3 years 60 (54%) of the ini-
tial sodium-channel-blocker group were seizure free, 40 (36%) had
only occasional seizures and 10 (9%) were pharmacoresistant. Alto-
gether 41 (38%) of the patients randomised to GABAergic AEDs were
seizure free, 59 (64%) had occasional seizures and 9 (8%) were phar-
macoresistant. Preliminary results at 5 years follow-up show a similar
pattern.
Conclusion: The rate of pharmacoresistant patients at 3 years of
follow-up was equally independent of the mechanism of action of the
initial AED.
094
SEXUAL DESIRE, SEXUAL CONFIDENCE AND TESTOS-
TERONE LEVELS IN MEN WITH EPILEPSY
1S. Duncan, 2K. Drinkwater, 1K. Easterford, 3P. Clough, and 4A. Talbot
(1Department of Neurology, Greater Manchester Neurosciences Centre,
Hope Hospital, Salford, UK, 2Department of Behavioural Medicine,
Greater Manchester Neurosciences Centre, Hope Hospital, Salford, UK,
3David Lewis Centre, Alderley Edge, Cheshire UK, 4Clinical Pathology
Medeval LTD Manchester Science Park, Manchester, UK)
Purpose: Sexual dysfunction in men with epilepsy (MWE) is said to
be common. AED induced reduction in testosterone levels have been
suggested as one mechanism. This ignores the psychosocial impact of
epilepsy.
Method: Sixty men with epilepsy aged between 18 and 60 years, tak-
ing AED monotherapy were recruited. None took antidepressant medi-
cation. A control group of 60 men drawn from patient’s spouses, friends
and hospital staff were recruited.
Each man completed the Hospital Anxiety and Depression Scale
(HADS), the WHOQL-BREF (UK), two validated questionnaires ex-
ploring desire for intimacy/ intercourse (SDI) and sexual confidence
(SSES). Men also answered 5 questions specifically about sexual dreams,
fantasies, and spontaneous arousal. 40 mls of blood was withdrawn be-
tween 9am and noon for testosterone, SHBG, albumin, androstenedione,
and estradiol.
Results: There was no significant difference between men and con-
trols SDI scores suggesting the MWE did not differ in their desire for
sexual intimacy. MWE had significantly lower SSES scores than con-
trols (p = 0.006) suggesting they believed themselves less likely to be
able to initiate or complete intercourse with a partner. They reported as
frequent sexual dreams/fantasies and episodes of arousal when alone as
controls. MWE had significantly higher anxiety and depression scores
(p < 0.05), and there was a significant correlation between depression
scores and SSES scores (p = 0.01, r = −0.26). There was no significant
difference in free testosterone, biologically active testosterone (BAT),
estradiol, or androstenedione between the groups.
Conclusion: There is no evidence in the literature to suggest that
MWE sustain a reduction of BAT to subphysiological levels. More stud-
ies exploring the psychosocial impact of epilepsy on sexual function are
required.
095
SEX AND GONADOTROPIN HORMONAL LEVELS AMONG
TEENAGE GIRLS WITH EPILEPSY
S. Kasradze, O. Toidze, T. Gagoshidze, I. Toidze, K. Geladze, and I.
Todria (Epilepsy Prevention And Control Centre; Tbilisi, Georgia)
Purpose: Reproductive-endocrine disorders (RED) are often found
among women with epilepsy on AED treatment, especially in women
with epilepsy manifested at puberty (EMP) and on AED therapy. We
investigated sex and gonadotropin hormonal levels in EMP teenage girls
in newly diagnosed patients and in girls under AED therapy.
Method: One hundred and seventeen consecutive girls with epilepsy
with age range 12–18 years (mean 16.2 ± 1.6) and EMP were re-
cruited; 64 had cryptogenic focal (CFE) and 53 idiopathic generalised
(IGE) epilepsy. In all cases levels of luteinising (LH), follicle stimu-
lating (FSH), prolactin (PRL), progesterone (PG) and free testosterone
(FTST) were measured on the days 11–14th with shorter (<24 days)
menstrual cycle (MC), on the days 21–22th with normal MC (24–34
days) or oligomenorrhea (34day<MC<3 month), and randomly in girls
with amenorrhea (no MC for 3 months). At admittance 50 patients had
never taken AEDs, while 67 had taken different AED therapy (mean for
2.6 ± 1.1 years). Statistical analysis used SPSS (12).
Results: Hyperandrogenism (HA) was revealed in 42 cases (35.9%)
and hyperprolactinemia (HPRL) in 29 girls (24.8%). Treated and non-
treated EMP girls did not significantly differ by the occurrence of HA
(p < 0.7) and HPRL (p < 0.9). Higher than normal LH level was more
often found among girls with (38.8%) than without (16%) AED treat-
ment (p < 0.014). Among patients with nontreated as well as treated
IGE, higher than normal levels of LH and PRL were more often found
than in patients with CFE (p < 0.019 and p < 0.022 respectively).
Conclusion: The teenage period is one of the critical periods for mat-
uration of the reproductive-endocrine system. Some anticonvulsants in-
crease the risk of RED development. So, in EMP girls, hormonal inves-
tigation is essential before AED treatment to prevent RED, especially
among patients with IGE.
096
STATUS EPILEPTICUS IN PREGNANCY
1D. Battino, 2E. Bonizzoni, 3J. Craig, 4D. Lindhout, 5E. Perucca, 6A.
Sabers, 7T. Tomson, and 8F. Vajda (1Carlo Besta National Neurological
Institute, Milan, Italy, 2Institute of Medical Statistics And Biometry, Uni-
versity of Milan, Italy, 3Department of Neurology, Royal Group of Hos-
pitals, Belfast, UK, 4Department of Medical Genetics, University Med-
ical Centre, Utrecht, The Netherlands, 5Clinical Pharmacology Unit,
University of Pavia, and Laboratories for Diagnostics and Applied Bio-
logical Research, Institute of Neurology IRCCS C. Mondino Foundation,
Pavia, Italy, 6Epilepsy Clinic, University Hospital, Glostrup, Denmark,
7Department of Neurology, Karolinska Hospital, Stockholm, Sweden,
8Monash University, Australian Raoul Wallenberg Center, Melbourne
University, Melbourne, Australia)
Epilepsia, Vol. 47, S3, 2006
7TH EUROPEAN CONGRESS ON EPILEPTOLOGY 27
Purpose: Traditionally, status epilepticus has been associated with
high foetal and maternal mortality. We used the EURAP study of
pregnant women on antiepileptic drugs (AEDs) to evaluate the occur-
rence and outcome of status epilepticus during pregnancy.
Method: EURAP (The International Registry of Antiepileptic Drugs
and Pregnancy) is a prospective study aimed at determining the compar-
ative risk of birth defects following intake of AEDs during pregnancy.
Originally set up in Europe in 1999, EURAP is now an international
project receiving data from 40 countries worldwide. The Registry is
based on an electronic database enabling real time checks of case record
forms and periodic audits. In addition to collecting data on AED expo-
sure, EURAP records information on occurrence of seizures and status
epilepticus each trimester. The present analysis is based on the first 3,358
prospective pregnancies completed by December 2005.
Results: Fifty-five cases (1.6%) of status epilepticus were observed
among 3,358 pregnancies. Of these, 16 were convulsive and 39 noncon-
vulsive. Cases were evenly distributed through the trimesters. Twenty-
seven women had localisation-related and 28 generalised epilepsy. No
episodes of status epilepticus resulted in maternal death. With regards to
foetal outcome 1 stillbirth occurred shortly after an episode of convul-
sive status epilepticus. One perinatal death, 1 spontaneous abortion and
1 induced abortion were also noted; none occurred close to the period of
status epilepticus.
Conclusion: The present study suggests a much more favourable prog-
nosis in terms of maternal and foetal outcome than previous reports of
status epilepticus in pregnancies of women on AEDs.
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097
NOVEL SYSTEM FOR AUTOMATED SEIZURE DETECTION
IN NEWBORNS
1S. Faul, 2G. Boylan, 1L. Marnane, 1G. Lightbody, and 3S. Connolly
(1Department of Electrical and Electronic Engineering, University Col-
lege Cork, Cork, Ireland, 2Department of Paediatrics and Child Health,
University College Cork, Ireland, 3Department of Clinical Neurophysi-
ology, St. Vincent’s Hospital, Dublin, Ireland)
Purpose: Seizures are a common neurological emergency in the
neonatal intensive care unit. Clinical signs of neonatal seizures can be
very subtle or entirely subclinical and hence the electroencephalogram
(EEG) is the only reliable tool for their detection. However, constant
supervision by trained specialists is still needed for adequate seizure de-
tection. An automated seizure detection system would remove the need
for constant EEG supervision. The aim of this study was to use a dig-
ital signal processing theory to develop a multistage seizure detection
system.
Method: The proposed system breaks the seizure detection problem
up into three sections: preprocessing, feature extraction and classifi-
cation. The preprocessing element, based on independent component
analysis, incorporates multichannel analysis and reduces the effect of
artifacts. Defining features are then extracted from the resulting signals
using techniques from a wide range of signal processing techniques,
from frequency analysis to modelling. Finally, a classification network
makes the final decision based on changes in the characteristic feature
set.
Results: Preliminary tests carried out on neonatal EEG data, extracting
10 features, detected 45 out of 46 seizures (97.82%) with a mean delay
of only 11.4 seconds between commencement of the seizure and its
detection.
Conclusion: The neonatal seizure detection system proposed in this
study produces rates and speed of detection surpassing previously docu-
mented methods. An implementation of the system will undergo clinical
tests after further simulation and development. This system will greatly
aid clinical neurophysiologists in detecting seizures rapidly, thus min-
imising the impact on the infant.
098
IN THE NEONATAL PERIOD, FOCAL MOTOR SEIZURES
WITH TYPICAL AUTOMATISMS AND WITH HYPERKINETIC
AUTOMATISMS ARE EPILEPTIC EVENTS
M. Mastrangelo (Servizio Di Neurologia Osp Buzzi AO ICP, for the
Italian League Against Epilepsy Study Group, On Neonatal Seizures,
Italy)
Purpose: Focal motor seizures with typical (temporal lobe) automa-
tisms and with hyperkinetic automatisms are comprised among epileptic
seizure types in Axis 2 of the Proposed Diagnostic Scheme for People
with Epileptic Seizures and with Epilepsy: Report of the ILAE Task Force
on Classification and Terminology (Engel J Jr, Epilepsia, 2001;42:796–
803). Regarding the neonatal period, Mizrahi and Watanabe in their Clas-
sification and Characterization of neonatal seizures, affirm that the pre-
sumed pathophysiology of motor automatisms is nonepileptic (Mizrahi
EM, Watanabe K. In Roger J. et al., Epileptic Syndromes (3rd ed) John
Libbey, 2002;15–31). In order to better understand this dichotomy, we
reviewed video EEG recordings of neonatal automatisms to examine the
pathophysiology of these ictal events.
Method: We carefully reviewed the video EEG recordings of more
than fifty seizuring neonates observed by the Italian League Against
Epilepsy Study Group on Neonatal Seizures, considering the clinical
ictal semiology with concomitant EEG activity, of oral-buccal-lingual
movements, progression movements and complex purposeless move-
ments.
Results: In our sample, some stereotypic oral-buccal-lingual move-
ments, some progression movements such as pedalling or bicycling or
rowing, some complex purposeless movements such as sudden arousal
with transient increased random activity or with asymmetric tonic pos-
turing, are generally associated to a less or more well defined ictal EEG
activity.
Conclusion: In the neonatal period, as in other ages, motor automa-
tisms have to be considered epileptic events. The peculiar and stereotyped
characteristics of clinical ictal events are suggestive for epileptic events
and in such a condition an ictal EEG concomitant activity is generally
recognisable.
099
HEART RATE VARIABILITY IN NEONATES WITH SEIZURES
1B. Greene, 2G. Boylan, 1R. Reilly, and 3S. Connolly (1School of Elec-
trical, Electronic & Mechanical Engineering, University College Dublin,
Dublin Ireland, 2Department of Paediatrics and Child Health, Univer-
sity College Cork, Ireland, 3Department of Clinical Neurophysiology,
St. Vincent’s University Hospital, Dublin, Ireland)
Purpose: To document and quantify heart rate variability changes in
neonates during seizures and to compare these changes with those in
controls.
Method: Time and frequency domain heart rate variability (HRV)
measures were compared for 12 records from 10 neonates with seizures
and 11 healthy controls. Measures were also compared for seizure and
non-seizure periods within each patient. Time domain HRV analysis
was performed by examining timing changes in the R–R interval time
series as well as changes in the R–R interval spectral entropy (H). The
frequency domain HRV was calculated by means of the R–R interval
“spectrum of intervals” power spectral density (PSD) method.
Results: A total of 658 EEG documented seizures were recorded in 10
neonates. A significant decrease in the mean R–R interval was observed
in 9 records during seizures when compared to non-seizure periods.
The mean R–R interval for neonates with seizures was significantly
less than for healthy neonates (μseizure = 0.45s, μcontrol = 0.50s, p <
0.05). An increase in R–R interval spectral entropy was observed in
seizure babies when compared to controls (p < 0.05). A decrease in H
was noted in 10 records (p < 0.05). This decrease was significant in 7
records. Significant changes in the R–R interval PSD were noted during
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seizures with decreases in the LF and HF power in 6 (p < 0.05) and 4
records (p < 0.05) respectively.
Conclusion: These results show consistent increases in heart rate dur-
ing clinical and subclinical neonatal seizures. Sudden changes in heart
rate in sick newborn babies with no obvious clinical seizure activity may
warrant further investigation with electroencephalography (EEG).
100
REFLEX ABSENCE SEIZURES: CLINICAL CASE WITH
VIDEO EEG
1F. Sanmarti, 2I. Ma´laga, and 2M. Pineda (1Epilepsy Unit. Neurol-
ogy Department. Hospital Univesitario Sant Joan De Deu. Barcelona.
Spain., 2Neurology Department. Hospital Univesitario Sant Joan De
Deu. Barcelona. Spain)
Purpose: To present a case of reflex absence seizures in an infant, an
extremely rare form of reflex seizures, described only twice before.
Method: Clinical data and video EEG recordings of the patient were
revised.
Results: A previously healthy 18-month male infant presented with
brief episodes of staring, unresponsiveness and interruption of activity
always after stimulation of the face. On the video EEG a normal baseline
pattern could be seen. Sudden stimulation of either the right or the left
cheek provoked: 1) isolated generalised spikes that did not have clini-
cal significance and 2) absence seizures with a characteristic pattern of
diffuse 3 Hz spike and wave complexes, with a duration that ranged one
to three seconds. Stimulation of other parts of the face or the body or
eating did not induce seizures. VPA was started, resulting in total seizure
control and normalisation of the EEG. After two years VPA was tapered
and the patient has remained asymptomatic ever since.
Conclusion: To our knowledge, reflex absence seizures have only
been reported twice before by De Marco (1990) and Voskuil (2002).
Both cases had similar clinical and video EEG characteristics to ours, all
having an excellent outcome. We believe that these 3 patients alone rep-
resent an extremely rare form of idiopathic generalised epilepsy (IGE)
that could be added to those known as “IGE not officially recognised by
the ILAE,” which are: IGE with absences of early childhood, perioral
myoclonia with absences, idiopathic generalised epilepsy with phan-
tom absences, Jeavons syndrome (eyelid myoclonia with absences), and
monogenic IGE syndromes.
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CSWS OR CSWS-LIKE SYNDROME: AN HETEROGENEOUS
GROUP COMPRISING CLINICAL AND ELECTROEN-
CEPHALOGRAPHIC FEATURES AND RESPONSE TO
TREATMENT
Y. Geerts (Epilepsy Centre S.E.I.N., Zwolle, The Netherlands)
Purpose: To look for different characteristics in clinical presentation
as evolution of cognitive impairment, dyspraxia, seizures and electroen-
cephalographic features in children with CSWS or CSWS-like syndrome
with or without cerebral lesion, with bilateral but independent foci, with
continuous spike waves during sleep or when awake and sleeping.
Method: We retrospectively reviewed all children with CSWS-like
syndrome referred to our epilepsy centre from 2000 to 2005. All under-
went at least one long term EEG/video registration including a full night
of natural sleep and one psychological examination. Many of them also
had an orthophonic evaluation.
Results: Twenty-eight children were found with CSWS; 7 had con-
tinuous spike waves even during daytime, 4 had cerebral lesions, 3 had
two independent epileptic foci with CSWS-features. Most of the children
were treated with valproate, ethosuximide and/or lamotrigine. Some also
received steroids or levetiracetam. Sometimes carbamazepine could not
be discontinued as is recommended in CSWS. The outcome with regard
to cognitive impairment, behaviour and dyspraxia was variable but no
specific differences were found between the group with or without cere-
bral lesion, or between the group with only a continuous spike and waves
during sleep compared to the group with CSW during sleep and when
awake. Even in the children with two independent CSWS-foci there was
a different response of the foci to treatment.
Conclusion: Until now no parameter, clinical or electroencephalo-
graphic, can be used for drug selection or for prediction of the outcome
in children with CSWS. It seems that the outcome in the symptomatic
group does not differ from the others.
102
SEIZURES IN IMMUNISED CHILDREN WITH SUBACUTE
SCLEROSING PANENCEPHALITIS (SSPE)
N. Jovic, P. Ignjatovic, and D. Vucinic (Clinic of Neurology and Psychi-
atry for Children and Youth, Serbia & Montenegro)
Purpose: SSPE is a progressive, fatal neurodegenerative disease
caused by defective measles virus. Early diagnosis is based on clinical
features, high titers of serum and cerebrospinal fluid measles antibodies
and EEGs.
Method: A group of 16 children (12 boys, 4 girls) with SSPE aged 4.5
to 16.5 years (mean 11.2) was diagnosed and treated in our Clinic from
1995 to 2005. Measles vaccination was given in 12 children. Disease
onset ranged from 4.5 to 15.5 years (mean 8.3 in nonimmunised and
13.2 in vaccinated patients). Epilepsy was analysed with respect to the
initial symptoms, clinical course and therapeutic response.
Results: Cognitive dysfunctions followed by myoclonic jerks occur-
ring after 15 days to 3.5 months, were recognised as typical initial symp-
toms in 5 children. Intractable seizures in 3 patients (focal motor with
secondary generalisation in 2 and atypical absences in 1 child) preceded
SSPE for 1.5 to 4 years. Five patients presented with focal motor deficits
(2), visual loss (2) and psychotic behaviour (1). Focal motor fits (2), gen-
eralised tonic–clonic seizures (1) and hemiconvulsive epileptic status (1)
occurred early and preceded cognitive decline and periodic myoclonus.
Initial segmental myoclonus was seen in 2 additional cases. Unilateral
myoclonic seizures persisted during phases II–IIIa in 1 of them. Four
non-vaccinated children (including 2 with early visual loss) with fulmi-
nant SSPE died 3 and 5 months after the disease onset. Chronic form
(mean 4.2 years) was seen in 3 patients (including 2 with seizures pre-
ceding SSPE). Intrathecal interferon provoked generalised seizures in
1 patient. There were no therapeutic effects of oral inosiplex, alpha-2b
interferon or AEDs on seizure control.
Conclusion: Immunisation seems to be associated with changing the
clinical SSPE expression. Later age of onset and atypical course (pre-
existing intractable epilepsy or seizures dominating in early SSPE stages)
could be an increasing problem in differential diagnosis and treatment.
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PHOTOSENSITIVE BENIGN MYOCLONIC EPILEPSY IN
INFANCY
1G. Capovilla, 1F. Beccaria, 2A. Gambardella, 1A. Montagnini, 1P. Avan-
taggiato, and 3,4S. Seri (1Epilepsy Center, C. Poma Hospital, Mantova,
Italy, 2Institute of Neurology, Universita` Magna Graecia, Catanzaro,
Italy, 3Dept of Neuroscience, II Universita` Tor Vergata, Rome, Italy,
4Aston University, Birmingham, UK)
Purpose: To describe the electroclinical features of subjects who pre-
sented with a photosensitive benign myoclonic epilepsy in infancy (PB-
MEI).
Method: The patients were selected from a group of subjects with
epilepsy with seizure onset in infancy or early childhood. Inclusion
criteria were the presence of photic-induced myoclonic seizures and
a favourable outcome. Cases with less than 18 month follow up were
excluded from the analysis.
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Results: Eight patients were identified (4 males, 4 females). Personal
history was uneventful. All of them had familial antecedents of epilepsy.
Psychomotor development was normal in 6 cases, both before and after
seizure onset. The remaining patient showed a mild mental retardation
and a further patient showed some behavioural disturbances. Neuroradi-
ological investigations, when performed (5 cases), gave normal results.
The clinical manifestations were typical and could vary from upward
movements of the eyes to myoclonic jerks of the head and shoulders, iso-
lated or briefly repetitive, never causing a fall. Age of onset was between
11 months and 3 years and 2 months. Characteristically, the seizures were
always triggered by photic stimulation. Non–photo-induced spontaneous
myoclonic attacks were reported in 2 cases during the follow-up. Other
types of seizures were present at follow-up in 2 cases. The outcome was
favourable, even if, usually, seizure control required high AED plasma
levels. Since the clinical symptoms were not recognised early, some
patients were treated only many years after the onset of symptoms.
Conclusion: Among BMEI patients, our cases constitute a subgroup
in which myoclonic jerks were always triggered by photostimulation, in
particular at onset of their epilepsy.
104
TYPICAL ABSENCE EPILEPSY DURING INFANCY: CLINI-
CAL DATA AND OUTCOME
E. Shahar, J. Genizi, Y. Nevo, and R. Kaufman (Child Neurology Unit &
Epilepsy Service, Meyer Children Hospital, Rambam Medical Center,
Rappaport School of Medicine, Haifa, Israel)
Purpose and Method: Attempt to allocate patients with characteristic
findings of childhood or juvenile absence epilepsy presenting before the
age of 3 years and delineate the clinical manifestations, EEG findings,
therapy and outcome for such infants.
Results: Seven infants presented at age of 11–36 months (mean:
26.4 months) with freezing episodes, one also with myoclonic jerks.
These corroborated with generalised epileptiform discharges of 3–4 Hz
spike/wave and normal background activity on the EEG, a photosensitive
response induced in 3 children. All 7 children were initially treated with
valproic acid in order to abort the absences. Six infants were initially
controlled but 2 relapsed when therapy was withdrawn after 3 years.
These 2 children, with still an epileptiform EEG, required prolonged
valproate therapy for 4–6 years that maintains them seizure free, prob-
ably transforming into the childhood form of absence epilepsy. These 6
children remain seizure-free within a follow-up period of 1.5–7 years.
Cognition was in the low normal range in 3 children, 1 of them with
recurrent absences requiring treatment with combined valproic acid and
lamotrigine.
Conclusion: The data presented here delineates a rare idiopathic gen-
eralised epilepsy presenting with typical absences during infancy prior
to age 3 years, very similar to childhood and juvenile absence epilepsy
recognised as distinct epileptic syndromes by the ILAE classification.
Therefore, early onset typical absences epilepsy before age 3 years may
also be added to the current ILAE classification of the epileptic syn-
dromes as a distinct generalised syndrome.
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AUTOMATISMS IN TYPICAL ABSENCES DO NOT CHANGE
THE PROGNOSIS
F. Beccaria, A. Montagnini, P. Avantaggiato, and G. Capovilla (De-
partment of Child Neuropsychiatry, Epilepsy Center, C. Poma Hospital,
Mantua, Italy)
Purpose: To evaluate prognostic differences related to the presence
of automatisms in typical absence seizures.
Method: We reviewed 96 patients presenting with typical absence
seizures. All had prolonged video-EEG polygraphic recordings and a
minimum of 6 recorded absence seizures in the same record.
Results: In the whole group, we found a positive familial history
for epilepsy in 39% and for febrile convulsions in other 19%. Seizure
onset was between 3 years 2 months and 13 years. Absence length var-
ied from 6 to 35 seconds. We found sporadic other types of seizures
(mostly generalised) in 15% of cases and all but one patient were seizure
free. Sixty-six (69%) presented automatisms during their absences. We
found no differences between the two groups regarding familiarity, age
at onset, response to treatment, other types of seizures and prognosis.
Regarding EEG characteristics, we found no differences for frequency
and morphology of the ictal discharge. The only significant difference
was longer length of ictal discharge in patients with automatisms. Fur-
thermore, compared to atypical absences and focal seizures, we noted
polymorphism of automatisms in typical absences in different episodes
in the same patient.
Conclusion: In our patients with typical absences we found no prog-
nostic differences related to the presence or not of automatisms. This
must be kept in mind since automatisms are always considered with
suspicion by clinicians. Polymorphism of automatisms in the same pa-
tient in different episodes is important in differential diagnosis of typical
absences versus atypical and focal seizures.
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PANAYIOTOPOULOS SYNDROME: CLINICAL AND EEG
CHARACTERISTICS OF CHILDREN
1N. Specchio, 1L. Fusco, 1J. Volkov, and 2F. Vigevano (1Neuroscience
Department, Division of Neurology, Bambino Gesu` Children’s Hos-
pital, Italy, 2Municipal Children’s Psycho-Neurological Consultative-
Diagnostic And Clinical Center, Novosibirsk, Russia)
Purpose: To review clinical and EEG data of children with
Panayiotopoulos syndrome followed by The Neurology Division of
Bambino Gesu` Children’s Hospital.
Method: Children with clinical and EEG features of Panayiotopoulos
syndrome consecutively referred for first seizures to our lab between
1992 and 2005, were reviewed. All EEG, MR images and clinical notes
were analysed. An interview with parents was performed where clinical
data was insufficient.
Results: Ninety-eight children were reviewed. The follow-up was be-
tween 1–14 years (mean 4 years). Age at onset was between 3.5 and 5
years. Family history of epilepsy was found in 60% of children. First
seizures occurred during sleep in 90% of patients, with all typical symp-
toms in 45%. It lasted 30 minutes (range 15–90 minutes). In 45% of
patients, seizures were stopped by the administration of drugs in the
Emergency Room. 5% of patients were referred to the intensive care
unit. The first seizure was a single event in 30% of children; it was
followed by one seizure or multiple seizures in the subsequent year, re-
spectively, in 15% and 30% of children. Interictal EEG showed occipital
spikes in 35% of patients, extraoccipital in 25%.
Conclusion: Panayiotopoulos syndrome is a benign idiopathic epilep-
tic syndrome of infancy, which can present itself with severe onset due
to the length of the first seizure. The evolution is benign due to sporadic
seizure frequency and to the normal intellectual and motor development
of children.
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CRYPTOGENIC LATE ONSET EPILEPTIC SPASMS: AN
OVERLOOKED SYNDROME OF EARLY CHILDHOOD?
1,2M. Eisermann, 1,2D. Ville, 2C. Soufflet, 2P. Plouin, 3C. Chiron, 3O.
Dulac, and 1,2A. Kaminska (1Clinical Neurophysiology, Saint Vincent
De Paul Hospital, Paris, 2Clinical Neurophysiology, Necker Enfants
Malades Hospital, Paris, 3Department of Pediatric Neurology, Necker
Enfants Malades Hospital, Paris)
Purpose: Few reports detailing late onset epileptic spasms have been
published. In order to determine whether this condition merely represents
a late variant of classical West syndrome or exhibits specific features
distinct from the latter and related to a later stage of brain maturation, we
analysed the whole population with this specific seizure type, excluding
symptomatic cases to avoid the effect of brain lesion.
Method: We reviewed the files of the 56 children evaluated for epilep-
tic spasms in clusters having begun at 12 months of age or later, and
analysed clinical and video-EEG data of the 22 patients (4–17 yrs, mean
8.5 yrs) without obvious aetiology.
Results: Interictal EEG did not show classic hypsarrhythmia. A tem-
poral or temporofrontal slow wave and/or spike focus could be identified
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in all cases. Twelve children showed spasms with a tonic component.
Ictal EEG revealed generalised high voltage slow wave followed by dif-
fuse voltage attenuation with superimposed fast activity. All children
also exhibited other types of recorded seizures consisting of bursts of
spike-waves with temporofrontal predominance, reminiscent of “atypi-
cal absences.” In contrast with the occurrence of tonic components within
a cluster of spasms, no tonic seizure stricto sensu was recorded nor re-
ported by the caregivers. In 10 children, treatment (2 vigabatrin, 7 hy-
drocortisone, 1 ACTH) achieved complete cessation of seizures and dis-
appearance of focal EEG anomalies, but spasms persisted in 12 children.
Conclusion: The cryptogenic group in our series without recognised
aetiology and temporal or temporofrontal EEG anomalies seems to rep-
resent a type of epileptic encephalopathy intermediary between West
and Lennox-Gastaut syndromes, in terms of seizure types and interictal
EEG, and could correspond to dysfunction of the maturation process of
the temporal lobe, possibly due to an undisclosed lesion.
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FOCAL CORTICAL DYSPLASIA MAY CAUSE LATE ONSET
INFANTILE SPASMS
L. Metsa¨honkala, E. Gaily, R. Paetau, and L. Valanne (Helsinki Univer-
sity Central Hospital, Helsinki, Finland)
Purpose: Our aim was to investigate the features and aetiology of late
onset infantile spasms (IS). Previous research has found that epileptic
spasms start after the first year of life in 2.5% of patients with infantile
spasm syndrome, and frontal lesions are associated with later onset than
other localisations (Bednarek et al., Epilepsia 1998;39(1):55–60, Koo
and Hwang, Epilepsia 1996;37(11):1068–71). Symptomatic aetiology
was found in half of late-onset IS patients in the study by Bednarek, but
no focal cortical dysplasias (FCD) were reported.
Method: A retrospective analysis of all children treated for IS with
onset between 1–3 years of life at the epilepsy unit of the Hospital for
Children and Adolescents from 1995 through 2005.
Results: Altogether 14 children with onset of spasms between 12–
30 months of age were identified. In 4, epileptic spasms were the only
seizure type. All patients had spasm clusters. Asymmetric spasms were
observed in 2 patients. Either ictal or interictal EEG was lateralising in 6
patients. Four patients had cryptogenic aetiology. Six of 10 patients with
symptomatic spasms had cortical dysgenesis (1 lissencephaly, 4 frontal
FCD and 1 temporooccipital FCD). Three of the patients with FCD have
so far been operated at age 36–53 months. All of them became seizure-
free with improved cognitive development after surgery.
Conclusion: FCD, especially frontal, appears to be an important cause
for late onset IS. Early surgery may significantly improve seizure out-
come and cognitive development in these children.
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STATISTICAL PARAMETRIC MAPPING AND QUALITATIVE
ANALYSIS OF PROVOKED ICTAL SPECT IN TEMPORAL AND
EXTRATEMPORAL DRUG-RESISTANT PATIENTS
2C. Barba, 1D. Di Giuda, 1D. Policicchio, 1M. Totaro, and 1G. Colicchio
(1Catholic University, Rome, Italy, 2Fondazione S. Lucia IRCCS, Rome,
Italy)
Purpose: To compare statistical parametric mapping (SPM) with vi-
sual analysis of provoked ictal SPECT in defining the epileptogenic zone
of drug-resistant epilepsy patients.
Method: Twenty patients, submitted to epilepsy presurgical evalua-
tion in the Epilepsy Surgery Unit of Catholic University in Rome, were
included in the study. They suffered from drug-resistant epilepsy: 14
symptomatic and 6 cryptogenetic (8 extratemporal, 8 temporal, and 4
multifocal). All patients underwent Technetium-99m Ethyl-Cysteinate-
Dimer interictal and pentylenetetrazol provoked ictal SPECT scans. Af-
ter visual interpretation of interictal and provoked ictal studies, SPM
analysis was performed on individual provoked ictal SPECT images in
comparison with an established normal brain SPECT database. SPM
results were compared to those of qualitative analysis.
Results: A good concordance between visual and SPM analysis was
found in 19/20 patients with temporal and extratemporal epilepsies.
Epileptogenic zone colocalised with the ictal hyperperfusion area in 15
subjects. In 1 case the lateralisation did not correspond, while the other
4 patients were multifocal. Nine subjects were operated with satisfying
results (6 Ia, 1 Ib, 1III, and 1 short follow-up).
Conclusion: Even though SPM and visual analysis seemed to be com-
parably sensitive and accurate in localising ictal SPECT foci in both
temporal and extratemporal epilepsies, SPM may overcome the inter-
observer variability of visual interpretation and allow a more detailed
anatomic localisation. The good concordance between qualitative and
SPM analysis of ictal studies would suggest the possibility of avoiding
performing the interictal SPECT. Finally, provoked ictal SPECT proce-
dure confirmed its efficacy in determining the ictal hyperperfusion area.
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MN ENHANCED MRI ASSESSMENT OF HIPPOCAMPAL
PLASTICITY AFTER KAINIC ACID INDUCED STATUS
EPILEPTICUS
R. Immonen, A. Pitka¨nen, and O. Gro¨hn (Department of Neurobiology,
A.I.Virtanen Institute For Molecular Sciences, University of Kuopio,
Finland)
Purpose: Mn2+-enhanced magnetic resonance imaging (MEMRI)
can reveal functional, structural and connectional alterations in high spa-
tial resolution. We hypothesised that MEMRI after systemic Mn injection
may provide a robust approach for detection of mossy fibre sprouting in
vivo.
Method: MnCl2 (45 mg/kg) was injected i.p. to 10 adult Wistar rats.
After 12 hours, 6 of the rats (Mn+SE–group) received kainic acid (KA)
injections inducing status epilepticus. T1 -MRI was performed at 4.7T,
3 and 25 hours after KA injection. Two months later, a follow-up MRI
was performed before and 24 hours after systemic Mn injection.
Results: No significant T1 differences between groups were detected
15h after KA-injection, indicating that activity dependent Mn accumula-
tion during generalised seizures must have been negligible. Two months
after KA administration there were clearly visible differences in the Mn-
enhanced structures in the hippocampus including thickening of the DG
CA3 region, and increased signal intensity in CA1 region. In Mn-SE
group the CA3 was 260 ± 40% thicker than in controls. The signal
intensity ratios of CA1 and adjacent corpus callosum in T1-weighted
images were 1.37 ± 0.03 and 1.22 ± 0.03 in Mn-SE and control group,
respectively (p < 0.05).
Conclusion: After systemic Mn injection MEMRI contrast is rather
associated with structural plasticity than brain activation. Alterations in
thickness and shape of the DG and CA3 region of the hippocampus can
be attributed to mossy fibre sprouting. The increased MEMRI contrast in
CA1 of KA injected animals indicates that MEMRI may have potential
to reveal the abnormal axonal growth in CA1.
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CORRELATION OF QUANTITATIVE MRI AND QUANTITA-
TIVE NEUROPATHOLOGICAL ANALYSIS OF WHITE MAT-
TER IN FOCAL EPILEPSY
S. Sisodiya, J. Duncan, S. Eriksson, S. Free, L. Martinian, M. Symms, and
M. Thom (Department of Clinical And Experimental Epilepsy, Institute
of Neurology, UCL, London, UK)
Purpose: Current optimal MRI sequences do not reveal either extent
or nature of all neuropathologies underlying focal extrahippocampal re-
fractory epilepsies. We wished to determine if new quantitative MRI
sequences correlated with underlying pathoanatomical features identi-
fied neuropathologically, thus validating their use in MR-negative cases.
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Method: Nine patients with known focal epileptogenic lesions (hip-
pocampal and extrahippocampal) were imaged at 1.5T using stan-
dard presurgical volumetric and quantifiable research sequences: dif-
fusion tensor, magnetisation transfer, FFT2. Careful perioperative mea-
sures, postsurgical imaging and correlation of presurgical imaging with
anatomy of the resection specimen allowed coregistration of presurgical
experimental imaging and postresection pathological material. Quanti-
tative neuronal counts, GFAP and synaptophysin immunohistochemical
data were obtained for comparison with quantitative imaging abnormal-
ities determined by comparison with imaging data from control subjects.
Results: Reliable coregistration of MRI and pathological data was
achieved. No correlation was observed between any quantified MR con-
trast and any quantitative neuropathological measure obtained in the
white matter. The newer sequences did not identify a subtle neuropatho-
logical abnormality (hamartia) in one case.
Conclusion: We did not find a correlation between quantitative MR
data and commonly-used neuropathological measures when quantified,
or with qualitative neuropathological analysis. The MR contrasts are
amongst the more frequently employed new sequences globally. The
findings emphasise the need for both biologically driven newer quantita-
tive MR contrasts, and newer exploratory neuropathological measures.
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EPILEPTIC FOCUS LOCALISATION AND MULTIMODAL
IMAGING IN A PAEDIATRIC POPULATION
1L. Spinelli, 1L. Goran, 1F. Sperli, 1M. Kurian, 2J. Delavelle, 2J. Willi,
3J. Villemure, and 1M. Seeck (1Presurgical Epilepsy Evaluation Unit-
Neurology-HUG-Geneva, Switzerland, 2Department of Radiology-
HUG-Geneva, Switzerland, 3Department of Surgery–CHUV–Lausanne,
Switzerland)
Purpose: In a paediatric population, the number of examinations
should be optimised in order to reduce evaluation time and complex-
ity of the presurgical exploration. EEG is still the most fundamental re-
quirement and is performed on all surgical candidates. Could advanced
EEG source imaging (ESI) of this always available data lead to a reliable
identification of the epileptogenic area?
Method: 31 patients who underwent surgical intervention and had a
follow-up of at least 12 months were retrospectively reviewed. All the pa-
tients had long-term video-EEG monitoring, high resolution MRI, PET,
and if possible an ictal and interictal SPECT. Preoperative EEGs recorded
from 19–29 scalp electrodes were reviewed, and interictal epileptiform
activity was analysed using a linear source imaging procedure in com-
bination with statistical parametrical mapping.
Results: In 28/31 patients (90%) the ESI correctly localised the epilep-
togenic region. These numbers compare favourably with the results from
other imaging techniques (PET: 83%, ictal SPECT: 71%). In extratem-
poral epilepsy patients ESI was correct in all cases, and in temporal lobe
patients in 10/13 cases. In 2 temporal lobe patients with less accurate
ESI results 128 electrodes data could be analysed, and in both cases the
128 electrode ESI was correct.
Conclusion: EEG recordings are fast, noninvasive and are the most
widely used technique in presurgical exploration units. Even more, this
does not require sedation for acquisition. Consequently, in a multimodal
imaging environment, ESI should be taken into account. This is more
crucial with paediatric patients for whom noninvasive techniques should
be considered as a priority.
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USING ICA DECOMPOSITION OF EEG SIGNAL IN SIMULTA-
NEOUS EEG-fMRI
1J. Marques, 1P. Figueiredo, 2F. Sales, and 1M. Castelo-Branco (1IBILI,
Universidade de Coimbra, Coimbra, Portugal, 2UMES, Hospital da Uni-
versidade de Coimbra, Coimbra, Portugal)
Purpose: Simultaneous EEG-fMRI is becoming a common tool in the
study of epilepsy due to its great clinical potential on the localisation of
the sources of interictal epileptiform activity. In this study, independent
component analysis (ICA) (Makeig S et al., Proc Natl Acad Sci U.S.A.
1997;94:10979–84;) of the EEG data is evaluated as a potential blind
method to detect interictal activity to then characterise the regressor to
be used in the fMRI event related design.
Method: Studies were performed using a 32 channel MRI compatible
EEG system (Micromed), and 1.5T MRI scanner (Siemens Symphony).
Three patients, out of the 6 selected to be studied using EEG-fMRI, had
anomalous activity during the fMRI. Their EEG data was post processed
using a Matlab toolbox, EEGLAB (software from SCCN, University of
California, San Diego). The fMRI processing was performed using FSL
(software from FMRIB, University of Oxford) using event related de-
signs based on: the neurologist’s characterisation of spikes (Stephanovic
B et al., Neuroimage 2005;28:205–215); the component that was found
to be more correlated with the interictal activity.
Results: The results from the fMRI studies showed good agreement,
and increased significance and size of activated regions (three fold) when
using the ICA component design to model neural activity instead of the
conventional spike characterisation.
Conclusion: These preliminary results indicate that this methodology
could increase the detectability of sources of interictal activity, as well
as reduce the time needed to create the event related model.
References: (1) Makeig S., et al, ProcNatlAcadSci. U.S.A. (1997), 94,
10979–84; (2) Stephanovic B. et al., Neuroimage 28 (2005) 205–215.
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FUNCTIONAL MAGNETIC RESONANCE OF INTERICTAL
SPIKES IN CHILDHOOD IDIOPATHIC OCCIPITAL LOBE
EPILEPSY
1A. Leal, 2A. Dias, 2J. Vieira, 3M. Secca, 4J. Fernandes, and 5C.
Jorda˜o (1Hospital Ju´lio De Matos, Lisbon, Portugal, 2Hospital Dona
Estefaˆnia, Lisbon, Portugal, 3New University of Lisbon, Lisbon, Por-
tugal, 4University of Aveiro, Aveiro, Portugal, 5Hospital Egas Moniz,
Lisbon, Portugal)
Purpose: Occipital lobe epilepsy (OLE) presents in childhood with
different syndromes, with typical clinical and neurophysiological char-
acteristics. Despite clearly distinct manifestations, the particular area of
the occipital lobe where epileptic activity is located for each syndrome it
is not known, nor is it known whether spatial segregation of these causes
the heterogeneous clinical ictal semiology.
Method: Three children (aged 13, 12, and 12 years) with idiopathic
OLE were submitted to simultaneous recording of EEG and functional
magnetic resonance imaging (fMRI). An event-related paradigm was
used to process the fMRI, taking the time of occurrence of spikes as
the events of interest. The activations and deactivations obtained were
represented in a high resolution anatomical T1 image.
A high resolution EEG was obtained outside the scanner and used to
optimise source analysis of interictal spikes.
Results: Two patients presented with the syndrome of late onset be-
nign OLE (Gastaut type), and the fMRI activation areas were concordant
and localised in the medial posterior parietal lobes. The EEG source anal-
ysis revealed discrepant results for one and concordant ones for the other
when compared with fMRI data. One patient presented with idiopathic
photosensitive OLE, and the fMRI activations involved the lower lat-
eral and inferior occipital areas, as well as the posterior temporal lobes.
Source analysis produced dipoles at a different localisation over the
parietal-occipital area.
Conclusion: fMRI of interictal spikes in idiopathic OLE of childhood
produces distinct maps of activation in different syndromes. EEG source
analysis methods are poor predictors of their localisation.
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ANTICONVULSANT ACTION OF A SUBUNIT-SPECIFIC
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NMDA RECEPTOR ANTAGONIST IFENPRODIL IN IMMA-
TURE RATS
P. Maresˇ and A. Mikulecka´ (Institute of Physiology, Academy of Sci-
ences of The Czech Republic, Czech Republic)
Purpose: To study possible anticonvulsant action of ifenprodil and its
side effects on motor performance in immature rats.
Method: Motor seizures were elicited by pentylenetetrazol (100
mg/kg s.c.) in 7-, 12-, 18- and 25-day-old rats. The incidence and latency
of minimal clonic and generalised tonic–clonic seizures were evaluated.
Motor performance was tested in 12-, 18- and 25-day-old rats using
age specific tests; spontaneouos locomotion was measured in open field.
Ifenprodil (10, 20 or 40 mg/kg i.p.) was administered 20 min before
pentylenetetrazol injection or behavioural testing. Open field was tested
once more one hour after ifenprodil administration.
Results: Minimal clonic seizures could be elicited only in 18- and
25-day-old rats. Ifenprodil did not influence their incidence and latency.
Specific anticonvulsant action (suppression of the tonic phase of gen-
eralised seizures) was found in 7-, 12- and 18-day-old rats. This effect
decreased with age and it failed to appear in 25-day-old animals. La-
tency of generalised seizures was prolonged in 7-day-old but paradoxi-
cally shortened in older animals. Locomotor activity was transiently in-
creased by ifenprodil only in 12-day-old rats; it remained uninfluenced
in older animals. Motor performace was moderately compromised in the
youngest group only. Motor activity was normalised one hour after the
administration.
Conclusion: Ifenprodil exhibits specific action against the tonic phase
of generalised seizures in the first three postnatal weeks. Unwanted side
effects on motor activitites were observed only in 12-day-old rats but
not in older animals. Ifenprodil thus differs from other NMDA receptor
antagonists. Supported by research projects LC554 and AV0Z5011009.
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INTRAHIPPOCAMPAL INJECTION OF ENDOTHELIN-1 IN-
DUCES EPILEPTIC SEIZURES AND BRAIN INJURY IN IM-
MATURE RATS
H. Kubova´, G. Tsenov, A. Ma´tte´ffyova´, J. Ota´hal, and P. Mares (Institute
of Physiology, Academy of Sciences of The Czech Republic, Czech
Republic)
Purpose: To find whether focal ischemia, induced by intracerebral
injection of endothelin-1 (ET-1) in immature rats results in development
of acute seizures and neuronal loss.
Method: ET-1 was injected in doses 10, 20 or 40 pmol into the left
dorsal hippocampus of Wistar rats 12 (P12; n = 34) and 25 (P25; n = 30)
days old. After ET-1 infusion, animals were video/EEG monitored for
100 min and monitoring was repeated 22 h later. Parameters of electro-
graphic seizures as well as pattern of their behavioural correlates were
evaluated. The pattern of behavioural seizures was used to develop a
model-specific scoring system. Cresyl violet and Fluoro Jade B-staining
were used to detect brain damage. Extension of the lesion was evaluated
semiquantitatively.
Results: After ET-1 injection, seizures occurred in 83–100% animals
of all age and dose groups. There were no differences in average seizure
duration (18–40s) or seizure frequency (3–7 seizures/100 min) among
individual experimental groups. The lowest dose of ET-1 induced more
frequent seizures in P12 than in P25 rats. Seizures persisted for 24h
except P12 rats with 10 pmol of ET-1. Electrographic seizures were
usually accompanied by clonus; the incidence of more severe convulsions
(barrel rolling or generalised clonic seizures) increased with dose of ET-
1. There were no dose-related differences in severity of hippocampal
damage. Damage was, however, more severe in P12 compared to P25
animals.
Conclusion: Our data suggest higher sensitivity of P12 rats to ET-
1-induced brain damage, however, no age- or dose-related differences
occurred in ictogenic effects of ET-1-induced focal ischemia. Supported
by grant 305/06/0713 (GACR).
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MODULATION OF HIPPOCAMPAL EXTRACELLULAR
DOPAMINE CONCENTRATION CONTRIBUTES TO THE
ANTICONVULSANT MECHANISM OF ACTION OF NEU-
ROPEPTIDE Y
1,2A. Meurs, 1R. Clinckers, 2G. Ebinger, 1Y. Michotte, and 1I. Smol-
ders (1Vrije Universiteit Brussel, Brussels, Belgium, 2Academisch
Ziekenhuis–Vrije Universiteit Brussel, Brussels, Belgium)
Purpose: Neuropeptide Y (NPY) exerts potent anticonvulsant effects
in several seizure models, and increases hippocampal dopamine when
administered intracerebroventricularly (Drumheller et al., Neuropeptides
1994). In the focal pilocarpine model, increased hippocampal dopamine
results in seizure suppression via D2-receptor activation (Clinckers
et al., J Neurochem 2004). Our aim was to investigate the origin of the
NPY-induced increase in hippocampal dopamine, and its involvement in
NPY’s anticonvulsant activity.
Method: Limbic seizures were evoked in freely moving rats by in-
trahippocampal pilocarpine administration via a microdialysis probe.
Prior to pilocarpine administration, NPY was administered intracere-
broventricularly (1–10 nmol), intrahippocampally via the microdialy-
sis probe (10–100 μM), or coadministered intrahippocampally with the
D2-receptor antagonist remoxipride (4 μM). Changes in hippocampal
extracellular dopamine, serotonin, glutamate and GABA concentrations
were monitored, and behavioural changes indicative of seizure activity
were scored.
Results: Intracerebroventricular (10 nmol) and intrahippocampal
(20 μM) NPY administration increased hippocampal dopamine dialysate
levels (188 ± 16% and 178 ± 26% respectively, p < .05), but had no ef-
fect on hippocampal glutamate, GABA or serotonin. Pilocarpine-induced
seizures were attenuated in both treatment groups (seizure scores 3.0 ±
1.4 and 3.8 ± 1.9 respectively, p < .05 compared to 12.8 ± 3.1 in control
group). Hippocampal D2-receptor blockade with remoxipride reversed
NPY’s anticonvulsant activity (seizure score 9.0 ± 1.2).
Conclusion: NPY-induced increases in hippocampal dopamine are
elicited locally in the hippocampus, possibly via activation of NPY recep-
tors on hippocampal dopaminergic terminals. Moreover, the activation
of hippocampal D2-receptors caused by increased dopamine is shown to
play a central role in NPY’s anticonvulsant mechanism.
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ANTICONVULSANT PROPERTIES OF HYPOTHERMIA IN EX-
PERIMENTAL STATUS EPILEPTICUS
1,2F. Schmitt, 2K. Buchheim, 2J. Matzen, 2H. Meierkord, and 2M.
Holtkamp (1Epilepsy Center Berlin-Brandenburg, Hospital “Ko¨nigin-
Elisabeth-Herzberge,” Berlin, Germany, 2Clinical And Experimental
Epileptology, Department of Neurology, Charite´-University Medicine,
Berlin, Germany)
Purpose: Status epilepticus refractory to first-line anticonvulsants fre-
quently requires treatment escalation with intravenous anaesthetics. Due
to potentially hazardous side effects alternative treatment options are
needed. We assessed the anticonvulsant properties of hypothermia in a rat
model of electrically induced self-sustaining status epilepticus (SSSE).
Method: Animals with SSSE underwent 3 h of external cooling
to 29◦C (n = 7), intraperitoneal administration of low-dose diazepam
(2 mg/kg; n = 8), or a combination of both (n = 9). Animals that
underwent cooling were rewarmed. Severity and number of motor
seizures and frequency and amplitude of epileptic discharges were as-
sessed for 5 h and compared with untreated controls (n = 10). Clini-
cal features were expressed as motor seizure index (MSI) incorporating
time in and severity of motor seizures. Electrophysiological parame-
ters were related to pre-treatment baseline and expressed as fraction
of 1.
Results: Diazepam reduced only amplitudes at single time points.
Hypothermia had no impact on electrophysiological features, but signif-
icantly reduced MSI (0.12 ± 0.31 vs 1.23 ± 1.4 in controls; p < 0.05).
Combining hypothermia and diazepam, MSI was also significantly re-
duced (0.08 ± 0.13; p < 0.05). Furthermore, there was a significant
reduction for amplitudes after 40 min (0.34 ± 0.25 vs. 0.84 ± 0.33 in
controls; p < 0.05) up to 160 min (0.13 ± 0.13 vs. 0.49 ± 0.29; p <
0.01) and for frequency after 20 min (0.58 ± 0.41 vs. 1.00 ± 0.15;
p < 0.01) up to 180 min (0.47 ± 0.24 vs. 1.02 ± 0.32; p < 0.01). After
rewarming, frequency reduction was partially reversible.
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Conclusion: In this animal model, coadministration of low-dose di-
azepam and hypothermia exhibits pronounced anticonvulsant properties.
Hypothermia, therefore, may become a reasonable endorsement to the
pharmacological management of SE in patients.
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RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR
(rAAV) MEDIATES NEUROPEPTIDE Y (NPY) GENE OVER-
EXPRESSION IN THE HIPPOCAMPUS OF EPILEPTIC RATS,
ARRESTS DISEASE PROGRESSION, AND REDUCES SPONTA-
NEOUS SEIZURES
1F. Noe’, 2J. Nissinen, 1M. Gobbi, 4G. Sperk, 3M. During, 2A. Pitka¨nen,
and 1A. Vezzani (1Mario Negri Institute For Pharmacological Research,
Milano, Italy, 2A.I. Virtanen Institute For Molecular Science, Kuopio,
Finland, 3Weill Medical College, Cornell University, New York, USA,
4University of Innsbruck, Austria)
Purpose: rAAV mediates long-term human NPY overexpression in
normal rat hippocampal neurons, reduces acute seizures and delays kin-
dling. We studied whether intrahippocampal application of rAAV-NPY in
epileptic rat hippocampus reduces spontaneous recurrent seizures (SS).
Method: Three months after electrically induced status epilepticus,
rats were video-EEG monitored 24h/day for 2 weeks to obtain baseline
SS frequency. Then, a rAAV-NPY or rAAV-empty cassette (5.2×1012
vg/ml) was intrahippocampally injected bilaterally; 4 weeks later rats
were video-EEG monitored for 2 weeks. NPY expression and release
were measured by immunohistochemistry and RIA. NPY receptor bind-
ing was assessed by autoradiography.
Results: In the rAAV-NPY group (n = 10), progression in SS was
observed in 3 rats which showed ∼1.5-fold increase in SS frequency and
total duration compared to their baseline. Four rats showed a ∼2-fold
reduction in SS frequency and total duration while 3 rats had similar
SS frequency as during baseline recording. In the AAV-Empty group
(n = 10), 7 rats showed progression in SS showing ∼3-fold increased
SS frequency and total duration. None of the rats showed decreased SS
frequency and 3 rats had SS frequency similar to baseline. NPY over-
expression did not affect hippocampal Y2 while reducing Y1 receptors.
In these rats, NPY release was enhanced compared to rats injected with
the AAV-Empty.
Conclusion: Overexpression of the human NPY gene in the epileptic
rat hippocampus produces a releasable pool of NPY which reduces SS
frequency and total duration and arrests disease progression. NPY gene
therapy may have a therapeutic potential for inhibiting recurrent seizures
at focal onset. Supported by Telethon Onlus Foundation.
120
ANTICONVULSANT EFFECTS OF BOTULINUM NEURO-
TOXIN E
F. Antonucci, E. Novelli, M. Caleo, and Y. Bozzi (CNR Neuroscience
Institute, Pisa, Italy)
Purpose: Botulinum neurotoxin E (BoNT/E) blocks neurotransmis-
sion by cleaving SNAP25, an essential component of the synaptic vesi-
cle release machinery. We previously showed that BoNT/E injection into
the rat hippocampus prevents kainic acid (KA) induced seizures. Here
we investigate whether BoNT/E administration after status epilepticus
(SE) can block spontaneous seizures in a chronic model of epilepsy in
the mouse.
Method: Adult C57Bl/6N male mice received intrahippocampal in-
jections of BoNT/E (25 nM, 0.25 microlitres). The duration of BoNT/E
effect was evaluated by in vivo recordings of hippocampal spike ac-
tivity, performed 1 to 21 days after toxin administration. To assess the
anticonvulsant effect of BoNT/E, SE was induced by a single injection
of KA (1 nmole) into the mouse hippocampus and seizures were mon-
itored by continuous EEG recordings. Thirty-five days later, following
the appearance of spontaneous seizures, BoNT/E was injected into the
hippocampus and its effects were evaluated by EEG and histology.
Results: BoNT/E administration into the mouse hippocampus com-
pletely abolished hippocampal spike activity, its effect lasting about 10
days. Intrahippocampal injection of KA induced SE which was followed,
after a two-week latency period, by spontaneous recurrent seizures ac-
companied by mossy fibre sprouting and granule cell dispersion. Ex-
periments are ongoing to determine whether BoNT/E administration in
chronically epileptic mice can have an anticonvulsant effect.
Conclusion: BoNT/E injection into the mouse hippocampus blocks
the spontaneous activity of pyramidal neurons and might be anticonvul-
sant in a chronic model of epilepsy.
Wednesday July 5, 2006
12:00–13:30
Ballroom 1
Platform Session
Neuropsychology
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COGNITIVE PERFORMANCE OF SCHOOL-AGED CHIL-
DREN EXPOSED TO ANTIEPILEPTIC DRUGS (AED) IN
UTERO
1,2E. Lewandowski, 1,2G. Leonard, 1,2A. Ptito, 3K. Silver, and 1,2,4E.
Andermann (1Montreal Neurological Hospital & Institute, McGill Uni-
versity, Montreal, Canada, 2Department of Neurology & Neurosurgery,
McGill University, Montreal, Canada, 3Department of Neurology, Uni-
versity of Chicago, Chicago, IL, USA, 4Department of Human Genetics,
McGill University, Montreal, Canada)
Purpose: Although major and minor congenital malformations and
abnormal growth parameters are known to be increased in children
of women with epilepsy, cognitive performance in children of these
mothers has not been well characterised. A better understanding of the
relative effects of AED exposure and maternal seizures on cognitive
functioning would be helpful in managing pregnancies of women with
epilepsy.
Method: Mothers with epilepsy (n = 58) were followed prospectively
with frequent monitoring of AED doses, plasma levels and seizure oc-
currence during pregnancy. Their school-age children (n = 96, ages
6–16) underwent detailed neuropsychological testing (NPT). Moth-
ers and fathers of these children also underwent NPT whenever pos-
sible. A control group of 93 children of mothers without epilepsy,
matched for age and education, also underwent NPT, as did their
parents.
Results: Children of mothers with epilepsy have a significantly lower
full scale IQ (FSIQ) than controls (exposed = 102; control = 112; p <
.001). There was no difference between FSIQ of children of mothers who
had seizures during the pregnancy than of those who did not (seizures =
102; no seizures = 103; p = 0.96). There was no significant difference
in FSIQ between children whose mothers had idiopathic generalised
epilepsy (IGE) and partial epilepsy (PE) (IGE = 101; PE = 103; p =
0.56). Children exposed to polytherapy had lower FSIQ compared to
monotherapy, but the difference was not statistically significant (poly =
100; mono = 104; p = 0.31). Children exposed to either dilantin or
tegretol monotherapy in utero showed no significant difference in FSIQ
(dilantin = 105; tegretol = 103; p = 0.68).
Conclusion: Cognitive ability was significantly reduced in children of
women with epilepsy. Our study suggests that this is due to exposure to
AED rather than to maternal seizures during pregnancy. Further analyses
will be carried out by trimester and on specific subtests of the NPT
battery, also taking into account AED doses and levels.
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NEUROPSYCHOLOGICAL CHARACTERISTICS OF TEMPO-
RAL LOBE EPILEPSY PATIENTS WITH TYPICAL AND ATYP-
ICAL LANGUAGE LATERALISATION
1,2M.P.H Hendriks, 2M. van Zundert, 3W.C.J Alpherts, and 1,4AP.
Aldenkamp (1Epilepsy Centre Kempenhaeghe, Heeze, The Netherlands,
2Institute of Cognition And Information (NICI) Radboud University Ni-
jmegen, Nijmegen, The Netherlands, 3Stichting Epilepsie Instellingen
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Nederland (SEIN), Heemstede, The Netherlands, 4Dept. of Neurology,
University Hospital Maastricht, Maastricht, The Netherlands)
Purpose: We studied the effects of language lateralisation and other
variables that may affect the crowding phenomenon. We hypothesised
limited nonverbal abilities compared to verbal abilities in temporal
lobe epilepsy patients with atypical language dominance particularly
in subjects with early seizure onset, and atypical language dominance
more frequently in patients with a left hemisphere focus.
Method: In a sample of 241 (113 male; 128 female) patients with right
or left TLE who are candidates for neurosurgical treatment, neuropsy-
chological assessment and an intracarotid amobarbital procedure were
performed. 212 (89%) Patients had a left hemisphere language domi-
nance, 12 (5.0%) patients showed a right hemisphere dominance and
14 (5.9%) patients a bilateral language dominance. Patients were cate-
gorised in 4 groups according to age at seizure onset. With a multivariate
analysis of variance we analysed the neuropsychological performances
by language dominance and epileptic focus, age at onset, handedness,
and gender.
Results: Results demonstrated handedness and epileptic focus to be
risk factors for atypical language dominance, while no associations be-
tween age at seizure onset or gender with language dominance were
observed in this sample. Neither language dominance nor language dom-
inance in combination with the lateralisation of the epileptic focus, age
at seizure onset, handedness of gender showed evidence for a crowding
effect. A significant apposite effect of the crowding phenomenon was
demonstrated at a univariate level, as right hemisphere language domi-
nance in patients with early left temporal lobe epilepsy was associated
with higher performance on non verbal IQ subtests.
Conclusion: In conclusion, left hemisphere epileptic focus and left
handedness are risk factors for atypical language dominance, while age
at onset and gender are not. We found no indications for the crowding
phenomenon in this population.
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OCCIPITAL CSWS AND VISUAL AGNOSIA
1,2A. Kyllia¨inen, 4H. Heinonen, 1P. Nieminen, and 2,3K.
Eriksson (1Department of Psychology, University of Tampere,
Finland, 2Department of Pediatrics, Tampere University Hospital,
Finland, 3Pediatric Research Centre, University of Tampere, Finland,
4Department of Clincal Neurophysiology, Tampere University Hospital,
Finland)
Purpose: To describe the long-term follow-up data of neuropsycho-
logical functions in a boy originally diagnosed with occipital continuous
epileptiform activity during sleep (CSWS) and visual agnosia (i.e., in-
ability to recognise objects without impairment of visual acuity).
Method: The boy was first diagnosed at the age of 8 years old with
CSWS by using digital 24-hour video EEG monitoring. Consecutive 24
hour video EEG recordings showed continuous spike and wave activity
covering approximately 80% of the non-REM sleep with the maximal
topographic distribution bilaterally on the occipitotemporoparietal re-
gions with the spike initiation on the left hemisphere. These were not
affected by adequate doses of antiepileptic drugs in mono- or polyther-
apy. The neuropsychological assessment comprised several tests (e.g.,
WISC-III, WMS-R, TVPS, Hooper Visual Organization test). Academic
achievement was measured using a standardised test of reading, spelling
and arithmetic skills.
Results: The original neuropsychological assessment showed that the
boy had normal verbal intelligence but major deficits in visual perception.
His neuropsychological profile resembled adult-type ventral simultanag-
nosia. After a 7 year follow up neuropsychological assessment and the
complete disappearance of the CSWS pattern in the latest video-EEG
recording at the age of 15 years, the deficits in visual perception were
still severe (PIQ 40) whereas verbal intelligence was intact (VIQ 96).
Visual perception was still characterised by piece-by-piece perception
which resembles the adult-type of ventral simultanagnosia. However,
more precise neuropsychological assessment revealed improvements in
visual perceptual skills especially in object recognition and used com-
pensatory mechanisms, and his academic achievements were relatively
good.
Conclusion: This follow-up case study suggests that general intellec-
tual measurement (IQ) is not enough and more precise assessment of
neuropsychological functioning and description of academic skills are
warranted in patients with CSWS, even after the disappearance of the
electrophysiological phenomena.
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MEMORY CONSOLIDATION AND ACCELERATED FORGET-
TING IN CHILDREN WITH IDIOPATHIC GENERALISED
EPILEPSY
1,2L. Dorris and 2M. Davidson (1Fraser of Allander Neurosciences Unit,
Royal Hospital For Sick Children, Glasgow, UK, 2Section of Psycho-
logical Medicine, University of Glasgow, Glasgow, UK)
Purpose: To determine whether children with idiopathic generalised
epilepsy (IGE) show accelerated forgetting of verbal and nonverbal in-
formation in comparison to healthy controls matched for age and IQ.
Method: Twenty-one children with IGE were compared with 21
healthy controls on measures of verbal and visuospatial memory at de-
lays of 30 minutes, and again at an extended delay of 1 week. Measures
included the Stories and Dot Location tests from the Children’s Memory
Scale and the Wechsler Abbreviated Scale of Intelligence. A minimum-
learning criterion controlled for initial learning effects was used.
Results: For the auditory-verbal memory test, group performance was
comparable at 30 minutes but children with IGE recalled significantly
less than controls after a delay of 1 week. When differences in the num-
ber of learning trials to criterion were controlled for, the main effects
of group and delay became nonsignificant (although the interaction re-
mained significant). There were no group differences for recognition
performance on this test. Group comparisons for the visuospatial task
were nonsignificant, although this may have been due to insufficient sta-
tistical power. The pattern of performance for this task was similar to
that for the auditory-verbal test.
Conclusion: Poor initial learning efficiency led to retrieval difficul-
ties at the longer delay, and was more common in the IGE group. This
pattern of deficits may be qualitatively different from those observed
in “accelerated forgetting” (Blake et al., Brain 2000; 123: 472–483) al-
though may present similarly in clinic. These findings are of interest to
theoretical accounts of consolidation and learning in childhood epilepsy.
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ATTENTION AND WORKING MEMORY IN CHILDREN WITH
EPILEPSY: AN EVENT-RELATED POTENTIAL STUDY
I. Myatchin and L. Lagae (University Hospitals KU, Leuven, Belgium)
Purpose: This study investigated attention and working memory in
children with epilepsy. We hypothesise that dysfunctions in these 2 neu-
ropsychological functions underlie the frequent learning problems in
children with epilepsy.
Method: Cohorts of children with epilepsy (n = 37) and age-matched
control children (n = 32) were tested with a visual go-no-go and 1-
back working memory task. Behavioural parameters (omission and com-
mission errors, reaction times) and event related potential (ERP) pa-
rameters (latencies x amplitude x position) were compared across the
groups.
Results: No differences in behavioural parameters across the groups
were found in either test. In the go-no-go task no differences were found
for P300 amplitude and latency. However, the amplitude of the P500
(at Fz electrode) was significantly lower in the epilepsy group (mean
0.1 ± 17.8 μV) than in the control group (mean 13.8 ±7.7 μV). In the
1-back task the amplitude of P300 differed significantly between the
epilepsy group (mean 2.4 ±5.4 μV) and the control group (mean –12.4
±5.6 μV). Also for the P500, a significant difference in amplitude was
found (Cz, mean 13.1 ±9.1 μV in epilepsy and −9.4 ±8.8 μV in the
control group). This latter difference was more prominent in generalised
epilepsy. Overall, no differences in peak latencies were found. There was
no effect of medication.
Conclusion: Although epilepsy and control patients performed
equally in attention and working memory tasks, ERP results clearly
showed other patterns of cortical functioning. Especially over the frontal
Epilepsia, Vol. 47, S3, 2006
7TH EUROPEAN CONGRESS ON EPILEPTOLOGY 35
and central regions, different activation patterns were seen in children
with epilepsy.
126
ASSOCIATION BETWEEN GENOTYPE AND NEUROLOGI-
CAL AND COGNITIVE SYMPTOMS IN PATIENTS WITH
TUBEROUS SCLEROSIS COMPLEX (TSC)
1O. Braams, 1F. Jansen, 2M. Nellist, 1K. Vincken, 1N. Anbeek, 2D. Hal-
ley, 1O. van Nieuwenhuizen, and 1A. Jennekens-Schinkel (1University
Medical Center, Utrecht, The Netherlands, 2Erasmus Medical Center,
Rotterdam, The Netherlands)
Purpose: To replicate and extend findings of an association between
type of mutation (TSC1, TSC2 and no mutation) and cognitive and neu-
rological symptoms in patients with TSC, using sophisticated valid, re-
liable, and reproducible methods.
Method: Fifty-eight patients (21 TSC1, 30 TSC2 and 7 without muta-
tion) were recruited at the neurology outpatient department. DNA analy-
sis established type of mutation. Computerised tuber segmentation pro-
gram with 3-D FLAIR MRI provided number and volume of tubers (tuber
load). Epilepsy characteristics and EEG recordings were obtained. With
a comprehensive neuropsychological battery six cognitive domains were
assessed.
Results: All but 6 patients had epilepsy. Age at seizure onset was later
in TSC1 (mean = 3.4; SD = 4.9) compared to 0.8, (SD = 1.2; p = .02)
and tuber volume was lower (mean = 0.7%; SD = 0.51) compared to
1.7% (SD = 0.98; p = 0.000) than in TSC2. Age at seizure onset was not
independently related to tuber volume. Seizure types did not distinguish
TSC1 and TSC2. Cognitive test were graded. Grades 1 (severely below
average) and 2 (below average) contained predominantly TSC2 patients,
whereas grades 3 (average) and 4 (above average) contained predomi-
nantly TSC1 patients. Results of patients with no mutation moved, grosso
modo, between those of TSC1 and TSC2.
Conclusion: A more favourable neurological outcome in TSC1 com-
pared to TSC2 is supported. With respect to cognition, the study high-
lights 1) a considerable overlap between the genotypes with 2) a pre-
dominance of quite severe impairment in TSC2.
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STATUS EPILEPTICUS IN POSTSTROKE EPILEPSY
1R. Ribacoba, 1M. Cuesta, 1M. Lafuente, 1V. De la Vega, and 1J. Salas-
Puig (1H. Alvarez Buylla, Mieres, Asturias, Spain, 2Hospital Central
Universitario, Asturias, Spain)
Purpose: To analyse the status epilepticus (SE) rate in poststroke
epilepsy.
Method: The study population was derived from the Area VII, Alvarez
Buylla Hospital, Asturias, Spain, database. Thirty consecutive patients
with poststroke SE were identified among a total of 107 patients diag-
nosed with poststroke epilepsy between 1999 and 2005 (58 males and
49 females) and were enrolled. Patients were evaluated by standard pro-
tocol including EEG (when myoclonus or low level consciousness was
observed), neuroimaging (head-CT or MRI) and routine blood testing.
Patients were grouped (12 males and 18 females) as having early-onset
(occurring at initial stroke and within two weeks of the stroke) and late-
onset (occurring more than two weeks after the stroke or during follow
up) SE. The mean age of males and females was 70 years (range 41–86)
and 72 (range 62–93) respectively.
Results: We found 9 early onset status epilepticus (EOSE): 3 males
and 6 females. In females the aetiology was: 1 case thrombopenic pupura
thrombotic, 3 ischemic cases and 2 haemorrhagic transformation stroke.
In males the cause was: 1 spontaneous intracerebral haemorrhage and 2
subarachnoid haemorrhages with old stroke. EEG recording revealed in
4 cases PLEDs and secondarily generalised polyspike/wave in another.
Recording could not be obtained for the rest of the patients. Twenty-
one patients suffered late onset status epilepticus (LOSE): 9 males and
12 females. In females the causes were: 1 superficial brain siderosis, 3
multi-infarct with leukoaraiosis, 5 stroke, 1 subdural haematoma in-
tracranial acute and 1 haemorrhagic transformation stroke. Between
the males we found: 3 stroke cases, 3 patients with multi-infarct and
leukoaraiosis, 2 spontaneous intracerebral hemorrhage and neurosar-
coidosis in 1 case. EEG recording during SS was obtained in 10 cases:
6 showed PLEDs, 1 BIPLED and finally 3 cases generalised or focal
polyspike.
Conclusion: The SE rate in poststroke epilepsy was 28%: 8.4% were
EOSE and 19.6% LOSE. The mortality of EOSE was 77.7% y en LOSE
was 31.5% but patients suffered cognition disorders.
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TREATMENT OF REFRACTORY STATUS EPILEPTICUS IN
ICU
1B. Kuzmanovska, 2E. Cvetkovska, 2I. Kuzmanovski, and 1Z. Nikolova
Todorova (1Clinic For Anaesthesiology, Reanimation And Intensive
Care Medicine, Skopje, Macedonia 2Clinic for Neurology, Skopje,
Macedonia)
Purpose: Refractory status epilepticus (RSE) is the most severe form
of status epilepticus which doesn’t respond to first and second line
antiepileptic drug therapy and represents a major neurological emer-
gency. We aimed to analyse the aetiology, treatment strategies and out-
come of RSE.
Method: A retrospective analysis of all patients treated at Central
Intensive Care Unit at University Hospital with a diagnosis of RSE be-
tween January 2001 and December 2005. Thirty-two patients (57.6%
female; 44.8% male), aged 14–67, mean 39.4 years, admitted in ICU
setting and treated with potent anesthetics and mechanically ventilated
were analysed in our study.
Results: Preexisting epilepsy was the most common cause of RSE
(62.5%); severe head trauma caused RSE in 15.6%, stroke caused RSE
in 12.5%, encephalitis in 6.2% and metabolic disorder in 3.1%. 62.5% of
patients were treated with propofol; 28.8% with thiopental and 9.6% with
propofol and subsequently with thiopental. Median duration of ICU stay
was 3.34 days (range 1–12). Twenty-nine patients survived the episode
of RSE; 2 patients died and 1 patient is in a persistent vegetative state
due to cerebrovascular complications.
Conclusion: There is no consensus for treatment of RSE, but for a
successful outcome, anaesthesia coma induction, mechanical ventilation
and vital function support is essential.
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PROLONGED EPILEPTIC SEIZURES OR STATUS
EPILEPTICUS?
1A. Kataja, 1L. Ritvanen, 2R. Ka¨lvia¨inen, and 1S. Soinila (1Helsinki
University Central Hospital, Finland, 2Kuopio University Hospital,
Finland)
Purpose: Although most epileptic seizures stop spontaneously within
a few minutes, some continue and may constitute a life-threatening status
epilepticus (SE). This study investigates the probability of SE among
patients exhibiting prolonged seizures.
Method: A retrospective study on all patients admitted to the HUCH
emergency room with the diagnosis epilepsy (G40) or convulsion (R56)
in 2003 (n = 1205). Based on medical records, all patients whose con-
vulsion lasted > 5 min were analysed.
Results: One out of 6 cases of all convulsions were prolonged over
5 min, 27% of them having no previous epilepsy diagnosis. 40% of
prolonged seizures ceased by 20 min, a further 9% by 30 min, 12%
by 60 min, while 39% continued over 60 min. The relative proportion
of various aetiologies differed in prolonged seizures (5–30 min), estab-
lished SE (30–60 min) and refractory SE (>60 min). Preceding alcohol
consumption was a common cause in the first two groups (19%, 16%),
while such cases were not found in the refractory SE group. The role of
previous intracerebral haemorrhage or brain tumour strongly accentu-
ated in convulsions lasting over 60 min. 20% of prolonged seizures (5–
30 min) ceased spontaneously, 44% stopped with benzodiazepine, 25%
with phenytoin and 11% required anesthesia. Of all cases classifiable as
SE based on seizure duration over 30 min, only 65% were diagnosed
SE.
Conclusion: SE is grossly underdiagnosed. Prolonged seizures bear a
considerable risk of SE, particularly if a previous haemorrhage or brain
tumour is the aetiological factor.
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ICTAL CARDIAC ASYSTOLE IN A PATIENT WITH FOCAL
STATUS EPILEPTICUS
G. Walser, J. Dobesberger, K. Seppi, A. Muigg, and E. Trinka (Inns-
bruck Medical University, Clinical Department of Neurology, Innsbruck,
Austria)
Purpose: Disturbances of autonomic functions are frequent findings
during epileptic seizures, mostly of temporal origin. We report a patient
with symptomatic right parietooccipital epilepsy, who experienced an
ictal cardiac asystole during a focal status epilepticus (SE).
Method: A case report.
Results: A 66-year-old woman with a right parietal-occipital cere-
bral tumour (metastases of an adenocarcinoma of the lung) experi-
enced her first focal motor seizure in March 2005. She received no
antiepileptic treatment at that time. Routine ECG showed sinus rhythm
with first degree AV-blocking. Four months later the patient was re-
ferred to our hospital with an episode of dizziness, intermittent jerk-
ing of the left arm and leg, at times interrupted by tonic stiffen-
ing followed by mild hemiparesis. The symptoms lasted for at least
2 hours. EEG showed continuous rhythmic parietooccipital activity on
the right side. Simultaneous coregistered ECG showed a sinus rhythm of
108 bpm, decreasing over 10 seconds and finally an asystole for 13
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seconds. EEG showed diffuse slowing. The patient lost consciousness
during that time. A focal SE was diagnosed and lorazepam 6 mg IV
was administered. Ictal EEG activity ceased subsequently and clinical
symptoms resolved completely except for a postictal Todd paralysis.
Antiepileptic treatment was started with gabapentin. A cardiac pace-
maker was not implanted. The patient remained seizure free for the
following 3 months.
Conclusion: Ictal asystole is potentially life threatening and may be
related to ictal cardiac autonomic dysfunction. The relationship to sudden
unexpected death in epilepsy patients is highly likely but remains unclear.
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ICTAL APHASIA AS MANIFESTATION OF PARTIAL STATUS
EPILEPTICUS PROVOKED BY BLEEDING CAVERNOMA: DI-
AGNOSTIC ROLE OF NEUROIMAGING
F. Sperli, A. Romigi, F. Placidi, F. Izzi, A. Cervellino, F. Corte, S. Zan-
nino, K. Grossi, and M. Marciani (University of Rome Tor Vergata,
servizio di Neurofisiopatologia, Italy)
Purpose: Cavernomas represent 5–20% of vascular malformations
in the central nervous system. Occurrence of epilepsy in patients with
cavernoma is 40%–70%. Magnetic resonance imaging (MRI) is the most
appropriate method to identify cavernomas; late diagnosis could occur
when MRI execution is delayed. Partial status epilepticus could represent
the manifestation of an acute bleeding cavernoma. Language disturbance
such as ictal aphasia may accompany other signs of seizure involving
dominant hemisphere, albeit it is infrequent as the sole symptom of
partial status epilepticus.
Method: A 55-year-old right-handed man, affected by partial epilepsy
since age 15, was treated with carbamazepine (CBZ) 600 mg/day. MRI
was never performed. The patient reduced CBZ in his own way. One week
later he was hospitalised because of recurrent episodes of aphasia. Ictal
EEG showed a spiky fast activity and sharp waves in the left temporal
region, involving homolateral frontal and occipital regions.
Results: Postictal neurological examination was normal but there was
an arithmetic calculation deficit. MRI revealed left parietal cavernoma
bleeding.
Conclusion: Anatomical lesion involving specific language in the
brain area provoked ictal aphasia; postictal impairment in arithmeti-
cal calculation is probably related to involvement of left parietal re-
gion. We hypothesised that sudden reduction of carbamazepine associ-
ated with bleeding cavernoma provoked partial status epilepticus. Al-
beit the diagnosis of epilepsy in our patient results was not recent,
MRI played a key role in the diagnosis of structural abnormalities un-
derlying the epilepsy and is mandatory in patients affected by focal
seizures.
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DELAY OF TREATMENT RESPONSE IN ADULT STATUS
EPILEPTICUS PATIENTS
1L. Ritvanen, 1A. Kataja, 1O. Ha¨ppo¨la¨, 2R. Ka¨lvia¨inen, and 1S. Soinila
(1Helsinki University Central Hospital, Finland, 2Kuopio University
Hospital, Finland)
Purpose: The need to treat prolonged seizures aggressively arises
from the observation that seizures lasting over 30 min. may cause cell
death and permanent brain damage. Little information is available on
factors causing delay of treatment. This study attempts to evaluate the
time from seizure onset to burst-suppression as a measure of treatment
response and to analyse the factors contributing to the delay.
Method: This is a retrospective study including all patients over 18
years of age, who were diagnosed as status epilepticus (SE) and treated
in 2002–2003 in HUCH (population base 1.4 million). The patients were
identified from the HUCH electronic patient database chronologically
by the ICD10 code G41 and patient data were collected, based on proper
permissions, from the medical records.
Results: The total case account is 87. Preliminary analysis of 57
cases shows that 91% of cases are convulsive. Epilepsy had been di-
agnosed prior to SE in 61% of patients. 72% of the 30 EEG-monitored
patients obtained burst-suppression. Mean delay of treatment response
(time from onset to burst-suppression) was 34 hours. Mean recov-
ery time (time from onset to return of consciousness) of all patients
was 95 hours. Mortality during hospital admission was 11%. De-
lay in treatment response did not correlate with time of recovery or
death.
Conclusion: Our study suggests that delayed treatment response of
SE may not predict slow recovery or death. It is yet unknown how delay
affects the long-term outcome of SE.
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NONCONVULSIVE STATUS EPILEPTICUS (NCSE) PRESENT-
ING WITH PURE ALEXIA (ALEXIA WITHOUT AGRAPHIA)
1B. Pakoz, 1E. Kutluay, 1A. Yuksel, and 2A. Beydoun (1Kent Hospital,
Izmir, Turkey, 2American University of Beirut, Beirut, Lebanon)
Purpose: Pure alexia is a rare disorder usually caused by stroke. It
is usually due to a lesion involving the occipitotemporal junction of
the dominant hemisphere. We present a case of NCSE with clinical
manifestation of pure alexia.
Method: A case of pure alexia associated with NCSE was investigated
in detail and the data is presented in the Results section.
Results: A 57-year-old man presented at the emergency department
with inability to read and fluctuations in his mental status. He was in
diabetic-ketoacidosis with a blood sugar of 678 mg/dl. Following stabil-
isation of his blood sugar, a neurology consultation was done. The neu-
rological examination revealed that the patient was unable to read any
words despite his ability to recognise individual letters. The patient was
able to write normally. A brain MRI showed cortical swelling and signal
increase in FLAIR sequences over the left temporooccipital junction.
During a routine EEG, two electrographic seizures originating from the
left temporooccipital regions were recorded. The electrographic seizures
were associated with eyes deviated to the right and inability to respond to
questions. A diagnosis of NCSE was done and the seizures were aborted
following initiation of treatment with antiepileptic medications. In a few
hours, the patient started to read most of the words and his alexia was
completely resolved 24 hours later. Follow-up EEG did not show any
ictal activity.
Conclusion: To our knowledge, this is the first case of pure alexia
associated with NCSE. NCSE may manifest in unusual forms and a high
index of suspicion is necessary to diagnose and treat those patients.
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INTRAVENOUS VALPROATE IN STATUS EPILEPTICUS: A
SYSTEMATIC REVIEW OF THE EVIDENCE
J. Larch and E. Trinka (Universita¨tsklinik Fu¨r Neurologie, Innsbruck,
Austria)
Purpose: Status epilepticus (SE) is a serious epileptic event as-
sociated with significant morbidity and mortality. First-line treat-
ment of SE traditionally involves intravenous administration of ben-
zodiazepines, principally lorazepam. However, sometimes, SE is re-
sistant to benzodiazepines and second-line treatments are required.
Thereby, the availability since the 1980s of intravenous valproate pro-
vides an interesting therapeutic alternative. A large number of reports
have suggested that such a treatment may be efficacious. We have
performed a systematic literature review to assess the evidence for
this.
Method: An electronic literature search was performed using “val-
proate,” “valproic acid” and “status epilepticus” as key-words to iden-
tify relevant studies published until 30 September 2005. All identified
studies were cross-referenced to identify further reports. The worldwide
pharmacovigilance database of Sanofi-Aventis was also interrogated to
identify reported adverse events.
Results: No randomised clinical studies were identified. 348 adults
or children were included in 6 prospective and 9 retrospective studies. In
around 34 of cases, seizure control was achieved during valproate infusion
or within 20 minutes. The most commonly reported effective doses were
15 mg/kg in bolus (adults) or 20 mg/kg (children) followed by 1 mg/kg/h
infusion. The incidence of adverse events (mainly hypotension, dizziness
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and thrombocytopenia) was low (less than 10%) and independent of
infusion rate.
Conclusion: Although no randomised double-blind clinical study has
been performed, available data from open-label studies have shown intra-
venous valproate to be effective in resolving SE in patients who have pre-
viously failed conventional first-line therapies such as benzodiazepines.
No specific safety issues have been identified.
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ARE EXPERIENTIAL EPILEPTIC PRODROMES NON-
CONVULSIVE STATUS?
1J. Alving and 2J. Erdal (1Danish Epilepsy Center, Dianalund, Denmark,
2Copenhagen University Hospital, Copenhagen, Denmark)
Purpose: 1) To assess the percentage of patients with chronic epilepsy
reporting prodromes (experiential symptoms lasting for at least 30 min.
before seizures). 2) By acute video-EEG during prodromes to clarify
whether prodromes were in fact nonconvulsive status epilepticus.
Method: The study included 985 adult out- and in-patients at a tertiary
referral centre, interviewed during a one-year period. The study was
approved by the medical ethics committee, and comprised 2 parts: 1) An
interview by the treating physician, and subsequently by the authors. 2)
Acute video-EEG recording in the case of prodromes.
Results: 23 patents (2.3%) reported prodromes. 16 had focal epilepsy
syndromes, and 5 had idiopathic generalised epilepsy (mainly juvenile
myoclonic). Two cases could not be classified. In 5, an ictal EEG was
obtained, 2 of them showing clear EEG evidence of nonconvulsive status
epilepticus (NCSE), and the 3rd had ambiguous findings. In the remain-
der, ictal EEG could not be performed due to practical problems.
Conclusion: To our knowledge, this study is the first attempt to clarify
the role of NCSE in prodromes. This is confirmed in 2 out of 5 cases
studied with acute video-EEG, and this mechanism should be borne in
mind for patients with experiential epileptic prodromes. Besides this,
we found a prevalence of prodromes far below those reported in pre-
vious studies (e.g. Hughes et al, Seizure 1993–2:201–203, Rajna et al,
Seizure 1997–6:361–368). Notably, prodromes were also quite frequent
in idiopathic generalised epilepsies.
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THE TRUE PREVALENCE OF EPILEPSY IN ADULTS EX-
CEEDS 1% IN RURAL NORWAY
E. Brodtkorb and O. Sjaastad (Department of Neurology and Clin-
ical Neurophysiology, Trondheim University Hospital, Trondheim,
Norway)
Purpose: Incomplete case finding is a problem in all epidemiological
studies in epilepsy. We tried to optimise case-ascertainment by personal
interviews.
Method: The study was carried out as part of an epidemiological
study of headache in the Va˚ga˚ community. During a 2-year period, 1838
inhabitants in the age range 18–65 (88.6% of the target population) were
interviewed based on a questionnaire. Individuals with learning disabil-
ity, mental disorders and dementia were excluded (Sjaastad O, et al.
The Va˚ga˚ Study: An outline of the design. Cephalalgia 1999;19 Suppl
25:24–30). One question concerning epilepsy was presented to 1793 con-
secutive cases: “Have you ever had convulsions, epileptic fits or other
epileptic symptoms?” The medical records of those who replied posi-
tively were reviewed, and telephone interviews were performed when
needed.
Results: 133 individuals confirmed possible epileptic symptoms.
Only 40 were diagnosed as ever having had epilepsy. 18 were treated
with antiepileptic drugs, of whom 10 had active epilepsy with seizures
within the last five years. The prevalence of epilepsy (active + in remis-
sion with treatment) was calculated to be 10.0/1000. The prevalence of
active epilepsy was 5.6/1000.
Conclusion: By this unique method of case-ascertainment, the preva-
lence rate of epilepsy was 1%, despite the fact that high risk groups
for epilepsy, such as children, old people and individuals with cognitive
deficits and communication problems were excluded from the study.
Although these findings were derived from a small population sample,
they may indicate that the true crude prevalence of epilepsy in Western
Europe is higher than previously presumed.
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RECURRENT ABSENCE STATUS AND UNILATERAL SUB-
CLINICAL PAROXYSMAL ACTIVITY: CLINICAL EVOLU-
TION AND PHARMACOLOGICAL SENSITIVITY
1P. Genton and 1,2R. Velizarova (1Centre Saint Paul, Marseille, France,
2Aleksandrov University Hospital, Sofia, Bulgaria)
Purpose: EEG remains the most essential distinguishing tool between
focal and generalised nonconvulsive status epilepticus. However, there
is evidence of variant or transitional forms with an intermediate EEG
state between focal and generalised NCSE.
Method: We report a patient with a history of rare generalised tonic–
clonic seizures (GTCS) and recurrent absence status (AS) in whom a
highly unusual interictal EEG with a unilateral continuous subclinical
paroxysmal activity was once recorded. Such features have never been
reported before to our knowledge in patients with idiopathic generalised
epilepsy.
Results and Conclusion: Phenobarbital, lamotrigine and topiramate
did not control AS, carbamazepine apparently aggravated AS, and etho-
suximide did not control GTCS. Total seizure control was only possible
with valproate at 1,000 mg/day, which the patient did not tolerate well
because of weight gain, and because of this is currently well-controlled
on a combination of valproate 1,000 mg/d and topiramate 200 mg/day.
p138
CHANGES OF SERUM LEVELS OF NATURAL NEUROTROPIC
AUTOANTIBODIES IN PATIENTS WITH PARTIAL SYMP-
TOMATIC/CRYPTOGENIC EPILEPSY
1A. Guekht, 1I. Lusnikova, 2A. Poletaev, 1A. Feyguina, 1I. Kovaleva,
and 1E. Gusev (1Russian State Medical University, Moscow, Russia,
2Research Center “Immunculus,” Moscow, Russia)
Purpose: To evaluate changes of the serum levels of neurotropic au-
toantibodies (nAb) against proteins S100b, GFAP, MP65 and NGF in
serum of patients with partial symptomatic/cryptogenic epilepsy. NGF
and MP65 appear essential to molecular mechanisms of synaptic plas-
ticity, and there are data that S100B, an astrocyte-derived cytokine, is
elevated in the temporal lobe of refractory epilepsy.
Method: 50 patients were investigated (age 29.58 ± 11.66 y.o.). As a
control 119 clinically healthy age-matched people were used. Levels of
nAb: idiotypic (nAbi) and anti idiotypic (nAIAb) against proteins S100b,
GFAP, MP65 and NGF were analysed with Enzyme Immunoassay Test-
System ELI-N-Test.
Results: Epilepsy patients had lower levels (compared to controls,
Mann-Whitney test) of the following neurotropic autoantibodies: nAbi
against S100b (p = 0.037), MP65 (p = 0.0001), NGF (p = 0.014),
nAIAb against S100b (p = 0.003), MP65 (p = 0.001), GFAP (p =
0.007). Interestingly, a patient with a long duration of epilepsy had a
relatively high level of the nAB, still not reaching the level of the control
group. Duration of epilepsy positively correlated with the level of nAbi
against S100b (r = 0.3; p = 0.03) and against NGF (r = 0.29; p = 0.037)
(Spearman rank correlation).
Conclusion: The significance of these changes should be further anal-
ysed with special attention to the pronounced decrease of nAb level in
epilepsy patients. The other important finding is the relative increase of
nAb against S100b and NGF that could be related to plasticity changes
in patients with a long duration of epilepsy.
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CURRENT USE OF SLEEP DEPRIVED EEG: RESULTS OF A
FRENCH SURVEY
O. Casez, S. Hamelin, L. Vercueil, and P. Kahane (Department of
Neurology, Epilepsy Unit, Grenoble University Hospital, Grenoble,
France)
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Purpose: Activation procedures improve EEG sensitivity. Among
them, sleep deprivation is a widely available, although not standard-
ised, technique. We investigated the current use of sleep-deprived (SD)
EEG in French adult epilepsy centres trying to identify guidelines for
this practice.
Method: A questionnaire was sent to 19 French epilepsy centres.
Physicians were asked when and how SD EEG proceeded and the results
they expected.
Results: Response rate was over 80%. On average, these centres con-
ducted two SD EEGs a week (range 0.2–7). Indications were mainly
syndrome diagnosis and clinical event recording. Sleep deprivation gen-
erally exceeded 50% of the sleep time (range 30–100%). Median duration
of EEG recording was 3h (range 1–24 h). Occurrence of sleep and video
recording were highly recommended by the majority of the centres. A
specific contribution to diagnosis was obtained in about 50% of cases,
depending on the accuracy of the indication.
Conclusion: This survey shows that the use of SD EEG remains het-
erogeneous among epilepsy centres in France. This could be improved
by promoting guidelines. On the basis of the literature, our proper ex-
perience and the present survey, two main procedures can be drawn
depending on the recording indication: 1) seeking syndrome classifica-
tion requires a 50% sleep deprivation delaying sleep onset. Recording
should last three hours including sleep and provoked arousal followed by
photic stimulation and hyperpnoea; 2) presurgical assessment and iden-
tifying the nature of paroxistic events requires a day recording. Sleep
deprivation can be more pronounced or even total.
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NOVEL TOOLS FOR EPILEPSY CARE AND RESEARCH (EPIL-
CARE): USE OF PROPOSED ILAE DIAGNOSTIC SCHEME
WITH SPECIALISED COMPUTER APPLICATION
1R. Ka¨lvia¨inen, 2T. Ma¨enpa¨a¨, 3E. Herrga˚rd, 1L. Jutila, 4E. Gaily,
5T. Kera¨nen, and 6K. Eriksson (1Department of Neurology, Kuo-
pio Epilepsy Center, Kuopio University Hospital, Kuopio, Finland,
2Marimedical Ltd, Helsinki, Finland, 3Department of Pediatric Neu-
rology, Kuopio Epilepsy Center, Kuopio University Hospital, Kuopio,
Finland, 4Hospital For Children And Adolescents, Helsinki University
Hospital, Helsinki, Finland, 5Department of Neurology, Tampere Uni-
versity Hospital, Tampere, Finland, 6Pediatric Research Centre, Tampere
University Hospital, Tampere, Finland)
Purpose: The purpose of this research is to describe the use of a spe-
cialised computer application and clinical database for epilepsy (Epil-
Care). EpilCare is a tool for supporting the daily registration and storage
of clinical events in epilepsy.
Method: The database contains structured terminology of seizure
types, syndromes, epilepsy type, aetiology and description of the impair-
ment(s) caused by the epilepsy. We used the new 2001 ILAE proposed
diagnostic scheme (Engel J Jr. Epilepsia 2001;42:796–803) consisting
of 5 axis as the basis of describing individual data in each patient. Med-
ications and other treatments are described in detail.
Results: The EpilCare application is built by MariMedical Ltd who are
also responsible for the maintenance of the database. Epilcare has now
been tested in the first 30 adult and paediatric patients with drug-resistant
epilepsy, with past and present multiple drug treatments and with various
seizure types, syndromes and aetiologies in Kuopio University Hospital.
We found the ILAE diagnostic approach very practical in daily use.
Conclusion: EpilCare is a novel method for collecting and storing
clinically relevant data from patients with epilepsy diagnosed with the
proposed ILAE diagnostic scheme. EpilCare allows a fast review of data
during the clinical visit or during a phone call. The application improves
the flow of information within the hospital information system. The
clinical database of EpilCare allows the standardisation of patients’ data,
and a better organisation of the patient management process.
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GENERIC PREPARATIONS OF ANTIEPILEPTIC DRUGS: EX-
PERIENCES IN GERMANY, AUSTRIA, AND SWITZERLAND
1G. Kra¨mer, 2B. Steinhoff, 3M. Feucht, 4M. Pfa¨fflin, and 4T. May
(1Swiss Epilepsy Center, Zurich, Switzerland, 2Epilepsy Center Kehl-
Kork, Kork, Finland, 3University Hospital, Vienna, Austria, 4Society For
Epilepsy Research, Bielefeld, Germany)
Purpose: The use of generic drugs may be without problems in some
health problems, but chronic diseases with the need of a stable medica-
tion may be different. This is especially true for epilepsies, where treat-
ment with antiepileptic drugs (AEDs) is guided with surrogate markers
like blood levels and where a single seizure recurrence may have severe
consequences. We were interested in the experience of physicians in
Germany, Austria and Switzerland with generic preparations of
antiepileptic drugs (G-AEDs).
Method: An internet based questionnaire study completed by mem-
bers of the German, Austrian and Swiss sections of the International
League Against Epilepsy, as well as members of the German Society
for Neurology. About 2.800 e-mails were sent, together with an accom-
panying letter signed by the presidents of the three league chapters on
1 December 2005. There was a link to a specially designed website for
easy online response.
Results: Until the end of January 2006 we received more than 600
responses. About 80% of the physicians had experience with G-AEDs.
About half of them reported problems with their usage, in decreasing
percentage additional telephone contacts or visits, hospital admissions,
calls for emergency doctors or visits of emergency rooms, disturbances
of the physician-patient relationship, sick certificates or injuries. In about
half of the physicians these experiences had led to changes in their pre-
scribing behaviour (restrictions for substitution), in addition to increased
patient counselling and blood level determinations of AEDs. The cur-
rent criteria for approval of G-AEDs were considered as inappropriate
by about 50% and 90% considered it unacceptable that pharmacists have
the possibility of substitution without consultation.
Conclusion: In line with the results of earlier reports our question-
naire study underlines the potential problems with the use of G-AEDs in
antiepileptic therapy and justifies recommendations to avoid switching
different preparations (from branded preparations to generics as well
as between generics or from generics to branded preparations) e.g., in
seizure free patients.
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FACTORS FAVOURING THE DIAGNOSIS OF STATUS PSEU-
DOEPILEPTICUS IN THE EMERGENCY SETTING
H. Meierkord, J. Othman, K. Buchheim, and M. Holtkamp (Department
of Neurology, Charite´-Universita¨tsmedizin Berlin, Germany)
Purpose: To assess features helpful in differentiating status pseu-
doepilepticus (SPE) with generalised convulsions from true refractory
generalised status epilepticus (rGCSE) in the emergency setting beyond
advanced knowledge in seizure semiology and unlimited availability of
EEG.
Method: Patients treated between 1993 and 2002 in the neurological
intensive care unit for assumed GCSE were reviewed. The diagnoses of
SPE and rGCSE were made retrospectively on the basis of patients’ his-
tory as well as clinical, electrophysiological, and imaging findings. We
looked for differences concerning age, sex, the presence of implanted
port systems, the amount of benzodiazepines administered until termi-
nation of seizures or occurrence of respiratory failure and expressed as
diazepam equivalent, and creatine kinase (CK) levels within 24 h after
onset of status epilepticus.
Results: There were 9 episodes of SPE and 10 of rGCSE. Subjects
with SPE (27 ± 8 years) were significantly younger than patients with
rGCSE (46 ± 20; p = 0.035). A port system was present in 4 patients
with SPE and in none with rGCSE (p = 0.033). The equivalent diazepam
dosage to terminate convulsions without respiratory failure was 61 ±
27 mg in patients with SPE and 33 ± 21 mg in rGCSE (p = 0.026).
Serum CK was 42 ± 23 U/l in SPE and 849 ± 857 U/l in RGCSE (p =
0.002).
Conclusion: In the emergency setting, SPE with generalised motor
convulsions is as common as rGCSE. Younger age, the presence of a
port system, the capability to tolerate high dosages of benzodiazepines
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without respiratory failure, and normal CK levels favour the diagnosis of
SPE. These factors should alert the clinician as to the correct diagnosis
of SPE.
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DIAGNOSIS AND AETIOLOGY OF TEMPORAL LOBE
EPILEPSY
1M. Tereshchuk and 2A. Tsoriev (11st Regional Hospital, Neurology
Department, Russia, 21st Regional Hospital, Rentgenology Department,
Russia)
Purpose: Among various aetiological factors, determining develop-
ment of temporal lobe epilepsy (TLE), medial temporal sclerosis (MTS)
brain disgenesis and tumours are considered to be the most important.
The issue of the aetiological role of perinatal encephalopathia in devel-
opment of MTS and amigdal-hippocampal epilepsy hasn’t been solved
up until now. The aim of this research is to estimate the role of different
aetiological factors and results of MRI methods in diagnosis of medial
and lateral forms of TLE.
Method: There were 117 patients involved in the research. The form
of epilepsy was defined on the basis of clinical seizures and changes of
EEG.
Results: Unilateral hippocampus sclerosis was found in 14 (21.2%)
patients with medial TLE and in 2 (10.8%) patients with lateral TLE. The
majority of patients with hippocampus sclerosis had perinatal ischemic
damage of CNS. Frequency of febrile seizures in a group of patients with
medial TLE was found to be 26.4%. The age of onset of medial TLE is
8–10 years younger that lateral TLE.
Conclusion: As the research showed, the leading role in development
of a medial form of TLE in our patients belongs to perinatal encephalopa-
tia. Brain damage and tumour were diagnosed for certain more often in
patients suffering from lateral TLE.
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EPILEPSY PATIENTS’ COMPLIANCE WITH PRESCRIBED
MEDICAL TREATMENT
1I. Lusic, 1M. Titlic, 2D. Eterovic, 1P. Filipovic-Grcic, and 1I.
Bilic (1Department of Neurology, University Hospital Split, Croatia,
2Department of Nuclear Medicine, University Hospital Split, Croatia)
Purpose: Medically treated patients’ noncompliance with the pre-
scribed scheme is an exceptionally important issue, faced relatively often
in medical treatment of epilepsy.
Method: Different demographic and clinical data, collected upon
questionnaire completion by 146 patients suffering from epilepsy, were
sorted and integrated in the present research analyses with the objec-
tive to determine the possibility of collected data, and compliance level
correlation, registered with the observed patients.
Results: Generally speaking, the examinees took rather regularly the
prescribed therapy: with 62% examinees the compliance level was reg-
istered as good, with 23% as satisfactory, while with the remaining 15%
of the examinees the compliance level was unsatisfactory. The following
data have been identified as the possible predictors of the less precise
adherence to the prescribed therapeutic regime (p < .01): regular con-
sumption of alcohol, medical treatment exceeding the period of 6 or more
years, and further, the data on three or more daily doses of the medicine
(respectively medicines). The correlation between the greater number
of prescribed antiepileptic medicines and lower compliance level (p =
0.05) has also been registered. The inclination towards a lower com-
pliance level with patients aged under 30, has also been registered in
the research. It is slightly surprising that the same tendency has been
noticed with the examinees with a more thoroughly controlled epilepsy
condition.
Conclusion: In spite of different experiments aimed to improve the
regularity in taking the prescribed therapy, the noncompliance issue still
presents a considerable obstacle to the more successful treatment of
epilepsy patients.
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EPILEPSY DIAGNOSIS AND PREVALENCE OF SEIZURE SUB-
TYPES IN AN OUTPATIENT SAMPLE
1M. Raoof and 2A. Sarmed (1Al-Kadhimiya Teaching Hospital, Bagdad,
Iraq, 2College of Medicine, Bagdad University, Bagdad, Iraq)
Purpose: This is a prospective clinical study aimed at the diagnosis
of epilepsy and estimation of the prevalence rates of its various subtypes
in a sample of outpatients who attended the Neurology and Psychiatry
Consultation Clinic in Baghdad Teaching Hospital over a period of 18
months.
Method: One hundred cases (48 males and 52 females) were gath-
ered randomly according to the inclusion criteria of the present study.
Diagnosis of epilepsy was based on the clinical history, with or without
abnormal EEG findings.
Results: The study revealed that partial epilepsy was relatively more
prevalent than generalised epilepsy (54% vs 46%). Partial epilepsy with
complex partial seizures was the most common subtype among the study
sample with a prevalence of 39%, while that with simple partial seizures
reached 13%. Secondary generalisation was high among cases with par-
tial epilepsy (37%), and in addition 37% had multiple seizure types. As
for generalised epilepsy, cases with tonic–clonic seizures reached 28%,
juvenile myoclonic epilepsy 17%, and absence epilepsy 1%.
Conclusion: The results conform to international data regarding the
prevalence of different seizure types, with predominance of complex
partial seizures.
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THE IMPACT OF LUNAR PHASES ON SEIZURE
OCCURRENCE
P. Polychronopoulos, A. Argyriou, V. Sirrou, V. Huliara, M. Aplada, P.
Gourzis, A. Economou, E. Terzis, and E. Chroni (University Hospital of
Patras-Neurology Department, Rion-Patras, Greece)
Purpose: To ascertain whether lunar phases and particularly the “full
moon” period is associated with seizure induction.
Method: All neurological case records of our emergency unit were
retrospectively reviewed over a 5 year period (1999–2003) and cases
admitted for a single or multiple epileptic seizures were identified and
divided into the four quarters of the synodic month according to the moon
phases. The crude overall incidence rate (IR) of seizures per quarter,
i.e., new moon, 1st quarter, full moon and last quarter was estimated.
Patients manifesting seizures of nonepileptic origin such as psychogenic
nonepileptic seizures were excluded.
Results: Overall 859 cases manifesting epileptic seizures were iden-
tified. 536 patients (62.4%), with mean age 43.8 ± 19.3, were males
and 323 (37.6%), with mean age 45.1 ± 20.9 were females. A striking
increase in overall seizure occurrence was observed for both genders
during the “full moon” days (n = 294, 34.2%), whilst at all other cycles
of the synodic lunar month the rates of seizure occurrence were signif-
icantly lower, ranging between 21.4% for the “new moon” days (n =
184) to 22.5% for the “1st quarter” lunar days (n = 193). The difference
of seizure IRs was strongly significant (chi-square test, p < 0.0001) in
all comparisons between the “full moon” days and all the other lunar
cycles.
Conclusion: A significant clustering of seizures around the “full
moon” period was observed, supporting the ancient belief of a periodic
increased seizure frequency during “full moon” days.
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PARANEOPLASTIC SYNDROME PRESENTED AS PRO-
LONGED FOCAL SEIZURES (EPILEPSIA PARTIALIS
CONTINUA)
1A. Hancu, 2C. Mihai, and 1M. Kaivani (1Neurology Department-
Emergency Hospital, Constanta, Romania, 2Pediatric Department-
Emergency Hospital, Constanta, Romania)
Purpose: We describe a man of 59 years old, a smoker (20 cigarettes
per day), without any pathologic background, with epilepsia partialis
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continua, with a relatively sudden appearance in the last 6 weeks. We
purpose to find the cause of these prolonged focal seizures.
Method: We made a history of this case, the physical and neurologi-
cal examination of the patient with involuntary movements of the right
upper limb permanently day and night, awake and during sleep. These
involuntary movements were labeled at the beginning as hemiballismus,
then after first admission as brachial myoclonia (right) and after second
admission the diagnosis was of Kojevnikov encephalitis, prolonged focal
seizures, cortical atrophy confirmed by cerebral CT scan and MRI. These
prolonged focal seizures were ameliorated by a complex of antiepileptic
drugs.
Results: After 5 months, cerebral MRI was repeated which revealed
along with the cerebral atrophy, hemispheric periventricular demyeli-
nating lesions, also infiltrative nasopharyngeal mass (left). Three na-
sopharyngeal biopsies were performed with an interval of 2 months and
finally the diagnosis of anaplastic small cell carcinoma was confirmed.
Immediately the chest was x-rayed, bronchopulmonary cancer was re-
vealed (confirmed by cervico-pulmonary MRI). Cerebral MRI revealed
a secondary cerebral tumour (right temporal lobe).
Conclusion: Paraneoplastic syndrome presented as encephalitis with
prolonged focal seizures preceded by 12 months the diagnosis of bron-
chopulmonary and pharyngeal cancer.
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POSTICTAL HEADACHE IN ADULT PATIENTS WITH
EPILEPSY
1S. Vujisic, 1M. Kolinovic, 2R. Ognjenovic, and 3K. Bozic
(1Neurological Clinic, Medical Faculty, University of Montenegro, Pod-
gorica, Montenegro, 2Specialised Hospital for Neurology, Neurosurgery
and Orthopedics, Risan, Montenegro, 3Institute for Neurology, Medical
Faculty, University of Novi Sad, Serbia)
Purpose: To determine the incidence and type of postictal headache
in adult patients with epilepsy and headache, as well as the connections
between the specific epileptic seizure and headache type.
Method: 86 out of 259 patients with a confirmed diagnosis of epilepsy
had headaches. The type of seizure is classified according to ILAE 1989,
and ICHD II 2004 was used in classification of headache types. All pa-
tients filled out a detailed questionnaire. Complete neurological exami-
nations, EEG, CT and/or MRI of the brain were performed.
Results: Among 86 (33.20%) patients with seizures and headache,
43 (50%) had postictal headaches. Postictal migraine headaches were
observed in 11 (28%) patients out of 40 patients with epilepsy and
migraine, and all were women. Generalised seizures were found in 7
(63.6%) patients. Four (36.4%) patients had partial complex seizures.
Thirty (76.9%) out of 46 patients with nonmigraine headaches had pos-
tictal tension headaches, and only 2 patients had thunderclap primary
headaches. Tension headaches occurred postictally in 23 (74.2%) pa-
tients after generalised epileptic seizures, and in 7 (22.6%) patients after
partial seizures. Thirty-two (74.4%) out of 43 patients with postictal
headaches had nonmigraine headaches. Migraine headache was present
in 11 (25.6%) patients. Headache postictally linked to seizure was sta-
tistically less frequent in patients with epilepsy and migraine than in
patients having epilepsy associated with nonmigraine headaches (p <
0.001).
Conclusion: Half of the patients with epilepsy and headache had
postictal headaches. Tension headaches were significantly more frequent
than migraine. Postictal headache more frequently occurred after tonic–
clonic seizures.
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LATERALISING VALUE OF AUTOMATISM IN MESIAL TEM-
PORAL LOBE EPILEPSY
A. Abubakr and I. Wambacq (Seton Hall University For Graduate Med-
ical Education, USA)
Purpose: To compare the clinical features of automatism between
right and left mesial TLE.
Method: We retrospectively reviewed the features of clinical seizures
in 28 consecutive patients (16 females and 12 males) with TLE, age
range 18–65 years. 17 patients had left TLE (78 seizures) and 11 had
right TLE (69 seizures). Automatistic behaviours of manual and pedal,
oro-alimentary, vocalisation (mumbling, grunting etc), nose wiping, face
wiping, water drinking and retching plus vomiting were assessed and
compared between left and right temporal lobe epilepsy focus.
Results: Manual automatism is the most frequent behaviour occurring
ipsilateral to the epilepsy focus in 64% in the right and 73% in the left
and bilaterally in 29% and 27% respectively. Pedal and oro-alimentary
automatism occurred in both sides and there is no significant difference
between right and left TLE focus (17.5% and 35% vs 27% and 36%
respectively). Vocalisation occurred in 41% of the left compared to 17%
of the right TLE focus, which is significantly different between the two
sides (p = 0.05). Similarly face wiping occurred in 17% on the left and
45% on the right, which is significantly different between the two sides.
Water drinking as well as retching plus vomiting occurred only in the
right TLE (18%).
Conclusion: Some automatistic behaviours may differentiate between
right and left temporal lobe focus, such as vocalisation lateralises to the
left TLE and face wiping, water drinking and retching plus vomiting to
the right temporal focus.
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EPILEPSY AND DRIVING LICENCE IN LITHUANIA
R. Mameniskiene, D. Jatuzis, and V. Budrys (Vilnius University Hospital,
Vilnius, Lithuania)
Purpose: In Lithuania driving is prohibited by law for patients with
a current diagnosis or history of epilepsy despite seizure activity. Our
aim was to analyse and to compare the view of doctors and patients with
epilepsy into the legalisation of driving in appropriate cases.
Method: 260 patients with epilepsy were given a questionnaire re-
garding epilepsy characteristics, social issues and impact of inability to
drive on their quality of life. 156 neurologists completed a questionnaire
regarding legal permission to get a driver’s license for patients with cur-
rent or past epilepsy.
Results: 64.2% of patients indicated that driving restrictions have
a negative impact on their quality of life. 28.1% of patients, despite
official prohibition, hold a driver’s license. 73.1% would support legal
permission to drive for seizure-free patients. 94.5% of neurologists look
with favour to driving of a clearly defined subgroup of epilepsy patients.
87.8% of them would permit the patient to drive if seizure-free without
medication. 39.7%, if they are on antiepileptic drug. 19.8% would allow
the patient to drive if seizures occur only during night sleep and 14.4% if
seizures are focal. 45.2% would permit driving after a 5 year seizure-free
period, 43.2% after 2 years. 26.7% would not withhold a driving license
after the first seizure. 94.5% would use EEG in the assessment of driving
fitness.
Conclusion: Most epilepsy patients and neurologists support legal
permission to drive for seizure-free patients. Results of our survey sup-
port currently ongoing revision of regulations of driving licensing in
Lithuania towards liberalisation according to EU directives.
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ICTAL SALIVATION IN TEMPORAL LOBE EPILEPSY
C. Watson, J. Shah, D. Fuerst, and H. Zhai (Wayne State University
School of Medicine; Detroit, Michigan, USA)
Purpose: We sought to determine whether hypersalivation helps lat-
eralise seizure onset during complex partial seizures of temporal lobe
origin. Several clinical signs, which help lateralise seizure onset, have
been reported in temporal lobe epilepsy (TLE). Increased salivation has
only occasionally been reported as a manifestation of partial epilepsy.
Method: of 590 consecutive patients admitted for EEG/video monitor-
ing, either as a part of a presurgical evaluation of medically intractable
epilepsy or for diagnosis and clarification of their paroxysmal symp-
toms, we identified 10 patients with ictal hypersalivation as a promi-
nent manifestation of complex partial seizures. We reviewed the clinical
features, scalp-sphenoidal EEG/video monitoring, intracarotid amytal
(Wada) testing, hippocampal volumetric MRI, and FDG-PET scans of
these patients.
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Results: of the 10 patients with ictal hypersalivation, 7 patients had
nondominant/right TLE, and 3 patients had dominant/left TLE. All pa-
tients had hippocampal atrophy on volumetric MRI. Eight of the 10 pa-
tients underwent standard temporal lobectomy with amygdalohippocam-
pectomy (6 right, 2 left). All of the operated patients had a seizure free
(Engel Class I) outcome, and their increased salivation resolved. Two pa-
tients, who did not undergo surgical treatment, continue to have complex
partial seizures with increased salivation.
Conclusion: We conclude that increased salivation as a prominent
ictal finding in complex partial seizures of temporal lobe origin is more
likely to be of nondominant temporal lobe origin. Further studies with
larger numbers of patients are needed to replicate this finding.
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CEREBRAL NONEPILEPTIC PAROXYSMAL CONVULSIVE
MANIFESTATIONS
P. Mihancea, C. Brisc, C. Brisc, and N. Havasi (Oradea University, Fac-
ulty of Medicine And Pharmacy, Romania)
Purpose: There are a great number of cerebral paroxysmal convulsive
manifestations which are less studied, but they are still frequently present
during neurological practice, and ignorance of them may lead to severe
diagnosis and treatment errors. Our goal is to emphasise them among
patients hospitalised in the Clinic of Neurology of Oradea.
Method: We studied 450 patients interned in our clinic and diagnosed
with epilepsy during 2005, using clinical and paraclinical methods. These
patients represent 10% of total hospitalisations during 2005.
Results: We found that only 112 patients out of the 450 (25%) were
detected with idiopathic epilepsy. The remaining 338 (75%) patients
presented nonepileptic paroxysmal convulsive manifestations of procon-
vulsionary diseases. We made an enumeration of the epilepsy-generating
diseases found in our study: strokes (20%), cranial-cerebral traumatisms
(10%), syncope (6%), alcoholism (5%), cerebral tumours (5%), infec-
tious diseases (5%), intestinal parasitoses (4%), hypoglycaemia (4%),
disorders of the hydro electrolytic metabolism (4%), deficit of B6 vita-
min (2%), febrile convulsions (2%), renal failure (1%), hepatic failure
(1%), porphyry (1%), sun exposure (1%), convulsive access induced by
electrocution (1%), hysterically induced convulsion (1%), degenerative
diseases of the central nervous system (1%), disembryoplasiae (1%).
Conclusion: Besides patients with idiopathic epilepsy, there are in
our clinic hospitalised patients diagnosed with diseases which have
an epilepsy-generating convulsive potential. These conditions must be
diagnosed quickly for the patient to benefit from antiepileptic ther-
apy, or by a specific cure, without which the patient may rapidly
decease.
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A HOSPITAL-BASED STUDY OF CLASSIFICATION OF
EPILEPSIES, EPILEPTIC SYNDROMES AND AETIOLOGIES
OF 728 EPILEPSY PATIENTS
1C. Ding, 1Y. Zhao, 1Z. Li, 1Y. Huang, 2Y. Zhou, 1X. Shao, and 3M.
Liu (1Epilepsy Center, Beijing Tiantan Hospital, Capital University for
Medical Sciences, Beijing, China, 2Department Epidemiology, Capital
University for Medical Sciences, Beijing, China, 3Department Epidemi-
ology, Peking University School of Medical Sciences. Beijing, China)
Purpose: The purpose of this study is to describe seizure types, types
of epilepsy and epileptic syndromes as well as aetiologies.
Method: Seizure types, epilepsy syndromes and aetiologies were clas-
sified according to classification of ILAE. A total of 728 patients attend-
ing our Epilepsy Center were recruited into this study. All patients were
examined by short or/and long-term Video EEG, cranial CT or/and MRI.
Results: (1) Initial onset in 67.17% of all subjects was under 20 years
of age, and the ratio of male to female was 1.67:1.22. 3.02% of all subjects
had a family history of epilepsy and 76 (10.43%) had a history of fever
convulsion. (2) Patients with one seizure type were about 25.14% and
with two or more seizure types were about 74.86%. The main seizure
types were complex partial seizures (67.44%) and generalised tonic–
clonic seizures (69.50%), and a majority of generalised tonic–clonic
seizures were secondary (88.14%). (3) Generalised epilepsy was about
90 (12.36%), focal epilepsy was about 621 (85.30%), and the other 17
(2.34%) of all subjects were unclassified as either focal or generalised
epilepsy. (4) Analysis of aetiologies showed that idiopathic epilepsy
was in 9.89%, cryptogenic in 28.57%, and symptomatic in 61.53%. A
majority of patients with idiopathic epilepsy were under the 20 years
of age. Meanwhile, the older the initial onset of age, greater was the
possibility of symptomatic epilepsy.
Conclusion: According to the classification of ILAE, complex par-
tial and secondary generalised seizures, partial epilepsies and epilep-
tic syndromes, and symptomatic epilepsy were the main types in this
hospital-based study.
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EPILEPTIC SEIZURES AS A FIRST MANIFESTATION OF
MULTIPLE SCLEROSIS
D. Vyskocilova and R. Vancurova (Department of Neurology, Faculty
Thomayer¨s Hospital)
Purpose: The occurrence of epileptic seizures in multiple sclerosis
(MS) is 3–4 times higher than that in the average population. In the
case of multiple sclerosis partial epileptic seizures may appear with less
typical symptoms with or without secondary generalisation. Sometimes
epileptic seizures occur even several years before clinical signs of MS
are manifested.
Method: According to McDonald’s diagnostic criteria 275 cases of
MS have been registered in our database among patients who attended
the Neurology Department in Faculty Thomayer’s Hospital in Prague
from 1 January 2002 to 31 December 2005 (36 months). In this group
of patients we analysed the data of 11 patients with history of epileptic
seizures. In 4 patients (1.8%), 2 male and 2 female, the onset of epilepsy
occurred several years before MS onset. We present the data of these
4 patients.
Results: MRI is an appropriate method for the diagnosis of MS, as
well as for the assessment of the relationship between EEG findings
and localisation of lesions in the central nervous system. The lesions
involved in the pathogenesis of the crises are plaques of demyelination
which affect the subcortical and cortical areas. Not only the lesion itself
but also the cytotoxic oedema that accompanies an active plaque, seems
to be responsible for the development of seizures.
Conclusion: Our data suggest that epileptic seizures are more com-
mon in MS than in the general population. Epileptic seizures can be
the first symptom of MS, appearing before other signs of the illness.
EEG is recomended when paroxysmal epizodes of altered perception or
cognitive function are reported by an MS patient.
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KNOWLEDGE OF AND ATTITUDE TOWARD EPILEPSY
AMONGST RELATIVES OF EPILEPSY PATIENTS AND THE
COMMUNITY IN QATAR
H. Al Hail (Hamad General Hospital, Qatar)
Purpose: Improving patients’ knowledge about epilepsy has been
suggested to be a key factor for the improvement of their quality of life.
Similarly, the attitude towards people with epilepsy is influenced by the
degree of knowledge in the environment about this clinical disorder.
Method: This study was conducted among relatives of epilepsy pa-
tients (REP) as well as in the community at large (CAL) in Qatar. The
age group targeted ranged from 10–50 yrs across all nationalities and re-
ligions. A semistructured questionnaire was used to evaluate the knowl-
edge and attitude of the interviewee towards epilepsy.
Results: The interview and questionnaire was administered to 28 in-
dividuals REP 35.7% and CAL 64.3%. Almost all the REP and CAL
had heard about epilepsy; 75% of them associating epilepsy with a cen-
tral nervous system disturbance. Some REP and CAL still thought that
epilepsy was contagious or caused by an evil spirit. Amongst REP and
CAL, 53.6% thought that discrimination against people with epilepsy
was justified. The knowledge of the interviewees about the clinical char-
acteristics and first aid measures to be taken for a person having a seizure
was unsatisfactory. Less than half believed that epilepsy could be cured.
57.1% thought that this disorder should be treated by modern medicine
and 28.6% believed in traditional medicines. The majority (64.3%) of
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REP and CAL were interested in helping epilepsy patients. One third of
people (32.1%) believed that it was safe for an epilepsy patient to drive
a car.
Conclusion: In conclusion, there is an urgent need for improving
the knowledge of the community especially people surrounding the
epilepsy patient. Public and governmental institutions including teach-
ers should create awareness and provide basic information and assis-
tance in health matters, such as epilepsy. The Ministry of Health physi-
cians and the Ministry of Education should ensure through different
sources of education that the community has sufficient knowledge of
epilepsy.
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VALUE OF STANDARDISED MENTAL STATUS TESTING FOR
NONCONVULSIVE STATUS EPILEPTICUS
1D. Audenino, 2L. Primavera, 1P. Fontana, 1G. Pedulla`, 1S. Bisio, 1S.
Stara, and 1A. Primavera (1Department of Neurosciences, University of
Genova, Italy, 2Department of Psychology, University of Padova, Italy)
Purpose: Nonconvulsive Status Epilepticus (NCSE) is a heterogeeous
disorder, with serious morbidity and mortality. Some reports have con-
sidered mental status impairment an important prognostic finding. The
aim of this study is to show that mental status examination is not per-
formed systematically in patients with suspected NCSE, during EEG and
in follow-up.
Method: We reviewed clinical and EEG data of 81 consecutive pa-
tients (mean age 66.6 years) meeting the accepted criteria for the diagno-
sis of NCSE. The number and type of tasks for evaluating mental status
of patients before and after EEG were collected, as well as whether the
patients were retested during follow-up. Mental status improvement after
benzodiazepine (BZD) administration was reported. NCSE was classi-
fied in focal and generalised form and in relation to degree of mental
impairment.
Results: Thirty-nine patients had absence status, 35 patients had com-
plex partial status, and 7 had aphasic status. The main clinical presen-
tation was delirium (60%) or stupor (31%). BZD administration was
reported in 61 cases during EEG. In all cases GCS was used, but a stan-
dardised mental status examination was performed in 22 cases. In par-
ticular, before and after BZD administration, a systematic mental status
testing was not perfomed, and only 10 cases had a neuropsychological
follow-up.
Conclusion: We found that consistent mental status examination is
not performed systematically before and after BZD administration dur-
ing EEG in patients with suspected NCSE. According to Kirby et al.
2004 we suggest a standardised mental status testing during EEG record-
ing, useful to confirm the severity of cognitive impairment. At follow-
up psychological reevaluation, including an Italian version of National
Adult Reading Test may be useful to demonstrate neuropsychological
sequelae.
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CAN SEIZURE SEMIOLOGY DIFFERENTIATE LESIONAL
FROM NONLESIONAL TEMPORAL LOBE EPILEPSIES?
1S. Khan (Riyadh Armed Forces Hospital, Saudi Arabia)
The syndrome of mesial temporal lobe epilepsy with hippocampal
sclerosis is now widely recognised. It is often medically resistant but
surgically remediable. The clinical, the electroencephalographic, the
neuroimaging and the histopathologic features are homogenous with
favourable prognosis of epilepsy surgery. On the contrary, neocortical
temporal lobe epilepsy and in particular the cryptogenic or the nonle-
sional temporal lobe epilepsy remains a controversial topic. The inci-
dence of nonlesional temporal lobe epilepsy is unclear. Data on non-
lesional temporal lobe epilepsy comes from surgical series as well as
genetic data on familial nonlesional temporal lobe epilepsy. The clinical
features and seizure semiology of nonlesional temporal lobe epilepsy
is non-homogenous in the literature. In this presentation, we review the
topic of seizure semiology in nonlesional temporal lobe epilepsy from
the available data at the Epilepsy Comprehensive Program at RKH and
compare the results to the international literature with video EEG illus-
trations.
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“LATE RESPONSIVENESS”: THE VALUE OF CHANGING
TREATMENT IN CHRONIC EPILEPSY: AN OBSERVATIONAL
STUDY
1A. Luciano and 2S. Shorvon (1Neurophysiopathology, Department
of Oncology and Neuroscience, University “G. D’Annunzio” Chieti-
Pescara, Pescara, Italy, 2Institute of Neurology, UCL., Queen Square,
London, UK)
Purpose: The response of epilepsy to its early therapy has been long
recognised to be important in long-term prognosis (Shorvon SD. The
temporal aspects of prognosis of epilepsy. J Neurol Neurosurg Psychia-
try, 1984;47:1157–1165) and recent studies have confirmed this in var-
ious ways (Kwan P et al. Early identification of refractory epilepsy, N
Engl J Med, 2000;3:314–319). Notwithstanding this, it is common clin-
ical experience that significant numbers of patients with long-standing
chronic epilepsy do show good responses to changes in their antiepilep-
tic drug (AED) regimens (“late responsiveness”). We investigated the
proportion of patients with chronic epilepsy who do respond well to the
addition of a new AED, and factors influencing this.
Method: We studied 200 consecutive patients with chronic epilepsy
(defined as epilepsy still active after 4 or more years of therapy)
from a single clinic between 2002 and 2004. The response (seizure
control/>50% improvement/no improvement) to the addition of a new
AED was ascertained over a minimum period of 6 months after the
medication change.
Results: There was a good response to the addition of an AED (either
add-on or substitution) in a sizeable proportion of patients (depending
on the nature of the new drug introduced, severity of epilepsy, aetiology,
duration of epilepsy and number of drugs taken) including a minority
who gained complete seizure control.
Conclusion: These data are the first of their kind to quantify the
response of chronic epilepsy to drug changes (“late-responsiveness”) in
the setting of everyday clinical practice. These show that drug changes
are helpful in many patients who have not responded to initial drug
therapy.
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JUVENILE MYOCLONIC EPILEPSY AND INHERITANCE
I. Fedotova (Kharkov Medical University, Ukraine)
Purpose: Juvenile myoclonic epilepsy (JME) is an idiopathic gener-
alised epilepsy (IGE) with complex inheritance. Previous studies have
suggested maternal inheritance and female excess in IGEs but have not
been specific for JME. We investigated evidence for maternal inher-
itance, female excess and patterns of familial seizure risk in a well-
characterised sample of JME families.
Method: We identified 77 families through a JME proband and 40
families through a non-JME IGE proband. JME families were divided
into those with and without evidence of linkage to the EJM1 susceptibil-
ity locus on chromosome 6. We analysed transmission in 39 multigen-
erational families, calculated the adjusted sex ratio for JME, and looked
for evidence of seizure specific risk in family members.
Results: We found evidence for preferential maternal transmission
in both EJM1-linked and unlinked families (2.3:1), evidence even more
marked when potential selection factors were excluded. The adjusted
female: male risk ratio (RR) was very high in JME (RR = 13.6; 90%
confidence intervals (CI): 1.7–88.3). Absence seizures in JME probands
increased the overall risk of seizures in first degree relatives (14.9% vs
8.2%, p = 0.01), as well as first-degree relatives specific risk of absence
seizures (7.1% vs 2.4%, p = 0.01), but not myoclonic seizures.
Conclusion: We have confirmed the finding of maternal inheritance
in JME, which is not restricted to JME families linked to the EJM1 lo-
cus. The striking female excess in JME may relate to anatomical and/or
endocrine sexual dimorphism in the brain. Evidence for independent in-
heritance of absence and myoclonic seizures in JME families reinforces
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a model in which combinations of loci confer susceptibility to the com-
ponent seizure types of IGE.
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LIMBIC ENCEPHALITIS AND SEIZURES: A PARANEOPLAS-
TIC PRESENTATION OF OAT CELL LUNG CANCER
S. Ljiljana (Health Center, Neurology Department, Sremska Mitrovica,
SCG)
Purpose: A case report of limbic encephalitis (LE) as a rare para-
neoplastic disorder that can initially present with partial or generalised
seizures, changes in personality, selective early memory loss suggestive
of Korsakoff psychosis, confusion or hallucinations.
Method: A 56-year-old man presented with partial and generalised
tonic–clonic seizures, drowsiness, agitated behaviour, irrelevant talking,
confusion and loss of memory. A month prior to hospital admission, he
had multiple generalised tonic–clonic seizures. He was a smoker and
nonalcoholic. His father died after lung carcinoma. Physical examina-
tion revealed no disturbance. Patient was conscious, incoherent, agitated,
talking irrelevant. He could not recognise his family members or remem-
ber anything. The patient’s mental state progressively deteriorated for 6
weeks. Ten weeks after admission he was seizure free and demented.
EEG showed diffuse theta 6/s activity. During and after chemotherapy
his neurological status didn’t change. Valproate and lamotrigine showed
efficacy in seizure control.
Results: Laboratory findings were normal. EEG showed predomi-
nant alfa activity along with excessive bitemporal spikes and slow wave
discharges. Brain CT scan was normal. CSF revealed 180 cells/cumm,
mostly lymphocytes and no malignant cells. Other CSF parameters in-
cluding protein, glucose, and viral analyses were normal. Oligoclonal
bands were positive. Cranial MRI revealed bilateral symmetrical hy-
perintensities on T2WI with no foci of haemorrhages seen. Thorax CT
revealed left hilar nodular change. Pathological examination showed mi-
crocellular lung carcinoma.
Conclusion: History, clinical picture, flow of illness and diagnos-
tic results strongly indicated that the patient had LE. The purpose of
this presentation will be to present LE as a possible cause in late onset
seizures.
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EFFICACY OF SEIZURE CONTROL WITH CONVENTIONAL
AEDs IN 376 ADULT PATIENTS WITH EPILEPSY IN ARME-
NIA: EPILEPSY DATABASE IN SITUATION OF NO OTHER
TREATMENT OPTIONS
V. Darbinyan, T. Stepanyan, G. Melikyan, H. Hambartcumyan, N. Yhe-
giazaryan, and N. Nahapetyan (State Medical University, Erebouni
Epilepsy Center, Yerevan, Armenia)
Purpose: To determine the basic epilepsy effectiveness of seizure
treatment in patients in a situation where there is a lack of modern AED
and epilepsy surgery.
Method: A retrospective analysis of the patients database set up for
selecting those who have been treated with first line AEDs only. Standard
examinations included MRI, routine and long-term EEG.
Results: 376 adult patients with distinct aetiology and epilepsy syn-
drome were identified. General characteristics were: childhood onset–
208, juvenile onset–66, late onset–102 patients. Idiopathic syndromes
accounted for 145, symptomatic–113, cryptogenic–57, not defined–61
patients. 115 patients suffered from primary generalised types of SZ
only; 89 of them had JME and juvenile onset absence epilepsy. In the
group of 170 patients with approved focal onset SZ 54 were diagnosed
as having TLE, 25–FLE and 91 patients had an undetermined localisa-
tion. 51 (14%) patients were SZ free for 1 year, 96 (26%) experienced
1–4 GTCS and 229 (61%) had monthly GTCS. The best control was
achieved in patients with PGE on VPA monotherapy and combination of
VPA and CBZ and/or PhB and late onset secondary epilepsies on CBZ,
PhB monotherapy or combinations with VPA.
Conclusion: The effectiveness of anticonvulsant treatment without
latest generation AEDs and non AED treatment options is rather low,
even in the case of adequate diagnostic and treatment protocols. Coun-
tries with this situation should intensify the implementation of modern
treatment approaches. Epilepsy surgery could be the most cost effec-
tive and affordable solution in countries like Armenia with sufficient
potential but no developed epilepsy care structure.
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INSULINOMA AS A CAUSE OF DECOMPENSATION OF PRI-
MARY GENERALISED EPILEPSY: CASE REPORT AND RE-
VIEW OF LITERATURE
I. Mareckova, Z. Vojtech, T. Prochazka, and M. Kalina (Department of
Neurology Na Homolce Hospital)
Purpose: Insulinomas are the commonest hormone-secreting tumours
of the gastrointestinal tract. Hypoglycaemia due to them can mimic a
number of acute and chronic disorders, including epilepsy. In the liter-
ature we found case reports of insulinomas misdiagnosed as intractable
adult-onset temporal lobe epilepsy. Reports of confirmed epilepsy wors-
ening due to insulinoma are rare. To our knowledge our patient is the first
reported for whom insulinoma caused worsening of myoclonic epilepsy.
Method: A 62 year old man has been treated for epilepsy since 20
years of age. He suffered from myoclonic jerks after awakening. The
frequency of myoclonic seizures was approximately twice a month and
he had GTCS once a year. He was treated with several AED (VPA, LTG,
PHB). The frequency of seizures changed 5 years ago with myoclonic
jerks occurring twice a week. He also experienced repeated attacks of
derealisation with automatic behaviour.
Results: On video EEG we found normal wakeful background activ-
ity and frequent generalised epileptiform discharges (polyspikes) during
sleep. The patient had an accumulation of myoclonic jerks in the morn-
ing. On MRI a small cavernoma of pons was present. PET brain scan
showed glucose hypometabolism in the right thalamus and very slightly
in left basal ganglia. Laboratory tests showed hypoglycaemia 2.1 mmol/l.
Abdominal MRI and CT scans were normal. Endosonography was done.
A small tumour at the head of pancreas was evident (16×12 mm) and
a biopsy was performed. Ultrasonography of the epigastrium and fast-
ing test (glycaemia 1,6mmol/l) confirmed the diagnosis. The patient was
operated on and the tumour was resected. He has been seizure free for 3
years on AED medication.
Conclusion: In our patient insulinoma and idiopathic generalised
epilepsy coexisted. As he was not completely seizure free with AED
we can guess that he had been having problems with hypoglycaemia for
many years. As he is seizure free after the operation it is highly probable
that clinical worsening before the diagnosis was made was due to in-
sulinoma. In conclusion, toxic and metabolic causes of seizures should
always be considered in the differential diagnosis because the diagnosis
is frequently delayed and they are often curable.
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CHRONIC POSTTRAUMATIC HEADACHE IN PATIENTS
WITH POSTTRAUMATIC EPILEPSY
R. Susak, S. Juric, D. Janculjak, M. Vladetic, and S. Soldo-Butkovic
(Osijek University Hospital, Department of Neurology, Croatia)
Purpose: The aim of the study was to evaluate the analgetic effect
on chronic posttraumatic headache (CPH) in patients who were treated
with antiepileptic drugs (AED) for posttraumatic epilepsy (PTE). Fur-
thermore, we assessed the value of electroencephalography (EEG) in
detection and monitoring of posttraumatic headache in those patients.
Method: We analysed a group of 102 outpatients with posttraumatic
epilepsy (78 males and 14 females, 42 ± 13.8 years). During a period of
one year we monitored the AED effect on CPH by the Visual Analogue
Scale. We also analysed EEG in those patients.
Results: 57% patients had a generalised form of epilepsy, 13% a partial
form, 13% a complex partial form and the rest had a combination of
attacks. Monotherapy was introduced to 62 patients (58 were on classical
AEDs), and the rest were on add-on therapy (mostly with lamotrigine
and topiramate). 36 out of 102 patients with PTE had CPH. Patients on
lamotrigine and topiramate had a better analgetic response than those on
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classical AEDs. Normal EEG findings were recorded in 1/3 of the group
of patients with PTE. Patients with CPH had more expressed pathological
changes on EEG (55%) than those without CPH (36%). The latter group
had more nonspecific dysthymic changes on EEG.
Conclusion: We observed a good analgetic response to AEDs in pa-
tients with PTE and CPH. Better results were recorded in patients on
lamotrigine and topiramate. EEG was not a very sensitive tool for mon-
itoring CPH in patients with PTE, although the pathological findings on
EEG were more specific in patients with CPH than those without it.
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EXCESSIVE DAYTIME SLEEPINESS IN A POPULATION OF
PATIENTS WITH EPILEPSY
1F. Villani, 1A. Pincherle, 2L. Zinno, 3F. Martinelli-Boneschi, 1L. Man-
toani, 4F. Ferrillo, 1M. de Curtis, and 1R. Spreafico (1Istituto Nazionale
Neurologico, 2Neurology Div, Ospedale Cremona, 3Neurology Div, Os-
pedale S. Raffaele, Milano, 4Sleep Center, University of Genova)
Purpose: Excessive daytime sleepiness (EDS) is a frequent complaint
among patients with epilepsy, and it is mainly ascribed to the antiepileptic
drugs. The role played by epileptologic variables, such as epilepsy type
and duration, focus and lesion localisation, circadian pattern, pharma-
coresistance, etc., on EDS is still not well defined. The aim of the study
is the evaluation of EDS in a well characterised epilepsy population.
Method: The study population comprises 137 consecutive epilepsy
patients. EDS has been evaluated by the Epworth Sleepiness Scale,
whereas the presence of sleep disturbances has been investigated by a
self-administered sleep indicators questionnaire. The effect of epilepsy
type, localisation, seizure type, morpheic seizures, pharmacoresistance,
brain lesions, age, gender, BMI, on EDS and sleep disturbance indicators,
has been analysed by logistic regression methods, including in the final
model the variables that were found associated at the univariate analysis
(t-Student’s and chi-square tests) and other demographic variables.
Results: Sleep disturbance indicators, as revealed by sleep question-
naires, were associated with EDS. EDS was reported in 26.2% of the
patients, regardless of age, BMI, epilepsy duration and sex. Among
epileptologic variables the univariate analysis revealed an association
between EDS, seizures during sleep (p = 0.027), pharmacoresistance
(p = 0.057), and polytherapy (p = 0.07). The final logistic regression
model, corrected for demographic variables, confirmed the association
between EDS and seizures during sleep (OR 2.3, 95% CI 1.01–5.33, p
= 0.047).
Conclusion: Our study is consistent with the presence of a signif-
icant relationship between EDS, seizures during sleep, and sleep dis-
turbances, independently by epilepsy type, focus localisation, and drug
treatment.
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NEWLY DIAGNOSED EPILEPSY IN STOCKHOLM, SWEDEN:
FIRST REPORT FROM THE STOCKHOLM INCIDENCE REG-
ISTRY OF EPILEPSY (SIRE)
1C. Adelo¨w, 1P. A˚mark, 1,2E. A˚ndell, 1A. Ahlbom, 1T. Andersson, 1E.
Hellebro, and 1T. Tomson (1Karolinska Institutet, Stockholm, Sweden,
2Nyko¨ping Hospital, Sweden)
Purpose: To set up a system for prospective identification, registra-
tion, and follow-up of patients with newly diagnosed epilepsy in Stock-
holm, Sweden.
Method: Since September 2001, a pilot system has been in action
to identify incident cases of unprovoked seizures and newly diagnosed
epilepsy in residents of northern Stockholm, an area with approximately
958,000 inhabitants, median age 37 years. Potential cases are identi-
fied through different mechanisms; reports from a network of physi-
cians and other health care professionals in the region; medical record
screening in specified units (e.g., the hospital neurooncology section);
and review of all requests for EEG-examination. Final classification of
potential cases is done six months after the index seizure based on a
review of information in relevant medical records. We report the experi-
ence from the first year of the Stockholm Incidence Registry of Epilepsy
(SIRE).
Results: A total of 315 persons met the criteria for inclusion as po-
tential cases, 151 of whom had a single unprovoked seizure while 164
fulfilled the final criteria for epilepsy. This yielded a crude incidence of
33/100,000 person years. The highest age-specific incidence, 49/100,000
person years was observed in the first year of life (neonatal seizures ex-
cluded). An underlying aetiology was identified in 33% of cases while
6% were classified as idiopathic. The estimated incidence was slightly
lower than in other studies and the age specific rates indicate an under-
ascertainment among the elderly in particular.
Conclusion: The registration system already works well, but efforts
will have to be made in order to improve case finding in the elderly.
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DYSFUNCTION OF THE CARDIAC SYMPATHETIC INNERVA-
TION: AN EXPLANATION FOR SUDEP?
1F. Kerling, 1M. Duetsch, 2T. Kuwert, and 1H. Stefan (1Epilepsy
Center, Department of Neurology, University Hospital Erlangen, Ger-
many, 2Department of Nuclearmedicine, University Hospital Erlangen,
Germany)
Purpose: Sudden unexplained death in epilepsy (SUDEP) concerns
7–18% of mortality in epilepsy patients. The pathophysiological mecha-
nism is not clearly defined. Ictal and interictal autonomic dysregulations,
which may lead to asystole or tachycardia, are also discussed as a reason
for SUDEP. We present a possible approach to the pathophysiology of
SUDEP.
Method: During 10 years of presurgical video-EEG-monitoring at
the epilepsy centre in Erlangen, 663 patients were admitted. 4 patients
showed in 8 out of 36 seizures, asystoles with a duration of up to 25
seconds. Cardiological tests (Holter-ECG, echocardiography) and an ex-
amination of the sympathetic cardiac innervation (MIBG-SPECT) were
performed on these patients.
Results: Whereas the cardiological measurements were without
pathological findings, the MIBG-SPECT revealed diminished tracer up-
take in the 2 patients with longer asystoles.
Conclusion: The lack of sympathetic cardiac activity shown in our
patients may lead to an insufficient counter regulation of the sympathi-
cus, when there is a higher ictal vagotonus and might be a reason for
SUDEP.
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WHEN COULD WE SUSPECT COELIAC DISEASE IN CRYP-
TOGENIC EPILEPSY?
E. Sasso, I. Florindo, and E. Bortone (Dept. of Neuroscience, University
of Parma, Italy)
Purpose: Coeliac Disease (CD) may increase the risk of epilepsy
although it is still debated that if ignored CD could be related to epilep-
togenesis. The silent course of CD increases the probability of delayed
diagnosis. The study aim was to investigate how and when CD may be
suspected in cryptogenic epilepsy (CE).
Method: 48 adults with CE have been recruited on the basis of an
uncertain history of food intolerance or event of weight loss in child-
hood and evidence of drug-resistant epilepsy. All patients underwent
haematologic screening for CD, EEG and CT-scan. Jeujunal biopsy has
been performed in positive circulating autoantibodies. Patients with CD
have been evaluated for at least 1 year after beginning a gluten-free diet
(GFD).
Results: For 7 screened patients a diagnosis of CD has been found
and confirmed by biopsy. Clinical histories revealed in 6 out of 7 the
occurrence of visual seizures, although only in 3 were occipital abnor-
malities found in the EEG. Cerebral calcifications were observed in 3 of
CD patients. Improved outcome of epilepsy under GFD was seen in 1
patient.
Conclusion: Although further studies on larger cohorts are manda-
tory our study suggests that in refractory CE the presence of visual
seizures may be of some relevance in ongoing decisions to investigate
CD with or without findings of occipital involvement on EEG and/or
CT-scan. This issue could reflect as occipital regions are often involved
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by epileptogenesis related to CD. Furthermore we believe that delayed
GFD may rarely improve the course of epilepsy.
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THE CATAMENIALITY, FOCI LATERALITY, AND AGE AT
ONSET OF EPILEPSY AND ENDOCRINE PATHOLOGY IN
FEMALES
V. Kalinin and E. Zheleznova (Moscow Research Institute of Psychiatry,
Moscow, Russia)
Purpose: The purpose of the current study was to find any possible
discrepancies in age at onset and duration of epilepsy and endocrine
pathology (reproductive dysfunction and thyroid pathology) between
catamenial and noncatamenial epilepsy.
Method: 26 women with catamenial and 107 with noncatamenial
forms within temporal lobe epilepsy (TLE) were investigated to identify
any discrepancies in variables, including the history of epilepsy and
concomitant endocrine pathology.
Results: Catamenial epilepsy with right-sided foci was characterised
by earlier onset than catamenial with left-sided foci (8.5 ± 5.5 vs 15
± 3.7 years, p = 0.029). Nevertheless, catamenial epilepsy with left-
sided foci caused the endocrine pathology in a shorter interval after
seizure onset in comparison with right-sided foci catamenial epilepsy
(2.2 ± 3.9 vs 9.3 ± 6.6 years, p = 0.032). For noncatamenial epilepsy
the opposite relationship was revealed: the earlier seizure onset for left-
sided foci (13.5 ± 8.8 vs 17.8 ± 7.9 years, p = 0.044) and development
of endocrine pathology in a shorter period after seizure appearance in
right-sided foci in comparison with left-sided foci (1.7 ± 8.8 vs 6.2 ±
8.8 years, p = 0.048).
Conclusion: The opposite relationship between catamenial and non-
catamenial epilepsy seems to exist in terms of epilepsy and comorbid
endocrine pathology, which may be determined by interaction between
foci laterality and endocrine functions in female epilepsy. Further re-
search to elucidate the pathogenesis of catamenial and noncatamenial
epilepsy is needed.
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EPILEPTIFORM ACTIVITY SUPPRESSION IN COURSE OF
COGNITIVE TASKS
1T. Zanoni, 1S. Romito, 2G. Bongiovanni, and 1G. Moretto (1Operative
Unit of Neurology, Borgo Trento Hospital, Verona, Italy, 2Clinical Neu-
rology, Policlinico “GB Rossi,” Verona, Italy)
Purpose: To report the case of a patient with an awake EEG pattern
at rest characterised by a continuous slow-spike wave activity, which is
inhibited by tasks requiring mental activation and attention.
Method: A 35-year-old man affected by mental retardation and sec-
ondarily generalised epilepsy since his infancy attended our laboratory
for a routine EEG check. Neuroradiological and functional exams per-
formed until now had unremarkable results. EEG recordings revealed
a diffuse epileptiform activity in the form of subcontinuous bilateral
sharp waves and poly-sharp-waves with inconstant prevalence in the left
hemisphere. During the recording in our laboratory the awake EEG pat-
tern was characterised by a continuous slow-spike wave activity, with
no clinical correlation; the EEG normalised suddenly when the patient
was asked to pay attention to an external stimulus. Thus the patient un-
derwent EEG during a series of tasks consisting of mental and aloud
reading, speaking, spatial construction, mental and written calculation,
listening to music.
Results: During the neuropsychological exercises we observed a
prompt suppression of epileptic electrical discharges that tended to reap-
pear soon as the patient lost mental concentration. Thus, with the intent to
use a less sedative drug, we are actually trying to substitute the previous
carbamazepine treatment by lamotrigine.
Conclusion: In the literature usually much interest is reserved for
the facilitatory effect of mental activity on epileptic seizure occurrence,
while suppressive effects are underestimated. In our opinion, this possi-
ble inhibitory effect deserves more consideration, and could be useful in
addressing the pharmacological choice toward drugs with low sedative
effect.
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PREVALENCE OF EPILEPSY IN CROATIA: A COMMUNITY-
BASED SURVEY
1I. Bielen, 2L. Cvitanoviæ-ˇSojat, 3B. Bergman-Markoviæ, 4M. KoˇSie`ek,
1M. Planjar-Prvan, and 1G. Miketek (1General Hospital “Sveti Duh,”
2University Hospital “Sestre Milosrdnice,” 3Medical School-Zagreb
University, 4Pliva Croatia Ltd, Zagreb)
Purpose: This study was conducted to investigate the prevalence of
epilepsy in Croatia.
Method: Data collection was performed by using the questionnaires
that were submitted to the primary care community physicians in all 21
administrative districts in Croatia. The randomly chosen physicians were
informed about the ILAE definition of active epilepsy by word and in
writing.
Results: A total of 127 out of 180 (71%) physicians responded by
giving requested details about patients whose personal identity remained
undiscovered. In this way a sample of 212,069 people (4.8% of the
population of Croatia) was studied. We identified 1022 persons having
active epilepsy: 54% males and 46% females. The prevalence (No/1000)
was calculated for the following age groups: age 0–7: 3.5 (CI 95% 3.2–
3.8); age 8–18: 6.4 (CI 95% 6.1–6.7); age 19–45: 5.0 (CI 95% 4.7–
5.3); age 46–65: 4.7 (CI 95% 4.4–5.0); age >65: 4.4 (CI 95% 4.1–4.7).
Adjustment by age to Croatia’s 2004 population was made according
to the population estimate from the Croatian Bureau of Statistics: the
overall prevalence including all age groups was 4.9/1000 inhabitants.
Conclusion: The prevalence of active epilepsy in Croatia is very sim-
ilar to the data recently reported in a systematic review covering mainly
North-European and Western Mediterranean countries (Forsgren L et al.
European Journal of Neurology 2005;12:245–253). This suggests that
there are no major differences in the crude prevalence rate of epilepsy
across Europe.
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CLINICAL FEATURES, TREATMENT AND OUTCOME OF
STATUS EPILEPTICUS
G. Kutlu, N. Kaya, Y. B Gomceli, L. Cavdar, B. Gonulal, and L. EInan
(Ministry of Health Ankara Research and Training Hospital Department
of Neurolog)
Purpose: To evaluate the clinical and electrophysiological features,
treatment and outcome of status epilepticus (SE) in adults.
Method: Sixty-three patients, who were admitted to our department
with diagnosis of SE, were evaluated between 2003 and 2005. Demo-
graphic data, clinical, electrophysiological features, treatment and out-
come of SE was investigated for each patient. Two patients were excluded
from the study because of pseudostatus.
Results: Sixty-one patients were included in the study. The mean age
of patients was 40.9 ± 19.8. Male to female ratio was 1.2:1. Cerebrovas-
cular disease (CVD) was the major risk factor (n = 21). Seventeen pa-
tients had previously diagnosed epilepsy. The causes of SE in epilepsy
patients were inadequate antiepileptic drug treatment, stopping drugs
suddenly, changing drug therapy and systemic infection. The other risk
factors were central nervous system (CNS) infection, metabolic causes,
intracranial tumours, multiple sclerosis, vasculitis, drug intoxification
and idiopathic. Eight patients had nonconvulsive SE, whereas remaining
53 had convulsive SE. In 78.7% of patients, seizures were controlled
with first and second line drug treatments (diazepam, phenytoin and/or
valproate). Thirteen patients had refractory SE (RSE) and needed infu-
sion of midazolam and/or tiopental. There was no mortality in patients
without RSE, but mortality rate was 38.5% for patients with RSE. There
was no significant relationship between RSE, age, sex and type of status.
Conclusion: SE is a life-threatening condition. There is a high mor-
tality rate in RSE. Epilepsy patients should be under regular follow up.
CVD was the most common cause of SE in our study.
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LONG-TERM EFFICACY AND TOLERABILITY OF LEVE-
TIRACETAM TREATMENT IN A PATIENT WITH EPILEPSY
AFFECTED BY SYSTEMIC LUPUS ERYTHEMATOSUS
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1A. Siniscalchi, 1F. Mancuso, 2L. Gallelli, and 2G. De Sarro
(1Dipartimento di Neuroscienze, U.O. di Neurologia, Azienda Os-
pedaliera di Cosenza, Italy, 2Cattedra di Farmacologia, Dipartimento
di Medicina Sperimentale, Universita` “Magna Grecia” di Catanzaro,
Italy)
Purpose: A case is reported of a young woman with systemic lupus
erythematosus (SLE) and complex partial seizures responsive to treat-
ment with levetiracetam (LEV).
Method: A 28-year-old woman taking prednisone 12.5 mg/day from
1995 for SLE was admitted to hospital after developing mental confu-
sion, 1–2 episodes/week, for the previous 2 months. A 24 hour EEG
showed left frontotemporal spike discharges with contralateral spread
and a diagnosis of complex partial seizures was made. The patient was
discharged on a regimen of prednisone (12.5 mg/day) and oxcarbazepine
(OXC 300 mg TID). Five days later, she had another complex partial
seizure, and analysis of blood chemistry revealed a clinically significant
decrease in total white blood cells. OXC therapy was promptly discontin-
ued and changed to topiramate (TPM final dose 150 mg BID) resulting
in seizure remission and normalisation of white blood cell count. Thirty
days after starting TPM, the patient developed somnolence, nervousness
and angle-closure glaucoma with acute myopia and ocular hyperaemia;
TPM was consequently withdrawn and replaced with phenobarbital (PB
100 mg BID), leading to recovery within 2 days. Seven days later, how-
ever, the patient showed a decrease in platelet cells that prompted the
discontinuation of PB, and LEV treatment was started (final dose 1500
mg/day).
Results: After about 4 years of follow-up on LEV, the patient remains
seizure-free with no adverse events reported. No dose adjustments of
LEV or corticosteroids have been required during treatment.
Conclusion: This case report suggests that LEV may be useful in
treating seizures in epilepsy patients with SLE.
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NO EVIDENCE FOR PHARMACOKINETIC INTERACTION OF
LEVETIRACETAM WITH OTHER ANTIEPILEPTIC DRUGS IN
JAPANESE AND WESTERN ADULTS WITH EPILEPSY
1C. Otoul, 1H. De Smedt, and 2A. Stockis (1Biostatistics, UCB Pharma,
Braine-l’Alleud, Belgium, 2Clinical Pharmacology, UCB Pharma,
Braine-l’Alleud, Belgium)
Purpose: To assess the effects of levetiracetam (LEV) add-on treat-
ment on plasma concentrations of other antiepileptic drugs (AEDs) in
both Japanese and Western adults with epilepsy.
Method: Retrospective analysis of plasma concentrations from two
placebo-controlled Phase III studies with the same design conducted
in Japan and the United States. At baseline and during the treatment
period, with either add-on LEV or placebo, multiple AED plasma
levels were evaluated by repeated measures covariance analysis, af-
ter logarithmic transformation and using 90% confidence intervals
(CI) of the geometric mean ratio between both periods in each ethnic
group.
Results: Two-thirds of 191 Japanese and 268 Western patients, aged
16–65 years, received LEV (1000–3000 mg/day) as add-on therapy to
other AEDs. In the Japanese, geometric mean plasma concentrations (CV
= coefficient of variation) varied from baseline to LEV treatment period:
carbamazepine (CBZ): 6.7–6.9 μg/mL (CV = 38%); valproate (VPA):
58–56 μg/mL (CV = 43%); phenytoin (PHT): 9.2–8.8 μg/mL (CV =
55%), phenobarbital (PB):18.1–17.8 μg/mL (CV = 36%); clobazam
(CLB):135–151 ng/mL (CV = 94%); clonazepam (CZP):19.3–20.7
ng/mL (CV = 57%); and zonisamide (ZNS): 18.3–17.9 μg/mL (CV =
40%). The geometric mean ratio of concentrations (LEV/placebo evalu-
ation vs baseline) was centered on 100% for CBZ, VPA, PHT, ZNS and
CI were within the 80–125% range. No relevant ethnicity difference was
observed.
Conclusion: LEV did not appear to modify plasma concentrations of
CBZ, VPA, PHT and ZNS when used concomitantly with these AEDs
in either study population. Thus it does not appear necessary to adjust
the dose of any of these AEDs when LEV is either added to, or removed
from combination therapy. UCB funded.
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CORTICAL REORGANISATION INDUCED BY LONG-TERM
EPILEPSY AND THE USE OF LEVETIRACETAM
1P. D’Alessandro, 2M. Piccirilli, 3O. Presciutti, 1G. Perticoni, and 3G.
Gobbi (1S.C. Neurofisiopatologia, Azienda Ospedaliera, Perugia, Italy
2Unita` Riabilitazione Cognitiva, Universita` degli Studi, Perugia, Italy,
3S.C. Fisica Sanitaria, Azienda Ospedaliera, Perugia, Italy)
Purpose: To investigate cortical reorganisation and the use of leve-
tiracetam (LEV) in a patient with long-term refractory epilepsy.
Method: A case study of a 30-year-old patient illustrating transfer of
language function within the right hemisphere. The first seizures (partial
seizures and right partial continuous epilepsy appeared at 6 years of age,
after normal language development. Serial CT and MRI scans showed
progressive atrophy of the left hemisphere and Rasmussen’s syndrome
was diagnosed. Three years later, the child was hemiplegic, with progres-
sive cognitive deterioration and global aphasia. Surgery was refused by
the parents. Follow-up showed stable right sensorimotor deficit. How-
ever, cognitive performances showed a slow progressive recovery. Oral
expression, comprehension, reading and writing are currently (at age 30
years) substantially normal. Seizures were polymorphous, very frequent
daily, and refractory to all antiepileptic drugs (AEDs). In 2003, LEV
2000 mg/day was added to phenobarbital and carbamazepine. To study
language function, a BOLD EPI fMRI (1.5 Tesla) was performed using
semantic and phonemic fluency tasks.
Results: The patient experienced∼80% seizure reduction after 2 years
of LEV add-on therapy. fMRI activated regions were restricted to the
right hemisphere, involving frontal (MFG and IFG, area 44) and tempo-
ral (STG, area 22) lobes. Language appears supported by a right-sided
network homologous with that usually observed on the left.
Conclusion: LEV add-on therapy achieved a high seizure frequency
reduction. This case study indicates that cerebral plasticity appears linked
to the natural history of disease and that epilepsy may induce a functional
reorganisation of cortical areas.
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CLINICAL AUDIT OF 676 PATIENTS TREATED WITH
LEVETIRACETAM
M. Kalina (Hospital Na Homolce, Prague, Czech Republic)
Purpose: To assess the efficacy and safety of levetiracetam (LEV) for
uncontrolled focal epileptic seizures in ‘real-life’ patients in the Czech
and Slovak Republics.
Method: A clinical audit of patients treated with LEV for partial onset
seizures between 2002 and 2004. Primary outcome parameters were re-
tention rate, reduction in frequency of partial seizures per month, change
in interictal state (rated 1 [best] to 5 [worst]), number of concomitant
antiepileptic drugs (AEDs), change in AED tolerability (rated 1 [best]
to 5 [worst]), adverse events (AEs).
Results: 676 patients were included: 657 treated with LEV add-
on therapy, since refractory to previous AEDs; 19 with primary LEV
monotherapy. Retention rates were 99.4% after 1 month, 92.9% af-
ter 4 months. Reasons for discontinuation were poor tolerability (1%),
lack of efficacy (3.7%) and unstated (2.4%). Mean frequency of partial
seizures/month decreased from 18.7 at baseline to 9.5 after 1 month and
6.5 after 4 months. Responder rate (≥50% seizure frequency reduction)
was 56.5% after 1 month and 67.8% after 4 months. Seizure freedom
(100% seizure frequency reduction) was achieved by 22.8% patients
after 1 month and 25.4% patients after 4 months. The mean interictal
state improved significantly from 3.2 at baseline to 2.2 at 4 months (p <
0.001). Mean AED tolerability improved significantly from 2.3 at base-
line to 1.6 (p < 0.001) at 4 months. Few AEs were reported; only 1%
(7/676) patients discontinued LEV due to poor tolerability.
Conclusion: LEV, add-on and monotherapy, was effective and very
well tolerated in ‘real-life’ patients with refractory focal epilepsy.
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AGE DISTRIBUTION OF PATIENTS WITH JUVENILE MY-
OCLONIC EPILEPSY IN AN OUTPATIENT CLINIC: ARE ALL
MYOCLONIC EPILEPSIES LIFELONG EPILEPSIES?
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A. Karlovassitou, E. Dimitrakoudi, P. Armentsoudis, D. Galios, G. Tim-
plalexi, G. Tsaleras, and S. Baloyannis (1st Neurological Clinic, Aristotle
University of Thessaloniki)
Purpose: Juvenile Myoclonic Epilepsy (JME) is an idiopathic gener-
alised epileptic syndrome that has only recently attracted considerable
attention. Remarkably, JME is often diagnosed with delay because the
physicians involved, including the specialists, are not familiar with a
disease whose nature has yet to unfold. JME is believed to be a lifelong
epilepsy. However, this view has been debated from time to time.
Method: In a period of 15 years of operation of our Epilepsy Out-
patient Clinic, at the 1st University Department of Neurology, a total
of 77 patients (5.8% of a total of patients with epilepsy) fulfilled the
diagnostic criteria for JME. The mean age of patients was 26.65 years
old.
Results: The age distribution of our patients was as follows: 56 were
15–34 years, 4 were 35–54 years and only 2 patients were aged more
than 55 years. Antiepileptic treatment had been withdrawn from the
remaining 15 patients, aged 32 to 35, who had been treated with low
dose valproic acid (VPA) and had remained free of seizures for more
than 3 years. 13 patients have been free of seizures without antiepileptic
treatment for more than 2 years. However, seizures recurred in one patient
after long term sleep deprivation and in one other after excessive alcohol
consumption.
Conclusion: Our results suggest that many JME are not lifelong
epilepsies. JME may not represent a single disorder. It remains to be
clarified which factors, clinical or EEG, are predictors of JME prognosis
and which factors, genetic, environmental or life-style, may influence
JME’s evolution.
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LAMOTRIGINE, FEMALE SEX, AND IDIOPATHIC EPILEPSY:
RISK FACTORS FOR SUDDEN UNEXPECTED DEATH IN
EPILEPSY (SUDEP)?
1D. Aurlien, 2E. Taubøll, and 2L. Gjerstad (1Stavanger University Hos-
pital, Neurological Department, Stavanger, Norway, 2Neurological De-
partment, Rikshosptalet, University of Oslo, Norway)
Purpose: Central or obstructive apnea and cardiac arrhythmia com-
prise potential pathophysiological mechanisms for SUDEP. Lamotrigine
(LTG) was recently shown to possess a potential to inhibit the cardiac
rapid delayed rectifier potassium ion current (Ikr) and Ikr. Blocking
drugs are generally considered to be associated with an increased risk of
cardiac arrhythmia and sudden unexpected death. However, no previous
studies have shown any excess of SUDEP in patients treated with LTG.
Method: During the 10-year period 1995–2005 4 consecutive cases
of SUDEP in nonhospitalised patients have come to our knowledge at
Neurological Department, Stavanger University Hospital, Norway.
Results: All 4 patients were young women (age:16, 24, 25, 37 yrs)
with idiopathic epilepsy on LTG monotherapy. Diagnosis after autopsy
was consistent with definite SUDEP. Since acidosis may increase the
blocking of Ikr the risk for arrhythmias is increased by seizure induced
acidosis. In addition, females have an increased risk for drug induced
torsade de pointes. Thus, a possible cardiac predisposition to arrhythmia
may have worked together with the Ikr blocking effect of lamotrigine to
induce a fatal arrhythmia during seizures in our patients.
Conclusion: The combination of female sex, idiopathic epilepsy and
the use of LTG may represent risk factors for SUDEP, possibly under the
influence of a seizure or a seizure induced acidosis. Further studies are
needed to reveal the full clinical importance of these observations.
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PROGRESS ON A STUDY OF SPONTANEOUS EEG ACTIV-
ITY IN RECORDS OF EPILEPSY PATIENTS WITH INTER-
ICTAL DISCHARGES AND EPILEPTIFORM DISCHARGES IN
HEALTHY SUBJECTS
1L. Kowalczyk, 2S. Dec, 1E. Zalewska, and 2J. Miszczak (1Institute of
Biocybernetics and Biomedical Engineering, Warsaw, Poland, 2Polish
Air Force Institute of Aviation Medicine, Warsaw, Poland)
Purpose: The aim of our study was to evaluate the prevalence of these
phenomena in a population of clinically healthy subjects and to develop
a method able to detect differences in EEG activity recorded from these
subjects and patients.
Method: The EEG recordings were collected using Neuroscan 4.3
system during screening studies in groups of healthy people, and in
epilepsy patients. Ten EEG recordings of healthy people and ten record-
ings of patients suffering from epilepsy were analysed. In the time do-
main EEG activity before and after an epileptiform episode was analysed
using signal similarity evaluation methods. In the frequency domain the
FFT analysis was applied. Coefficients such as: mean frequency, global
spectrum power, width of the spectrum and correlation of spectra were
utilised.
Results: The prevalence of epileptiform activity in EEG recordings
from healthy subjects was around 2%. Spectral analysis coefficients have
shown significant changes in spontaneous activity after discharge in pa-
tients whereas that was not the case in healthy subjects. The special
multi-similarity method able to detect changes of spontaneous EEG ac-
tivity after an epileptiform episode has been developed.
Conclusion: The results suggest that an epileptiform activity does not
significantly change spontaneous EEG activity in healthy subjects as it
does in patients. These changes could be detected using a multi-similarity
method and using some coefficients of FFT spectrum.
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PREDICTIVE FACTORS OF THE POSTINFARCTION
SEIZURES
A. Chukhlovin, V. Guzeva, and M. Chukhlovina (St Petersburg State
Pediatric Medical Academy)
Purpose: The aim of our study was to assess some predictors of post-
stroke epilepsy (PSE).
Method: We observed group 1 of the patients with 110 cases of is-
chemic stroke without epileptic seizures (40 to 90 years old; males,
52.7%), and group 2 that consisted of 26 cases with PSE (37 to 79
years old; males, 58%). Epileptic seizures developed 6 to 12 months af-
ter ischemic stroke (an average of 7.5 ± 0.7 months). Upon admission,
the patients were examined using NIH Stroke Scale, Barthel Index, CT
scans of the brain, EEG, ECG, general biochemical and haematological
parameters.
Results: The mean age of PSE patients was significantly lower than
for group 1 (59.8 ± 1.8 vs. 66.9 ± 1.3; p = 0.003), whereas heart disorder
(atrial fibrillations) tended to be more common in the PSE group (46%
vs 19%, p = 0.07). There were no sex differences between groups 1 and
2. Neurological deficiency, as assessed by NIH stroke scale, has shown
medium-grade clinical severity of stroke, and, like the Barthel Index, did
not sufficiently differ between the two groups under study. In the cases of
PSE, large brain lesions were more common (59% vs 37% in the group
without seizures, p = 0.02).
Conclusion: When examining a representative group of patients after
ischemic stroke, the following PSE predictors are registered, i.e., age of
the patient, presence of atrial fibrillations, large brain lesions.
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COMPLETE SLEEP DEPRIVATION IN PATIENTS WITH FIRST
SINGLE SEIZURE: AN UNCONTROLLED PILOT STUDY
L. Kaitazki (Medical Institution of Internal Affairs Government,
Bulgaria)
Purpose: The main goal of this study was to determine how far com-
plete 24 hrs sleep deprivation (SD) can play a role in the diagnosis
of epilepsy as an additional method of confirming suspected epileptic
seizures in patients with first single fits.
Method: In present study included 10 patients, all males aged between
21–42 years hospitalised by reason of an unexpected syncope-like attack.
An EEG was performed prior to SD, and the next morning a prolonged
EEG recording was performed and the latter was compared with the first
EEG record.
Results: Six of the 10 patients had no EEG abnormality before exam;
subtle EEG abnormalities were found in 4 of the group. In deprived EEG,
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ms were determined paroxysmal epileptiform discharges in 5 persons;
in the remaining 5 patients EEG, ms did not show changes.
Conclusion: In conclusion, it can be said that complete SD has a
useful role as an additional tool for individuals with a suspected epileptic
disorder.
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EFFECTS OF HYPONATREMIA ON SEIZURES IN PATIENTS
WITH EPILEPSY AND POLYDIPSIA
M. Okazaki and M. Ito (Department of Psychiatry, National Center of
Neurology And Psychiatry, Musashi H, Tokyo, Japan)
Purpose: We evaluated aggravation of seizures due to hyponatremia
with epilepsy and polydipsia.
Method: We report on 5 patients with epilepsy and polydipsia-
hyponatremia (cases 1–5; 1 female and 4 male, aged 24–39 years). Case
1 had an average of 2 complex partial seizures (CPS) per month and the
others (cases 2–5) had an average of 2 or 3 CPSs per year under normal
conditions. Four of 5 patients had intellectual impairment due to closed
head injury (case 1), brain tumour (case 4) or postencephalitic sequelae
(cases 2 and 3). Three (cases 2, 4 and 5) of the 5 patients suffered psy-
chotic episodes. Carbamazepine had been given to 4 (cases 1, 2, 4 and 5)
of the 5 patients for treatment of seizures. Neuroleptics had been given
to all patients for delusions or psychomotor excitement.
Results: The patients experienced marked increases in frequency of
their habitual seizures when their serum sodium level decreased to 118–
127 mEq/l, a decrease of about 10 mEq/l from the normal level. In all
cases, the serum sodium level returned to normal through restriction of
water, and the clinical seizures improved, but death resembling sudden
unexplained death in epilepsy occurred in case 5.
Conclusion: Hyponatremia caused by polydipsia appears to be a risk
factor for aggravation of habitual seizures and even death in patients with
epilepsy, even if the hyponatremia is mild and at a subclinical level.
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INTERLEUKIN-6 AND INTERLEUKIN-1 RECEPTOR AN-
TAGONIST LEVELS IN TEMPORAL AND FRONTAL LOBE
SEIZURES DURING VIDEO-EEG RECORDINGS
1J. Peltola, 2R. Ma¨kinen, and 1T. Alapirtti (1Department of Neurol-
ogy and Rehabilitation, Tampere University Hospital, Tampere, Finland,
2Department of Clinical Neurophysiology, Tampere University Hospital,
Tampere, Finland)
Purpose: Experimental and clinical studies have shown that prolonged
seizures result in increased cytokine production in the central nervous
system. However, the effect of seizure type on cytokine production is
not well established. The purpose of this study is to examine the concen-
trations of two key cytokines in patients with temporal and frontal lobe
epilepsy undergoing a video-EEG study.
Method: Here we determined the levels of interleukin-6 (IL-6) and
interleukin-1 receptor antagonist (IL-1RA) in serum from 16 patients
before and after seizure during continuous video-EEG monitoring in
Tampere University Hospital. The definition of the seizure focus and
classification of epilepsy was based on concordant findings in this in-
vestigation, and on MRI examination. Patients were divided into two
groups: the temporal epilepsy patient group (n = 9), and the frontal
epilepsy patient group (n = 7).
Results: In all patients with complex partial seizures originating from
temporal lobe and in 4 out of 7 originating from frontal lobe there
was increased production of IL-1RA with peak levels 6–12 hours af-
ter the seizures. Two TLE patients with complex partial seizures had
increased concentrations of IL-6 whereas none of the FLE patients with
partial seizures only had elevated levels of IL-6. Secondarily generalised
seizures were associated with more profound increases in IL-6 concen-
trations.
Conclusion: The present study demonstrates that single seizures in
chronic epilepsy are followed by activation of the cytokine network.
The production of IL-1RA and IL-6 are influenced by the origin of the
seizures from either temporal or frontal lobes. Since also the laterality
of the seizures may affect the cytokine production, larger patient groups
with well-characterised seizures need to be studied in order to fully assess
the importance of the cytokine responses in chronic epilepsy.
p183
PARTNERS IN EPILEPSY (PIE): EPILEPSY MANAGEMENT
WITH INTERNATIONAL ELECTRONIC RECORDS REG-
ISTRY SYSTEM: DATA ANALYSIS UPDATE IN ADULTS
1A. Gil-Nagel, 2P. Despland, 3F. Pinto, 4P. Ryvlin, and 5P. Participants
(1Hospital Ruber Internacional, Madrid, Spain, 2University Hospital
CHUV, Lausanne, Switzerland, 3Hospital Santa Maria, Lisbon, Portu-
gal, 4Neurological Hospital, Lyon, France, 5On behalf of PIE Project
Participants)
Purpose: To analyse epilepsy characteristics, outcome, and
antiepileptic drug (AED) treatment in a large international adult patient
naturalistic data cohort.
Method: Electronic records management in daily clinical practice
(demographics, aetiology, syndrome, treatment) in epilepsy centres in
Belgium, France, Portugal, Spain, Switzerland and United Kingdom:
data analysed from 5262 patients (M/F = 50.5%/49.5%).
Results: Mean age at first attack: 26.7 (range 0–102 years), 4901 had
follow-up visits, mean total observation: 776 days (median = 314, range:
1–53 years). Of 2646 with aetiology/risk factors recorded, the most com-
monly identified were: trauma (11%); family history of epilepsy (8.5%);
perinatal history of hypoxia (6%); benign cerebral tumour (5%); and cor-
tical malformations/developmental disorders (5%). Epilepsy was classi-
fied in 41% of patients: localisation-related (23%), generalised (9.6%),
undetermined (6.8%), and other syndromes (1.6%). 49% were seizure-
free at last follow-up visit after ≥6 months. Among those still experi-
encing seizures, 34% had predominantly focal seizures, 21% generalised
seizures. Monthly seizure rate averaged 11.2 (0–750) for partial seizures,
15.8 (0–900) for generalised seizures. Of the 4216 adults using AEDs
at the last follow-up visit, 58% were on monotherapy: valproate (VPA:
20%), carbamazepine (CBZ: 14%), lamotrigine (LTG: 9.5%), levetirac-
etam (LEV: 3.0%), topiramate (TPM: 2.9%), phenytoin (PHT: 2.7%).
28% were on two, 14% on three or more AEDs. Most common AED
combinations: LTG/VPA (2.8%), CBZ/VPA (2.2%), CBZ/LTG (1.9%)
Most common side effects: somnolence, weight gain, tremor, dizziness,
headaches.
Conclusion: Registry analysis provided valuable information on
epilepsy characteristics, outcome and AED treatment patterns. Epilepsy
was classified in only 41% (predominantly localisation-related). About
half were seizure-free. The majority were on monotherapy. (PIE is sup-
ported by Janssen-Cilag).
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SEX AND GONADOTROPHIC HORMONAL LEVEL DISBAL-
ANCE IN MALES WITH EPILEPSY
1N. Jurjane and 2I. Purina (1Riga 1.St. Hospital, University of Latvia,
2Univerity of Latvia)
Purpose: To detect the sex steroid and pituitary trophic hormone levels
and clinical symptoms of hormonal disbalance in males with epilepsy.
Method: 22 male patients with idiopathic epilepsy (age 18–68) and
11 controls were examined in the neurological department of Riga 1st.
Hospital and Diagnostic Center of Epilepsy in Riga 2004–2005. Special
questionnaires were used for collecting anamnestic data. Every patient
and the controls underwent EEG investigation and blood hormone level
tests: follicle stimulating hormone (FSH), luteinising hormone (LH),
estradiol (E2), progesterone (PRG), rostendione (ANDR), total testos-
terone (T), and dihydroepiandrosterone sulphate (DHEAS).
Results: Hormone imbalance was identified in 15 (68%) males with
epilepsy. Low DHEAS blood level in 8 (32%) cases, increased ANDR
in 3 (12%) patients, total testosterone decreased in 6 (24%) cases giving
evidence of testis dysfunctions. There was an increase of LH and FSH
both in 4 (16%) cases. Patients with abnormalities of sex hormones
had subjective sexual disorders: erectile dysfunction 6 (24%), decrease
of sexual disposition 4 (16%) cases. The frequency of seizures in male
patients with epilepsy with sex hormone disbalance was 1 to 6 per month
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in comparison with 1 per month or rarer for those of normal hormone
levels.
Conclusion: Hormone imbalance was identified in 68% of males
with epilepsy. The increased level of gonadotrophic hormones can be
estimated as a compensatory stimulating factor for the decreased testis
function and as a possible activating factor of seizures.
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HIPPOCAMPAL VOLUME DECREASE IN DEMENTED
CHRONIC TEMPORAL EPILEPSY PATIENTS
C. Siemianowski (Department of Neurology and Epileptology, Center
for Postgraduate Medical Education)
Purpose: Many observations indicate the relationship between de-
mentia and long duration of temporal lobe epilepsy (TLE), particularly
among patients with secondary generalisation. Memory impairment may
be a result of structural hippocampal damage, which sensitive measure-
ment is hippocampal volumetry.
Method: We examined 15 patients with drug resistant TLE with sec-
ondary generalised partial complex seizures and cognitive disorders es-
tablished by clinical features and psychological tests: clock drawing and
Mini Mental State Examination (MMSE). All patients also had magnetic
resonance imaging (MRI) and volumetric assessment of hippocampal
volume (HV).
Results: The group consisted of 8 men and 7 women. Mean age was
34.7, and mean duration of epilepsy was 15.9 years. Average frequency
of partial complex seizures was 10.9 per month. There were no abnor-
malities in qualitatively assessed MRI in 9 patients, and abnormal results
of MRI in 6 persons. Mean asymmetry of HV (asymmetry between right
and left HV) in the group was 10.7% compared at max. 5% was estab-
lished as a norm in a control study group. Average MMSE was 21.8, and
clock drawing has given at least 2 false elements in every patient.
Conclusion: The results of our study support the opinion that seizure
induced neuronal loss of hippocampus may cause dementia disorders in
patients with drug resistant TLE.
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EEG PHENOVENAS IN EPILEPSIA PARTIALIS CONTINUA
(CASE OF RUSSIAN TICK-BORNE ENCEPHALITIS)
1S. Gulyaeva, 1A. Ovchinnicova, 1S. Gulyaev, and I. Archipenco
(1Vladivostok State Medical University, 2Vladivostok State Medical
University, 3Vladivostok State Medical University, 4Vladivostok State
Medical University)
Purpose: Epilepsy partialis continua is one of syndromes of Russian
tick-born encephalitis.
Method: We investigated 560 EEG of 37 patients suffering from
epilepsy partialis continua in the structure of tick-born encephalitis.
Results: The results of our investigation allow the division of EEG
into three types.
Type I characterised good modulated alfa-activity without space dis-
organisation.
Type II characterised a significant rhythmical disorganisation with
slow wave prevalence and was divided in two subtypes: the first subtype
was characterised by high amplitude and low modulated oscillations with
slow wave prevalence; the second was presented by polymorphic activity
without rhythmical domination.
Type III EEG presented low amplitude rhythmical and space disor-
ganisation.
Autocorrelation analysis found the low periodical significant in all
EEG types.
The functional probes with activation and photostimulation were dif-
ferent in the EEG of the three types. In the EEG of the Type I we could
observe significant reply, such as rhythm depression on the opened eye
and rhythm appearing on the closed eye. In case of the rhythmical pho-
tostimulation we observed a photoactivity reaction. In the Type II EEG
photostimulation effects were lost, but reaction on the opened eye was
presented. In Type III all EEG reactions were lost. In the disease’s devel-
opment 28 patients had local periodical EEG oscillations in both brain
hemispheres. In this case we observed a presentation of pathological
local EEG activity in the contralateral hyperkinetic hemisphere. Parox-
ysms of bilateral-synchronous low oscillations were observed in 439
EEG which included 3 EEG of Type I, 18 of Type II, 103 of Type III. In
the first group of cases (18 patients) we observed slow wave paroxysmal
activity with amplitude prevalence in the frontal and occipital regions.
In the second group (19 patients) we observed paroxysmal activity such
as spike-slow wave and sharp-slow wave complexes.
Conclusion: The results have shown that in a case of epilepsy par-
tialis continua we can observe a complex brain disorder on different
levels which combine as real epileptiform activity as specific hyperki-
netic activity in a case with a subcortical lesion.
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GENDER DIFFERENCES IN REPORTING ICTAL FEAR IN
EPILEPSY PATIENTS: AN ANALYSIS OF CASE HISTORIES
1V. Chiesa, 1M. Canevini, 2E. Gardella, 3L. Tassi, 3G. Lo Russo, and 1R.
Canger (1Regional Epilepsy Centre, San Paolo Hospital, University of
Milan, Italy, 2Department of Neuroscience, Bellaria Hospital, Univer-
sity of Bologna, Italy, 3“C. Munari” Epilepsy Surgery Centre, Niguarda
Hospital, Milan, Italy)
Purpose: Male-female differences in emotional expressiveness are
the object of research. Many emotions, including fear, are reported more
frequently by women than by men. Some studies conducted across dif-
ferent cultures indicate that females verbalise more fear than do males
(Brody L.R., Gender, emotion, and the family. Cambridge, MA: Har-
vard University Press, 1999). The purpose of our study is to determine if
there are some differences in reporting fear as a symptom of the epilep-
tic seizure in a group of drug-resistant epilepsy patients evaluated for
surgery.
Method: All clinical charts (n◦ 2530) of patients evaluated at the
“C.Munari–Epilepsy Surgery Center” of Milan from 1990 to June 2005
were reviewed, looking for patients with subjective ictal fear or fright-
ened expression during seizures.
Results: 266 patients with ictal fear were found, 100 male and 166
female (p < 0.001); of those, gender difference is even higher considering
patients with ictal fear as a steady element of their seizure semiology (59
male and 121 female, p < 0.001), while no gender difference was found
considering patients with ictal frightened expression (42 female and 40
male, p = 0.825). Interestingly many more male than female (14:3)
with ictal fear in childhood showed a disappearance of that symptom in
adulthood.
Conclusion: Ictal fear is reported more frequently by females than
males, but no gender difference is observed in ictal frightened expression.
Males that reported ictal fear in childhood show more often than females
a disappearance of this ictal sensation in adulthood.
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CORRELATION OF FOCAL SIGNS AND LONG-TERM OUT-
COME IN JUVENILE MYOCLONIC EPILEPSY
1N. Tatishvili, 2S. Tatishvili, and 2X. Davituliani (1Central Child Hos-
pital, Tbilisi, Georgia, 2Center of Child Neurology and Neurorehabili-
tation, Tbilisi, Georgia)
Purpose: Juvenile myoclonic epilepsy (JME) is an age related idio-
pathic generalised syndrome. During recent years different chromosomal
mutations were discovered for different clinical subtypes of JME. Data
appeared about metabolite abnormalities, neuronal loss and dysfunction
in frontal lobes in JME. In clinical practice some cases of JME are char-
acterised by the existence of clinical or EEG focal signs, in particular
asymmetrical or focal myoclonic seizures and polyspike-wave (PSW)
discharges, mostly presented in the frontal lobes. The aim of our study
was to identify the frequency of such focal signs and try to find their
correlation with long term prognosis.
Method: Sixty-three patients with JME were evaluated and followed
for 10 years. In all cases MRI, repeated and long term EEG was
performed.
Results: MRI was normal in all cases. In 44 cases clinical presentation
was typical for JME with symmetrical myoclonic seizures and symmet-
rical, synchronous PSW waves on EEG-group 1. In group 2 (19 cases)
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myoclonic seizures were predominantly focal with prevalence on the
right side. Focal myoclonic seizures were correlated with bursts of asym-
metrical PSW predominantly in frontal regions on EEG. Interictal EEG
was also characterised by short bursts of PSW in the left frontal region.
There was significant difference in frequency of generalised seizures
(GS) in two groups. In group 2 GS were significantly more frequent and
disabling than in group 1 (p < 0.005). Long term outcome for seizure
control, relapse rate and development was worse in group 2 (p < 0.001).
Conclusion: Existence of focal clinical and EEG signs in JME cor-
relate with poor long term outcome for seizure control, relapse rate and
development.
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THE IMPACT OF INCLUDING GREY AND NON-ENGLISH LIT-
ERATURE ON COMBINED EFFECT ESTIMATES FROM NON-
RANDOMISED ADD-ON ANTIEPILEPTIC STUDIES
1M. Maguire, 2J. Hutton, and 1A. Marson (1The Walton Centre, Liver-
pool UK, 2The University of Warwick, Department of Statistics, UK)
Purpose: Exclusion of non-English and grey literature (i.e., literature
not published in peer reviewed journals or limited distribution) stud-
ies from systematic reviews may introduce bias and impact on overall
treatment effect estimates. We investigated this by using nonrandomised
add-on studies of topiramate and levetiracetam in refractory epilepsy.
Method: Electronic searches of MEDLINE (1902–2005), EMBASE
(1974–2004), CINAHL (1982–2005), ZETOC (1993–2005), and hand
searches of congress proceedings were performed to identify relevant
studies. Data was extracted for study attributes, 50% responder and
seizure freedom rates. Effect estimates were compared for non-English
versus English studies and for studies published in full versus those pub-
lished in abstract form only. Funnel plots were used to assess publication
bias.
Results: Ninety-four nonrandomised studies (42 published in full, 52
abstracts) were identified for add-on topiramate therapy and 80 non-
randomised studies (36 published in full, 44 abstracts) for add-on leve-
tiracetam therapy. Median reported responder and seizure freedom rates
were higher in topiramate studies published in full versus those from ab-
stracts (62% vs 55%) and (16% vs 8%) respectively. Combining studies
resulted in smaller median responder and seizure freedom rates com-
pared to summary estimates from studies published in full. Including
non-English topiramate studies published in full did not impact on over-
all treatment effect estimates. Similar results were noted for levetiracetam
studies.
Conclusion: The exclusion of grey literature from systematic reviews
could lead to over inflated summary effect estimates for an interven-
tion. An attempt to retrieve all relevant data is paramount to systematic
reviews.
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ICTAL SINGING
1,2J. Pimentel, 1,2C. Bentes, 1,2J. Costa, 1,2R. Santos, and 2V. Rolo
(1Faculdade De Medicina De Lisboa, Portugal, 2Hospital De Santa
Maria, Lisbon, Portugal)
Purpose: Vocalisations are frequent ictal manifestations. However,
ictal singing is extremely rare (4 cases described) and its mechanism
barely studied. We will describe a case helping to define the cerebral lat-
eralisation of this automatism and emphasising the cerebral mechanisms
responsible for musical production.
Method: A 41-year-old, illiterate woman, with no musical education,
able to sign and embroil with her left hand with refractory seizures since
the age of 12 months, consisting of an epigastric aura followed by clonic
jerks of the right limbs and simple automatisms.
Results: MRI suggested left mesial sclerosis. Interictal SPECT show-
ing left frontal-temporal hypoperfusion. Video-EEG monitoring revealed
bilateral, left predominant, frontotemporal interictal epileptiform activ-
ity; ictal chewing and blinking automatisms followed by speech and
singing with late right frontal-temporal epileptiform activity. Musical
ictal evaluation: key (D major), beat (binary), rhythm (seminim-1.8 Hz),
and character (Portuguese folksong malha˜o). Left selective amygdalo-
hippocampectomy was performed, and microscopic confirmation of
mesial sclerosis associated to neuronal dysplasia and amygdaloid nu-
cleus atrophy. Patient is seizure free 8 months after surgery.
Conclusion: In this patient, the dominant hemisphere is probably the
right one. Although the diagnostic search failed to precisely identify the
ictal onset zone the described seizures favoured a nondominant hemi-
sphere onset. Musical production requires the orchestration of several
components (rhythm, pitch, lyrical content). In the ictal singing, several
diffuse musical elements are probably brought together and vocalised in
such a way to produce a recognisable tune. There is growing evidence
that musical functions dynamically recruit several mechanisms/neuronal
networks involving regions in both hemispheres.
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ELECTROENCEPHALOGRAPHIC AND CLINICAL CHARAC-
TERISTICS OF PHARMACORESISTANT FOCAL EPILEPSIES
M. Milovanovic, Z. Martinovic, N. Buder, and P. Simonovic (Institute
of Mental Health, Belgrade, Serbia and Montenegro)
Purpose: To determine the electroencephalographic (EEG) and clin-
ical characteristics of pharmacoresistant focal (partial) epilepsies in a
sample of adult patients.
Method: Patients with proven pharmacoresistant epilepsy were com-
pared with a control group of patients with focal epilepsy and complete
seizure control. All patients first referred to our department were con-
secutively included in this study with a follow-up period of three years.
EEG and brain neuroimaging were performed in all patients. Seizures,
epilepsy and epilepsy syndromes were classified according to the pro-
posals of the International League Against Epilepsy. Patients with pseu-
dopharmacoresistance due to incorrect diagnosis and/or inadequate ther-
apy were excluded.
Results: According to demographic characteristics, a group of 60
patients with pharmacoresistant focal epilepsy (mean age 32.4 years,
48% males) was comparable with a control group also including 60 pa-
tients (mean age 29.8, 45% males). When the pharmacoresistant group
and the control group were compared, the following characteristics of
an unfavourable outcome reached statistical significance: interictal delta
activity in EEG (p < 0.01), complex focal seizures with a prolonged pos-
tictal disorientation phase (p < 0.01), mesiotemporal location of epilep-
togenic lesion (p < 0.05), neurological deficits (p < 0.05), symptomatic
aetiology (p < 0.05) and comorbid psychiatric disorders (p < 0.05).
Temporal interictal rhythmic delta activity showed correct lateralisation
of epileptogenic lesion involving mesiotemporal location.
Conclusion: Focal epilepsies contain a cluster of clinical and EEG
characteristics which can early be suggestive both of pharmacoresis-
tance and the need for the use of surgical and other nonpharmacological
treatment modalities.
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SEIZURES FOLLOWING MILD TRAUMATIC BRAIN INJURY
AND WHIPLASH: A CASE REPORT
H. Schmidt and R. Schaumann–von Stosch Suva, (Swiss Accident In-
surance Fund, Switzerland)
Purpose: In epidemiological studies, post traumatic epilepsy after
mild traumatic brain injury (MTBI) is found to have a low rate of oc-
currence. In light of the findings in our case, we question the reliability
of the diagnosis of epilepsy in these studies. Especially in the context of
compensation seeking, an attack disorder occurring after MTBI and/or
whiplash (WAD I, II) requires critical investigation and analysis.
Method: Habitual seizures were registered by video-monitoring.
Results: An 18 year old patient was involved in a car accident re-
sulting in mild traumatic brain injury (MTBI) and whiplash trauma
(WAD II). Approximately 6 months later the patient presented for the
first time paroxysmal alterations of consciousness and sensory mo-
tor deficits of the right extremities. Requirements for compensation 8
years post-accident led to the first neurological evaluation including
a standard EEG. Posttraumatic epilepsy was diagnosed, and treatment
with VPA was indicated. One year later, during the continuing medico-
legal process, a video-EEG seizure recording in a specialised epilepsy
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centre, and a cerebral MRI, were performed. These investigations led to
the diagnosis of a non epileptic attack disorder (NEAD). The psychiatric
exploration revealed an adequate psychic conflict.
Conclusion: The early and detailed exploration of seizure semiology,
video-EEG monitoring and adequate imaging is essential to diagnose
NEAD. The early diagnosis of NEAD is of great value with regard to
prognosis and development of the disorder. The management of post
traumatic symptoms after head and cervical trauma without structural
lesions needs to be optimised, as shown by this case report.
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CALLOSOTOMY VERSUS VAGUS NERVE STIMULATION IN
DRUG-RESISTANT EPILEPSIES
1D. Policicchio, 2C. Barba, 1M. Meglio, 1F. Papacci, and 1G. Colicchio
(1Catholic University, Roma. Italy, 2IRCCS, Santa Lucia, Roma. Italy)
Purpose: To compare results obtained by two different “palliative”
surgeries, callosotomy and vagus nerve stimulation (VNS) in drug-
resistant epilepsy patients.
Method: 56 drug-resistant epilepsy patients were submitted to pal-
liative surgery. From 1985–1998 22 patients underwent callosotomy.
Surgical indication was based on high frequency of “tonic-atonic falling
seizures” with either an impossibility to perform, or failure, of a previ-
ous ablative surgery. From 1995–2005 34 patients suffering partial and
secondary generalised seizures underwent vagus nerve stimulation (7 of
them were treated less than a year ago). Besides being drug resistant, sur-
gical indication was also based on either an impossibility to perform, or
failure of a previous surgery (callosotomy or ablative surgery). “Good”
outcome was defined as a reduction of seizures by at least 50%. “Un-
changed”: reduction of seizures by less than 50%. VNS patients were
further evaluated on the basis of epileptic status, clusters and handicap-
ping effects of the seizures.
All patients were assessed 1 and 5 years after surgery, taking into
consideration the total number of residual attacks as well as differing
types of seizures.
Results: Callosotomy: “good” results were obtained in 15 patients
(68.2%), 4 are seizure free; 6 (27.3%) were “unchanged” and 1 wors-
ened. The best results were obtained with generalised seizures, which
disappeared in 11 patients (50%), while partial seizures had a worse
outcome. Vagus nerve stimulation: “good” outcome were obtained in 5
(18.5%) out of the 27 considered patients, 2 of them are seizure free
and no patient worsened. Evaluating surgical outcome considering also
cluster, status and handicapping effects of the seizures, “good” results
were obtained in 11 patients (40.8%), the remaining 16 (59.2%) were
unchanged.
Conclusion: With respect to VNS, callosotomy is shown to be more
efficient in reducing the occurrence of tonic-atonic seizures. The differ-
ences between VNS and callosotomy are evident in both the reversibility
of VNS and the invasiveness of callosotomy. For this reason the two surg-
eries could be considered, for a single patient, in successive steps: VNS
first, while callosotomy could be a second approach if surgical indica-
tions are still present. Both types of interventions, when efficient, show
unchanging results over time: 1 and 5 years follow up studies.
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DIFFERENT CLINICAL MANIFESTATIONS OF HYPERAM-
MONEMIC ENCEPHALOPATHY
Y. Bicer Gomceli, G. Kutlu, F. Sanivar, B. Gonulal, and L. Inan (Ministry
of Health Ankara Training and Research Hospital)
Purpose: Valproate is an effective anticonvulsant; although it is usu-
ally well tolerated, it has been associated with many neurological,
hematopoietic, hepatic and digestive system side effects. Among these
side effects hyperammonemia without clinical or laboratory evidence of
hepatotoxicity is a rare and important clinical consideration. The aim of
this presentation is to evaluate the reasons for unexpected symptoms of
four epilepsy patients while being treated with valproate.
Method: We evaluated 4 adult patients with localisation-related
epilepsy who presented with different acute or subacute neurological
symptoms related to valproate induced hyperammonemic encephalopa-
thy (VHE).
Results: Two of the 4 patients were women and 2 were men. The
ages of patients ranged from 20–56 (mean: 31.7). Three of 4 patients
had an acute onset of confusion, decline in cognitive abilities and ataxia.
Among these patients one had a decline in speech, and the other one had
increased seizure frequency and new onset tremor. Except these, the last
patient had subacute behavioural alteration, an increase in appetite and
urinary incontinence. Ammonia levels were elevated in all the patients.
After the discontinuation of valproate, complete clinical improvements
were observed within 5–10 days.
Conclusion: The pathogenesis of VHE is still unclear, but it has been
suggested that hyperammonemia can produce encephalopathy via inhi-
bition of glutamate uptake by astrocytes which may lead to potential neu-
ronal injury and perhaps cerebral edema. In this presentation we suggest
that ammonia levels of a patient, who has new neurological symptoms
and has been taking valproate, must be checked. The clinicians should
be aware that these clinical symptoms may be related to VHE, and the
symptoms may resolve dramatically after withdrawal of the drug.
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A DETAILED ANALYSIS OF HYPERMOTOR SEIZURES
SEMIOLOGY
1S. Rheims, 2P. Kahane, 2L. Minotti, 2D. Hoffmann, 3M. Gue´not, and 1P.
Ryvlin (1Department of Functional Neurology And Epileptology, Neuro-
logical Hospital, Lyon, France, 2Epilepsy surgery Unit, CHU Michallon,
Grenoble, France, 3Department of Neurosurgery, Neurological Hospital,
Lyon, France)
Purpose: To describe the detailed semiology and the underlying
epileptogenic zone of hypermotor seizures.
Method: We analysed ictal manifestations of 105 hypermotor seizures
in 10 consecutive patients who underwent intra-cerebral EEG monitoring
and successful surgery.
Results: Two types of hypermotor seizures could be distinguished in
this population: Type 1 mainly consisted of marked agitation that either
included body rocking, kicking or boxing, without associated dystonic
posture or tonic head version. Type 2 seizures mainly consisted of less
marked agitation that either included horizontal movements or rotation
of trunk and pelvis while lying on a bed, usually associated with dystonic
posture or tonic head version. Various auras, vocalisation, grasping and
standing up were observed in the two seizure types. Among the 6 patients
with type 1 hypermotor seizures, 4 (66%) demonstrated a seizure onset
zone that included the orbitofrontal cortex and/or the rostral portion of
the anterior cingulate gyrus, whereas the latter brain regions were not
involved in the 4 other patients with type 2 hypermotor seizures. In most
other patients with either type 1 or type 2 seizures, intracerebral EEG
ictal onset was observed in the mesial cortex of the superior frontal gyrus
and/or in the dorsal cingulate cortex.
Conclusion: We have identified two types of hypermotor seizures,
primarily distinguished on the type and intensity of agitation, and the
associated dystonic posture and head version. This distinction might help
to determine the underlying EZ, and in particular the involvement of the
orbitofrontal cortex and/or the rostral portion of the anterior cingulate
gyrus.
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HYPERANDROGENISM IN WOMEN WITH EPILEPSY IN THE
CHILDBEARING YEARS
G. Timarova (Faculty of Medicine, Comenius University, Bratislava,
Slovak Republic)
Purpose: Occurrence of hyperandrogenism (HA) and menstrual dis-
orders is higher among women with epilepsy than in the population
without epilepsy. One of the probable reasons is the antiepileptic medi-
cation used in these patients. We performed open prospective follow-up
for symptoms of HA in women in the childbearing years treated with
lamotrigine (LTG) as their first monotherapy or after switching to LTG
from valproate (VPA), carbamazepine (CBZ) or combination therapy
VPA plus CBZ.
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Method: Data were collected on 181 women aged 15–50 years. Symp-
toms like acne, hirsutism (HIR), excessive hair lost (HL), oligomenor-
rhea (OMR), amenorrhea (AMR), shortened menstrual cycle (SMC) and
prolonged menstrual cycle (PMC) were checked-up in patients at two,
five and eight months after introducing LTG as afirst-line monotherapy
or after switching to LTG from VPA, CBZ or combination therapy VPA
+CBZ.
Results: Thirty-eight women started LTG as their first monotherapy;
4 (10.5%) of them had acne, 2 (5.3%) had HL, 1 (2.6%) had OMR, HIR,
AMR or PMC, 3 (7.9%) had SMC at the time of introducing the therapy.
Eight months later there was no significant change in the frequency of
their symptoms. One hundred and seven women switched from VPA to
LTG; 31 (28.9%) had acne, 31 (28.9%) had HL, 15 (14%) HIR, 3 (2.8%)
AMR, 16 (14.9%) OMR, 13 (12.1%) SMC and 11 (10.3%) had PMC
at the beginning of the follow-up. Eight months later 13 (12.1%) had
acne (decrease significant p = 0.001), 7 (6.5%) had HL (p = 0.001), 2
(1.9%) HIR (p = 0.01), 6 (5.6%) OMR (p = 0.01), 6 (5.6%) SMC (p =
0.05), 1 (0.9%) AMR (NS) and 8 (8.4%) had PMC (NS). Sixteen women
switched from CBZ to LTG; the frequency of symptoms of HA was not
significantly different from the group with LTG first-line monotherapy
at the beginning of the follow-up and 8 months later. Twenty women
who switched from VPA+CBZ to LTG had a higher incidence of some
symptoms of HA than group VPA (acne 10 (50%), AMR 8 (40%), HL 9
(45%), 8 (40%) OMR). Eight months later there was a significant decline
in the frequency of acne, HL and OMR in this group.
Conclusion: There was a significantly higher rate of symptoms of
HA in the patients treated with VPA alone or combination therapy
VPA+CBZ at the beginning of the follow-up compared to the group of
patients treated with primary LTG monotherapy. Switching these women
to LTG led to a significant decline in the frequency of acne, hirsutism, hair
loss, oligomenorrhea and shortened menstrual cycle at 5 and 8 months
of follow-up.
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THYROID DISEASE AND EPILEPSY: CLINICAL AND ELEC-
TROPHYSIOLOGICAL FINDINGS
K. Aslan, H. Bozdemir, and Y. Sary´ca (Department of Neurology, Med-
ical Faculty, University of Cukurova, Adana, Turkey)
Purpose: The main objective of this study is to determine the relation
of epilepsy development and prognosis of the patients who have thyroid
dysfunction (TD) or disease.
Method: Fourteen patients (10 women, 4 men) with a mean age of
32.64 ± 16.27 (16–70) years were selected. The patients were classified
in to 2 groups according to relation of TD to their epilepsy. In group 1
(n = 6), TD was diagnosed before epilepsy, in group 2 (n = 8); TD was
detected after epilepsy diagnosis.
Results: Epileptic disorder was classified as partial epilepsy in 9, and
primary generalised epilepsy in 5 of the patients. Six of the patients were
on monotherapy, 8 were on polytherapy. All of the patients in group 1,
and 4 (50%) patients of group 2 were on treatment because of TD. On the
other hand, hypothyroid was detected in 5 (83.3%) of group 1, and in 2
(25%) of group 2 patients (p = 0.031). EEG revealed focal abnormalities
in 66.6% of the group 1, and subcortical epileptic activity in 50% of group
2. MR imaging showed abnormal findings in 5 (83.3%) of group1 and
in 2 (25%) of group 2 patients (p = 0.025).
Conclusion: 43% (n = 6) of the patients were seizure free and 42.9%
(n = 6) had partially controlled seizures with regular and continuous
antiepileptic therapy. However, 1 patient in each group had no change in
seizure frequency in spite of regular therapy for both diseases.
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INVOLUNTARY FACIAL TWITCHING INDUCED BY
TOPIRAMATE
1E. Kutluay, 1B. Pakoz, and 2A. Beydoun (1Kent Hospital, Izmir, Turkey,
2American University of Beirut, Beirut, Lebanon)
Purpose: We present 2 cases treated with topiramate (TPM) who
developed a hitherto undescribed side effect consisting of involuntary
twitches of facial musculature.
Method: Two cases with partial-onset seizures were investigated in
detail. The data is reported in the Results section.
Results: Case 1 is a 28-year-old male with complex-partial seizures
(CPS). Since phenytoin was only partially efficacious, it was decided to
convert him to TPM as monotherapy. Treatment with TPM was initiated
at 25 mg/day with 25 mg weekly increments. The patient tolerated TPM
until a daily dose of 150 mg was reached. At that dose, he started to expe-
rience twitching of his facial muscles, more prominent in his forehead.
The twitches recurred at an average frequency of 5 Hz (documented by
EMG) and occurred in clusters several times daily, with each lasting up
to 10 seconds. The muscle twitches were not associated with any epilep-
tiform activity on a surface EEG. Case 2 is a 49-year-old woman with
new-onset CPS. Treatment with TPM was initiated at 50 mg/day with
25 mg weekly increments. The patient reported no adverse events until a
daily dose of 150 mg. At that dose, she experienced facial twitches simi-
lar to those described for Case 1 but more prominent around the eyes and
mouth. Neurological examinations and routine blood work were normal
for both patients. These muscle twitches resolved in both patients upon
discontinuing TPM.
Conclusion: TPM may cause twitching of the facial muscles which
resolve upon discontinuation of the drug. The mechanisms responsible
for this unusual adverse event are not clear.
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SOME FEATURES OF EPILEPSY AND EPILEPTIC SEIZURES
IN ELDERLY PATIENTS
T. Litovchenko, O. Zinchenko, and O. Tondiy (Kharkiv Medical
Academy of Postgraduate Education, Ukraine)
Purpose: Epilepsy and single epileptic seizures are third among of the
most serious neurological problems in elderly persons. Appreciably it is
symptomatic seizures or epilepsy caused by age changes of the brain, and
also acute symptomatic attacks, as the remote consequences of trauma,
or progressing diseases of CNS. The purpose of this research was to
reveal the interrelation between cerebral pathology in persons of elderly
and senile age and development of symptomatic seizures and epilepsy
for optimisation of antiepileptic treatment.
Method: Material for the research was 10 years supervision which had
been carried out in the central clinical hospital of Kharkov. We surveyed
238 patients, with symptomatic seizures or epilepsy de novo from 60 to
79 years old.
Results: Epileptic seizures and epilepsy in the elderly were caused by
urgent cerebrovascular diseases in 46%; by metabolic or toxic diseases
in 18%, head traumas in 13%, tumours in 9%, infections of CNS in 3%,
dementias in about 3%, and some cases was referred as obscure aetiology.
The type of seizures in elderly and senile patients depends from aetiology
of epilepsy. Generalised seizures prevail in the patients with metabolic
and toxic encephalopathy, partial and secondary generalised seizures are
characteristic for organic focal lesion of the brain. Most frequently we
observed complex partial seizures (on the average 48–52%), secondary
generalised seizures (20–27%), simple partial seizures (13–16%).
Conclusion: Acute cerebrovascular diseases were the most common
reason of developmental symptomatic epilepsy in the elderly. The treat-
ment of epileptic seizures and “vascular” epilepsy should be individual
with application of mainly monotherapies by antiepileptic drugs and
parallel treatment of the cerebrovascular pathology.
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PROGNOSTIC SIGNIFICANCE OF SYNDROMIC CLASSIFI-
CATION IN NEWLY DIAGNOSED EPILEPSY PATIENTS
1A. Del Felice, 2C. Ruffmann, 2G. Bogliun, and 2,3E. Beghi (1Clinical
Neurology Department, Policlinico GB Rossi, University of Verona,
Verona, Italy, 2Epilepsy Center, S.Gerardo Hospital, University of
Milano-Bicocca, Italy, 3Pharmacological Research Institute Mario Ne-
gri, Milano, Italy)
Purpose: To assess the frequency, timing, patterns and prognostic
significance of change of the syndromic diagnosis in a cohort of newly
diagnosed adults with epilepsy.
Epilepsia, Vol. 47, S3, 2006
54 7TH EUROPEAN CONGRESS ON EPILEPTOLOGY
Method: 180 newly diagnosed adults from an epilepsy centre were
included and followed for 852.4 person years. For each patient, the
syndromic diagnosis was made at entry according to simplified cate-
gories. Changes of the diagnostic categories were then recorded retro-
spectively during follow-up. A change of the syndromic diagnosis was
made and dated, based on new data on seizure types and/or EEG find-
ings and/or neuroimaging results. Using survival analysis, the cumula-
tive time-dependent probability of change of syndromic category and of
2-year remission was measured. Differences were tested with the log-
rank test. A multivariate analysis was performed using Cox’s propor-
tional hazard function.
Results: The sample included 104 men and 80 women aged 15 through
84 years. At entry, 61 patients (33.9%) had partial epilepsies, 42 (23.3%)
had generalised epilepsies, 19 (10.6%) had undetermined epilepsies,
and 58 (32.2%) had isolated seizures. The syndromic diagnosis was
changed during follow-up in 54 cases (30%). The cumulative probabil-
ity of change was 10% at six months, 16%, 19%, and 25% at 12, 24,
and 36 months. 83% of changes were in patients with isolated seizures
who relapsed (45 cases). A total of 105 patients (58.3%) achieved 2-year
remission. The cumulative probability of remission was similar when
comparing patients with and without change of the syndromic diagnosis
(log-rank 0.11; p = ns), after excluding those with isolated seizures at
entry, and when adjusting for age, sex, disease duration at entry, and
treatment in the multivariate analysis model.
Conclusion: Except for isolated seizures, the syndromic diagnosis at
entry changed infrequently (mostly during the first year) in adults and
did not affect the chance of long-term remission of epilepsy.
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CARBAMAZEPINE AND OXCARBAZEPINE DRUG UTILI-
SATION PATTERNS AND IMPACT ON LIFE IN ADULTS
AND CHILDREN WITH PARTIAL SEIZURES: A CROSS-
SECTIONAL STUDY
1M. Carren˜o and R. Miguel (1Director of The Epilepsy Unit, Hospital
Clı´nic de Barcelona, Spain, 2Head of The Neurology Service, Hospital
Virgen del Rocı´o, Spain)
Purpose: Carbamazepine is a well known antiepileptic drug (AED)
indicated for partial seizures and has been widely used during the last
decades. Oxcarbazepine has been marketed in Europe since the 1990s.
Our aim is to describe drug utilisation patterns of carbamazepine and
oxcarbazepine, in routine clinical practice and to study the impact of
epilepsy on patients’ lives, in adult and child populations.
Method: A cross-sectional survey conducted in specialised clinical
settings under the Spanish National Health System. Patients being treated
with any of the specified AEDs were asked to participate. Inclusion crite-
ria involved patients suffering partial seizures on maintenance treatment
during the previous 4 months. The prescribing patterns for AEDs are
established according to titration schedule, dose, and combined AED
therapy. Self-reported impact of epilepsy on patients’ lives is recorded
in adults using the Sheehan Disability Scale and in children using the
Cuestionario de Calidad de Vida del Nin˜o con Epilepsia (CAVE).
Results: Fifty patients were included in the study by 63 specialists
from around the country. A description of the drug utilisation pattern is
documented in the adult and child populations based on the severity and
the type of seizure according to ILAE classification of epileptic seizures.
Conclusion: It is relevant to provide data on the utilisation of AEDs
in specialised clinical settings from large populations. Information on
the impact of epilepsy on patients’ lives is also needed, in adults and
children, to document the social burden of this chronic condition. This
study was funded by Novartis.
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A RASMUSSEN ENCEPHALITIS CASE TREATED WITH IN-
TRAVENOUS IMMUNOGLOBULINS
A. Ceyhan Dirican, S. Baybas, V. Sozmen, Y. Altunkaynak, and B.
Sahinoglu (Bakirkoy State Hospital for Neurologic and Psychiatric Dis-
eases)
Purpose: Rasmussen encephalitis is characterised by epilepsia par-
tialis contunia accompanied with focal seizures, progressive neurologic
deficiency, hemispheric atrophy and histopathological inflammation.
Method: A case study: A 20-year-old male patient had his first sec-
ondary generalised seizure with left side adversion when he was 11 years
old and following this seizure focal motor seizures on the left arm and
left side of the mouth were observed. At the beginning, the seizures
were controlled with antiepileptic therapy, but later epilepsia partialis
continua emerged. Neurologic examination was normal except for focal
motor seizures. Cranial MRI revealed signal change in the right pari-
etooccipital region and cortical atrophy on the perisylvian fissure. All
the other tests did not reveal any other reason for epilepsia partialis con-
tinua, so the patient was diagnosed as having Rasmussen encephalitis
with cortical hemiatrophy. The patient was treated with intravenous im-
munoglobulins intermittently in addition to antiepileptic drugs for four
years. The patient does not have new neurological deficiency. He still
has epilepsia partialis continua intermittently without affecting his daily
activities.
Results: Medical or surgical therapy choices for Rasmussen syndrome
are still being discussed.
Conclusion: In this paper, we present a patient with Rasmussen en-
cephalitis who was treated with intravenous immunoglobulins effectively
and safely.
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QUALITY OF LIFE IN ELDERLY PATIENTS WITH CHRONIC
EPILEPSY
G. Muscas, E. Rosati, E. Bertini, B. Chiocchetti, and V. Bessi (Depart-
ment of Neurological and Psychiatric Sciences, Epilepsy Center, Careggi
Hospital, Florence, Italy)
Purpose: To investigate the clinical features of elderly patients (>60
years) with chronic epilepsy living in the community and to evaluate
patients’ quality of life (QOL).
Method: Over a 1 year period data from a consecutive cohort of
outpatients were prospectively collected. Patients completed the Health-
related QOL 36-item Short Form (SF-36) and the Adverse Events Profile
(AEP) questionnaire; comorbility was rated using to the Cumulative Ill-
ness Rating Scale (CIRS). Principal cognitive, functional and psycholog-
ical/behavioural measures were: Folstein Mini-Mental Status Examina-
tion (MMSE), cognitive subscale of the Alzheimer’s Disease Assessment
Scale (ADAS-cog), Clinical Dementia Rating (CDR), Neuropsychiatric
inventory (NPI), Geriatric Depression Scale (GDS), Katz activities of
daily living (ADL), and Lawton’s Instrumental activities of daily liv-
ing (IADL). Dementia was diagnosed by means of DSM III-R criteria
and according to consensus procedure a more complete neuropsycho-
logical examination was used to identify subtle cognitive deficits such
as cognitive impairment nondementia (CIND). SF-36, GDS and AEP
scores were compared with those of a reference group without chronic
conditions with the same sociodemographic characteristics.
Results: Seventy-five patients (mean age 72.6 years, SD 8.1) com-
pleted the evaluation. The mean age at seizure onset was 54.8 years
(range 2–93 years, SD 24.5), with the majority experiencing seizures
after age 60 years (58.7%). Thirty-one (44%) were 1 year seizure free.
Forty-seven (63%) were on monotherapy and 28 (37%) on polytherapy.
CIRS comorbidity and severity average score was respectively 1.75 (SD
1.28) and 1.40 (SD 0.22). Mean score on MMSE was 21.8 (SD 0.6) and
mean score on ADAS-cog was 18.76 (SD 7.1) with 28 patients (37%)
that were considered demented and 22 (29%) with CIND. Mean ADL
and IADL scores were respectively 4.72 (SD 3.22) and 5.29 (SD 4.24).
Depression, anxiety, sleep disturbances and other psychiatric symptoms
were detected on NPI in 59 (79%) patients. The z-scores on many SF-36
domains, AEP, and GDS scores were worse than those of the reference
group.
Conclusion: In an epilepsy centre of a tertiary referral hospital aged
patients with epilepsy frequently present drug-resistant seizures, cog-
nitive impairment, psychiatric symptoms and worse QOL. Long-term
studies in the general population are warranted to establish if incorporat-
ing health status information into therapeutic decision making may help
to attain the ultimate goal of improving patients’ health.
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RETROSPECTIVE INVESTIGATION OF PREGNANCY AND
DELIVERY COURSES FOR WOMEN SUFFERING FROM
EPILEPSY DURING THE LAST THREE YEARS
A. Prusakova, A. Prusakou, and H. Navumava (Vitebsk Regional Center
For Medical Diagnostics, Belarus)
Purpose: The aim of the investigation was to investigate special fea-
tures of pregnancy in women suffering from epilepsy, taking as an ex-
ample, the population of Vitebsk region (Belarus).
Method: We performed a population based case ascertainment of all
available sources of medical care from April 2002 until December 2005.
Women of fertile age, suffering from epilepsy, were analysed. Only cases
with active epilepsy (at least one seizure during the last 5 years, regardless
of treatment) were included. All patients were examined by a neurologist
or psychiatrist.
Results: There were 4 pregnant women suffering from epilepsy in
2002. Mean age of patients was 23 years (18–29 years). There were
19 patients in 2003 (mean age 25 years, 18–34). In 2004, there were 48
women, mean age 26 years (18–41). In 2005 there were 35 women, mean
age 26 years (19–40). All the women were primiparous. Idiopathic gen-
eralised epilepsy was the prevailing form. Frequent seizures were in only
2 women (1.8%). Caesarian section was performed in 20% of cases. One
woman died from eclampsia at 30–weeks gestation in 2004. Two women
had nondeveloping pregnancies at 12 and 18 weeks of gestation. 60% of
women were treated with depakin-chrono. 98% of all patients received
monotherapy. None of the offspring had abnormalities or malformations.
Conclusion: In connection with the creation of specialised centers,
dealing with epilepsy problems and new antiepileptic drugs resulting in
more effective treatment for epilepsy, more and more women are eager
to have children.
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FALSE ALARMS FROM EPILEPSY ALARMS IN THE DANISH
EPILEPSY CENTRE, DIANALUND
2R. Mathiasen and 1C. Hansen (1The Danish Epilepsy Centre, Di-
analund, Denmark)
Purpose: To assess the occurrence of false alarms from bed alarms
and pulse-oxymetres in patients admitted to the Danish Epilepsy Centre,
Dianalund.
Method: In 5 short term departments patients were prospectively
subjected to close supervision using video camera when they were un-
dergoing significantly increased risk of potentially dangerous epileptic
seizures. Patients were included from April 2004 to January 2006. When
the patients were in bed, they were constantly supervised by video record-
ing. Each supervised patient carried a pulse-oxymetre, and the bed was
equipped with an epilepsy alarm. The video supervision allowed iden-
tification of epileptic seizures, and the nursing staff registered alarms
from the bed alarms and pulse-oxymetres (desaturation and/or change
of pulse), likewise alarms without seizures were registered.
Results: Ninety-five patients (47 female and 48 male), aged 1–63
years (mean 23.8 years) were included. They were under supervision
between 1 and 49 days (mean 8.0 days). In total 1471 seizures were
observed by video recording. At the same time 273 false alarms by bed
alarms (between 0 and 4.3 per day), and 585 false alarms from pulse-
oxymeters (between 0 and 4 per day) were registered.
Conclusion: Bed alarms and pulse-oxymeters used in the Danish
Epilepsy Centre, Dianalund, have a significant frequency of false alarms.
As the sensitivity of these devices is also suboptimal, further develop-
ment of epilepsy alarms is needed.
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FREQUENCY OF SEIZURES AND BRAIN BIOELECTRICAL
ACTIVITY DURING STABLE AND UNSTABLE WEATHER
CONDITIONS IN SPRING
E. Motta, Z. Kazibutowska, M. Strzala-Orzel, A. Golba, M. Deˆbski, and
G. Wo ¨Ynik (Silesian Medical Academy, Katowice, Poland)
Purpose: Patients with epilepsy tend to combine the incidence of
seizures with weather conditions especially atmospheric pressure and
seasons. The aim of this study is to examine the real influence of atmo-
spheric pressure and temperature changes on seizure frequency and if
the incidence of seizures increases during unstable weather conditions
is this combined with worsening of EEG findings.
Method: 30 patients (18 men and 12 women) with complex partial
seizures and secondary generalised seizures (aged 19–54, mean 32.6)
were studied. They have claimed an increase of seizure frequency be-
cause of atmospheric pressure changes for at least two years. All patients
underwent EEG recordings twice during the spring while there were sta-
ble and unstable weather conditions. Each seizure was registered. Data
about atmospheric pressure were obtained from The Meteorological In-
stitute. EEG recordings in women were performed during the follicular
phase of the menstrual cycle.
Results: During the unstable weather conditions in the spring, seizure
frequency increased in 13 (43%) patients while in 16 (53%) it did not
change. In 1 patient seizure frequency decreased. Unstable meteorologi-
cal factors caused worsening of EEG recordings in 17 (57%) patients and
in 5 of them changes in EEG so far normal appeared. In other 5 persons
EEG changes deteriorated while in 7 epileptiform activity occurred.
Conclusion: The positive relationship between atmospheric changes
and seizure frequency was found in less than half of our patients. The
greater percentage of the patients with EEG changes during unstable
weather conditions compared with those in stable may suggest the influ-
ence of meteorological factors on bioelectrical discharges with or without
clinical manifestation.
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COMPLETE CHANGE OF SEIZURE AND SPIKE LATERALI-
SATION IN TEMPORAL LOBE EPILEPSY AT TWO SEPARATE
MONITORING SESSIONS
1A. Koukou, 2,3,4S. Dupont, 5W. Szurhaj, 2,3,4M. Baulac, 5P. Derambure,
and 2,4,6C. Adam (1Psychiatric Hospital of Attica, Greece, 2Epileptology
Unit, Hoˆpital de La Pitie´-Salpeˆtrie`re, Paris, France, 3INSERM EMI 0224
‘Cortex & Epilepsie’, Hoˆpital de La Pitie´-Salpeˆtrie`re, Paris, France,
4Universite´ Pierre et Marie Curie, Paris, France, 5Clinical neurophysi-
ology department, R. Salengro Hospital, Lille, France, 6CNRS UPR640
‘Neurosciences Cognitives et Imagerie Ce´re´brale’, Hoˆpital de La Pitie´-
Salpeˆtrie`re, Paris)
Purpose: Video-EEG monitoring is a widely accepted method to de-
termine the epileptogenic focus during presurgical evaluation of phar-
macoresistant epilepsy. In the case of temporal epilepsy bilateral epilep-
togenic foci are frequent. Sometimes, a single video-EEG can miss the
existence of a second focus.
Method: The charts of patients recorded in Salpeˆtrie`re Hospital be-
tween 1991 and 2005 were retrospectively reviewed. Among them, 115
had two independent monitoring sessions and at least one seizure per
session. Only 2 cases showed a complete change in epileptic lateralisa-
tion at two successive monitoring sessions. We report on these 2 patients,
both suffering from bitemporal lobe epilepsy, and who could have been
interpreted as unilateral from a first video-EEG monitoring. However,
the second video-EEG session revealed the second epileptic focus lo-
cated in the opposite temporal lobe. Patient 1: a 23-year-old male, first
developed temporal lobe seizures when he was 6 years old. A right tem-
poral lobe dermoid cyst was discovered on MRI and a simple puncture
of this cyst relieved the patient from seizures for 6 months. Afterwards
seizures reappeared. Patient 2: a 45-year-old female, first experienced
temporal lobe seizures when she was 37 years old. No noticeable lesion
was observed on brain MRI.
Results: Patient 1: during the first monitoring a clear EEG expres-
sion of 5 typical seizures and 4 auras was present on the left temporal
lobe region associated with an interictal spike focus in the same region.
During a second video-EEG 9 typical seizures were expressed on the
right temporal lobe region associated with an interictal spike focus of
the same location. Patient 2: during the first video-EEG 1 crisis was ex-
pressed on the left temporal lobe region. Interictal epileptic abnormalities
were bitemporal, right-sided predominant. During a second video-EEG,
5 epileptic attacks were expressed on the left temporal lobe region as
were the interictal epileptic abnormalities. During a video-SEEG with
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bitemporal electrodes 15 seizures originated from the right hippocampal
contacts. Their scalp EEG expression was also right temporal. Interictal
spiking of right temporal origin was present during the 24 h period. Left
hippocampal interictal epileptic abnormalities occurred during sleep.
Conclusion: A bilateral TLE can occasionally be masked during a
routine video-EEG monitoring. Patients without a visible lesion on MRI
may benefit from the repetition of video-EEG monitoring sessions and
a bilateral intracranial exploration. In patients showing a clear discor-
dance between a lesional site and monitoring results, further monitoring
sessions can reveal seizures coming from the lesional site.
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PREVALENCE OF EPILEPTIC SEIZURES IN PATIENTS WITH
MULTIPLE SCLEROSIS (MS)
1,4C. Lund, 2E. Gulowsen Celius, 3A. Edland, and 4K. Nakken
(1Department of Neurology, Vestfold Central Hospital, Norway,
2Department of Neurology, Ullevaal University Hospital, Norway,
3Department of Neurology, Buskerud Central Hospital, Norway,
4National Centre for Epilepsy)
Purpose: The objective of this study was to find the prevalence of
“active epilepsy” in patients with MS. Previous studies on prevalence of
epilepsy in MS patients report a wide variation of figures from 0.5% to
10.8%. This variation could be due to differences in methodology, small
sample sizes, and differences in study populations.
Method: Data on MS patients living in a county in Norway with
218,120 inhabitants (Vestfold, January 1, 2003) in the period 1983–2003
were retrospectively collected. There were 501 patients who fulfilled the
Poser criteria for probable or definite MS. 367 patients were still alive
on 1 January 2003. “Active epilepsy” was defined as seizures within the
last five years.
Results: of the 501 patients, we identified 30 with nonrecurrent
seizures (n = 9) or epilepsy (n = 21). On 1 January 2003, the prevalence
of “active epilepsy” was 3.5% (n = 13). After excluding 1 patient with
a known aetiology other than MS, the prevalence was 3.3% (n = 12).
Conclusion: The prevalence of “active epilepsy” at prevalence date
in our population of MS patients was 3.3% (3.5%). This is 3.8 times
higher than expected in the general population in Norway (0.9%, Svend-
sen, 2004), and comparable to a previous Norwegian MS study (3.2%,
Engelsen, 1997).
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INVESTIGATION OF THE LEVEL OF NEUROTROPIC
AUTOANTIBODIES IN PATIENTS WITH POSTSTROKE
SEIZURES
1A. Feygina, 1A. Guekht, 1V. Alferova, 1A. Lebedeva, 2A. Poletaev, and
2A. Abrosimova (1Russian State Medical University, 2Research Center
“Immunculus,” Moscow, Russia)
Purpose: To evaluate changes of level of autoantibodies of IgG class
to neurotropic proteins (n-AAB) in patients with poststroke seizures.
Method: We examined 37 patients (17 female, 20 male; mean age was
64.35 ± 11.61) including 22 patients with partial symptomatic poststroke
epilepsy, 15 patients with a single seizure after ischemic stroke. All
patients had partial and/or secondarily generalised tonic–clonic seizures.
As a control 119 clinically healthy people were used. Evaluation of
features of serum immunoreactivity was made by standard variants of
IEA.
Results: The levels of nAAB to S100β, GFAP, MP-65, NGF were
reliably higher in patients with poststroke seizures compared to control
group (e.g. 139.00 ± 21.34 vs 100.60 ± 19.25, I = 0.0000 for S100β;
137.91 ± 21.12 vs 103.27 ± 20.11, I = 0.0000 for GFAP etc). The
positive Spearman rank correlation was revealed between duration of
epilepsy and the levels of nAAB to GFAP (r = 0.405, p = 0.032) and
NGF (r = 0.383, p = 0.019). Also the level of nAAB to GFAP (r = 0.484,
p = 0.003) and MP-65 (r = 0.364, p = 0.034) significantly correlated
with the number of seizures since the onset of disease.
Conclusion: Our investigations showed that the levels of n-AAB to
S100b, GFAP, MP-65, NGF were higher in patients with poststroke
seizures vs control, especially in patients with a long history of epilepsy
and a high number of seizures
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INFLUENCE OF NUMBER AND TYPE OF SEIZURES ON
QUALITY OF LIFE
M. Bar and J. Slonkova (Faculty Hospital Ostrava, Czech Republic)
Purpose: A reduction of the number of seizures is a basic parameter
of evaluation of antiepileptic treatment. We wanted to find out if the
reduction of the number of seizures or if the type of seizure influence
the quality of life.
Method: All patients with two and more seizures in the past 8 weeks
were examined repeatedly with the QOLIE 31, 1.0 version. Patients were
divided into 3 groups according to the type of seizure, also according to
the change in the number of seizures in the following 6 month period
(no change, 50% reduction and reduction with more than 75%).
Results: We enrolled 86 patients, 41 male, 45 female. 58% of patients
only suffered from CPS seizures (mean QOLIE in this group was 69),
23% only GTCS (mean QOLIE 63), and 19% both types (mean QOLIE
62). We did find a difference between these groups (p = 0.14). During
the following 6 months we found a reduction of the number of seizures
more than 75% in 29 patients, more than 50% in 35 patients; 26 patients
were in the no change group. We found a significant change in QOLIE
in group on1 (more than 75% reduction) in comparison with the others
(p < 0.05).
Conclusion: The reduction in number of seizures by more than 75%
during a 6 month period improved the quality of life in our study. The
type of seizures did not influence the quality of life in our group of
patients.
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FREQUENCY OF CARDIAC SYMPTOMS IN EPILEPSY AND
CASE REPORTS
R. Ca´ceres, L. A˚kerstedt, C. Lindell, and A. Landtblom (Department of
Neurology, Linko¨ping, Sweden)
Purpose: Sudden unexpected death in epilepsy (SUDEP) is an un-
common but feared complication. Several theories have been proposed
to explain this phenomenon mostly affecting young patients with refrac-
tory epilepsy. Ictal central apnoea (Walker R, Fish DR. Recording res-
piratory parameters in patients with epilepsy. Epilepsia 1997;38 (suppl
11):41–2.) and cardioarrhythmia Rugg Gunn FJ, Simister RJ, Squirell
M, Holdright DR, Duncan JS. Cardiac arrhythmias in focal epilepsy: a
prospective long-term study. Lancet 2004;364 (9452):2157–8. are the
most believed theories for these deaths.
Method: Frequency of cardiac symptoms using 200 journals of pa-
tients with epilepsy are in the process of being analysed. In addition, 7
case reports are under assessment. The symptoms presented by patients
in the case reports are suspected SUDEP (2 cases), paroxysmal supraven-
tricular tachycardia (3 cases), asystole with remaining AV block III (1
case) and preictal angina pectoris (1 case).
Results: In the frequency analysis, we discovered that many patients
without any known heart symptoms, i.e., not investigated according to
the journal, fulfilled several risk factors for SUDEP proposed in the liter-
ature. After preliminary evaluation of 100 journals, 4 out of 10 patients
have registered cardiac symptoms. Of 49 patients over 60 years, 30 had
cardiac symptoms. In this category, most symptoms were thought not
to be epilepsy induced. In the cohort between 40–60 years, 4 out of 22
had symptoms, and among patients below 40 years, 5 out of 30 had
symptoms. However, it has not yet been assessed to what extent these
symptoms can be explained as an epileptic manifestation. This will be
discussed.
Conclusion: Our aim is to evaluate whether any cardiac symptoms
could be epilepsy related and if so, are they seizure related or not? In our
clinical case reports we describe cardiac symptoms of suspected epileptic
origin. Another objective is to evaluate to what extent these patients are
currently investigated and monitored regarding heart symptoms. In the
future we hope this study can contribute to a safer management of patients
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with epilepsy and risk factors for SUDEP, particularly in the in-patient
setting.
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PROPORTION OF PATIENTS WITH HYPOGLYCEMIA MIS-
DIAGNOSED AS EPILEPSY IN PATIENTS WITH CHRONIC
EPILEPSY
1D. Sokic, 2M. Sumarac-Dumanovic, 1A. Sindjelic, 1A. Ristic, 1N. Vo-
jvodic, and 1S. Jankovic (1Institute of Neurology CCS, 2Institute of
Endocrinology CCS)
Purpose: To determine the proportion of patients with hypoglycaemia
erroneously diagnosed as epilepsy in patients with chronic epilepsy.
Method: We retrospectively identified 1567 patients with the diag-
nosis of chronic epilepsy treated between 1998 and 2005 at the Institute
of Neurology, Belgrade, Serbia. We tried to classify their epilepsies in
syndromes and to determine their aetiology with all available means. All
patients were treated with antiepileptic drugs (AED) and followed for at
least 1 year.
Results: During the follow-up, symptoms consistent with hypogly-
caemia occurred in 5 patients (0.32%). They presented with periods of
disorientation, agitation, sopor, or coma of various durations. Besides,
obvious generalised tonic–clonic seizures occurred either at some period
of deranged consciousness or independently. Hypoglycaemia (ranging
from 0.21 to 1.1 mmol/l) associated with symptoms was repeatedly con-
firmed in all 5 patients. The diagnosis of insulinoma in 3, ketotic hypo-
glycaemia due to the glycogen synthetase deficiency in 1 and possible
mesidioblastosis in 1 patient was established. We successfully withdrew
AED with no reappearance of seizures in the patient with ketotic hy-
poglycemia and in 3 patients with successfully resected insulinoma. In
the patient with mesidioblastosis, pancreatectomy was performed and
insulin supplementation was introduced. However, seizures recurred af-
ter AED withdrawal, and carbamazepine was continued. In the control
group of 26 patients (1.66%) with insulin dependent diabetes mellitus
and epilepsy occasional episodes of hypoglycemia were unrelated to the
course of epilepsy and AED treatment was sustained.
Conclusion: Hypoglycemia is a rare but important cause of repeated
seizures that resemble the course of chronic epilepsy.
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COURSE OF ALPHA ATTENUATION TEST AFTER ONE
NIGHT SLEEP DEPRIVATION FOR PATIENTS WITH
EPILEPSY
M. Tomovic, N. Rajsic, Z. Sundric, and T. Ilic (Medical Military
Academy, Serbia and Montenegro)
Purpose: To evaluate the vigilance fluctuation of Alpha Attenuation
Test (AAT) in patients with epilepsy.
Method: A total of 94 patients, free of medication, were investigated
by means of combined neurophysiological techniques: the AAT after one
night sleep deprivation and sleep. Before the test, all patients evaluated
their sleepiness level by the Visual Analogue Scale. We measured the
course of changes of relative and absolute alpha power values six times
every two minutes in five second artifact free epochs in the channel O1-
A2 before and after eyes closure and calculated the quotient (the AAC,
Alpha Attenuation Coefficient).
Results: The epileptic population (34 subjects, 28 male) has similar
relative alpha powers before and after eye closure as the control group
(18.27% ± 4.8; 16.76% ± 2.5, Mean ± SD respectively). Absolute alpha
powers during epochs with eyes open showed a gradually increment
in both groups as subjects got sleepier, ranging from 26 to 86 picoW.
The same variable during eyes closed showed the fluctuation around
one line, but significantly higher values among patients with epilepsy.
The third variable, AAC, decreased in a significantly steeper decline in
patients with epilepsy (from 16 at the first measure to 5.7 at the sixth) in
comparison to the control group (7.6 to 5.2).
Conclusion: Patients with epilepsy have a much greater synchronisa-
tion of physiological activities, greater values of alpha power and greater
fluctuation of the vigilance level than the control group.
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SUDDEN UNEXPECTED DEATH IN EPILEPSY: A SEARCH
FOR RISK FACTORS
K. Kelly, S. Suratman, L. Stephen, N. Hitiris, G. Sills, and M. Brodie
(Epilepsy Unit, University Division of Cardiovascular & Medical Sci-
ences, Western Infirmary, Glasgow, Scotland)
Purpose: Mortality is higher in people with epilepsy than in the gen-
eral population. Sudden unexpected death in epilepsy (SUDEP) is a
major cause of concern with an estimated incidence of between 1:100
and 1:1000. We reviewed clinical variables in our SUDEP cases with the
aim of ascertaining risk factors.
Method: Deaths were identified in the 6000 patients registered with
the Epilepsy Unit at the Western Infirmary since 1982. SUDEP was de-
fined as the cause if the death was sudden, unexpected, witnessed or un-
witnessed, nontraumatic and nondrowning, with or without evidence of
a seizure having occurred and excluding documentation of status epilep-
ticus. For each case, two living controls were randomly matched for year
of birth (±5 years), gender and epilepsy syndrome by computed number
generation. Details of death were amassed from family practitioner and
hospital records, coroners’ reports, death certificates and witnesses.
Results: of 529 deaths, 62 (12%) were SUDEP cases [26 females,
36 males; mean age 36 years (range 18–77 years)]. Mean duration of
epilepsy was 18.4 years in cases compared with 11.5 years in controls
(p = 0.000). Early age of seizure onset was significantly associated with
risk of SUDEP (p = 0.000). There was a significant association between
the risk of SUDEP and having at least one seizure within the last year (p
= 0.007).
Conclusion: Clinicians counselling patients about SUDEP should
particularly target patients taking polytherapy with poorly controlled
seizures. A multicentre international approach to the pathophysiology
of SUDEP is essential to explore more closely the predictive factors in
individual cases.
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EPILEPSY WITH BILATERAL HIPPOCAMPAL HYPERIN-
TENSITY AND CELIAC DISEASE: COMORBIDITY OR A REAL
ASSOCIATION?
1I. Naldi, 1F. Bisulli, 2R. Canapicchi, 3U. Volta, 1R. Gallassi, 4B. Cruci-
atti, 4A. Pomes, 1F. Pittau, 1L. Licchetta, and 1P. Tinuper (1Department
of Neurological Sciences, University of Bologna, 2Department of In-
ternal Medicine, Cardioangiology And Hepatology. S. Orsola-Malpighi
Hospital, University of Bologna, 3MR Lab. S.Cataldo Research Area,
CNR Pisa, 4Neurophysiopathology and Cerebrovascular Diseases Divi-
sion, “S. Maria degli Angeli” Hospital, Pordenone)
Purpose: To describe a 20-year-old woman with celiac disease (CD),
bitemporal epilepsy with bilateral hippocampal hyperintensity and se-
vere memory impairment.
Method: At age 14 the patient presented 10–15 daily seizures with
partial seizures resistant to therapy. Since age 15 she has had gastroin-
testinal disturbances with a 25 kg weight loss during the last 4 years. At
age 19 a severe deficit of fixation memory appeared.
Results: Neurological examination was normal. Repeated neuropsy-
chological evaluations showed severe memory impairment in immediate
and delayed recall. Interictal EEG showed frequent epileptiform abnor-
malities over both temporal regions. Ten seizures with the same clinical
symptoms were recorded, starting independently from the two temporal
lobes. CT scan of the brain was normal. Brain MRI and functional MRI
with diffusion sequences disclosed a signal change on both hippocam-
pal gyri, hyperintense in T2 weighted sequences. Laboratory screening
revealed autoimmune thyroid disease, positivity for antigliadin, antien-
domisium and antitransglutaminase antibodies. PCR for HHV6 in the
blood and CFS was positive and oligoclonal bands were present in the
CFS. Duodenal biopsy confirmed CED.
Conclusion: We hypothesise an aetiopathogenetic relationship differ-
ent from the usual relationship between CED and epilepsy. In our pa-
tient CED might be the epiphenomenon of a more generalised immune
impairment with concomitant involvement of mesial structures. Another
possibility is comorbidity, i.e., two unrelated diseases in the same patient.
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The hippocampal alterations and memory impairment could be the con-
sequence of recurrent prolonged seizures.
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USE OF LEVETIRACETAM VERSUS OTHER ANTIEPILEPTIC
DRUGS IN THE NEUROSCIENCE INTENSIVE CARE UNIT
1,2,3J. Szaflarski, 1J. Meckler, 4,5M. Szaflarski, 1,2,6L. Shutter, 1,2,3M.
Privitera (1University of Cincinnati Department of Neurology, Cincin-
nati, OH, USA, 2The Neuroscience Institute, Cincinnati, OH, USA,
3Cincinnati Epilepsy Center, Cincinnati, OH, USA, 4Institute for the
Study of Health, University of Cincinnati, Cincinnati, OH, USA,
5University of Cincinnati Department of Family Medicine, Cininnati,
OH, USA, 6University of Cincinnati Department of Neurosurgery,
Cincinnati, OH, USA)
Purpose: NSICU patients require AEDs for seizure manage-
ment/prophylaxis. Newer AEDs have better side effects and safety pro-
files than older AEDs. We examined the presence of complications in
patients treated in NSICU based on AED use.
Method: We retrospectively reviewed charts of NSICU patients be-
tween 1 September 2003 and 30 September 2004 and examined frequen-
cies/percentage distributions for complications, AED prophylaxis before
admission, and AEDs administered. We used cross-tabulations/Pearson
chi-square tests to determine differences (p < 0.05) in complications by
AED(s).
Results: of 552 patients treated in NSICU 379 received AEDs. 358
(94.4%) were included in the study. 268 (74.9%) had complications
(2% hypotension, 24.9% encephalopathy, 12.3% toxicity, 2% rash, 7.5%
agitation, 1.1% ARF, 0.6% liver failure, 2.8% bleeding, 5.9% low
platelets, 59.2% other); 27.6% had ≥2 complications. 88 (24.6%) re-
ceived AED prophylaxis before admission: 42 (11.7%) phenytoin,∗ 11
(3.1%) levetiracetam,∗ and 39 (10.9%) other (∗alone or in combina-
tion with other AEDs). No differences in complications were noted
before admission. 33.3% of patients receiving levetiracetam monother-
apy in NSICU had complications vs 73–81% of other AED(s) includ-
ing levetiracetam in combination; among patients with complications,
1.9% received levetiracetam monotherapy vs 20–45% multiple AEDs
or phenytoin monotherapy (p = 0.001). Among specific complications,
encephalopathy occurred in 0/15 levetiracetam monotherapy patients vs
7–34% of other patients (p = 0.009).
Conclusion: This study describes complications and AED use in
NSICU. The retrospective nature of this study does not allow for conclu-
sions whether the complication rates are related to other AEDs vs leve-
tiracetam vs underlying neurological conditions, but patients treated with
levetiracetam had overall lower complication rates. Prospective studies
are needed to determine differences in complication rates by AED(s).
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FREQUENCY OF SEIZURES IN A COHORT OF PATIENTS
WITH ALZHEIMER’S DISEASE
S. Bernardi, A. Francia, C. Delena, N. Scaldaferri, A. Trebbastoni,
M. Morreale, and M. Prencipe (Policlinico Umberto 1◦-“La Sapienza
University”-Rome- Italy)
Purpose: To evaluate the frequency of seizures in patients affected
by Alzheimer’s disease (AD) and possible concomitant reasons for pre-
senting seizures in demented patients.
Method: We retrospectively examined records of AD patients who
had visited our memory clinic. For this study we considered patients
who had, at least, two neurological controls each year, registered in
our record, starting from January 2001. Missing data were collected by
phone and inviting patients for an outpatients visit. Of these patients, we
recorded sex, age, years of disease, severity, concomitant pathological
complaints, concurrent therapy as selective serotonin reuptake inhibitors
(SSRI), antipsychotic, acetylcholinesterase inhibitors (AChEI) and N-
methyl-D-aspartate (NMDA)-r antagonists drugs (time and dosage) and
history of epileptic seizures.
Results: We selected 120 patients with AD (according the NINCDS-
ADR-DA criteria). Up to now we found 9 subjects presenting partial or
generalised seizures or both (7.5%, mean age 72.1 ± 7.59, M/F = 6/3).
Generalised seizures were preponderant (8 patients). Seizures occurred
after an average of 3.8 years from dementia onset. Three patients were
treated with AChEI, 2 with AChEI and SSRI, 1 with NMDA-r antagonists
and antipsychotic drug, 1 with the new antipsychotic drug. The review
of the records is still in process.
Conclusion: Literature data related to seizure frequency in AD pa-
tients are very different (from 5 to 25%). Seizures usually occur in later
stage of the disease. Many factors may contribute to the development
of epileptogenesis in AD: neurotransmitters alteration, loss of inhibitory
neurons, changes in cellular excitotoxicity and also some medications
used in AD. We found early seizure onset in our patients. It might be re-
lated to the concurrent therapy as antipsychotic drugs, SSRI and AChEI
that lower the seizure threshold. Seizures are a dangerous complication
in the progression of AD and their occurrence should be specially con-
sidered in the therapy management of these patients. These data need to
be confirmed.
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EPILEPTIC SEIZURE AS A NEURO-PROTECTIVE
PHENOMENON
T. Arbab (A.S.S.T Orgnaisation And Institute, Khartoum, Sudan)
Purpose: Epilepsy has come to be regarded as a primary disturbance
of the central nervous system function, and medical treatments have
been directed at stabilisation of neuronal activity. The objective: epileptic
seizures; are they good or bad? Are they useful or harmful? The design:
randomised clinical, prospective with retrospective study combined with
met analysis study of 25 previously published papers.
Method: Fluorodeoxyglucose studies show that any activity in any
particular muscle group results in increased cerebral blood flow in the
motor area responsible for the activity. SPECT scans of 127 cases of
epilepsy were studied. 104 were temporal lobe, 4 were frontal lobe and
19 were complex seizures. I have classified Ictal SPECT scan studies
into two categories: 1) hyperperfusion pattern only, 2) combined patterns
of hyperperfusion with hypoperfusion. I assumed that in category (1),
hyperperfusion pattern only, may have resulted from reversible vascular
spasm with reversible vascular ischaemia.
Results: From the data given above we can evaluate the degree of
ischaemia in relation to epilepsy. Retrospective with prospective studies
showed that ictal hyperperfusion alone was 18% of the cases; 93% for
ictal hyperperfusion combined with interictal hypoperfusion study; 75%
for interictal hypoperfusion, (without considering ictal studies). Thus
epileptic seizures are associated with hyperperfusion to overcome an
aggravated brain ischaemic attack.
Conclusion: This study demonstrated that epileptic seizures are in
fact, valuable, important neuroprotective phenomena. Epileptic seizures
help restore intracranial blood flow and prevent severe brain ischaemia
and infarction; it is good and wise to treat epileptic seizures and not just
to stop them.
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EPILEPSIA PARTIALIS CONTINUA: A RARE AND EARLY
PRESENTATION OF DIABETES MELLITUS: KOSHENIKOV
SYNDROME
I. Singla (UPMC, Pittsburgh, USA)
Purpose: To recognise the clinical profile, differential diagnosis and
management of patients with Koshenikov Syndrome.
Method: We reviewed the clinical findings and laboratory data of our
patient who presented with epilepsia partialis continua (EPA) as a first
manifestation of diabetes. PUBMED literature was searched using terms
“Diabetes” “Epilepsy” “Koshenikov syndrome.”
Results: A 59-year-old male with no past history of diabetes presented
to our clinic with a 2 week history of jerking of his right arm. The
movements occurred approximately 15–20 times per hour and lasted
30–40 seconds. Laboratory tests revealed arterial pH 7.299, glucose 552
mg/dl. His diabetic ketoacidosis was treated with fluids and insulin. No
anti seizure medication was started. His movement disorder resolved
over 3–4 days.
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Conclusion: EPC is a rare and serious epileptic disorder. It involves
persistent, clonic movement of one localised muscle group; it is also
called Koshenikov syndrome. EPC is aetiologically related to metabolic
diseases such as hepatic encephalopathy, non ketotic hyperglycemia, di-
abetic ketoacidosis and infections such as Ramsussen encephalitis, HIV,
CMV and EBV. Seizures can be an initial manifestation of diabetes. In
diabetic patients presenting with seizures EPC was noted in 20%. In one
study EPC led to diagnosis of diabetes mellitus in 9 out of 21 patients. In
patients with diabetes it has been related to hyperglycemia, hyperosmo-
larity, hyponatremia and elevated Anti GAD-65 antibodies. Treatment of
EPC depends on the underlying disorder and the effect of antiepileptics
is disappointing. In diabetes, treatment consists of aggressive hydration
with fluids and insulin. A surgical approach has been recommended for
cases related to cortical dysplasia and brain tumours. Low frequency
transcranial magnetic stimulation (rTMS) has been considered a safe
and effective treatment in some cases of EPC.
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TONIC AUTOMATIC ATTACKS REVISITED: A VIDEO EEG
STUDY
I. Unterberger, A. Auckenthaler, J. Dobesberger, N. Embacher, G.
Walser, G. Luef, G. Bauer, and E. Trinka (Universita¨tsklinik fu¨t Neu-
rologie, Innsbruck, Austria)
Purpose: “Tonic automatic attacks” were first described by Oller Dau-
rella (1970) in patients with Lennox-Gastaut syndrome (LGS). The aim
of this study is to further delineate the electroclinical feature of this
unusual seizure type, which is currently not recognised in the ILAE
classification of epileptic seizures (1981).
Method: A retrospective analysis of all patients with generalised
epilepsies who were examined in our epilepsy monitoring unit from
1999–2005. Four patients demonstrated clinical and EEG patterns cor-
responding to the description of “tonic automatic attacks.”
Results: Four patients [4 w, mean age 28 yrs (range 21–38), mean
age at seizure manifestation 11.5 yrs (range 2–28 yrs)] were studied.
All patients showed mild cognitive dysfunction. MRI was normal in all
patients. A total of 86 seizures could be recorded. The main clinical fea-
tures were tonic phenomena of the neck and/or both upper limbs followed
by arrest, clouded consciousness and oral or gestural automatisms. Ictal
EEG demonstrated generalised activity (low voltage fast activity, spikes
and polyspike waves) in 3 patients with consecutive slowing in 2 and
slow sharp waves in 1. A right temporal alpha-theta activity and con-
secutive generalised slowing was recorded in 1. Interictal EEGs showed
generalised activity in all patients, an independent right temporal fo-
cal slowing was recorded in 1. We suggested a kryptogenic generalised
epilepsy in all patients.
Conclusion: Tonic automatic attacks should be classified as gener-
alised seizures. They can be observed in several kryptogenic generalised
epilepsies, not only in LGS.
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EARLY SEIZURES IN ISCHEMIC STROKE: RESULTS OF A
MULTICENTRE HOSPITAL-BASED STROKE REGISTRY
1P. Gallmetzer, 1B. Glawar, 2J. Ferrari, 3W. Lalouschek, and 1B.
Mamoli (1Ludwig Boltzmann Institute for Epilepsy, Neurological Hos-
pital Rosenhu¨gel, Vienna, Austria, 2Department of Neurology, Kranken-
haus der Barmherzigen Bru¨der, Vienna, Austria, 3Clinical Department
of Clinical Neurology, University Clinic of Neurology, University of
Vienna, Austria)
Purpose: To assess incidence and predictive factors of immediate and
early seizures after an ischemic cerebrovascular event (CVE).
Method: A total of 2581 patients (mean age 67.8 years) with a recent
CVE (including TIA) were enrolled in a prospective multicentre hospital-
based stroke registry, with a mean follow-up of 18.5 months. Seizures
occurring within the first 14 days after the CVE were classified as early
seizures, recurrence of unprovoked seizures as poststroke epilepsy. Im-
mediate seizures (occurring within 24 h after the CVE) were analysed
separately. Patients who had seizures before the CVE, were excluded
from statistical analysis.
Results: 2% of the patients (n = 52) experienced immediate seizures
and 2.5% (n = 64) experienced early seizures. Multivariate analysis
showed leukocytosis (>13G/litre) and a secondary parenchymal haem-
orrhage to be significantly (p < 0.05) associated with both immediate
and early seizures after the CVE. Moreover, early seizures were associ-
ated with an NIHSS>12. Poststroke epilepsy occurred in 21% (n = 11)
of the patients with a previous immediate seizure, and in 19% (n = 12)
of the patients with early seizures.
Conclusion: Secondary parenchymal haemorrhage was associated
with the occurrence of immediate- and early seizures after a CVE, and
stroke severity (NIHSS>12) with early seizures. A leukocytosis was
found in patients with immediate or early seizures which were thought
to be secondary to the seizure. Due to the low incidence of epilepsy after
immediate and early seizures, antiepileptic treatment does not seem to
be justified after a first immediate or early seizure. Acknowledgment:
The work was supported by a financial grant of Sanofi Synthelabo and
Bristol Meyers Squibb.
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SLEEP DEPRIVED WAKE-SLEEP EEG IN NEWLY DIAG-
NOSED GENERALISED IDIOPATHIC EPILEPSIES
G. Kiteva-Trenchevska (Clinic of Neurology, Clinical Center-Skopje,
Skopje, R. Macedonia)
Purpose: There are reports of delay in correct diagnosis of the syn-
dromes of generalised idiopathic epilepsies (GIE) with consequences
on patient morbidity/mortality. There are reports of nondiagnostic EEG
findings in the syndromes of GIE. The aim of the study was to present the
activation of interictal spike-wave (S-W) discharges and multiple S-W
discharges in newly diagnosed GIE in sleep deprived (SD) wake-sleep
EEG, but with a normal or nondiagnostic initial routine EEG.
Method: A total of 50 patients, 27 females and 23 males, mean age 18
years, standard deviation 5, with a clinical history consistent with newly
diagnosed GIE: juvenile myoclonic epilepsy (JME), juvenile absence
epilepsy (JAE), grand mal on awakening and generalised tonic–clonic
seizures (GTCS), had both routine EEG and sleep deprived single session
wake-sleep EEG for the presence of interictal/ictal S-W/multiple S-W
discharges. Somatoneurological and imaging findings were normal in
all patients.
Results: Initial routine EEG was normal or without specific findings
for the syndromes of GIE in all patients. SD produced activation of my-
oclonic seizures in 1 patient with JME and absences in 1 patient with JAE.
SD wake-sleep EEG produced activation of interictal generalised S-W/
multiple S-W discharges in all patients, with occasional frontocentral
appearance in JME, occasional focal appearance in 1 patient with GTCS
on awakening or asymmetric appearance in 11 patients with JME, and
GTCS. S-W discharges were recorded in wake and in non-REM sleep
EEG and in the transitional wake-sleep intervals. Interictal S-W dis-
charges during non-REM sleep caused sleep fragmentation producing
awakenings and shifts towards light non REM sleep stages.
Conclusion: Generalised S-W discharges were the only objective
findings in the SD wake-sleep EEG in newly diagnosed patients with a
clinical history of GIE, contributing to the epilepsy syndrome diagnosis.
Occasional focal and asymmetric appearance of S-W discharges should
not be misleading for the correct diagnosis of the GIE. Non REM sleep
EEG contributed to the evaluation of the impact of the S-W discharges
on the sleep structure.
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CONTRALATERAL SPIKES IN MESIAL TEMPORAL LOBE
EPILEPSY (mTLE): PREDICTORS OF UNFAVOURABLE SUR-
GICAL OUTCOME?
S. Bonelli, F. Zimprich, B. Seidl, E. Sto¨gmann, S. Lurger, and C. Baum-
gartner (Department of Neurology, Medical University of Vienna)
Purpose: In this study we wanted to address the question, whether the
presence of contralateral spikes can be considered as a negative predictive
factor in patients with TLE and unilateral hippocampal sclerosis as it has
been claimed recently.
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Method: In this retrospective study patients with intractable mesial
TLE, who underwent presurgical evaluation including high-resolution
MRI and prolonged video-EEG-monitoring prior to selective amygdala
hippocampectomy, were included. Interictal spikes were registered by
video-EEG-monitoring during a minimum of three days. Patients with
less than 25 spikes during this period were excluded. Spikes were divided
into predominant ipsilateral spikes (≥60% of all spikes originating from
the hemisphere with the hippocampal sclerosis) and predominant con-
tralateral spikes (<40% of all spikes originating from the side with the
hippocampal sclerosis). Postsurgical outcome was assessed one to ten
years after surgery according to Wieser’s classification.
Results: Ninety patients (45 with left sided (l) TLE, 45 with right sided
(r) TLE) met the inclusion criteria. Twenty-five patients with lTLE and
33 patients with rTLE presented with good postoperative outcome (class
I, Ia, 2); 23 patients with lTLE and predominant ipsilateral spikes had
a good postoperative outcome versus 12 patients with bad postoperative
outcome (class 3, 4, 5). Twenty-nine patients with rTLE and predominant
ipsilateral spikes presented with good and 11 with bad postoperative out-
come. When correlating postoperative outcome with contralateral spikes
we observed a striking difference between right- and left-sided TLE. In
lTLE there was a significant association of predominant contralateral
spikes with worse outcome (8 patients with bad versus 2 patients with
good outcome; p = 0.014); in rTLE 4 patients with contralateral spikes
presented with good and 1 with bad postoperative outcome.
Conclusion: In lTLE patients with predominant ipsilateral spikes
(≥60% per definition) corresponded with a significant better postop-
erative outcome than patients with contralateral spikes. These findings
were not observed in patients with rTLE.
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PURE SLEEP SEIZURES IN THE ELDERLY
L. Benavente, J. Salas-Puig, J. ´Alvarez-Carriles, S. Rodrı´guez, J. Vil-
lafani, and A. Garcı´a (Department of Neurology Hospital Universitario
Central De Asturias)
Purpose: To compare the risk of seizures while awaking (SWA) with
pure sleep seizures (PSS) in patients with an epilepsy onset under or
above 60 years of age.
Method: Fifty-nine patients with PSS followed at a Neurology De-
partment. Group A: 49 patients aged from 18 to 60 at epilepsy onset.
They suffered PSS for at least ten years. Group B: 10 patients aged >60
at epilepsy onset. They suffered PSS for at least five years. Clinical, EEG
and neuroimaging features for both groups were analysed and compared
by nonparametric Fisher test.
Results: Group A: mean age 48.8 (18–82). PSS for 24.9 years (10–
67). Epilepsy syndrome: undetermined 42.8%; focal cryptogenic 32.7%;
focal symptomatic 22.4%; generalised 2%. At the end of the follow-up
59.2% received monotherapy; 4.1% without any treatment. 34.7% (17)
suffered one or more SWA. 88.9% suffered seizures after withdrawal of
treatment. Group B: mean age 81.2 (71–88). PSS for 11.3 years (5–25).
Epilepsy syndrome: undetermined 50%; focal cryptogenic 40%; focal
symptomatic 10%. At the end of the follow-up 90% received monother-
apy; 10% without any treatment. Nobody suffered SWA. 80% suffered
seizures after withdrawal of treatment. Polytherapy (p < .05) and SWA
(p < .02) were only found in group A. There was no difference in re-
lapsing seizures (p < .5).
Conclusion: PSS in patients with age of onset over 60 years have a bet-
ter prognosis. They achieve good control of their seizures on monother-
apy and they have less risk of SWA. Nevertheless they have a similar
risk of relapsing than younger patients.
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INFLUENCE OF DEPAKINE TO THE CORRECTION OF MEN-
TAL AND PSYCHOEMOTIONAL DISORDERS OF EPILEPSY
Y. Madjidova, D. Nalibaeva, M. Makhmudova, D. Yangurazova, D.
Umargaliev, and N. Mukhamedjanova (Tashkent Medical Academy,
Tashkent, Uzbekistan)
Purpose: Epilepsy is a chronic disease of the brain, characterised by
regular unexpected assaults with disorders of movement, sensitive, veg-
etative, mental and psychic functions, occurring as a result of excessive
neuronal discharges. As known, the therapeutic aspects of epilepsy are
important and difficult. Among the new anticonvulsants, widespread over
recent years, the derivatives of valproic acid have a particular place, for
example, one of the better known, depakine. But the effects of depakine
to the correction of mental and psychoemotional functions, which are ex-
ponents of the quality of patients’ lives, are not estimated. Last year more
attention was allotted to not only anticonvulsant effects, but their influ-
ence on the quality of a patient’s life. The purpose of the investigation
was to study the efficiency of depakine-chrono to the course of epilep-
tic assaults in adults and its influence on mental and psychoemotional
functions.
Method: Forty-five epilepsy patients were inspected in the neurologi-
cal clinic of the Central Railway Hospital from 2003 to 2006. At the time
of including patients in the investigation we used diagnostic criteria of
epilepsy and epileptic assaults, according to the International Classifica-
tion of Epilepsies of 1989. The majority of patients have a generalized
epilepsy 57.3%; focal 25.5%; patients with different assaults 17.7%. Sep-
arate disorders of high cortex functions such as deterioration of memory,
attention and mental retardation until treatment were 86.8%. Investiga-
tion methods included: neurological, neurovisualisation (CT, MRT) and
neurophysiological inspection (EEG, ECHO, REG, USDG and other).
The Spielberger physiological test of was used for estimation of emo-
tional exponents, and test MMSE was used for estimation of mental
exponents in the dynamic of the treatment. Depakine was appointed as
monotherapy in the beginning dose 300–600 mg/day with gradual pro-
motion to middle therapeutical doses (1000–1500 mg/day). Estimation
of efficiency began from the 8th day of treatment.
Results: Common quantity of positive effects of treatment was 81.7%.
Negative effects of treatment were 19.3%, including the deterioration of
patients’ general condition (outside effects). Outside effects were ex-
pressed by nausea, vomiting, giddiness, shivering, and weight changes.
These disorders were lost by reducing the drug dose. According to the
investigations, results among patients treated by depakine, at the end of
the first month of therapy noted significant improvement of condition
with reduction of frequency and gravity of epileptic assaults, but com-
plete control of assaults was attained only in 72%. 30% of the patients
had an indication of reduced convulsive activity threshold and increase
in slow-wave activity in functional tests. Normalisation of EEG rhythms
with the disappearance of paroxysmal activity was noted in 61%. Dur-
ing the use of depakinmental functions improved and their dynamic was
27% on the 4th week of treatment and 40% on the 8th week of treat-
ment. The dynamic of emotional-personal disorders was more resistant
and comprised 15% on the 4th week of treatment and 32% on the 8th
week.
Conclusion: 1) Including depakine in the therapeutic scheme assists
the overcoming of therapeutic resistance by epilepsy patients. 2) Ac-
cording to the results of therapy, depakine is a high efficiency medicine
82.5% for patients with generalised and partial epilepsy. 3) Depakine
has not only an anticonvulsive effect, but it has a neurotrophic action,
expressed by normalisation of mental functions, and normal rhythmic
action, expressed by normalisation of emotional-personal functions. 4)
The significant anticonvulsive and normal rhythmic action of depakine
permits us to estimate this medicine as expedient, and able to improve
the quality of patients’ lives with epilepsy.
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SEXUAL DYSFUNCTIONS AND EPILEPSY: PILOT STUDY
R. Marak, R. Herzig, and P. Kanovsky (Department of Neurology, Uni-
versity Hospital, Olomouc, Czech Republic)
Purpose: Sexual dysfunctions (SD) occur in almost 50% of the pop-
ulation. They can be subclassified as organic (predominating in males)
and psychogonical (predominating in females). Neurological diseases
belong to the most frequent organic SD reasons. In epilepsy patients, SD
incidence ranges between 30–60%. The aim of this study was to assess
(1) the SD occurrence in epilepsy patients, and the associations between
SD occurrence and (2) epilepsy compensation and (3) treatment with the
second or/and third generation of antiepileptic drugs (AEDS).
Method: The set consisted of 15 patients (8 males, 7 females, aged
22–54, mean 36.3 years). 12 patients presented with focal, 3 with gen-
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eralised seizures. All patients were treated with the second or/and third
generation AEDS. Patients completed a shortcut version of the interna-
tional questionnaire of sexual function: International Index of Erection
Function and Female Sexual Function Index. The full international ques-
tionnaire was completed in case of the indication of possible SD in the
shortcut version.
Results: The following SD occurrence (serious/light/not present) was
found: 4/2/2 in males, 1/4/2 in females. Erection dysfunction in males
and absence of sexual appetence in females were the most frequent SD.
An indirect relationship was present between the degree of epilepsy
compensation and SD incidence. No apparent association between SD
severity and the use of the 2nd/3rd AEDS was found.
Conclusion: Both the importance of SD assessment in epilepsy pa-
tients, and the need for the best epilepsy compensation to reduce SD
occurrence was confirmed in this study.
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CORPORA AMYLACEA IN REFRACTORY MESIAL TEM-
PORAL LOBE EPILEPSY: CLINICOPATHOLOGICAL
CORRELATIONS
A. Radhakrishnan, C. Joseph, V V. Radhakrishnan, K. Radhakrishnan,
and P.S. Sharma (Sri Chitra Tirunal Institute for Medical Sciences and
Technology Thiruvananthapuram, Kerala, India)
Purpose: Although corpora amylacea (CoA) is recognised as a marker
of mesial temporal sclerosis (MTS), its significance in patients with
mesial temporal lobe epilepsy (MTLE) is uncertain. We undertook a
study to define the prevalence of CoA in the surgical specimens of pa-
tients with MTLE and assess its significance.
Method: We scored, in a semiquantitative scale, the presence of CoA
in the CA1sector of the hippocampus and graded as >10/HPF (grade 3),
6–10/HPF (grade 2), <5/HPF (grade 1) and none (grade 0). We com-
pared the demographic, clinical, neuropsychiatric, electrophysiological
and outcome data of patients with (CoA+) and without (CoA−).
Results: Out of 387 temporal lobectomy specimens from MTLE pa-
tients with ≥1 year postoperative follow-up, CoA was present in 129
(34.5%) specimens. The mean age at surgery of the CoA+ patient group
was significantly higher than that of CoA− group (24.5 yrs vs 31.8 yrs, p
< 0.0001). The mean duration of epilepsy prior to surgery in the CoA+
group was longer (21.7 yrs vs 15.5 yrs, p < 0.0001). Other variables like
age at seizure onset, febrile seizures, interictal and ictal EEG data and
postoperative seizure outcome did not differ between the two groups.
Psychiatric symptoms occurred more in the CoA+ group. Fourteen of
the 16 (87.5%) patients with major psychiatric comorbidities, showed
grade 2–3 deposition (p = 0.001).
Conclusion: Our results lend support to the progressive nature of
pathology in MTS, and the pathogenetic role of CoA in the psychiatric
morbidity of MTLE.
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EFFECTS OF FATIGUE ON THE QUALITY OF LIFE OF
EPILEPSY PATIENTS
1F. Erdogan, 2F. Soyuer, 2V. Senol, and 1F. Arman (1Erciyes Univer-
sity Medical Faculty Neurology Department, Kayseri-Turkey, 2Halil
Bayraktar Health Service Vocational Collage, Kayseri-Turkey)
Purpose: Fatigue and its effects are not adequately researched in
epilepsy. In this study the rate of fatigue and its effect on the quality
of life (QOL) have been assessed.
Method: Seventy epilepsy patients were evaluated. QOL was assessed
with QOLIE-89 and fatigue with fatigue severity scale (FSS). Patients
were divided according to whether or not they had fatigue and the QOL
values of the two groups were compared. The correlation analyses were
done between QOLIE-89 and FSS.
Results: The QOLIE-89 scores in patients with fatigue (n = 33) are
significantly lower than in patients without fatigue (n = 37). In par-
ticular, the mental and epilepsy related subscales of QOLIE-89 were
significantly lower in the fatigue group (p < 0.05). There was a statis-
tically significant correlation between the QOLIE-89 scores and fatigue
scores in the whole group (p < 0.05). When QOLIE-89 scores decreased,
fatigue scores increased.
Conclusion: Our findings suggest that there is very strong relation-
ship between the low QOL scores and fatigue in epilepsy patients. We
concluded that fatigue is a very important finding in epilepsy patients.
In clinical evaluation and the treatment of epilepsy, understanding the
reasons and quality of fatigue is very important for the improvement of
QOL in epilepsy patients.
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ATTITUDE OF EPILEPTIC PATIENTS TOWARD THE LABEL
EPILEPSY (SARAA): STUDY FROM SAUDI ARABIA
T. Obeid (King Khalid National Guard Hospital, King Abdulaziz Med-
ical City, Jeddah, Saudi Arabia)
Purpose: Saraa is the synonymous word for epilepsy in Arabic. It
means falling violently as if struck. The purpose of this study is to explore
the attitude, the acceptance and understanding of the meaning of Saraa
(epilepsy) among our epilepsy patients.
Method: Seventy consecutively seen patients in our Adult Epilepsy
Clinic were interviewed by the author using a structured questionnaire.
All patients were diagnosed as having had epilepsy for more than 2 years.
All patients were asked about their understanding and acceptance of the
term Saraa (epilepsy), and whether they would prefer an alternative label.
Results: There were 39 males, 31 females with age range 16 to 62,
mean age of 30 ± −16.5. Fifty one subjects (72.6%) understood Saraa
(epilepsy) as convulsions. Sixty-two patients (88.6%) preferred not to
disclose that they suffer from Saraa, while only 5 cases did not mind to
reveal their Saraa to other people. Most patients dislike the term Saraa
(epilepsy) and preferred other labels such as dizzy spells (27 subjects;
38.6%), convulsions (11 subjects; 15.7%), electro-cerebral disturbance
(11 subjects; 15.7%). Interestingly 22 patients believed that supernatural
power (Jinn) is one of the causes of epilepsy.
Conclusion: The term Saraa (epilepsy) is misinforming, stigmatis-
ing and disliked by most patients. A simple, informative, nonstigmatis-
ing and an internationally unified term like electrocerebral disturbance
should replace an obsolete label like Saraa (epilepsy). This will help to
take epilepsy “Out of the Shadows” and improve the social acceptability
of the disorder world-wide as aimed by The Global Campaign against
Epilepsy.
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NONINVASIVE DETECTION OF APNOEA
1P. Corbishley, 1E. Rodriguez-Villegas, and 2J. Duncan (1Imperial Col-
lege, UK, 2University College London, UK)
Purpose: Apnoea is not uncommon in generalised tonic–clonic and
prolonged complex partial seizures. Sudden unexpected death in epilepsy
(SUDEP) occurs in 1/200/year of those with refractory epilepsy. The
mechanism of SUDEP is uncertain. The leading contenders are central
or obstructive apnoea and cardiac asystole, as a consequence of seizure
activity. The prompt detection of apnoea would allow for resuscitation
to begin promptly and improve the possibility to avert death.
Method: A new technique for detecting apnoea is presented, for the
long-term noninvasive monitoring of respiration. The technique can be
used in home and residential care settings, and alert carers to the occur-
rence of potentially fatal apnoea. The physical implementation of the
technique will consist of a miniature sensor device placed on the user’s
neck with a micropower electronic chip realising a number of filters and
sorting algorithms to reject noise artifacts found in the domestic environ-
ment. A prototype has been tested, replacing the electronic components
for software with identical functionality of the final design. With noise
artifacts removed, a reliable detection of apnoea is achievable.
Results: The technique was evaluated in 10 healthy controls who
were able to maintain voluntary apnoea for 20–40 seconds. The device
reliably detected apnoea in individuals at rest, when moving and with
loud ambient noise.
Conclusion: Clinical trials of this device will begin in one year,
and will have wide applicability for longterm monitoring of those with
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epilepsy, and also for respiratory monitoring of those with respiratory
and other neurological diseases, and for monitoring of infants.
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MOLECULAR MECHANISMS OF MDR1 EXPRESSION IN HU-
MAN EPILEPTIC ASTROCYTES
1,2C. Perju, 3M. Agarwal, 1N. Marchi, 1V. Fazio, and 1D. Janigro
(1Center For Cerebrovascular Research, Cleveland Clinic Foundation,
USA, 2Kent State University, 3Department of Molecular Biology, Cleve-
land Clinic Foundation, USA, 4Molecular Medicine, Lerner College of
Medicine, Cleveland Clinic Foundation, USA)
Purpose: The multidrug transporter MDR1 is overexpressed in re-
sponse to a variety of signals, including stress or noxious stimuli. The
cell cycle and apoptosis controller p53 is also induced by stress and is
implicated in MDR1 gene expression. In cancer cells, both up and down
regulation of MDR1 in response to p53 have been reported. Epilep-
tic brain astrocytes express low levels of p53 but exaggerated levels of
MDR1, suggesting a negative regulatory link.
Method: Astrocytes cultured from resected cortices were analysed for
p53 and MDR1 protein levels prior or after transfection with p53 over-
expressing vectors. Hypoxia was mimicked by cell exposure to CoCl2.
Results: p53 basal expression did not correlate with MDR1 levels.
However, p53 transfection resulted in increased MDR1. CoCl2 (300 μM
for 18 and 48 hrs) caused a progressive and rapid increase in MDR1
expression (500% of control at 48 hours).
Conclusion: We confirmed that p53 expression in human epileptic
astrocytes is low. Since overexpression of p53 correlated with increased
MDR1 levels and hypoxia induced MDR1, it seems that p53 alone cannot
be the chief regulator of MDR1 in epileptic glia. We thus propose that
increased MDR1 expression may depend on low metabolic activity in
epileptic brain as suggested by positive correlation with CoCl2 exposure.
Supported by NIH HL51614, NS43284, NS38195, NS49514.
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EFFICACY OF LEVETIRACETAM: A RETROSPECTIVE
STUDY
M. Lo´pez-Go´ngora, A. Campolongo, A. Martı´nez-Domen˜o, C. Garcı´a-
Sa´nchez, and A. Escartı´n (Sant Pau Hospital, Barcelona, Spain)
Purpose: To assess the effectiveness of levetiracetam in a group of
adult patients with refractory epilepsy.
Method: Clinical records of patients in treatment with levetiracetam
were reviewed. We included 53 patients (29 women, 24 men) and col-
lected data regarding age, age at onset of epilepsy, previous treatment,
number of seizures, levetiracetam dosage and outcome.
Results: Mean age of participants was 37.49 years old (SD = 13.13),
and mean age at onset of epilepsy was 122 months SD = 110. Thirty
patients were on monotherapy, 17 on bitherapy and 6 were under treat-
ment with 3 antiepileptic drugs. The mean period of treatment with
levetiracetam was 16.6 months SD = 7.8. Dosages of levetiracetam dif-
fered: 5 patients received 1000 mg/day, 31 took 2000 mg/day, 16 started
with 2000 mg/day and then increased to 3000 mg/day and one started
with 2000 mg/day and increased to 3500 mg/day. Findings showed that
47% of patients (confidence interval 33.7–60.7) were seizure free for at
least 7 months SD = 5.2, 32.07% had fewer seizures, 11.3% showed no
changes, and 9.4% had stopped taking levetiracetam, mainly due to lack
of efficacy.
Conclusion: These results support previous findings regarding the
efficacy of levetiracetam as add-on treatment for refractory epilepsy,
and the few side effects of the treatment. This study is ongoing in order
to obtain a larger sample and to assess long term results of treatment
with levetiracetam.
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EPILEPSY AND NEUROCYSTICERCOSIS IN QATAR
B. Mesraoua, H. Soub, Y. Eldeeb, A. Naveed, D. Deleu, and A. Hamad
(Hamad Medical Corporation, Doha, Qatar)
Purpose: Taenia solium neurocysticercosis (NCC) is increasingly be-
ing reported in patients suffering from epilepsy. However, its true preva-
lence and association with late onset epilepsy is largely unknown in the
Middle East particularly in Qatar. Our study will demonstrate that NCC
is also a major cause of first seizures in an increasingly young population
in Qatar.
Method: This is a retrospective and prospective study, based on hos-
pital populations. Neurocysticercosis was diagnosed on the basis of the
following: consistent radiographic findings and a compatible epidemio-
logic and clinical history (without diagnostic serological findings). All
individuals with a suspicion of NCC at the emergency department were
admitted for further investigations and treatment. Complementary ex-
aminations included an awake EEG, a CT SCAN or MRI of the brain
and serum and CSF studies.
Results: Fifty patients were diagnosed as having NCC on the basis of
the above criteria. A large majority of patients were male (98%, most of
them expatriate from the Asian subcontinent). At first presentation, most
of the patients (80%) were older than 20 years. 96% of them presented
with seizures. Neurological findings, brain CT and MRI abnormalities,
EEG as well as cysticidal therapy and seizure presentations and outcome
will be discussed.
Conclusion: This study confirms that NCC is a major cause of
epilepsy in a hospital based (increasingly young) population in Qatar.
NCC is a relatively new disease in this country, imported recently from
areas where NCC is endemic in a growing Indian subcontinent work
force. However, the prognosis of NCC related seizures is good.
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INCIDENCE OF EPILEPTIC SEIZURES ASSOCIATED WITH
ISCHEMIC STROKE
1,2L. Iuhtimovschi and 1S. Groppa (1State Medical and Pharmaceutical
University “N. Testemitanu,” Chisinau, Moldova, 2National Practical-
Scientific Center of Medical Emergencies, Chisinau, Moldova)
Purpose: Patients who suffer ischemic strokes might develop subse-
quent epileptic seizures or symptomatic vascular epilepsy. Our aim was
to determine the frequency and predisposing factors for occurrence of
epileptic seizures in patients with cerebral ischemic stroke.
Method: We studied patients with acute or previously supported is-
chemic stroke admitted during a 5-year period to the Neurology Depart-
ment of Emergency Hospital, with stroke or epileptic seizures related to
stroke. All patients were given a clinical examination, laboratory tests,
EEG and cerebral CT.
Results: In our study 76 patients (mean incidence 6.37%) developed
epileptic postischemic seizures, 39 male and 37 female. Twenty-four
patients (37.6%) had early seizures (during first week) and 52 (68.4%)
late seizures (after one month or more). Ischemia involved the cerebral
cortex in 58 patients (76.3%). EEG changes with slow rhythms and
pathological waves were found in 48 patients (63.2%).
Conclusion: Mean incidence of epileptic poststroke seizures in our
study is 6.37%. There is no significant gender prevalence in the studied
cohort. Late seizures (after one month or more) developed more often
than early seizures. Cortical involvement is associated with a higher risk
of seizures and epilepsy. EEG changes are predictors of seizures.
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LEVETIRACETAM MONOTHERAPY IN PATIENTS WITH
SYMPTOMATIC FOCAL EPILEPSY AND ALCOHOLIC
CHRONIC EXOTOXICOSIS
S. Romito, T. Zanoni, and G. Moretto (Neurology Unit –Ospedale Borgo
Trento, Verona, Italy)
Purpose: To evaluate levetiracetam efficacy in 3 patients with symp-
tomatic focal epilepsy and a history of alcohol abuse.
Method: Three patients with a 10-year history of alcohol abuse,
with posttrauma (2) and postsurgery (1) focal epilepsy have been eval-
uated to verify levetiracetam efficacy in reducing seizures along with
its effect on liver functions. Patients characteristics: 1) B.L. (female)
aged 64, with posttrauma epilepsy since 2000 and hepatopathy evolving
to cirrhosis (transaminases were up to 3 folds over normal). Seizures
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occurred monthly. 2) T.M. (male) aged 41, with posttrauma epilepsy
since 1995 and hepatic steatosis (transaminases were up to 6 folds over
normal). Seizure frequency: 3–4 episodes/year. 3) B.G. (male) aged 58,
with epilepsy since 1988 following surgery for right frontal basal AVM
and with hepatopathy evolving to cirrhosis (transaminases were up to 4
folds over normal). Seizures occurred monthly. Patients were all alcohol
abusers. At our initial evaluation, patients were on phenobarbital (100
mg/die). Due to unsatisfactory therapeutic effects and to minimize the
effect of AED treatment on livers compromised by alcohol abuse, phe-
nobarbital was replaced with levetiracetam (mean dosage 1666 mg/die).
Results: Patient 1 and 2 have respectively been seizure free for 4 and
12 months. Patient 3 had only 1 seizure during the last 6 months. Lev-
etiracetam had no impact on liver functions as values of transaminases
significantly decreased in 2 cases and were normalised in 1 case.
Conclusion: Our limited experience suggests that levetiracetam may
be considered as a valid treatment for epilepsy patients with a history of
alcohol abuse.
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SEMIOLOGY OF GRAND MAL SEIZURES
J. Dobesberger, F. Aichner, G. Walser, N. Embacher, I. Unterberger, G.
Luef, and E. Trinka (Innsbruck Medical University, Clinical Department
of Neurology, Innsbruck, Austria)
Purpose: Grand mal (GM) seizures (SZs) are classified as generalised
tonic clonic SZs according to the current ILAE classification. (Com-
mission on Classification and Terminology of the International League
Against Epilepsy. Proposal for revised clinical and electroencephalo-
graphic classification of epileptic seizures. Epilepsia 1981;22:489–501.)
However, the sequence of GM SZs is not stereotyped and only a few stud-
ies investigated the varied semiology. Therefore, we aimed to describe
the semiology in detail.
Method: We retrospectively evaluated all video-EEG recordings of
patients (pts) admitted to the Epilepsiemonitoringeinheit of the Univer-
sita¨tsklinik fu¨r Neurologie Innsbruck, Austria, over a period of 3.5 years
with primary generalised tonic–clonic SZs (GM).
Results: In 19 pts (9 M/10 W), median age 31 yrs, range 13 to 63),
36 GM were registered. Five pts had idiopathic generalised epilepsy
(IGE), 7 symptomatic or cryptogenetic generalised epilepsy (SGE) and
7 had primary generalised seizures without a clear syndromatic diagnosis
(“unclassified” group). According to the sequence of the tonic and clonic
phases, four GM seizure types were defined: I tonic–clonic (n = 15), II
clonic–tonic–clonic (n = 10), III at least two tonic and clonic phases
(n = 7), IV mixed tonic-(myo)clonic phase (n = 4). Pts with IGE mainly
showed SZ type II (p < .005), while pts with SGE exhibited all SZ types
and pts in the “unclassified group” mostly had type I GM (p < .005).
Pts with IGE showed focal/lateralising signs in 3/7 SZs, pts with SGE
in 12/15 SZs and pts with unclassified epileptic SZs in 13/14 SZs.
Conclusion: The semiology of GM is not homogeneous; four different
GM types are described. The term “generalised tonic–clonic seizures”
is misleading and does not apply to all GM.
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EFFECT OF ANTIEPILEPTIC DRUG MONOTHERAPY ON
SEXUAL FUNCTION IN MEN SUFFERING FROM EPILEPSY
1R. Kuba, 2M. Pohanka, 1I. Novotna´, 1J. Za´kopcan, and 1I. Rektor
(1Department of Neurology, Masaryk University, St Anne’s Hospital,
Brno, Czech Republic, 2Department of Sexuology, St Anne’s Hospital,
Brno, Czech Republic)
Purpose: We compared the incidence of sexual dysfunction and blood
hormonal profile in males suffering from various types of epilepsy and
taking various antiepileptic drugs (AEDs) in monotherapy.
Method: We analysed prospectively sexual functions and hormone
blood levels in 42 male patients (age ranged 24–45 years, with average
of 34.6 ± 4.2 years) with both focal and generalised epilepsy treated by
monotherapy AEDs. Seventeen patients received carbamazepine (CBZ),
16 patients one of the newer antiepileptic drugs (NAEDs) [8 patients
lamotrigine, 4 patients levetiracetam and 4 patients topiramate] and 9
patients received valproates (VPA). We used the Czech version of the
structured questionnaire called “International Inventory of Erectile Func-
tion” (IIEF) to assess patient’s sexual functions. The subscales of this
questionnaire evaluate separately the erectile function (IIEF I), orgasmic
function (IIEF II), sexual desire (IIEF III), satisfaction of sexual inter-
course (IIEF IV) and overall satisfaction with sex life (IIEF V). In all pa-
tients the following blood tests were performed: quantitative assessment
of blood levels of prolactin (PRL), total testosterone (total-T), free an-
drogen index (FAI), sexual hormone binding globulin (SHBG), estradiol
(E2), dihydroepiandrosterone–sulfate (DHEAS), progesterone (PRG),
follicle stimulating hormone (FSH) and luteinising hormone (LH). All
these quantitative laboratory data were correlated with the type of the
treatment and results of IIEF. Chi-quadrate and Wilcoxon tests were
used for statistical analysis. p < .05 was considered to be statistically
significant.
Results: Although the proportion of age, duration of epilepsy, type
of epilepsy and seizure frequency were comparable in all “treatment
groups,” we found the higher incidence of all types of sexual dysfunction
(IIEF I–III) and lower score of overall satisfaction with sex life (IIEF
V) in patients treated with CBZ in comparison to patients treated by
NAEDs (p < .01). Similarly we found the higher incidence of erectile
dysfunction (IIEF I), disorder of sexual desire (IIEF III) and lower score
of overall satisfaction with sex life (IIEF V) in patients treated with VPA
in comparison to patients treated by NAEDs (p < .05). In patients treated
by CBZ we noticed the significant increase of SHBG and decrease of
DHEAS and FAI in comparison to patients treated by NAEDs and VPA
(p < .01). We did not find any difference in hormonal profile between
patients treated by VPA and NAEDs.
Conclusion: Our study showed that males with epilepsy treated by
monotherapy of NAEDs (lamotrigine, levetiracetam, topiramate) have
greater sexual functions and are more satisfied with their sex life than
those treated by CBZ or VPA.
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TREATMENT CHALLENGES IN PATIENTS WITH EPILEPSY
ASSOCIATED WITH ARTERIOVENOUS MALFORMATION
1D. Hodorog, 2F. Danciu, and 1F. Stefanache (1University of Medicine
and Pharmacy Gr.T.Popa, Iasi, Romania, 2Clinical Hospital Sf. Treime,
Ist Clinic of Neurology, Iasi, Romania)
Purpose: Epilepsy is an important manifestation of cerebral arteriove-
nous malformations (AVMs). Epileptogenic and ruptured AVMs surgery
is supposed to allow a good control of epilepsy. The failure to eliminate a
seizure disorder after AVMs surgical treatment is presented in our cases.
Method: We report 5 cases of epilepsy associated with cerebral vas-
cular malformations. All patients were admitted to the Clinic of Neurol-
ogy for partial motor seizures with secondary generalisation or primary
generalised epilepsy. EEG, CT and MRI were performed. The patients
were submitted to surgery for vascular malformation and they received
anticonvulsant therapy.
Results: In 2 cases the examination showed mild pyramidal signs.
Laboratory examinations were within normal limits. EEG was abnormal
in 2 cases with generalised synchronous discharges of spikes. Computed
tomography (CT) of the brain revealed a hyperdense lesion with contrast
enhancement and corticosubcortical topography in 2 cases. IRM angiog-
raphy revealed vascular malformation in the other 3 cases. The patients
where put on anticonvulsant treatment and all cases were submitted to
surgery. The patients continued anticonvulsant therapy after surgery and
remained seizure free for a few months, when new seizures occurred.
Conclusion: These cases prove that surgical treatment in the AVMs
is not always efficient to prevent new seizures. The localisation and
architectural characteristics of the AVM might contribute to the risk of
post surgical seizures.
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SUDDEN UNEXPECTED DEATH IN EPILEPSY: PILOT STUDY
IN THE WEST OF IRELAND
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1,2D. O’Rourke, 1M. Hennessy, and 2N. Delanty (1University College
Hospital Galway, Co. Galway, Ireland, 2Beaumont Hospital, Beaumont,
Dublin, Ireland.)
Purpose: To review initial data from the National Study on Sudden
Unexpected Death in Epilepsy (SUDEP).
Method: Cases were ascertained by contacting general practitioners
and neurologists, to report epilepsy-related deaths from October 2000 to
September 2005. For all cases identified, we reviewed medical records
and postmortem reports, where available, to determine circumstances of
death, and to classify as definite, probable, possible and non-SUDEP
deaths, and to identify any potential risk factors.
Results: Eleven cases of epilepsy-related death were identified in the
pilot area (population 380,297). Four were definite SUDEP, 1 probable
SUDEP, 1 possible SUDEP, 1 non-SUDEP death, and 5 cases had in-
sufficient data to classify at present. Details of ten additional cases are
pending. In the 5 cases of definite or probable SUDEP (2 male, 3 female)
average age at death was 30.2 years (range 6–45 years). All had a history
of generalised convulsions. One had daily seizures, 2 had more than one
seizure per week, 1 had more than one seizure per month, and 1 patient
had been seizure free for more than two years. Three patients were on
polytherapy. Only 2 of 5 patients had attended a neurologist.
Conclusion: In this retrospective case series, which represents a
subanalysis of an ongoing population-based incidence study, 5 of 11
epilepsy-related deaths were due to definite or probable SUDEP. Of
note, 60% had never seen a neurologist, but the sample size was small
and further population-based data will be required to confirm these re-
sults.
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PROGNOSIS OF EPILEPSY DUE TO NEUROCYSTICERCOSIS:
A LONG TERM FOLLOW-UP
1,2,3,4P. Trevisol-Bittencourt, 2,4A. Eckeli, 2,4F. Dach, 1,3A. Marasci-
ulo, 3F. Brohering, 1,3P. Tomaselli, 2,4C. Collares, and 4M. Molinari
(1Universidade Fedederal de Santa Catarina, Brazil, 2Hospital Santa
Tereza, Brazil, 3Hospital Universita´rio, Brazil, 4Clı´nica Interdisciplinar
de Epilepsia do Estado de Santa Catarina, Brazil)
Purpose: Evaluate the prognosis of symptomatic epilepsy due to cere-
bral calcifications secondary to neurocysticercosis (NCC).
Method: An observational and transversal study of 83 patients with
secondary epilepsy due to calcifications caused by NCC, who have been
followed up as outpatients at a multidisciplinary centre for epilepsy care
in southern Brazil from 1991 to 2002. The diagnoses were based on clini-
cal history, EEG findings, epidemiological settings and neuroimage (CT
scan and MRI) to register the calcifying process. NCC were classified
according to Del Bruto as definitive, probable and possible, but only the
first two were included in this study. Epileptic seizures, epileptic syn-
dromes, active and in remission epilepsies were classified according to
that proposed by the Commission on Classification and Terminology of
the International League Against Epilepsy (ILAE). Kaplan-Meyer test
was applied to the data.
Results: Of the 83 patients included in the reported study, 53 (63.9%)
were women. The mean age of the whole group was 30 ± 10.4 years
[10–57] at admission. They were followed during an average 7.4 ± 2.5
years. CT scans showed a lesion in all patients, 51 (61.4%) presented
multiple lesions while 32 (38.6%) showed 1. The frequency and severity
of seizures decreased as the study came to an end. Actually, epilepsy went
into complete remission in 30.2% of patients, 12% were in withdrawal of
antiepileptic drug therapy, and 57.8% still presented seizures. Although
an important decrease of seizure frequency and severity were seen in
most of those patients suffering from active epilepsy, the Kaplan-Meyer
test showed half of the sample went into remission after 8.3 years of
starting seizures.
Conclusion: NCC is a major cause of epilepsy in Latin American
countries. There is an ancient proverb among neurologists: “epilepsy
due to NCC is easy to treat but difficult to cure.” However it should be
reviewed, because in our sample, epilepsy related to NCC was a benign
condition. It seems that the natural history of this symptomatic epilepsy
is going into remission of seizures as the time goes by.
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LONG-TERM OUTCOME OF SURGERY IN PATIENTS WITH
REFRACTORY TEMPORAL LOBE EPILEPSY
1R. Kuba, 1I. Tyrlı´kova´, 2Z. Nova´k, 1M. Bra´zdil, 2J. Chrastina, 1J.
Kocvarova´, 1I. Novotna´, and 1I. Rektor (1Department of Neurology,
Masaryk University, St Anne’s University Hospital, Brno, Czech Re-
public, 2Department of Neurosurgery, Masaryk University, St Anne’s
University Hospital, Brno, Czech Republic)
Purpose: Our retrospective study was aimed at evaluating the five-
year outcome in surgically treated patients with refractory temporal lobe
epilepsy (TLE).
Method: We had a group of 39 patients (24 males and 15 females
aged 15 to 55 years) with refractory TLE who underwent surgery in
our centre from 1996 to 2000. The patients were assessed according
to Engel classification annually for 5 years. All the patients underwent
MRI evaluation before the surgery. Hippocampal sclerosis was found in
20 of them. Amygdalo-hippocampectomy was performed in 12 patients;
anterior medial temporal resection was performed in 10 patients and
tailored lesionectomy in 17 patients.
Results: According to the Engel classification we obtained the fol-
lowing results:
After 1 year: I = 77%, II + III = 23%, IV + V = 0%; after 2 years:
I = 82%, II + III = 15.5%, IV + V = 2.5%; after 3 years: I = 77%,
II + III = 20.5%, IV + V = 2.5%; after 4 years: I = 74%, II + III =
23.5%, IV + V = 2.5%; after 5 years: I = 62.5%, II + III = 35%, IV
+ V = 2.5%. 24 patients achieved the “Ia” classification one year after
the surgery. Sixteen (66.5%) remained in the “Ia” category for the five
years.
Conclusion: These excellent outcomes of epilepsy surgery measured
by Engel classification in patients with TLE remained relatively stable
over the first three years after surgery. A slight decrease in the number of
patients classified “I” and an increase in the number of patients classified
“II” + “III” in the fourth and fifth years after surgery is associated with
a reduction of antiepileptic drugs in about 50% of them. In spite of the
said decrease, surgery of refractory TLE is an effective procedure in
these patients.
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EPILEPSY OF THE TEMPORAL LOBE: CASE REPORT
E. Obdrzalkova and P. Kanovsky (Departement of Neurology, University
Hospital Olomouc, Czech Republic)
Purpose: Temporal epilepsy is a frequent diagnosis. Nevertheless, it
can cause diagnostic problems because it can imitate other neurological
disorders.
Method: A 34-year-old female had a history of two generalised tonic–
clonic epileptic seizures in 2000. Treatment with topiramate was started
and afterwards she was without epileptic manifestation. In 2003 the med-
ication was changed to lamotrigine (LMT). After an interval of several
months a low back pain occurred with widespread pain irritation of the
right leg, followed by spontaneous semiflexion of the hip and the knee,
with pronation of the foot. Since 2003 the frequency of these symptoms
has increased, finally occurring every night. Nonsteroid antiflogistic and
analgesic-anodyne drugs were added to the therapy, but no effect was
observed. She was admitted to our department in November 2005. A
physical examination, x-ray and MRI of the lumbal spine, ultrasound
examination of the pelvis and electromyography were normal. Serology
for viruses and IgM Borrelia antibodies were negative as well as cere-
brospinal fluid analysis. Because of persisting symptoms and unknown
aetiology electroencephalography was performed, in which a focus of
specific activity at the left frontocentral area was found. An analogous
pathological finding with spike-waves episodes occurred also in the EEG
after sleep deprivation and during the clinic seizure on video-EEG. The
dose of LMT was increased, and clonazepam was gradually discontin-
ued.
Results: The symptoms resolved completely after four weeks of
boosted antiepileptic therapy.
Conclusion: Temporal epilepsy with partial simplex seizures can
rarely imitate vertebral problems. This can lead to mistaken diagnosis
and long-term unsuccessful treatment.
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PSYCHOLOGICAL EVALUATION OF QUALITY OF LIFE IN
SEIZURE-FREE EPILEPSY PATIENTS
1S. Gasverde, 1M. Coletti Moja, 2L. Ostacoli, 2P. Furlan, 2M. Agnesone,
1L. Durelli, and 1M. Genesia (1Neurology Department, Ospedale S Luigi
Gonzaga, Orbassano, Italy, 2Psychiatry Department, Ospedale S Luigi
Gonzaga, Orbassano, Italy)
Purpose: Epilepsy and its treatment have a great chronic impact on
the life of those affected. Epilepsy patients are mostly young and the di-
agnosis sometimes has a stigmatising nature. Quality of life (QoL) is an
important tool for understanding the distress of epilepsy patients, even
when seizures are well controlled. The purpose of this study is to in-
vestigate the psychological, social and physical aspects of health related
quality of life in patients suffering from epilepsy, who have been seizure-
free for the past year, and to identify patients who are at risk of developing
an adjustment disorder. Moreover, we correlated QoL and INTERMED,
identifying patients at risk of poor QoL and high complexity of care.
Method: Fifty patients, seizure-free for the past year, aged 18 to 60,
without cognitive deficits and 50 age matched controls were enrolled.
The patients were invited to a clinical interview about multidimensional
domains of QoL. We used the INTERMED interview to assess biopsy-
chosocial factors of risk. At the end of the interview, QoL was assessed
and quantified using a self-completion questionnaire, the Quality of Life
in Epilepsy–31 (QOLIE-31), a sensitive measure of the impact of the
condition on daily life. CES-D and Zung Anxiety Scale were completed
by patients to determine the contributions of depression and anxiety on
quality of life.
Results: There was a good correlation between QoL test scores and
seizure control.
Conclusion: In conclusion psychopathological assessment is crucial
in evaluating drug epilepsy therapy benefits, in addition to standard neu-
rological evaluation and seizure control.
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COHERENCE FLUCTUATIONS OF BACKGROUND EEG AC-
TIVITY HIGHER IN GENERALISED EPILEPSY THAN IN TEN-
SION HEADACHE
O. Vysata and L. Pazdera (Neurocenter Caregroup, Rychnov nad Knez-
nou, Czech Republic)
Purpose: In the present study, the difference between coherence fluc-
tuations in the group of 20 patients with generalised epilepsy and the
group of 20 tension headache patients is studied. Higher coherence fluc-
tuations may reflect pathophysiological processes involved in human
epilepsy.
Method: EEG coherence analysis has been used to estimate the dy-
namics of background EEG activity in a group of 20 patients with pri-
mary or secondary generalized epilepsy and 20 patients with tension
headache. Low artifact, 31 sec. segment of EEG background activity
was manually selected for each patient. Rectified difference between 1
second segments were estimated for all pairs of 19 scalp electrodes in the
range 1–32 Hz. Wilcoxon-Mann-Whitney test was used for comparison
of coherence fluctuations between both groups.
Results: Significantly higher fluctuations in the range 3–15 Hz and
19–32 Hz were found in the epilepsy group. The mean coherence differ-
ence between both groups was 0.016. The most prominent differences
were found for frequencies 7–8 Hz and 24 Hz.
Conclusion: These results can be interpreted as a functional decou-
pling of distant brain sites followed by an abnormally high recoupling
in epilepsy patients, as also observed in other studies (F. Wendling et al.
2003). They may reflect the concept of “disruption” that is complemen-
tary to that of “activation,” both giving insights into our understanding
of pathophysiological processes involved in human epilepsy.
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GENDER DIFFERENCES IN THE ASSESSMENT OF LEVEL OF
NEUROTIZATION AND QUALITY OF LIFE INDICES IN PA-
TIENTS WITH TEMPORAL LOBE EPILEPSY
V. Mikhailov, E. Eroshina, and S. Gromov (St. Petersburg V.M.
Bekhterev Psychoneurologica Research Institute, St. Petersburg,
Russia)
Purpose: To study the differences in the level of neurotisation and
quality of life indices in male and female patients with temporal lobe
epilepsy.
Method: One hundred patients with temporal lobe epilepsy (47 males
and 53 females aged from 15 to 50 years) were studied. To assess the
level of neurotisation of the patients, the J. Aleksandrowicz Neurotic
Disorders Inventory was used. QL was assessed using the core module
of the WHOQOL-100 questionnaire. QL was assessed dynamically: at
admission and at discharge, after the completion of a restorative therapy
course. Drugs in the carbamazepine and lamotrigine group were the most
often used in the pharmacotherapy of patients.
Results: The severity of neurotisation in the females was higher than
that in the males on the majority of the scales. Differences were found on
the affective strain scale and on the scales of depressive, neurasthenic,
hypochondriac, and somato-vegetative disorders. Statistically significant
differences were found on the hysteric disorders scale (p < .05). The
females assessed their QL lower than the males, except for the social
relationships and spirituality domains. The mean physical domain index
in the females was significantly lower than in the males (p < .05). The
overall QL increased in the course of restorative therapy from 84.92 to
89.95 scores in the males and from 83.96 to 84.6 scores in the females.
Conclusion: Females with temporal lobe epilepsy, in comparison with
male patients, have a higher level of neurotisation and lower subjective
QL indices.
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SECONDARY EPILEPSY AFTER ISCHEMIC ICTUS IN A CON-
TEXT OF FAMILIAL ANGIOPATHY
1M. Macovei, 1C. Popa, and 2D. Pantelimon (1Institute of Cerebro-
Vascular Diseases, Bucharest, Romania, 2CMI Neurologie, Iancului
Policlinic, Bucharest, Romania)
Purpose: The authors studied 7 cases of facomatosis, which were
investigated clinically and paraclinically through MRI and Angio MRI.
The clinical picture in all cases suggested neurocutaneous melanosis:
1) giant pigmented naevi with a marked tendency to originate from the
posterior midline–cervical region predominantly; 2) smaller, multiple
pigmented naevi on the thoracal region and limbs; 3) blue naevi with left
radicular D6–D8 topography. In all cases patients presented repetitive
TIA or pseudo-TIA (haemometakinesia phenomenon), in time lacunar
infarcts in carotidian and vertebro-basilar territory. Two cases presented
cicatricial epilepsy after middle cerebral artery; in 3 cases infarcts have
pseudotumoural evolution, 1 in the left carotid artery, and 2 in the right
carotid artery territory, with focal seizures and secondary generalisation.
Method: The biopsy of the pigmented naevi in 3 cases suggested the
junctional naevocellular naevus. The paraclinical investigations were
normal: CSF, VEP, AEP, Doppler and echocardiography. MRI revealed
infarcts of different ages. Immunological investigations excluded para-
sites vasculitis, brain microabcess, and other vascular diseases.
Results: We concluded that the ischemic infarcts with secondary
epilepsy were determined by a familial genetic angiopathy.
Conclusion: Both the melanin forming cells and the cells from the
muscular tissue of the cervical arteries have a common embryological
origin in the neural crest. The authors suggested the pathogenic role of
the cells with origin in the neural crest in programming infarcts.
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LEVETIRACETAM THERAPY IN PATIENTS WITH BRAIN
TUMOURS AND EPILEPSY
1M. Maschio, 2F. Albani, 2A. Baruzzi, 1A. Zarabla, 1L. Dinapoli,
1A. Pace, 1A. Pompili, 1C. Carapella, 1E. Occhipinti, and 1B. Jan-
dolo (1Epilepsy Outpatient’s Centre, Department of Neuroscience and
Cervical-Facial Pathology, Rome, Italy, 2Laboratory of Clinical Neu-
ropharmacology, University of Bologna, Bologna, Italy)
Purpose: Epilepsy is common in patients with brain tumours; tumour-
related seizures are often difficult to control, with treatment complicated
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by frequent interactions between antiepileptic drugs (AEDs) and anti-
neoplastic agents. Levetiracetam (LEV) is a new AED with a unique
mode of action and no clinically relevant pharmacokinetic drug inter-
actions. This open study investigated the safety and efficacy of LEV in
patients with brain tumours and epilepsy.
Method: Patients with supratentorial gliomas were included. LEV
1500–3000 mg/day was added to existing AED treatment for persisting
seizures. Patients visited the Outpatient Centre every 1–3 months and
were followed for 5–47 months (mean 22.1, median 17 months).
Results: 19 patients (6 females; age 28–70, mean 48 years) with
brain tumours (7 glioblastoma multiforme, 2 anaplastic astrocytoma,
9 low grade astrocytoma, 1 meningioma) were enrolled. Seizure types
were simple partial in 4 patients, complex partial in 4, complex par-
tial with secondary generalisation in 7, and generalised tonic–clonic in
4. Eight (42%) patients became seizure-free (seizure-free period 5–33,
mean 14.9, median 10.0 months); 5 (26%) patients showed ≥50% seizure
frequency reduction. Seizure frequency was unchanged in 5 patients and
increased (<50%) in 1. No LEV-related adverse effects were observed,
and no significant changes in blood chemistry reported. LEV plasma
concentrations monitored in 13 patients ranged from 11.9–93.7 μg/ml.
Conclusion: These preliminary data indicate that add-on treatment
with LEV in patients with brain tumours is safe and efficacious. Con-
trolled studies on larger populations are warranted to confirm these ob-
servations.
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THIRTEEN YEAR INTERIM RESULTS FROM AN INTERNA-
TIONAL OBSERVATIONAL STUDY OF PREGNANCY OUT-
COMES FOLLOWING EXPOSURE TO LAMOTRIGINE
1J. Weil, 2R. Kustra, and 2J. Messenheimer (1Epidemiology, Glaxo-
SmithKline, Harlow UK, 2Epilepsy Clinical Development, Research
Triangle Park, USA)
Purpose: To characterise the overall risk of major congenital malfor-
mations (MCM) associated with exposure to lamotrigine.
Method: Physicians report exposure to lamotrigine during pregnancy
and subsequent outcomes on a voluntary basis. Prospective reporting
(prior to any knowledge regarding the possible outcome of the preg-
nancy) early in pregnancy is encouraged. Major congenital malforma-
tions (MCMs) are classified according to CDC criteria and are reviewed
by an external scientific advisory committee paediatrician. The percent-
age of MCMs is calculated using only prospective first trimester lamot-
rigine monotherapy and polytherapy exposures. Conclusions are devel-
oped and endorsed by the scientific advisory committee.
Results: As of September 2005, 20 MCMs were observed among 707
first trimester monotherapy exposures giving a risk of 2.8% (95% CI
1.8%–4.4%). The observed risk among 118 lamotrigine and valproate
polytherapy exposures was 11.8% (95% CI 6.8%–19.3%) and was 2.7%
(95% CI 1.2%–5.8%) among 256 exposures to lamotrigine polytherapy
without valproate. The mean and median monotherapy doses for subjects
with MCMs respectively were 250.7 and 200 mg/day; the mean and
median doses for those without defects were 281.1 and 200 mg/day. No
consistent pattern of malformation types was observed.
Conclusion: The current data do not indicate any substantial increase
in the overall risk of major defects associated with prenatal lamotrig-
ine exposure, though the sample size is insufficient to allow definitive
conclusions concerning specific defect types. The higher frequency of
major malformations following lamotrigine-valproate polytherapy expo-
sure was consistent with publications on valproate monotherapy. Con-
tinued registration of exposed pregnancies will enhance the statistical
power of the study.
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WHO AMONG PATIENTS WITH ISCHEMIC STROKE IS
PRONE TO SEIZURES?
1M. Neufeld, 1M. Medvedovsky, 2M. Gumis, 2V. Novak, 1S. Kiper-
vasser, 3T. Vander, and 4A. Schifrin (1EEG And Epilepsy Unit, Depart-
ment of Neurology,Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel,
2Internal Medicine Dviision, Soroka University Medical Center, Beer-
Sheva, Israel, 3Beit Loewenstein Rehabilitation Center, Raanana, Israel,
4Neurology Department, Rambam Medical Center, Haifa, Israel)
Purpose: Only a small percentage of patients with ischemic stroke
(IS) develop seizures. The aim of our study was to evaluate the risk
factors for seizures in a population of patients with IS.
Method: We retrospectively reviewed the records of all patients with
IS who had seizures and were hospitalised in two major medical centres
in Israel during 1993–2000. We identified 78 patients. Their data was
compared with 55 randomly chosen IS patients without seizures who
were admitted to the same hospitals during that period and included:
medical history, medications, neurological examination, laboratory tests,
ECG, echocardiography and brain CT.
Results: Forty three (32%) patients had a seizure the first day of
stroke (immediate), 6 (5%) after 24 hours and within 14 days follow-
ing stroke (early), and 29 (22%) later than two weeks. Risk factors for
atherosclerosis were not more prevalent in any group of patients with IS
and seizures compared to controls. Pharmacologically treated diabetes
was significantly less prevalent in patients with immediate (5%) (p =
0.002) and late (7%) (p = 0.018) seizures compared to controls (29%).
Cardio-embolic stroke was observed at a significantly higher frequency
in patients with late seizures (55%), when compared with both controls
(24%) (p = 0.004) and patients with immediate seizures (21%) (p =
0.003).
Conclusion: Patients with cardioembolic stroke may be more prone to
late, but not to immediate. seizures. Atherosclerotic risk factors were not
increased in patients with IS who had seizures compared to IS patients
without seizures.
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PSYCHOGENIC NONEPILEPTIC SEIZURES IN PATIENTS
WITH LEARNING DISABILITY
1A. Wooton, 1M. Oto, and 2R. Duncan (1Epilepsy Centre, Quarriers
Homes, Bridge of Weir, Scotland, 2West of Scotland Regional Epilepsy
Service, Galsgow, Scotland)
Purpose: A cohort of patients with psychogenic nonepileptic seizures
(PNES) and learning disability was studied in order to determine the
characteristics of this PNES population and the semiology of the PNES
themselves.
Method: A retrospective observational study of 27 consecutive pa-
tients admitted to a short term residential centre for evaluation of patients
with epilepsy who had a diagnosis of mild or moderate learning disability
and PNES.
Results: For 21 patients diagnosis was based on video EEG recording
of attacks. For the remainder, diagnosis was based on ambulatory EEG
and video recording of direct observation of attacks. Eighteen patients
(67%) had a dual diagnosis of PNES and epilepsy. Mean age at onset
of PNES was 28 (9–48) years. Fifteen (56%) were female. Five patients
(19%) had a history of abuse (sexual = 2, physical = 2, both = 1). PNES
semiology consisted of falls (6), unresponsiveness with limb movement
(10), tantrum-like spells (5), or blanks (6). In the 18 patients who had
epilepsy, PNES semiology did not resemble that of epileptic seizures.
Conclusion: If generalisable, our results suggest that patients who
have LD and PNES more often have epilepsy, have a more even gender
ratio, and less often have a history of sexual or physical abuse than a gen-
eral population of patients with PNES. Our data also suggests possible
differences in PNES semiology.
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MEN WITH EPILEPSY: THE LOST TRIBE?
1G. Sare, 1S. Duncan, and 2M. Rawnsley (1Greater Manchester Neuro-
sciences Centre Hope Hospital, Salford, UK, 2Epilepsy Action, (British
Epilepsy Association) Leeds, UK)
Purpose: Epidemiological studies show a higher incidence of epilepsy
in men compared with women. Yet there is a clear publication bias in
favour or women, and a relative lack of information specifically for men.
Against this backdrop Epilepsy Action (British Epilepsy Society) carried
out an extensive study of men’s experience of living with epilepsy, their
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views on services and their opinions about how access for men could be
improved.
Method: 1200 questionnaires were distributed to a random sample of
men who had contacted Epilepsy Action helpline in the previous year;
373 were returned and analysed.
Results: 27% were seizure free at time of study, 48% had “occasional”
seizures, 93% took AEDs, 39% were in employment, 46% lived with
a partner and 33% said epilepsy had affected their relationship with
their partner, and 27% their sex life. The most commonly cited adverse
impact on lifestyle was driving at 69%. 74% considered themselves,
“knowledgeable” or “very knowledgeable” about their epilepsy, 43%
said they would turn first to their GP for advice, 16%, their consultant,
11.8% a specialist nurse. When asked what they would do if they had
a specific question about epilepsy 85% said they would find out for
themselves. When asked to give their 3 preferred options for accessing
information 57% said their GP, 45% consultant, 34% the internet and
33% a telephone helpline. Specialist nurses were ranked 5 in their order
of preference after books and leaflets.
Conclusion: Men may differ from women in how they access infor-
mation about their condition. Further studies are needed to gain a greater
insight into the needs of men with epilepsy.
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A COMPARISON OF SELF-REPORTED QUALITY OF LIFE BE-
TWEEN PATIENTS WITH EPILEPSY AND NEUROCARDIO-
GENIC SYNCOPE
1H. Fowler, 2J. Santhouse, 2C. Carrier, 3S. Arya, and 2S. Duncan
(1Department of Behavioural Medicine Greater Manchester Neuro-
sciences Centre Hope Hospital, Salford, UK, 2Department of Neurol-
ogy Greater Manchester Neurosciences Centre Hope Hospital, Salford,
UK, 3Department of Cardiology Royal Albert Edward Infirmary, Wigan
Lancashire, UK)
Purpose: Generalised tonic-clonic seizures and complex partial
seizures have very different pathophysiological mechanisms to syncope,
but share a final common pathway of loss of consciousness with social
disruption. Quality of life has been studied in epilepsy and to a lesser
extent syncope; there have been no studies comparing these two popu-
lations.
Method: Fifty-two consecutive patients between the ages of 16 and
60 referred for tilt table testing were recruited. Patients had at least
2 episodes of syncope in the preceding year. Ninety-two consecutive
patients attending an epilepsy clinic (71 localisation related and 21
IGE) were recruited. Twenty-eight had been seizure free for at least
one year at time of study. A control group of 100 people consisting of
spouses/partners of patients and hospital employees were recruited. All
completed HADS and WHO-QOL-Bref.
Results: There were no significant differences between the syncope
and seizure groups in depression and anxiety subscales of the HADS.
Both syncope and seizure groups were significantly more depressed and
anxious than controls (p < 0.01). There were no significant differences
between the seizure and syncope groups in overall quality of life and
in the 4 domains of the WHO-QOL-Bref. In 3 of the 4 domains of
WHO-QOL-Bref the epilepsy and syncope groups, however, reported
significantly poorer quality of life than controls (p < 0.001).
Conclusion: This is to our knowledge the only study comparing qual-
ity of life in syncope and epilepsy. If our results are replicated it implies
repeated loss of consciousness has as great an impact on quality of life
as epilepsy’s many comorbidities.
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DESIGN AND DEVELOPMENT OF A WEB-BASED DATABASE
SYSTEM FOR THE MANAGEMENT AND ANALYSIS OF
EPILEPSY PATIENTS’ DATA: EPILEPSY DATABASE EPILDA
1G. Polychronaki, 1J. Stoitsis, 1G. Tsirogiannis, 1G. Giannakakis, 1A.
Psegiannakis, 2,3S. Gatzonis, 3A. Chatzis, 2,3A. Siatouni, 2,3M. Ste-
fanatou, 2N. Georgakoulias, 2M. Papathanasiou, 2,3M. Remoundou, 3E.
Aggelopoulos, 2,3C. Baltogiannis, 3P. Sdrolias, 2,3E. Singounas, 2,3D.
Sakas, and 1K. Nikita (1Biomedical Simulations and Imaging Labora-
tory, National Technical University of Athens, 2Epilepsy Surgical Treat-
ment Unit, Department of Neurosurgery, University of Athens, “Evan-
gelismos” Hospital, 3Greek Center for Neurosurgical Research “Prof.
Petros Kokkalis”)
Purpose: To present a database system (EPILDA), designed and de-
veloped for the efficient management, processing and analysis of epi-
demiological, clinical and other patient related data concerning epilepsy
in Greece. Furthermore, given the high diversity of cases and the variety
of available treatment approaches, the system aims at assisting objective
therapy evaluation.
Method: The EPILDA system is based on web technologies enabling
accessibility from remote medical centres and hospitals. The study and
processing of epilepsy data is accomplished via a user friendly interface
on either desktop PCs or portable devices such as laptops or PDAs. Since
medical data protection is of paramount importance, the implementation
of strict security measures at the data storage and transmission level as
well as at the application level is the cornerstone of the EPILDA system.
Results: The EPILDA system maintains data related to the general
characteristics of a patient, the patient’s visits, the drug treatment, the
characteristics of epilepsy, medical imaging data, surgical treatment data,
EEG and video-EEG recordings. The basic system functionalities com-
prise data entry, search and review as well as the generation of reports
based on specific criteria.
Conclusion: The proposed system can (a) assist the user toward the
efficient management of a large volume of available epilepsy-related data
(b) contribute to the automation of statistical analysis towards the extrac-
tion of major epidemiological conclusions, as well as towards therapy
planning, monitoring, and evaluation.
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DIABETES MELLITUS AND EPILEPTIC SEIZURES
H. Bozdemir, K. Aslan, and Y. Sary´ca (Neurology, Istanbul, Turkey)
Purpose: Disturbance of glucose regulation in patients with diabetes
may result in an epileptic disorder.
Method: Twenty-six patients (12 women, 14 men) with a mean age
of 54 years were selected for this study.
Results: For 7 patients mean epilepsy duration was 12 years and mean
diabetes mellitus (DM) was 4.5 years (Group A). For 19 patients the
mean DM duration was 11 years and epileptic disorder was detected on
an average of 4 years after DM diagnosis (Group B). Epileptic disorder
was primary generalised in 3, and partially generalised in 23 patients.
For Group B stroke (n = 7), DM (n = 11), MTS (n = 1) were risk
factors for epilepsy. The aetiologic factors of group A were, tumour,
head trauma, idiopathic (3) and criptogenic (1). EEG revealed active
subkortical epileptic abnormalities in 2, lateralized abnormal activity in
14. MRI revealed cortical infarct in 1 of the group A, and in 4 of the
group B patients. In 15 of the patients in group B antiepileptic treatment
(AET) was proposed. For the remaning patients, for 2 convulsions began
during a hypoglicemic coma, and in 2 during a nonketotic hyperglycemic
coma (NKHC) state. For these patients convulsions were under control
after blood glucose regulation. AET was proposed to the patients who
were hospitalised because of NKHC and right hemiparesia.
Conclusion: Cerebral ischemia or infarct can be detected without
hypo or hyperglycemic coma, and these cerebral changes can be risk
factors for an epileptic disorder.
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UNVERRICHT-LUNDBORG DISEASE: A CONDITION WITH
SELF-LIMITED PROGRESSION
1E. Ferlazzo, 1A. Magaudda, 2V. Nguyen, and 2P. Genton (1Centre for
Diagnosis and Care of Epilepsy, Department of Neurosciences, Anaeste-
siological and Psychiatric Sciences, University of Messina, Italy, 2Centre
Saint Paul, Marseille, France)
Purpose: To assess the long-term evolution of Unverricht-Lundborg
disease (ULD), especially concerning myoclonus, seizures and EEG
characteristics.
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Method: We retrospectively evaluated 20 patients (6 F, 14 M, mean
age 37.9 years, range 26–53) with ULD who had been closely followed
since the onset of the disease (mean age: 12.3 years, range 6–17) for
an average of 25.6 years (range 13–41). ULD was confirmed by genetic
tests in all. We used simplified myoclonus and seizure rating scales.
Results: The geographic origin of the patients was Northern African
in 9, French in 2, Italian in 6, mixed European in 3. Three patients were
severely handicapped, 6 led fully autonomous lives and 11 required var-
ious degrees of social support. Myoclonus progressed only during the
first 5 years of disease. Major seizures occurred in 19. Three patients had
a single seizure and 8 became seizure-free, while 6 retained rare seizures
and 2 frequent attacks. Overall, seizures became much less frequent af-
ter 10 years of evolution. EEG changes abated during follow-up: back-
ground activity remained stable or improved, spontaneous discharges
disappeared, and photoparoxysmal responses were abolished in all pa-
tients but 2.
Conclusion: This study shows that ULD progresses only over a limited
period and stabilises thereafter. This self-limited progression may be the
consequence of age related apoptosis of selected neuronal populations.
Monday July 3, 2006
13:30–15:00
Poster Session 1
Alternative Therapies
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ROLANDIC EPILEPSY: COMPARISON OF ALLERGEN-FREE
DIET AND CONVENTIONAL TREATMENTS
1A. Pelliccia, 2S. Frediani, and 2T. Frediani, 2S. Lucarelli (1Department
of Pediatrics, Faculty of Medicine II, La Sapienza University of Rome,
Italy, 2Department of Pediatrics, Faculty of Medicine I, La Sapienza
University of Rome, Italy)
Purpose: Rolandic epilepsy is the best known form of idiopathic par-
tial epilepsy and unquestionably the one with the best prognosis. When
such treatment does prove necessary, sodium valproate (VPA) or carba-
mazapine (CBZ) are nearly always used. In view of previous experiences
showing the efficacy of an elimination diet for cow milk in cases of par-
tial idiopathic epilepsy, a study was carried out on children with rolandic
epilepsy to compare the results of treatment with VPA or CBZ and an
elimination diet for proteins of cow milk.
Method: All the patients were subjected to a diagnostic procedure
to ascertain allergy to this foodstuff. The diagnosis was confirmed by
means of an elimination/ provocation test with the foodstuff in question.
The subjects were divided into 3 random groups: group A (17 cases)
treated with VPA, group B (17) treated with CBZ, and group C (20)
treated with an allergen-free diet.
Results: The children of group A displayed complete remission in 14
cases out of 17 (82.3%). In group B only 6 cases out of 17 (30%) dis-
played complete remission. The allergen-free made it possible to obtain
complete clinical remission in all the children of group C as well as the
normalisation of EEG.
Conclusion: The study suggests that while CBZ and VPA are effec-
tive drugs with comparatively few undesired effects, an allergen-free
diet makes it possible to obtain complete clinical and electroencephalo-
graphic remission with no side effects as well as a behavioural improve-
ment in cases where there is valid evidence of hypersensitivity.
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PRESENTING THE DEFINITIVE DIAGNOSIS OF PSY-
CHOGENIC NONEPILEPTIC SEIZURES MAY HAVE THERA-
PEUTIC EFFECTS
N. Vojvodic, A. Ristic, D. Sokic, S. Jankovic, and A. Sindjelic (Institute
of Neurology, Clinical Centre of Serbia)
Purpose: The aim of this retrospective study was to evaluate the
therapeutic effects of informing patients with psychogenic nonepileptic
seizures (PNES) about the accurate diagnosis, coexisting psychological
problems and possible provocative factors.
Method: During the five year period we treated 73 patients (17 men
and 56 women, aged 16–57 years) with PNES. Definitive diagnosis of
PNES was established in all patients according to clinical and inpatient
video EEG findings. During video EEG monitoring all patients had their
seizures without ictal EEG abnormalities. After family members or eye-
witnesses confirmed that the recorded seizures were habitual events,
45 patients were informed about the accurate diagnosis and coexisting
psychiatric disorders and possible precipitating factors were explained.
Twenty-eight patients didn’t get such convincing information about the
nature of their condition. Those two categories of patients were followed
at six months; in order to compare the frequency of seizures prior to and
after the definitive diagnosis of PNES was established.
Results: Six months after the diagnosis of PNES was established we
found a statistically better outcome in the first category of patients: 18
vs 7 (39.5% vs 25%, p < 0.05) had seizure cessation, 18 vs 11 (39.5% vs
40%) had a reduction in seizure frequency by at least 50% and 9 vs 10
(21% vs 35%, p < 0.05) continued with undiminished seizure frequency.
Conclusion: The treatment of PNES should start with clear and con-
vincing communication of the accurate diagnosis to patients and their
families, which may have therapeutic effects on seizure frequency.
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MEDICINAL PLANTS AND EPILEPSY: AN ANIMAL MODEL
1V. Ivetic, 2M. Popovic, 3M. Radenkovic, and 2B. Kaurinovic (1Medical
Faculty, Department of Physiology Novi Sad, Serbia and Montenegro,
2Institute of Chemistry, Faculty of Sciences, Novi Sad, Serbia and Mon-
tenegro, 3Medical Faculty, Institute of Physiology Novi Sad, Serbia and
Montenegro)
Purpose: Medicinal herbs have a broad spectrum of application in folk
medicine, but rarely anyone regards their unwanted effects, especially
for chronic diseases. In our experiment we investigated the potential
effects of Ginkgo biloba and Panax ginseng on epilepsy in rabbits with
kindling epileptogenic focus in the hippocampus. We investigated the
number of epileptic seizures and their duration in rabbits before and
after applications of different extracts.
Method: Electroencephalographic method of registering bioelectric
activity of different brain structures (EEG) was used. Gingko biloba
was administered orally at a dose of 2 mm per BW, Panax ginseng was
administered orally at a dose of 1 mm per BW (the doses of the substances
were defined after experience from our former investigations). EEG was
registered immediately before and after administration of the substances
in a period not shorter than two hours.
Results: The results obtained clearly reveal that the application of
Gingko biloba and Panax ginseng increased the number as well as the
duration of epileptogenic seizures in most of the experimental animals.
Conclusion: The question is still open regarding which active compo-
nents of the analysed medicinal plants influence experimental epilepsies.
The answer requires further neurophysiological investigation.
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INCREASE IN BRAIN SEROTONIN IMPROVES CLINICAL
OUTCOME IN EPILEPSY PATIENTS
C. Albano, P. Mainardi, and A. Leonardi (Department of Neuroscience,
University of Study of Genoa, Genoa, Italy)
Purpose: The hypothesis that an increase of brain serotonin could
have an anticonvulsant effect turned up in the early 1990s; moreover
fluoxetine (an SSRI) has shown an antiepileptic effect. Serotonin is syn-
thesised in the brain from tryptophan (Trp), an essential amino acid, so
a decrease brain influx of Trp is expected to affect brain serotonin syn-
thesis. In previous work we found a decreased plasma level of Trp and
a significant 30% reduction of Trp brain uptake rate in epilepsy patients
compared to controls. Trp competes across blood brain barrier with the
other large neutral amino acids (LNAAs), and the same competition is
in gastrointestinal mucosal. Furthermore, Trp is the limiting amino acid
Epilepsia, Vol. 47, S3, 2006
7TH EUROPEAN CONGRESS ON EPILEPTOLOGY 69
in most sources of protein and most proteins, thus causing a decrease in
plasma Trp-LNAAs ratio and therefore not suitable for supplementation
of Trp. Alpha-lactalbumin (ALAC) is a whey protein, naturally occurring
in human milk, with the highest Trp-LNAAs ratio of all quantitatively
relevant, food-derived proteins. It was shown that ALAC can increase
the plasma Trp-LNAAs ratio of up to 48% compared to casein. The
use of the food supplement Serplus (Giofarma S.r.l) as an add-on drug,
containing ALAC, in drug resistant epilepsy patients was then tested.
Method: Fifteen epilepsy patients, 6 male and 9 female; 9 drug resis-
tant patients, the others with from 2 to 5 seizures a month, but showing a
drug intolerance, in therapy with: 2 pts: PB, CBZ, VPA, 4 pts: PB, CBZ,
1 pt: PB, VPA, 1 pt: PB, VPA, LTG, 1 pt: PB, CBZ, LTG, 2 pts: PB, 3
pts: CBZ, 1 pt: VPA since, at least from 2001. Average age: 48, ranging
from 28 to 67. Ten patients were affected by partial complex seizures,
2 patients myoclonic, 1 patient partial complex with atonic, 1 patient
atonic and 1 patient tonic–clonic. The add-on Serplus therapy was of
1.5 g/die in 3 daily administrations. After 2 months an auto evaluation
test was performed (0 = no benefit, 10 = full benefit). Furthermore an
evaluation of clinical outcome (seizure frequency) was performed.
Results: Before Serplus treatment 6 pts showed from 4 to 10 seizures
a month, 5 from 21 to 30, 2 from 31 to 100, 2 over 100, after Surplus
9 pts showed from 0 to 5 seizures a month, 4 from 21 to 30, 2 from 31
to 100. The average percent in decrease of the number of seizures was
60% in patients. No patient has shown worsening of seizure frequency
or relevant side effects. Auto evaluation test was: 0, 2, 2, 3, 4, 5, 5, 5,
6, 7, 7, 9, 10, 10, 10; with an average of 5.6. In 13 patients the seizures
were milder than before Serplus, in 5 pts we also noted an antidepressant
effect. Eleven pts showed a percent decrease of seizure frequency from
50% to 100%, 5 pts from 80% to 100%.
Conclusion: Our data is completely in agreement with Jobe’s theory
(2005) on the role of serotonin in depression and epilepsy. Serplus, being
able to increase Trp/LNAAs ratio in plasma, could be able to increase
Trp brain uptake rate and therefore brain serotonin. Then Serplus is able
to correct the reduction in Trp brain uptake rate found by our previous
work with epilepsy patients. We outline that our results were obtained
with a low Serplus dosage, being Alac in human milk at about 2 g/l, the
dosage could be increased without side effects.
Monday July 3, 2006
13:30–15:00
Poster Session 1
Basic Science
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REELIN METHYLATION ASSOCIATES WITH GRANULE
CELL DISPERSION IN EPILEPSY PATIENTS WITH HIP-
POCAMPAL SCLEROSIS
1K. Kobow, 1F. Siebzehnru¨bl, 1R. Buslei, 2J. Hauke, 2E. Hahnen, 3H.
Stefan, 4J. Romsto¨ck, and 1I. Blu¨mcke (1Department of Neuropathol-
ogy, Erlangen, 2Institute for Human Genetics, Cologne, 3Department of
Neurology, Erlangen, 4Department of Neurosurgery, Erlangen)
Purpose: Hippocampal sclerosis (HS) is the most common lesion in
chronic, intractable temporal lobe epilepsies (TLE) and is characterised
by segmental loss of pyramidal neurons in sector CA1, CA3 and CA4.
Another histological hallmark includes granule cell dispersion (GCD),
an architectural dysplasia of the dentate gyrus (DG) encountered in ap-
proximately 50% of HS patients. The reelin molecule is synthesised
and released by Cajal-Retzius cells of the molecular layer, plays a key
role in cortical development and previous studies have shown that reelin
transcript levels are down-regulated in surgical specimens with GCD.
Mutational analysis of reelin and components of the signalling cascade
virtually exclude a genetic pathomechanism. Our present study focussed
on epigenetic regulation of reelin expression by promotor methylation.
Method: Hippocampal sectors CA1 and DG were microdissected
from human specimens. Genomic DNA was isolated, Bisulphite modi-
fied and used for nested PCR amplification of the reelin promoter, subse-
quent cloning and sequencing. Surgical specimens were retrieved from
12 TLE patients with AHS, 8 of which displayed severe GCD. Autopsy
samples from 3 patients without neurological histories served as controls.
Results: Our analysis revealed increased methylation levels of the
reelin promotor in all TLE-patients with GCD. In addition, striking dif-
ferences were observed for the methylation pattern between CA1 and
DG sectors of same patients.
Conclusion: These findings point to epigenetic regulation of the hu-
man reelin promoter in TLE-patients with GCD as a potential path-
omechanism. In addition, our data would be compatible with an inti-
mate relationship between neuronal hyperactivity (“epileptogenesis”)
and functional gene regulation.
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LEVETIRACETAM ADMINISTERED AFTER PROLONGED
STATUS EPILEPTICUS IN AN EXPERIMENTAL MODEL OF
STATUS EPILEPTICUS DOES NOT PROTECT AGAINST MI-
TOCHONDRIAL DYSFUNCTION
H. Cock, and J. Gibbs (St Georges, University of London, UK)
Purpose: Status epilepticus (SE) is associated with reduced activities
of essential mitochondrial enzymes, linked to neuronal damage (Cock
et al. Epilepsy Res 2002;48:157–168). We previously showed, using the
perforant pathway stimulation model, that levetiracetam (LEV) adminis-
tration during established SE prevents mitochondrial dysfunction (Gibbs
et al., J Neurol 2005;252(S2):16). This study addresses whether this
protective effect is simply consequential of the reduced seizure severity
associated with LEV treatment.
Method: Stimulating and recording electrodes were implanted into
the perforant pathway and dentate granule cell layer, respectively, of
anaesthetised rats. 6 days later, rats underwent 2h, 20 Hz stimulation
followed by 3h of self-sustaining SE, terminated with diazepam. LEV
(1000 mg/kg) or saline was subsequently administered i.p. and then
bi-daily. 44h post-SE, the hippocampi were extracted and prepared for
spectrophotometric assays to measure mitochondrial enzyme activity in
saline/LEV treated SE rats compared to sham-operated rats.
Results: There were no significant differences in EEG spike frequency
or behavioural seizure severity between treatment groups. In confirma-
tion of earlier studies, activities of alpha-ketoglutarate dehydrogenase,
aconitase, citrate synthase (and to some extent complex I) fell signifi-
cantly in the hippocampi of saline treated SE rats. In contrast to results
following LEV administered during SE, LEV administration after pro-
longed SE did not reverse this attenuation.
Conclusion: Administration of LEV post-SE did not protect against
mitochondrial dysfunction. This may be because LEV has no indepen-
dent neuroprotective biochemical effects; our previous results reflected
subtle reductions in seizure severity. Alternatively the level of mitochon-
drial damage induced by 5 h uninterrupted seizures may be irreversible.
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ACUTE MODULATION OF UNIT FIRING BY DEEP BRAIN
STIMULATION IN THE HUMAN HIPPOCAMPUS
1,3W. V. Wadman, 2D. van Roost, 1P. Claeys, 2F. de Waele, 1V. De
Herdt, 1K. Vonck, 1L. Waterschoot, and 1P. Boon (1Laboratory for Clin-
ical and Experimental Neurophysiology (LCEN), UZG, Ghent, Belgium,
2Department of Neurosurgery, UZG, Ghent, Belgium, 3SILS-Center for
NeuroScience, UvA, Amsterdam, The Netherlands)
Purpose: About 30% of epilepsy patients do not respond adequately to
specific (combinations of) antiepileptic drugs. Besides resective surgery,
they can try deep brain stimulation (DBS) as a new therapy. Here high
frequency stimulation is applied to a selected brain region in an attempt to
reduce excitability and/or increase seizure threshold. Basic mechanisms
are not understood and optimal protocols are under development.
Method: We investigated the response of units to DBS in patients that
underwent surgery for focus localisation. During anaesthesia, micro-
electrode tracks were made in the left/right hippocampus. Units were
characterised and their response to stimulation with a macroelectrode in
the same structure was evaluated in 7 patients, who were selected for not
having structural abnormalities on 3T MRI and who were all potential
candidates for resective surgery and/or DBS.
Epilepsia, Vol. 47, S3, 2006
70 7TH EUROPEAN CONGRESS ON EPILEPTOLOGY
Results: A total of 87 single units were recorded from 46 sites. 45
were recorded from the site that was classified as the ictal onset zone,
as evidenced by the results of a comprehensive dEEG analysis. The
remaining 42 units were recorded in the hippocampus contralateral to
the temporal lobe generating the habitual seizures. The mean firing rate
of neurons was higher (8.6 ± 0.7 Hz; p < 0.005), in the ictal onset zone
than in the contralateral side (6.3 ± 0.7 Hz). Stimulation activated 21 out
of 46 units tested. Sixteen were inhibited for 200 ms, while 5 showed a
sharply timed activation during the inhibition.
Conclusion: A surprisingly large fraction of the spontaneously active
units responded to stimulation; the majority with a long period of inhi-
bition. The cellular mechanisms and the correlation with DBS outcome
need to be established.
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DENTATE GYRUS NEUROGENESIS IN HUMAN TEMPORAL
LOBE EPILEPSY
1M. Giulioni, 1E. Pozzati, 1M. Zucchelli, 1G. Marucci, 1G. Rubboli,
2M. Paradisi, 2M. Fernandez, 2L. Giardino, 2L. Calza`, 2P. Tinuper, 2C.
Tassinari, and 1F. Calbucci (1Bellaria Hospital, Bologna, Italy, 2Bologna
University, Bologna, Italy)
Purpose: Adult neurogenesis is the process by which new neurons are
created in the mature central nervous system. This phenomenon has been
shown to occur in the dentate gyrus (DG) of the hippocampal formation
in a wide variety of species, including humans. Experimental works have
suggested that seizure discharges stimulate dentate gyrus neurogenesis,
while chronic temporal lobe epilepsy appears associated with a declined
production of new neurons.
Method: We studied the dentate gyrus neurogenesis in 2 patients
submitted to anterior-mesial temporal resection for pharmacoresistant
temporal lobe epilepsy. Presurgical duration of epilepsy was 18 and 30
years, age at surgery was 37 and 41 years, 1 was right-sided; the other
one was left-sided. Histopathological examination showed architectural
dysplasia of temporal pole and amygdala in 1 case and Ammon Horn
sclerosis in the other.
Results: Our study demonstrates the presence of neural stem cells in
the dentate gyrus of 2 adult patients with temporal lobe epilepsy. These
neural stem cells were cultured in vitro and neurospheres were obtained.
In the absence of any specific proliferative stimulus, these neurospheres
differentiated in all the three mature cell types: neuron, astrocyte and
oligodendrocyte.
Conclusion: Our results show that neurogenesis can persist in humans
with chronic epilepsy and in patients with hippocampal sclerosis. Further
studies are necessary to better define the stimulating factors for each
cellular lineage, and to investigate the role that a persistent postnatal
neurogenesis may have in the development of an epileptic network and
cortical dysplasia.
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INCREASE ON CALCINEURIN ACTIVITY AFTER IN VIVO
ACTIN DEPOLYMERIZATION BY LATRUNCULIN A MICRO
PERFUSION IN THE RAT HIPPOCAMPUS
G. Sierra-Paredes, A. Vazquez-Lo´pez, and G. Sierra-Marcun˜o (Univer-
sity of Santiago De Compostela, Medical School, Santiago de Com-
postela, Spain)
Purpose: The role of calcineurin in epileptic seizures is still con-
troversial. Calcineurin activity increases after kindling and pilocarpine
administration, and an important link has been established between cal-
cium influx leading to calcineurin activation and the intrinsic excitability
of pyramidal neurons. The aim of this study is to improve the knowledge
about the possible role of calcineurin in latrunculin A-induced epileptic
seizures.
Method: Latrunculin A (4 μg/ml) was dissolved in ringer fluid and
perfused into the rat hippocampus during 8 hours for three consecutive
days using a CMA/120 microdialysis system for freely moving animals
and CMA/12 microdialysis probes, with continuous EEG and video-
tape recording. Calcineurin activity was measured in hippocampal ho-
mogenates using the Promega ProFluorTM Ser/Thr phosphatase assay
kit in three groups of rats: controls, after 3-days acute latrunculin A
administration, and when spontaneous seizures started to be observed.
Results: During latrunculin A microperfusion, at least one seizure
was recorded from 70% of the animals. 40 days after treatment, 80%
of the rats studied had shown a variable number (4.3 ± 1.7) of spon-
taneous seizures. When compared to controls, a significant increase
(p < 0.0001 by one-way ANOVA) in calcineurin activity was found
in the hippocampus of latrunculin A-treated rats showing chronic spon-
taneous seizures. However, no significant differences were found just
after the 3-days latrunculin A treatment.
Conclusion: This study provides additional evidence of the involve-
ment of dephosphorylation mechanisms in epileptogenesis. Our results
show that calcineurin activity is chronically increased in rats showing
spontaneous seizures after hippocampal latrunculin A microperfusion,
and support previous data suggesting that calcineurin inhibition may be a
possible strategy in the search for new anticonvulsant drugs. (Supported
by grant XUGA PGIDIT03PXIB20803PR from the Consellerı´a de Ed-
ucacio´n e Ordenacio´n Universitaria, Xunta de Galicia, Galicia, Spain.)
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STIMULATION OF THE ANTERODORSAL THALAMUS IN
GENETIC ABSENCE EPILEPSY RATS FROM STRASBOURG
(GAERS)
1L. Waterschoot, 1S. Dedeurwaerdere, 1T. Wyckhuys, 2P. Van Hese, 1R.
Raedt, 1T. De Smedt, 3C. Van den Broecke, 1K. Vonck, 4W. Wadman, and
1P. Boon (1Laboratory For Clinical and Experimental Neurophysiology,
Department of Neurology, Ghent University Hospital, Ghent, Belgium,
2Department ELIS, Ghent University, Ghent, Belgium, 3Department of
Pathology, Ghent University Hospital, Ghent, Belgium, 4Centre For Neu-
roscience, University of Amsterdam, Amsterdam, The Netherlands)
Purpose: Deep brain stimulation (DBS) is a widely used treatment
option for refractory patients with various neurological disorders. Ge-
netic Absence Epilepsy Rats from Strasbourg (GAERS) constitute a well
established genetic animal model for absence epilepsy. The aim of the
study was to investigate the effect of acute (3 s) and subacute (15 min)
electrical stimulation of the anterodorsal thalamus in GAERS.
Method: 12 GAERS (4–5 months) were implanted with bipolar elec-
trodes in the anterodorsal thalamus. During the acute experiment, the
rats (n = 8) received unilateral high (130 Hz) (HFS) and middle fre-
quency (60 Hz) (MFS) stimulations when spike-and-wave discharges
(SWDs) appeared on the electroencephalogram (EEG). In the subacute
experiment, the animals were continuously stimulated for 15 min. The
number, duration and cumulative duration of the SWDs were compared
before, during and after the stimulation period. Electrode positions were
verified postmortem by histological analysis.
Results: Acute HFS reduced the duration of SWDs (p < 0.01). Acute
MFS had a similar effect, that failed to reach statistical significance
(p = 0.07). Subacute HFS and MFS did not influence the number or the
duration of SWDs.
Conclusion: In GAERS, acute HFS but not MFS of the anterodorsal
thalamus resulted in an antiepileptic effect, noticeable as a significant
reduction in SWD duration. Subacute HFS and MFS did not result in a
similar effect. These data confirm the involvement of the anterodorsal
thalamus in the control of generalised seizures and suggest that this
region could be a target for focal stimulation to treat intractable seizures
in humans.
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PHARMACOLOGICAL PROFILE OF GABAA RECEPTOR SUB-
TYPES IS ALTERED BY STATUS EPILEPTICUS IN THE DE-
VELOPING RAT BRAIN
H. Laure´n, F. Lopez-Picon, T. Kukko-Lukjanov, M. Uusi-Oukari, and I.
Holopainen (Department of Pharmacology and Clinical Pharmacology,
University of Turku, Finland)
Purpose: GABA is the main inhibitory neurotransmitter in the adult
brain, whereas it acts as a trophic excitatory transmitter in the developing
brain. Enhanced excitation, i.e., seizures, alters GABAA receptor struc-
ture, function, and pharmacology in adult rats, but whether this occurs in
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the developing brain is not known. We have studied the binding proper-
ties of GABAA/benzodiazepine receptors using [3H]flunitrazepam and
zolpidem, a ligand selective for α1β2γ 2 receptor subtype, in immature
rats after status epilepticus (SE).
Method: Receptor ligand autoradiography was used to study the dis-
placement of the GABAA receptor agonist [3H]flunitrazepam by zolpi-
dem, in 9 day old rats acutely (6 h) and subacutely (7 days), after kainic
acid (KA)-induced SE. The regional changes in the binding properties
were further corroborated at the cellular level by using specific GABAA
receptor subunit antibodies and fluorescent secondary antibodies.
Results: The binding results revealed that SE significantly decreased
the affinity of zolpidem in displacing the [3H]flunitrazepam ligand in
certain brain regions. The displacement was decreased 6 h after KA
treatment in the dentate gyrus of the hippocampus, in the frontal and
parietal cortex, and thalamus, whereas a reduction was found one week
after KA treatment in the hippocampal CA3 and CA1 cell layers.
Conclusion: Our results show that SE region-specifically alters the
pharmacological properties of GABAA receptors in the immature rat
brain during the sensitive postnatal period. Based on our results we
suggest that seizures could disturb the normal, strictly developmentally-
regulated maturation of GABAA receptors, and alter the balance between
excitation and inhibition.
Acknowledgements: The Arvo and Lea Ylppo¨ Foundation, the
Finnish Graduate School of Neuroscience, the Foundation of Univer-
sity of Turku, the Oskar ¨Oflund Foundation, the Research and Science
Foundation of Farmos, the Special State Grant for Clinical Research
(EVO).
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ASSESSMENT OF THE EFFECT OF CHRONIC LEVETIRAC-
ETAM TREATMENT ON EPILEPTIFORM ACTIVITY AND
PAIRED PULSE INTERACTIONS IN THE DENTATE GYRUS
OF FREELY MOVING RATS DURING ALTERNATE DAY RAPID
KINDLING
T. De Smedt, R. Raedt, W. Wadman, and P. Boon (Laboratory for Clinical
and Experimental Neurophysiology (LCEN), Ghent, Belgium)
Purpose: In kindling, testing for antiepileptogenic properties usu-
ally involves administering drugs prior to stimulation, hampering a
clear-cut distinction between antiepileptic and antiepileptogenic effects.
This study investigates the effect of chronic postkindling levetirac-
etam (LEV) administration on paired pulse interactions (PPi) and es-
tablishment of the fully kindled state in alternate day rapid kindling
(ADRK).
Method: Using intraoperative EEG, rats (n = 20) were implanted
with a hexapolar stimulation/recording electrode-complex in the hip-
pocampus. PPi were sampled prior to each ADRK session (12 stimula-
tions/day on 4 alternating days). The rats were then implanted with an
osmotic minipump containing either LEV (500 mg/ml) or saline (0.9%
NaCl). After one week of treatment, PPi were analysed and the kindled
state was reassessed using the Racine seizure score and the electro-
encephalographic afterdischarge duration (ADD).
Results: Following chronic LEV treatment, a significant decrease of
seizure severity was noticeable only during the first of 12 retest stimula-
tions: seizure score was reduced from 4.2 ± 0.8 to 2.1 ± 0.8 compared to
controls, while ADD showed a decline from 93.0 s ± 42.5 s to 40.2 s ±
27.1 s (p < 0.05). Analyses of the PPi revealed a shift towards increased
inhibition over larger intervals in both groups.
Conclusion: Chronic LEV administration had a prolonged effect on
the kindled state but could not prevent seizures. For the first time in
ADRK, a detailed characterisation of in vivo PPi in the epileptogenic
focus is presented; PPi in ADRK proved to be comparable to standard
kindling and provided a refined, complementary tool for assessing local
excitability.
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AMYGDALA KINDLING IN RAT PUPS WITH GENETIC AB-
SENCE EPILEPSY
1N. C¸arc¸ak, 2R. Aker, 1O. ¨Ozdemir, and 2F. Onat (1Istanbul Univer-
sity Faculty of Pharmacy Department of Pharmacology, 2Marmara Uni-
versity School of Medicine Department of Pharmacology and Clinical
Pharmacology)
Purpose: A recent kindling study in rats with genetic absence epilepsy
showed that Genetic Absence Epilepsy Rats from Strasbourg (GAERS)
failed to progress beyond stage 2 after the application of 25 electri-
cal stimulations. Spike-and-wave discharges start to appear on postnatal
day (PN) 40. In order to evaluate age-related changes on the kindling
progress in GAERS pups, we examined the amygdala kindling rate and
afterdischarge characteristics of PN30 and PN60 GAERS.
Method: Electrodes for stimulation and recording were stereotaxi-
cally implanted into the basolateral amygdala and cortex of male Wistar
(n = 6 each group) and GAERS (n = 6 each group). After a recovery pe-
riod, animals were stimulated every 90 min at 400 μA. Animals received
kindling stimulation until they reached five stage 5 or the maximum num-
ber of stimulations (45). The seizures were scored by using Racine’s
5-stage scale.
Results: All the nonepileptic control rats and five out of six (83.3%)
PN30 GAERS achieved stage 5, whereas 1 (16.7%) PN30 GAERS stayed
at stage 2 after 45 stimulations. Four out of 6 (66.6%) PN60 GAERS
reached stage 5, 2 of 6 (33.4%) PN60 GAERS stayed at stage-2 and
no motor seizures was observed after the application of 45 stimulations.
Additionally, the amygdala kindling rate of 5 PN30 and 4 PN60 GAERS
was significantly slower when compared to nonepileptic control rats.
Conclusion: The results of our study demonstrate that resistance to the
secondary generalisation of limbic seizures during amygdala kindling in
GAERS is age-related.
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PARTIAL RECOVERY OF CYTOCHROME C OXIDASE ACTIV-
ITY IN THE HIPPOCAMPUS AFTER STATUS EPILEPTICUS IN
THE RAT IS BOTH AGE AND STRUCTURE DEPENDENT
1,2J. Ota´hal, 2S. Va´vrova´, 1L. Suchomelova´, 1R. Druga, and 1H. Kubova´
(1Institute of Physiology, Czech Academy of Sciences, Czech Republic,
2Faculty of Physical Education and Sport, Charles University, Prague,
Czech Republic)
Purpose: Dysfunction of the respiratory chain enzymes was described
in various pathologies including temporal epilepsy. In the present study
we addressed the question of whether change of activity of the mito-
chondrial respiratory chain Complex IV–cytochrome c oxidase (COx)
during status epilepticus (SE)-induced epileptogenesis is age and struc-
ture dependent.
Method: SE was induced by LiCl/pilocarpine in P12, P25 and P90
rats as described before (Otahal et al., Epilepsia, 2005; 46:S5:89–93).
In order to assess COx activity, rats were decapitated one week (latency
period) or three months (chronic period) after the SE. Coronal sections
(1-of-5 series) throughout the entire brain were used for COx histo-
chemistry. Adjacent sections were used for Nissl staining to identify
anatomic boundaries. COx activity of the hippocampus was then eval-
uated by corrected optical density measurement of CA1, CA3, dentate
gyrus (DG) and hilus separately. To evaluate Cox recovery ratio of values
from 3M/1W after SE was calculated.
Results: COx-activity was lower in all age-and-interval groups in all
hippocampal regions compared to controls (on average −7.29% ± 1.96).
Recovery ratio increased significantly (p < 0.05) in all regions except the
hilus. The difference was most pronounced in P12 and decreased with
age. In controls, COx activity showed significant decrease with ageing
in both P25 and adult rats.
Conclusion: Our data suggests that after SE, age and structure both
show dependent partial recovery of the respiratory metabolism. Sup-
ported by grant 1QS501210509 (Academy of Sciences of the Czech
Republic). Experiments were approved by the Animal Care and Use
Committee.
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EFFECTS OF ß-HYDROXYBUTYRATE ON NEUROGENESIS
AFTER PILOCARPINE-INDUCED SEIZURES IN MICE
Epilepsia, Vol. 47, S3, 2006
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1,3D. Kim, 2,3S. Jeong, and 3E. Choi (1Department of Pediatrics,
Inje University Ilsan Paik Hospital, Goyang, Korea, 2Department of
Neurology, Inje University Ilsan Paik Hospital, Goyang, Korea, 3Clinical
Research Center, Inje University Ilsan Paik Hospital, Goyang, Korea)
Purpose: Epileptic seizures have been shown to stimulate the prolifer-
ation rate of granule cell progenitors in the brain. Recently, we reported
that ketogenic diet (KD) enhanced neurogenesis after seizures in mice
[Kim DW et al., Epilepsia 2004;46(Suppl 6):373]. KD remains a ther-
apy in search of explanation although it is an established treatment for
patients with intractable seizures. It was originally devised to mimic the
biochemical changes seen upon fasting, specifically the formation of
ketone bodies: β-hydroxybutyrate (BHB), acetoacetate, and to a lesser
extent, acetone. In this study, we investigated the effects of BHB on
neurogenesis after pilocarpine-induced seizures in mice.
Method: Eight male ICR mice were divided into two groups. Ex-
perimental mice (n = 4) were injected intraperitoneally with BHB (20
mmol/kg), while control mice (n = 4) with normal saline. Fifteen min-
utes later, seizures were chemically induced by intraperitoneal injection
of pilocarpine (300 mg/kg) in both groups. Then, bromodeoxyuridine
(BrdU, 50 mg/kg) was subsequently administered once a day for 6 con-
secutive days, staring at 24 hours after pilocarpine treatment. Mice were
sacrificed 7 days after pilocarpine administration. BrdU-positive cells in
the hippocampus were counted in every seventh section in a series of 30
μm coronal sections.
Results: In the experimental group treated with BHB, BrdU-labeled
cells increased significantly compared to the control group (377.57 ±
150.40 vs. 230.55 ± 59.50, p < 0.0002).
Conclusion In this study, quantitative analysis of BrdU labelling re-
vealed a significant increase in the proliferation rate of neuronal pro-
genitor cells after pilocarpine-induced seizures in BHB-treated mice.
Our results suggest that BHB enhances neurogenesis after seizures. This
study was supported by a grant of the Korea Health 21 R&D Project,
Ministry of Health & Welfare, Republic of Korea (02-PJ1-PG10-21301-
0001).
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UNEXPECTED SHORT-LASTING EFFECTS OF VIGABATRIN
ON ABSENCE SEIZURES IN WAG/RIJ RATS
1C. Van Rijn, 1M. Perescis, 2L. Vinogradova, 3B. Bouwman, and 2I.
Midzyanovskaya (1NICI, Biological Psychology, Radboud University
Nijmegen, The Netherlands, 2Institute of Higher Nervous Activity and
Neurophysiology RAS, Moscow, Russia, 3TNO, Defence, Security and
Safety Research Group Diagnosis and Therapy, Rijswijk, The Nether-
lands)
Purpose: The duration of the effects of a single dose of vigabatrin
on spontaneous spike-wave-discharges (SWDs) in the EEG of WAG/Rij
rats was studied. The WAG/Rij rat is recognised as an animal model
for generalised absence epilepsy in humans. Both GABAA and GABAB
receptor agonists have pro-absence effects in these animals. Vigabatrin
inhibits GABA transaminase irreversibly. Consequently, the endogenous
GABA concentration is enhanced for days, even after a single dose.
Method: Male WAG/Rij rats received a single dose of vigabatrin (500
mg/kg, isotonic intraperitoneal) or an equal volume of saline (12.5 ml/kg)
(n = 8 each group). EEG was recorded until 48 hours post injection (p.i.)
in freely moving animals.
Results: The mean incidence of SWDs in the controls was 16/h. Viga-
batrin increased the incidence by a steep S-shaped time-effect curve with
a maximum of 150/h (SEM 30/h) at 3.1 hours (SEM 0.4h) p.i. About the
7th hour the SWD incidence abruptly returned to baseline level. Never-
theless, other effects of vigabatrin treatment were observed for well over
24 hours p.i.: the morphology of the SWDs was changed from the 1st
hour p.i. until the end of the observation period.
Conclusion: Tolerance to the changed incidence of the SWDs was ob-
served within 7 hours but the EEG remained altered long after this period.
The question is whether a (neuro)-pharmacokinetic origin together with
differences in dose response curves for the various effects are enough
to explain this unexpected, short lasting effect of vigabatrin or whether
pharmacodynamic-neuroplastic changes are involved as well.
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EVALUATION OF TWO SEIZURE PREDICTION METHODS
BASED ON LONG-TERM INTRACRANIAL EEG RECORDINGS
1,2H. Feldwisch, 1,2M. Winterhalder, 1,2B. Schelter, 1,3J. Nawrath,
1,3J. Wohlmuth, 3A. Brandt, 1,2J. Timmer, and 2,3A. Schulze-Bonhage
(1Center for Data Analysis and Modeling, University of Freiburg, Ger-
many, 2Bernstein Center for Computational Neuroscience, University of
Freiburg, Germany, 3Epilepsy Center, University Hospital of Freiburg,
Germany)
Purpose: Concerning the predictability of epileptic seizures, recent
work has shown that methods from nonlinear dynamics can be used
to analyse neurophysiological recordings for detection of preseizure
changes. When utilising these methods for seizure prediction it is crucial
to assess their prediction performance on long-term EEG data, including
tests for statistical significance.
Method: A bivariate phase synchronisation index and the univari-
ate “Dynamic Similarity Index” were adapted for seizure prediction
(Mormann et al., Physica D 2000;144:358–369 and Le Van Quyen et
al., NeuroReport 1999;10:2149–2155). Based on the seizure prediction
characteristic (Winterhalder et al., Epilepsy Behav 2003;4:318–325) and
a long-term intracranial EEG database with continuous recordings of 15
patients for up to 14 days (mean 7.5) including 330 seizures we per-
formed an analysis with prediction windows up to 4 hours. All results
have been validated by a statistical test procedure (Schelter et al., Chaos
2006;16:013108).
Results: When using the phase synchronisation index for seizure pre-
diction, significant prediction performance could be observed for 11
patients with a mean sensitivity of 52.1% ranging from 38.1% to 66.7%,
for a maximum false prediction rate of 0.15 false predictions per hour.
Sensitivity increased selecting specific EEG frequency bands for several
patients by 10% to 20%. Results for the dynamical similarity index were
significant for 11 patients with a mean sensitivity of 51.7%.
Conclusion: The investigated univariate and bivariate analysis tech-
niques have shown similar performance in predicting epileptic seizures.
Both methods have achieved statistical significant prediction perfor-
mance on long-term EEG data with considerable interpatient variability.
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BRAIN CORTEX INVOLVEMENT IN CHRONIC EPILEPTISA-
TION IN PILOCARPINE TREATED RATS
1R. Vastyanov, and 2A. Oleynik (1Odessa State Medical University,
Ukraine, 2Odessa State Medical University, Ukraine)
Purpose: Pilocarpine (Pi) -induced epilepsy is a model of limbic re-
current seizures and status epilepticus (SE). The goal of the present work
was electrophysiological registration of the Pi-induced SE free of recur-
rent seizures period with the aim of evaluation of structures responsible
for epileptic activity (EpA) initiation.
Method: Wistar rats were implanted with electrodes into the brain
cortex left frontal, temporal and occipital lobes, substantia nigra (SN),
ventral hippocampus (VH), amygdala (A) and nucleus caudatus (NC).
7–10 day animals were free of trials. 30 min after scopolamine hydro-
bromide (1.0 mg/kg, s.c.) pretreatment, a generalised convulsive SE was
induced in rats by Pi hydrochloride (300 mg/kg, i.p.) injection. EEG
was recorded 210 min after SE induction. Recordings were made using
discrete frequency of 2 kHz with the help of National Instruments DAQ
(PCI-6071E) and specially designed software. Signals were filtered and
sampled at 0.5 to 40 Hz. Repetitive data files recorded from each animal
during experiments were used for the Pi-induced EpA analysis in the
time-frequency domain.
Results: Electrical activity progressive enhancement was registered
20–25 min after Pi injection that was mostly evident in VH, frontal
and temporal lobes. It was synchronised in frontal and occipital lobes,
NC and VH in all rats 25–30 min after Pi administration. Convulsions
started at 36 ± 3 min after Pi injection also had EEG correlates in the
form of epileptic spike amplitude increasing in the frontal lobes, NC
and VH. Highly amplitude spikes (0.8–1.0 mV, frequency 12–17 Hz)
appeared firstly in VH in 12 rats of 16. 3 rats showed EEG signs of
seizure initiation in the temporal lobe (0.5–0.6 mV, frequency 2-3 Hz)
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and Pi-induced convulsions appeared firstly in SN in 1 rat that was
characterised by spike amplitude of 0.35-0.45 mkV and their frequency
of 2-3 Hz.
Conclusion: Brain cortex (mainly frontal and temporal lobes) has
direct participation in chronic Pi-induced EpA initiation and its follow-
ing spread over the whole brain. These data might also further our un-
derstanding of chronic epileptogenesis pathophysiological mechanisms
contributing to certain brain cortex lobes importance in Pi-induced SE
initiation and cessation.
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GENE ARRAY ANALYSIS OF DNA-DAMAGE SIGNALING
PATHWAYS AFTER PROLONGED SEIZURES: DIFFEREN-
TIAL RESPONSE IN YOUNG ADULT VERSUS AGED RATS
A. Kondratyev, S. Crowe, and F. Vanevski (Georgetown University,
Washington, DC, USA)
Purpose: Status epilepticus (SE) results in neuronal cell death and
DNA damage. Little is known about the regulation of DNA-damage
response pathways following seizures. Here we examined the regulation
of these pathways after SE as a function of age.
Method: SE was induced in young adult and aged rats by systemic
administration of kainate at doses ensuring comparable seizure mani-
festations between the age groups. SE was terminated after 30 min with
diazepam, and the rats were sacrificed for tissue collection at 4 or 8 hr.
DNA-damage Signaling Pathways Gene Array (SuperArray) containing
96 genes was used to examine changes in gene expression in the rhinal
cortex. A two-fold change in expression was used as the cutoff criteria
for analysis.
Results: Approximately 25 genes showed greater expression levels
in control young adult rats as compared with aged rats. In young adult
rats, at 8 hr following SE, 4 genes were upregulated and 8 genes were
downregulated as compared to corresponding control animals. In aged
rats under the same conditions, only 1 gene was upregulated as com-
pared to age-matched controls following seizures, while 15 genes were
downregulated.
Conclusion: Our results indicate that DNA-damage response path-
ways are activated following prolonged seizures and that the level of
activation of specific pathways is age-dependent. Aged rats displayed
overall lower levels of expression of the DNA-damage/repair pathways
and a diminished response of these pathways to SE. These results suggest
that impairment of this response may contribute to age-dependent vulner-
ability to seizure-evoked injury. Supported by NIH grants F31NS461991,
MH02040, NS041231, and AG019165.
p275
NEOVASCULARISATION OF THE EPILEPTIC FOCUS IN RAT
LIMBIC EPILEPSY: CONSEQUENCES ON BLOOD–BRAIN
BARRIER FUNCTION
M. Morin, M. Rousset, V. Rigau, J. Bockaert, and M. Lerner-Natoli
(Institute of Functional Genomic, Montpellier France)
Purpose: In human temporal lobe epilepsy (TLE), an increase of vas-
cularisation was noted in the focus, compared to nonepileptic tissue.
We hypothesised that this pathological vascularisation is associated with
changes in microvessel density and with the secretion of angiogenic fac-
tors and the expression of their receptors. To understand the mechanisms
and the kinetic of this pathologic vascularisation, we used a rodent model
of TLE (lithium-pilocarpine).
Method: Rats that underwent status epilepticus (SE) were sacrificed
at different time points (as from 1 hour until 2 months after SE). Brains
and/or hippocampi were collected and treated for histology, immunohis-
tochemistry or immunoblotting. We checked: i) the density of microves-
sels, ii) the expression of angiogenic factors and their receptors, iii) the
disruption of the blood brain barrier (BBB).
Results: As from 2 weeks after SE, the density of hippocampal mi-
crovessels was significantly increased compared to those of age-matched
control animals. A strong neuronal expression of the angiogenic factor
VEGF was observed rapidly after seizures, whereas its receptor Flk-1
was expressed by endothelial cell from one week after the SE. Both
VEGF and Flk-1 were still expressed at later time points. Moreover,
at all stages studied, a BBB disruption was evidenced by IgG leakage
around capillaries.
Conclusion: Severe seizures induce in adult rats a vascular remod-
elling of the epileptic focus, due to the release of angiogenic factors. This
neo-vascularisation is associated with an increase of BBB permeability
and with inflammatory reactions that may contribute to the secondary
epileptogenesis.
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GABAA RECEPTORS IN THE HUMAN NEOCORTEX: DIFFER-
ENTIAL DISTRIBUTION AND SUBTYPE-SPECIFIC ALTER-
ATIONS IN TEMPORAL LOBE EPILEPSY
1F. Loup, 3F. Picard, 5V. Andre´, 4P. Kehrli, 2Y. Yonekawa, 2H.
Wieser, and 1J. Fritschy (1University of Zurich, Zurich, Switzer-
land, 2University Hospital, Zurich, Switzerland, 3University Hospital,
Geneva, Switzerland, 4Centres Hospitaliers Universitaires, Strasbourg,
France, 5University of California, Los Angeles, USA)
Purpose: Imaging studies have revealed both increases and decreases
in flumazenil binding in the neocortex of patients with refractory tempo-
ral lobe epilepsy (TLE). We investigated whether these changes reflect
differences in the expression of specific GABAA receptor subtypes.
Method: Neocortical tissue was obtained at surgery from patients
with TLE resulting from hippocampal sclerosis (HS) or other causes
(non-HS), and was compared with postmortem control samples. The
distribution of the GABAA receptor subunits alpha1, alpha2, alpha3,
beta2.3 and gamma2 was visualised immunohistochemically.
Results: In control grey matter tissue, labelling for the three alpha
subunits was layer-specific whereas expression patterns of beta2.3 and
gamma2 subunits largely followed those of the alpha1 subunit. In control
white matter tissue, which contains large numbers of neurons in the
human, the alpha1 subunit was expressed in numerous pyramidal cells
and interneurons, the alpha3 subunit only in pyramidal cells, and the
alpha2 subunit in virtually no neurons. In the two patient groups, subunit-
specific changes were observed in grey and white matter. In a subset of
patients, it was exclusively the expression of the alpha3 subunit that was
decreased, and this only in the superficial layers. Striking alterations in
soma size and dendritic morphology of neurons positive for the alpha1
subunit were seen in white matter.
Conclusion: These results show a stereotypic layer and cell type-
specific expression of GABAA receptor subtypes in the human neo-
cortex. The marked changes detected in white matter neurons and their
GABAA receptors may contribute to the disease mechanisms underlying
epilepsy.
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FUNCTIONAL ANALYSIS OF A NOVEL KCNQ2 GENE VARI-
ANT FOUND IN A LARGE PEDIGREE WITH BENIGN FAMIL-
IAL NEONATAL CONVULSIONS (BFNC)
1,2L. Volkers, 2M. Rook, 2W. Groenewegen, 1D. Lindhout, 1B. Koele-
man, and 1M. van Kempen (1Clinical Genetics Section or Complex Ge-
netics Section, DBG-Department of Medical Genetics, University Med-
ical Center Utrecht, Utrecht, The Netherlands, 2Department of Medi-
cal Physiology, Heart Lung Centre Utrecht, University Medical Center
Utrecht, Utrecht, The Netherlands)
Purpose: Benign familial neonatal convulsion (BFNC) is a rare
epilepsy disorder with autosomal dominant inheritance. Mutations in
the potassium channel genes KCNQ2 and KCNQ3 are highly associated
with BFNC. KCNQ2 and KCNQ3 subunits form tetrameric voltage-
gated channels via assembly of their conserved A-domain, located in
the carboxy-terminus of the proteins, resulting in a classical M-current.
Previously, we reported a splice-site mutation in the KCNQ2 gene in a
BFNC family with 13 affected members (de Haan GJ et al., Epilepsia
in press). This mutation (c.IVS14-6C>A) creates a new, preferentially
used, splice site, that results in a premature stop codon and a predicted
protein truncation (p.R588X). This study reports the biophysical prop-
erties of this mutant.
Epilepsia, Vol. 47, S3, 2006
74 7TH EUROPEAN CONGRESS ON EPILEPTOLOGY
Method: Wild-type (WT) and mutant channel cDNAs were co-
expressed in HEK293 cells. Transfection with KCNQ2/KCNQ3 cDNAs
in a 1:1 ratio mimicked expression in healthy subjects. Transfection with
KCNQ2/3 WT and c.IVS14-6C>A cDNAs in a 0.5:1:0.5 ratio mimicked
expression in patients heterozygous for the mutation. The resulting potas-
sium currents were measured using whole-cell patch-clamp techniques.
Results: Cells expressing WT heteromeric KCNQ2/KCNQ3 channels
revealed a large noninactivating, slowly deactivating M-type potassium
current (current density 781 ± 170 pA/pF, n = 7). Cells expressing
mutant channels showed a significant reduction in M-current (224 ± 53
pA/pF, n = 7). Furthermore, the voltage dependence of mutant channel
activation was shifted in the depolarising direction by 6 mV.
Conclusion: The decreased current density and depolarising shift in
activation caused by the mutant channels may result in hyperexcitability,
which is likely to cause epilepsy in neonates.
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MITOCHONDRIAL COMPLEX I INHIBITION IN CEREBRAL
CORTEX OF IMMATURE RATS FOLLOWING HOMOCYS-
TEIC ACID-INDUCED SEIZURES
J. Folbergrova´, P. Jesˇina, Z. Drahota, V. Lisy´, R. Haugvicova´, and J.
Housˇtı`k (Institute of Physiology, Academy of Sciences of The Czech
Republic)
Purpose: Mitochondrial dysfunction (in terms of the deficiency of
complex activities) has been demonstrated in brains of adult rats follow-
ing status epilepticus (SE). We asked whether it may also occur in the
brain of immature rats following SE.
Method: Seizures (having a character of SE) were induced by bilat-
eral icv infusion of DL-homocysteic acid (DL-HCA, 600 nmol/side) in
12-day-old male Wistar rats with implanted cannulae. Control animals
received a corresponding volume of the vehicle. The activities of citrate
synthase (CS) and respiratory chain complex activities were determined
in isolated mitochondria by spectrophotometric assays.
Results: A marked decrease (∼64%) of complex I (evident when
expressed either as the specific activity or as a ratio to CS) was already
observed during the acute phase of seizures (60–90 min after DL-HCA
infusion) and it still persisted at ∼20 h of survival following seizures. The
activities of complex II and IV remained in the control range at both time
intervals. Decrease of complex I activity was substantially attenuated
when animals were treated with substances providing an anticonvulsant
effect and also with selected free radical scavengers.
Conclusion: These findings suggest that mitochondrial dysfunction
may also occur in the immature brain following seizures. Supported by
Grant Agency of the Czech Republic, Grant No.309/05/2015.
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INFLUENCE OF RECURRENT EARLY FEBRILE SEIZURES
ON THE DEVELOPMENT OF ABSENCE EPILEPSY IN ADULT
RATS
1K. Abbasova, 2G. Van Luijtelaar, 1N. Chepurnova, and 1S. Chepurnov
(1Lomonosov Moscow State University Moscow Russia, 2NICI Rad-
boud Nijmegen University, The Netherlands)
Purpose: The aim of the present experiment was to evaluate the effect
of early recurrent experimental febrile seizures on the development of
absence epilepsy in adult rats.
Method: Pups of two litters (n = 6 each) of WAG/Rij rats were used.
The experimental febrile seizures were conducted in a mild regime by
light (lamp 200 W) from a distance, providing a temperature a 38◦C
inside a box. The modified scale developed by Mares was used to eval-
uate the seizures. The mean temperature of pups was measured before
and after seizures with a lubricated probe from the rectum. The control
group of pups was placed in the same box at room temperature. For
experimental febrile seizures pups were heated on the 3th, 5th, 7th, 9th
and 11th postnatal days. EEG was recorded after 6 months for 1 hour.
EEG electrodes were chronically implanted into the frontal cortex. The
mean duration and number of SWDs were calculated.
Results: A significantly larger mean duration of SWDs (F1.8 = 15.77;
p < 0.01) was found for the treatment group compared to the control
rats, while there was no significant interaction effect between treatment
and litter, nor a litter effect. Analysis of number of SWDs showed no
significant effects.
Conclusion: It is known that children with long-lasting febrile convul-
sions are at risk for temporal lobe epilepsy. According to our results we
can suggest that febrile convulsions of WAG/Rij pups in early postnatal
ontogenesis does not affect the excitability of the corticothalamic system
later in life, however, it does affect a stopping mechanism, responsible
for the ending of an ongoing seizure.
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CONVULSIVE SEIZURES, NONCONVULSIVE SEIZURES,
AND NEURODEGENERATION: LESSONS FROM A RODENT
PENTYLENETETRAZOLE KINDLING MODEL
1N. Gulyaeva, 1T. Pavlova, 2V. Kovalzon, and 3A. Guekht (1Institute of
Higher Nervous Activity and Neurophysiology RAS, Moscow, Russia,
2Severtsov Institute of Ecology and Evolution RAS, Moscow, Russia,
3Department of Neurology and Neurosurgery, Russian State Medical
Institute, Moscow, Russia)
Purpose: Pentylenetetrazole (PTZ) kindling, the regular application
of subthreshold doses of PTZ, provokes a behaviour in rodents very
similar to chronic secondary generalised seizures. As a rule, there is a
portion of PTZ-resistant animals which do not demonstrate convulsive
behaviour and are removed from the experiment. The purpose of the study
was to perform a comparative investigation of PTZ-prone (PTZPR) and
PTZ-resistant rats (PTZRR) from a population of Wistar rats.
Method: Oxidative stress, neurodegeneration in hippocampus was
studied, and EEG pattern was monitored.
Results: Intraperitoneal injection of PTZ at a subconvulsive dose re-
sulted in the separation of two distinct groups, PTZPR demonstrating the
development of clonic seizures, while PTZRR displayed preconvulsive
stages. In hippocampi of both groups, a similar decrease of glutathione
level was revealed indicative of oxidative stress accompanied by a sim-
ilar degree of hippocampal neurodegeneration (8–13%). PTZ challenge
of kindled animals induced similar short generalised discharges (2–3
sec, 5–8 Hz) in neocortex and hippocampus (amplitude 800-900 μV in
PTZPR vs. 400–500 μV in PTZRR). Further changes of EEG pattern in
PTZPR corresponded to the development of convulsions, while short dis-
charges in EEG of PTZRR (7–8 Hz) corresponded to freezing episodes.
Other differences in EEG characteristics of PTZPR and PTZRR were
revealed (latency, number of discharges, frequency power peak).
Conclusion: Generalised nonconvulsive epileptic activity found in
PTZRR may be intimately involved in gross structural changes in the
brain, including neurodegeneration. Our data confirm supposed injurious
effects of absence epilepsy on neuronal cells. Supported by RHSF and
RAS Grant Fundamental Medicine.
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THE NOVEL SV2A LIGANDS BRIVARACETAM AND SE-
LETRACETAM MANIFEST DIFFERENT EFFECTS AGAINST
THE EPILEPTIFORM MARKERS OF FIELD POTENTIALS
IN A “HIGH K+–LOW CA2+” RAT HIPPOCAMPAL SLICE
MODEL
D. Margineanu and H. Klitgaard (UCB S.A., CNS Research, Braine
L’Alleud, Belgium)
Purpose: Brivaracetam (ucb 34714; BRV) and seletracetam (ucb
44212; SEL) bind to the synaptic vesicle protein 2A (SV2A) with affinity
10-fold higher than levetiracetam ( Keppra), and display superior but dis-
tinct profiles in animal models of epilepsy. Here we compare the effects
of SEL vs BRV on field potentials recorded in rat hippocampal slices in
vitro, under perfusion with a “high K+− low Ca2+fluid” (HKLCF).
Method: Perfusing rat hippocampal slices with HKLCF induces spon-
taneous field bursts in CA3 area of slices silent when in normal physi-
ological solution. Also, HKLCF increases population spike (PS) ampli-
tude and leads fimbrial stimuli, which evoke a single PS under normal
perfusion, to elicit repetitive PSs. The effects of either BRV, or SEL 1–
10 μM, added to the perfusion 20 min before shifting to HKLCF, were
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quantified via the rate of spontaneous bursts, the amplitude of PS and
the number of repetitive PSs evoked by constant stimuli.
Results: Either BRV, or SEL inhibited these epileptiform markers to
various extents, most consistently at 3.2 μM. BRV (3.2 μM) significantly
reduced (by ∼=40%) the rate of spontaneous bursting, while SEL (1– 10
μM) had no effect on this parameter. BRV (3.2 μM) inhibited less the
HKLCF-induced increase in PS amplitude (PS), but it reduced by
>33% the number of evoked PSs. In contrast, SEL (3.2 μM) strongly
inhibited PS, while reducing by only <25% the number of evoked
PSs. BRV, but not SEL, tended to shift the peak of power spectra of
spontaneous bursts towards lower frequencies.
Conclusion: The difference in antiepileptic effects in vitro of
BRV and SEL suggest distinct abilities of these two high affinity
SV2A ligands to inhibit epileptiform synchronisation and neuronal
hyperexcitability.
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DEVELOPMENTAL AND STATUS EPILEPTICUS-INDUCED
CHANGES IN THE EXPRESSION OF MICROTUBULE-
ASSOCIATED PROTEIN 2 (MAP-2) IN THE DEVELOPING RAT
HIPPOCAMPUS
N. Puustinen, F. Lope`z-Picon, and I. Holopainen (University of Turku,
Turku, Finland)
Purpose: The cytoskeletal MAP-2 proteins are involved in the devel-
opment, maintenance and plasticity of neuronal processes. They promote
microtubule assembly, and by promoting interaction with neurofilaments
and actin, MAP-2 may contribute to plastic changes in the cytoskeletal
structure in response to external stimuli. The purpose of this study was
to analyse developmental changes in the expression and localisation of
MAP-2 isoforms, and their reactivity in status epilepticus (SE) in the
postnatal (P) rat hippocampus.
Method: MAP-2a-d expression in the hippocampi of P1 to P21 rats,
and their temporal expression patterns (0.5 h to 7 d) after kainic acid
(KA)-induced SE in P9 rats were studied with Western blotting. Immuno-
cytochemistry was used to localise MAP-2a and b in the hippocampi of
P1 to P21 rats, and the effect of SE on their localisation in P9 rats.
Results: The expression of MAP-2a and b significantly (p < 0.0001)
increased, whereas those of MAP-2c and d significantly decreased (p <
0.0001) in the rat hippocampus through P1 to P21. KA-induced SE sig-
nificantly (p < 0.0001), rapidly, but transiently increasing the expression
of MAP-2a and b. MAP-2a/b immunostaining was temporally and spa-
tially heterogeneous in neuronal compartments and the staining intensity
increased through P1 to P21 particularly in dendritic regions.
Conclusion: Our results show that MAP-2 isoform expression is
strictly developmentally regulated, and that MAP-2a/b distribution is het-
erogeneous in different neuronal compartments in the hippocampus. The
SE-induced reactivity of MAP-2 could contribute to structural integrity
of intracellular cytoskeleton and enhance neuronal viability during cell
stress. Acknowledgements: Sigrid Juselius Foundation, the Special State
Grant for Clinical Research to I.E.H, and Lea and Arvo Ylppo¨ Founda-
tion.
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LONG-LASTING ANTICONVULSIVE EFFECT OF LEVE-
TIRACETAM ON AUDIOGENIC SEIZURES IN RATS
1L. Vinogradova and 2C. van Rijn (1Institute of Higher Nervous Activity
and Neurophysiology, RAS, Moscow, Russia, 2NICI, Radboud Univer-
sity, Nijmegen, The Netherlands)
Purpose: The duration of the anticonvulsive effect of a single dose of
levetiracetam on audiogenic seizures in rats was tested.
Method: Rats of the Krushinski-Molodkina strain (n = 24) in which
sound stimulation induces seizures consisting of running and clonic–
tonic convulsions received a single intraperitoneal injection of a low (3
or 6 mg/kg), a high (50 mg/kg) dose of levetiracetam or saline (n = 6
in each group). Audiogenic seizures were induced one hour, one, two
and three weeks after drug injection. At the three-week time point, those
rats previously injected with the 3 mg/kg dose were again treated with
6 mg/kg. Incidence and latency of running and tonic components of
audiogenic seizures were recorded.
Results: The single injections of the low doses (3 or 6 mg/kg) did
not significantly change the seizure pattern as compared to the saline
group. The 50 mg/kg dose blocked tonic convulsions in 4 of 6 rats and
completely suppressed audiogenic seizures in the others. The effect of the
high dose was long lasting: a significant increase in the seizure latency
was observed for at least three subsequent weeks postreatment (p <
0.05). Moreover, the double injection of the low dose, with the three-
week interval, showed a significant anticonvulsive effect blocking tonic
convulsions in 4 of the 6 rats and completely suppressing audiogenic
seizures in 1 rat.
Conclusion: A single injection of levetiracetam induces a long-lasting
anticonvulsive effect on audiogenic seizures. Treatment, with even low
doses of levetiracetam, increases susceptibility of rats to subsequent drug
injections for at least three weeks postreatment.
p284
CHARACTERISATION OF THE INTRAHIPPOCAMPAL
KAINIC ACID STATUS EPILEPTICUS MODEL USING LONG-
TERM VIDEO-EEG MONITORING
A. Van Dycke, R. Raedt, D. Van Melkebeke, T. De Smedt, T. Wyckhuys,
L. Waterschoot, V. De Herdt, K. Vonck, and P. Boon (Ghent University
Hospital, Reference Center for Refractory Epilepsy and Laboratory for
Clinical and Experimental Neurophysiology, Belgium)
Purpose: The intrahippocampal kainic acid (KA) status epilepticus
(SE) model has been extensively described histopathologically and dur-
ing short term EEG monitoring. However, no studies have characterised
this model using long term video-EEG monitoring to determine other
seizure parameters such as mean frequency, duration and severity.
Method: Female Sprague-Dawley rats (n = 17, 200–250 g) were
stereotactically implanted with a guide cannula in the right hippocam-
pus and depth recording electrodes in both hippocampi. One week after
implantation KA (0.4 μg/0.2 μl) was injected in awake rats. Video-EEG
monitoring was performed during SE and 72 hours/week for 16 weeks.
A second recording of one week was performed 9 months after SE in 4
rats.
Results: Injection of KA resulted in the occurrence of SE in all rats.
One rat died during the first week after KA administration. 87% (14/16)
of the rats had spontaneous seizures during the first monitoring period.
In the remaining 2 rats, seizures were detected during the second moni-
toring. On average, 1.41 ± 2.05/24 h convulsive seizures (mean duration
71 ± 22 sec) and 0.55 ± 1.08/24 h periods with interictal discharges
(mean duration 43 ± 22 sec) were detected on EEG during the first
monitoring period. During the second recording period on average 1.88
± 2.90/24 h convulsive seizures (mean duration 75 ± 39sec) and 1.17 ±
1.70/24h periods with interictal discharges (mean duration 41 ± 19sec)
were detected on EEG.
Conclusion: The intrahippocampal KA SE model is a reliable model
to induce spontaneous epileptic seizures in rats. Mortality is very low, a
reasonable number of seizures occur and by 9 months after KA admin-
istration epileptic discharges are found in all rats.
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DEVELOPMENT OF SPATIOTEMPORAL DYNAMICAL
TRANSITIONS DURING EPILEPTOGENESIS
1,8S. Nair, 1,8D. Shiau, 1,4,5,6P. Carney, 6W. Norman, 1,3P. Pardalos,
1,2J. Principe, and 1,4,5,7,8J. Sackellares (1Biomedical Engineering, Uni-
versity of Florida, 2Electrical and Computer Engineering, University
of Florida, 3Industrial and Systems Engineering, University of Florida,
4Neurology, University of Florida, 5Neuroscience, University of Florida,
6Pediatrics, University of Florida, 7Psychiatry, University of Florida,
8Malcolm Randall VA Medical Center)
Purpose: We have used a spontaneously seizing animal model of lim-
bic epilepsy to investigate the occurrence of spatiotemporal transitions
involving dynamical convergence among different regions in an epilep-
togenic brain. We hypothesise that the frequency of these transitions
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increases progressively from the time of initial insult to the subsequent
manifestation of epilepsy.
Method: Young adult male Sprague-Dawley rats (N = 4) were used
in the study. The model was developed using chronic hippocampal stim-
ulation (CHS). The animals were connected to an automated system that
monitored the T-index calculated from short-term maximum Lyapunov
exponents estimated from multiple brain regions. A transition was de-
fined as a drop in T-index from a preset upper threshold (UT = 10) to a
lower threshold (LT = 2.662). The time leading to the first seizure was
divided into blocks of 12 hours and the frequency of transitions in each
block was calculated. The null hypothesis is rejected if the regression
slope is found to be significantly positive (p < 0.05).
Results: Two out of the 4 animals developed spontaneous seizures
after CHS. The first showed a progressive increase in frequency of spa-
tiotemporal transitions leading up to the first seizure (recording time
before seizure ∼232.9 hrs, slope = 0.09, p = 0.0005), the second ani-
mal showed an abrupt increase in incidence immediately preceding the
seizure (recording time before seizure ∼142.5 hrs, slope = 0.07, p =
0.0228). No dynamical transitions were observed in the 2 animals that
did not develop spontaneous seizures.
Conclusion: These results suggest that spatiotemporal transitions in-
volving convergence of dynamical values among brain regions may be
a marker for epileptogenesis.
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DAILY POSTNATAL MATURATION OF RAT CORTICAL NEU-
RON SIZES, ORIENTATIONS, AND THEIR GLUTAMATE
RECEPTORS AFTER PRENATAL RADIATION: IMMEDIATE
CORTICAL DYSPLASIA BUT DELAYED ONSET OF CORTI-
CAL EPILEPSY
T. Babb (Departments of Pediatrics and Neurology)
Purpose: Cortical dysplasia (CD) is a frequent pathology in infants
with intractable epilepsy. Cellular characteristics of the paediatric dys-
plastic cortex have altered subunit proteins of the N-methyl-d-aspartate
receptor. This study determined if and when the dysplastic cortex of post-
natal rat pups also showed altered NMDA subunit expressions compared
to age-matched controls.
Method: Dams were radiated with 145 Rads at embryonic day 17;
all offspring were studied at 24 hour intervals, ages 0 through 6. Cre-
syl violet stains were used to measure neuron sizes and orientations.
Immunocytochemical (ICC) stains for receptor subunits NR1 and NR2
were compared to the CV cytology, and the NR1 and NR2 protein lev-
els were measured by Western blots. Statistical comparisons between
control and radiated age matched pups were made within and between
treatment groups.
Results: Cresyl violet stains showed radiated pups sacrificed at
birth had cortical dysplasias and their siblings, examined subsequently,
showed neuron sizes and disorientations that increased linearly daily.
Daily increases were significant for neuronal lengths (p >0.002) and
neuronal diameters (p >0.01). NR1 and NR2 protein expressions in-
creased daily, but the groups were not significantly different.
Conclusion: We conclude that neurons surviving prenatal radiation
have all the molecular mechanisms for protein synthesis in the cytoplasm
(cell sizes), in the specialised receptors (NMDA subunits) and in neuritic
extensions that appear as early as day two. Hence, the process of epilepsy
likely occurs weeks later when all the axo-dendritic connections are fully
mature. (Support: NS 41375)
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ROLE OF OXIDATIVE STRESS IN PENTOXIFYLLINE-
INDUCED PROTECTION AGAINST STATUS EPILEPTICUS IN
IMMATURE RATS
M. Tariq, M. Ahmad, S. Al Deeb, and K. Al Moutaery (Armed Forces
Hospital, Riyadh, Saudi Arabia)
Purpose: Status epilepticus (SE) is a common neurological disorder
associated with significant neurodegenerative changes. Role of oxidative
stress (OS) in neuronal structure and function has been suggested in
SE patient. Recently, pentoxifylline (PTX), a potent immunomodulating
agent and free radical scavenger has been shown to protect pups against
experimentally induced SE. The present study was designed to determine
the role of oxidative stress in PTX-induced protection against SE in
immature rats.
Method: SE was induced in immature rats by administering a single
dose of lithium chloride (Li) (3mEq/kg, i.p.) on post natal day 19 (PD19)
followed (24 h later) by pilocarpine (Pc) (20 mg/kg, s.c.) on PD20. The
animals in test group received PTX (0, 20, 40 and 60 mg/kg, i.p.) 30
minutes before pilocarpine administration. The animals were sacrificed
at 1 and 24 h after the dose of Pc, their hippocampus and striatum were
removed for the determination of OS marker thiobarbituric acid-reactive
substances (TBARS) and glutathione (GSH).
Results: Ninety percent of the pups developed a SE seizure within 5
minutes of Pc injection which lasted for around 30 minutes. A significant
increase in TBARS and decrease in GSH was observed in the striatum
and hippocampus region both at 1 and 24 h after SE induction clearly
suggesting the role of OS. PTX dose-dependently attenuated the seizure
and OS in SE.
Conclusion: PTX significantly protected the pups against Li-Pc in-
duced SE and the OS. The protective effect of PTX may be attributed to
its antioxidative activity.
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ANTIEPILEPTOGENIC EFFECT OF ANTERIOR THALAMIC
HIGH FREQUENCY ELECTRICAL STIMULATION (ES) ON
PENTYLENETETRAZOL (PTZ) KINDLING IN RATS
A. Shandra (Odessa State Medical University, Odessa, Ukraine)
Purpose: Previous reports indicate that focal ES of discrete brain
structures inhibited seizure activity. The aim of this study was to analyse
the effect of single and multiple ES of anterior thalamic (AN) on the
PTZ-induced kindling in rats.
Method: Adult male Wistar rats were implanted with bipolar stimulat-
ing electrodes in the AN bilaterally. After recovery kindling was induced
by PTZ (30 mg/kg) i.p. administration daily for 4 weeks. Stimulation pa-
rameters of AN were: 100 Hz, 300-800 μA, 0.1 ms pulse duration for 30
sec. Two protocols were used: 1) single ES of the AN at the early stage of
development kindling and fully kindled animals, 2) multiple ES-effects
after 7 daily ES of the AN in kindled animals.
Results: Bilateral ES of the AN completely suppressed EEG epilep-
tiform activity in the early stage of PTZ-kindling and partially in fully
kindled rats. Acute ES of the AN did not appear to have any effect
on behaviour seizures. Multiple ES of the AN decreased by two-thirds
the number of rats with constantly generalised clonic-tonic convulsions
produced by PTZ-kindling. This ES resulted in increasing intensity of
seizure severity in kindled rats with seizures of stages 2-3.
Conclusion: We conclude that high-frequency ES of the AN can be
anticonvulsant, but the effects appear to depend on the intensity and type
of seizures.
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INFLUENCE OF DIPHOSPHONATE GERMANIUM WITH
NICOTINAMIDE (MIGU-5) ON THE ANTICONVULSIVE AC-
TIVITY OF CONVENTIONAL ANTIEPILEPTIC DRUGS IN
MICE
D. Voloshenkov, O. Kaschenko, V. Godovan, and V. Kresyun (Odessa
State Medical University, Odessa, Ukraine)
Purpose: We previously reported antiepileptic effects of MIGU-5 on
different forms of seizure activity. Since polytherapy is required for about
30% of epilepsy patients, the aim of this study was to characterise the ef-
fect of MIGU-5 on the protective activity of the conventional antiepileptic
drugs.
Method: Electroconvulsions were produced with corneal electrodes
and alternating current (50 Hz, 0.2 s stimulation duration) delivered by
a Grass S48 stimulator. The full tonic extension of hindlimbs was used
as an endpoint. The protective effect of MIGU-5 was evaluated in the
threshold test, while that of phenobarbital, carbamazepine, phenytoin and
valproate in the maximal electroshock test induced by current intensity
of 30 mA.
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Results: MIGU-5 (100 mg/kg, 30 min before the test) significantly
elevated the threshold for MES from 11.8 to 16.5 mA, being ineffective
up to 25 mg/kg. In the subprotective dose of 25 mg/kg MIGU-5 sig-
nificantly decreased the ED50 value of phenobarbital from 22.7 to 16.4
mg/kg, phenytoin (from 7.8 to 5.2 mg/kg), carbamazepine (from 9.5 to
6.1 mg/kg), valproate (from 286 to 190 mg/kg).
Conclusion: The results suggest that MIGU-5 possesses the potential
of an antiepileptic drug and can be used as an adjuvant antiepileptic drug.
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INFLUENCE OF SUPEROXIDE DISMUTASE ON CONVUL-
SIONS EVOKED BY PENTYLENETETRAZOL
1A. Jelenkovic, 1M. Jovanovic, 1M. Ninkovic, 1M. Maksimovic, and
1B. Boskovic (1Institute For Biological Research “Sinisˇa Stankoviæ,
2Military Medical Academy, Beograd, Serbia)
Purpose: In the pathogenesis of epilepsy, as well as in experimental
convulsions, oxidative stress has an important role.
Method: We thus investigated whether superoxide dismutase (SOD), a
part of the antioxidative defense system, can modulate pentylenetetrazol-
evoked convulsions in adult mail Wistar rats (n = 7). For intracere-
broventricular application of SOD, in pentobarbital anesthesia we in-
serted polyethylene cannula in the left lateral ventricle. Seven days after
recovery from surgery, rats received SOD (0.06 mg). It was applied
25 minutes before pentylenetetrazol (PTZ, 80 mg/kg of body weight,
intraperitoneally). In the first four minutes after PTZ application, we
recorded the appearance and latent period of forelimb dystonia (FLD),
generalised clonic (GCC) and clonic–tonic convulsions (CTC).
Results: All convulsive patterns were evoked by PTZ. Pretreatment
with SOD significantly influenced GCC and CTC, although in a differ-
ent way. The latent period of GCC was shortened (p = 0.03), but the
incidence was not changed. Opposite to GCC, CTC, defined as hind
limb extension, did not appear in any rat, but in all of them we recorded
front leg extension, with a shortened latent period than for hind limbs
extension in PTZ-treated rats (p = 0.02).
Conclusion: In the applied experimental model, SOD action depended
on the convulsive pattern. It deteriorated in the latent period for GCC,
prevented CTC, but it evoked tonic extension of front limbs, a pattern
that was not evoked by PTZ.
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ROLE OF SEX STEROID HORMONES IN THE REGULATION
OF ABSENCE SEIZURES
1,2E. Tolmacheva, 1S. Chepurnov, and 2G. Van Luijtelaar (1Dept. Hu-
man and Animal Physiology, Biological Faculty, Moscow State Uni-
versity, Moscow, Russia, 2Dept. Biological Psychology, NICI, Radboud
Nijmegen University, The Netherlands)
Purpose: A few recent studies have demonstrated that membrane ef-
fects of progestins are important in the regulation of typical absence
seizures in humans and in rats. In an animal genetic model of absence
epilepsy, acute injections of progesterone exacerbate the number of
spontaneous spike-wave discharges (SWDs) in both male and female
WAG/Rij rats (van Luijtelaar et al., Epilpesy Res 2001;46:225–239).
However, in contrast to this, we found that chronic elevation of proges-
terone during pregnancy is accompanied by a decrease of SWDs during
this period (Tolmacheva et al., Physiol and Behav 2004;81:623–627). In
the present study we tested whether castration and ovariectomy, which
eliminate the resource of gonadal steroids, would alter basal level of
spike-wave activity.
Method: The present study was performed in castrated and sham-
operated males and in ovariectomised and sham operated females of
WAG/Rij rats equipped with permanent EEG electrodes. Castration,
ovariectomy and sham operations were performed 2 weeks after im-
plantation of electrodes. EEG recordings (4 hours) were made before
and at 4th, 6th, 8th, 10th, 20th, 23th, and 35th day after the operation.
Results: The ANOVA showed a time effect in the dynamic of both the
number and duration of SWDs for all groups of rats, but no difference
between groups: either between castrated and sham operated male rats
or between ovariectomised and sham-operated female rats.
Conclusion: The present results suggest that a decrease in plasma level
of sex steroid hormones has no effect on the occurrence and duration of
absence seizures in WAG/Rij rats in basal conditions.
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EPILEPTOGENESIS AFTER CORTICAL PHOTOTHROM-
BOTIC LESIONS IN RATS
1,2H. Karhunen, 1Z. Bezvenyuk, 2J. Jolkkonen, and 1A. Pitka¨nen (1A.I.
Virtanen Institute for Molecular Sciences, Kuopio, Finland, 2Department
of Neuroscience and Neurology, University of Kuopio, Kuopio, Finland)
Purpose: To investigate the development of epilepsy after experimen-
tal photothrombotic stroke.
Method: Male Spraque-Dawley rats (n = 78) were included in
the study. Lesions to the somatosensory cortex or the motor cor-
tex were induced with intravenous injection of Rose Bengal dye and
photoactivation. Sham-operation included only injection of the dye. Con-
trol rats had only electrode implantation. Epileptic seizures were moni-
tored with video-electroencephalography 2, 4, 6, 8, and 10 months post-
stroke (24 h/d, 7–14 d). At the end memory was assessed with the Morris
water-maze, and brains were processed to detect mossy fibre sprouting
in the hippocampus.
Results: Epilepsy developed in 19% of the rats with lesions in the
somatosensory cortex. Electrographic seizures were accompanied by
bilateral forelimb clonus or rearing and falling. Mean daily seizure fre-
quency was 0.22 ± 0.17 and seizure duration 104 ± 65 sec. Seizures
were not detected after lesioning the motor cortex. Memory impairment
was detected in rats with lesion in the somatosensory cortex (p < .05).
Histological analysis revealed that the epileptic rats had increased mossy
fibre sprouting in the hippocampus (p < .01).
Conclusion: Lesion to the somatosensory cortex results in epilepsy
in a subpopulation of rats. The model provides a tool to investigate
pathophysiological changes leading to poststroke epilepsy.
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NEUROPROTECTIVE EFFECT OF ZONISAMIDE ON HY-
POXIC ISCHEMIC BRAIN INJURY IN NEONATAL RATS
1E. Baik-Lin, 1C. Hyung Chol, 1S. Dong Han, 1E. So Hee, 1C. Byung
Min, 2S. Woong, and 2K. Hyun (1Department of Pediatrics, Korea Uni-
versity College of Medicine, Korea, 2Department of Anatomy, Korea
University College of Medicine, Korea)
Purpose: The objective of this study was to determine the ability
of a novel sodium channel blocking compound, zonisamide, to reduce
neuronal damage by preventing the ischemia-associated accumulation
of extracellular glutamate in postnatal day 7 Sprague-Dawley rats.
Method: The right common carotid artery of the rat was coagulated
and then the rat was exposed to 8% oxygen for 2 hrs. Zonisamide (20, 50,
100, 200 mg/kg, every 12 hrs for 5 days) administered by intraperitoneal
injection in pre- and posttreatment regimens, and controls received ve-
hicle. Severity of injury was assessed 5 days later by visual evaluation
of ipsilateral hemispheric infarction, and by measurement of bilateral
hemispheric cross sectional areas.
Results: Zonisamide pretreatment resulted in a decreased incidence of
liquefactive cerebral infarction (p < 0.05). Quantitation of hemispheric
areas in rats receiving zonisamide and control littermates confirmed the
results of initial inspection (p < 0.01).
Conclusion: Pretreatment with zonisamide decreases the incidence
and severity of ischemic brain damage in this animal model of perinatal
cerebral hypoxia ischemia. These data indicate that zonisamide plays
a role in the evolution of hypoxic ischemic injury to the developing
brain, and that zonisamide pretreatment may offer an effective means to
decrease the incidence and severity of perinatal hypoxic ischemic brain
injury.
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INFLUENCE OF 1.4-BENZODIAZEPINE DERIVATIVES ON
SPONTANEOUS NEURONAL BURSTS OF HIPPOCAMPAL CA1
PYRAMIDAL CELLS
1A. Oliynyk, and 1R. Vastyanov (1Odessa State Medical University,
Ukraine)
Purpose: Synaptic networks are important for epileptiform ac-
tivity (EpA) genesis, spreading and cessation. Hypersynchronisa-
tion of neuronal activity takes place without participation of action
potential-dependent chemical synaptic transmission (low-Ca2+/low-
Mg2+mediums). Using in vitro extracellular recording in area CA1 we
characterised the antiepileptic properties of 1.4-benzodiazepine deriva-
tives diazepam, gidazepam and cinazepam.
Method: Male Wistar rats were used for the experiments and slice
preparations. After decapitation the rats’ transverse slices were incu-
bated at 32◦C using aCSF. Other solutions lacking Ca2+and Mg2+ ions
were used. Populational responses were recorded by placing a tungsten
microelectrode in the stratum pyramidale of the hippocampal CA1 field.
The population spikes (PS) were bandpass filtered at 300 Hz before being
digitised (PCI-6071E, National Instruments, USA) at 5 kHz sampling
rate. Quantitative parameters of electrical activity (spikes amplitude,
numbers, threshold of excitation etc) were analysed with a programme
entirely written in LabVIEW.
Results: Perfusing of the slices with low-Ca2+/low-Mg2+aCSF in-
duced self-excitation of pyramidal neurons (8–15/min, 3,5–5 mV) at
14–17 min of observation. Coinfusion with diazepam completely pre-
vented and with gidazepam delayed the appearance of low-Ca2+/low-
Mg2+EpA. Cinazepam administration statistically failed in spikes gen-
eration but decreased their frequency and amplitude.
Conclusion: Thus, in the model of spontaneous paroxysmal bursting
activity induced by decreasing Ca2+and Mg2+contents we showed the
importance of GABA mediated processes in epileptiform process in the
CA1 region of rat hippocampal slices. A different profile of effects of
1.4-benzodiazepine derivatives was revealed. This model in vitro might
be of great value for the potential antiepileptic substances efficacy in-
vestigation.
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COMPARISON OF ANTICONVULSANT EFFECT OF TWO DIF-
FERENT NONCOMPETITIVE NMDA RECEPTOR ANTAGO-
NISTS IN IMMATURE RATS
D. Lojkova´, and P. Mares (Institute of Physiology, Academy of Sciences
of The Czech Republic)
Purpose: To compare the anticonvulsant action of noncompetitive
NMDA-receptor antagonists, memantine and ifenprodil.
Method: Cortical stimulation and registration electrodes were im-
planted to 12-, 18- and 25-day-old Wistar rats. Memantine (10 and 20
mg/kg) and ifenprodil (20 and 40 mg/kg) were administered i.p. Control
siblings received saline. All individual groups were formed by 8 rats.
Stimulation started 20 min after administration. Electrical stimulation
of sensorimotor cortex was repeated with increasing current intensity
(0.2–15 mA). EEG was recorded before and during stimulation, during
the AD and 2 min afterwards. Behaviour of animals was marked into
the recording. ADs duration and threshold current intensities for four
different phenomena were evaluated.
Results: Memantine: Threshold intensity necessary for elicitation of
movements accompanying stimulation was increased by the higher dose
in 18- but decreased in 25-day-old rats. Threshold for spike-and-wave
type of ADs was increased by the higher dose in 12- and 18-day-old
rats whereas threshold for transition into the limbic type of ADs was
increased only in 25-day-old rats. Both doses used led to shortening
of ADs in all three age groups. Ifenprodil: Threshold intensities for
movements and spike-and-wave ADs were not significantly changed. In
contrast, ifenprodil decreased thresholds for transition into the limbic
type of ADs in 18- and 25-day-old animals. Duration of ADs was not
changed in 12-day-old rats but it was increased in both 18- and 25-day-
old rats.
Conclusion: Memantine exhibited anticonvulsant action whereas
ifenprodil mostly potentiated cortical epileptic afterdischarges in
immature rats. Supported by research projects 305/06/1188 and
AV0Z5011009.
p296
COMBINATION OF DELTA SLEEP-INDUCING PEPTIDE
AND VALPROATE IN METAPHIT MODEL OF AUDIOGENIC
SEIZURES IN RATS
O. Stanojlovic, D. Hrncic, D. Zivanovic, A. Rasic, and V. Susic (Depart-
ment of Physiology, School of Medicine, University of Belgrade, Serbia
and Montenegro)
Purpose: Effects of delta sleep-inducing peptide (DSIP), a nat-
ural nona-peptide and valproate, a conventional antiepileptic drug
on metaphit (1-[1-(3-isothiocyanatophenyl)-cyclohexyl]-piperidine)-
induced audiogenic seizures as a model of generalised, reflex audiogenic
epilepsy were studied.
Method: For that purpose, valproate in the dose of 50 or 75 mg/kg
and DSIP (1.0 mg/kg) were i.p. injected either alone or in combination
with DSIP (1 mg/kg,i.p.) to adult Wistar rat males with fully devel-
oped metaphit seizures after 8th audiogenic testing. The animals were
stimulated using an electric bell (100 ± 3 dB and 5–8 kHz, for 60 s)
60 min after metaphit injection and afterwards at hourly intervals during
the experiment. For power spectra and EEG recordings, three gold-plated
screws were implanted into the scull.
Results: In metaphit-treated animals EEGs appeared as polyspikes,
spike-wave complexes and sleep-like patterns, while the power spectra
were increased comparing to the corresponding controls. Neither val-
proate nor DSIP given alone expressed significant effects on behavioural
characteristics of metaphit-induced seizures. However, when given in
combination, valproate and DSIP significantly decreased the incidence
and intensity of seizures and prolonged the latency period for 6 h after
administration. None of the applied dose combinations eliminated the
EEG signs of metaphit-provoked epileptiform activity.
Conclusion: The results of the present study suggest that the combina-
tions of valproate and DSIP could be considered as beneficial polytherapy
in metaphit model of epilepsy.
p297
PROPHYLACTIC TREATMENT WITH VALPROATE AFTER
STATUS EPILEPTICUS IN RATS PREVENTS HIPPOCAMPAL
DAMAGE AND IMPROVES BEHAVIOUR BUT HAS NO EFFECT
ON THE DEVELOPMENT OF EPILEPSY
C. Brandt, A. Gastens, M. Sun, M. Hausknecht, and W. Lo¨scher (Uni-
versity of Veterinary Medicine, Hannover, Germany)
Purpose: The development of temporal lobe epilepsy (TLE) is often
associated with an initial insult such as status epilepticus (SE). TLE is
frequently accompanied by cognitive and behavioural alterations. An
intriguing aim in the treatment of TLE is to prevent epileptogenesis after
the initial insult or at least to modify this process in such a way that
the developing epilepsy is easier to treat and without cognitive decline.
One strategy to interfere with epileptogenesis is the prevention of the
occurring neurodegeneration. We investigated the effect of prophylactic
valproate (VPA) treatment on the development of spontaneous recurrent
seizures (SRS), hippocampal sclerosis and cognitive and behavioural
alterations in a TLE-model.
Method: Self-sustained SE was electrically induced in rats and was
interrupted after 4 hours by diazepam. VPA (400 mg/kg i.p.) was ad-
ministered immediately thereafter and was continued 3 times daily (200
mg/kg) for 4 weeks. Rats treated with saline after SE served as controls.
Four weeks after drug treatment SRS were monitored by continuous
video/EEG-recording for 1 week. Subsequently, the rats were tested in
a battery of behavioural tests. Neurodegeneration was evaluated in the
hippocampus in horizontal thionin stained sections.
Results: Prophylactic treatment with VPA prevented neurodegenera-
tion in the hippocampus. Still, all rats developed SRS after the treatment
was terminated but VPA-treated rats showed marked improvement in
several behavioural paradigms compared to the vehicle-treated epileptic
rats.
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Conclusion: VPA seems to be a valuable tool to reduce neurodegen-
eration and behavioural alterations in a rat model for TLE but it does not
prevent the development of epilepsy.
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IS ETHOSUXIMIDE INEFFECTIVE IN KINDLING PROCESS?
A. Azizova Gurbanova, R. Gu¨lhan Aker, A. Ergu¨n ¨Ozkaynakc¸y´, and
F. Yy´lmaz Onat (Marmara University, School of Medicine, Istanbul,
Turkey)
Purpose: Ethosuximide (ETS), a first choice antiabsence drug, has
no consistent efficacy for any convulsive type of epilepsy. In this study,
we aimed to evaluate the effect of ethosuximide on epileptogenesis in a
kindling model.
Method: In the experiments Wistar animals were instrumented stereo-
taxically with bilateral stimulation and recording electrodes into the ba-
solateral amygdala and recording electrodes on the cortex. After one
week recovery period, animals were injected intraperitoneally with phys-
iological saline (control group, n = 7), ETS 50 mg/kg (n = 2) or ETS
100 mg/kg (n = 4) an hour before each electrical stimulation. Animals
were electrically stimulated twice daily at their afterdischarge thresh-
olds. The seizure severity was evaluated using Racine’s 5-stage scale.
Animals were considered as fully-kindled when they experienced five
stage 5 seizures.
Results: All animals in the control group were fully kindled and the
mean number of stimulations for the development of the first stage 5
seizure was 13 ± 0.6. Wistar rats treated with ETS (50 mg/kg) showed
a similar rate and pattern of kindling with control group. ETS delayed
the development of forelimb clonus in 100 mg/kg treated group. Two
out of 4 Wistar rats in this group remained at stage 3 or 4 although
30 stimulations were applied. The mean number of stimulations for the
development of the first stage 5 seizure in the remaining 2 animals was
25 ± 2.1.
Conclusion: Although ETS is considered as ineffective on convulsive
seizures it may delay the development of convulsive seizures in a kindling
model.
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NEUROPATHOLOGICAL CLASSIFICATION OF AMMON’S
HORN SCLEROSIS
1M. Hildebrandt, 2E. Pauli, 3J. Romsto¨ck, 2H. Stefan, 4J. Schramm, 4H.
Clusmann, 5A. Becker, 6C. Elger, 7J. Zentner, 7C. Scheiwe, 8B. Volk,
9A. Schulze-Bonhage, 10H. Meencke, 10T. Lehmann, and 1I. Blu¨mcke
(1Department of Neuropathology, Erlangen, Germany, 2Department of
Neurology, Erlangen, Germany, 3Department of Neurosurgery, Erlan-
gen, Germany, 4Department of Neurology, Bonn, Germany, 5Department
of Neuropathology, Bonn, Germany, 6Department of Neurology,
Bonn, Germany, 7Department of Neurosurgery, Freiburg, Germany,
8Department of Neuropathology, Freiburg, Germany, 9Department of
Neurology, Freiburg, Germany, 10Epilepsy Center, Berlin-Brandenburg,
Germany)
Purpose: Histopathological investigation of hippocampal specimens
obtained from patients with temporal lobe epilepsies shows different
degrees of neuronal loss within hippocampal subfields and dentate gyrus.
We employed cluster analysis to identify distinct pathological groups.
Method: We obtained 178 surgically resected hippocampal speci-
mens. Neuronal cell counts per mm2 were performed within hippocam-
pal subfields CA1-CA4 and dentate gyrus using immunohistochemistry.
These data provided a basis for cluster analysis. All clusters were corre-
lated with clinical data.
Results: Cluster analysis revealed five pathological subgroups (clus-
ters). A first cluster revealed neuronal densities within normal range (n
= 34, 19%). Three clusters showed severe cell loss within hippocam-
pal sector CA1 and different degrees of neuronal loss within the other
anatomical subfields. We could separate CA1-sclerosis (n = 10, 6%)
with moderate neuronal loss from classic hippocampal sclerosis (n =
33, 18%) with marked, and severe hippocampal sclerosis (n = 94, 53%)
with extensive neuronal loss in all other segments. End folium sclerosis
was defined by moderate loss within CA2-CA4 and dentate gyrus and
neuronal cell densities nearly normal in CA1. Correlation with clini-
cal parameters showed significant differences between age at fist event
and distinct clusters: in classic and severe hippocampal sclerosis the first
event occurred within the first three years of life, in CA1-sclerosis within
six years and in end folium sclerosis and normal appearing hippocampus
within 13 or 16 years, respectively (p = 0.001).
Conclusion: Cluster analysis identified five distinct grades of hip-
pocampal pathology. CA1-sclerosis occurred as a new entity. Manifes-
tation of the first event, respectively the developmental state at which
the first event compromised brain maturation influences patterns of hip-
pocampal pathology.
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ASTROCYTES MIGHT PLAY A ROLE IN EPILEPTOGENESIS
G. Argan˜araz, 1S. Perosa, 1E. Cavalheiro, and 1M. Naffah-Mazacoratti
(Universidade Federal de Sa˜o, Sa˜oPaulo, Brazil 2Universidade Federal
de Saˇo, SaˇoPaulo, Brazil
Purpose: The pilocarpine model is used to study complex partial
seizures with secondary generalisation. The astrogliosis is a prominent
feature of epileptic foci, and may play a causal role in the development
of seizures and the persistence of this epileptic disorder. Previous stud-
ies demonstrated that the rodent Proechimys guyannensis (PG) exhibits
resistance to experimental models of epilepsy. The Wistar rats present
long-lasting status epilepticus (SE), and spontaneous seizures and PG
shows short-lasting SE, which did not evolve to the chronic phase. Thus,
reactive astrogliosis was compared in PG and Wistar rats, submitted to
the pilocarpine model of epilepsy.
Method: The brains of both species of rodents were removed 3 h after
pilocarpine-induced SE. Immunohistochemistry (n = 3) and Western
Blotting (n = 6) were performed to study the expression of glia fibrillary
acid protein, (GFAP) in the hippocampal formation from both species of
rodents. Both protocols were used in saline-treated animals and with 3h
after SE onset.
Results: Show i) The saline-treated PG showed, by both experi-
mental protocols, increased expression of GFAP, when compared with
saline-treated Wistar rats (∗p = 0.0123); ii) When compared with their
proper control, both species showed increased expression of hippocam-
pal GFAP, after SE (PG ∗∗p = 0.00019; Wistar ∗∗∗p = 4.29 × 10−9).
When both SE-groups were compared no difference was found.
Conclusion: Both species showed astrogliosis after SE onset but, as
the expression of GFAP is already major in saline-treated PG animals,
its increase is minor compared with those observed in Wistar rats, sug-
gesting a possible function of gliosis in the epileptogenic process.
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HIPPOCAMPAL EXPRESSION OF KININ B2 RECEPTOR IN
FEMALE RATS SUBMITTED TO THE PILOCARPINE MODEL
OF EPILEPSY
S. Perosa, G. Argan˜araz, F. Carvalho, J. Silva Jr, J. Pesquero, E. Cav-
alheiro, D. Amado, and M. Naffah-Mazzacoratti (Universidade Federal
de Sa˜o Paulo, Sa˜o Paulo, Brazil)
Purpose: Kinins, a class of polypeptides represented by bradykinin,
kallidin, and their metabolites, acting via B1 and B2 receptors, have
been related to inflammation, cytokines action, glutamate release and
prostaglandin production. Several studies indicate that in the central ner-
vous system and peripheral tissues, estrogen regulates the expression
of the B2 receptor and reduces cytokine production and inflammatory
responses. Accordingly, the present work aimed to investigate the expres-
sion of kinin B2 receptors in normal and neutered female rats, submitted
to the pilocarpine model of epilepsy.
Method: The brains of Wistar adult females of rats in both groups were
removed 6h, 12h, 5 days and 60 days after pilocarpine-induced status
epilepticus and immunohistochemistry (n = 4) was performed to study
the expression and distribution of kinin B2 receptor in the hippocampal
formation.
Results: The results showed decreased immunoreactivity against B2
receptor in non-neutered rats during the acute and silent periods of this
epilepsy model. In contrast, the immunoreactivity against B2 receptor
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in neutered rats was increased during the acute and silent periods when
compared with control neutered rats.
Conclusion: This study provides evidence that the expression of kinin
B2 receptor in the hippocampus is modified in female rats during epilep-
togenesis and that the expression of this receptor is modulated by steroid
hormones. Supported by FAPESP, CNPq, CAPES.
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TRANSGENIC MICE CARRYING APPSWE/PS1(DE9) MUTA-
TIONS EXHIBIT EPILEPTIC SEIZURES
R. Minkeviciene, H. Tanila, and A. Pitka¨nen (A. I. Virtanen Institute for
Molecular Sciences, University of Kuopio, Finland)
Purpose: Alzheimer’s disease (AD) increases the risk of epilepsy 9-
fold (Hesdorffer et al., Neurology 1996;46(3):727-30) and is one of the
most common underlying factors for epilepsy in the elderly. Occurrence
of seizures is especially high in rare familial cases of AD with mutation in
presenilins (Velez-Pardo et al., Epilepsia 2004;45(7):751-6). Until now
there is no animal model for AD-related epilepsy.
Method: In the study we used 12 week old male mice, 21 APP-
swe/PS1(dE9) (Jankowsky et al., Hum Mol Genet 2004;13(2):159–70),
and 9 nontransgenic littermates. A week before the recording all mice
were implanted with chronic cortical electrodes. Mice were video-EEG
monitored (La¨hteinen et al., Eur J Neurosci 2002;15(4):721–34) for 2
weeks (24 h/day) to detect spontaneous seizures.
Results: Electrographic seizures were detected in 24% (5) of trans-
genic animals (duration 0.22 ± 0.02 SEM) and none of the controls.
Interictal spiking activity was found in 43% (9) of transgenic mice but
in no control mice. Epileptiform discharges were present in 48% (10) of
transgenic and in 11% (1) nontransgenic mice.
Conclusion: APPswe/PS1(dE9) mice provide a promising model to
study molecular mechanisms underlying AD-related epileptogenesis.
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GENERATION OF EPILEPTOID ACTIVITY IN THE ˜N `A1 HIP-
POCAMPAL AREA UNDER THE ACTION OF EXCITATORY
AMINO ACID RECEPTOR ANTAGONISTS
Y. Garkun, V. Kulchitsky, A. Denisov, and V. Evstigneev (Institute of
Physiology, Natl. Acad. Sci., Minsk, Belarus)
Purpose: This work was aimed at the study of formation of field
excitatory postsynaptic potentials (fEPSPs) and population spikes (PS) in
the CA1 area of rat hippocampus with respect to glutamatergic synapses.
Method: Experimental series were performed on 400 μm-thick hip-
pocampal slices from 4-week old rats. PS and fEPSPs in the CA1 area
evoked by the first and second paired pulses (50 ms interval, 30–50 μA,
200 μs/phase) were recorded in series on 58 hippocampal slices from 18
young rats. Slices were perfused with 10−4−10−10 M of ibotenic acid
or 10−3−10−10 M of kynurenic acid.
Results: Ibotenic acid in the concentration of 10−4−10−10 M resulted
in a simultaneous decrease of fEPSPs and PS amplitudes. Ibotenic acid in
the toxic concentration of 10−4−10−5 M completely inhibited responses
after 90 sec of application. At concentration of 10−6−10−10 M a progres-
sive decrease of fEPSPs and PS amplitudes was achieved down to a level
30-50% to initial, where the amplitudes finally stabilised. Kynurenic acid
in the 10−3−10−10 M concentration resulted in the decrease of fEPSPs
and PS amplitudes. At concentration of 10−3 M the toxic effect of full
blockade of responses was observed. After application of 10−4–10−7
M ibotenic or kynurenic acids (agonist and antagonist excitatory amino
acid receptors) in the CA1 hippocampal area the convulsive activity not
typical for this hippocampal area was found out.
Conclusion: Thus, this model of epileptoid activity in the CA1 area
is supposed to be used for screening of new anticonvulsive drugs.
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LAMOTRIGINE (LTG) ENHANCES ENDOGENOUS
ANTIEPILEPTIC PROCESSES IN THE SINGLE NEURON
(BUCCAL GANGLIA, HELIX POMATIA)
1L. Horva´th, 2H. Hesekamp, and 2U. Altrup (1Central Pharmacy, Med-
ical and Health Science Centre, University of Debrecen, Debrecen,
Hungary, 2Institute of Experimental Epilepsy Research, University of
Mu¨nster, Mu¨nster, Germany)
Purpose: Mechanisms of LTG in the nervous system are still poorly
understood.
Method: Effects of LTG were studied in the buccal ganglia of He-
lix pomatia used as a model nervous system. Under in vitro conditions
the buccal ganglia are structurally and functionally intact. Ganglia con-
tain identified giant neurons. The snail nervous system corresponds in
all epileptogenic aspects to a mammalian nervous system. Epileptiform
activity (paroxysmal depolarisation shifts, PDS) was induced with bath
application of pentylenetetrazol (1 mM to 40 mM). LTG (5 μM to 200
μM) was added to the solutions.
Results: Endogenous antiepileptic processes terminate “neuronal
seizures” and block status epilepticus. Endogenous antiepileptic pro-
cesses depend on [Mg2+]o which could not be replaced by Sr2+. LTG en-
hanced endogenous antiepileptic processes; its effects cannot be washed
out. Pretreatment with LTG weakened subsequent epileptiform activity.
LTG-effects survive LTG application for hours.
Conclusion: Slow commencement as well as lack of wash out of LTG-
effects is not in agreement with direct effects of LTG by receptor bind-
ing. LTG appears to accelerate and enhance endogenous antiepileptic
processes in the single neuron. Cell’s natural defence was strengthened
by Mg2+ and LTG.
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EFFECT OF ACUTE AND CHRONIC LIGHT/DARK CYCLE AL-
TERATION ON SEIZURE THRESHOLD IN MICE: MODULA-
TION BY MELATONIN
N. Yahyavi-Firouz-Abadi, P. Tahsili-Fahadan, K. Riazi, and A. Dehpour
(Tehran University of Medical Sciences (TUMS),Tehran, Iran)
Purpose: Changes in seasonal and circadian rhythms have been shown
to alter the anticonvulsant properties of various drugs. In this study, we
investigated the effect of light/dark (LD) cycle alteration on pentylenete-
trazol (PTZ)-induced clonic seizure threshold in male mice.
Method: In acute experiments, LD cycle of 2 groups (n = 6–7 for
each group) of mice were changed from 12/12 to 8/16 or 16/8 LD cycles
and seizure threshold was determined at zeitgeber time (ZT) = 4 of the
next day. In chronic experiments, 3 distinct sets of mice were maintained
on 12/12, 8/16 and 16/8 LD cycles for 2 weeks prior to testing.
Results: In acute experiment, mice maintained on a longer photope-
riod showed a significant decrease (seizure threshold as mean ± SEM:
25.63 ± 0.88) in seizure threshold, while keeping animals under longer
photoperiod (32.72 ± 0.89) did not produce a significant proconvul-
sant effect compared to animals under 12/12 LD cycle (32.41 ± 0.68).
This proconvulsant effect was reversed by single i.p. administration of
melatonin (10 mg/kg) at ZT = 10 on the first day. Chronic LD cycle
alterations (both 8/16 and 16/8) decreased the seizure threshold signif-
icantly in comparison to animals under 12/12 LD cycle (26.69 ± 1.63,
26.57 ± 0.80, 34.52 ± 0.73 respectively). Chronic i.p. administration of
melatonin (10 mg/kg) at ZT = 10 in these photoperiod groups reversed
the effect of LD cycle alteration on seizure threshold.
Conclusion: These results suggest that both acute and chronic alter-
ation of LD cycle may influence seizure susceptibility and this effect
could be modulated by administration of exogenous melatonin.
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COMPARATIVE ANALYSIS OF TWO ANTIEPILEPTIC DRUGS
IN DIFFERENT ANIMAL MODELS
1,2S. Borbe´ly, 1D. Lojkova, 1P. Mares, and 1,2I. Vila´gi (1Institute of
Physiology, Academy of Sciences of The Czech Republic, Prague, Czech
Republic, 2Eo¨tvo¨s University, Institute of Biology, Budapest, Hungary)
Purpose: Epilepsy is a widespread chronic brain disorder with dif-
ferent backgrounds. Introducing a new specific antiepileptic drug can
improve life conditions of several patients. In a recent series of experi-
ments we tested the efficacy of the sodium channel blocker lamotrigine
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and the non-competitive NMDA receptor antagonist memantine in dif-
ferent epilepsy models.
Method: In in vitro cortical brain slice experiments the effect of lam-
otrigine or memantine on evoked field responses was tested. Slices were
prepared from young, male Wistar rats and sensitised with different
convulsants (4-aminopyridine, bicuculline-methiodide, Mg2±free so-
lution). The efficacy of memantine was also investigated in immature
rats (12, 18 and 25 days old) both with in vitro and in vivo methods.
In slices the change of evoked field responses while, in freely moving
rats with implanted electrodes the cortical epileptic discharges in the
sensorymotor area were analysed.
Results: In the presence of the three convulsants a late component of
evoked responses developed which was significantly reduced by lamot-
rigine. Memantine hardly affected the pattern of evoked responses either
in the in vivo or in vitro models, however it suppressed cortical epileptic
afterdischarges in all three age groups of rat pups studied.
Conclusion: Our data indicate that lamotrigine effectively blocks the
overexcitation of different underlying mechanisms. Memantine has a
weak inhibitory effect on overexcitation, however, strongly suppresses
seizure activity.
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MATRIX METALLOPROTEINASE-9 INDUCES INTEGRIN-
ASSOCIATED HIPPOCAMPAL CELL DEATH IN MICE WITH
PILOCARPINE-INDUCED SEIZURE
B. Lee, K. Heo, G. Kim, Y. Cho, K. Cho, H. Kim, and H. Kim (Yonsei
University College of Medicine, Seoul, South Korea)
Purpose: Recent evidence has demonstrated that matrix
metalloproteinase-9 (MMP-9) is activated and involved in neu-
ronal cell death in response to excitotoxic stresses such as ischemia or
seizure. However, the exact role of the MMP-9 in the seizure-related
cell death remains to be elucidated. In this study, we investigated the
role of MMP-9 in seizure-related hippocampal cell death, hypothesising
that the activation of MMP-9 after seizure would induce cell death by
interrupting integrin signaling.
Method: Seizures in C57BL/6 mice were induced by intraperitoneal
pilocarpine injection. Hippocampal cell death was evaluated using cre-
syl violet staining and TdT-mediated UTP-biotin nick end labelling
(TUNEL). The expression and activity of MMP-9 after a seizure were
evaluated by zymography, Western blot analysis, and immunohisto-
chemistry. Caspase-3 activity and integrin expression were also inves-
tigated. MMP-9 specific hydroxamic inhibitor was administered intrac-
erebroventrically 3 hours after a seizure.
Results: The activity and expression of MMP-9 increased after a
pilocarpine-induced seizure. TUNEL-positive cells and neuronal death
were evident in the hippocampus 24 hours after a seizure. Caspase-3
activity was also increased, but the integrin level was markedly reduced
after a seizure. MMP-9 specific inhibitor attenuated MMP-9 activity and
hippocampal cell death. DNA fragmentation and caspase-3 activity were
reduced also. Furthermore, the reduction of integrin expression after a
seizure was alleviated by treatment of MMP-9 inhibitor.
Conclusion: Our results suggest MMP-9 may be associated with
mice hippocampal cell death after pilocarpine-induced seizures, in part,
through inhibition of integrin signalling.
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OXYGEN GLUCOSE DEPRIVATION (OGD) INDUCED TOL-
ERANCE UP-REGULATES THE NOVEL NEUROPROTECTIVE
PROTEIN, 697-27, IN RAT CORTICAL CULTURES
1,5K. Kurkinen, 3Z. Chi, 4C. Dai, 2D. Liang, 1,2,3T. Dawson, and 1,2,3,4V.
Dawson (1Institute for Cell Engineering, 2Department of Neurology,
3Department of Neuroscience, 4Department of Physiology, Johns Hop-
kins University, Baltimore, MD, USA, 5A.I.Virtanen Institute For Molec-
ular Sciences, Dep. Neurobiology, Univ. Kuopio, Kuopio, Finland)
Purpose: Ischemic preconditioning is a powerful phenomenon in
which a sublethal stimulus provides protection against subsequent lethal
stress; however, the exact mechanism of ischemic preconditioning in the
brain is not known. Understanding the molecular mechanisms behind
preconditioning could provide valuable information for drug design to
prevent or repair tissue from cerebral ischemia or epileptic seizures.
Method: In this study we examined more precisely one of the novel
cytoprotective genes that was found from OGD preconditioned rat cor-
tical neurons using a functional screening strategy.
Results: The transcript of, 697-27, is ∼ 2.7 kb in length. Its pro-
tein encoding region results in a 303 aa protein, 34 kD in size. The
C-terminal part of 697-27 possesses an ATPase domain belonging to
the AAA+ protein family. 697-27 also has a longer transcript from its
N-terminus resulting in a 40 kD protein. The full-length form of 697-27
protein has a putative transmembrane domain in the most N-terminal
part. Northern blot reveals that 697-27 mRNA is expressed in a vari-
ety of organs studied including several brain regions. Our polyclonal
C-terminal peptide antibody detects 697-27 protein from all the organs
studied. OGD preconditioning up-regulates 697-27 protein as early as
1 hour after treatment and protein levels return back to the basal level
at 72 hours. Transient transfection 697-27 protects rat cortical neurons
against subsequent lethal OGD.
Conclusion: These findings suggest that 697-27 protein might play a
crucial protective role in OGD preconditioning.
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PERSISTENT SUSCEPTIBILITY TO SEIZURES AFTER TRAU-
MATIC BRAIN INJURY
I. Kharatishvili, J. Nissinen, R. Immonen, O. Grohn, and A. Pitkanen
(University of Kuopio, A.I.Virtanen Institute, Department of Neurobiol-
ogy, Kuopio, Finland)
Purpose: To examine long-term seizure susceptibility in rats with
traumatic brain injury (TBI) with or without epilepsy.
Method: TBI was induced by lateral fluid-percussion injury to 30 rats
(10 shams). Twelve months postinjury, rats with TBI were divided into
nonepileptic and epileptic subgroups based on occurrence of spontaneous
seizures in video-EEG monitoring. Seizure susceptibility was tested by
injecting pentylenetetrazol (PTZ, 30 mg/kg, i.p.) and monitoring be-
havioural/electrographic responses for 1 h. Latency to the first epilep-
tiform change in EEG, latency to the first behavioural/electrographic
seizure, duration, and behavioural seizure severity were measured.
Results: PTZ produced seizures in 100% of rats with TBI with
epilepsy, in 82% of rats with TBI without epilepsy, and in 73% of shams.
Latency to the first change in EEG was the shortest in nonepileptic an-
imals (1.9 ± 0.8 min) compared to epileptic rats (2.6 ± 2.6 min) and
shams (3.5 ± 4.6 min), (p > 0.05). Latency to the first electrographic
seizure differed between the epileptic rats, nonepileptic rats and shams
(1.9 ± 0.8 vs 3.3 ± 1.8 vs 7.2 ± 6.0 minutes, respectively, p < 0.05).
Post hoc analysis indicated a difference between the shams and both TBI
groups (p < 0.05). In both TBI groups, latency to the first behavioural
symptom was 30% of that in shams (p < 0.01, no difference between the
TBI groups). Behavioural seizure score was the lowest in the TBI non-
epileptic rats (3.3 ± 0.8) compared to epileptic rats (4.8 ± 0.4) or shams
(5.0) (p < 0.01). Seizure duration did not differ between the groups.
Conclusion: Our data show that TBI results in chronic neuronal ex-
citability also in rats without overt behavioural and electrographic spon-
taneous seizures.
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NEWLY ONSET CLUSTER SEIZURES CAUSED BY ORAL
CONTRACEPTIVES: RELATED CEREBRAL VENOUS
THROMBOSIS
S. Lai, C. Hsieh, and M. Lan (Kaohsiung Chang-Gung Memorial Hos-
pital, Taiwan)
Purpose: Newly onset focal seizures with a history of pill taking are
an important diagnostic clue for venous thrombosis.
Method: We evaluated two females with new onset cluster seizures
and pills use.
Results: Case one is a 42-year-old female. First seizure attack pre-
sentation was right upper limb twitching evolving to 4 limbs twitching
with impairment of consciousness. These episodes occurred three times.
Epilepsia, Vol. 47, S3, 2006
82 7TH EUROPEAN CONGRESS ON EPILEPTOLOGY
Neurological signs revealed right upper limb weakness. The brain CT
showed hyperintensity of superior sagittal sinus (SSS). She took pills for
3 years. Further brain MRI with MRV showed high density at the pre-
central gyrus of the left frontal lobe with poor visualisation of SSS. The
homeostatic investigation revealed normal levels of protein C, protein
S, antithrombin III and Leiden V. The seizure and the focal weakness
improved after treatment. Case two is a 45-year-old woman. She experi-
enced headache for three days followed by focal seizure of the left arm
and leg. Focal seizure later evolved to generalised seizures two times.
She took oral contraceptives for one month. Neurological examination
showed left hemiparesis. Brain MRI revealed right side occipitoparietal
high density. MRV showed disappearance of SSS. The weakness of limbs
and consciousness were more downhill during heparinization. Three di-
rect focal streptokinase injections were administered into the sinus for
the thrombosis.
Conclusion: During the gestational age in women with newly
onset seizures, oral contraceptive history is very important for the
early diagnosis and prognosis for cluster seizures and cerebral venous
thrombosis.
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PARALDEHYDE ADMINISTRATION DURING NONCONVUL-
SIVE STATUS EPILEPTICUS IN YOUNG RATS MODIFIES ITS
LATE CONSEQUENCES
G. Tsenov, H. Kubova, and P. Mares (Department of Developmental
Epileptology, Institute of Physiology AS CR, Prague, Czech Repulbic)
Purpose: To study delayed consequences of paraldehyde intervention
during nonconvulsive status epilepticus (NCS) induced in immature rats.
Method: NCS was elicited by pilocarpine (40 mg/kg i.p.) in 25 day old
rats pretreated with LiCl (3 meq/kg, i.p.). Paraldehyde (0.3 ml/kg i.p.)
was administered after two hours of continuous NCS. Control groups
received saline instead of paraldehyde or only saline instead of all drugs.
Cortical stimulation and registration electrodes were implanted 2 months
after NCS. After one week recovery cortical epileptic afterdischarges
(ADs) were elicited by a 15-second series of low-frequency pulses. In-
tensity was increased stepwise from 0.2 to 15 mA, interval between
stimulation series was 10 minutes. Threshold intensities for movements
during stimulation, spike-and-wave ADs, clonic seizures, and transition
to limbic (mixed) ADs and recurrent ADs as well as durations of spike-
and-wave (SW) and mixed ADs were measured.
Results: Threshold for movements bound to stimulation was identical
in the three groups. Higher stimulation intensities had to be applied to
elicit SW ADs in paraldehyde-treated NCS rats than in saline control
group. A significantly higher threshold for clonic seizures was found in
NCS rats with paraldehyde in comparison with NCS rats without par-
aldehyde and saline controls. No differences were observed in thresholds
for mixed and recurrent ADs. Duration of both SW and mixed ADs did
not differ among the three groups.
Conclusion: Paraldehyde administration during NCS in 25 day old
rats resulted in an increase of thresholds for SW ADs and accompanying
clonic seizures in adulthood, i.e., the excitability of system generating
this type of ADs was changed.
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MICROINFUSION OF γ -VINYL-GABA BUT NOT MUSCIMOL
INTO THE ANTERIOR SUBSTANTIA NIGRA PARS RETIC-
ULATA EXERTS ROBUST ANTICONVULSANT EFFECTS IN
MALE KINDLED RATS
1M. Nolte, 2A. Heile, and 1M. Gernert (1University of Veterinary
Medicine Hannover; Department of Pharmacology, Toxicology, and
Pharmacy, Germany, 2International Neuroscience Institute (INI) Han-
nover, Germany)
Purpose: The substantia nigra pars reticulata (SNr) is critically in-
volved in seizure propagation in various models. Intranigral potentia-
tion of GABA-mediated transmission has been shown to inhibit seizure
spread in such models. While unconsidered in former studies, more re-
cent observations emphasise that the effects on seizures are site-specific
within the SNr and seem to depend on age, gender, strain, and seizure-
model.
Method: In order to reevaluate former studies, we investigated the
effects of bilateral microinfusions of γ -vinyl-GABA (GVG, vigabatrin,
10 μg) and muscimol (60 or 120 ng), respectively, in the anterior or
posterior SNr of amygdala-kindled rats of different strain and gender.
24 hours (GVG) or 30 minutes (muscimol) after microinfusion, seizure
parameters were determined in each rat.
Results: Compared to vehicle controls, GVG microinfused to the an-
terior SNr significantly increased the threshold for the induction of af-
terdischarges in the amygdala in male Spraque-Dawley rats. The seizure
severity tended to be reduced in response to local GVG. Although not
significantly different from controls, in 3 out of 6 animals a dramatic
increase in the threshold for generalised seizures could be observed.
However, muscimol failed to exert pronounced anticonvulsant effects
independent of strain and gender.
Conclusion: The data extend previous findings that in kindled rats the
anterior SNr is not a site at which muscimol causes robust anticonvul-
sant effects. However, using GVG, anticonvulsant effects could be ob-
served, suggesting that increasing GABA-mediated neurotransmission
in given pathways seems to be more important than increasing the overall
GABAA-receptor activity, at least in the kindling model of epilepsy.
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SUBTHRESHOLD CHANGES OF VOLTAGE-DEPENDENT
ACTIVATION OF THE KV7.2 CHANNEL IN NEONATAL
EPILEPSY
1S. Maljevic, 2J. Hunter, 2A. Shankar, 2A. Siegel, 3B. Weissman,
3P. Holt, 3L. Olson, 2A. Escayg, and 1H. Lerche (1Department Neu-
rology and Applied Physiology, University of Ulm, Ulm, Germany,
2Department of Human Genetics, Emory University, Atlanta, USA,
3Department of Pediatrics, Emory University, Atlanta, USA)
Purpose: A benign familial neonatal convulsion (BFNC) is an auto-
somal dominant epileptic disorder resulting from mutations in KCNQ2
and KCNQ3, encoding the potassium channels KV7.2 and KV7.3.
Method: We screened both genes in two unrelated BFNC families
and performed functional studies using expression in Xenopus oocytes
and two-microelectrode voltage clamping.
Results: We identified novel KCNQ2 mutations in both families. In
Family 1, the mutation c.740C>A was identified in the 5 affected family
members. This mutation will generate a truncated protein (S247X) that
lacks the channel’s pore region and C-terminus. The mutation c.365C>T,
predicting the amino acid substitution S122L in the S2 segment of KV7.2,
was observed in the 3 affected members of Family 2 and was not detected
in 800 control chromosomes. Comparison of the biophysical properties
of the mutant S122L channel with wild-type (WT) KV7.2 revealed a
significant positive shift in the voltage dependence of activation with an
increased slope and a slowing of the activation time course. The shift
was most pronounced in the subthreshold range of an action potential
predicting a current reduction of 75% at –50 mV, which is likely to be the
physiologically relevant voltage range for this noninactivating potassium
channel to regulate neuronal firing.
Conclusion: These results establish an important role of the KV7.2
S2 segment in voltage-dependent channel gating and suggest that sub-
tle mutation-induced gating alterations restricted to the physiologically
relevant subthreshold range can cause neonatal epilepsy.
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DEVELOPMENT OF HIPPOCAMPAL SCLEROSIS IN RATS
EXPOSED TO IN UTERO IRRADIATION AND POSTNATAL
HYPERTHERMIA
1M. Uzan, 2G. Erkanli, 2S. Sirvancy´, 2F. Ercan, 3F. Onat, 4C.
Ozkara, 1R. Kemerdere, 1C. Isler, 1O. Ulu, and 3A. Ozkaynakcy´
(1Istanbul University, Cerrahpasa Medical School, Department of Neu-
rosurgery, Cerrahpasa, Istanbul, Turkey, 2Marmara University School
of Medicine, Histology-Embriology Department, Uskudar, Istanbul,
Turkey, 3Marmara University School of Medicine, Pharmacology
and Clinical Pharmacology Department, Uskudar, Istanbul, Turkey,
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4Istanbul University, Cerrahpasa Medical School, Departments of Neu-
rology, Cerrahpasa, Istanbul, Turkey)
Purpose: Hippocampal sclerosis (HS) is characterised by gliosis, neu-
ronal loss and synaptic reorganisation in the hippocampus where patho-
physiology remains obscure with several hypothesis. Clinical studies
implied a relationship between HS and febrile seizures (FS) in early
childhood. Experimental studies showed hyperthermia (HT) induced
seizures are more easily elicited and have higher mortality accompa-
nied by neuronal loss in rats with cortical dysplasia. The aim of this
study is to investigate the role of HT induced FS in genesis of HS, ap-
plied during the maturation period of rats with irradiation (IR) induced
cortical dysplasia.
Method: Three groups of rats were designed. 1) HT group; had FS
induced by HT in postnatal 10th day. 2) IR group; were exposed to 225
cGy IR on the 17th gestational day. 3) HT-IR group; were exposed to
both in utero IR then postnatal HT. Control group were sham operated.
Three and 6 months after the experimental procedure, the animals were
perfused with paraformaldehyde and glutaraldehyde. Forty μm cryostat
sections were obtained from the hippocampus and then stained with
cresyl violet and examined with the light microscope.
Results: No damage was seen in the HT group. The hippocampus
was atrophic with neuronal loss (in CA1, CA3 and CA4 regions) and
ectopic neurons in IR group. More severe damage in all regions with
more atrophy was demonstrated in the HT-IR group. The control group
had normal hippocampus.
Conclusion: This study supported the double hit hypothesis in devel-
opment of HS as in utero IR and HT applied consequently caused more
degeneration in the hippocampus than IR and HT alone.
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EFFECT OF LACOSAMIDE ON STRUCTURAL AND FUNC-
TIONAL RECOVERY AFTER TRAUMATIC BRAIN INJURY IN
RATS
1J. Nissinen, 1R. Immonen, 2T. Sto¨hr, 1O. Gro¨hn, and 1A. Pitka¨nen
(1A.I.Virtanen Institute/ University of Kuopio, Kuopio, Finland, 2Dept.
Pharmacology/Toxicology, Schwarz Biosciences, Monheim, Germany)
Purpose: Traumatic brain injury (TBI) can result in early and late
epileptic seizures that are treated with antiepileptic drugs (AEDs). Be-
cause treatment with AEDs occurs in parallel with the cerebral recovery
process, it is important to show that AEDs do not compromise postinjury
functional outcome. We evaluated the effects of a novel AED, lacosamide
(LCM), on structural and functional recovery following TBI.
Method: Lateral fluid-percussion brain injury (FPBI) was induced
in adult rats that were randomised to vehicle (FPBI-vehicle, n = 12)
or lacosamide (FPBI-LCM, n = 12) treatments. Treatment was started
30 min postinjury (30 mg/kg, i.p.) and continued at 8 h intervals for 3 d.
Sham-vehicle (n = 8) and sham-LCM (n = 7) served as nontraumatised
controls. Motor function was evaluated using composite neuroscore and
beam walking tests 1 d before FPBI and on days 2, 7, and 15 post-
injury. Spatial learning was tested using Morris water-maze 12 d after
FPBI. Hippocampal and cortical damage were assessed from magnetic
resonance images (MRI) and histologic sections.
Results: At 2 d post-injury, lesion severity in MRI did not differ be-
tween FPBI-vehicle and FPBI-LCM groups. Also, no difference was
found in the severity of cortical or hippocampal neuronal or axonal dam-
age 15 d postinjury (p > .05). There were no differences in neuroscore
or beam walking performance between FPBI-vehicle and FPBI-LCM
groups (all time points, p > .05). Also, spatial learning did not differ
between groups (p > .05).
Conclusion: Lacosamide treatment started 30 min postinjury at a dose
of 3 × 30 mg/kg/d for 3 d did not compromise the structural or functional
outcome after TBI.
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EPILEPTIFORM ACTIVITY IN THE HIPPOCAMPUS CAN BE
EVOKED BY DISTURBANCE OF THE GABAergic INTRASEP-
TAL INTERRELATIONS
M. Butuzova, V. Sinelnikova, and V. Kitchigina (Institute of Theoretical
and Experimental Biophysics, Pushchino, Russia)
Purpose: The medial septum region (MSR) is the major subcortical
input to the hippocampus and theta oscillation generator, but its role in
temporal lobe epilepsy is not clear. Investigations in this direction may
provide a better understanding of seizure genesis mechanisms.
Method: Activity of inhibitory interneurons and EEG were recorded
extracellularly in the CA3 field of the hippocampus in control and after
intraseptal microinjection of bicuculline, the GABAA receptor antago-
nist (1 nM/1 μl). Neuronal activity was processed using the software for
calculation of mean frequency, autocorrelation and spectral functions.
EEG was converted by fast Fourier transform.
Results: Bicuculline delivery into MS led to sharp increasing of back-
ground activity of hippocampal interneurons (50.02 ± 19.1 versus 21.6 ±
7.6 imp/s in control, p < .01). Theta oscillations became more regular,
mean frequency of theta bursts increased on 1 ± 0.3 Hz (p < .05). Delta
component of neuronal activity also increased. Strong augmentation of
both theta and delta bands and 13–15 Hz oscillations was observed in
simultaneously recorded hippocampal EEG. Repeated daily bicuculline
injections brought to periodical appearance of the expressed epilepti-
form activity, which was accompanied by anxiety of animal. Intraseptal
infusion of GABAA receptor agonist muscimol (10–20 nM/1 μl) usually
weakened an expression of epileptiform discharges. However, in the an-
imals with steady pathological activity, injection of the muscimol could
exert the opposite influence, increasing the expression of epileptical dis-
charges and anxiety.
Conclusion: Thus, it has been revealed that GABAA receptors block-
ade in the MSR increases the oscillatory activity in the hippocampus and
forms epileptic focus in it.
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SYNAPTIC LOCALISATION OF ADENOSINE A1 RECEPTORS
IN THE RAT DENTATE GYRUS
1,2N. Hamil, 1H. Cock, and 2R. Empson (1St Georges, University of
London, UK, 2Royal Holloway, University of London, UK)
Purpose: Status epilepticus (SE) is a serious clinical condition, oc-
curring when normal termination of a seizure is impaired. Adenosine,
acting via A1 receptors (A1Rs) to inhibit neurotransmitter release or hy-
perpolarise neurons, has been shown to have anticonvulsant properties in
several models of epilepsy and may be important in regulating the tran-
sition from self-terminating seizures to SE. In order to understand the
underlying mechanisms, we investigated the expression of A1Rs in the
dentate gyrus (DG), the gateway to the seizure susceptible hippocampus.
Method: 50 μm horizontal slices containing the hippocampus and en-
torhinal cortex were prepared from paraformaldehyde fixed adult (6–8
weeks old) Wistar rat brains. Using immunohistochemistry and confocal
microscopy we examined the cellular localisation of A1Rs in the den-
tate gyrus and assessed colocalisation with the synaptic marker proteins
synaptophysin and PSD-95.
Results: We have shown A1Rs to be expressed abundantly in den-
tate granule cells and some hilar neurons. The expression pattern was
punctate both at the cell body and in the molecular layer, suggesting
dendritic as well as somatic expression. Some puncta of A1R expres-
sion were shown to colocalise with those of presynaptic synaptophysin
expression, whereas they did not colocalise with puncta of postsynaptic
PSD-95 expression.
Conclusion: Our results indicate that adenosine released during
seizures may exert an inhibitory influence in the DG by acting pre-
synaptically to modulate glutamate release, thereby behaving as an en-
dogenous anticonvulsant. Further studies aim to identify the nature of
synapses expressing A1Rs.
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3-NITROTYROSINE IS INCREASED IN RAT BRAIN 44 HOURS
AFTER STATUS EPILEPTICUS
A. Kelso and H. Cock (St Georges, University of London, UK)
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Purpose: Many of the short- and long-term consequences of epilepsy
may be due to excitotoxicity, of which protein nitrosylation is a central
feature. Levels of 3-nitrotyrosine (3NT) are raised in other neurological
diseases, and known to have key functional consequences. We set out
to establish whether 3NT was also raised in the hippocampus following
electrically induced status epilepticus (SE).
Method: Using the perforant path model of epilepsy, self-sustaining
SE was induced for 3 hours, and terminated with diazepam. After 44
hours, the rats were decapitated under anaesthesia, the hippocampal
subregions dissected on ice, and snap frozen. Sham controls underwent
identical procedures, with the exception of electrical stimulation. 3NT
was quantified using high performance liquid chromatography with elec-
trochemical detection.
Results: Overall Hippocampal mean 3NT levels (expressed as a ratio
to L-tyrosine) were higher in status animals (5.26 × 10−5 ± 1.57 ×
10−5 SEM) compared with controls (3.18 × 10−5 ± 0.68 × 10−5 SEM).
Subregional analysis demonstrated this difference was most marked in
the dentate gyrus/hilar (DG/H) region (SE 7.97 × 10−5 ± 3.18 × 10−5,
sham 2.22 × 10−5 ± 0.63 × 10−5), with no differences in the SE vs
sham Ca1 or Ca3 regions.
Conclusion: This is the first study of 3NT in a model which avoids the
use of potentially confounding chemoconvulsants, which confirms that
as in other degenerative brain diseases, 3NT is significantly increased in
rat brain following SE. That the change was most marked in the DG/H
section is intriguing given the relative protection of the DG area following
SE. Further studies are required to understand the functional localisation
and consequences of this protein nitrosylation following SE.
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REVISED PHARMACOKINETIC PROFILE FOR A WIDELY
USED NEUROTOXIN, METHYLAZOXYMETHANOL AC-
ETATE: HOW SHORT IS A SHORT HALF LIFE?
1S. Santaguida, 2V. Barnes, 3G. Battaglia, 1L. Cucullo, 1N. Marchi, 3S.
Bassanini, and 1,2D. Janigro (1Cerebrovascular Research Center, Cleve-
land Clinic Foundation, Cleveland, USA, 2Department of Cell Biology,
Cleveland Clinic Foundation, Cleveland, USA, 3“Carlo Besta” Neuro-
logical Institute, Milan, Italy)
Purpose: Methylazoxymethanol (MAM) is widely employed to study
as model of cortical dysplasia. MAM is believed to selectively affect
neuroblasts and, owing to an extremely short half life (12 hrs) to have
specific actions on developing neocortex. These properties are derived
by indirect experimental evidence but were never truly studied. We now
report pharmacokinetic results obtained after MAM exposure.
Method: Pregnant rats received 2 injections of MAM on day E15 at
doses of 15 mg/Kg at 12 hour intervals. Maternal blood, foetal brain
and liver MAM levels were measured by HPLC at 30’ and12, 24, 36, 48
hours after exposure.
Results: MAM’s half life in maternal blood and in foetal brain was
around 32 hrs, or three times longer than previously assumed. The max-
imum concentration of MAM (75 uM) was well below the toxic concen-
trations used to ablate neuroblasts in vitro (>500 uM) but was signifi-
cantly higher than the dosage capable of inhibiting angiogenesis in vitro
and in vivo (<100 uM).
Conclusion: Our results demonstrate that MAM may exert persistent
and perhaps non-neuronal effects in the foetal brain by virtue of its long
lasting serum and brain levels. These findings warrant a reinterpretation
of the commonly accepted pharmacokinetic and mechanistic details of
its action. Supported by HL51614, NS43284, NS38195, and NS49514.
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EVALUATION OF NUMBER OF AXONS IN THE FORNIX IN
MESIAL TEMPORAL LOBE EPILEPTIC AUTOPSIES USING
ELECTRON MICROSCOPY
1S. Cavdar, 1 ¨O. ¨Ozdogmus, 1E. Saka, 1Y. ¨Ozgu¨r C¸akmak, 2Yasemin,
2F. Ercan, and 3F. Onat (1Departments of Anatomy, Marmara Univer-
sity School of Medicine, Istanbul, Turkey, 2Department of Histology,
Marmara University School of Medicine, Istanbul, Turkey, 3Department
of Pharmacology, Marmara University School of Medicine, Istanbul,
Turkey)
Purpose: The aim of this study was to assess the number of fornical
fibres in 4 mesial temporal lobe sclerosis (MTS) and 4 normal human
autopsies.
Method: To evaluate the average number of fibres forming the fornix,
cross sectional area, fibre density and the ratio of myelinated and un-
myelinated fibres, light, electron microscopy and computer programs
were used.
Results: Morphometric results showed that the number of fibres form-
ing the left and right fornix in the nonepileptic autopsies was higher than
autopsies with MTS. The average number of fibres forming the right
fornix was higher than the left in both nonepileptic and MTS autop-
sies. A striking reduction in the average number of unmyelinated fibres
was observed in MTS autopsies compared to nonepileptics. Electron mi-
croscopic evaluations showed degeneration of the myelinated fibres in
MTS autopsies. The right and the left fornix of MTS autopsies showed
reduction in the cross-sectional area, the reduction on the right was more
striking. An increase in the average density of myelinated fibres for both
right and left fornix in the MTS autopsies and a decrease in the average
density of unmyelinated fibres were observed.
Conclusion: The neuronal loss observed in the dentate gyrus and
the CA3 sector of the hippocampus in the present study, may result
in Wallerian or transneuronal degeneration causing a decrease in the
number of fornical fibres in the MTS autopsies. Further, the reduction
of unmyelinated fibres in the MTS autopsies may play a role in the
assessment of the MTS and other limbic system abnormalities.
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DIFFERENT EXPRESSION OF P-GLYCOPROTEIN IN PHE-
NOBARBITAL AND LEVETIRACETAM TREATED MADIN-
DARBY CANINE KIDNEY (MDCK) CELLS
1A. Pavone, 2V. Cardile, and 2L. Lombardo (1Garibaldi Hospital, Cata-
nia, Italy, 2Department of Physiological Sciences, University of Catania,
Catania, Italy)
Purpose: Levetiracetam (LEV) is a new antiepileptic drug (AED) ef-
fective in reducing partial seizures. LEV has a unique mode of action that
is, currently, incompletely characterised. This study investigated LEV’s
effects on the expression of P-glycoprotein (Pgp), a transmembrane pro-
tein of 170 kDa, MDR1 (or hABCB1) gene product, and used the AED
phenobarbital (PB) as a control.
Method: Madin-Darby canine kidney (MDCK) cells were treated with
LEV and PB at 30 and 300 μM for 72 hours. Drug-containing medium
was replaced every 24 hours. Expression of Pgp was determined by
Western blot analysis using a primary mouse monoclonal Pgp antibody.
To verify the effects of the study drugs on cell viability, a tetrazolium
salt assay (MTT) was performed.
Results: PB interfered with cell viability in a weakly significant man-
ner (85% at 30 and 76% at 300 μM compared to the control MDCK cells
(p = 0.001), and induced dose-dependent overexpression of Pgp (+50%
at 30 and +53% at 300 μM). LEV had no effects on cell viability (93%
at 30 and 92% at 300 μM) compared to the controls, and produced Pgp
expression (alkaline DNA unwinding (ADU) = 0.53 ± 0.02 and 0.53 ±
0.03 at 30 and 300 μM, respectively) almost similar (ADU = 0.50 ±
0.03) to the controls.
Conclusion: LEV may be particularly useful in patients who are un-
responsive to other AEDs. Further investigations are in progress using
other cellular systems.
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PRECLINICAL PROFILE OF THE NOVEL ANTICONVUL-
SANT LACOSAMIDE
1T. Stoehr, 1C. Heers, 2J. Stables, 3K. Wilcox, and 3S. White
(1Schwarz Bioscience, 2Anticonvulsant Drug Development Program,
3Anticonvulsant Drug Development Program, Monheim, Germany)
Purpose: Lacosamide, previously called harkoseride or SPM 927,
belongs to a series of functionalised amino acids which have been
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synthesised as a new class of anticonvulsant agents. A series of experi-
ments was designed to describe its anticonvulsant profile and potential
mode of action.
Method: Lacosamide was evaluated in standard rodent models for
epilepsy as part of the antiepileptic drug development program by the
NIH (White HS et al.. Adv. Neurol 1998;76:29-39.). In addition, la-
cosamide’s effects on targets described for other antiepileptic drugs were
assessed in radioligand binding and electrophysiological experiments.
Finally, potential neuroprotective effects of lacosamide were measured
in organotypic hippocampal slice cultures following exposure to oxygen
glucose deprivation or glutamate.
Results: Lacosamide showed anticonvulsant activity in various rodent
models for partial and generalised seizures in the dose range 1–20 mg/kg.
In contrast, lacosamide was largely inactive against seizures induced
by various chemoconvulsant agents such as picrotoxin or bicuculline.
Radioligand binding experiments did not show binding to GABAergic
or glutamatergic targets. Moreover, no modulation of calcium (N-, L-, P-
and T-type) and potassium currents (A-type, delayed rectifier, KCNQ2/3)
were observed. In addition, lacosamide did not affect fast inactivation of
sodium channels–a mechanism shown by a variety of antiepileptic drugs.
Finally, lacosamide displayed neuroprotective properties in hippocampal
slice cultures.
Conclusion: In summary, the overall anticonvulsant profile of la-
cosamide in animal models for epilepsy appears to be broad and its
mode of action unlike that of other AEDs but currently unknown.
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MILD PHENOTYPE IN TUBEROUS SCLEROSIS PATIENTS
WITH CODON 905 MISSENSE MUTATIONS IN THE TSC2
GENE
1,2,3E. Andermann, 1,2A. Jansen, 4O. Sancak, 1,2M. D’Agostino,
1,2A. Badhwar, 5P. Roberts, 6R. Wilkinson, 2,7D. Melanson, 2,7D.
Tampieri, 4A. Maat-Kievit, 4M. Goedbloed, 4A. Van Den Ouwe-
land, 4M. Nellist, 8M. Pandolfo, 9K. Sims, 10E. Thiele, 2F. Dubeau,
2F. Andermann, 5D. Kwiatkowski, and 4D. Halley (1Neurogenetics
Unit, Montreal Neurological Hospital and Institute, Montreal, Canada,
2Department of Neurology and Neurosurgery, McGill University, Mon-
treal, Canada, 3Department of Human Genetics, McGill University,
Montreal, Canada, 4Department of Clinical Genetics, Erasmus Mc, Rot-
terdam, The Netherlands, 5Hematology Division, Brigham and Women’s
Hospital, Boston, USA, 6Department of Dermatology, McGill Univer-
sity, Montreal, Canada, 7Department of Radiology, McGill University,
Montreal, Canada, 8Department of Neurology, Brussels Free University
(ULB), Brussels, Belgium, 9Department of Neurology, Massachusetts
General Hospital, Harvard Medical School, Boston, USA, 10Department
of Pediatric Neurology, Massachusetts General Hospital, Harvard Med-
ical School, Boston, USA)
Purpose: Tuberous sclerosis complex is an autosomal dominant dis-
order characterised by hamartomatous growth in various organs, and
caused by mutations in the TSC1 (9q34) or TSC2 (16p13) genes. Over-
all, TSC2 mutations have been associated with a more severe disease
phenotype than TSC1 mutations. We report the clinical and molecular
features in16 families with TSC2 mutations and mild phenotypes.
Method: We carried out a detailed study of the TSC phenotype and
genotype in a large French-Canadian kindred (Family A). In addition,
clinical and molecular data on 15 families with mutations at the same
codon were collected. Functional studies were performed on three dif-
ferent missense mutations and related to the phenotypes.
Results: A 2714G > A (R905Q) missense mutation in exon 23 of
TSC2 was identified in 25 individuals in Family A. The TSC phenotype
in this family was unusually mild, characterised mainly by depigmented
skin lesions and by seizures that remitted spontaneously or that were
easily controlled with antiepileptic drugs. Diagnostic criteria were met
in only a minority of family members, delaying diagnosis. All other
families with the R905Q mutation were found to have a similar mild
phenotype. Patients with a 2713C > T (R905W) mutation or a 2713C >
G (R905G) mutation had a more severe phenotype. In 3 different assays,
the R905W and R905G substitutions had a more severe effect on tuberin
function than the R905Q substitution.
Conclusion: We identified 16 families with codon 905 missense
changes in TSC2. In the R905Q families, the TSC phenotype was un-
usually mild, consistent with the functional studies. Our findings support
the observation that familial TSC is less severe than sporadic TSC, even
when it is due to a TSC2 mutation. Genotype-phenotype correlations in-
dicate that mild TSC phenotypes may be associated with specific TSC2
mutations.
p324
CHOREA-ACANTHOCYTOSIS (ChAc) IN FRENCH CANADI-
ANS: FOUNDER EFFECT, SEIZURE CHARACTERISATION
AND GENOTYPE-PHENOTYPE CORRELATIONS
1,2,3F. Andermann, 1,2A. Jansen, 1,2F. Dubeau, 1,2S. Chouinard, 5F.
Robert, 6A. Lang, 7C. Dobson-Stone, 8A. Danek, 9A. Monaco, and
1,2,10E. Andermann (1Montreal Neurological Hospital & Institute,
McGill University, Montreal, Canada, 2Department of Neurology &
Neurosurgery, McGill University, Montreal, Canada, 3Department of
Pediatrics, McGill University, Montreal, Canada, 4Andre Barbeau
Movement Disorders Unit, University of Montreal, Montreal, Canada,
5North Bay Genetics Clinic, North Bay, Ontario, Canada, 6Department
of Neurology, University of Toronto, Canada, 7The Garvan Insti-
tute of Medical Research, University of New South Wales, Sydney,
Australia, 8Department of Neurology, University of Munich, Ger-
many, 9Wellcome Trust Centre For Human Genetics, University of
Oxford, England, 10Department of Human Genetics, McGill University,
Montreal, Canada)
Purpose: To characterise the clinical and molecular findings in French
Canadian (FC) families with chorea-acanthocytosis, and to determine
genotype-phenotype correlations.
Method: We ascertained 12 affected individuals in four families. De-
tailed medical and family histories were obtained. EEG, video-telemetry,
brain MRI with volumetric studies of the amygdala and hippocampus, as
well as neuropsychological testing were performed. Blood smears were
examined for acanthocytes, and CK levels were determined. Field trips
in two families yielded over 175 blood samples for mutation analysis.
Results: All families originated from Quebec. There was parental
consanguinity in 4 of 6 affected sibships, and probably in a fifth. Epilepsy
was a prominent feature, although family members had very diverse
clinical manifestations, including tics, chorea, psychosis and dementia.
Seizures preceded the onset of movement disorders by up to 15 years.
Most seizures were suggestive of mesial temporal onset. EEGs showed
temporal or bitemporal epileptic discharges and seizure onsets. There
was no evidence for hippocampal atrophy. Seven affected individuals
were homozygous for a deletion including exons 70–73 of VPS13A and
exons 6–7 of GNA14 (EX70-EX73del). These patients shared a common
haplotype in the same region. Two affected sisters were homozygous for
a splice mutation 4242 + 1G > T, whereas their 2 male cousins were
heterozygous for EX70-EX73del and 4242 + 1 G>T. Of 9 patients with
the deletion, including 2 heterozygotes, 7 had epilepsy (77%). The 2
sisters with the splice mutation did not develop seizures.
Conclusion: The identification of a common 9q21 haplotype associ-
ated with EX70-EX73del in 4 apparently unrelated FC ChAc families
implies a founder effect. Routine testing for EX70-EX73del in suspected
ChAc cases may be worthwhile in this population. Genotype-phenotype
correlation suggests that the deletion mutation is strongly associated with
epilepsy.
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FUNCTIONAL POLYMORPHISM IN THE SCN1A GENE AND
TREATMENT OF REFRACTORY EPILEPSY
1F. Zimprich, 1E. Stogmann, 1S. Bonelli, 1C. Baumgartner, 2,3J. Mu¨ller,
3P. Lichtner, 3T. Meitinger, 1A. Zimprich, and 3T. Strom (1Department
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of Neurology, Medical University of Vienna, Austria, 2Institute for
Medical Statistics and Epidemiology & Institute for Psychiatry and
Psychotherapy, Technical University, Munich, Germany, 3Institute of
Human Genetics, GSF National Research Center for Environment and
Health, Munich, Germany and Institute of Human Genetics, Klinikum
Rechts Der Isar, Technical University, Munich, Germany)
Purpose: Recently, a polymorphism in the voltage gated sodium chan-
nel gene SCN1A has been identified that presumably affects the alter-
native splicing of the gene. This SNP (rs3812718, A -> G) has been
reported to be associated with dosages of prescribed antiepileptic drugs
acting on this channel (carbamazepine and phenytoin) (Tate et al., 2005).
The purpose of this study was to investigate the association of this SNP
with treatment refractory focal epilepsy and with the dosages of pre-
scribed carbamazepine.
Method: We genotyped 334 patients and 364 matched controls for
the SCN1A gene rs3812718-SNP. Patients suffered from mesial tem-
poral lobe epilepsy or cryptogenic focal epilepsies; 88% of them were
considered treatment refractory. Genetic stratification between controls
and patients was largely excluded by genotyping 11 unrelated control
polymorphisms.
Results: We detected a significant overrepresentation of A alleles
(59.1% vs 51.2%) and AA genotypes (33.8% vs 27.2%) amongst patients
in comparison to controls (allelic and genotypic tests, uncorrected p
= 0.003). However, there was no significant difference in the average
carbamazepine dose between the three genotype groups (AA, AG, and
GG, ANOVA: p = 0.26).
Conclusion: The significant association between the rs3812718-SNP
with largely treatment refractory epilepsy supports the notion that genetic
variations in the SCN1A gene may underlie an individual’s susceptibility
to epilepsy and/or may influence the severity of the condition.
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CLINICAL AND ELECTROPHYSIOLOGICAL FEATURES OF
ITALIAN NEURONAL CEROID LIPOFUSCINOSIS PATIENTS
WITH CLN8 MUTATIONS
1,2P. Striano, 3N. Specchio, 2R. Biancheri, 3N. Cannelli, 4A. Simonati,
2D. Cassandrini, 3L. Fusco, 5R. Gaggero, 3F. Vigevano, 3E. Bertini, 2F.
Zara, 3F. Santorelli, and 1S. Striano (1Federico II University, Naples,
Italy, 2Muscular and Neurodegenerative Disease Unit, Institute “G
Gaslini–University of Genova, Genova, Italy, 3Molecular Medicine and
Neurology, IRCCS-Bambino Gesu` Hospital, Roma, Italy, 4Department
Neurological and Visual Sciences-Neurology, University of Verona Med-
ical School, Verona, Italy, 5Child Neurology and Psychiatry Unit, Insti-
tute G. Gaslini, Genova, Italy)
Purpose: Neuronal ceroid lipofuscinoses (NCLs) are neurodegenera-
tive disorders characterised by epilepsy, visual failure, psychomotor de-
terioration and accumulation of autofluorescent lipopigment. Six NCLs
genes have been identified so far. CLN8 mutations result in Northern
Epilepsy and Turkish variant late infantile NCL (v-LINCL). We describe
the clinical and neurophysiological findings of 3 Italian patients carrying
CNL8 mutations.
Method: Three patients from southern Italy underwent neurologi-
cal examinations, EEG, MRI and skin biopsy. Genetic analysis showed
CLN8 mutations in all cases.
Results: Psychomotor regression was the first manifestation. Un-
steady gait and epilepsy appeared within the first years of life, with
myoclonic, tonic–clonic and atypical absence seizures. EEGs showed
focal and/or generalised abnormalities and progressive signal deteriora-
tion. In all cases, cortical blindness and progressive attenuation of the
electroretinogram were observed. MRIs showed progressive cerebral and
cerebellar atrophy, thinning of corpus callosum and deep white matter
hyperintensity. In all cases hyperintensity of the posterior limb of in-
ternal capsules was also evident. Skin biopsy revealed storage in the
cytoplasm of fibroblasts. Epilepsy was drug-resistant with valproate and
clonazepam giving some benefit.
Conclusion: The clinical picture of our patients closely resembles the
phenotype of the Turkish patients whereas it clearly differs from Northern
Epilepsy showing a more prolonged course and lacking myoclonus and
visual loss. The identification of different CLN8 mutations in a subset of
Italian v-LINCL patients would suggest that the present phenotype is that
commonly associated to CLN8 mutations. The definition of the clinical
spectrum of this condition will help its recognition with implications for
the diagnosis and genetic counselling.
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MAPPING OF CHROMOSOMAL BREAKPOINTS ASSO-
CIATED WITH CORPUS CALLOSUM AGENESIS AND
EPILEPSY: A BYPASS FOR ISOLATION OF CANDIDATE DIS-
EASE GENES
1,2R. Møller, 2Z. Tu¨mer, 1C. Hansen, and 2N. Tommerup (1Danish
Epilepsy Centre, Dianalund, Kolonivej 1, Dianalund, Denmark,
2Wilhelm Johannsen Centre for Functional Genome Research, Insti-
tute of Medical Biochemistry and Genetics, University of Copenhagen,
Denmark)
Purpose: Agenesis of corpus callosum (ACC) is a congenital anomaly
that can manifest as partial agenesis, hypoplasia across the entire struc-
ture, or complete agenesis. To date ACC has been found to occur in
over 50 different human congenital syndromes, but the nonsyndromic
forms are more common. In the majority of the nonsyndromic forms
the underlying gene defects are unknown. Here we present a case of an
11-year-old girl with a de novo balanced translocation t(2;11) (p25.1;
p15.1) and mental retardation, epilepsy and partial agenesis of corpus
callosum.
Method: Cytogenetic analysis was conducted on G-banded
metaphases of cultured peripheral lymphocytes. Translocation
breakpoints were mapped by fluorescence in situ hybridisation (FISH)
using bacterial artificial chromosomes (BACs) from the regions of
interest. DNA samples were prepared according to standard protocols.
Results: By G-banding of chromosomes from peripheral lympho-
cytes, a balanced translocation t(2; 11)(p25.1; p15.1) de novo was iden-
tified. The breakpoint on chromosome 2p25 is mapped within a 200 kb
region and the 11p15 breakpoint disrupts an evolutionary conserved gene
empty region.
Conclusion: The present case reports a balanced translocation in a
patient with epilepsy and partial corpus callosum agenesis. This study
may add new genes and regulatory mechanisms to the current list of
candidate loci involved in epilepsy and corpus callosum agenesis.
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READING EPILEPSY AND PARTIAL DUPLICATION OF
CHROMOSOME 18: A NEW SYNDROME?
1R. De Simone, 2C. Ceccarini, and 2A. Novelli (1Neurology Department,
S. Eugenio Hospital, Rome, Italy 2IRCCS-CCS S. Giovanni Rotondo-
CCS Gregorio Mendel, Rome, Italy)
Purpose: A 20-year-old man was admitted to the neurology unit after
a focal seizure, involving facial and perioral area, started during a reading
activity, executed with a loud voice. This type of seizure was the third in
his life, with the same characteristics and mode of starting. Therefore, the
diagnosis of reading epilepsy was performed on clinical bases. The neu-
rological examination was normal, a neuropsychological test showed
mild attentional and behavioural problems, an electroencephalogram
(EEG) performed during a prolonged lecture showed no pathological
findings, but a mild facial dysmorphia, with large low-positioned ears
and hypertelorism, was evident: in his family both his 31-year-old brother
and his 30-year-old sister showed the same facial features and mild cog-
nitive deficits but they did not report an epilepsy history. Nevertheless,
they showed EEG focal bitemporal sharp potentials.
Method: The patient and his family we given a prolonged EEG ac-
cording to 10–20 International System, neuropsychological tests, and
a cell culture (cultural test) for karyotype examination (GIEMSA stan-
dard; GAG; GTG) with standard and molecular cytogenetic analysis
were performed.
Results: The karyotype study revealed a duplication 18q seg-
regated from the mother to her 3 sons. Standard and molec-
ular cytogenetic analysis revealed the presence of two cell
lines in the mother and her karyotype has been interpreted as:
mos46,XX,dup(18)(q21.3q22.2)[90]/46,XX[10]. Instead, the karyotype
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of the 3 sons was homogeneous: 46,XY,dup(18)(q21.3q22.2) mat for the
2 males and 46,XX,dup(18)(q21.3q22.2)mat for the female.
Conclusion: For the first time, a chromosomal defect has been iden-
tified in a patient with reading epilepsy. This could be only a casual
association, but the presence of focal EEG alterations in other members
of the family appears very intriguing. The hypothesis of a new syndromic
complex could be put forward: partial duplication of chromosome 18q,
cortical hyperexcitability (in our patient expressed as reading epilepsy),
mild cognitive deficits and mild dysmorphic features.
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TUBEROUS SCLEROSIS COMPLEX: ATYPICAL FAMILY
PRESENTATION
1R. Vittorini, 1I. Pieri, 2M. Barberis, 2N. Migone, and 1G. Capizzi
(1Division of Child Neurology and Psychiatry OIRM University of Turin
(Italy), 2Department of Genetics, Biology and Biochemistry University
of Turin (Italy))
Purpose: Tuberous sclerosis complex (TSC) is a genetic disease with
a wide clinical spectrum even within the same family. We describe a
three-generation Italian family with multiple cortical dysplasias in 5
members, suggestive of a TSC phenotype restricted to the brain.
Method: The proband II:1, both parents I:1-I:2, the sister II:2, the
son III:1 and the two sister’s children III:2 and III:3 were investigated
for signs and symptoms in the major organs involved in TSC by imag-
ing (brain, kidneys, thorax), neurophysiological recordings, heart-skin-
fundus oculi evaluation, and mutation analysis of TSC1 and TSC2 genes.
Results: Originally, the proband came to our attention after 8 years
of epilepsy seizures; MRI showed multiple cortical tubers without any
other sign of TSC. Later on, due to onset of neurological symptoms
in the son, the sister and the first sister’s son, the full TSC evaluation
was extended to 7 family members. No signs were found in skin, heart,
kidneys and fundus oculi of any subjects. Clinically, II:2 and III:1 had
partial epilepsy seizures. I:2, II:2, III:1 and III:2 showed cortical tubers
on MRI. The thorax CT scan showed a diffuse pulmonary fibrosis in
II:2. The genetic test revealed a variant never described before in TSC2
(c.1922G > T; p.461 Ser > Ile) in all 5 subjects with pathological MRI
and in the youngest (35-months-old) III:3 with normal MRI.
Conclusion: If the pathogenicity of the TSC2 variant will be confirmed
by functional tests, these data suggest that aminoacid changes might
account for organ- or tissue-specific phenotypes not fulfilling the current
TSC diagnostic criteria.
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TEMPORAL LOBE EPILEPSY AND SOMATOSENSORY
AURAS
V. Fedotov (Kharkov Medical University, Ukraine)
Purpose: To determine the prevalence, manifestations, lateralising
value, and surgical prognostic value of somatosensory auras (SSAs) in
patients with refractory temporal lobe epilepsy (TLE).
Method: Thirty-two consecutive patients undergoing temporal lobec-
tomy for refractory complex-partial seizures were screened for SSAs.
The characteristics of the somatosensory phenomena, occurrence of
other aura types, seizure semiology, findings of EEG and imaging stud-
ies, temporal lobe neuropathology, and postoperative seizure outcome
were determined in each patient with SSAs.
Results: Nineteen (17.1%) of 111 patients with refractory temporal
lobe seizures reported distinct SSAs as part of their habitual seizures.
The most common manifestation of SSAs was tingling (16 of 19), but
sensory loss (2 of 19) and pain (1 of 19) also were reported. Eight patients
had unilateral somatosensory symptoms, and 5 patients had bilateral so-
matosensory symptoms. Seizure origin was in the contralateral temporal
lobe in 6 of 8 patients with unilateral SSAs, including all patients with
unilateral SSAs affecting a limb. Partial temporal lobe resection pro-
duced complete seizure remission in all patients 2 years after surgery
and in 5 patients 3 years after surgery.
Conclusion: SSAs occur more frequently than previously appreciated
in patients with refractory temporal lobe seizures and usually manifest
as either unilateral or bilateral tingling. In patients with temporal lobe
seizures, unilateral SSAs involving a limb suggest a seizure origin in
the contralateral temporal lobe. The surgical outcome of TLE patients
with SSAs is favourable. Thus the presence of SSAs should not serve
as a deterrent to temporal lobe resection in patients with clearly defined
TLE.
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POLYMORPHIC VARIATION IN GENES ENCODING
METABOLISING ENZYMES FOR CARBAMAZEPINE:
ALLELE AND GENOTYPE FREQUENCIES IN A WEST OF
SCOTLAND EPILEPSY POPULATION
1M. Makmor-Bakry, 1E. Butler, 1G. Sills, and 1M. Brodie (1University
of Glasgow, Glasgow, Scotland, UK)
Purpose: The pharmacokinetics of carbamazepine (CBZ) exhibit sig-
nificant interindividual variability. CBZ undergoes extensive biotransfor-
mation by the drug metabolising enzymes (DMEs), CYP3A4, CYP3A5,
CYP1A2 and microsomal epoxide hydrolase (EPHX1). Genes encoding
these enzymes show polymorphic variation. To understand the relative
contribution of polymorphisms to variability in CBZ pharmacokinetics,
we first investigated common genetic variants of DMEs involved in CBZ
metabolism.
Method: Four hundred epilepsy patients from across the West of
Scotland (201 male; median age 40 years, range 18–84 years) were
included in this analysis. DNA was extracted from venous blood and
common genetic variants in CYP3A4, CYP3A5, CYP1A2, and EPHX1
identified by either conventional polymerase chain reaction-restriction
fragment length polymorphism (PCR–RFLP) or direct sequencing.
Results: All genotype frequencies were consistent with Hardy-
Weinberg equilibrium (p > 0.10). The variant allele and genotype fre-
quencies were similar to published data for Caucasian populations, with
minor allele frequencies ranging from 3.5% CYP3A4∗1B) to 31.1%
(EPHX1 337C). Association between variant markers was demonstrated
for CYP3A4∗1B and CYP3A5∗3 alleles (p < 0.001), but not between the
common 337T>C and 416A>G polymorphisms in EPHX1 (p = 0.087).
Conclusion: This study indicates that the West of Scotland epilepsy
population has a relatively stable genotype frequency distribution and
one that is consistent with other Caucasian populations. The implications
of the apparent coexpression of CYP3A4∗1B and CYP3A5∗3 alleles are
not immediately clear but this phenomenon does not appear to extend
to common genetic variants in the EPHX1 gene. These results are being
used in an ongoing investigation of CBZ pharmacogenetics.
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EPILEPTIC SEIZURES AS MAIN SYMPTOM IN A MALE PA-
TIENT WITH A HETEROPLASMIC 7.4 KB mtDNA DELETION
1T. Dorn, 2S. Gallati, and 1G. Kra¨mer (1Swiss Epilepsy Centre, Zurich,
Switzerland, 2Molecular Genetics, University Hospital for Children,
Berne, Switzerland)
Purpose: Although epileptic seizures are frequently reported in pa-
tients with mtDNA point mutations, they usually do not dominate the
phenotype of syndromes due to mtDNA deletions. We present a male
with an mtDNA deletion and epileptic seizures as prominent phenotyp-
ical feature.
Method: Case report
Results: Male, born 1950 with partial seizures and sometimes my-
oclonic jerks since 1960, seizure freedom since 2000 under antiepileptic
polytherapy with oxcarbazepine, primidone and clobazam, normal MRI,
mild left frontotemporal neuropsychological signs. Repeatedly observed
slight increases of creatine kinase without clinical signs of myopathy led
to an EMG which showed only mild neurogenic changes. An ophthalmo-
logical examination including VEP and perimetry because of increasing
visual disturbances since 2001 disclosed optic nerve atrophy without oc-
ular movement disorders. After exclusion of an autoimmune disease an
extended analysis of mtDNA in blood cells demonstrated a homoplasmic
polymorphism (T9582C) which was also found in his two asymptomatic
brothers. Finally in mtDNA of a muscle biopsy which otherwise showed
only mild neurogenic changes, no ragged red fibres and normal oxphos
activity a heteroplasmic 7.4 kb deletion going beyond the Kearns-Sayr
deletion was found.
Epilepsia, Vol. 47, S3, 2006
88 7TH EUROPEAN CONGRESS ON EPILEPTOLOGY
Conclusion: mtDNA deletions can be associated with epileptic
seizures as a leading symptom. Thus, patients with epilepsy and an aeti-
ology remaining unknown after a routine diagnostic programme should
be closely checked for mitochondrial signs and, if positive, molecular
genetic tests, if necessary in different tissues, should be performed.
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UNCOMMON RELATIONS OF DISTINCT GENETIC DISOR-
DERS WITH EPILEPSY
T. Mayer (Saxonian Epilepsy Center, Radeberg, Germany)
Purpose: In some chromosomal disorders (e.g., trisomy 21, Angelman
syndrome) epilepsy is quite frequent (1). We investigated 3 patients with
different genetic syndromes, in which epilepsy is uncommon.
Method: Three case reports describe the correlation of epilepsy in
aberrations of chromosome 22 (n = 2) and in Klinefelter syndrome.
Results: T.A. 9.4-year-old, suffered from Catch syndrome (22q11
deletion) with ventricle septum defect, persistent Ductus Botalli, steno-
sis of the larynx and hyperbilirubinaemia. After 2 febrile convulsions in
early childhood 2 afebrile generalised tonic–clonic seizures happened
at the age of 9. Her MR scan showed heterotopias in both hemispheres,
the EEG-recording focal slowing right temporal. S.O., 10.7-year-old,
had first atonic seizures at the age of 7 months with good response to
valproic acid. Due to developmental delay intensive diagnostic investi-
gations showed a trisomy 22. Aetiology of the epilepsy may be seen in
small white matter lesions in the frontal cortex (MRT). EEG-recording
presented focal slowing in the right hemisphere. At the age of 7.1 years
seizures reappeared as hemi-grand mal on the right side, with a frequency
of 2–3 seizures a month. Since the age of 9.9 she is now seizure-free with
valproic acid and levetiracetam. J.L., now 2.5 years old, suffered from
Klinefelter syndrome (49, XXXXY, male) with typical clinical signs:
Dandy Walker syndrome, hydrocephalus internus, anomalia of the geni-
tals, facial dysmorphia and strong developmental delay. Epilepsy started
at the age of 1.3 with clonic seizures of the left face, spreading to the
left side of the body without the patient losing consciousness. Some of
these seizures lasted 30 minutes and had to be stopped with diazepam.
All seizures happened during sleep. Carbamazepine remained without
any effect (160 mg/d). The EEG during the first contact in our outpatient
clinic showed typical rolandic sharp waves right central and central. With
sulthiame (75 mg/d) he has now been seizure-free for 6 months.
Conclusion: Epilepsy may occur in abnormalities of chromosome 22
(2, 3). Furthermore, it is known that the first time rolandic epilepsy was
diagnosed was in Klinefelter syndrome, which may be accidental, but it
may be helpful to find out the gene of rolandic epilepsy.
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BENIGN FAMILIAL NEONATAL CONVULSIONS: CLINICAL
AND GENETIC ANALYSIS IN SEVEN DUTCH FAMILIES
1N. Verbeek, 1M. van Kempen, 2W. Arts, 3H. Stroink, 1A. Bader, 1K.
ten Berg, 4J. Starreveld, 5R. Baarsma, 1F. van Berkesteijn, 1O. van
Nieuwenhuizen, and 1D. Lindhout (1University Medical Centre Utrecht,
Utrecht, The Netherlands, 2Erasmus MC, Rotterdam, The Nether-
lands, 3TweeSteden Ziekenhuis, Tilburg, The Netherlands, 4Groene Hart
Ziekenhuis, Gouda, The Netherlands, 5Medisch Spectrum Twente, En-
schede, The Netherlands)
Purpose: To study the yield and spectrum of mutation analysis of the
KCNQ2 gene (20q13.3) in Dutch benign familial neonatal convulsions
(BFNC), and the phenotypic expression regarding late onset epilepsy
and mental retardation.
Method: Clinical data were obtained from 7 families. Sequence anal-
ysis of the KCNQ2 gene was performed in all, including linkage analysis
in 1 family.
Results: Four different mutations were detected; 1 nonsense muta-
tion (c.1756C>T, p.Gln586Stop), 1 missense mutation (c.1076C > A,
p.Thr359Lys) and 2 frameshifts (c.1229delC, p.Pro410fs; c.1601delC,
p.Pro534fs). The smallest family had only 2 affected members and a
de novo mutation was demonstrated in the affected parent. In the fam-
ily with the 1229delC-mutation, epilepsy after the neonatal period was
reported, but was not cosegregating with the mutation. In a fifth large
family, linkage analysis was compatible with the 20q13.3-locus. KCNQ2
analysis did not reveal a mutation, but gave some indication for a large
deletion. Two out of 10 subjects with BFNC in this family had subse-
quent epilepsy and 1 of them mental retardation. Several other family
members also had mental retardation and epilepsy, but clinical and DNA
data on BFNC-status were not available.
Conclusion: Five different mutations in the KCNQ2 gene were de-
tected in 7 families with BFNC (71%). Mutation analysis should include
testing for large deletions. Small families or sporadic patients may also
benefit since they may represent new or recent mutations. The diag-
nostic results helped to avoid other expensive and stressing diagnostic
procedures in affected newborn relatives, but cannot reliably predict the
occurrence of late onset epilepsy.
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SEGMENTAL ANEUPLOIDIES IN PATIENTS WITH EPILEPSY
OF UNKNOWN ETIOLOGY DETECTED BY ARRAY-CGH
M. Swinkels, J. van Hoek-Terluin, K. ten Berg, F. Beemer, E. Brilstra, M.
Eleveld, S. van der Wijst, D. Lindhout, R. Hochstenbach, M. Poot, and
1O. van Nieuwenhuizen (University Medical Center Utrecht, Utrecht,
the Netherlands)
Purpose: Epilepsy and epileptic EEG abnormalities are common
symptoms and signs of specific chromosomal abnormalities. The
objective of this study was to determine the value of array-CGH in
patients with epileptic disorders and to evaluate the use of a clinical
checklist in preselecting patients.
Method: In a cohort of 675 pediatric patients that underwent an EEG-
examination at the University Medical Centre Utrecht, 35 patients were
selected for analysis by array-CGH. Inclusion criteria were refractory
epilepsy of unknown etiology, mental retardation and at least one of the
items described in the 5-item checklist developed by de Vries et al. (J
Med Genet 2001;38;145–150). Array-CGH was applied to the first 16
patients with scores ranging from 1–5 items.
Results: Four out of 16 (25%) patients analyzed by array-CGH
showed segmental aneuploidies, including duplications involving chro-
mosomes 9 and 16, and combinations of deletions and duplications in-
volving chromosomes 3 and 4. Two of those aberrations were found in
patients with a normal karyotype. All four patients had a score 4 on
the clinical checklist, whereas no abnormalities were found in patients
scoring 3.
Conclusion: We demonstrate the added value of array-CGH by detec-
tion of submicroscopic segmental aneuploidies in patients with epilepsy
of unknown etiology. This study shows that a clinical checklist is useful
in preselecting candidate patients with epilepsy for analysis by array-
CGH. Early recognition of chromosomal abnormalities might prevent
patients from undergoing unnecessary diagnostic investigations and is
important for genetic counseling. Array-CGH may also contribute to
more refined mapping of genes involved in epilepsy.
p336
PHARMACOGENETICS OF ABCB1 AND BRAIN KINETICS OF
99m-Tc-MIBI IN EPILEPSY PATIENTS
1S. Jensen, 3A. Di Paolo, 3M. Lastella, 2P. Erba, 1M. Baldini, 1D. Perini,
1C. Pecori, 3R. Danesi, 1A. Iudice, 2G. Mariani, 3M. Del Tacca, and
1L. Murri (1Department of Neurology, University of Pisa, Pisa, Italy,
2Department of Oncology, Transplants And Advanced Technologies
In Medicine, University of Pisa, Pisa, Italy, 3Department of Internal
Medicine, University of Pisa, Pisa, Italy)
Purpose: ABCB1 expression is associated to antiepileptic treatment
sensitivity, and two single nucleotide polymorphisms (SNPs) in exon 26
(C3435T) and exon 21 (G2677T) predict for ABCB1 gene expression.
Moreover, 99mTc-methoxyisobutylisonitrile (99mTc-MIBI), an ABCB1
substrate, can be used to investigate the transporter activity in vivo by
means of brain scintigraphy. Therefore, the present study was aimed at
evaluating epilepsy patients’ response to treatment, their ABCB1 geno-
type and the pattern of brain 99mTc-methoxyisobutylisonitrile kinetics.
Method: Genomic DNA from 50 consecutive patients with partial
seizures was analysed for C3435T and G2677T SNPs by polymerase
chain reaction-restriction fragment length polymorphism assay. Within
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this population, 16 patients, divided into 2 groups with high (n = 6) and
low (n = 10) seizure frequency respectively (cut >4 seizures/month),
underwent a brain scintigraphy with 99mTc-MIBIoff.
Results: Among 37 subjects responsive to antiepileptic treatment,
10% had a TT/TT genotype (exons 21 and 26, respectively), 45% were
GT/CT, but nobody was GG/CC. On the contrary, 61% of 13 pharmacore-
sistant patients was GG/CC, but none of them was TT/TT. Early 99mTc-
MIBI uptake was significantly lower (p < 0.05) in the high seizure fre-
quency group than in the low frequency group, especially when GT/CT
heterozygous patients were considered (p < 0.01).
Conclusion: Pharmacogenetic analysis allows detection of a correla-
tion between clinical response to antiepileptics and patients’ genotype.
A reduced early uptake of 99mTc-MIBI was detected in epilepsy patients
with clinically unfavourable prognostic factors.
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PIPECOLIC ACID CONCENTRATIONS AND MOLECULAR
ANALYSIS OF THE ANTIQUITIN (ALDH7 A1) GENE IN PA-
TIENTS WITH PYRIDOXINE-DEPENDENT EPILEPSY
1B. Plecko, 2K. Paul, 2E. Paschke, 2W. Erwa, 3H. Hartmann, 3T. Luecke,
4M. Di Capua, 4G. Seganti, 5C. Korenke, 6C. Hikel, 7R. Seidl, and 8S.
Sto¨ckler-Ipsiroglu (1Department of Pediatrics, University Hospital Graz,
Austria, 2Institute for Clinical and Chemical Laroratory Diagnoses, Uni-
versity Hospital Graz, Austria, 3Department of Pediatrics, Medizinische
Hochschule Hannover, Germany, 4Ospedale Pediatrico Bambino Gesu,
Rome, Italy, 5Department of Pediatrics, Klinikum Oldenburg, Germany,
6Katholisches Klinikum Duisburg, Universita¨t Du¨sseldorf, Germany,
7Department of Pediatrics, University Hospital Vienna, Austria, 8British
Columbia Children’s Hospital, Vancouver, Canada)
Purpose: Following the description of elevated pipecolic acid (PA)
as a diagnostic marker of pyridoxine dependent epilepsy (Plecko B.
et al.. Annals of Neurology 2000;48:121–125, Neuropediatrics 2005;36:
200–205), the molecular background has been identified by mutations
of the antiquitin (ALDH7 A1) gene on chromosome 5q31 (Ph. Mills et
al., Nature Medicine in press). We report on biochemical and molecular
findings of 14 patients with probable or definite pyridoxine-dependent
epilepsy.
Method: Following parental consent, 1 ml of plasma and 5 ml of
EDTA blood were collected while on pyridoxine-HCl. PA was deter-
mined by GCMS. Mutation analysis of the ALDH7 A1 gene was per-
formed by direct sequencing of all 18 exons and flanking introns. De-
tected mutations were confirmed by restriction fragment polymorphism
analysis.
Results: We were able to detect homozygous or compound heterozy-
gous mutations in 8 patients, while in 3 patients only one mutation and
in 3 patients no mutation of the ALDH7 A1 gene have yet been iden-
tified. We found elevated PA (3.4–16.8 μmol/l, normal <2.46) in all
patients with mutations on both alleles and in 2 patients with one muta-
tion identified. PA in plasma was normal in 3 patients with no mutation
identified and in 1 heterozygote, while her affected sibling did not carry
the mutation.
Conclusion: With respect to limited data, PA in plasma seems to be a
reliable marker of pyridoxine-dependent epilepsy caused by mutations of
the ALDH7 A1 gene. Molecular analysis of the ALDH7 A1 gene enables
prenatal diagnosis in forthcoming pregnancies.
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FUNCTIONAL ASSOCIATION OF THE GABAA RECEPTOR
BETA3 SUBUNIT GENE PROMOTER WITH CHILDHOOD AB-
SENCE EPILEPSY
1,2L. Urak, 1M. Feucht, 3K. Hornik, 2W. Sieghart, and 2K. Fuchs
(1Medical University of Vienna, Department of Pediatrics, Austria,
2Medical University of Vienna, Center for Brain Research, Division
of Biochemistry and Molecular Biology, Austria, 3Vienna University of
Economics, Department of Statistics, Austria)
Purpose: Childhood absence epilepsy (CAE) is considered to be a
genetic disease, but the genes responsible have not yet been identified. In
a previous study of our group, association between the GABAA receptor
beta3 subunit gene (GABRB3) and 48 CAE cases was found (Feucht M
et al., Biol Psychiatry 1999;46:997–1002). Subsequently, we identified
several SNPs (single nucleotide polymorphisms) in the GABRB3 gene
sequence. In the present work, we performed an associated study with
haplotypes of the GABRB3 gene and we examined the transcriptional
activity of the promoter haplotypes using a luciferase reporter assay.
Method: Haplotypes were determined by cloning and sequencing of
the respective DNA fragments and tag-SNPs were genotyped in 45 CAE
core families. Further, exon1a promoter haplotypes were cloned in front
of the reporter gene luciferase. These constructs were transfected into
human NT-2 cells and luciferase activity was measured.
Results: Four haplotypes were defined and a subsequent associa-
tion study showed significant association (p = 0.007075) between the
GABRB3 gene and CAE. We further verified that the promoter haplo-
type2 associated with CAE has a significantly lower activity in an in
vitro luciferase expression assay compared with those haplotypes over-
represented in controls. In silico analyses of the GABRB3 exon1a region
suggested that haplotype2 differs in putative transcription factor binding
sites. Currently, electromobility shift assays are performed to confirm
these results, which will be presented.
Conclusion: These data suggest a role for the exon1a promoter hap-
lotype2 in the pathogenesis of CAE. Supported by the Jubila¨umsfonds
of the Austrian National Bank.
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MUTATIONS IN THE EFHC1 GENE ARE FREQUENT IN FA-
MILIAL IDIOPATHIC EPILEPSIES
1E. Sto¨gmann, 2P. Lichtner, 1C. Baumgartner, 1S. Bonelli, 1F. Zimprich,
and 1A. Zimprich (1Medical University of Vienna, Vienna, Austria,
2Institute of Human Genetics, Neuherberg, Germany)
Purpose: Previously on chromosome 6p12-p11, a region associated
with juvenile myoclonic epilepsy (JME), a gene called EFHC1 (EF-hand
domain C-terminal containing 1) was described. This gene encodes a pro-
tein which is supposed to induce apoptosis. Mutation analysis identified
five missense mutations in this gene in families with JME. In experi-
mental studies these newly described mutations were shown to lower
significantly the apoptotic activity of EFHC1 and therefore might lead
to increased density of neurons and hyperexcitable circuits. To confirm
this finding in our patient sample we screened 96 patients with idiopathic
generalised epilepsy (IGE) and temporal lobe epilepsy (TLE).
Method: We screened the entire open reading frame of the EFHC1
gene consisting of 11 exons by direct sequencing 61 patients with IGE,
28 with a positive family history for seizures, and 35 with TLE with
a positive family history for seizures (FH-TLE). Possible pathogenic
variations were tested in a further sample of 300 patients with sporadic
TLE and 368 control individuals.
Results: We identified three heterozygous mutations, all resulting in
amino acid substitutions (I174V, C759Y, A394S). None of those could
be detected in controls and have been described previously. Interestingly
the I174V mutation was found in 2 patients, 1 with juvenile absence
epilepsy (JAE) and the other with TLE. Haplotype analysis suggested
that this is not due to a common founder, but is generated by recurrent
mutational events. The other described mutations were both found in
patients with IGE.
Conclusion: We describe three new heterozygous mutations in a
newly described gene called EFHC1 in patients with different epilepsy
syndromes. These data suggest an important contribution of the EFHC1
gene to the genetic background of epilepsy syndromes.
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MUTATION ANALYSIS OF SCN1A AND SCN2A IN FINNISH PA-
TIENTS WITH INFANTILE ONSET INTRACTABLE EPILEPSY
1,2A. Anttonen, 2V. Ahonen, 3E. Gaily, 3E. Liukkonen, 4M. Aine, 5E.
Herrga˚rd, 3L. Metsa¨honkala, 6H. Rantala, 2A. Sire´n, and 2A. Lehesjoki
(1Department of Medical Genetics, University of Helsinki, Helsinki, Fin-
land, 2Folkha¨lsan Institute of Genetics and Neuroscience Center, Univer-
sity of Helsinki, Helsinki, Finland, 3Department of Pediatric Neurology,
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Hospital for Children and Adolescents, Helsinki University Central Hos-
pital, Finland, 4Department of Child Neurology, Lapland Central Hos-
pital, Rovaniemi, Finland, 5Department of Pediatrics, Division of Child
Neurology, Kuopio University Hospital, Kuopio, Finland, 6Department
of Pediatrics, University of Oulu, Oulu, Finland)
Purpose: Mutations in SCN1A are associated with many epilepsy syn-
dromes such as severe myoclonic epilepsy of infancy (SMEI) and gener-
alised epilepsy with febrile seizures plus (GEFS+). Mutations in SCN2A
have been described in benign familial neonatal-infantile seizures and
GEFS+ but to date only one SCN2A mutation has been associated with
intractable epilepsy. We evaluated the contribution of SCN1A and SCN2A
mutations to infantile onset intractable epilepsy in Finnish patients.
Method: SCN1A and SCN2A were screened for mutations in 33 pa-
tients, 21 of which had a clinical suspicion of SMEI. We amplified all
exons and exon-intron boundaries of SCN1A and SCN2A from genomic
DNA and sequenced the PCR products with an ABI 3730 DNA analyser.
Sequences were analysed using the Sequencher4.5 program.
Results: We found 6 different de novo mutations in SCN1A: 1 non-
sense, 2 splice site, 1 frameshift-causing and 2 missense mutations that
change highly conserved amino acids. One of the mutations was previ-
ously described. The clinical presentation in 3 of the mutation positive
patients is SMEI. Two patients have borderline SMEI and 1 has a milder
phenotype with normal cognitive development. We also found 1 previ-
ously undescribed de novo missense mutation of a conserved amino acid
in SCN2A in a patient with infantile onset epilepsy and episodic ataxia.
None of the mutations were observed in 192 control chromosomes.
Conclusion: Our findings are compatible with previous findings
showing that de novo SCN1A mutations are a major cause of SMEI.
SCN2A mutations are found only in a small subset of infantile onset
intractable epilepsy.
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SUGGESTION OF LINKAGE TO CHROMOSOME 3p24.3 IN A
SPANISH FAMILY WITH AUTOSOMAL RECESSIVE FAMIL-
IAL TEMPORAL LOBE EPILEPSY
1J. Morales-Corraliza, 1P. Gomez-Garre, 1E. Gutierrez-Delicado, 2J.
Herna´ndez, and 1J. Serratosa (1Fundacion Jimenez Diaz, Madrid, Spain
2Complejo Hospitalario de Albacete, Spain)
Purpose: To characterise the genetic and clinical features of a four
generation consanguineous Spanish family with familial temporal lobe
epilepsy.
Method: We identified an extended family including 3 affected indi-
viduals presenting temporal lobe epilepsy. Personal interviews and DNA
samples were obtained from 5 individuals. A whole-genome-screen us-
ing microsatellite markers and haplotype and linkage analysis were per-
formed. The coding sequence of the candidate gene KCNH8 (H8 subunit
of the channel of potassium) was sequenced.
Results: The affected individuals presented temporal lobe seizures
characterised by feelings of being out of their body, de´ja` vu´, and de-
creased levels of consciousness. Age of seizure onset ranged from 16
to 25 years. The EEGs showed temporal discharges and the brain MR
was normal. The mode of inheritance was consistent with an autosomal
recessive pattern. We excluded linkage to the autosomal dominant partial
epilepsy with auditory features (ADPEAF) 10q24 locus. A suggestion of
linkage to chromosome 3p24.3 with a maximum lod score of 2.08 (theta
= 0) was found. This locus has been recently associated with autoso-
mal dominant nocturnal frontal lobe epilepsy (ADNFLE). The KCNH8
gene is localised within the candidate gene region but no mutations were
found.
Conclusion: We describe a family that may represent an autosomal
recessive form of familial temporal lobe epilepsy. A suggestion of linkage
to chromosome 3p24.3 was found.
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MUTATION ANALYSIS OF THE SCN1A GENE IN 92 PATIENTS
WITH SEVERE MYOCLONIC EPILEPSY OF INFANCY
1,2C. Depienne, 2O. Trouillard, 3R. Nabbout, 4I. Gourfinkel-An, 5A. Arz-
imanoglou, 3O. Dulac, 4M. Baulac, and 1,2E. Leguern (1Inserm U679,
Hoˆpital Pitie´-Salpeˆtrie`re, Paris, France, 2De´partement De Ge´ne´tique,
Cytoge´ne´tique Et Embryologie, AP-HP, Hoˆpital Pitie´-Salpeˆtrie`re,
Paris, France, 3Service De Neurope´diatrie, Hoˆpital Necker-Les-Enfants
Malades, Paris, France, 4Poˆle D’Epileptologie, Hoˆpital Pitie´-Salpeˆtrie`re,
Paris, France, 5Unite´ D’Epileptologie Pe´diatrique, Service De Neurolo-
gie Pe´diatrique Et Des Maladies Me´taboliques, Hoˆpital Robert Debre´,
Paris, France)
Purpose: De novo mutations in the SCN1A gene, encoding the
alpha1-subunit of the neuronal voltage-gated sodium channel Nav1.1,
are the most frequent genetic cause of severe myoclonic epilepsy of in-
fancy (SMEI) known so far. In order to establish genotype-phenotype
correlations and investigate the pathological mechanisms responsible for
SMEI, we analysed a large group of patients including 86 isolated SMEI
probands, 5 SMEI sib pairs and 1 SMEI patient in a large family with
generalised epilepsy with febrile seizures plus (GEFS+).
Method: The SCN1A gene was screened by DHPLC and abnormal
profiles were systematically sequenced.
Results: We identified 39 SCN1A mutations, 31 of which are novel.
Most of the SCN1A mutations responsible for SMEI were de novo events,
but in 10% of cases, they were inherited from an asymptomatic or mildly
affected parent. In 2 unrelated families, we showed evidence that so-
matic and germline mosaicism in the transmitting asymptomatic parents
resulted in recurrent transmission of the disease.
Conclusion: This first report of parental mosaicisms in the SCN1A
gene has major consequences for genetic counselling for parents with a
SMEI child.
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DOES THE G-PROTEIN BETA-3 SUBUNIT C825T POLYMOR-
PHISM HAVE AN IMPACT ON TEMPORAL LOBE EPILEPSY
(TLE)?
1S. Osberg, 2Ø. Melien, 1E. Taubøll, and 1L. Gjerstad (1Department
of Neurology, Rikshospitalet University Hospital, Oslo, Norway,
2Department of Clinical Pharmacology, Rikshospitalet University Hos-
pital, Oslo, Norway)
Purpose: Experimental studies suggest a role of G protein-coupled
receptors in epileptogenesis. A genetic variation in the G protein sub-
unit Gβ3 denoted the C825T polymorphism has been reported to be
associated with several diseases including hypertension, diabetes type
II and obesity, as well as major depressive disorders. The present study
is the first to examine whether this polymorphism is associated with
TLE.
Method: The study included 227 TLE-patients, 186 controls and 106
family members of TLE patients. DNA was extracted from blood sam-
ples, and typing of the polymorphism performed. Case record forms were
analysed for all the homozygote TLE patients and homozygote controls
as well as for 28 matched TLE patients without the mutation (16 females,
12 males).
Results: Typing showed that 14 of the cases (6%; 8 females, 6 males),
13 of the controls (7%; 6 females, 7 males) and 8 of the family members
(7.5%) were homozygote for the polymorphism. 100 of the cases (44%),
70 of the controls (38%) and 43 (41%) of the family members were
heterozygote, while 113 of the cases (50%), 103 of the controls (55%)
and 55 of the family members (52%) were normal. The homozygote
TLE patients had higher BMI, weight and waist circumference than
TLE patients without the mutation, but did not show higher frequency
of hypertension and diabetes.
Conclusion: There was no increased frequency of TLE in the ho-
mozygote group compared to healthy controls or family members with-
out epilepsy. The homozygote patients, however, had increased obesity
in consistence with earlier studies.
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MIGRAINE HEADACHE OR PHOTOSENSITIVE EPILEPSY?
1M. Piccioli, 2D. Kasteleijn-Nolst Trenite´, 1P. Tisei, 2B. Koeleman, 1M.
Latella, 2D. Lindhout, 1M. Tasillo, and 1C. Buttinelli (1University of
Rome “La Sapienza,” II Faculty of Medicine, Rome, Italy, 2University
of Utrecht, Department of Medical Genetics, Utrecht, The Netherlands)
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Purpose: To find out whether complaints of migraine in a photosensi-
tive family are the expression of an inherited liability to photosensitivity
or comorbid migraine attacks.
Method: After clinical histories, video-EEG recordings with extra vi-
sual stimulation were carried out on a mother at age 45, and her daughters
of 21 and 16 years. Intermittent photic stimulation (IPS) was performed
in accordance with the European protocol with determination of photo-
sensitivity ranges. Likewise, thresholds of pattern sensitivity were deter-
mined with black-and-white striped patterns.
Results: Mother had a history of photosensitive epilepsy since the
age of 15 with generalised photoparoxysmal EEG responses (PPRs).
The video-EEG with VPA 500 mg showed sharp-waves over the left
temporal occipital region. Her photosensitivity range was 8 to 60 Hz.
Daughter A had a history of complex partial seizures since the age of 13
with also generalised PPRs. Her video-EEG with 700 mg VPA showed
40 sec after pattern stimulation sharp-waves in both occipital regions
lasting for 18 seconds. During that episode she complained of headache.
Daughter B suffered since one year from episodes of vertigo, loss of
vision followed by headache. Her EEG showed sharp-waves over the
right temporal occipital region and generalised PPRs between 12 and 25
Hz. During IPS she complained of her headache.
Conclusion: In this family the headaches were shown to be epilepto-
genic and photosensitive during video-EEG recordings. Even when no
clear photosensitive seizures are reported, headache can be an ictal sign
and part of the phenotype of photosensitivity.
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ASSOCIATION BETWEEN GEFS+3 LOCUS AND GEFS+ SYN-
DROME IN TWO AFFECTED TUNISIAN FAMILIES
1F. Kamoun, 2N. Fendri, 1D. Kolsi, 2F. Fakhfakh, and 1C. Triki
(1Neuropediatric Unit, Sfax, Tunisia, 2Genetic laboratory, Sfax, Tunisia)
Purpose: The aim of this report is to search for a correlation between
clinical phenotype and genotype in affected Tunisians families with gen-
eralised epilepsy with febrile seizure plus (GEFS+).
Method: A total of 69 members belonging to two large Tunisian fam-
ilies with a phenotype compatible with GEFS+ were studied. Seizures
and syndromes of probands and affected relatives were classified ac-
cording to the international classifications. Genetic analysis has been
performed using microsatellite markers spanning all FS and GEFS+
loci.
Results: Nineteen patients with a history of seizures were collected.
The phenotype comprised febrile and afebrile seizures. Afebrile seizures
were generalised tonic–clonic. There was no patient with childhood ab-
sence epilepsy or juvenile absence. A genetic study was performed for
14 patients and 55 collateral members of the two families. Statistical
analysis demonstrates an association with the GEFS+3 (GABRG2) loci
with a significant p value.
Conclusion: The position and/or severity of the mutation in GABRG2
may determine different phenotypes. Our families were probably linked
to a different mutation in the GABRG2.
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EXPANDING THE AGE SPECTRUM OF INFANTILE CONVUL-
SIONS (BFIC) BEYOND THE FIRST YEAR OF LIFE
1Y. Weber, 1M. Jacob, 2G. Weber, and 1,3H. Lerche (1Department of
Neurology of the University of Ulm, Germany, 2Department of Neuro-
pediatry and Pediatric Epileptology of the Clinic for Pediatrics, Duisburg,
Germany, 3Department of Applied Physiology of the University of Ulm,
Germany)
Purpose: Benign familial infantile convulsions (BFIC) belong to the
idiopathic epilepsies with an autosomal dominant mode of inheritance.
BFIC is characterised by partial and generalised tonic–clonic seizures
appearing between months 3 and 12 of life. The disease has a benign
course with a good response to antiepileptic drugs and normal psychomo-
tor development. The main locus for BFIC is on chr 16p12-q12, while
infantile seizures can be associated with paroxysmal dyskinesias in some
families. Another locus for pure BFIC was identified on chr 19q. Here
we describe a three generation BFIC family with 8 affected members
with a slightly different clinical picture.
Method: We collected a BFIC family of German origin with 8 affected
members and performed a standard two-point linkage analysis.
Results: Mainly generalised tonic–clonic seizures, and in rare cases
complex partial or atonic seizures were observed. They occurred in typi-
cal clusters and responded well to anticonvulsive treatment with sulthiam
or other AEDs. Uncommonly for BFIC, the onset of the seizures was
between months 14 and 16 of life. We performed a linkage analysis and
found a positive linkage to the known BFIC locus on chr 16p12-q12.
Conclusion: Our results expand the clinical spectrum of this syndrome
and suggest that either a potentially similar but different gene at the same
locus or alternatively other modifier genes or the genetic background are
responsible for the late onset within this family.
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GABBR1 POLYMORPHISMS IN PORTUGUESE MESIAL TEM-
PORAL LOBE EPILEPSY PATIENTS
1C. Pereira, 2J. Chaves, 1B. Leal, 1,4A. Carvalho, 3C. Bettencourt, 3P.
Costa, 2L. Monteiro, 2J. Lima, 2A. Silva, 1,5D. Pinto, and 1,3,4B. Silva
(1ICBAS/University of Porto-Porto, Portugal, 2Neurology Service–
HGSA-Porto, Portugal, 3INSA Dr. Ricardo Jorge-Porto, Portugal,
4CECA/ICETA/University of Porto–Porto, Portugal, 5University Medi-
cal Centre Utrecht-Utrecht, The Netherlands.)
Purpose: Mesial temporal lobe epilepsy (MTLE) associated with
hippocampal sclerosis (HS) is of unknown aetiology, although there is
emerging evidence for a genetic component. A variant, G1465A, in the
GABBR1 gene, which encodes the gamma-aminobutyric acid type B re-
ceptor 1, has been suggested as a risk factor for TLE (Gambardella et
al., 2003), but was not confirmed in subsequent replication studies (Cav-
alleri et al, 2005). Prolonged febrile seizures (FS) are associated with
hippocampal cell death and may predispose some individuals to develop
MTLE-HS. Here we analysed two GABBR1 variants 1465G > A and
1974T > C in a sample of MTLE-HS patients of Portuguese origin. We
further evaluated a possible relationship between these variants and the
occurrence of FS.
Method: Seventy-two unrelated MTLE-HS patients, of which 36 had
FS, and 141 unaffected controls were studied. Genomic DNA was ob-
tained from peripheral blood and genotyping of the two SNPs was per-
formed using PCR-RFLP methodology.
Results: We found the 1465G > A variant in 1 epileptic patient that
was not detected in any of the control subjects. The allele frequency
of 1974T>C did not differ significantly between the control group and
patients, with or without FS.
Conclusion: The present results do not provide evidence that the
GABBR1 polymorphisms 1465G > A and 1974T > C confer a sub-
stantial susceptibility to MTLE-HS, preceded or not by FS. Our studies
do not support the previous described relationship between such vari-
ants and TLE. Work supported by a TECNIFAR 2005 Grant for Epilepsy
Research.
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VANISHING WHITE MATTER (VWM) DISEASE AS A CAUSE
OF PROGRESSIVE MYOCLONUS EPILEPSY
1,2A. Jansen, 1,2,3E. Andermann, 4I. Creveaux, 5F. Niel, 5O. Boespflug,
and 1,2,6F. Andermann (1Montreal Neurological Hospital & Institute,
McGill University, Montreal, Canada, 2Department of Neurology &
Neurology, McGill University, Montreal, Canada, 3Department of Hu-
man Genetics, McGill University, Montreal, Canada, 4Inserm UR582,
Institut de Myologie, GH Pitie´-Salpeˆtrie`re, Paris, France, 5Biologie et
Genetique de la Reproduction, AP-HP Hopital Antoine Beclere, Cla-
mart, France, 6Department of Pediatrics, McGill University, Montreal,
Canada)
Purpose: The progressive myoclonus epilepsies (PMEs) are a group
of symptomatic generalised epilepsies with a progressive course and poor
outcome. Advances in molecular genetics have begun to elucidate the
causes of PME, including Lafora disease, Unverricht Lundborg disease,
neuronal ceroid lipofuscinosis, dentatorubral-pallidoluysian atrophy
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(DRPLA) and myoclonic epilepsy with ragged red fibres (MERRF).
We report eIF2B related leucoencephalopathy with VWM as another
cause of PME.
Method: Detailed medical and family histories were obtained on the
proband and his relatives. EEG, MRI and MRS of the brain, EMG, MRS
of the muscle, skin-muscle-nerve biopsy, brain biopsy, bone marrow
biopsy, CSF studies, metabolic work-up and molecular genetic studies
for MERFF, DRPLA, spinocerebellar ataxia types 1 and 3, and VWM
leucodystrophy were performed on the proband.
Results: The proband, a 38 year-old man, developed learning prob-
lems at age 9, after head trauma with loss of consciousness. At age 22,
he began to have myoclonic jerks as well as generalised tonic–clonic
seizures. At age 38, he had a cerebellar syndrome with severe dysarthria
and ataxia, as well as a bilateral pyramidal syndrome. He was wheelchair
bound since age 31. The myoclonus that had been very disabling had al-
most disappeared. Infrequent brief generalised seizures persisted. EEGs
showed diffuse slow waves and epileptic activity from both temporal
regions. MRI showed marked selective loss of white matter volume with
extreme thinning of the corpus callosum. Brain biopsy revealed loss of
white matter. The proband was homozygous for the R113H mutation in
the eIF2B5 gene.
Conclusion: Mutations in any of the 5 genes encoding subunits of
the translation initiation factor eIF2B can cause vanishing white matter
leucodystrophy (VWM)/childhood ataxia with central nervous system
hypomyelination (CACH). Mutations in these genes should be included
in the differential diagnosis of progressive myoclonus epilepsy.
Monday July 3, 2006
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Psychiatry
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PERSONALITY OF PATIENTS WITH SYMPTOMATIC
EPILEPSY AS A FUNCTION OF LESION LOCALISATION
AND SEIZURE CONTROL: A ONE-YEAR PRE- TO POSTOP-
ERATIVE FOLLOW-UP STUDY OF 151 PATIENTS
1C. Helmstaedter, 2K. Hollmann, 2J. Hennig, and 1C. Elger (1University
Clinic of Epileptology Bonn, Germany, 2Department of Psychology,
Justus Liebig University, Gießen, Germany)
Purpose: Since Kraepelin (1923) the question of a relationship be-
tween epilepsy and personality is a recurring issue in epileptology. This
study evaluated this issue in patients with focal symptomatic epilepsy
before and after epilepsy surgery.
Method: 151 patients were evaluated before and one year after
epilepsy surgery. Dependent measures were 4 scales (organic psycho-
syndrome, intro-extraversion, neuroticism, addiction) and 21 subscales
of a personality inventory for epilepsy patients, which was standardised
with 300 healthy subjects. Independent measures were focus localisation,
pathology, AED, onset & duration of epilepsy, demographic variables,
and seizure outcome.
Results: Introversion was the major problem in the epilepsy group
(38%), followed by 28% with elevated/lowered neuroticism scores, 16%
with hints of an organic psycho-syndrome, and 10% with elevated addic-
tion scores. Gender predicted neuroticism, mesial temporal lobe epilepsy
introversion. Follow-up analysis indicated an effect of surgery on neu-
roticism and an interaction effect of seizure control by surgery on organic
psycho-syndrome scores. Subscale analysis revealed a differential effect
of seizure control on personality change dependent on the side of surgery.
Right TLE patients reported decrease of anxiety, vegetative symptoms,
somatisation, and external control, left TLE patients reported emotional
stabilisation and improved impetus.
Conclusion: Introversion appears as a frequent trait particularly in
patients with temporal lobe epilepsy. Neuroticism or a psycho-organic
syndrome are less common and appear more state dependent. Postopera-
tive changes dependent on seizure outcome indicate hemisphere specific
release effects after temporal lobe surgery.
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PREVALENCE AND SEVERITY OF NEUROPSYCHIATRIC
DISORDERS IN EPILEPSY – RESULTS OF THE GERMAN
DAS-PROJECT, A NATIONWIDE EPIDEMIOLOGICAL EVAL-
UATION FOCUSING ON DEPRESSION, ANXIETY, AND SLEEP
DISORDERS
1M. ¨Uberall, and 2H. Stefan (1Institute for Neurological Sciences, Nuern-
berg, Germany, 2University Epilepsy Center, Erlangen, Germany)
Purpose: Neuropsychiatric disorders (depression, anxiety and sleep
disturbances) are common in patients with epilepsy, although often un-
derdiagnosed. We report on the results of the German DAS-Project, a
Nationwide Epidemiological Evaluation Focusing on Depression, Anx-
iety and Sleep Disorders.
Method: Profile survey of patients suffering from partial or gener-
alised epilepsy (PE/GE) using standardised questionnaires focussing on
depression, anxiety and sleep disorders to evaluate their prevalence in
German epilepsy patients.
Results: Six hundred sixty-four patients (49.5% female) participated
(P/GE: 52.7/47.3%). Overall, 16.8% suffered from depression, 22.0%
from anxiety and 12.1% reported sleep disturbances. Seizure free pa-
tients were significantly less impaired (12.0% vs 22.6%; 15.1/29.7%;
9.2/15.2%) as well as patients suffering from GE: depression (GE
vs PE): 11.8/5.1/24.7% vs 20.7/18.0/23.2%; anxiety (GE vs PE):
18.0/10.8/31.8% vs 24.0/15.6/31.0%; sleep disturbances (GE vs PE):
7.3/4.4/12.9% vs 15.1/11.7/17.5%).
Conclusion: Depression, anxiety and sleep disturbances are frequent
neuropsychiatric problems, even in seizure free patients with epilepsy.
Frequency and severity depend with respect to epilepsy type (PE > GE)
and increase with seizure frequency.
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RISK FACTORS FOR PSYCHOTIC DISORDERS IN PATIENTS
WITH TEMPORAL LOBE EPILEPSY
L. D´Alessio, B. Giagante, V. Ibarra, C. Papayannis, S. Oddo, P. Solı´s, D.
Consalvo, V. Donnoli, and S. Kochen (Ramos Mejia Hospital, Epilepsy
Center, Argentina)
Purpose: Temporal lobe epilepsy patients are at higher risk for acute
and chronic psychotic disorders but the aetiology of this association is
not clearly defined. The aim of this study was to determine risk factors
for psychosis in temporal lobe epilepsy patients.
Method: 118 patients with neurological, neurophysiologic and neu-
roimaging criteria for temporal lobe epilepsy were included. Two groups
of patients were determined: 61 patients (52%) with psychotic disorders
codified in Axis I of DSM IV were compared with 57 patients (48%)
without psychotic disorders. Psychotic disorders were defined by DSM
IV criteria (SCDI I and II), and postictal and/or interictal psychoses were
additionally diagnosed. Sex, age, age of epilepsy onset and epilepsy time
duration, febrile convulsions, generalised seizures, status history, pres-
ence of unilateral and bilateral hippocampal sclerosis, and laterality of
epileptic discharges diagnosed by video-EEG were determined. Student
t-test and chi-square were carried out.
Results: The more frequent DSM IV psychotic disorders diag-
nosed were brief psychotic disorders (39%), schizophrenia (24%) and
schizophreniform disorder (13%). Postictal psychotic episodes were re-
ported in 29 patients with DSM IV psychotic disorders (47%). Topira-
mate in 4 patients and vigabatrin in 1 patient induced interictal psychosis
(8%). Age of epilepsy onset was earlier and epilepsy time duration longer
in the psychotic group, compared with the control group: p = 0.04 / p
= 0.017. Status epilepticus history, and bilateral hippocampal sclerosis
were more prevalent in psychotic patients p = 0.02 / 0.00.
Conclusion: In this study longer evolution, status epilepticus history,
and bilateral hippocampal sclerosis (risk factors for epilepsy severity)
were significantly more frequent in patients with psychotic disorders.
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NONEPILEPTIC SEIZURES AND OTHER FUNCTIONAL NEU-
ROLOGICAL SYMPTOMS: PREDISPOSING, PRECIPITAT-
ING, AND PERPETUATING FACTORS
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M. Reuber, S. Howlett, A. Khan, and R. Gru¨newald (University of
Sheffield, UK)
Purpose: About 10% of patients presenting to neurologists have
nonepileptic seizures or other functional symptoms. These patients are as
disabled as patients with epilepsy or “neurologically explained” symp-
toms and experience higher rates of psychopathology and distress. This
has prompted increased interest in treatment, especially with psychother-
apy. This study describes the range and prevalence of predisposing, pre-
cipitating and perpetuating factors and explores whether different factors
are related to particular symptoms.
Method: In this naturalistic study of 59 consecutive neurological out-
patients referred for psychotherapy, aetiological factors were elicited by
a single therapist during a semistandardised two-hour screening inter-
view. The factors identified in the therapist’s contemporaneous records
were subjected to retrospective analysis.
Results: The most prominent predisposing or precipitating factors
were trauma (78.0%), family dysfunction (62.7%) and bereavement
(62.7%). The most prevalent perpetuating factors were family dysfunc-
tion (54.2%), affective disorder (42%) and health anxiety or hypochon-
driasis (23.7%). Trauma was more commonly identified in patients with
nonepileptic seizures than in those with other functional symptoms (p =
0.03). Health anxiety was found more commonly in men (p = 0.003),
family problems in women (p = 0.033).
Conclusion: Functional symptoms in neurology are heterogeneous.
There are important aetiological differences between patients with
nonepileptic seizures and other functional symptoms and between men
and women. The results of this study suggest that trauma and anxiety
are important targets for therapy but that treatment needs to be tailored
to be appropriate for individual patients.
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INTERNATIONAL SURVEY OF PSYCHIATRIC DISORDERS
AND PSYCHIATRIC SERVICE PROVISION FOR PATIENTS
WITH EPILEPSY
1J. Moriarty, 2S. Malhi, and 3B. Schmitz (1Institute of Psychiatry, Lon-
don, UK, 2St. Bernard’s Hospital, London UK, 3Charite, Berlin, Ger-
many)
Purpose: To establish the perception among epileptologists of the
role a psychiatric disorder plays in the lives of persons with epilepsy and
the role of psychiatrists and other mental health professionals in service
delivery.
Method: On behalf of the psychobiology subcommission of the ILAE,
we conducted an e-mail based survey of the chapters of the ILAE. All
chapter presidents and secretaries were sent an e-mail with an attached
questionnaire to be circulated to up to 5 epilepsy centres represented by
that chapter. Each centre was asked to describe its characteristics and
estimate the burden of mental illness in its patient group. Responders
were also asked to describe staffing and available treatments. Finally
they were asked to comment on the ideal, in their view.
Results: Twenty-five replies were received from 18 countries. Es-
timates of the prevalence of psychiatric disorders ranged from 5% to
70%. Just under half said epilepsy specialists had training in psychiatry.
Affective disorders and somatoform disorders were thought to be most
common, with 50% of respondents estimating these affected more than
20% of their patients. Talking therapies were unavailable or of limited
availability in most centres. More centres believed they were meeting
the psychiatric needs of their patients than not.
Conclusion: The results show widespread recognition of the prob-
lems posed by mental illness or psychological problems for persons
with epilepsy. Service provision is highly variable and clinicians have
differing views on how the services should ideally be configured. To
encourage further responses we have made the questionnaire available
on-line at the ILAE website.
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ADOLESCENTS WITH EPILEPSY: NOT AT GREATER PSY-
CHOSOCIAL RISK?
1,3I. Ravnik, 2,3K. Kobilsek, 2,3Z. Zavirsek, 1,3L. Vrba, and 2M. Tomori
(1Centre For Epilepsy, Department Child Neurology, Clinical Centre
Ljubljana, Slovenia, 2Department of Psychiatry, Ljubljana, Slovenia,
3Slovenian Chapter of ILAE, Ljubljana, Slovenia)
Purpose: To assess psychosocial risk factors for adolescents with
epilepsy.
Method: We administered a questionnaire to 84 unselected adoles-
cents attending outpatient service, and receiving mainstream education.
Answers from 68 adolescents (R) were compared to those previously
collected from 4260 healthy controls (C). Medical files were analysed
for epileptological factors and comorbidity.
Results: R-rate was 81%. Mean age 16.4 yrs. Medical files: epilepsy
onset mean age 10.4 yrs; family history + 20/68; focal 29, generalised
23, both focal and generalised 14, undetermined 2, photosensitivity 21.
Mean epilepsy severity 2.4. (1–5). Mean seizure-freedom 29 mo (0–108).
AEDs mean 1.25/patient, on at least one mood stabilising drug 61/68;
taken regularly in 63/68. Comorbid medical complaints: 40%. Psycho-
social problems: 46% had independent and/or epilepsy-related problems.
42% had been seen by mental health professionals. Questionnaire R:C.
No significant difference: depression, self-esteem, suicidal behaviour.
Suicidal attempts were detected in 9. In 8 this was ignored by the parents
and not detected by the health service. Significant differences: R take less
drugs, sedatives, alcohol, nicotine, have less stress, personal problems,
more conflicts, easily discussed, emotional support, desire for a family,
professional support. Within R: females less parental support, less sports,
more suicidal (not significant).
Conclusion: Comparisons between R and C seem to indicate equal
or even smaller risks in R. Possible reasons: milder epilepsy (study se-
vere cases!), medication effects, other unexplained (family?). However,
the risks are not negligible. Their having escaped parents’ and profes-
sionals’ attention requires better adjusted professional services for the
unrecognised needs of the adolescent population. Proposals discussed.
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EPILEPSY AND DEPRESSION
J. Slonkova, M. Bar, and D. Skoloudik (Faculty Hospital, Department
of Neurology, Ostrava, Czech Republic)
Purpose: Depression occurs in 25–55% of patients with epilepsy. We
wanted to analyse the signs of depression and its dependence on number
or type of seizures.
Method: A retrospective analysis of a group of 57 patients with
epilepsy investigated from September 2005 to January 2006 using the
questions of the PRIME-MD PHQ-9 Quick Depression Assessment.
Patients were divided into groups according to number and type of
seizure. Each group was correlated with the results from the question-
naire PRIME-MD PHQ-9, score from 0 to 27.
Results: We investigated 57 patients; 33 men, 24 women. Mean age
34.6 ± 12 years. Patients presented with partial seizures (PS) in 28 cases
(49.12%), generalised tonic–clinic (GTCS) seizures in 14 cases (24.56%)
and in 15 cases (37.93%) PS with secondary generalisation (PS + SG).
The total number of PS in the last month was 1.3 ± 2.5, GTCS 2.7 ±
3.0. PRIME-MD PHQ-9 score was 0–17; median was 5 ± 3.8.
23% of the patients are treated with antidepressants. In the group of
patients without seizures the median was PRIME-MD PHQ-9:4 and in
the group of patients with seizures the median was PRIME-MD PHQ-9:7;
p < 0.01 and Pearson’s coefficient 0.53. Patients with PS had median
PRIME-MD PHQ-9:5, patients with GTCS had median PRIME-MD
PHQ-9:4, patients with PS +SG had median PRIME-MD PHQ-9:6, p
> 0.1.
Conclusion: In our group 55 patients (96.49%) suffered at least from
minimal depression, the severity of which was dependent on the number
of seizures. We did not prove the dependence on the type of seizure.
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POSTPARTUM DEPRESSION IN WOMEN WITH EPILEPSY
VERSUS WOMEN WITHOUT EPILEPSY
Epilepsia, Vol. 47, S3, 2006
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1K. Turner, 1A. Piazzini, 1A. Franza, 1R. Chifari, 2C. Fumarola, 1M.
Canevini, and 1R. Canger (1Epilepsy Center, St. Paolo Hospital, Uni-
versity of Milan, Italy, 2Department of Obstetrics And Gynecology, St.
Paolo Hospital, University of Milan, Italy)
Purpose: The goal of this study was to verify whether there was a
significant difference in the incidence of postpartum depression among
patients with epilepsy and healthy controls. All patients were selected at
the Epilepsy Center and at the Department of Obstetrics and Gynecology,
University of Milan, St Paolo Hospital (Italy).
Method: 35 pregnant women with epilepsy and an equal number of
pregnant women without epilepsy were assessed with the Edinburgh
Postnatal Depression Scale (EPDS) to screen postpartum depression
(PPD), a clinical interview, and a sociodemographic questionnaire. Pa-
tients receiving medication other than antiepileptic drugs (AEDs) and pa-
tients with a psychiatric background were excluded. None of the patients
or controls had previously experienced mood and anxiety disorders.
Results: We found a statistically significant major incidence of PPD
in patients with epilepsy compared with controls (p < 0.05). The re-
sults of the multiple linear regression analyses, in which the association
of EPDS with demographic and clinical variables was explored, were
not statistically significant. EPDS scores were not associated with age,
education, type of epilepsy, duration of epilepsy, age at epilepsy onset,
seizure frequency, aetiology or number of drugs.
Conclusion: It is very important to point out that pregnant women
with epilepsy develop PPD more easily than those without epilepsy. In
this regard, women at higher PPD risk can be identified earlier and treated
as soon as possible to control this pathology and improve their quality
of life.
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TWO CASES OF NONCONVULSIVE STATUS EPILEPTICUS
(NCSE) WITH SCHIZOPHRENIA
S. Takahashi, M. Okazaki, N. Okamoto, K. Takagi, and M. Ito (National
Center Hospital For Mental, Nervous and Muscular Disorders, National
Center of Neurology and Psychiatry, Tokyo, Japan)
Purpose: We report 2 cases of patients with schizophrenia who devel-
oped stupor-like nonconvulsive generalised status epilepticus (NCSE).
Method: Case 1: A 40-year-old woman with schizophrenia who had
been treated with neuroleptics since 18 years of age. She had a clini-
cal history of diabetes mellitus (DM), but had no previous history of
seizures. She developed constant myoclonic movements in her limbs
and stereotypic movements such as stupor after one month’s noncom-
pliance with medication. On admission, her EEG showed a continuous
rhythmic generalised 2–3 Hz spike-and-slow wave complex. This lasted
for about 30 minutes, after which it gradually disappeared, with her EEG
normalising.
Case 2: A 60-year-old man with schizophrenia who had been treated
with neuroleptics since 27 years of age. He had a clinical history of DM
and alcohol abuse, but had no previous history of seizures. He showed
incoherent speech and psychomotor excitement. On admission, his EEG
showed a continuous rhythmic generalised 3 Hz spike and slow wave
complex. Intravenous injection of diazepam resulted in a rapid normali-
sation of the EEG, with disappearance of the clinical manifestations.
Results: At first, the symptoms that the patients presented with
were believed to have resulted from aggravation of the symptoms of
schizophrenia. Their EEGs, however, revealed that these symptoms were
due to NCSE.
Conclusion: It is sometimes difficult to distinguish NCSE from stupor
caused by other psychotic disorders, such as schizophrenia. We believe
monitoring of the patient’s EEG to be quite useful in confirming diag-
nosis of this condition.
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SUICIDAL AND HETERO-AGGRESSIVE BEHAVIOUR IN
EPILEPSY PATIENTS
Y. Shcheglova (Epilepsy Center, Kyiv, Ukraine)
Purpose: To analyse the occurrence and forms of hetero-aggression in
epilepsy patients who had history of suicidal behavior (suicidal ideations,
threats, attempts).
Method: The basic group of 150 adult epilepsy patients with a history
of suicidal behaviour (suicidal ideas, threats, attempts) was compared to
a control group consisting of 80 adult epilepsy patients who had never
displayed suicidal behaviour. Occurrence and forms of hetero-aggression
were investigated in each group. Groups were comparable in age, gender
and psychiatric diagnoses. For statistical analysis Fisher’s test φ∗was
used.
Results: Hetero-aggressive behaviour occurred significantly more of-
ten in the basic group—in 83 (55.3%) patients versus 18 (22.5%) pa-
tients in the control group (p < 0.01). Hetero-aggression had various
forms in both groups: nonprovoked verbal aggression, threats, destruc-
tive behaviour, aggressive acts with assault and battery, violence and
even murder attempts. Victims of these aggressive acts were mainly pa-
tients’ relatives, but not infrequently chance persons and medical staff.
Hetero-aggressive behaviour was more often connected with such psy-
chopathologic conditions as dysphoric disorders, interictal and postic-
tal psychoses, and twilight states. Statistically significant differences
between the basic and control groups in types or heaviness of hetero-
aggression were not revealed.
Conclusion: Epilepsy patients with a history of suicidal behaviour sig-
nificantly more often committed hetero-aggressive acts. Probably, this
fact testifies to substitution of object of aggressive emotions in epilepsy
patients and mutual transformations of hetero- and self-aggression. Any-
way, the problem of hetero-aggression in epilepsy patients expects much
attention of psychiatrists and lawyers.
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TREATMENT OF PATIENTS WITH PSYCHOGENIC PSEUDO-
EPILEPTIC ATTACKS: AN EVALUATION STUDY
J. Kuyk, M. Swinkels, and M. Siffels (Epilepsy Institute of The Nether-
lands (SEIN), The Netherlands)
Purpose: This study was performed to evaluate the effect of a 3-
month open clinical treatment programme for patients with psychogenic
pseudo-epileptic attacks (PPEAs). The treatment was based on cognitive-
behavioural theories and included individual and group psychotherapy,
psychomotor therapy, creative therapy and family therapy.
Method: Twenty-eight patients with PPEAs (5 with coexistent
epilepsy) participated in the study. Questionnaires measuring anxiety,
depression, quality of life, psychological distress, dissociation and cop-
ing were administered at the start (n = 28) and the end (n = 25) of the
treatment programme and 6 months after discharge (n = 16). Seizure
frequency was also evaluated.
Results: At the time of discharge, statistically significant improve-
ments were seen on all questionnaires and especially those concern-
ing anxiety, depression and dissociative symptoms. Also, self-perceived
quality of life was improved. 20% of the PPEA-only patients (n = 20)
were seizure free and 50% of them had a seizure reduction of >50%.
After 6 months the improvements on all questionnaires were maintained
and even increased in most cases. At that time 38% of the PPEA-only
patients (n = 13) were seizure free.
Conclusion: The treatment programme results in an improvement of
psychological functioning and a decrease of symptoms and seizures. It
seems that what is learned during treatment is applied successfully in the
normal life situation and leads to a healthier functioning and a further
decrease of seizures.
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EPILEPSY SURGERY AND DEPRESSIVE DISORDERS: FUR-
THER DATA
1V. Barbieri, 1O. Gambini, 1A. Luoni, 2S. Francione, 2G. Lo Russo, and
1S. Scarone (1Psychiatric Branch, Department of Medicine, Surgery And
Dentistry, University of Milan Medical School And San Paolo Hospital,
2Epilepsy Surgery Centre “C. Munari,” Niguarda Ca’ Granda Hospital,
Milan, Italy)
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Purpose: Depression is the most frequent comorbid psychiatric dis-
order in patients with epilepsy. The objective of this study is to identify
which patients may experience depression after surgery and if antide-
pressant therapy will be needed.
Method: 134 patient candidates for epilepsy surgery were evalu-
ated by means of psychiatric interview and psychiatric rating scale pre-
surgery. 116 and 91 have been evaluated respectively 6 months and 1
year after surgery. Relations between depression and localisation, later-
alisation, crisis frequency, seizure duration, antiepileptic drugs, family
and personal history for psychiatric disorders, were tested.
Results: 49 subjects had a DSMIV-TR psychiatric diagnosis pre-
surgery, 57 six months and 42 one year after surgery. 9 subjects were
depressed presurgery. After 6 months 7 patients were still depressed, 12
had a new diagnosis for depression (McNemar test p < 0.003). After 1
year, 9 patients were still depressed, 2 had a new diagnosis for depres-
sion. Lateralisation of focus was different with 8 of 9 depressed patients
with left side focus (p < 0.04). After 6 months this correlation was not
significant. A personal history for depression is more frequent in patients
who have a depressive episode at the presurgical evaluation (p < 0.00)
and 6 months after surgery (p < 0.01). Patients who were depressed
worsened if they didn’t receive antidepressant therapy.
Conclusion: Left-side seizure focus shows a higher incidence of de-
pression. A personal history of depression seems to be a risk factor for
depression at presurgical time and 6 months after surgery. For these pa-
tients an antidepressant therapy could be suggested at presurgery time.
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IS ICTAL DEREALISATION A TYPICAL SYMPTOM OF TEM-
PORAL LOBE EPILEPSY?
1A. Luoni, 1O. Gambini, 1V. Barbieri, 2S. Francione, 2G. Lo Russo, and
1S. Scarone (1Psychiatric Branch, Department of Medicine, Surgery and
Dentistry, University of Milan Medical School and San Paolo Hospi-
tal, Milan, Italy, 2Epilepsy Surgery Centre “C. Munari” Niguarda Ca’
Granda Hospital, Milan, Italy)
Purpose: The psychiatric literature has been dominated by the concept
that ictal dissociative symptoms like derealisation and depersonalisation
are considered typical of temporal lobe epilepsy. The purpose of this
study is to check if ictal dissociative symptoms occurred more frequently
in temporal lobe epilepsy than in other localisations.
Method: 134 patients affected by epilepsy were evaluated by
means of a psychiatric interview in order to cover ictal derealisa-
tion/depersonalisation information and interictal psychiatric disorders.
Ictal depersonalisation/derealisation occurred in 22% of the sample. We
compared 2 groups of patients: 54% affected by temporal lobe epilepsy,
46% affected by extratemporal lobe epilepsy. Relations between ictal
depersonalisation/derealisation and localisation, lateralisation, presence
of mesial temporal sclerosis and interictal anxiety disorders were tested
by statistical analysis.
Results: Ictal depersonalisation/derealisation occurred in 24% of sub-
jects affected by temporal lobe epilepsy and in 19% of those affected by
extra temporal lobe epilepsy.
Relations between ictal depersonalisation/derealisation and TLE, lat-
eralisation and mesial temporal sclerosis are not statistically significant.
Ictal depersonalisation/ derealisation appears to be more common in pa-
tients with DSMIV-TR anxiety disorders (p < .02).
Conclusion: Ictal depersonalisation/derealisation doesn’t appear to be
more frequent in TLE. The relationship between ictal dissociative symp-
toms and interictal anxiety disorders suggests that the same anatomic
structures are implicated in the development of both these disorders.
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EMOTIONAL DISORDERS: REFRACTORY VERSUS WELL-
CONTROLLED EPILEPSY
M. Candrlic, M. Vladetic, S. Juric, and R. Susak (University Hospital
Osijek, Osijek, Croatia)
Purpose: Emotional disorders are very common in patients with
epilepsy. The aim of the study was to investigate the prevalence and char-
acteristics of emotional disorders in patients with refractory epilepsy in
comparison with those whose epilepsy is well-controlled.
Method: For detection of emotional disorders we used Crown-Crisp
Experience Index, which consist of 6 scales: generalised anxiety, pho-
bic behaviour, obsessive behaviour, somatised anxiety, depression and
hysteric behaviour. A group of 45 patients were analysed, 20 of them
suffering from refractory epilepsy and 25 patients with well-controlled
epilepsy.
Results: Results show a presence of emotional disorders in both in-
vestigated groups, but much greater in a group of patients with refractory
epilepsy, statistically significant (p < 0.01) on scales of depression, pho-
bic disturbances and somatised anxiety.
Conclusion: Our study confirms the presence of emotional disorders
in epilepsy, especially refractory, and also emphasises the importance of
their recognition.
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HANDEDNESS AND PSYCHOSIS IN EPILEPSY: REVISITED
1K. Hara, 2N. Adachi, 3M. Matsuura, 4R. Muramatsu, 5M. Kato, 5T.
Onuma, 6Y. Okubo, 7Y. Oana, and 8T. Hara (1Asai Hospital, Chiba,
Japan, 2Adachi Mental Clinic, Sapporo, Japan, 3Tokyo Medical and
Dental University, Tokyo, Japan, 4National Center for Neurology and
Psychiatry, Tokyo, Japan, 5Musashino Kokubunji Clinic, Tokyo, Japan,
6Nihon Medical School, Tokyo, Japan, 7Saint Paul Hospital, Tokyo,
Japan, 8Komagino Hospital, Tokyo, Japan)
Purpose: Taylor reported a marked interaction between psychosis
and left handedness in patients with psychomotor epilepsy (Taylor DC.,
Psychological Medicine 1975;5:249–254). However Oyebode and Davi-
son found a significant reduction of mixed and left handedness in male
epilepsy patients with psychosis (Oyebode F, Davison K., Br J Psychia-
try 1990;156:228–230). Since there has been no established conclusion,
we revisited this problem in a multicentre study in Japan (Matsuura M
et al., Epilepsia 2005;46. (Suppl 1):11–14.).
Method: We examined 3 patient groups: 30 partial epilepsy with
psychosis, 32 partial epilepsy without psychosis, and 25 schizophrenia.
Handedness (right/ambidextrous/left) was determined with the Annette
Handedness Schedule. We also investigated intelligence quotient (IQ)
with the Wechsler Adult Intelligence Scale-Revised.
Results: The prevalence of each handedness was equivalent among the
3 groups (Fisher’s exact test, p = 0.86). Although there was a significant
difference in intelligence (one-way ANOVA, p = 0.002) among 3 groups,
handedness was not significantly associated with the full-IQ (one-way
ANOVA, p = 0.6).
Conclusion: Results of the current study suggest that handedness is
not a risk factor to development of psychosis in patients with or without
epilepsy.
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SCHIZOTYPAL PERSONALITY TRAITS AND TEMPORAL
LOBE EPILEPSY: A CONTROLLED STUDY
1,2A. Cavanna, 1M. Mula, 1L. Collimedaglia, 1D. Barbagli, 1G. Tota, 3P.
O’Callaghan, 1R. Cantello, and 1F. Monaco (1Department of Neurol-
ogy, Neuropsychiatry Research Group, Amedeo Avogadro University,
Novara, Italy, 2Institute of Neurology, Queen Square, UK 3School of
Psychology, Brunel University, UK)
Purpose: To investigate the prevalence of schizotypal personality
traits in patients with temporal lobe epilepsy (TLE) and to identify the
main clinical features associated with schizotypy.
Method: Fifty-two consecutive patients with TLE referred to our
Epilepsy Unit and a control group of 52 healthy subjects matched for
age and sex, were assessed with the Schizotypal Personality Question-
naire (SPQ), the Beck Depression Inventory (BDI), and the State-Trait
Anxiety Inventory (STAI). All subjects were also evaluated using the
MMPI-2, with special attention to the Sch scale.
Results: TLE patients scored significantly higher for schizotypy than
the control group. However, there were no correlations between total
Epilepsia, Vol. 47, S3, 2006
96 7TH EUROPEAN CONGRESS ON EPILEPTOLOGY
SPQ scores and age, sex, duration of disease, localisation of EEG fo-
cus, or antiepileptic drug regimen. Total SPQ scores and subscores for
Cognitive-Perceptual and Interpersonal (but not Disorganized) schizo-
typy dimensions correlated significantly (p < 0.01) with BDI and STAI
scores. Comparing the MMPI-2 profile of the subgroup of patients with
TLE and high schizotypy scores with the subgroup with TLE but low
schizotypy scores, only the Sc scale was significantly different (p <
0.01).
Conclusion: Schizotypy was significantly prevalent in patients with
TLE compared to healthy subjects and correlated with comorbid psy-
chopathology. Our findings are consistent with shared pathoaetiological
mechanisms underlying expression of specific schizotypal symptoms
and comorbid affective disorder in TLE.
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EPILEPTIFORM ABNORMALITIES IN CHILDREN DIAG-
NOSED WITH ATTENTION-DEFICIT/HYPERACTIVITY DIS-
ORDER: CLINICAL CORRELATIONS, TREATMENT, AND
OUTCOME
1D. Socanski, 2D. Aarsland, and 3A. Herigstad (1Stavanger University
Hospital, Stavanger Hospital Trust, Division of Psychiatry, 3Stavanger
University Hospital, Stavanger Hospital Trust, Department of Clinical
Neurophysiology, Stavanger, Norway)
Purpose: To investigate the frequency of different causes of epilep-
tiform abnormalities (EAs), treatment implications and prognosis in a
group of 526 children (82% males) with ADHD.
Method: 41 children (71% male) aged between 5–14 years, mean
9.6 ± 2.7, with ADHD and EAs were identified and followed for 3.7
± 1.7 years. Different causes of EAs, treatment implications, epileptic
seizure occurrence and prognoses were analysed. At least two EEGs
were performed on all patients.
Results: 27 children (66% males) had no epilepsy comorbidity,
whereas 14 patients (79% males) had epilepsy. Active epilepsy was
diagnosed in 11 patients; of these, 8 had idiopathic and 3 had symp-
tomatic epilepsies. Developmental disorders were diagnosed in 31
(76%) patients, conduct disorder in 8, depression/anxiety in 7, and
Tourette’s syndrome in 6. 38 of the 41 ADHD patients were treated
with methylphenidate, 3 with dextroamphetamine and 2 with atomox-
etine during the observation period. Two children who received only
AEDs showed improved ADHD symptoms. AEDs were administered to
16 patients: monotherapy to 9 and polytherapy to 7 patients. No seizure
exacerbation was observed in any patient with epilepsy. Seizure control
was achieved in 9 of 11 patients. None of the 27 children who had only
EAs developed epileptic seizures during follow up. At the end of the
study EAs were still present in 16 patients.
Conclusion: The majority of our patients with ADHD and EAs have
no epilepsy comorbidity. Medical treatment of ADHD is safe and not
associated with an increased seizure frequency. Multiple comorbidities
occur frequently and affect the clinical outcomes.
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INTERICTAL PSYCHOPATHOLOGY IN PATIENTS WITH
TEMPORAL LOBE EPILEPSY (TLE) AND EXTRA-TLE
M. Swinkels, W. van Emde Boas, and J. Kuyk (Epilepsy Institute of The
Netherlands (SEIN), The Netherlands)
Purpose: This study was performed to investigate the relationship
between symptoms of interictal depression, anxiety, personality traits
and psychological dissociation with the localisation and lateralisation of
the epileptogenic zone in patients with partial epilepsy.
Method: One hundred thirty one patients were diagnosed according
to the localisation related concept of the 1989 ILAE Classification of
Epilepsies and Epileptic Syndromes, and the localisation and lateralisa-
tion of the epileptogenic zone was established using the clinical criteria
for noninvasive presurgical evaluation. This resulted in 67 patients with
temporal lobe epilepsy (TLE) and 64 patients with extra-TLE. All pa-
tients were assessed on the various aspects of psychopathology using a
comprehensive battery of standardised diagnostic instruments.
Results: The hypothesised excess of psychiatric symptoms in patients
with (mesial) TLE was not found. We also found no differences between
patients with the lateralisation of the epilepsy in the left versus the right
hemisphere.
Conclusion: In spite of the strict diagnostic criteria applied to present-
day epilepsy diagnosis and the wide variety of diagnostic instruments that
were used, we found no evidence for associations between the different
parameters of psychopathology and the localisation and lateralisation of
the epilepsy syndromes. It seems that TLE per se cannot be considered as
a risk factor in developing more and severer symptoms of psychopathol-
ogy in patients with partial epilepsy. Concomitant factors, such as the
duration of epilepsy, seizure frequency and frontal lobe dysfunction may
play an additional role.
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SUBACUTE POSTICTAL AGGRESSION IN PATIENTS WITH
EPILEPSY
M. Ito, M. Okazaki, S. Takahashi, K. Takagi, and R. Muramatsu (National
Center of Psychiatry And Neurology. Japan)
Purpose: Aggressive behaviour during postictal periods has been ob-
served in some patients with epilepsy. We present 3 cases of patients
who showed brief bouts of violent behaviour shortly after a seizure.
Method: Case 1: A 62-year-old man with a history of complex par-
tial seizures (CPSs) and secondarily generalised tonic–clonic seizures
(SGTCS) since the age of 18 years. Following CPSs he displayed ag-
gressive behaviour toward his wife, both physically and verbally. This
aggression lasted for approximately 30 minutes. He was not quite am-
nesiac, and was remorseful afterward. Case 2: A 59-year-old man with
CPSs and SGTCS since the age of 17 years. Immediately after CPSs, he
displayed aggressive behaviour toward his wife or nurse, both physically
and verbally. This behaviour lasted for 10 minutes, and he regretted his
behavior afterward. Case 3: A 38-year-old man with a history of simple
partial seizures and CPSs followed by SGTCS since the age of 11 years.
He showed aggression toward objects for 5 minutes several hours after a
seizure. He regained consciousness immediately after, but was amnesic
of his behaviour.
Results: Our patients were all male, and had both CPSs and SGTCSs.
Postictal aggression occurred shortly after each seizure and lasted for 5
to 30 minutes. They regained consciousness immediately after, and then
showed regret. These episodes appeared approximately 30 to 40 years
after onset of epilepsy. Their EEGs showed temporal spikes.
Conclusion: These cases were consistent with the subacute postictal
aggression reported by Gerard et al. (Neurology. 1998;50:384–388). A
long duration of epilepsy and temporal lobe dysfunction may be associ-
ated with the occurrence of this phenomenon.
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COGNITIVE AND BEHAVIOURAL PROBLEMS IN CHILDREN
WITH FRONTAL LOBE EPILEPSY
E. Essenson (Tartu University Childrens`Clinic, Tartu, Estonia)
Purpose: The purpose of the study was to find psychopathological
behavioural features and cognitive characteristics in children aged 4 to
12 years old with frontal lobe epilepsy.
Method: 32 patients (15 boys/17 girls) with a confirmed diagnosis
of frontal lobe epilepsy (clinical symptoms and EEG findings) were
included in the study. All The children were investigated by a child
psychiatrist and neuropsychologist with Achenbach’s Child Behavior
Checklist (CBCL) for Parents and Kaufman Assessment Battery for
Children (K-ABC) to assess mental development and psychiatric dis-
turbances. Wilcoxon-Mann-Whitey test for statistical analysis was used,
statistically significant p < 0.05.
Results: K-ABC showed that the mean of the group for mental pro-
cessing composite (MPC = IQ) was below the average mean of 87. There
was a higher frequency of disturbance in simultaneous information pro-
cessing than in sequential processing. Results in CBCL showed that
there was no significant association between the age of patient, the age
of the start of epilepsy, gender and behavioural problems. Internalising
scale demonstrated problems (T score > 67) 12/32, externalising scale
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16/32 of cases. The most prominent problem was delinquent behaviour
and it was associated with right-sided frontal foci, p = 0.0394. Social
and attention problems were associated with lower IQ (p = 0.0091; p =
0.0208).
Conclusion: The mental abilities of the children with frontal lobe
epilepsy were lower than average. Externalising behavioural syndromes
were more prominent than internalising behavioural syndromes.
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EFFECTS OF SOCIAL STRESS ON THE PROCESSING
OF THREAT IN PATIENTS WITH PSYCHOGENIC-PSEUDO-
EPILEPTIC ATTACKS
1P. Bakvis and 2K. Roelofs (1Epilepsy Institute of The Netherlands
(SEIN), 2University Leiden, Leiden, The Netherlands)
Purpose: Psychogenic-pseudo-epileptic attacks (PPEAs) are widely
considered as a stress related disorder. High rates of reported abuse are
repeatedly found in this patient population. The main purpose of this
study was to investigate the effect of stress on the processing of threat
stimuli in patients with PPEAs.
Method: Eighteen patients and 20 healthy controls were administered
a masked emotional stroop task in a rest and a social stress condition. This
task measures the preconscious selective attention to threat by comparing
colour-naming latencies for angry and neutral faces. Attentional bias
scores were calculated by subtracting the reaction times for neutral faces
from those for angry faces, with negative scores being indicative of
avoidant reactions and positive scores indicating vigilance. Stress was
induced by means of the Trier Social Stress Test.
Results: Whereas healthy controls showed an avoidant attentional
bias in the rest condition, the PPEA patients were vigilant to angry
faces in the rest condition. After stress induction, these group differences
disappeared and both groups showed an avoidant attentional bias to angry
faces.
Conclusion: These results indicate that in relative neutral conditions
patients with pseudo epileptic attacks display an attentional bias toward
threat stimuli, which can be interpreted as a tendency to scan the envi-
ronment for signs of potential threat.
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ELECTROENCEPHALOGRAPHIC ASPECTS OF ATTENTION-
DEFICIT/HYPERACTIVITY DISORDER
I. Dobrescu, I. Eparu, and O. Paun (“Al. Obregia” Psychiatry Hospital,
Child and Adolescent Psychiatry Department, Bucharest, Romania)
Purpose: To investigate the eventual electroencephalographic
(EEG) differences between children diagnosed with attention-
deficit/hyperactivity disorder (ADHD) and children with ADHD and
conduct disorder (CD), one of the most important comorbidities of
ADHD, and to quantify the nature of these differences.
Method: We’ve compared 3 samples (ADHD, ADHD and CD, con-
trol), 40 boys each, 7–14 years old, inpatients in Child and Adolescent
Psychiatry Department, “Al. Obregia” Psychiatry Hospital, Bucharest,
from 2002-2005. For each child a standard 16 derivation EEG exam was
performed, and a 15-second, eyes closed, without artifacts or pathologi-
cal graphic elements fragment was analysed, counting different wave
types. Student’s t-test, Pearson’s correlation and ANOVA were per-
formed for statistical analysis.
Results: An increase in slow wave numbers (delta, theta) was ob-
served, as well as a decrease of alpha and beta wave numbers for ADHD
children. The derived quotients, theta/alpha and theta/beta, were much
higher than in normal controls in all regions (frontal, central and pos-
terior). Our data were able to discriminate, with statistical significance,
between ADHD and normal subjects, with a few exceptions (frontal
and central alpha and posterior beta). We could not detect a statistically
significant difference between ADHD and ADHD + CD samples.
Conclusion: EEG can discriminate between ADHD and normal sub-
jects. Conduct disorder does not modify EEG profile of ADHD. Though
at the time being there is no recommendation for the routine use of EEG
in ADHD, the potential of this method to discriminate ADHD suggests
that further research should be done to certify its utility.
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ASSESSMENT OF DEPRESSION AND ANXIETY IN ADULTS
WITH EPILEPSY
E. Navickiene, R. Mameniskiene, and D. Jatuzis (Department of
Neurology, Vilnius University Hospital Santariskiu Klinikos, Vilnius,
Lithuania)
Purpose: To determine frequency of depression and anxiety in patients
with epilepsy; to analyse the relationship between depression, anxiety
and clinical characteristics of epilepsy, and patients’ demographic and
social characteristics.
Method: 193 patients (95 men, 98 women) with epilepsy were given
a questionnaire regarding epilepsy characteristics, social issues and the
fear of a recurrence of seizures. Depression and anxiety were measured
by the Lithuanian version of Hospital Anxiety and Depression Scale
(HAD Scale).
Results: 193 patients with epilepsy, aged 18–78 (39.65 ± 13.52), with
mean duration of disease 14.1 ± 12.34 years were interviewed up to
date. Mean frequency of seizures per month was 4.8 ± 8.3. Depression
was determined in 38 (19.7%) patients, anxiety in 77 (39.9%). Both
symptoms (depression and anxiety) were found in 32 (16.6%) patients
without a significant difference between men and women. 84.2% of
patients with depressive symptoms had significant anxiety symptoms. 87
(45.1%) patients notified about frequent or permanent fear of seizures.
Depression and anxiety highly correlated with the fear of seizures (p <
0.01). Older age (>45 years), unemployment and shorter education of
patients were associated with more severe depression, anxiety and fear
of seizures (p < 0.01). Patients with generalised epilepsy or secondary
generalised seizures had more severe anxiety than patients with partial
seizures without secondary generalisation (p < 0.01).
Conclusion: Depression and anxiety are common and important in-
terictal problems in patients with epilepsy. Severity of depression and
anxiety were associated with older age, unemployment, shorter educa-
tion of patients and the type of epilepsy and were highly related to the
fear of a recurrence of seizures.
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ASSESSMENT OF PERSONALITY AND EMOTIVE PROFILE
IN TEMPORAL DRUG-RESISTANT EPILEPSY PATIENTS: A
FOLLOW-UP STUDY
1F. Pelle, 1,2P. Scarpa, 3G. Zanardi, 4S. Francione, 4G. Lo Russo, and
1,3G. Bottini (1Neuropsychology Laboratory, Neurosciences Depart-
ment, Niguarda Hospital, Regional Epilepsy Surgical Center “C. Mu-
nari,” Niguarda Hospital, Milan, Italy, 2Psychology Department, Uni-
versity of Milan-Bicocca, Italy, 3Psychology Department, University of
Pavia, Italy, 4Regional Epilepsy Surgical Center “C. Munari,” Niguarda
Hospital, Milan, Italy)
Purpose: We wanted to explore in the pre- and postsurgical stage the
personality profile of drug-resistant temporal lobe epilepsy (TLE) pa-
tients. We investigated whether the hemispheric side of the epileptogenic
area and surgery, age of onset, clinical outcome (Engel’s Classification)
relate to the personality profile.
Method: Thirty-three patients were studied before and after surgery
(18 F, 15 M; 18 left TLE, 15 right TLE; mean age 32.5, SD 8.7; mean edu-
cational level 11.06 yrs, SD 2.6). Patients completed the Beck Depression
Inventory (BDI) and the Minnesota Multiphasic Personality Inventory
(MMPI-2). A semistructured interview was administered. This inter-
view explored a subjective perception of epilepsy, awareness of severity
of the disease per se and expectations about changes in quality of life
after surgery. The post-surgical follow-up was staged at one year.
Results: We applied a repeated measures univariate ANOVA. De-
pendent variables: subjects’ performance on 3 measures (BDI; MMPI-
2; semi-structured interview). Between-subjects independent variables:
hemispheric side of the epileptogenic area and surgery; age of onset;
clinical outcome. Within-subjects independent variables: pre- vs post-
surgical stage. No significant effects resulted from this analysis. We
found a correlation between awareness of disease severity and depres-
sion from BDI (Spearman’s Rho; B1-Beck, r = 0.184, p = .03; B1-D, r
= 0.188, p = .031).
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Conclusion: Scores on MMPI-2 and BDI were within the normal
range. TLE patients did not show psychopathological indices as a group.
No significant changes between the pre- and postsurgical personality
were found independently of the clinical outcome. These results sug-
gest that neurosurgery does not induce psychiatric morbidity per se. A
significant correlation emerged between awareness of epilepsy severity
and depressive symptoms as revealed by the BDI in the post-surgical
follow-up.
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COPING STRATEGY IS A PREDISPOSITION FACTOR
IN EPILEPSY PATIENTS WITH PSYCHOGENIC NON-
EPILEPTIC SEIZURES?
B. Szuromi, Z. Hidasi, P. Salacz, and E. Csibri (Semmelweis University,
Dept. Psychiatry, Budapest, Hungary)
Purpose: In spite of scientific and technical developments, diagnosis
and management of psychogenic nonepileptic seizures (PNES) remains
difficult, especially in the case of epilepsy patients. The purpose of our
study was to investigate the psychological profile of epilepsy with PNES
in order to provide better therapy.
Method: Eighteen consecutive epilepsy patients from our epilepsy
outpatient clinic were recruited. Eight of them had only epilepsy (2 males
and 6 females, mean age 31.4 ± 10.4) and 10 had epilepsy with PNES
(2 males and 8 females, mean age 39.5 ± 12.6). Psychogenic seizures
were documented by ictal observation. Patients answered Rosenberg
Self-esteem Scale, Felton’s Acceptance of Illness Scale and DISQ-H
Questionnaire. Psychiatric diagnoses were based on DSM-IV. Data were
evaluated using Student’s t-test.
Results: Most of the patients showed an increased level on Rosen-
berg test, but there was no significant difference in self-esteem between
groups. Patients with epilepsy and PNES had a significantly lower score
on Felton’s Scale concerning active coping strategies than patients with
epilepsy alone (1.37 ± 0.52 versus 2.06 ± 0.55, p = 0.008). There was
no significant difference between groups on DISQ-H Questionnaire. Op-
posite to patients with epilepsy alone, all the patients with epilepsy and
PNES had a diagnosis on axis I or axis II of DSM IV.
Conclusion: The background of psychogenic seizures may be hetero-
geneous, not only a dissociative disorder that has a role in the mechanism
of PNES. Our preliminary data suggest that appropriate coping strategies
may be very important in prevention and therapy of PNES as well.
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PREVALENCE OF MOOD DYSFUNCTION IN EPILEPSY PA-
TIENTS IN CROATIA
H. Hecimovic, S. Miskov, R. Covic-Negovetic, and V. Demarin (Zagreb
Epilepsy Center, Croatia)
Purpose: To determine the prevalence of depressive symptoms in a
tertiary epilepsy centre in Croatia.
Method: Fifty consecutive and consenting epilepsy patients from the
Zagreb Epilepsy Center were examined for the presence of depressive
symptoms using the Beck Depression Inventory (BDI). Clinical variables
for age, gender, seizure factors and social and vocational factors were
analysed.
Results: Mean age of the patients was 30.8 ± 13.5 years, and 60.4%
were females. The majority of them were employed (72.9%) and sin-
gle (62.5%), and 35.4% had a university degree. Most of the patients
had complex partial seizures (n = 40, 80%), and 6 (12%) were diag-
nosed with idiopathic generalised epilepsy. The mean monthly seizure
frequency was 2.0 ± 3.4. At the time of their office visit 31.3% were
newly diagnosed patients, and of the remaining, 45.8% were on AED
monotherapy, 18.8% on two, and 4.2% on three AEDs. Assessment with
the BDI showed that 33.3% of patients had depressive symptoms: 6.3%
had mild depressive symptoms, 8.4% moderate and 18.6% had severe
depressive symptoms, with the total BDI score of ≥24. Three patients
(6.4%) attempted suicide in the past, 2 of them had current suicidal
ideation, and all of them were severely depressed.
Conclusion: This is the first study assessing mood dysfunction in
epilepsy patients in Croatia. Increased prevalence of depression in
epilepsy patients suggests specific approach and need for early treat-
ment. This work was supported by the Epilepsy Foundation grant to HH.
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VIDEO-EEG MONITORING IN PAROXYSMAL EVENTS
B. Gurda, M. Starczewska, M. Zarowski, and B. Steinborn (Chair and
Department of Developmental Neurology Poznan University of Medical
Sciences, Poznan, Poland)
Purpose: Video-EEG monitoring with use of methods of EEG acti-
vations is a means to distinguish different types of seizures. The purpose
of this study was to determine the utility and results of video-EEG ex-
aminations in paroxysmal events in children and adults.
Method: In the Department of Developmental Neurology, K.
Marcinkowski University of Medical Science in Poznan´, 302 video-EEG
were performed from 2003-2005. Video-EEG monitoring was executed
by means of computer electroencephalograph “Ceegraph” (Biologic-
USA). The examinations involved a group of 302 patients with diag-
nostic doubtful paroxysmal events. In this group were 37 children aged
0–3 years, 216 children aged 4–18 years and 49 adults aged 19–56 years.
During the examinations various EEG activation methods were used: hy-
perventilation, photostimulation, sleep deprivation and in patients with
suspected psychogenic seizures, placebo application or psychogenic pro-
voking test.
Results: In the group of younger children video-EEG allowed confir-
mation and more precise characteristics of seizures in 11 of 37 (29.7%)
patients (epileptic seizures in 7, nonepileptic events in 4), whereas the
corresponding number of older children was 93 of 216 (43%) patients
(epileptic seizures in 27, psychogenic pseudoepileptic seizures in 51,
syncope in 4, tics in 7, and others in 4). In the group of 49 adults parox-
ysmal events were recorded in 21 (42.8%) patients; among them psy-
chogenic pseudoepileptic seizures in 18, tics in 1, generalised convul-
sions in 1, nonconvulsive epileptic status in 1 were diagnosed. Most of
the psychogenic pseudoepileptic seizures were observed after placebo
application (58%) or psychogenic provoking test (28%). Epileptiform
activity in EEG was found in 44% patients, including 15% during clini-
cal events.
Conclusion: Video-EEG monitoring is an efficient and valuable pro-
cedure in the diagnosis of paroxysmal events in children and adults. In
the group of younger children the most frequent types of events were
epileptic seizures. The largest group among older children and adults
were psychogenic pseudoepileptic seizures.
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DEPRESSION IN EPILEPSY: HIGH PREVALENCE, RARELY
TREATED
1M. Hauf, 1T. Haefeli, 1J. Mathis, and 1,2F. Donati (1Department of
Neurology, University of Berne Inselspital, Berne, Switzerland, 2Clinic
of Neurology, Spitalzentrum Biel/Bienne, Biel, Switzerland)
Purpose: To determine the prevalence of major depression in epilepsy
in Switzerland and the independent effects of antiepileptic medication,
neurological and nonneurological comorbidity compared with demo-
graphic and clinical epilepsy variables.
Method: Adult subjects (n = 75), ambulatory and seen in 1 secondary
and 1 tertiary centre of Epileptology in Switzerland completed the Beck
Depression Inventory (BDI) questionnaire. (Jones JE et al., Screening for
Major Depression in Epilepsy with common self-reported Depression In-
ventories. Epilepsia 2005;46(5):731–735.) Information was derived re-
garding the subject’s epilepsy syndrome, last seizure, neurological and
nonneurological comorbidity, medical treatment and demographic char-
acteristics.
Results: Major depression defined by a BDI-Score > 111was reported
by 20 subjects (26.7%) of whom 3 are treated by antidepressants. As-
sociation between depression, clinical and demographic features were
disclosed for taking antiepileptic polytherapy (chi-Quadrat 6.818, p <
0.019) and time of seizure freedom (Mann-Whitney, p < 0.041). No
correlation was found for age, gender, seizure type, neurological or non-
neurological comorbidity and antidepressant therapy. In unemployed
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subjects the BDI Score was significantly higher (Mann-Whitney p <
0.028).
Conclusion: Depression is a frequent (26%) and often untreated
comorbidity in adults with epilepsy in Switzerland. Factors reflecting
epilepsy-related aetiological processes (poor seizure control), treatment
related aetiological processes (antiepileptic polytherapy) and social aeti-
ological processes (unemployment) are associated with depression.
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INTELLECTUAL FUNCTIONING IN POSTTRAUMATIC
EPILEPSY PATIENTS COMPLICATED AND NON-
COMPLICATED BY ALCOHOLISM
V. Sergeev, and P. Sergeeva (Ural State Medical Academy of Post-
Diploma Education, Chelyabinsk, Russia)
Purpose: To study the character and the degree of influence of three
reciprocal pathological processes: traumatic, epileptic and chronic al-
coholism of cognitive abilities in patients with posttraumatic epilepsy
complicated and noncomplicated by alcoholism in connection with their
sociopsychological functioning.
Method: A comparative study of IQ by means of Raven’s progressive
matrices in 215 patients with paroxysms: 65 with consequences of CCT
complicated by alcoholism (PTE + A); 65 with posttraumatic epilepsy
non-complicated by alcoholism (PTE); 85 with no traumatic epilepsy
without alcohol addiction (E-C) as a control group.
Results: In all groups the majority of patients had middle IQ in its
low limits. The lower IQ index was in PTE + A patients, and signif-
icantly differed this group from others (p < 0.01) with no significant
differences between PTE and E-C groups. A correlation was not found
between IQ and heaviness of trauma in any group. In PTE + A group low
IQ correlated with more duration of trauma, epileptic process, alcohol
addiction, alcoholic psychosis in anamnesis, the number and frequency
of alcoholic relapses (r = 0.4–0.5; p < .01). In PTE + A and E-C groups
low IQ correlated with higher frequency of paroxysms, polymorphism,
absences, secondary-generalised seizures and epileptic status: in the first
one, vegetovisceral paroxysms, automatisms, twilight conditions; in the
second one (r = 0.3–0.5; p < .001). The study determined the correlation
between IQ indices and psychosocial adaptation of examined patients,
revealing a correlation between low IQ and low level of education in
PTE + A and PTE groups (r = 0.35; p < 0.05) and decreasing socio-
professional status in all groups. Higher IQ showed PTE patients, who
continued studies and kept a premorbid level of professional activity (r
= 0.3–0.45; p < 0.005–0.04).
Conclusion: In most cases reducing intellectual abilities was observed
in patients with mixed pathology: trauma, alcoholism, epilepsy. Their se-
riousness is connected with a number of clinicobiological factors, each
of which depends on significance, interaction and progradience of indi-
cated pathological processes. Features of psychosocial adaptation of the
patients are mainly defined by clinicobiological factors.
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ANTICONVULSANTS IN SPORTS: ETHICAL
CONSIDERATIONS
K. Kaufman, R. Aaron, and A. Prager (UMDNJ-Robert Wood Johnson
Medical School, New Brunswick, USA)
Purpose: Antidoping codes in sport are intended to deter and sanction
athletes using performance enhancing agents while promoting an even
playing field for all competitors. Monetary rewards to athletes associ-
ated with superior performances have led to ingenious attempts to skirt
these codes: erythropoietin, modafinil and designer steroids. Although
the World Anti-Doping Code (WADC) permits anticonvulsants in gen-
eral, harmonisation of antidoping permits international sport federations
(IF) to prohibit specific medications within that IF. Anticonvulsants lev-
etiracetam, tiagabine and lamotrigine may pose ethical dilemmas and
could be considered violations of antidoping codes.
Method: Literature review with analysis.
Results: Lamotrigine, with antiglutaminergic and sodium channel
properties, is FDA-approved for bipolar depression and has been used to
treat major depression. Tiagabine, a selective GABA reuptake inhibitor,
has mood stabilising and anxiolytic properties. Levetiracetam, whose
unique mechanism involves modulators beta-carboline and zinc, has anx-
iolytic and mood stabilising properties. Anxiolytics and antidepressants
are banned in archery; under strict liability, all three anticonvulsants vio-
late WADC/IF for that specific sport and could result in disqualification
unless therapeutic use exemptions (TUE) had been obtained. Ethical de-
cisions regarding choice of anticonvulsant for athletes with epilepsy is
addressed in addition to means of obtaining TUE.
Conclusion: WADC with harmonised IF policies are meant to pre-
vent doping in athletes but not appropriate medical treatment. When
anticonvulsants have other psychotropic properties, ethical issues arise.
Athletes should list all medications taken with diagnoses, obtain TUE
as indicated, and contact the appropriate IF or Olympic organisation to
determine status of the proposed medication (banned, restricted, non-
banned).
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POSTICTAL PSYCHOSIS: A RETROSPECTIVE STUDY OF PA-
TIENTS WITH REFRACTORY TEMPORAL LOBE EPILEPSY
M. Falip, A. Donaire, M. Carren˜o, I. Maestro, L. Pintor, N. Bargallo, T.
Boiget, A. Raspall, J. Rumia, and X. Setoain (Hospital Clinic I Provincial,
Barcelona, Spain)
Purpose: Postictal psychosis (PIP) represents 25% of the psychoses
seen in epilepsy patients. A high frequency of bilateral independent
epileptiform activity has been observed in patients with PIP. The ob-
jective of this study was to find the frequency of PIP in patients with
temporal lobe epilepsy (TLE) who underwent video-EEG monitor-
ing and to investigate possible differences between PIP and control
patients.
Method: Clinical, electroencephalographic and neuroimaging data of
5 PPI patients with TLE were compared with data of 50 patients with TLE
without psychotic antecedents. Patients with a past history of interictal
psychosis were excluded.
Results: of 55 patients, 5 had PIP and 50 were controls. 31 (62%)
were men, 9 (16.4%) had a history of encephalitis and 6 (10.9%) of status
epilepticus. The mean age was 42.2 (SD 12.93). Mean age at epilepsy
onset 16.95 (SD 12.93) and mean seizure frequency 5 seizures/month
(SD 1.87). The frequency of PIP was 5/55 (9.1%). History of encephalitis
was more frequent in PIP patients than in controls. (p = 0.024). PIP
patients more frequently had a nonlateralising ictal EEG than controls (p
= 0.031). Bitemporal lobe dysfunction revealed by neuropsychological
studies was greater than expected by the observed lesion on MRI studies
in patients with PIP. Moreover the presurgical study was less conclusive
for PPI than for control patients (p = 0.049).
Conclusion: PPI is observed in up to 9% of patients undergoing
video EEG monitoring and seems to be a marker of bitemporal lobe
dysfunction.
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PSYCHOPATHOLOGY OF PSYCHOGENIC NONEPILEPTIC
SEIZURES: CLINICAL OBSERVATIONS
1M. Valenti, 2M. Mazza, 3A. Martini, 4M. Scoppetta, 5M. Vaccario, 6R.
Rodriguez, 7G. Ruggeri, 8G. Della Marca, 9P. Bria, and 10S. Mazza
(1Institute of Neurology, Epilepsy Centre, Neurophysiopathology, Uni-
verita` Del Sacro Cuore, Policlinico Agostino Gemelli, Rome, Italy,
2Institute of Psychiatry e Psychology, Universita` Cattolica del Sacro
Cuore, Policlinico Agostino Gemelli, Rome, Italy, 3Institute of Psy-
chiatry e Psychology, Universita` Cattolica del Sacro Cuore, Policlin-
ico Agostino Gemelli, Rome, Italy, 4Institute of Psychiatry e Psy-
chology, Universita` Cattolica del Sacro Cuore, Policlinico Agostino
Gemelli, Rome, Italy, 5Institute of Neurology, Epilepsy Centre, Neu-
rophysiopathology, Univerita` Del Sacro Cuore, Policlinico Agostino
Gemelli, Rome, Italy, 6Institute of Psychiatry e Psychology, Universita`
Cattolica del Sacro Cuore, Policlinico Agostino Gemelli, Rome, Italy,
7Institute of Psychiatry e Psychology, Universita` Cattolica del Sacro
Cuore, Policlinico Agostino Gemelli, Rome, Italy, 8Institute of Neu-
rology, Epilepsy Centre, Neurophysiopathology, Univerita` Del Sacro
Epilepsia, Vol. 47, S3, 2006
100 7TH EUROPEAN CONGRESS ON EPILEPTOLOGY
Cuore, Policlinico Agostino Gemelli, Rome, Italy, 9Institute of Psy-
chiatry e Psychology, Universita` Cattolica del Sacro Cuore, Policlin-
ico Agostino Gemelli, Rome, Italy, 10Institute of Neurology, Epilepsy
Centre, Neurophysiopathology, Univerita` Del Sacro Cuore, Policlinico
Agostino Gemelli, Rome, Italy)
Purpose: Our aim is to examine the psychopathological features of
patients with psychogenic nonepileptic seizures (PNES) in order to find
useful patterns for differential diagnosis and to optimiSe psychological
and psychopharmacological treatments.
Method: 17 patients with a diagnosis of PNES, confirmed by video-
EEG recordings, were tested using the Hamilton Rating Scale for Depres-
sion (HDRS), Dissociative Experience Scale (DES), Minnesota Multi-
phasic Personality Inventory-2 (MMPI-2) and Short Form Health Survey
36 (SF-36). The same procedure was applied to 13 epilepsy patients and
16 healthy subjects matched for sex and age.
Results: Our data confirm previous studies showing that psychogenic
seizures typically occur between 20 and 30 years of age, more frequently
in women (70% of patients). Besides, these data confirm a pathogenetic
role of dissociative mechanisms, traumatic experiences, conversion, and
DSM–IV axis I disorders comorbidity. DES ratings are significantly
higher in patients with PNES (Bonferroni test; p < 0.05), supporting the
hypothesis of dissociative psychopathogenetic features. Conversion is
an important aetiological mechanism: MMPI-2 profiles of patients with
PNES revealed high scores on the hypochondriasis (Hs), conversion hys-
teria (Hy), schizophrenia (Sc), depression (D) and paranoia (Pa) scales
and 3 patients showed a typical “Conversion V” pattern. Depression is an
important aetiopathogenetic factor: HDRS scores are higher in patients
with PNES (p < 0.05). Quality of life results are higher in patients with
PNES compared with epilepsy patients: psychogenic seizures probably
represent an outlet for emotional distress.
Conclusion: Our study confirms that complex psychosocial, environ-
mental and intrapsychic mechanisms interact in the aetiology of psy-
chogenic seizures.
Monday July 3, 2006
13:30–15:00
Poster Session 1
Social Issues/Nursing
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ANALYSIS OF COGNITIVE IMPAIRMENT AND INDEPEN-
DENT RISK FACTORS OF PATIENTS WITH NEWLY DIAG-
NOSED CRYPTOGENIC EPILEPSY
C. Ziyi, Z. Liemin, Z. Jueqian, Z. Xia, and L. Weifeng (The First Affili-
ated Hospital of Sun Yatsen University, China)
Purpose: To evaluate the cognitive functions of patients with newly
diagnosed cryptogenic epilepsy and to explore the effect of the related
factors of epilepsy on cognition
Method: 60 registered patients met the criteria of the study, were
arranged for the Wechsler intelligence scales and registered their clin-
ical manifestations including onset age of seizure, seizure type, fre-
quency, duration of seizure disorder, family history and the localisation
of epileptic lesion before treatment. 60 healthy volunteer controls were
paired.
Results: Epilepsy patients had lower FIQ, VIQ and PIQ than the
healthy controls (99.96 ± 18.03 vs 116.80 ± 12.53, 103.92 ± 19.63
vs 120.68 ± 13.62, 95.32 ± 16.60 vs 108.85 ± 11.76, separately), with
significant difference. Similar results were reported in the adult subgroup
and child subgroup. The results on the risk factors showed that FIQ, VIQ
and PIQ had a negative correlation with duration of seizure disorders
(−0.478, −0.487, −0.406, separately, p < 0.001), and seizure frequency
(−0.493, −0.474, −0.443 separately, p < 0.001);similar results were
seen in the adult subgroup and child subgroup. No statistical difference
in FIQ, VIQ and PIQ existed in analysis of other risk factors. Suggesting
duration as a covariant, correlation index of FIQ and seizure frequency
was −0.243 p < 0.01 while suggesting seizure frequency as covariant,
the counterpart was −0.092 p > 0.05.
Conclusion: These findings indicated that IQs of patients with
epilepsy were lower than those of the healthy population and that seizure
frequency was the independent risk factor of impaired cognition in
epilepsy.
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EPILEPSY NARRATIVES: THE DIFFERENCES IN BEING
DIFFERENT
D. Snape (University of Liverpool, Liverpool, UK)
Purpose: By exploring the nature of having epilepsy and issues of
related stigma from the perspective of people with epilepsy (PWE), this
qualitative study seeks to enhance understanding about the impact of
this condition on daily living and life trajectories and to represent the
heterogeneity of the meaning of having epilepsy. The overall aim is to
contribute to both stigma theory and to the debate on the need for holistic
care for PWE.
Method: Drawing upon research on illness narratives, the subjective
experiences of living with epilepsy are explored in order to identify
how conceptions of self evolve over biographical time. Using theoretical
sampling a series of life history interviews are being conducted with 12
participants attending epilepsy out patient clinics. Interview transcripts
are subjected to content and paradigmatic analysis to examine thematic
similarities and differences between the narratives provided.
Results: Early findings relate to perceptions about the causes of
epilepsy, knowledge, understanding and treatment choice. How PWE
feel about and see themselves in relation to their epilepsy provides insight
into the element of epilepsy stigma and serves to highlight how individu-
als perceive the (positive/negative) influence of their epilepsy in different
phases of their life (past, present, future).
Conclusion: The research has implications for theories of stigma,
healthcare intervention and policymaking. It is essential for health care
professionals and “significant others’ to understand the lived experi-
ences of PWE and their individual needs; and identify the diversity of
approaches to helping them improve their coping mechanisms.
Acknowledgement: This research is partially funded by a Postgrad-
uate Research Bursary from Epilepsy Action.
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EDUCATION IMPROVES SOCIAL KNOWLEDGE ABOUT
EPILEPSY: EDUCATION, EPILEPSY AND SOCIETY IN SPAIN.
1A. Moreno Gonzalez, 2M. Diaz-Obregon Santos, and 2A. Morales
(1Asociacion Espan˜ola De Ayuda Al Epileptico, Spain, 2Hospital Clin-
ico San Carlos, Madrid, Spain)
Purpose: Spanish society still has a very low level of knowledge about
epilepsy and its social repercussions on the patient’s quality of life. This
is mostly due to lack of information among the general population, plus
low educational levels. AEAE together with the Epilepsy Unit at Hospital
Clı´nico, San Carlos, have researched the general population with the aim
of testing the degree of knowledge about epilepsy and its consequences
on the patient’s social environment. The research results show that the
higher the level of education, the better the understanding of epilepsy
and its social consequences.
Method: We carried out a poll on a sample of 237 people from the
metropolitan area of Madrid. Individuals were of both sexes, aged be-
tween 19 and 73. We classified the educational levels on three categories:
primary education, high school level and university level. The question-
naire had 14 questions related to epilepsy and its consequences on the
patient’s environment.
Results: Most representative data extracted from the answers are
shown on the graphics. Individuals from the youngest group and the
highest educational level know and better understand epilepsy and its
repercussions on different aspects of the patient’s daily life.
Conclusion: People understand and accept epilepsy better due to 2
different factors: high education and youth. Following this direction,
epilepsy will get rid of the stigma associated to it, because of lack of
information and social prejudices. Thus, all actions to give information
and develop educational policies about epilepsy from childhood will
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be to the advantage of a promising, gratifying and better future for the
general population and for epilepsy patients and their environment in
particular.
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EXPLORING PATIENT VIEWS OF CONSULTANT NEUROLO-
GIST AND EPILEPSY SPECIALIST NURSE INTERVIEW AT
FIRST SEIZURE PRESENTATION: WHO WOULD THE PA-
TIENT PREFER TO SEE?
M. Goodwin (Northampton General Hospital, Northampton, UK)
Purpose: Historically medical diagnoses are made by medical practi-
tioners. However, the development of specialist/advanced nursing prac-
tice blurs the boundaries of medicine and nursing. Were nurses to diag-
nose epilepsy how might the patient feel? Would patients identify dif-
ferences between the doctor and specialist nurse and would they prefer
one to the other?
Method: As part of an exploratory study to compare consultant neu-
rologist (CN) to epilepsy specialist nurse (ESN) opinion at first seizure
presentation patients were asked their views of the interviews with the CN
and ESN. Participants consisted of 20 consecutive referrals to the first
seizure clinic, following at least one suspected seizure. Patients were
randomly allocated to see either CN or ESN first, and then swapped.
Following both interviews and prior to diagnosis patients underwent a
third interview. This interview used open-ended questions to explore pa-
tient’s feelings about the two previous interviews. Interviews were tape
recorded and transcribed verbatim. Individual interviews were analysed
for common themes then compared across cases to identify common-
alities. Patients were finally asked whom they would recommend to a
friend with a similar medical problem.
Results: The common themes raised focus on 1) Personality 2) Gender
3) Language and terms 4) Note taking 5) Speed/time 6) Number of
questions. Six patients recommended the ESN, 4 recommended the CN
and 8 would opt for either. (2 were not asked specifically).
Conclusion: This study compares patient views of the CN and ESN
interviews. It suggests most patients liked the ESN interview and would
accept a diagnosis made by a specialist nurse.
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FOLLOW-UP OF PATIENTS REJECTED FOR EPILEPSY
SURGERY: HOW ARE THEY DOING?
1M. Zijlmans, 1M. Hersevoort, 2E. Buskens, 1G. Huiskamp, 1F. Lei-
jten, and 1A. van Huffelen (1Rudolf Magnus Institute of Neuroscience,
University Medical Center Utrecht, Utrecht, The Netherlands, 2Julius
Center for Health Sciences and Primary Care, University Medical Cen-
ter Utrecht, Utrecht, The Netherlands)
Purpose: To describe the medical and social status and quality of life
of patients rejected for epilepsy surgery.
Method: We approached 70 patients from a national database, who
were rejected for epilepsy surgery between 2001 and 2005, were older
than 16 and capable of filling in questionnaires. For 50 patients we
checked medical charts, recent social status and quality of life by means
of three questionnaires: EQ5D, Qolie-31 and RAND-36. Relatives com-
pleted questionnaires as well. The outcomes were cross-compared and
compared to earlier studies on quality of life in epilepsy and to the general
population.
Results: Two patients had been seizure-free for more than six months.
Averaged EQ5D-score was 81.8 ± 0.26, which is lower than the score
of the general population, corrected for age and sex (p = 0.03 1-
tailed). In all domains except for physical functioning, the RAND-36
scores were lower compared to those for unselected Dutch patients
with epilepsy. The employment ratio was 56%, compared to 67.2%
for a comparable Dutch general population. It was not lower than for
unselected Dutch patients with epilepsy (51%). The experienced care
load by relatives was greater with lower quality of life scores (Qolie-
31: R-square 0.24), but not dependant on seizure frequency (R-square
0.00).
Conclusion: 4% of patients rejected for epilepsy surgery became
seizure-free and in retrospect would not to have needed surgery. The
group of rejected surgery candidates forms a particular group within the
group of patients with epilepsy in general, with comparatively low scores
on quality of life in spite of equal employment ratios.
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MONO- AND POLYTHERAPY FOR IDIOPATHIC AND SYMP-
TOMATIC FORMS OF EPILEPSY TREATMENT IN CHILDREN
T. Yarmolyuk, V. Martynyuk, V. Kharytonov, and A. Nadonenko
(Ukrmedcenter, Kiev, Ukraine)
Purpose: To determine treatment efficacy for idiopathic and symp-
tomatic forms of epilepsy in children (6 months–16 years).
Method: Analysis of treatment of the children’s epilepsy group (153)
has been carried out.
Results: The group consisted of 153 children with different forms
of epilepsy. The idiopathic group, 72 children: 61 from this group un-
derwent monotherapy (84.7%). The monotherapy of the group mostly
consisted of valproic acid (Depakine) 78%, topiramate (Topamax) 12%;
polytherapy (11 children 15.3%) mostly consisted of combinations: val-
proic acid and Topamax (topiramate) and valproic acid and lamictal
(lamotrigine). The symptomatic group treatment (81): monotherapy was
used for 41 children (50.6%), 51% of children were on carbamazepine,
25% on valproic acid, and 24% on Topamax. Polytherapy consisted of
combinations of valproic acid and topiramate (Topamax) for 11 children;
and valproic acid and lamotrigine (Lamictal), 8 children; carbamazepine
and valproic acid, 4 children; carbamazipine and lamotrigine (Lamictal),
4 children; also rare combinations of valproic acid, carbamazepine and
benzodiazepine (clonazepam, antilepsin) for 2 children or VPA, CBZ
and phenobarbital for 1 child.
Conclusion: The study confirms the recommendations of ILAE of
superiority of monotherapy for treatment of idiopathic forms of epilepsy
(the drug of choice is depakine). The symptomatic forms need rational
polytherapy (mostly combinations of valproic acid and topiramate or
lamotrigine).
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SEIZURE PRECIPITATION IN UNCONTROLLED EPILEPSY
G. Helde, L. Vedeld, and E. Brodtkorb (Institute of Neuromedicine,
Faculty of Medicine, Norway)
Purpose: To explore the pattern of seizure precipitating factors in
patients with uncontrolled epilepsy.
Method: One hundred and thirteen patients were asked to indicate
situations with an increased risk of seizures, first by report of their own
experience and then by ranking 10 specific items.
Results: 88% of patients identified one or several precipitating factors,
with a mean of 3. The most frequent single factors were sleep depriva-
tion (66%), stress (54%) and missing drug intake (40%). No significant
differences between partial and generalised epilepsy were found. The
percentage of patients reporting each factor increased when they were
introduced to the list of the 10 items, a finding that emphasises the im-
portance of addressing single factors directly in clinical practice.
Conclusion: Most patients with uncontrolled epilepsy are aware of
circumstances which may contribute to the initiation of seizures. Their
frequency varies among individuals, and many represent a cascade of
dependent factors which may relate to psychosocial difficulties. The
most frequent single factors are stress, lack of sleep and treatment non-
compliance. Any complete epilepsy program must consider the relation-
ship between seizures and behaviour. An increasing number of epilepsy
specialist nurses are now involved in the educational and social sup-
port of patients with uncontrolled epilepsy. Assessment of the individual
seizure precipitant profile may be a useful approach in this intervention.
This study underscores that the interaction between seizure precipita-
tion and epilepsy-related psychosocial difficulties should receive ample
attention.
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PSYCHOSOCIAL REHABILITATION IN EPILEPSY: AN
OVERVIEW OF A THREE-YEAR PRACTICE
1B. Gueguen, 1,2B. Piel-Desruisseaux, and 1F. Odier (1Sainte Anne’s
Hospital, Paris, France, 2Epilepsy France)
Purpose: Social and psychological support have been shown to partic-
ipate in the improvement of epilepsies (Oosterhuis 1994, Collings 1995,
Ogata 2000) in adjunction of drug therapy or surgery. To cure patients
with epilepsy, give them the wish to improve their quality of life and
also give the epileptologists the duty to help patients to improve their
psychosocial condition. The authors report in the present study on a 3
year experience of comprehensive care in epilepsy.
Method: Three hundred patients with psychosocial disability were
enrolled in a special programme of rehabilitation driven in a multidis-
ciplinary approach by a medico-psycho-social network. Patients were
evaluated by an epileptologist, a psychologist, a neuropsychologist and
social workers specialised in occupational rehabilitation.
Results: Epilepsy patients with heavy socio-professional disability
are most often of poor educational level (level V to VI according to ed-
ucational scale = 78%). 57% have no occupational activity from 1 to 2
years or more. Epilepsy is not at all the main cause of poor social inte-
gration. The main grounds for unemployment and/or poor social life are
in increasing frequency order: the severity of epilepsy; incorrect treat-
ment; lack of professional qualification; stigmatisation in occupational
environment; associated handicap (mainly cognitive and psychiatric) and
psychological disturbances (self-esteem and confidence, ambivalence in
relation with work, social life . . .).
Conclusion: To help patients to improve their social conditions one
needs to take into account the cognitive status of the patients, their ability
to take care of themselves and to built up a project for their life.
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HUMANISTIC IMPACT AS ASSESSED BY QUALITY OF LIFE,
DEPRESSION, ANXIETY, AND HEALTH STATUS IN PATIENTS
WITH REFRACTORY EPILEPSY: A CROSS-SECTIONAL
EVALUATION IN SPAIN
1J. Sancho, 2M. Rufo, 3P. Pen˜a, 4G. Palacios, 5S. Martı´nez, 5X. Mas-
ramon, and 6J. Rejas (1Department of eurology, General University
Hospital, Valencia, Spain, 2Department of Pediatric Neurology, Uni-
versity “Virgen del Rocio,” Sevilla, Spain, 3Department of Neurology,
University Hospital “12 de Octubre,” Madrid, Spain, 4Department of
Neuroscience, Medical Unit, Pfizer Espan˜a, Madrid, Spain, 5European
Biometrics Institute, Barcelona, Spain, 6Health Outcomes Research De-
partment, Medical Unit, Pfizer Espan˜a, Madrid, Spain.)
Purpose: To assess the humanistic impact of disease (quality of life,
depression, anxiety and health status) in adult patients with refractory
epilepsy in Spain.
Method: A cross-sectional study was carried out in both neurology
outpatient clinics and epilepsy units between March and September 2005.
Consecutive male and female adult patients (over 18 years) with refrac-
tory epilepsy were enrolled. Health-related quality of life (QoLIE-10),
anxiety and depression (HADS), and health status (0–100 mm VAS)
were assessed.
Results: A total of 762 consecutive patients [728 valuables, (95.5%);
50.8% males, 40.5 (13.5) years, 24.3 (13.4) years of evolution] were in-
cluded by 169 neurologists. Mean overall scoring in QoLIE-10 was 58.0
(19.5), with dimensions ranging between 50.9 (26.8), energy domain, to
64.2 (23.7) in emotional well-being. Any degree of anxiety was showed
by 43.5% of patients; 21.2% mild, 15.8% moderate and 6.5% severe
according with HADS scoring, while this scale detected any degree of
depression in 32.0% of patients; 16.3% mild, 11.8% moderate and 3.9%
severe. Mean health status on the 0–100 VAS was scored at 57.2 (19.9)
mm. Women showed worst emotional well-being and seizure-worry than
men; 61.8 (24.6) vs 66.5 (22.7), p = 0.012, and 47.1 (31.3) vs 56.8 (31.5),
p = 0.0003, respectively. More women than men showed any degree of
anxiety; 47.9% vs 39.2% (p = 0.004).
Conclusion: Refractory epilepsy impacts negatively on a patient’s
quality of life, health status and level of anxiety and depression, partic-
ularly in women who showed slightly worse scoring on anxiety and two
dimensions of health-related quality of life. This study was financed by
Pfizer Spain.
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EPILEPSY IN MOTION: WHAT’S ON IN A WEEK?
P. Breia (South Delegation of Portuguese League against Epilepsy,
Lisbon, Portugal)
Purpose: Awareness and knowledge of the Portuguese population
concerning epilepsy is insufficient and some misjudgments about people
with epilepsy still prevail.
The “aim a week” for epilepsy in Portugal was to promote knowledge,
to contribute to demystification and to improve integration of people with
epilepsy into society.
Method: The main goals were local and national media, schools and
cultural institutions. With support of social partners and motivation and
work of members of self-supporting groups and health technicians the
1st week of epilepsy was held.
Results: An exhibition of paintings and drawings by people with
epilepsy was open to the public at the Zoo Auditorium in Lisbon, ending
in a party that joined self supporting groups and the general population.
Workshops about “Epilepsy and Learning” and “Living with Epilepsy”
were held in schools and cultural centres. A group of children with
epilepsy lived the unique experience of “Sleeping with the Sharks” in
Lisbon Aquarium. Wearing the T-shirt and cap of the week: “Epilepsy in
Motion,” people with epilepsy, their families and friends ended the week
participating in the “15th Mini-Marathon of Lisbon.” All the events were
reported by the media and many people with epilepsy were interviewed.
Conclusion: We accomplished the objective of epilepsy being the
focus of interest of the media in Portugal for a whole week, resulting
in a national impact. A week for epilepsy is a must every year and
contributes to reduce social stigma and to improve self-esteem of people
with epilepsy and their families.
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PREVALENCE AND BURDEN OF ILLNESS IN PATIENTS WITH
REFRACTORY EPILEPSY IN SPAIN: THE PATIENT/FAMILY
PERSPECTIVE
1P. Pen˜a, 2J. Sancho, 3M. Rufo, 4G. Palacios, 5S. Martı´nez, 5X. Mas-
ramon, and 6J. Rejas (1Department of Neurology, University Hospital
“12 de Octubre,” Madrid, Spain, 2Department of Neurology, General
University Hospital, Valencia, Spain, 3Department of Pediatric Neu-
rology, University “Virgen del Rocio,” Sevilla, Spain, 4Department of
Neuroscience, Medical Unit, Pfizer Espan˜a, Madrid, Spain, 5European
Biometrics Institute, Barcelona, Spain, 6Health Outcomes Research De-
partment, Medical Unit, Pfizer Espan˜a, Madrid, Spain)
Purpose: To ascertain prevalence and family/patient burden of illness
in adult patients with refractory epilepsy in Spain.
Method: A two-phase (prevalence and burden) cross-sectional and
retrospective study was designed. Consecutive adult patients (over 18
years) with epilepsy attending neurology outpatient clinics and epilepsy
units in the year 2005 were enrolled. Refractory epilepsy was consid-
ered as a patient not seizure-free after being treated with, at least, three
different antiepileptic drugs, as monotherapy or in combination, for a
minimum time of one year, and having, at the least, a seizure within
the last three months. Caregiver need, disease burden on caregivers and
family were assessed.
Results: A total of 1,448 (22.7%) out of 6,374 screened patients
fulfilled the criterion for refractory epilepsy; males (22.9%), females
(22.5%), outpatients (18.9%) and epilepsy units (36.3%), p < 0.001 be-
tween level of care. 762 patients [728 valuables, (95.5%); 50.8% males,
40.5 (13.5) years, 24.3 (13.4) years of evolution] were included in burden-
of-illness assessment. Only 56.0% were workers and 44.7% reduced the
workday duration. Absenteeism was showed by 33.3% [mean yearly
absence; 72.6 (73.0) days]. 8% needed house-adaptations and 3.4%
were institutionalised. An informal caregiver was needed by 36.4% of
whom 40.2% reduced their workday by a daily mean of 4.0 (2.5) hours.
Mean monthly out-of-pocket spent was 251.4 (566.5). Absenteeism and
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institutionalisation were higher in men; 60% vs 44% (p < 0.0001) and
5% vs 2% (p = 0.036), respectively.
Conclusion: Refractory epilepsy is prevalent and constitutes a con-
siderable burden to family and patients in Spain. A substantial portion
of costs are paid by own patient/family. This study has been financed by
Pfizer Spain.
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HEALTH CARE AND NON–HEALTH CARE RESOURCES USE
IN PATIENTS WITH REFRACTORY EPILEPSY: A COST OF
ILLNESS STUDY IN SPAIN
1M. Rufo, 2P. Pen˜a, 3J. Sancho, 4G. Palacios, 5S. Martı´nez, 5X. Mas-
ramon, and 6J. Rejas (1Department of Pediatric Neurology, University
Hospital “Virgen del Rocı´o,” Sevilla, Spain, 2Department of Neurology,
University Hospital “12 de Octubre,” 3Department of Neurology, Gen-
eral University Hospital, Valencia, Spain, 4Department of Neuroscience,
Medical Unit, Pfizer Espan˜a, Madrid, Spain, 5European Biometrics Insti-
tute, Barcelona, Spain, 6Health Outcomes Research Department, Medi-
cal Unit, Pfizer Espan˜a, Madrid, Spain.)
Purpose: To ascertain health and non–health care resources use and
to estimate the cost of illness in adult patients with refractory epilepsy
in Spain.
Method: A cross-sectional and retrospective study was designed.
Male and female adult patients (over 18 years) with refractory epilepsy
were enrolled in neurology outpatient clinics and epilepsy units between
March and September 2005. Health care and non-health care resources
were collected.
Results: 762 consecutive patients [728 valuables (95.5%); 50.8%
males, 40.5 (13.5) years, 24.3 (13.4) years of evolution] were included.
Yearly health care use included any type of EEG (56.5% of patients),
MR scans (33.8%), spectroscopy (3.7), SPECT (4.3%), PET (1.9%),
medical visits (4.3 per year), emergency visits (0.8 per year), hospital-
isations (15.3%) and drugs (mean number: 2.2). Only 56% of subjects
were workers, with 44.7% reducing the workday and absenteeism being
present in 33.3%. Total yearly costs were 6,838 (8,100): health costs;
4,977 (6,490), and non–health costs; 1,873 (4,921). Emergency visits
were higher in women: 1.1 (2.9) vs 0.7 (1.3); p = 0.021, and institu-
tionalisation needs in men: 5% vs 2%; p = 0.036. Males showed sig-
nificantly higher annual health care costs [ 5,528 (7,516)] than females
[4,431 (5,259)], p = 0.024 yielding to near significant total costs: [7,414
(8,979)] and [6,279 (7,097)], respectively (p = 0.061).
Conclusion: Health care, and to a lesser extent non health care, re-
sources use are high in patients with refractory epilepsy in Spain, yielding
a considerable cost to both the National Health System and Society. This
study has been financed by Pfizer Spain.
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IMPACT OF IDIOPATHIC EPILEPSY ON MOTHERS AND FA-
THERS: STRAIN, BURDEN OF CARE, WORRIES AND PER-
CEPTION OF VULNERABILITY
1G. Ramaglia, 2A. Romeo, and 3G. Cioffi (1Department of Educational
Sciences, University of Turin, Turin, Italy, 2Epilepsy Centre, Depart-
ment of Pediatric Neurology, Fatebenefratelli Hospital, Milan, Italy,
3Department of Psychology, University of Milano-Bicocca, Milan, Italy)
Purpose: To examine a) strain, burden of care, worries (regarding
stigma, academic underachievement, uncertainty of future) and percep-
tion of child’s vulnerability in parents of children with newly diagnosed
“epilepsy only,” compared with parents of healthy children who had an
acute illness during the last 6 months before the beginning of the study;
b) changes in every variable after 12 months; c) relationships among
strain (dependent variable), and the other variables in parents of children
with epilepsy at baseline (T0) and 12 months after (T1).
Method: Twenty-seven parental couples of children with epilepsy and
27 parental couples of controls filled out: two questionnaires on parents’
burden of care and worries; the Family Strain Questionnaire (FSQ) and
the Child Vulnerability Scale (CVS). Statistical analysis included t-test,
ANOVAs, stepwise regression analysis.
Results: a) At baseline parents of children with epilepsy had signifi-
cantly higher CVS scores (F1,52 = 7.607; p = 0.008) and higher levels of
worries (stigma F1,52 = 17.186; p = 0.000 and academic underachieve-
ment F1,52 = 14.09; p = 0.000) than controls; in each group, mothers
had sustained a greater burden of care (F1,52 = 67.186; p = 0.000) and
exhibited higher FSQ scores than fathers (F1,52 = 9.075; p = 0.004); b)
after 12 months, the FSQ and CVS scores significantly diminished both
for mothers (respectively T26 = 3.253; p = 0.0034 and T26 = −3.499;
p = 0.0018); and fathers (respectively T26 = 2.731; p = 0.0117 and T26
= −3.153; p = 0.0043), while burden of care, worries and relationships
among variables remained stable; c) the strain was significantly associ-
ated with perception of child’s vulnerability (mothers R2(T0) = 0.331;
R2(T1) = 0.29) and uncertainty (fathers R2(T0) = 0.19; R2(T1) = 0.277).
Conclusion: Diagnosis of epilepsy “only” induces a perception of
vulnerability and worries (uncertainty of future) which in turn associate
with the parents’ strain.
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LIVING CIRCUMSTANCES OF PERSONS WITH SEVERE
EPILEPSY AND AN INTELLECTUAL DISABILITY
1W. Blarikom van, 1,2A. Aldenkamp, 3A. Gennep van, and 1I.
Tan (1Epilepsy Centre Kempenhaeghe, The Netherlands, 2Department
of Neurology, University Hospital of Maastricht, The Netherlands,
3University of Maastricht, The Netherlands)
Purpose: Epilepsy affects approximately 25% of people with an in-
tellectual disability and is more common in those with an IQ below 50.
There is a lack of knowledge about the effect of epilepsy on living cir-
cumstances and consequently on quality of life in this population. In
this study we will explore a) the relationship between the severity of the
epilepsy, the intellectual disability and living conditions; b) the role of
epilepsy in this relationship: is epilepsy a modulating or inhibitory factor
with respect to living conditions and quality of life? How do the different
aspects of the severity of epilepsy contribute to this role?
Method: The study is a clinical descriptive, nonrandomised study.
During 18 months aspects of living conditions, quality of life and epilepsy
are monitored. In this we follow Felce (Journal of Intellectual Disabil-
ity Research 1997;41:126–135) who developed a model for measuring
quality of life, defining it as an overall general well- being that comprises
objective factors and subjective evaluations of physical, material, social,
productive, emotional and civic well-being all weighted by a personal
set of values. Aspects of the severity of their epilepsy are obtained in
order to compute a score.
Results: 98 patients have been included and all assessments were
carried out. All participants have epilepsy and are on antiepileptic drug
treatment (on average 3 AED’s). 40% have to deal with permanent re-
strictions due to their epilepsy, such as protective helmet or fixation. Five
aspects of epilepsy are gathered to a score.
They have a mild to severe intellectual disability (IQ ranging 30 to 60).
Most of them have comorbid problems (somatic, behavioural, physical
handicaps). The participants all live in groups (mean size 11.2 persons)
in units of the long-stay department of the epilepsy centre outside the
community. The mean length of stay is 28 years. Their possibilities to
control their own living circumstances are limited. Nonetheless most of
them (89%) are satisfied with their life (QOL interview).
Conclusion: Living conditions of a group of 98 institutionalised adults
with epilepsy and intellectual disability are described. Compared to
persons with an intellectual disability without epilepsy (Bowley et al.,
2000;44:529–543) their quality of life seems to be less). The role of
epilepsy will be further explored.
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MEASURING STIGMA IN CHILDREN WITH EPILEPSY AND
THEIR PARENTS
1R. Hardwick, 2S. Brown, and 2C. White (1Wales College of Medicine,
UK, 2Children’s Epilepsy Service, Morriston Hospital, Swansea, Wales,
UK)
Purpose: This study aims to assess the application of a promising tool
for measuring stigma developed by Austin et al. (Austin J et al., Epilepsy
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& Behaviour 2004;5:472–482). Although stigma is recognised in both
children with epilepsy and their parents, levels of such have not been
measured extensively. The questionnaires will be tested for suitability in
a clinical setting, and will determine the value of the resulting data.
Method: The questionnaires were developed for children with
epilepsy and their parents; they included Austin et al.’s stigma scales,
and questions gathering sociodemographic data (child/parent age, child
gender, residential area, age of diagnosis, epilepsy duration, seizure fre-
quency and social class). Patients will be recruited from specialist pae-
diatric epilepsy clinics in Swansea NHS trust, UK. All patients up to
19 years old will be included. If children are unable to complete the
questionnaire, parent’s questionnaires will still be collected.
Results: Twenty-nine children and 38 parents completed the ques-
tionnaires. The average stigma score for children was 1.82 (SD 0.86)
and 2.61 (1.08) for parents. No correlations were found between child
and adult stigma scores, or between stigma and the sociodemographic
data collected.
Conclusion: The questionnaires were easily implemented in the clin-
ical setting. Problems encountered included parental influence over the
children’s answers and collecting data from children with learning diffi-
culties. The stigma scores were lower than those collected in the Austin
et al. study. Although no significant correlations were found when con-
sidering sociodemographic factors, it is hoped that with the collection of
further data, correlations will become apparent.
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SELF-SUPPORTING GROUPS: PSYCHOSOCIAL
INTERVENTION
A. Silvestre, R. Fernandes, S. Morais, and P. Breia (South Delegation of
the Portuguese League Against Epilepsy (LPCE), Lisbon Portugal)
Purpose: Epilepsy is a neurological chronic disease affecting the well
being of patients and their families, with repercussions in psychosocial
adjustment and quality of life. The self-supporting groups promote social
interactions, intercommunication, sharing of feelings and positive rela-
tional experiences increasing self-esteem and emotional stability. The
aim of this work is to demonstrate the importance of self-supporting
groups for people with epilepsy and for their families and to estimate
their evolution along time.
Method: A 12 item questionnaire was applied, to each member of the
3 self-supporting groups of the South Delegation of LPCE (2 groups of
parents/family and 1 group of people with epilepsy). The results were
submitted to a descriptive analysis by SPSS 11.0.
Results: Our sample is composed of 23 subjects (14 female; 9 male)
between 21 and 68 years of age. Most of the individuals were informed
of these groups by the neurologist or neuropaediatrician. 83% answered
that their initial expectations concerning the groups were accomplished.
56% realise they need another kind of psychological support besides
the self-supporting group. 72% affirmed that the groups had a positive
psychological impact in their lives and in helping to accept epilepsy as
a chronic disease. To inform others about epilepsy, to divulge and to
expand the self-supporting groups are the aims of these individuals.
Conclusion: This work demonstrates that interacting with self-
supporting groups promotes positive personal and psychological changes
and determines a call to action attitude of their members in society.
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QOL IN ADOLESCENTS WITH EPILEPSY: RESULTS OF SEMI-
STRUCTURED IN-DEPTH INTERVIEWS WITH SWEDISH
TEENAGERS
K. Wide and L. A˚stro¨m (Div Peditrics, CLINTEC Institution, Karolinska
Institute, Stockhom, Sweden)
Purpose: It is a challenge to treat chronic disease in adolescents, es-
pecially epilepsy with unpredictable seizures. In a previous study based
on a questionnaire sent to 86 13–19y old teenagers with epilepsy we
found that >50% were not seizure free, experienced side effects from
the anticonvulsant medication, and had low self-esteem. In order to im-
prove the medical and psychosocial caretaking we performed semistruc-
tured indepth interviews with 8 adolescents with epilepsy in mainstream
schooling.
Method: Semistructured in-depth interviews, analysed with a com-
puterised aid (open code).
Results: Three boys and 5 girls were interviewed; only 1 teenager
knew the exact diagnosis. Six had GTC, and 2 absences, 6/8 had experi-
enced seizures during the last six months, 1 of them had daily seizures.
There were 9 categories of concern in the interviews: seizures (debut, di-
agnosis) (n = 65), obstacles (n = 51), medication (n = 50) (side effects,
treatment), feelings (n = 20), friends (n = 24), family (n = 19), (spare
time), schooling (n = 17), and future (n = 13). On the question of what
kind of care-giving, the adolescent wanted a less childish waiting area,
they wanted to talk to the physician without the parents, they wanted
information on rules for a driving licence, and work opportunities.
Conclusion: This group of patients need special care with emphasis
on both medical care with information directly from the physician but
also help to cope with the psychosocial situation, help to focus on the
salutogenetic factors from the epilepsy nurse, possibilities of find infor-
mation on and possibilities to chat with the nursing staff on the Internet.
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GENERAL KNOWLEDGE AND ATTITUDES TOWARD
EPILEPSY AMONG PRIMARY LEVEL TEACHERS IN
MACEDONIA
1A. Doneva, 1D. Petrovski, 1K. Pili-Kuzeva, and 2V. Donev (1Clinical
Hospital Dr. T. Panovski, Bitola, Macedonia, 2Oral Surgery, Bitola,
Macedonia)
Purpose: The study was conducted to determinate the knowledge
regarding epilepsy among primary level teachers in Bitola, Macedonia,
their knowledge regarding management of seizures in children, and the
influence by the degree of knowledge to the attitudes toward epilepsy.
Method: A self-administered questionnaire was answered by 101
teachers, in three primary schools, with different levels of education
(university 81 (80.2%), academy 20 (19.8%)) and different work expe-
rience (15 teachers up to 5 years, 33 from 5 to 15 years, 17 from 15 to
25 and 36 with more than 25 years work experience).
Results: All the teachers had heard about epilepsy. Forty-five of them
(44.6%) have had a pupil with epilepsy (usually teachers with longer
work experience) and 44 (43.6%) have witnessed a seizure. All knew that
epilepsy is not contagious. Most information was from family/friends and
TV (movies). Regarding the aetiology 78.2% answered that epilepsy is a
brain disorder, 29 (28.7%) answered that epilepsy is a psychiatric disor-
der, 33 (32.7%) hereditary and 4 accepted it as “good punishment” (mul-
tiple choice question). Fifteen teachers (14.9%) answered that death can
frequently occur during a seizure. They all knew that epilepsy isn’t con-
tagious. Some of the elements of the GTCS were recognised by almost all
of them, but no one recognised the description of an absence seizure. 89%
(91 teachers) thought that seizures could be controlled, 75.2% elected
medications as treatment (17 in combination with psychotherapy, two
medications and diet, two medications and an operation). 63% judged
themselves as educated about what to do if a seizure occurred, but unfor-
tunately only 15 (14.8%) answered correctly. Almost 84% chose pulling
the tongue and putting an object between the teeth as first aid. Twenty
teachers (19.8%) thought that pupils with epilepsy have to be isolated
(special schools), mostly from the teacher group with longer work ex-
perience (attitudes). Eleven (10.9%) had objections if they had a pupil
with epilepsy in the class (stigma). More than 33% had different criteria
during the evaluation.
Conclusion: Almost all the teachers had heard about epilepsy, but their
awareness did not equate with acceptance and understanding of epilepsy.
Negative attitudes and bias towards epilepsy was still deeply ingrained
among them, especially among teachers with longer work experience.
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TUBEROUS SCLEROSIS RESOURCE CENTRE IN NORWAY:
AN EVALUATION OF FAMILY AND NETWORK COURSES
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1A. Ingvaldsen, 2M. Veenstra, 1M. Lossius, 1R. Solhoff, 1A. Eriksson,
1T. Alsaker, 1B. Langslet, and 1P. Brandt-Hansen (1National Centre for
Epilepsy, Sandvika, Norway, 2Department of Biostatistics, Rikshospi-
talet, Oslo, Norway)
Purpose: Tuberous Sclerosis Resource Centre (TSRS) in Norway
is, to our knowledge, the only registered resource centre for tuberous
sclerosis complex (TSC). The Centre was established in 1998 to: 1)
inform patients and family members with a newly diagnosed TSC about
the disease; 2) organise network courses for the social and health services
in the patient’s residential area. The main purpose of this study was
to evaluate the participants’ satisfaction with the courses provided by
TSRC. A secondary objective was to assess any geographical variation
in satisfaction with the network courses.
Method: 168 participants at either family (n = 14) or network courses
(n = 154) during 2004 and 2005 filled in a questionnaire. Overall sat-
isfaction with the courses was measured on a five-point response scale,
with score = 1 indicating dissatisfaction and score = 5 indicating a
high degree of satisfaction. We used Fischer’s exact test, Kruskal Wallis,
and Pearson’s chi-square to analyse the relation between type of course,
geographical region and the percentage of patients with maximum sat-
isfaction scores (score = 5).
Results: The satisfaction rates (= 5) were somewhat higher for the
family courses compared to the network courses (77% versus 62%),
but not statistically significant. The mean total satisfaction scores were
4.77, 4.63, and 4.45 respectively (p = 0.009). The percentage scoring 5
(maximum score) were significantly higher in West/Central (80%), and
South/East (67%) compared to Northern (47%).
Conclusion: The participants expressed a high degree of satisfaction
with both courses. The variation in satisfaction rates between geograph-
ical regions indicates a potential for quality improvement of the courses
provided in Northern Norway.
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THE PAMs EXPERIENCE: AN UPDATE
1V. He´zser-V.Wehrs, 2J. Mifsud, 2V. Dimech, 3J. Be´ke´s, 3G. Czikora, 4H.
Sudbrock, and 4M. Pfa¨fflin (1EUREPA, European Epilepsy Academy,
2Caritas Malta Epilepsy Association, 3Budapest Bethel Epilepsy Centre
Foundation, Hungary, 4Bielefeld-Bethel Epilepsy Centre, Gemany)
Purpose: A learning partnership has been set up which aims to mo-
bilise resources and improve competence among the partners for training
and education of adults working in the medical field with an interest in
epilepsy (PAMs). This project would provide European professionals al-
lied to medicine (PAMs) with tools and methods to improve knowledge
and expertise for prevention, diagnosis and treatment in epileptology and
thus help to improve the quality of care to patients with epilepsy.
Method: This project is being realised from two sides: 1) A working
group consisting of ILAE and IBE members is working out the con-
tent of this curriculum: essential knowledge about epilepsy, diagnostics
of epilepsy, and principles of epilepsy treatment, therapy of epilepsy:
pharmacological treatment; living with epilepsy; and communication
and interaction. 2) Funding has been obtained as an EU Grundtvig 2
project which involves development of pedagogical skills needed for
both individual and organised learning and the promotion of strategies
for change in this educational sphere of adult learning, which to date
has been very fragmented. The partners were from Malta, Hungary, Ger-
many, and Eurepa. The main methods used were e-learning, elements of
the moderation method, group work and problem-based learning.
Results: While the first year of the project was mainly dedicated to
get an overview of already existing PAMs programmes, and to try out
and evaluate teaching methods on their usability in different settings, in
the second year, the first year results’ are related to the content being
worked out by the ILAE/IBE Working Group.
Conclusion: The project has been extremely successful with PAMs
in member countries and an application has been made for a third year
(2006–2007) in order to be able to finalise the basic curriculum. Ac-
cording to the action plan of the project, the curriculum should then be
published and disseminated as well as a system for Train-the-Trainers
courses and certification should be worked out.
Tuesday July 4, 2006
13:30–15:00
Poster Session 2
Clinical Neurophysiology
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VALPROATE TREATMENT IS SUCCESSFUL IN PATIENTS
WITH PHOTOSENSITIVE EPILEPSY: IS IT TRULY SUS-
TAINED EFFICACY OR MERELY AGE-RELATED SPONTA-
NEOUS REMISSION?
1D. A. Kasteleijn-Nolst Trenite´ and 2R. Reed (1Department of Neuro-
logical Sciences, University of Rome, Italy, 2Research and Development,
Abbott Laboratories, Abbott Park, Illinois, USA)
Purpose: To determine whether the sustained therapeutic effect of
sodium valproate (VPA) in treating patients with photosensitive epilepsy
is due to its intrinsic pharmacodynamic effect or to natural disease re-
mission. Although evidence exists that demonstrates VPA’s continued
positive clinical and EEG effect, determination of its true long-term effect
is confounded by evidence indicating spontaneous remission. The mere
finding of continued suppression of a photoparoxysmal response (PPR)
with VPA use after serial testing over time is not sufficient evidence of
its sustained efficacy.
Method: A chart review of patients with annual serial testing with
standardised intermittent photic stimulation (IPS) was conducted. Those
selected had IPS during VPA monotherapy without interruption for ≥
2 years, and after withdrawal of VPA. Spontaneous remission meant no
change in PPR range 30 days after the discontinuation of VPA.
Results: Fourteen patients (11F/3M) met our criteria, age = 10 to
69 yrs. The VPA monotherapy total daily dose (13 as Na salt) ranged
between 150 and 1800 mg with a median of 600 mg. The suppressive
effect of VPA continued up to 12 years (median = 4 yrs). In 1 patient
with abolition of the PPR on VPA 600 mg, no change was seen after
withdrawal of VPA at age 32; most likely, this is an age effect.
Conclusion: Repeat IPS PPR testing well after VPA withdrawal indi-
cated spontaneous remission of photosensitivity had not occurred in all
but 1 patient selected. VPA has proven sustained efficacy (median = 4
years, up to 12 years).
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LOBAR LOCALISATION INFORMATION: COMPARISON OF
EEG AND MEG
1A. Paulini, 1M. Fischer, 1G. Scheler, 1R. Hopfenga¨rtner, 1S. Rampp,
1M. Kaltenha¨user, 3A. Do¨rfler, 3M. Buchfelder, 3J. Romsto¨ck, and
1H. Stefan (1Epilepsy Center Erlangen, University of Erlangen, Ger-
many, 2Department of Neuroradiology, University of Erlangen, Ger-
many, 3Clinic of Neurosurgery, University of Erlangen, Germany)
Purpose: The aim of this study was to describe the contribution
of MEG in presurgical focus localisation compared to video-EEG-
monitoring. The study concerns the precision of focus information and
the additional benefit of MEG in cases of no or not clearly localised EEG
findings.
Method: Eighty-four patients with presurgical video-EEG-
monitoring and MEG investigation, who underwent surgical treatment
between 1998 and 2004, were included. The anatomical lobe(s) of
localisation results were compared to the resection affected lobe(s).
Postsurgical outcome was used for validation. Data were analysed in
respect of: 1) percentage of the results located in one anatomical lobe,
2) number of patients for whom MEG provided a localisation result
within only one lobe, when interictal and/or ictal EEG localised to two
or more lobes or yielded no localisation at all.
Results: 1) MEG results localised in 84% (n = 48 of 57 patients with
spikes) within one anatomical lobe. Ictal EEG in 70% (n = 51 of 73),
interictal EEG in 64% (n = 49 of 77).
2) In 20 (of all 84) patients a clear localisation within one lobe was
not found either in interictal or in ictal EEG. In 10 of these cases MEG
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provided a unilobar localisation which matched the resected lobe. These
10 patients became seizure free or achieved a reduced seizure rate.
Conclusion: MEG localised within one anatomical lobe in more cases
compared to video-EEG-monitoring. MEG provided a unilobar benefi-
cial localisation result in half the patients with no or multilobar video-
EEG-findings. MEG yields additional information to video-EEG moni-
toring in the workup for epilepsy surgery and shows higher precision in
presurgical focus localisation.
p403
SEIZURE PREDICTION ALGORITHM ON SCALP EEG IS SEN-
SITIVE TO CHANGES IN STATE OF VIGILANCE
1A. Bruzzo, 2B. Gesierich, 3G. Rubboli, 3C. Tassinari, and 4N. Bir-
baumer (1University of Bologna-Department of Psychology, Italy,
2University of Ferrara-Department of Biomedical Sciences and Ad-
vanced Therapies, Italy, 3University of Bologna-Department of Neu-
rological Sciences, Italy, 4University of Tuebingen-Institute of Medical
Psychology and Behavioral Neurobiology, Germany)
Purpose: To evaluate a novel prediction algorithm on scalp-EEG of
patients with temporal lobe epilepsy in order to preventively treat seizures
in real time.
Method: We analysed data from 5 patients with a total of 19 seizures.
We initially used the nonlinear measure of permutation entropy (PE)
(Bandt & Pompe Physical Review Letter 2002;88:174102–6) to predict
epileptic seizures online on the basis of scalp-EEG. PE is known to be
similar to the Lyapunov Exponent, which is often suggested for seizure
prediction. Permutation entropy was calculated over time using a moving
window technique. ROC analysis was applied to evaluate the separabil-
ity of amplitude distributions of PE resulting for preictal and interictal
phase. The possibility to use a unique threshold for seizure prediction was
tested. An additional analysis was undertaken to control for a possible
dependency of PE on vigilance state.
Results: We found a good separability of interictal and preictal phase
by means of PE. PE was also found to be sensitive to changes in the
vigilance state. The changes of PE during the preictal phase were in
most cases found to coincide with changes in the vigilance state.
Conclusion: This forecasting method shows firstly, that detection and
real time prediction of the epileptic seizure on the basis of scalp-EEG
can be done with a high performance. However, the dependency of the
algorithm on vigilance state extremely restricts its possible application.
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EXPLORATION OF MOTOR CORTEX EXCITABILITY IN
PATIENTS WITH AUTOSOMAL DOMINANT NOCTURNAL
FRONTAL LOBE EPILEPSY: A TRANSCRANIAL MAGNETIC
STIMULATION STUDY
R. Nardone, H. Ausserer, A. Bratti, P. Lochner, R. Marth, and F. Tezzon
(“F. Tappeiner” Hospital–Department of Neurology–Merano–Italy)
Purpose: Autosomal dominant nocturnal frontal lobe epilepsy
(ADNFLE) has been found to be associated with five distinct muta-
tions in the two genes coding for the alpha4 or beta2 subunits of the
neuronal nicotinic acetylcholine receptor, which lead to altered receptor
properties. We aimed to elucidate the origin of the epileptic seizures and
to clarify the major structural features responsible for the induction of
convulsions in the ADNFLE.
Method: Transcranial magnetic stimulation (TMS) was performed on
2 patients with ADNFLE, and on 10 control subjects. Measures of corti-
cal excitability included the resting and active motor thresholds to TMS,
the duration of the cortical silent period, the short latency intracortical
inhibition (SICI) and intracortical facilitation using a paired-pulse TMS
technique.
Results: SICI was significantly reduced in ADNFLE patients (p <
0.05, Mann-Whitney test). The other TMS parameters did not differ
significantly between patients and controls (p > 0.05).
Conclusion: SICI is thought to depend on GABAergic inhibitory
mechanisms; since cortical interneurones containing GABA have nico-
tinic as well as muscarinic receptors and receive rich cholinergic affer-
ents, projecting principally from the brainstem and basal forebrain, the
changes in SICI here described in ADNFLE patients may be due to an
altered nicotinic receptor function. It could be hypothesised that an im-
paired nicotinic activity may deprive inhibitory GABAergic neurons of
a source of excitatory inputs and thus reduce intracortical inhibition.
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ECHOENCEPHALOGRAPHY MIDLINE SPIKE SHIFT AT IC-
TUS AS STRONG EVIDENCE OF A FOCAL EPILEPTIC
SEIZURE
V. Andreev (Moscow State Medical Stomatological University, Russia)
Purpose: The aim of the present work is to study the midline echo-
spike shift (MESS) at the focal epileptic ictus. This work was intended to
find a reliable method of bedside diagnostic of focal epileptic seizures.
Method: This study was carried out with an ULTRAMED A-mode
cranioscope echoencephalograph. A 1.5 mega Hz ultrasound transducer
was fixed to an area above the root of the ear. We observed 12 patients with
focal epileptic adversive seizures, 14 patients with epileptic hemiclonic
seizures, and 6 patients with hemiclonic psychotic seizures. The age
range was 17 to 46. The problem has been studied for 2 years at our
neurotraumatology department.
Results: The 4–7 mm MESS occurred towards an undamaged brain
hemisphere. The maximum MESS was during hemiclonic epileptic
seizures. The minimum MESS occurred during focal adversive epileptic
seizures. During psychotic hemiclonic seizures no MESS was observed.
In focal adversive epileptic seizures the MESS was in 10 patients (83%).
During epileptic hemiclonic seizures the MESS was in 13 patients (92%).
Conclusion: A-mode MESS at focal ictus may be strong evidence
of an increase in the cerebral regional blood flow. At the same time
there is evidence of focal epileptic seizures. Our results are coincident
with the findings of a functional transcranial dopplerography. The MESS
method can be used to identify the side of the epileptic focus. This MESS
method of application is covered by patent 2182463 (2001) registered in
the Russian Federation.
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AUDITORY BRAINSTEM RESPONSE, MIDDLE-LATENCY RE-
SPONSE, AND SLOW CORTICAL POTENTIAL IN EPILEPSY
PATIENTS WITH ANTICONVULSANT TOXICITY
1G. Japaridze, 1O. Toidze, 1S. Kasradze, and 2Z. Kevanishvili (1Epilepsy
Prevention And Control Centre, Georgia, 2Centre of Audiology and
Hearing Rehabilitation, Georgia)
Purpose: Auditory evoked potentials (AEPs) under anticonvulsant
neurotoxicity have rarely been investigated. The aim of the present study
was the inspection of AEPs in patients suffering from antiepileptic drug
toxicity.
Method: Auditory brainstem responses (ABRs), middle-latency re-
sponses (MLRs), and slow cortical potentials (SCPs) have been estimated
in 14 epilepsy patients of 14–44 years age, 3 females and 11 males. All
subjects possessed symptoms of anticonvulsant neurotoxicity. Out of 14
patients, 8 were treated by monotherapy, carbamazepine-2, phenytoin-5,
valproate-1, and 6 by polytherapy, various combinations with valproate-
2, phenytoin-2, and clonazepam-2. The AEP parameters in individual
patients were compared with the respective data in 33 age- and gender-
matched healthy individuals.
Results: ABR abnormalities were revealed in 6 of 14 patients, 42.8%.
Five patients from those were under phenytoin monotherapy. MLR ab-
normalities were detected in 10 patients, 71.1%. In all of them peak-
latency prolongations have been observed. SCP alterations were detected
in 13 patients, 92.8%, and were similarly manifested in latency lengthen-
ing. In 6 patients, individual SCP components were missing additionally.
In 5 patients, exhibiting no clear EEG signs of drug toxicity, AEPs also
demonstrated abnormal parameters. In 3 patients from those, SCP abnor-
malities were rough. After 1–4 weeks of drug or dose adjustments and,
as a result, recoveries from intoxication, the occurrence and severity of
AEP abnormalities decreased. In some cases, nevertheless, abnormalities
remained unaltered.
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Conclusion: Anticonvulsant neurotoxicity is reflected in AEP param-
eters. SCP alterations seem particularly characteristic. ABR shifts appear
selectively typical for PHT intoxication. AEP measurements thus permit
objectifying and proper monitoring of anticonvulsant neurotoxicity.
p407
STUDY OF THE MORPHINE EFFECT ON FREQUENCY OF
HIPPOCAMPAL SEIZURES IN MICE
1E. Saboory, 1F. Ghaderi-Pakdel, 1H. Moghanchizadeh, and 2M.
Mehrzad Sdaghiani (1Dep of Physiology, Faculty of Medicine, Urmia
University of Medical Sciences, Urmia, Iran, 2Dep of Gynecology, Fac-
ulty of Medicine, Urmia University of Medical Sciences, Urmia, Iran)
Purpose: This study was designed to determine the effect of morphine
on the frequency of different components of seizures induced by low
Mg2+ACSF in whole hippocampus preparation of mice.
Method: C57/BL6 mice 11 to 19 days of age were used. The ani-
mals were anaesthetised and the brain was removed (n = 25) and placed
in ice-cold, continuously oxygenated ACSF for 3 min. Then the hip-
pocampi were dissected and incubated in normal ACSF at room temper-
ature for one hour before electrophysiological recording. Seizure activity
was induced by perfusing the hippocampus with low Mg2+ACSF. Ex-
tracellular recordings were performed mainly in the CA1 pyramidal cell
layer. Seizure activity was quantified by measuring the frequency of ictal
events.
Results: All applied concentrations of morphine and naloxone 10 μM
decreased the frequency of seizures, more effectively in the tonic part of
the seizure. Naloxone 10μM not only did not inhibit the inhibitory effects
of morphine on seizures but also markedly suppressed the frequency of
epileptiform activities. Also, the combined application of morphine and
naloxone completely blocked the bursting activity.
Conclusion: Our results indicate that morphine may decrease the fre-
quency of hippocampal seizures through different receptors than opi-
oid receptors, because naloxone, the opioid receptors antagonist, cannot
block the effect.
Key words: hippocampus, naloxone, morphine, seizure, epilepsy, fre-
quency, low Mg2+ACSF.
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PROPAGATION TIME COURSE OF CONTRALATERAL AND
IPSILATERAL SYNCHRONISED SPIKES: HIGH-DENSITY
ELECTRICAL MAPPING COMPARISON
A. Yoshino and O. Kobayashi (National Defense Medical College, Toko-
rozawa, Japan)
Purpose: In some patients with localisation-related epilepsy, focal pri-
mary discharges activate the contralateral homologous cortex as a mirror
focus. On the other hand, some patients with parietal and occipital lobe
epilepsies show apparently synchronised spikes within the ipsilateral
cortex. Although these intrahemispherically synchronised spikes might
be generated by a mechanism resembling that of a mirror focus, their
actual basis has not yet been explored. To investigate the nature of these
spikes, we analysed their peak latency disparity and propagation patterns
of the spikes.
Method: Subjects were 5 patients with a temporal mirror focus and
3 patients with intrahemispherically parietofrontopolar synchronised
spikes. We estimated the time lags between the peak latency of the interic-
tal synchronised spikes and determined how the spikes were propagated
over the scalp recording using 64-channel spherical spline mapping with
a sampling rate of 1000 Hz.
Results: Mean time lags of peak latency of temporal mirror foci were
20.9 to 69.2 ms. In 3 cases, mirror foci appeared in both temporal areas.
Parietal spikes were always followed by frontopolar spikes. Mean time
lags of peak latency were 20.6 to 27.1 ms. Spherical spline mapping
demonstrated that spikes originating in the parietal area were propagated
directly to the frontopolar area without cortical spread.
Conclusion: Parietal spikes were always directly followed by ipsilat-
eral frontopolar spikes without cortical spread, while temporal mirror
foci were produced in both directions in some patients.
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TIME-FREQUENCY DYNAMICS OF SPIKE-WAVE DIS-
CHARGES IN ABSENCE EPILEPSY PATIENTS USING
WAVELET TRANSFORM
1A. Gabova, 2D. Bosnyakova, 1G. Kuznetsova, 3V. Gnezditsky, and 4G.
Van Luijtelaar (1Institute of Higher Nervous Activity and Neurophysi-
ology RAS, Moscow, Russia, 2Institute of Radioengineering and Elec-
tronics RAS, Moscow Russia, 3Institute of Neurology RAMS, Moscow,
Russia, 4Radboud University Nijmegen,The Netherlands)
Purpose: Time-frequency structure of spike-wave discharges (SWDs)
of absence epilepsy is sparing investigated. Recently the modified
wavelet Morlet transform was developed by us and used for SWD time-
frequency analyses in animal model of absence epilepsy (Bosnyakova
et al., J. Neurosci Methods 2006, in press). Now we present the results
of SWDs time-frequency analyses in patients with different forms of
absence-epilepsy.
Method: SWDs of 22 patients were investigated. EEG was registered
from 16 electrodes placed by scheme 10 × 20. For the registration Neuro-
cartograph (MBN, Moscow) was used. The time-frequency dependence
in SWDs was analysed using modified wavelet Morlet transform.
Results: In 12 of 22 patients SWDs’ time-frequency dynamics were
of the same type. The discharge’s beginning had the largest frequency
(5.7 ± 1.3Hz). This frequency decreased fast up to 3.9 ± 0.4 Hz and
then it reduced slowly with the periodicity 1–2 sec. By the end of the
discharges the frequency decreased up to 3.5 ± 0.5 Hz. In the case of
short discharges (1-2 sec) the frequency dropped up to 2.6 ± 0.2 Hz and
the discharge abruptly ended. In the remaining 10 patients the SWDs’
time-frequency dynamics differed from those described above and were
of various types.
Conclusion: Some types of SWDs’ time-frequency dynamics were
revealed and compared with neurological patients’ examination. New
information about this kind of paroxysmal activity was found. Some
assumptions could be made about mechanisms of discharges abrupt ces-
sations on the basis of obtained data in absence epilepsy patients and
animal models.
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FOCUS DIAGNOSIS USING ELECTROCORTICOGRAPHY
ANALYSIS SOFTWARE AND THREE-DIMENSIONAL RECON-
STRUCTED MRI IN PATIENTS WITH MULTICHANNEL IN-
TRACRANIAL ELECTRODES
M. Yamazaki, T. Maehara, T. Momose, K. Ohno, and M. Matsuura
(Tokyo Medical And Dental University, Tokyo, Japan)
Purpose: Invasive intracranial recording provides dynamic neuronal
activity in patients with neocortical epilepsy. However, it is not always
easy to define the epileptic focus on electrocorticography (ECoG) be-
cause ictal discharges are recorded simultaneously on many channels or
rapidly propagate to the surrounding cortex. We investigated the use-
fulness of computerised voltage topographic mapping analysis of ictal
spikes on multichannel grids using three-dimensional reconstructed MRI
(3-D MRI), which enhanced spatial and time resolution.
Method: We studied 3 neocortical epilepsy patients with long-term
ECoG monitoring. We took photographs of cortical surface electrodes by
digital camera and then took CT scans immediately after surgery to create
a 3D electrode template with MRI. After ictal recording, spike voltage
topographic maps were created with review and analysis programmes
(Insight and Prism) on the electrodes template of the grid of cortical
surface and 3-D MRI. In 1 patient, we also analysed ictal spikes with
continuous wavelet.
Results: In 2 cases, ictal discharges appeared on many channels si-
multaneously. We had difficulty in identifying the epileptogenetic area
by conventional assessment. Voltage topographic mapping showed the
extent of ictal discharges, which enabled us to recognise visually the
ictal onset zone and its time course. In one patient, ictal ECoG showed
bilateral synchronised spikes and voltage map of a preceding spike rep-
resented broad activated area. With the detail wavelet analysis of the
preceding spike, the ictal onset zone was more clearly localised.
Conclusion: Application of electrocorticography analysis software
and three-dimensional reconstructed MRI is useful to visualise and
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detect the ictal onset zone in patients with multi-channel intracranial
electrodes.
p411
K COMPLEX AS A TRIGGERING FACTOR FOR SEIZURES
IN AUTOSOMAL DOMINANT NOCTURNAL FRONTAL LOBE
EPILEPSY (ADNFLE)
J. El Helou, V. Navarro, I. An, C. Depienne, E. Leguern, and C. Adam
(Pitie´-Salpeˆtrie`re Hospital, Paris, France)
Purpose: Seizures in ADNFLE occur preferentially during cyclic al-
ternating patterns (CAP) of NREM sleep [Zucconi et al., J Clin Neuro-
physiol 2000;17:77–86]. The precise relation of seizures to CAP events
is not yet well described. Our purpose is to study the relationship between
K complex and seizures in a case of genetically confirmed ADNFLE.
Method: Four day video-EEG monitoring of an ADNFLE case with
CHRNA4 gene mutation.
Results: We report the case of an 18-year-old woman presenting an
ADFNLE with a CHRNA4 gene mutation, who had nocturnal motor
seizures, starting with head extension, mouth opening, dystonic move-
ments of the right then left arm, oro-alimentary automatisms, associated
with athetotic movements of right then both arms followed by apnea or
vomiting-like movements. They ended with an intense snoring sound.
The video-EEG monitoring showed that most episodes took place dur-
ing a CAP in different stages of NREM sleep. They started just after a
K complex. Interestingly, many were triggered by a sound that induced
the appearance of a K complex which was immediately followed by the
motor episode. The ictal EEG showed anterior bilateral rapid low volt-
age rhythms (10–11 Hz), followed by slower high voltage waves in the
anterior midline region. Episodes lasted 20 to 30 seconds. Interictal EEG
recordings showed no abnormalities.
Conclusion: K complex is one of the possible triggering factors of
seizures in ADNFLE.
We will discuss the role of the different sleep stages in the occurrence
of seizures in this disease.
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CLINICAL AND NEUROPHYSIOLOGICAL ASPECTS OF
EPILEPSY WITH STIMULUS-INDUCED SEIZURES
V. Karlov, and O. Andreeva (The Moscow State Medico-Stomatological
University, Russia)
Purpose: To study the trigger factors, clinical and neurophysiological
comparisons of patients with epilepsy seizures that are always induced
by various stimuli.
Method: 191 patients (134 children, 57 adults) from 5 to 45 years
(mean 16.7 ± 6.9) were studied. All had different types of epileptic
seizures, induced by various stimuli. Idiopathic epilepsy was diagnosed
in 59 patients (31.0%), cryptogenic epilepsy in 105 patients (54.9%) and
symptomatic epilepsy in 27 patients (14.1%). Clinical, MRI, EEG, in-
cluding, if needed, video EEG sleep monitoring, the method of multistep
dipole localisation (MDL) of spike activity and visual evoked potentials
(VEP) were used.
Results: The patients with photosensitive epilepsy; 158 (82.7%) were
predominant. 8 (4.2%) patients had pattern-sensitive seizures, 10 (5.2%)
patients had seizures induced by eye-closing (FOS-seizures). There were
5 (2.6%) patients with seizures induced by thinking, 2 (1.1%) patients,
with seizures induced by eating. In single patients the trigger factors of
the seizures were: fright (startle-seizures), sound, music, walking, read-
ing and hot water. We also, for the first time, described 2 patients (1.1%)
with epileptic seizures precipitated by laughter. Two patterns of epilep-
tiform activity have been revealed in thinking-epilepsy: the first started
from the left hemisphere (thinking-speech) and the second started from
the right hemisphere (thinking space). In photosensitive epilepsy two
different variants of VEP responses were revealed. The first: early com-
ponents transformation into spike-slow wave form and late components
of alpha-theta diapason; the second: absence of spike-wave pattern and
alpha-diapason oscillations. In 7 of 10 patients with FOS epilepsy the
focuses of spike activity were identified in the mediobasal frontal lobe
by MDL’s method.
Conclusion: This study demonstrates epileptic systems that realise
stimulus sensitive responses by involving one or another part of the
neural network and have a complex and nonsynonymous character. In this
connection, the term “stimulus-dependent seizures” is more adequate.
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DIAGNOSTIC VALUE OF INVASIVE RECORDING FOR TEM-
PORAL LOBE EPILEPSY: THE HOMOLKA EXPERIENCE
T. Procha´zka, Z. Vojtı`ch, I. Maree`kova´, and M. Kalina (Na Homolce
Hospital, Prague, Czech Republic)
Purpose: Temporal lobe epilepsy (TLE) is the most common type of
surgically remediable epilepsy. In the majority of cases, only noninvasive
evaluation is required before surgery. However, invasive monitoring with
intracranial EEG electrodes is sometimes necessary. The objective of this
study was to determine the correlation of invasive video EEG (VEEG)
recordings with data obtained during noninvasive evaluations.
Method: We retrospectively reviewed data of all adult epilepsy
surgery candidates who had undergone invasive EEG monitoring at the
Epilepsy Center na Homolce from 1999 to 2004 (n = 53). Only those
patients with suspected TLE were included in the study (n = 33). For
each patient we compared invasive VEEG result with hypothesis based
on noninvasive methods.
Results: There were 13 patients with nonconvergence of imaging
with scalp EEG, 10 patients with nonlesional TLE, 5 patients with sus-
pected bitemporal epilepsy and 5 patients with lesional TLE. The con-
cordance between invasive VEEG and noninvasive hypothesis was seen
only in 22 (66%) patients. Among 11 nonconcordant patients, 4 were
from bitemporal group, 5 were imaging/EEG nonconvergent and 2 were
nonlesional. Noninvasive hypothesis was accurate in all patients with
unilateral hippocampal sclerosis with contralateral scalp ictal onset and
in those with MRI-negative PET-positive TLE. 27 patients underwent re-
sective surgery with >12 months follow-up. Of those, 56% were seizure
free and 26% were without significant improvement.
Conclusion: In our series of adult patients with TLE, the value of
invasive recording in presurgical evaluation was surprisingly high.
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FRONTAL AND PARIETAL INTERHEMISPHERIC INTEGRA-
TIVE INTERACTIONS IN THE MODEL OF EPILEPSY
G. Selitsky, and N. Sorokina (Institute of Higher Nervous Activity and
Neurophysiology, Moscow, Russia)
Purpose: The aim of the study was to analyse the interaction of frontal
areas with parietal, temporal, and occipital areas of contralateral hemi-
spheres in patients with symptomatic epilepsy.
Method: The changes of higher integrative (mental) functions were
evaluated in 4 groups (26 patients in each, mean age 32.5, S.D. 6.5 years)
with different lateralisation and localisation of epileptic focus. The map-
ping of EEG spectral power and coherence was used for the analyses of
the brain bioelectrical activity and was analysed with Program Statistical
Package WinStat-7.0.
Results: Controversial data in the literature and our examinations de-
serve special attention. There is numerous evidence for separate right-
and left-hemisphere epilepsies: clinical examinations and literature data
mainly confirm this viewpoint. Our results (electrophysiological, psy-
chological, clinical) displayed that in a number of cases in epilepsy,
functional communications between the frontal area and somatosensory
area of contralateral hemispheres may cause the “additional” clinical and
behavioural events symptomatic of epilepsy, which is affected by con-
tralateral hemisphere dysfunction. The statistical analysis of the brain
bioelectrical activity showed the increase of spectral power and coher-
ence in the EEG delta band in the frontal area of one hemisphere and
in the parietal brain regions of the contralateral hemisphere. The data
obtained testify to functional integrative interactions between fontal and
parietal areas of opposite hemispheres.
Conclusion: The data obtained testify to functional integrative inter-
actions between frontal and parietal areas of opposite hemispheres. The
results permit us to assume it may be it possible to explain a number of
uncleared clinical cases, the formation of nonmirror foci, heteronymous
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to the epileptic focus clinical picture, and inefficiency of antiepileptic
drug therapy. The features of cortical interhemispheric associations ac-
cording to data in the literature data is not pathognomonic for epilepsy
and reflects one of the forms of functional flexibility causing a new level
of the reorganisation of integrative activity.
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EYE MOVEMENTS AND ANTIEPILEPTIC DRUGS
C. Lo, and S. Shorvon (Institute of Neurology, University College Lon-
don, UK)
Purpose: The aim of this study was to test the hypothesis that saccade
velocity (or other saccadic parameters) can be used as a surrogate marker
to predict/evaluate the clinical effects of antiepileptic drugs (AEDs). This
abstract presents the findings of initial proof of the principle stage of this
study.
Method: Epilepsy patients on monotherapy with carbamazepine
(CBZ) and other AEDs were recruited. A package of eye movement ex-
aminations was performed, related to serum drug levels measured before
and after taking the morning dose. The responsiveness of eye movement
to changes in serum level (trough and peak) was correlated to clinical
responsiveness.
Results: Saccadic velocities were presented in a series of patients
showing the marked variation within individuals to changing drug doses.
30% differences were noted in some patients between different serum
levels, with conversely little change in others. For carbamazepine, epox-
ide levels also influence velocity and are included in carbamazepine
measures. Latency of saccades is less sensitive to the changes of serum
concentration. The relation of saccadic changes to clinical effect is shown
in terms of effectiveness.
Conclusion: The computerised measurement of eye movements is
robust and easily applied to routine clinical settings. In this study, the
reliability and variance of changes in eye movement measures in relation
to drug responsiveness was explored. As the molecular and neuronal
mechanisms which underpin the effect of drugs on eye movements is
similar to those involved in the antiepileptic effect, it seems possible
that this simple clinical test will be a useful predictor of the therapeutic
effect.
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SERIAL EVOLUTION OF PLEDS
1J. Kim, 2S. Lee, and 1Y. Kim (1Department of Neurology, Chungnam
National University Hospital, South Korea, 2Department of Neurology,
College of Medicine, Keimyung University, South Korea)
Purpose: Periodic lateralised epileptiform discharges (PLEDs) are
defined as spikes or sharp waves occurring at approximately regular in-
tervals. According to Reiher’sclassification, PLEDs can be subdivided
into benign PLEDs proper (including class 1, 2, and 3) and malignant
PEDs plus (including class 4 and 5). This study was performed to in-
vestigate 1) the serial pattern of PLEDs. 2) the evolution of malignant
PLEDs plus to benign PLEDs proper, and 3) to suggest a more benign
form in the same PLEDs class.
Method: Thirty-seven patients who had two or more available EEGs
were included in this study. All patients had structural brain lesions
identifiedin the brain CT/MRIs. Patients with hypoxic brain damage or
uncertain diagnosis were excluded. 237 EEGs from 37 patients were
retrospectively analysed and the pattern of PLEDs classifiedaccording
to Reiher’s classification.
Results: One hundred and two PLEDs were identified out of 237
EEGs. (PLEDs proper: 100 EEGs, PLEDs plus: 12 EEGs). Seventy one
EEGs belonged to class 3. We subdivided them into 1) simple group, 2)
benign group, 3) vigorous group, and 4) suppressed group. Most PLEDs
started with a vigorous or suppressed pattern of class 3 evolving into class
3 of simple or benign pattern, and then changing to class 1 or class 2.
During the course, medium to high amplitude, complex sharp waves be-
came lower amplitude and broader basis, simple sharp waves (class1/2).
And finally they buried into theneighboring background waves. PLEDs
started with class 3 of benign or simple pattern rapidly changing into
class 1 or 2 and patients whose EEG started with class 1 or 2 showed the
most rapid improvement in the EEGs and better prognosis.
Conclusion: PLEDs have five distinguished classes. As time goes by,
with proper treatment, they evolved from a malignant class to a benign
class and finally disappeared. Class 3 had more diverse patterns and we
suggest a vigorous and suppression pattern in more malignant forms of
PLEDs in this class.
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DIFFERENCES BETWEEN INTRACEREBRAL ACTIVITIES
OF PATIENTS WITH IDIOPATHIC GENERALISED EPILEPSY
BEFORE AND AFTER CHRONIC VALPROATE THERAPY
1M. Toth, 1I. Kondakor, and 2B. Clemens (1Department of Neurology,
University of Pe´cs, Pe´cs, Hungary, 2Epilepsy Center, Department of
Neurology, Kene´zy Gyula Memorial Hospital, Debrecen, Hungary)
Purpose: EEG background activity was localised by LORETA to test
the possible differences between brain electrical activities of untreated
and valproate-treated patients with idiopathic generalised epilepsy
(IGE).
Method: 19-channel EEG data of 15 IGE patients before and after
chronic valproate therapy were studied. For source localisation of brain
electrical activity LORETA, a new tomographic method was applied,
where localisation is based on images of standardised current density.
The method is able to localise electrical generators in 3 dimensions
in four frequency domains: delta (1.5–3.5 Hz), theta (3.5–7.5 Hz), al-
pha (7.5–12.5 Hz) and beta (12.5–25 Hz). For the analysis 42 (S.D.:
1.7) artifact-free, 2 sec epochs were selected from the filtered raw EEG
(1.5–25.0 Hz) and were processed by LORETA. Statistical differences
between pairs of conditions were computed as images of t-values. To as-
sess the possible differences in background EEG activity, voxel-by-voxel
dependent t-tests were computed. The t-statistic images were examined
to localise regions showing statistically significant effects thresholded at
1% probability level.
Results: All patients became seizure-free. Valproate caused a statisti-
cally significant (p < 0.01) decrease of delta and theta band EEG activity
in the frontal cortex, and in part of the temporal cortex. Valproate did not
alter the activity of the parietal and occipital cortex, and in the remaining
areas of the temporal cortex.
Conclusion: The selective effect of valproate is related to areas of the
cortex that might be responsible for the initiation of the seizures in IGE.
The relationship between clinical and EEG effect of valproate might be
suggested.
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ELECTRICAL SOURCE IMAGING OF SPATIAL RELATION-
SHIPS BETWEEN LESIONAL AND IRRITATIVE ZONES
IN MEDICALLY INTRACTABLE POSTERIOR PARTIAL
EPILEPSIES
1L. Maillard, 1,2L. Koessler, 1J. Vignal, 3A. Thiriaux, 2M. Braun, and 1H.
Vespignani (1Service de Neurologie, Centre Hospitalier Universitaire
de Nancy, France, 2IADI, Eri 13, Inserm, Nancy, France, 3Service De
Neurologie, Centre Hospitalier Universitaire De Reims, France)
Purpose: Medically intractable posterior partial epilepsies (MIPPE:
occipital, parietal, TPOJ) remain a challenge in term localising the ir-
ritative zone (which generates interictal spikes) and the epileptogenic
zone (which generates seizures). This may directly explain the low rate
of success of surgery compared with temporal or frontal lobe epilepsies.
Recent development of high resolution EEG (HR-EEG) which allows
electrical source imaging of generators of spikes could help to localise
the irritative zone and to study its relationships with MRI lesion.
Method: Prospective, multicentric (Nancy, Reims) study of patients
with MIPPE. Each patient had a comprehensive presurgical evaluation
comprising video-EEG recordings of seizures, HR-EEG (64 channels
and dipole modelling with ASA, ANT) and cranial MRI.
Results: Since the beginning of the study, 3 patients have been in-
cluded. In patient EN, the generator of interictal spikes (IIS) is centered
on the left lateral occipitotemporal sulcus, overlapping the lesional zone
(regional subcortical atrophy). In the patient PN, IIS are localised in
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the right inferior parietal gyrus outside but next to the lesional zone
(periventricular nodular heterotopia) suggesting a pathological connec-
tion between these two distant neuronal assemblies. In the last patient,
IIS have a right temporal pole generator related to the ispilateral hip-
pocampal atrophy but distant from the occipital dysplasia.
Conclusion: In MIPPE, relationships between the lesions and the
irritative networks are complex. HR-EEG is a promising tool to study
these relationships and take a place in presurgical investigations.
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FRACTAL DYNAMICS OF THE THETA RHYTHM IN
EPILEPSY
E. Korsakova, V. Slezin, and S. Khorshev (V.M.Bekhterev Psychoneu-
rological Research Institute, Saint-Petersburg, Russia)
Purpose: The purpose of the present study consisted of in investigation
of fractal dynamics of the theta rhythm at initial and later stages of
epileptogenesis during the absence of paroxysmal discharge (PD).
Method: The examination was carried out with 30 healthy subjects, 32
patients with a preclinical stage of epilepsy who had a single unprovoked
seizure and no PD, 29 epilepsy patients with a clinical stage of epilepsy
(CSE), but without PD on the routine EEG, 34 patients with CSE and
PD. The power spectrum of the theta rhythm envelope were calculated
for monopolar EEG on the 3 min recoding devoid of PD. Power spectrum
form had the appearance of 1/fβwhere f = frequency, β = fractal index.
Fractal indexes were calculated within the range of low-frequency (β1)
and medium-frequency (β2) fluctuations of the theta rhythm amplitude.
Results: In case of discovery of paroxysms on the EEG in epilepsy,
a sharp change of the theta activity fractal characteristics more marked
with β2 takes place. The appearance of PD in epilepsy leads to that
in the range of the theta rhythm. The values of β1 reach the greatest
magnitudes in F3, F4, C3, F7, F8 and T3 as compared with all other
groups of examinees (p < 0.05). The same changes occur with the values
of β2, but already over all the cortical areas (p < 0.01).
Conclusion: Thus, increase in stability, and regularity and decrease
in complexity of the theta rhythm represent an indicator of a high prob-
ability of paroxysms appearance, a precursor of the development of PD
on the EEG.
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ACHIEVING SLEEP STATE DURING EEG IN CHILDREN: SE-
QUENCE OF ACTIVATION PROCEDURES
J. Kaleyias, S. Kothare, M. Pelkey, H. Geofrey, A. Legido, and D. Khu-
rana (Division of Child Neurology, Department of Pediatrics, St Christo-
pher’s Hospital For Children, Philadelphia, USA)
Purpose: Hyperventilation (HV) during an EEG is often followed
by drowsiness. The effect of intermittent photic stimulations (IPS) on
awake/sleep state is unclear. The current study was conducted to deter-
mine if the sequence of activation procedures have an impact on acqui-
sition of sleep during a routine, non–sleep deprived EEG.
Method: Children, scheduled between 9 to noon, who were not sleep
deprived and able to hyperventilate, were included in a 3-month prospec-
tive study undertaken at the Neurophysiology Laboratory of a tertiary
children’s hospital. In the first 48 children evaluated, IPS was started 5
minutes into the EEG recording and HV was elicited at the end of the
session (group I). For the next 48 children, HV was started 5 minutes
into the EEG recording and IPS were presented at the end of the EEG
(group II). Both groups were assessed for the presence or absence of
sleep during their EEG recording.
Results: Only 3 of the 48 (6.2%) children in group I versus 17/48
(35.5%) in group II attained sleep (p < .0001, OR = 8.68, 95% CI 2.34-
32.22). Therefore, the children who hyperventilated at the beginning of
the session had an 8-fold increase chance to attain sleep in comparison
with children who received IPS at the beginning of the recording followed
by HV at the end.
Conclusion: We recommend that when performing routine non-sleep
deprived EEGs in children, HV be performed first with IPS at the end
of the EEG in order to maximize the yield of attaining sleep recording
during the study.
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HYPNOGENIC PAROXYSMAL DYSTONIA: DOES IT EXIST?
M. Cenusa, I. Mothersill, A. Bauerfeind, and G. Kra¨mer (Swiss Epilepsy
Centre, Zu¨rich, Switzerland)
Purpose: Nocturnal or hypnogenic paroxysmal dystonia (HPD) are
rarely reported complex motor attacks occurring abruptly during sleep,
especially NREM sleep. The existence of HPD as a distinct nosological
entity has been the cause of much discussion. Many authors consider
these nocturnal motor attacks to be frontal lobe epileptic seizures (FLS).
In many of the patients presented to support the hypothesis that HPDs are
in fact FLS the dystonia is mostly only a minor part of what is obviously
an epileptic seizure and should not be a point of discussion. The majority
also have in addition to their nocturnal “dystonic” attacks, seizures of
obvious epileptic origin or epileptiform activity in the interictal EEG.
However, patients do exist who experience pure HPD that show no other
semiology which would relate them to FLS. In the EEG during such
episodes the typical delta arousals pattern that is otherwise associated
with NREM parasomnias is seen.
Method: A retrospective review was made of all patients who were
referred for unclear nocturnal events. All night polysomnographic-video
EEG recordings were performed utilising all 10–20 electrodes.
Results: We found a total of 12 patients who had pure nocturnal
dystonic attacks, during which the EEG showed delta arousals. On com-
plete awakening the semiology abruptly ceased. There was no additional
semiology that would support a diagnosis of epilepsy.
Conclusion: Our findings support the fact that HPD as a distinct
nosological entity does exist. We suggest that it be considered, in analogy
to confusional arousals, an incomplete motor awaking with associated
delta arousal in the EEG.
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POSTLESION FOCAL NEOCORTICAL EPILEPSY IN HU-
MANS: THE ROLE OF THE BLOOD–BRAIN BARRIER
1O. Tomkins, 1,4A. Korn, 1,2A. Friedman, 2A. Cohen, and 3I. Shelef
(1Department of Physiology, Ben Gurion University of the Negev, Beer-
Sheva, Israel, 2Department of Neurosurgery, Soroka University Medi-
cal Center, Beer-Sheva, Israel, 3Department of Neuroradiology, Soroka
University Medical Center, Beer-Sheva, Israel, 4Department of Pediatric
Neurosurgery, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel)
Purpose: Recent studies in experimental animals suggest that lesions
of the blood–brain barrier (BBB) play a key role in the pathogenesis of
focal neocortical epilepsy (Seiffert et al., J Neurosci 2004;24:7829–36).
The purpose of the present study was to evaluate possible correlations
between areas of enhanced BBB permeability and areas with abnormal
neocortical electrical activity in human patients suffering from lesion-
related seizures.
Method: Included in this study were patients with mild-moderate
blunt head trauma. Patients underwent standard magnetic resonance
brain scan sequences, as well as dynamic studies aimed at evaluating
the integrity of the BBB. In addition, a postgadolinium T1 sequence was
used to evaluate statistically significant changes in cortical signal, sug-
gesting diffusion of the contrast material across an altered BBB. EEG
was recorded from subjects using a clinical EEG unit (CEEGRAPH
IV, Bio-logic Systems Corp., Mundelein, Illinois). Areas of aberrant
power spectra slowing and interictal like events were localised using
low resolution electrotomography (LORETA) and statistical parametric
mapping.
Results: Increased BBB permeability following focal brain trauma
can be measured and localised in the neocortex. In some cases BBB per-
meability may last up to several months following the traumatic event.
In ca. 30% of the patients (n = 21) examined under this study, spa-
tial correlation was found between regions with enhanced BBB perme-
ability and regions with localised focal cortical slowing or inter-ictal
activity.
Conclusion: Our data suggest that a prolonged increase in BBB per-
meability following head trauma may be associated with abnormal, hy-
persynchronised neocortical activity, perhaps predisposing to epileptic
seizures.
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INTEROBSERVER RELIABILITY OF VIDEO-
POLYSOMNOGRAPHIC DIAGNOSIS OF NOCTURNAL
FRONTAL LOBE SEIZURES
F. Bisulli, L. Vignatelli, F. Provini, F. Pittau, I. Naldi, A. Zaniboni, P.
Montagna, and P. Tinuper (Department of Neurological Sciences, Bol-
gna, Italy)
Purpose: The diagnosis of nocturnal frontal lobe epilepsy (NFLE)
is mainly based on video-polysomnographic examination. Paroxysmal
sleep-related disturbances distinguishing NFLE are characterised by
one or all of the following movement-related subtypes: 1) paroxys-
mal arousals (PA–brief and sudden recurrent motor paroxysmal be-
haviour), 2) supplementary motor area seizures (SMAs–motor attacks
with dystonic features), 3) hypermotor seizures (HMs–motor attacks
with complex dyskinetic features) 4) episodic nocturnal wanderings
(ENW–stereotyped, agitated somnambulism). The aim of this study was
to estimate interobserver reliability of video-polysomnographic diag-
nosis in patients with suspected NFLE among sleep medicine experts,
experts in epileptic disorders and trainees in sleep medicine.
Method: Sixty-six patients referred to our sleep centre for suspected
NFLE were included. All underwent nocturnal video-polysomnographic
recording. Six doctors (3 residents and 3 trainees) independently classi-
fied each case as “NFLE ascertained” (according to the above specified
subtypes: PA, SMAs, HMs, ENW) or “NFLE excluded.” Interobserver
reliability was calculated by means of Kappa statistics, and interpreted
according to standard classification (0.0–0.20 = slight agreement; 0.21–
0.40 = fair; 0.41–0.60 = moderate; 0.61–0.80 = substantial; 0.81–1.00
= almost perfect).
Results: The observed raw agreement on the diagnosis of NFLE
ranged from 63% to 79% between each pair of raters; the interobserver re-
liability ranged from “moderate” (kappa = 0.50) to “substantial” (kappa
= 0.72). The major source of variance was the disagreement in inter-
preting arousal movements as PA or not. There were no differences in
the level of agreement between residents and trainees.
Conclusion: Among sleep medicine/epileptologist residents and
trainees, interobserver reliability of diagnosis of NFLE on the basis
of videotaped observation of sleep motor phenomena is not satisfac-
tory. One of the sources of variance is probably the interpretation of
motor phenomena resembling simple arousals or PA. Explicit video-
polysomnographic criteria for the classification of paroxysmal sleep mo-
tor phenomena are needed.
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CLINICAL, MRI AND DIPOLE LOCALISATION ANALYSIS IN
DIFFERENT SUBTYPES OF MALFORMATIONS OF CORTI-
CAL DEVELOPMENT (MCD)
1,2S. Kochen, 1,3C. Papayannis, 1,3H. Laforcada, 1D. Consalvo, 1W.
Silva, 4J. San Martin, 4N. Von Elleniueder, and 4,2C. Muravchik
(1Epilepsy Center, Hosp “R.Mejia,” School Medicine, Univ Buenos
Aires, Argentina, 2CONICET, Buenos Aires, Argentina, 3Health Sec-
retary Buenos Aires City, Argentina, 4School Engineering, University
La Plata, Argentina)
Purpose: MCD represent the second cause of refractory epilepsy in
adults. Clinical, epidemiological and localisation of the epileptogenic
zone, through dipole localisation of the different subtypes, were com-
pared.
Method: For dipole localisation, our work group developed software
that allowed optimisation of the application of Polhemus and BESA.
The EEG (10-10 system) were obtained for 3 hours with 64 channels
(Stellate). The patients were divided in 3 groups: G1: abnormal prolif-
eration (cortical focal dysplasia and neoplasias), G2: abnormal migra-
tion (heterotopias), and G3: abnormal organization (polymicrogyria).
We analysed different variables, particularly the occurrence of gradient
of divergence (GD) clinical-MRI-dipole localisation.
Results: We included 80 patients. The significance data, in G1
(n = 40): women 42.5%, neurological deficit (ND) 7.5%, GD 12.5%. G2
(n=24): women 75%, ND 8.3%, GD 16.7%. G3 (n=16): women 43.7%,
ND 75%, GD 31.2%.
Conclusion: We found between the subtypes of MCD a significant
difference in relation to sex, women’s majority in G2, neurological deficit
in G3. And we observed a gradient of divergence minor in G1 and most
important in G3, corresponding with the worst postsurgical prognostic in
the last group. The clinical information, MRI and the source localisation
methods proved useful in distinguishing the differences and the prognosis
in the patients with MCD.
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DYNAMIC CHANGES OF ICTAL HIGH FREQUENCY OSCIL-
LATIONS IN NEOCORTICAL EPILEPSY: USING MULTIPLE
BAND FREQUENCY ANALYSIS
1A. Ochi, 1H. Otsubo, 1K. Imai, 1E. Donner, 2J. Rutka, and 1C. Snead
(1Division of Neurology, The Hospital for Sick Children, Toronto,
Canada, 2Division of Neurosurgery, The Hospital for Sick Children,
Toronto, Canada)
Purpose: To characterise the spatial and temporal course of ictal high
frequency oscillations (HFOs) recorded by subdural EEG in children
with intractable neocortical epilepsy.
Method: We retrospectively studied 9 children (4 girls and 5 boys, 4 to
17 years) who presented with intractable extrahippocampal localisation-
related epilepsy and underwent extraoperative video subdural EEG and
cortical resections. We performed multiple band frequency analysis
(MBFA) to evaluate the frequency, time course and distribution of ictal
HFOs. We compared ictal HFO changes before and after clinical onsets,
and postsurgical seizure outcomes.
Results: Seventy-eight of 79 seizures presented HFOs. MBFA distin-
guished multiple band and sustained single band HFOs. Three patients
with partial seizures alone and 4 with epileptic spasms showed mul-
tiple band HFOs. Three patients with partial seizures with secondary
generalisation had multiple band HFOs before clinical onset and follow-
ing sustained single band HFOs after clinical onset. In 4 patients with
postoperative seizure freedom, there were more electrodes with HFOs
and faster HFOs inside the resection area than outside both before and
after clinical onsets. In 5 patients with residual seizures, after clinical on-
sets, there were more electrodes with HFOs and faster or equal frequency
of HFOs outsides.
Conclusion: In partial seizures with secondary generalisation, multi-
ple and sustained single band ictal HFOs were confined to a small area.
In partial seizures alone and epileptic spasms, multiple band HFOs were
presented in a larger area. When the surgical resection included all ic-
tal HFOs present throughout the seizure, post-surgical seizure freedom
was obtained. The area of confined ictal HFOs correlated to the discrete
epileptogenic zone.
p426
INTRACRANIAL ELECTROPHYSIOLOGICAL FINDINGS
SUGGESTING PRIMARY EPILEPTOGENIC REGION IN
NONLESIONAL SECONDARY GENERALISED EPILEPTIC
ENCEPHALOPATHY
1S. Eun, 1B. Eun, 2J. Seo, and 2H. Kim (1Department of Pediatrics, Col-
lege of Medicine, Korea University, Seoul, South Korea, 2Department of
Pediatrics, Yonsei University College of Medicine, Severance Hospital,
Seoul, South Korea)
Purpose: To characterise electrophysiological features suggesting pri-
mary epileptogenic region to differentiate from irritative zone in non-
lesional secondary generalised epileptic encephalopathy.
Method: We retrospectively reviewed the long-term intracranial
EEG’s in 6 patients of nonlesional infantile spasm or Lennox-Gastaut
syndrome, who became seizure free after surgery. We compared the ictal
and interictal characteristics differentiating the primary epileptogenic
region from the secondary irritative area by visual review for 10 ran-
domised 2 minutes of interictal recordings during patient’s non-REM
sleep.
Results: 1) Interictal features such as repetitive spikes, paroxysmal
fast activities, high voltage rhythmic sharp and slow wave discharges,
electrodecrements, and interictal localised rhythmic slow waves are sig-
nificantly prominent in the primary epileptogenic region. 2) Localised
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paroxysmal fast activities are the most significant finding for localising
the epileptogenic region. 3) The frequency of isolated spike activities
are not significantly different between these areas. 4) Ictal patterns of
repetitive spasms or atonic seizures were repetitive spiking, rhythmic
sharp and waves, or paroxysmal fast activities followed by slow waves
or electrodecrements. 5) All these ictal features were significantly more
prominent in the primary epileptogenic region.
Conclusion: Interictal findings such as repetitive spikes, paroxys-
mal fast activities, high voltage rhythmic sharp and slow wave dis-
charges, electrodecrements, and localised slow rhythmic waves as well
as more prominent ictal features in intracranial EEG recording can be
critical electrophysiological features to determine the primary epilep-
togenic region in nonlesional cases of secondary generalised epileptic
encephalopathy.
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POSTERIOR ALPHA RHYTHM IS ACTIVATED BY DISAP-
PEARANCE OF A VISUAL FIXATION STIMULUS
1G. Mo¨ddel, 2G. Kalamangalam, 1M. Viehoff, 1F. Bo¨sebeck, and 1S.
Evers (1Klinik und Poliklinik fu¨r Neurologie, Universita¨tsklinikum
Mu¨nster, Germany, 2Department of Neurology, Southern General Hos-
pital, Glasgow, UK)
Purpose: Activation and suppression of the posterior alpha rhythm
(AR) by eye closure and opening is a commonly known phenomenon.
The underlying neurophysiological mechanisms are not clear. This study
investigates the relationship between AR and fixation.
Method: 10–20-EEG was recorded from healthy individuals (n =
8). Via a monitor (dark room) subjects were presented black objects on
white background for 5sec: (1) randomly distributed small squares (0.6◦
size), (2) regularly distributed small squares (0.6◦), (3) large squares
(6◦), (4) large diamonds (6◦). Following each object, a homogenous
light-grey screen was presented for 5 sec. Screen luminance remained
constant throughout the experiment. The protocol was repeated with fix-
ation eliminated by Frenzel lenses. The amplitude of AR (peak-to-peak,
O1-T1/O2-T2) was determined for the first (S1) through fifth seconds
(S5) following object disappearance. Statistical comparisons were made
using Wilcoxon’s test.
Results: AR was present in all individuals. During object presen-
tation, AR was suppressed. Disappearance of objects (presentation of
grey screen) resulted in AR activation (ARA). There was no correlation
with eye blinks. ARA was more robust after disappearance of larger
(3.4), compared to smaller objects (1.2): average amplitudes 64 μV and
24 μV (p < 0.05). After disappearance of larger objects, AR was more
pronounced in S1, compared to S5 (p < 0.05). Eliminating fixation abol-
ished ARA.
Conclusion: Eye closure is not required for ARA. AR can be gen-
erated while a subject is looking at a homogenous bright background.
AR is facilitated by a sudden disappearance of structured visual input.
Disappearance of large objects leads to more robust ARA than disap-
pearance of smaller objects. ARA is abolished when visual fixation is
eliminated.
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DESCRIPTIVE ELECTROENCEPHALOGRAPHIC STUDY OF
EYELID MYOCLONUS
1M. Centeno, 2M. Sueiras, 2R. Rovira, 1M. Toledo, 1M. Quintana, 2M.
Gratacoss, 2A. Ferrer, 3A. Donaire, 1M. Edo, 1J. de Francisco, 1J.
Sumalla, and 1M. Molins (1Neurology Department, Hospital, Vall De
Hebron, Spain, 2Neurophysiology Department, Hospital Vall De He-
bron, Spain, 3Epilepsy Unit, Hospital Clinic Barcelona, Spain)
Purpose: Epileptic eyelid myoclonia (ELM) are repetitive and short
shakes of palpebral muscles with simultaneous epileptiform discharges
on surface EEG. ELM is a frequent manifestation of epileptic myoclonus
and has been described associated to different brain pathologies. Epilep-
togenic zone location and physiopathology of ELM are still controver-
sial. Trying to contribute to ELM knowledge, we describe the clinical
features and EEG characteristics of a population with ELM.
Method: We reviewed patients with epileptic or other brain disorders
whose main symptom was ELM.
Results: Our study population (29 patients: mean age: 25.1 ± 5; 55%
female) had heterogeneous disorders: 20% juvenile myoclonic epilepsy,
20% absence, 20% symptomatic epilepsy, 10% generalised criptoge-
netic; 7% Lennox-Gastaut, drug induced seizures and Lance-Adams;
3% West, Angelman’s and progressive myoclonic epilepsy. Most pa-
tients had generalised seizures (85%). ELM was associated to simul-
taneous segmentary or generalised myoclonia (32%). ELM most com-
mon triggers were hyperpnoea (39%) and wake-up (35%). EEGs showed
generalised synchronous spikes, polyspike and sharp waves of variable
duration (0.5 to 58 seconds), predominantly over frontocentral areas
(80%). 33% of patients showed impairment of consciousness related to
the duration of the epileptic discharges (p = 0.003) and independently
of pathologic background activity, absence of alpha rhythms.
Conclusion: Generalised EEG patterns were the most electroen-
cephalographic features associated to ELM. Impairment of conscious-
ness in patients with ELM was associated to long EEG generalised dis-
charges, independently from the background activity or the underlying
pathology. Participation of oculomotor nerves and the occasional loss of
consciousness suggest the involvement of brainstem and reticular ascen-
dant system in the genesis of ELM.
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TMS IN TREATMENT OF DEPRESSION: AN ATTEMPT AT EX-
PLAINING THE POOR EFFECTIVENESS OF THE METHOD
1T. Zyss, 1A. Zieˆba, 1D. Dudek, 2A. Krawczyk, 3B. Sawicki, 1M. Siwek,
1A. Wro´bel, 1W. Datka, 1B. Grabski, and 1G. 1Mczka (1Department
of Psychiatry, CMUJ, Krako´w, Poland, 2CIOP, Warszawa, Poland,
3Warsaw University of Technology, Warsaw, Poland)
Purpose: In 1992, Zyss suggested the application of prolonged rapid-
rate transcranial magnetic stimulation as an alternative to electroconvul-
sive therapy.
Method: TMS was regarded as the method that could bring about an
antidepressant effect without evoking seizures.
Results: In our own examinations 18 patients with a diagnosis of de-
pressive disorders were subjected to rTMS (1.5T, 5 Hz, 5 min, n = 8–10;
left DLPF cortex). The effects of therapy in the rTMS group were com-
pared with those obtained in the groups receiving only pharmacotherapy
and those treated with pharmacotherapy and ECT.
The effects in the rTMS group were similar to those in pharmacother-
apy group. The ECT treatment resulted in a significant acceleration of
recovery–disappearance of depressive symptoms. In a subsequent 2 pa-
tients a different frequency parameter was applied (50 Hz). In both pa-
tients generalised discharges in EEG were observed during the first stim-
ulation, causing termination of the experiment.
Conclusion: The results confirm that antidepressant effects of non-
convulsive TMS are little or absent. Application of higher parameters
(frequency) of the magnetic field may induce a seizure, i.e., the effect
that was initially to be avoided. The seizure seems to be a condition sine
qua non of an effective antidepressant therapy.
Our computed model investigations confirm that the density of the
stimulating current in ECT technique is significantly higher (10–100×)
than in TMS technique. Increasing both the amplitude of the magnetic
field and its frequency seems extremely difficult from the construction
point of view. Neither does it seem that we could expect any special
advantages of a seizure obtained in magnetic stimulation as compared
to one obtained in ECT.
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STUDY OF EVENT-RELATED POTENTIALS (ERP) IN PATIENT
WITH PARTIAL EPILEPSY (PE)
A. Lebedeva, T. Mitrokhina, I. Kovaleva, and I. Lusnikova (Russian State
Medical University, Russia)
Purpose: To evaluate the auditory ERP (P300) in patients with partial
epilepsy.
Method: Auditory P300 was analysed in 64 patients with PE (age
36.09 ± 9.63 years). Forty-four patients had uncontrolled seizures, 20
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patients were seizure-free. Fifteen healthy volunteers were also included
as controls. All the patients with PE were diagnosed as having epilepsy
according to the criteria of Commission on Classification and Termi-
nology of the International League against Epilepsy. All patients were
using antiepileptic drugs. All patients and controls were administrated
the Mini-Mental State Examination.
Results: P300 amplitudes at Pz were higher in patients with epilepsy
(11.59 ± 5.84 uV) than in the control group (5.76 ± 4.18 uV) (p < .05). P
300 latency also were higher in patients with epilepsy (392.26±59.14 ms
and 315.84 ± 92.43 ms, p < .05). The mean P300 latency in patients with
uncontrolled seizures (391.16 ± 47.14 ms) was significantly prolonged
compared with that of seizure-free patients (335.14 ± 52.53 ms) (p <
.05). However, P 300 amplitudes decreased in the group of patients with
uncontrolled epilepsy (6.65 ± 3.72 uV) compared with the seizure-free
group (10.16 ± 4.18) (p < .05).
Conclusion: The effects of antiepileptic drugs on P300 latency pro-
longation have been intensively studied and controversial results have
been reported. The results of our study suggest that prolongation of P300
latency in patients with resistant epilepsy possibly depends on higher
doses of antiepileptic drugs in this group.
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LATERALISATION OF CHANGES IN EEG PATIENTS SUFFER-
ING FROM EPILEPSY AND PSYCHOSOMATIC REACTIONS
D. Mrakovic (Institute For Neuropsychiatric Diseases, Belgrade, Serbia
and Montenegro)
Purpose: A pilot examination of psychosomatic reactions in patients
suffering from epilepsy in relation to the lateralisation of changes in
EEG.
Method: We used Lu¨sher short colour test (LCT) and analysed psy-
chosomatic reactions of 15 patients suffering from epilepsy, then we
compared results with changes in EEG.
Results: Patients of both sexes (11 females and 4 males), aged between
20 and 63 years, had the following lateralisation of EEG changes: left, 8
patients (LCT showed psychosomatic reactions for all of them), right, 4
(for 3 of them LCT did not show psychosomatic reactions), generalised
EEG changes:3 patients (LCT did not show psychosomatic reactions in
any of them).
Conclusion: The sample was small, but we noticed that patients suf-
fering from epilepsy with changes in EEG left, showed a tendency to
psychosomatic reactions and that the patients with changes in EEG right
and generalised did not show a tendency to psychosomatic reactions. We
are inclined to think that the LCT makes it possible to follow a relation-
ship between lateralisation of changes in EEG patients suffering from
epilepsy with psychosomatic reactions.
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INTEREST OF SYSTEMATIC HYPERVENTILATION DURING
EEG-VIDEO MONITORING FOR PRESURGICAL EVALUA-
TION OF DRUG-RESISTANT TEMPORAL LOBE EPILEPSY
(TLE)
B. Godet, P. Tapie, M. Tuillas, M. Khalil, and J. Vallat (Department of
Neurology, University Hospital, Limoges, France)
Purpose: Hyperventilation (HV) is an activation method that pro-
vokes physiological slowing of brain rhythms, interictal discharges and
seizures, especially in generalised idiopathic epilepsies. The aim of this
study was to assess the effectiveness of HV in inducing temporal seizures
during video-EEG monitoring in drug-resistant TLE patients.
Method: We included 4 patients with medically intractable temporal
lobe epilepsy in our study. Patients performed HV for 4 minutes, 5 times
daily. Interictal epileptic discharges (ED) during HV were evaluated
according to Celesia and Paulsen criteria (Arch Neurol 1972;27:361–
363). Antiepileptic drugs were progressively tapered during monitoring.
All patients underwent brain MRI, SPECT and FDG PET to localise the
epileptogenic zone.
Results: Only 1 patient had increased frequency of ED during HV.
There was a greater activation of ED in sleep stage II than during HV (2
patients of 4). Five of the 9 recorded seizures occurred during HV. Three
patients had positive seizure activation.
HV induced seizures occurred earlier than spontaneous seizures in
the video-EEG recording. Most spontaneous seizures took place in the
morning, whereas most activated seizures occurred during the afternoon.
Spontaneous and activated seizures were clinically similar.
Conclusion: HV seems to be a safe and effective method of seizure ac-
tivation in temporal lobe epilepsy during EEG monitoring. Sleep seems to
be more interesting in the diagnosis step (inducing interictal discharges),
whereas HV is useful for localisation of the epileptogenic zone by in-
ducing seizures. HV could help to shorten this presurgical evaluation,
thus facilitating access of candidates to epilepsy surgery.
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MORNING SESSION RECORDING INCREASES THE SENSI-
TIVITY OF THE EEG IN PATIENTS WITH JUVENILE MY-
OCLONIC EPILEPSY (JME)
1,2A. F. Labate, 1R. Ambrosio, 1M. Sturniolo, 1E. Colosimo, 1U. Leggio,
1F. Pucci, 1,2A. Quattrone, and 1,2A. Gambardella (1Institute of Neurol-
ogy, University Magna Græcia, Catanzaro, Italy, 2Institute of Neurolog-
ical Sciences, National Research Council, Mangone, Cosenza, Italy)
Purpose: In each laboratory of neurophysiology the EEG can be
recorded in either morning or afternoon sessions. Both myoclonic and
generalised tonic–clonic seizures in patients with JME have a typical
circadian pattern; they occur almost exclusively on or soon after awak-
ening. In this study we evaluated whether the EEG abnormalities follow
the same clinical circadian pattern.
Method: We recruited 29 consecutive epilepsy patients (23 females,
mean age 22.3± 6.3yr; age at onset 15.7 ± 3.5yr) from August 2004 to
August 2005 referred to our clinic. All patients received a diagnosis of
JME. In detail, 5 patients were untreated, 23 were taking a monotherapy
(8 lamotrigine, 9 valproate, 6 levetiracetam), and only 1 was taking a
bitherapy (valproate and phenobarbital). Two interictal EEGs acquired
during the same day at 9 a.m. and at 3 p.m. were reviewed in each
subject. The interictal EEG investigation was a routine awake with no
sleep deprivation and without withdrawing medications.
Results: In 22/29 patients (76%) the morning recording showed
epileptiform abnormalities (general spike and waves (GSW), photo-
sensitivity response (PPR), only PPR). In these patients the afternoon
recording was normal (18/22; 82%), or showed dramatic reduction of
the epileptiform abnormalities (4/22). Overall 25 patients out of 29 had
normal EEG during the afternoon session (p < 0.001).
Conclusion: We found that in patients with JME a morning EEG
recording is more sensitive to detect epileptiform abnormalities than the
afternoon recording. Therefore, our results suggest that EEG features
follow the same circadian pattern as clinical features.
p434
EPILEPTIC ACTIVITY IN TWO CHILDREN WITH PRENATAL
UNILATERAL BRAIN INFARCT AND CSWS: AN EEG SOURCE
IMAGING STUDY
1M. Maeder-Ingvar, 2G. Lantz, 3C. Mayor-Dubois, 2M. Seeck, 2C.
Michel, and 3E. Roulet-Perez (1Department of Neurology, Lau-
sanne, Switzerland, 2Department of Neurology, Geneva, Switzerland,
3Department of Pediatry, Lausanne, Switzerland, 4Department of Neu-
rology, Geneva, Switzerland, 5Department of Neurology, Geneva,
Switzerland, 6Department of Pediatry, Lausanne, Switzerland)
Purpose: Electrical source imaging (ESI) was used to study 2 chil-
dren with a MCA infarct and early epilepsy (7 and 32 months). Case
1 developed right parietal-occipital activity and right sided CSWS at
5 years. Case 2 developed at age 4 left central-parietal epileptic and
frontal-central epileptic activity and generalised CSWS.
Method: Several single spike wave complexes, selected from standard
EEG, were analysed using a distributed linear inverse solution in the pa-
tients own magnetic resonance. Then a statistical parametrical mapping
approach was used to determine which areas were significantly more
active during the different phases of the spike wave complex compared
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to a baseline period. In this way a measure over time of spike propagation
could be obtained.
Results: Case 1: ESI showed right occipital activity with propagation
to the right hemisphere parietal, temporal and frontal region, correlating
with attention deficit and stagnation of visual-spatial skills. Case 2: ESI
showed left parietal-occipital activity with propagation to the left frontal
and central regions and right temporal, frontal-temporal and parietal
regions, correlating with severe mental deterioration.
Conclusion: In these 2 cases, with similar lesions but very different
clinical pictures, interictal ESI, showed different propagation patterns of
epileptic activity that seemed to correlate with the neuropsychological
evolution. FNS grant number 3200–068105.
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LOCALISATION OF THE NEOCORTICAL EPILEPTIC FOCUS
FROM SEIZURE-FREE SUBDURAL EEG BY ANALYSIS OF
LONG-RANGE TEMPORAL CORRELATIONS
1S. Monto, 1S. Vanhatalo, 2M. Holmes, and 3M. Palva (1Helsinki Uni-
versity Central Hospital, Helsinki, Finland, 2University of Washington,
Seattle, Washington, USA, 3University of Helsinki, Helsinki, Finland)
Purpose: Video-EEG monitoring is a standard procedure for presur-
gical evaluation of localisation-related epilepsies. Long-term intracra-
nial recordings, however, often involve significant burdens to patients
and health care. We tested whether the neocortical epileptogenic area
could be circumscribed by analysing the temporal properties of ongoing
seizure-free EEG activity.
Method: We recorded 5 neocortical epilepsy patients with subdural
grids during 20 min rest period. Detrended fluctuation analysis (DFA)
was applied to quantify long-range temporal correlations (LRTC). We
compared the distribution of LRTCs to seizure foci found with standard
clinical methods, and confirmed by postsurgical outcome. Two patients
were remeasured after administering 2 mg of lorazepam, a widely used
antiepileptic drug.
Results: We found that the LRTCs are stronger at the focus of seizure
onset than in surrounding cortical areas. The effect was most salient in
ß-frequency band (significance for correlation of LRTC vs distance-to-
focus: p = 0.009 ± 0.015, n = 5). Additionally, we found that lorazepam
otherwise increases LRTCs, but selectively decreases the ß-band LRTC
in the area of the epileptic focus.
Conclusion: Our findings show that the brain activity close to the
epileptic focus presents abnormally strong temporal correlations during
seizure-free periods, and suggest that LRTC analysis may be utilised as
an additional tool in focus localisation efforts. The observations are cor-
roborated by the finding that the seizure-preventing effect of lorazepam
is reflected in focal decay of LRTC. This decorrelation originates in re-
normalisation of local network activity. Our approach may also open new
possibilities for noninvasive localisation of seizure foci with electro- and
magnetoencephalography.
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TOPOGRAPHIC MOVIE OF ICTAL HIGH-FREQUENCY OS-
CILLATIONS ON THE BRAIN SURFACE USING SUBDURAL
EEG IN NEOCORTICAL EPILEPSY
1H. Otsubo, 1T. Akiyama, 1A. Ochi, 1E. Donner, 2J. Rutka, and 1C.
Snead (1Division of Neurology, The Hospital for sick Children, Toronto,
Canada, 2Division of Neurosurgery, The Hospital for Sick Children,
Toronto, Canada)
Purpose: To understand the rapid dynamic changes of ictal intracra-
nial high-frequency oscillations (HFOs) in neocortical epilepsy.
Method: We integrated multiple band frequency analysis and brain-
surface topographic maps of HFOs from ictal subdural EEG (SDEEG)
recordings. We used SDEEG to record partial seizures consisting of
right arm jerks with secondary generalisation in a 17-year-old right-
handed girl. We selected 20-second EEG sections that included pre-
clinical seizure recordings. We averaged the HFO power between 60–
120 Hz for 25 selected electrodes, made topographic maps from these av-
eraged powers, and superimposed the maps on the brain-surface image.
We filmed consecutive HFO maps at a 10 ms frame rate.
Results: Before clinical seizure onset, high-power HFOs emerged at
the superior portion of the left precentral gyrus, then appeared in the
middle of the left postcentral gyrus, and subsequently reverberated be-
tween both regions as well as the posterior portion of the left postcentral
gyrus. Right arm extension and facial grimacing started as the HFO
power decreased. As generalised tonic–clonic seizures evolved, HFO
power increased but remained within the central region.
Conclusion: Topographic movies of intracranial HFOs on the brain
surface allow visualisation of the dynamic ictal changes in neocortical
epilepsy.
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ANATOMICAL DEGENERATION AND FUNCTIONAL DETE-
RIORATION IN THE RAT EPILEPTIC CORTEX
O. Friedman (Zlotowsky Center of Neuroscience Ben Gurion University,
Beer Sheva, Israel)
Purpose: Recent studies in experimental animals have shown that le-
sions of the blood–brain barrier (BBB) in the rat neocortex may lead to
focal epileptiform activity (Seiffert et al., J Neurosci 2004;24:7829–36).
The purpose of the present study was to evaluate molecular, anatomi-
cal and functional long-term alterations in the BBB-disrupted epileptic
neocortex.
Method: BBB disruption (using bile salts) or sham operation was
performed on the motor cortex of 85 adult male Wistar rats. Animals
were followed for up to 11 months, and were tested repeatedly for motor
and behavioural capabilities. Epileptiform activity was recorded in the
in vitro slice preparation. Changes in specific neuronal and astrocytic
markers were identified using immunostaining and confocal microscopy.
Results: Epileptiform activity was recorded from the 4th day follow-
ing treatment. However, motor functions showed increasing deterioration
from the 4th week onwards. This was associated with a reduction in to-
tal cell numbers. Specifically, we found a reduced number of neurons
(immunolabelled with MAP2) together with fewer dendritic branching
(labelled with biotin). In addition, in GFAP labelled astrocytes, glu-
tamine synthase (GS) immunolabelling was significantly reduced both
in the neuropil and the perivascular area.
Conclusion: While epileptiform activity can be observed in the pres-
ence of an apparently anatomically intact cortex, with time it may be as-
sociated with neuronal damage and functional deterioration. Astrocytic
changes including reduced GS may play a role in neuronal excitotoxicity.
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SEIZURE IN TAKAYASU ARTERITIS AS A FIRST SYMPTOM
1I. Yavasoglu, 2A. Ozkul, 1G. Kadikoylu, 3K. Koseoglu, 1Z. Bola-
man, and 2A. Akyol (1Adnan Menderes University Faculty of Medicine
Hematology Department, Turkey, 2Adnan Menderes University Faculty
of Medicine Neurology Department, Turkey, 3Adnan Menderes Uni-
versity Faculty of Medicine Hematology Department, Turkey, 4Adnan
Menderes University Faculty of Medicine Radiology Department,
Turkey, 5Adnan Menderes University Faculty of Medicine Hematology
Department, Turkey, 6Adnan Menderes University Faculty of Medicine
Neurology Department, Turkey)
Purpose: Takayasu arteritis is a chronic granulomatous inflamma-
tory arteritis affecting large vessels, predominantly aorta and its main
branches. The symptoms of Takayasu arteritis are related with end organ
ischemia. The main clinical symptoms are weakness, fever, arthralgia,
skin rash, hypertension, intermittent claducation, cardiac diseases (car-
diac failure, valvular or ischemic heart disease, pulmonary hypertension,
pericarditis), and impaired renal functions. Cerebrovascular manifesta-
tions which can also be seen in Takayasu arteritis consist of transient
ischemic attack, stroke, hypertensive encephalopathy, spastic paraple-
gia, and elevated intracranial pressure. According to our knowledge,
convulsion is not commonly reported in this disease.
Method: A Case report.
Results: We wanted to present a 15-year-old girl with the diagnosis
of Takayasu arteritis. She was admitted to our hospital with generalised
seizures which had begun 15 months previously. She was healthy, and her
family history was unremarkable. Although no pathology was detected in
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neurological examination, brachial artery pulse was decreased and blood
pressure couldn’t be measured. High sedimentation and CRP levels were
also found. With detailed radiological diagnostic approaches, she was
diagnosed as Takayasu arteritis. After steroid therapy (1 mg/kg/day), her
complaints improved within 10 days.
Conclusion: Our patient is a rare case of Takayasu arteritis suffering
from seizures. Despite the well known characteristics of this disease, the
first symptom can be a convulsion.
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CORTICAL MOTOR EXCITABILITY IN UNVERRICHT-
LUNDBORG AND LAFORA DISEASE
L. Canafoglia, C. Ciano, P. Anversa, F. Panzica, C. Marelli, E. Visani, G.
Avanzini, and S. Franceschetti (Neurological Institute C. Besta, Milan,
Italy)
Purpose: To test cortical motor excitability in progressive myoclonus
epilepsy using transcranial magnetic stimulation.
Method: We assessed the cortical threshold in 10 patients with
Unverricht-Lundborg and Lafora types of progressive myoclonus
epilepsy and in a group of healthy subjects and we applied paired-stimuli
protocols aimed at evaluating short interval intracortical inhibition and
facilitation, as well long interval intracortical inhibition.
Results: Patients had a significant increase of cortical threshold
(Kruskal-Wallis test; p < 0.05). Short-interval intracortical inhibition
was reduced at all interstimulus intervals (ISI) and statistically different
from healthy subjects at 1 and 2 ms (p < 0.05). Lafora patients, but
not Unverricht-Lundborg patients showed a significantly decreased in-
tracortical facilitation at 10 ms ISI (p < 0.05). Long interval intracortical
inhibition was similar in patients and controls.
Conclusion: Paired magnetic stimuli protocols revealed a defect of
intracortical inhibition in all patients with progressive myoclonic epilep-
sies; however, Lafora patients only had an extensive impairment of the
intracortical modulation profile. These findings suggest a more severe
and widespread disruption of the cortical network in Lafora patients.
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ELECTROPHYSIOLOGICAL PROFILING OF BASAL AND
LATERAL AMYGDALOID NUCLEI NEURONS RESISTANT TO
STATUS EPILEPTICUS–INDUCED DAMAGE
S. Ka¨rkka¨inen, A. Pitka¨nen, and M. Penttonen (Department of Neuro-
biology, A. I. Virtanen Institute for Molecular Sciences, University of
Kuopio, Finland)
Purpose: To probe altered membrane properties of neurons resistant
to status epilepticus induced damage in kainic acid (KA) model by using
whole-cell patch-clamp technique.
Method: Amygdala-hippocampal projection was identified by inject-
ing retrograde axonal tracer Fluoro-Gold into the CA1/Subiculum. Eight
male Wistar rats were treated with kainic acid (10 mg/kg, i.p) and 5 with
saline. After 3 and 4 weeks coronal slices comprising amygdaloid com-
plex at 1.3–3.3 mm posterior to bregma were prepared. Target neurons
were identified by using fluorescence illumination, and whole-cell mea-
surements were performed in current-clamp mode. Nissl staining was
used to assess the injection site and the recorded nuclei. Six KA and
three control neurons were included.
Preliminary Results: The resting membrane potentials were
−65.6 ± 1.2 mV in KA and –64.5 ± 3.5 mV in control group indi-
cating that KA neurons were not depolarised/hyperpolarised compared
to control neurons. The maximum input resistance and steady-state re-
sistance were 159 ± 29 MOhm and 145 ± 30 MOhm in KA and 159
± 12 and 143 ± 15 in the control group; therefore passive membrane
potential responses did not differ between groups. Thresholds to rect-
angular currents were –49.9 ± 2.2 mV in KA and –56.6 ± 2.9 mV in
control, but changed during ramp current pulses to –38.3 ± 3.2 in KA
compared to –53.3 ± 1.8 (p < .05) in control.
Conclusion: The action potential threshold depends on the functional
history of the neuron. In KA neurons, the threshold was higher than in
control cells, indicating a change in sodium channel inactivation prop-
erties, which might help the neurons to endure the decreased inhibition
due to the loss of GABAergic interneurons.
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SUCCESSFUL SCREENING OF NEOCORTICAL EPILEPSY
USING ROUTINE MEG RECORDINGS
1P. Ossenblok, 1A. Colon, 2J. de Munck, 1W. Drolsbach, 1L. Nieuwen-
huis, and 1,3P. Boon (1Epilepsy Center Kempenhaeghe, Heeze, The
Netherlands, 2VU Medical Center, Amsterdam, The Netherlands,
3Ghent University Hospital, Ghent, Belgium)
Purpose: It is well known that the diagnosis of a large percentage
of the initial awake routine EEG records is inconclusive. In such cases
additional sleep deprived EEG is required. Since it has recently been
shown that in the case of neocortical epilepsy spike sensitivity is higher
for MEG then EEG, we investigated whether with optimal procedures for
screening and localising interictal epileptiform MEG discharges (MEG
spikes) additional EEG recordings could be avoided.
Method: Twenty eight (n = 28) patients with a suspicion of locali-
sation bound neocortical epilepsy whose routine EEG records were in-
conclusive underwent routine MEG recordings. This MEG was visually
reviewed following the standard procedures of the routine EEG records.
Furthermore, equivalent dipole analysis was applied, which enabled the
localisation of MEG spike clusters.
Results: Visual inspection of routine MEG records yielded for 17 of
the 28 patients studied (60.7%) ten or more detected interictal events.
For 15 of these patients (53.6%), the clustering algorithm revealed sub-
classes of spikes corresponding clearly to dipolar magnetic field maps.
Inverse computations applied on the selected spike subaverages yielded
anatomical plausible localisations for 8 of the patients studied (28.6%).
Conclusion: Although routine EEG records of the patients studied
were inconclusive, the MEG yielded a significant number of interictal
events in many of these patients. Moreover, a reliable categorisation
of these spikes was obtained or even a plausible localisation. How-
ever, further evaluation in relation to the patients’ epilepsy is needed
to decide whether routine MEG records may replace additional EEG
investigations.
p442
CORRELATION BETWEEN REGIONAL GLUCOSE
METABOLISM AND INTRAOPERATIVE ELECTROCOR-
TICOGRAPHY IN TEMPORAL LOBE EPILEPSY
1,2,3N. Akanuma, 3A. Valentin, 2,3M. Koutroumanidis, 4N. Adachi, 3L.
Reed, 3C. Martin Miguel, 2,3T. Adachi, 3P. Marsden, 3C. Binnie, 3C.
Polkey, and 3 G. Alarcon (1South London & Maudsley NHS Trust,
London, UK, 2St Thomas Hospital, London, UK, 3King’s College Lon-
don, London, UK, 4Adachi Mental Clinic, Sapporo, Japan)
Purpose: To determine the relation between cerebral regional
metabolism and epileptiform activity in patients with temporal lobe
epilepsy (TLE).
Method: We analysed interictal [18F]FDG-PET and rate of epilepti-
form discharges (ED) in the acute electrocorticography (ECoG) in 30
TLE patients who underwent standard anterior temporal lobectomy. We
correlated regional [18F]FDG uptake and ED rate in the hippocampus,
anterior and posterior infratemporal cortex by regions of interest (ROI)
and voxel-based statistical parametric mapping (SPM). Patients were
grouped into those with the highest ED rate at the hippocampus (group
H) and those with highest ED rate outside the hippocampus (group exH).
Results: Among all patients and in group H, there was no correlation
between ROI values from each structure and ED rates. In exH patients,
there was a positive correlation between the hippocampal ED rates and
ROI metabolic values in ipsilateral medial, lateral and infratemporal
areas, ipsilateral basal ganglia and thalamus bilaterally (r = 0.624 to
0.771, p < 0.05). SPM analysis showed correlations only in group exH,
between hippocampal ED rates and metabolic rates in ipsilateral amyg-
dala and anterior hippocampus, anterior portion of ipsilateral superior
and mid temporal gyri, and contralateral amygdala and hippocampus
(p < 0.001).
Conclusion: A positive correlation was found between ED and
metabolic rates in several ipsilateral temporal regions among patients
with the highest ED rate outside the hippocampus. This may be due
to increased surround inhibition. Correlations with metabolism in ipsi-
lateral temporal, subcortical regions and contralateral medial temporal
Epilepsia, Vol. 47, S3, 2006
116 7TH EUROPEAN CONGRESS ON EPILEPTOLOGY
structures may reflect the involvement of these structures in propagation
or generation of ED.
p443
INTRACTABLE FOCAL EPILEPSY DUE TO CORTICAL DYS-
PLASIA IS ASSOCIATED WITH INCREASED CORTICAL MO-
TOR THRESHOLD: A NAVIGATED BRAIN STIMULATION
STUDY
1L. Eskola, 1S. Ma¨a¨tta¨, 1S. Teitti, 1M. Ko¨no¨nen, 1,5J. Karhu, 2E.
Herrga˚rd, 3L. Jutila, 4A. Immonen, 3R. Ka¨lvia¨inen, and 1E. Mervaala
(1Department of Clinical Neurophysiology, Kuopio Epilepsy Center,
Kuopio University Hospital, Kuopio, Finland, 2Department of Child
Neurology, Kuopio Epilepsy Center, Kuopio University Hospital, Kuo-
pio, Finland, 3Department of Neurology, Kuopio Epilepsy Center, Kuo-
pio University Hospital, Kuopio, Finland, 4Department of Neurosurgery,
Kuopio Epilepsy Center, Kuopio University Hospital, Kuopio, Finland,
5Nexstim Ltd., Finland)
Purpose: Navigated brain stimulation (NBS) combines transcranial
magnetic stimulation (TMS) with accurate guidance by individual MRI.
NBS allows noninvasive study of local cortical inhibition-excitation.
Simultaneous EEG monitoring adds the safety required for studies of
epilepsy patients.
Method: We determined the motor threshold (MT) in 2 patients (Case
1: 11 y left-handed female, Case 2: 13 y right-handed male) with in-
tractable focal epilepsy due to a single area of cortical dysplasia beyond
primary motor cortices. Patients received normal individual AEDs. Op-
timal stimulation sites to activate abductor pollicis brevis muscle were
localised on the motor strip (M1) and MT for these sites was deter-
mined. MT was defined as the lowest stimulation intensity which elicited
a motor-evoked potential (MEP) of 0.1 mV or greater in surface EMG
for at least 4 out of 10 consecutive pulses. Single monophasic pulse was
delivered out with Magstim 200 via figure eight coil. Simultaneous EEG
recording was performed.
Results: Case 1: left hemisphere MT ipsilateral to seizure onset was
75% of maximum intensity, right MT was 43%. MTs on the seizure on-
set hemisphere were fluctuating during assessment. Case 2: right hemi-
sphere MT ipsilateral to seizure onset was 56% of maximum intensity,
left MT was 58%.
Conclusion: We found that MT is increased outside the actual seizure
onset zone. MT increase was marked only ipsilaterally to seizure onset
(Case 1), or was seen bilaterally (Case 2). Possible mechanisms include
remote effects of focal epileptogenic pathology (cortical dysplasia), very
active interictal epileptiform EEG activity (Case 1), and maximal toler-
ated AED dosages due to medical intractability.
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MEG DIPOLES FROM MESIAL TEMPORAL STRUCTURES IN
THE ABSENCE OF LATERAL TEMPORAL CORTEX
K. Imai, H. Otsubo, I. Mohamad, A. Ochi, and C. Snead (Division of
Neurology, The Hospital for Sick Children, Toronto, Canada)
Purpose: The lateral temporal cortex has a great influence on mag-
netoencephalography (MEG) because of the location between detecting
coils and mesial temporal structures. To reveal patterns of magnetic fields
from mesial temporal structures alone, we analysed temporal spike dis-
charges in a patient with intractable seizures secondary to porencephaly.
Method: We analysed mesial temporal discharges on MEG in a 12
year old boy with intractable epileptic seizures. MRI showed a left poren-
cephalic cyst of temporoparietooccipital regions including most of the
lateral and anterior temporal cortices but mesial temporal structures left.
We recorded 151 channels MEG (VSM MedTech. Canada) and simulta-
neous international 10-20 EEG. We analysed MEG dipoles, using MEG
single moving dipole models. We placed synthetic aperture magnetom-
etry virtual sensors (SAM-VS) in left mesial and lateral temporal struc-
tures to reconstruct the current density waveforms from MEG data.
Results: We captured MEG dipoles with two F7-T3 spikes (group-
A) and ten T5 spikes (group-B) on EEG. Dipoles were estimated in the
anterior mesiobasal temporal region with vertical orientation in group-A
and in posterior temporal basal cortex with vertical orientation in group-
B. SAM-VS analysis of group-A showed spikes on the adjacent area of
the hippocampus and fusiform gyrus.
Conclusion: By dipole modeling, Ebersole divided magnetic fields
of temporal spikes into 3 types including anterior temporal horizontal,
anterior temporal vertical (ATV) and posterior temporal vertical. ATV
dipoles are probably correlated to mesial temporal discharges including
basal temporal region in this case with left temporoparietal porencephaly.
SAM-VS projected mesial and basal temporal discharges associated with
these dipoles with vertical orientations.
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ICTAL TACHYCARDIA CAN BE USED FOR AUTOMATED
SEIZURE DETECTION DURING VIDEO-EEG MONITORING
B. Schreiner, B. Steinhoff, and C. Kurth (Epilepsy Centre Kork, Kork,
Germany)
Purpose: It is well known that temporal and extratemporal epileptic
seizures may cause a significant increase in heart rate. This shift in fre-
quency seems to precede the seizure onset in EEG up to several seconds.
The aim of this study was to demonstrate that computerised evaluation
of heart rate change can be used for automated seizure detection.
Method: 317 hours of EEG/ECG-recordings of 3 patients with focal
epilepsies of temproal or extratemporal origin were evaluated. A LAB-
VIEW based software measured the RR-interval in ECG continously.
If the heart rate was in a range between 120 and 230 beats per minute
for more than 15 heart beats a seizure was indicated. Seizure detections
within the next 2 minutes were ignored to prevent repeated signaling of
the same seizure. The results of the detection algorithm were compared
to evaluation of the video-EEG recordings. Sensitivity and rate of false
positives were calculated.
Results: Eight complex partial or secondary generalised tonic–clonic
seizures could be analysed. Sensitivity was 100% in 2 patients and 80%
in 1 patient. Rate of false positive detections ranged between 1 within
2h–4h 42min. Seizures were detected between 1min 24s before and 12s
after seizure onset in EEG. In 1 patient 7 auras without accelaration of
heart frequency occurred and, of course, were not detected.
Conclusion: Automated evaluation of heart rate is a sensitive method
for seizure detection with an acceptable rate of false positives in a video-
EEG monitoring setting. Therefore we started with online evaluation of
ECG in our monitoring unit.
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SLEEP DEPRIVATION: A SIMPLE METHOD SPECIFICALLY
FOR EPILEPSY PATIENTS
M. Tasillo, M. Piccioli, M. Ferraldeschi, T. Vitale, P. Tisei, E. Grassi,
M. Latella, A. Romaniello, and C. Buttinelli (University of Rome “La
Sapienza,” II Faculty of Medicine, Rome, Italy)
Purpose: To evaluate how much EEG sleep deprivation became posi-
tive after a negative EEG at rest in patients affected by epilepsy, making
a comparison with patients affected by other neurological pathologies.
Method: We conducted a retrospective study on our database of 292
patients who came to our EEG service at the Second Faculty of Medicine
of the University of Rome “La Sapienza” from 2001 until the present.
We focused on those patients who performed a sleep deprivation after
attending a normal EEG at rest. All of the patients investigated underwent
a partial sleep deprivation; in fact, they were allowed to sleep from
midnight to 3.00 a.m. Because of the wide variety of our population,
we decided to study a group of 146 patients known as suffering from
epilepsy with a consecutive group of 146 patients affected by head injury,
syncope, paraesthesia, vertigo, dementia and Parkinson’s disease. All
patients were investigated with a longitudinal montage with 21 channels
according to the 10–20 International System both for EEG at the rest and
for partial sleep deprivation. We compared the results of the 2 groups of
patients using the t-test.
Results: From our statistical analysis we found out that there is a
significant difference (p < 0.005) between the EEG that became positive
after partial sleep deprivation in the patients affected by epilepsy and the
other group of patients, in favour of the first group.
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Conclusion: We empathise with this retrospective study the specificity
of a simple neurophysiology method that can discover in a simple way
anomalies that otherwise could be hidden.
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USEFULNESS OF VIDEO-EEG MONITORING IN PAROXYS-
MAL EVENTS IN THE ELDERLY
M. Neufeld, and S. Kipervasser (EEG and Epilepsy Unit, Department of
Neurology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel)
Purpose: The incidence of seizures increases with age, however, be-
cause of diverse clinical manifestations on the one hand and other parox-
ysmal events mimicking seizures on the other hand, the diagnosis can
be difficult. Surprisingly, very few papers relate to video-EEG monitor-
ing (VEEGM) as a diagnostic aid in the elderly. The study’s aim was
to determine the importance of VEEGM in elderly patients with various
paroxysmal events.
Method: Out of 834 consecutively admitted persons to our Video-
EEG unit from 1997-2005, we identified 16 elderly (≥60) patients
(1.9%). We evaluated their demographic, clinical, EEG and imaging
data.
Results: There were 7 females and 9 males, ages 67.8 ± 7.7 years;
disease onset 51.1 ± 21.4 years, disease duration 16.6 ± 17.6 years.
The number of events during VEEGM was 5.3 ± 4.3, and the duration
of VEEGM was 6.9 ± 5.3 days. In 7 patients, epilepsy was verified
and antiepileptic drug (AED) treatment was adjusted. In 8 patients, non-
epileptic seizures (NES) were diagnosed, 1 patient had both epileptic and
NES, and 2 patients had nonconclusive events. Following hospitalisation,
the frequency of monthly events decreased for the whole group from 26.3
± 16.2 to 4.7 + 8.3 (p < 0.001); reduction for NES patients was from
22.8 ± 12.2 to 5.8 ± 10.6 (p < 0.027); in patients with epilepsy, the
rate was from 31.2 ± 21.1 to 1.8 ± 1.6 (p < 0.031). VEEGM impacted
diagnosis and treatment in 14/16 (88%) patients.
Conclusion: VEEGM in these elderly patients lead to verification of
diagnosis as well as to better AED treatment in the vast majority of our
patients. Our experience shows that this diagnostic tool is underutilised
in this population group.
Tuesday July 4, 2006
13:30–15:00
Poster Session 2
Drug Therapy
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CLINICAL DECISION MAKING REGARDING THERAPY AD-
JUSTMENT USING SYSTEMATIC SCREENING OF ADVERSE
ANTIEPILEPTIC DRUG EFFECTS
1S. Lukic, 2Z. Cojbasic, and 1M. Spasic (1Epilepy Department, Univer-
sity Clinical Centre Nis, Serbia and Montenegro, 2Faculty of Mechanical
Engineering, University of Nis, Serbia and Montenegro)
Purpose: To evaluate the clinical application of the Adverse Events
Profile questionnaire AEP (Gilliam et al., Neurology 2004;62:23–27) for
systematic screening of adverse AED effects, and to propose potential
improvement.
Method: Patients were recruited from a consecutive sample of eligi-
ble, consenting outpatients in the adult university epilepsy clinics. En-
rolment criteria included age >17 years, ≥2 seizures that required AED
treatment at the time of evaluation, ability to give informed consent and
complete self-report documents, and absence of symptomatic chronic
illness or use of medications with significant potential for side effects.
Patients were randomly assigned for examination by two investigators.
Primary outcome measure was correlation between clinical decision and
AEP score, as well as improvement in adverse effects reporting for 4
months. Also, we developed a fuzzy model which simulates clinical de-
cision making using AEP in a more complex manner, which was tested
on 30 patients.
Results: For a majority (38/42) of patients with AEP score of >45, a
clinical decision was made adjust therapy. However, for 10/18 patients
with an AEP score of ≤45, a clinical decision was also directed to a dose
adjustment. In 40/48 patients we observed significant improvement in
adverse effects. The developed fuzzy inference model demonstrated a
high compliance with clinical decisions, producing expected judgment
in a great majority of patients.
Conclusion: We found good specificity and moderate sensitivity of
the AEP score in clinical judgment, which could be better simulated by
fuzzy logic principles, rather than by binary logic based on a simple
threshold value.
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DEVELOPMENT AND IMPLEMENTATION OF EPILEPSY
DATABASE AND REGISTRY (EDAR)
M. Spasic and S. Lukic (University Clinical Centre Nis, Serbia and Mon-
tenegro)
Purpose: The purpose of this research is to develop and implement a
unique, specialised Windows-based epilepsy management and research
tools, for supporting the daily registration and storage of clinical events
in epilepsy clinics.
Method: The collection of patient-specific clinical data forms the pa-
tient database. The database contains structured terminology of seizure
types, syndromes, epilepsy type, aetiology, therapy and follow up proce-
dures. Developed Visual Basic 6.3 modules allow editing and personal
adjustment of tool items. The database has been written in English to
allow international use. Epilepsy database and registry (EDAR) has been
developed without any involvement or help from the sponsor company.
Results: Adult epileptologists have provided the knowledge of diag-
nostics and treatment of epilepsy for the basis of the application. Data
on over 500 adult epilepsy patients have been entered and used for rou-
tine and research purposes at the University Epilepsy Department. The
system offers the possibility to easily access all patient data at a local
level, without the need of looking for paper files. Moreover, it allows the
collection of anonymous data via the internet.
Conclusion: EDAR is a novel method for collecting and storing clini-
cally relevant data from epilepsy patients. EDAR allows the standardisa-
tion of patient data, and a better organisation of the patient management
process. It can be used as a comprehensive and powerful resource to
provide routine practice and clinical management as well as for epilepsy
research and an information exchange channel.
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INFLUENCE OF MATERNAL EPILEPSY AND ITS TREAT-
MENT ON THE DEVELOPMENT OF THE CHILD: PREG-
NANCY, LABOUR AND THE NEWBORN
M. Briggs (Central Manchester University Hospitals NHS Trust, UK)
Purpose: To report early findings in a longitudinal study of child
development from pregnancy to school years.
Method: Prospective, controlled, observational study of pregnancy
and its outcome in 292 women with epilepsy and 339 matched controls
receiving hospital antenatal care. Clinical data came from mothers and
case records. Minor congenital abnormalities were excluded (Eurocat
2005). Development of children was assessed at intervals. Statistical
analysis: chi-square or unpaired t-test.
Results: Mothers with epilepsy left school earlier and had less further
education (χ235.3; p < 0.001). Seizures in pregnancy: free 53%, non-
convulsive 29%, convulsive 18%. Drug therapy: none 22%, mono 61%
(CBZ 25%; VPS 20%; LTG 11%), poly 16%.
Pregnancies with complications were similar (patients 26.4%, controls
27.1%, χ20.05, p = 0.83). Most patients had normal deliveries (65.9%,
controls 58.1%, χ23.06, p = 0.08) although breech presentation was
more common (8.3%, controls 4.1%, χ2 3.83; p < 0.05). There was no
difference in gestational age at birth (patients 38.8 (0.3) weeks (SEM),
controls 38.9 (0.4), t = 0.08; p = 0.93) or in admissions to the special
baby care unit (patients 7.4%, controls 9.6%, χ20.78; p = 0.38). Pa-
tients had more prenatal scans and a small increase in major congenital
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abnormalities (4.1% controls 2.6%, χ20.92; p = 0.34). They were less
likely to breast-feed (37.0%, controls 52.9%, χ211.7; p < 0.01).
Conclusion: Differences in maternal education, seizures during preg-
nancy, drug exposure in utero and breast-feeding are expected to influ-
ence neuro-behavioural development. The likelihood of an uncompli-
cated pregnancy and normal delivery will reassure the would-be mother
with epilepsy.
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HOW WELL ARE NEURAL TUBE DEFECTS DIAGNOSED PRE-
NATALLY WHEN THE MOTHER IS TAKING ANTIEPILEPTIC
DRUGS?
1K. ten Berg, 1E. Brink, 1C. van Donselaar, 1C. van Oppen, 2P. Schie-
len, and 1D. Lindhout (1University Medical Center Utrecht, Utrecht,
Netherlands, 2National Institute of Public Health and the Environment,
Bilthoven, Netherlands)
Purpose: 1) To describe the clinical spectrum in 56 cases of neural
tube defects (NTDs) when the mother was on antiepileptic drugs (AEDs)
during pregnancy; 2) to evaluate the reliability of prenatal diagnosis in
The Netherlands.
Method: We collected data on congenital malformations, maternal
disease, use of AEDs and folic acid, and prenatal testing.
Results: From AED prescription rates and NTD risks specific to AED,
we estimated that, since 1970, there should be ∼150 NTD cases associ-
ated with maternal AED use in The Netherlands. Our first 56 NTD cases
included 52 (93%) spina bifida aperta (SBA), 1 spina bifida occulta, and 3
anencephaly, with 46 (82%) lumbar/sacral NTDs. Other CNS abnormal-
ities were: hydrocephalus (37), Arnold-Chiari II malformation (17), and
microcephaly (4). Non-CNS abnormalities occurred in 17 cases (30%),
predominantly urogenital (4) and cardiac (4) malformations. The moth-
ers took valproate (30), carbamazepine (10), phenobarbital (1), or poly-
therapy (15) that included valproate or carbamazepine in 14/15 cases.
19/56 (34%) used folic acid supplements (0.5–5 mg/day). Some form of
prenatal testing was performed in 36/56 (64%) cases. Open NTDs were
detected by measuring maternal serum alpha-foetoprotein (AFP) in only
3/8 (38%), but foetal ultrasound identified 30/36 (83%) and measuring
amniotic fluid AFP detected 20/22 (91%). Five live-born SBA babies
were missed by prenatal ultrasound.
Conclusion: NTDs were almost exclusively associated with valproate
or carbamazepine treatment, despite supplementary folic acid being
taken in one-third of these cases. Maternal serum AFP proves to be unre-
liable for diagnosing NTDs associated with maternal AED use. Funding:
National Epilepsy Fund (grant 03-18).
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EFFECT OF AED AND ENDOCRINE FACTORS ON SEIZURE
REDUCTION AND SUSTAINED REMISSION IN WOMEN
WITH EPILEPSY
E. Zheleznova and V. Kalinin (Moscow Research Institute of Psychiatry,
Moscow, Russia)
Purpose: The current study was carried out in order to find the op-
timal combinations of AED and endocrine factors for maximal seizure
reduction and support of remission in women with epilepsy.
Method: One hundred thirty women with epilepsy (23 with catame-
nial and 107 with noncatamenial epilepsy) were recruited into the study.
MANOVA was performed for the purposes of the study, and AED, thy-
roid and gynecologic data were used as fixed factors, while the data on
reduction (%) of each type of seizure and duration of sustained remission
were used as dependent variables.
Results: The isolated factor of reproductive dysfunction has no ef-
fect on reduction of any seizure type, although catamenial epilepsy was
characterised as a whole by poor seizure reduction. The isolated factor of
thyroid pathology has significant influence on reduction of simple partial
seizures (SPS). Their maximal reduction was observed in diffuse thyroid
enlargement in noncatamenial epilepsy under topiramate (TPM) treat-
ment. The maximal reduction of SPS was under carbamazepine (CBZ)
treatment, while the maximal reduction of primary generalised (PGS)
and secondary generalised (SGS) was revealed for TPM-CBZ combi-
nation. The valproates (VPA) had the maximal effect on absences and
myoclonus reduction, while the combination of VPA-CBZ was optimal
for sustained remission in catamenial epilepsy.
Conclusion: The AED type, comorbid endocrine pathology and cata-
meniality should be taken into account in the treatment of female epilepsy
in order to achieve maximal efficacy.
p453
CONGENITAL MALFORMATIONS IN CHILDREN OF MOTH-
ERS WITH EPILEPSY
1J. Riol Lozano, 1A. Garcı´a Medina, 1J. Rodrı´guez Garcı´a, 2R. Mene´ndez
Garcı´a, 3R. Ferna´dez Alech, and 4J. Garcı´a Fidalgo (1Neurology Depart-
ment, Abel Santamarı´a University Hospital, Cuba, 2Genetic Department
of Pepe Portilla Pediatric Hospital, Cuba, 3Gynecology Department of
Abel Santamaria University Hospital, Cuba, 4Epilepsy Section, National
Neurological Institute, Havana, Cuba.)
Purpose: The incidence of congenital malformations (CM) in children
of mothers with epilepsy (EM) is higher than in the general population,
and has a multifactorial origin. We investigated the frequency of CM in
children of EM and some related risk factors.
Method: A prospective study of 370 children of EM was carried out
from January 1995 to January 2005. A form was designed to record
demographic, clinical and genetic data. Final results were recorded on a
data base to make statistical analysis. Results were compared to those of
a control group of 500 children from mothers who did not have epilepsy
(NEM).
Results: CM were diagnosed in 9.85% of children from EM (36/370),
4.20% (21/500) in children from NEM (odds ratio = 2.7; IC of 95% =
2.0–3.3). The rate of CM with only one antiepileptic drug (DAEs) was
3.1% to 1.2% of the control (RR = 2.1; IC 95%; 1.3–3.5%). The rate
was 4.9% when taking 2 DAEs (RR = 3.6; IC 95%; 2.1–6.5%) and
9.7% if taking 3 or more DAEs (RR = 6.3; IC 95%; 2.5–16.3). The most
common CM were cardiac defects (1.63% to 0.4%), cleft palate (1.15%
to 0.18%), urogenital abnormalities (1.80% to 0.61%) and defects of the
neural tube (1.30% to 0.50%). CM were more frequent in children under
valproic acid (14.38%) than those under other DAEs (2.7%) (p < 0.001).
The daily dose of valproic acid was higher in children with CM than those
without CM (1750 to 1000 mg; p < 0.01). 37.5% of MC were diagnosed
in children from EM with tonic–clonic seizures during the first trimester
of pregnancy.
Conclusion: CM were more frequent in children from EM use of
DAEs in pregnancy. Polytherapy, high doses and seizures during the
first trimester are some risk factors of CM in children from EM.
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ANTIEPILEPTIC DRUGS AND BONE MASS IN MENOPAUSE
1L. Antonelli, 1J. Rudez, 1I. Antoe`iæ, 1O. Perkoviæ, 2K. Popoviæ, and
3D. Cvjetoviæ (1Clinical Hospital Center Rijeka, Department of Neurol-
ogy, Rijeka, Croatia, 2Psychiatric Hospital Rab, Rab, Croatia, 3General
Practice Center Cavle, Rijeka, Croatia)
Purpose: The purpose of our study was to determine the effects of
anti epileptic drugs (AEDs) on mineral metabolism and whether use of
them had an adverse effect on bone mass, particularly in women during
menopause, who have been suffering from epilepsy and have been taking
AEDs for 5 years and more.
Method: We analysed 25 women with epilepsy, in menopause, on
long-term antiepileptic drug therapy (carbamazepine, valproate, phe-
nobarbital), for a five-year period (2001–2005). Their urine levels of
minerals and serum level of calcium, magnesium, phosphor, alkaline
phosphatase, liver enzymes, testosterone, estradiol, FSH and prolactin
hormone were measured, including bone density measurement.
Results: The results showed that only one, a 35-year-old woman,
who was taking AEDs (carbamazepine, valproate, and phenobarbital)
for 20 years and was in post ovariectomy menopause for five years, had
low calcium concentration in serum and in urine, high levels of alkaline
phosphatase in serum, and osteoporosis.
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Conclusion: With our study we cannot confirm that long-term
antiepileptic therapy causes changes in calcium concentration levels
and increases possibility of osteoporosis development. The literature
describes these long-term side effects in patients who were taking
mostly phenytoin. In our case only one woman, who has entered early
menopause because of an ovariectomy, was taking different kinds of
antiepileptic drugs in mono or polytherapy during her life. Did she get
osteoporosis because of early menopause induced by prematurely re-
moving her ovaries or because of long-term treatment with AEDs, or is
it a combination of those two factors?
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A HUMANISED IN VITRO BLOOD–BRAIN BARRIER MODEL
TO SCREEN FOR BRAIN PENETRATION OF ANTIEPILEPTIC
DRUGS
1S. Santaguida, 2P. Couraud, 1D. Janigro, and 1L. Cucullo (1Cleveland
Clinic Foundation, USA, 2Institut Cochin, France)
Purpose: We compared the transendothelial permeation properties of
sucrose, phenytoin and diazepam in three humanized blood-brain bar-
rier (BBB) models based on cocultures of human astrocytes and different
types of endothelial cells (HUVEC, AVM EC, HBMEC/D3) differenti-
ated in a BBB phenotype under dynamic conditions (DIV-BBB) .
Method: EC and astrocytes were cocultured for 14 days using
polypropylene capillaries inside a sealed chamber. EC were exposed
to physiological levels of shear stress generated by intraluminal medium
flow. Permeability to 3H sucrose 14C phenytoin and 14C diazepam were
measured and compared to BBB integrity by transendothelial electrical
resistance (TEER) measurements.
Results: The TEER was ≈1200 Ohm cm2 for AVM EC and HB-
MEC/D3 DIV-BBB based models while only 800 Ohm cm2 for HUVEC.
Sucrose permeability (n = 3) was 5.7 × 10−8 cm/sec in HBMEC based
cartridges against 1.06 × 10−7 cm/sec in AVM and 4.93 × 10−7cm/sec
in HUVEC. Phenytoin permeability ranged from 3 × 10−5 cm/sec in
HBMEC and AVM-EC models to 1.24 × 10−4 cm/sec in HUVEC. Per-
meability to diazepam was ≈3 × 10−4 cm/sec in both AVM-EC and
HBMEC but twice as permeable in HUVEC.
Conclusion: These results demonstrate that the humanised DIV-BBB
recapitulates the in vivo rank order for AED permeability thus making
it an ideal vector to study brain penetration of new CNS drugs. HBMEC
models achieved the highest reliability for drug screening application.
Supported by ARDF and Philip Morris USA and Philip Morris Interna-
tional external research award to LC.
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PROFILE OF ANTIEPILEPTIC PHARMACOTHERAPY IN
TERTIARY REFERRAL CENTRE IN SERBIA: A PHARMA-
COEPIDEMIOLOGICAL STUDY
A. Ristic, A. Sindjelic, N. Vojvodic, S. Jankovic, and D. Sokic (Institute
of Neurology, Clinical Center of Serbia, Serbia and Montenegro)
Purpose: To study current practices of pharmacotherapy of epilepsy
in a developing country in economic transition (Serbia).
Method: Current practices of pharmacotherapy of epilepsy were anal-
ysed retrospectively at the Institute of Neurology in Belgrade, Serbia,
for two consecutive years (2004 and 2005).
Results: We analysed 177 inpatients (females 55.9%; mean age
41.1 ± 14.8 years), the majority of which were treated at the Department
of Epileptology. There were 75 patients (42.3%) with newly diagnosed
and 102 patients with previously diagnosed epilepsy. Symptomatic cause
of epilepsy was found in 26.7% of cases. Among the previously diag-
nosed patients the most frequently used drugs on admission were val-
proate (51.9%, average dose 1255 ± 525 mg), carbamazepine (43.1%,
average dose 785 ± 400 mg), lamotrigine (39.2%, average dose 275 ±
183 mg), phenobarbital (35.2%, average dose 96 ± 29 mg) and topira-
mate (21.5%, average dose 264 ± 155 mg). Newly diagnosed patients
were initially treated with valproate (50.6%), lamotrigine (13.3%), and
carbamazepine (13.1%) or with various combinations. In the previously
treated group different antiepileptic drugs (AED) were introduced in 55%
of patients, among which the most prevalent were valproate (38.8%),
lamotrigine (31.4%), topiramate (20.3%), levetiracetam (1.7%), oxcar-
bazepine (1.7%), and various combinations (9% of patients). Epileptic
seizures were controlled in 74.6% (easily in 7%, and with difficulty in
67.6%) and pharmacoresistant in 25.4% of patients. Polytherapy at the
end of hospitalisation was registered in 39%, mostly prevalent in phar-
macoresistant (100%), difficult to treat (44.5%), and symptomatic cases
(29%). Most frequently discontinued drugs were phenobarbital and car-
bamazepine.
Conclusion: Profile of AED therapy in the Serbian tertiary referral
centre is approaching the standards in developed countries.
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LONG-TERM MONITORING FOR LEUKOPENIA IN
EPILEPSY PATIENTS ON ANTIEPILEPTIC DRUGS
1,2K. Hara and 1M. Hara (1Hara Clinic, Yokohama, Japan, 2National
Center of Neurology And Psychiatry, Musashi Hospital, Tokyo, Japan)
Purpose: Patients with epilepsy are typically required to take
antiepileptic drugs (AEDs) for many years. Leukopenia, a reduction
in blood leukocytes, is a common side effect of AEDs. We evaluated
leukopenia in epilepsy patients on long-term AED treatment for more
than 20 years.
Method: We retrospectively evaluated records from epilepsy patients
who received AED and white blood cell (WBC) counts two or more
times a year for over 20 years. Patients with other diseases that may
contribute to leukopenia were excluded. We defined severe leukopenia as
WBC<3000/. We further examined the course of WBC counts in patients
who showed severe leukopenia more than once during this monitoring
period.
Results: 183 patients were examined (mean age = 48.5 years, mean
duration of follow-up = 26.2 years). Severe leukopenia was detected in
43 patients (23.5%) at least once during the monitoring period. However,
27 out of 43 patients (62.8%) recovered to WBC.3000 by their next blood
test. 8 patients showed continued WBC.3000 (or 3500) after a display of
leukopenia (duration = 2 to 20 years; mean duration; 11.4 years). Four
patients were required to reduce AEDs due to severe leukopenia.
Conclusion: This is the first report to evaluate leukopenia in patients
with long-term AED treatment. We found that leukopenia is very com-
mon in patients with epilepsy during long follow-up. However, in most
cases, AED reductions were unnecessary. Even patients who exhibited
repeated leukopenia eventually showed recovery. Future studies will in-
vestigate the mechanisms by which AEDs contribute to leucopenia.
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EFFECT OF ANTIEPILEPTIC DRUGS ON HOMOCYSTEINE
LEVEL
1K. Kierkus-Dluzynska and 1,2A. Klimek (1Department of Neurology,
Regional “Copernicus” Hospital, Lodz, Poland, 2Department of Neurol-
ogy and Epileptology, Medical University, Lodz, Poland)
Purpose: In the last decade the theory was established on the cytotoxic
effect of homocysteine excess and its high level was recognised as a risk
factor for vascular diseases. Recently it was found that patients taking
anticonvulsant drugs have a higher homocysteine level. It is thought that
a higher homocysteine level might be connected with taking epileptic
drugs which are the inducers of cytochrome P 450.
Method: The aim of the study was to measure the plasma homocys-
teine level of 60 patients with epilepsy. We also measured the level of
vitamin B12 and folic acid. These measurements were made in 4 groups:
the 1st group consisted of 20 patients after the first epileptic seizure; the
2nd group 21 patients on monotherapy, the 3rd group 19 patients on
polytherapy, and the 4th was a control group of 20 patients suffering
from low back pain.
Results: 21% of patients treated for epilepsy had higher mean ho-
mocysteine levels. The highest homocysteine level was in patients on
monotherapy with inductors of cytochrome P450 (14.02 ± 5.56) and it
was higher than in the control group (10.05 ± 2.03) and was statistically
significant. Also, a higher mean homocysteine level was in patients on
polytherapy (12.24 ± 3.78).
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Conclusion: Current results show that higher homocysteine levels in
epilepsy patients are connected with treatment. The study was financed
by Medical University in Lodz program Nr 502-15-386.
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ENZYME INDUCING ANTIEPILEPTICS: CONCERN FOR
DRUG INTERACTIONS IN GENERAL PRACTICE
1T. Haefeli, 1M. Hauf, and 1,2F. Donati (1Department of Neurology, Uni-
versity of Berne Inselspital, Berne, Switzerland, 2Clinic of Neurology,
Spitalzentrum Biel/Bienne, Switzerland)
Purpose: Up to 6% of all hospitalisations are due to adverse drug
reactions and 20% of these are caused by drug-drug interactions. Some
antiepileptic drugs (AED) have enzyme inducing properties with poten-
tially life-threatening adverse effects as comedication. These drug-drug
interactions are published in detail (Patsalos PN et al., The importance
of drug interactions in epilepsy therapy. Epilepsia 43(4) 2002; 365–85).
In spite of this, no data is available on adult epilepsy concerning the
implementation of this knowledge in general practice of prescription.
Method: We included 192 adult subjects consecutively seen am-
bulatory in one secondary and one tertiary centre of Epileptology in
Switzerland. Information was derived regarding prescription of enzyme-
inducing (CBZ/PHT/PBT) and other AEDs as well as comedication. We
screened for potentially dangerous interactions. Subject’s epilepsy syn-
drome, neurological and nonneurological comorbidity and demographic
characteristics were collected.
Results: Eighty-two (42.7%) were female. Mean age was 45.2 years
(range 16 to 84). 132 (68.8%) received comedication. 67 (34.9%) had
enzyme-inducing AED, of whom 46 (68.7%) had comedication. Poten-
tially dangerous combinations (Patsalos PN et al., The importance of
drug interactions in epilepsy therapy. Epilepsia 43(4) 2002; 365–85)
were seen in 35 patients (18.2%) concerning 52.1% of patients treated
with enzyme-inducing AED; including 4 subjects on Warfarin, 2 using
contraceptives and 1 on chemotherapy.
Conclusion: Two-thirds of our patients with epilepsy receive poly-
medication with various AEDs and non-AEDs. Potentially dangerous
drug-drug interactions (mainly due to enzyme inducing AEDs) were
disclosed in 18% of patients. This subgroup is particularly at risk of
developing adverse events if their medication regime is changed.
Reference
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SEIZURE CONTROL IN EIGHT PATIENTS WITH CORTI-
CAL DEVELOPMENT MALFORMATIONS AFTER SHIFTING
FROM OLD TO NEW AEDS
1A. Ferrari, 2A. Arrigo, 1F. De Merra, 2S. Vallone, and 1A.
Leonardi (1Department of Neurology S. Paolo Hospital, Savona, Italy,
2Department of Neuroradiology Ospedale Civile, Imperia, Italy)
Purpose: Cortical development malformations (CDM) are a major
aetiology of chronic drug-resistant epilepsy. Evolution from high resolu-
tion neuroimaging techniques allows easier diagnosis of partial epilepsy
due to CDM thus reducing the number of cases of “Cryptogenetic” par-
tial epilepsy. Complete pharmacological control of seizures in partial
epilepsy due to CDM is rarely obtained and neurosurgical treatment be-
comes mandatory. We report our experience with 8 patients whose elec-
troclinical and MRI data pointed out diagnosis of drug-resistant partial
epilepsy due to CDM; in these patients the shift from old antiepilep-
tic drugs (AEDs) to new AEDs made patients seizure-free after a mean
follow-up of 17.33 months.
Method: Eight patients, 3 males, 5 females, with a mean age of 27.37
years (range 19–46), came to our ambulatory clinic for persistent partial
seizures while treated with old AEDs. Neuroimaging studies showed
cortical dysplasia in 6 patients, band heterotopia in 1 patient and dysem-
bryoplastic neuroepithelial tumour (DNET) in 1 patient. Electroclinical
studies confirmed matching between type of seizure and lesion topogra-
phy.
Results: All patients obtained benefit from a therapeutic shift and
are seizure-free after a mean follow-up of 17.33 months (range 8–56).
Three of the 6 patients with cortical dysplasia are on monotherapy with
topiramate, 2 are on topiramate plus valproic acid, 1 on topiramate plus
oxcarbazepine. The remaining 2 patients, 1 with band heterotopia and 1
with DNET are both on monotherapy with oxcarbazepine.
Conclusion: In 100% of our patients where old AEDs failed, we
achieved total seizure control with new AEDs. The possibility of com-
plete pharmacological seizure control in patients with CDM is not yet
assessed. Rationalisation and simplification of pharmacological therapy
might obtain excellent results in these patients, usually destined to neu-
rosurgery.
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INFLUENCE OF ANTIEPILEPTIC THERAPY ON STRUCTURE
OF SLEEP IN PATIENTS WITH PARTIAL EPILEPSIES
S. Jankovic, D. Sokic, N. Vojvodic, A. Ristic, and A. Sindjelic (Institute
of Neurology, Clinical Center of Serbia, Serbia and Montenegro)
Purpose: To establish the influence of antiepileptic therapy (AET) on
sleep in patients with different types of partial epilepsies.
Method: Sleep was recorded in 37 male and female patients (mean
age: 28.72 years) with cryptogenic partial epilepsy (PE), prior to and
approximately 3 weeks after the initiation of AET (carbamazepine, val-
proic acid, phenobarbital and clonazepam). Statistics included 9 hours
of night sleep. Neurological and radiological findings were normal.
Results: AET fragments sleep period time (SPT) in PE, prolongs it
in PSSG and shortens it in PCSG. AET has a positive effect on wake
after sleep onset (WASO ≥ 120 sec) in PS and PSSG: it is shortened
and less fragmented; it is more fragmented only in PCSG. AET has a
positive effect on WASO < 120 sec in PSSG: it is shortened and less
fragmented. AET has no influence on any parameter (SPT, WASO ≥ 120
sec, WASO < 120 sec and MT) in PC epilepsy. AET has no influence on
sleep stage I in patients with different types of PE; it worsens the quality
of sleep stage II (shortens it) in PC and PCSG. It has no influence on PE
as a group, or on PS and PSSG. AET both prolongs and fragments sleep
stage III in PEs as a group, PS and PSSG. It has no influence on PC and
PCSG.
Conclusion: In patients with different forms of partial epilepsy AET
prolongs the duration of sleep, but it also fragments it by increasing the
number of sleep stage shifts.
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RISK FACTORS FOR SEIZURE RECURRENCE DURING
TREATMENT
D. Chavdarov (ERC “Sacer,” Sofia, Bulgaria)
Purpose: To investigate the rate and factors for seizure recurrence
after one year effective response.
Method: 1098 patients with partial epilepsy with secondary generali-
sation were treated with VPA (285), LTG (222), TPM (192), OXC (123),
CBZ (84) and polytherapy (192). Seizure recurrence was scored after a
one year seizure free period without dose alteration.
Results: Seizure reappearance was established in 352 patients (32.1%)
treated with individually adjusted dose monotherapy in 273 (30.1%) and
polytherapy in 79 (41.1%) patients. The seizure free period varied from
12 to 42 months, 20 months average. The most frequent reason suspected
for relapse was abrupt AED withdrawal in 74 (21.0%) patients, followed
by illness in 34 (9.7%), alcohol intake in 31 (8.8%), sleep deprivation in
29 (8.2%), combined factors (TV, workload, discotheques, basking in the
sun) in 57 (16.2%). The reason is unknown for 102 patients (29.0%) and
in only 25 (7.1%) patients there was epilepsy progression. For different
AEDs the percentage of the seizure reappearance varied from 17.9% for
CBZ, 25.3% for VPA to 30–40% for LTG, TPM and OXC (AED choice
depended on clinical severity).
Conclusion: Omitted doses are the most important factor for seizure
relapse, followed by intercurrent illness, alcohol intake, sleep depriva-
tion and extreme lifestyle. The aggravation of the disease affected an
insignificant number of patients.
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EFFICACY OF NEW ANTIEPILEPTIC DRUGS IN REFRAC-
TORY FOCAL EPILEPSY
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V. Iva´n˜ez, J. Ojeda, and S. Martı´n (Hospital Universitario La Paz, Madrid,
Spain)
Purpose: Adult focal epilepsy is often drug-resistant. Unfortunately
there is little information on the comparative efficacy of new antiepileptic
drugs (AEDs) concerning this group.
Method: An oobservational study based on 96 Patients from our new
Epilepsy Unit Data Bank. We included consecutive adult outpatients with
refractory focal epilepsy RFE. We studied the efficacy of lamotrigine
LTG, levetiracetam LEV and topiramate TPM. AED dosages must be
stable for at least three months. AED efficacy was classified as: 1: seizure
free; 2: reduction of 50–99% in seizure frequency; 3: reduction of 1–49%;
4: no changes or worsening.
Results: Ninety-six patients with RFE were studied; 51 of them on
LTG, LEV or TPM. Epileptic Syndromes were: temporal lobe epilepsy
TLE with hippocampal sclerosis, 30 patients (61%); frontal lobe epilep-
sies, 10 (20%); nonlesional TLE, 10 (20%); lesional neocortical TLE, 8
(16%); parietal lobe epilepsy, 2 (4%); occipital lobe epilepsy and Ras-
mussen syndrome, 1 (2%). LMT: 24 patients (47%) 2 on monotherapy
MT. Average time on LTG: 1270 days (range 259–2155 days). Average
dosage: 300 mg/day (range: 100–450). Efficacy: 1:2 patients; 2:2; 3:12;
class 4:8.
LEV: 29 patients (49%) 1 MT. Average time: 576 days (range: 188–
967 days). Average dosage: 2,500 mg/day (range: 1000–3000). Efficacy:
1:1 patient; 2:2; class 3:10; class 4:13 patients. TPM: 9 patients (17.6%)
1 MT. Average time: 415 days range: 296–1037 days). Average dosage:
225 mg/day (range 100–400). Efficacy: 1:0; 2:2; 3:3; 4:4 patients.
Conclusion: LMT, LEV and TPM have a similar efficacy in RFE. In
our study, the frequency of patients being seizure free or with a significant
reduction in seizure frequency was low (3–25%).
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SAFETY AND LONG-TERM EFFECTIVENESS OF NEW ANTI-
EPILEPTIC DRUGS IN SYMPTOMATIC LENNOX-GASTAUT
SYNDROME
G. Pauletto, L. Cecotti, M. Bassetti, G. Gigli, and P. Bergonzi (Diparti-
mento Interaziendale Di Neurologia E DPMSC, Udine, Italy)
Purpose: Treatment of Lennox-Gastaut syndrome consists of poly-
therapy, which usually fails to achieve a significant control on seizures:
our aim is to evaluate safety and long-term effectiveness of new anti-
epileptic drugs (AEDs) as add-on therapy in patients affected by symp-
tomatic Lennox-Gastaut syndrome.
Method: This is an open label, observational study. Patients under-
went accurate anamnesis, EEG and neuroimaging. During the 3 months
preceding the introduction of new AEDs, the mean number of seizures
was 60/month. New AEDs (lamotrigine LMT, levetiracetam LEV and
topiramate TPM) were introduced, reaching a mean dosage of 160
mg/die, 1344 mg/die and 182 mg/die, respectively. Every 3 months,
patients underwent a neurological examination and routine laboratory
tests. Therapeutic response was assessed in a semiquantitative way, as a
percentage of reduction in number of seizures (<50%, >/ = 50%, >/ =
75%, seizure-free, stationary, worsened). Adverse effects were collected
by clinical interview.
Results: We collected data from 13 adults (7 males and 6 females),
with a mean age of 37 years. New AEDs as add-on therapy were dis-
tributed as follows: 5 patients were administered TPM, 4 patients LMT
and 4 patients LEV. Mean observational period length was 36 months.
Nine of 13 patients over a reduction in number of seizures equal or greater
than 50%; 2 patients are presently seizure-free as regards atonic seizures.
Only 2 patients complained of adverse effects, mostly attributable to cen-
tral nervous system (dizziness, sedation).
Conclusion: In our patients, new AEDs demonstrated to be effec-
tive and safe in long-term treatment of symptomatic Lennox-Gastaut
syndrome, particularly in case of hypoxic encephalopathy.
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HYPERHOMOCYSTEINEMIA AND FOLATE SUPPLEMENTA-
TION IN PATIENTS WITH EPILEPSY: INFLUENCE OF MTHFR
POLYMORPHISMS AND OF CONVENTIONAL AND NEW
ANTIEPILEPTIC DRUGS
1V. Belcastro, 2G. Gorgone, 1D. Italiano, 1L. Pisani, 1G. Badolato, 3P.
Striano, 1G. Oteri, 2R. Ientile, 3S. Striano, and 1F. Pisani (1Department
of Neurosciences, of Psychiatric and Anaesthesiologic Sciences, First
Neurology Clinic, University of Messina, Italy, 2Department of Bio-
chemical, Physiological and Nutritional Sciences, University of Messina,
Italy, 3Department of Neurological Sciences, Epilepsy Centre, Federico
II University, Naples, Italy)
Purpose: To compare the influence of conventional and new
antiepileptic drugs (AEDs) on plasma homocysteine and folate and to
determine the therapeutic schedule of folate supplementation on the ba-
sis of the antiepileptic medication and the methylenetetrahydrofolate
reductase (MTHFR) mutation.
Method: One hundred twenty-two patients, 70F/52M, 19–61 years
of age, were screened for plasma homocysteine, folate and MTHFR
polymorphisms. Forty-four of these were on conventional AEDs, 38
on new AEDs and the remaining 40 on different drug combinations.
Patients exhibiting plasma hyperhomocysteine (i.e.>13 μmol/L) and
low (i.e.< 3.4 nmol/L) folate were treated with folate supplementation
(5 mg/day) for 30 days and monitored every two months for six months.
Statistical analysis was carried out by student t-test for independent data
and analysis of variance (one-way, ANOVA).
Results: 46 patients on conventional drugs (mono-/polytherapy) but
none on new drugs exhibited hyper-homocysteinemia and low folate
levels. These patients had the diplotypes TT677/AA1298 (26) and
CT677/AC1298 (20). Following folate supplementation, homocysteine-
mia fell within the physiologic range in all patients and returned to the
basal values six months after discontinuation of folate therapy in 37
patients. In the remaining 9 patients, treated with CBZ or PHT and ex-
hibiting the 677TT/1298AA genotype, homocysteinemia exceeded the
normal values already at 2–4 months after folate discontinuation.
Conclusion: The risk of hyperhomocysteinemia, very low/absent in
patients on new AEDs, is highest in patients on CBZ or PHT therapy
exhibiting the 677TT/1298AA genotype. These patients need a more fre-
quent folate supplementation over time to maintain homocysteine levels
within the normal values.
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EFFECT OF ENZYME-INDUCING AEDS ON THE CHOLES-
TEROL AND LIPOPROTEIN PROFILE OF ADULT EPILEPSY
PATIENTS: EVIDENCE FOR ELEVATED GGT ENZYME AS
A KEY DISCRIMINATOR OF THE HIGH LIPID PATIENTS
GROUP
1J. Mendes Ribeiro, 2J. Guimara˜es, 1I. Pires, and 1G. Sousa
(1Neurophysiology Unit, Hospital de Sa˜o Joa˜o, Porto, Portugal,
2Neurology Department, Hospital de Sa˜o Joa˜o, Porto, Portugal)
Purpose: Serum total cholesterol (TC), low-density lipoprotein (LDL-
c), high-density lipoprotein cholesterol (HDL-c) and triglycerides (TG)
have been shown, albeit not consistently, to be increased in those epilepsy
patients taking enzyme-inducing antiepileptic drugs (AEDs). Recently,
gamma-glutamyl transferase has been found to be an indicator of car-
diovascular disease death risk. The aim of this study was twofold: to
investigate the effect of AEDs on the lipid and lipoprotein levels in adult
epilepsy patients and evaluate the role played by elevated GGT enzyme
concentrations as an indicator of high lipid risk epilepsy patients.
Method: A total of 108 patients with epilepsy on long-term AED
treatment attending the outpatient epilepsy department, S. Joa˜o Hospital,
Porto, Portugal, were investigated. Serum total cholesterol (TC), LDL-
c, HDL-c, TG, GGT, AST, ALT, and the body mass index (BMI) were
measured.
Results: Patients on carbamazepine monotherapy showed signifi-
cantly higher TC, LDL and TG, which was found to be correlated to
elevated GGT (respectively p = 0.0001; p = 0.002 and p = 0.01).
Conclusion: Our findings showed that enzyme-inducing AEDs in-
crease total cholesterol and LDL-c but additionally provide evidence
supporting that only those patients with elevated GGT are truly likely to
have a significant increase in these lipid serum concentrations. Therefore,
the increase in serum GGT may have clinical relevance with respect to the
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incidence of atherosclerosis in patients with epilepsy receiving enzyme-
inducing AEDs, mediated, at least in part, by the increase in cholesterol
levels.
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REFLEX EATING SEIZURES IN SYMPTOMATIC EPILEPSY
1E. Herrga˚rd, 2P. Karttunen-Lewandowski, 3T. Ojala, 3S. Westere´n-
Punnonen, and 4T. Kiviranta (1Department of Paediatrics, Division of
Child Neurology, Kuopio University and University Hospital, Kuopio,
Finland, 2Central Hospital of Mikkeli, Mikkeli, Finland, 3Department of
Clinical Neurophysiology, Kuopio University and University Hospital,
Kuopio, Finland, 4Ma¨ntykangas Special School, Special Education and
Rehabilitation Resource Center, Kuopio, Finland)
Purpose: Reflex eating seizures are rare, difficult to control and are
usually related to symptomatic epilepsy. We enlighten the clinical context
and drug responsiveness of these seizures.
Method: We report patient histories, EEG and neuroradiological find-
ings of two paediatric patients. Video EEGs are available for demonstra-
tion.
Results: Patient 1, aged 8 years was born at term. After birth he needed
a shunt operation for congenital hydrocephalus. He is multiple disabled.
At 5 months of age he began to have focal clonic seizures, and later
focal seizures with automatisms and arrest. Daily serial epileptic spasms
provoked by eating appeared at 6 years of age. Ictal EEG showed bilater-
ally and frontally slow wave complexes followed by suppression or fast
activity. MRI revealed aqueduct stenosis, polymicrogyria, periventricu-
lar heterotopia, hypoplastic corpus callosum and cerebellum. Epileptic
spasms did not respond to AEDs. Corticosteroid treatment was added
and epileptic spasms stopped. He has been seizure free for 9 months.
Patient 2, aged 14 years, was born prematurely. Psychomotor develop-
ment was normal but later she showed learning difficulties. At 7 years
of age she began to have focal seizures with arrest and version and
asymmetric tonic posturing. Seizures have been resistant to multiple
AEDs. Right frontal lobe is atrophic on MRI. During the last catastrophic
phase of seizures (seizures up to 136/day) she had short focal seizures
with arrest and slight head deviation and eye blinking spontaneously
and similar seizures triggered by eating. Ictal EEG showed progressive
epileptiform discharge in right central-centrotemporal region. Pheny-
toin as add-on combined with corticosteroids left her seizure free until
now.
Conclusion: Both patients had symptomatic epilepsy with sponta-
neous seizures and disabling reflex eating seizures. Seizures were re-
sistant to conventional AEDs. Patients with eating seizures may benefit
from corticosteroids when neuronal network is highly excitable.
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MEDICAL DECISION MAKING IN EPILEPSY: EXPLORING
PATIENTS’ REASONING AND UNDERSTANDING OF RE-
CENT AED DECISIONS MADE WITH A HEALTH CARE
PROFESSIONAL
D. McCorry, A. Marson, and A. Jacoby (Liverpool University, UK)
Purpose: Antiepileptic (AED) decision making has not previously
been explored from the patients’ perspective. Understanding AED deci-
sion making is important because: 1) treatment failure is increasingly
used as a primary outcome for many randomised control trials; and
in defining a treatment failure patients almost always involve health
care professionals; 2) shared decision making has been advocated as
an ethically desirable approach, leading to improved clinical outcomes
(Coulter, A. Paternalism or partnership? Patients have grown up-and
there’s no going back. BMJ 319(7212), 719–20. 99); but levels of par-
ticipation the clinician or patient adopt have not been examined in
epilepsy.
Method: Fifty-nine individuals with epilepsy were recruited from the
Mersey regional epilepsy clinic (49) and a major trial (SANAD) of AED
treatment (10). All individuals were taking AEDs and had recently seen
a health professional. In depth qualitative interviews were conducted by
a researcher (DM) using a semistructured approach. The interviews were
recorded and transcribed. Using NVIVO software, recurring data themes
were examined using content analysis; grounded theory methodology
was used to construct a model of decision making.
Results: Dominant themes included that (i) patients consider doctors
as the decision makers (ii) potential AED dose or drug changes are rarely
considered prior to the consultation (iii) the language of decision making
is universally “they decided” rather than “I” or “we” decided.
Conclusion: The individuals studied considered that it is doctors who
make decisions about AED changes. A paternalistic rather than shared
decision making model is suggested. Ongoing analysis involves exami-
nation of tape-recorded consultations between patients with epilepsy and
their health care professionals.
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UTILISATION OF HISTORICAL DATA IN ACTIVE-CONTROL
MONOTHERAPY STUDIES WITH ANTIEPILEPTIC DRUGS
1C. Tudur Smith, 1P. Williamson, 2J. French, 2E. Perucca, 3M. Baulac,
and 1A. Marson (1University of Liverpool, UK, 2University of Penn-
sylvania, USA, 3Hopital Pitie-Salpetriere, University Paris VI, Paris,
France)
Purpose: There are no randomised placebo controlled monotherapy
trials for standard antiepileptic drugs such as carbamazepine. The ef-
fectiveness of carbamazepine in actively controlled trials has differed,
implying underlying differences in newly diagnosed populations. This
hinders the interpretation of actively controlled trials, particularly equiv-
alence and noninferiority trials and creates major problems for drug reg-
ulatory authorities. Modeling data from patients taking standard treat-
ments in existing trials may identify predictors of response and provide
evidence of assay sensitivity, and hence aid trial interpretation.
Method: Data from 7 antiepileptic drug monotherapy trials are used
to model the outcome for patients prescribed carbamazepine. For the
analysis of time to first seizure and time to 12 month remission, Cox
regression models are used to explore within and between trial relation-
ships for patient characteristics: age, sex, number of prerandomisation
seizures, time from first pre-randomisation seizure, epilepsy type, neu-
rological signs, EEG/CT scan results.
Results: Individual patient data are available for 552 newly diagnosed
epilepsy patients treated with carbamazepine within 7 randomised trials.
The patient factor that consistently has a significant influence upon out-
come is the number of prerandomisation seizures, and this factor may
account for up to 40% of the variability in some trials (for the outcome
time to first seizure). Full clinical results will be presented.
Conclusion: First seizure occurs more rapidly for individuals that
have experienced more seizures before randomisation and 12 month
remission occurs more rapidly for individuals with less seizures. Future
equivalence or noninferiority trials restricting entry according to number
of seizures may have greater assay sensitivity.
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LIVER ULTRASONOGRAPHY CHANGES DURING THE LONG
ANTICONVULSANT THERAPY
V. Voitenkov and E. Borisova (Institute of Experimental Medicine, Neu-
rology Clinic, Saint-Petersburg, Russia)
Purpose: We did an investigation that was going to prove the idea
that long anticonvulsant therapy could lead to the pathological changes
of liver structure.
Method: 40 patients were studied, all diagnosed with different forms
of epilepsy. All of them received anticonvulsants longer than 2 years;
average duration of therapy was 8 years. Average age of patients was
26.2 years.
We excluded patients with smoking, chronic alcohol intoxication, pro-
longed usage of any pharmacological medicaments, endocrinological
pathology, hematological diseases, diseases with any metabolism shift,
occupational diseases.
Design of experiment included standard ultrasonograpy study of liver,
its size, structure, portal system’s vessels and liver veins; also we mea-
sured the activity of alaninaminotranspherase and aspartataminotrans-
ferase.
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Results: 26% of patients had no pathological changes of liver. 38% had
moderate pathological changes, including changing of liver’s size and
structure without involving of portal vein system and other liver vessels.
36% of patients had ultrasonography symptoms of chronic hepatitis.
ALT and AST activities were close to normal parameters in 90% of
cases.
Conclusion: Thus we did the conclusion that long anticonvulsant
therapy could have side effects on liver, chronic hepatitis can develop in
36% of cases.
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ANALYSING THE PRACTICE OF ANTIEPILEPTIC AND CON-
COMITANT MEDICAL TREATMENT AMONG EPILEPSY
OUTPATIENTS IN EASTERN HUNGARY
1I. Fekete, 1S. Puska´s, 1E. Barna, 2E. Cso´to´, and 2L. Horva´th
(1Department of Neurology, University of Debrecen, Hungary, 2Central
Pharmacy, University of Debrecen, Hungary)
Purpose: Epilepsy needs chronic medical treatment throughout life.
The patients can suffer from different concomitant neurological and psy-
chiatric disorders. This is why, besides management of epilepsy, the con-
comitant drug therapy also has an important role in the clinical practice.
Method: We analysed 60 parameters of 986 adult outpatients with
epilepsy in the Eastern-Hungarian Database at the Department of Neu-
rology, from 1992–2005. We collected and analysed the data that are
connected to epilepsy treatment and concomitant drug therapy.
Results: The mean age was 44.8 years. During the examination period
720 patients took antiepileptic treatment: 78.6% monotherapy, 17.4%
bitherapy and only 4% polytherapy. More than half of the patients took
carbamazepine (53.5%) and 16.5% valproate monotherapy. AE side ef-
fects were only 8.4%. The concomitant drug therapy investigation was
surprising, since at the onset of the registration 30.0% of the patients
took different drugs affecting the CNS and which may also influence the
AEs metabolism. After carefully analysing the anamnesis and the con-
comitant disorders, we could decrease the use of the concomitant drugs
(diazepam, antidepressants, minor and major tranquillants, alprazolam)
to 15.5% of patients. The compliance was good in 77.0% of patients.
Conclusion: The analysis of the Epilepsy Database may give useful
information for clinical practice. The analysis, and if possible, also elim-
ination of concomitant drug therapy may decrease side effects and drug
interactions. These will improve the compliance and the quality of life
in patients with epilepsy.
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POTENTIAL DRUG INTERACTIONS IN PATIENTS WITH
EPILEPSY: CONCOMITANT MEDICATION USE BY AGE AND
GENDER
1B. Gidal, 2P. Grossman, 3J. French, and 4C. Bugli (1School of Pharmacy,
University of Wisconsin, Madison, USA, 2UCB, Global Outcomes Re-
search, Smyrna, USA, 3School of Medicine, University of Pennsylvania,
Philadelphia, USA, 4Laco, Diegem, Belgium)
Purpose: While prevalence of antiepileptic drug–non-antiepileptic
drug comedication and interactions is described for the elderly, few data
exist regarding gender and age patterns of potentially important interac-
tions. We describe patterns of cardiovascular and psychotropic comedi-
cation in epilepsy patients.
Method: A retrospective cohort study was conducted in epilepsy
patients using a US claims database (1/2001-12/2004). Patients
were sub-grouped: enzyme inducing AEDs (EIAEDs) or noninducing
(NEIAEDs).Usage of comedications was compared for: children (C)(0-
17yo), young adults (YA)(18-34 yo), adults (A)(35-54yo), older adults
(OA)(55-64yo), elderly (E)(65+yo).
Results: of n = 15,869 epilepsy patients (43%men/57%women), n =
9,296 received EIAEDs (54%women), NEIAEDs (61%women). Overall
comedication exposure was 4.3 drugs/person, increasing with age: C =
2.6, YA = 3.4, A = 5.5, OA = 7.1, E = 7.0. Many patients used more
than 5 prescription medications: 18–44 yrs 31%, 45–64 yrs 54%, 65+
yrs 64%. Statin use was high in those >35yo (EIAED/NEIAED; A =
12.9/13.9%, OA = 29.6/31.0%, E = 34/36%). Calcium channel blocker
(all AEDs: C = 0.5%, YA = 2.8%, A = 9.2%, OA = 17.46%, E =
27.1%) and warfarin use were also common (all AEDs: C = 0.9%, YA
= 1.32%, A = 4.24%, OA = 8.3%, E = 14.2%). Overall SSRI use was
28.6% for those >34 yo while TCA use was most common in A (10.4%).
Antipsychotic use was 11.1%, (EIAED/NEIAED C = 5.7%/12.4%,
YA = 8.9%/12.6%, A = 10.9%/14.4%, OA = 12.8%/12.8%, E =
16.9%/15.2%). SSRI and TCA use was higher in women 24.7%–9%
respectively vs 16%–4.6% in men.
Conclusion: Discrimination in drug selection based on potential drug-
drug interactions was not found. Importantly, concomitant drug use lead-
ing to potential interactions occurs across all age groups, not simply the
elderly. No specific gender differences were seen with cardiovascular
medications, but possibly with antidepressants. These findings suggest
more caution be used when prescribing an EIAED.
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LONG-TERM EFFICIENCY OF ANTIEPILEPTIC DRUGS IN
ADULTS
A. Staack and B. Steinhoff (Epilepsy Center Kork, Germany)
Purpose: Due to the pharmacological advantages of some of the new
antiepileptic drugs (AEDs) the question of the long-term efficacy and
safety of classical AEDs becomes more and more important. We prospec-
tively investigated a consecutive group of 197 adult outpatients treated
in our centre for more than 10 years in order to assess the efficiency of
their chronic AED therapy.
Method: From April to June 2005 we consecutively assessed the de-
mographic data, epilepsy syndromes, seizure types, seizure frequency,
EEG findings, medication schedules and the adverse effects as well as
the therapeutic consequences such side effects had. The main target was
the rate of seizure-free patients and the probability that a highly effica-
cious treatment with classical AEDs may be complicated by tolerability
problems.
Results: One hundred and ninety-seven patients were analysed (94
women, 103 men, mean age 41.1 ± 14.7 years, range 18–83 years).
One hundred thirty patients (66%) were seizure-free for more than
3 months, 70 patients (36%) more than 5 years. Long-term seizure free-
dom was achieved with one AED in 60%, with two AEDs in 33% and
with three AEDs in 4%. 3% of the long-term seizure-free patients were
off medication. The most frequently used AEDs were valproate and
carbamazepine. Among the new AEDs levetiracetam had the highest
proportion (13% of all seizure-free patients). Potential long-term side-
effects occurred under classical AEDs exclusively and were found in
14% of the seizure-free patients. Polyneuropathies were the most fre-
quent of those side effects. 70% of the patients suffering from long-term
adverse effects refused any dose change or the offering of a complete
medication change because of their fears of risking seizure freedom.
Conclusion: It is possible to achieve seizure freedom in a high per-
centage of adult patients even in a specialised Epilepsy Centre whose
referrals should reflect more complicated cases. The long-term prognosis
is good once seizure freedom is achieved. Clinically relevant side effects
are relatively rare even under treatment with classical AEDs. Seizure
freedom is such a spectacular achievement for patients that the majority
accept side effects more than risking a seizure relapse during the process
of AED changes.
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REDUCTION OF MOTOR CORTEX EXCITABILITY BY THE
ANTICONVULSANT DRUG SULTHIAME: A TMS STUDY
1S. Groppa, 1M. Siniatchkin, 2H. Siebner, and 1U. Stephani
(1Neuropediatric Department, University of Kiel, Germany, 2Neurology
Clinic, University of Kiel, Germany)
Purpose: Sulthiame (STM), a carbonic anhydrase inhibitor, is a
widely used drug for treatment of partial and myoclonic seizures es-
pecially in children. However, the mechanisms of the anticonvulsant
effect of sulthiame in humans are insufficiently characterised.
Method: Transcranial magnetic stimulation (TMS) was performed
on 11 healthy adults (age 28.7 ± 7.9). Motor-evoked potentials were
recorded using Ag/AgCl electrodes placed over the m. abductor pollicis
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brevis of the nondominant left hand. The EMG signal was amplified
(Nihon Kodhen), bandpass-filtered (1 Hz–2 kHz), digitised (5 kHz) and
recorded using Signal 3.0 software (CED Co., UK). TMS was deliv-
ered through a figure-of-eight-shaped coil connected to two Magstim
200 stimulators. In a randomised single-blind placebo-controlled cross-
over study, the effects of the single oral doses of 5 mg/kg STM on mo-
tor thresholds (MT), recruitment curves, cortical induced silent period
(CSP), intracortical inhibition (ICI) and facilitation (ICF) were studied.
Results: The only significant ANOVA effect was the interaction
“Change × Group” for the motor threshold (F (1, 11) = 13.57; p =
0.004). Sulthiame induced a significant increase of MT compared with
placebo. No other effects and interactions for recruitment curve, ICI,
ICF, CSP, were found to be significant.
Conclusion: Because the changes in MT are related to ion-channel
function (sodium-mediated), it seems likely that sulthiame exerts its
antiepileptic effect through modulation of this function and reduction
of cortical excitability. GABAergic or glutamatergic mechanisms seem
to be less important in vivo as measured by TMS.
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CONTROLLED TRIAL OF LAMOTRIGINE FOR THE TREAT-
MENT OF REFRACTORY PARTIAL SEIZURES
1M. Carignani, 2J. Matassa, and 3D. Rosso (1Rosario National Uni-
versity, Rosario, Argentina, 2Open Interamerican University, Argentina,
3Rosario Private Children’s Clinic, Rosario, Argentina)
Purpose: Lamotrigine is an inhibitor of dihydrofolate reductase, an
approach based on the folic acid deficiency seen in patients with a long
history of phenytoin or phenobarbital treatment. Tested in 1985 in the
USA and approved for use in 1994, lamotrigine is a triazine derivate
of pyrimethamine, poorly soluble in water, not related to other AEDs.
Lamotrigine basically has an inhibitory effect on sodium, and possibly
potassium channels. Acting similarly to phenytoin and carbamazepine,
lamotrigine differs in better blocking the release of glutamate. Lamotrig-
ine is also more efficacious on slow inactivation of the sodium channel,
avoiding fast inactivation and consequently possibly provides better neu-
roprotection and less behavioural effects. Experience in USA and UK on
reducing Sz frequency has been good on partial and generalised epilepsy.
Dizziness, blurred vision, somnolence, ataxia and diplopia were the most
frequent adverse effects, but the most serious side effect is thrush, which
is more probable when used together with VPA, and can be potentially
lethal.
Method: In this group of epilepsies, partial seizures are of multi-
form semiology, with more or less conscious affectation, mixed motor-
cognitive-sensitive-autonomic symptoms, and all intent to classify as a
syndrome (exception made of localisation criteria), are naive, according
to our criteria, because clinical modifications and EEG showed initial
site activation of a system of neurons in a specific brain area (usually
deep temporal lobe), with different propagation of the discharge in dif-
ferent brains, (aetiology being so wide that is impossible to describe
here), excluding idiopathic partial seizures, which are not included in
our group. Focusing on a heterogeneous group of 47 patients, cognitive
functions basically normal, with different minor focal abnormalities, all
belonging a to crypto-remote symptomatic group, aged 14–27 years,
with at least 6 yrs of disease duration, gender prevalence of males (wide
variability between authors), all with simple partial, complex partial and
secondary generalised tonic–clonic seizures, having been treated with at
least 3 different programmes of efficient drug therapy, most frequently a
combination of DPH, CBZ, VPA, PB or VGB, never alone, always in a
different pattern of combination. These patients were enrolled with writ-
ten consent, into an add-on programme of LTG, starting with very low
doses, especially those with previous treatment with VPA. A randomised,
double-blind, placebo-controlled trial enrolling 47 patients with at least
4 partial remote symptomatic seizures/month sometimes going to gener-
alisation on different plans of therapy, was conducted at 4 Argentine sites
to assess lamotrigine efficacy and dose response as adjunctive therapy
for refractory partial-onset seizures. Lamotrigine dosages were elevated
by 25 mg/d each week. The study design allowed parallel comparisons
with placebo for 3 dosages and a final crossover to 400 mg/d of lamot-
rigine fsor all patients. The primary efficacy comparison was a change
in seizure frequency from a 4-week placebo baseline to weeks 4 through
10 on double-blinded therapy.
Results: At 400 mg/d, lamotrigine reduced the median frequency of
all seizures by 46% from baseline, compared with a 6% reduction (p =
0.0007) with placebo treatment, and produced a 60% seizure reduction
(responder rate) in 56% of patients. A dosage of 100 mg/d produced a
22% reduction in median seizure frequency (p = 0.043 compared with
placebo) and a dosage of 200 mg/d produced a 28% reduction in median
seizure frequency (p = 0.005 compared with placebo). Dropouts from
adverse events (10%) did not differ from placebo (11%). The only ad-
verse event differing significantly from placebo was thrush, weight loss,
though blurred vision, somnolence, anorexia, and ataxia were slightly
more common with lamotrigine treatment, as long as placebo shows
mostly digestive discomfort.
Conclusion: Lamotrigine is effective and well tolerated as an adjunc-
tive agent for refractory partial-onset seizures. The minimal effective
dosage was 100 mg/d, but 400 mg/d was the most effective dosage.
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THE INCIDENCE OF COMPONENTS OF POLYCYSTIC
OVARY SYNDROME IS HIGHER IN YOUNG WOMEN
WITH EPILEPSY TREATED WITH VALPROATE VERSUS
LAMOTRIGINE
1R. Kustra, 2M. Morrell, 3F. Hayes, 3P. Sluss, 1C. Warnock, 1H. Con-
klin, and 1J. Isojarvi (1GlaxoSmithKline, Research Triangle Park, USA,
2Stanford University, Stanford, USA, 3Massachusetts General Hospital,
Boston, USA)
Purpose: To evaluate the development of components of polycystic
ovary syndrome (PCOS) in women with epilepsy (WWE) initiating either
valproate (VPA) or lamotrigine (LTG) therapy.
Method: This prospective, randomised, open-label, multicentre study
(LAM30007) enrolled WWE ages 13–40 years with regular menstrual
cycles, and either newly diagnosed or inadequately controlled epilepsy
(1 chronic AED). Subjects were randomised to VPA or LTG and were
treated for up to 12 months. Serum androgen levels were measured every
3 months, and urinary pregnanediol glucuronide levels were measured
weekly to assess ovulation for two 3-month periods. The primary end-
point was development of components of PCOS (hyperandrogenism or
ovulatory dysfunction) during the study. To exclude the confounding
effect of puberty on the results, a post hoc analysis was conducted in
women who were >2 years post menarche.
Results: 363 women (177 LTG, 186 VPA) aged 12 to 40 years were
evaluated in the post-hoc analysis. The incidence of components of PCOS
was higher in the VPA group than the LTG group (36% VPA vs 23% LTG;
p = 0.007). The high incidence of components of PCOS was evident in
the VPA group if the medication was started at 25 years of age or younger
(44% VPA vs. 23% LTG, p = 0.002), whereas the incidence was similar
if the medication was started after age 25 (24%VPA vs. 22% LTG).
Conclusion: This large, multiethnic, prospective, randomised study
shows that a greater proportion of WWE receiving VPA than LTG de-
velop components of PCOS symptoms, especially if the medication is
started before age 26 years.
p477
THERAPEUTIC DRUG MONITORING OF LAMOTRIGINE IN
A PAEDIATRIC POPULATION
J. Mifsud, H. Shabbi, and D. Soler (University of Malta, Malta)
Purpose: Therapeutic drug monitoring is important for drugs that
exhibit interindividual variability in pharmacokinetics, and where drug-
drug interactions, concurrent disease or age alters the kinetics of that
drug. This is of particular importance in a chronic neurological condition
such as epilepsy. In this study, the value of therapeutic drug monitoring
for lamotrigine, a novel antiepileptic drug, was investigated in a group
of paediatric patients.
Method: Plasma lamotrigine levels in 20 paediatric patients (mean ±
S.D., age 8.85±3.47 years and weight, 32.22±20.81 kg) were measured
using a novel validated high performance liquid chromatography (HPLC)
technique that gave a retention time for lamotrigine and internal standard
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of 1.258 min and 2.30 min respectively. The method proved to be linear,
precise and reproducible over the plasma concentration range of 0.08–20
mg/.
Results: Plasma lamotrigine levels at steady state (mean ± S.D.) in
epilepsy patients were thus measured using this novel analysis. The lev-
els thus estimated were 10.1 ± 4.95 mg/L in the lamotrigine monother-
apy group. In the valproate co-medication group; carbamazepine co-
medication group; clonazepam comedication group; and valproate and
clonazepam comedication group, these were 8.11 ± 5.48, 1.89 ± 1.55,
8.33 ± 0.91 and 8.86 ± .98 mg/L respectively. A statistically significant
difference (p < 0.05) was obtained between the valproate co-medication
group and carbamazepine comedication group, between the valproate
comedication group and clonazepam comedication group, and between
the valproate comedication group and valproate, clonazepam comedica-
tion group.
Conclusion: Overall, the results thus obtained from the studies in
this research indicate the important need to streamline pharmacokinetic
data for the use of antiepileptic drugs in children. Most physicians use
ad hoc reasoning in the design of therapeutics and dosage regimens for
these drugs in children. Our studies have shown that there are too many
variables that could influence the plasma drug concentrations obtained.
There is still a lack of satisfactory models and software packages that
will allow accurate predictions of drug levels with these drugs in these
populations
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EURAP GERMANY: SEIZURE CONTROL AND DOSE MOD-
IFICATIONS DURING PREGNANCY UNDER TREATMENT
WITH VALPROATE, CARBAMAZEPINE, AND LAMOTRIGINE
IN MONOTHERAPY
V. Gaus, I. Coban, R. Kretz, and B. Schmitz (Charite´ University Medicine
Berlin, Germany)
Purpose: Antiepileptic drugs (AED) underlie modified pharmacoki-
netics during pregnancy. A clinically relevant decrease of serum concen-
tration levels has been reported with lamotrigine (LTG). In the 2nd and
3rd trimester compared to the 1st trimester the best seizure control has
been shown for valproate (VPA)-monotherapy. A significantly high num-
ber of dose changes were performed in patients with LTG-monotherapy
(EURAP study group, Neurology 2005). EURAP is a prospective study
to investigate pregnancies with AED exposition.
Method: In 37 patients with completed pregnancies who were treated
with VPA (n = 13), carbamazepine CBZ (n = 14) or LTG (n = 10)
in monotherapy we retrospectively investigated seizure control and dose
modifications 1 year preconception and 3 months postpartum in addition
to the data of the EURAP Registry.
Results: There was no relevant change in seizure frequency in
the VPA- and CBZ-groups, whereas in the LTG-patients we found a
favourable development with a continuous decrease of seizure frequency
during pregnancy (percentage of patients with seizures: 75% precon-
ception, 50% 1st trimester, 40% 2nd trimester, 30% 3rd trimester, 50%
postpartum). In 80% of LTG-patients dose modifications were performed
during pregnancy. In 2/3 of these patients the dose was increased due to
low serum concentration levels, in 1/3 the dose was raised because of
seizures.
Conclusion: The seizure situation of patients with LTG-monotherapy
shows a favourable development with decrease of seizure frequency in
the course of pregnancy. A causal relation to prophylactic increases of
dosages seems likely. We plan to extend the retrospective analysis to
other EURAP centres.
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PATIENTS WITH PSYCHOSIS UNDER LAMOTRIGINE
C. Brandt, N. Fueratsch, V. Boehme, M. Pieridou, C. Stegner, A. Villa-
gran, F. Woermann, B. Pohlmann-Eden (Bethel Epilepsy Centre, Ger-
many)
Purpose: Lamotrigine (LTG) is an antiepileptic drug (AED) with a
broad efficacy, also licensed in Germany for the prevention of depressive
episodes in patients with bipolar affective disorder. Only a few cases
are reported with psychoses under lamotrigine, mainly due to alternative
psychosis with the EEG finding of forced normalisation (Clemens 2005).
Method: To our knowledge, there are only 6 patients who developed
psychoses among 1,400 treated with LTG up until now in our centre.
These cases are presented below.
Results: Five patients suffered from symptomatic partial epilepsy
(left-sided hippocampal sclerosis in 2, both-sided in 1, bilateral pos-
terior gliosis in 1), one from idiopathic generalised epilepsy with an
additional focal component after traumatic brain-injury. One patient had
a history of postictal psychoses, another of bipolar disorder, another of
pseudologia phantastica. We found LTG-serum levels of 3.5–9.8 μg/ml
before the onset of the psychotic episodes, during the psychoses up to
21.8. At least 1 patient suffered from disturbed night-sleep. There were
no signs of alternative or postictal psychosis in any case. LTG had to
be withdrawn in 3 cases, dose reduction was sufficient for remission of
symptoms in the others. Five patients had to be treated with neuroleptics.
Conclusion: Psychoses are a very rare side effect under LTG treat-
ment. A toxic or substance-specific cause of the psychoses has to be
discussed, but more cases with additional EEG-recordings are neces-
sary.
p480
TOLERABILITY OF LAMOTRIGINE (LTG), LEVETIRAC-
ETAM (LEV), AND TOPIRAMATE (TPM) IN INTRACTABLE
FOCAL EPILEPSY
J. Ojeda, V. Ivan˜ez, A. Rodriguez-Albarin˜o, and S. Martin-Balbuena
(Stroke Unit, Hospital Universitario La Paz. Madrid, Spain)
Purpose: Focal epilepsy is the most common type of epilepsy in
adults. The high rate of drug resistance in this group is well known.
This drives usually to polytherapy and to use new AEDs. Medical Treat-
ment Guidelines published in the US and Europe agree on the efficacy,
safety and tolerability of new AEDs and recommend their use as add-on
treatment in refractory epilepsies.
Method: An observational study using Epilepsy Unit Databank. Con-
secutive adult outpatients included (1995–2006). We studied the toler-
ability of three new AEDs (lamotrigine (LTG), levetiracetam (LEV),
topiramate (TPM)), as monotherapy or add-on therapy, in patients with
refractory focal epilepsy (RFE). Tolerability was studied in terms of
withdrawal due to adverse effects.
Results: Ninety-six patients with RFE. Epileptic syndromes: tempo-
ral lobe epilepsy (TLE) with hippocampal sclerosis, 52 patients (61%);
frontal lobe epilepsy, 16; lesional neocortical TLE, 14; non lesional TLE,
10; parietal lobe epilepsy, 2; occipital lobe epilepsy and Rasmussen syn-
drome,1. LTG, 42 patients (44%); 2 on monotherapy (MT). Withdrawal,
12 (28%); seizure frequency increase, 1; rash, 5; dizziness, 2; tremor,
1; diplopia, 2; constipation, 1. LEV, 38 patients (39%); 2 on MT. With-
drawal, 13 (34%); cognitive disturbance, 4; rash, 2 (and LTG); weight-
loss, 2; mammary glands volume increase, 1; tremor, 1; somnolence, 1;
not specified, 2.
TPM, 31 patients (32%) 1 on MT. Withdrawal, 14 (45%). Seizure
increase, 4; weight loss, 3; cognitive disturbances, 1; diplopia, 1; som-
nolence,1; nephrolithiasis, 1; not specified, 3.
Conclusion: It is said that new AEDs are well tolerated. In our study,
LMT, LVT and TPM, mostly used as add-on therapy in RFE, have a
withdrawal rate between 28–41%. LMT appears to be the best tolerated.
TPM has the highest withdrawal rate.
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COMPARATIVE DAILY PROFILES OF VARIOUS LAMOTRIG-
INE PREPARATIONS
1M. Dahl and 2P. Wolf (1Danish Epilepsy Centre, Dianalund, Denmark,
2Rigshospitalet, Copenhagen and Danish Epilepsy Centre, Dianalund,
Denmark)
Purpose: To discuss the purpose and methodology of comparative
daily profiles of Lamotrigine (LTG).
Method: In Denmark, since 2005, legislature requests that pharma-
cies always deliver the cheapest of several preparations of any drug
regardless of the doctors’ prescriptions. The prices of preparations are
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evaluated every 2 weeks which results in multiple changes of prepa-
rations for drugs with multiple marketed preparations. This legislation
coincided with the end of patents for branded lamotrigine (Lamictal),
and at present 7 different generic preparations are available. Doctors can
apply for patients to be exempt from preparation shifts but the health au-
thority requires comparative plasma level data to consider an exception.
We have started to determine comparative daily profiles of LTG as only
these provide sufficiently detailed data which include Cmax, Cmin, tmax,
Cmax/min and Cx. Our data are observational, and generated with patients
who reported problems with shifts of preparation. There are no standard
methods to establish such profiles. Ideally, blood sampling would have to
take place at 30–60 min intervals after drug intake, followed by slightly
longer intervals until the next dose. But compromises are necessary be-
cause blood sampling needs to be integrated into daily hospital routine.
Another question is the adequate interval between the two comparative
profiles. In addition, possible pharmacokinetic interactions with comed-
ications need to be considered.
Results: We present preliminary findings with sampling intervals of 3
and 4 hours, and with intervals between profiles of 1 and 3 weeks. The 3
hour schedule appears to provide reasonably informative data, whereas
a 4 hour schedule may fail to detect differences in tmax and carries a risk
of rather imprecise Cmax measurements from which other calculations
depend. Significant deviations were detected in profiles collected 1 week
apart, but these may become clearer after 3 weeks especially but not only
in cases with a long half-life where readjustment to a new steady state
may take more time. Although the Danish authorities have set a range of
90–110% in the bioequivalence studies for acknowledgment of equiv-
alence of a new antiepileptic drug preparation, larger deviations could
be observed with continuous medication. These were not necessarily
apparent, when only morning trough levels were compared.
Conclusion: Comparative daily profiles provide differentiated infor-
mation on the bioequivalence of different LTG preparations. In clinical
conditions, deviations outside the accepted bioequivalence range were
observed. For clinical purposes, a 3 hour sampling schedule seems to be
adequate. It is recommended to determine the comparative profiles at an
interval of 3 weeks.
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ONSET OF EFFICACY WITH LAMOTRIGINE IN PRIMARY
GENERALISED TONIC–CLONIC SEIZURES (PGTCS): A RAN-
DOMISED, PLACEBO-CONTROLLED STUDY
A. Vuong, A. Hammer, R. Kustra, and J. Messenheimer (GlaxoSmith-
Kline, Research Triangle Park, NC, USA)
Purpose: This abstract reports efficacy, including time to onset, and
tolerability results from a study with LTG as adjunctive therapy in pa-
tients with primary generalised tonic–clonic seizures (PGTCS).
Method: LTG-naive patients (≥2 years, ≥13 kg) with inadequately
controlled PGTCS, receiving a regimen of 1 or 2 AED(s) and an elec-
troencephalogram (EEG) with evidence of generalised epileptiform dis-
charges or no evidence of interictal expression of partial seizures were
enrolled in a randomised, double-blind, placebo-controlled trial. Patients
having ≥3 PGTCS over an 8 week baseline were randomised to receive
LTG or placebo (PBO). Treatment period: escalation phase (12 weeks
for patients 2–12 years, 7 weeks for patients >12 years) and maintenance
phase (12 weeks).
Results: of the 184 patients enrolled, 117 were randomised to LTG or
PBO. LTG group: n = 58, 50% male, median age = 27 years, 50% with
1 concurrent AED, median PGTCS during baseline = 2.4. PBO group:
n = 59, 56% male, median age = 25 years, 59% with 1 concurrent AED,
median PGTCS during baseline = 2.9. The median percent decreases
from baseline in PGTCS were 56% and 30% (p = 0.036) 5 weeks after
treatment initiation with LTG and PBO, respectively; in patients >12
years, the decreases were 63% and 33% (p = 0.045) 3 weeks after treat-
ment initiation. The median percent decreases from baseline in PGTCS
were 82% and 43% (p = 0.006) during maintenance, and 66% and 34%
(p = 0.006) during the entire treatment phase, for LTG and PBO, respec-
tively. The median PGTCS counts per month were 2.4 and 2.9 during
baseline for LTG and PBO, respectively, 1.0 and 2.3 (p = 0.013) during
escalation, and 0.4 and 1.6 (p = 0.001) during maintenance, and 0.8 and
2.0 (p = 0.003) during the entire treatment phase.
Conclusion: The results from this study, combined with the efficacy
of LTG for partial seizures, demonstrate that LTG is a broad spectrum
AED for patients with either partial or generalised seizures.
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PARADOXICAL SEIZURES INDUCED BY GABAPENTIN: A
CASE REPORT
J. Denq (Department of Neurology, Tri-Service General Hospital,
Taiwan)
Purpose: We describe a status epilepticus (SE) due to accidental over-
dosing by incorrect prescription of gabapentin (GBP) up to 5400 mg/day
in a patient with epilepsy due to previous meningoencephalitis. After se-
quential titration down of GBP dosage, the SE phenomenon subsided
and the series of EEG recordings suggested successful treatment with
clinical improvement.
Method: A 34-year-old female had suffered from meningoencephali-
tis with epilepsy since 8 years old. Her anticonvulsant included Deparkin
(1200 mg/day), Sabril (4 gm/day) and GBP (3600 mg/day). One week
before admission, her dosage of GBP was increased to 5400 mg/day. Sud-
den onset of twitching over right side of face and upper limb evolved,
lasting for more than one hour. An EEG done on admission revealed
evidence of SE. On examination, she was intubated with a ventilator.
She was comatose and unresponsive. Fundi were normal. Pupils were
5 mm and nonreactive. Corneal reflexes were absent. All four limbs were
mildly spastic.
Results: A CT scan of her brain was performed without contrast en-
hancement and revealed atrophy of bilateral cerebral hemispheres, more
severe in the frontal and temporal lobes. The cerebral ventricles are
moderately dilated. Titration of GBP from 5400 mg/day to 3600 mg/day
in two weeks; the last EEG showed poor sustained background alpha
rhythm of 8 Hz without epileptic waveform. The patient recovered and
was discharged three weeks after admission.
Conclusion: High doses or rapid increase of GBP could result in SE.
Careful reduction of GBP was a mandatory treatment in this case.
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LEVETIRACETAM VERSUS GABAPENTIN: COMPARISON
OF HEALTH CARE UTILISATION, COSTS, AND INCIDENCE
OF ADVERSE EVENTS IN EPILEPSY PATIENTS USING A RET-
ROSPECTIVE CLAIMS ANALYSIS
1C. Bugli, 2A. Joyce, 3P. Grossman, and 2D. Ollendorf (1Laco, Diegem,
Belgium, 2PharMetrics (A Business Unit of IMS Health), Watertown,
USA, 3UCB, Global Outcomes Research, Smyrna, USA)
Purpose: To investigate health care utilisation and costs, and to com-
pare the incidence of adverse events (AEs) in commercially insured
epilepsy patients initiating levetiracetam (LEV) or gabapentin (GBP).
Method: A retrospective cohort analysis of epilepsy patients was con-
ducted using a large US claims database (July 2001–December 2003).
Patients with a 6-month baseline period were classified into mutually
exclusive treatment groups based on their first LEV or GBP prescrip-
tion, propensity-matched on a 1:1 basis and followed between 3 and
12 months. Utilisation and cost were analysed using non-parametric
Wilcoxon rank-sum tests. Risk of AEs was assessed using Cox propor-
tional hazards models.
Results: Treatment groups (n = 816 each) were comparable regard-
ing clinical and demographic characteristics. Patients received more
prescriptions for LEV compared to GBP (mean/patient/year: 8.3/6.0,
p < 0.001), which generated higher LEV pharmacy costs ($1,319/$648,
p < 0.001). Health care utilisation was significantly (all p < 0.05)
lower in LEV patients for number of physician office visits (18.1/20.8),
emergency-room visits (8.5/11.0), other outpatient visits (35.7/40.6)
and medications other than antiepileptic (24.4/36.5). Costs were sig-
nificantly in favour of LEV for emergency-room visits ($880/$1,094,
p < 0.01) and medications other than antiepileptic ($1,995/$2,396,
p < 0.001). The percentage of patients with AEs was significantly lower
for LEV (62%/71%, p < 0.001). Median time to first AE was longer for
LEV (42/28 days). The hazard ratio for time to first AE (LEV vs GBP)
was 0.76 (95% CI: 0.68, 0.86).
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Conclusion: In a commercially insured setting, increased persistency
generates higher LEV pharmacy costs. However, LEV was associated
with significantly less utilisation and costs of common health care ser-
vices and lower risk of AEs than GBP.
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LEVETIRACETAM IS AN EFFECTIVE ADD-ON TREAT-
MENT FOR ADULTS WITH EPILEPSY AND INTELLECTUAL
DISABILITIES
S. Deb and S. Siani (University of Birmingham, UK)
Purpose: Evaluate the effect of levetiracetam both in terms of its effi-
cacy as well as its adverse effects on adults with intellectual disabilities
and epilepsy.
Method: This is a prospective audit of case notes based data collected
from a tertiary clinic for the treatment of epilepsy among adults with
intellectual disabilities at the University of Birmingham, UK. The study
includes 21 patients with epilepsy and intellectual disabilities of vari-
ous degrees for whom levetiracetam has been prescribed as an add-on
therapy for the first time. Of them 10 were also treated with lamotrigine
simultaneously. Data were collected at baseline before starting levetirac-
etam and then at 3, 6, 9 and 12 months follow-up. The patients were on
an average of 2.3 antiepileptic drugs prior to starting add-on levetirac-
etam. Data were analysed using an intention to treat (ITT) analysis at
the 12-month follow up.
Results: 14% (n = 3) became totally seizure free. An additional 43%
(n = 9) showed >50% reduction in seizure frequency, 19% (n = 4)
showed <50% reduction in seizure frequency, 5% (n = 1) showed im-
provement which was not quantified and 14% (n = 3) did not show
any change in seizure frequency but 5% (n = 1) showed an increase
in seizure frequency. Overall in 81% (n = 43) of cases there was an
improvement in seizure frequency. Seizure improvement was observed
for complex partial seizures (71.5%), primary or secondarily generalised
tonic–clonic seizures (77%), and absence seizures (58%). Some patients
have experienced a positive effect on mood and behaviour.
Conclusion: Levetiracetam is an effective add-on therapy for adults
with intellectual disabilities and epilepsy.
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EFFICACY OF LEVETIRACETAM AS ADD-ON TREATMENT
FOR PATIENTS WITH TEMPORAL LOBE EPILEPSY
A. Painold, M. Feichtinger, K. Zaar, E. Koerner, and E. Ott (Medical
University Graz, Austria)
Purpose: The efficacy of levetiracetam in the treatment of partial
seizures is already confirmed by many studies. However, its efficacy has
not been evaluated specifically for temporal lobe epilepsy (TLE) until
now.
Method: In a retrospective analysis the effect of levetiracetam as add-
on treatment on seizure frequency was studied in 38 TLE patients (15
males, 23 females). Levetiracetam was used with a median dose of 2290
mg/day (range: 500 to 6000 mg/day) in combination with various other
antiepileptic drugs. The frequency of seizures was assessed 1 (n = 38),
6 (n = 33), 12 (n = 26) and 24 (n = 14) months after starting the
adjunctive therapy with levetiracetam and related to the baseline median
seizure frequency.
Results: We found a statistical significant reduction of seizure fre-
quency at each control (1, 6, 12 and 24 months). After 1 month 12 of
38 patients (31.6%) had no seizures, after 24 months 1 of 14 patients
(7.1%) was still seizure free. In addition, levetiracetam led to a more
than 50% seizure reduction in 7 patients (18.4%) within the first month,
and after 2 years in 5 patients (35.7%). There was a reduction of the num-
ber of patients over 24 months because of discontinuation of levetirac-
etam as a result of side effects like fatigue and increasing aggressiveness
(n = 3), non–compliance (n = 5) or shorter treatment with levetiracetam
(n = 16).
Conclusion: This retrospective study demonstrates an excellent ther-
apeutic response of levetiracetam in patients with TLE. Prospective stud-
ies to confirm these results are recommended.
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ANTIMYOCLONIC EFFECT OF LEVETIRACETAM IN
MERRF SYNDROME
1M. Mancuso, 1R. Galli, 1C. Pizzanelli, 2A. Choub, 2G. Siciliano, and 2L.
Murri (1Unit of Neurophysiopathology Pontedera, Italy, 2Neurological
Institute University of Pisa, Italy)
Purpose: To test the efficacy and safety of levetiracetam (LEV) in
MERRF syndrome. The treatment of progressive myoclonic epilepsy
(PME) is largely empirical, even though valproic acid (VPA) is consid-
ered the drug of first choice. However, VPA should be used with caution
in PME due to mitochondrial dysfunction, i.e. in MERRF (myoclonic
epilepsy with ragged-red fibers) syndrome, because of its interaction
with mitochondrial respiration and metabolism.
Method: LEV treatment was started in combination with VPA in a
patient with MERRF due to a mutation on the tRNA-phenilalanine gene
(G611A). A detailed simplified myoclonus rating scale was adminis-
tered, and repeated screening of side effects and overall well-being was
performed. The effect of LEV was assessed at follow-ups (six and ten
months) and compared with the patients’ status at initiation of LEV. The
Holter-EEG was performed before, after 2 months of treatment with LEV
as add-on and in monotherapy with LEV.
Results: The patient before LEV experienced disabling refractory
action-induced myoclonus, with significant impairment in activities of
daily living. With less than 1500 mg of LEV, the average myoclonus score
improved dramatically, as well as the quality of life and no side effects
were observed, even after having withdrawn VPA. The initial Holter-
EEG showed generalised spikes and spike-and-wave complexes with
background slowing. After 2 months of add-on therapy, those complexes
disappeared, and did not reappear after another 6 and 8 months.
Conclusion: LEV may benefit myoclonus in PME of mitochondrial
origin without altering mitochondrial function, and it could be considered
the drug of first choice for the treatment of myoclonus in MERRF.
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LEVETIRACETAM IN IDIOPATHIC GENERALISED
EPILEPSY AND PORPHYRIA CUTANEA TARDA: A CASE
REPORT
1L. Bilo, 2R. Meo, 1P. Ruosi, and 1M. de Leva (1Epilepsy Center, De-
partment of Neurological Sciences, “Federico II” University, Naples,
Italy, 2Neurology Outpatients Service, Azienda Sanitaria Locale Napoli
1, Naples, Italy)
Purpose: Many drugs inducing hepatic metabolism, in particular the
cytochrome P-450 system, can exacerbate latent porphyrias because
they increase heme synthesis. Consequently, noninducing antiepileptic
drugs (AEDs) are usually considered a safe choice in epilepsy patients
with porphyrias. However, there are several reports which describe por-
phyrinogenic activity in noninducing AEDs as well. Treatment of epilep-
tic seizures in patients with porphyrias may consequently be a challenge.
Method: In this case report we are the first to describe levetiracetam
usage in porphyria cutanea tarda, the most common form of porphyria.
So far, only two reports of levetiracetam use in porphyria are found in the
literature, one describing use in coproporphyria and the other in acute
intermittent porphyria. Our patient is a 50 year old male affected by
idiopathic generalised epilepsy and porphyria cutanea tarda. Valproate
and phenobarbital controlled seizures but exacerbated porphyric symp-
tomatology, while clobazam, clonazepam and lamotrigine were safe on
porphyric disturbances but did not control seizures.
Results: Levetiracetam monotherapy was accompanied by complete
control of seizures and normal liver function and blood count.
Conclusion: Lack of hepatic metabolism in levetiracetam might rep-
resent an indicator of its safety in porphyric patients. However, evaluation
of experimental models of porphyria is warranted for levetiracetam and
for all new AEDs.
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SIX MONTH FOLLOW-UP OF LEVETIRACETAM TREAT-
MENT IN ELDERLY PATIENTS: AN INITIAL APPROACH FOR
AN OBSERVATIONAL STUDY
Epilepsia, Vol. 47, S3, 2006
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1M. Lo´pez, 2J. Bueno, 2J. De Leo´n, 3R. Lamare, and 4S. Mirdavood
(1Hospital Febles Campos, Sta Cruz De Tenerife, Spain, 2Hospital Can-
delaria, Sta Cruz De Tenerife, Spain, 3Clı´nica San Roque, Las Palmas
De Gran Canaria, Spain, 4Hospital Insular, Gran Canaria, Spain)
Purpose: To perform a pilot study of efficacy of levetiracetam as
monotherapy in elderly patients.
Method: Longitudinal, observational study. Participants were elderly
patients initiating monotherapy with levetiracetam. Number of seizures
(NS), levetiracetam daily dose and adverse events were recorded at 1, 3
and 6 months from treatment initiation.
Results: Mean age was 73.9 years; 4 patients were female. 8 patients
had generalised seizures (GS) and 1 patient had partial and generalised
seizures (P&GS). In GS patients, at month 1, the dose ranged from 500–
2000 mg/day (mean: 1125 mg/day) and mean NS was 0.57. At month
3, mean NS between study visits decreased to 0.33 and the dose was
increased in only 1 patient experiencing 2 seizures. At month 6, mean
NS was 0.20, and the dose was increased in 1 patient (dose rank: 1000–
3000 mg/day, mean: 1600 mg/day). The P&GS patient was taking a
1000 mg/day dose by month 1, with 1 partial seizure recorded during
this period; from month 1–month 3 no seizures were registered, though
the dose was increased to 2000 mg/day at month 3. During months
3–6, no seizures or dose modifications occurred. None of the patients
discontinued treatment with LEV or presented AE during the 6 month
follow-up period.
Conclusion: This pilot study indicates that monotherapy with LEV
may be an effective and safe therapeutic option in elderly patients with
epilepsy. A longer term study in a larger group of patients is needed to
confirm these results.
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EFFICACY OF LEVETIRACETAM AS MONOTHERAPY
TREATMENT IN PATIENTS OF ALL AGES
L. Giampaola (Ospedale S.Maria Della Speranza ASL/SA2, Battipaglia,
Italy)
Purpose: LEV is a new antiepileptic drug used as add-on therapy
in the treatment of refractory partial epilepsy seizures. The aim of this
study was to evaluate the efficacy of LEV as monotherapy in patients
with partial and generalised epilepsy.
Method: This is a retrospective study where 10 patients (5 males and
5 females) were evaluated. Mean age was 38.5 (age range 12–84) years.
They were followed for a mean duration of LEV treatment of 8.5 (range
1–12) months. Six patients had acryptogenic epilepsy and 4 patients
had a secondary epilepsy. LEV was added to other AEDs (TPM; CBZ;
LTG) for 5 patients, and then they were progressively switched to LEV
monotherapy. The other 5 patients received LEV as the initial AED.
LEV was used at doses of 1000–3000 mg/a day with a low titration for
4 weeks. The monthly frequency of seizures was 3.6.
Results: Six of 10 patients became completely seizure free (5 patients
were affected by CPC and 1 patient was affected by CGTC). Reduction
in seizure frequency >50% was seen in 3 patients (30%). One patient
reported some adverse events of irritability and aggressiveness; so LEV
treatment was interrupted.
Conclusion: LEV showed itself effective in 90% of patients with
CGTC and CPC. It was generally well tolerated. This study confirms the
high efficacy of LEV as monotherapy treatment.
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PLASMA LEVEL MONITORING OF LEVETIRACETAM IN
ADULT PATIENTS WITH EPILEPSY
1G. De Maria, 1B. Guarneri, 2A. Panzali, 1L. Valente, 1L. Antonini
(1Epilepsy Centre, Spedali Civili, Brescia, Italy, 23rd Laboratory,
Spedali Civili, Brescia, Italy)
Purpose: The aim of this study was to investigate the influence of
LEV dosage, age, and comedication on LEV serum concentration.
Method: Plasma levels of LEV were evaluated in 157 patients with
epilepsy, 89 females and 68 males, mean age 36.98 years, range 17
to 71 years; 113 patients received enzyme inducing comedication and
44 patients received comedication considered not enzyme inducing. The
LEV serum concentration in relation to LEV dose per body weight (level-
to-dose ratio, LDR) was calculated and compared for patients receiving
enzyme inducing and not enzyme inducing antiepileptic drugs (AEDs).
Results: In our patient population, the mean LEV dosage was 2156
± 818 mg/day, the mean LEV dose per body weight was 33.29 ± 12.63
mg, the mean LEV serum concentration was 12.64 ± 7.06 μg/mL, the
mean LDR was 0.41 ± 0.26.
The LEV dose per body weight was significantly correlated with LEV
serum concentration (r = 0.37, p < 0.001); the LDR did not correlate
with age (r = 0.17, p > 0.1); although there was a trend for the LDR
to be lower among patients on enzyme inducers. The LDR for patients
receiving enzyme inducing comedication did not differ significantly from
the LDR for patients receiving comedication considered not enzyme
inducing (0.05 < p < 0.1).
Conclusion: These results suggest that determination of LEV serum
concentration seems not to be necessary to adjust LEV dosage in patients
on co-medication with or without enzyme inducing AEDs.
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EFFECTS OF LEVETIRACETAM ON MOTOR ACTIVITY AND
SLEEP ARCHITECTURE: AN ACTIGRAPHIC STUDY
H. Yilmaz (Celal Bayar University, School of Medicine, Department of
Neurology, Manisa, Turkey)
Purpose: Levetiracetam-treated patients commonly report daytime
sleepiness, somnolence, tiredness, and asthenia. However, objective data
on the character and/or severity of these findings with levetiracetam
(LEV) are missing in the literature. So this prospective, open-label study
was conducted to evaluate the effects of levetiracetam (LEV) on motor
activity and sleep architecture.
Method: At least 2 days before treatment and 7 days after 3 weeks of
treatment, sleep architecture and motor activities of the 22 levetiracetam-
treated patients (10 monotherapy, 12 add-on therapy) were evaluated by
Epworth Sleepiness Scale (ESS), sleep log and the actiwatch (Mini-
Mitter Co., Inc., Bend, OR). Actiwatches are small, rugged, actigraphy-
based data loggers that record a digitally integrated measure of gross
motor activity and automatically collect all data for sleep parameters.
In evaluating nocturnal sleep, the following sleep parameters were esti-
mated: bedtime, wake-up time, sleep-onset time, sleep-offset time, sleep
latency (SL), sleep period time (SPT), total sleep time (TST), wake time
after sleep onset (WASO), and sleep efficiency (SE). Each subject gave
written informed consent for this investigation.
Results: After treatment with LEV (in particular with add-on therapy),
motor activity scores statistically significantly decreased and napping
episodes statistically significantly increased. But ESS, sleep log, SL,
TST and SE weren’t different from before treatment.
Conclusion: These results suggest that LEV (in particular add-on
therapy) decreases daytime vigilance but does not have major effects on
sleep structure.
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TWO YEARS CLINICAL EXPERIENCE OF LEVETIRACETAM
IN A RUSSIAN ADULT EPILEPSY CLINIC
P. Vlasov and V. Karlov (Department of Neurology of Moscow State
Medico-Stomatological University, Moscow, Russia)
Purpose: To evaluate the efficacy of levetiracetam (LEV) as adjunc-
tive therapy in adult patients with pharamacoresistant partial epilepsy
(PE) and idiopathic generalised epilepsy (IGE).
Method: Open-label prospective study of patients enrolled from 1
February 2004. LEV up-titration was performed at a rate of 500 mg/day
to a maintenance dose of 1000–3000 mg/day. Seizure frequency and
adverse events (AEs) were analysed after 1 and 2 years’ follow-up.
Results: 101 patients, aged 19-51 (mean 25.3 ± 2.3) years, with an
epilepsy duration ranging from 3-27 years were included. Of these, 84
patients had PE, 17 had IGE. LEV was dosed at 1000-3000 (mean 1500)
mg/day. 72 (PE 55, IGE 17) patients received 1 year of LEV treatment
and 29 (all PE) received 2 years LEV treatment. After 1 year, 76.5%
(13/17) IGE patients achieved 100% seizure freedom, 11.8% (2/17)
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demonstrated a ≥75% and 5.9% (1/17) a ≥50% seizure frequency reduc-
tion; 5.9% (1/17) showed no change. 25.5% (14/55) PE patients achieved
100% seizure freedom, 12.7% (7/55) demonstrated a ≥75%, 47.3%
(26/55) a ≥50% seizure frequency reduction, 14.5% (8/55) showed no
change. After 2 years, 24.1% (7/29) PE patients achieved 100% seizure
freedom, 17.2% (5/29) demonstrated a ≥75%, 55.2% (16/29) ≥50% and
only 3.4% (1/29) showed no change. AEs led to LEV discontinuation (at
500 mg/day) in 2 patients (agitation, dizziness, nausea, tremor). Other
AEs were mild somnolence, asthenia and nervousness, reported during
LEV titration.
Conclusion: Our data confirm the efficacy and tolerability of LEV
adjunctive therapy in pharamacoresistant PE and IGE patients.
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COMPARATIVE CNS TOLERABILITY OF NEW ANTIEPILEP-
TIC DRUGS: AN EVALUATION OF DATA FROM PLACEBO-
CONTROLLED STUDIES
1G. Zaccara, 1F. Balestrieri, 2G. Burchini, and 2A. Messori (1Neurology
Unit, S. Maria Nuova Hospital, Florence, Italy, 2Osservatorio del far-
maco, Careggi, Firenze, Italy)
Purpose: To compare CNS adverse effects (CNS-AE) of new
antiepileptic drugs (AEDs) through an evaluation of key double-blind
studies.
Method: All published placebo-controlled clinical studies conducted
in adults using new AEDs, were selected for descriptive analysis. The
number of patients reporting CNS-AEs when treated with an active drug
(by dose level) or placebo was extracted from each study and the per-
centage of patients (receiving active drug or placebo) was calculated.
The complaint rate of each CNS-AE (ie percentage of CNS-AE patients
receiving the active drug minus the percentage of CNS-AE from patients
receiving a placebo) was then calculated according to Cramer JA et al.
(Epilepsia, 1999). Finally, complaint rates were summed to calculate a
“summary complaint score” (SCS) for each different class of CNS-AEs.
Results: Thirty-four studies were included in our analysis. The re-
spective SCS for 4 classes of CNS-AEs (somnolence, tremor, vestibular-
cerebellar [ataxia, dizziness, diplopia, blurred vision and lack of gait co-
ordination] and cognitive impairment) were as follows: gabapentin 9.6%,
2.3%, 21%, 0%; lamotrigine 0%, 0%, 69%, 0%; levetiracetam (LEV) 7%,
0%, 7%, 0%; pregabalin 11.6%, 4%, 41%, 9%; oxcarbazepine 14.8%,
4.6%, 76%, 0%; tiagabine 0%, 26%, 17%, 5%; topiramate 30.3%, 0%,
94%, 67.8%; zonisamide 6.3%, 0%, 9%, 0%. Overall, LEV had the best
CNS tolerability profile. The SCS of these AEs will also be presented
for different dose levels for each drug.
Conclusion: Although only a descriptive analysis of these data could
be performed, there are clear differences in the CNS tolerability profiles
of the AEDs evaluated; of these LEV appears advantageous.
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FULL SEIZURE CONTROL AFTER LEVETIRACETAM ADD-
ON IN DRUG-RESISTANT PATIENTS WITH EPILEPSY
1J. Fattouch, 1C . Di Bonaventura, 1G. Egeo, 1F. Mari, 1A. Vaudano, 1M.
Prencipe, 1,2M. Manfredi, and 1A. Giallonardo (1Epilepsy Unit, Depart-
ment of Neurological Sciences, University of Rome “La Sapienza,” Italy,
2Neuromed Institute of Pozzilli (IS), University of Rome “La Sapienza,”
Italy)
Purpose: To examine the factors underlying the unexpected response
to levetiracetam (LEV) add-on therapy in patients with a history of drug
resistance.
Method: Case review of patients with partial refractory epilepsy
achieving full seizure control with LEV, despite not responding to ≥3
polytherapies (combination of 2 or 3 AEDs). Clinical, neurophysiolog-
ical and neuroimaging data were reviewed.
Results: Fifteen patients (7 males, aged 19-75 [mean 42] years) were
selected from 250 consecutive patients. All patients suffered from par-
tial epilepsy (cryptogenic [12/15] and symptomatic [3/15]). Mean daily
LEV add-on dose was 2000 (range 1500–3000) mg. All patients achieved
seizure freedom on LEV therapy, on average, within the first 2 weeks.
Mean follow-up was 26 (range 18–36) months. Analysis of clinical, neu-
rophysiological and neuroimaging data predominantly showed: crypto-
genic aetiology (12/15), frontal (8/15) or temporal (5/15) seizures. EEG
data showed generalised spike-and-wave discharges as expression of sec-
ondary bilateral synchrony (12/15). The AEDs to which LEV was most
commonly added were carbamazepine, valproate and phenobarbital, al-
though no specific association showed superior efficacy.
Conclusion: Our results suggest that LEV’s effectiveness in this pop-
ulation may be related to its pharmacological profile circumventing some
of the drug-resistance mechanisms, avoiding the excessive expression of
multidrug transporter and the related removal of AEDs from epilepto-
genic tissue. LEV’s mechanism of action may offer new opportunities
of synergy when used in combination with old AEDs.
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SELETRACETAM SINGLE RISING DOSE SAFETY: TOLERA-
BILITY AND PHARMACOKINETICS IN HEALTHY SUBJECTS
1D. Goldwater, 2Z. Lu, 2V. Salas, 3N. Toublanc, 2D. Chen, 3M.
Sargentini-Maier, and 3A. Stockis (1Parexel Clinical Pharmacology
Research Unit, Baltimore, MD, USA, 2UCB, Clinical Pharmacology,
Braine-l’Alleud, Belgium, 3Smyrna, GA, Braine-l’Alleud, Belgium)
Purpose: Seletracetam (UCB 44212) is an investigational antiepilep-
tic drug (AED) with high affinity toward the synaptic vesicle protein
SV2A. This first human study investigated its safety, tolerability and
pharmacokinetics in healthy subjects.
Method: Single rising oral doses were administered in a randomised,
double-blind, placebo controlled manner to healthy male subjects. Three
alternating panels of 9 subjects (6 active, 3 placebo) received 2, 4, 10,
20, 50, 100, 200, 400, and 600 mg of seletracetam. Food effect was
assessed in an additional group of 8 subjects. Bond and Lader, ARCI-49
and DSS tests were used to explore CNS effects. Plasma and urinary
concentrations were determined by LCMSMS.
Results: The maximum dose of 600 mg was not intolerated. Ad-
verse events at all doses were of mild to moderate severity, resolved
quickly and were mostly CNS in origin, including dizziness, somno-
lence, nausea, euphoria, feeling drunk, fatigue and headache. There
were no laboratory abnormalities. Seletracetam was rapidly absorbed
and followed first-order monocompartmental kinetics, with a half-life
of 8 hours. Pharmacokinetics were linear from 2 to 600 mg. Coadmin-
istration with a high fat meal resulted in a 39% reduction in Cmax and
no change in AUC. Urinary excretion was 60% of the dose in 48 hours
(approximately 20% as parent and 40% as a carboxylic acid metabolite).
Conclusion: The MTD of seletracetam was greater than 600 mg after a
single oral dose. Absorption was rapid and pharmacokinetics linear over
more than two orders of magnitude. Food had no effect on the extent of
absorption. UCB funded.
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SELETRACETAM MULTIPLE DOSE SAFETY, TOLERABIL-
ITY, AND PHARMACOKINETICS IN HEALTHY SUBJECTS
1P. Leese, 2R. Hulhoven, 3V. Salas, 2N. Toublanc, 3D. Chen, 2M.
Sargentini-Maier, and 2A. Stockis (1Quintiles Phase I Services, Lenexa,
MD, USA, 2UCB, Clinical Pharmacology, Braine-l’Alleud, Belgium,
3UCB, Clinical Pharmacology, Smyrna, GA, USA)
Purpose: Seletracetam (UBC 44212) is an investigational antiepilep-
tic drug (AED) with high affinity toward the synaptic vesicle protein
SV2A. This study investigated its safety, tolerability and pharmacokinet-
ics in healthy subjects, following 2 weeks of multiple oral dosing.
Method: Three different panels of 12 male subjects (9 active; 3
placebo) received 40, 120 and 400 mg/day in 2 daily doses for 2 weeks.
CNS effects were explored using psychomotor tests, rating scales and
neurological assessments. PK profiles were obtained after the first dose,
and after 7 and 14 days of twice daily dosing.
Results: Treatment emergent adverse effects (TEAEs) occurred in
44%, 89%, 78% and 100% of subjects receiving placebo, 40, 120 and
400 mg/day, respectively, the most frequent being dizziness, drowsiness,
euphoria and feeling drunk. Their onset was generally within 1 hour of
the seletracetam first dose and was resolved within 24 hours and of mild
to moderate severity. There were no serious adverse events (AEs), nor
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changes in laboratory, vital signs, ECGs or neurological examinations.
Seletracetam pharmacokinetics were linear, dose-proportional and time
invariant, with a plasma half-life of 8.0 hours.
Conclusion: The maximum dose of seletracetam in this study (400
mg/day for 2 weeks) was well tolerated, with AEs limited to mild to
moderate CNS effects at initial dosing. UCB funded.
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PHARMACOKINETICS AND METABOLISM OF 14C-
SELETRACETAM IN HEALTHY SUBJECTS
1S. Ramael, 2M. Sargentini-Maier, 2N. Toublanc, 3G. Dubin, and 2A.
Stockis (1SGS Life Science Services, Antwerp, Belgium, 2UCB, Clini-
cal Pharmacology, Braine-l’Alleud, Belgium, 3UCB, Drug Metabolism,
Braine-l’Alleud, Belgium)
Purpose: Seletracetam (UCB 44212) is an investigational antiepilep-
tic drug (AED) with a high affinity for the synaptic vesicle protein SV2A.
This study investigated the excretion balance and metabolism of orally
administered [14C]-seletracetam in healthy male volunteers.
Method: Six subjects received a single oral dose of 100 mg seletrac-
etam labelled with 3.7 MBq of radiocarbon. Plasma, whole blood and
expired air samples were obtained serially and urine and faeces were col-
lected for 7 days and analysed for total radioactivity, seletracetam and
metabolites (plasma and urinary levels). Ex vivo plasma protein binding
was also determined.
Results: Radioactivity excretion was rapid (>90% in 48 hours) and
almost complete (92% in urine and 3.2% in faeces) within 168 hours.
Main urinary components were seletracetam (25%) and UCB-101596-1
(53%), a carboxylic acid formed by hydrolysis of the amide moiety. Two
minor metabolites were also detected, each representing less than 2% of
the total radioactivity. No radioactivity was found in exhaled air. Peak
plasma concentrations were reached 3 hours postdose. Approximately
90% of plasma radioactivity was identified as seletracetam over the 24
hour period postadministration, while the remainder was associated with
ucb-101596-1. Respective half-lives were 8.7 and 9.8 hours. Protein
unbound fraction was 95%.
Conclusion: The oral bioavailability of seletracetam is >90%. Plasma
protein binding is negligible. Rapid and complete recovery of radioac-
tivity indicates a lack of retention in the body. Seletracetam is eliminated
by urinary excretion as the unchanged compound and as the carboxylic
acid metabolite ucb-101596-1. UCB funded.
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LONG-TERM EFFECTIVENESS OF LEVETIRACETAM IN
THE TREATMENT OF EPILEPSY ASSOCIATED WITH LIVER
DISEASES
1F. Mari, 1C . Di Bonaventura, 1G. Egeo, 1J. Fattouch, 1A. Vaudano,
1M. Prencipe, 1/2M. Manfredi, and 1A. Giallonardo (1Epilepsy Unit,
Dept of Neurological Sciences, University of Rome “La Sapienza,” Italy,
2Neuromed Institute of Pozzilli (IS), University of Roma “La Sapienza,”
Italy)
Purpose: Levetiracetam (LEV) has a good pharmacological profile.
This study investigated LEV’s efficacy in patients with comorbid liver
diseases.
Method: Patients affected by partial or generalised epilepsy associ-
ated with liver disease (chronic or acute hepatopathies), where treatment
with old antiepileptic drugs (AEDs) produced complications, were in-
cluded. EEG, clinical and blood parameters were assessed before LEV
initiation and existing AED therapy withdrawn. Clinical, EEG and lab-
oratory assessments were performed again at 3, 6, 12 and 18 months.
LEV’s efficacy was assessed by seizure frequency reduction; tolerability
by adverse event (AE) reporting.
Results: Eighteen epilepsy patients were recruited (partial n = 12,
generalised n = 6). In 15/18 (83%) patients, seizures were not fully con-
trolled by previous AED therapy. Concomitant liver pathology comprised
hepatitis C virus chronic hepatopathies (13/18) and acute toxic hepatitis
(5/18). AED therapy was changed for liver failure or increased hepatic
values in those patients in which acute or chronic hepatotoxic effects
were documented, and/or interactions observed with specific medica-
tion (i.e. interferon) with enzyme inducing AEDs. LEV mean daily dose
was 2000 (range 1000–3000) mg. LEV was effective and after 18 months
follow-up, seizure recurrence was not observed, and an improvement in
basal medical conditions was confirmed. LEV’s efficacy was particu-
larly evident in patients in whom previous poor seizure control was due
to drug interactions or low dose AED monotherapy. No significant side
effects were reported.
Conclusion: LEV is effective and well tolerated and should be con-
sidered as a first choice AED in the treatment of epilepsy associated with
acute or chronic hepatopathies.
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SAFETY OF LEVETIRACETAM 1000–3000 mg DAILY AS AD-
JUNCTIVE THERAPY IN ADULT PATIENTS WITH PARTIAL
EPILEPSY (SKATE STUDY): THE GREEK EXPERIENCE
1K. Karageorgiou, 2S. Giannakodimos, 3S. Balogiannis, 3A. Karlova-
sitou, 4C. Piperidou, and 5A. Tsakiris (1Director, Neurology Department,
Athens General Hospital “G. Genimatas,” Athens, Greece, 2Epilepsy
Unit/Neurology Department, Athens General Hospital “G. Genimatas,”
Athens, Greece, 3Neurology Department, Hospital AHEPA, Univer-
sity of Thessaloniki “Aristotle,” Thessaloniki, Greece, 4Neurology De-
partment, University of Thrace “Democritus,” Alexandroupolis Univer-
sity Hospital Alexandroupolis, Greece, 5Neurology Department, Pireaus
General Hospital “Aghios Panteleimonas,” Pireaus, Greece)
Purpose: To evaluate the safety and efficacy of levetiracetam (LEV) as
adjunctive therapy in patients with epilepsy experiencing partial seizures,
with or without secondary generalisation, in daily clinical practice.
Method: A 16 week, prospective, multicentre, open-label, phase-IV
pharmacovigilance study of LEV in an adult population receiving at least
one concomitant antiepileptic drug (AED). A 2-week baseline and/or 4-
week titration schedule was used; LEV was uptitrated from 1000 mg/day
to 3000 mg/day (maximum). The intention-to-treat (ITT) population was
used for safety and efficacy analysis.
Results: Thirty-five patients (16 male, 19 female), mean age
40.1 (range 17.0–69.8) years were included. LEV mean dose was
1382.1 mg/day. 10/35 (29%) patients achieved seizure freedom and 25
(71%) ≥50% seizure reduction (23.5% and 61.8% for partial seizures
respectively) with a median seizure reduction of 79.5% (78.2% partial).
Of 24/35 (68.5%) responders, 22 (63%) achieved marked or moderate
improvement on a Global Evaluation Scale. LEV 16 week retention was
82.9%. AEs were reported in 10/35 (29%) patients; most mild to moder-
ate, with 1 serious AE considered drug-related. Nonserious drug-related
AEs were: vertigo (n = 1), diarrhoea (n = 1), nausea (n = 2), anorexia
(n = 2), dizziness (n = 1), impaired balance (n = 1), headache (n = 5),
somnolence (n = 6). AEs caused LEV discontinuation in 1/35, LEV dose
change or temporary discontinuation in 2/35 patients. Lack of efficacy
caused LEV discontinuation in 3/35 patients.
Conclusion: LEV add-on therapy was effective and well tolerated
in managing partial seizures, with or without secondary generalisation,
with a retention rate of 82.9%. The majority of patients were identified
as CGI-responders
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SAFETY PROFILE OF LEVETIRACETAM INTRAVENOUS IN-
FUSION (1000–3000 mg/day IN BID ADMINISTRATION) IN PA-
TIENTS WITH PARTIAL-ONSET SEIZURES
1M. Baulac, 2G. Voss, 3C. Krygier, and 3U. Falter, LEV N 01166 Study
Group1 (1Hoˆpital de la Pitie´ Salpe´trie`re, Service de Neurologie 1, Paris,
France, 2UCB GmbH–Pharma Sector, Kerpen, Germany, 3UCB SA,
Pharma Sector, Braine l’Alleud, Belgium)
Purpose: To assess the safety profile of intravenous (IV) levetiracetam
(LEV, 1000–3000 mg/day), a new formulation intended for patients tem-
porarily unable to take oral LEV. Bioequivalence between oral and IV
formulations is previously demonstrated.
Method: A multicentre, open label, single arm study. Patients tak-
ing oral LEV were switched to the equivalent IV dosage (mg-by-mg
substitution, without washout). 1 to 3 LEV ampoules (500 mg/5 mL)
were injected into 100 mL pouches 0.9% saline and 15 minute infusions
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administered BID for 4 days. Adverse events (AEs), vital signs, phys-
ical and neurological examinations, and LEV and other AED plasma
concentrations were recorded. On days 1 and 4, 2 electrocardiograms
(ECGs) were performed (predose and end of morning infusion). On day
5 patients were switched back to oral LEV. Any seizure occurrence was
recorded.
Results: Twenty-five adults with partial-onset seizures (12 male, 13
female; mean age 40.8 ± 10.6 years, age at epilepsy onset 0–46 years)
completed the study. AEs, mostly mild or moderate, were consistent
with LEV’s known AE profile. Eleven subjects (44%) experienced at
least one treatment-emergent AE. Most frequently reported AEs were
headache (n = 5) and fatigue (n = 3). No serious AEs or deaths occurred,
nor clinically relevant vital sign, ECG or clinical laboratory changes
noted. No temporal relationship between IV infusion and AE onset was
observed, nor infusion site reactions. No seizure worsening was reported
during the study or brief follow-up.
Conclusion: IV LEV appears well tolerated and may be a useful
alternative for patients with partial-onset seizures temporarily unable to
take oral LEV. Supported by funds from UCB.
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LEVETIRACETAM AS MONOTHERAPY FOR EPILEPSY IN
ADULTS: A CASE SERIES
1F. Habetswallner, 1A. Fels, 2F. Marrosu, 1G . De Joanna, and 1V. Rossi
(1Department of Clinical Neurophysiology, Epilepsy Unit, A. Cardarelli
Hospital, Naples, Italy, 2Department of Cardiovascular and Neurological
Sciences, University of Cagliari, Italy)
Purpose: To evaluate efficacy and tolerability of levetiracetam (LEV)
monotherapy in adult patients with epilepsy, both newly diagnosed and
converting from another antiepileptic drug.
Method: Adult patients affected by partial or generalised epilepsy,
with idiopathic, cryptogenic or lesional aetiology, received LEV
monotherapy. Patients were either newly diagnosed or converting from
add-on therapy. All patients underwent objective neurological and psy-
chological examination, EEG, and encephalic CT/MRI at baseline; EEG,
neurological examinations and routine laboratory tests were performed
every 3 months.
Results: Fifty-four patients (25 male, 29 female), aged 15–71 (mean
37) years, mean baseline seizure frequency 4.4/month, received LEV
monotherapy 1000–3000 (mean 2120) mg/day for between 6 and 33
(mean 13.3) months. Twenty-four patients were newly diagnosed, 30
converted from add-on therapy (46.6% from carbamazepine, 10% from
oxcarbazepine, 20% from phenobarbital, 10% from topiramate, 13.3%
valproate). Overall responder rates (≥50% seizure reduction) were 45/54
(83%) at 6 months and 43/54 (79%) at 12 months. Seizure freedom was
achieved in 21/54 (39%) of all patients both at 6 and 12 months. 16/24
(66.6%) patients in the newly diagnosed group and 5/30 (16.6%) pa-
tients who converted from add-on therapy achieved seizure-freedom.
9/54 (17%) patients showed no significant improvement in seizure fre-
quency. Adverse events reported were somnolence, anxiety, depression,
vertigo. LEV was otherwise well tolerated, with no clinically relevant
changes in laboratory parameters.
Conclusion: In this case series, LEV showed good efficacy as
monotherapy and was well tolerated, with initial monotherapy appearing
more effective than conversion to monotherapy.
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EFFICACY OF LEVETIRACETAM AS PROPHYLAXIS TREAT-
MENT IN COMPLEX FOCAL STATUS EPILEPTICUS: A CASE
REPORT
R. Scarpello (U.O. Neurology, Civil Hospital “F. Ferrari,” Casarano,
Italy)
Purpose: To evaluate the efficacy of levetiracetam (LEV) as prophy-
lactic treatment in a patient with complex focal status epilepticus.
Method: This case concerns a female aged 65 years with partial sta-
tus epilepticus whose EEG showed focal paroxysmal anomalies which
disappeared after treatment with intravenous (IV) diazepam (DZP). Two
weeks before this episode, she had experienced a confusional state for
a few minutes. Her initial symptoms of meningism, right hemiparesis
and fever could be attributed to other diseases (eg encephalitis). Inves-
tigations performed 12 after symptoms appearing; CT scan, MRI and
cerebrospinal fluid analysis were normal. After IV DZP administration
as acute treatment, LEV was selected as the antiepileptic drug (AED)
for prophylactic treatment. This patient has Hepatitis C hepatopathy and
so the use of AEDs metabolised by the liver would be contraindicated;
LEV was thus chosen since it does not undergo any significant hepatic
metabolism. LEV was uptitrated over a 5 week period with a starting
dose of 250 mg/day, and increased by 250 mg/day every week to a target
dose of 2000 mg/day.
Results: After 3 months of LEV treatment (2000 mg/day) the patient
remained seizure-free without the occurrence of adverse events. A con-
trol EEG performed during the follow-up visit showed no abnormalities.
Conclusion: This case study suggests that LEV may be safe and
effective when used as prophylactic treatment to prevent complex focal
status epilepticus. Larger studies are needed to confirm this preliminary
finding.
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LONG-TERM EFFICACY AND TOLERABILITY OF LEVE-
TIRACETAM IN PATIENTS WITH EPILEPSY WITH SEVERE
CONCOMITANT DISEASES
R. Vitelli and R. Spagliardi (Neurology Unit, Azienda Ospedaliera della
Provincia di Lodi Largo Donatori del Sangue, Lodi, Italy)
Purpose: To evaluate the long-term efficacy and safety of levetirac-
etam (LEV) in patients with focal epilepsy and other severe concomitant
neurological and/or clinical diseases.
Method: Retrospective study of patients with focal epilepsy and
partial seizures with or without secondary generalisation, who also
had concomitant diseases including neurological copathologies such
as: cerebrovascular disease, Alzheimer’s disease and posttrauma out-
comes; and/or other conditions such as: cardiopathy (atrial fibrillation),
nephropathy and hepatopathy. All patients received additional drugs for
these copathologies. LEV was administered either as monotherapy or as
add-on to existing antiepileptic drugs (AEDs) eg PB, CBZ, VPA, LTG,
GBP. At end of follow-up period, seizure reduction, safety and drug-drug
interactions between AEDs and other concomitant drugs were evaluated.
Results: Fifty-four patients (33 Males, 21 Females), mean age 57.2
(range 23–91) years were included. LEV mean dose was 1420 (range
1000–4000) mg/day. Mean follow-up was 20 (range 6–44) months. 9/54
(16.7%) patients who were seizure-free with previous AEDs and who
were switched to LEV (5 monotherapy, 4 add-on) due to adverse effects
of previous therapy, remained seizure-free. Of the remaining patients
17/45 (37.8%) achieved seizure freedom. Seizure reductions of ≥75%
were achieved by 11/45 (24.4%), and ≥50% by 5/45 (11.1%). 8/45
(17.8%) achieved seizure reduction <50%. 4/45 (8.9%) patients discon-
tinued LEV due to AEs (drowsiness, migraine, restlessness, rash). Other
reported AEs, not requiring discontinuation were transient somnolence
and restlessness.
Conclusion: These data confirm LEV’s good efficacy and safety pro-
file in patients with specific therapeutic needs such as those on polyther-
apy for other copathologies.
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CLINICAL AUDIT OF 218 PATIENTS TREATED WITH
LEVETIRACETAM
R. Kuba and I. Rektor (Faculty Hospital U Sv. Anny, Brno, Czech Re-
public)
Purpose: To assess the safety and efficacy of levetiracetam (LEV) in
patients with uncontrolled partial (focal) seizures.
Method: A clinical audit of adults and children (≥14 years) treated
with LEV for partial onset seizures between 2002 and May 2005.
Main outcome parameters were retention rate (Kaplan-Meyer analysis),
seizure frequency reduction/month, AED treatment changes and adverse
events (AEs).
Results: Two hundred and eighteen (92 male, 107 female) patients,
aged 14–68 (mean 37.2 ± 12.1) years, epilepsy duration 0–54 (mean 18.5
Epilepsia, Vol. 47, S3, 2006
132 7TH EUROPEAN CONGRESS ON EPILEPTOLOGY
± 11.4) years were included. LEV was initial monotherapy in 8/218 pa-
tients and as add-on to: 1 AED 85/218, 2 AEDs 113/218, 3 AEDs 12/218.
LEV retention rates after 6 months, 1, 2 and 3 years were 84.8%, 72%,
62% and 50%, respectively. Mean seizure frequency/month decreased
from 19.2 at baseline to 12.7 and 7.1 after 6 months and 3 years re-
spectively. Mean percentage seizure reductions were 45.7% and 64.2%
after 6 months and 3 years and responder rates (≥50% seizure reduc-
tion) 51.5% and 62.2% after 6 months and 3 years respectively. Seizure
freedom (100% seizure reduction) was achieved by 18.6% and 6.2% af-
ter 6 months and 3 years. Concomitant AED use decreased; 25 patients
received LEV monotherapy, 94, 97 and 2 patients received 1,2 and 3
concomitant AEDs. AEs were experienced by 18.3% (40/218) patients;
mild to moderate, commonly somnolence (24/218), dizziness (8/218)
and mood changes (11/218). 6.4% (14/218) patients discontinued LEV
due to AEs.
Conclusion: LEV add-on therapy demonstrated long-term efficacy
and favourable tolerability in patients with refractory focal epilepsy and
its use decreased substantially concomitant AED requirements.
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LEVETIRACETAM IN MESIAL TEMPORAL LOBE EPILEPSY
S. Quadri (Ospedali Riuniti Di Bergamo, Italy)
Purpose: To evaluate the efficacy and safety of Levetiracetam in
mesial temporal lobe epilepsy.
Method: Thirteen patients (6 males+7 females, aged between 21–53
years old), all diagnosed, during adolescence, with mesial temporal lobe
epilepsy have been included in this retrospective study. At adult age and
after several years of seizure freedom, all patients showed recurrence of
seizures (from 2–3 seizures/month to a maximum of 15–20). At baseline,
all patients were already on treatment with 2 or more AEDs (CBZ,
VPA, PB, PHT, CLB). Considering our prior positive experience with
levetiracetam in symptomatic epilepsy, we tried to optimise patients’
therapy to improve their outcome in terms of efficacy (seizure freedom,
seizure reduction, seizure intensity) and in terms of safety (less AEs)
and therefore shifted all patients to CBZ+LEV therapy. Levetiracetam
mean dosage was: 1750 mg/die (range 1000–3000 mg/die). Patients were
followed up to 15–28 months.
Results: Five patients (38.4%) were seizure free. Four patients
(30.8%) had a 50% reduction of seizure frequency and seizures are now
less intensive (only minor oral automatism and/or a prolonged epigas-
tric aura). Four patients had no improvement (30.8%). The main adverse
event reported by patients was somnolence (mild to moderate).
Conclusion: Even if our experience is limited because of the small
population, we believe that levetiracetam, in association with CBZ, is
effective and well tolerated and represents a valid alternative in the treat-
ment of MTLE, a pathology where surgical treatment is an important
therapeutic choice.
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LEVETIRACETAM: A POTENTIAL TREATMENT OPTION IN
REFRACTORY CANINE EPILEPSY
1H. Volk, 2L. Wieczorek, 2S. Platt, and 1K. Chandler (1Royal Veterinary
College, Department of Veterinary Clinical Sciences, Neurology, Hat-
field, UK, 2Centre for Small Animal Studies, The Animal Health Trust,
Newmarket, UK)
Purpose: Epilepsy is the most common chronic neurological disorder
in dogs. In veterinary medicine approximately 33% of dogs with epilepsy
are refractory to pharmacological treatment. Refractory canine epilepsy
was discussed as a model for pharmacoresistant human epilepsy. As in
humans, new pharmacological treatment options with greater efficacy
are urgently needed. The aim of this study was to find a well tolerated
antiepileptic drug, which reduces seizure frequency by more than 50%
in pharmacoresistant canine epilepsy patients.
Method: The second generation antiepileptic drug (AED) levetirac-
etam was administered to 6 pharmacoresistant epileptic dogs as an ad-
junct to standard treatment protocols with phenobarbital and potassium
bromide. The seizure frequency, pattern, severity and side effects were
recorded. Dogs received 10 mg/kg 3 times daily for 2 months. If no
response was obtained 20 mg/kg 3 times daily was used.
Results: One dog showed no response, 5 dogs had a decrease of
seizure frequency by 80% (responders). Four responded to the lower dose
of levetiracetam, 1 to the higher dose. Three responders had days with
cluster seizures. The number of days with clusters was reduced by 90%
on treatment. Four of the responders had complex focal seizures with
secondary generalisation prior to levetiracetam. In 3 of these dogs 65%
of the seizures did not generalise during the drug period. One dog was
severely sedated on levetiracetam, no other side effects were observed.
Conclusion: Preliminary data suggest that levetiracetam is well toler-
ated in dogs and reduces seizure frequency and severity in 83% of cases.
p508
LEVETIRACETAM ALTERNATIVE MONOTHERAPY FOR EL-
DERLY PATIENTS WITH DIFFICULT TO TREAT EPILEPSY
E. Rosati, G. Muscas, E. Bertini, B. Chiocchetti, and V. Bessi (Depart-
ment of Neurological and Psychiatric Sciences, Epilepsy Center, Careggi
Hospital, Florence, Italy)
Purpose: This open-label 1 year follow-up study was designed to
evaluate levetiracetam (LEV) as a possible alternative for patients who
previously failed other antiepileptic drug monotherapy.
Method: Patients aged 60 years or more with partial seizures with
or without secondarily generalisation, were eligible if they were receiv-
ing a major antiepileptic drug and needed to discontinue it because of
unacceptable side effects or inadequate seizure control. The study pro-
tocol comprised: 1) an 8 week retrospective screening phase; 2) a dose-
escalation phase lasting up to 12 weeks; 3) an open treatment phase.
For the dose-escalation phase, LEV was started at a dose of 250 mg
b.i.d., increased to 500 mg b.i.d. in 3–4 weeks and then based on pa-
tients’ clinical response up to 3000 mg/day or up to seizure freedom.
Concomitant antiepileptic drug was gradually discontinued after week
4 of the beginning of the dose-escalation phase. The treatment phase
began when patients had achieved an initial maintenance dose of LEV
monotherapy. Baseline assessments obtained during the screening visit
included historical seizure frequency, vital signs, physical examination,
medical history, health-related quality of life measured with the Quality
of Life in Epilepsy Inventory (QOLIE-31) and the self-report Adverse
Events Profile (AEP). At each follow-up visit, which occurred every 12
weeks, patients compiled the QOLIE-31 and AEP questionnaires and
investigators rated patients’ global clinical status according to seizure
(frequency, duration, and intensity), adverse events, and cognitive, psy-
chic, motor, and social functioning with the 7-point scale Clinical Global
Impression (CGI).
Results: Twenty-four patients agreed to participate and 17 entered
the treatment phase. Six patients failed by discontinuing concomitant
antiepileptic drug for seizure recurrence. Seven patients reported adverse
events within two weeks of starting LEV. Of these patients, 1 discontin-
ued LEV while the others continued with LEV. At the 6 months visit 3
patients were lost to follow-up and an additional 2 patients discontinued
treatment for lack of efficacy. Remaining 12 patients completed 1 year
of follow-up. The CGI, the QOLIE-31 and the AEP scores showed that
LEV monotherapy was perceived by both physicians and patients to have
more benefits than monotherapy with previous antiepileptic drugs.
Conclusion: LEV is a promising alternative monotherapy for el-
derly patients as a substitution of other ineffective or poorly tolerated
antiepileptic drugs.
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LEVETIRACETAM FOR THE TREATMENT OF “NOT SO BE-
NIGN” PARTIAL EPILEPSIES OF CHILDHOOD WITH CEN-
TROTEMPORAL SPIKES (BECTS)
M. Feucht, G. Pahs, E. Reiter, and L. Urak (Universita¨tsklinik fu¨r Kinder-
Und Jugendheilkunde, Vienna, Austria)
Purpose: This currently ongoing prospective open study aims to de-
fine the efficacy and safety of LEV in children with BECTS who did
Epilepsia, Vol. 47, S3, 2006
7TH EUROPEAN CONGRESS ON EPILEPTOLOGY 133
not respond to sulthiam (STM) and to assess its effect on interictal EEG
activity and cognition.
Method: Children are consecutively recruited from the Vienna uni-
versity paediatric epilepsy outpatient department. Diagnosis is based on
clinical and EEG criteria (including prolonged sleep recordings) by us-
ing the ILAE criteria. LEV is administered after STM failure. In case
of treatment success, STM is tapered. EEG and comprehensive neu-
ropsychological assessments are conducted before treatment and then
periodically. Study end points are the electroclinical state and cognitive
performance after 12 months’ continuous treatment with LEV monother-
apy.
Results: We present pilot data on 15 children who were recruited be-
tween September 2003 and December 2004. Data so far demonstrate
that all of these children remained seizure-free and are experiencing no
reported side effects. In 2 cases, nonconvulsive status epilepticus (oro-
motor dyspraxia with speech deterioration and drooling) was promptly
interrupted. In addition EEG spikes diminished in all of them and have
not reoccurred so far. No further cognitive and/or behavioural decline
has been found.
Conclusion: LEV seems to be an effective and safe alternative treat-
ment option to STM in children with BREC. Further studies will have
to compare both drugs concerning first-line treatment. Strict syndrome
diagnosis is crucial, as the same positive effect was not seen by us in
other idiopathic localisation-related epilepsy syndromes, especially be-
nign epilepsy with occipital paroxysms and familial frontal lobe epilepsy.
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EFFICACY OF LEVETIRACETAM IN THE TREATMENT OF
CHILDREN WITH BECTS: A PROSPECTIVE, OPEN-LABEL
PILOT TRIAL PRIOR TO A CONTROLLED, RANDOMISED,
DOUBLE-BLIND GERMAN MULTICENTRE STUDY (HEAD-
STUDY)
M. Bonfert, S. Armbruster, B. Bastian, and F. Heinen (Abteilung Fu¨r
Neuropa¨diatrie, Dr. von Haunersches Kinderspital, LMU Mu¨nchen,
Germany)
Purpose: To conduct a prospective, open-label pilot trial to evaluate
the efficacy and tolerability of levetiracetam (LEV) monotherapy in a
cohort of 10 children with benign childhood epilepsy with centrotem-
poral spikes (BECTS), paying special attention to effects on cognitive
function.
Method: To date 8 patients aged 3 to 12 years with BECTS were
recruited. LEV was titrated up to 20 mg/kg. Efficacy was assessed by
seizure freedom and alteration of electroencephalogram (EEG) findings
over a 6 month period. Neuropsychological testing of 7 patients took
place before the start of treatment and after 6 months of treatment. Tol-
erability was assessed by evaluation of adverse events (AE).
Results: All 8 patients are seizure-free under treatment. EEG abnor-
malities showed significant reduction. Neuropsychological assessment
before the start of treatment revealed average performance in 5 and below
average performance in 2 patients. In 4 patients who have reached the
endpoint of the trial by now no changes in test results were seen. Mild
AEs were reported in 2 patients (n = 1: mild temporary behavioural
changes within the first week of treatment, n = 1: mild weight loss). In
both cases no adjustment or discontinuation of LEV dosage was neces-
sary.
Conclusion: These preliminary data show that LEV seems to be an
effective and well-tolerated option in the treatment of children with
BECTS. Concerning effects on cognitive function preliminary data are
promising, but the complete data of retesting are to be awaited. Based on
these encouraging results a controlled, randomised, double-blind multi-
centre trial to evaluate the application of LEV in a representative cohort
of 120 children with BECTS is going to start in Germany in spring 2006
(HEAD-Study).
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DETERMINATION OF LEVETIRACETAM IN PATIENTS WITH
EPILEPSY AND INTELLECTUAL DISABILITY
1P. Kaipainen, 1T. Westermarck, 1M. Kaski, 1M. Iivanainen, and 2F.
Atroshi (1Rinnekoti Research Centre, Espoo, Finland, 2Department of
Clinical Science, Pharmacology and Toxicology, Faculty of Veterinary
Medicine, University of Helsinki, Helsinki, Finland)
Purpose: Levetiracetam (Keppra) is a new drug that has a therapeutic
application in epilepsy and disorders involving cognitive disturbances.
We measured twice the concentrations of levetiracetam in sera of 8 pa-
tients with epilepsy and intellectual disability.
Method: We used an isocratic high performance liquid chromatog-
raphy (HPLC) method for the quantification of levetiracetam. Chro-
matograms were run at 35◦C with Zorbax Eclipse XDB-C8 column. A
mobile phase of acetonitrile/38 mM potassium phosphate buffer (pH 4.3.,
12:88 vol/vol) at a flow rate of 1.0 ml/min was used and it was monitored
at 220 nm (Contin et al 2004. Therapeutic Drug Monitoring 26(4):375–
379). All chromatograms were run with Agilent 1100 equipment. The
patient population consisted of 8 patients with difficult-to-treat epilepsy
and intellectual disability who were on antiepileptic multidrug therapy
including levetiracetam.
Results: The mean value of levetiracetam concentrations in these sam-
ples was 130 μmol/l (from 60 to 255). The dose of levetiracetam in these
patients was 2000–4000 mg per day.
Conclusion: This HPLC method is rapid and simple for the deter-
mination of levetiracetam in patients with epilepsy. It seems that the
dose 2000–4000 mg per day will give the necessary therapeutic level.
The detailed relationship between efficacy and the concentration of lev-
etiracetam in serum is under analysis.
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EFFICACY OF LEV IN POSTSURGICAL PATIENTS WITH
CONTINUING SEIZURES
A. Carius and A. Schulze-Bonhage (University of Freiburg, Epilepsy
Centre, Freiburg, Germany)
Purpose: To evaluate the efficacy of levetiracetam (LEV) newly in-
troduced in postoperative patients still experiencing seizures.
Method: At the University Hospital, Freiburg, in Germany patients
with ongoing seizures after elective brain surgery were identified. From
2001 to 2005 LEV was started in 32 of these patients after surgery.
LEV treatment was started after up-titration of preexisting AEDs. A
retrospective chart review was performed to assess seizure freedom and
responder rates.
Results: Thirty-two patients were analysed. In 31 patients LEV
was started as add-on therapy (1-3 preexisting AEDs), in 1 patient as
monotherapy. 21/32 patients (69%) became seizure free and an additional
6 patients (19%) experienced a seizure reduction of at least 50% after
administration of LEV 500–4000 mg/d. The follow-up period ranged
from 3 to 41 months (mean 16.5 months) per patient. Eight of the pa-
tients had been treated preoperatively with LEV without success. Seven
of these patients became seizure free post-operative when the treatment
with LEV was started again.
Conclusion: LEV proved highly effective (69% seizure freedom) in
the post-operative treatment of brain surgery patients still experienc-
ing seizures. Epilepsy surgery, although not leading to seizure freedom,
rendered some patients pharmaco-responsive to LEV.
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EEG EFFECTS OF LEVETIRACETAM IN PATIENTS WITH
EPILEPSY
M. Radionova (Medical University. Sofia, Bulgaria)
Purpose: To study EEG changes during Levetiracetam (LEV) as add-
on therapy in patients with epilepsy.
Method: The study included 23 patients with refractory epilepsy (par-
tial with secondary generalisation) treated with LEV as add-on therapy.
The basic antiepileptic drug was kept constant during the evaluated pe-
riod. The EEG findings after 3 months of treatment were compared to
the baseline period.
Results: Fifteen (65.22%) patients achieved more than 50% seizure
control, and 8 (34.78%) showed insufficient effect. Two (8.7%) patients
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reported on sleep and mood disturbances. In the EEG no changes were
found in the organisation of background activity during LEV. The initial
diffuse slowing in 4 (17.39%) patients was reduced in 3 (13.04%) of
them. Focal activity was found in 11 (47.83%) patients before LEV
followed by reduction in 2 (8.7%) and aggravation/provocation in 7
(30.43%) patients. Paroxysmal activity showed in 7 (30.43%) patients
initially. During LEV reduction was found in 2 patients (8.7%), no change
in 3 (13.04%) and activation/new in 4 (17.39%) patients. No correlation
was found between the evolution of focal and paroxysmal activity and
seizure control.
Conclusion: LEV does not affect the background activity in patients
with epilepsy. No correlation was found between clinical efficacy and
evolution of focal and paroxysmal activity. Investigations are needed to
study the EEG changes in patients with epilepsy treated with LEV as
monotherapy.
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LEVETIRACETAM SERUM LEVELS ARE INFLUENCED BY
ENZYME-INDUCING AND NON–ENZYME-INDUCING CO-
MEDICATION
1,2C. Reinsberger, 2H. Juch, and 2G. Kra¨mer (1Department of Neurology,
Julius-Maximilians-University Wu¨rzburg, Wu¨rzburg, Germany, 2Swiss
Epilepsy Center, Zurich, Switzerland)
Purpose: Levetiracetam (LEV) is a new antiepileptic drug (AED) ap-
proved for add-on therapy up until now. As there is no major metabolism
of LEV, its serum levels are usually considered not to be influenced by
other AEDs, especially enzyme-inducing AEDs (EI-AEDs).
Method: To evaluate the effect of AEDs on serum levels of LEV
we retrospectively analysed data of 541 in- or outpatients of the Swiss
Epilepsy Center between January 2002 and May 2005. 2007 mea-
surements (188 with LEV as monotherapy, 410 with EI-AEDs as co-
medication, 1179 with non–enzyme-inducing AEDs (NEI-AEDs) and
230 with both EI-AEDs and NEI-AEDs were processed. Repeated mea-
surements in the same patient were considered only if the drug regimen
or dosages were changed.
Results: Serumlevel-to-dose ratios of LEV are significantly lower
when AEDs are administered simultaneously (median 3.22 vs 3.86,
p = 0.003). This effect is primarily induced by EI-AEDs as indicated
by significant differences in this group (median 3.10, p = 0.001) com-
paring to a nonsignificant difference in combination with NEI-AEDs
(median 3.26, p = 0.591). When only fasting values were taken into
account (LEV monotherapy n = 47, LEV & EI-AEDs n = 212, LEV &
NEI-AEDs n = 559) significantly lower LEVserum level-to-dose ratios
were also seen in combination with EI-AEDs (median 2.32 vs 2.52, p =
0.022), whereas simultaneous application of NEI-AEDs lead to signifi-
cantly higher LEV-serum level-to-dose ratios (median 2.56 vs 2.16, p =
0.003).
Conclusion: Serum levels of LEV are influenced by other AEDs.
Whether these findings are of clinical significance has to be evaluated in
further studies. More data on fasting values in monotherapy should be
available soon, as LEV is about to be approved for monotherapy.
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EFFICACY OF LEVETIRACETAM AS AN ADD-ON THERAPY
IN PATIENTS WITH STARTLE EPILEPSY
F. Ciftci, K. Alpay, C. Gurses, N. Bebek, B. Baykan, and A. Gokyigit
(Istanbul University, Istanbul Faculty of Medicine, Department of Neu-
rology, Turkey)
Purpose: Our aim is to evaluate the use of levetiracetam as an add-on
therapy in patients with startle epilepsy.
Method: Thirteen patients suffering from seizures triggered by un-
expected stimulus were evaluated. Touching or striking any part of the
body was the main triggering stimulus. Sudden noise in 2, touching and
noise in 7, touching in 4 patients were the stimuli. Onset of seizures in
4 male and 9 female patients varied from birth to 13 years. Head trauma
in 3, birth injury in 4, febrile or nonfebrile convulsions in 3 and epilepsy
in a family of 3 patients was found in their stories. Neurologic examina-
tion abnormality was found in 10 and mental retardation in 9 patients.
Neuroimaging studies showed abnormality in 10 patients. EEG abnor-
malities were seen in 12 patients, and normal in 1. Levetiracetam was
started as an add on therapy to other antiepileptic drugs and doses could
be adjusted individually.
Results: Thirteen patients were enrolled, data were analysed for 9
patients. The frequency of seizures increased in 1 patient, 1 was unre-
sponsive and levetiracetam therapy was stopped in 2. The response rates
were 100% in 1, 70–99% in 2, 50–70% in 2, and 0–20% in 2 patients.
Conclusion: Levetiacetam can be an alternative treatment as an add
on therapy in startle epilepsy. This study may serve as pilot data for trials
of levetiracetam for startle induced seizures.
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EFFICACY AND TOLERABILITY OF LEVETIRACETAM AS
AN ADD-ON THERAPY IN 40 PATIENTS WITH EPILEPSY
K. Alpay, F. Ciftci, C. Gurses, N. Bebek, B. Baykan, and A. Gokyigit
(Istanbul University, Istanbul Faculty of Medicine, Department of Neu-
rology, Turkey)
Purpose: Our aim is to evaluate the efficacy and tolerability of leve-
tiracetam as an add-on therapy in patients with epilepsy.
Method: Levetiracetam was administered to 40 patients with epilepsy
older than 16. Onset of seizures of 21 males and 19 females patients var-
ied from birth to 74 years. Head trauma in 11, birth injury in 3, febril or
nonfebril convulsions in 7 were found in their stories. Four patients had
a history of status epilepticus and 6 patients had other systemic disor-
ders. Neurologic examination abnormality was found in 22 and mental
retardation in 16 patients. Neuroimaging studies showed abnormality in
22 patients. EEG abnormalities were seen in 34 patients, and normal in
6. The seizure pattern was different: 35 generalised or partial intractable
epilepsy, 5 generalised or partial epilepsy. Two patients with progressive
myoclonic epilepsy, 2 with Jacob Creutzfeldt Disease were also evalu-
ated. Levetiracetam was started as an add on therapy to other antiepileptic
drugs and doses could be adjusted individually.
Results: 40 patients were enrolled; data were analysed for 26 patients.
The patients included in this study were studied prospectively and these
are the early results of this study. Five patients were seizure free, 50–90%
decrease in 6, 25–50% decrease in 6, no change in 9, and more seizures
were seen in 1. Five of 9 startle epilepsy patients had good response.
Lack of efficacy in 7%, and adverse effects in 17.5% of patients were
seen.
Conclusion: Levetiracetam was effective and well tolerated as an add-
on therapy in patients with partial, generalised, startle epilepsy and JCD
myoclonies.
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RETROSPECTIVE STUDY OF LEVETIRACETAM TREAT-
MENT AS MONOTHERAPY FOR PATIENTS WITH EPILEPSY
M. D’Argenio, M. Feleppa, and A. Rummo (Epilepsy Center U.O. Neu-
rologia, Benevento, Italy)
Purpose: To evaluate the efficacy and safety of levetiracetam (LEV)
as monotherapy for patients with epilepsy.
Method: A retrospective analysis of patients treated with LEV
monotherapy, either as first-line antiepileptic drug (AED) therapy, or
having previously been treated unsuccessfully with other AEDs.
Results: 25 patients were identified (11M/14F, age 19–80 years); 52%
(13/25) with partial seizures and 48% (12/25) with generalised seizures.
Aetiologies were symptomatic (52%; 13/25), idiopathic (36%; 9/25) and
cryptogenic (12%; 3/25). 32% (8/25) patients received LEV as first-line
therapy, having presented with monthly or multi-monthly seizures; 68%
(17/25) patients converted to LEV monotherapy having been treated
unsuccessfully with valproate (VPA; n = 5), lamotrigine (LTG; n = 5),
oxcarbazepine (n = 2), phenobarbital (PB; n = 2), carbamazepine (CBZ;
n = 1), CBZ + PB (n = 1) and VPA + LTG (n = 1). In patients treated
as first-line therapy, LEV was uptitrated to 1500–2000 mg/day; after 6
months (n=2) and 2 years (n=6) follow-up, all patients achieved seizure
freedom, without adverse events (AEs). In patients converted from other
AEDs, LEV was uptitrated to 1500–3000 mg/day; 94.1% (16/17) pa-
tients achieved seizure freedom after 6 months follow-up without AEs;
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1 patient (5.9%), who had cryptogenic epilepsy with absences, discon-
tinued treatment due to lack of efficacy.
Conclusion: This analysis suggests that LEV monotherapy is effec-
tive and well tolerated both as first-line therapy and in patients convert-
ing from previously unsuccessful treatment with other AEDs. Retention
rate was good, with many patients continuing LEV treatment for >6
months. AEs occurring before conversion to LEV monotherapy (eg.,
weight gain, pruriginous exanthema, intense tremor) disappeared after
conversion.
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NEUROPSYCHOLOGICAL AND PSYCHIATRIC IMPACT OF
ADD-ON TITRATION OF PREGABALIN VERSUS LEVE-
TIRACETAM: A COMPARATIVE STUDY
1A. Ciesielski, 2S. Samson, and 1B. Steinhoff (1Epilepsy Center Kork,
Kehl-Kork, Germany, 2University of Lille 3, Villeneuve D’Asq, France)
Purpose: Cognitive and behavioural impairments are common in pa-
tients with epilepsy. Multiple factors may contribute to these difficul-
ties; among them is antiepileptic drug (AED) treatment. We examined
the impact of two new add-on AEDs, pregabalin (PGB) and levetirac-
etam (LEV), on cognition and psychiatric states in 20 adult patients with
medically refractory partial epilepsies.
Method: According to an open, prospective comparative trial add-on
PGB was titrated to 300 mg or LEV to 1000 mg in 10 patients each.
Patients were assessed before (T1) and two weeks after (T2) the addition
of the AED.
Results: During the short trial the seizure frequency did not change
significantly in either group. PGB seemed to impair episodic memory of
verbal and visual information, although it did not influence psychiatric
states. With LEV treatment we saw improvements of visual short-term
memory, attention span and psychiatric states (i.e., interpersonal sensi-
bility, depression and anxiety).
Conclusion: This study suggests a favourable neuropsychological and
psychiatric impact of add-on LEV. The somewhat disappointing results
with PGB may reflect temporary effects under titration, but still they did
not confirm the promising profile concerning psychiatric co-morbidity
factors that have been emphasised by other reports.
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EFFICACY OF LEVETIRACETAM AS MONOTHERAPY IN
SUPPRESSING INTERICTAL DISCHARGES IN FOCAL AND
GENERALISED EPILEPSY
F. Habetswallner, A. Fels, G. De Joanna, V. Rossi, and A. Baldini (A.
Cardarelli Hospital, Naples, Italy)
Purpose: To assess the efficacy of levetiracetam as monotherapy in
suppressing interictal EEG epileptiform activity.
Method: In this open retrospective trial 20 patients (9 males and
11 females, aged 10–70 years, mean 38) affected by partial or gener-
alised epilepsy, with idiopathic, cryptogenic or lesional aetiology, re-
ceived LEV monotherapy (doses: 1000–4000 mg daily, mean 2250).
8 patients were newly diagnosed; the remaining 12 were converted to
LEV monotherapy from add-on therapy (4 VPA, 5 CBZ, 2 OXC, 1 LTG).
At baseline the mean seizure frequency was 4.0/month and all patients
showed EEG interictal epileptic activity (strictly following the IFCN
definition). The efficacy was tested by evaluating suppression of such
epileptic activity after 3 and 6 months of therapy and by calculating the
rate of patients with significant (>50%) reduction of baseline seizure
frequency (responder rate).
Results: After 3 months of therapy we observed a complete disap-
pearance of interictal epileptic activity with normal EEG in 13 patients
(65%); 5 patients (25%) showed a marked improvement of EEG with
disappearance of epileptic activity and persistence only of slow and non
specific abnormalities. In 2 cases (10%) the EEG showed no significant
modifications of epileptic activity. After 6 months these results were
unchanged. Overall responder rate (≥50% seizure reduction) was 18/20
(90%) at 3 and 6 months. We observed the lack of clinical response in
the same two patients who didn’t show EEG improvement.
Conclusion: In our case series, LEV as monotherapy showed a good
efficacy both in suppressing interictal EEG epileptic activity and con-
trolling seizures.
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THERAPEUTIC DRUG MONITORING IN NONRESPONDING
AND RESPONDING PATIENTS TREATED WITH KEPPRA
K. Nielsen, M. Khinchi, M. Frangu, M. Nikanorova, E. Hansen, and V.
Nikanorov (Danish Epilepsy Centre, Denmark)
Purpose: The purpose is to study the possibilities of identification
and clinical characterisation of subgroups of patients that will respond
to Keppra after exhibiting nonresponding features to a number of medical
treatments. The hypothesis is that such an investigation may elucidate
an epilepsy patient’s disposition for intractable epilepsy and the risk of
a patient to develop drug resistance.
Method: Retrospective studies of therapeutic drug monitoring val-
ues of children with a well-characterised epilepsy diagnosis were per-
formed. Investigation of drug profiles was limited to children either re-
ceiving Keppra medication or children withdrawn from Keppra due to
non response or accumulation of side effects. The subjects were identi-
fied among patients at the Danish Epilepsy Centre and the patients were
characterised as nonresponders to at least three previously tested medical
treatments prior to introducing Keppra therapy. For each patient the di-
agnosis, seizure type, seizure frequency and level of Keppra efficacy was
characterised and compared to seizure types and frequencies observed
during earlier therapeutic regimes.
Results: Children characterised in terms of seizure control, adverse
drug reactions, and manifestation of the epileptic syndrome were sub-
grouped into responders exhibiting 100% seizure control and partial
responders exhibiting either >50% or <50% reduction in seizure fre-
quency. Based on these data a cohort with full seizure control and a
cohort without seizure control were defined.
Conclusion: Responding patients becoming seizure free on Keppra
therapy after at least 3 insufficient drug treatments were found as were
patients that did not respond to Keppra. These preliminary results are the
background for further characterisation of both subgroups and finding
potential responders to Keppra therapy.
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COGNITIVE EFFECTS OF LOW-DOSE TOPIRAMATE: A
COMPARATIVE STUDY WITH LAMOTRIGINE IN EPILEPSY
PATIENTS
S. Park, H. Lee, D. Jung, and C. Suh (Kyungpook National University
Hospital, Daegu, South Korea)
Purpose: Cognitive effects of topiramate (TPM) during low-dose
monotherapy have not been established. We evaluated the cognitive ef-
fects of low-dose TPM compared with lamotrigine (LTG), because LTG
has not been shown to negatively affect cognitive function.
Method: This retrospective study comprised 60 epilepsy patients who
had undergone two sets of neuropsychological tests (baseline and a year
of medication) who were newly diagnosed, or untreated in the preceding
6 months. The results of cognitive function of 30 patients with low-dose
TPM monotherapy (50–100 mg/day) were compared with those of a
random sample of 30 patients with LTG monotherapy. Groups did not
differ with respect to epilepsy relevant variables. Their neuropsycholog-
ical tests at baseline did not differ. After a year of treatment, an average
daily dose of TPM and LTG were 75 mg and 100 mg, respectively.
Results: TPM group showed a significant difference in the perfor-
mance of list learning (p < 0.05), forward digit span (p < 0.05), backward
digit span (p < 0.05), and verbal fluency (p < 0.01) compared with the
LTG group. TPM group showed worse performances of digit span and
verbal fluency. LTG group showed a better performance of list learning.
The incidence of cognitive complaints was higher in TPM group (50%)
than LTG group (20%) (p < 0.05). These cognitive effects shown in the
TPM group were dose-related. The cognitive dysfunction was trivial for
patients taking 50 mg/day TPM.
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Conclusion: Even low-dose TPM monotherapy certainly has a nega-
tive effect on short-term memory and speech compared with LTG.
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TOPIRAMATE IN BRAIN-TUMOUR ASSOCIATED EPILEPSY:
OUTCOME AND TOLERABILITY
1M. Maschio, 1A. Zarabla, 1L. Dinapoli, 2D. Giannarelli, 1A. Pace, 1C.
Carapella, 1A. Pompili, 1E. Morace, 1E. Occhipinti, and 1B. Jandolo
(1Epilepsy Outpatient’s Center, National Institute for Cancer “Regina
Elena,” Rome Italy, 2Biostatistical Unit, National Institute for Cancer
“Regina Elena” Rome, Italy)
Purpose: In patients with brain tumours, conventional antiepileptic
drugs (AED) may interact with chemotherapeutics and corticosteroids,
leading to reduced efficacy and/or more frequent side effects. Topiramate
is a newer well-tolerated broad-spectrum AED with low potential for
interactions. The aim of this study was to investigate its efficacy and
tolerability in brain-tumour associated epilepsy. We selected topiramate
because of its favourable pharmacokinetics.
Method: In this single-centre, open-label, observational study, 46 pa-
tients (mean age 48 years, 20M/26F) with epilepsy related to brain tu-
mours received topiramate according to the dose recommendations in
the label. Twelve patients were treatment-naive, 34 were converted from
other AEDs to topiramate add-on or monotherapy because of poor seizure
control or intolerable side effects. Seizure frequency was captured ret-
rospectively (baseline) for up to 12 months prior study entry and at the
final follow-up visit (mean (range): 13.1 (5–43) months).
Results: During topiramate (67.4% monotherapy, 32.6% add-on),
54.4% of patients were seizure-free; at least 50% seizure reduction was
observed in another 23.9%. Seizures remained unchanged in 17.4% and
worsened in 4.3% (increasing less than 50%). Seizure control remained
stable during tumour progression. The overall responder rate was 78%;
75% with versus 83% without tumour progression. Side effects during
topiramate (1 paraesthesia, 1 weight loss, 1 confusion) were mild and
didn’t lead to changes in therapies.
Conclusion: Topiramate appears to be a good choice for patients
with brain-tumour associated epilepsy: the data support adequate seizure
control (also stable during tumour progression) and paucity of adverse
events.
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EFFICACY AND SAFETY OF TOPIRAMATE MONOTHERAPY
IN ELDERLY EPILEPSY
L. Martinez, J. Mauri, C. Tejero, G. Pin˜ol, T. Corbalan, and E. Mostacero
(Clinical Hospital, Zaragoza, Spain)
Purpose: In the elderly with epilepsy we need to consider better-
tolerated and less toxic drugs than those classically used. Topiramate is
a wide spectrum antiepileptic drug which is effective in the treatment
of all types of seizures and offers considerable advantages (approved
in monotherapy, absence of interactions in patients generally polymedi-
cated) over other antiepileptic therapies for the treatment of the elderly.
The goal of the present study is to assess the efficacy and tolerance of a
low dose of topiramate as monotherapy for elderly patients with epilepsy.
Method: A prospective, descriptive, observational study was carried
out on a total of 31 patients over 65 years old. All patients started with a
single daily dose of 25 mg of topiramate. Their dosages were adjusted to
treatment response. Where further seizures arose, the dose of topiramate
was increased. Efficacy and tolerance checks were carried out after one
month, three and six months.
Results: Median daily dose was 90 mg. At the end of the study 23
(74.2%) patients continued to be seizure free. The drug was withdrawn
in 2 cases. Median reduction in seizure frequency from baseline to study
end was 91%. The most common adverse events (19.3%) were dizziness
and somnolence. One patient discontinued because of adverse events.
Conclusion: Topiramate is an effective therapy for the control of
epilepsy in elderly patients at low doses, with good tolerance and a
low rate of adverse effects.
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EFFECTS OF TOPIRAMATE (TOPAMAX) IN PATIENTS WITH
REFRACTORY EPILEPSY
D. Kvernadze, S. Kasradze, O. Toidze, T. Gagoshidze, and I. Bokhua
(Epilepsy Prevention and Control Centre, Tbilisi, Georgia)
Purpose: Topiramate (TPM), a novel AED of broad spectrum, is often
used in the treatment of patients with refractory epilepsy. The effects of
TPM have not yet been investigated in patients with epilepsy in Georgia.
The aim of the study was to evaluate the effects of TPM in patients with
refractory epilepsy.
Method: The effect of TPM was observed in 12 patients (4 females,
8 males; age range 6–54 years, MD = 25.3 years) with seizures resistant
to old generation AEDs. Five patients with temporal lobe, 5 with frontal
lobe, and 2 with unclassified seizures were investigated (seizure fre-
quency by individual calendars, EEG, neuropsychological testing, MRI)
before starting and 6 months after starting TPM-therapy. Three patients
from those remained on TPM monotherapy, while 9 patients remained
on polytherapy. The initial daily dose of TPM was 25 mg and titra-
tion rate 25 mg per week. Average dosage of TPM varied between 50–
400 mg/day.
Results: With a dose of TPM under 50–200 mg/day, 6 patients, 50%,
(3 with temporal, 2 with frontal, and one with unclassified seizures)
became seizure free. In 4 patients seizure frequency was reduced by
>50%, in 2 cases by <50%. Observed side effects of TPM were weight
loss in 2 cases and cognitive impairment (concentration problems and
word finding difficulty) at high dosage (400 mg/day) of TPM in 1 patient.
Conclusion: Topiramate is very effective in the treatment of refractory
epilepsy in patients with focal seizures.
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OBSERVATIONAL STUDY OF THE OUTCOME OF EPILEPSY
FOLLOWING USE OF TOPIRAMATE AS A BROAD-
SPECTRUM ANTIEPILEPTIC DRUG IN ROUTINE CLINICAL
CARE
1S. Magureanu, 2L. Perju, 3M. Marinescu, and 4I. Iosif (1“Al. Obre-
gia” Clinical Hospital, Bucharest, Romania, 2County Clinical Hospi-
tal, Cluj-Napoca, Romania, 3Janssen-Cilag Romania, Bucharest, Roma-
nia, 4Biostatistician CNLAS (National Committee For Fight Against
AIDS), Bucharest, Romania, 5And The TOPMATEPY4020 Investiga-
tors Group)
Purpose: Controlled clinical trials support the efficacy and safety
of topiramate in various types of epilepsy. This survey documents its
outcome as a broad-spectrum antiepileptic drug (AED) in a Romanian
population of epilepsy patients.
Method: Open-label observational study in patients (≥2 years old)
with epilepsy (newly diagnosed, unresponsive to previous AEDs because
of insufficient efficacy/tolerability, or responding but with unacceptable
weight gain). Patients were titrated to optimal dose according to usual
regimen over 2 months and then maintained for 6 months. Concomitant
AEDs were discontinued if possible. Seizures and adverse events were
documented. Monthly seizure rate was calculated at baseline (3 months
retrospectively) and during month 8 in trial completers.
Results: 607 patients (44.8% children ≤18years; 74.5% refractory to
prior AEDs, various seizure types) were started on topiramate monother-
apy (14.5%) or combined therapy (85.5%); 460 patients (231 children)
completed the study, 58.7% receiving monotherapy. During month 8,
86.1% of children and 71.9% of adults were seizure-free; in the other
completers, monthly seizure rates decreased significantly (p < 0.001)
from 24.5 at baseline to 3.6 in children (n = 71), and from 5.3 to 1.0 in
adults (n = 65). Median topiramate dose was 100 mg/day in children,
150 mg/day in adults. The most common treatment-emergent adverse
event was weight decrease (n = 26). Topiramate was discontinued due
to adverse events in 1.5% (1 child, 8 adults).
Conclusion: The findings corroborate those of randomised clinical
trials: they support topiramate as an effective and well-tolerated broad-
spectrum AED; at month 8, complete seizure control can be achieved by
topiramate monotherapy in a substantial portion of patients. Funded by
Janssen-Cilag.
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EFFICACY AND TOLERABILITY OF TOPIRAMATE IN PA-
TIENTS WITH EPILEPSY PREVIOUSLY TREATED WITH
CARBAMAZEPINE OR OXCARBAZEPINE
B. Schauble and A. Schreiner (Medical & Scientific Affairs, Janssen-
Cilag, Neuss, Germany)
Purpose: To evaluate seizure frequency and tolerability in patients
with epilepsy treated with topiramate (TPM) after transition from car-
bamazepine (CBZ) or oxcarbazepine (OXC).
Method: Interim analysis of a multicenter open-label non-
interventional study. Patients with epilepsy ≥12 years of age previously
unsuccessfully treated (lack of efficacy and/or lack of tolerability) with
CBZ (71% of patients) or OXC (29%) were prospectively followed for 26
weeks after initiation of, and transition to, TPM. A 12 week retrospective
seizure frequency was used as baseline.
Results: Seventy-five patients (64% female, mean age 46 ± 17 years)
were enrolled. The most frequent seizure types at baseline were gen-
eralised tonic-clonic (48%), complex partial (28%), and simple partial
(17%). Main reasons for CBZ/OXC discontinuation were side effects
in 81% (reported side effects: somnolence 74% and dizziness 55%
(CBZ); somnolence 64% and concentration difficulties 42% (OXC)
and lack of efficacy (73%). At endpoint, the median TPM dose was
100mg/day. Mean seizure frequency decreased from 4.5/month at base-
line to 0.9/month at endpoint (p < .00001). The responder rate (≥50%
seizure reduction) was 90%, and 64% of patients remained seizure-free
for more than the last 3 months of the study. 83% of patients completed
the study. 9% discontinued TPM prematurely due to an adverse event
(AE), 1% due to lack of efficacy. The only AEs reported in ≥5% were
paraesthesia (11%) and weight decrease (11%).
Conclusion: After transition from CBZ or OXC, topiramate was as-
sociated with a substantial reduction in seizure frequency, including a
high seizure-free rate, and was well tolerated.
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EFFICACY AND TOLERABILITY OF TOPIRAMATE IN
PATIENTS WITH EPILEPSY AFTER TRANSITION FROM
VALPROATE
A. Schreiner and B. Schauble (Medical & Scientific Affairs, Janssen-
Cilag, Neuss, Germany)
Purpose: To seizure and tolerability in patients with epilepsy treated
with topiramate monotherapy (Topamax; TPM) after transition from val-
proate (VPA).
Method: Interim analysis of a multicenter open-label non-
interventional study. Patients with epilepsy independent of seizure type,
age 12 and above and previously unsuccessfully treated with VPA (lack
of efficacy and/or lack of tolerability) were prospectively followed for
20 weeks after initiation of, and transition onto TPM.
Results: One hundred patients (66% female, mean age 42 ± 20
years) were enrolled. Most frequent seizure types at baseline were gener-
alised tonic–clonic (46%), complex partial (20%) and absence seizures
(13%). Reasons for VPA discontinuation were side effects in 82% (re-
ported side effects: tremor 44%, somnolence 34%, cognitive symp-
toms 28%) and lack of efficacy (57%). At end point, the median TPM
dose was 100mg/day, with 23% of patients receiving less than 100 mg
TPM/day. Mean seizure frequency decreased from 14.3/month at base-
line to 4.4/month at endpoint (p < .0001). The responder rate (≥50%
seizure reduction) was 76%, and 51% of patients remained seizure-free
for at least the last 3 months of the study. 85% of patients completed
the study. 7% discontinued TPM prematurely due to an adverse event
(AE), 2% due to lack of efficacy. The only AEs reported in ≥5% were
paraesthesia (6%) and weight decrease (5%).
Conclusion: After transition from VPA, topiramate was associated
with a substantial reduction in seizure frequency including a high seizure-
free rate, and was well tolerated.
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SAFETY AND TOLERABILITY OF TOPIRAMATE IN EL-
DERLY PATIENTS WITH EPILEPSY: RESULTS FROM A
PROSPECTIVE OBSERVATIONAL STUDY
1U. Runge and 2A. Schreiner (1Department of Neurology, Ernst-Moritz-
Arndt-University, Greifswald, Germany, 2Medical & Scientific Affairs,
Janssen-Cilag, Neuss, Germany)
Purpose: To observe safety and tolerability in elderly individuals with
epilepsy age 65 and above treated with topiramate (TPM) monotherapy
in a naturalistic setting.
Method: Multicenter, open-label, observational study. Individuals
with epilepsy independent of seizure type aged 65 and above were
prospectively followed for 6 months after first ever initiation of TPM.
Seizure frequency was recorded for a 6-month retrospective baseline and
prospectively. Adverse events (AEs) were assessed at each visit.
Results: One hundred and forty-five patients (mean age 72.7, range
64–100, 49% women) were documented prospectively and followed for
up to 6 months. Median duration of epilepsy was one year (range, 0–33).
The most frequent aetiologies were cerebrovascular (68%) and degener-
ative disease (14%). Overall, 93% patients had a least one concomitant
disease and 90% had at least one other non–anticonvulsant concomitant
medication. TPM doses ranged between 50 and 100 mg/day in most pa-
tients. Seizure frequency decreased from 2.9 ± 15.8 at baseline to 0.5 ±
1.7 at endpoint. 73.1% of patients had at least a 50% seizure reduction
compared to the retrospective baseline, and 40.7% remained seizure-free
throughout the study. 5.5% of patients had an AE, with dizziness being
the only AE reported in ≥2% of patients (2.1%). The only cognitive
adverse event was psychomotor slowing in 1 patient (0.7%). In 89.7%
of patients investigators rated the tolerability of TPM as very good or
good.
Conclusion: In this naturalistic setting topiramate was safe, well toler-
ated and associated with a substantial seizure reduction in elderly patients
with epilepsy.
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EFFICACY AND TOLERABILITY OF TOPIRAMATE IN THE
TREATMENT OF EPILEPSY IN ELDERLY PATIENTS: RE-
SULTS OF A PHASE IV CLINICAL TRIAL
1H. Stefan, 2B. Schauble, and 2A. Schreiner (1Friedrich-Alexander-
University, Department of Neurology, Erlangen, Germany, 2Medical &
Scientific Affairs, Janssen-Cilag, Neuss, Germany)
Purpose: To assess seizure reduction and tolerability of topiramate
(Topamax, TPM) in mono- or combination therapy in elderly patients
with epilepsy.
Method: In this multicenter phase IV clinical trial, patients ≥60 years
of age were prospectively followed for 12 months. Doses of TPM and
concomitant antiepileptic drugs (AEDs) could be adjusted individually.
Seizure frequency and adverse events were documented at each visit.
Results: One hundred and seven patients (53% male, mean age 69 ±
7 years) were enrolled. The most frequent seizure types at baseline were
generalised tonic-clonic (58%) and complex partial (25%). After enroll-
ment, 49 patients received TPM as monotherapy, 58 in combination with
at least one other AED. The number of patients on TPM monotherapy
increased from 49 to 70 during the study at the discretion of the investiga-
tor. At endpoint, the mean TPM dose as monotherapy was 98mg/day and
153 mg/day as add-on. The mean monthly seizure frequency decreased
from 3.5 ± 14.6 to 1.6 ± 7.7 (p < .0001 versus baseline). 78% of patients
were responders (seizure reduction ≥50%), and 44% remained seizure-
free throughout the study. 46 patients (43%) had at least one treatment
emergent adverse event (TEAE). TEAEs ≥5% were somnolence (9.4%),
dizziness (7.5%) and paraesthesia (5.6%). Main reasons for study dis-
continuation (40% overall) were a TEAE (15.9%) or loss to follow-up
(12.2%).
Conclusion: In elderly patients with epilepsy, TPM was well tolerated
and is associated with a significant decrease in seizure frequency.
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LONG-TERM SEIZURE FREEDOM IN REFRACTORY PAR-
TIAL EPILEPSY TREATED WITH LEVETIRACETAM AS
COMPARED WITH TOPIRAMATE
Epilepsia, Vol. 47, S3, 2006
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1G. Boero, 1L. Specchio, 2P. D’alessandro, 1M. Stuppiello, 1A. Papanto-
nio, 3N. Specchio, 4A. De Palo, 4G . De Agazio, 4T. Francavilla, 4M. La
Dogana, 5E. Beghi, and 4A. La Neve (1Clinic of Nervous System Dis-
eases, University of Foggia, Italy, 2Division of Neurophysiopathology,
Azienda Ospedaliera, Perugia, Italy, 3Division of Neurology, Ospedale
Bambino Gesu`, Rome, Italy, 41st Neurologic Clinic, University of Bari,
Italy, 5Centro per l’epilessia, Ospedale S. Gerardo, Monza, Italy)
Purpose: To compare the efficacy of levetiracetam and topiramate
add-on long-term treatments in obtaining seizure freedom in adults with
refractory partial epilepsy.
Method: Patients with ≥2 focal seizures over an 8 week baseline pe-
riod received LEV or TPM in two distinct open-label, add-on, prospective
phases. LEV was titrated up to 1000 mg/day (2 weeks) and TPM up to
100 mg/day (4 weeks) or 200 mg/day (with inducers, 6 weeks). Follow
up lasted 24 months. Efficacy evaluation started after titration: number of
seizure-free patients over the study period and during the last six months
of observation; retention rate. Tolerability was evaluated recording type,
duration and intensity of AEs
Results: LEV group: 157 patients (90 F, mean age 41 years, range 11–
77, 61% remote symptomatic, mean dose 2200 mg/day). TPM group:103
patients (66 F, mean age 37 years, range 15–71, 50.4% remote symp-
tomatic; mean dose 430 mg/day). Mean follow-up duration was 15 (0-24)
and 12 months (0-24) respectively. 16 (10.2%) patients with LEV and
3 (2.9%) with TPM were seizure-free over the study period (21.6m.
LEV, 14.6m. TPM). 30 (19.1%) with LEV and 7 (6.8%) with TPM were
seizure-free during the last 6 months of observation. 100 (63.7%) and
62 (60.2%) patients, respectively, still remain in the study. 25 (15.9%)
patients on LEV and 16 (15.5%) on TPM dropped out for AEs, 57 (32
(20%) LEV, 25 (24.3%) TPM) for other reasons.
Conclusion: This study showed a better long-term efficacy of leve-
tiracetam in the treatment of refractory partial epilepsy with three-fold
patients achieving a seizure remission over the study period compared
to topiramate.
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WITHDRAWAL TO MONOTHERAPY: A PRACTICE-BASED
STUDY ON TOPIRAMATE
1,2R. Velizarova, 1M. Portugal, and 1P. Genton (1Centre Saint Paul, Mar-
seille, France, 2Aleksandrov University Hospital, Sofia, Bulgaria)
Purpose: Withdrawal to monotherapy may, in a clinical setting, un-
cover specific indications for new anticonvulsants, which are usually
used as add-ons for a long period.
Method: Over a one year period, of 114 patients on topiramate (TPM),
18 had reached monotherapy (10 men, 8 women, aged 10–60 years); 14
had refractory focal epilepsy and 4 had idiopathic generalised epilepsy
(IGE). At each visit, the treatment and seizure logs were studied, and
routine biology and peak TPM blood levels were assessed.
Results: Eleven patients continued TPM monotherapy after 1 to 7 yrs.
Seven were seizure-free: 3 patients with idiopathic generalised epilepsy,
2 patients after successful epilepsy surgery, and 2 with cryptogenic focal
(frontal lobe) epilepsy. Five patients had a worthwhile improvement,
with seizure reduction ≥ 75% in 4 (3 with symptomatic focal epilepsy;
parietal in 1 and temporal in 2, and 1 with IGE), and ≥ 50% in 1 with
cryptogenic frontal lobe epilepsy. TPM monotherapy was discontinued
in 6 due to inefficacy and in 1 because of side effects. Age, sex and peak
blood levels did not influence efficacy, side effects or retention time.
Conclusion: TPM monotherapy was successfully maintained (1) in
patients with idiopathic generalised epilepsy when weight loss was
necessary, (2) as the last drug after successful epilepsy surgery, (3)
in various cases of symptomatic focal and (4) in cryptogenic focal
epilepsy of frontal lobe origin. Retrospective demonstration of successful
withdrawal to monotherapy may highlight possible promising selective
indications.
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SAFETY AND TOLERABILITY OF TOPIRAMATE WITH CUR-
RENT VERSUS MORE RAPID TITRATION
1C. Kurth, 1B. Steinhoff, 2B. Scha¨uble, and 2A. Schreiner (1Epilepsy
Centre Kork, Kork, Germany, 2Medical and Scientific Affairs, Janssen-
Cilag GmbH, Neuss, Germany)
Purpose: To evaluate the safety and tolerability of two different titra-
tion regimens of adjunctive topiramate (Topamax, TPM) in a specialised
epilepsy center.
Method: During this single-center noninterventional study, refractory
epilepsy patients (≥12 years) were prospectively followed for 12 weeks.
Based on seizure frequency and severity, adjunctive TPM was titrated
either according to current prescribing information (NT = normal titra-
tion, 100 mg TPM/day was attempted at day 12) or more rapidly (RT,
100 mg TPM/day was attempted at day 3) per investigator’s discretion.
Results: Fifty patients (58% female, mean age 35 years, 86% par-
tial epilepsy) were followed for a median of 102 days (range 6–278).
Twenty-nine patients were in the RT group, 21 in the NT group. Age and
gender showed no significant difference. In the RT group, significantly
more patients had symptomatic epilepsy (81 vs 48%), and preexisting
cognitive deficits (71 vs 59%). Mean TPM maintenance was 136 mg/day
(NT) versus 213 mg/day (RT), p < 0.05. Median seizure frequency (all
patients) decreased from 7.5 (baseline) to 2.0 (end point), 46% had a 50%
responder rate and 14% remained seizure free without significant dif-
ferences for both groups. Thirty-two patients had a treatment-emergent
adverse event (AE), and 15 patients (30%) discontinued TPM due to an
AE with no statistically significant difference between RT (29%) and
NT (31%). Only paraesthesia occurred more frequently in the RT group.
Conclusion: In this study patients with treatment resistant epilepsy
titrated more rapidly with topiramate and had comparable tolerability and
efficacy profile compared to those titrated using currently recommended
regimen.
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LONG-TERM TREATMENT WITH ZONISAMIDE: RESULTS
OF A 2 YEAR OPEN-LABEL EXTENSION STUDY
1S. Wroe and 2R. Duncan (1National Hospital for Neurology and Neu-
rosurgery, London, UK, 2Southern General Hospital, Glasgow, UK)
Purpose: To demonstrate the long-term safety and efficacy of zon-
isamide in patients with refractory partial onset epilepsy.
Method: A total of 243 patients (aged ≥12 years, on 1–3 AEDs) who
had previously received placebo or zonisamide 100, 300 or 500 mg/day
for 18 weeks on a fixed-dose study, were enrolled in a 2 year, open-label
extension study. Following a 6 week titration phase all patients received
zonisamide 500 mg/day, then commenced the 104 week flexible dosing
(100–600 mg/day) phase, during which zonisamide dose was adjusted
to optimum effect (mean dose 500 mg/day). Concomitant AEDs were
adjusted as required. Efficacy evaluations (every 3 months; n = 240)
included reduction in seizure frequency (complex partial seizures and
total seizures) and time on study. Safety assessments (n = 243) included
reporting of adverse events (AEs).
Results: 104 (44%) patients remained in the study for 2 years, 35
patients (14.6%) showed a reduction in concomitant medication and 11
(4.6%) achieved zonisamide monotherapy. Adverse events and treatment
related AEs were reported by 196 and 103 patients, only 28 (11.5%)
patients discontinued due to AEs. The majority of AEs (81%) were
considered mild to moderate; the most common treatment related AEs
were weight loss (8.6%), somnolence (6.6%) and dizziness (6.6%).
Conclusion: Long-term treatment (up to 2 years) with zonisamide
for partial refractory epilepsy is well tolerated, with a safety profile
consistent with that reported in double-blind trials, and allows some
patients to reduce concomitant medications or achieve monotherapy.
This study was supported by Eisai Ltd.
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DOSE RESPONSIVE EFFICACY OF ZONISAMIDE
MONOTHERAPY DURING 40 WEEKS TREATMENT OF
PARTIAL SEIZURES IN PATIENTS WITH NEWLY DIAG-
NOSED EPILEPSY
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D. Naritoku (School of Medicine, Southern Illinois University, Spring-
field, Illinois, USA)
Purpose: To evaluate the relationship between efficacy and dose of
zonisamide (ZNS) as monotherapy in patients with newly diagnosed
epilepsy (complex partial seizures [CPS] with and without secondary
generalisation).
Method: 167 patients (aged ≥16 years) received ZNS 25 (n = 56), 100
(n = 52) and 300 (n = 59) mg/day in a double-blind, randomised, 42 week
trial with a 40 week treatment period. The primary efficacy endpoint
was time from first dose of study drug to occurrence of two CPS or one
generalised tonic–clonic seizure (GTC). Secondary endpoints included
the proportion of patients seizure free for ≥6 months, and the proportion
completing 40 weeks of treatment.
Results: All patients were included in the efficacy analyses and base-
line demographics were similar across treatment groups. There was
a trend to dose-dependent seizure frequency reduction (p = 0.06);
fewer patients receiving ZNS 300mg/day experienced endpoint seizures
(22.0% compared with 41.1% and 40.4% for ZNS 25 and 100 mg/day).
A similar trend was observed for seizure freedom (≥6 months), 33.9%,
30.8% and 50.8% for the 25, 100 and 300 mg/day groups (p = 0.06),
respectively. The proportion of patients treated for 40 weeks was similar
for all treatment groups, 41.1%, 40.4% and 40.7% for ZNS 25, 100 and
300mg/day, respectively.
Conclusion: ZNS was suitable as monotherapy for patients with newly
diagnosed epilepsy. ZNS displayed a trend towards dose dependent effi-
cacy and at 300 mg/day reduced the proportion of patients experiencing
CPS or GTC seizures and increased the proportion remaining seizure
free at ≥6 months, compared with ZNS 25and 100mg/day. This study
was supported by Eisai Ltd.
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EPILEPSY IN THE OLDER PATIENT: US EXPERIENCE WITH
LONG-TERM ZONISAMIDE THERAPY
W. Tosches and J. Tisdell (University of Massachusetts, Hopedale, Mas-
sachusetts, USA)
Purpose: To provide a retrospective review evaluating the efficacy and
safety of long-term zonisamide therapy for older patients with epilepsy.
Method: Neurology clinic records were reviewed to identify patients
aged ≥60 years treated with zonisamide for ≥3 months. Efficacy was
assessed via reduction in seizure frequency during zonisamide therapy,
and safety was evaluated by adverse events (AEs), based on physicians’
notes and patient reporting.
Results: Sixty patients (mean age 76 [range 60–97] years) were iden-
tified and 53 were included in the efficacy analysis. For patients on
monotherapy (n = 37), mean zonisamide dose and duration were 200.0
mg/day and 28.2 months; 20 patients (54.1%) achieved seizure freedom;
seizure frequency was reduced by ≥50% in an additional 5 patients
(13.5%) and by <50% in 2 patients (5.4%). For patients receiving ad-
junctive therapy (n = 16), mean zonisamide dose and duration were
268.8mg/day and 35.3 months; 5 (31.2%) were seizure-free; seizure fre-
quency was reduced by ≥50% in an additional 7 patients (43.8%) and
by <50% in 3 patients (18.8%). Zonisamide had no effect in 3 patients
and 8 patients were lost to follow-up. AEs included gastrointestinal up-
set, mild sedation, and rash (n = 2 each), anorexia, vision changes,
headache and lightheadedness (n = 1 each). Six patients discontinued
zonisamide, 5 due to AEs. Positive neurological effects reported with
zonisamide therapy included increased alertness (n = 2) and improve-
ments in parkinsonian tremor (n = 2), postherpetic neuralgia, mood and
restless legs syndrome (n = 1 each).
Conclusion: Long-term zonisamide was effective as monotherapy and
adjunctive therapy and was well tolerated in older patients with epilepsy.
This study was supported by Eisai Ltd.
p536
LONG-TERM EFFICACY OF ZONISAMIDE IN PAEDIATRIC
PATIENTS: AN OPEN LABEL STUDY
1S. Shinnar and 2W. Rosenfeld (1Comprehensive Epilepsy Management
Center, Montefiore Medical Center, Albert Einstein College of Medicine,
Bronx, New York, USA, 2The Comprehensive Epilepsy Care Center For
Children And Adults, St Louis, Missouri, USA)
Purpose: To assess the long-term efficacy of zonisamide in paediatric
patients with various types of epilepsy.
Method: This open-label study included 134 paediatric patients (mean
age 8.2 [range 2–16] years) experiencing ≥4 seizures per month while on
a stable dose of 1 or 2 concomitant antiepileptic drugs (AEDs). Efficacy
was evaluated by change in “all seizure” frequency (average number of
seizures per week) and global assessments for each 3-month follow-up
period, until study end or discontinuation (final assessment). Baseline
seizure counts were only available for patients new to zonisamide (n =
109).
Results: In the overall study population, the median seizure frequency
for “all seizures” significantly decreased over the study period (–1.5;
p = 0.025), for patients (n = 86) who provided start-of-study and fi-
nal assessment data. The median seizure frequency decreased from 5.85
for months 1–3 (n = 92) to 3.15 in months 19–21 (n = 24) and was
3.70 (n = 93) at the final 3-month assessment. Similarly, for patients
new to zonisamide, there was a progressive decrease in median seizure
frequency over time, the median seizure frequency was 8.95 at baseline
(n = 106), then decreased from 5.90 in months 1–3 (n = 69) to 0.60 in
months 19–21 (n = 16). For new patients, the median seizure frequency
decreased by 50% on average relative to baseline by months 7–9 (me-
dian seizure frequency 1.4 per week). Global assessments also indicated
improvement in response to zonisamide.
Conclusion: Long-term zonisamide add-on therapy significantly im-
proved seizure rates in children with epilepsy. This study was supported
by Eisai Ltd.
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SHORT-TERM AND LONG-TERM EFFICACY AND SAFETY
OF RUFINAMIDE AS ADJUNCTIVE THERAPY IN PATIENTS
WITH INADEQUATELY CONTROLLED LENNOX-GASTAUT
SYNDROME
1G. Kluger, 2T. Glauser, 3R. Sachdeo, 4G. Krauss, 5C. Perdomo, and
5S. Arroyo (1Behandlungszentrum Vogtareuth, Germany, 2Cincinnati
Children’s Hospital Medical Center, Cincinnati, Ohio, USA, 3St. Peter’s
University Hospital, New Brunswick, New Jersey, USA, 4Johns Hopkins
University Medical Center, Baltimore, Maryland, USA, 5Eisai Global
Clinical Development, Ridgefield Park, New Jersey, USA)
Purpose: To evaluate the short- and long-term efficacy and safety of
adjunctive rufinamide therapy for patients with inadequately controlled
Lennox-Gastaut syndrome (LGS).
Method: This was a multicentre, double-blind, placebo-controlled,
randomised, parallel-group study followed by a long-term extension
study. During the double-blind study, patients were randomised to receive
either adjunctive rufinamide (10 mg/kg per day of rufinamide titrated to
45 mg/kg per day) or placebo; those who completed all study visits
could enter the 3 year long-term study. Efficacy was evaluated by the
percent change in total and tonic-atonic seizure frequency per 28 days
and the change in seizure severity rating. Safety analysis included ad-
verse events (AEs), laboratory parameters, physical examinations, vital
signs, and electrocardiogram recordings.
Results: Patients, mean age 14.1 years (range 4–37 years), received
either rufinamide (n = 74) or placebo (n = 64); median dose at each
visit was 42.16 mg/kg per day (range, 4.17–60.10 mg/kg per day). Ru-
finamide, versus placebo treatment, was associated with a greater me-
dian percent reduction in total seizure frequency (32.7% vs 11.7%, p =
0.0015), tonic-atonic seizure frequency (42.5% vs –1.4%, p < 0.0001),
and improved seizure severity (p = 0.0041). Eligible patients (n = 124)
entered an open-label, long-term, extension study of rufinamide therapy.
Efficacy of rufinamide observed in the short-term study was maintained
during long-term treatment. The majority of AEs were mild or moder-
ate and were similar in both the short- and long-term studies. The most
common AEs were somnolence, vomiting, pyrexia, and diarrhea.
Conclusion: Adjunctive rufinamide therapy was effective and gen-
erally well tolerated as short- and long-term therapy in patients with
inadequately controlled LGS. This study was supported by Eisai
Inc.
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EFFICACY AND SAFETY OF RUFINAMIDE AS ADJUNCTIVE
THERAPY IN ADULT PATIENTS WITH INADEQUATELY CON-
TROLLED PARTIAL SEIZURES
1W. Rosenfeld, 2M. Brodie, 3B. Vazquez, 4R. Sachdeo, 5D. Ko, 6C.
Perdomo, and 6S. Arroyo (1The Comprehensive Epilepsy Care Center for
Children and Adults, St. Louis, Missouri, USA, 2University of Glasgow,
Glasgow, Scotland, UK, 3Comprehensive Epilepsy Center, New York,
USA, 4St. Peter’s University Hospital, New Brunswick, New Jersey,
USA, 5University of Southern California, Los Angeles, California, USA,
6Eisai Global Clinical Development, Ridgefield Park, New Jersey, USA)
Purpose: The objective of this study was to assess the efficacy and
safety of rufinamide as adjunctive therapy in adult patients with inade-
quately controlled partial seizures.
Method: Adult patients (aged ≥16 years) with partial seizures, taking
stable doses of ≤2 other antiepileptic drugs, were enrolled in this mul-
ticentre, double-blind, placebo-controlled, randomised, parallel-group
study. Patients were randomised to receive either rufinamide (3200 mg/d)
or placebo for the duration of the 91-day double-blind phase. Efficacy
was evaluated by the percent change in partial seizure frequency during
the double-blind phase relative to the baseline phase and the percentage
of treatment responders (patients with ≥50% reduction in partial seizure
frequency). The safety assessment included monitoring of adverse events
(AEs), laboratory parameters, vital signs, physical examinations, and
electrocardiogram recordings.
Results: A total of 313 adult patients were randomised to receive ei-
ther rufinamide (n = 156) or placebo (n = 157). Rufinamide treatment
was associated with a 20.4% median reduction in partial seizures, per
28 days relative to baseline, compared to a 1.6% median increase with
placebo treatment (p = 0.0158). Furthermore, a significantly higher per-
centage of rufinamide-treated patients (28.2%) were treatment respon-
ders compared to placebo-treated patients (18.6%) (p = 0.0381). The
majority of AEs were mild to moderate in severity; the most commonly
reported AEs were headache, dizziness, nausea, diplopia, somnolence,
and fatigue. Study discontinuations due to AEs occurred in 14.1% of
rufinamide-treated patients and 3.2% of placebo-treated patients.
Conclusion: Rufinamide (3200 mg/d) demonstrated a significant re-
duction in seizure frequency compared to placebo and was generally well
tolerated as adjunctive therapy for adult epilepsy patients. This study was
supported by Eisai Inc.
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DOSE-RANGE RELATIONSHIPS OF RUFINAMIDE IN PA-
TIENTS WITH INADEQUATELY CONTROLLED PARTIAL
SEIZURES
1C. Elger, 2H. Stefan, 3C. Perdomo, and 3S. Arroyo (1Klinik fu¨r Epilep-
tologie, Bonn, Germany, 2Neurologische Klinik, Erlangen, Germany,
3Eisai Global Clinical Development, Ridgefield Park, New Jersey, USA)
Purpose: The objective of this study was to assess the dose-dependant
efficacy and safety of rufinamide in patients with inadequately controlled
partial seizures.
Method: This was a multicenter, double-blind, randomised, placebo-
controlled, parallel-group study involving patients who received 1 to 3
concomitant antiepileptic drugs (AEDs). Patients with ≥9 seizures on
stable AED dosages were randomised to 1 of 5 treatment groups: rufi-
namide 200, 400, 800, and 1600 mg/d, or placebo. The primary efficacy
variable was total seizure frequency per 28 days in the double-blind treat-
ment phase; the secondary efficacy variables included the seizure fre-
quency ratio (seizure frequency per 28 days in the double-blind treatment
phase divided by that in the baseline phase) and response to treatment.
Safety was evaluated by adverse events (AEs), vital signs, electrocardio-
gram recordings, and laboratory tests.
Results: A total of 737 patients were enrolled; 647 patients were
randomised to the 5 treatment arms. Rufinamide demonstrated a statisti-
cally significant linear trend of dose response for seizure frequency per
28 days (p = 0.003) and for ≥50% treatment responders (p = 0.0319).
The median seizure frequency ratio was significantly reduced in patients
treated with rufinamide 400 mg/d (11%, p = 0.0274), 800 mg/d (16%,
p = 0.0123), and 1600 mg/d (17%, p = 0.0163) compared to placebo. The
occurrence of AEs was similar to placebo for all rufinamide doses ≤800
mg/d. At 1600 mg/d, dizziness, somnolence, diplopia, and nystagmus
were reported.
Conclusion: Rufinamide demonstrated a significant reduction in
seizure frequency with increasing dosages in patients with inadequately
controlled partial seizures and was generally well tolerated.
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SHORT-TERM AND LONG-TERM SAFETY OF RUFINAMIDE
IN PATIENTS WITH EPILEPSY
1G. Krauss, 2C. Perdomo, and 2S. Arroyo (1Johns Hopkins University
School of Medicine, Baltimore, Maryland, USA, 2Eisai Global Clinical
Development, Ridgefield Park, New Jersey, USA)
Purpose: The aim of this analysis was to evaluate the safety of rufi-
namide during short-term (placebo-controlled) and long-term (extension
or open-label) therapy in patients with epilepsy.
Method: Safety data from short-term, double-blind, placebo-
controlled studies and long-term, open-label, extension studies of ad-
junctive rufinamide therapy were integrated into a single database for
analysis. All patients who received at least 1 dose of rufinamide were
included in the analysis. Adverse events (AEs) were analysed using the
Medical Dictionary for Regulatory Activities and were presented by pre-
ferred term. Serious adverse events (SAEs) and clinical laboratory test
results abnormalities were also identified.
Results: Safety data were derived from 23 studies involving patients
with epilepsy. Short-term therapy safety data were derived from 11 stud-
ies involving 1875 patients treated with rufinamide (n = 1240) or placebo
(n = 635). The most frequently reported AEs for rufinamide included
headache, dizziness, fatigue, somnolence, and nausea; most AEs were
mild to moderate in severity. The time to onset of these AEs was com-
parable between the groups. Serious adverse events occurred in 6.3% of
rufinamide-treated and 3.9% of placebo-treated patients. During long-
term therapy, safety of rufinamide was assessed in 1978 patients. The
most frequently reported AEs with long-term follow-up were headache,
dizziness, and fatigue; 13.1% of patients discontinued rufinamide treat-
ment due to AEs. The rates of AEs generally increased with increases in
median dose of rufinamide. The most common SAEs were convulsion,
status epilepticus, and pneumonia.
Conclusion: Rufinamide was well tolerated in patients with epilepsy
during short- and long-term therapy.
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EFFECTS OF VALPROATE EXPOSURE IN UTERO TO BE-
HAVIOUR AND NEED FOR EDUCATIONAL SUPPORT IN
SCHOOL-AGE CHILDREN
1K. Viinikainen, 2K. Eriksson, 3A. Mo¨nkko¨nen, 1M. ¨Aikia¨, 4P. Niemi-
nen, 5S. Heinonen, and 1R. Ka¨lvia¨inen (1Kuopio Epilepsy Center, De-
partment of Neurology, Kuopio University Hospital, University of Kuo-
pio, Finland, 2Pediatric Research Centre, University of Tampere and
Department of Pediatric Neurology, Tampere University Hospital, Fin-
land, 3Department of Education, City of Kuopio, Finland, 4Department
of Psychology, University of Tampere, Finland, 5Department of Obstet-
rics and Gynecology, Kuopio University Hospital, University of Kuopio,
Finland)
Purpose: An increasing amount of information is available concerning
the teratogenic effects of antiepileptic drugs (AED) exposure in utero
but less is known about the long-term cognitive and behavioural effects
of AEDs. We compared in a controlled, blinded study the effects of
valproate (VPA) and carbamazepine (CBZ) monotherapy exposures in
utero to behavioural and cognitive development of the child.
Method: We identified from the community-based pregnancy registry
of Kuopio University Hospital area (1989–2000) all children who had
been exposed to VPA monotherapy in utero and were first-born and of
school age (N = 13). Age and gender-matched children of mothers with
epilepsy and with CBZ exposure or without AED exposure served as
controls. Neurological and neuropsychological assessments were made
clinically and behavioural problems were assessed with the Conners’
Teacher Rating Scale (CTRS) questionnaire.
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Results: Eight children (61.5%) exposed to VPA and 2 (15.4%) in
both CBZ and no-exposure group (p = 0.022) had needed educational
support. Minor dysmorphic features were noted in 8 children (61.5%)
exposed to VPA and in 3 children (23.1%) in both CBZ and no-exposure
groups. In CTRS there was a systematic tendency of children exposed
to VPA to score higher indicating more behavioural problems. This was
seen especially in domains representing social problems (p = 0.07) and
cognitive problems/inattention, p = 0.09.
Conclusion: Children exposed to VPA in utero seem to have more be-
havioural problems and need for educational support than CBZ exposed
and unexposed controls. This difference is seen clearly when assessing
each child individually but many confounding factors explaining at least
some of this difference are difficult to control.
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ENDOCRINE EFFECTS OF VALPROATE IN GIRLS WITH
EPILEPSY
H. Goldberg-Stern, L. de Vries, A. Sochovitski, Z. Landau, M. Philip,
and A. Shuper (Schneider Medical Center, Petach Tiqva, Israel)
Purpose: Valproate has been associated with weight gain, hyperan-
drogenism and polycystic ovaries. The objective of this study was to
investigate whether valproate or epilepsy itself causes these adverse
effects.
Method: Anthropometric measurements, pubertal stage, waist-hip ra-
tio, bioelectrical impedance, levels of fasting insulin, androgens, sex
hormone-binding globulin, and thyroid function and transabdominal
pelvic ultrasound were compared between girls with epilepsy receiv-
ing valproate and girls with epilepsy with no treatment.
Results: The sample included 88 girls with epilepsy aged 6–20 years
(14 prepubertal, 26 pubertal, 48 postpubertal), 45 treated with valproate
for 3.5 years (range 1–9.5) and 43 untreated. The treated postpubertal
subgroup had higher testosterone levels than the postpubertal controls
(2.12 ± 1.74 vs 0.91 ± 0.25 p = 0.007). However, no significant differ-
ences were found in biochemical, hormonal, anthropometric, or ultra-
sound parameters, either in comparison of the groups as a whole or by
pubertal stage. BMI-SDS was 0.75 in the treated group and 0.63 in the
untreated group; rates of obesity were 16.3% and 15.5% respectively.
There were no between-group differences in menses irregularities, hir-
sutism, or acne. No correlation was found between duration of treatment
or dosage and BMI-SDS, height SDS or androgen level. The treated
group had higher levels of TSH and lower levels of free T4 than the
untreated group, although still within normal range.
Conclusion: Long-term treatment with valproate for girls with
epilepsy is associated with increased testosterone levels in the post pu-
bertal period, without clinical hyperandrogenism, PCOS or an increase
in BMI-SDS. Careful endocrine observation is recommended in post-
pubertal girls taking valproate.
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SAFETY AND EFFICACY OF INTRAVENOUS VALPROATE
IN COMPARISON WITH DIAZEPAM IN ADULT STATUS
EPILEPTICUS
1H. Wu, 2D. Zhou, and 3L. He (1Department of Neurology West China
Hospital Chengdu City Sichuang Province P.R. of China, 2Department
of Neurology West China Hospital Chengdu City Sichuang Province
P.R. of China, 3Department of Neurology West China Hospital Chengdu
City Sichuang Province P.R. of China)
Purpose: To evaluate the safety and efficacy of intravenous infusion
of valproate in comparison with diazepam in status epilepticus.
Method: A cohort study was carried out by dividing 90 status epilepsy
patients into 2 groups: VPA group (n = 38) and diazepam group
(n = 42). 15 adult patients in SE with generalised tonic–clonic seizures
(GTCS) and 13 with simple partial motor seizures were administered
IV VPA (Depakine injectable 400 mg, Sanofi corp.) in a bolus dose of
15 mg/kg and then 30 min later as a continuous infusion of 1 mg/kg/h
for 24 h. 42 patients with SE were administered diazepam in a bo-
lus dose of 10 mg and then a continuous infusion of 0.1 mg/kg/h for
24 h. The therapeutic effect was evaluated by response latency time and
seizure cessation rate. Safety was evaluated by monitoring ECG, blood
pressure, serum concentration and adverse reactions before, during, and
after infusion.
Results: Response latency time is 24 ± 7 min in VPA group and 9 ± 4
min in diazepam group (p < 0.01). Seizure cessation rate is 62% in VPA
group and 83% in diazepam group (p > 0. 05). There is no significant
difference on efficacy of IV VPA between different seizure types. No
significant changes in ECG or blood pressure were found in either group
before, and after infusion. Postinfusion plasma VPA levels ranged from
46∼147g/mL(86 ± 19 g/mL). Times taken to regain normal mental state
were 2 ± 1.3 hours in VPA group and 8 ± 2.4 hours in diazepam group.
Conclusion: IV valproate can be administered safely and rapidly for
SE patients. Efficacy between VPA and diazepam is similar. Diazepam
acts more quickly while VPA is less mentally disturbing.
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EFFICACY OF MONOTHERAPY AND POLYTHERAPY BY
TOPIRAMATE AND VALPROATE IN CHILDHOOD EPILEPTIC
ENCEPHALOPATHY (LENNOX-GASTAUT SYNDROME)
I. Martsenkovsky, J. Bikshaeva, I. Martsenkovska, and V. Shvejkina
(Ukrainian Research Institute of Social and Forensic Psychiatry and Drug
Abuse, Ukraine)
Purpose: To define the comparative efficacy of monotherapy and
polytherapy by topiramate and valproate in childhood epileptic en-
cephalopathy (the Lennox-Gastaut syndrome) (LGS).
Method: Thirty-eight children, age 1–8 years were investigated. The
research was divided into 2 phases: for 28 days patients received the
same doses of standard antiepileptic drugs, then, for carrying out com-
parative control research, four groups of patients were formed: 1) receiv-
ing valproate; 2) receiving topiramate; 3) receiving no more than 100
mg topiramate + valproate (300–900 mg); 4) receiving no more than
600 mg valproate + topiramate (100–300 mg).
Results: In the groups receiving monotherapy by topiramate and val-
proate, the reduction in the number of total seizures was 19% and 22%,
for atonics seizures, 19% and 12%. Monotherapy by valproate showed
no change; with topiramate some of the children had an increase in gen-
eralised convulsions. Of the patients receiving topiramate in common
with valproate, the degree of reduction of number of total and atonic
attacks changed, and varied from 30% to 40%, generalized convulsions
made 73%. Side effects from monotherapy by topiramate and valproate
and polytherapy topiramate (100–200 mg) + valproate (100–600 mg)
for children with LGS did not differ statistically.
Conclusion: Polytherapy by topiramate at a dose of 100–200 mg per
day and valproate at a dose of 600–1000 mg per day is more effective
than monotherapy by topiramate at an average dose of 100–300 mg per
day and monotherapy by valproate at its maximum transferable dose in
the treatment of children with LGS.
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VALPROATE DOES NOT ELIMINATE EPILEPTIC KK
N. Rajsic, M. Tomovic, Z. Sundric, and T. Ilic (Military Medical
Academy, Belgrade, Serbia and Montenegro)
Purpose: To evaluate the effect of valproate therapy on the epileptic
K complexes (e-KK).
Method: Long-term EEG (LT-EEG) was applied 3 times in a period
of 5 years to investigate the frequency of epileptic events in 1 patient
with primary generalised epilepsy. His first LT-EEG was recorded when
he was 29. More than 177 epileptic paroxysmal discharges in one night
have been revealed when he was under phenobarbital therapy. Because
his epileptic seizures were not under control, his therapy was changed
from phenobarbital to slow-releasing valproate medication.
Results: The conversion from phenobarbital to valproate therapy
was performed successfully. Neither rebound epileptic seizures nor new
seizures have happened while taking 2000 mg slow releasing valproate
separated in 2 daily doses. Three years later the second LT-EEG has re-
vealed 23 e- KK in one night. After slow reduction of therapy 2 years later
a series of 3 epileptic seizures occurred. There were 56 e-KK obtained
during the one night.
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Conclusion: Valproate therapy eliminated the epileptic paroxysmal
discharges of 3/s spike-and-slow-wave complexes completely, but was
unable to push out e-KK in our patients with primary generalised
epilepsy. It seems there exists a dose dependent suppression of e-KK
with valproate therapy.
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RETENTION RATE OF PREGABALIN IN PATIENTS WITH RE-
FRACTORY EPILEPSY
1T. May, 1E. Nieder, 1C. Brandt, 1K. Witte-Boelt, 2H. Elsner, and 1B.
Pohlmann-Eden (1Bethel Epilepsy Centre (Hospital) Epilepsy Centre
Bethel (Hospital), Germany, 2Epilepsy Centre Bethel (Vocational Train-
ing Centre), Germany)
Purpose: Pregabalin (PGB) was licensed as an add-on treatment for
partial epilepsy in adults in Germany in 09/2004. Controlled clinical trials
demonstrated that PGB is an efficient and well tolerated antiepileptic
drug (AED). The aim of this study (open label, mostly phone interviews)
was to evaluate the efficacy and the tolerability of PGB in patients with
refractory epilepsy under clinical conditions.
Method: We included all patients of the Bethel Epilepsy Centre who
started with PGB from 09/2004 to 12/2005. The patients were inter-
viewed after 3, 6 and in some cases after 12 months. We assessed the
discontinuation of PGB, type of epilepsy, seizure type and frequency,
comedication etc. The retention rate of PGB was the primary parameter
for efficacy and tolerability.
Results: One hundred and nine adult patients were treated with PGB,
on average in combination with 2.1 AED. Twelve patients had a vagus
nerve stimulator. The mean observation period was 158 days. 51% of the
patients continued PGB with the following outcome: 5% seizure free,
19% 50%-responders, in 27% seizure frequency remained unchanged or
increased. Reasons for withdrawal were lack of efficacy (33%) or side
effects (17%). Weight gain was the most frequently mentioned adverse
effect (19 patients, 17.4%). Other adverse effects mentioned were tired-
ness (9.2%, n = 10), dizziness (5.5%, n = 6) and allergic skin reactions
(5.5%, n = 6).
Conclusion: The retention rate of 50% indicates that add-on treatment
with PGB is effective and well tolerated even in patients with refractory
epilepsies.
Development of a questionnaire used for this study was partly sup-
ported by Pfizer.
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PREGABALIN IS EFFECTIVE AND WELL TOLERATED AS
ADD-ON TREATMENT FOR PATIENTS WITH HIGHLY RE-
FRACTORY PARTIAL EPILEPSY: A TERTIARY CENTRE
EXPERIENCE
I. Maestro, M. Falip, A. Donaire, and M. Carreno (Hospital Clı´nic,
Cantabria, Spain)
Purpose: Pregabalin (PGB) is a new antiepileptic drug (AED) that
has shown a high efficacy as add-on therapy in controlled trials, with
responder rates close to 50%. The objective of our study was to analyse
the efficacy and tolerability of PGB in clinical practice when used as
add-on therapy in highly pharmacoresistant epilepsy patients.
Method: We retrospectively identified patients who received PGB as
add-on treatment from March 2005 until November 2005. We analysed
the efficacy to decrease seizure frequency and the emergent adverse
effects. A patient was considered a responder if ≥50% seizure reduction
was attained.
Results: We identified 50 patients (31 women) who received PGB.
Mean age was 37.31 (SD9.7); mean time of epilepsy evolution was 25
(0.5–53; SD 11.5). The mean number of previous AEDs tried was 7.
Twenty patients had a history of clusters of seizures or previous status
epilepticus, which prevented them from participating in controlled trials.
Patients received a mean dose of 384 mg (150–900; SD181). Dose of
concomitant AEDs were decreased in 25 patients to improve tolerabil-
ity. Twenty-three patients (46%) were responders and 7 patients (14%)
became seizure free. Two patients reported seizure worsening. Adverse
effects were reported by 23 patients (46%), the most common being
weight gain (12 patients), ataxia/dizziness (8), somnolence (5), blurred
vision (3), and malleolar edema (3). Adverse effects were generally mild
to moderate, but caused treatment discontinuation in 4 patients (8%).
Conclusion: In clinical practice, PGB is effective and generally well
tolerated as add-on treatment in patients with highly refractory partial
epilepsy.
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SAFETY AND TOLERABILITY PROFILE OF PREGABALIN
IN THE LONG-TERM TREATMENT OF PATIENTS WITH
PARTIAL-ONSET SEIZURES
1F. Baldinetti, 2B. Uthman, 3C. Bazil, 1J. Barrett, 1E. Whalen, 4K.
Spiegel, and 1T. Griesing (1Pfizer Global Pharmaceuticals, Pfizer Inc,
New York, USA, 2University of Florida, College of Medicine and Mal-
colm Randall, VA Medical Center, Gainesville, USA, 3Columbia Uni-
versity Medical Center, New York USA, 4Pfizer Global Research and
Development, Ann Arbor, USA)
Purpose: To evaluate the long-term safety and tolerability profile of
pregabalin as add-on treatment in adult patients with partial seizures.
Method: Three long-term, open-label (OL) add-on trials enrolled
1057 patients (386 de novo; 671 from double-blind randomised, placebo-
controlled trials). Patients took pregabalin 150–600 mg/day, BID or TID,
and kept seizure diaries. Results for patients receiving pregabalin treat-
ment for 30 months (n = 344) are presented.
Results: Mean age was 40 years; mean epilepsy duration was 27
years. All patients were taking at least 1 concurrent AED, 91.9% took
≥2 AEDs. Baseline median seizure rate was ∼11/28d. Approximately
half of patients received pregabalin 600 mg/d; one-third received 450
mg/d; and the remainder received 150 or 300 mg/d. Dosing remained
relatively stable throughout the 30 month period, as did the 50% re-
sponder rate (6 months: 49.1%; 30 months: 64.8%). The most common
AEs reported during the first 6 months of OL treatment were dizziness
and somnolence, which tended to resolve over time. Overall AE inci-
dence and intensity resolved or diminished over time. At 30 months, the
most common AEs were dizziness (3.5%), asthenia (3.2%), somnolence
(1.8%), and weight gain (0.6%). Over the 30 months of treatment, 64.5%
patients discontinued for any reason, with 8.4% withdrawing due to AEs
that included weight gain and dizziness.
Conclusion: Long-term pregabalin treatment is well tolerated and the
safety profile is favourable in patients treated for up to 30 months, at
doses up to 600 mg/d. Most AEs were mild-to-moderate and resolved
with continued treatment. Supported by Pfizer Inc.
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PHARMACODYNAMIC COMPARISON OF PREGABALIN AND
GABAPENTIN
1H. Bockbrader, 1R. Miller, 2S. Chapel, and 2J. Barrett (1Pfizer Global
Research and Development, Pfizer Inc, Ann Arbor, MI, USA, 2Pfizer
Global Pharmaceuticals, Pfizer Inc, New York, NY, USA)
Purpose: To compare the dose-response (seizure frequency) rela-
tionship of pregabalin and gabapentin add-on treatment in patients
with refractory partial epilepsy. Preclinical studies with pregabalin and
gabapentin indicate similar anticonvulsant pharmacological profiles;
however, pregabalin shows 3- to 6-fold greater potency. Pregabalin,
unlike gabapentin, exhibits linear absorption with observed maximum
plasma drug concentration (Cmax) and area under the plasma drug
concentration-time profile (AUC) increasing proportionally with dose.
In contrast, the extent of gabapentin absorption decreases with increasing
dose.
Method: Data from 3 pregabalin clinical trials (1042 patients) and 6
gabapentin trials (551 patients) were analysed using a nonlinear mixed-
effects model to characterise the relationship between seizure frequency
and pregabalin and gabapentin dose. Percent of responders among pa-
tients was estimated.
Results: Pregabalin (50–600 mg/d) and gabapentin (600–1800
mg/d) showed an asymptotic dose-related decrease in seizure fre-
quency. Both pregabalin- and gabapentin-treated patients demonstrated
a dose-response relationship; however, the maximal decrease in seizure
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frequency from baseline with pregabalin was 100%, while the maximal
decrease with gabapentin therapy was only 24.5%. Based on this in-
formation, pregabalin was estimated to be 4 times more effective than
gabapentin in patients who responded to treatment. Pregabalin was also
2.5 times more potent than gabapentin in responding patients, as mea-
sured by the dose that reduced seizure frequency by ≥50%.
Conclusion: The observed improvement in potency and effectiveness
combined with the pharmacokinetic and pharmacodynamic properties of
pregabalin relative to gabapentin offer distinct advantages over standard
gabapentin therapy for the treatment of refractory partial seizures.
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PREDICTIVE PERFORMANCE OF WEIGHT CHANGE ASSO-
CIATED WITH PREGABALIN ADMINISTRATION
1J. Barrett, 2R. Miller, 3C. Elger, 2B. Frame, 3C. Hoppe, and 4S. Beal
(1Pfizer Global Research and Development, Pfizer Inc, New York, New
York, USA, 2Pfizer Global Research and Development, Ann Arbor,
Michigan, USA, 3Universita¨tsklinikum Bonn, Klinik und Poliklinik fu¨r
Epileptologie, Germany, 4University of California at San Francisco, San
Francisco, CA, USA)
Purpose: Validate a pharmacodynamic model characterising change
from baseline weight over time following pregabalin administration.
Method: Open-label pregabalin-treated patients (n = 141) received
daily dosage of 75 mg per week up to 300 or 450 mg per day after
4-6 weeks, respectively. Dosage was increased in some patients after
3 months based on clinical outcome using similar regimen to 900 mg/d
maximum dose (n = 2). Expected fractional change from baseline weight
was estimated using baseline weight, age, time, and average pregabalin
exposure for this cohort using a pharmacodynamic model. Bias was as-
sessed using median error (median of observed minus predicted weights)
and variability, or precision, was assessed using median absolute error,
after 6 months of treatment. For subjects with observations at 3 months
only (drop outs), posterior predictions were generated for 6 month ex-
posure.
Results: Mean pregabalin exposure was 279.5 mg/day. The median
error (bias) was 0.84 kG at 6 months (n = 93). The median absolute error
(variability) was 2.6kG at 6 months. Comparison of model-predicted
weights to observed weights suggested that the model slightly under-
predicted 6 month weights. Subjects with observations at 3 months only
had median predicted 6 month weights of 1.017 times their baseline
weight. Subjects observed at 6 months had median weights of 1.037
times their baseline value.
Conclusion: Overall, the model was relatively unbiased and reason-
ably precise. The predicted values were not significantly different from
those observed. The substantial intersubject variability in weight change
remains to be explained. Differences in weight trajectories between sub-
jects lost to follow-up and those who completed warrant investigation.
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MODELLING OF WEIGHT CHANGE ASSOCIATED WITH
PLACEBO AND PREGABALIN ADMINISTRATION
1R. Miller, 2S. Beal, 1B. Frame, 3J. Barrett, and 1P. Burger (1Pfizer
Global Research and Development, Ann Arbor, Michigan, USA,
2University of California at San Francisco, USA, 3Pfizer Global Re-
search and Development, Pfizer Inc, New York, New York, USA)
Purpose: To characterise change from baseline weight over time for
pregabalin and placebo administration.
Method: Asymptotic fractional change from baseline weight was
modelled with a nonmixture model and a mixture model as a function of
baseline weight, exposure, time, covariate effects, and subject-specific
random effects. Model fit was assessed using standard diagnostic plots.
Predictive performance was assessed using both data similar to the orig-
inal data, and open-label data.
Results: The nonmixture model indicated that a typical patient (base-
line weight, 82 kg) receiving placebo or 300 mg/day pregabalin ap-
proached an asymptotic fractional increase from baseline weight of
[mean (95% prediction interval for typical individual)] 0.7% (−5.5%
to 7.4%) or 2.5% (−3.8% to 9.1%), respectively, with a “half-life” of
17 days. Substantial between-subject variability is observed, with some
drug-treated subjects remaining weight neutral or losing weight, at all
levels of exposure. Structural fixed effects parameters for the two sub-
models (mixture model) were in close agreement with each other and
with those for the nonmixture model. The mixture model described
two subpopulations differing in interindividual variability. No signifi-
cant interindividual-varying covariates influencing the mixture proba-
bilities were identified other than exposure. Both models had adequate
fit; both models performed well during external validation. Predictive
performance (nonmixture model) was adequate to ∼900 days.
Conclusion: Though substantial between-subject variability exists,
the weight of a typical 82-kg patient receiving placebo or pregabalin
(300 mg/day) approaches an asymptotic fractional increase from baseline
weight of 0.7% or 2.5%, respectively, with a “half-life” of 17 days.
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LONG-TERM RESPONSE IN PATIENTS WITH PARTIAL-
ONSET SEIZURES TREATED WITH ADD-ON PREGABALIN
1K. Spiegel, 2C. Bazil, 3B. Uthman, 4J. Barrett, 4E. Whalen, 4T. Griesing,
and 4F. Baldinetti (1Pfizer Global Research and Development, Ann
Arbor, MI, USA, 2Columbia University Medical Center, New York,
USA, 3Malcolm Randall VA Medical Center and the University of
Florida College of Medicine, Gainesville, USA, 4Pfizer Global Phar-
maceuticals, Pfizer Inc, New York, USA)
Purpose: To evaluate the long-term efficacy and safety of pregabalin
as adjunctive therapy in adult patients with partial-onset seizures
Method: 671 patients completed three 12 week, randomised, placebo-
controlled, double-blind pregabalin trials and entered open-label (OL)
trials. Patients took pregabalin up to 600 mg/day, BID or TID, and kept
seizure diaries. Data from those treated for ≤30 months were evaluated.
Results: 261/671 patients received OL pregabalin treatment for 30
months. Median baseline seizure rate was ∼11/28d, despite use of 1–5
concomitant AEDs. Mean age was 40 years; mean duration of epilepsy
was 27 years. Most patients received pregabalin 600 mg/d or 450 mg/d. At
30 months, 64.8% of patients experienced a ≥50% reduction in seizure
frequency (SF); 84 patients (32.2%) attained a 76–100% decrease in SF;
85 (32.6%) attained a 51–75% decrease; and 83 (31.8%) decreased SF
up to 50%. Nine patients (3.4%) worsened, with 8 reporting an increase
in SF of ≤50%. Response rates remained relatively consistent through-
out the 30-month period. The mean number of seizure-free days/28d
among responders was 25.5 ( ± 2.7), compared with 22.8 ( ± 4.5) among
nonresponders. With ongoing treatment, somnolence, weight gain, and
dizziness were observed most frequently and were generally considered
to be mild-to-moderate. Adverse events led to discontinuation in 8.4%
patients over the 30 months, with weight gain and dizziness cited most
often.
Conclusion: After 30 months of pregabalin treatment, two-thirds
of patients were responders and demonstrated maintenance of seizure-
frequency reduction throughout the observation period. Long-term pre-
gabalin treatment was safe and well tolerated. Supported by Pfizer Inc.
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EFFICACY AND TOLERABILITY OF PREGABALIN IN RE-
FRACTORY PARTIAL SEIZURES ARE NOT ALTERED BY
BACKGROUND ANTIEPILEPTIC DRUGS
1T. Tomson, 2E. Whalen, and 2F. Baldinetti (1Karolinska Institutet,
Stockholm, Sweden, 2Pfizer Global Pharmaceuticals, Pfizer Inc, New
York, NY, USA)
Purpose: To assess the response and tolerability of pregabalin relative
to types of background antiepileptic drugs (AEDs) in add-on trials of
patients with refractory partial-onset seizures.
Method: In this post hoc analysis, pooled data from 4 large pregabalin
add-on trials in patients with partial seizures were analysed. Analyses
were restricted to the greatest pregabalin dose (600 mg/d) and placebo.
The type of AED comedication was classified into 3 groups based on pre-
sumed mode of action: (1) Na+-channel blocker AEDs; (2) GABAergic
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AEDs; and (3) multimodal-action AEDs. Outcome in the ITT population
(n = 899) was analysed by type of AED comedication.
Results: The response rates (proportion of patients with ≥50% reduc-
tion from baseline in seizures) for pregabalin-treated groups (45.9% to
47.2%) were significantly greater than those for patients who received
placebo (6.6% to 10.7%), irrespective of class of background AED. There
were no significant differences in placebo-corrected responder rates in
patients who received pregabalin and were comedicated exclusively with
either Na+-channel blockers, GABAergic AEDs, or multimodal-action
AEDs. Similarly, there were no significant differences in responder
rates between pregabalin-treated patients who received different com-
binations of classes of background AEDs (eg, Na+-channel blocker
AEDs plus multimodal-action drugs; Na+-channel blocker AEDs plus
GABAergic AEDs; a combination of all three classes). Differences in
placebo-corrected withdrawal rates (18.9% to 20.5%) were similar when
comparing patients treated with the different classes or combinations of
background AEDs.
Conclusion: Pregabalin is effective and well-tolerated as add-on treat-
ment for partial seizures, and was not altered by background AEDs.
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LONG-TERM SEIZURE FREEDOM IN PATIENTS WITH PAR-
TIAL SEIZURES TREATED WITH ADD-ON PREGABALIN:
ANALYSIS OF OPEN-LABEL STUDIES
1B. Uthman, 2C. Bazil, 3T. Griesing, 3E. Whalen, 4K. Spiegel, and 3J.
Barrett (1University of Florida, College of Medicine and Malcolm Ran-
dall, VA Medical Center, Gainesville, USA, 2Columbia University Med-
ical Center, New York, USA, 3Pfizer Global Pharmaceuticals, Pfizer Inc,
New York, USA, 4Pfizer Global Research and Development, Ann Arbor,
USA)
Purpose: To evaluate differences over time in measures of seizure
freedom among adults with poorly controlled partial-onset epilepsy
treated with pregabalin.
Method: Three long-term, open-label, add-on trials enrolled 1057
patients (386 de novo and 671 from double-blind randomised, placebo-
controlled trials). Patients took pregabalin 150–600 mg/d, BID or TID,
and kept seizure diaries. Results at 30 months are reported.
Results: 344 patients received OL pregabalin treatment for 30 months.
Mean age was 40 years; mean epilepsy duration was 27 years. All pa-
tients were taking ≥1 concurrent AED; 92% were taking ≥2 AEDs. Most
patients received pregabalin 600 mg/d or 450 mg/d. The proportion of
patients seizure-free for the last 6, 12, 18, 24, and 30 months of treat-
ment was 8.0%, 5.1%, 4.6%, 2.9%, and 2.6%, respectively. The median
maximum seizure-free interval was 12 days at baseline. At 1 year, the
seizure-free interval was 62 days, and was 98 days in patients treated
for 30 months. The median number of seizure-free days/28d for this 30-
month cohort was 25.6. Pregabalin was generally well tolerated. Most
AEs were mild-to-moderate and tended to resolve over time. The most
common AEs at 30 months were dizziness (3.5%), asthenia (3.2%), and
somnolence (1.8%). Over the 30-month treatment period, 8.4% patients
discontinued due to AEs.
Conclusion: In patients with treatment-refractory epilepsy who re-
ceived add-on pregabalin up to 600 mg/d, nearly 10% were seizure-free
for the last 6 months of treatment, with seizure-free intervals of 3.5
months for patients treated for 30 months. Pregabalin was generally well
tolerated. Supported by Pfizer Inc.
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OXCARBAZEPINE FOR ELDERLY EPILEPSY PATIENTS
J. Mauri, C. Tejero, G. Pin˜ol, L. Martinez, and E. Mostacero (Clinical
Hospital, Zaragoza, Spain)
Purpose: In the elderly with epilepsy we need to consider better-
tolerated and less toxic drugs than those classically used. Oxcarbazepine
is a modern antiepileptic drug (AED) used as both monotherapy and
adjunctive therapy for the treatment of partial seizures with and without
secondary generalisation in adults and children. The goal of the present
study is to assess the efficacy and tolerance of oxcarbazepine in elderly
patients with epilepsy.
Method: A prospective, descriptive, observational study was carried
out in a total of 40 patients over 65 years old. All patients started with
a double daily dose of 150 mg of oxcarbazepine. Their dosages were
adjusted to treatment response. Where further seizures occurred, the
dose of oxcarbazepine was increased. Efficacy and tolerance checks
were carried out after one month, three months and six months.
Results: Median daily oxcarbazepine dose was 832.5 mg. Thirty-one
patients (77.5%) were taking low doses (less or equal to 900 mg/day).
At the end of the study 28 (70%) patients continued to be seizure-free.
The drug was withdrawn in 2 cases because of adverse events. The
most common adverse events (37.5%) were dizziness (7 patients) and
somnolence (8 patients). Mild hyponatremia was detected in 6 patients.
Conclusion: Oxcarbazepine is an effective therapy for the control of
epilepsy in elderly patients at low doses, with good tolerance and a low
rate of adverse events.
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OXCARBAZEPINE IN PATIENTS WITH BRAIN TUMOURS
AND EPILEPSY: IS IT SAFE?
1L. Dinapoli, 1M. Maschio, 1A. Zarabla, 2A. Fabi, 3A. Mirri, 4A. Pace,
4A. Pompili, 4C. Carapella, 4E. Occhipinti, and 4B. Jandolo (1Epilepsy
Outpatient’s Centre, Department of Neuroscience and Cervical-Facial
Pathology, National Institute For Cancer “Regina Elena,” Rome,
Italy, 2Deparment of Oncology National Institute for Cancer “Regina
Elena,” Rome, Italy, 3Department of Radiotherapy National Institute
for Cancer “Regina Elena,” Rome, Italy, 4Department of Neuroscience
And Cervical-Facial Pathology, National Institute For Cancer “Regina
Elena,” Rome, Italy)
Purpose: Seizures affect 20-40% of patients with primary brain tu-
mours or brain metastases and significantly alter their quality of life. Fur-
thermore, anticonvulsant treatment is complicated by pharmacological
interactions between antiepileptic drugs (AED) and chemotherapeutic
agents. Among the newer AEDs, oxcarbazepine (OXC) has a fast and
complete absorption and it rarely interferes with other therapies. The
aim of this retrospective study was to investigate the safety and efficacy
of OXC in monotherapy in a group of patients affected by brain tumour
associated epilepsy.
Method: We studied 18 patients affected by brain tumour and epilepsy
(11 males, 7 females, mean age 51). Twelve patients underwent radio-
therapy and chemotherapy. In 7 patients OXC was the first therapeutic
choice, in 7 it substituted the first therapy because of heavy side effects
and in 4 it was introduced because of persisting seizures. Follow-up
ranged between 2 to 43 months.
Results: Oxcarbazepine did not induce any significant side effect:
during the whole period of follow up liver and haematic values were in
the normal ranges. OXC induced complete seizure control in 15 patients
(83.3% of whole population), a seizure rate reduction higher than 50%
in 1 patient, an unmodified seizure rate in 1 patient, and a worsening of
seizure rate lower than 50% in 1 patient.
Conclusion: These preliminary data seem to indicate that OXC treat-
ment in patients with brain tumours is quite safe and efficacious. Con-
trolled studies on larger populations are suggested to confirm these open
observations.
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PLASMA HOMOCYSTEINE LEVELS IN OXCARBAZEPINE
TREATED EPILEPSY PATIENTS
1O. Erdinc, 1D. ´Ylhan, 2O. Alatas, 2O. Colak, and 3S. Oner (1Eskisehir
Osmangazi University Medical Faculty Department of Neurology, Es-
kisehir, Turkey, 2Eskisehir Osmangazi University Medical Faculty De-
partment of Biochemistry, Eskisehir, Turkey, 3Eskisehir Osmangazi Uni-
versity Medical Faculty Department of Biostatistics, Eskisehir, Turkey)
Purpose: It is known that plasma homocysteine (HS), folic acid (FA)
and vitamin B12 levels may be affected by antiepileptic drugs (AED)
(Tamura T. et al., Epilepsy Res 2000;40:7–15). Elevated plasma con-
centrations of HS are associated with increased risk of coronary artery
disease, peripheral vascular disease and thrombosis (Duell PB et al., The
Endocrinol 1998;8:170–177). The aim of this study was to assess the
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effects of oxcarbazepine (OXC) on plasma HS, FA and vitamin B12
levels.
Method: A total of 31 epilepsy outpatients receiving AED therapy
were selected. The patients in group1 received OXC for less than 1 year
(n = 7), group 2 received OXC for more than 1 year (n = 8), group 3
received OXC with valproate (VPA) for more than 1 year (n = 9), group
4 received VPA monotherapy (n = 7). A control group of 30 healthy
subjects without any AED medication was also included. The plasma
HS, FA and vitamin B12 levels of the groups were compared with each
other using one way ANOVA.
Results: The levels of plasma HS for groups 1, 2, 3 and 4 and the
controls were 10.7 ± 4.1 μmol/l, 15.5 ± 10.7 μmol/l, 12.7 ± 4.10
μmol/l, 10.2 ± 2.9 μmol/l, 10.6 ± 4.7 μmol/l respectively. No significant
difference could be found between HS, FA and vitamin B12 levels (p >
0.05).
Conclusion: According to the findings of our study, it seems that
OXC does not have any influence on plasma HS, FA and vitamin B12
levels, but HS levels in patients with nutritional FA supports may not be
affected.
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RELATIONSHIP BETWEEN THE PLASMA CONCENTRA-
TIONS OF THE MONOHYDROXY DERIVATIVE OF OXCAR-
BAZEPINE AND ITS EFFICACY AND SIDE EFFECTS
J. Martı´nez-Simo´n, M. Rodrı´guez, R. Saiz Diaz, P. De la Pen˜a, A. Lo´pez
Jimenez, and C. Manzanares (Hospital Doce De Octubre, Madrid, Spain)
Purpose: To describe the relationship between oxcarbazepine (OXC)
plasma concentration and its monohydroxy derivative (MHD) with the
therapeutic effect and side effects in epilepsy patients. We pretend to
determinate the therapeutic levels of the drug to achieve a seizure-free
state without side effects to get a reference in clinical practice.
Method: Data have been obtained from 30 adult and paediatric
epilepsy clinic outpatients, 16 adults (10 men, 6 women) with mean
38 ± 16.3 years old and 14 children (8 male, 6 female) with mean
10.6 ± 2.89 years old. All of them suffered from chronic epilepsy with
partial or generalised seizures. Measurement of OXC plasma concen-
trations was made in stable level phase before the first dosage in the
morning and OXC + MHD concentrations were obtained by high reso-
lution chromatography (HPLC).
Results: The mean MHD plasma levels in children was 19.03 ± 4.67
mg/l (mean OXC daily dosage of 982.91 ± 364.22 mg). In adults the
mean MHD plasma levels was 21.28 ± 4.8 mg/l (mean OXC dosage
1407.7 ± 309.47 mg/d). Global efficacy curve shows that a seizure-free
state can be achieved in 84% of patients with plasma concentrations
of OXC+MHD between 13.21 and 27.86 mg/l. With regard to side ef-
fects, only 9% of the patients had any adverse effects which were mild
somnolence. None were related to high OXC plasma concentrations. No
haematological or biochemistry anomalies were found in our series.
Conclusion: We consider that OXC metabolite MHD plasma con-
centrations between 13.21 and 27.86 mg/l are correlated with a good
efficacy without significant side effects.
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EFFICACY AND TOLERABILITY OF OXCARBAZEPINE DUR-
ING ONE-YEAR FOLLOW-UP AS ADD-ON THERAPY IN PA-
TIENTS WITH TREATMENT-RESISTANT EPILEPSY
E. Kkolou, K. Kleopa, and S. Papacostas (The Cyprus Institute of Neu-
rology and Genetics, Cyprus)
Purpose: To investigate the efficacy and tolerability of Oxcarbazepine
(OXC) as add-on therapy for Cypriot patients with treatment-resistant
seizures.
Method: Twenty patients with partial-onset epilepsy, ages 12–71,
were studied retrospectively for 12 months. Patients received OXC as
add-on therapy to 1–4 anticonvulsants. We compared mean seizure fre-
quency for a 3-month period prior to and 12 months after introduction
of OXC. All subjects had physical and neurological examinations, rou-
tine baseline haematological, biochemical, and urinary investigations at
entry.
Results: Two patients (10%) became seizure free. Four patients (20%)
had a seizure reduction of 75% or greater. Two patients (10%) had a
seizure reduction of 50–74% or greater. Seven patients (35%) had no
significant change from baseline and 2 patients (10%) worsened. Ox-
carbazepine was discontinued in 3 patients (15%) due to side effects. A
reduction of 32.4% of concomitant antiepileptics was achieved. Diplopia
(15%), dizziness/ataxia (15%), rash (10%), behavioural/psychiatric side
effects (10%), cognitive impairment (10%) and numbness (10%) were
the most frequently reported side effects.
Conclusion: OXC was effective in focal epilepsy as demonstrated by
significant reduction of seizures. A substantial rate of our population
became seizure free. 40% of our patients with refractory epilepsy ex-
perienced a reduction of 50% or more on their seizure frequency with
the addition of OXC. Oxcarbazepine was generally well tolerated by all
patients with only 15% discontinuing it due to adverse reactions.
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CITALOPRAM DOES NOT CAUSE HYPONATREMIA IN
EPILEPSY PATIENTS TREATED WITH CARBAMAZEPINE OR
OXCARBAZEPINE
V. Wegere, U. Ju¨rges, B. Steinhoff, and C. Kurth (Epilepsy Centre Kork,
Kork, Germany)
Purpose: Hyponatremia is a side effect of treatment with carba-
mazepine (CBZ), oxcabazepine (OXC) or citalopram. Thus the aim of
this study was to evaluate the aditional effect of citalopram on sodium
blood level in epilepsy patients being already treated with CBZ or OXC.
Method: Epilepsy patients with a stable dose of CBZ or OXC were in-
cluded. Dosage of CBZ, OXC, citalopram and blood levels of antiepilep-
tics and sodium before and after titration of citalopram were analysed
applying a t-test for paired samples.
Results: Data of 17 patients (7 male, 10 female, age: 25–76 years)
were evaluated. 14 patients received CBZ (800–2100 mg/day), 3 pa-
tients were treated with OXC (1200–1800 mg/day). Daily dose of citalo-
pram was 20–40 mg. Average time between titration of citalopram
and assesment of sodium levels was 12.75 months. The average CBZ
blood level before titration of citalopram was 9.25μg/ml in contrast to
10.1 μg/ml after titration of citalopram. No significant difference be-
tween the CBZ levels before and during treatment with citalopram was
found (p = 0.31). The average sodium level before titration of citalopram
was 135.5 mmol/l in contrast to 135 mmol/l after citalopram titration.
No significant difference between the sodium levels before and during
treatment with citalopram was found (p = 0.86).
Conclusion: No drop of sodium levels could be found in epilepsy
patients treated with constant dosages of CBZ or OXC due to additional
antidepressant therapy with citalopram. In general citalopram treatment
in this group of epilepsy patients can be supposed to be safe with regard
to changes in sodium levels.
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EVALUATION OF THE EFFECT OF ORAL LACOSAMIDE
ON ADJUNCTIVE CONCOMITANT ANTIEPILEPTIC DRUG
PLASMA CONCENTRATIONS IN SUBJECTS WITH PARTIAL
SEIZURES
1D. Jatuzis, 2V. Biton, 3E. Ben-Menachem, 4B. Abou-Khalil, 5M. Hack-
enson, and 5D. Rudd (1Vilnius University Hospital, Vilnius, Lithua-
nia, 2Clinical Trials, Inc., Little Rock, USA, 3Sahlgrenska University
Hospital, Goteborg, Sweden, 4Vanderbilt University, Nashville, USA,
5Schwarz Biosciences, Inc., USA)
Purpose: Lacosamide (LCM) reduced seizure frequency in a double-
blind trial of subjects with uncontrolled partial seizures (SP667).
Steady-state plasma concentrations of concomitant antiepileptic drugs
(conAEDs) were evaluated for possible pharmacokinetic interactions
that could affect seizure frequency.
Method: After an 8-week baseline, subjects (n = 418) taking 1 (16%)
or 2 (84%) conAEDs were randomised to placebo, 200, 400, or 600
mg/day LCM (given bid), titrated over 6 weeks by 100 mg/week, and
maintained on treatment for 12 weeks. ConAED dose regimens were to
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remain constant. Descriptive statistics compared end of baseline and end
of maintenance conAED plasma concentrations.
Results: Mean change from baseline (μg/mL) at the end of mainte-
nance was 0.4, 0.6 for CBZ; 1.0, −1.4 for LEV; and 0.4, −0.7 for LTG
in placebo and 600 mg/day LCM groups, respectively. LCM also did
not affect mean AED concentrations for TPM, OXC (MHD), PHT and
VPA. Similar results were observed in the 200 and 400 mg/day LCM
groups. LCM (400 and 600 mg/day) produced a statistically signifi-
cant median percent reduction in seizure frequency from baseline (p =
0.0023 and 0.0084, respectively); 200 mg/day exhibited a 26% reduction
in seizures (p = 0.1010). The most common adverse events (≥ 10% in
any LCM group) include dizziness, nausea, fatigue, ataxia, vision ab-
normal, diplopia, and nystagmus. No clinically relevant LCM influence
was observed on ECG, laboratory, vital sign, or body weight variables.
Conclusion: Lacosamide does not affect the mean plasma concen-
trations of commonly used AEDs. Thus, observed reductions in seizure
frequency were not due to increased AED plasma concentrations.
Study supported by: Schwarz Biosciences, Inc.
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LACOSAMIDE HAS LOW POTENTIAL FOR DRUG-DRUG
INTERACTION
1D. Thomas, 2U. Scharfenecker, 1B. Schiltmeyer, 1B. Koch, 3D. Rudd,
1W. Cawello, and 1R. Horstmann (1Clinical Development, Schwarz
Biosciences GmbH, Monheim, Germany, 2Department of ADME,
Schwarz Biosciences GmbH, Monheim, Germany, 3Clinical Develop-
ment, Schwarz Biosciences GmbH, USA)
Purpose: Lacosamide is an investigational drug being developed for
the treatment of epilepsy and neuropathic pain. Phase 3 development
is currently ongoing for both indications. Information about the phar-
macokinetic drug-drug interaction (DDI) potential of lacosamide is an
important part of the safety profile.
Method: Regarding DDI potential the results of several preclinical
studies, Phase 1 trials (n = 184 subjects) and a Phase 2 trial (n = 91
patients) are presented.
Results: In vitro lacosamide is not substantially metabolised. In vitro
results also show no or low potential to inhibit or to induce CYP isoforms.
Since lacosamide has low protein binding (<10%), drug displacement
interactions are unlikely. In a Phase 1 trial the activity of CYP2C19 had
no clinically relevant effect on the metabolic fate of lacosamide. Further
phase 1 DDI trials with the antiepileptic drugs carbamazepine and val-
proic acid showed that lacosamide had no influence on rate or extent of
absorption of carbamazepine or valproic acid and vice versa. DDI trials
with digoxin and metformin showed no relevant influence of these drugs
on lacosamide and vice versa. Lacosamide did not influence the pharma-
cokinetics and pharmacodynamics of the oral contraceptive Microgynon
(containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel). A clin-
ical trial in subjects with epilepsy showed no influence of lacosamide on
plasma levels of common antiepileptic drugs including phenytoin.
Conclusion: No relevant DDI have been observed in these studies and
therefore the data suggest that lacosamide may have a low potential for
DDI in clinical use.
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MULTICENTER OPEN-LABEL TRIAL INVESTIGATING
SAFETY AND TOLERABILITY OF INTRAVENOUS SPM 927
AS REPLACEMENT FOR ORAL SPM 927 IN SUBJECTS WITH
PARTIAL SEIZURES
1N. Vaiciene, 2R. Mameniskiene, 3V. Biton, 4M. Brock, and 5K. Som-
merville (1Kaunas Medical University Hospital, Kaunas, Lithuania,
2Vilnius University Hospital, Vilnius, Lithuania, 3Clinical Trials, Inc.,
Little Rock, USA, 4Schwarz Biosciences, Inc., 5Schwarz Biosciences,
Inc., USA)
Purpose: Lacosamide (LCM) belongs to a novel class of function-
alised amino acids specifically synthesised as anticonvulsant drug can-
didates. LCM has a favourable pharmacokinetic profile and when give
orally twice daily (bid) has been shown to reduce seizure frequency in
patients with partial seizures. LCM solution for intravenous (iv) infusion
is being developed as a short-term replacement for oral LCM. Infusion
of 200 mg iv LCM over 30- or 60-minutes has been shown to be bioe-
quivalent (Cmax, AUC) to 200 mg oral LCM. The objective of SP757 is
to investigate whether iv LCM is safe and well tolerated when given bid
as short-term adjunctive therapy for partial seizures.
Method: Subjects (n = 40) currently receiving adjunctive, stable, bid
dosing (200 to 600 mg/day) were enrolled as Cohort A1. These subjects
were administered iv LCM bid as 30-minute infusions for 2 consecu-
tive days. Safety was evaluated through reported adverse events (AEs),
12-lead electrocardiogram (ECG), vital signs and clinical laboratory
data.
Results: Forty subjects completed the trial. Seventeen (43%) reported
AEs, all of which were mild or moderate in intensity; CNS-related events
were most commonly reported. Analysis of ECG and vital signs data
showed no issues of clinical concern.
Conclusion: In this trial, administration of 30-minute iv LCM infu-
sions for short-term replacement of oral LCM had a similar AE profile
to oral LCM. Funding supported by: Schwarz Biosciences, Inc.
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EFFECT OF PHENYTOIN AND PRIMIDONE ON HUMAN
SPERM MOTILITY AND CERVICAL MUCUS PENETRATION
1I. Blatt, 1M. Boxer, and 2R. Weissenberg (1Epilepsy Clinic, Department
of Neurology, Sheba Medical Center, 2Male Fertility Institute, Sheba
Medical Center, Tel-Hashomer, Israel)
Purpose: Antiepileptic drugs (AEDs) effects on sperm motility have
been shown. We previously demonstrated the ability of CBZ and VPA to
decrease sperm motility and reduce sperm ability to penetrate cervical
mucus (a functional test not studied before in relation to AEDS). In
the present study we investigated the effect of phenytoin (PHT) and
primidone (PRM) on these parameters.
Method: PHT was dissolved in PBS + ethanol 2% + propylene glycol
8%, PRM in PBS + ethanol 2.5%. Normal semen from healthy human
donors (sperm count>20 million/mL, >50% progressively motile) was
incubated for 2hr with several dilutions of PHT or PRM. Parameters
analysed included sperm motility (%motile cells), EC50, motility quality
grade, abnormal motility patterns, ability of spermatozoa to penetrate
into bovine cervical mucus after 10 min contact (depth of penetration).
Statistical analysis employed the Wilcoxon Signed Ranks Test.
Results: PHT significantly (p < 0.05) decreased sperm motility at
concentrations ≥156 mg/L, with EC50 = 625 mg/L. Motility qual-
ity grade was decreased at concentrations ≥156 mg/L. Cervical mu-
cus penetration was inhibited at concentrations ≥156 mg/L. “Shaking”
(abnormal motility pattern) was observed at ≥625 mg/L. PRM signifi-
cantly (p < 0.05) decreased sperm motility at concentrations ≥150 mg/L;
EC50 was not reached with concentrations ≤300 mg/L. Motility qual-
ity grade was decreased at concentrations ≥75 mg/L. Cervical mucus
penetration was inhibited at concentrations ≥75 mg/L.
Conclusion: PHT and PRM impair sperm motility, quantitatively and
qualitatively, at concentrations above the therapeutic range, and also im-
pair the ability of human spermatozoa to penetrate into bovine (with
composition and properties similar to human) cervical mucus. This im-
plies impairment of the physiological function of spermatozoa by high
concentrations of these AEDs.
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CAN THE WIDE-FIELD MULTIFOCAL ELECTRORETINO-
GRAM DIFFERENTIATE BETWEEN VIGABATRIN-
ASSOCIATED RETINAL TOXICITY AND CONVENTIONAL
VISUAL FIELD DEFECTS?
1P. Gonzalez, 1A. McCall, 1A. McQuistan, 1S. Parks, 1D. Keating, 2K.
Kelly, 2L. Stephen, 2G. Sills, and 2M. Brodie (1Electrodiagnostic Imag-
ing Unit, University of Glasgow, Glasgow, Scotland, UK, 2Epilepsy Unit,
University of Glasgow, Glasgow, Scotland, UK)
Purpose: This study was designed to differentiate between neuroreti-
nal toxicity associated with vigabatrin (VGB) therapy and nonspecific
visual dysfunction in people with epilepsy.
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Method: A total of 204 epilepsy patients were grouped according
to antiepileptic drug therapy as follows: current VGB treatment (n =
56), previous VGB treatment (n = 49), current GABAergic treatment
(no VGB exposure; n = 46) and current non-GABAergic treatment (no
VGB exposure; n = 53). Groups were matched for age, sex, seizure-
type, and seizure frequency. All patients underwent wide-field multifocal
electroretinography (WFmfERG), logMar visual acuity testing, colour
vision assessment, static perimetry (Humphrey) and ISCEV standard
electroretinography.
Results: When assessed by static perimetry, visual field constriction
was observed in 33 current-VGB patients (59%) and 21 of the previous-
VGB group (43%). However, significant visual field abnormalities were
also demonstrated in 24 patients (24%) with no prior exposure to VGB.
Assessment of retinal function by WfmfERG revealed abnormal re-
sponses in 27 current-VGB patients (48%), 11 previous-VGB patients
(22%), but none (0%) of the patients with no prior exposure to VGB.
The incidence of WfmfERG abnormalities was directly related to VGB
drug load. There was no difference between groups in terms of visual
acuity, colour vision and electroretinography assessments.
Conclusion: Visual field abnormalities are common in the treated
epilepsy population. VGB causes peripheral retinal dysfunction that can
be manifest as visual field constriction when investigated using perime-
try but which is more readily and reliably identified by WfmfERG. Con-
ventional assessments are unlikely to be sufficiently specific to identify
VGB-related retinal toxicity. Patients with current or previous exposure
to VGB should be considered for WfmfERG.
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USE OF ZONISAMIDE IN FOUR PATIENTS WITH LAFORA
DISEASE
1F. Longaretti, 2S. Cardinali, 1E. Alfei, 1C. Cortesi, and 1P. Veggiotti
(1Department of Childhood Neuropsychiatry, Neurological Institute C.
Mondino, Pavia, Italy, 2Childhood Neuropsychiatry Unit, G. Salvini
Hospital, Garbagnate Milanese, Milan, Italy)
Purpose: To evaluate the efficacy of zonisamide (ZSM) in control-
ling seizures in patients with Lafora disease (LD) with a retrospective
observational study performed in 4 adolescents.
Method: Six adolescents with Lafora disease (LD) attending our De-
partment were identified. Four patients were treated with ZSM. We ret-
rospectively reviewed changes in seizure frequency and semiology, EEG
findings, alertness and ideomotor slowing, comparing the 3 months pre-
ceding the introduction of ZSM with the following 1 month, 3 months
and 1 year. Side effects were described when observed.
Results: Four patients affected by LD (1 male: 3 female; median
current age: 20 ys 10 mths; range: 19 ys–21 ys 4 mths) were ascertained.
All patients were taking 2 or 3 AEDs and Ketogenic diet. The median
highest dose was 5.3 mg/Kg/die (range: 3–12 mg/Kg/die). The median
period of ZSM administration was 1 y 11 mths (range: 1 y–3 ys 7 mths)
and 2 patients are currently taking the drug. In 2 patients (50%) we
observed a complete control of generalised tonic–clonic seizures during
the first month and at 3 months a reduction > 50% of seizure frequency
recorded during the 3 months preceding the ZSM introduction. At 1 year
the seizure reduction was unchanged. We did not observe an efficacy in
controlling other types of seizures such as absences or myoclonic jerks.
In the other 2 girls ZSM was not effective.
Conclusion: ZSM allows a long-lasting reduction of tonic–clonic
seizures in some LD patients.
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EFFECT OF ESLICARBAZEPINE ACETATE (BIA 2-093) ON
THE STEADY-STATE PHARMACOKINETICS AND PHARMA-
CODYNAMICS OF WARFARIN IN HEALTHY SUBJECTS
L. Almeida, M. Vaz-da-Silva, A. Falca˜o, J. Maia, E. Soares, and P. Soares-
da-Silva (BIAL–Portela & Ca SA, S Mamede Do Coronado, Portugal)
Purpose: To investigate the effect of eslicarbazepine acetate (ESL) on
the steady-state pharmacokinetics and pharmacodynamics of warfarin in
13 healthy subjects (7 males and 6 females).
Method: Open-label study consisting of three consecutive phases: A:
up to 21 day run in phase, for identifying an individualised warfarin
dose stabilising INR between 1.3–1.8; B: warfarin pharmacokinetics
and INR profiling following a 7 day ESL 1200 mg once daily treatment,
concomitantly with the individualised warfarin dose; C: 7 day period
with warfarin alone.
Results: Mean S-warfarin Cmax was respectively 0.375 mg/L and
0.455 mg/L with Test (warfarin plus ESL, day 8 of phase B) and Ref-
erence (warfarin alone, day 1 of phase B) treatments; point-estimate
(PE) and 90% CI of Test/Reference ratio were 0.81 and 0.76, 0.86.
Mean S-warfarin AUCτ was respectively 5.56 mg.h/L and 7.05 mg.h/L
with Test and Reference, and PE and 90%CI of Test/Reference ratio
were 0.77 and 0.72, 0.82. Mean R-warfarin Cmax was respectively 0.556
mg/L and 0.575 mg/L with Test and Reference, and PE and 90%CI of
Test/Reference ratio were 0.97 and 0.91, 1.02. Mean R-warfarin AUCτ
was respectively 9.85 mg.h/L and 9.93 mg.h/L with Test and Reference,
and PE and 90%CI of Test/Reference ratio were 0.98 and 0.92, 1.04.
Mean ± SD INR was 1.45 ± 0.10 following warfarin alone (phase A)
and 1.51 ± 0.25 following warfarin combined with ESL (phase B). Fol-
lowing discontinuation of ESL administration (phase C), a slight INR
decrease of −5.42% was found (90% CI of −8.85, −1.98).
Conclusion: Following ESL administration, a small although statisti-
cally significant decrease in systemic exposure to S-warfarin was found.
However, R-warfarin pharmacokinetics and the INR were not affected.
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PHARMACOKINETICS OF ESLICARBAZEPINE ACETATE
(BIA 2-093) USING A CHIRAL METHOD
J. Maia, M. Vaz-da-Silva, L. Almeida, A. Falca˜o, and P. Soares-da-Silva
(BIAL (Portela & Ca, S.A.), S Mamede Do Coronado, Portugal)
Purpose: Pharmacokinetic studies showed that eslicarbazepine ac-
etate (ESL) is rapidly and extensively metabolised to the active metabo-
lites eslicarbazepine (S-licarbazepine) and R-licarbazepine. However, a
non-chiral drug plasma assay method was used in most studies with ESL;
the nonchiral method does not distinguish between S-licarbazepine (es-
licarbazepine) and R-licarbazepine, and the mixture has been reported as
BIA 2-005. In this study, a chiral method for plasma drug assay was used,
allowing us to distinguish between eslicarbazepine and R-licarbazepine.
Method: Open-label administration of ESL 900 mg single-dose (n =
12) and 900 mg once-daily for 8 days (n = 11) to healthy volunteers.
Results: Following ESL 900 mg single-dose, plasma eslicarbazepine
and R-licarbazepine mean Cmax was respectively 15.7 ± 3.8 μg/mL
and 0.4 ± 0.1 μg/mL and mean AUC0−∞ was respectively 301.7 ±
63.9 μg.h/mL and 16.8 ± 3.6 μg.h/mL. Median tmax occurred at 3 h for
eslicarbazepine and 15 h for R-licarbazepine. Following the last dose of
a 8-day ESL 900 mg once-daily regimen, plasma eslicarbazepine and
R-licarbazepine mean Cmax was respectively 22.2 ± 7.3 μg/mL and
0.7 ± 0.2 μg/mL and mean AUC0−∞ was respectively 389.3 ± 97.3
μg.h/mL and 24.0 ± 24.0 μg.h/mL. Median tmax occurred at 3 h for
eslicarbazepine and 10 h for R-licarbazepine.
Conclusion: Following single-dose and repeated dose oral admin-
istration, ESL was rapidly and extensively metabolised to the active
metabolites eslicarbazepine (S-licarbazepine) and R-licarbazepine. Es-
licarbazepine was the major metabolite, representing about 95% of drug
systemic exposure. Supported by BIAL (Portela & Ca SA).
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TIAGABINE ADMINISTRATION FOR TRIGEMINAL AND
GLOSSOPHARYNGEAL NEURALGIA: PRELIMINARY
RESULTS
1T. Mandat, 1R. Manowiec, 2B. Brozyna, and 3B. Brodacki
(1Department of Neurosurgery, Military Institute of Health Services,
Warsaw, Poland, 2Department of Maxillofacial Surgery, Military Insti-
tute of Health Services, Warsaw, Poland, 3Department of Neurology,
Military Institute of Health Services, Warsaw, Poland)
Purpose: The authors present a group of TN and GPN patients treated
with tiagabine. Safety and efficacy of the treatment were evaluated.
Epilepsia, Vol. 47, S3, 2006
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Method: Nine neuralgia patients (6 male, 3 female), aged 36–77
(mean 54) were treated with tiagabine. Seven patients had TN and
two GPN. All patients had previously been treated with the first choice
antiepileptic drugs with no improvement. Tiagabine was administered:
5 mg/d for 7 days and increased to 15 mg/d for 21 days. Dose was then
adjusted according to efficacy/tolerability up to a maximum of 30 mg/d.
Treatment lasted from 1 to 8 months. The effect was assessed by visual
analog scale (VAS).
Results: of the 9 patients enrolled, 4 patients with TN and 2 patients
with GPN reported improvement; VAS pain reduction by 5 points or
more. Noticeable tiagabine analgesic effect appeared from 2 to 6 weeks
of treatment (mean 28 days). Effective daily dosage of tiagabine varied
from 15 to 30 mg (mean 20 mg). One patient reported minor improve-
ment by two points in VAS with minor side effect and the treatment
was discontinued. Two patients did not report any improvement after 4
weeks and the treatment was discontinued. Tiagabine therapy was well
tolerated. Three patients complained of minor sleepiness. One patient
complained of nausea.
Conclusion: These preliminary findings suggest that tiagabine treat-
ment of TN and GPN in a selected group of patients is effective and safe.
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ESTIMATION OF EFFICACY AND TOLERABILITY OF CAR-
BAMAZEPINE AND VALPROIC ACID IN TREATMENT OF
PARTIAL EPILEPSY IN CHILDREN: A PRELIMINARY STUDY
E. Emich Widera, B. Szwed-Bialozyt, and E. Marszal (Department of
Pediatrics and Child Neurology of Silesian Medical University of Silesia
in Katowice, Poland)
Purpose: To estimate the efficacy of carbamazepine and valproic acid
in the treatment of partial epilepsy in children with seizures of various
aetiology (cryptogenic and symptomatic) and different clinical symp-
tomatology. Side effects analysis was also performed.
Method: Fifty-four children aged from 14 months to 17 years with
diagnosed (based on clinical and electroencephalographic criteria) focal
epilepsy were analysed. For all children the first chosen and used drug
was CBZ or VPA. We divided them into two groups: I–initially treated
with CBZ and II–initially treated with VPA.
Results: Generally, efficacy of pharmacotherapy in the two analysed
groups was similar. Positive results of treatment were observed in 31.5%
of patients treated with CBZ and 27.4% treated with VPA. Disturbances
in lipid metabolism were noted in some children treated with CBZ. Mild
decreasing of red and white blood cells and increasing of transaminase
level were found in the VPA group. In a few cases in both investigated
groups the disturbances of thyroid gland hormones and concentration of
immunoglobulins IgA and IgG were also present.
Conclusion: The efficacy of CBZ and VPA in treatment of partial
epilepsy in children is similar. The use of both drugs may cause side
effects but their type is different
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REGIONAL DIFFERENCES IN HIPPOCAMPAL (R)-
[11C]VERAPAMIL DISTRIBUTION IN PATIENTS WITH
MEDICALLY REFRACTORY TEMPORAL LOBE EPILEPSY
1M. Bauer, 1O. Langer, 2E. Pataraia, 3R. Karch, 1A. Abrahim, 2F. Zim-
prich, 1C. Joukhadar, 1M. Brunner, 4G. Luurtsema, 4M. Lubberink, 4A.
Lammertsma, 5R. Dudczak, 5K. Kletter, 1M. Mu¨ller, and 2C. Baum-
gartner (1Department of Clinical Pharmacology, Medical University of
Vienna, Austria, 2Department of Neurology, Medical University of Vi-
enna, Austria, 3Department of Medical Computer Sciences, Medical
University of Vienna, Austria, 4Department of Nuclear Medicine, Med-
ical University of Vienna, Austria, 5Department of Nuclear Medicine &
PET Research, VU University Medical Center, Amsterdam, The Nether-
lands)
Purpose: The radiolabelled P-glycoprotein (P-gp) substrate (R)-
[11C]verapamil has been developed as a probe for in vivo evaluation of
P-gp function at the human blood–brain barrier with positron emission
tomography (PET). Since P-gp is discussed as being implicated in phar-
macoresistance in epilepsy patients, we studied brain (R)-[11C]verapamil
distribution in patients (n = 6) with medically refractory temporal lobe
epilepsy.
Method: After i.v. bolus injection of about 400 MBq of (R)-
[11C]verapamil (specific activity: >20 GBq/μmol) dynamic brain PET
imaging and arterial blood sampling was performed for 60 min. Regions
of interest comprising the epileptogenic focus and the contralateral hip-
pocampal area were outlined in MRI-coregistered PET scans. Data were
modelled by a standard 1-tissue compartment model using a metabolite-
corrected arterial input function.
Results: Focal (R)-[11C]verapamil influx and efflux rate constants (K1
and k2) were significantly increased compared with control regions (p <
.05; t-test for dependent samples) with differences ranging from +7% to
+108% and +6% to +71% for K1 and k2, respectively. No significant
differences were observed for focal and non-focal (R)-[11C]verapamil
distribution volumes.
Conclusion: Our preliminary data point to a locally increased P-gp ac-
tivity in the epileptogenic area which might lead to increased brain elimi-
nation of antiepileptic drugs and thus explain refractoriness to antiepilep-
tic drugs. Our method could allow non-invasive in vivo assessment of
the mechanisms underlying medically refractory epilepsy.
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POSTSURGICAL fMRI ASSESSMENT OF TEMPORAL LOBE
EPILEPSY (TLE): A CASE STUDY
M. Korsnes, S. Andresen, and H. Bjørnæs (The National Centre for
Epilepsy, Sandvika, Norway)
Purpose: We used fMRI to investigate temporal lobe activation in
a TLE patient after temporal lobe resection where the anterior part of
the left temporal lobe was removed, including most of hippocampus.
Preoperative IAT indicated intact bilateral memory functions, and neu-
ropsychological assessment showed that figurative memory functions
were intact. We were interested in functional activation after resection;
in particular if any correlates corresponding to processing of novel pic-
tures (as compared to learned pictures) were evident in the left temporal
lobe
Method: Preoperative neuropsychological results were compared
with postoperative results, in order to evaluate changes in figurative mem-
ory function. fMRI activation was analysed with focus on ROIs within
the temporal lobe. We anatomically defined ROIs including anterior
hippocampus, posterior hippocampus, amygdala and parahippocampal
gyrus and looked for differential activation between novel and repeated
pictures. Novel pictures (50%) and repeated (and prelearned) pictures
were presented in a variable block length design (180 pictures in total).
Imaging was performed with a 1.5 Tesla scanner, and data were analysed
using SPM2.
Results: An area close to the anterior left hippocampus showed higher
activation (p = 0.01) for novel than repeated pictures. This activation was
located just outside the surgical area. No other ROIs (left or right) showed
significant activation at the p = 0.001 level.
Conclusion: Higher activation in the left area (close to the surgical
area) than in the right area, raise the possibility that some functional
ability, i.e., processing novel pictures, is overtaken by surrounding areas
after resection, and perhaps the peak is amplified since the functionality
is confined to a smaller area in the left temporal lobe due to surgery.
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PROEPILEPTOGENIC EFFECTS OF HUMAN BLOOD–BRAIN
BARRIER DISRUPTION
1N. Marchi, 2L. Angelov, 3T. Masaryk, 1V. Fazio, and 1D. Jani-
gro (1Cleveland Clinic Department of Neurological Surgery, USA,
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2Cleveland Clinic Brain Tumor Institute, USA, 3Department of Radi-
ology, USA)
Purpose: The cerebral vasculature is functionally impaired in an
epileptic brain. Defects in glucose and drug transport, hypoperfusion and
blood–brain barrier (BBB) leakage have all been described in the epilep-
tic brain. We tested the possibility that acute cerebrovascular events could
trigger motor seizures. We monitored the onset of behavioural seizures
in a population of patients undergoing osmotic BBB disruption (BBBD)
to treat primary CNS lymphoma.
Method: The procedure consists of the following steps: 1) Selective
catheterisation of the carotid or vertebral artery. 2) Osmotic disruption of
the BBB by infusing 25% mannitol in the previously catheterised artery.
3) Intrarterial infusion of antineoplastics in the disrupted circulation. 4)
Termination of procedure and documentation of the degree of disruption
by CT scan or serum S100B.
Results: Failure of the endothelial protection of the CNS lead to acute
seizures occurring controlateral to the hemisphere where the blood-brain
barrier was disrupted. Seizures occurred immediately after BBBD in
25% of procedures in spite of premedication with anaesthetic dosages
of thiopental. There was no significant correlation of seizure occurrence
with age, gender or tumour size/length of previous BBBD treatment. The
only predictors of focal motor seizures were positive indices of blood-
brain barrier disruption, namely radiological evaluation by contrast-
enhanced CT scans or serum S100B.
Conclusion: The most parsimonious explanation of our findings is that
BBBD leads to motor seizures even in absence of obvious predisposing
serum factors, such as drugs (e.g., penicillin) or unbalanced electrolytes.
This may be a mechanism of ictal-to-ictal transition or a trigger for post-
traumatic seizures.
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STRUCTURAL MRI ANALYSIS OF PATIENTS WITH JUVE-
NILE MYOCLONIC EPILEPSY USING OPTIMISED VOXEL-
BASED MORPHOMETRY
R. Roebling, N. Scheerer, and H. Lerche (Department of Neurology,
University of Ulm, Germany)
Purpose: MRI scans of patients with idiopathic generalised epilepsy
(IGE) are normal on visual inspection. Previous studies have shown large
cerebral structure changes in patients with juvenile myoclonic epilepsy
(JME). The purpose of this study was to analyse the MRI scans of patients
with JME with a group of healthy controls with the optimised voxel-based
morphometry (VBM) using the SPM2 software.
Method: We compared the MRI scans (1.5 Tesla, MP-RAGE) of 18
patients with JME with the scans of 31 healthy controls. The groups
were matched for age, sex and education and the healthy subjects had no
history of seizures and no history of IGE among first-degree relatives. We
compared both groups as well as each patient with the group of healthy
subjects using optimised VBM both with and without modulation.
Results: The VBM did not show any significant changes in grey matter
between the group of patients and the healthy controls or between any
single patient and the group of healthy controls.
Conclusion: Optimised VBM was unable to find significant grey mat-
ter abnormalities in patients with JME. This contradicts the results of pre-
vious studies using a different approach for grey/white matter segmen-
tation, which had shown large mediofrontal grey matter abnormalities in
patients with JME.
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DIFFUSE LANGUAGE PATHWAY ABNORMALITIES IN TEM-
PORAL LOBE EPILEPSY
1R. Powell, 2G. Parker, 3D. Alexander, 1M. Symms, 4G. Barker,
1M. Koepp, and 1J. Duncan (1Institute of Neurology, London, UK,
2University of Manchester, Manchester, UK, 3University College
London, London, UK, 4King’s College London, London, UK)
Purpose: Temporal lobe epilepsy (TLE) is associated with disrupted
lateralisation of language function. Functional imaging studies have
shown that there is increased atypical language dominance in left TLE pa-
tients. The structural abnormalities underlying this have not been demon-
strated previously but may be important when planning anterior temporal
lobe resection (ATLR).
Method: We performed language fMRI and MR tractography on 14
patients with unilateral TLE (7 left and 7 right) and 10 controls. Verb
generation and reading comprehension paradigms were used to define
functional regions which were then used to generate starting regions
for tractography. MR-tractography was used to trace the white mat-
ter pathways underlying the language functions in both controls and
patients.
Results: Controls and right TLE patients both had a left-lateralised
pattern of language connections. Left TLE patients had reduced fronto-
temporal connections in the left hemisphere and increased connections
on the right, in comparison with both controls and right TLE patients.
Significant interactions between group and hemisphere were observed
between controls and left TLE, and between left and right TLE patients,
characterised by reduced left-sided and increased right-sided connec-
tions in left TLE patients.
Conclusion: We have demonstrated widespread structural changes
in language pathways in patients with unilateral TLE. The pattern of
structural connections seen reflects the pattern of functional activation
with less lateralised, more symmetrical connections in left TLE patients.
This method, combining fMRI and tractography, offers a promising tool
for studying the relationship between brain structure and function and
may prove useful in predicting language deficits following ATLR.
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ICTAL SPECT USING ATTACHABLE AUTOMATIC RADIONU-
CLIDE INJECTING TECHNIQUE
1S. Lee, 1J. Lee, 1K. Park, 2D. Lee, and 3C. Chung (1Department of Neu-
rology, Seoul National University Hospital, South Korea, 2Department
of Nuclear Medicine, Seoul National University Hospital, South Ko-
rea, 3Department of Neurosurgery, Seoul National University Hospital,
South Korea)
Purpose: Ictal SPECT is a valuable method in localising the ictal on-
set zone in presurgical candidates. Conventionally, radionuclide, such as
99mTc-HMPAO, is injected by medical personnel, which often results in
a considerable time lag for many reasons. We developed an automatic de-
vice for radionuclide injection for reducing the interval between seizure
onset and injection. Comparing the automatic injection method with the
conventional method, we could evaluate the clinical usefulness of this
device.
Method: The authors compared ictal SPECT patterns by an automatic
injection technique with that by a conventional method in 95 patients who
were admitted in our epilepsy monitoring unit from 1 January 2003. In
39 patients, the automatic injection technique was performed, and in 56
patients, the conventional technique was performed. First, we evaluated
the time lag between seizure onset and injection. Second, we evaluated
ictal SPECT patterns. If increased perfusion was limited to one hemi-
sphere, we regarded it as a lateralised pattern. If increased perfusion was
observed at one specific lobe, it was regarded as a localised pattern.
Results: The mean delay time was 13.1 ± 14.2 seconds in the au-
tomatic injection method, and 42.5 ± 25.4 seconds in the conventional
way, respectively. A localised pattern was observed in 16 out of 39 pa-
tients in the automatic injection group, and 12 out of 56 patients in the
conventional injection group (p < 0.05). In patients with extratemporal
epilepsy, a localised pattern was observed in 7 out of 20 patients who
were treated with the automatic injection device, and 2 out of 21 patients
treated by the conventional method (p < 0.05). In the patients whose
injection time was less than 10 seconds or duration of seizure was less
than 20 seconds, the outcomes were not good.s
Conclusion: The attachable automatic radionuclide injection method
is superior to the conventional way in reducing the time delay at ra-
dionuclide injection, and also, more helpful in localising the ictal on-
set area in partial epilepsy, especially in extratemporal epilepsy. How-
ever, an injection too early could result in poor lateralisation and
localisation.
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TEMPORAL LOBE EPILEPSY, CORRELATION ANALYSIS OF
MRI VOLUMETRY, 1H MRS AND PET
C. Jiang, H. He, T. Shen, and C. Zuo (Institute of Neurology, Fudan
University, Shanghai, China)
Purpose: To discuss the aetiology of temporal lobe epilepsy (TLE) and
the mechanism of1H MRS and PET abnormality by correlation analysis
of MRI volumetry, 1H MRS and PET results of 20 patients.
Method: 20 patients with intractable TLE (hippocampal sclerosis)
verified by operation and pathology were studied. MRI volumetry, 1H
MRS and PET were performed before operating. The asymmetry index
(AI) of hippocampal volume of both sides, AI of NAA/(Cr+Cho) ratio
and AI of glucose metabolism of both temporal lobes were calculated.
Correlation analysis was made respectively.
Results: The AI of hippocampal volume of 20 patients was
−27.14% ± 24% (7.73% −71.81%). The AI of NAA/(Cr+Cho) ra-
tio was −19.45% ± 10.37% (3.08% −41.86%). The AI of glucose
metabolism of the medial temporal region was volume, respectively
(r = 0.50, p = 0.029; r = 0.56, p = 0.011).
Conclusion: MRI volumetry, 1H MRS and PET are different methods
to evaluate TLE. They reflect the structural abnormality, pathophysiol-
ogy and metabolic changes of the brain, respectively. The correlation of
them helps to understand the aetiology of TLE and the mechanism of 1H
MRS and PET abnormality.
p578
PRESENTATION OF A NEW METHOD FOR AUTOMATIC
CURVILINEAR REFORMATTING OF 3D MRI
1H. Huppertz, 2J. Kassubek, 3D. Altenmu¨ller, 4T. Breyer, and 3S. Fauser
(1Swiss Epilepsy Center, Zu¨rich, Switzerland, 2Department of Neurol-
ogy, University of Ulm, Germany, 3Epilepsy Center, University Hospi-
tal Freiburg, Germany, 4Section of Neuroradiology, University Hospital
Freiburg, Germany)
Purpose: Curvilinear reformatting of three-dimensional MRI data
(i.e., creating serial convex planes parallel to the cortical surface; Bastos
et al., Ann Neurol. 1999;46:88–94) is a well-established tool which im-
proves the display of the gyral structure, permits a precise localisation
of lesions, and helps to identify subtle abnormalities difficult to detect in
planar slices due to the brain’s complex convolutional pattern. However,
the method is time-consuming because it requires interactive manual de-
lineation of the brain surface contour. We present a novel technique for
automatic curvilinear reformatting.
Method: A T1-weighted MRI volume data set is normalised using
SPM2. Due to the normalisation to a common stereotactic space, pre-
defined masks can be applied to cover skull and outer brain regions in
different depths from the brain surface. Thereby, the outer brain regions
are subsequently removed in 2 mm slices parallel to the brain surface
like onion skins. The serial convex planes enclosing the residual inner
part of the brain are presented 3-dimensionally using the “Volume Ren-
dering Tool”’ of MRIcro software. If necessary (e.g., for intraoperative
navigation), the normalised data can be easily transferred to the original
stereotactic space.
Results: Compared to cross-sectional images, curvilinear reformat-
ting offers a markedly superior visualisation of topographic relations
between lesions and cortical structures and helps to assess the lesions’
extent. In addition, the possibility of different view angles improves
planning of operations.
Conclusion: We present a new method for curvilinear reformatting
which is automated by a batch script, requires no manual input and is
based on freely available software.
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TRACTOGRAPHY OF OPTIC RADIATION AFTER TEMPO-
RAL LOBE RESECTION
1D. Nilsson, 2G. Starck, 2M. Ljungberg, and 1B. Rydenhag (1Institute
of Neuroscience and Physiology, Go¨teborg, Sweden, 2Department of
Medical Physics, Go¨teborg, Sweden)
Purpose: To investigate whether damage to optic radiation, as studied
by diffusion tensor imaging and tractography, correlates with visual field
defects after temporal lobe resection.
Method: Two patients with temporal lobe resections for temporal lobe
epilepsy with normal preoperative perimetry were included. Patient A
had an anterolateral temporal lobe resection and patient B had a posterior
temporal lobe resection. Postoperative diffusion-tensor imaging (DTI)
data was acquired using a Philips Intera 1.5T MR system (Release 9,
HARDI, singleshot EPI, TE 76 ms, nearly isotropic 2mm voxels, 15
diffusion-sensitising gradient directions, b-factor 900 s/mm2, Philips,
The Netherlands). Fibre tracking was performed using the DTI tool in
the PRIDE research software (Philips, The Netherlands). Regions of
interest were set anterior to the lateral geniculate body. Damage to the
tracked fibres was compared to postoperative perimetry results.
Results: Both patients developed a partial contralateral upper quad-
rantanopia. Damage to the optic radiation, affecting Meyer’s loop, could
be clearly demonstrated in patient A. In patient B tractography showed
only minor damage to the anterior part of the optic radiation, whereas
the posterior part of the optic radiation was affected.
Conclusion: Diffusion tensor imaging and fibre tracking can be used
to show damage to optic radiation after temporal lobe resection. The cor-
relation of visual field defects and damage to tractography-demonstrated
fibres needs to be further evaluated.
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SLOW-WAVE DIPOLE DENSITY LOCALISATIONS IN
MAGNETOENCEPHALOGRAPHY (MEG) ARE NEARBY
MEG-SPIKE LOCALISATIONS IN PATIENTS WITH FOCAL
EPILEPSY
M. Kaltenha¨user, G. Scheler, S. Rampp, A. Paulini, and H. Stefan (De-
partment of Neurology, Epilepsy Center, Erlangen, Germany)
Purpose: Magnetoencephalographic localisation of interictal epilep-
tiform activity is clinically used to search for epileptogenic focus. In
epilepsy diagnostic routine it is known that the occurrence of slow wave
activity can be an indicator for local functional disturbance or a lesion
(Binnie CD, Stefan H, Clin Neurophysiology 1999;110(10):1671–97).
The aim of the study is to examine whether in patients with monofo-
cal epilepsy, localisation results based on slow wave (2 to 6 Hz) dipole
density calculations are spatially correlated to spike localisation results.
Method: Spontaneous MEG was recorded in 11 patients with focal
epilepsy and 5 healthy subjects. Spike source localisation was performed
in accordance to the protocol of our lab. Analysis of slow-wave activity
consisted of filtering, principal component analysis, single dipole fit and
dipole density calculation. Voxels of 1 millilitre with clearly increased
number of dipoles were displayed on MR-images together with spike
localisations.
Results: In all patients, a local increase of slow wave dipole density
was obtained. Spike area and regions of increased slow wave dipole
density showed a small partial overlap and were close to each other. The
distances between the centre of mass of spike activity and dipole density
maxima were in the range from 0.8 to 3.8 cm. Five healthy subjects didn’t
show a significant increase in slow wave dipole density. Cutoff criteria
to separate patient’s data from those of healthy subjects was discussed.
Conclusion: This study indicates that evaluation of slow wave dipole
density might be helpful to provide additional information leading to the
epileptogenic zone in patients with focal epilepsy.
p581
CORRELATION BETWEEN INTERICTAL ACTIVITY IN EEG,
SEIZURES AND METABOLIC ALTERATIONS IN 1H-MR
SPECTROSCOPY
1T. Hammen, 1F. Kerling, 1M. Schwarz, 2M. Do¨lken, 2T. Engelhorn,
2A. Do¨rfler, and 1H. Stefan (1Clinics of Neurology, Center Epilepsy
Erlangen (ZEE), University of Erlangen-Nuremberg, Germany, 2Clinics
of Neuroradiology, University of Erlangen-Nuremberg, Germany)
Purpose: In our study the degree of hippocampal metabolite alter-
ations in 1H-MR Spectroscopy (1H-MRS) was correlated to findings
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of intensive video-EEG monitoring and duration of clinical features in
patients with temporal lobe epilepsy (TLE).
Method: Hippocampal structures of 14 patients diagnosed with mesial
TLE by clinical patterns and intensive video EEG monitoring were in-
vestigated by 1H-MRS at 1.5 T. Post processing was carried out using the
LCModel. Seizures were analysed by number of clinical seizures, dura-
tion of clinical symptoms, frequency of interictal epileptiform discharges
(IEDs) and ictal activity, duration of ictal activity and IEDs occurring
within 24h EEG monitoring. Results were correlated to metabolite alter-
ations in 1H-MRS.
Results: Negative correlation was found between tNAA values and
degree of IEDs (p = 0.048). Duration of clinical features registered by
video monitoring correlated to increased Cr levels (p = 0.013). Neither
degree of ictal discharges in EEG nor duration of ictal patterns in EEG
monitoring correlated to metabolite alterations. No correlation was found
between metabolite alterations and average number of seizures/24h, du-
ration since last seizure, and seizure frequency under antiepileptic ther-
apy before admission to hospital.
Conclusion: Our study supports that 1H-MRS is able to refer severity
of TLE in which tNAA reduction, indicating neuronal dysfunction, is
correlated with degree of interictal spiking in EEG. Correlation between
duration of clinical symptoms and increased Cr levels are probably based
on increased energy turnover during seizure activity in which Cr plays an
important role in transfer of the phosphate group. The question of how
epileptic activity in EEG is related to metabolic dysfunction remains still
unclear.
p582
USEFULNESS OF MEG IN EPILEPSY PATIENTS
1M . Diaz-Obregon Santos, 1B . Lopez Hernandez, 2F. Maestu Unturbe,
1M. Dominguez Salgado, and 1H. Bhathal (1Hospital Clinico San Carlos,
Madrid, Spain., 2Centro De Magnetoencefalografı´a Dr. Pe´rez-Modrego,
Madrid, Spain)
Purpose: Evaluate the usefulness of magnetoencephalography
(MEG) in epilepsy patients (EP) beyond surgical candidates.
Method: 79 MEG have been carried out on EP assigning them to
different groups: Group 1: 12 patients with generalised epilepsy (GE),
normal EEG and without seizures that show EEG anomalies and seizures
once treatment is withdrawn. Group 2: 9 patients without diagnosis with
some GE not close in time and normal EEG. Group 3: 23 neocortical
drug resistant patients with a difficult to detect focus. Group 4: 35 tem-
poral lobe EP in whom it was necessary to determine lateralisation using
language and memory tasks.
Results: 58.3% of patients of Group 1 showed some generalised spike-
waves for which medication was not withdrawn. In 77.7% of patients of
Group 2 MEG showed epileptiform activity not present in the EEG. In
43.47% of Group 3 MEG localised a congruent focus that made inter-
vention possible, and the other 56.52% were controlled with medication.
In Group 4, MEG gave results about lateralisation and 54.29% were suc-
cessfully operated.
Conclusion: MEG is new technique that in epilepsy has been used
specially for presurgical studies. Nevertheless its contribution is still
major, since: a) it contributes to the clinical decision whether or not to
withdraw medication in EP with a normal EEG and without seizures;
b) facilitates diagnosis and treatment of those patients with seizures and
normal EEG; c) it is more sensitive for detecting extratemporal epilepsy
focus; d) using neuropsychological tasks MEG determines lateralisation
on temporal lobe EP. For these reasons we think MEG should be part of
the normal protocol to study EP.
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WHITE MATTER ABNORMALITIES IN SCLEROSIS
TUBEROUS COMPLEX: AN UNDERDIAGNOSED “MINOR”
CRITERION?
R. Chifari, A. Piazzini, K. Turner, L. Caverni, A. Formenti, R. Canger,
and M. Canevini (Epilepsy Regional Center, San Paolo Hospital, Brazil)
Purpose: Neuroimaging studies of tuberous sclerosis complex (TSC)
have previously focused mainly on tubers or subependymal nodules.
Subtle pathological changes occur as white matter abnormalities in the
structure of the brain have not been focused. We utilised MRI techniques
for a reliable study of brain structure to reach an accurate computation
of brain abnormalities in patients with TSC.
Method: Dual-echo, FLAIR and IR MRI data were acquired from 28
TSC patients with a cognitive level ranging from mild to severe. Differ-
ences in grey matter and white matter abnormalities were estimated at
each intracerebral voxel. FLAIR images were acquired for neuroradio-
logical rating of tuber number.
Results: We also found significant alteration of white matter as stripes
and candle guttering excrescences of groups of atypical cells perpendicu-
lar to the ventricular wall 21 of 28 TSC affected patients involving major
intrahemispheric tracts and a bilateral cerebellar region. Furthermore,
the white matter abnormalities are not related to the tubers.
Conclusion: Neuropathological changes of white matter associated
with TSC may be more extensive than prior suspected and it could be an
underdiagnosed “minor” criteria.
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COMBINING ADVANCED NEUROIMAGING TECHNIQUES IN
PRESURGICAL WORKUP OF NONLESIONAL INTRACTABLE
EPILEPSY
1M. Brazdil, 1M. Mikl, 1,2P. Chlebus, 2M. Pazourkova, 3Z. Novak, 3J.
Chrastina, 4J. Prasek, 5K. Bolcak, 1D. Fojtikova, 6J. Horky, 1J. Tomcik,
7E. Lzicarova, and 1I. Rektor (1Brno Epilepsy Centre, Department of
Neurology, St. Anne University Hospital, Brno, Czech Republic, 2Brno
Epilepsy Centre, Department of Neuroimaging, St. Anne University Hos-
pital, Brno, Czech Republic, 3Brno Epilepsy Centre, Department of Neu-
rosurgery, St. Anne University Hospital, Brno, Czech Republic, 4Clinic
of Nuclear Medicine, University Hospital Bohunice, Brno, Czech Re-
public, 5PET Unit, Masaryk Memorial Cancer Institute, Brno, Czech
Republic, 6Department of Nuclear Magnetic Resonance, Institute of Sci-
entific Instruments Academy of Sciences, Brno, Czech Republic, 7Brno
Epilepsy Centre, Department of Neuropathology, St. Anne University
Hospital, Brno, Czech Republic)
Purpose: The rationale for this case report is to assess the de-
gree of congruency between the results of several advanced functional,
metabolic, and structural neuroimaging techniques used in patients with
MRI-negative focal epilepsy.
Method: We investigated the presurgical evaluation and operative out-
come of a patient with intractable extratemporal epilepsy. Because of the
simple induction of habitual seizures in this patient, six advanced neuro-
diagnostic techniques were successively applied (SISCOM, ictal FDG-
PET, ictal fMRI, postictal diffusion-weighted imaging, voxel-based mor-
phometry, and MRS imaging).
Results: Fairly congruent findings of the investigated neuroimaging
methods within the left central region were obtained from our patient.
Subsequent invasive EEG recordings revealed a seizure-onset zone at
the site where most of the neuroimaging had shown abnormal findings.
Surgical removal of the epileptogenic zone, as defined by concordant
neuroimaging and SEEG data, resulted in a seizure-free postoperative
outcome. Histopathological findings revealed mild focal cortical dyspla-
sia.
Conclusion: Great efforts should be made to combine most of the
advanced neuroimaging methods in the preoperative assessment of non-
lesional epilepsy surgery candidates.
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VISUALISATION OF SEIZURE SPREAD INCLUDING ACTIVA-
TION AND DEACTIVATION BY ICTAL FMRI
1T. Auer, 1,2A. Schwarcz, 1,3T. Do´czi, 4K. Veto˜, 5V. Juhos, and 1J. Jan-
szky (1University of Pe´cs, Medical School, Pe´cs, Hungary, 2Diagnostic
Centre of Pe´cs, Pe´cs, Hungary, 3Hungarian Academy of Sciences, Bu-
dapest, Hungary, 4University of Pe´cs, Faculty of Business and Eco-
nomics, Pe´cs, Hungary, 5Szent Istva´n Ko´rha´z, Epilepsy Center, Bu-
dapest, Hungary)
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Purpose: The aim of the study was to visualise the spread of activation
and deactivation in the whole brain during epileptic seizures by means
of functional MRI.
Method: An optimised EPI based 2D sequence was applied to yield
functional MR images during a clonic seizure of a 19-year-old woman
suffering from intractable localisation related epilepsy. Temporal resolu-
tion (repetition time) was 2.5 seconds and spatial resolution (voxel size)
was 3 × 3 × 5mm. The whole brain was divided into 16 slices and cross
correlation function was used to compare the MR signal alterations in
each voxel.
Results: The seizure onset appeared to be in the left insular region
40 seconds before the first ictal clinical signs. The activation showed re-
gional spread, then involved the whole ipsilateral hemisphere and prop-
agated to the contralateral frontal and temporal lobes as well as to the
cerebellum. Clinical signs of seizure consisting of right-sided facial cloni
appeared at the time of the ipsilateral spread. Perifocal and contralateral
deactivation were also observed.
Conclusion: To our knowledge this is the first study that describes a
whole brain activity during epileptic seizures under acceptable temporal
and good spatial resolution. Our observations can help understand the
pathophysiology of the seizure-activity and antiseizure inhibition pro-
cess. Moreover, the identification of the seizure-onset area can be crucial
for presurgical evaluation of epilepsy.
p586
EPIGAUSS: ANALYSING SPATIOTEMPORAL PATTERNS IN
OCCIPITAL EPILEPSY
1J. Fernandes, 2A. Leal, and 1J. Cunha (1IEETA/ DET, Universidade de
Aveiro, Portugal, 2Hospital Ju´lio de Matos, Lisboa, Portugal)
Purpose: EpiGauss is a method to characterise active brain generators
in space and time through single dipole model analysis over EEG events.
We applied it to study epileptogenic activity in 6 patients with early onset
childhood occipital lobe epilepsy, an epileptic syndrome where children
have a consistent clinical picture but multifocal and variable spike activity
and for which no clearly defined common epileptogenic brain area has
been established.
Method: EEG was acquired (10–20 with occipital coverage) and
spikes manually identified. For each spike, single moving dipoles were
fitted using a standard headmodel during an interval enclosing the spike
onset phase to the highest EEG power latency nearer the spike peak. Re-
sulting dipoles were analysed through dipole density distributions and
analysis of dipole agglomerations using a cluster analysis method based
on Gaussian Mixture Model (Harris et al., J Neurophysiol 2000,84:401-
14) where dipole time related information was discarded. Stable sources
and inter cluster propagation patterns were identified through the analy-
sis of both cluster time structure and their spatial relation. The findings
were coregistered with standard MRI and compared with an expert EEG
visual analysis.
Results: Three patients exhibited clear focal activity in EEG while oth-
ers were multifocal. EpiGauss demonstrated different clusters of dipoles,
with a common area in the most posterior occipital lobes suggesting that
epileptic activity originates in this region and then spreads to other areas
(parietal and temporal).
Conclusion: EpiGauss identified consistent sources on the posterior
occipital lobes not clear in EEG visual inspection. The method is auto-
matic needing minor user intervention and no technical expertise.
p587
USING INDEPENDENT COMPONENT ANALYSIS IN SIMUL-
TANEOUS EEG/fMRI FOR IDENTIFICATION AND LOCALI-
SATION OF INTERICTAL SLOW BRAIN ACTIVITY
1M. Ha¨rle, 2B. Feige, 1L. Frings, 1K. Wagner, 2L. Tebartz van Elst,
and 1A. Schulze-Bonhage (1University Hospital of Freiburg, Section of
Epileptology, Germany, 2University Hospital of Freiburg, Department
of Psychiatry, Germany)
Purpose: The different methods for examination of functional brain
activity provide several advantages and disadvantages. The most out-
standing feature of EEG is its excellent temporal resolution while
fMRI offers a high spatial resolution. The combination of these aspects
promises an improved measurement of ongoing brain activity. Since the
first combination of EEG and fMRI in 1993 several aspects of the EEG
like frequency-ranges, sleep stages or epileptic spikes have been shown
to elicit a corresponding BOLD-response. For epilepsy patients the ex-
amination of epileptic activity was mainly focused on spike like activity
(ictal and interictal). Interictal epileptic activity also comprises slow po-
tentials like delta and theta activity. The purpose of the present study is
to identify and locate interictal slow brain activity in epilepsy patients
by an ICA based approach to EEG data in combination with fMRI.
Method: A 62 channel EEG was recorded simultaneously with the
functional MR (3 T). Patients were instructed to open and to close their
eyes every 30 seconds. The gradient related artefacts and the ballisto-
cardiogram were removed offline. An extended ICA was applied to the
EEG data to extract the components rendering the slow brain activity.
The components carrying the slow brain activity were then used as a
regressor for fMRI-activation.
Results and Conclusion: One advantage of ICA is that it uses the
whole EEG-topography and delivers the time-course of activity of inde-
pendent sources. Results show that it is possible to show brain activation
associated with interictal slow brain activity.
p588
MULTIPLE INTRACRANIAL RING ENHANCING CT LESIONS
IN PATIENTS WITH NEW-ONSET SEIZURES
R. Garg, P. Desai, and A. Kar (Department of Neurology, King George’s
Medical University, Lucknow, India)
Purpose: Single enhancing CT lesions are the commonest imaging
finding in children and young Indian patients with new-onset seizures.
In the majority these spontaneously disappearing lesions are cysticercal
granuloma. The precise causes of multiple intracranial ring enhancing
CT lesions are not known. In this study an effort was made to determine
the aetiology with the help of a battery of investigations.
Method: Sixty patients with multiple ring enhancing lesions on CT
scan were included. Routine blood biochemical parameters, ELISA for
HIV, tuberculosis, and cysticercosis, and chest x-ray were performed. In
addition, magnetic resonance imaging, MR spectroscopy, lumbar punc-
ture, abdominal ultrasonography was carried out. Treatment was initi-
ated based on the provisional diagnosis. Patients were followed for six
months. Repeat neuroimaging study was done after 6 months.
Results: Among 60 patients, diagnosis was established in 55 while in
5 patients no conclusion could be made regarding final diagnosis. Tu-
berculoma was the leading cause of multiple ring enhancing lesions in
27 patients followed by neurocysticercosis in 15 patients and metastatic
lesions in 9 patients. Of the remaining 4 patients pyogenic brain abscess,
fungal granuloma, multiple infarcts and primary brain tumour were the
causes. In the children and adolescent age group (<18 years), tubercu-
loma and neurocysticercosis had an equal incidence. In the adult age
group (18–45 years), tuberculoma was the most common cause while in
the older age group (>45 years) metastasis was the leading cause.
Conclusion: In contrast to single enhancing CT lesions, tuberculoma
is the leading cause of multiple intracranial ring enhancing lesions fol-
lowed by neurocysticercosis. Metastatic lesions predominate among el-
derly individuals.
p589
SINGLE SMALL ENHANCING CT BRAIN LESION IN MID-
DLE AGED AND ELDERLY PATIENTS WITH NEW-ONSET
SEIZURES
A. Kar, V. Paliwal, and A. Agarwal (Department of Neurology, King
George Medical University, Lucknow, India)
Purpose: Single enhancing CT lesions are the commonest imaging
finding in children and young Indian patients with new-onset seizures. In
the majority these lesions are cysticercal granuloma and in a few they are
caused by tuberculoma. In middle-aged and elderly the causes of single
enhancing CT lesions are not known. In this study an effort was made
to determine the aetiology of these lesions with the help of a battery of
investigations.
Epilepsia, Vol. 47, S3, 2006
7TH EUROPEAN CONGRESS ON EPILEPTOLOGY 153
Method: Nineteen patients age 45 years or more with a single en-
hancing CT lesion of size less than or equal to 20 mm were included.
The battery of tests employed included routine blood biochemical and
haematological parameters along with CSF examination, serum ELISA
for HIV, neurocysticercosis and tuberculosis, chest x-ray and ultrasound
abdomen. Antiepileptic drugs were administered. Treatment was also
given according to the provisional diagnosis. Each patient was followed
for 6 months. A repeat CT brain was done after 6-months.
Results: The mean age of patients was 53.4 years (range 45–78). There
were 7 female patients in the series. Fifteen patients were diagnosed with
neurocysticercosis; in all these patients lesions had spontaneously dis-
appeared. Two patients had tuberculoma of brain and 1 had secondaries
in the brain. In 1 patient a diagnosis could not be reached.
Conclusion: Like in younger patients, in most of the older and elderly
patients single enhancing CT lesions are caused by neurocysticercosis.
Occasionally there may be tuberculoma and metastasis of the brain as
well.
p590
AUTOMATIC IMAGE PROCESSING SYSTEM FOR QUAN-
TIFYING DIFFERENCES BETWEEN ICTAL/INTERICTAL
BRAIN SPET SCANS AND REGISTRATION WITH MRI
J. Isidoro, P. Rachinhas, M. Cunha, A. Moreira, F. Sales, J. Lima, and L.
Pereira (Hospitais Da Universidade De Coimbra, Coimbra, Portugal)
Purpose: Cerebral ictal/interictal single photon emission tomography
(SPET), in patients with partial epilepsy refractory to medical therapy,
constitutes an important aid in the localisation of the epileptogenic fo-
cus. This analysis can be improved calculating the statistically significant
differences obtained by regression analysis (SSDORA) between the ic-
tal/interictal SPET scans and visualising these results overlapped on the
magnetic resonance (MRI). The aim of this work was the implementation
of an automatic image processing system that calculates the SSDORA
3D map and aligns SPET datasets with MRI.
Method: This system was implemented on Linux, using bash
scripts. The following software packages were used: MedCon
(http://xmedcon.sourceforge.net), ImageJ (http://rsb.info.nih.gov/ij/),
DCMTK (http://dicom.offis.de/dcmtk.php.en), AIR (http://bishopw.
loni.ucla.edu/AIR5/) and CISG (http://www.ipg.umds.ac.uk/cisg/); all
with free access and with open source; some of these packages were
slightly modified. The methodology can be summarised in the follow-
ing steps: 1) SPET’s acquisition in 128 × 128 matrix, with 2mm pixel
size; 2) SPET’s reconstruction by iterative OSEM, without attenuation
correction, with 3D Butterworth postfilter; 3) coregistration (AIR) be-
tween ictal/interictal SPET scans; 4) datasets obtained in last step are
processed using a new Image plugin (SSDORA); 5) interictal/MRI reg-
istration (AIR/CISG); the same transformation matrix is applied to ictal
and SSDORA 3D map.
Results: After this automatic processing the 3D map and the ic-
tal/interictal SPET are aligned with MRI. All datasets are ready for vi-
sualisation in image processing stations of the nuclear medicine and/or
neurology departments.
Conclusion: An automatic image processing system was imple-
mented that allows getting the statistically significant differences be-
tween the ictal/interictal SPET aligned with MRI.
p591
DIAGNOSTIC USEFULNESS OF A QUANTIFICATION
METHOD TO ASSESS DIFFERENCES IN ICTAL-INTERICTAL
BRAIN SPET: COMPARISON TO SIDE-BY-SIDE VISUAL
EVALUATION, MRI AND VIDEO-EEG
A. Moreira, M. Cunha, J. Isidoro, P. Rachinhas, E. Rovira, F. Sales,
C. Bento, F. Lobo, A. Costa, J. Lima, and L. Pereira (Hospitais Da
Universidade de Coimbra, Portugal)
Purpose: To compare results of an ictal/interictal SPET (single pho-
ton emission tomography) image difference method with side-by-side
visual SPET analysis, MRI (magnetic resonance imaging) and video-
EEG (video-electroencephalogram), for localisation of an epileptogenic
focus in patients with partial epilepsy refractory to medical therapy.
Method: Ictal and interictal SPET of 41 patients, mean age 30 years,
were retrospectively reconstructed. A new software, SSDORA (statis-
tically significant differences obtained by regression analysis), was de-
veloped for SPET comparison. SSDORA images were blindly reviewed
and results compared to SPET, video-EEG and MRI. Coregistration of
SSDORA to MRI was performed.
Results: The mean latency period of the injection after seizure onset
was 44.1s (7-75s). From the total, 66% of SPET results were concordant
for localisation of an epileptogenic area, relative to other techniques.
SSDORA was concordant to other diagnostic modalities in 83%. 50% of
not concordant SPET were not localising / lateralising and SSDORA was
localising and concordant in 57% of negative SPET. MRI and video-EEG
were concordant in 63% between themselves and SPET was concordant
with 81% of them. Of this group, SSDORA was concordant with 88%.
In the group where MRI and video-EEG were not concordant (37%),
SPET was concordant with one of the techniques in 40% and SSDORA
was concordant in 73%.
Conclusion: SSDORA was concordant with other techniques in a
higher proportion of cases then SPET visual analysis and was local-
ising in some negative/not concordant SPET cases. Coregistration of
SSDORA results with MRI was always useful in anatomic localisation
of the epileptogenic focus.
p592
ICTAL HAEMODYNAMIC CHANGES DURING ABSENCE
SEIZURES IN IDIOPATHIC GENERALISED EPILEPSY
1A. Vaudano, 1C. Di Bonaventura, 2,4M. Carnı`, 1P. Pantano, 1V. Nuccia-
relli, 2,3,4G. Garreffa, 2,4B. Maraviglia, 1M. Prencipe, 1L. Bozzao, 1,3M.
Manfredi, and 1A. Giallonardo (1Department of Neurological Sciences,
University of Rome “La Sapienza,” Italy, 2Department of Physics, Uni-
versity of Rome “La Sapienza,” Italy, 3Neuromed Institute of Pozzilli,
Isernia Italy, 4 Enrico Fermi Center, University of Rome “La Sapienza,”
Italy)
Purpose: Recently EEG/fMRI has been proposed in the field of
epilepsy research to detect brain regions activated during EEG epilepti-
form abnormalities. In recent years some studies have documented cor-
tical and subcortical haemodynamic involvement during interictal and
ictal generalised spike-and-wave discharges (GSWDs) confirming the
significant role of thalamocortical interactions in the pathophysiology
of idiopathic generalised epilepsy (IGE). By using EEG/fMRI we inves-
tigated the BOLD responses in the thalamus and cerebral cortex during
absence seizures in patients with IGE.
Method: Using EEG/fMRI, we studied haemodynamic changes as-
sociated with spontaneous ictal GSWDs in 5 patients (2 M, 3 F) affected
by IGE (childhood or juvenile absences epilepsy). fMRI images were
acquired using a clinical 1.5 T magnet (Philips Gyroscan). The EEG
signal was recorded using an MR-compatible system (Micromed, Italy).
Absence seizures were retrospectively recognised on the EEG, and the
number of the dynamic scan corresponding to each GSWD was recorded.
fMRI data were preprocessed and analysed using SPM99.
Results: In all patients EEG/fMRI data analysis revealed a thalamic
symmetrical positive BOLD response related to ictal generalised spike-
and-wave discharges whereas no activation was found in cortical regions;
concomitant deactivation areas were found in diffuse cortical regions
(2 patients), in symmetrical frontal regions (2 cases) and in bilateral
parietal-occipital regions (1 case).
Conclusion: Our fMRI findings confirm the role of the thalamus and
its relationship with the cortex in absence seizures and offer a contribu-
tion to a better understanding of the mechanisms underlying epileptic
phenomena.
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VOXEL-BASED MORPHOMETRY (VBM) IN UNILATERAL
TEMPORAL LOBE EPILEPSY: NEURODEGENERATION BE-
YOND THE SEIZURE ONSET ZONE
1N. Embacher, 1C. Brenneis, 1I. Unterberger, 1J. Dobesberger, 1G.
Walser, 2K. Egger, 2T. Trieb, 1M. Delazer, 1T. Benke, 3M. Ortler, and
1E. Trinka (1Department of Neurology, Medical University Innsbruck,
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Innsbruck, Austria, 2Department of Radiology, Medical University Inns-
bruck, Innsbruck, Austria, 3Department of Neurosurgery, Medical Uni-
versity Innsbruck, Innsbruck, Austria)
Purpose: Voxel-based morphometry (VBM) is an indirect volumetric
tool which allows one to investigate the entire brain. Recent VBM studies
were able to show hippocampal degeneration in TLE patients, however,
there was also a marked extrahippocampal loss of brain volume.
Method: We applied an optimised VBM protocol on high resolution
T1 weighted MR-images of 47 patients (m:w = 22:25; mean age = 41
± 13yrs) with unilateral temporal lobe epilepsy (TLE) in comparison
to 94 age and gender matched healthy controls. 27 patients had left and
20 had right sided TLE. Age at onset was 14 ± 12 yrs. Diagnosis for
unilateral TLE was confirmed by video-EEG-monitoring, MRI, interictal
FDG-PET, and neuropsychology.
Results: VBM revealed a marked volume loss in the tail of the hip-
pocampus at the site of seizure onset. Furthermore, left TLE patients
showed marked volume loss ipsilateral in the gyrus parahippocampus,
thalamus and prefrontal cortex; ipsi- and contralateral in the cingulum
and cerebellar hemispheres. Right TLE patients had additional volume
loss in the ipsilateral gyrus parahippocampus and bilateral volume loss in
the prefrontal cortex, thalamus, as well as in the cerebellar hemispheres.
Conclusion: Our study confirms a widespread structural change in
unilateral TLE ipsilateral to the side of seizure onset, which is far beyond
the primary lesion and may probably reflect acquired neuronal damage
due to repetitive seizure activity.
p594
MULTIFOCAL PERFUSION ABNORMALITY IN A PATIENT
WITH MALIGNANT MIGRATING PARTIAL SEIZURES IN
INFANCY
J. Ko´bor, and L. Pa´vics (Szeged Univ, Faculty of Medicine, Department
Pediatrics, Szeged, Hungary)
Purpose: Malignant migrating partial seizures in infancy is a rare
epileptic syndrome, described in 1995. It begins during early infancy and
is characterised by very frequent, commonly continuous partial seizures
of varying semiology. EEG is highly characteristic: ictal activity of high
amplitude repetitive rhythmic discharges, jumping randomly from one
cerebral region to the other during consecutive seizures, can be seen.
Arrest of psychomotor development is the rule. Traditional antiepileptic
drugs or steroids can hardly ever control the seizures, which is crucial
for favourable further development of the infant. The cause is unknown;
brain malformation, metabolic disorder, or an acquired cerebral insult
could not be shown. In view of its strict age dependency, malignant
migrating partial seizures in infancy are dependent on the special mat-
uration of the infantile brain. Functional neuroimaging can be expected
to shed some light on the pathomechanism of the unique electroclinical
features of this epileptic syndrome.
Method: An ictal and a periictal brain perfusion investigation were
performed by means of Tc99m-HMPAO SPECT in a patient with a
typical course of malignant migrating partial seizures in infancy.
Results: The ictal study revealed hyperperfusion over the right frontal,
and the periictal one a similar change over the right central and left frontal
cerebral regions. These changes corresponded with the location of ictal
discharges on scalp EEG.
Conclusion: These results argue against a possible deeply located
single irritative focus spreading ictal discharges to brain surfaces at ran-
domly migrating locations.
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COMPARISON OF BOLD SIGNAL CHANGES IN THE
FRONTAL CORTEX AND THE HIPPOCAMPUS IN PATIENTS
WITH MEDIAL TEMPORAL LOBE EPILEPSY
1K. Wagner, 1L. Frings, 1M. Ha¨rle, 2R. Schwarzwald, 2J. Spreer, 3U.
Halsband, and 1A. Schulze-Bonhage (1Epilepsy Centre, University Hos-
pital Freiburg, Germany, 2Department of Neuroradiology, University
Hospital Freiburg, Germany, 3Neuropsychology, Department of Psy-
chology, University of Freiburg, Germany)
Purpose: The goal of the present study is to compare the lateralisation
of activation patterns within frontal language areas to those within the
hippocampi (HC) during a verbal episodic memory task using fMRI.
Method: Twenty-five patients with symptomatic temporal lobe
epilepsy and hippocampal sclerosis (HS) performed a verbal episodic
memory task including encoding and recognition of word-pairs (12 HS
left, Mage = 37 yrs, 14 males) within the scanner (1.5T). Data were anal-
ysed with SPM2, using 2 different regions of interest (ROI): (1) anterior
language area defined as BA 44 and 45, and (2) a medial temporal ROI
including the hippocampus. For individual activation patterns within the
ROIs lateralisation indices [LI = R−L/R+L)] were calculated for the
contrast “encoding vs control condition” using a number of suprathresh-
old voxels. The LI for the different anatomical areas were compared
between the two groups (Mann-Whitney U Test).
Results: The lateralisation of frontal activation patterns showed an
LI of −0.52 (SEM = 0.28) for the patients with left-sided and −0.63
(SEM = 0.15) for right-sided HS patients respectively (not significant),
whereas the lateralisation indices within the hippocampus differed sig-
nificantly between the groups (LI HS left = −0.14 (SEM = 0.20), LI
HS right = −0.69 (SEM = 0.18), p < .05).
Conclusion: The deviating lateralisation of activation patterns within
the hippocampus could be explained by a decrease of ipsilesional or
increase of contralesional activations; the latter reflecting a shift of ver-
bal memory functions to the contralesional hippocampus, whereas basic
language functions are not reorganised.
p596
Z-SCORE TRANSFORMATION OF INDIVIDUAL VOXEL-
INTENSITY-DISTRIBUTIONS IMPROVES DETECTION OF
STRUCTURAL ABNORMALITIES IN MR-IMAGES
1,2B. Weber, 1,2F. Mormann, 2A. Reinartz, 1,2K. Fliessbach, and 1,2C. El-
ger (1Department of Epileptology, University of Bonn, Bonn, Germany,
2Life&Brain Science Center, Department of NeuroCognition-Imaging,
Bonn, Germany)
Purpose: An important issue in epileptology is the detection of struc-
tural lesions in MRI images. In recent years automated, voxel-based
techniques have been utilised to detect structural abnormalities in dif-
ferent MR sequences. These techniques usually rely on the comparison
of individual patients with a healthy control group. The high variabil-
ity between individual subjects greatly compromises the ability of such
methods to detect subtle structural differences between patients and con-
trols. In this study we use a renormalisation of individual distributions
of voxel intensities by means of z-score transformation to improve the
effectiveness of a voxel-based approach to detect hippocampal sclerosis
with T2-Relaxation-Maps.
Method: We performed the acquisition of T2-Relaxation-Maps with
a resolution of 1.5 × 1.5 × 5 mm in up to now 30 healthy subjects
and 2 patients with hippocampal sclerosis. Images were segmented into
gray and white matter. Voxelwise mean and standard-deviation (SD)
was calculated from the original T2 values of 30 healthy subjects and
were used to define thresholds to detect structural abnormalities. To
improve this method, an additional processing step was introduced by
renormalising all segmented images using z-score transformation prior
to further processing.
Results: Final SD-images showed a much higher spatial variance if
no z-score transformation was used, causing a substantial bias in the
detection of exemplary patients with hippocampal sclerosis. Use of z-
score transformation on the other hand improved detection of aberrant
T2-Values.
Conclusion: Findings indicate that voxel-based techniques for an au-
tomated detection of individual abnormalities can be improved by renor-
malising individual distributions of signal-intensities.
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TEMPORAL LOBE SURGERY AND SUSTAINED ATTENTION
1W. Alpherts, 1J. Vermeulen, and 2P. Van Rijen (1Department of Psy-
chology, Epilepsy Centre of The Netherlands (SEIN), Heemstede, The
Netherlands, 2Rudolf Magnus Institute For Neurosciences, University
of Utrecht, Utrecht, The Netherlands)
Purpose: Growing evidence suggests that the cerebral hemispheres
are asymmetric in the role they play in sustained attention. Studies have
suggested that parietal, temporal and prefrontal regions may be involved
in the maintenance of a state of vigilance. The present study investi-
gates the effect of left (LTL) vs. right temporal lobectomy (RTL) on a
computerised vigilance task (part of the FePsy battery).
Method: The 188 subjects (86 LTL, 102 RTL) were tested before and
6 months after epilepsy surgery. They were presented with 450 stimuli in
a signal detection paradigm, equally divided into ”signal” (XXXXXXX)
or ”noise” (XXXAXXX). Duration of the stimuli was 100 msecs, Inter
Stimulus Interval 4 secs. The task lasted for 30 minutes. Dependent
variables were d’ (perceptual sensitivity) as a measure of vigilance and
ß (response bias, employing a lax or a conservative criterion).
Results: The LTL group showed a gain in d’: before surgery of 2.05
(SD 0.94), and after of 2.17 (SD 1.15) whereas the RTL group showed
a decline: 2.23 (SD 1.01) before and 2.03 (SD 0.98) after surgery. This
interaction effect is significant, p = .016. No difference was found in
betas in either group: LTL group 0.60 (SD .40) pre surgery vs. 0.69 (SD
0.49) post and the RTL group 0.63 (SD .54) pre vs. 0.66 (SD .54) post.
Conclusion: The RTL group cannot profit from a retest effect. These
results suggest a strong involvement of the right temporal lobe in vigi-
lance, i.e., sustained attention and the disruption of this mechanism after
RTL.
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MESIAL TEMPORAL LOBE EPILEPSY IMPAIRS ADVANCED
SOCIAL COGNITION
R. Winkler, M. Schacher, T. Grunwald, G. Kraemer, M. Kurthen, V.
Reed, and H. Jokeit (Swiss Epilepsy Center, Switzerland)
Purpose: While memory, language and executive functions have
been extensively studied in patients with mesial temporal lobe epilepsy
(MTLE), investigations into advanced social cognitive abilities have been
neglected. In the present study we investigated the ability to detect so-
cial faux pas and studied possible mediating clinical and demographic
variables in patients with MTLE compared to patients with an epilepsy
not originating within the MTLE and healthy controls.
Method: 27 MTLE patients (16 were investigated pre- and 11 postop-
eratively), 27 patients with an extra-mesiotemporal epilepsy (excluding
frontal lobe epilepsy) and 8 healthy controls performed a shortened ver-
sion of the Recognition of Faux Pas Test. Standardised tests to measure
intelligence were administered. Only patients with intact reading com-
prehension abilities were included in the study.
Results: MTLE patients, both pre and postoperative, performed sig-
nificantly worse in the faux pas test than patients with extra-mesio-
temporal lobe epilepsy (p < .001) and healthy controls (p < .001).
The latter two groups showed comparable performance. No statistical
association was found between the MTLE patients’ deficit in recog-
nising a faux pas and the variables IQ, age, age at seizure onset, and
duration of epilepsy. Although no sex differences in recognising a faux
pas were found, an interaction effect between side of MTLE and sex
was observed, favouring females with right-sided MTLE and males with
left-sided MTLE (p < 0.5).
Conclusion: We report for the first time that patients with MTLE
are specifically impaired in recognising faux pas, suggesting that
MTLE as such is a specific aetiology of deficits in higher-order social
cognition.
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LATERALISING ABILITY OF THE WECHSLER MEMORY
SCALE-III IN PATIENTS WITH MESIAL TEMPORAL LOBE
EPILEPSY
S. Lee, K. Cho, Y. No, I. Kim, J. Kang, H. Yoo, and J. Lee (Asan Medical
Center, University of Ulsan College of Medicine, Seoul, Korea)
Purpose: The Wechsler Memory Scale-III (WMS-III) including new
visual memory tests was developed to overcome the limitation of WMS-
Revised (WMS-R). We examined the usefulness of the WMS-III in pre-
dicting laterality of memory impairment in patients with mesial temporal
lobe epilepsy.
Method: We included 49 consecutive patients with unilateral mesial
temporal lobe epilepsy who had left hemisphere dominance for language
by WADA test and underwent temporal lobectomy. Methods of analysis
included evaluation of group means on the various indices and subtest
scores of WMS-III, the use of ROC curves, an examination of Auditory-
Visual Index (AVI) discrepancy scores and correlation analysis between
AVI discrepancy scores and age, and age of onset in patients.
Results: 1) Patients with left mesial temporal lobe epilepsy had signif-
icantly lower scores on several scores and indices compared to those with
right mesial temporal lobe epilepsy. 2) Analysis of ROC curves showed
the area under the curve and the suggested cutting score were 0.696 and
4 (a sensitivity 0.704, a specificity 0.727) for immediate AVI discrep-
ancy score and 0.702 and 5 (a sensitivity 0.556, a specificity 0.773) for
delayed one, respectively. 3) In the right lesion, there was a tendency for
linear correlation between AVI discrepancy scores and age, onset age.
Conclusion: Overall, WMS-III has limited value in identifying par-
ticular memory deficits associated with either left or right tempo-
ral lobe dysfunction. AVI discrepancy scores may be more useful in
predicting right hemispheric dysfunction rather than left hemispheric
dysfunction.
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NONCONVULSIVE STATUS EPILEPTICUS: FRONTAL AS-
SESSMENT BATTERY DURING EEG AND IN FOLLOW-UP
1A. Primavera, 2L. Primavera, and 1D. Audenino (1Department of Neu-
rosciences University of Genova,Italy, 2Department of Psycholgy, Uni-
versity of Padova, Italy)
Purpose: The absence variant of nonconvulsive status epilepticus
(NCSE) has been reported as the initial form of epilepsy in the elderly
and it is mandatory to consider NCSE in the differential diagnosis for
patients presenting an altered mental status or behavioural changes from
baseline, even when there is no history of seizures. Cognitive impair-
ment may be subtle, mild or severe. We report on 5 elderly patients with
a neupsychological evaluation during critical EEG and in follow-up.
Method: Five consecutive elderly patients (mean ± SD; age 75 ± 13.6
years) meeting the criteria for NCSE with acute onset of subtle or mild
cognitive deficits were studied with a brief mental status examination:
Mini-Mental State Examination (MMSE), TIB, an Italian version of
National Adult Reading Test (NART), Digit Span, Frontal Assessment
Battery (FAB) during EEG showing prolonged spike and wave diffuse
discharges and at follow-up. Neuroimaging excluded focal lesion.
Results: Evidence of acute, transient impairment of cognitive func-
tions was found in all patients: in particular frontal system functions
appeared impaired. The mean FAB score significantly differed between
examination during NCSE and in follow-up (3.8 vs. 12.2).
Conclusion: Thomas et al. (Neurology 1999) stressed that NCSE of
frontal origin is a heterogeneous syndrome and emphasised the similari-
ties between NCSE of frontal origin and absence variants of NCSE. Our
results with FAB in patients with generalised NCSE support the influ-
ence of EEG discharges on frontal cognitive functions and the difficulty
of a close and sure topographic electroclinical correlation.
p601
THE IMPACT OF IN UTERO EXPOSURE TO ANTIEPILEPTIC
DRUGS ON NEUROPSYCHOLOGICAL DEVELOPMENT: THE
FIRST THREE YEARS
R. Entwistle, L. McEwan, S. Dutton, and G. Baker (University of Liv-
erpool, UK)
Purpose: This study informs the debate on the impact of anti epileptic
drugs (AEDs) in utero, specifically on neuropsychological development,
Epilepsia, Vol. 47, S3, 2006
156 7TH EUROPEAN CONGRESS ON EPILEPTOLOGY
where previous research has been conflicting. The results of a follow up
assessment at age 3 are reported for a prospective cohort of children.
Method: Interim analyses of 57 children (19 exposed and 38 age and
gender matched controls) were blindly assessed using the Reynell Lan-
guage Test and the Griffiths Developmental Scales. Each mother com-
pleted the National Adult Reading Test (NART) to measure intellectual
functioning and the Vinelands Adaptive Behaviour Scales to document
a subjective view of their child’s development.
Results: Using an independent samples t-test analysis children ex-
posed to AEDs yielded significantly lower scores on both language com-
prehension (m = exp 41.28 vs 50.63, p = 0.0195) and expression (m =
exp 36.65 vs 46.61, p = 0.012). Exposed children also yielded a sig-
nificantly lower performance across motor (m = exp 82.73 vs 108.76,
p = <0.001), personal and social (m = exp 106.06 vs 121.97, p =
0.003), language (m = exp 97.00 vs 127.68, p = <0.001), hand and
eye coordination (m = exp 86.63 vs 103.05, p = 0.001), performance
(m = exp 94.35 vs 107.87, p = 0.001) and practical reasoning (m = exp
95.50 vs 115.05, p = 0.007) skills. No maternal IQ classification differ-
ences were found. No significant differences for reported developmental
progress on the Vinelands were found with the exception of the motor
domain.
Conclusion: The results suggest that prenatal exposure to AED’s may
be associated with developmental delay at 3 years of age. Further anal-
ysis at 6 years will identify the existence of specific drug effects for
neurodevelopment.
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NATURAL HISTORY OF COGNITIVE IMPAIRMENT IN
EPILEPSY: THE IMMEDIATE IMPACT OF TREATMENT
J. Taylor and G. Baker (University of Liverpool, Liverpool, UK)
Purpose: The neuropsychology arm of the SANAD trial provides a
unique opportunity to assess: 1) The natural history of cognitive impair-
ment in people with newly diagnosed epilepsy, prior to AED treatment;
2) The differing profiles of cognitive side effects with novel and standard
AED treatment.
Method: In a prospective, randomised controlled trial, 257 newly di-
agnosed patients with epilepsy were assessed at baseline on an extensive
battery of neuropsychological tests. Of those 204 were re-assessed after
3 months using the same measures.
Results: Interim analyses have shown that performance on a nondom-
inant tapping task deteriorated after three months (50.58 ± 8.94 vs 49.56
± 8.97, p = 0.047). Fewer words were recalled on the fifth trial and on
both the immediate and delayed aspects of a verbal learning test (44.59
± 9.37 vs 42.99 ± 10.25, p = 0.006; 8.51 ± 3.30 vs 7.87 ± 3.30, p =
0.002; 10.82 ± 2.35 vs 10.46 ± 2.62, p = 0.021). Motor speed decreased
at three month follow up (44.60 ± 10.63 vs 43.20 ± 10.53, p = 0.015;
46.41 ± 11.12 vs 45.20 ± 10.85, p = 0.037). However, ratings of tension
improved on the Profile of Mood Scale (44.84 ± 9.46 vs 42.82 ± 9.98,
p = 0.004).
Conclusion: Preliminary analyses have revealed that patients with
newly diagnosed epilepsy show reduced functioning in psychomotor
speed and some aspects of memory and learning in the three months
following diagnosis. This study provides a unique opportunity to un-
derstand the natural history of cognitive impairment and the impact of
seizures and treatment.
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EFFECT OF OXCARBAMAZEPINE AND TOPIRAMATE
ON COGNITIVE PERFORMANCE IN NEWLY DIAGNOSED
EPILEPSY PATIENTS
1Y. Higueras, I. Jime´nez-Martı´n, and M. Martı´n-Moro (University Gen-
eral Hospital Gregorio Maran˜o´n, Madrid, Spain)
Purpose: To valuate possible changes in cognitive functioning in
adults who take oxcarbamazepine (OXC) and topiramate (TPM) as
monotherapy after 6 months of treatment.
Method: We evaluated 51 patients, 26 took TPM, 25 OXC and 1
received both. Each subject has a measure in our cognitive battery be-
fore and 6 months after starting their treatment. We assessed learning
and memory (Test de Aprendizaje Verbal Espan˜a-Complutense and de-
layed recall of Rey-Osterrieth Complex Figure Test (ROCFT)), executive
function (direct digits, backwards digits, fluency tasks of animals and
words beginning with F and trail making test), visuoconstruction (copy
of ROCFT), naming (Aphasia Diagnostic Boston Test) and depression
(Beck Depression Scale). Our hypothesis is that after 6 months there will
be no important changes in cognitive performance in either group.
Results: In OXC group, 25 of 26 patients (1 had an allergic reaction)
were finally evaluated and in TPM group 22 of 25 (3 washed out because
of psychophysics alterations). We found after 6 months of OXC treatment
a statistically important improvement in learning and verbal memory
items (p < 0.05 in Mann-Whitney), more speed of processing (p =
0.014) and better naming (p = 0.004). In TPM group, we found there
was better verbal recall but more perseverance (p = 0.032) and worse
execution in executive test (direct digits (p = 0.05) and fluency tasks
(p = 0.025) in words starting with F and p = 0.009 in animals)).
Conclusion: There was a soft worsening only in the TPM group in
executive function but it didn’t indicate a wash out of treatment or any
impairment in the patient’s life.
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IS THERE A COGNITIVE DECLINE IN PATIENTS WITH FO-
CAL EPILEPSY? A LONGITUDINAL STUDY
1A. Piazzini, 1K. Turner, 1R. Chifari, 2A. Morabito, 1R. Canger, and
1M. Canevini (1Epilepsy Center, St. Paolo Hospital, University of Mi-
lan, Italy, 2Department of Statistics And Biometry S. Paolo Hospital,
University of Milan, Italy)
Purpose: The aim of this study is to assess the possible cognitive alter-
ations in epilepsy patients compared with controls over five years, and to
investigate the clinical variables mainly implied in mental impairment.
Method: In our longitudinal single-centre study, 50 patients with focal
epilepsy and 50 controls were administered the same battery of compre-
hensive neuropsychological tests at baseline and after five years.
Results: Epilepsy patients showed a significant impairment in atten-
tion compared with controls after five years, while the other cognitive
domains did not exhibit any important changes. The worsening of atten-
tion was mainly related to the duration of epilepsy, the age at onset, a
history of tonic-clonic seizures and a low educational level.
Conclusion: Our results could have important implications, consid-
ering the influence of attention on other cognitive functions, its impact
on the quality of life and one’s work status.
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TOPIRAMATE AND DEPAKINE EFFECTS ON COGNITIVE
FUNCTIONS IN PATIENTS WITH FRONTAL LOBE EPILEPSY
N. Sorokina and G. Selitsky (Institute of Hiher Nervous Activity And
Neurophysiology, Moscow, Russia)
Purpose: The study was aimed to analyse the cognitive effects of
the new antiepileptic drug topamax (TPM) in patients with symptomatic
frontal lobe epilepsy (left and right-sided epileptic foci) manifested by
focal seizures with secondary generalisation as compared with depakine
(VPA) effect and control group.
Method: Three groups of epilepsy patients and a control group
(healthy subjects of the same age) were administered neuropsychological
and cognitive tests for attention, psychomotor speed, language, memory,
and frontal lobe functions (Wisconsin Card Sorting Test), emotion con-
ceptualization task (ECT), and others. The 1-d and 2-d groups included
patients with symptomatic frontal lobe epilepsy with focal secondarily
generalised seizures (left and right-sided foci, 79 and 74 subjects, respec-
tively, mean age 24 years, S.D. 4.5). All patients had a medication change
from DPA to TPM 1.5 ± 0.5 years ago, on average. They were free from
seizures and had a medium TPM dosage of 200 mg/day. The patients of
3-d group had the same form of epilepsy and had long-term VPA ther-
apy without withdrawal, mean DPA dosage of 400 mg/day (162 subjects,
mean age 32.5 years, S.D. 6.5). The statistical intergroup comparisons
were analysed (WinStat-7.0) for all tests in double-blind study.
Results: The statistically significant differences on measures of atten-
tion, digits backwards, speed performance, and frontal lobe associated
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functions (WCST and ECT tests, etc.) were obtained for groups of pa-
tients and control. Higher scores in cognitive performance and tests for
frontal lobe associated functions were obtained in 1 and 2 TPM groups
as compared with the VPA group. Results demonstrate also the more
distinct improvement (p < 0.01) in patients of the TPM-1 group with
left-sided foci in frontal areas as compared the TPM-2 and DPA groups:
in scores for temporal ordering, sorting of cards, synthesis, depression,
estimation of emotions presented, planning and control functions, etc.
Conclusion: In symptomatic partial epilepsy with secondarily gener-
alised seizures, VPA therapy displayed slight adverse cognitive effects
in the majority of cognitive tests; 1 and 2 groups showed only mild neg-
ative effects in psychomotor speed (compared with the control group).
Data obtained in the TPM-1 group demonstrated the positive alterations
in the left frontal lobe associated functions (this may be explained by
anticonvulsive, cerebroprotective, and activating psychotropic effects of
TPM). The results help to elucidate the contradictory data concerning
the cognitive effects of topamax.
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EXPERIENCE ABOUT COGNITIVE FUNCTIONING IN 161
EPILEPSY PATIENTS
1B . Lopez Hernandez, 1M. Diaz-Obregon Santos, and 2F. Maestu
Unturbe (1Hospital Clinico San Carlos–Unidad De Epilepsia, Madrid,
Spain, 2Centro De Magnetoencefalografı´a Dr. Pe´rez-Modrego, Madrid,
Spain)
Purpose: To evaluate the number of epilepsy patients with cogni-
tive difficulties and analyse the correspondence relating to the patients
perception.
Method: 161 epilepsy patients were assessed with a neuropsycholog-
ical battery including executive function skills, memory, attention and
language tasks. All of them were asked before the examination about
their difficulty with perception in daily life. We used these results as a
measure of patient’s consciousness of deficit. We also took into consid-
eration other variables such as age of onset, frequency and treatment.
Results: The most frequent age of evaluation was between 18 and 50
years. Age of onset was early: 41.61% between 0–15 years, and 32.92%
between 16–25 years. 68.94% have a frequency higher than one or more
seizures a year, and 61.49% are on monotherapy. Although 90.68% show
some kind of cognitive deficit, the personal perception is only 46.58%,
specially referred to memory, denomination and concentration difficul-
ties. Therefore, only 53.42% have a clear consciousness of deficit. How-
ever, these difficulties do not prevent a normal labouring life because
79.50% are working and only 4.35% receive any help for this handicap.
Conclusion: Although the percentage of epilepsy patients with cog-
nitive dysfunction is high (90.68%), these difficulties are hardly seen,
because 79.50% are capable of preserving a normal working life, in spite
of recurrent seizures and antiepileptic drugs. This and the low percent-
age of patients with an adequate consciousness of deficit, justifies the
relevance of neuropsychological assessments that detect possible dete-
rioration produced by seizures and provide the patients with strategies
to minimize the impact on daily life.
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EFFECTS OF LAMOTRIGINE AND OXCARBAZEPINE ON
SEIZURES, COGNITION, MOOD AND HEALTH-RELATED
QUALITY OF LIFE IN PATIENTS WITH UNTREATED
EPILEPSY
N. Fritz, C. Elger, and C. Helmstaedter (Epileptology, University of
Bonn, Germany)
Purpose: To compare the two novel antiepileptic drugs (AED) lamot-
rigine (LTG) and oxcarbazepine (OXC) as monotherapy in patients with
untreated epilepsy regarding cognition, mood and health-related quality
of life (HRQL).
Method: The prospective, open-label study comprised 48 untreated
patients with epilepsy (26 men; 22 women, aged 15–61), who were
randomly assigned to LTG (N = 21) or OXC (N = 27). Neuropsycho-
logical examination took place before titration and 6 months later and
included tests on attention, word fluency, language comprehension, con-
frontational naming, short term and working memory as well as episodic
memory. Questionnaires addressed depression and HRQL.
Results: Intention-to-treat analysis showed seizure freedom in 42.5%
of the patients (8 LTG; 12 OXC); a further 10.6% had a significant seizure
reduction (greater than 50% or only simple seizures remaining) (2 LTG;
3 OXC). Twenty five patients (52.1%) completed follow-up (10 LTG;
15 OXC). Both groups showed improvement in verbal learning and in
one out of four measures of attention. In addition, patients under OXC
improved in word fluency. Improved mood was reported with OXC only.
Conclusion: Seizure reduction was seen in 53.2% of the patients with
comparable outcomes for both groups. Consistent with previous find-
ings, the results indicate unchanged if not improved neuropsychological
performance (LTG 2/16, OXC 3/16 parameters improved). Under OXC
additionally improved mood was noted. Yet, the inclusion of further pa-
tients and long-term follow up still have to confirm these preliminary
findings. This study was supported by funds from Novartis.
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SHORT-TERM EFFECTS OF COGNITIVE REHABILITA-
TION ON MEMORY OUTCOME AFTER TEMPORAL LOBE
SURGERY
1B. Loer, 2R. Wohlfahrt, 2A. Hammen, 3A. Quiske, 3A. Schulze-
Bonhage, 4B. Steinhoff, and 1C. Helmstaedter (1University Clinic of
Epileptology Bonn, Germany, 2Median-Kliniken, Rehabilitation Cen-
ter, Bad Krozingen, Germany, 3Epilepsy Center, University of Freiburg,
Germany, 4Epilepsy Center Kork, Kehl-Kork, Germany)
Purpose: To study the short term effects of cognitive rehabilitation
on memory outcome after temporal lobe surgery.
Method: Two groups of patients, one with (n = 55) and one with-
out postoperative rehabilitation (n = 57) were evaluated with respect
to memory and attention before and three months after temporal lobe
surgery. The groups stemmed from different epilepsy centres but were
matched with regard to age, sex, type of surgery, and seizure outcome.
Results: After surgery, 78% of the patients were seizure free.
MANOVA revealed a significant “side X surgery” effect on verbal recog-
nition and a “rehabilitation X surgery” effect on verbal learning and
recognition. There were no effects for loss in verbal delayed recall or
figural memory. Detailed analyses indicated gains due to rehabilitation
particularly after right surgery. Attention generally improved.
Conclusion: The results indicate major effects of rehabilitation on
short term aspects rather than long term aspects of verbal learning and
memory. Figural memory was not affected at all, and attention also im-
proved without rehabilitation. Finally, left resected patients who mostly
needed rehabilitation showed less profit than right resected patients. Thus
although rehabilitation had some positive effect on memory outcome its
usefulness for risk groups is debatable.
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PRE- AND POSTOPERATIVE MEMORY PERFORMANCE IN
MESIAL TEMPORAL LOBE EPILEPSY AS A FUNCTION OF
HIPPOCAMPAL PATHOLOGY
1E. Kockelmann, 2M. Hildebrandt, 2I. Blu¨mcke, and 1C. Helmstaedter
(1Department of Epileptology, University of Bonn Medical Center,
Bonn, Germany, 2Department of Neuropathology, University of Erlan-
gen, Erlangen, Germany)
Purpose: We investigated the influence of hippocampal morphologi-
cal integrity (as measured by neuron cell density) on preoperative verbal
memory and postoperative memory change in 67 patients with mesial
temporal lobe epilepsy (mTLE) and unilateral hippocampal sclerosis
(HS, 31 right-, 36 left-sided).
Method: Pre- and postoperative performance on verbal learning and
memory were correlated to cell counts (neurons per mm2) within dif-
ferent subregions of the resected hippocampus [i.e. external and internal
dentate gyrus (GDE/GDI), CA1-4].
Results: Preoperatively, verbal learning was correlated (r = .39–.41,
p = .01–.02) with cell densities in GDE and CA3/CA4 regions, respec-
tively, and this was seen only in patients with left mTLE. In contrast,
preoperative memory recall and recognition were correlated with cell
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densities in CA2–4 regions in patients with both right and left mTLE
(r = 0.32–0.48, p = 0.01–0.05). For patients with left-sided mTLE, cell
densities in GDE and CA3/CA4 regions predicted outcome in verbal
learning (r = 0.49–0.53, p = 0.001–0.004), whereas no relation was
found for loss in verbal memory.
Conclusion: The data indicate a differential role of the left and right
hippocampus and its subfields for verbal learning and memory in uni-
lateral mTLE. While verbal memory (long term consolidation retrieval)
appears to be subserved bilaterally, verbal learning (or short-term mem-
ory) appears rather lateralised to the left hippocampus, whose integrity is
also predictive for losses in this function. As for hippocampal subfields
the left dentate gyrus was differentially associated to verbal learning but
not memory.
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A STUDY OF FACTORS RELATED TO COGNITIVE FUNCTION
IN EPILEPSY PATIENTS
Z. Hong, P. Yu, Q. Guo, and D. Ding (Institute of Neurology, Huashan
Hospital, China)
Purpose: To investigate the factors related to cognitive function in
epilepsy patients.
Method: We evaluated 166 epilepsy patients (65 newly diagnosed)
using neuropsychological tests. The battery of neuropsychological tests
included auditory verbal learning (AVL), logical memory (LM), digital
symbol (DS), Stroop colour word (SCW), trail making (TM), verbal flu-
ency (VF), Rey-Osterrieth complex figure (ROCF) and Boston Naming
(BN). We used multivariate progressive regression analysis to determine
the relation between the scores of neuropsychological tests and the fac-
tors.
Results: Seizure onset age was inversely related to the scores of de-
layed recall, cued recall, recognition task of the AVL, immediately and
delayed recall of LM, SCW-A and TM. Epilepsy duration was inversely
related to the scores of immediate recall of AVL and VF. The decreased
score of semantic clustering of the AVL and VF was associated with pri-
mary of secondary GTCS. The decreased score of delayed recall, cued
recall, and semantic clustering of the AVL and remind naming score of
BN was associated with CPS. The account of antiepileptic drugs was
inversely related to the scores of the immediate and delayed recall, cued
recall, and recognition task of the AVL, immediate and delayed recall of
ROCF, VF, DS, TM and SCW.
Conclusion: Besides sex, age and evaluation degree, the cognitive
function of epilepsy patients is related to seizure onset age, epilepsy
duration, seizure severity, seizure type and the account of antiepileptic
drugs.
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PRE- AND POSTSURGICAL FIGURAL MEMORY SCORES
AMONG LEFT AND RIGHT TLE PATIENTS IN A RECURRING
FIGURES TEST (RFT)
H. Haettig, S. Erler, and H. Meencke (Epilepsy Center Berlin Branden-
burg, Berlin, Germany)
Purpose: Material-specific memory deficits are well established for
left TLE and the verbal domain. The complementary deficit for the figural
domain in right TLE patients is still under debate. We analysed the figural
memory data of TLE patients for effects of the side of seizure origin and
sex before surgical treatment and 12 months postoperatively.
Method: 54 female and 58 male TLE-patients passed two parallel
forms of a RFT in which a sequence of 120 curved (C) and geometric
(G) abstract figures were presented. Within the presented sequence some
C and G figures recur 5 times. The subjects have to recognise these
recurring figures. For the factors sex and side of seizure origin an ANOVA
with repeated measurements for figure type (C vs G) was computed.
Handedness and speech lateralisation were controlled.
Results: Pre- and postoperatively the recognition of the curved figures
were substantially more difficult (p < 0.000001) for men and women.
There was a main effect on the operation side. Right TLE patients per-
formed worse than patients with left TLE (p = 0.04). In respect to the
figure type, there was a tendency (p = 0.09) for only the male subgroup
to perform pre-operatively specifically worse on the recognition of the
curved figures.
Conclusion: Effects of the side of the seizure onset on a RFT were
relatively marginal. The tendency for the interaction of side of seizure
origin and gender is probably due to item difficulty. Women may find it
easier to verbalise even curved figures and hence do not show specific
deficits in a RFT even in the case of right TLE.
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EMOTIONAL VULNERABILITY IN PATIENTS WITH TEMPO-
RAL LOBE EPILEPSY: EVIDENCE FROM A STUDY OF AT-
TENTIONAL BIASES
1L. Lanteaume, 2M. Bastien, and 3F. Bartolomei (1CNRS et Universite´
de Provence UMR 6054, France, 2NRS et Universite´ de Provence UMR
6054, France, 3INSERM U 751-Universite´ Aix Marseille II, France)
Purpose: Some studies have suggested a higher prevalence of anxiety
and depression in temporal lobe epilepsy (TLE). Moreover, cognitive
studies provided evidence that anxiety and depression are associated with
selective attentional biases that could favour the processing of negative
emotional information. In this study, we investigated: i) the prevalence of
anxiety and depression in TLE patients, ii) the related attentional biases
for negative emotional information, iii) the incidence of patients in whom
seizures were triggered by emotional factors.
Method: TLE patients were compared with normal controls and pa-
tients with other types of epilepsy. Attentional biases were investigated
using an emotional Stroop task, in which participants were instructed
to give the colour of words, with negative or neutral emotional valence.
Anxiety and depression were assessed by Spielberger anxiety scales
and Beck depression inventory. Finally, patients were asked to report if
seizures were elicited by specific emotional factors.
Results: There was no effect of groups on the levels of anxiety and
depression. No effect was found for reaction times during the emotional
Stroop task (to name the colour of negative emotional words compared
to neutral emotional words). Furthermore, 45% of TLE patients reported
to have emotional factors favouring seizures. In this subpopulation, we
found significant attentional biases toward negative words compared to
neutral words.
Conclusion: In our TLE patient population, we identified a subgroup
of patients who disclose an emotional vulnerability. These patients have
emotional factors which favoured seizures, accompanied by selective
attention toward negative information.
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UNILATERAL HEMISPHERE INVOLVEMENT ASSOCIATED
PREDOMINANTLY WITH VIQ>PIQ DISCREPANCIES IN
CHILDREN WITH REFRACTORY EPILEPSY
L. Van Iterson and P. Augustijn (Dutch Epilepsy Clinics Foundation,
SEIN, The Netherlands)
Purpose: Although verbal (VIQ) versus performance IQ (PIQ) dis-
crepancies in intelligence tests are thought to be equally distributed in
both directions (VIQ>PIQ, VIQ<PIQ) on psychometric and on empiri-
cal bases, in children with developmental disorders discrepancies are of-
ten skewed; in adults they reflect brain pathology imperfectly. We studied
the relation between hemisphere involvement and verbal-performance
discrepancies in childhood epilepsy.
Method: The Wechsler test scores of 102 children with epilepsy, mean
age = 10 years (5−19), mean IQ = 84 (60−120), mean age epilepsy
onset = 7 years (0−16), 61% male, 81% right-handed, were collected.
Classification was based on EEG/MRI information on brain involve-
ment: partial left (LH, n = 23), right (RH, n = 24) or bilateral (bi, n =
24); generalised (n = 15), and uncertain (n = 16) onset. Rates of occur-
rence of large VIQ-PIQ discrepancies were contrasted to those normally
expected using chi-square statistics.
Results: Group means (2-sided-t-test) did not differ for age of seizure
onset, age of testing, IQ-scales or VIQ-PIQ differences. Children with
partial seizures present more often with large discrepancies than “ex-
pected”; surprisingly, irrespective of side of hemisphere involvement,
they relate predominantly to large VIQ>PIQ discrepancies (VIQ>PIQ:
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significant values for LH, RH and bi against “expected”; VIQ<PIQ:
significant value for RH). Results are most pronounced in LH involve-
ment; right-handed boys; IQs<90. The “generalized” and the “uncer-
tain” group do not show these results (“expected” versus VIQ>PIQ or
VIQ<PIQ n.s.).
Conclusion: Counterintuitive, unilateral hemisphere involvement ap-
pears not to be mirrored in its IQ-scale; rather, both left and right uni-
lateral involvement is associated with higher rates of unusually large
VIQ–PIQ discrepancies, suggesting that PIQ-task solving also recruits
abilities dependent on an intact left hemisphere.
Studying frequencies discloses valuable information on discrepancies.
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CORRELATION BETWEEN DENSITY OF NEUROPEPTIDE Y-
POSITIVE NEURONS IN DIFFERENT NUCLEI OF THE AMYG-
DALA AND SELF-REPORTED ANXIETY AND DEPRESSION IN
EPILEPSY PATIENTS
1C. Frisch, 2J. Hanke, 3S. Tulke, 3S. Richter, 4A. Becker, 1C. Elger, 3J.
Schramm, 2D. Yilmazer-Hanke, and 1C. Helmstaedter (1Department of
Epileptology, University of Bonn Medical Center, 2Institute of Anatomy,
Otto Von Guericke-University of Magdeburg, 3Department of Neu-
rosurgery, University of Bonn Medical Center, 4Department of Neu-
ropathology, University of Bonn Medical Center Germany)
Purpose: Amygdaloid neuropeptide Y (NPY) has been implicated in
depression, anxiety and memory. In the rat, the number of NPY-positive
neurons in the amygdala correlates with anxiety related behaviour. Fur-
thermore, increased NPY expression in the epileptic rat brain is supposed
to represent an adaptive mechanism counteracting epilepsy-related hy-
perexcitability. We attempted to investigate whether NPY in the human
brain is also involved in these processes.
Method: In 37 adult epilepsy patients, who underwent temporal lobe
surgery for seizure control, the density of NPY-positive neurons was
assessed in basal, lateral and accessory-basal amygdala nuclei. In 11 to 26
patients cell counts were related to self reported depression, anxiety, and
personality, to measures of verbal/figural memory, to clinical parameters
(onset/duration of epilepsy, seizure frequency), and to amygdala and
hippocampal MRI volumetric measures.
Results: Cell counts of NPY-positive basolateral amygdala neurons
showed significant positive correlations to self-reported depression (r =
0.53/n = 26) anxiety (r = 0.85/n = 11), drive impairment (r = 0.53/n
= 25), and compulsivity (r = 0.58/n = 25). Furthermore, correlation
baso-dorsal cell counts with verbal memory recall could be obtained
(r = 0.475/n = 22). NPY cell counts showed no relation to epilepsy
related factors (n = 26–37) or to amygdala and hippocampal volumes
(n = 19).
Conclusion: The results point to a role of the human amygdaloid
NPY in negative emotion, and might reflect both state- and trait-related
processes at least in patients with temporal lobe epilepsy. Furthermore,
a role of NPY in human memory was indicated. However, no relation to
common clinical parameters of epilepsy was found. This study is funded
by DFG SFB/TR3 TP C3 to D.Y.-H. and TP A1 to C.H. and J.S.
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MEMORY FUNCTION DURING WADA TESTING USING
SODIUM AMYTAL VERSUS BREVITAL IN EPILEPSY
SURGERY PATIENTS
1F. Andelman, 2S. Kipervasser, 3I. Reider-Groswasser, 1,4I. Fried, and
2M. Neufeld (1Functional Neurosurgery Unit, SouraskY Medical Center,
2EEG and Epilepsy Unit, Neurology Department, Sourasky Medical
Center, 3Radiology Department, Sourasky Medical Center, 4Division of
Neurosurgery, Univ. of California, USA)
Purpose: The intracarotid amobarbital procedure (IAP) is the standard
method for lateralisation of memory function, used to predict the risk of
postoperative amnesia in epilepsy surgery patients (Milner et al, 1962).
Because of recent shortage of amobarbital supply sodium methohexital,
or brevital, has been used in some centres as an anesthetic agent (Buchtel
et al 2002; Grote and Meador, 2005). The purpose of this study was to
compare the neuropsychological effects of Wada testing using IAP versus
intracarotid brevital procedure (IBP).
Method: 32 patients who underwent the IAP were compared with 20
patients who underwent IBP at the Tel-Aviv Sourasky Medical Center.
The IBP procedure was based partially on the protocol developed at the
University of Florida (Buchtel et al, 2002). Results of the Wada ipsilateral
and contralateral memory scores in these patients were analysed and
compared, as well as differences in neurological status during the action
of the drugs.
Results: There were no patients with significant memory decline after
surgery. No significant difference was found between Wada contralateral
memory scores (first injection) using the IAP (M = 81.17%) or IBP
(M = 84.91%). However, significant differences in memory scores of
the hemisphere ipsilateral to the epileptogenic focus (second injection)
were observed between IAP (M = 30.74%) versus IBP (M = 55.26%)
(p = 0.01).
Conclusion: These results suggest that the Wada procedure performed
by the use of Brevital provides information on prediction of postsurgical
amnesia in epilepsy patients. However, they raise the question of the
ability of IBP to adequately assess the ipsilateral memory reserve of the
epileptogenic hemisphere.
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EFFECT OF TIME ON VISUOSPATIAL WORKING MEMORY
PERFORMANCE
1R. Meneses, 2J. Pais-Ribeiro, 3A. Martins da Silva, and 4A. Gio-
vagnoli (1FCHS-Fernando Pessoa University & IBMC-Porto Univer-
sity, Porto, Portugal, 2FPCE/IBMC-Porto University, Porto, Portugal,
3ICBAS/IBMC-Porto University & Hospital Geral Santo Anto´nio, Porto,
Portugal, 4Laboratory of Neuropsychology, Carlo Besta National Neu-
rological Institute, Milano, Italy)
Purpose: Knowing the variables that can affect neuropsychological
performance and test reliability is crucial to plan assessments and cog-
nitive rehabilitation. Individuals with epilepsy usually complain about
attention and memory deficits which may reflect seizure frequency and
anti-epileptic drug (AED) side effects. The aim of the present study was
to analyse the effect of time on the performance of individuals with fo-
cal epilepsy on the Corsi Test, a widely used visuospatial test exploring
attention and working memory.
Method: A sample of N = 30 individuals with mild severity focal
epilepsy (50% female; Mean age = 37.23, DP = 11.88, 17–61 yrs; mean
education = 9.27, DP = 4.84, 3–18 yrs) was assessed, and re-assessed,
about 6 months later, with the Corsi Test.
Results: There was a considerable variability on performance: in the
fist assessment, scores varied from 3 (n = 1) to 7 (n = 2); on the second
from 3 (n = 2) to 8 (n = 1). There were no statistically significant
differences between the first and second assessments on the Corsi Test
(mean score 1 = 4.87, SD = 0.86; mean score 2 = 4.80, SD = 1.09).
Conclusion: These results suggest there are no practice/learning ef-
fects on the Corsi Test that can be detected about 6 months after the first
assessment. Given the multiple determinants of cognitive impairment
in epilepsy patients, these findings support the inclusion of the Corsi
Test in neuropsychological protocols assessing AED or rehabilitation
treatments.
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DIFFERENTIAL EFFECTS OF TEMPORAL POLE RESEC-
TION WITH AMYGDALOHIPPOCAMPECTOMY VERSUS SE-
LECTIVE AMYGDALOHIPPOCAMPECTOMY ON MATERIAL
SPECIFIC MEMORY IN PATIENTS WITH MESIAL TEMPO-
RAL LOBE EPILEPSY
1S. Richter, 1S. Thulke, 2H. Haettig, 3T. Lehmann, 1J. Schramm, and
4C. Helmstaedter (1University Clinic of Neurosurgery, Bonn, Germany,
2Epilepsy Center Berlin-Brandenburg, Berlin, Germany, 3Clinic of Neu-
rosurgery, Charite´, Berlin, Germany, 4University Clinic of Epileptology,
Bonn, Germany)
Purpose: To compare the effect of different surgical approaches to
mesial TLE on memory outcome one year after surgery.
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Method: Cognitive outcome was evaluated in 97 patients with MTLE
and hippocampal sclerosis, who were postoperatively seizure free, and
who received temporal pole resection with amygdalohippocampectomy
(TPR, N = 33, 48% left) or selective transsylvian amygdalohippocam-
pectomy (SAH N = 64, 56% left). The project was part of a multicentre
study (SFB/TR3) where patients with TPR and SAH underwent surgery
at different epilepsy centres, which otherwise followed the same presur-
gical protocol. Neuropsychology included psychomotor speed, attention,
language function, and verbal/figural memory.
Results: Except for worse verbal memory performance in SAH pa-
tients, surgical groups did not differ in clinical or demographic variables
at baseline. MANOVA with “pre-post” cognitive tests as within and
“side” and “type” of surgery as between group factors, revealed a “test
X side” interaction for verbal learning, recognition, and naming, an ef-
fect of “test” on psychomotor speed, and “test X side” and “test X type”
interactions for figural memory. Post hoc t-tests showed generally im-
proved attention and speed, and improved verbal functions after right
SAH. Mild versus severe decrease in figural memory was observed in
right SAH and TPR respectively. Verbal learning and recognition dete-
riorated significantly after left SAH.
Conclusion: On the basis of the neuropsychological tests used in this
study, different surgical approaches are suggested in left and right mesial
TLE. While transsylvian SAH appears to be favourable in right MTLE,
TPR appears safer in left MTLE. Supported by DFG (SFB/TR3).
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AFFECT AND SPIRITUALITY PREDICT QUALITY OF LIFE IN
EPILEPSY
1A. Giovagnoli, 2J. Ribeiro, 3R. Meneses, 4A. Picherle, and 5A. Martins
da Silva (1Laboratory of Neuropsychology, Carlo Besta National Neuro-
logical Institute, Italy, 2PFCE/IBMC-Porto University, 3FCHSFernando
Pessoa University, Italy, 4Epilepsy Center, Carlo Besta National Neu-
rological Institute, Italy, 5ICBAS/IBMC-Porto University and Hospital
Geral Santo Antonio, Italy)
Purpose: Individuals with comparable severity of epilepsy may differ
widely in perceived quality of life (QOL). Studies of disease-related and
psychological determinants have in part explained the variability of QOL,
suggesting a role for unexplored personal facets. This study evaluated
spirituality in patients with focal epilepsy and healthy subjects aiming
to assess its contribution to QOL.
Method: Thirty-six adult patients with partial epilepsy and 45 healthy
subjects compiled the WHO QOL-100 and Spiritual, Religious and Per-
sonal Beliefs (SRPB) scales, Beck Depression Inventory, State-Trait
Anxiety Inventory, and Multiple Ability Self-Report Questionnaire for
QOL, spirituality, mood, and cognitive self-efficacy, and underwent neu-
ropsychological tests.
Results: T statistics comparing the two groups showed significant dif-
ferences in the total WHO QOL-100 score, spirituality, mood, cognitive
self-efficacy, and neuropsychological performances with lower scores in
epileptics. Of these, the WHO QOL-100 total score significantly corre-
lated with SRPB dimensions (meaning and purpose in life, wholeness
and integration, inner peace, spiritual strength, hope and optimism, ac-
ceptation, inner independence), and the levels of anxiety and depression.
Spiritual strength and mood were significant predictors of overall QOL.
No relationship was found for disease-related variables. In the controls,
the WHO QOL-100 total score significantly correlated with different
SRPB dimensions, anxiety, depression, and cognitive self-efficacy.
Conclusion: These findings suggest that, although QOL is worse in
people with epilepsy than in those without epilepsy, for both groups
spirituality has an important role in QOL, paralleling the influence of
mood. Spirituality may be a missing element in the understanding of the
QOL of these patients, explaining differences between individuals with
the same clinical severity.
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NEUROPSYCHOLOGICAL PERFORMANCE IN PATIENTS
WITH TEMPORAL LOBE EPILEPSY AND INTERICTAL
(SCHIZOPHRENIA-LIKE) PSYCHOSIS: CORRELATION
WITH MAGNETIZATION TRANSFER IMAGING
1,4D. Fluegel, 1A. O’Toole, 1P. Thompson, 1M. Koepp, 2M. Cercignani,
2M. Symms, and 3J. Foong (1Department of Experimental And Clinical
Epilepsy, The National Hospital of Neurology And Neurosurgery, Lon-
don, UK, 2NMR Research Unit, Institute For Neurology, 3Department
of Neuropsychiatry, The National Hospital of Neurology And Neuro-
surgery, Queen Square, London, UK, 4Department of Neurology, Kan-
tonsspital St Gallen, Switzerland)
Purpose: Cognitive deficits in patients with temporal lobe epilepsy
(TLE) and interictal (schizophrenia-like) psychosis were compared to a
matched group with TLE without psychosis and their relationship with
magnetization transfer imaging was examined.
Method: 20 patients with TLE and interictal psychosis were com-
pared to 20 nonpsychotic TLE patients. Patients were matched with
respect to previous IQ, age and conventional MRI findings. A battery
of neuropsychological tests assessing intellectual level, memory and ex-
ecutive function was administered. The neuropsychological tests which
showed significant group differences were used for correlational analysis
with magnetization transfer ratio (MTR) which provides a quantitative
measure of macromolecular structural integrity.
Results: Patients with interictal psychosis were significantly more
impaired on executive (spatial working memory, spatial span, arithmetic)
and semantic memory tasks (verbal fluency, vocabulary) than the non
psychotic control group. Vocabulary test scores correlated significantly
with MTR reduction in the left fusiform gyrus in the psychotic but not
the non psychotic group.
Conclusion: Patients with TLE and interictal psychosis were more
cognitively impaired resembling the pattern of patients with schizophre-
nia. In contrast to schizophrenia where neuropsychological deficits tend
to remain stable, cognitive deterioration in patients with interictal psy-
chosis may occur as the illness progresses. MTR may be useful in inves-
tigating structural correlates of cognitive impairment.
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NEUROPSYCHOLOGICAL OUTCOME FOR THREE PA-
TIENTS WITH EPILEPTIC STATUS INDUCED BY EYE
CLOSURE
1P. Veggiotti, 2C. Termine, 1F. Teutonico, 2U. Balottin, 1M. Fasce, 2M.
Ferri, 2S. Perna, 2P. Piccinelli, and 3G. Rubboli (1Neurological Institute
C. Mondino, Pavia, 2Child Neuropsychiatry Unit, Department of Clinical
and Biological Sciences, 3Department of Neurology, Bellaria Hospital,
Bologna, Italy)
Purpose: To detect the presence of transient or stable cognitive im-
pairment (TCI/SCI) in 3 patients with photosensitive epilepsy showing
continuous epileptic activity during eye closure.
Method: Three children with electric status induced by eye closure
underwent periodical clinical evaluations and EEG investigations during
a mean follow-up period of 10 years (range: 8–14 yrs). A complete
neuropsychological assessment was carried out at first evaluation (T0)
and at the end of the follow-up (T1) to detect SCI. Some tasks were
performed during video-EEG monitoring either with eyes closed or with
eyes open, to evaluate possible TCI related to ongoing epileptic activity.
Results: The results of neuropsychological assessment during eyes
closed as compared to performances with eyes open did not show signif-
icant differences at T0 as well as at T1. In all the patients the Wechsler In-
telligence Scale documented deterioration of performances at T1 respect
to T0. Moreover, we observed at T1 impairment in facial recognition and
block design.
Conclusion: Deterioration of IQ in the follow up period could be due
to disruption of cognitive processes possibly related to the continuous
epileptic activity during eye closure over the years. A dysfunction of
visual processing in posterior cortical areas could be involved in impair-
ment in face recognition and block design tests as well as in eye closure
sensitivity.
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DYSLEXIA IN THE FAMILY OF WOMEN WITH EPILEPSY
1B. Wiœniewska and 2J. Wendorff (1Polish Mother’s Memorial Hos-
pital Research Institute, 2Polish Mother’s Memorial Hospital Research
Institute, Poland)
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Purpose: The aim of the study is the analysis of symptoms of devel-
opmental dyslexia in mothers with epilepsy and their offspring.
Method: The study group consisted of 40 women with idio-
pathic/cryptogenic epilepsy and their offspring who were born in 1990–
92 in our hospital and were prospectively evaluated neuropsychologi-
cally. Raven, Benton tests were used as well as 15 words Rey memo-
rising test and lateralisation test. Dyslectic symptoms questionnaire was
administered and statistic analysis and Fisher exact test were performed.
Results: 16 children were diagnosed as dyslectic and 24 without devel-
opmental dyslexia (40%). 12 mothers of dyslectic children had symptoms
of developmental dyslexia and only 2 mothers of nondyslectic children
(p < 0.01)
Conclusion: Developmental dyslexia occurred in a considerable per-
centage of women whose idiopathic/cryptogenic epilepsy was more
frequent in women whose children have developmental dyslexia. Fur-
ther evaluations concerning the occurrence of dyslexia in women with
epilepsy are needed.
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DIFFERENT PATTERNS OF HIPPOCAMPAL PATHOLOGY IN
TEMPORAL LOBE EPILEPSY ARE ASSOCIATED WITH DIF-
FERENT SEVERITY OF MEMORY DEFICITS
1E. Pauli, 2M. Hildebrandt, 1H. Stefan, and 2I. Blu¨mcke (1Epilepsy Cen-
ter, Dept. of Neurology, University Erlangen-Nu¨rnberg, 2Insitut of Neu-
ropathology, University Erlangen-Nu¨rnberg, Germany)
Purpose: Hippocampal sclerosis (HS) and associated memory de-
cline is a common finding in refractory temporal lobe epilepsies (TLE).
Cluster analysis was used to identify distinct homogeneous subgroups
in hippocampal sclerosis and their relation to memory dysfunction.
Method: Cluster analysis in a large sample of hippocampal neuronal
cell counts, obtained from surgically en bloc resected specimens, re-
vealed 4 distinct subgroups of hippocampal sclerosis beside normal find-
ings (Hildebrandt et al. 2006). We investigated 42 surgically treated TLE
patients who had Intracarotid-Amytal-Test (IAT) for memory as part of
presurgical evaluation. The hippocampal specimens were analysed neu-
ropathologically by counting neuronal cell density within hippocampal
subfields CA1-CA4 and internal/external limb of dentate gyrus. The re-
sulting patterns of neuronal cell loss were classified to distinct clusters:
healthy hippocampus (n = 12), CA1 sclerosis (n = 4), classic (n = 9) and
severe hippocampus sclerosis (n = 16). No patients were found with end
folium sclerosis. IAT memory scores of the awake ipsilateral hemisphere
were transformed into z-scores according to normative values (Pauli
et al., 2006).
Results: The different subgroups of hippocampal sclerosis were ac-
companied by different degrees of memory loss. Most interestingly,
patients with neuronal cell loss restricted to CA1 showed no memory
deficits, and memory performance corresponded to those observed in
healthy individuals. In contrast, classic and severe hippocampal sclero-
sis was associated with significant memory deficits.
Conclusion: Although a complex interplay between hippocampal sec-
tors is likely to be involved in memory formation and recall, selective loss
of CA1 pyramidal neurons appears not to be associated with significant
memory deficit in patients with refractory TLE.
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EXECUTIVE FUNCTIONS OF CHILDREN AND ADOLES-
CENTS WITH TEMPORAL LOBE EPILEPSY
1S. Vo¨lkl-Kernstock, 1C. Fro¨hndrich, and 2M. Feucht (1Vienna Medical
University, Department of Neuropsychiatry for Children and Adoles-
cents, 2Vienna Medical University, Department of Pediatrics, Austria)
Purpose: Executive functions are cognitive processes like problem
solving, mental planning, the selection of action goals as well as the
control and regulation of action. According to actual knowledge of the
science the frontal lobe takes an authoritative part in these processes.
Deficits in executive functions are clear hints of damage of the pre-
frontal cortex and subcortical structures, like the thalamus and the basal
ganglion (McPherson & Cummings, 1998). A frequent form of focal
epilepsy is epilepsy of the temporal lobe. Aetiopathogenetic dysontoge-
netic neoplasms, dysplasia, as well as mesial temporal sclerosis, play an
important role. Because of the important aspect of the attack manifesta-
tion within the bounds of brain development, it might be possible that
not only are functions disturbed in the area of lesion but also in the areas
which are connected to this lesion (Huttenlocher, 1977). Although re-
search is on-going, knowledge of function and performance of the brain
of children with epileptic attacks is limited. The cognitive stage of devel-
opment at the point of manifestation as well as the duration of epilepsy
is very important. If the epileptic excitement has got a harmful effect on
cell metabolism, an impairment of executive function is possible even
the structural damage lies in the frontal lobe. Therefore the present study
should make a contribution.
Method: Executive functions were examined postoperatively for 25
children age 10 to 18 with epilepsy because of a neoplasm, dysplasia
or hippocampal sclerosis, and for a control group of healthy children,
paralleled on age, gender and IQ. The registration of executive functions
took place with a neuropsychological test battery, consisting of 9 special
tests. Information about the personality of the children was established
with CBCL/ 4- 18 (Achenbach, 1991).
Results: First outcomes show significantly worse results concerning
attention and planning of actions of patients with epilepsy.
Conclusion: Based on these results, the fundamental importance of a
differentiated neuropsychological examination of children with temporal
lobe epilepsy, also when examining executive functions, becomes clear.
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EXECUTIVE FUNCTIONS IN LEFT AND RIGHT FRONTAL
LOBE EPILEPSY: AN EXPLORATORY ANALYSIS
1J. Alvarez-Carriles, 1J. Salas-Puig, 1L. Benavente, 2J. Ferna´ndez-
Martı´nez, and 1C. Lahoz (1Neurology Service, Hospital Universitario
Central de Asturias, Spain, 2Radiodiagnostic Service, Hospital Univer-
sitario Central de Asturias, Spain)
Purpose: To describe the frontal-executive functioning in frontal lobe
epilepsy (FLE), as well as to evaluate the lateralisation value of different
frontal executive measures in this sort of epilepsy.
Method: Participants in this investigation were 18 patients with uni-
lateral FLE (10 left and 8 right) and 18 controls. Both groups were as-
sessed with a broad neuropsychological battery made up of 26 different
frontal-executive measures.
Results: As a group, FLE patients showed a significant (p < .05)
impairment in almost 70% (18/26) of the executive measures. However,
a more detailed analysis confirmed that it was actually the left FLE group
which showed a wider executive impairment (left: 73% of the measures
vs right: 42%). Thus, the left FLE group performance was specially
impaired on verbal and design fluency, inhibition processes (Stroop test,
Go-Nogo task) and set-shifting abilities (Trail Making Test). On the
other hand, different regression analyses showed that epilepsy related
variables, such as age of seizure onset and duration of epilepsy, have a
significant effect over the executive performance of both FLE groups.
Conclusion: FLE shows a clear dysexecutive syndrome, more sig-
nificant when the focus is lateralised to the left hemisphere and when
the epilepsy has an early age of onset and a longer duration. Finally,
as well as in temporal lobe epilepsy, current neuropsychological assess-
ment procedures are able to characterise this lateralised profile, proving
its utility in the presurgical context.
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EFFICACY AND TOLERABILITY OF OXCARBAZEPINE IN
PARTIAL EPILEPSY: RESULTS OF THE GERMAN LEUKO-
TRIAL FOCUSSING ON QUALITY OF LIFE AND COGNITION
1K. Stollhoff, 2C. Ettrich, 3A. Zellner, 4N. Menger, and 5M. Ueber-
all (1Neuropediatric Medical Practice, Hamburg, Germany, 2University-
Department for Pediatric and Adolescent Psychiatry, Leipzig, Germany,
3Neuropediatric Center St. Martin, Regensburg, Germany, 4Novartis
Pharma, Nuernberg, Germany, 5Institute for Neurological Sciences,
Nuernberg, Germany)
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Purpose: Exposure response analysis of oxcarbazepine (OXC) in pa-
tients with partial epilepsy (PE) depending on application time and pre-
treatment.
Method: Prospective observational study on efficacy and tolerability
of OXC [special focus on quality of life (QoL) and cognition] as first
line or supplementary treatment in PE.
Results: One hundred and fifty-two patients participated (48.7% fe-
male, age: 16.0 ± 11.9 yrs.). OXC-related seizure free rates were 43.4%
in newly diagnosed patients (n = 53) vs 32.1/21.7% in those who re-
ceived OXC after one or two (n = 53/46) other AEDs. Overall, QoL,
assessed with the side effects and life satisfaction and the quality of
life in epilepsy scale improved in 77.4/79.2/78.3% (SEALS) and in
64.2/79.2/82.6% (QOLIE) respectively. Cognitive functioning (assessed
with a trail-making test, TMT) improved in 54.7% of patients who re-
ceived OXC as first line AED and in 79.2/67.4% after one/two prior
AEDs. Non-responders to carbamazepine (CBZ) vs other AEDs be-
came seizure free in 29.6 vs 21.4%, showed higher QoL-improvement
rates (SEALS/QUOLIE) than those changed to OXC from other AEDs
(83.1/85.9% vs 67.9/67.9%) and comparable cognitive improvement
rates: 73.2 vs 75.0%.
Conclusion: OXC is not only a highly efficacious 1st line AED for
PE, but also the drug of choice for AED non-responders (even to CBZ).
Its use was, irrespective from AED pre-treatment and application time,
followed by significant improvements in QoL and cognition.
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COGNITIVE FUNCTIONING IN PATIENTS WITH TEMPORAL
LOBE EPILEPSY
R. Altdungarova, B. Altayeva, O. Arinova, G. Zhalimbetova, and G.
Nyamdorzhiyn (Kazakh National Medicine University, Almaty, Kaza-
khstan)
Purpose: In this follow-up study we decided to evaluate cognitive
functions in patients with drug-resistant and newly diagnosed temporal
lobe epilepsy (TLE) before and after six months of treatment.
Method: 154 patients with resistance and 97 patients with newly di-
agnosed TLE underwent extensive neuropsychological interviews which
included measures of attention, memory, initiation, perseveration, word
fluency and mood before and after six months of treatment.
Results: Comparative analysis of cognitive functioning before treat-
ment showed that patients with drug–resistant TLE performed more
poorly in neurocognitive tests and exhibited higher scores of depression
than patients with newly diagnosed TLE. Patients taking antiepileptic
drug (AED) polytherapy showed more distinct cognitive dysfunctions
than patients taking AED monotherapy. 49 (31.8%) patients with drug
resistant TLE became seizure free after correcting the AED therapy. Af-
ter six months treatment 47 (30.5%) patients with resistant TLE showed
a reduction of cognitive disadvantage and 35 (22.7%) patients showed an
improvement of cognitive abilities. In the group with newly diagnosed
TLE 41 (42.2%) patients were seizure free, 40 (41.2%) showed a reduc-
tion of cognitive dysfunction, 18 (18.5%) an improvement of cognitive
abilities.
Conclusion: Drug resistance and AED polytherapy negatively affect
the extent of cognitive dysfunction.
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AFFECTIVE AND BEHAVIOURAL PROBLEMS IN PATIENTS
WITH EPILEPSY AND SLEEP DISORDERS
1E. Mojs, 1M. Glowacka, and 2M. Zarowski (Department of Health
Sciences University of Medical Sciences, Poznan, Poland, 2Department
of Dev Neurology, University of Medical Sciences, Poznan, Poland)
Purpose: Epilepsy is a factor influencing the sleep and it is defined
as an important risk factor in disturbing emotional functioning and be-
haviour in patients. Data analysis shows a two-way dependence between
sleep disorders and disturbances of behaviour and emotions. The aim
of the study was to state the prevalence of behavioural problems in pa-
tients with epilepsy and sleep disorders and its correlated disturbances
in emotional functioning.
Method: 40 patients aged 14–18 years with epilepsy participated in
the study. The median of age was 16.2 yrs with normal intelligence quo-
tient. The median time of epilepsy treatment was 2.4 yrs. The patients
underwent pharmacological treatment in monotherapy mode with con-
ventional antiepileptic drugs. The reference group was a group of healthy
teenagers with sleep disorders (40 pts) and a group of healthy persons
(40) without any disorders. They were matched according to age, sex
and level of intelligence. A questionnaire of sleep disorders and TRF
and YSR scales was used in the study.
Results: The data shows the prevalence of sleep disorders in the exam-
ined epilepsy group. The prevalence of behavioural problems in a group
of epilepsy patients is estimated as 50%; emotional disturbances, ag-
gression, lack of emotional control, impulsivity estimates are over 40%.
The average of these disorders grows in a group of epilepsy patients with
sleep disorders to 60% in behaviour and 50% of emotional disturbances
as well. There is an important correlation between sleep disturbances and
behavioural problems and emotions in the reference group. However, the
average appearance of the disorders in patients with sleep disturbances
50% and 40% are lower.
Conclusion: Sleep disorders and epilepsy correlate and are the reason
for important behavioural problems and emotional dysfunction including
aggression.
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SUBJECTIVE COMPLAINTS, NEUROPSYCHOLOGICAL
FUNCTIONING AND DEPRESSION IN PATIENTS WITH
EPILEPSY
1M. Liik, 2L. Vahter, 2K. Gross-Paju, 1A. ˜Oun, and 1S. Haldre
(1University of Tartu, Tartu, Estonia, 2West Tallinn Central Hospital,
Tallinn, Estonia)
Purpose: The aim of the study was to investigate subjective complaints
of epilepsy patients, to compare self-reported complaints with objective
neuropsychological functioning and to assess the influence of possible
depression on self-reported cognitive problems.
Method: Forty-eight patients with epilepsy were included to the study.
The patients had to have a definite diagnosis of epilepsy, have no other
neurological diseases, be aged between 18–65 years, and be native Es-
tonian speaking. Patients with symptomatic epilepsy and patients inca-
pable of filling out the questionnaires were not included in the study.
There were 31 female and 17 male patients, and the mean age of the
study sample was 35.3 (13.3) years. The majority of patients had fo-
cal epilepsy, mainly temporal lobe epilepsy. The subjective complaints
questionnaire, Beck Depression Inventory (BDI) and a series of neu-
ropsychological tests were carried out. Data was analysed using Pearson
correlation (r); the level of significance was set at 0.05.
Results: There were no statistically significant correlations between
the self-reported complaints assessed by the score of subjective com-
plaints questionnaire and objective neuropsychological test measures.
There were strong correlations between subjective complaints and sever-
ity of depression assessed by the score on BDI (r = 0.68, p < 0.05). BDI
score did not correlate to the results of neuropsychological tests.
Conclusion: The results indicate that subjective and objective cog-
nitive functioning are not necessarily associated, not only in case of
memory but in a wide range of different cognitive domains. Depression
is strongly related to the number of subjective problems reported by the
patients.
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SPEECH DEVELOPMENT AFTER REMOVAL OF FOCAL
CORTICAL DYSPLASIA
1M. Kaczorowska, 2A. Maryniak, 3M. Roszkowski, 1T. Kmiec, and 1S.
Jozwiak (1Department of Neurology and Epileptology, The Children’s
Memorial Health Institute, Warsaw, Poland, 2Department of Clinical
Psychology the Children’s Memorial Health Institute, Warsaw, Poland,
3Department of Neurosurgery, the Children’s Memorial Health Institute,
Warsaw, Poland)
Purpose: Cortical dysplasia is a known cause of epilepsy, of-
ten drug-resistant and associated with additional neurodevelopmental
Epilepsia, Vol. 47, S3, 2006
7TH EUROPEAN CONGRESS ON EPILEPTOLOGY 163
disturbances. Neurosurgical treatment has been proved to be effective in
certain cases of cortical dysplasias.
We would like to present a patient whose neurosurgical treatment
not only improved seizure control but also released suppressed speech
development.
Method: A 4-year-old boy was admitted to the neurosurgical depart-
ment for assessment and qualification for surgical treatment of drug
resistant epilepsy. He had had a history of GTCS and left-sided seizures
since 3rd month of age.
Results: On neurological examination left spastic hemiparesis was
found. Psychological evaluation revealed lateralisation to the right side
and intellectual functioning at the level of mild delay (Psyche-Cattel scale
II58). The boy understood even complex commands, however, word ex-
pression remained severely delayed (hardly spoke single words). On MR
examination a large focal cortical dysplasia in the right frontocentropari-
etal area was found. Interictal EEG revealed high amplitude theta activity
over the affected area, spreading to the left frontal area during seizures.
The boy was operated on at 5 years of age (right hemispherectomy), the
surgery complicated by massive bleeding, cardiac arrest and purulence
requiring partial cranium removal.
Conclusion: After the surgery the boy remains almost seizure free.
Additionally, shortly after the surgery an explosion of speech develop-
ment could be observed. He is 15 years old now and his intellectual
functioning remains at the level of mild to moderate delay with verbal
capabilities masking worse results of performance tests.
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NEUROCOGNITIVE FUNCTIONING OF PRESCHOOL CHIL-
DREN WITH “EPILEPSY ONLY”
1K. Rantanen, 1P. Nieminen, and 2,3K. Eriksson (1Department of Psy-
chology, University of Tampere, 2Department of Pediatrics, Tampere
University Hospital, 3Pediatric Research Centre, University of Tampere,
Finland)
Purpose: The aim was to investigate neurocognitive functioning of 3–
6 year old children with “epilepsy only,” i.e., seemingly age appropriate
neurological and social development. They were compared with matched
healthy controls, and the neurocognitive impairments of epilepsy only
children in this age range were described.
Method: The neurocognitive functioning of the children with
“epilepsy only” (n = 13) was compared with matched controls (n =
13). Wechslers Primary and Preschool Scale of Intelligence-Revised
(WPPSI-R) and the Developmental Neuropsychological Assessment
(NEPSY) were administered. Functions of attention, language, senso-
rimotor, visuospatial and memory were included in the assessment.
Results: Preliminary results indicated that verbal IQ and full scale
IQ differed significantly between the study and control groups, but no
differences between the two groups was found in performance IQ. VIQ
of children with “epilepsy only” also differed statistically significantly
from WPPSI-R normative data, but no differences between PIQ or FIQ
and normative data were found. Children with epilepsy had significant
difficulties in verbal short-term memory (p < .01) and attention (p <
.05).
Conclusion: Children with early onset (i.e., before or during preschool
age) “epilepsy only” seem to have difficulties, especially in short-term
memory and attention skills compared to healthy preschool children.
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EPILEPSY AND MEMORY: LEARNING PROCESSING AND
WORKING MEMORY COMPROMISE IN FRONTAL LOBE
EPILEPSY
I. Santana, R. Lemos, C. Cunha, and V. Barbosa (Department of Neu-
rology. Hospitais da Universidade de Coimbra, Portugal)
Purpose: It is conceptualised that temporal lobes are critical in
episodic memory while frontal regions are dominant in semantic and
working memory. Localised epilepsies are a good study model of focal
cognitive defects, and in a previous work we demonstrated that perfor-
mance in frontal lobe epilepsy (FLE) was poorer in the Trail Making
Test, which evaluates working memory processing. To further investi-
gate the intervention of frontal lobe in memory processes and to evaluate
the relevance of working memory compromise in epilepsy we compared
learning primacy and recency effects in frontal and mesial temporal lobe
epilepsy patients.
Method: We studied 15 patients with FLE and 51 patients with me-
dial temporal lobe epilepsy (mTLE). Primacy and recency effects were
evaluated in the first learning trial of California Verbal Learning Test
(CVLT). Primacy (recall of the first four items) indicates storage in a
more long-term memory while recency (recall of the last four items)
indicates storage in short-term memory (working memory).
Results: Mean and standard deviation (SD) of primacy effect score
(total) for the FLE and mTLE were 1.5 (SD0.8) and 2.1 (SD0.9) (p < .05).
For the same groups and parameters recency effects were 1.2 (SD0.7)
and 2.0 (SD1.2) (p < .05) indicating that FLE patients were poorer in
both effects. Meanwhile, the evaluation of the relative scores of the same
indexes demonstrated that only the recency effect was significant: FLE
20.9 ± 12.2 and mTLE 31.4 ± 18.7 (p < .05).
Conclusion: These results indicate that 1) frontal lobe has a cru-
cial role in encoding processes of memory, 2) in FLE patients, learning
defects seem to be conditioned mainly by a compromise of working
memory processing.
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PROSPECTIVE FIVE-YEAR FOLLOW-UP OF COGNITIVE
FUNCTION IN ADULTS WITH NEWLY DIAGNOSED FOCAL
EPILEPSY
1M. ¨Aikia¨, 1A. Kantanen, 1,3L. Jutila, 2E. Mervaala, and 1,3R. Ka¨lvia¨inen
(1Department of Neurology, Kuopio Epilepsy Center, Kuopio University
Hospital, Kuopio, Finland, 2Department of Clinical Neurophysiology,
Kuopio Epilepsy Center, Kuopio University Hospital, Kuopio, Finland,
3Department of Neuroscience and Neurology, University of Kuopio,
Kuopio, Finland)
Purpose: To evaluate cognitive performance of newly diagnosed adult
patients with focal epilepsy before antiepileptic drug treatment and after
five years of treatment.
Method: Altogether 122 patients had comprehensive neuropsycho-
logical evaluation at the time of the diagnosis and after five years of
follow-up. The test battery measured intellectual ability, verbal ability,
verbal memory, attention and flexible mental processing, and psychomo-
tor speed.
Results: At five-year evaluation cognitive performance was signifi-
cantly better in the majority of tests (15/22, 68%), losses were shown in
only one task (Letter Cancellation). Patients with complete seizure con-
trol showed improvement in 63% of the tests and patients with seizures
in 18%. When the patients were classified according to age at baseline,
younger patients (<55 yrs) had better scores at five years in 77% of the
tests and older patients (≥55 yrs) in 5% of the tests. In the group of older
patients 4 tests (18%) showed significant slowing of psychomotor speed.
Conclusion: Cognitive performance of adult patients with focal
epilepsy and complete seizure control remains the same or improves
due to practice effects during the five-year time period. Patients with
seizures show practice effects less consistently in repeated testing sug-
gesting mild adverse cognitive changes. Patients who are older at the
time of the diagnosis show a slowing of psychomotor speed, possibly
because of a combination of adverse cognitive changes and aging effects.
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NEUROPSYCHOLOGICAL FINDINGS IN PATIENTS WITH
HIPPOCAMPAL SCLEROSIS: INFLUENCE OF ASSOCIATED
MALFORMATION OF CORTICAL DEVELOPMENT IN TEM-
PORAL POLE
1P. Marusic, 2A. Javurkova, 1M. Tomasek, 1H. Krijtova, 3J. Zarubova,
and 1J. Zamecnik (1Charles University, 2nd Medical Faculty, Motol
Hospital, Prague, The Czech Republic, 2Hospital Kralovske Vinohrady,
Prague, The Czech Republic, 3Institute for Postgraduate Medical Train-
ing, Thomayer Hospital, Prague, The Czech Republic)
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Purpose: Presence of temporal pole pathology, mainly malformation
of cortical development (MCD) in addition to hippocampal sclerosis
(HS) might correspond to a different aetiology of mesial temporal lobe
epilepsy (MTLE). The aim was to compare neuropsychological findings
in groups of MTLE/HS patients with and without associated microscopic
MCD.
Method: Thirty-four patients with a diagnosis of refractory MTLE
were included–mean age 31.8 years, range 21–58. No overt pathology
except HS was revealed by MRI examination. Following anteromedial
temporal lobe resection hippocampus and part of temporal pole were
histopathologically examined. HS was confirmed in all cases and patho-
logical changes in the temporal pole classified. Patients with atypical
language lateralisation were excluded (n = 7). Of the remaining, 16
patients had left-sided surgery; on histopathological examination MCD
was present in 10 (left HS+) and was absent in 6 patients (left HS).
Right-sided surgery was performed in 11 patients; MCD was found in 3
(right HS+) and absent in 8 (right HS). Results of presurgical neuropsy-
chological assessment were compared in distinct groups of patients.
Results: In comparison with left-sided groups: HS patients scored
worse in general intellectual performance and verbal learning; HS+ pa-
tients showed lower performance in delayed verbal recall and had lower
scores on contralateral application in intracarotid metohexital procedure
(IMP). In comparison with groups with isolated HS (left vs right), right-
sided patients had lower performance in delayed visual recall and on
contralateral application in IMP; they also scored lower for depression
and neuroticism.
Conclusion: The neuropsychological finding in MTLE/HS patients
may be influenced by the presence of associated microscopic MCD in
the temporal pole.
p635
EPILEPTIC DEVELOPMENTAL RIGHT-HEMISPHERE
SYNDROME
1L. Zenkov, 2P. Konstantinov, 2I. Shiriayeva, 2V. Miasnikov, and 2E.
Sirazitdinova (1Kozhevnikov’s Clinic of Neurology of Moscow Med-
ical Academy, Moscow, Russia, 26-th Childrens Psychiatric Hospital,
Moscow, Russia)
Purpose: In a class of epileptic encephalopathies, neuropsychological
frontal lobe, agnosia, apraxia and speech dyspraxia epileptic syndromes
are described. We present an epileptic developmental right-hemisphere
syndrome, caused by continuous epileptiform discharges in right hemi-
sphere in a girl not having actual epileptic seizures.
Method: An 8-year-old girl with educational problems was submitted
for neurological, neuropsychological and EEG studies.
Results: In early childhood the girl had slight left leg pyramidal in-
sufficiency and one generalised epileptic seizure. At the present time she
presents dyslexia, marked slowness of performance, inability to join so-
cial group activities, marked deficit of orienting in nearest environment
and interpersonal and emotional problems. A neuropsychological study
reveals a decrease of visual memory, deficit of attention, dyscalculia,
and a visuospatial cognitive deficit. In EEG continuous slow-spike-and-
slow-wave discharges in right occipital, posterior temporal and parietal
area are present combining with intermittent bilateral slow-spike-and-
slow-wave discharges with larger amplitude right. Treatment with val-
proate suppressed epileptiform activity and improved cognitive func-
tions. So the girl presents all the criteria of nonverbal learning disability
developmental right-hemisphere syndrome described by V.Gross-Tsur
et al. (1995) in non epileptic disorders: 1) emotional and interpersonal dif-
ficulties, 2) paralinguistic communication problems, 3) impaired visuo-
spatial skills, 4) dyscalculia, 5) neurological signs on the left side of
the body. Close correspondence of the localisation of epileptiform dis-
charges to functional localisation of impaired function and effectiveness
of antiepileptic treatment suppressing epileptiform activity in EEG sup-
ports interpretation of the epileptic discharges as a casual factor of the
disorder.
Conclusion: Epileptic discharges in posterior regions of the right
hemisphere may cause epileptic encephalopathy presenting as non-
verbal learning disability developmental right-hemisphere syndrome.
Valproate treatment improves cognitive development in this case.
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IMPACT OF A SINGLE EPISODE OF STATUS EPILEPTI-
CUS ON THE COGNITIVE DEVELOPMENT OF YOUNG
CHILDREN
1H. Roy, 2F. Lussier, 1,2H. Sauerwein, 2A. Lortie, 2J. Lacroix, and 1,2M.
Lassonde (1Universite´ de Montre´al, Canada, 2Hoˆpital Sainte-Justine,
Montre´al, Canada)
Purpose: Status epilepticus (SE) is a serious, potentially life-
threatening neurological condition. Although better medical manage-
ment has improved the clinical outcome, the impact on cognitive de-
velopment remains uncertain. The aim of the present study was to as-
sess the effect of SE on cognitive functioning and self-regulation of
behaviour.
Method: In the first experiment, 20 infants (mean age: 12.9 mo.)
treated for a single episode of SE and a comparison group consisting of
9 children having experienced a first febrile seizure (FS) were assessed
on the Griffith Developmental Scales 4 months after the episode. The two
groups were further compared to 34 healthy age-matched controls. In the
second experiment, 12 SE children (mean age: 24.11 mo.), 7 FS children
and 12 healthy controls were submitted to 3 measures of self-regulation
of behaviour 9 months after the first and only seizure.
Results: The SE children scored significantly lower than the control
group in the social, language and performance domains of the Griffiths.
The FS children differed neither from the SE children nor the controls.
Compared to healthy subjects, the SE group also had significantly more
difficulties on 2 tasks assessing self-regulation of behaviour but they
were inferior to the CF group on only one of these tasks.
Conclusion: It seems that a single prolonged seizure suffices to inter-
fere with the normal development of higher mental functions. Although
the effect may be global, it is reasonable to assume that the functions
that are emerging at the time of impact are most vulnerable to such
interference.
p637
LEXICAL AMBIGUITY AND SEMANTIC KNOWLEDGE IN
EPILEPSY
1Z. Kouvatsou, 1R. Pita, 2V. Kimiskidis, 2D. Kazis, 2S. Papagiannopou-
los, and 2A. Kazis (1Psychology Department, Aristotle University of
Thessaloniki, Greece, 2III Deparment of Neurology, Aristotle Univer-
sity of Thessaloniki, Greece)
Purpose: A limited number of previous studies suggested that the
ability to interpret lexical ambiguity is impaired in patients with par-
tial and to a lesser extent generalised epilepsy. It is currently unclear
whether this deficit occurs as an isolated phenomenon or in the context
of a wider semantic deficit in the “mental lexicon” of these patients.
Accordingly, the present study was designed in order to investigate
lexical ambiguity in relation to the status of conceptual knowledge in
epilepsy.
Method: Thirty-five patients with partial (20) and generalised (15)
epilepsies and 39 matched controls entered the study. Two separate exper-
iments were designed. All subjects were given the Ambiguous-Words-
Test (AWT) and three subtests of the Psycholinguistic Assessments of
Language Processing in Aphasia (PALPA).
Results: Total scores for the AWT were found to differ significantly
between the patient and the control groups (one-way ANOVA, p < 0.05).
In patients with partial epilepsy, a significantly disturbed conceptual
knowledge was found which resulted in the production of semantic errors
during performance (Mann–Whitney Test, p < 0.05). In patients with
generalised epilepsy, a more restricted deficit was found that is difficulty
in processing specific kinds of words, particularly verbs and words with
low image ability (Mann–Whitney Test, p < 0.05).
Conclusion: The present results suggest that impairment in lexical
ambiguity interpretation occurs within the context of a wider semantic
deficit in epilepsy. In patients with generalised epilepsy this latter deficit
is characterised by difficulties in interpreting words with complex rep-
resentations in the “mental lexicon.” In contrast, patients with partial
epilepsy have difficulty in processing all kinds of administered lexical
items.
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SWITCHING FROM AN OLD TO A NEW ANTIEPILEPTIC
DRUG: ASSESSMENT OF SLEEP, QUALITY OF LIFE AND
NEUROPSYCHOLOGICAL EVALUATION
P. Tisei, M. Piccioli, A. De Carolis, M. Tasillo, M. Ferraldeschi, and C.
Buttinelli (University of Rome “La Sapienza,” II Faculty of Medicine,
Rome, Italy)
Purpose: To analyse the perception of quality of life (QoL), the
cognitive abilities and the quality of sleep in 9 patients switched
from carbamazepine (CBZ) to oxcarbazepine (OXC), and to evalu-
ate whether performances improved with the new antiepileptic drug
(AED).
Method: We investigated 9 patients (7 M, 2 F; 49.5 yrs ± SD 13.6) all
with complex partial seizures, 5 with secondary generalisation. The neu-
rological examination was normal. All were under treatment with CBZ,
2 of them were under polytherapy, 1 with lamotrigine, the other with phe-
nobarbital. All underwent, at baseline and 6 months after switching from
CBZ to OXC, the QOLIE-89 to assess the QoL; a neuropsychological
evaluation for intelligence, attention, memory, language and a nocturnal
sleep recording to evaluate the quality of their sleep. A comparison was
made between the data collected at baseline and that collected after 6
months.
Results: The patients under OXC had a better score in the QOLIE-
89 in: health perception, social function, energy/fatigue, social support,
overall QoL, medication effects. They reported better performances also
in neuropsychological evaluations such as verbal and nonverbal memory.
Concerning sleep we found no differences between the 2 groups.
Conclusion: The patients under treatment with OXC showed a sub-
jective improvement concerning QoL and an objective ameliorating with
regard to the neuropsychological evaluation. Seizure worry was not taken
into account from our population.
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SUBCLINICAL EPILEPTIFORM ABNORMALITIES AND
COGNITIVE FUNCTION: DATA FROM DEVELOPMENTAL
ATTENTION AND LEARNING DISORDERS
S. Zaimo lu and D. Tu¨rkdo an (Marmara University Neurological Sci-
ence Institute, Istanbul,Turkey)
Purpose: Recently, we have reported EEG abnormalities in 39% of 98
children diagnosed as Attention Deficit Hyperactivity Disorder (ADHD)
and/or Learning Disorder (LD) based on strict criteria (Zaimoglu S, Turk-
dogan D. When EEG is indicated in attention deficit and learning disor-
ders? Eur J Paed Neurol 2005;9:286). In the present research, we aimed
to study the effects of subclinical epileptiform potentials on cognitive
functions in children with ADHD and/or LD.
Method: Thirty-three children with subclinical epileptiform activity
and 33 children with normal EEG matched for age (mean: 8.8 ± 1.7), sex
(5 female), grade (mean: 3.5 ± 1.8) and diagnosis (2 with LD, 19 with
ADHD and 12 with LD+ADHD) were assessed neuropsychologically.
Epileptiform discharges were classified based on the following features:
frequency (rare-moderate: 54%, frequent: 46%), location (generalised:
17%, frontal: 37%, extrafrontal: 46%), relation with vigilance (sleep:
6%, sleep and wakefulness: 85%, wakefulness: 9%) and relation with
activation (9%).
Results: The presence of epileptic discharges was significantly as-
sociated with a worse performance on California Verbal Learning and
Memory Test. Higher free-recall intrusions (p = 0.015) and false-
positive responses on recognition (p = 0.006), and lower recognition
discriminability index (p = 0.017) were found in children with epilep-
tiform activity compared to children with normal EEG. On the other
hand, the percentage of primacy score was higher in children with
epileptiform activity (p = 0.034). The scores of Stroop Task, Wiscon-
sin Card Sorting Test, Category Naming and Visual Memory Span,
which assess attention and executive functions, were not significantly
different.
Conclusion: Our results clearly indicate that subclinical epileptiform
discharges have been associated with source memory deficit.
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SHORT-TERM MEMORY IN PATIENTS WITH FOCAL AND
PRIMARY GENERALISED EPILEPTIC SEIZURES
1T. Gagoshidze, 1A. Karaulashvili, 1T. Chincharauli, 1S. Mamukadze,
K. Philauri, T. Khajalia, G. Japaridze, L. Jijilashvili, S. Kasradze,
1O. Toidze, 1K. Geladze, 1D. Kvernadze, 1L. Sturua, 1L. Abesadze,
1I. Toidze, 1T. Tsintsadze, 1G. Lomidze, 1T. Tsuladze, and 1V. Ro-
manchenko (Epielpsy Prevention And Control Center, Tbilisi, Georgia)
Purpose: Short-term memory characteristics are known to be vulner-
able in epilepsy, although the findings are controversial in verbal and
non-verbal short-term memory.
The goal of the study was the investigation of disease variable effects
on the short-term verbal and visual memory indicators in patients with
epilepsy.
Method: One hundred forty-five consecutive patients (74 women, 71
men) were studied by Benton Visual Retention Test (BVRT) and short-
term verbal memory test (STVT); clinical and EEG parameters were
considered. One hundred six had focal seizures (35 without and 75 with
secondary generalisation), 25 had primary generalised seizures and 14
had unclassified epilepsy. Effects of localisation, type of seizures, side
of foci, sex, seizure frequency, and disease duration were taken into
account. Results were analysed by SPSS-12.
Results: Effects of seizure type were revealed in both tests; especially,
significantly lower total scores had patients with secondary generalised
seizures and with unclassified epilepsy (p < .001). In BVRT these groups
had higher distortion, metric and omission-adding errors (p < .001). Ef-
fect of localisation was significant only in BVRT; namely, misplacement
and metrical errors were significantly higher in temporooccipital lo-
calisation; reversion errors were significantly higher in fronto-temporal
localisation. In BVRT, when seizure type was controlled, women had
significantly lower total score (p < 0.02) and higher errors (omission,
reversion).
Conclusion: Significant effects of seizure type, localisation of foci,
gender were revealed in BVRT. Higher BVRT errors occurred in cases
where temporal epileptic activity was involved.
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CASE REPORT: STATUS EPILEPTICUS AND STURGE-WEBER
A. Arsovska and A. Popovski (Clinic of Neurology, Skopje, Macedonia)
Purpose: Sturge-Weber syndrome (SWS) is a neurocutaneous disor-
der with angiomas on the leptomeninges and the face. Neurologic symp-
toms include seizures, focal deficits, and developmental disorders. A case
of a 28-year-old male patient with SWS is reported. He was admitted
to hospital due to status epilepticus (SE) with generalised tonic–clonic
seizures (GTCS).
Method: The patient had epilepsy from his earliest childhood with rare
GTCS. They became more frequent in adolescence and were provoked
by infections. The patient regularly took antiepileptic therapy (AET).
One month before hospitalisation, he had 2–3 GTCS everyday. Then,
he suffered from acute gastroenterocolitis and cholecystopancreatitis.
AET was completely abolished and the patient had no AET for 5 days.
On the 5th day, he fell into SE with GTCS for a duration of 8 hours
and was admitted to hospital, where therapy for SE was applied. At
admission the patient was in a soporous condition, febrile, with port
wine stain hemangioma, glaucoma, mental retardation and spastic right
hemiparesis.
Results: Blood analysis: increased levels of leucocytes, fibrinogen,
alpha amylase, lipids; other parameters were normal. Brain CT: Massive
calcified arteriovenous malformation in the left parietal and occipital
lobe. EEG: slow wave background activity, with epileptogenic activity
consisting of single and multiple sharp waves. Chest x-ray: massive
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bilateral bronchopneumonia. During the stay in hospital, the first day,
the patient had another 2 GTCS in the afternoon. The next day he had
1 more GTCS. Afterwards, no seizures were registered until he was
released from hospital. Also, his physical condition improved, he became
conscious and afebrile. The patient was released after 2 weeks with
recommended AET.
Conclusion: Physicians should be very careful when treating patients
with SWS because episodes of SE can worsen the neurologic symptoms
secondary to metabolic disturbances.
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COELIAC DISEASE, EPILEPSY, CEREBRAL CALCIFICA-
TIONS: INCOMPLETE FORMS
P. Benna, R. Colonna, and E. Montalenti (Dipartimento Di Neuroscienze,
Universita` Di Torino, Torino, Italy)
Purpose: The syndrome “coeliac disease, epilepsy, occipital calcifi-
cations” (CEC) is a rare condition characterised by bilateral serpiginous
shaped occipital calcifications, epilepsy with onset in the first decade and
coeliac disease, often latent at the time of diagnosis. Seizure semiology
initially suggests a posterior onset, but may evolve towards an epilep-
tic encephalopathy, with progressive cognitive deterioration. EEGs may
show occipital spike and wave discharges stopped by eyes opening. In-
complete forms of CEC syndrome, because of clinically silent celiac
disease or absence of epilepsy, are described. We describe two case re-
ports of patients with incomplete CEC.
Method: The two cases have been extracted from a 2500 patient
database of our Centre. The patients had been followed with periodic
clinical and instrumental check.
Results: Two male adult patients suffered from incomplete CEC syn-
drome, both presenting typical clinical and EEG features: seizure onset
in the first decade of life with occipital semiology, good response to
therapy followed by worsening of seizure frequency, drug resistance and
evolution to an epileptic encephalopathy. EEG of both patients showed
sub-continuous diffuse paroxysmal anomalies with a posterior preva-
lence and fixation-off sensitivity. One of the two patients had no occip-
ital calcification; the other did not show clinical or laboratory findings
of celiac disease but underwent in infancy radio and chemotherapy for
acute lymphatic leukaemia.
Conclusion: The CEC syndrome can appear as an incomplete form
in which only two elements of the triad are evident; particularly, in
the presence of typical epileptic syndrome and cerebral occipital cal-
cifications, the possibility of other uncommon aetiologies must be
considered.
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INTERICTAL HAIR PHENOMENA IN EPILEPSY
A. Boika (5th City Clinic, Minsk, Belarus)
Purpose: To study interictal changes of hair patterns on the body of
patients with epilepsy.
Method: Face, neck, torso and extremities of 120 patients with dif-
ferent types of epilepsy were examined twice by us for hair patterns
to exclude casual results. Hair patterns and their localisation, described
by Straubesand J (Sobotta atlas of human anatomy. 11th English ed.
Munich: Urban & Schwarzenberg 1989; Vol.1.P.382-383), serve as a
standard. Changes were recorded by digital camera.
Results: Seventy-three patients had changes. They were: (a) defor-
mation of normal patterns (30 cases); (b) additional pattern on the body
(36 cases); (c) combined–deformation and additional patterns (7 cases).
Conclusion: Autonomic epileptic phenomena may not characterise
only piloerection as example of ictal changes of hair (Scoppetta C.
et al. Funct Neurol 1989;4:283-286) but also deformation and additional
hair patterns on the body of patients with epilepsy which are examples
of interictal changes of hair.
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TONIC ABSENCES: 3 CASE REPORTS
1A. Pasnicu, 2D. Taussig, 2A. Michel, 1K. Beauvais, and 1A. Biraben
(1Neurology Department, CHU Rennes, France, 2Electrophysiology
Department, CHU Rennes, France)
Purpose: To characterise and discuss an unusual type of seizure, the
tonic absence, in the evolution of drug-resistant idiopathic generalised
epilepsies (IGE).
Method: We undertook a retrospective case study of 3 epilepsy pa-
tients with absences and rare tonic–clonic seizures since the age of 3 to 9
years. The patients are now 45 to 59 years old. We reviewed the clinical
and video-electroencephalographic (EEG) data from the beginning of
the disease.
Results: Typical absences were recorded in all 3 patients during child-
hood. They all had absence status epilepticus as well. After several years
of inappropriate treatment, and as the patients reached adult age, two
new types of seizures were recorded recurrently on video-EEG: atypi-
cal absences and tonic absences. The latter were previously described
in symptomatic generalised epilepsies (SGE) and have a particular EEG
pattern with fast generalised discharges of spikes (10-20 Hz, 0.5 to 7
s) followed or preceded by slow and irregular spike and polyspike and
wave complexes. There is no considerable clinical tonic component.
They persist with an adapted drug regimen. The patients still have many
features of IGE: normal background activity; unremarkable history; nor-
mal psychomotor childhood development, neurological examination and
socio-professional insertion; unremarkable cerebral magnetic resonance
imagery.
Conclusion: The tonic absences were described in SGE. However
they can occur in apparently typical IGE on inappropriate treatment
and maybe because of an individual predisposition. A tonic generalised
discharge of spikes is not necessarily synonymous of a SGE but it is likely
a drug-resistance marker. These data suggest an SGE-IGE continuum,
with intermediate evolution and prognosis.
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HOT WATER EPILEPSY: CLINICAL AND ELECTROEN-
CEPHALOGRAPHIC FEATURES
D. Yalc¸y´n, H. Toydemir, ¨U. Anadol, and H. Forta (1 i li Etfal Education
Hospital Neurology Clinic, 19 Mayy´s Mahallesi, i li, 34360, ´Ystanbul,
Turkey)
Purpose: Our purpose is to analyse the clinical and electroencephalo-
graphic findings of 25 patients with hot water epilepsy.
Method: The personal and family history, neurological state, age of
onset and types of seizures, provoking factors, bathing habits, EEGs and
neuroimages were all reviewed. The follow-up period for 18 patients
with regular visits every 3 months and many EEG recordings ranged
between 1–6 years. Seven patients could not be reached at the address
or phone number noted at their first visit.
Results: The age of onset of seizure ranged from 6 months to 37 years.
Twenty patients had complex partial seizures. Eight patients had sponta-
neous seizures as well, 1 of them was typical for idiopathic photosensitive
occipital lobe epilepsy. One patient described an episode interpreted as
nonconvulsive status. In our study group, pouring the water over the
head and the temperature of the water were the most common trigger-
ing factors. A special kind of soap and entry of water into the mouth
were determined as unusual triggering factors. Interictal EEGs revealed
epileptogenic abnormalities located over the temporal regions in 9 pa-
tients. Seventeen patients had neuroimaging mostly cranial magnetic
resonance imaging. One had right mesial temporal sclerosis and 1 had
cortical atrophy, others had normal findings. Sixteen patients received
antiepileptic drugs, mainly carbamazepine, and stayed seizure free.
Conclusion: The high rate of epileptogenic abnormalities localised in
the temporal region and the complex partial seizures observed in most of
our patients indicate the considerable role of temporal lobe in hot water
epilepsy.
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WHEN VALPROATE DOES NOT CONTROL CHILDHOOD AB-
SENCE EPILEPSY
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O. Tarta-Arsene, N. Butoianu, D. Craiu, and S. Magureanu (Departa-
ment of Pediatric Neurology, Clinical Hospital “Al Obregia,” Bucharest,
Romania)
Purpose: In our department, valproate is the first line treatment for
childhood absence epilepsy. We noticed some patients respond only
partially and need combination or replacement for complete control of
seizures. The aim of this study is to find predictive factors for this ther-
apeutic response.
Method: We retrospectively evaluated all case records of patients di-
agnosed in our department with childhood absence epilepsy between
January 2002 and December 2005. Considering responses to valproate,
patients were classified as responsive if seizures were controlled com-
pletely on monotherapy, and nonresponsive if replacement or combined
therapy was needed. The differences and common features between the
two forms were outlined.
Results: We retrospectively evaluated all case records of patients di-
agnosed in our department with childhood absence epilepsy between
January 2002 and December 2005. Considering responses to valproate,
patients were classified as responsive if the seizures were controlled com-
pletely on monotherapy, and nonresponsive if replacement or combined
therapy was needed. The differences and common features between the
two forms were outlined.
Conclusion: It is known that absences are very sensitive to valproate,
and monotherapy controls childhood absence epilepsy in 60% of patients.
A clinical difference has been found on the age of debut, which was for a
nonresponsive form, and EEG differences on the appearance of specific
complexes predominantly in hyperventilation for nonresponsive patients.
To confirm those hypotheses, larger comparative studies are necessary.
p647
CLINICAL EXPERIENCE WITH ZONISAMID (ZNS) IN PA-
TIENTS WITH SEVERE DRUG RESISTANT EPILEPSIES
H. Meencke, C. Dehnike, M. Merschhemke, and D. Meincken-Ja¨ggi
(Epilepsy Center Berlin Brandenburg at Ev. Krankenhaus Ko¨nigin Elis-
abeth Herzberge Herzberstr. 79; 10365 Berlin, Germany)
Purpose: Zonisamid (ZNS) is a well established antiepileptic drug in
the treatment of focal and generalised epilepsies. This drug was recently
licensed in Germany in June 2005. We now report our first clinical expe-
rience with the drug in the treatment of patients with severe, so far drug
resistant, epilepsies.
Method: This is a retrospective observational study. The data was
collected from patient records and diaries. We report on 40 patients with
a median observational period of 10 weeks. The median age was 36.8
years. The median duration of epilepsy was 20.5 years. The number of
previous prescribed antiepileptic drugs was 8. The median steady state
dosage of the drug was 300 mg.
Results: 35% of the patients responded with 8% seizure free. 22%
patients suffered from adverse events with predominantly widespread
unspecific somatic disturbances. Only 3 of the patients suffered from
sedation.
Conclusion: We report on a group of patients with severe highly
drug resistant epilepsies. Nevertheless, we have excellent efficacy in this
group of patients. We have to keep in mind that the average number
of previously prescribed antiepileptic drugs was 8. Also this difficult to
treat group has high tolerability to the drug. These preliminary results
indicate that ZNS is a helpful treatment option in this difficult to treat
patient group.
p648
FOUR YEARS OF REMISSION IN THE FIRST UNVERRICHT-
LUNDBORG CASE IN THE BALKAN REGION
1M. Ercegovac, 2M. Stevanoviæ, 1L. Beslaæ Bumbasˇireviæ, 1D.
Jovanoviæ, 2S. Romac, and 3D. Ercegovac (1Institute of Neurology,
2Faculty of Biology, University of Belgrade, 3Center for Epilepsy and
Migraine, Belgrade, Serbia and Montenegro)
Purpose: Progressive myoclonic epilepsies (PME) are a heteroge-
neous group of rare inherited disorders. Unverricht-Lundborg disease
(ULD) is the most common, prevalent around the Baltic Sea and in the
western Mediterranean region.
Method: A 30-year-old male patient had the first symptoms of PME at
the age of 15, with stimulus sensitive myoclonus and slowly progressive
cerebella symptoms, rare GTC and low concentration. He was treated
with mono- and polytherapy (carbamazepine, phenytoin, phenobarbital,
valproic acid), inadequately responding to any. At age 26 he was hos-
pitalised with myoclonic epileptic status. He responded to new therapy
(carbamazepine excluded, dosage of valproic acid increased, piracetam
slowly introduced) and after two months became self-functional. Dur-
ing hospitalisation all laboratory tests were normal, evoked potentials
showed giant SEP, with normal EEG, CT and MRI findings. Neuropsy-
chological examination showed minor reduction of attention, without
cognitive deterioration. Molecular diagnostics (PCR based Southern blot
hybridisation) confirmed ULD, which is the first case of this form of PME
in this region.
Results: Today, our patient is age 30, has rare stimulus sensitive my-
oclonic seizures after emotional stress, but is still self-functional after
4 years. Improvement in general condition and life expectancy in ULD
patients nowadays is due to the increase in social contacts, intensive
rehabilitation, treatment of infections, and avoidance of phenytoin, car-
bamazepine and barbiturates in medication, in contrast to 1960s and early
1970s when the mean survival period was about 14 years, the patients
were often confined to bed and died of infections or other incidental
causes.
Conclusion: This case report is followed by video sequences at the
time of hospitalisation and after four years of remission.
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IDIOPATHIC GENERALISED EPILEPSY: NONPHARMACO-
LOGICAL FACTORS INFLUENCE ON JUVENILE MY-
OCLONIC EPILEPSY
T. Mazurczak, I. Terczynska, D. Antczak-Marach, A. Jeziorek, K.
Szymanska, J. Tryfon, D. Hoffman-Zacharska, and E. Szczepanik (Clinic
of Neurology, Epileptology and Sleep Disorders in Children and Ado-
lescents, Institute of Mother and Child, Warsaw, Poland)
Purpose: Although antiepileptic drug therapy offers complete seizure
control for the majority of patients with juvenile myoclonic epilepsy
(JME), relapses occur in about 10–50% of patients due to the fact that
nonpharmacological factors have a great impact on the progression of
the condition. The purpose of this survey was to determine the frequency
of relapses in patients with juvenile myoclonic epilepsy (JME) and to
determine causes of treatment failure.
Method: The records of clinical and EEG data from 36 patients (31
female and 4 male) with JME, treated between 1990–2004 with follow-up
lasting at least one year, were studied retrospectively. Clinical picture,
seizure types, relapse rates, seizure precipitating factors were analysed.
Results: In the study group 14 patients had myoclonic and generalised
tonic-clonic seizures (GTCS), 5 patients had absence and myoclonic
seizures, 16 patients had three types of seizures and one patient had only
myoclonic seizures. A photoparoxysmal response in EEG tracing was
present in 28 of 32 patients. All but 1 patient received valproic acid (VPA)
in the average dosage of 1000±380 mg (as monotherapy or in bitherapy).
The average period of treatment was 5 years (range 1–5). During follow-
up, 12 of 36 patients had relapses of GTCS. Among them in 4 seizure-
free patients >3 years dosages of VPA were reduced by doctors to 300–
400 mg per day, but this resulted in relapses of GTCS (group of “relapses
due to doctor’s fault”).The remaining 8 patients relapsed because of
non-compliance (group of “relapses due to patient’s fault”). Relapses
were precipitated by sleep deprivation (6 patients), failure to keep to
drug dosing regimen (3), flashing light stimuli (3) and fatigue (1). Three
patents had more than one seizure.
Conclusion: The important cause of relapses in patients with JME is
poor drug compliance with abnormal life style, so education of a treated
patient about nonpharmacological factors as seizure precipitants should
be considered.
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EYELID MYOCLONIA WITH ABSENCES (JEAVON’S
SYNDROME)
D. Domanska-Pakiela, M. Bachanski, J. Kasprzyk-Obara, D.
Chmielewski, and S. Jozwiak (The Childrens’ Memorial Health Institute,
Warsaw, Poland)
Purpose: This syndrome is a form of epilepsy manifested by my-
oclonic jerks of the eyelids and brief absences. Most authors support the
view that it is an idiopathic epileptic syndrome, genetically determined,
age related and affects normal children with a female preponderance.
Method: An 11-year-old girl was admitted to our hospital because of
episodes of squinting and upward deviation of the eyes, which occurred
many times a day. She was born as a third child; pregnancy and deliv-
ery were without complications. She attended elementary school, with
average results due to dyslexia, dysgraphia.
Results: Routine awake EEG showed generalised discharges of mul-
tiple spikes and polyspikes–slow waves 3-6HZ lasting 0.5-1 sek with
preponderance of the left side. Therapy with valproic acid was launched,
with fast cessation of seizures. Control EEG after 10 months of therapy
revealed many generalised discharges as above, active for closing eyes
and hyperventilation. The patient and her mother continued to deny any
epileptic episodes. Full Video EEG (awake, sleep, awaking) was per-
formed to confirm or exclude any epileptic presentations and showed
many eyelid myoclonias and short absences correlating well with gener-
alised discharges of polyspikes-slow wave complexes 2-3-4HZ, lasting
0.5–several sek, mostly observed after waking.
Conclusion: Video EEG figured out to be the only diagnostic tool in
recognising full symptomatic Jeavon’s syndrome.
p651
CLINICAL REVIEW OF PATIENTS WITH UNVERRICT-
LUNDBORG DISEASE IN SLOVENIA
1M. Perkovic Benedik, 1Z. Rener Primec, 2T. Zgur, and 1I.
Ravnik (1Children’s Hospital, Clinical Centre, Ljubljana, Slovenia,
2Neurological Clinic, Clinical Centre, Ljubljana, Slovenia)
Purpose: To assess the epidemiology of Unverricht-Lundborg disease
(ULD) in Slovenia, and to review its clinical evolution.
Method: Phone questionnaire by the Centre for Epilepsy–Children
and Adolescents (CfECA)–the only one in the country, addressed to re-
gional neurological/neuropaediatric wards to exclude patients with pro-
gressive myoclonus epilepsy (PME) that might have ULD. Retrospective
review of medical records for the last 25 years to study the clinical evo-
lution of the disease and its management.
Results: A similar study 20 years ago detected no ULD patients in
addition to patient 1. Between the years 1980 and 2005 2 more patients
were diagnosed with ULD at the CfECA. Rare older incompletely di-
agnosed patients with PME having not been notified to the CfECA may
still be reported in future. Patient 1 is now 40 years old; diagnosis of
ULD was made on clinical and EEG grounds. Valproate enabled the
wheel-chair bound adolescent to independently walk for 3 more years.
Patient 2 and patient 3 are siblings, 21 and 16 years old; clinical suspi-
cion of the diagnosis in both, was genetically confirmed in one. Beside
a typical clinical picture of ULD, all patients developed arterial hyper-
tension. Suspicion of extrapyramidal signs was not confirmed in patient
2, cognitive deterioration was mild in all, psychiatric disorder severe in
patient 3.
Conclusion: In Slovenia (2 million) 3 patients have ULD. Clinical
course has been typical; open questions remain. How to reach diagnosis
earlier? Is arterial hypertension coincidental or part of the syndrome?
Best psychiatric management?
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VERBAL ABILITIES IN PATIENTS WITH NOONAN
SYNDROME
2S. Golubovic, and 1N. Prica (1The Clinics For Cerebral Parallysis
and Developmental Neurology In Belgrade, Serbia and Montenegro,
2Faculty of Special Education and Rehabilitation University of Belgrade,
Serbia and Montenegro)
Purpose: Noonan syndrome was described for the first time in 1963,
as the pseudo Turner’s syndrome, XX or XY Turner phenotype with the
normal cariotype XY. It falls into genopathies and the last time it was
described by us (The Clinics for Cerebral Paralysis and Developmental
Neurology in Belgrade) in 1999, 2001 and 2002.
Method: A boy, born in 2002, with the normal male cariotype 46, XY,
weighing 3700 gr., body length 52 cm, chest circumference 36 cm, AS
9; mother 24, father 33 years old. After birth, he had a prolonged physi-
ological jaundice, slept long, woke up infrequently in comparison with
other babies, did not open one eye, occasionally as if he was suffocating,
stopped breathing and sucked weakly. Hydrocephalus, strabismus, epi-
canthus, a minor ptosis of the left eyelid, antimongoloid position of the
eyes, IQ 75-80 (RPM), dysphagia, compromising logomotorics, drawn
in tongue, tongue dyspraxia, high palate, head big and wide in the frontal
part EEG, the left findings temporally irritable (sparse single sharp waves
on the left side, with partial phase changes during sleeping), due to pos-
sible EPI fits, the therapy was introduced. The hearing, both peripheral
and central, was in order. He had poor vision with ptosis of the eyelids.
Results: The logopedic findings (speech and language pathologist):
there was not the prelingual period at the projected age, as with children
with typical development. When he utters, he speaks loudly, laughs and
cries loudly, while playing, he pronounces onomatopoeic sounds on his
own initiative. He grimaces on his own initiative or as a belated reac-
tion. He is inclined to imitate gestures of the mimic musculature in front
of a mirror, together with the model and the logopedist’s stimulation.
We stimulate the uttering by following the phonological developmen-
tal scale; the vowel-plosive, sound games and the frequent occurrence
of sound clusters or typical words or syllables typical of commencing
speech.
Conclusion: After three months logopedic treatment, the patient
names an idea with a single sound, a sign of approval, while more familiar
ideas with a single sound, a sing of approval, while more familiar ideas
with an onomatopoeia or with a part of the word. He understands the
words MAMA (mummy), BABA (granny), and connects them with the
idea; occasionally he pronounces them as whole words and in syllables
on request.
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EPILEPTIC MIGRAINE IN A RASMUSSEN’S ENCEPHALITIS
PATIENT
L. Fusco, N. Specchio, and F. Vigevano (Neuroscience Department, Di-
vision of Neurology, Bambino Gesu` Children’s Hospital, Italy)
Purpose: To report the documentation of epileptic migraine attacks
in a patient with Rasmussen encephalitis developed some years after a
hemispherotomy.
Method: A 14-year-old boy had a diagnosis of right side Rasmussen
encephalitis at the age of 6 and a half years, one month after the onset
of seizure. The illness had a typical and quick course, and the child was
operated on one year later. In the following two years he had a striking
recovery, except for the onset of sporadic migraine attacks of brief du-
ration. After discontinuation of therapy, migraine attacks increased in
frequency and duration and the child was readmitted for further study.
Results: A video/EEG recording was performed during a migraine
attack and showed subcontinuous ictal discharges over the disconnected
hemisphere, mainly over the central regions. The administration of
10 mg of diazepam i.v. caused the disappearance of epileptic discharges
and simultaneously the disappearance of migraine. MR image failed to
show any surgery complication and a video/EEG performed out of mi-
graine returned to basal value. Antiepileptic and analgesic drugs were
ineffective, while high dosages of corticosteroids were able to stop EEG
seizures and migraine.
Conclusion: The present case illustrates a late and very rare complica-
tion of Rasmussen encephalitis, and demonstrates how migraine attacks
can be not only triggered by epileptic discharges but also remitted with
their remission.
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COMPARATIVE EVOLUTION OF THE CLASSIFICATIONS OF
EPILEPSIES AND HEADACHES
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J. Gomez Alonso, B. Giraldez, M. Rodriguez, and P. Bellas (Servicio de
Neurologia, Hospital Universitario Xeral-Cies. Vigo, Spain)
Purpose: To compare the results of the efforts made by the Inter-
national Headache Society (IHS) and the International League Against
Epilepsy (ILAE) to improve the Classifications of Headaches and Epilep-
sies.
Method: Comparative clinical applicability of the classifications
launched by the IHS and the ILAE.
Results: Both the 1988-IHS and the 1989-ILAE Classifications had
worldwide acceptance. The 1988 Classification of Headaches is a 90-
page document that includes definitions and descriptions of the disor-
ders, operational diagnostic criteria, and rules to classify difficult cases,
as well as 373 selected references. The 1989 Classification of Epilepsies
appeared in an 11-page paper which included 6 references, and provided
a brief description of the syndromes, although lacked operational diag-
nostic criteria. Moreover, some fundamental criteria were imprecisely
defined, and irregularly used along with the classification. Finally, some
proposed subgroups were not mutually exclusive. After meticulous work
by several subcommittees and open discussions in international meet-
ings, the IHS published an improved version of the Classification of
Headaches in 2004. Meanwhile, the ILAE has not been able to revise the
imperfect and outdated 1989 Classification. In 2001, an ILAE document
(8 pages, 5 references) considered that the 1989 Classification could not
be replaced by a similar one, and proposed a diagnostic scheme which
would permit a variety of approaches to classification.
Conclusion: The IHS has been more successful than the ILAE in de-
veloping an updated and useful classification in their respective fields.
The different methods used by both Societies might have had some in-
fluence on the divergent results.
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EFFECTS OF SUBCLINICAL EEG DISCHARGES ON BE-
HAVIOUR IN CHILDREN
N. Ismail and Y. Yy´lmaz (Marmara University, Istanbul, Turkey)
Purpose: To investigate the effects of subclinical EEG discharges on
behaviour in children.
Method: Children under 10 years of age attending the outpatient clinic
with behavioural problems whose EEG examination showed epilepti-
form discharges were included in the study. Patients with neurological,
neuroradiological findings, epileptic seizures, medical or familial prob-
lems, and mental retardation which might effect the behaviour pattern
were excluded. Behaviour was assessed with the Conners rating scales
for parents and teachers. Valproic acid 20 mg/kg/day was started. EEG
examination and Conners rating scales for parents and teachers were
repeated again after 4 weeks and the results compared.
Results: Preliminary results of 6 patients assessed are included and the
study is still continuing. Those patients started on valproic acid showed
a significant improvement in behaviour on the Conners rating scales.
Conclusion: Our data suggests that suppressing subclinical discharges
can improve behaviour in children. With an increase in the number of
patients assessed at the end of the study a more detailed result will be
discussed.
Wednesday July 5, 2006
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CHANGING INCIDENCE OF EPILEPSY IN FINLAND
1M. Sillanpa¨a¨, 2R. Ka¨lvia¨inen, 3T. Klaukka, 4H. Helenius, and 5S.
Shinnar (1Child Neurology And Public Health, University of Turku,
Turku, Finland, 2Neurology, Kuopio University Hospital, Kuopio, Fin-
land, 3Social Insurance Institution, Helsinki, Finland, 4Biostatistics, Uni-
versity of Turku, Turku, Finland, 5Neurology, Montefiore Medical Cen-
ter, Bronx, USA)
Purpose: To study possible changes in the incidence of epilepsy in
Finland.
Method: Secular trends in the incidence of epilepsy are poorly known.
All residents with epilepsy have been granted full-refundable antiepilep-
tic drugs since 1967, and the patients are centrally registered by the Social
Insurance Institution. We analysed these data from the years 1986–2002.
Results: There was a marked decreasing trend in the incidence of
epilepsy, from 72 in 1986 to 53/100,000 in 2002. The incidence was
throughout all age groups, and was higher in men than in women during
the whole observation period. The incidence significantly decreased in
children (0.77; 0.71–0.84, p < .0001) and middle-aged (0.83; 0.77–
0.89, p < .0001), but increased in the elderly (1.18; 1.10-1.26, p <
.0001). In children, the decrease was least in the age group 0–4 years,
more considerable in 5–9 year olds and most marked in 10–14 year olds.
Among the elderly, the trend was an increasing one in all subgroups. The
trend varied nonsignificantly between the five-year age groups in men,
but invariably increased from the age of 70 years in women.
Conclusion: The incidence of epilepsy has consistently decreased in
the 1980s and 1990s in Finland. The decrease is in children and adults
of working age, while a distinct increase in the elderly has taken place.
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CORTICOSTEROID EFFICACY IN EPILEPTIC SYNDROMES
WITH CONTINUOUS SPIKES AND WAVES DURING SLOW
SLEEP
P. Van Bogaert, A. Aeby, D. Verheulpen, N. Poznanski, and M. Buzatu
(ULB-Hoˆpital Erasme, Brussels, Belgium)
Purpose: To report our experience in treating patients with continuous
spikes and waves during slow sleep (CSWS) with corticosteroids.
Method: Children who received corticosteroid therapy for be-
havioural and/or cognitive deterioration associated with the CSWS pat-
tern were retrospectively reviewed. In all cases, awake and sleep EEG
records, clinical examinations and neuropsychological assessments were
available before and after corticosteroid therapy. Eleven patients received
hydrocortisone, 5 mg/kg/day for 1 month, and the other 2 patients re-
ceived prednisolone, 2 mg/kg/day for 1 month. In children with clinical
and EEG improvement, the treatment was continued at a low dose until
21 months.
Results: Thirteen patients, aged 3–12 years, were included. Eleven
cases were cryptogenic and 2 cases were related to perisylvian polymi-
crogyria. All but 1 patient (a child with Landau-Kleffner syndrome) were
refractory. The antiepileptic drugs (AEDs) which had failed were val-
proate (12 cases), clobazam (12 cases), lamotrigine (9 cases), topiramate
(7 cases), and levetiracetam (3 cases). Ten patients (77%), including the
symptomatic cases, showed disappearance of the CSWS pattern with
normal EEG in 5 cases. This evolution was associated with cognitive
and behavioural improvement. Only in 1 case was the treatment stopped
because of side effects. In 3 patients, corticosteroid discontinuation was
followed by relapse of the CSWS pattern.
Conclusion: This study suggests that children with CSWS show better
response to corticosteroid therapy than to classical AEDs.
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COMPARING THE EFFECT OF INTERMITTENT CLON-
AZEPAM WITH DIAZEPAM IN PROPHYLAXY OF FEBRILE
CONVULSIONS IN CHILDREN
T. Mahmoudian and S. Bajoghli (1Pediatric Neurology Department,
Medical University of Isfahan, Iran)
Purpose: Febrile convulsion (FC) is one of the most common neuro-
logical disorders in children. There are many different studies about FC
treatment and many different drugs have been used for it, but since there
is not any proved document about the prophylactic effect of clonazepam
for FC, this study wants to compare the effect of intermittent clonazepam
with diazepam in prophylaxy of FC.
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Method: This is an experimental study and was done with two groups
using a randomised trial control method. For the first group, clonazepam
0.05 mg/kg/day was administered during the fever period and for the
second group diazepam 1 mg/kg/day was administered. The occurrence
of FC was compared between the two groups.
Results: In our study there was no significant difference in age, sex,
type of seizure and family history of FC between the two groups. Thus
each group had a similar risk for recurrence of FC. In the first group
(clonazepam) 30 patients were selected and 6 patients were exited from
the group. 162 febrile episodes occurred in 24 patients and none of
them had a convulsion during episodes of fever (this means clonazepam
was 100% effective). In the second group (diazepam) 30 patients were
selected and 7 patients were exited from the group. 100 febrile episodes
occurred in 23 patients in this group and 2 cases had a convulsion with
fever with consumption of diazepam (this means that diazepam was
98% effective). Statistically the p value between the two groups was
0.14 which means there is a difference between the two groups but this
difference isn’t meaningful statistically.
Conclusion: An important result of this study is that clonazepam is as
effective as diazepam for FC prophylaxis. In our study clonazepam was
100% effective. There are mild complications such as ataxia, restlessness
and somnolence but these complications were not severe enough to dis-
continue the drug. With respect to similar effectiveness of clonazepam
and diazepam in our study and absence of significant complications,
this study is an introduction for more extensive studies of the effect of
clonazepam on FC prophylaxis.
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LEVETIRACETAM INFLUENCE ON CONTINUOUS SPIKES
AND WAVES DURING SLOW SLEEP
M. Nikanorova and J. Alving (Danish Epilepsy Centre, Dianalund, Den-
mark)
Purpose: To assess levetiracetam (LEV) effect on continuous spikes
and waves during slow sleep (CSWS).
Method: 10 children (6 boys, 4 girls), aged between 6 and 14 years,
with CSWS have been treated with LEV for 3–6 months. In all cases
CSWS was refractory to conventional AEDs and corticosteroids. LEV
was used as an add-on drug at the doses 25–45 mg/kg/day. LEV efficacy
was assessed with 24-hour EEG monitoring after 2, 4 and 6 months of
therapy initiation.
Results: After 2 months of LEV treatment awake EEG became normal
in 3 patients, in 2 a marked decrease of multifocal activity was observed;
CSWS disappeared in 7 children, one case showed moderate reduction
of CSWS (from 85 to 53% during whole night recording), in 2 cases
there was no effect. In those 7 responders CSWS did not recur after 6
months of LEV therapy. LEV was well tolerated by all patients.
Conclusion: LEV can be considered as an additional therapeutic op-
tion in children with CSWS, especially in cases refractory to conventional
antiepileptic drugs and corticosteroids.
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SYMPTOMATIC EPILEPSY IN SHAKEN-IMPACT SYNDROME
1C. Mikhail and 2M. Olga (1Russian Medical Academy of Postgraduate
Education, Russia, 2Russian Medical Academy of Postgraduate Educa-
tion, Russia)
Purpose: To evaluate the influence of different treatment methods on
Shaken-Impact Syndrome (SIS) outcome.
Method: Twenty-one patients with SIS, aged 2 to 9 months, were ob-
served and treated in the acute and residual period. The following clinical
investigations were performed on all patients: fundoscopy, roentgenog-
raphy, lumbar puncture, CT, EEG.
Results: The diagnosis of SIS was established in the acute period
according to the criteria of Pediatric Community on Child Abuse and
Neglect (American Academy). Severity of clinical state, neurological
symptoms and CT data (zones of brain ischemia) in the acute phase were
comparable in all patients. Symptomatic epilepsy developed in 11 cases.
All patients were divided into 3 groups, according to the therapeutic
approach in the acute phase and outcome. In groups 1 and 2 manage-
ment in the acute period corresponded to conventional recommendations
(symptomatic in general). In group 1 (8 patients) symptomatic epilepsy
developed in 6 cases (none drug-controlled), motor deficit remained se-
vere in 8 and development was ceased also in 8 cases (outcome was poor
in all cases). In group 2 (7 patients) symptomatic epilepsy developed in
5 cases (drug controlled in 3), motor deficit remained significant in 5 and
development delay was expressed in all. None had even a satisfactory
outcome. In group 3 (6 patients) our original treatment was conducted
immediately after registration of retinal haemorrhages. None of the pa-
tients developed symptomatic epilepsy, neither motor nor sensory deficit;
development was not delayed in anyone (good outcome).
Conclusion: Outcome in SIS (symptomatic epilepsy, motor and sen-
sory deficit development, mental retardation) depends upon management
in the acute stage.
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CHILDHOOD AND JUVENILE ABSENCE EPILEPSY
O. Milovanova (Russian Medical Academy of Postgraduate Education,
Russia)
Purpose: To analyse types and dynamics of seizures in childhood and
juvenile absence epilepsy. Anamnesis, clinical-instrumental investiga-
tion findings were taken into account.
Method: 16 patients with childhood absence epilepsy, aged from 4
to 9 years 3 months and 4 patients with juvenile absence epilepsy, aged
from 10 years 2 month to 14 years, were examined. All children were
studied with a full clinical assessment including CT, MRI and EEG.
Results: Among all 16 patients with childhood absence epilepsy the
condition manifested from complex absence seizures, which were the
leading seizures type. Absence seizures were characterised by the sud-
den suppression of mental functioning of brief duration (5–15 sec). Ab-
sence frequency was from dozens to hundreds per day. In 12 patients
more then one motor component was observed during an absence attack.
In 4 patients tonic–clonic seizures appeared later during the course of
disease. All children with childhood absence epilepsy (16 patients) had
a normal intelligence level before and after seizure manifestation. EEG
features of typical absence attacks consists of generalised, symmetri-
cal, and synchronous spike-wave complexes with frequency of 3–3.5
Hz. Hyperventilation provoked these EEG patterns in all patients. CT
and MRI examinations did not reveal any abnormalities. Sodium val-
proate monotherapy showed a good final seizure response in 80% of
patients. Among the examined 4 patients with juvenile absence epilepsy
the condition manifested from tonic–clonic seizures; in 3 cases simple
absence attacks and in one case complex absence seizures with motor
components appeared later. Nonpyknoleptic seizures were characterised
by the sudden suppression of mental functioning of brief duration (5–
10 sec), non-pyknoleptic seizure frequency was lower: 3–4 per week.
All children with juvenile absence epilepsy (4 patients) had normal in-
telligence level before and after seizure manifestation. EEG features of
non-pyknoleptic absence attacks consisted of generalised, symmetrical,
and synchronous spike-wave complexes with frequency of 3.5–4 Hz.
Hyperventilation provoked these EEG patterns in 3 patients. In juvenile
absences consciousness loss was superficial and difficult to register. CT
and MRI examinations did not reveal any abnormalities. Sodium val-
proate monotherapy showed a good final seizure response in 75% of
patients with juvenile absences.
Conclusion: Childhood absence epilepsy prevails among epileptic
syndromes of childhood with typical absence seizures. It is important to
follow-up patients with childhood absence epilepsy until adolescence,
because sodium valproate dosage decrease at this age might result in
the development of generalised tonic–clonic attacks. Juvenile absence
epilepsy manifests with tonic-clonic seizures with absences developing
later during the disease course. Sodium valproate monotherapy ensures
seizure control in 75% of patients.
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COMPARISON OF TOPIRAMATE AND GABAPENTIN IN RE-
FRACTORY EPILEPSY IN CHILDREN
Epilepsia, Vol. 47, S3, 2006
7TH EUROPEAN CONGRESS ON EPILEPTOLOGY 171
G. Dizdarer, N. Harputoglu, O. Bag, and N. Aksu (Tepecik Teaching
Hospital, Izmir, Turkey)
Purpose: Childhood epilepsy represents a significant clinical chal-
lenge. Since it is a chronic disorder the long term effectiveness and
tolerability of the medications are very important. Topiramate (TPM)
and gabapentin (GBP) are two new antiepileptic drugs (AEDs) used in
patients refractory to conventional drugs. The aim of the study is to in-
vestigate the efficacy, safety and adverse event profile of these two agents
used as add-on therapy in children with refractory epilepsy.
Method: Sixty-five patients (38 males, 27 females) suffering from
epilepsy were enrolled consecutively from September 2002 to Septem-
ber 2003 and evaluated in January 2005. All patients underwent haema-
tologic, biochemical investigations and all had EEG and cranial MRI
at enrollment. In group I, TPM was started with 0.6–1.1 mg/kg/day and
was titrated to a target dose of 6 mg/kg/day. In group II, GBP was admin-
istered with a dose of 30–40 mg/kg/day. The efficacy, safety and adverse
event profile of these two agents used in children with refractory epilepsy
were studied allowing at least one year follow-up. Data were calculated
on the SPSS 11.0 Windows programme and Pearson correlation test,
Mann-Whitney U test, Willcoxon test and Fisher’s exact test.
Results: The mean age was 9.5 ± 2.8 with a range of 4.1 and 13.8 years
old. The median frequency of seizure at baseline was 4 and 4.5 monthly
in group I and II respectively. In group I, seizure control was seen in
78.3% of the patients at the end of one year with the avarage dose of
6.3 ± 1.8 mg/kg/day. The final seizure control rate for the second group
was 60.7% with the avarage dose 50 ± 4.5 mg/kg/day. Seizure frequency
decreased significantly after one year of add-on therapy to I and II. Side
effects were reported in 14 patients in group I (37.8%) and 6 patients
in group II (21.4%). Most common adverse effects in both groups were
nervousness and headache.
Conclusion: The two drugs decreased the seizure frequency but no
difference in efficacy of seizure types was observed; so they were effec-
tive, safe and well tolerated but none was prior to the other.
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WEIGHT CHANGE BY OXCARBAZEPINE MONOTHERAPY
IN CHILDHOOD EPILEPSY
S. Nam and Y. Kim (Department of Pediatrics, Pusan National University
Hospital, Pusan, Korea)
Purpose: To evaluate the changes of body weight associated with
oxcarbazepine monotherapy in children with epilepsy.
Method: We conducted a retrospective review of 71 childhood
epilepsy patients (40 boys, and 31 girls) attending Pusan National Uni-
versity Hospital on oxcarbazepine monotherapy for at least 3 months.
We evaluated the changes of standard deviation scores (SDS) between
the baseline body weight and the posttreatment body weight.
Results: The mean age of the patients at diagnosis was 7.3 years old
and the mean body weight SDS at diagnosis was 0.389 ± 1.560. After the
administration of oxcarbazepine, the mean body weight SDS increased
substantially to 0.577 ± 1.795 (p < 0.05). A significant increase of the
body weight SDS were observed especially in boys, children under 7
years old, patients with partial seizures, patients with idiopathic epilep-
sies, and patients with negative body weight SDS at diagnosis.
Conclusion: Oxcarbazepine monotherapy was associated with sig-
nificant weight gain in children with epilepsy. It is necessary to warn
patients starting oxcarbazepine medication of the possible body weight
gain and to advise them to start a diet and routine exercise.
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EARLY EFFECT OF CARBAMAZEPINE MONOTHERAPY
ON HOMOCYSTEINE METABOLISM IN CHILDREN WITH
EPILEPSY
1K. Voudris, 2A. Attilakos, 3E. Papakonstantinou, 3K. Schulpis,
2N. Gavalakis, 1E. Katsarou, 1S. Mastroyianni, and 2A. Garoufi
(1Department of Neurology, Panagiotis And Aglaia Kyriakou Children’s
Hospital Athens, Greece, 2 Second Department of Pediatrics, University
of Athens, Panagiotis And Aglaia Kyriakou Children’s Hospital Athens,
Greece, 3Institute of Child Health, Aghia Sophia Children’s Hospital
Athens, Greece)
Purpose: Hyperhomocysteinemia is an independent risk factor for
cardiovascular disease and thrombosis. Prolonged treatment with some
antiepileptic drugs, including carbamazepine, may cause hyperhomocys-
teinemia. The aim of this study was to investigate whether a short-term
period of carbamazepine monotherapy may have an effect on homocys-
teine metabolism.
Method: Fasting plasma total homocysteine, serum folate, serum vi-
tamin B12 and plasma pyridoxal-5′-phosphate was measured in 20 chil-
dren (aged 4–14 years, mean age ± SD: 9.2 ± 3.2 years) before and after
a 20-week period of carbamazepine monotherapy.
Results: The mean fasting plasma total homocysteine value signifi-
cantly increased in the 20-week period of carbamazepine treatment (6.8
± 1.5 vs 7.7 ± 1.7 μmol/l, p ∼ 0.009). The mean values of serum folate
and plasma pyridoxal-5′-phosphate significantly decreased (7.9 ± 3.2
vs 6.2 ± 1.9 nmol/l, p ∼ 0.033 and 48.4 ± 11.3 vs 42.1 ± 8.7 nmol/l,
p ∼ 0.001, respectively), while the mean concentration of serum vitamin
B12 did not significantly change during therapy. Serum levels of car-
bamazepine were within the therapeutic range during the period of the
study. There was no correlation between the above parameters and the
serum carbamazepine levels at 20 weeks of therapy.
Conclusion: Carbamazepine monotherapy may increase fasting
plasma total homocysteine early in the course of treatment in children
with epilepsy. This increase seems to be associated with low concentra-
tions of serum folate and plasma pyridoxal-5′-phosphate.
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PSEUDOGENERALISED SEIZURES CAUSED BY SEC-
ONDARY BILATERAL SYNCHRONY PHENOMENON IN
SYMPTOMATIC FRONTAL LOBE EPILEPSY
K. Mukhin, M. Mironov, M. Tisatchina, and A. Petrukhin (Child Neu-
rology Clinic of Russian State Medical University, Moscow, Russia)
Purpose: To investigate the electroclinical correlates of seizures
caused by secondary bilateral synchrony phenomenon (SBS) among pa-
tients with symptomatic frontal lobe epilepsy (SFE).
Method: We observed 14 patients (8 men and 6 women) aged 2–
20 years (medium 10.4 years) with the established diagnosis of SFE
with SBS on the EEG. Detailed anamnestic data, neurological investi-
gation, video-EEG monitoring (VEM) (Biola, Medicom, Russia), MRI,
antiepileptic drug levels in blood were detected.
Results: According to anamnestic data, and at the moment of ex-
amination, focal seizures were observed in 57% of patients. Syn-
chronously with SBS phenomenon, the following seizure types were
clinically marked: atypical absences 57% cases, short tonic spasms
with asymmetric motor phenomena 36%, eyelid myoclonia with ab-
sences 29%, myoclonic seizures 14%, myoclonic absences 7%, atonic,
including atonic-astatic seizures 7%. Atypical absences had video-
EEG correlation with diffuse bilateral-synchronous spike-and-wave
discharges; myoclonic absences with diffuse bilateral-synchronous
polyspike-waves; eyelid myoclonia with absences, with diffuse asyn-
chronous discharges of polyspike-wave complexes; and myoclonic
seizures with diffuse asynchronous discharges of polyspike-waves (or)
diffuse polyspikes; short tonic spasms with diffuse fast activity with
the frequency about 30 Hz (“recruiting rhythm”). In all cases the begin-
ning of diffuse discharges of SBS phenomenon was preceded by regional
epileptiform activity. In all patients the deficit of cognitive functions was
observed. Seizures were resistant to antiepileptic drugs in all patients.
Valproic acid was the drug of first choice as monotherapy. For the cases
resistant to valproates, we combined it with levetiracetam, ethosuximide
or topiramate.
Conclusion: Registered seizures during VEM had clinical and EEG
features of generalised seizures, but their origin was focal due to SBS
phenomenon. For such seizures we offer the term “pseudogeneralised
seizures.”
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CLINICAL CHARACTERISTICS AND TREATMENT OF
EPILEPSY IN CHILDREN WITH CHROMOSOMAL DISEASE
Epilepsia, Vol. 47, S3, 2006
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1G. Diaconu, 2I. Grigore, 1M. Burlea, and 1M. Frasin (1Children Hospital
“Sf. Maria,” Iasi, Romania, 2University of Medicine And Pharmacy “Gr.
T. Popa” Iasi, Romania)
Purpose: The aim of this study is to estimate the outcome of epileptic
seizures in children with chromosomal disease.
Method: We included in the study 21 children (9 girls and 12 boys)
diagnosed with genetic syndromes and epilepsy (14.28% Angelman syn-
drome, 9.52% Klinefelter syndrome, 33.36 Down syndrome, 14.28%
trisomy 18, 9.52% trisomy 13, 19.04% X-fragile).
Results: The age of onset of epilepsy was 2 months–8 years. At the
beginning seizures were: febrile (19.04%), partial complex (23.80%),
partial (4.76%), generalised (42.36%), and infantile spasms (14.28%).
Nine patients have a family history of epilepsy. The evolution of seizures
was heterogenic: 38.09% generalised epilepsy, 61.91% partial epilepsy.
The EEG was abnormal for all children; the epileptiform discharges were
multifocal or focal in 6 cases, hypsarrhythmia in 3, generalised spike-
wave discharges in 8 and attenuation of background activity with bilateral
or generalised spikes discharges in 4 patients. The children were treated
employing ACTH, sodium valproate, lamotrigine, clonazepam single or
add-on. Therapeutic efficacy was estimated by the percentage of patients
who had achieved a significant clinical response. Seizure control was
achieved in 61.9% patients.
Conclusion: Epilepsy is particularly common with chromosomal dis-
ease and the risk for seizures varies in different types of this disorder.
Our data suggest that a family history of seizures and association with
mental retardation increased the risk for epilepsy in children with chro-
mosomal disease. Therapeutically efficacy was variable depending on
type of seizures or antiepileptic drugs used.
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CHARACTERISTIC AND PROGNOSIS OF SEIZURES FOR
CHILDREN WITH CEREBRAL PALSY
I. Grigore, G. Diaconu, M. Burlea, and M. Frasin (University of Medicine
And Pharmacy “Gr. T. Popa” Iasi, Romania)
Purpose: To reveal the clinical types and prognosis of seizures for
children with cerebral palsy (CP)
Method: We used a group of 117 children (aged 4.5–17 years) diag-
nosed with different types of CP (spastic tetraplegia-43, spastic diplegia-
35, hemiplegia-29, mixture-10). A family history of epilepsy or febrile
seizures was present in 16.24% of patients. 79.48% of children had as-
sociated mental retardation.
Results: All types of seizures were present (generalised tonic–clonic
44.44%, simple or complex partial seizures 38.46%, atypical absence
17.09%, tonic 6.83%, myoclonic-astatic 14.53% and atonic 18.08%).
The age of onset was correlated with type of CP. 18 patients had a
history of infantile spasms and in evolution 8 have the diagnosis of
Lennox-Gastaut syndrome (LGS). 67 patients have a history of sta-
tus epilepticus. A correlation between the distribution of seizures and
different forms of CP was observed. Partial seizures were more fre-
quent in patients with hemiplegia (79.31%) and generalised tonic–clonic
was more common in diplegia and tetraplegia (55.13%). Children with
tetraplegia revealed a high incidence of LGS (18.60%) and epilepsy
with myoclonic-ataxic seizures (27.90%). 37.60% of children received
monotherapy and 62.40% polytherapy with different antiepileptic drugs.
Patients with tetraplegia and hemiplegia more often needed polytherapy
(48.83% and 37.93%). A significant seizure reduction (50%) was ob-
served in 29.05% of patients, 52.13% had seizure refractory to treatment
and 18.82% were seizure-free for 36 months.
Conclusion: All types of seizures can be present in children with
CP. Associated CP and mental retardation increase the risk of epilepsy.
Antiepileptic therapy raised important problems to those children be-
cause the type of CP represents an aggravating factor.
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AGE- AND DOSE-RELATED HYPONATREMIA DURING CAR-
BAMAZEPINE AND OXCARBAZEPINE THERAPY IN CHIL-
DREN WITH EPILEPSY
1S. Chung, and 2E. Cho (1Department of Pediatrics, Kyunghee Uni-
versity Hospital, Seoul, Korea, 2Department of Pediatrics, Cheongju
Medical Center, Chungbuk, Korea)
Purpose: To assess the prevalence of biochemical hyponatremia (BH)
and the clinically relevant hyponatremia (CRH) in children with epilepsy
who are receiving carbamazepine (CBZ) or oxcarbazepine (OXC), ret-
rospectively.
Method: We reviewed the clinical data of 197 patients, who were
divided into 67 CBZ-treated, 75 OXC-treated and 55 patients CBZ or
OXC with add-on treated as group I, II and III. S- Na+ levels (mEq/L)
before treatment were used as controls. We defined hyponatremia as S-
Na+ < 135. Predictive factors for occurrence of hyponatremia according
to age, serum CBZ(S-CBZ) levels, and daily OXC dose were examined.
Results: Mean S-Na+ level was 140.8 ± 3.8 before treatment. The
overall prevalence of hyponatremia was 20.8%, and this was significantly
lower in groups II and III compared with controls (p < 0.05). Serum
Na+ levels relation to S-CBZ levels: those with levels >10ug/ml were
significantly lower than those with <10 ug/ml), and to daily OXC dose:
those with >30mg/kg/day were significantly lower than those 20–30
mg/kg/day (p < 0.05), but, not in age-related: patients less than 10 years
compared with patients over 10 years old. Out of 41 patients having BH,
7 had CRH (3.7%) (5 patients: 120 ≤ Na+ < 125, 2 patients: Na+<120).
There were clinical symptoms in each 0.5–2.0%: nausea and vomiting,
headache, seizure, mental confusion, anxiety, and delusion.
Conclusion: The prevalence of BH and CRH were 20.8% and 3.7%,
respectively. Hyponatremia occurred more often in the OXC and/or add-
on treated group. There were significant differences with high S-CBZ
and high daily OXC dose for occurrence of hyponatremia, but not in age
related.
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EPILEPSY IN CHILDREN WITH CEREBRAL PALSY MIGHT
BE REVEALED DURING THE SECOND DECADE OF LIFE
P. Po´lrola and J. Wendorff (1Neuropaediatric Department of Medical
University In Lo´dz Polish Mothers Memorial Hospital, Poland)
Purpose: The majority of studies concerning the occurrence of
epilepsy with cerebral palsy (CP) points out the particular frequency
of epilepsy occurrence in the first years of life, and the severity of its
course. The aim of this study was to establish the onset and the course
of epilepsy during the period from 1 to 20 years.
Method: The clinical records of 106 children with epilepsy and CP
were retrospectively evaluated from the first seizures to 20 years of life.
Results: The occurrence of the first seizures was most frequent at age
4 (63% in hemiparetic cp, 87% in quadriparetic CP form). In 28% of
cases epilepsy revealed after age 10; most frequently in diparetic and
hemiparetic cp. In 21% of patients the treatment was finished before age
20. 75% of cases were on monotherapy. In the 10th and 14th year of
life the frequency of epileptic attacks decreased respectively in 27% and
14% and at the same time increased in 14th to 18th year of life in 18%
and 10% of the group.
Conclusion: 1. The first epileptic attack might occur in CP patients
during their second decade 2. The majority of epilepsy patients with CP
are well controlled on monotherapy 3. During the second decade of life
the course of epilepsy in CP improved in almost one third of patients,
but frequency of the attacks might also increase in the teen years and in
early adulthood.
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EFFECT OF ANTICONVULSANTS ON SERUM COPPER AND
ZINC CONCENTRATION
K. Lee, H. Jeong, and W. Kim (College of Medicine, Chungnam National
University, Daejeon, Korea)
Purpose: Anticonvulsants have a number of side effects and some of
them may be attributable to a disturbance of serum trace metal homeosta-
sis. Although there are minor components in tissues, they play important
functional roles in the peripheral and central nervous system. We mea-
sured serum copper and zinc levels in children with epilepsy who were
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treated with anticonvulsants to find the effects of the anticonvulsant on
serum copper and zinc levels.
Method: Serum copper and zinc levels were determined in 64 epilepsy
patients receiving anticonvulsant therapy for more than 6 months in
Chungnam National University Hospital, and in 20 normal controls.
Sixty-four epilepsy patients were divided into three groups: 16 patients
treated with valproic acid monotherapy; 26 patients treated with valproic
acid in addition to another anticonvulsant; and 22 patients treated with
an anticonvulsant other than valproic acid.
Results: All patients receiving anticonvulsants had significantly lower
serum copper levels (80.21 ± 19.42 /dL) in comparison to the normal
controls (102.12 ± 32.8 /dL). Serum zinc levels in patients receiving
anticonvulsants (79.78 ± 21.88 /dL) were not statistically different
from those of controls (85.26 ± 29.81 /dL). There were no significant
differences of serum copper and zinc levels among the three groups.
Conclusion: In this study, we clearly showed that anticonvulsants
decreased serum copper levels. Although we did not observe any clinical
findings related to copper deficiency, we should pay attention to copper
deficiency in patients with anticonvulsants.
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STUDY OF THE NEUROPROTECTIVE EFFECT OF THE L-
TYPE CALCIUM CHANNEL BLOCKER FLUNARIZINE ON
THE DEVELOPMENTAL OUTCOME OF INFANTS WITH
WEST SYNDROME
1,2H. Sauerwein, 2E. Goodyear, 2L. Carmant, and 1,2M. Lassonde
(1Universite´ De Montre´al, Canada, 2Hoˆpital Sainte-Justine, Montre´al,
Canada)
Purpose: West syndrome is considered to be one of the “catastrophic”
childhood epilepsies and is associated with arrest or regression of cog-
nitive development. Only 15 to 20% of the children develop normally.
Evidence from animal studies and clinical research suggests that the
L-type calcium blocker flunarizine (nimodipine) possesses neuroprotec-
tive properties against seizure-induced brain damage. In the pilot study
reported here we intended to test the effect of flunarizine on cognitive
outcome in infants afflicted with West syndrome.
Method: Flunarizine or a placebo was administered as an add-on drug
to standard treatment (vigabatrin) to 11 infants, aged 4 to 17 months, with
new onset of infantile spasms in a double-blind, randomised paradigm.
The patients were assessed on the Griffiths Mental Developmental Scales
at diagnosis (baseline) and 6 and 12 months after initiation of treatment.
Results: The infants in the active treatment group showed substantial
improvement of their global developmental quotient (mean gain of 7.8
points) with normalisation of the psychomotor status in 2 patients. The
children in the placebo group failed to show any notable improvement
(mean loss of 4.7 points: 15 points in 1 and no changes in 2 others),
except for a patient with tuberous sclerosis who improved on vigabatrin
alone. Significant differences between the two groups were observed in
object manipulation (performance), hearing and speech and eye-hand
coordination (p < 0.05).
Conclusion: Flunarizine may have the potential to arrest, and possibly
reverse cognitive deterioration in infants with West syndrome. A Canada-
wide, multicentre study is presently underway to further explore this
hypothesis.
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COMBINATION OF DEPAKIN AND MEXIDOL IN TREAT-
MENT OF CHILDREN WITH PRIMARY GENERALISED
EPILEPSY AND MONOTHERAPY WITH MEXIDOL FOR
FEBRILE SEIZURES
S. Natriashvili, G. Natriashvili, and N. Kapanadze (Tbilisi State Medical
University, Georgia)
Purpose: The aim of our study was to estimate the role of a com-
bination of depakin and mexidol (antioxidant) in stopping epileptic fits
and improving electroencephalographic (EEG) pathological patterns in
children.
Method: 180 patients with generalised epilepsy (from 4 to 16 years
old) were investigated. All patients were treated by depakin chrono–30
mg/kg. Children were divided into 2 groups. The study group consisted of
90 children with a combined treatment of depakin and mexidol (5mg/kg).
In the control group (90 children) only depakin was administered. 140
children with the first episode of febrile seizures (from 6 month to 4 years
old) were investigated. 70 children comprised the study group treated by
mexidol and 70 patients the control group without any treatment.
Results: Using depakin in combination with mexidol in the study
group of patients with generalised epilepsy has revealed improvement
of the clinical picture of disease and normalisation of EEG patterns in
93% of cases. In the study group of patients with febrile seizures, nor-
malisation of EEG pathological patterns and its improvement was seen
in 82% and 18% of cases, relatively. The relapse of febrile seizures was
observed in 3 cases. In the control group EEG patterns were improved
only in 20% and in 41% its worsening was seen. The relapse of febrile
seizures was observed in 26 cases.
Conclusion: Mexidol titrated to the target doze of 5mg/kg may be
effective in combination with depakin for treatment of patients with
generalised epilepsy and as a monotherapy in patients with a first episode
of febrile seizures.
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TREATMENT RESULTS IN EPILEPSY CAUSED BY CY-
TOMEGALOVIRUS INFECTION
Dunin–D. Wasowicz, J. Kasprzyk-Obara, and M. Kapusta (The Chil-
dren’s Memorial Health Institute, Warsaw, Poland)
Purpose: Symptomatic epilepsy can be caused by viral infections,
including cytomegalovirus infection, which is the most frequent con-
genital viral infection. Seizures occur in the neonatal period, during the
1st year of life or later in early childhood. We therefore investigated the
evaluation of treatment results in infants with different types of epilepsy
in congenital/perinatal human cytomegalovirus infection categories.
Method: We reviewed 84 infants (47 female, 37 male) treated in The
Children’s Memorial Health Institute in Warsaw from 1 January 1995 to
31 December 2005 with epilepsy and confirmed cytomegalovirus infec-
tion established as the aetiological factor of the seizures. DNA HCMV
was found by PCR method in cerebrospinal fluid, blood leukocytes and
urine. Infants were treated with different AEDs and followed up from
neonatal period on.
Results: In 10 infants, tonic–clonic seizures started during the 1st
month of life. In 2 infants with cytomegalovirus infection diagnosed
in the 2nd month of life, partial onset seizure began in the 3rd year of
life. Onset of infantile spasms, partial onset seizures with and without
generalisation and myoclonic seizures, in the vast majority of infants
occurred during the 1st year of life. Nine featured very severe, drug re-
sistant epilepsy. One infant died. Vigabatrin, phenobarbital, lamotrigine
and carbamazepine monotherapy were effective in 26 cases. In 11 treated
alongside antiviral with ganciclovir, after more than 2 years seizure-free
period antiepileptic drugs were withdrawn.
Conclusion: 1) Early treatment of epilepsy caused by HCMV infec-
tion can result in long term cassation of seizures. 2) Antiviral treatment
should be considered.
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ANTIEPILEPTIC EFFECT OF ZONISAMIDE IN PAEDIATRIC
INTRACTABLE EPILEPSY
1T. Ko, 1M. Yum, and 2S. You (1Asan Medical Center, Seoul, South
Korea, 2Sanggye Paik Hospital, Inje University College of Medicine,
Seoul, South Korea)
Purpose: To confirm the effectiveness and safety of zonisamide in
paediatric intractable epilepsy.
Method: We retrospectively reviewed the medical records of 41 chil-
dren with intractable epilepsy, who had taken zonisamide and had been
followed up for more than 6 months at the Division of Paediatric Neu-
rology, Asan Medical Center.
Results: The study cohort included 41 patients with intractable
epilepsy, some of whom had more than one antiepileptic drug but whose
seizures were medically intractable. There was a male predominance
(24/17). Zonisamide starting age was 7.7 ± 5.3 years. Seizure reduction
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rate of more than 50% was 43.9% (18/45). According to seizure types, re-
sults were as follows: 1) generalised seizures (n = 25), {Lennox-Gastaut
syndrome (n = 15), infantile spasm (n = 2), myoclonic seizures (n =
2), and generalised tonic–clonic seizures (n = 3)} was 52% (13/25); 2)
secondarily generalised tonic–clonic seizure (n = 9) was 22.2% (2/9);
3) complex partial seizure (n = 1) was 100% (1/1); 4) mixed seizure
(n = 6) was 33.3% (2/6). Mean effective dose was 10.4 ± 3.9mg/kg/day.
Major side-effects were not detected.
Conclusion: Zonisamide is effective and safe as an adjunctive
antiepileptic drug for paediatric intractable epilepsy.
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HIGH NEONATAL MORTALITY RATE IN PRETERM NEW-
BORNS WITH NEONATAL SEIZURES AND THE ASSOCIA-
TION WITH VIDEO-ELECTROENCEPHALOGRAPHY
G. Marchio` and F. Pisani (Neuroscience Department of Parma’s Univer-
sity, Italy)
Purpose: The aim of the study was to examine the neonatal mortality
rate of preterm infants with seizures and the association with the first
video-electroencephalography.
Method: We analysed all preterm infants consecutively admitted to
the neonatal intensive care unit of the University Hospital of Parma, from
January 1999 to June 2003. 34 newborns were selected according to the
following criteria: gestational age below 37 weeks, repeated neonatal
video-EEG confirmed seizures, need of chronic anticonvulsant therapy,
neurological follow-up up to 24 months of corrected gestational age.
Results: An abnormal video-EEG recording is significantly associ-
ated with mortality rate (p < 0.001). Normal EEG activity or activity
with mild alteration were found in 10 newborns in our study group and
their mortality rate was 10% (1/10); moderate abnormality in EEG ac-
tivity was found in 13 newborns and their mortality was 23.1% (3/13);
finally severe abnormality in EEG activity was found in 11 infants, with
a mortality rate of 81.8% (9/11). In a comparison between 21 preterm
infants in our study group (with seizures and with gestational age below
34 weeks), and a control group of 217 preterm infants with the same
gestational age and without seizures, the mortality of our study-group
was 39%, while the control-group reports a mortality of 14.7% (p =
0.002).
Conclusion: In our study the first EEG, performed during the neonatal
period, appears to be a strong predictor of mortality rate in preterm
infants with seizures, and among these the percentage of mortality is
significantly higher than that of newborns without seizures and with the
same gestational age.
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NONEPILEPTIC SEIZURES IN CHILDREN AND YOUNG
PEOPLE WITH COMPLEX EPILEPSY AND LEARNING
DISABILITY
K. Chomtho, S. Aylett, K. Wickham, T. Lax-Pericall, and K. Das (The
National Centre For Young People With Epilepsy, Surry, UK)
Purpose: To describe the clinical features of nonepileptic seizures
(NES) and to review management strategies and outcomes in children
and young people with complex epilepsy and learning disability.
Method: Retrospective review of case notes of patients attending a
specialist epilepsy centre in the UK from 2001–2005. Further informa-
tion was obtained by interviewing carers. EEG/video telemetry reports
were reviewed for detail of the attacks and to confirm the diagnosis.
Results: Fifteen patients with NES (7 males, 8 females) aged 12–21
years were included. All patients have coexisting epilepsy, 14 cases have
learning disability, and 7 cases have psychiatric conditions. The most
frequent manifestations of NES were convulsive-like (46.6%) and with
motor symptoms (33.3%), similar to previous reports. Common char-
acteristics observed were: maintenance of responsiveness, awareness of
events, absence of seizure-related injuries, and presence of witnesses.
NES were confirmed by EEG/telemetry in 14/15 patients; this led to
medication reduction or change in emergency treatment in 4 cases. 12
patients received psychological treatment: cognitive behaviour therapy,
behavioural management, relaxation training, or supportive counselling.
7 patients (58%) showed a reduction or elimination of NES, which is less
than the outcomes in previous studies in populations with no associated
co-morbidities.
Conclusion: Despite various presentations, NES episodes share com-
mon characteristics that may distinguish them from epileptic seizures.
The high percentage of coexisting epilepsy and learning disability in this
study group, may contribute to the differences noted in the clinical man-
ifestations and treatment outcomes when compared to previous studies.
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SOME RISK FACTORS FOR CHILDHOOD EPILEPSY: A CASE-
CONTROL STUDY
1A. Serdaro lu, 1A. Cansu, 2D. Yu¨ksel, 1V. Do an, 3S. ¨Ozkan, 2N.
Senbil, 1T. Hy´rfano lu, 1K. Gu¨cu¨yener, and 2Y. Gu¨rer (1Gazi Univer-
sity Faculty of Medicine, Department of Pediatric Neurology, Turkey,
2Dr. Sami Ulus Pediatric Diseases Training And Research Hospital De-
partment of Pediatric Neurology, Turkey, 3Gazi University Faculty of
Medicine, Department of Public Health Specialist, Turkey)
Purpose: The goal of this case-control study was to identify the sig-
nificance of certain risk factors for epilepsy in Turkey.
Method: A total of 805 cases aged 1–16 years, followed-up for
epilepsy at the Pediatric Neurology Departments of Gazi University
Medical Faculty and Dr. Sami Ulus Pediatric Diseases Training and
Research Hospital, and a control group consisting of 846 age matched
cases without epilepsy, followed-up at the Gazi University Medical Fac-
ulty General Pediatric Outpatient Department, were included in the study.
The data on the patients and control subjects were obtained through a
questionnaire via personal interviews. The medical records were then
reviewed and were analysed.
Results: Univariate analysis showed an increased risk for epilepsy
with male sex (1.38-fold), abnormal neurological signs (5.92-fold), his-
tory of febrile seizure (9.29-fold), severe and moderate head injury
(27.76- and 7.09-fold respectively), CNS infection (4.76-fold), history
of epilepsy in first-, second- or third-degree relatives (6.42-, 3.09- and
2.66-fold respectively), presence of maternal hypertension (4.31-fold),
an apgar score ≤6 at any time (7.78-fold) and neonatal jaundice (3.12-
fold). Possible significant variables from the univariate analysis were
grouped to observe the total number of variables present in a single child
from the case and control groups.
Conclusion: The most important risk factors for epilepsy in this study
were neurological impairment and severe head trauma. Other important
risk factors were history of febrile seizures, a history of epilepsy in the
family and a low apgar score.
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IMPORTANCE OF PATIENT HISTORY AND SEIZURE CHAR-
ACTERISTICS IN DISCRIMINATION OF EPILEPTIC AND
NONEPILEPTIC SEIZURES IN CHILDREN
1A. Cansu, 1A. Serdaro lu, 2E. Bilir, and 1T. Hy´rfano lu (1Gazi Univer-
sity Faculty of Medicine, Department of Pediatric Neurology, 2Gazi Uni-
versity Faculty of Medicine, Department of Neurology, Ankara, Turkey)
Purpose: The aim of this study was to compare some ictal and postictal
seizure characteristics, history of febrile seizures and cranial magnetic
resonance images for nonepileptic seizures (NES) and epileptic seizures
(ES) and to determine the differences.
Method: A total of 43 nonepileptic and 104 epileptic patients with
generalised tonic–clonic seizures (GTCS) were included in the study.
Following a literature search, we specified 5 items that could be used
to differentiate nonepileptic and epileptic seizures. These items were
evaluated as present or absent in every patient with ES and NES, and the
results were compared statistically.
Results: There was a statistically significant difference between the
two groups for the presence of ictal and postictal altered consciousness
(p < 0.0001), a seizure duration of more than 2minutes (p < 0.001), the
presence of febrile seizures (p < 0.008) and the presence of pathological
findings in cranial magnetic resonance images (p = 0.002).
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Conclusion: Patients who experience tonic–clonic seizures should be
evaluated for ictal and postictal altered consciousness as it plays a key
role in differentiating ES from NES. Seizure duration, history of febrile
seizures and cranial MRI findings may help in making the differential
diagnosis.
p679
POSTSURGICAL SEIZURE OUTCOME IN CHILDREN WITH
REFRACTORY LOCALISATION-RELATED EPILEPSY AND
NORMAL OR NONSPECIFIC MRI FINDINGS
R. Ramachandran Nair, H. Otsubo, M. Shroff, S. Weiss, E. Donner,
J. Rutka, and C. Snead III (The Hospital For Sick Children, Toronto,
Canada)
Purpose: To identify the predictors of postsurgical seizure freedom
in children with refractory epilepsy and normal or nonlateralised MRI
findings.
Method: We analysed 22 children (M10:F12) under 18 years with nor-
mal, subtle or nonlateralised MRI findings, who underwent surgery for
intractable epilepsy following intracranial EEG. Clinical profiles, neu-
rophysiological data (VEEG, magnetoencephalography and intracranial
EEG) and surgical data (type, location and completeness) were com-
pared to post-operative seizure outcome (good seizure outcome = >90%
seizure control).
Results: We performed combined lobectomy and corticectomy (10),
corticectomy (9), lobectomy (2) and multiple subpial transections (1).
Seventeen children (77%) had good seizure outcome; 8 (36%) seizure
free and additional 9 (41%) with >90% seizure control. Ictal onset
confined to <5 adjacent intracranial electrodes (5/5) predicted seizure
freedom p = 002). Children with more than one type of seizure
(5/5) (p = 0.07) and children with both generalised spike and wave
and extra-resection site epileptic discharge (4/4) did not become seizure
free. Age of onset, duration of epilepsy, presence of developmental de-
lay, number of lobes involved in resection, completeness of the resec-
tion or pathology (cortical dysplasia-9, dysembryoplastic neuroepithelial
tumour-1, mesial temporal sclerosis-1, non-specific gliosis-6, no patho-
logical lesion-4) did not correlate with seizure freedom.
Conclusion: Surgery for intractable partial epilepsy in children with
normal MRI findings can provide good seizure outcome in the majority
of children. Restricted localised ictal onset zone predicted postoperative
seizure freedom. Seizure freedom less likely occurred in multiple seizure
types and incomplete resection of the proposed epileptogenic zone.
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ADVERSE EFFECTS OF ANTIEPILEPTIC DRUGS AND THEIR
IMPACT ON QUALITY OF LIFE IN CHILDREN WITH
EPILEPSY
M. Mazurkiewicz-Beldzinska (Dept. of Developmental Neurology Med-
ical University of Gdansk, Poland)
Purpose: Epilepsy is a major cause of childhood disability. Addition-
ally AED through their potential to evoke side effects can potentiate this
disability. Both efficacy and safety of treatment are important parameters
in assessing quality of life as an outcome measure. In order to assess the
impact of side effects of antiepileptic drugs (AED) on quality of life in
children with epilepsy following study was performed.
Method: Two hundred fifty children with epilepsy (aged 3–13 years)
and their caregivers participated in the study. The quality of life ques-
tionnaire specially developed in our department for parents of children
with epilepsy was applied. Additionally, 5 questions especially designed
to describe side effects were asked. Comparisons between parents and
medical staff opinions were made.
Results: The most frequent side effects observed in 70% of pa-
tients were tiredness, poor concentration, nervousness, headache, ver-
tigo, weight loss or gain, rush and other skin problems, abdominal pain
and others. Occurrence and number of side effects as well as the efficacy
of treatment significantly correlated with quality of life. It also corre-
lated with the caregiver’s opinion about the disease and their fear about
its influence on the children. Interestingly parents reported their worries
about the effects of drugs on cognition much stronger than effects of
epilepsy itself.
Conclusion: Not only epilepsy by itself but also the side effects of
AED have an important impact on quality of life in children with epilepsy.
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PAEDIATRIC EPILEPSY: LOWER COSTS OF ADVERSE
EVENTS WITH LEVETIRACETAM ADD-ON FOR PARTIAL
ONSET SEIZURES
1L. Gerlier and 2W. Mitchell (1Keyrus Biopharma, Levallois-Perret,
FRANCE, 2Childrens Hospital Los Angeles, Los Angeles CA, USA)
Purpose: To estimate and compare the costs of adverse events (AE)
leading to medication and hospitalisation in a paediatric epilepsy trial
comparing levetiracetam (LEV) and placebo (PBO) as add-on therapy.
Method: Data from a double-blind-randomised controlled trial (LEV,
N = 101; PBO, N = 97) were analysed. Unit costs were assigned to
medications and hospitalisations related to AE using average wholesale
prices and diagnosis-related groups respectively (2003 values), from a
US third-party payer perspective. Comparisons of the mean medication
costs were conducted using t-bootstrap at baseline and over the 20 week
treatment period which included titration, evaluation and withdrawal
periods.
Results: The frequency and cost of medications due to AE were com-
parable between the 2 groups at baseline. The mean cost of medications
per patient was significantly lower in the LEV group vs PBO during
the treatment ($56.9 vs $120.8, p = 0.032), evaluation ($38.3 vs $88.5,
p = 0.022) and withdrawal periods ($1.9 vs $19.8, p = 0.046). Over
the titration period, a nonsignificant higher mean cost in the LEV group
vs PBO was observed ($16.7 vs $12.5, p = 0.520). Mean cost of hos-
pitalisations and per hospitalised patient were lower in LEV vs PBO
during the treatment period ($189.4 vs $452.8 and $3188.5 vs $4880.1
respectively).
Conclusion: Lower costs of medications and hospitalisations due to
AE were demonstrated with LEV add-on in paediatric epilepsy vs PBO.
Both of these cost components are considered important medical cost
drivers of epilepsy disease management. (Work supported by UCB).
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TRANSIENT COGNITIVE DETERIORATION ASSOCIATED
WITH VALPROATE: A CASE STUDY
E. Kantola-Sorsa, E. Gaily, T. Ha¨yrinen, and M. Ha¨ma¨la¨inen (Hospital
For Children And Adolescents, Helsinki University Hospital, Finland)
Purpose: Few reports are available on cognitive deterioration associ-
ated with valproate in children.
Method: A previously healthy boy with no family history of epilepsy
started having daily seizures with brief arrest of activity at 12 months.
EEG at 2.3 years showed generalised spike-wave discharges. Valproate
was started at 35 mg/kg/day at 2.4 years; seizures disappeared within two
weeks. Generalised spike-waves persisted until age nine years. Valproate
was continued until age seven (from age five on at 600 mg/day). As
interictal EEG continued to show epileptiform abnormalities, valproate
300 mg/day was restarted at age eight and continued for a year.
Results: The boy was considered normally developed at two years.
Marked developmental delay was observed by a neuropsychologist at
age five and confirmed at six. The boy started special education for the
mentally retarded. Two months after discontinuing valproate teachers
reported that he was much too bright for his class. When reassessed, he
performed within low average range. He was placed in a mainstream
class, where he did well except for some attentional difficulties. While
back on a lower dose of valproate, the cognitive test scores were slightly
lower again, but the boy was doing well enough at school. His school
career has since been uneventful.
Conclusion: The patient probably had idiopathic absence epilepsy
although with unusually early onset. Cognitive decline after commenc-
ing valproate and rapid improvement after its discontinuation after a
long seizure-free period suggest that valproate was the cause of the
deterioration. The importance of cognitive monitoring in epilepsy is
emphasised.
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EFFICACY OF ACTH IN INTRACTABLE FRONTAL LOBE
EPILEPSY
1N. Paciello, 2G. Della Marca, 1M. Chiummiento, 1L. Discepolo, 2S.
Mazza, and 1M. Paciello (1San Carlo Hospital, Neurology Unit, Potenza,
Italy, 2UCSC, Institute of Neurology, Rome, Italy)
Purpose: We analysed the short- and long-term efficacy of brief ad-
ministration of adrenocorticotropic hormone (ACTH) in 2 patients af-
fected by intractable frontal lobe epilepsy.
Method: The subjects were 2 children, 1 boy and 1 girl, characterised
by daily high frequency of seizures of frontal lobe onset. They had re-
ceived a high dosage of carbamazepine, sodium valproate and a com-
bination of these drugs. We performed a clinical examination on both
patients, including MRI and EEG during sleep before and after ACTH
treatment.
Results: The clinical examination and MRI were normal. Both pa-
tients showed remarkable secondary frontal bisynchronism on the EEG
and they did not respond to the above mentioned drugs before ACTH
treatment. After a low dose of ACTH (0.010 mg/kg/dose), administered
for 2 weeks, the patients showed significant reduction in frequency of
seizures, disappearance of secondary frontal bisynchronism on the EEG
and a good response to carbamazepine. The follow-up of our patients is
12 months and, at the moment, they continue to present a good response
to carbamazepine.
Conclusion: We believe that our results suggest a good efficacy and
tolerability of a low dose of ACTH in drug-resistant frontal lobe epilepsy.
Moreover, we could explain these results with a possible mechanism of
action of ACTH on the secondary frontal bisynchronism by decreasing
CRH release and by direct, steroid-independent, action on melanocortin
receptors, according to data existing in the literature.
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EEG IN CHILDREN SUSTAINED ON THE KETOGENIC DIET:
DO RESULTS CORRELATE WITH SEIZURE OUTCOME?
M. Mills, E. Neal, H. Chaffe, and H. Cross (Great Ormond Street Hospital
For Children NHS Trust, Neurosciences Unit, Institute of Child Health,
London, UK)
Purpose: To determine if the routine electroencephalogram (EEG) is
a useful indicator of response to the ketogenic diet in the treatment of
epilepsy.
Method: As part of a randomised controlled trial of the use of the
ketogenic diet in the treatment of drug resistant epilepsy, children un-
derwent an EEG recording at baseline, after 3 months on the diet, after
6 months and after 12 months. For inclusion in the study children had
been tried on at least 2 anticonvulsant medications and had at least 7
seizures/week. EEGs were visually scored for background and paroxys-
mal/epileptiform activities by an experienced clinical physiologist and
compared with clinical response.
Results: EEG data were reviewed in 48 children (29 males) with
age range 19 months to 15.2 years, at baseline and after 3 months, 36
children after 6 months and 24 children after 12 months on the diet. In the
24 who had completed the 12 months study period, the background EEG
remained similar in 16, worse (∼50%) in 5 and significant improvement
(∼50%) in 3. A significant reduction in paroxysmal activity/discharges
(up to 50%) was seen in 6 children; 14 had no change and 4 worsened.
No correlation was seen between seizure control and degree of change
in EEG. 22 children were able to reduce medication with no decline in
seizure control.
Conclusion: In this cohort of patients treated with the ketogenic diet
for varied seizure disorders, the EEG does not appear to be a good
indicator of seizure response.
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HEALTH-RELATED QUALITY OF LIFE IN CHILDREN WITH
EPILEPSY AND CEREBRAL PALSY: PRELIMINARY RESULTS
M. De Rinaldis, M. Massimo, L. Russo, M. Gesualdi, P. Profice, and
A. Trabacca (Scientific Institute I.R.C.C.S. Eugenio Medea”– “La Nos-
tra Famiglia” OSTUNI (Brindisi), 2Scientific Institute I.R.C.C.S. Eu-
genio Medea”– “La Nostra Famiglia” OSTUNI (Brindisi), 3Scientific
Institute I.R.C.C.S. Eugenio Medea”– “La Nostra Famiglia” OSTUNI
(Brindisi), 4Scientific Institute I.R.C.C.S. Eugenio Medea”– “La Nos-
tra Famiglia” OSTUNI (Brindisi), 5Institute of Neurology, University
Cattolica, 6Scientific Institute I.R.C.C.S. Eugenio Medea”– “La Nostra
Famiglia” OSTUNI (Brindisi)
Purpose: The aim of this study was to compare health related quality
of life (HRQL) of children with cerebral palsy (CP) with and without
epilepsy.
Method: Eleven children suffering from CP and epilepsy and 11 chil-
dren suffering from CP without epilepsy (aged between 5 and 18 year)
participated in a comparative study. The two groups were comparable for
type and severity of CP. For all children we evaluated the type of epilepsy,
and any other disorder in comorbidity and social status of family. Parents
of children rated their child’s quality of life with the Impact of Child-
hood Neurological Disability Scale (ICND). The severity of a child’s
motor disability was assessed using a paediatric functional measure, the
Wee-Functional Independence Measure (WeeFIM).
Results: Parents reported significantly reduced HRQOL (p < 0.01)
in the group of children with CP and epilepsy compared to the group of
children with CP without epilepsy.
Conclusion: Children with CP and epilepsy have reduced HRQOL
and the degree to which it is reduced is related to the severity of their CP.
In our study there is a clear relationship between seizure frequency and
health related quality of life and other clinical variables (overall sensorial
disorder and mild–severe mental retardation).
p686
KETOGENIC DIET FOR INFANTS IS POSSIBLE WITH
KETOCAL
P. Uldall, C. Nielsen, and H. Vestergaard (Rigshospitalet, Copenhagen,
Denmark)
Purpose: A formula for a ketogenic diet has been marketed for chil-
dren above 1 year of age (Ketocal SHS). Infants with medical intractable
catastrophic epilepsy are in desperate need for an alternative treatment.
We describe the use of Ketocal for 5 infants.
Method: Five infants treated with Ketocal were reviewed. All had
medical intractable epilepsy. The ages of the children at the start of the
diet were: 3, 7, 7, 8 and 11 months. Ketocal contains a higher load of
lipids including transfatty acids and sodium than recommended. Kidney,
liver function and sodium were closely monitored. Ketocal was gradually
introduced over 3 days without fasting. Caloric intakes were set to 85%
of recommended requirements and regulated depending on ketosis and
weight increase.
Results: All infants tolerated the formula and were able to develop
moderate or large ketonuria within 2 weeks. Four of the 5 infants had
marked seizure reduction including 2 temporarily seizure free children.
One child was seizure free for 12 months followed by epilepsy surgery
after seizure recurrence. The child started on Ketocal at age 3 months
and has only been followed for 1 month. Introduction and short term
observations revealed no complications including normal blood sample
results.
Conclusion: Ketogenic diet is possible to introduce and seems to be
effective in some infants under 12 months of age. Longer follow-up on
Ketocal in small infants is necessary to evaluate the sufficiency of the
formula.
p687
PREVALENCE OF ATTENTION DEFICIT DISORDER IN PAE-
DIATRIC EPILEPSY PATIENTS IN MEXICO
E. Barraga´n, E. Cruz, M. Urrutia, M. Herna´ndez, and J. Herna´ndez (Hos-
pital Infantil De Me´xico Federico Go´mez, Mexico)
Purpose: To evaluate the prevalence of attention deficit disorders in
the paediatric epilepsy population in Mexico. It is an important issue
to try to differentiate the attention problems secondary to epilepsy and
treatment and the attention deficit disorder itself, because the treatment
for these two conditions is independently suggested.
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Method: We evaluated all patients with epilepsy, 6 and 12 years old,
in the neurology department of Hospital Infantil de Mexico between
January and December 2005. The patients were evaluated with clinical
history, neurological examination, WISC-R, Conner’s scales, ADHD-
RS, CGI and DSM-IV-TR, independently of type of seizure, number of
antiepileptic drugs or aetiology.
Results: We analysed data from 450 patients, both genders, between
6 and 12 years old. 234 patients had one of the symptoms of ADHD
(inattention, hyperactivity or impulsivity). Of these (178 males and 56
females) only 89 patients met all the criteria for the disorder. The most
frequent subtype of ADHD in males was the combined type, in females
the inattentive subtype. Only 23 of these patients had received treatment
support with medications specific for the disorder. The prevalence of
ADHD in our population was 19%; very similar to that in the normal
population.
Conclusion: ADHD is a biologic-genetic condition that affects the
normal population, and we find the same prevalence in the paediatric
epilepsy population. It is important to differentiate the symptoms of this
disorder from epilepsy symptoms, because the therapeutic approach is
different for each group, and the impact and prognosis is better for ADHD
patients.
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RISK FACTORS OF UNPROVOKED SEIZURES AFTER ACUTE
SYMPTOMATIC SEIZURES IN CHILDREN
1W. Kim and 2E. Lee (1Department of Pediatrics, Chungbuk Univer-
sity Hospital, Chungbuk National University, Cheonju, South Korea,
2Department of Pediatrics, Chungbuk University Hospital, Chungbuk
National University, Cheonju, South Korea)
Purpose: Some patients with acute symptomatic seizures (ASS) have
related unprovoked seizures during follow-up. So we were going to eval-
uate the risk factors of unprovoked seizures after ASS in children.
Method: We retrospectively reviewed the medical records of 167 chil-
dren with ASS admitted to Chungbuk National University Hospital be-
tween January 1998 and December 2003, and the patients were followed
up for 2 years.
Results: Acute symptomatic seizures were most common in younger
children aged 13 to 24 months, and sexual distribution did not differ.
Most of the children had generalised seizures (73.6%). Acute gastroen-
teritis (32%) was main cause. Minor infections (22%) involving urinary
tract or upper respiratory infections were noted. During follow-up, 52
children (31%) had unprovoked seizures after ASS. The mean age at
the onset of first seizures was 40 months. Causes in order of frequency
were minor infection (24%), CNS infection (9%) and acute gastroenteri-
tis (9%). Partial seizures were more common than generalised seizures.
The risks of unprovoked seizures were greater for those with ASS with
status epilepticus (SE) (56.3%) than without SE (25%). The risks of un-
provoked seizures were also high in preterm babies, postictal lethargic
states and delayed development.
Conclusion: Based on this retrospective study, the risks of unprovoked
seizures after acute symptomatic seizures were high in partial seizures
with status epilepticus, developmental delay, and perinatal problems. The
risks of subsequent unprovoked seizures are determined by underlying
precipitation factors, so children with acute symptomatic seizures with
SE should be followed up carefully.
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EFFICACY OF LEVETIRACETAM AS ADD-ON THERAPY IN
10 CHILDREN WITH AUTISTIC REGRESSION AND EPILEPSY
J. Garcı´a-Pen˜as, F. Romero-Andu´jar, M. Ruiz-Falco´, L. Gonza´lez
Gutie´rrez-Solana, A. Duat Rodrı´guez, and L. Arrabal Ferna´ndez (Pedi-
atric Neurology Unit. Hospital Infantil Universitario Nin˜o Jesu´s, Madrid,
Spain)
Purpose: To evaluate the clinical usefulness and safety of levetirac-
etam (LEV) as add-on therapy in children with autistic regression and
epilepsy.
Method: We introduced LEV as add-on therapy in 10 children age
22 months to 14 years affected by autistic regression and epilepsy. Eight
patients had partial-onset seizures and 6 had generalised seizures in-
cluding 5 children with myoclonic epilepsy. Efficacy was assessed by
measuring changes in seizure frequency per month and achievement of
seizure freedom. Patients were analysed for possible improvement in
attention and behaviour using CAVE scale for quality of life in children
with epilepsy, Conners test for parents and teachers, Ladd child behaviour
scale for parents and teachers, autism behaviour checklist scale (ABC)
and Kauffman brief intelligence test (K-BIT). Safety was assessed by
evaluating LEV-related adverse events.
Results: Eight of 10 patients (80%) showed a seizure frequency reduc-
tion of more than 50% including 4 children (40%) who became seizure-
free. In 5 of 10 patients (50%) there was a significant improvement in
behaviour, alertness and attention. Only 2 patients (20%) showed addi-
tional improvement in verbal responses and cognition. Adverse events
were reported in 4 patients (40%) and were mild and transient. Somno-
lence (30% of children) was the most common referred adverse event.
Conclusion: LEV is an effective and safe alternative as add-on therapy
in children with autistic regression and epilepsy. LEV has a positive
neuropsychological effect not directly related to seizure control.
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CONVULSION AS THE MOST COMMON PRESENTING SIGN
OF ACUTE DISSEMINATED ENCEPHALOMYELITIS (ADEM)
IN CHILDREN
1S. Noorbakhsh, 2H. Tonkaboni, and 3F. Khodapanahandeh (1Iran
Medical University, Research Center of Ped Infectious Disease, Iran,
2Medical University, Research Center of Ped Infectious Disease, Iran,
3Iran Medical University, Research Center of Ped Infectious Diseases,
Iran)
Acute disseminated encephalomyelitis is an uncommon inflamma-
tory demyelinating disease of the central nervous system. Approximately
70% of patients report a precipitating event, e.g., viral or bacterial infec-
tion or vaccination. The true incidence of the disease in Iran is undeter-
mined; exanthematous fevers and other viral infections, which predis-
pose to ADEM, are still prevalent.
A 2-year descriptive, retrospective chart review of children with a di-
agnosis of ADEM is presented. Fifteen cases 53% male; 47% female,
age: 1–12 years (33%), 9–12 years (36%), 6–8 years (26%), 1–2 years
(25%), no cases aged between 2–5 years. 88% presented in either winter
or spring. 46.4% had a recent upper respiratory tract illness. A previous
vaccination was administered to 13.6%; 40% had no URI or vaccina-
tion. VZV infection was present in 1; UTI in 2. Mycoplasma pneumo-
nia was present in 1 case. Presentation signs were: ataxia 60%; altered
consciousness 60%; fever+nausea and vomiting 46%; cranial nerve in-
volvement 33%; dysarthric speech 26%; convulsions 20%; hemiparesis
20%; paresthesia 13%; meninsismus 13%; headache 6%. Twelve patients
were treated with corticosteroids, and 3 with intravenous immunoglob-
ulins. Only 1 death was recorded. Three patients (20%) had long-term
neurologic sequelae. Probably, with advances in disease control, ADEM
in our country, as in other developing countries, there could be a change
from traditional exanthematous diseases to nonspecific respiratory in-
fections. Here, only one case of VZV infection developed ADEM. The
prognosis for survival and outcome was excellent.
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EPILEPSIES IN CHILDREN DURING ONE YEAR IN OUR
CLINIC
V. Tashko, A. Bushati, and A. Haruni (University Hospital Centre
“Mother Theresa,” Tirana, Albania)
Purpose: Studying of new cases presented at our clinic during the
year 2002.
Method: Our study is a prospective one. We have studied all new cases
presented in our clinic and out patients. Every child has gone under
neurological examination, EEG, ophthalmic examination. In children
under one year old we have performed also transfontanelar ultrasound;
for children with neurological impairments we have performed CT scan
of the head. The study is based on ILAE 1985, 1989 classifications.
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Results: We studied 511 children with seizures, of which 278 were
female (45.4%) and 279 male (54.5%). The study included children from
1 month to 14 years old: 1–12 months 73 children, 13 months–4 years
165 children, 5–10 years 179 children, 11–15 years 94 children. We
have reported: with partial epilepsy 298 children. 15.2% with benign
centrotemporal spikes, 8% with temporal spikes, 23.2% with occipital
spikes and 11.7% with plurifocal spikes. Twelve cases are symptomatic
with anomalies at CT scan of the head. With partial secondary gener-
alised epilepsy 103 children; 29 of them are evolving from simple partial
seizures and 74 from complex partial seizures. With generalised epilepsy
67 children: 16 atonic seizures, 23 tonic–clonic, 3 clonic, 11 tonic, and 4
myoclonic seizures. 5 children presented with absence, 4 children with
West syndrome and one child with epileptic encephalopathy. 40 children
presented with febrile convulsions and 3 children were unclassified.
Conclusion: From 511 children with epilepsy during the year 2002
most of them, 53.3%, presented with partial epilepsy and 20.2% with par-
tial secondary generalised. We noticed a predominance in males (54.5%).
Most of the cases (35%) were 5–10 years old. 7.8% of cases had febrile
convulsions. The most common forms of epilepsy are idiopathic (partial
86.26% and generalised 76.71%).
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AUTISM SPECTRUM DISORDERS AND TEMPORAL LOBE
EPILEPSY: REPORT OF 30 PAEDIATRIC PATIENTS
1F. Romero-Andu´jar, 1J. Garcı´a-Pen˜as, 1L. Gonza´lez Gutie´rrez-Solana,
1M. Ruiz-Falco´, 2M. Alcamı´, 1A. Duat Rodrı´guez, and 1L. Lo´pez-Marı´n
(1Pediatric Neurology Unit. Hospital Infantil Universitario Nin˜o Jesu´s,
Madrid, Spain, 2Pervasive Depelopmental Disorders Unit. Hospital In-
fantil Universitario Nin˜o Jesu´s, Madrid, Spain)
Purpose: To describe the natural outcome of 30 paediatric patients
with autism spectrum disorders, temporal lobe epilepsy and temporal
lobe lesions.
Method: This was a retrospective chart review of 30 consecutive
paediatric patients aged 36 months to 18 years who were diagnosed
with symptomatic temporal lobe epilepsy and fulfilled clinical criteria
of autism spectrum disorders according to DSM-IV. In all patients, we
analysed age at onset, sex, type of seizure, psychopathological disorders,
evidence of paroxysmal activity on EEG and neuroimaging findings.
Results: All patients had normal psychomotor development prior to
seizure onset. Epileptic seizures were the first neurologic sign and ap-
peared between 6 and 24 months of age. Convulsive status epilepticus
was the first ictal manifestation in 15 patients. Autistic regression was
well-defined in all patients between 24 and 36 months of age. Eight
children had temporal lobe sclerosis, 7 had cortical dysplasias, 5 had
tuberous sclerosis complex, 6 had arachnoid cysts and 4 had gangli-
ogliomas. Temporal lobe lesions were on the left-side in 13 patients, on
the right-side in 12 and were described as bilateral in 5.
Conclusion: Early onset seizures (<2 years) with temporal lobe
epileptiform activity on the EEG are associated with pervasive devel-
opmental disorders and mainly with autistic regression syndrome. It is
difficult to know if patients became autistic because of repetitive epileptic
seizures and/or persistent paroxysmal activity on the EEG, or because of
the epileptogenic and psychopathologic effect of temporal lobe lesions
during infancy and early childhood.
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SUBCLINICAL HYPOTHYROIDISM AND EPILEPSY IN
CHILDREN
A. Gniatkowska-Nowakowska (Outpatient Clinic of Neurology And
Epilepsy, Kielce, Poland)
Purpose: To analyse the correlation between epilepsy and subclinical
hypothyroidism in children.
Method: During two years (2001–2003) I measured the levels in
serum triiodothyronine (T3), thyroxine (T4) and thyroid-stimulating hor-
mone (TSH) in 132 children with epilepsy. They were receiving VPA (32
children), CBZ (12 children), LTG (11 children), TPX (16 children) in
monotherapy and add-on therapy of two drugs: VPA+CBZ (10 children),
VPA+LTG (27 children), VPA+TPX (17 children) and LTG+TPX (7
children). The results of T3, T4, TSH levels were compared with a control
group of 121 healthy children. Children were 5–16 years old and had
different kinds of epilepsy. All the results were assessed by statistical
methods.
Results: In all treated groups the mean of T3, T4 levels in serum was
statistically lower than in the control healthy group (p < 0.05) and the
TSH level was significantly higher (p < 0.05) in patients with epilepsy
(especially in the group receiving VPA or CBZ in mono and add-on
therapy).
Conclusion: The epilepsy treatment with antiepileptic drugs (espe-
cially VPA and CBZ) induces subclinical hypothyroidism.
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SYMPTOMATIC EPILEPSY IN CHILDREN WITH HEMI-
PLEGIC CEREBRAL PALSY
B. Olga and G. Valentina (St. Petersburg State Pediatric Medical
Academy, Russia)
Purpose: The aim of this study was to investigate clinical and elec-
troencephalographic (EEG) features of symptomatic epilepsy in children
with hemiplegic cerebral palsy.
Method: The population based study group comprised 70 children
with hemiplegic cerebral palsy (41 (58%) with right-sided hemiparesis,
30 (42%) with left-sided hemiparesis), 5–15 years of age. All were as-
sessed by case history, neurological, EEG, CT/MRI brain imaging and
psychological examination.
Results: Epileptic seizures developed in 40% children with hemi-
plegic cerebral palsy. Epilepsy was as common in boys as in girls (56%
boys and 44% girls respectively). The median age of onset of epilepsy
in children with right-sided hemiparesis was 2.5 years, in children with
left-sided hemiparesis the median age of onset of epilepsy was 5.5 years.
Among the patients with right-sided hemiparesis 35% had their first
seizure during the first year of life. Among the patients with left-sided
hemiparesis the first seizure appeared after 3 years in 50%. 61% children
with right-sided hemiparesis and 80% children with left-sided hemi-
paresis had abnormal brain CT or MRI findings (unilateral ventricular
dilatation, cortical and/or subcortical atrophy). Epileptic abnormalities
on EEG were observed in 35% children with right-sided hemiparesis and
58% children with left-sided hemiparesis. Lower IQ was found in 58%
children with right-sided hemiparesis and 62% children with left-sided
hemiparesis.
Conclusion: The onset of epileptic seizures was previous in chil-
dren with right-sided hemiparesis and developed with equal frequency
on right-sided hemiparesis and left-sided hemiparesis. In children with
left-sided hemiparesis epilepsy was more severe with focal epileptic ab-
normalities on EEG.
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ELECTROENCEPHALOGRAPHY IN CHILD EPILEPTOLOGY
M. Knezevic Pogancev (Institute For Child And Youth Health Care, Novi
Sad, Serbia and Montenegro)
Purpose: Electroencephalography is the most commonly used di-
agnostic method in children’s neurology. Electroencephalography is a
standard diagnostic method of assessment used after any disorders of
consciousness with children but is not of primary importance in making
a diagnosis. The aim of this study was to show that the EEG has been
applied too often in the process of getting information it cannot obtain.
Method: The study was conducted in the period from 1993 to 2003
in the Institute for Child and Youth Health Care in Novi Sad in 2000 for
first time hospitalised children after any consciousness disorder.
Results: Starting from the fact that an EEG checkup is expected to
confirm the presence of a change, and having in mind that the absence
of the latter does not necessarily mean excluding epileptic activity, it has
been found that 75% of EEG findings do not meet expectations.
Conclusion: The dominance of normal EEG findings compared to
those changed due to epilepsy, is the result of the fact that a large number
of EEG checkups are being done in order to “exclude epilepsy.” The EEG
has been applied too often in the process of getting information it cannot
obtain. The EEG checkup only, without precise anamnestic data and
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clinical observations, is not enough, neither to diagnose epilepsy nor to
deny its existence.
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LEVETIRACETAM IN CHILDREN AND ADOLESCENTS WITH
REFRACTORY EPILEPSY: A CLINICAL EXPERIENCE
1J. Arcas, 1A. Martinez Bermejo, 1M. Roche, 1R. Velazquez, and 2M.
Merino (1Paediatric Neurology Department, La Paz Hospital University,
Madrid, Spain, 2Neurophysiology Department, La Paz Hospital Univer-
sity, Madrid, Spain)
Purpose: Levetiracetam (LEV) is a new antiepileptic drug (AED) with
proven efficacy in partial and generalised seizures in adults and children.
This study evaluated the effect of LEV on 86 children and adolescents
with refractory epilepsy.
Method: Patients aged 2–20 years with refractory epilepsy (based on
ILAE classification and EEG), not adequately controlled with existing
AEDs or with adverse events (AEs) were included. LEV, as monotherapy
or add-on therapy, was commenced (at 20 mg/kg/day for most patients),
and uptitrated individually according to efficacy and tolerability. Patients
were followed for 3–48 months.
Results: Eighty-six patients (54 males [62.8%], aged 2–20 [mean 8.8]
years) were enrolled. Eight patients (9.3%) received LEV monotherapy;
78 (88.7%) received LEV as add-on therapy: 8 (9.3%) patients valproate
(VPA) + oxcarbazepine (OXC); 5 (5.8%) topiramate (TPM) + OXC; 5
(5.8%) TPM+VPA; 31 (36%) VPA; 25 (29.1%) OXC; 18 (20.9%) TPM;
11 (12.8%) phenytoin (PHT). Mean final LEV dose was 40.8 (maximum
62) mg/kg/day), reached in a mean of 3 weeks. Mean treatment duration
was 14.3 months. 19 (22.1%) patients became seizure-free; 63 (73.3%)
patients had ≥50% reduction in seizure frequency. LEV was withdrawn
due to lack of efficacy in 16 patients. AEs were reported in 13 (15.1%)
patients; transient somnolence in 4 (4.7%), irritability in 3 (3.5%). Pos-
itive effects were reported in 23 (26.7%) patients, 10 of whom reported
improved cognition.
Conclusion: LEV is effective and well tolerated in children and ado-
lescents with refractory epilepsy and has a positive effect on cognition.
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LEVETIRACETAM IN CHILDREN AND ADOLESCENTS: NO
TRADE-OFF BETWEEN SAFETY AND EFFICACY
H. Oslejskova, D. Sochurkova, and M. Ryzi (Children Neurology Clinic,
Brno, Czech Republic)
Purpose: To assess the safety, efficacy and impact on EEG-specific
epileptic abnormalities of levetiracetam (LEV) treatment in children with
uncontrolled partial seizures.
Method: Clinical audit of children treated with LEV add-on treat-
ment for partial onset seizures since 2002. LEV was up-titrated to
achieve seizure control and maintain tolerability. Safety and efficacy
were compared before, and 1 and 3 months after LEV initiation. The
main outcome parameters were retention rate, reduction in seizure fre-
quency/month, changes in EEG-specific abnormalities (rated 1 [im-
proved], 2 [no change], 3 [worsened]), and adverse events (AEs).
Results: 74 patients were included. Mean age was 11.1 ± 3.9 (range
4–19) years; mean duration of epilepsy was 5.8 ± 3.4 years; median
number of concomitant AEDs was 1; aetiology was lesional in 64.9%
(48/74) patients. Mean LEV dose was 27.1 ± 10.1 (median 27.0; range
8-54) mg/kg/day. Responder rate (≥50% seizure frequency reduction)
was 41.9% after 1 month and 39.2% after 3 months. Seizure freedom rate
(100% seizure frequency reduction) was 22.9% after 1 month and 16.2%
after 3 months. EEG recordings significantly improved in responders
compared with nonresponders (p = 0.019 after 1 month and p < 0.001
after 3 months). AEs were reported in 9.5% (7/74) patients; majority
were of mild-to-moderate severity (somnolence n = 2, asthenia n = 1,
fatigue n = 1, slight worsening of aggressiveness n = 1, abdominal pain
n = 1, worsening of behaviour n = 1). LEV was discontinued in 17.6%
(13/74) patients (lack of efficacy n = 12, AE n = 1).
Conclusion: LEV add-on treatment was efficacious and well tolerated
in children with refractory focal epilepsy, and significantly improved
EEG abnormalities.
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EFFECTIVENESS AND SAFETY OF LEVETIRACETAM IN
TREATMENT OF THERAPEUTICALLY RESISTANT EPILEP-
SIES IN CHILDHOOD
V. Bojinova and P. Dimova (Clinic of Child Neurology, University Hos-
pital of Neurology “Sv.Naum” Sofia, Bulgaria)
Purpose: To prospectively assess the effectiveness and safety of lev-
etiracetam (LEV) add-on therapy in children and adolescents with ther-
apeutically resistant epilepsy.
Method: LEV was administered to patients refractory to all conven-
tional and new antiepileptic drugs registered in Bulgaria at a mean dose of
40 mg/kg. Follow-up was 4-24 months. Efficacy was assessed as respon-
der rate (≥50% seizure frequency reduction) and seizure freedom rate
(100% seizure frequency reduction); safety, by evaluating LEV-related
adverse events (AEs).
Results: Forty-nine children, mean age 12.4 years, were included;
67.3% (33/49) had focal epilepsy, 22.4% (11/49) had generalised
epilepsy (idiopathic, n = 9 [myoclonic-astatic, n = 4; generalised tonic-
clonic seizures, n = 4; absences, n = 1]; symptomatic, n = 2), and
10.2% (5/49) had epileptic encephalopathies (Dravet’s syndrome, n =
3; Lennox-Gastaut syndrome, n = 2). Mean epilepsy duration was 7.7
years. Seizures occurred daily in 59.2% (29/49) patients and weekly in
40.8% (20/49). Overall responder and seizure freedom rates were 85.7%
(42/49) and 16.3% (8/49), respectively. LEV was effective in all types of
epilepsy syndromes: responder and seizure freedom rates were, respec-
tively: 93.9% (31/33) and 24.2% (8/33) for focal epilepsy patients; 72.7%
(8/11) and 9.1% (1/11) for generalised epilepsy patients; and 60% (3/5;
Dravet’s, n = 2; Lennox-Gastaut, n = 1) and 0% for patients with en-
cephalopathies. LEV was effective for all seizure types. In 78.6% (33/42)
patients showing clinical improvement, EEG abnormalities also reduced.
8.2% (4/49) patients experienced AEs (irritation, n = 3; headache, n =
1); none experienced aggravation of epileptic syndrome.
Conclusion: LEV is highly effective in children and adolescents with
long-lasting therapeutically refractory epilepsies, with a good safety pro-
file.
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LEVETIRACETAM OR OXCARBAZEPINE AS MONOTHER-
APY IN NEWLY DIAGNOSED BENIGN ROLANDIC SEIZURES
IN CHILDREN: AN OPEN-LABEL, PARALLEL GROUP STUDY
1G. Coppola, 2E. Franzoni, 3A. Verrotti, 2C. Garane, 2J. Sarajlija, 1F.
Operto, and 1A. Pascotto (1Clinic of Child Neuropsychiatry, Second
University of Naples, Italy, 2Clinic of Child Neuropsychiatry, University
of Bologna, Italy, 3Clinic of Child Neuropsychiatry, University of Chieti,
Italy)
Purpose: To evaluate the efficacy and tolerability of levetiracetam
(LEV) or oxcarbazepine (OXC) as monotherapy in children with newly
diagnosed benign epilepsy with centrotemporal spikes (BECTS).
Method: Children with BECTS were randomised to receive
monotherapy with either LEV or OXC. LEV was titrated up to 20–30
mg/kg QD or BID, and OXC up to 20–35 mg/kg QD or BID. Efficacy
was assessed by evaluating seizure frequency reduction and tolerability
by evaluating treatment-related adverse events (AEs).
Results: Thirty-nine consecutive patients (21M/18F), age 3.3–14
(mean 10.7) years, were recruited into the study. 21 received LEV
(11M/10F; mean age 10.5 years), and 18 received OXC (10M/8F; mean
age 8.4 years). After a mean follow-up of 18.5 (range 12–24) months,
90.5% (19/21) LEV patients and 72.2% (13/18) OXC patients achieved
seizure freedom. Mean serum levels were 4.1 (range 1.3-9.0) mcg/mL for
LEV and 15.2 (range 4.2-27.5) mcg/mL for mono-hydroxy-derivative of
OXC. Mild and transient AEs were reported in 14.3% (3/21) LEV pa-
tients (decreased appetite n = 2 and cephalalgia n = 1) and in 11.1%
(2/18) OXC patients (headache n = 1 and sedation n = 1).
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Conclusion: These preliminary data from an open, parallel group
study suggest that LEV and OXC as monotherapy may potentially be
effective and well tolerated in the treatment of children with BECTS.
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LEVETIRACETAM IN EPILEPSIES WITH CONTINUOUS
SPIKES AND WAVES DURING SLOW SLEEP
P. Dimova and V. Bojinova (Clinic of Child Neurology, St. Naum Uni-
versity Hospital of Neurology and Psychiatry, Sofia, Bulgaria)
Purpose: A prospective study on 6 children to evaluate the efficacy of
levetiracetam (LEV) add-on therapy in children with continuous spikes
and waves during slow sleep (CSWS), in terms of EEG, seizures and
neuropsychological functioning.
Method: LEV add-on therapy was initiated at a dose of 40–60
mg/kg/day and uptitrated weekly by approximately 10 mg/kg to a main-
tenance dose of 40–60 mg/kg/day. Patients’ medical charts and EEGs
were reviewed to analyse LEV’s effects on seizures, paroxysmal EEG
activity, and cognitive functions and behaviour. Awake and sleep EEGs,
as well as neuropsychological tests, were performed at baseline and 1
month after LEV treatment initiation. In children with clinical and/or
electrophysiological improvement after 1 month, LEV was continued
with regular evaluations after 3 and 6 months.
Results: Six children, aged 6–12 years, with CSWS in the course of
their idiopathic (n = 3) or symptomatic (n = 3) epilepsy were included.
After 1 month of LEV treatment, 50% (3/6) patients showed CSWS ces-
sation and full seizure control; 33.3% (2/6) demonstrated EEG improve-
ment and >50% seizure frequency reduction; 1 child (16.7%) showed
no improvements and LEV was discontinued. In 83.3% (5/6) patients,
neuropsychological functioning improved in parallel with clinical and
EEG improvement. In 1 child, despite excellent efficacy, aggression was
noted during the second month and LEV was discontinued. 66.7% (4/6)
patients continued LEV after 3 and 6 months because of maintained
clinical, EEG and neuropsychological efficacy.
Conclusion: Although small, this prospective study suggests that LEV
has an overall positive effect on the seizures, EEG, and neuropsycho-
logical functions of children with CSWS in epilepsies with different
aetiologies.
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LEVETIRACETAM TREATMENT IN RARE EPILEPTIC SYN-
DROMES OF EARLY CHILDHOOD: A CASE SERIES
B. Ryzhkov and V. Grigoryev (District Children Clinic No.1, Voronezh,
Russia)
Purpose: To assess the efficacy of levetiracetam (LEV) in the treat-
ment of rare epileptic syndromes of early childhood.
Method: LEV was administered to children previously unsuccessfully
treated for 3–8 months with combined antiepileptic drug (AED) and
hormone therapy.
Results: LEV was administrated to 15 children, age 4–18 months
with different childhood syndromes: 1) West syndrome, aged 8–18
months (n = 5): LEV (50 mg/kg/day) + topiramate (TPM) (n = 3)
or LEV monotherapy (50–80 mg/kg/day) (n = 2). 2 children (LEV
monotherapy) achieved seizure freedom and improved cognitive func-
tion, 3 children (add-on LEV) a marked seizure frequency reduction, up
to 83%. 2) Otahara syndrome (n = 1): LEV (50 mg/kg/day) + valproate
(VPA) + clobazam (CLB) resulted in marked seizure frequency reduc-
tion, 60–70%. 3) Focal epilepsy from birth (n = 5): LEV monotherapy
(60–90 mg/kg/day) (n = 3) resulted in seizure freedom; LEV (30–40
mg/kg/day) + TPM + CLB (n = 2) produced 80% seizure frequency
reduction. 4) Lennox-Gastaut syndrome (n = 4): LEV monotherapy
(40–80 mg/kg/day) produced seizure freedom in 2 patients, but was in-
effective in 2 patients. 5) Neuronal ceroid lipofuscinosis (n = 1): LEV
(60–70 mg/kg/day)+ ethosuximide resulted in marked seizure frequency
reduction of ≥50%. 6) Unspecified infant myoclonic epilepsy with en-
cephalopathy (catamnesis 2 month) (n = 1): LEV (40 mg/kg/day) +
TPM resulted in myoclonic status reduction, 70–80% seizure frequency
reduction and marked psychomotor development improvement.
LEV was well tolerated in all patients with no adverse events.
Conclusion: Our results demonstrate LEV’s efficacy in rare, refrac-
tory, progressive childhood epilepsy syndromes. Over 3–14 months
follow-up there was a marked reduction in seizure frequency and some
cognitive improvement.
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EFFICACY AND SAFETY OF LEVETIRACETAM AS ADJUNC-
TIVE TREATMENT IN ADULT AND PAEDIATRIC PATIENTS
SUFFERING FROM IDIOPATHIC GENERALISED EPILEPSY
WITH PRIMARY GENERALISED TONIC–CLONIC SEIZURES
J. Morrow, N01057 PGTC Study Group (Department of Neurology,
Royal Victoria Hospital, Belfast, Northern Ireland, UK)
Purpose: To assess the efficacy and safety of adjunctive levetiracetam
(LEV) in children and adults with idiopathic generalised epilepsy with
primary generalised tonic–clonic seizures (PGTCS).
Method: A multicentre, double-blind, randomised, placebo-
controlled parallel-group study of adjunctive LEV in patients 4 to 65
years old with PGTC seizures uncontrolled on 1–2 AEDs. Eligible pa-
tients with ≥3 PGTCS during 8 weeks baseline (4 week historical, 4
week prospective) randomly received LEV (target dose 3000 mg/day
adults, 60 mg/kg/day paediatric) or placebo. Four weeks titration was
followed by 20 weeks at stable dose. Efficacy, adverse events (AEs),
neurological, physical status and ECGs were assessed.
Results: Two hundred twenty-nine patients were screened, 164 ran-
domised; 140 completed treatment (titration and stable dose period); pri-
mary efficacy analysis based on 163 (ITT population). PGTCS weekly
frequency reduction of LEV over placebo during treatment (primary end-
point) was 28.3% (p = .004). Patients with ≥50% reduction of PGTCS
frequency was 72.2% (57/79 patients) for LEV patients, 45.2% (38/84
patients) for placebo (p = .0005). 24.1% (19/79) LEV patients were
seizure-free throughout the entire stable dose period compared with 8.3%
(7/84) on placebo (p = .009), and 34.2% (27/79) receiving LEV were
PGTCS seizure-free, compared to 10.7% (9/84) on placebo (p = .0003).
During the double-blind period, 1.3% (1/80) LEV patients vs 4.8% (4/84)
placebo withdrew with AEs.
Conclusion: Levetiracetam proved to be effective in reducing PGTCS
frequency in patients with IGE and the known tolerability profile of
LEV was confirmed. This study further demonstrates the broad spectrum
antiepileptic activity of LEV.
Funding supported by UCB.
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SEIZURE FREEDOM RATES IN DIFFERENT EPILEPSY POP-
ULATIONS TREATED WITH LEVETIRACETAM
1L. Sander, 2T. Glauser, 3B. Schmitz, 4R. Hiersemenzel, and 5P. Edrich
(1Institute of Neurology, Queen Square, London, UK, 2Comprehensive
Epilepsy Program, Children’s Hospital Medical Center, Department of
Neurology, Cincinnati, OH, USA, 3Department of Neurology, Charite´–
Humboltd University Berlin, Germany, 4Global Medical Affairs CNS,
UCB S.A., Anderlecht, Belgium, 5Biostatistics, UCB S.A., Braine-
l’Alleud, Belgium)
Purpose: Seizure freedom reduces mortality, morbidity and improves
quality of life. This review assessed seizure freedom rates in adults,
adolescents and children with refractory epilepsy treated with add-on
LEV for partial onset seizures (POS), idiopathic generalised epilepsy
(IGE) with myoclonic seizures and IGE with primary generalised tonic-
clonic seizures (PGCTS).
Method: All studies were double-blind, placebo-controlled with 4
weeks uptitration and 10–20 weeks evaluation. Adult POS patient data
were pooled from 2 Phase III studies of add-on LEV 3000 mg/day, and
paediatric (3–17 years) POS data from a study of LEV 60 mg/kg/day.
Adolescents and adults (12–65 years) with IGE and myoclonic seizures
received LEV 3000 mg/day and adults and children (4–65 years) with
PGTCS LEV 3000 mg/day adults, 60 mg/kg/day paediatric. Patients
were considered seizure-free if achieving freedom from all seizure types
throughout the entire evaluation (dropouts not considered seizure-free).
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Seizure freedom rates are expressed as percentages of all patients ran-
domised, taking at least one dose of study drug (ITT population).
Results: For each epilepsy population LEV-treated patients achieved
higher seizure freedom rates than did placebo-treated: POS adults, LEV
7.8% (22/282), placebo 0.5% (1/200) (p < .001); POS paediatric patients
LEV 8.9% (9/101), placebo 3.1% (3/97) (p = 0.135); IGE with my-
oclonic seizures LEV 21.7% (13/60), placebo 1.7% (1/60) (p = 0.001);
IGE with PGTCS LEV 24.1% (19/79), placebo 8.3% (7/84) (p = 0.009).
Conclusion: LEV add-on therapy was associated with high seizure
freedom in different epilepsy patient populations confirming its efficacy
across a large spectrum of seizure types in patients with IGE and focal
epileptic seizures.
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LEVETIRACETAM: TWO YEARS EXPERIENCE WITH
CHILDREN
E. Franzoni, J. Sarajlija, C. Garone, C. Celotti, I. Cecconi, V. Marchiani,
E. Malaspina, and F. Moscano (Child Neuropsychiatry Unit, University
Polyclinico S. Orsola-Malpighi, Bologna, Italy)
Purpose: Levetiracetam (LEV) was recently licensed for paediatric
use. We evaluated its efficacy and tolerability in our paediatric popula-
tion.
Method: Forty-eight patients with refractory epilepsy were included;
3 were later excluded with <1 month follow-up. LEV’s efficacy was
assessed by seizure frequency reduction and tolerability by adverse event
(AE) reporting.
Results: Forty-five (31 male, 14 female) patients, mean age 11 years
4 months were analysed. 32 (66.7%) had partial epilepsy with secondary
generalisation; 5 (11.1%) simple partial, 4 (8.9%) complex partial, 6
(13.3%) generalised seizures from birth; of these 2 patients had more
than one seizure type. 6/45 (13.3%) patients received LEV monotherapy,
2 with primary generalised seizures. In 18 (39.6%) children seizure fre-
quency decreased by ≥25%, 11/45 (24.5%) achieving seizure freedom.
29/48 (60.4%) patients experienced no seizure reduction, 4/48 (13.8%)
showed initial improvement. 6/48 (12.5%) patients experienced seizure
worsening. In 4 children aged<4 years, LEV was discontinued for lack of
efficacy or seizure worsening. LEV appeared less effective when com-
bined with topiramate. Responders received lower mean doses (33.9
mg/kg/day) than nonresponders (49.5 mg/kg/day). Mean doses were
25.7 mg/kg/day in seizure-free; 36.5 mg/kg/day in ≥50% responders;
45.7 mg/kg/day in ≥25% responders; 40.4 mg/kg/day in non-responders.
Patients with seizure worsening received 64.5 mg/kg/day. Moderate AEs
were reported in 15 (31.2%) patients, not requiring LEV discontinuation.
Conclusion: Our study showed LEV as effective and well tolerated in
nearly 40% of our patients and supports widespread evidence of LEV’s
broad spectrum of activity and good safety profile.
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EFFICACY AND SAFETY OF LEVETIRACETAM IN JUVENILE
MYOCLONIC EPILEPSY (JME)
G. Candeliere, A. Mazzeo, B. Lecce, and A. Tartarino (Neuroscience De-
partment, Clinical Neurophysiology Clinic, Ospedali Riuniti di Foggia,
Italy)
Purpose: To evaluate the efficacy and safety of levetiracetam (LEV)
in patients with JME.
Method: Twenty-one patients with JME (5 male, 16 female) aged
12–54 (mean 26.4) years, (SD ± 11.2) were retrospectively evaluated.
All had previously been treated with one or more antiepileptic drugs
(AEDs) (mostly valproate). 15/21 (71.4%) patients had received LEV as
monotherapy and 6/21 (28.6%) LEV as add-on therapy. Follow-up was
from 6–48 (mean 21.7) months. Efficacy was evaluated using the follow-
ing parameters: number of patients achieving seizure freedom, seizure
frequency reduction and EEG improvements. Safety was evaluated by
recording the intensity and duration of adverse events (AEs).
Results: 85.7% (18/21) patients achieved seizure freedom of between
6–48 (mean 23.3) months duration. One patient achieved a seizure fre-
quency reduction of 33% and in 2/21 (10.5%) patients, no change in
seizure frequency was observed. Of the 18 patients achieving seizure
freedom, 13/15 (86.7%) were receiving LEV monotherapy and 5/6 (83%)
were receiving LEV as add-on. The mean dose of LEV used was 2810
mg/day. EEG improvement was seen in 7/21 (33.3%) patients, with no
change observed in 12/21 (57.2%); in 2/21 (9.5%) patients the EEG wors-
ened. Minor, transient AEs were reported; drowsiness (n = 2), asthenia
(n = 1), diarrhoea (n = 1) and irritability (n = 1).
Conclusion: The results of this study demonstrated LEV to be both
effective and well tolerated in patients with JME.
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EPIDEMIOLOGICAL ANALYSIS OF CHILDHOOD EPILEPSY
FOR THE POPULATION OF LATVIA
1I. Macane, 2G. Rozentals, 1,3E. Vitols, and 2A. Kovaldins (1Riga
Stradin’s University, Riga, Latvia, 2Children’s Clinical University Hos-
pital, Riga, Latvia, 3Clinical Hospital “Gailezers,” Riga, Latvia)
Purpose: To analyse the incidence of epilepsy in a Latvian child
population according to gender, seizure type, and aetiology.
Method: This retrospective study includes analysis of 868 hospital
medical records in the period from 2001 to 2004. Provoked and repeat-
edly treated cases were not included. Diagnosis was classified according
to International Classification of Epilepsy of the International League
Against Epilepsy. For statistical analysis, Windows SPSS version 11.0
was used.
Results: The mean annual incidence rates vary from 24.3 to 36.8
cases per 100,000 population. The incidence rate was significantly higher
in males compared to females: 32/100,000 versus 25/100,000, respec-
tively (p = 0.031). The mean age (±SD) of the study population was
9.54 (±5.1) years. Generalised seizures (58%) were diagnosed more
frequently than partial seizures (40%) and unclassified seizures (2%).
Symptomatic epilepsy was diagnosed in 50%, and idiopathic epilepsy in
42% of cases. Aetiology of epilepsy was recognised as unclear in 8% of
cases. In 4% of patients, a family history of epilepsy was confirmed.
Conclusion: The observed incidence rates of childhood epilepsy in
Latvia are relatively consistent with data reported from other Baltic coun-
tries and Scandinavia. Generalised seizures were noticed more frequently
than partial seizures. Epilepsy was diagnosed more frequently in the male
population.
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NEUROPHYSIOLOGICAL BACKGROUND OF THE CLINICAL
SPECTRUM OF LANDAU-KLEFFNER SYNDROME
R. Ka´lma´nchey and L. Szabo´ (II.Department of Paediatrics, Semmelweis
University, Budapest, Hungary)
Purpose: The clinical course and outcome of the Landau-Kleffner
syndrome (LKS) can vary significantly in different children. The purpose
of this study was to clarify the impact of the electrophysiological char-
acteristics in the course and the outcome of the disease.
Method: Clinical and EEG data were analysed in the cases of 7 chil-
dren with typical LKS. The following data were observed and consid-
ered: age of children at the onset of epilepsy, of aphasia, of treatment
with antiepileptics, with ACTH/steroids. The pattern of the awaking
EEG and sleep EEG at the time of the onset of epilepsy, of aphasia, dur-
ing aphasia, during severe behavioural disturbances, during antiepileptic,
ACTH/steroid treatment, and after remission of aphasia, or after the cure.
Event related potential (ERG), source-localisation and PET study were
performed on 1 of the children during the course.
Results: Better outcome, and slighter clinical course in linguistic
and cognitive respect were related to the later onset, earlier treatment,
more anterior (central) or predominantly right sided SW activity in
awakeness, less bilateral ESES during sleep, quicker and more pro-
nounced normalisation of the sleep EEG pattern on the ACTH/steroid
treatment.
Conclusion: The language and cognitive course and outcome of LKS
seems to be related to the spreading tendency of the partial, “benign”
SW activity of the dominant hemisphere to the whole hemisphere during
awakeness, and to the contralateral hemisphere during sleep in the “crit-
ical” period of language development. Early ACTH/steroid treatment of
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this spreading seems by this time to be the best prevention of the fixation
of linguistic and cognitive defect.
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REFRACTORY EPILEPSY AND DEVELOPMENTAL BRAIN
DEFECT
V. Guzeva, M. Fomina, and D. Korostovtsev (1St. Petersburg State Pe-
diatric Medical Academy, Russia, 2St. Petersburg State Pediatric Medi-
cal Academy, Russia, 3St. Petersburg State Pediatric Medical Academy,
Russia)
Purpose: The problem of diagnosis and treatment of most severe
refractory epilepsy in childhood is the main problem in epileptology.
This disease may be established after retrospective observation for two
or more years.
Method: We studied 1957 patients with different forms of epileptic
syndromes, aged 0–16 years from St. Petersburg during 2000–2005.
Children aged 0–3 years, 1070; 4–10 years, 493, 10–16 years, 394. Neu-
rological examination, MRI scans, CSF study, EEG and EEG-video,
immunological and virological tests were done in all.
Results: Idiopathic forms had 750 patients (38.4%), cryptogenic 286
(14.6%), symptomatic 921 (47%). Refractory epilepsy was diagnosed
in 235 patients (25.5% of symptomatic forms). Developmental brain
defects were detected in 169 children (71.9%): microcephalia in 61,
Dandy-Walker syndrome in 17, Aicardi syndrome in 31, lissencephaly
in 12, pachygyria in 24, double cortex and other cortical disgenesies in
24 patients. Metabolic disturbances were confirmed in 36 children and
mitochondrial diseases in 15. Other factors causing refractory epilep-
tic seizures were diagnosed in 10 patients (cerebral tumour, Rasmussen
syndrome). West syndrome was established in 151 causes (64.3% of
refractory epilepsies). Aetiological factors of West syndrome: develop-
mental defect in 78 patients, perinatal hypoxia in 39, TORCH-infection
in 14, tuberous sclerosis in 17, neuroinfection in 3. After 2 years of onset
of refractory West syndrome in more cases (118) with established par-
tial symptomatic epilepsy: Lennox-Gestalt syndrome was diagnosed in
25 patients (10.6%); partial symptomatic epilepsy as primary diagnosis
in 59 (25.1%). All patients with refractory epilepsy showed neurologi-
cal signs: developmental retardation, speech and behavioural problems,
and motor defects. Diagnosis of refractory forms was detected after two
years non effective treatment with high doses of 4 (or more) antiepilep-
tic drugs. Neurosurgical correction was provided for 12 patients in this
group.
Conclusion: Developmental brain defects are a main cause of re-
fractory epilepsy (71.9%). The most common form of refractory symp-
tomatic generalised epilepsy in children aged 0–3 years is West syn-
drome. After long term observation of this group more cases established
the transformation of seizures in partial (partial symptomatic epilepsy).
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BENIGN CHILDHOOD OCCIPITAL EPILEPSY WITH LE-
SIONS IN CRANIAL MRI INVESTIGATION
D. Yalc¸y´n, H. Toydemir, L. C¸elebi, and H. Forta ( i li Etfal Education
Hospital Neurology Clinic, 19 Mayy´s Mahallesi, i li, 34360 ´Ystanbul,
Turkey)
Purpose: Our purpose is to describe the clinical and electroencephalo-
graphic features of 7 patients diagnosed with benign childhood occipital
epilepsy (BCOE) with different lesions detected in cranial MRI.
Method: Our study was based on patients seen in our Epilepsy Out-
patient Department where we initiated a prospective study of BCOE in
1995. Our records revealed 30 patients with Panayiotopoulos syndrome
(PS) and 50 patients with Gastaut syndrome (GS); among them 7 with
cranial lesions in their MRI.
Results: The onset was between 5 and 13 years. According to ictal
symptomatology 3 patients were classified with PS and four with GS.
The seizures of patients with PS included mainly autonomic symptoms
such as pallor, mydriasis, urinary and faecal incontinence. The seizures
of the other 4 patients always started with visual symptoms such as
multicolored, bright, moving lights or blindness. All patients had occip-
ital spike-wave complexes in their EEG blocked by eye opening. In the
cranial MRI, 1 patient had bilateral and another had unilateral occipi-
tal encephalomalacic lesions, 2 had mild hippocampal atrophy and high
signal intensity on Flair images in the described region, 1 had a neuroep-
ithelial cyst whereas another 1 had an arachnoid cyst and colpocephaly
in lateral ventricles. The last patient had millimetric focal focuses in
the subcortical regions as well as in the superior and inferior tempo-
ral gyri. All patients, except for 1, received carbamazepine treatment
450–600 mg/day. None of our patients had a seizure under antiepileptic
treatment.
Conclusion: We concluded that different lesions can be detected in
patients with BCOE.
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NEUROLOGICAL CHARACTERISTICS OF CHILDREN WITH
CRYPTOGENIC LOCALISATION–RELATED EPILEPSY COR-
RELATED WITH ACADEMIC DELAY
1R. Reijs, 1S. van Mil, 1M. van Hall, 1J. Arends, 2J. Weber, 3W.
Renier, and 1,2A. Aldenkamp (1Epilepsy Centre Kempenhaeghe, Heeze,
The Netherlands, 2Maastricht University Hospital, The Netherlands,
3University Medical Centre, St Radboud, Nijmegen, The Netherlands)
Purpose: The prognosis of cryptogenic localisation–related epilepsy
(CLRE) with childhood onset is difficult to study: due to the defini-
tion the population constantly changes. Epilepsy can influence academic
achievement. In a multidisciplinary programme data were collected re-
garding school-aged children with epilepsy, to correlate clinical, neu-
ropsychological, neurophysiological and academic variables and obtain
an overview of a CLRE cohort.
Method: Seventy children with CLRE were assessed, mean age 10.2
years (6.1–15.11). A standardised program was administered to all chil-
dren. Using SPSS, correlations between clinical neurological variables
and academic achievement were computed.
Results: For 60 children the onset of epilepsy could be determined;
mean age at onset was 6.4 years. Seizure types varied considerably, nev-
ertheless 44 children experienced absence-like complex partial seizures.
Thirteen children had been seizure free for at least one year, 36 ex-
perienced at least one seizure per week. Nine children did not use
antiepileptic drugs, 46 were on monotherapy. EEG abnormalities were
absent in one-third of the children, and present in less than 1% of
the time in another third. Mean IQ was 88 (70–127). Mean delay
in school (two subsets of language, and arithmetic) was almost one
year (6.59, 8.44, 9.95 months; ten months equivalent to one year).
Only age at onset was positively and significantly correlated with aca-
demic delay, not with IQ. This was not explained by duration of the
epilepsy.
Conclusion: Age at onset is the main characteristic defining academic
delay in children with CLRE.
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CYTOCHROME P450 CYP2C9 AND CYP2C19 GENETIC POLY-
MORPHISMS IN CROATIAN CHILDREN WITH EPILEPSY
1R. Gjergja, 1L. Cvitanovic-Sojat, 1L. Bielen, 1T. Sojat, and 2M. Ste-
fanovic (1Department of Pediatrics, University Hospital Sestre Milos-
rdnice, Zagreb, Croatia, 2Department of Pediatrics, University Hospital
Sestre Milosrdnice, Zagreb, Croatia, 3Department of Pediatrics, Univer-
sity Hospital Sestre Milosrdnice, Zagreb, Croatia, 4Department of Pedi-
atrics, University Hospital Sestre Milosrdnice, Zagreb, Croatia, 5Clinical
Institute of Chemistry University Hospital Sestre milosrdnice, Zagreb,
Croatia)
Purpose: The aim of this study was to clarify the effects of CYP2C9
and CYP2C19 genotyping on ongoing antiepileptic drug (AED) treat-
ment and on AED choice. The correlation of efficacy or adverse events of
each AED with the CYP2C9 and CYP2C19 polymorphisms was carried
out.
Method: Croatian children with epilepsy, treated with different AEDs
(n = 68) and before the introduction of therapy (n = 20) were genotyped
for CYP2C9 and CYP2C19 alleles (∗1, ∗2 or ∗3). Children were divided
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into three subgroups: A (n = 19) received AED inducers of CYP isoforms
(CBZ, PH); B (n = 49) AEDs noninducers of CYP metabolism (VPA,
LTG, TPM, GBP, CLB, ESM, CZP, LEV) and C (n = 20) before AED
treatment.
Results: There were 44 girls and 44 boys, average 6.5 yrs. CYP2C9
genotyping results revealed: 47 extensive metabolisers (EM)–∗1/∗1 and
8 poor metabolisers (PM)–∗2/∗2 (n = 3), ∗2/∗3 (n = 3) and ∗3/∗3 (n =
2). There were also 33 heterozygous patients for CYP2C9 (intermediate
metabolisers (IM)–∗1/∗2 (n = 22) and ∗1/∗3 (n = 11). Genotyping of
CYP2C19 revealed: 71 homozygous patients for ∗1/∗1 (EM) and only 17
heterozygous (IM) for ∗1/∗2. Following these results 13 patients in group
A were substituted by noninducing AEDs. In 13 patients in group B, VPA
(substrate and inhibitor of CYP2C9) was substituted with LTG/TPM
because of poor seizure control. In 7 patients in group C genotyping
guided a first-choice AED.
Conclusion: For the better management of childhood epilepsy we
should put greater emphasis on the influence of CYP2C9 and CYP2C19
genotyping on the optimal choice of AEDs.
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EPILEPSY AND EPILEPTIFORM EEG: ASSOCIATION WITH
AUTISM SPECTRUM DISORDERS
1G. Pustorino, 1M. Spano`, 1D. Bellantone, 1F. Bitto, 1D. Sgro, 1G.
Tricomi, 1G . Di Rosa, 2A. Adamo, 1M. Bonsignore, 2A. Spina, 1E.
Germano`, and 1G. Tortorella (1Unit of Child Neuropsichiatry, Policlinico
Universitario, Messina, Italy, 2Unit of Child Neuropsichiatry, Ospedali
Riuniti, Foggia, Italy)
Purpose: To assess, retrospectively, the prevalence of EEG abnormal-
ities and/or seizures in a sample of autistic children and to describe EEG
and epileptic features.
Method: Eighty-six children with primary autism (CARS score ≥30)
were investigated regarding age of onset and severity of autism, IQ, main
characteristics of seizures and EEG abnormalities. The prevalence and
the relationship among the examined features were determined.
Results: Twenty-one percent showed epilepsy and/or epileptiform
EEG; only 14% suffered from epilepsy. Forty-two percent of epilepti-
form abnormalities were focal. The totality of focal abnormalities was
temporal, left-sided in 80% of the recordings. Higher frequencies of EEG
abnormalities were associated with more severe autistic symptoms. Lan-
guage was most severely compromised when EEG abnormalities were
located in the left temporal lobe. Sixty-six percent of seizures were gen-
eralised, 17% were focal, 17% were secondarily generalised. Children
presenting with epilepsy and/or epileptiform abnormalities showed a
lower IQ and the trend to a later onset of autistic symptoms.
Conclusion: Our results are in accordance with literature data (Tuch-
man R. et al. Epilepsy in autism, Lancet Neurology 2002,1:352–8) show-
ing that in autism the risk of EEG abnormalities and/or epilepsy is higher
compared to the general population. Our data support the hypothesis that
epileptiform abnormalities and epilepsy could interfere with the presen-
tation and the course of autism. It would be interesting to test whether
antiepileptic treatment is also relevant for autism.
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REFRACTORY GENERALISED CONVULSIVE STATUS
EPILEPTICUS IN CHILDREN: A LOCAL EXPERIENCE
1M. Tan, 1R. Bernardino, and 1B. Sanchez (Philippine General Hospital,
Manila, Philippines)
Purpose: To describe clinical characteristics of children with refrac-
tory generalised convulsive status epilepticus (RGCSE) in the local set-
ting and analyse factors affecting outcome.
Method: A prospective cohort study of all patients <19 years old with
RGCSE in Philippine General Hospital over a 7 month period was con-
ducted. Demographic data, seizure characteristics, therapeutics, compli-
cations of seizure and hospitalisation were determined. Factors affecting
outcome were analysed independently.
Results: Eight Filipinos (mean age 6.28 ± 7.35 years) were included.
Acute symptomatic RGCSE occurred in 5 patients who were neurolog-
ically normal prior to seizure onset. Three with epilepsy-related RSE
had developmental delay. Six patients received treatment within 1 hour
from seizure onset. All received at least 1 dose of diazepam and a ther-
apeutic dose of a second line anticonvulsant. In addition, midazolam
infusion was administered to 2 patients. Mean treatment duration be-
fore seizure control was 7.49 ± 5.17 hours. Outcome was poor for all.
Of 4 deaths, 3 patients had acute symptomatic RGCSE. Death occurred
in 60% of patients who had normal baseline neurodevelopmental status
and in 57% whose seizures were controlled >2 hours from treatment ini-
tiation. However, there seemed to be no association between age, time
before treatment initiation and outcome. Survivors developed neurologic
deficits.
Conclusion: Occurrence of RGCSE is associated with poor outcome
and an increasing trend to mortality in patients with acute symptomatic
RGCSE, normal baseline neurodevelopmental status and seizures lasting
>2 hours before control. These data emphasise the need for aggressive
management of an underlying cause and termination of seizures.
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ELECTROCLINICAL FEATURES OF INFANTILE SPASMS AS-
SOCIATED WITH ASYMMETRIC MRI FINDINGS
S. Kim, H. Kim, J. Lee, H. Hwang, J. Chae, J. Choi, K. Kim, and Y.
Hwang (Seoul National University Hospital, South Korea)
Purpose: Pathophysiology and underlying epileptogenesis of infan-
tile spasms (IS) have not been fully understood. The aim of this study
was to investigate the clinical and EEG features of IS associated with
asymmetric lesions on brain MRI.
Method: Twelve IS patients (male 5, female 7) who had asymmet-
ric MRI findings were reviewed. Brain MRI findings were as follows:
focal cortical dysplasia in 6, asymmetric periventricular leukomalacia
with unilateral porencephalic cyst in 2, asymmetric hydrocephalus in 2,
tuberous sclerosis in 1 and Sturge-Weber syndrome in 1. We analysed the
ictal semiology and EEG by long-term video-EEG monitoring (VEM)
and compared them with interictal EEG.
Results: Interictal EEG showed symmetric hypsarrhythmia in 6 pa-
tients and asymmetric hypsarrhythmia in 6 patients. During the VEM
symmetric spasms were noted in 5 patients, while 4 patients had asym-
metric spasms and 3 patients showed symmetric as well as asymmet-
ric spasms. Ictal EEG revealed an asymmetric ictal pattern in 10 pa-
tients, however, 2 patients showed symmetric ictal EEG features. Among
the 6 patients who had symmetric hypsarrhythmia on interictal EEG,
all showed asymmetric ictal EEG patterns. Asymmetric delta bursts
were found in 5 patients, and in a patient who showed symmetric
delta bursts, concurrent focal rhythmic sharp wave discharges were also
noted.
Conclusion: Interictal EEG may not reflect asymmetric features of
structural imaging, but may imply cortical phenomenon according to
the propagation of epileptiform activity. Ictal EEG was more helpful in
determining the contribution of focal structural abnormality for devel-
oping infantile spasms.
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EVOLUTION OF SEIZURE TYPE AND EEG PATTERN IN
A PATIENT WITH VERY EARLY ONSET OF HUNTINGTON
DISEASE
1,3D. Hoffman-Zacharska, 2K. Wojaczynska-Stanek, and 2E. Marszal
(1Neurogenetics Unit, Clinic of Neurology, Epileptology and Sleep Dis-
orders in Children and Adolescents, Institute of Mother and Child, War-
saw, Poland, 2Department of Pediatrics and Child Neurology, Medical
University of Silesia, Katowice, Poland, 3Department of Genetics, Insti-
tute of Psychiatry and Neurology, Warsaw, Poland)
Purpose: Huntington’s Disease (HD) is an autosomal dominant, neu-
rodegenerative disorder caused by dynamic mutation in the IT15 gene.
The onset of disease is usually in the 4th/5th decade of life but under the
age of 20 in about 10% of patients. This Juvenile Huntington’s Disease
(J-HD) is clinically distinct from the adult-onset form. One of the J-HD
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characteristics features epilepsy and occurs in 90% of patients with onset
in the first five years of life. Although it is so common in J-HD, the type
of seizures, and the main EEG data are still poorly described. We report
the case of a patient with an evolution of seizures in the context of data
referring to epilepsy in patients with J-HD.
Method: The patient was a boy with J-HD of very early onset (died
at the age of 11). The clinical diagnosis was confirmed by DNA analy-
sis [(CAG)95/(CAG)17]. The first symptoms were observed at the age
of 3 as a worsening of speech and episodes of absence (controlled
with valproate). At the age of 8 EEG showed sharp waves, polyspike
and spike-and-wave discharges with right side predominance. At the
age of 9 intractable tonic–clonic and myoclonic seizures were noticed.
At the age of 11 the patient suffered from intractable epilepsy and
EEG showed reduction of background activity without any epileptiform
discharges.
Results: In the case of the presented patient the noncharacteristic
symptoms started at the age of 3, but J-HD was suspected when he was
9, showing cognitive and psychomotor decline, rigidity and involuntary
movements (there was no HD in his family). The seizure evolution started
very unusually, from absences, when the most common seizure types in
HD are GTC and myoclonic seizures. Knowing the molecular data we
can say now that clinical presentation was not very unusual for such
an early form of J-HD, but without the family history of disease the
differential diagnosis was not so obvious.
Conclusion: Our data, as well as that published elsewhere, shows
that J-HD is not self-evident from a clinical point of view and should be
considered in children with intractable epilepsy and signs of progressive
encephalopathy even without a family history of the disease.
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PARTNERS IN EPILEPSY (PIE): EPILEPSY MANAGEMENT
WITH INTERNATIONAL ELECTRONIC RECORDS REG-
ISTRY SYSTEM: ANALYSIS UPDATE IN PAEDIATRICS
1L. Lagae, 2F. Pinto, 3P. Ryvlin, 4A. Gil-Nagel, 5H. Cross, and
6P. Participants (1University Hospitals KULeuven, Leuven, Belgium,
2Hospital Santa Maria, Lisbon, Portugal, 3Neurological Hospital, Lyon,
France, 4Hospital Ruber Internacional, Madrid, Spain, 5Institute of Child
Health/Great Ormond Street Hospital for Children, NHS Trust, London,
6On behalf of PIE Project Participants)
Purpose: To study current practices and clinical outcomes based on a
large naturalistic data cohort, and to identify needs in paediatric epilepsy
management.
Method: Electronic records management in daily clinical practice
(demographics, aetiology, syndrome and treatment) in epilepsy centres
in Belgium, France, Portugal, Spain, Switzerland, and United Kingdom.
Results: Data was analysed from 1420 children (M/F =
54.4%/45.6%), mean age at first attack: 5.6. Follow-up was avail-
able for 1359 children, [mean = 227 days, median = 320, sd = 403
(range 1 day–12.4 yrs.)] Aetiology reported for 37% of total children.
Of these, the most frequent cause was cortical/developmental disor-
ders/malformations (11.7%). In 39% of the cohort, epilepsy syndrome
was defined: 49% diagnosed with partial epilepsy, 36% with gener-
alised epilepsy, 10% with undetermined epilepsy, and in 5% special
epilepsy syndromes were described. 52% were seizure-free at last follow-
up visit. Among children still experiencing seizures, the most frequent
seizure type was partial seizures, 55% (median: 3/month; range: 0–
600/month). Of those using AEDs at the last follow-up visit, 72% were
on monotherapy: valproic acid (36%), carbamazepine (17%), lamotrig-
ine (6.4%), and topiramate (43.6%). 18% were on two, 8% on three,
and 2% on four AEDs. The most common AED combinations were:
lamotrigine/valproate (2.7%), carbamazepine/valproate (2.3%), topira-
mate/valproate 1.7% and carbamazepine/lamotrigine (1.1%).
Conclusion: Registry analyses provide valuable naturalistic informa-
tion on epilepsy characteristics, outcome and AED treatment patterns in
children. Partial epilepsy was the most common type identified. In the
majority, however, the epileptic syndrome was not recorded. Five out
of 10 were seizure-free at the last consultation. The majority received
monotherapy. Side effects were not often reported. (PIE is supported by
Janssen-Cilag)
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FAST TITRATION OF ADJUNCTIVE TOPIRAMATE IN PAEDI-
ATRIC PATIENTS WITH DIFFICULT-TO-TREAT EPILEPSY
1G. Kluger, 2A. Schreiner, 2B. Schauble, and 1H. Holthausen
(1Neuropediatric Clinic and Clinic for Neurorehabilitation; Epilepsy
Center for Children and Adolescents, Vogtareuth, Germany, 2Medical
& Scientific Affairs, Janssen-Cilag, Neuss, Germany)
Purpose: To evaluate efficacy and tolerability of adjunctive topiramate
(Topamax, TPM) using fast titration in children with difficult to treat
epilepsy and frequent seizures.
Method: A 12 week single centre prospective noninterventional study
in topiramate-naive hospitalised patients age 2 to 12 years. If clinically
indicated, TPM was started at the discretion of the investigator at ap-
proximately 1mg/kg/day bodyweight with dose increments of 1mg/kg
every 3 days and a target dose up to 8mg/kg/day. Seizure frequency and
adverse events were documented at each visit.
Results: Nineteen children (64% male, mean age 4.4 ± 3.5 years,
median epilepsy duration 1.6 years) were enrolled. Difficult to treat
epilepsy was characterised by frequent seizures (84% of patients), and
unsuccessful use of other antiepileptic drugs (AEDs) (mean 5.2). All
patients had ≥1 concomitant AEDs at baseline, (valproic acid (59%),
clobazam (47%) or oxcarbazepine (22%)). Mean TPM starting dose was
1.1 ± 0.5mg/kg/day and 3.3 ± 2.0mg/kg/day at endpoint (range 0.5–
6.7mg/kg). Median seizure frequency was approx. 182 in the 4 week
retrospective baseline. 47% of patients were TPM responders with a
50% seizure reduction, 1 patient was seizure free at time of study con-
clusion. TPM efficacy was rated very good or good in 42% of patients,
tolerability in 37%. No serious adverse events occurred. Adverse events
≥5% were somnolence (21%), psychiatric symptoms (14%), decreased
appetite (10%) and nervousness (7%).
Conclusion: In children with difficult to treat epilepsy, a fast titration
of TPM appears to be effective, and given the difficult situation, well
tolerated. Interestingly, relatively low doses of adjunctive TPM provided
significant improvement in seizure frequency.
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THALAMIC LESION AND EPILEPSY WITH ELECTRICAL
STATUS EPILEPTICUS IN SLOW WAVE SLEEP AND/OR GEN-
ERALISED SPIKE-WAVE PATTERN
1A. Kelemen, 1P. Halasz, 1P. Barsi, 2Z. Gyorsok, 3J. Sarac, and 4M.
Neuwirth (1National Institute of Psychiatry and Neurology, Budapest,
2National Institute of Neurosurgery, Budapest, Hungary, 3Heim Pal Chil-
dren’s Hospital, Budapest, Hungary, 4Bethesda Children’s Hospital, Bu-
dapest, Hungary)
Purpose: To report on 4 patients, who have unilateral thalamic lesion
and epilepsy with clinical and electrical features of generalised epilepsy.
Method: Clinical, MRI and awake and sleep EEG data were evaluated.
Results: The first 3 patients have unilateral perinatal lesion, 1
with generalised tonic–clonic seizures (GTCS) on awakening and later
nonconvulsive status epilepticus with 2.5 Hz SW pattern, 1 with Landau-
Kleffner-like syndrome, and the 3rd with mainly atonic seizures. During
the course of the disease all children developed electrical status epilep-
ticus in slow wave sleep (ESES). The 4th patient has a dominantly uni-
lateral thalamic tumour and epilepsy that mimics juvenile myoclonic
epilepsy. All the patients have a lesion located in the postero-inferior
medial part of the thalamus. The role of some thalamic nuclei in the
generalised spike-wave (GSW) electrical pattern pathophysiology is dis-
cussed, with emphasis on the possible role of dorsal intralaminar nuclei
and zona incerta.
Conclusion: A unilateral thalamic lesion located in the postero- infe-
rior medial part of the thalamus may facilitate ESES.
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SPECTRUM OF SYNDROMES WITH MYOCLONIC SEIZURES
IN DIFFERENT PAEDIATRIC AGE GROUPS
N. Tatishvili, S. Tatishvili, and L. Kandareli (Central Child Hospital,
Tbilisi, Georgia)
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Purpose: Myoclonic seizures are frequent seizure types in the paedi-
atric age group. They appear as different syndromes at different ages and
are frequently associated with difficulties in classification and manag-
ing. The aim of the study was the identification of frequency of different
syndromes with myoclonias for classification according to age groups.
Method: During 2001–2002 we examined 397 patients with my-
oclonic seizures. Ages varied from neonatal to 18. All patients under-
went long term EEG, MRI, neuropsychological testing. Clinical data
was analysed prospectively with reevaluation in 2005. Distribution of
patients according to age groups was as follows: neonates 51, infants
126, children (2–11) 152, adolescents 66. Reevaluation was carried out
on 385 patients. 12 patients were missed during follow up.
Results: Patients were divided according to syndromes and age
groups. For 10.5% classification was impossible. Problems were mini-
mal in adolescence: 3%.
Classification difficulties most frequently occurred in infancy, 14.8%;
in childhood in 10.1%. Distribution of syndromes was: neonatal seizures
13.2%, benign myoclonic epilepsy 1.3%, severe myoclonic epilepsy
(SME) 2.3%, early myoclonic encephalopathy 1.3%, epilepsy with my-
oclonic astatic seizures 6.49%, childhood absence epilepsy 11.7%, juve-
nile absence epilepsy 10.1%, epilepsia with myoclonic absences 4.4%,
LGS 2.9%, infantile spasms 23.9% and juvenile myoclonic epilepsy
13.2%. Unclassifiable cases were difficult for treatment. In 35 such cases,
full seizure control was not achieved, reduction of seizure frequency oc-
curred only in 3 cases, while even in severe epilepsy syndromes such as
SME, LGS and IS seizure control was significantly (p < .001) better.
Conclusion: Myoclonic seizures are frequent in all age groups. Dif-
ficulties in classification and treatment are more prominent in infancy.
Resistance to treatment is higher in unclassifiable cases.
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EARLY ONSET EPILEPSY: AETIOLOGICAL STUDY AND
FOLLOW-UP ON 59 PATIENTS
1I. Pieri, 1R. Vittorini, 2A. Castella, and 1G. Capizzi (1Division of Child
Neurology and Psychiatry OIRM University Turin. Italy, 2Department
of Public Health and Microbiology University of Turin, Italy)
Purpose: We reviewed data of 59 patients admitted to the Division of
Neuropsychiatry of “Regina Margherita” Hospital in their first year of
life in order to evaluate peculiar aspects of clinical features and follow-up
between subjects with infantile spasm and early onset epilepsies without
spasms.
Method: We analysed demographic features, clinical aspects, aetiol-
ogy, neuroimaging studies, neurophysiological recordings, therapy and
psychomotor development of 27 subjects with infantile spasms (Group
I) and 32 subjects with other types of epilepsy without spasms (Group
II) in a 5 year period (2000–2005).
Results: Age at onset of seizures ranged from 1 to 9 months, mean
age 4.7 months (SD ± 2.6) in group I, and ranged from 1 to 12 months,
mean age 5.9 months (SD ± 2.8) in group II. Prevalent aetiology was
prenatal injury (group I: 27%, group II: 16%), cerebral malformation
(I: 26%; II: 28%), idiopathic (I: 11%, II: 31%), and others: vascular, ge-
netic, metabolic disorders, neurocutaneous syndromes (I: 36%, II: 25%).
Neuroimaging studies showed a normal brain (I: 19%, II: 38%), brain
abnormalities (I: 69%, II: 59%), cerebrospinal fluid abnormalities (I:
12%, II: 3%).
Seizure free patients were 52% in group I and 62% in group II after
onset of drug therapy. Psychomotor development was delayed in 40% of
subjects in group I and 20% in group II.
Conclusion: Our data show worse prognosis in terms of cognitive
and psychomotor development, than in terms of poor seizure control, in
those patients whose epilepsy started with infantile spasms.
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MALIGNANT MIGRATING PARTIAL SEIZURES OF IN-
FANCY: ANALYSIS OF ICTAL VIDEO-EEG
E. Cesaroni (Pediatric Neuropsychiatric Department Ospedali Riuniti
Presidio Ospedaliero Di Alta Specializzazione G. Salesi, Ancona, Italy)
Purpose: Malignant migrating partial seizures of early infancy
(MMPSI) is a rare and age-specific epileptic condition characterised
by onset within the first 6 months of life in which nearly contin-
uous intractable partial seizures involve multiple independent areas
of both hemispheres with progressive severe psychomotor retarda-
tion. Few authors who reported this epileptic encephalopathy have
attempted to recognise the aetiology but there are no identifiable
causes.
Method: We retrospectively reviewed 4 patients who arrived in our
institution over the last 3 years, and who fulfilled the diagnostic criteria
for MMPSI. Electroclinical characteristics by video-EEG were recorded
and therapeutic options were evaluated.
Results: All patients have early seizures with motor and autonomic
components, consisting of apnea, cyanosis, and flushing, lasting a few
minutes. Many of these seizures were clinically mild and easily over-
looked without video-EEG recording. Later, seizures were more poly-
morphic, arising independently from multiple regions of both hemi-
spheres, lasting a few to many weeks. Extensive investigations failed to
identify an underlying cause. There was no response to antiepileptic drug
therapy and no developmental progress. Two infants have been implanted
with vagus nerve stimulation (VNS). No patients became seizure-free
but a reduction in seizure frequency and severity was observed mainly
in VNS implanted patients.
Conclusion: Our patient data confirm the peculiar clinico-EEG pat-
tern of the syndrome, the lack of evidence for an underlying disor-
der, the severity of prognosis despite multiple therapies and also sug-
gest that the syndrome could be overlooked in absence of serial VEEG
recordings.
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EPILEPTIC SEIZURES IN CHILDREN WITH SUBACUTE
SCLEROSING PANENCEPHALITIS
1D. Craiu, 2P. Avram, 1O. Tarta Arsene, 1I. Minciu, 1N. Butoianu, 1C.
Burloiu, 1C. Iliescu, 1M. Budisteanu, and 1S. Magureanu (1Pediatric
Neurology Clinic, National Refernce Center Against Epilepsy, Al.
Obregia Hospital, Bucharest, Romania, 2Pediatric Clinic I, Institute of
Mother and Child Care, Bucharest, Romania)
Purpose: This is a retrospective analysis of epileptic seizures occur-
ring in SSPE (subacute sclerosing panencephalitis), either as a first sign
or in evolution of the disease. Prognostic correlations relating to different
aspects of seizures were made.
Method: Ninety-one SSPE cases admitted in our clinic during a 16
yr period (1990–2005) were analysed. Data was extracted from medical
records and directly from families (telephone calls). CSF evaluation for
measles virus antibodies was performed in all patients except 4, but all
cases had clinical and EEG features for SSPE. Thirty-eight cases had
imagistic evaluation (CT, MRI). Extensive clinical, electrical data will
be presented.
Results: The group included 63 males and 28 females. Seventy-one
patients had measles (37 < 2yr of age) and 10 were vaccinated. In
our group, 1 patient presented seizures, 9 as a first sign and 8 dur-
ing the course of SSPE. Six patients presented focal seizures at on-
set, compared with 3 patients with generalised seizures, and generalised
seizures in the course of the disease (11 patients from 17), developed
mainly in stage II (15 patients) or III (2 patients), raising the idea of a
widespread pathological process as SSPE progresses. Two patients had
atypical absences documented by clinical and electroencephalographic
findings. AEDs had a good effect on seizures, but not on the overall
prognosis. No correlation between duration, frequency, age of onset,
type of seizures and prognosis was established. Resistance to AEDs (3
cases) was correlated with poor prognosis (exitus in 2 at 5 months after
onset).
Conclusion: SSPE diagnosis was delayed by 1 to 7 months in cases
with epileptic seizure onset compared with cases with typical onset
that were diagnosed immediately. 1) Seizures resistant to AEDs were
correlated with a poor prognosis. 2) There is a high percent (11%)
of SSPE patients who developed the disease after declared immunisa-
tion, raising problems concerning correct and careful vaccination of all
children.
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IDENTIFICATION OF BRAIN ABNORMALITY IN CHILDREN
WITH INTRACTABLE FOCAL EPILEPSY AND NORMAL
IMAGING USING VOXEL BASED MORPHOMETRY
1C. Riney, 2A. Connelly, and 1J. Cross (1Great Ormond Street Hospital
for Children and The Institute of Child Health (UCL), London, UK,
2Brain Research Institute, Melbourne, Australia)
Purpose: Children with intractable focal epilepsy and normal imaging
pose a difficult management problem. Seizure remission rates with med-
ical therapy are low and the option of surgery is limited by the absence of
visible abnormality on MR. Cortical dysplasia has been reported in op-
erative specimens from this patient group. MRI is a noninvasive tool and
development of MR techniques might allow detection of such “occult”
pathology. We propose that voxel-based morphometric (VBM) analysis
of diffusion tensor (DTI) and 3D structural images may allow detection
of focal brain abnormality, not seen on conventional imaging.
Method: Patients were recruited from the Epilepsy clinics at Great
Ormond Street Hospital, London. All patients underwent full presurgical
evaluation including ictal EEG. 3D structural datasets and DTI were
acquired preoperatively. VBM was performed using SPM2 (Wellcome
Department of Imaging Neuroscience, London).
Results: VBM identified abnormality concordant with the seizure
focus (determined by ictal EEG) in 2/7 of the 3D structural images and
in 1/5 fractional anisotropy (FA) maps. Other areas of abnormality were
also noted outside the seizure focus in 4/7 3D structural images and
1/5 FA maps. These may represent separate areas of developmental or
acquired pathology, and are not visible on conventional imaging.
Conclusion: Initial results suggest that VBM may demonstrate fo-
cal abnormality in children with intractable focal epilepsy and negative
conventional imaging. Correlation of these areas of abnormality with
operative pathology may provide support for the use of VBM in the
pre-surgical evaluation of this patient group.
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SLEEP DISTURBANCES IN CHILDREN WITH EPILEPSY
1R. Praninskiene, 1O. Kutuzova, 1G. Markvaldiene, and 2A. Jucaite
(1Vilnius University Children’s Hospital, Vilnius, Lithuania, 2Astrid Lin-
grens Children’s Hospital, Stockholm, Sweden)
Purpose: Children with epilepsy often have cognitive deficits that
affect their quality of life. Some of them experience daytime somnolence
and poor attention during daytime school activities, which may be related
to the concomitant sleep disorders. The aim of the present study was to
investigate the incidence and type of sleep disorders among children with
epilepsy.
Method: Parents of 80 children with epilepsy were asked to fill out
the questionnaire screening for the sleep disturbances, SDSC (Bruni
et al, 1996).
Results: Twenty-one children (36%) had total SDSC scores indicat-
ing the presence of sleep disturbances. The most prevalent were sleep
wake transition disorders (SWTD 37.46%), followed by disorders of
excessive somnolence (DOES 21.26%) and disorders of arousal and
nightmares (DA 20.25%), disorders of initiating and maintaining sleep
(DIMS19.22%). Two other groups of sleeping disturbance, sleep breath-
ing disorders (SBD 8.10%) and sleep hyperhidrosis (6.7%), seldom oc-
curred. Seven children had a high T-score value (>70) on ≥4 subscales,
showing a distributed pattern of sleep disturbances. The age of children
ranged from 5 yr 6 mo to 17 yr 9 mo (11.9 ± 3.33) and age had a signif-
icant effect on the DA scores. The type of sleep disturbance was related
to the type of epilepsy: SBD ocurred significantly more often among
children with rolandic epilepsy, and DIMS among children with tempo-
ral epilepsy. DA and SWDT scores were significantly higher in children
with night seizures (p = 0.01).
Conclusion: Children with epilepsy have a high frequency of sleep
disorders. Their timely management may improve the quality of daily
activities.
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DECREASE OF ARTIFACTS OF EEG ELECTRODE METAL-
LIC PARTS WITH ELECTROLESS NICKEL-PHOSPHOROUS
COATINGS
1M. Monir Vaghefi and 2T. Mahmoudian (1Isfahan University of Tech-
nology, Iran, 2Medical University of Isfahan, Iran)
Purpose: In this research, the contacting of EEG electrode metallic
parts to head scalps was studied. If the electrode to scalp contact is not
proper, the EEG signal shows artifact. To avoid this, ensure that all elec-
trodes are securely placed. This check is very critical for the reference
electrode. If the contact of the reference electrode is poor, all the chan-
nels get artifact. One of the EEG artifacts is electrode pop and its poor
impedance (lack of conductivity). This artifact is related to some impurity
and oxide and corrosion products in the metallic portion of the electrode
due to the chemical reactions between corrosive materials as sweating
water of patient, gel, paste or NaCl dionised water with metallic portions
of electrodes. Already the coatings of metallic portions of electrodes are
nickel coatings, but these coatings have not the corrosion resistance and
so after using for many patients cause artifact. In this study, with the aim
of increasing corrosion resistance of electrode metallic portions, plated
electroless nickel-phosphorous (Ni-P) coatings were used. Electroless
Ni-P coatings are widely used because of their good resistance to cor-
rosion and wear. The corrosion resistance is a result of the amorphous
nature and passivity of Ni-P deposit.
Method: The Ni-P coatings on electrode metallic parts were deposited
in a commercially available bath that contained nickel sulfate and sodium
hypophosphite. Temperature of 90◦C and pH 4.6 were employed. The
thickness of coatings was about 60 micron. Then, the corrosion resistance
of electroless Ni-P coated metallic parts of the electrode was compared
with common Ni coatings after EEG tests of 1000 paediatric patients in
6 months.
Results: The results show that the life of electrode metallic parts with
Ni-P electroless coatings had 10 times of Ni coatings and the electroless
Ni-P coatings had not any artifacts on EEG comparing with Ni coating.
Conclusion: Using the electroless Ni-P coatings on electrode metallic
parts can reduce major parts of instrumental artifact due to elimination of
electrode pop, oxide and corrosion products and this may be suggested
to EEG machine manufacturing companies.
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CEREBRAL PALSY AND EPILEPSY: FACTORS ASSOCIATED
WITH UNSATISFACTORY SEIZURE CONTROL
P. Ignjatovic and N. Jovic (Clinic of Neurology and Psychiatry for Chil-
dren and Youth, Belgrade, Serbia and Montenegro)
Purpose: To analyse factors associated with incomplete seizure con-
trol in children and adolescents with cerebral palsy (CP).
Method: The group of 59 patients with CP and epilepsy with a
mean age of 8 years (range, 2 to 27 years) was studied retrospec-
tively. The criteria for inclusion included the follow-up period for at
least 1 year. Distribution of clinical forms disclosed 46 patients with
spastic CP, 2 patients with a dyskinetic form and 11 patients with a
mixed form. Other factors associated with CP and epilepsy such as
mental retardation, age of seizure onset and types of seizures were also
analysed.
Results: All patients were treated with 1, 2 or 3 AEDs. More than one
half of our patients (56%) were treated with AED polytherapy. Forty
patients in our group (68%) became seizure-free. Complete seizure con-
trol was mainly achieved in children with spastic hemiplegia (16/40) and
diplegia (15/40) while patients with mixed form and spastic quadriplegia
belonged to the subgroup with incomplete seizure control (8/18 each).
Early seizure onset (in the first 2 years of life) occurred in 52% of
children with complete seizure control as compared to 79% of chil-
dren without well-controlled seizures. Partial seizures with secondary
generalisation occurred more frequently in the subgroup with seizure
reduction of >50% (9/19) than in the subgroup with complete control
of seizures (7/40). Associated mental retardation was seen in 52% of
seizure-free patients and in 78% of patients with unsatisfactory seizure
control.
Conclusion: Severe neurological condition, mental retardation, ear-
lier age of seizure onset and focal seizures with secondary generalisation
are factors mainly associated with unsatisfactory seizure control.
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NONCONVULSIVE STATUS EPILEPTICUS AND NEURODE-
VELOPMENTAL DELAY
E. Dirik, U. Yi , O. Hu¨dao lu, and S. Kurul (Dokuz Eylul University,
´Yzmir, Turkey)
Purpose: Nonconvulsive status epilepticus is characterised with
continuous or near continuous epileptiform discharges on electroen-
cephalography without overt motor or sensory phenomena. It is a symp-
tomatic condition related to a disease such as epileptic encephalopathy
or a metabolic disorder. It consists of very different syndromes and it
is divided into typical absence status epilepticus, complex partial status
epilepticus, and nonconvulsive status epilepticus in patients with learning
difficulties (including electrical status epilepticus during sleep, atypical
absence status epilepticus and tonic status epilepticus).
Method: The diagnoses are dependent on EEG and have different
prognoses and treatments (Walker MC. CNS Drugs 2001;15(12):931–
939). Children with isolated nonconvulsive status epilepticus rarely
present with global neurodevelopmental delay (Shinawi M. J Child Neu-
rol 2001;16:215–217). We report an 18-month boy who presented with
global neurodevelopmental delay and decreased alertness in whom elec-
trical status epilepticus during sleep, which is a form of nonconvulsive
status epilepticus, was determined.
Results: Metabolic investigations and cranial magnetic resonance
imaging were normal. He began to achieve developmental milestones
following treatment with valproic acid.
Conclusion: We consider that, although rare, paediatric neurologists
and paediatricians must be aware of this condition in making the dif-
ferential diagnosis of global neurodevelopmental delay and decreased
alertness.
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PROGRESS OF TREATMENT FOR SUBACUTE SCLEROSING
PANENCEPHALITIS WITH MYOCLONIC JERKS
1T. Hwang, 2W. Bae, and 3J. Lee (1Department of Pediatrics, College
of Medicine, Inje University, Busan, Korea, 2Department of Pediatrics,
College of Medicine, Inje University, Busan, Korea, 3Department of
Pediatrics, College of Medicine, Inje University, Busan, Korea)
Purpose: Subacute sclerosing panencephalitis (SSPE) is a progressive
neurologic disorder of childhood and early adolescence by persistent
latent measles virus infection. We have diagnosed and experienced a case
of SSPE in an 11-year-old child with the chief complaint of myoclonic
jerks, progressive deterioration in scholastic performance and cognitive
function.
Method: We checked a brain MRI, and electroencephalogram. We
measured the measles IgG and IgM level, oligoclonal band, PCR in
serum and cerebrospinal fluid.
Results: We treat an intrathecal interferon-alpha and oral inosi-
plex. On the 5th day of admission, inosplex (100 mg/kg/day, per oral)
treatment was initiated. On the 18th hospital day, interferon-alpha
(450,000U/m2/three times a week, intrathecal) treatment began. Cere-
brospinal fluid protein, sugar, cell count were within the reference val-
ues. Measles IgG antibody in the CSF and serum were checked at
38,508mIU/ml and 17,293mIU/ml by ELISA. Measles virus RNA can be
detected by PCR, but the oligoclonal band was not detected. There were
no abnormal findings in brain MRI. The EEG showed periodic com-
plexes consisting of bilaterally symmetrical, synchronous, high voltage
bursts of polyphasic, stereotyped delta waves. These periodic complexes
repeat at fairly regular 4–10 second intervals and have a 1:1 relationship
with myoclonic jerks.
Conclusion: This patient was diagnosed with a subacute sclerosing
panencephalitis by measles virus PCR and IgG level in the CSF. We are
treating this patient for 4 months. Myoclonic jerks are improving, but still
remain. Cognitive function and scholastic performance is improving.
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EPILEPSY IN CHILDREN WITH BILATERAL CEREBRAL
PALSY (CP): CORRELATION WITH MAGNETIC RESONANCE
IMAGING (MRI) FINDINGS
1A. So¨o¨t, 1T. Tomberg, 2A. Napa, 2R. Rein, 1M. Ha¨marik, and 1T. Talvik
(1University of Tartu, Tartu, Estonia, 2Children’s Clinic of Tartu Univer-
sity Hospital, Tartu, Estonia)
Purpose: CP refers to a group of disorders characterised by abnormal
movement and posture due to nonprogressive insult to the brain. Seizures
are often present. The purpose of this study was to determine the rela-
tionship between epilepsy and MRI findings in patients with tetraparetic
forms of CP.
Method: We studied 101 children with tetraparetic forms of CP. All
of them had perinatal asphyxia. Epilepsy was found in 18 of the 101
patients. The types of seizures were focal in 16 children, generalised in
1 child and polymorphic in 1. In 15/18 hypoxic-ischaemic encephalopa-
thy was diagnosed. The first epileptic seizure appeared at the median
age of 2.5 years. Paediatric neurologist, neurophysiologist, psycholo-
gist, speech therapist and physiotherapist examined all children. MRIs
were performed on 1.5 Tesla Siemens (Magnetom) scanner using a
256 × 256 matrix. MRI findings were divided into the following cate-
gories: (a) central atrophy and periventricular (PV) white matter lesions;
(b) diffuse white matter lesions; (c) cortical atrophy and/or basal ganglia
lesions; (d) normal.
Results: Normal MRI was found in 1 child with generalised epilepsy.
In 17 patients pathology in MRI was diagnosed. In 6 patients, cen-
tral atrophy and PV white matter lesions, in 6 diffuse white matter
lesions and in 5 cortical atrophy and/or basal ganglia lesions were
found.
Conclusion: Ventricular dilatation and PV white matter lesions were
related to motor development and well treatable epilepsy (p < 0.05).
Significant correlations between problems of mental development, in-
tractable epilepsy and diffuse white matter lesions and cortical atrophy
and/or basal ganglia lesions were found (p < 0.05).
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HOMOCYSTEINE LEVELS IN CHILDREN RECEIVING
ANTIEPILEPTIC DRUGS
A. Unalp, S. Kurul, U. Yi , and E. Dirik (Dokuz Eylu¨l University Faculty
of Medicine, Department of Pediatrics, Division of Pediatric Neurology,
Izmir Turkey)
Purpose: Hyperhomocysteinemia is a risk factor for atherosclerotic
vascular disease. In adults, it has been reported that some antiepileptic
drugs cause elevated homocysteine levels due to reduced folic acid con-
centrations. We aimed to investigate the serum homocysteine, folic acid
and vitamin B12 levels in children with epilepsy receiving antiepileptic
drugs.
Method: Twenty five children with idiopathic epilepsy (13F, 12M)
were included in the study. Of them 8 were receiving valproate, 11 were
receiving carbamazepine and 6 were receiving oxcarbazepine monother-
apy. Ten healthy children (6F, 4M) served as the control group. Serum
homocysteine, folic acid and vitamin B12 levels were measured and were
compared between the two groups.
Results: The mean age of the study patients was 11.44 ± 3.33 and
the mean age of the control subjects was 12.00 ± 3.94 (p = 0.595). The
mean plasma homocysteine, folic acid and vitamin B12 levels in the
study group were 7.57 ± 3.78 μmol/L (normal: 5–15 μmol/L), 10.19 ±
4.05 ng/mL (normal: 3.0–17 ng/mL) and 428.20 ± 256.12 pg/mL (nor-
mal: 193–983 pg/mL), respectively. In the control group, the mean
plasma homocysteine, folic acid and vitamin B12 levels were 7.66 ±
2.34 μmol/L, 9.76 ± 3.57 ng/mL and 406.80 ± 172.18 pg/mL, respec-
tively. The differences between the two groups were not significant (p =
0.522; p = 0.855; p = 0.798). There was also no significant difference
between the valproate, carbamazepine and oxcarbazepine groups in re-
spect to homocysteine, folic acid and vitamin B12 levels (p = 0.794;
p = 0.183; p = 0.165).
Conclusion: Although the number of our study patients was lim-
ited, we thought that hyperhomocysteinemia is not a serious prob-
lem in children with epilepsy receiving valproate, carbamazepine or
oxcarbazepine.
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ATROPHY IN CHILDREN WITH PRIMARY IDIOPATHIC
EPILEPSY
1O. Hu¨dao lu, 2A. Babayi it, 2D. ¨Olmez, 1U. Yi , 2N. Uzuner, 2 ¨O.
Karaman, 1E. Dirik, and 1S. Kurul (1Dokuz Eylul University Faculty
of Medicine Department of Pediatrics Division of Pediatric Neurology,
Izmir, Turkey, 2Dokuz Eylul University Faculty of Medicine Department
of Pediatrics Division of Pediatric Allergy, Izmir, Turkey)
Purpose: Some studies have indicated a high incidence of allergic
illness in adult patients with epilepsy, but few studies provide adequate
clinical and laboratory data to document the higher incidence of allergy
in children with epilepsy. The aim of this study was to evaluate the
relationship between atrophy and epilepsy in children with idiopathic
epilepsy and compare the results with those of healthy children.
Method: Thirty-nine children with idiopathic epilepsy were included
in the study. They were grouped according to the type of epilepsy and
antiepileptic drug regimen. Allergic complaints and family history of
allergy were investigated. Plasma IgE levels and total eosinophil content
was measured and epidermal pinprick was applied. The results were
compared with those of a group of healthy children.
Results: Twenty-one patients (54%) had primary generalised and 18
patients (46%) had partial epilepsy. Twenty-one patients (54%) were
treated with valproic acid and 18 patients (46%) were treated with ox-
carbazepine. Regarding the allergic complaints, family history of allergy,
plasma IgE levels, eosinophil counts and pinprick test results, no signifi-
cant differences were found between the generalised and partial epilepsy
group. Again, there were no significant differences between the valproic
acid and oxcarbazepine group. Positive pinprick results were signifi-
cantly higher in epilepsy patients when compared with healthy control
subjects (p = 0.001, p < 0.05).
Conclusion: The significantly higher positive pinprick results in chil-
dren with epilepsy suggest a role of atopy as a possible predisposing
factor in the development of epilepsy.
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CANTAB NEUROPSYCHOLOGICAL PROFILES OF PAEDI-
ATRIC PATIENTS: A COMPARATIVE STUDY
1I. Benga, 2O. Benga, 1S. Palade, and 2L. Petra (1“Iuliu Hatieganu”
University of Medicine and Pharmacy, Cluj-Napoca, Romania, 2 “Babes-
Bolyai” University, Cluj-Napoca, Romania)
Purpose: The neuropsychological profiles of paediatric populations
are still unclear, and the impact of early neural damage remains largely
undefined, maybe due to the fact that, during development, reduction in
learning potential and greater functional plasticity are both at work, in
opposite directions. Our study aimed to circumscribe specific neuropsy-
chological profiles of paediatric patients (8–12 years of age) compared
to their normal counterparts.
Method: Five categories of neurological and psychiatric populations
were compared to normal children: a) children with craniocerebral trau-
matic injuries; b) children with temporal epilepsy; c) children with ex-
tratemporal epilepsy (benign rolandic, frontal or generalised); d) children
with other neurologic disorders (Wilson disease, neurofibromatosis type
II, cerebellar ataxia); e) children with psychiatric disorders (affective
or somatoform disorders). All subjects were tested with the Cambridge
Neuropsychological Testing Automated Battery (CANTAB), a comput-
erised battery valid for the assessment of frontal, temporal, and striatal
functions.
Results: Although temporal lobe memory functions, measured via
CANTAB subtests like Delayed Matching to Sample or Paired Asso-
ciates Learning, were shown to reach mature stable levels by the age
of 8 (e.g., Luciana et al. Developmental Neuropsychology 2002;22:595–
624), our results indicate significant impairments in paediatric patients
versus normal children, the most severely affected being, somehow para-
doxically, children with extratemporal epilepsy. Tests sensitive to frontal
lobe functions indicated most acute deficits in children with craniocere-
bral traumatic injuries (e.g., Spatial Working Memory), or psychiatric
patients (e.g., Spatial Recognition Memory).
Conclusion: Specific neuropsychological impairments individualised
categories of paediatric patients. Such information remains largely un-
detected during routine neurological assessment.
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ERRATIC MYOCLONIA AND DIHYDROPYRIMIDINE DEHY-
DROGENASE DEFICIENCY (DPD)
C. Korff, D. Nordli, Jr., and K. Kelley (Children’s Memorial Hospital–
Epilepsy Center, Chicago, USA)
Purpose: To present the case of an infant diagnosed with dihydropy-
rimidine dehydrogenase deficiency (DPD).
Method: Case report.
Results: AK is a male infant, who presented at age 3 months with
erratic myoclonia, poor weight gain, arching, and abnormal movements.
He had no reciprocal smile and poor visual interaction. Examination
was significant for irritability, hypertonicity, and opisthotonus. EEG was
diffusely slow, disorganised with shifting delta and multifocal spikes
similar to that in B-6 dependency. There was no response to IV pyridoxine
100-mg. Urine had increased uracil, thymine, and pyrimidine. Urine
Pipecolic acid was 18.9 Umole/G Cr (2.3–62.0) and carnsosine was
not detected. MRI was normal. Enzyme analysis showed a complete
deficiency of dihydropyrimidine dehydrogenase.
Treatment with vigabatrin led to better-organised bilateral myoclonic
seizures and extreme irritability and no change in EEG. Levetiracetam
decreased myoclonia, as did the addition of zonisamide. Clonazepam
showed modest improvement of seizures and no change in arching. L-
carnosine 500-mg/day increasing to 1000-mg resulted in improved alert-
ness with increases in urine carnosine and alanine. EEG continued to
show slowing and poor organisation. Pyridoxal-5-phosphate 80-mg/day
was added.
Conclusion: DPD is an autosomal recessive disease is linked to chro-
mosome 1p22 and is associated with a variable clinical phenotype in-
cluding severe epilepsy, mental retardation, and hypertonia. Dihydropy-
rimidine dehydrogenase is the initial and rate-limiting enzyme in the
pathway leading to the formation of beta-alanine. L-carnosine was sup-
plemented in order to increase brain beta-alanine. Furthermore, reason-
ing that there may be a secondary deficiency of pyridoxine as is postu-
lated in pyridoxine dependent epilepsy (PDE) and given the similarity in
the EEG to that seen in untreated PDE, pyridoxal-5-phospahate was also
supplemented.
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RELATIONSHIP BETWEEN THE AGE AT DISEASE ON-
SET AND VERBAL DISTURBANCES IN PATIENTS WITH
ROLANDIC EPILEPSY
G. Gelziniene, G. Jurkeviciene, M. Endziniene, N. Vaiciene, J.
Vainauskiene, and I. Laukiene (Kaunas Medicine University Hospital,
Kaunas, Lithuania)
Purpose: To evaluate the relationship between the age at onset of
rolandic epilepsy (RE) and the results of speech evaluation tests.
Method: We studied verbal functioning in patients with RE (n = 64)
and in healthy controls (n = 35) by using sub-tests of the Neuropsycho-
logical Development Study (NEPSY).
Results: Relationship between the age of RE patients at the onset of
the disease and the results of the speech evaluation tests were as follows:
(1) verbal fluency r = 0.66 (p < 0.001); (2) speed naming: time of task
accomplishment r = −0.60 (p < 0.001), number of errors r = −0.21
(p = 0.09); (3) comprehension of instructions: number of errors in the
first part r = −0.33 (p = 0.01), number of errors in the second part r =
−0.49 (p < 0.001).
Conclusion: Relationship was established between the age of epilepsy
onset and the results of the speech and attention evaluation tests: the
younger the age of epilepsy onset, the worse were the results of the
evaluation tests (p < 0.05).
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EPILEPSY IN CHILDREN WITH PERIVENTRICULAR
LEUKOMALACIA: OUTCOME IS RELATED TO LESION
PATTERN AND TYPE OF EPILEPTIFORM ACTIVITY IN THE
EEG
M. Wolff, C. Zu¨rcher, and I. Kra¨geloh-Mann (University Childrens Hos-
pital, Tu¨bingen, Germany)
Purpose: Periventricular leukomalacia (PVL) occurs in children as a
consequence of cerebral ischemia or haemorrhage in the immature brain.
Since pathogenesis and timing of the lesion are homogeneous, this could
serve as a model to study the impact of brain lesions on manifestation
and outcome of epilepsy. Therefore, we investigated the relation between
lesion patterns, epilepsy and EEG findings in children with PVL.
Method: Twenty-four children (mean age 6:3 years, range 3:2–10:10
years) with bilateral periventricular lesions and a follow-up of more than
three years were included in the study. MRI, clinical data and EEG were
systematically reviewed by patient-blinded evaluators.
Results: From the children with mild lesions, i.e. <50% reduction of
the periventricular white matter (n = 14) only 2 had epilepsy. From the
children with severe lesions (n = 10) 7 had epilepsy (p < 0.01). Five
children initially had West syndrome with a favourable course. In only
1 child was the epilepsy considered severe. Fifteen children (62%) had
benign focal spikes in the EEG; in 10 this constituted the only type of
epileptiform activity. Of these children, only 3 had epilepsy.
Conclusion: In children with PVL outcome of epilepsy, this is closely
related to (1) the extent of the periventricular lesion and (2) the type of
epileptiform activity in the EEG. Benign focal spikes are found much
more often than expected indicating that PVL constitutes a trigger mech-
anism for this genetic trait.
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CLINICAL AND ICTAL VIDEO-EEG CHARACTERISTICS OF
28 CASES WITH INFANTILE SPASMS
1J. Liang, S. Hong, and C. Feng (1Department of Child Neurology, Chil-
dren’s Hospital, Chongqing University of Medical Sciences, 400014,
China. University of Medic, 2Department of Child Neurology, Children’s
Hospital, Chongqing University of Medical Sciences, 400014, China,
3Department of Child Neurology, Children’s Hospital, Chongqing Uni-
versity of Medical Sciences, China)
Purpose: Infantile spasms (IS) are generally divided into 3 types in-
cluding flexion, extension or mixed, but nothing more definitive has been
stated as to the duration, extent or mode of muscle contraction or asso-
ciated ictal electroencephalographic changes. The aim of the study is to
investigate the clinical interictal and ictal video-EEG characteristics of
28 cases with IS and evaluate clinical significances for early diagnoses
and treatment.
Method: Clinical observation and video-EEG monitoring were anal-
ysed and followed up in 28 babies with IS.
Results: Twenty-eight babies (19 male) were diagnosed to have IS af-
ter clinical spasms and hypsarrhythmia at the onset of initial seizures. The
babies ranged in age from 2 ∼ 16 months with an average of 6.5 months.
All cases were involved in the axial musculature with three generally
divided types including flexion, extension or mixed by 12, 9 and 7 cases
respectively. After analysis (64 times) of clinical spasms and video-EEG
recordings in all babies, the spasm patterns of this group were clini-
cally classified as follows: symmetric spasms in 14 cases, asymmetric/
asynchronous spasms in 8 cases, focal or hemispasms in 6 cases, spasms
combined with partial seizures in 8 cases, spasms preceded by brief atonia
in 2 cases, subclinical spasms in 5 cases; in addition, subtle spasms were
found alone or in coexistence with most cases. Interictal EEG showed the
typical and atypical hypsarrhythmia in 8 and 20 cases respectively, fo-
cally polyspike/sharp and slow waves or hemihypsarrhythmia in 5 cases;
at least three different patterns of ictal-EEG were associated with clini-
cal spasms: fast wave bursts, diffuse polyphasic high slow voltage wave
complex and desynchronisation or decremental activity, in which the
prominent positivity of the polyphasic high voltage slow wave complex
of negative-positive-negative deflection was usually parallel with clinical
tonic or tonic spasms. Video-EEG monitoring was more valuable than
the routine EEG for the early diagnosis and treatment of IS, particularly
in those babies with a history of hypoxic-ischemic encephalopathy and
subclinical spasms. Although most of the clinical spasms were usually
symmetric, focal lesions could not be excluded. EEGs were not surely
synchronous and symmetric.
Conclusion: IS was a special type of epileptic seizure as well as an
epileptic syndrome with different patterns and could be associated with
partial and other types of seizures; video-EEG was much more valuable
for its early diagnosis and treatment.
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IDIOPATHIC CHILDHOOD OCCIPITAL EPILEPSIES: AN UN-
DERDIAGNOSED EPILEPTIC SYNDROME
R. Chora˜o, I. Carrilho, B. Roma˜o, F. Santos, R. Rego, C. Barbot, A.
Ribeiro, and M. Santos (Hospital De Crianc¸as De Maria Pia, Porto,
Portugal)
Purpose: To identify and characterise the clinical and EEG aspects of
idiopathic childhood occipital epilepsies (ICOE) in our epilepsy clinic
patients.
Method: We retrospectively reviewed the ictal phenomenology, in-
terictal EEG findings, and prognosis in patients diagnosed with ICOE.
Results: Fifteen patients were identified, 9 with Panayiotopoulos-
type, 4 with Gastaut-type, and 2 atypical cases. In the first group, sleep-
related seizures, with ictal vomiting and tonic eye deviation were the rule.
Secondarily generalised seizures occurred in 3 patients and focal status
epilepticus in 1. In Gastaut-type patients, visual phenomena were promi-
nent. The other 2 patients did not fulfil the criteria of any of the two above
mentioned, and had a single seizure. Prognosis was very favourable in
the first and variable in the second group. Interictal EEG revealed oc-
cipital paroxysmal discharges strictly in the occipital regions in only 1
patient of each group. In the remaining cases, they were found also in
temporal or parietal regions. Eye closure elicited epileptic discharges in
only a few patients.
Conclusion: In most of our patients we could identify two subgroups
of ICOE, with different seizure patterns and prognosis. This epileptic
syndrome corresponds to about 10% of all focal idiopathic childhood
epilepsies in our epilepsy outpatient clinic, maybe because the epileptic
nature of these complaints is not often recognised.
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INFLUENCE OF ANTIEPILEPTIC THERAPY ON BONE MIN-
ERAL DENSITY AND SERUM CALCIUM LEVELS IN ADOLES-
CENTS WITH EPILEPSY
1N. Dimix, 2N. Jovic, 3J. Vojinovic, and 4A. Dimic (1Clinic for Men-
tal Health Protection, Clinical Center Nis, Serbia and Montenegro,
2Department for Neurology and Psychiatry for Children and Youth, Bel-
grade, Serbia and Montenegro, 3Department for Paediatric Rheumatol-
ogy, University Clinic Center Nis, Sebia and Montenegro, 4Institute for
Rheumatism “Nika Banja,” Serbia and Montenegro)
Purpose: Antiepileptic therapy (AET) can produce disturbances in
bone and calcium metabolism: decrease of bone mineral density (BMD)
and hypocalcemia. Risk factors are: drug enzyme induction, usage of
multiple AET drugs, duration of therapy and its introduction at early
age.
Results: Our results have shown significant BMD differences between
AET and control group in boys (0.934 ± 0.15 vs 1.064 ± 0.112; p < 0.05)
while in girls BMD was not significantly lower in the AET group when
compared to controls (1.131 ± 0.135 vs 1.167 ± 0.085; ns). We have not
found a significant correlation between age at which AET was introduced
and BMD results achieved in both boys’ and girls’ ATE groups. Duration
of AET have shown significant influence on BMD achievements in girls’
group (p < 0.01). Serum total calcium levels were significantly lower
in the boy patients’ group (p<0.05), while serum ionized calcium levels
were not significantly lower in both groups, as compared to controls.
Conclusion: Study results clearly indicate that AET therapy strongly
influences BMD and serum total calcium levels, especially in boys at
age 13–18 years. Duration of AET is important for bone quality mea-
sured by BMD only in girls. An early start of vitamin D and calcium
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supplementation could be of great importance for future bone quality in
children on long-term antiepileptic therapy.
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A REAUDIT OF PAEDIATRIC EEG REQUESTS: 10 YEARS
LATER
S. Macleod, R. Appleton, M. Beirne, and B. Acomb (Roald Dahl EEG
Unit, Liverpool, UK)
Purpose: An audit of EEG requests in this institution in 1995 demon-
strated an inadequacy of clinical information and 40% of requests were
considered unnecessary (Nicolaides P, Appleton RE, Beirne M. EEG
requests in paediatrics: an audit. Archives of Disease in Childhood
1995;72:522–523). Guidelines were subsequently published on the role
of EEG in the diagnosis/classification of the epilepsies and our institu-
tion introduced a computerised request system to guide clinicians when
requesting an EEG. The current study has reaudited EEG requests.
Method: All children undergoing an EEG over 6 months were au-
dited. The standardised audit form collected data on the reason for re-
questing the EEG, the adequacy of clinical information and the result of
the EEG. The electro-clinical usefulness of the EEG was classified as be-
ing “helpful,” “unhelpful” or “potentially misleading” by the paediatric
neurologist reporting the EEG.
Results: Four hundred sixty-five EEG’s were audited. Adequate clini-
cal information was provided in 371 requests (79.7%). The most common
reasons for requesting an EEG included, “syndrome classification,” a
“clinical suspicion” of epilepsy and to “exclude a diagnosis of epilepsy.”
The EEG was considered “unhelpful” in 195 (41.9%) and “potentially
misleading” in 7 cases. The reduction in inappropriate EEG requests
compared with the previous audit (Nicolaides P, Appleton RE, Beirne
M. EEG requests in paediatrics: an audit. Archives of Disease in Child-
hood 1995;72:522–523) was statistically significant at p < 0.05 (x2).
Conclusion: This audit has demonstrated that the EEG is still being
used inappropriately to diagnose epilepsy. There was a statistically sig-
nificant reduction in the number of inappropriate EEG requests, which
may in part reflect on-going educational activities.
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OUTCOME OF INFANTS WITH NEONATAL SEIZURES BY
HYPOXIC-ISCHEMIC ENCEPHALOPATHY AETIOLOGY
1G. Visa, 2V. Ene, and 3L. Ognean (1Pediatrics Clinical Hospital, Sibiu,
Romania, 2Psychiatry Hospital Child Neurology Department, Sibiu,
Romania, 3Clinical County Hospital Neonatology Department, Sibiu,
Romania)
Purpose: We followed infants with hypoxic–ischemic encephalopa-
thy (HIE) and seizures in the neonatal period to determine the neurolog-
ical outcome.
Method: We studied 112 infants admitted to Neonatal Care Unit of
Sibiu Maternity between 1995 and 2000. They had neonatal seizures
by HIE aetiology and were assessed by neurological evaluation, cranial
ultrasound, electroencephalogram (EEG), CT or MRI, and psychological
evaluation.
Results: From 112 patients 11 (9.8%) died in the neonatal period
and 2 (1.78%) in the follow–up period. 44 infants (39%) had associated
intracranial haemorrhage. The mean follow–up period was 2.97 ± 2.37
years (0–9 years). The onset of seizures was in the first 24 hours of life
for 56% of cases. The most frequent seizure type was subtle followed
by clonic, tonic, myoclonic and generalised tonic–clonic seizure. The
patients with hypoxic lesions in 80.8% of cases had one or two types
of seizure. The infants with intracranial haemorrhage had 3 or more
types of seizure or status epilepticus in 43.2% of cases. The complexity
of seizures had a significant correlation with psychomotor retardation
(p < 0.05), cerebral palsy (p < 0.01), hydrocephalus (p < 0.05). In the
follow–up period 9 cases (8.03%) developed epilepsy, 3 cases (2.67%)
febrile seizures, 36 cases (32.14%) psychomotor retardation, 19 cases
(16.96%) cerebral palsy, 6 cases (5.35%) hydrocephalus, 2 cases (1.78%)
ventriculomegaly, 6 cases (5.35%) sensorial impairments.
Conclusion: The HIE facilitated neonatal seizures but intracranial
haemorrhage increased the complexity of the seizures and sequel at long
time follow–up.
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CSWS AND THALAMIC CYSTS IN CHILDREN
A. Wiemer-Kruel and J. Ernst (Epilepsy Centre Kork, Kork, Germany)
Purpose: Epilepsy with continuous spike-waves during slow sleep
(CSWS) is difficult to treat and leads to disastrous cognitive disturbances,
stagnation and behavioural problems. In symptomatic CSWS therapy is
even more problematic, especially if thalamic cysts are present. The
question is whether there are aetiological coherences between CSWS
and thalamic lesions. The long term courses of 12 children with CSWS
and thalamic cysts are investigated.
Method: Twelve children (9 girls, 3 boys) aged 7 to 19 years, with
thalamic cysts (twice on the right, 7 times on the left, 3 times on both
sides) because of perinatal problems and CSWS were treated with sev-
eral antiepileptic drugs. Epilepsy, EEG and cognitive development were
controlled for at least 3 years, mostly much longer.
Results: The seizures were usually easy to control, but the CSWS
could not be stopped, not even with corticoids. The cognitive functions
deteriorated in 10 cases, 2 children were already severely handicapped at
the beginning. After reduction of the spike-wave activity during awake as
well as during sleep, especially when CSWS is dissolved, the cognitive
situation gets more stabilised and progress is seen, but the patients remain
mentally handicapped.
Conclusion: Corresponding to the literature we could prove that chil-
dren with thalamic cysts and lesions due to perinatal problems develop
with great certainty an epilepsy with CSWS. Even with cerebral lesions
the epilepsy and the CSWS seem to become better during puberty.
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TYPICAL ABSENCE: NOT ALWAYS TYPICAL?
N. Dimitrijevic, D. Nikolic, D. Bogicevic, and V. Mitic (University Chil-
dren’s Hospital, Belgrade, Serbia and Montenegro)
Purpose: To determine clinically prognostic parameters of absence
epilepsy in children.
Method: Diagnostic criteria of typical absence epilepsy: onset of
seizures from age 4–10 years, a sudden loss of consciousness lasting
over 4 seconds, EEG charges of a 3 Hz spike-wave complex lasting
4–20 seconds. The criteria that exclude typical absence epilepsy: oc-
currence of other seizures in the active phase of the absence seizures:
generalised tonic–clonic (GTCS), myoclonic, stimulus-sensitive absence
with eyelid myoclonia, perioral myoclonia and massive myoclonia of ex-
tremities, head and trunk. We performed a retrospective analysis of 101
children, aged 1.5–14 years, with absence epilepsy. Seventy-five chil-
dren (group A) had typical absence seizures, while 26 children (group
B) had non-typical absence seizures. All children had normal psychomo-
tor development.
Results: Relation group A/group B: 2-year remission of absences
100%/77%, GTCS seizures 8%/35%, recurrence after cessation of ther-
apy 1.3%/27%, monotherapy 92%/62%, mean therapy duration 3.5
years/4.8 years. Gender, age, family history of epilepsy and EEG findings
were not significant prognostic parameters.
Conclusion: In childhood absence epilepsy unfavourable prognostic
factors are nontypical absence seizures (eyelid and perioral myoclonia,
massive myoclonia of head, shoulders and hands) and the occurrence of
GTCS in the active phase and remission of absence seizures.
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RELATIONSHIP BETWEEN THE CHARACTERISTICS OF
SLOW-WAVE COMPONENTS AND COGNITIVE IMPAIR-
MENT IN ROLANDIC EPILEPSY
1C. De Cock, 2A. Nonclercq, 1D. Verheulpen, 1M. Foulon, 2P. Mathys,
and 1J. Jacquy (1CHU de Charleroi, Charleroi, Belgium, 2Universite´
Libre de Bruxelles, Brussels, Belgium)
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Purpose: Rolandic epilepsy is a common form of partial and idio-
pathic epilepsy in childhood. The course is generally benign. However,
some children develop neuropsychological regression. The slow-wave
component of the spike-and-wave complex represents the excess of in-
hibition following cortical hyperexcitability. This inhibition could lead
to neuronal injuries when repeated. We studied the impact of the slow
wave characteristics (duration and amplitude) on the behavioural and
developmental prognosis of these children.
Method: Eleven children were analysed retrospectively and divided
in two groups. Group one (C) for patients (n = 6) without intellectual
impairment, developmental regression or school difficulties. Group two
(U) (n = 5) for those with at least one of these criteria.
Results: No statistical difference was observed between the two
groups according to mean amplitude and duration of the slow wave
during the first cycle of non-REM sleep. Nevertheless the presence of
bilateral foci was correlated with a worse prognosis (p = 0.066, IC95%
[Fisher’ exact test]; p = 0.0303, IC 95% [Fisher’ exact test two-tailed]).
Continuous spike and wave during slow sleep, multiple interictal parox-
ystique activities, variability of paroxysms, focus laterality, and the age
at onset are signs of worsening evolution but did not reach statistical
significance.
Conclusion: “Benign” childhood epilepsy with centrotemporal spikes
can lead to cognitive impairment when the foci are bilateral. More data
are needed to determine the influence of the slow wave component of
the spike and wave complex on the clinical evolution.
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EARLY-ONSET ABSENCES: STILL UNDERDIAGNOSED
EPILEPSY?
M. Borkovic (Clinic of Neurology and Psychiatry for Children and
Youth, Belgrade, Serbia and Montenegro)
Purpose: The classification of epilepsies and epileptic syndromes
recognises many syndromes with typical absences, none of which are
characterised by onset in early childhood, and little is known about the
nosology and prognosis of early-onset absences.
Method: We describe the clinical and electroencephalographic fea-
tures of 3 female infants (aged 2–4) diagnosed as early-onset absence
seizures (onset of absences as the only seizure type before age 3).
Results: The age at onset of the seizures ranged between 9 and 22
months. Ictal EEG revealed a normal background and generalised spike-
and-wave complexes at 3–3.5 Hz accompanied by disruption of ongo-
ing activity in keeping with absence seizures. The duration of seizures
ranged from 5 to 20 s. Clinical and electroencephalographic follow-up
ranged from 10 months to 3 years. Two children were on treatment with
valproate and in 1 case, the rational combination of valproate and etho-
suximide with adjunctive clonazepam was necessary. Complete control
of absence seizures was achieved in all our cases. The neurological eval-
uation was normal in all patients. Neuropsychological assessment during
clinical follow-up disclosed mild mental retardation in 2 girls, while the
remaining patient showed normal intelligence on WISC measurement.
Conclusion: Early onset of absences is uncommon, and multicenter
studies are necessary to better define both their nosology and prognosis.
A video-electroencephalography is the method of choice in the diagnos-
tic evaluation and syndromic classification of these seizures.
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EVALUATION OF NIGHT SLEEP EEG MONITORING TO DI-
AGNOSE EPILEPSY IN CHILDREN AND ADOLESCENTS
J. Mlodzikowska-Albrecht, M. Zarowski, B. Gurda, and B. Steinborn
(Chair and Department of Developmental Neurology, Poznan University
of Medical Sciences, Poznan, Poland.)
Purpose: The main aim of this study was to estimate the usefulness
of night sleep EEG monitoring (NSEM) to paroxysmal EEG activity
detection during sleep in children with the tentative diagnosis of epilepsy.
Method: The analysis was performed on a group of 76 children admit-
ted to the Department of Developmental Neurology from January 2004
to December 2005, to diagnose epilepsy or to estimate the effectiveness
of antiepileptic therapy. The average age of the children was 10.4 ±
5.1 years. Fifty children (65.8%) from the group of 76 were admitted
for diagnosis of seizures, 26 (34.2%) children were admitted to control
treatment efficiency. The AEDs were administered as monotherapy in
17 patients and as polytherapy in 9 children.
Results: Clinical events appeared in 23 (30.3%) patients during EEG
recording. The correlation between the clinical event and EEG parox-
ysmal activity was noticed in only 8 children (10.5%). A nonepileptic
seizure took place in 15 patients (19.7%) and it had a form of an awaken-
ing, sleep terror, sleepwalking, sleep starts, making tense muscles, swing-
ing and other motor activities. Seizure-like epileptiform EEG changes
during wakefulness were found in 17 (41.5%) patients and during sleep
in 38 cases (92.7%).
Conclusion: The analysis revealed that NSEM recording was an effec-
tive and sensitive method to estimate patients with the tentative diagnosis
of epilepsy, particularly with night seizures. The NSEM recording seems
to be better for detecting paroxysmal activity than the standard EEG.
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LEVETIRACETAM MONO- AND ADD-ON THERAPY IN CHIL-
DREN WITH FOCAL AND GENERALISED EPILEPSY: A RET-
ROSPECTIVE STUDY
E. Martinz, M. Rauchenzauner, S. Foerster, W. Schoppel, D. Karall,
and E. Haberlandt (Department of Pediatrics, University of Innsbruck,
Austria)
Purpose: Levetiracetam (LEV) is licensed as add on therapy for chil-
dren older than 4 years. Studies trying to evaluate efficacy of LEV as
monotherapy are of interest.
Method: This is a single centre, retrospective study. We investigated
28 paediatric patients with focal and generalised epilepsy between 2002
and 2005. All were treated with levetiracetam as mono- or add-on ther-
apy. We recorded seizure frequency i.e. reduction, tolerability i.e. side
effects, and serum concentrations in relation to dosage.
Results: of the patients, 73% had a focal and 27% a generalised
epilepsy. Mean age was 10.4 ± 4.6 years (median 10 years, range 3–
20 years). Mean given dosage of levetiracetam was 46.5 mg/kg b.w./day.
For 48%, we gave levetiracetam as monotherapy. We measured serum
concentrations between 3.5 and 34.2 μg/ml (aimed 5-52 μg/ml). Mean
observation time was 9.6 months (median 4 months, range 1–34 months).
We achieved complete seizure control in 54%; in almost half of these
patients (47%) after introduction of levetiracetam as monotherapy. In 1
patient seizures were reduced by 75%. We stopped therapy in 14% due
to ineffectiveness after 6-8 weeks. Side effects were observed in 9/28
patients. No patient had to stop therapy due to side effects.
Conclusion: We consider LEV to be a potent new anticonvulsant
for treatment of generalised and focal epilepsy in childhood, also as
monotherapy. With similar dosage children reach significantly lower
serum concentrations than adults. Thus, dosage should be increased until
side effects appear. We plan further prospective pharmacokinetic studies
for confirmation of our observations.
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MULTIMODAL IMAGING FOR FOCUS LOCALISATION IN
PAEDIATRIC EPILEPSY
1M. Kurian, 1L. Spinelli, 2J. Delavelle, 3J. Willi, 3M. Velazquez, 1V.
Chavez, 4K. Villemure, 4E. Roulet, 5J. Villemure, and 1M. Seeck
(1Presurgical Epilepsy Evaluation Unit, Functional Neurology and Neu-
rosurgery Progam of the University Hospitals Lausanne and Geneva,
Switzerland, 2Department of Radiology, University Hospital, Geneva,
Switzerland, 3Deaprtment of Nuclear Medicine, University Hospital,
Geneva, Switzerland, 4Department of Pediatric Pathology, Pathology
Institute, Lausanne, Switzerland, 5Department of Neurosurgery, Uni-
versity Hospital, Lausanne, Switzerland)
Purpose: To determine the extent to which combined multimodal
imaging techniques contribute to improved focus localisation in paedi-
atric pharmacoresistant epilepsy.
Method: Fifty children and adolescent patients evaluated and operated
between 1996 and 2004 and followed up after surgery for a period of at
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least 12 months were included in the study. Outcome was measured by
postoperative seizure frequency using Engel’s classification.
Results: 78% of patients (n = 39) were completely seizure free. All
patients operated within two years of epilepsy onset had a favourable
outcome (class 1 and 2). No difference was noted in the outcome in
children with or without special education needs as well as in younger
and older children. PET provided better localising information in patients
with extra temporal epilepsy and/or dysplastic lesions, whereas SPECT
was superior to PET in temporal lobe epilepsy and/or tumours (p < 0.05).
The likelihood to benefit from surgical treatment was significantly higher
if more examinations were concordant with respect to the resected brain
area (p < 0.001).
Conclusion: Multimodal imaging techniques improve the yield in
epileptogenic focus localisation in paediatric epilepsy, both for extra
temporal and temporal lobe epilepsy. Early surgical intervention is worth-
while, given the potential benefit of complete postoperative seizure con-
trol, particularly in younger patients.
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DAILY CHANGES OF INTERICTAL EEG ABNORMALITIES IN
CHILDREN WITH IDIOPATHIC OCCIPITAL LOBE EPILEPSY
M. Brinciotti, L. Cantonetti, M. Matricardi, A. Mittica, G. Lauretti, and
M. Pugliatti (University “La Sapienza,” Rome, Italy)
Purpose: To evaluate the changes of epileptic EEG abnormalities in
relation to daily activities and to awake/sleep cycle in idiopathic occipital
lobe Epilepsy (IOE).
Method: At home 24-h ambulatory EEG was obtained by a 12 chan-
nel recording system in 18 patients (11 males, 7 females; age 6–16.7 yrs,
mean 10.2 yrs) with IOE. Previous informed consent was obtained and
we asked parents to mark on the EEG the start and end of all activities
and any clinical events. At least 30 minutes of EEG (including hyper-
ventilation) were recorded in the laboratory. The amount (N) of epileptic
abnormalities within each period (T) of activity was used to compute an
index of abnormalities (N/T). Wilcoxon test and ANOVA were used for
statistical analysis.
Results: The index was higher in sleep than in awake at rest
(7.51 ± 17 vs 3.15 ± 11; p < 0.05). Significantly higher values were
found in the afternoon than in the morning for both awake at rest (3.55
± 12 vs 2.65 ± 8; p < 0.035) and awake during activity (3.79 ± 13 vs
2.01 ± 6; p < 0.015). With respect to the rest, abnormalities were in-
creased by hyperventilation (6.34 ± 12.8; p < 0.005) and TV watching
in the afternoon (5.92 ± 13; p < 0.008) but not in the morning. Five pa-
tients reported ictal events; 3 seizures in the afternoon (2 while watching
TV, 1 at rest), and 2 nonepileptic manifestations during sleep.
Conclusion: Patients with IOE show significant changes in the amount
of epileptic EEG abnormalities in everyday life, closely related to the
awake/sleep cycle and to activities involving visual function. TV watch-
ing seems to be more epileptogenic in the afternoon than in the morning.
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EEG FINDINGS IN CHILDREN WITH CEREBRAL PALSY
M. Jovanovic, B. Jocic-Jakubi, D. Stankovic-Jankovic, and L. Dimitri-
jevic (Clinic of Mental Health and Child Neuropsychiatry, Nis, Serbia
and Montenegro)
Purpose: Epilepsy is common in children with cerebral palsy (CP).
15–60% of children with CP have epilepsy according to population based
studies. Children with spastic CP have a higher incidence of epilepsy than
patients with other forms of CP. We evaluated EEG findings in children
with CP with or without epilepsy in our sample.
Method: We retrospectively analysed clinical and EEG data on 59
children with CP (23 girls and 36 boys) age 12 months to 18 years.
Follow up period was 6 months to 2 years.
Results: In the group of 59 children with CP, 50 had spastic CP, 2
dystonic CP, 3 ataxic CP and 4 mixed CP. Thirty-three (55.9%) of the
children had epilepsy. Different types of epilepsy occurred, and epileptic
encephalopathy (West syndrome) and localisation related seizures were
the most common types. Epilepsy most commonly affected children
with spastic CP (27 children, 81.8%). In the group of children with CP
and epilepsy, 6 (18.2%) had no epileptic discharges on EEG recording.
Another 27 children in this group (81.8%) had abnormal EEG findings,
mostly focal but also with secondary generalised discharges. In a group
of 26 children with CP but no evidence of epilepsy, 13 children (50%)
had epileptic discharges on EEG recordings.
Conclusion: CP is associated with a high incidence of epilepsy but
also with EEG abnormalities which are not always associated with clin-
ical manifestations of epilepsy.
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VERBAL FLUENCY IN CHILDREN WITH FOCAL EPILEPSY
B. Jocic Jakubi, M. Jovanovic, and D. Stankovic Jankovic (Clinic of
Mental Health and Child Neuropsychiatry, Nis, Serbia and Montenegro)
Purpose: Impaired verbal fluency is associated with frontal lobe dam-
age, particularly the left anterior frontal lobe. Fluency in speech is usually
measured by the quantity of words produced, usually within restricted
categories and within a time limit.
Method: The results of verbal fluency test (VFT), for both categories:
phonological and semantic, of 80 children aged 7–16 years suffering from
focal epilepsy were compared with results of 80 healthy age matched
controls. We compared the results of VFT between two groups of chil-
dren: those who have EEG epileptogenic focus in left (L) hemisphere
(n = 38), versus right (R) side epileptogenic focus (n = 42). We also
compared scores on VFT in a group children with temporal (T) (n = 36)
with scores in a group children with extratemporal epileptic focus (ExT)
(n = 44). The effects of type of seizures, number of seizures, and age at
seizure onset were also examined.
Results: We found significant differences between results in the ex-
perimental and control group, for both categories. Group differences
were found when we compared results of LT vs RT group, only for the
phonological category (p < 0.05). Age at seizure onset (under 7 years)
was related with low performances on VFT only for semantic category
(p < 0.05), but the number of seizures was not significant. Complex
seizures were a significant predictor for both categories, phonological
(p < 0.02) and semantic (p < 0.001), respectively.
Conclusion: Children with focal epilepsy have impaired verbal flu-
ency, for both categories. Children with EEG focus in left T lobe have low
performance, only for the phonological category. Age at seizure onset
(for semantic category only) and type of seizure (for both categories) are
very important predictive factors for cognitive functioning in children
with focal epilepsy, including verbal fluency.
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NITRAZEPAM IN REFRACTORY FRONTAL LOBE PAEDI-
ATRIC EPILEPSY
P. Parisi, A. Pelliccia, A. Luchetti, S. Miano, S. Franci, and M.
Villa (Child Neurology & Paediatric Sleep Centre, Pediatr. Dept. “La
Sapienza” University c/o Sant’Andrea Hospital, Rome, Italy)
Purpose: Nitrazepam (NZP) has been found to be of benefit in
some epileptic conditions, such as myoclonic seizures and epileptic en-
cephalopathies. Unfortunately, development of tolerance, reported after
1 to 12 months (Allen JW, et al., BMJ 1983;286:1246–7), had drasti-
cally reduced its use in clinical practice. Up until now, NZP therapy
has never been tried taking into account the clinical-EEG focal aspects.
On the other hand, more recently, with an understanding of molecu-
lar complexities of the GABA receptors and its subtypes (Wafford KA.
Curr Opin Pharmacol 2005;5:47–52), we clarified that affinity, toler-
ance, and efficacy of the most clinically used benzodiazepine, critically
depend both on the specific subunit composition of the receptor and on its
selective topographic brain distribution (Rowlett JK. CNS Spectr 2005;
10:40–8).
Method: We retrospectively investigated safety and efficacy of NZP
treatment in refractory frontal epilepsy, both as mono- and add-on ther-
apy in 33 children (3 idiopathic) previously treated (all, old and new,
AEDs), aged between 2.8 to 18 years (mean = 4.3). Mean follow-up =
2.8 years.
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Results: Six children (18.18%) are taking nitrazepam as monother-
apy and are seizure-free (mean follow-up: 14 months). Twenty-seven
(81.8%) children decreased in seizure frequency (at least 50%) and only
in 3 patients (9%) was reappearance and worsening of seizures observed.
Conclusion: Focal electroclinical aspects should be considered in or-
der to choose the best antiepileptic treatment. To assess its safety and
long-term efficacy, NZP needs studies in a large cohort of patients, al-
though our preliminary results seem to be promising.
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THE PHE365SER MUTATION IN SCN1A GENE CAUSES SE-
VERE MYOCLONIC EPILEPSY OF INFANCY
1N. Barisic, 2P. de Jonghe, 2L. Claes, 2L. Ann, 2K. Claeys, and 1I.
Lehman (1Clinical Medical Center Zagreb, Department of Pediatrics,
Zagreb, Croatia, 2Department of Molecular Genetics, University of
Antwerp, Antwerp, Belgium)
Purpose: We present an 11 year old boy with severe myoclonic
epilepsy of infancy due to a SCN1A mutation (Phe 365 Ser).
Method: Clinical examination, EEG, brain MR scans, laboratory tests
for exclusion of inherited metabolic disorders and molecular genetic
analysis were performed. The patient was born from a normal preg-
nancy, parents are nonconsanguineous. He developed the first seizures
at the age of 16 months during febrile illness. The seizures included hemi-
convulsions with transitory postictal hemiparesis, atypical absences, sec-
ondary generalised grand mal seizures and status epilepticus. He devel-
oped ataxia and speech regression at the age of 3 years. He was treated
unsuccessfully with all combinations of available antiepileptics.
Results: EEG shows slow background activity, with high voltage
slow waves, focal and paroxysmal discharges. His brain CT and MR
scans are normal. On examination he showed mild mental retardation
associated with ataxia, bradykinesia and bradylalia, as well as signs of
corticospinal tract involvement. DNA sequencing analysis of the coding
exons of SCN1A showed nucleotide change c. 1094T > C in exon 8 pre-
dicting phenylalanine to serine substitution at codon 365 (Phe 365 Ser).
Parents are not carriers of the same mutation. Patient is a heterozygous
carrier of a mutation in SCN1A which has not yet been described.
Conclusion: Newly discovered Phe 365Ser de novo mutation in
SCN1A gene is most probably the cause of SMEI in our patient.
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ANTIEPILEPTIC TREATMENT FOR CHILDREN
WITH LEARNING DISABILITIES WITHOUT EPILEPY
BUT WITH EPILEPTIFORM ACTIVITY IN THE
ELECTROENCEPHALOGRAM
1E. Porras, 1T. Harmony, 1J. Ricardo, 1E. Santiago, 1T. Ferna´ndez, 1G.
Avecilla, 1L. Sa´nchez, and 2E. Valencia (1Neurobiology Institute, Na-
tional Autonomous University of Mexico, 2Women’s and Children Hos-
pital, SESEQ, Juriquilla, Mexico)
Purpose: In clinical practice there is no evidence as yet to justify rou-
tine use of antiepileptic drugs to treat children with learning disabilities
without epilepsy but with epileptiform discharges in EEG. This study
aimed to find whether it is useful to treat these children.
Method: One hundred eleven children with specific learning disabili-
ties without epilepsy were assessed. A randomised, double blind, single
crossover trial was carried out with magnesium valproate (20 mg.kg.day),
carbamazepine (20 mg.kg.day) or placebo for six months on 18 children
who showed epileptiform discharges in EEG. Previously they had per-
formed cognitive testing (BTL, Lecture Disabilities Assessing Battery
for Latin-American Children; WISC-RM, Wechsler Intelligence Scale
for Children, Mexican Version and DIANA, Neurocognitive Automa-
tized Diagnosis). Children were reevaluated at the end of the treatment.
Results: Children who received magnesium valproate or carba-
mazepine improved in long term memory, visual perception, word encod-
ing, phonetic analysis, working memory, semantic memory, phonologic
knowledge, visual attention and visuospatial organisation, among other
cognitive domains. No changes in epileptiform discharges in EEG were
observed but in Brain Electrical Source Analysis (BESA) there were
positive changes in children who received magnesium valproate or car-
bamazepine in 3.90, 4.29, 4.68, 5.07, 5.46 y 10.92 Hz for cortex and
basal ganglia.
Conclusion: Our data support the idea that magnesium valproate or
carbamazepine may be a useful treatment in children with learning dis-
abilities without epilepsy and electrographic epileptiform discharges in
EEG.
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EPIDEMIOLOGICAL CHARACTERISTICS IN SCHOOL-AGE
CHILDREN WITH EPILEPSY IN THE CENTRAL SERBIA RE-
GION (CITY OF KRAGUJEVAC)
N. Todorovic (Clinical Center Kragujevac, Serbia and Montenegro)
Purpose: Epilepsy represents one of the commonest neurological dis-
orders in childhood. The aim of our research was to determine epidemi-
ological characteristics of epilepsy in school-age children (7–14 years
old).
Method: The research was performed as retrospective and longitudi-
nal for a five year period (2001–2005), and the region of investigation
was the territory around the city of Kragujevac with 180,000 inhabitants.
There were so-called hospital statistics data used in the research.
Results: In the five year period of the research there were 486 children
with epilepsy treated; 34.8% of whom had symptomatic or cryptogenic
epilepsy and 65.2% had idiopathic epilepsy. There were slightly more
male than female patients (52.9%:47.1%), but without statistical sig-
nificance regarding the type of epilepsy. The prevalence rate has been
determined and on 31 December 2005, it was 25.2/1000; the prevalence
of symptomatic-cryptogenic epilepsy was 8.8/1000 and of idiopathic
epilepsy was 16.5/1000.
Conclusion: The established data point out the scope and the signif-
icance of this problem in our surrounding are and also can be used by
child health care planners in recognising the need for a type and way of
organising health care, as well as the need for outpatient and hospital
capacities. These data are valuable for promoting preventive measures
and activities of taking care of this category of disability from epilepsy.
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EFFECTS OF METABOTROPIC GLUTAMATE ANTAGONIST
ON NEURAL STEM CELLS IN FRAGILE X SYNDROME
1M. Castre´n, 2V. Ka¨rkka¨inen, and 2K. A˚kerman (1Department of Hu-
man Genetics, University of Helsinki, Finland, 2A.I. Virtanen Institute,
University of Kuopio, Finland)
Purpose: Fragile X syndrome is a common cause of inherited mental
retardation. The majority of affected individuals display EEG abnormal-
ities and about 20% of patients develop childhood seizures. The syn-
drome is caused by the absence of the FMR1 protein (FMRP) and the
fmr1-knockout mice (fmr1-KO mice) serve as a mouse model for the syn-
drome. The transgenic mice exhibit elevated susceptibility to audiogenic
seizures and treatment with metabotropic glutamate receptor antagonist,
MPEP, suppressed epilepsy phenotype. We have previously shown that
the differentiation of neural stem cells (NSCs) is altered in fragile X syn-
drome. An increase in the number of cells with metabotropic glutamate
response was a unique feature in the differentiation of FMRP-deficient
NSCs.
Method: We investigated the effects of MPEP on growth and dif-
ferentiation of NSCs in neurosphere cultures generated from brains of
fmr1-KO mice using the MTT assay and calcium imaging.
Results: Treatment with 1-10 μM MPEP did not affect growth of
proliferating wild-type or FMRP-deficient mice NSCs. However, treat-
ment with 100 μM MPEP caused a significant reduction in the cell
growth in transgenic but not in wild-type neurosphere cultures suggesting
that FMRP-deficient NSCs were more sensitive to the high concentra-
tion of MPEP. Calcium imaging studies confirmed the expression of
metabotropic glutamate receptors in a subpopulation of differentiated
NSCs. Exposure to MPEP significantly increased (4-fold) the number
of cells in this subpopulation of NSCs derived from the fmr1-KO mice
after differentiation for 2–3 days.
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Conclusion: These studies provide evidence that antagonism of
metabotropic glutamate receptor signalling influences differentiation of
FMRP-deficient NSCs.
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CLINICAL EXPERIENCE WITH ZONISAMIDE ADJUNCTIVE
THERAPY FOR PAEDIATRIC EPILEPSY
1H. Kang, 2H. Kim, and 3H. Moon (1Department of Pediatrics and
Epilepsy Center, Sanggye Paik Hospital, Inje University College of
Medicine, Seoul, Korea, 2Department of Pediatrics, Severance Hospi-
tal, Handicapped Children’s Research Institute, Brain Research Institute,
Yonsei University College of Medicine, Seoul, Korea, 3Department of
Pediatrics, Yeungnam University College of Medicine, Daegu, Korea)
Purpose: To reveal the outcomes from using zonisamide adjunctive
therapy for paediatric epilepsy.
Method: A clinical retrospective study was performed for 2 years
from September 2003 to August 2005 at a tertiary epilepsy centre. All
75 patients (male 50, female 25) experienced more than four seizures
per month. They were not controlled by an initial combination of two
or more conventional antiepileptic drugs and could be followed up for
at least 6 months after prescribing zonisamide for various epilepsies or
epileptic syndromes of childhood. The target dosage of administered
drug was decided to be 10mg/kg/day and adjusted depending on each
patient’s tolerability.
Results: Thirty-five patients (46.6%) out of 75 showed a reduction
of seizure frequency of more than 50%, and 12 patients (16.0%) were
seizure free. Of 27 patients who mainly manifested myoclonic seizures,
16 (59.2%) showed a seizure reduction of more than 50% and 6 patients
(22.2%) had no further seizures. The mean maintenance dosage of drug
was 8 mg/kg per day (range 3–15 mg/kg per day). 9 patients (12.0%)
showed adverse reactions in the following order of frequency: somno-
lence 5 patients, rashes and agitation respectively, 1 patient. Zonisamide
should be discontinued due to acute pancreatitis in 1 patient, and in an
additional patient the dosage should be reduced due to enuresis.
Conclusion: Zonisamide is believed to be an effective, safe anticon-
vulsant when used as an adjunctive therapy for various refractory child-
hood epilepsies.
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KETOGENIC DIET IN INTRACTABLE CHILDHOOD
EPILEPSY WITH MITOCHONDRIAL RESPIRATORY CHAIN
ENZYME COMPLEXES (MRC) DEFECT
1H. Kim, 1Y. Lee, 2H. Kang, 1J. Lee, and 3A. Slama (1Department of
Pediatrics, Institute For Handicapped Children, Yonsei University Col-
lege of Medicine, Seoul, Korea, 2Department of Pediatrics, Inje Uni-
versity College of Medicine, Sang-Gye Paik Hospital, Seoul, Korea,
3Laboratoire De Biochimie 1, APHP, Hopital De Bicetre, Le Kremlin-
Bicetre, France)
Purpose: To reveal the efficacy of ketogenic diet (KD) in patients
with intractable childhood epilepsy caused by mitochondrial respiratory
chain enzyme complexes (MRC) defect.
Method: We retrospectively analysed 13 children (M/F:5/8) with in-
tractable epilepsy who received KD over 3 months. MRC defects were
confirmed by biochemical enzyme analysis from patients; muscle and/or
lymphocytes using spectrophotometry.
Results: 1) KD started at the age of 3.7 ± 3.0 years (8 months–4.8
years), and mean duration between seizure onset and KD was 1.5 ± 1.3
years. 2) MRC I defect was seen in 8 cases (61.5%), II in 1 case (7.7%), IV
in 3 cases (23.1%), and combined I and IV defect in 1 case. 3) Two cases
were Leigh’s encephalopathy, but 11 other cases were not categorised to
any clinical diagnostic classification. 4) Five cases were infantile spasm,
4 cases with Lennox-Gastaut syndrome, 1 case with generalised epilepsy,
and 3 cases were partial epilepsy. 5) Seven cases became seizure free after
KD, 1 case showed seizure reduction more than 90%, 3 cases between
50 and 90% seizure reduction, and 2 cases showed no benefit in seizure
reduction. 6) Hypoglycemia was complicated in 2 cases, which were
controlled by additional oral steroids. 7) Global developmental function
improved in 8 cases (61.5%) on KD.
Conclusion: KD is effective in treating intractable epilepsy with MRC
defect as well as global cerebral function in children.
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ELECTRICAL STATUS EPILEPTICUS DURING SLOW SLEEP
(ESES): A STUDY ON SPECTRUM OF EPILEPTIC SYN-
DROMES, CLINICAL AND ELECTROENCEPHALOGRAPHIC
FEATURES AND THERAPEUTIC RESPONSE
1I. Pacheva, 1I. Ivanov, and 2P. Dimova (1Department of Pediatrics and
Medical genetics, Medical University of Plovdiv, 2Clinic of Child Neu-
rology, St. Naum University Hospital, Sofia, Bulgaria)
Purpose: ESES is a rare but potentially devastating phenomenon that
may complicate various epileptic syndromes or present independently.
We aimed at revealing pre-ESES epileptic presentation, the features of
ESES and its response to treatment.
Method: All epilepsy patients with unexplained neuropsychological
and/or motor deterioration underwent prolonged sleep EEG recordings.
From a cohort of 600 children with epilepsy in the last 5 yrs ESES was
diagnosed in 7 of them. They were neurologically and psychologically
evaluated. Therapeutic regimen of ESES started with clonazepam (Czp)
and if it failed ACTH or steroids were introduced.
Results: ESES developed in 2 children with an atypical variant of
BECTS and initial normal development; in 2 other patients with cryp-
togenic or symptomatic partial epilepsy and mental retardation (MR),
in 1 child with symptomatic Lennox-Gastaut syndrome and severe MR
and in another 2 patients with non-classifiable epilepsy and mild MR.
When ESES developed motor impairments and/or psychological regres-
sion appeared and a new type of seizures occurred or existing focal and
generalised seizures got worse. Two of the 7 cases responded to Czp
0.05–0.2 mg/kg with full recovery, but after 2–5 months ESES relapsed.
They and 3 of the 5 nonresponders to Czp were successfully treated
with ACTH 0.5–1 mg every other day. Three patients relapsed after
discontinuation of ACTH and a second course of ACTH or another ben-
zodiazepine were applied. Two of the nonresponders to Czp were lost
for further treatment.
Conclusion: ESES appears to be a complication of various epileptic
syndromes rather than an independent syndrome. It should be suspected
in every child with epilepsy with neuropsychological regression. Ben-
zodiazepines and ACTH are reaffirmed as treatments of choice.
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INTRAVENOUS IMMUNOGLOBULINS (IVIG) IN REFRAC-
TORY CHILDHOOD EPILEPSY: PROSPECTIVE STUDY OF
EFFECTS ON SEIZURE FREQUENCY, EEG ACTIVITY, AND
CEREBROSPINAL FLUID CYTOKINE PROFILE
1L. Lagae, 1P. Witters, 2B. Ceulemans, 1A. Kasran, 1C. Wouters, and
1A. Billiau (1 University Hospitals KU, Leuven Belgium, 2 Epilepsy and
Revalidation Centre, Pulderbos, Belgium)
Purpose: Several studies have reported a favourable effect of IVIG
in refractory epilepsy. Data substantiating an immunomodulatory effect
are scarce. We prospectively investigated the effect of IVIG on clinical,
EEG and serum/CSF immunological parameters in refractory childhood
epilepsy.
Method: Thirteen children (median 6.9 years (range 1.6y–25.8y))
with a median monthly seizure frequency of 152 (range 3–1286) de-
spite 3 or more therapeutic AEDs were given IVIG (Sandoglobulin,
ZLB-Behring, add-on, 4 × 400 mg/kg/3weeks). Before and after com-
pletion of the course, seizure frequency, 24h-videoEEG (automatic spike
counting), and CSF and serum routine immunological parameters and
cytokine profiles (IL-6/IL-8/IL-12/IL-10 (CBA/BD Biosciences) were
documented.
Results: Seizure frequency was reduced by > = 50% in 4, and 25–
50% in 3 children. In contrast, spike-counts (1-hour-wake and -sleep)
did not decline, but increased significantly in 6 children. Serum and
CSF routine immunological parameters were normal, CSF immunoblot-
ting showed transsudate patterns in 6, and oligoclonal bands in 2 pa-
tients. IL-6 and IL-8 were detectable in all CSF samples but only in
7 serum samples, with CSF IL-8-levels being significantly higher than
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serum-IL-8 levels. Detectable IL-10- and IL-12-levels in CSF and serum
were rare. These profiles did not change under IVIG.
Conclusion: In 7 of 13 refractory childhood epilepsy patients, with-
out preexisting immunological disorders, a proinflammatory cytokine
profile was documented, with selective intrathecal presence of IL-8,
supporting a possible role for inflammatory immune responses in the
pathogenesis/potentiation of epilepsy. In contrast to clinical efficacy,
EEG and cytokine profiles were not influenced by IVIG treatment and
no clear association between these parameters was found.
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SIGNIFICANCE AND CUTOFF VALUE OF SERUM GLU-
COSE IN DIAGNOSIS OF FEBRILE STATUS EPILEPTICUS IN
CHILDHOOD
1H. Yoo, 1J. Song, and 2S. Lee (1Myongji Hosital, College of Medicine,
Kwandong University, Koyang, Kyunggi, South Korea, 2Masan Sam-
sung Hospital, College of Medicine, Sungkyunkwan University, Masan,
Kyungnam, South Korea)
Purpose: Status Epilepticus (SE) is a potentially life-threatening and
poor prognostic disease. But SE caused by febrile seizure (febrile SE) has
an excellent prognosis and very little sequelae. We investigated the sig-
nificance and cutoff value of serum glucose in diagnosis and prediction
of febrile SE in childhood.
Method: We selected 40 children who were admitted to our hospital
due to SE from May 2000 to June 2004. Their medical records were
reviewed retrospectively. We surveyed clinical features, aetiology and
laboratory findings, especially serum glucose. Subjects were classified
into febrile SE and nonfebrile SE according to aetiology. For diagnosis
and prediction of febrile SE we investigated the statistical significance
and predictive cut-off value of serum glucose between febrile SE and
nonfebrile SE.
Results: Twenty-three patients (58%) had febrile SE and 17 patients
(42%) nonfebrile SE. Aetiology of nonfebrile SE were encephalitis (9
patients), epilepsy (5 patients), head trauma (1 patient), Reye syndrome
(1 patient) and near drowning (1 patient). The mean value of serum
glucose in febrile SE was 209.6 ± 67.7 mg/dL and nonfebrile SE was
127.8 ± 43.7mg/dL (p = 0.0021). The predictive cutoff value of serum
glucose in febrile SE was 167mg/dL in confidence of 95 percentile.
Conclusion: The serum glucose level in febrile SE is significantly
higher than in nonfebrile SE. The predictive cutoff value is 167mg/dL.
Therefore we suggest that SE above 167mg/dL of serum glucose has a
high likelihood of febrile SE and it is possible to discriminate the cause
of SE by checking serum glucose.
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EPILEPSY IN ANGELMAN SYNDROME
1E. Marszal, 1J. Paprocka, 1E. Jamroz, B. Szwed-BiaA˚,oA˚ 14 yt,
2A.
Jezela-Stanek, and 1I. Kopyta (1Child Neurology Department, Silesian
Medical University, Katowice, Poland, 2Deparment of Medical Genet-
ics, Children’s Health Memorial Institute, Warsaw, Poland)
Purpose: The authors present 9 children (5 girls and 4 boys) with
Angelman syndrome (AS). The purpose of this study was to analyse the
type of epilepsy and EEG pattern.
Method: The diagnosis was based on clinical criteria, EEG and molec-
ular examinations. The patients’ age at the time of diagnosis ranged from
12 months to 10 years. Polymorphic epileptic seizures (atypical absence,
myoclonic, tonic–clonic, atonic and infantile spasms) were present in 7
children. One child suffered from tonic seizures only. The most fre-
quently used drugs were valproic acid, clobazam, clonazepam, lamot-
rigine and topiramate.
Results: The children fulfilled the clinical criteria according to
Williams et al. EEG showed disturbances in the sleep architecture, gen-
eral discharges more pronounced in the posterior areas. In 4 patients
MRI of the head revealed demyelination, cortical atrophy with ventric-
ular enlargement, thin corpus callosum and perisylvian syndrome. AS
was confirmed by deletion of chromosome 15 (UBE3A) or disturbed
methylation pattern in 4 children.
Conclusion: Angelman syndrome accounts for 6% of the children
presenting with severe mental retardation and epilepsy. Epileptic seizures
start between 1 month and 5 years (mean 2–3 years) and they initially
present with febrile convulsions in the 1st year of life. The most frequent
seizures types in infancy are tonic–clonic, atypical absence, myoclonic
and tonic. In that period seizures are difficult to control.
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CLINICAL CHARACTERISTICS OF MITOCHONDRIAL
RESPIRATORY CHAIN ENZYME COMPLEX DEFECT IN
CHILDREN
1Y. Lee, 2A. Slama, 3H. Kang, 1J. Lee, and 1H. Kim (1Department of Pe-
diatrics, Institute for Handicapped Children, Yonsei University College
of Medicine, Seoul, Korea, 2Laboratoire De Biochimie 1, APHP, Hopi-
tal De Bicetre, Le Kremlin-Bicetre, France, 3Department of Pediatrics,
Inje University College of Medicine, Sang-Gye Paik Hospital, Seoul,
Korea)
Purpose: To characterise clinical and laboratory features for mito-
chondrial respiratory chain enzyme complex (MRC) defects to provide
more precise diagnosis and effective treatments.
Method: We retrospectively reviewed clinical and laboratory features
of 28 patients who showed defects in MRC activity, confirmed by bio-
chemical assay from spectrophotometry in muscle and/or lymphocytes.
Results: 1) Mean age was 6.67 ± 4.44 years and sex ratio was 1.15:1.
2) Eighteen (64.3%) were MRC I deficient, 8 (28.5%) of VI deficient,
1 (3.5%) of II deficient, and 1 case of combined deficiency of I and
IV. 3) Eight cases (28.5%) were classified as Leigh syndrome, 1 case
(3.5%) each as MELAS, Kearns-Sayre syndrome, and Alpers disease,
but 17 cases (60.7%) were not clinically categorised for specific disease
criteria. 4) Epilepsy was seen in 21 (75.0%) patients, developmental
delay in 27 of 28 (96.4%). 5) Clinical symptoms most commonly started
before 1 year of age, in 15 (53.6%) patients. 6) Brain MRI showed
diffuse cortical atrophy in 18 (64.3%) and basal ganglia signal changes
in 12 cases (42.9%). 7) Positive rate for laboratory studies were: 92.9%
in lactic acidosis, 62.5% in urine organic acid assay, 26.1% in serum
amino acid assay, and 57.9% in MR spectroscopy. 8) Ketogenic diet and
mitochondrial cocktail with coenzyme Q10 and multivitamin showed
clinical improvements in 75% of patients.
Conclusion: MRC defect can be the cause of many unexplained neuro-
logical disorders including epilepsy. Treatments with coenzyme, multi-
vitamin and/or ketogenic diet have shown considerable benefits.
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DEVELOPMENTAL OUTCOME OF EPILEPSY SURGERY IN
INTRACTABLE CHILDHOOD EPILEPSY
1S. Lee, 1K. Lim, 1Y. Lee, 2H. Kang, 1J. Lee, and 1H. Kim (1Department
of Pediatrics, Institute for Handicapped Children, Yonsei University Col-
lege of Medicine, Seoul, Korea, 2Department of Pediatrics, Inje Univer-
sity College of Medicine, Sang-Gye Paik Hospital, Seoul, Korea)
Purpose: We aimed to determine the developmental outcome in-
cluding cognitive function after various epilepsy surgeries in intractable
childhood epilepsy.
Method: We retrospectively analysed clinical features and data of our
66 patients {mean age 7.51 ± 4.98 yrs (ranging from 1.3-19.1 yrs) M:F
= 1.4 :1} who underwent epilepsy surgery between October 1998 and
September 2003 due to intractable epilepsy based on their symptoms,
imaging study results and electroencephalography. Neuropsychological
assessment was done prior to and 1 year after surgery with age matched
batteries (Bayley Scales, K-WISC).
Results: 1) 48 cases (72.7%) were retarded with DQ < 70, and 10
cases (15.1%) were within the normal range intelligence level between
85 and 115. 2) Short duration of epilepsy and young age at surgery
were significant factors for better developmental quotients. 3) 40 cases
(60.6%) became seizure free (Engel class I) during the follow up period,
and 21 cases (31.8%) showed a significant reduction of seizures (Engel
class II, III). 4) Patients without a seizure-free outcome showed a ten-
dency of developmental decline. 5) 10 cases (15.1%) showed significant
developmental gaining with DQ over 10 points in patients with a seizure
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free outcome. 52 Cases (78.8%) showed stable developmental progress
after surgery. 6) Developmental improvement was significantly higher
with partial seizures, infantile spasms and Lennox-Gestalt syndrome in
order of improvement. 7) Developmental gain was better in patients with
abnormal pathologic findings.
Conclusion: We could conclude that successful epilepsy surgery at
an earlier age can provide a better developmental outcome.
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RESULTS OF SURGICAL TREATMENTS ON INTRACTABLE
EPILEPSY WITH INFANTILE SPASM
1J. Seo, 1B. Noh, 1Y. Hur, 2S. Eun, 1Y. Lee, 3H. Kang, 1J. Lee, and 1H.
Kim (1Department of Pediatrics, Institute for Handicapped Children,
Yonsei University College of Medicine, Seoul, Korea, 2Department of
Pediatrics, Korea University College of Medicine, Korea, 3Department
of Pediatrics, Inje University College of Medicine, Sang-Gye Paik Hos-
pital, Seoul, Korea)
Purpose: To determine the surgical outcome of intractable childhood
epilepsy with infantile spasm (IS), Lennox-Gastaut syndrome (LGS),
and intractable partial seizure (PS) later evolving from IS.
Method: We retrospectively reviewed 22 cases of intractable child-
hood epilepsy, who received epilepsy surgery since 1999, 5 cases were
IS, 14 cases were LGS, and 3 cases evolved from IS. EEG features, imag-
ing studies including MRI, SPECT and PET, types of surgery, pathologic
findings and seizure outcome were reviewed.
Results: Sex ratio of 22 cases was 1:1.4 (M:F). The mean duration
from diagnosing epilepsy until the operation was 6–10 years in 8 (36%)
cases, 1–2 years in 7 (32%). In preoperative EEG, abnormalities implying
possible focal lesion were seen in all 22 patients. Seven (32%) out of 22
cases showed focal lesions in MRI while 12 (92%) out of 13 cases in
ictal SPECT, 8 (62%) out of 13 cases in interictal SPECT, and 11 (61%)
out of 18 cases of PET showed abnormal findings. Single lobectomy was
most commonly performed, in 13 (59%) cases, among whom a frontal
lobectomy was performed in 11 cases. Also, multilobar resection was
performed in 6 (27%) cases and hemispherotomy in 2 (9%). During
the pathological examination, cortical dysplasia was most commonly
observed, in 11 (50%) cases, microdysgenesis in 3 (14%), gliosis in 2
(9%) and tuberous sclerosis in 2 (9%) as well. Nineteen (86%) patients
were classified as Engel class I after surgery.
Conclusion: In cases of children with IS not controlled by medical
treatment, epilepsy surgery should be strongly considered when cortical
pathology can be identified from various studies.
p765
POSSIBILITY OF MAKING PAEDIATRIC SOFTWARE TO DI-
AGNOSE NEUROLOGICAL DISEASES
1Y. Monir Vaghefi, 2T. Mahmoudian, and 1N. Ghasem Aghaee
(1Software Engineering Department, Sheikh Bahaee University, Iran,
2Pediatric Neurology Department, Medical University of Isfahan, Iran)
Purpose: Expert system is a computer program that simulates the
thought process of a human expert to solve complex decision problems
in a specific domain. Human experts have limited resources. They get
tired, forget crucial details of a problem and are not available anytime
and everywhere. Human expert knowledge is a composition of rational
knowledge and heuristic knowledge. It is easy for an expert system to
have rational knowledge and hard for it to have heuristic knowledge.
Software engineers therefore like to define problems which need rational
knowledge more than heuristic knowledge for their expert systems. They
are able to build an expert system that is capable of diagnosing by asking
the patient or patient’s parents a number of questions.
Method: In this study the knowledge engineer works in close co-
operation with the paediatric neurologist. Symptoms and types of
epilepsy, tools and methods of diagnosis and paths of reasoning were
described. The knowledge engineer tries to find the best possible solu-
tions to describe symptoms for software and to make software able to
reason based on these inputs.
Results: Computers do not need to rest. They do have a truly accurate
and permanent memory so they do not forget crucial details of a problem.
When software engineers work on a medical expert system they don’t
try to make it work as well as a physician. Physicians have a lot of
abilities that an expert system can never reach. Software and hardware
limits make software engineers define simple problems for an expert
system to solve. Paediatric neurologists are able to diagnose and treat a
number of diseases such as epilepsy, floppy infants, microcephaly and
macrocephaly. An expert system may not be able to diagnose and treat all
these diseases but it is possible for a software engineer to define simpler
problems for the expert system to solve. Questioning is easy for personal
computers, because they do not need any extra hardware to perform this
operation. But physical examination as an important part of diagnosing
is not easy and in most cases is not possible for a personal computer.
Conclusion: Expert systems can greatly help physicians in diagnosis
and treatment of childhood neurological diseases but they are not yet
able to act alone.
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TREATMENT WITH OXCARBAZEPINE IN CHILDHOOD:
HIGH EFFICACY WITH LOW RISK OF AGGRAVATION
I. Ivanov, and I. Pacheva (Medical University of Plovdiv, Bulgaria)
Purpose: To determine the efficacy of OCBZ in paediatric patients
with special attention to its insufficiently known seizure aggravation
profile.
Method: A retrospective observational study of 136 children aged 1–
18 yrs was conducted; 42.7% with idiopathic, 34.3% with symptomatic
and 23.1% with cryptogenic epilepsy. The percentages of partial, gener-
alised and undetermined epilepsies were accordingly 88, 5.6 and 5.6%.
OCBZ treatment duration varied from 1mo to 5 yrs (mean 1.6) at daily
doses from 10 to 40 mg/kg (mean 22.5). Aggravation was defined as in-
crease in frequency and severity of seizures or appearance of new seizure
types after introduction of OCBZ.
Results: In 49 patients (36.0%) OCBZ abolished seizures. In 52
(38.2%) the seizure reduction was higher than 50%. In 27 children
(19.9%) OCBZ was ineffective. Aggravation was observed in 8 patients
(5.9%; CI 0.5–11.3%). It was noticed in the first month after introduc-
tion of OCBZ (mean 8 days) at a relatively low daily dose (mean 13.9
mg/kg) and always ceased after OCBZ discontinuation. OCBZ induced
absences in 4 patients (2 with continuous spike-wave during slow sleep,
1 with Lennox-Gastaut syndrome, 1 with idiopathic partial epilepsy).
Myoclonic seizures worsened in 1 patient with juvenile myoclonic and 1
with myoclonic-astatic epilepsy. Partial epilepsy was aggravated in other
2 patients.
Conclusion: OCBZ has high efficacy (74.3% responders) when used
for mainly partial epilepsy in paediatrics. The risk of aggravation is this
setting is low (5.9%) and mostly in cases with generalised epilepsy.
OCBZ may induce or worsen absences, myoclonic or partial seizures.
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WHEN CHILDREN WITH EPILEPSY AND MENTAL RE-
TARDATION BECOME SEIZURE-FREE, DISCONTINUATION
OF AEDs IS OFTEN SUCCESSFUL: A POPULATION-BASED
STUDY
P. Camfield, and C. Camfield (IWK Health Centre and Dalhousie Uni-
versity, Halifax, Canada
Purpose: Children with epilepsy and mental retardation (MR) have a
poor prognosis for seizure control. We report the success rate of discon-
tinuing AED treatment when children with MR become seizure-free.
Method: The Nova Scotia population-based epilepsy cohort has fol-
lowed 693 children with all types of epilepsy beginning 1977–85. We
focused on those with documented mental retardation.
Results: of 693 total epilepsy patients, 138 (20%) had mental retar-
dation. 27 died, 1 was untreated, leaving 110 for study with average
follow-up 20.6 ± 5.3 years (range 1.5–28). 58% became seizure-free
and attempted discontinuation of AEDs, 74% with mild MR, 62% with
moderate, 43% with severe/profound. Overall 44% stopped AEDs for a
first time successfully and remained seizure-free for 13.2 ± 7 years of
further follow-up. Some who failed the first discontinuation, tried again
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successfully. Overall 54% discontinued AEDs at least once and were
eventually successful.
The 51% with symptomatic partial epilepsies were more likely to at-
tempt discontinuation of AEDs (p = 0.006) compared with the 49%
with secondary generalised epilepsies but the success rate was the same
(p = 0.8). Of the 395 children with normal intelligence and epilepsies
characterised by convulsive and partial seizures, 294 (74%) discontin-
ued medication at least once and on the first discontinuation 73% were
successful; a higher rate than those with MR (p < 0.0001).
Conclusion: The challenge for children with epilepsy and mental
retardation is to become seizure-free. Once they do so, their rate of
successfully stopping AED treatment was 44–54%, less than those with
normal intelligence but still worth the attempt.
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EMOTIONAL DISTURBANCES IN CHILDREN AND ADOLES-
CENTS WITH SLEEP DISORDERS AND EPILEPSY
1M. Glowacka, 1E. Mojs, and 2M. Zarowski (1Univ. of Medical Sciences,
Department of Health Sciences, Poznan, Poland, 2Department of Dev.
Neurology, University of Medical Sciences, Poznan, Poland)
Purpose: The prevalence of sleep disorders (SD) estimates as 30%
in a healthy population; in a population with epilepsy it is higher, even
50–60%. The classification of disorders based on ICSD 2005 criteria,
includes eight main groups. They appear in children and adolescents as
well. The aim of the study was the estimation of the level of anxiety
understood as trait and state in children and adolescents with SD.
Method: Sixty school boys and girls aged 7–18 yrs of age partici-
pated in the study. They were treated with antiepileptic drugs, because
of epilepsy, in monotherapy mode. The time of duration of epilepsy was
1.5 yrs. They underwent a two step examination. First, they completed a
questionnaire of the SD. In the second part, 30 patients with diagnosed
sleep disorders chosen from the examined group participated in psy-
chological and neurological examinations. The STAI and STAIC scale,
Bender Gestalt test, d-2 test were used in the psychological examination.
They underwent an intelligence examination as well.
Results: Statistical analysis (analysis of variance) shows the signif-
icance at p < 0.05 level correlation between SD and the prevalence
of emotional disorders; anxiety as a state, impulsivity in patients with
epilepsy. There was no correlation between the duration of the SD and the
results of psychological tests. The median IQ was 98.4. There was a sig-
nificant correlation between high level of anxiety and sleep disturbances
in a subgroup with intelligence quotient lower than 90.
Conclusion: The conclusion is that the relationship between SD and
anxiety in epilepsy is close and may have a two-way phenomenon. Emo-
tions and its disturbances, which are very strong in the epilepsy group,
can be a reason or a consequence for the SD prevalence. The diagnosis
of it is important data for planning therapy for the patients with SD and
epilepsy as well.
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INFLUENCE OF ANALYSIS TOOL SETTINGS ON RESULTS OF
COMPUTERISED INVESTIGATION IN EPILEPSY
Z. Hrncı´r, K. Sterbova´, and V. Koma´rek (Department of Paediatric Neu-
rology, 2nd Medical School, Motol Hospital, Prague, Czech Republic)
Purpose: All analysis methods (AMs) developed for investigation of
brain dynamic have their intrinsic parameters. Evaluation features of the
AM’s are affected and preset by these parameters. Answers on given
investigation problems could also be influenced by (in-) appropriate se-
lection (setting) of time sections from analysed EEG recordings that are
usually associated with specific patient clinical statuses. Both settings
can have influence upon results from AMs. The aim of this presentation
is an indication of influences (effects) upon obtained results in our 2
studies when 1) different settings of AM-tools are applied and when 2)
various time sections of EEG recordings are chosen.
Method: Our 2 studies were: 1) sensitivity of AM-tools in seizure pre-
diction, 2) effect of therapy detected by AM-tools. Two basic intrinsic
parameters of AM’s are “window length” (WL) and “window overlap”
(WO). We used 4 combinations of WL/WO (chosen within mathemati-
cal and practical boundaries). Different wakeful states and sleep stages
were used as appropriate sections compared with inappropriate (random)
sections. All these pre-settings were applied with 31 available AM-tools
on groups of 16 and 12 patients for investigation of results consistency.
Results: In both studies we found similar effects: different WL/WO
settings influenced analysis results only in some types of AM’s, mostly
they had no effect. Selection of (in-) appropriate sections produced dis-
tinct results in all AM’s.
Conclusion: Different settings of AM-tools produced notable varia-
tions in comparable analysis results. Next studies should be based on
database of “AM’s-references.” Presentation of data on used settings is
a necessary rule in publications dealing with EEG analysis.
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COGNITIVE OUTCOME IN WEST SYNDROME
1Z. Rener Primec, 1V. G.Tretnjak, and 2J. Stare (Department of Child
Neurology, University Children’s Hospital, Slovenia, 2Institute of Bio-
statistics, Medical School, University of Ljubljana, Slovenia)
Purpose: To find out the spectrum of cognitive deficits in children
after West syndrome.
Method: A retrospective analysis of medical records provided data
about the age of IS onset, psychomotor development before IS, aetiology
and treatment schedules. The hypsarrhythmia duration in weeks was esti-
mated from data on age of onset of spasms, the first EEG pattern and from
consecutive EEGs. At follow up study children were psychologically ex-
amined according to the child’s age and mental level, by standardised
psychometric tests; the minimum follow-up time was 3 years after the
IS onset.
Results: Normal mental development was established in 14 children
(29%) out of 48, mild mental retardation was found in 6 children, moder-
ate in 10 and severe mental retardation in 14 children (29%); 4 children
died. The outcome was statistically significantly related to aetiology
(p = 0.001); only 6 out of 30 children with a symptomatic aetiology had
a favourable outcome in comparison with 13 out of 18 children from the
cryptogenic and idiopathic groups. Specific cognitive tests showed the
following deficits: in visual functions in 11 out of 42 children capable
of testing, language in 15/30, graphomotor field 25/30, autistic features
in 7/37 and behaviour disturbances in 8 out of 30 children.
Conclusion: The presence of hypsarrhythmia during the period of
rapid development of the brain may cause damage to cognitive abilities.
The duration of hypsarrhythmia is of major importance as short term
disturbances are believed to be not harmful to the brain cortex.
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UTILITY OF CONVENTIONAL ELECTROENCEPHALO-
GRAM IN THE MANAGEMENT OF NEONATAL SEIZURES
1M. Djuric, 1R. Kravljanac, 1B. Jankovic, 1L. Nikolic, 1B. Vucetic, and
2T. Pekmezovic (1Mother and Child Health Care Institute of Serbia “Dr
Vukan Cupic” Belgrade, Serbia and Montenegro, 2Institute of Epidemi-
ology, School of Medicine, Belgrade, Serbia and Montenegro)
Purpose: To evaluate the effectiveness of limited use of electroen-
cephalographic investigation for neonates with clinically registered
seizures
Method: Medical records and EEG files of all neonates treated in
Neonatal Unit and Intensive Care Unit with registered seizures (Volpe’s
classification) from January 2003 to December 2005 were surveyed for
aetiology of seizures, type of attack, need for mechanical ventilation and
type of EEG abnormalities. Severity of EEG changes was opposed to the
clinical presentation of 3 categories of patients: a) with 1 to 5 seizures,
b) with many seizures but no vital signs compromised, c) with seizures
and mechanical ventilation.
Results: There were 101 neonates with seizures who had 148 EEGs
done during hospital stay with only 6 ictal tracing. First EEG was normal
in 14 and abnormal in 87 neonates. Basic activity was abnormal (low
voltage, rhythmic or discontinuous) in 26 and Rolandic sharp waves
were detected in 12 records. In the group with seizures and mechanical
ventilation (32), 16 had significant EEG abnormalities (depressed basic
rhythm, inactive or discontinuous EEG). None had normal EEG. In the
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group with less than 5 seizures, 8 had depressed basic activity, discon-
tinuous EEG or rolandic sharp waves, but none inactive EEG. Seven had
normal EEG. The EEG abnormalities correlated significantly with the
gravity of the basic condition in the neonates with seizures.
Conclusion: Conventional EEG is a powerful tool of managing
neonates with seizures, which gives insight to the extent of brain com-
promise.
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EPILEPSY IN THE COURSE OF FAMILIAR LEUKOEN-
CEPHALOPATHY WITH D-BIFUNCTIONAL PROTEIN
DEFICIENCY
1E. Jamroz, 1J. Paprocka, 2T. Stradomska, 1E. Gluszkiewicz, 3A. Jezela-
Stanek, and 1E. Marszal (1Child Neurology Department, Silesian Medi-
cal University, Katowice, Poland, 2Department of Laboratory Diagnos-
tics, Children’s Memorial Health Institute, Warsaw, Poland, 3Department
of Clinical Genetics, Children’s Memorial Health Institute, Warsaw,
Poland)
Purpose: The authors present siblings (girl 11 months, boy 6 months)
with polymorphic seizures in the course of familiar leukoencephalopa-
thy. In a younger brother peroxisomal disorder, namely D-bifunctional
protein deficiency was confirmed. The sister died at the age of 14 months,
before a diagnosis was possible.
Method: The pregnancy period of the sibling was uneventful. At birth,
a profound hypotonia with a reflexia and a reactivity, myoclonic seizures
and breathing difficulties were noticed. Antiepileptic therapy with phe-
nobarbital, valproic acid, carbamazepine and benzodiazepines was in-
troduced. In physical examination craniofacial dysmorphia and failure
to thrive, large frontal fontanelle, severe axial hypotonia and hypertonia
of the limbs were found.
Results: MRI of the head showed demyelination in both patients and
ventricular enlargement in the girl. EEG disclosed paroxysmal changes
with right temporal lobe predominance. Neurophysiological study de-
tected peripheral neuropathy in a brother. In a boy increased level of very
long chain fatty acids (VLCL) serum and fibroblasts, decreased phytanic
acid oxidation, normal level of phytanic acid and a decreased number
of peroxisomes pointed to deficiency of a single enzyme, deficiency of
D-bifunctional protein.
Conclusion: 7-αbeta-hydroxysteroid dehydrogenase IV is involved
in the degradation of VLCL, as well as of the branched-chained fatty
acids, pirystanic acid, and the bile–acid intermediates: di-, trihydrox-
ycholestanoic acid. To data, D-bifunctional protein deficiency consti-
tutes one of the most frequently occurring single-peroxisomal-enzyme-
deficiency disorders. Among the inborn errors of metabolism epilepsy
is relatively frequent in peroxisomal disorders.
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ESTIMATION OF THE INFLUENCE OF VALPROATES ON
PSYCHOMOTOR DEVELOPMENT IN CHILDREN WITH IN-
FANTILE SPASMS BY USING COHERENCE ANALYSIS OF
ELECTROENCEPHALOGRAM
V. Zykov, S. Badalova, I. Stepanichshev, and O. Milovanova (Russian
Medical Academy of Postgraduate Education, Moscow, Russia)
Purpose: To study the influence of valproates on psychomotor devel-
opment in children with infantile spasms and alterations of the exponents
by using coherence analysis of electroencephalogram (EEG).
Method: Twenty-four children with infantile spasms (23-
symptomatic and 1-cryptogenic) aged from 3 months to 3 years
were examined. The estimation of psychomotor development was
conducted using the L.T. Jurba, E.M. Mastyukova scale, the G.V.
Pantyukhina, K.L. Pechora, E.L. Frukht scale. All children were studied
and clinically assessed including CT, MRI and EEG with its coherence
analysis.
Results: The estimation of coherence analysis of EEG, when patients
entered hospital, revealed that in all the children the coherence was re-
duced in intra- and between-pairs (p < .001; p < .05) to compare to
norm. With valproate treatment in average dose of 59 ± 5,6 mg/kg/day
and synacten-depo in average dose 0.04 mg/kg/day convulsions ceased
in 12 cases; the frequency of seizures was reduced in 8 and there was
no effect in 4 cases. After treatment the coherence analysis of EEG re-
vealed an increase in exponents of intracerebral coherence (p < .001;
p < .01). The improvement of coherence combined with improvement
of psychomotor development (p < .05). In catamnesis over 2 years the
stable anticonvulsant effect was reached in 7 cases (29%), revival of
seizures occurred in 5 cases (40%). Transformation in partial epilepsy
was in 16 (66.6%) cases; in Lennox-Gastaut syndrome in 1 case (4.2%).
In patients with stable anticonvulsant effect the coherence was stable
or had a tendency to increase. But in the children with revival seizures
the intracerebral coherence (in frontal and temporal parts) decreased be-
low norm side by side with worsening of the exponents of psychomotor
development.
Conclusion: Valproates don’t negatively influence psychomotor de-
velopment and vice versa by suppression of epileptic activity, standardise
functional activity of the brain, which can be seen by using coherence
analysis of EEG and improved psychomotor development.
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NEW-ONSET NARCOLEPSY IN A PATIENT SURGICALLY
TREATED FOR RASMUSSEN’S ENCEPHALITIS
E. Freri, F. Villani, C. Antozzi, F. Ragona, A. Pincherle, A. Dominese,
and T. Granata (National Neurological Institute C. Besta, Milan, Italy)
Purpose: To describe the onset of narcolepsy in a patient with Ras-
mussen encephalitis (RE), four years after left hemispherotomy.
Method: Case report
Results: A 23-year-old female patient, affected from the age of 11
by left sided RE, underwent hemispherotomy at the age of 19. Surgery
stopped seizures and progressions of right hemiparesis and aphasia. At
the age of 23 the patient began to experience fatigue, excessive day-
time sleepiness, and the need for daytime naps. The symptoms progres-
sively worsened in a few months. At clinical examination the patient
was drowsy, frequently yawning, postural control was impaired. Neither
spontaneous nor provoked cataplectic phenomena were observed. The
excessive daytime sleepiness was assessed by polysomnography (PSG)
and multiple sleep latency test (MSLT). PSG showed a normal sleep or-
ganisation with the exception of a REM sleep onset period (SOREMP)
with a latency of 2′, and excluded other sleep related disturbances. MSLT
showed a mean sleep latency of 4′05” with 1 SOREMP. The search for
HLA DQB1∗ 0602 was negative. The MRI showed the expected discon-
nection of the left hemisphere; but also signal abnormality and stretching
of the left postero-lateral aspect of the hypothalamus. The endocrinologic
assessment was normal.
Conclusion: The clinical, PSG and MSLT picture is consistent with
the diagnosis of probable narcolepsy. This is the second reported case
of the association between RE and narcolepsy. Our findings lend sup-
port to the hypothesis that these two conditions may share common
immunologic pathogenetic mechanisms. Alternatively, postsurgical hy-
pothalamic dysfunction cannot be excluded.
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MENKES DISEASE: A RARE DIFFERENTIAL DIAGNOSIS OF
EARLY-ONSET PROGRESSIVE ENCEPHALOPATHY
1R. Trollmann, 2I. Kra¨geloh-Mann, 1M. Kuhlen, 3L. Birk Moller, 1W.
Rascher, and 1D. Wenzel (1Department of Pediadrics, University of Er-
langen, Germany, 2Department of Pediatrics, University of Tu¨bingen,
Germany, 3The John F. Kennedy Institute, Glostrup, Denmark)
Case Report: Menkes disease (MD) is a rare X-linked multisystemic
lethal disorder of copper transport metabolism due to a defect of a trans-
membrane P-type ATPase. We report a case of MD with proven ATP7A
gene mutation and rapidly progressive phenotype. The boy was born
as the first child of healthy nonconsanguineous parents. After an un-
eventful delivery a cephalic haematoma was present. At age of 11 wks
the child was presented for treatment of pharmaco-refractory seizures.
Clinical examination showed severe generalised muscular hypotonia and
nystagmus. No dysmorphic features or hair abnormalities were noted.
Intractable multifocal seizures and progressive loss of sensor-motor func-
tions complicated the clinical course. EEG showed severe abnormalities
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with multifocal irregular slow-wave activity. Repeated CSF analysis
revealed elevated lactate (3.1–4.9 mmol/l) and alanine concentrations
(79 μmol/l). Mitochondrial encephalopathy was excluded by analysis of
respiratory chain enzymes in muscle tissue. Initially, brain MRIs showed
no abnormalities except mild bifrontal atrophy. At the age of 16 wks,
neuroimaging revealed diffuse demyelination, severe brain atrophy, and
subdural effusions/haematomas. By MR-angiography tortuosity of in-
tracranial vessels was demonstrated representing a typical radiological
sign of MD. Diagnosis was confirmed by low serum ceruloplasmin level
(0.06 g/l) and detection of a deletion in the ATP7A gene (exons 18/19).
Conclusion: Characteristic MRI changes together with clinical fea-
tures of a rapidly progressive neurodegenerative disorder led to the
diagnosis of MD. MD should be included in the differential diagno-
sis of early-onset progressive encephalopathy and unexplained subdural
haematomas in infants.
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EPILEPSY IN IFAP SYNDROME (ICHTHYOSIS FOLLICU-
LARIS, CONGENITAL ALOPECIA, PHOTOPHOBIA)
1N. Zupancic, 2M. Groselj Grenc, 3N. Meglic Pecaric, 1N. Krajnc, and 4I.
Ravnik (1University Children’s Hospital, Department of Child Neurol-
ogy, Ljubljana, Slovenija, 2University Medical Center, Pediatric Inten-
sive Care Unit, Ljubljana, Slovenia, 3University Medical Center, Insti-
tute for Radiology, Ljubljana, Slovenia, 4University Children’s Hospital,
Center for Epilepsy, Ljubljana, Slovenia)
Purpose: Better information on seizure (sz) types in a rare syndrome.
Method: Heteroanamnestic description of seizures in a 6 year old boy.
Results: Developmental delay, skin abnormalities, inguinal hernia,
urinary tract stenosis, hypoplasia of corpus callosum and localised
left temporoparietooccipital hemimegalencephaly in favour of sporadic
IFAP syndrome. Epilepsy onset 1.3 yr: tonic–clonic generalised (G)
febrile. Age 3–4.6 yr: G to-clo, head to left/unstable gait, G limb jerks,
2 hrs postictal rigidity right/G to-clo 10 minutes, followed by increased
muscle tone 30 minutes, whole-day persisting jerking. Sz change at 4.5
yr: G less, focal (F) more articulated: as if fighting against it (aura?).
Stares, drops down slowly, floppy, or falls suddenly. Stiffens as if pulled
down, cries, vomits, bothered by light. Vomits 10 min, sleeps whole day.
Age 5 yr: long stare, lacrimation, head pulled backwards, eyes right,
eyebrows upward, floppy body, falls backwards. Postictal stiffness of
the right side of the body described twice: valproate: partial mprove-
ment (sz shorter).
Conclusion: The syndrome includes a variety of epileptic F and G
seizures: initial G, then F with or without secondary generalisation be-
come more prominent. Unusual features: photophobia as a part of ictal
episode, but no photosensitivity. Ictal and postictal increase of muscle
tone. More detailed electroclinical analysis to follow.
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ASPECTS OF EPILEPTIC SEIZURES IN CHILDREN WITH
PRETERM BIRTH
C. Burloiu, M. Budisteanu, C. Iliescu, and S. Magureanu (Clinical Hos-
pital of Psychiatry “Prof. Dr. Al. Obregia,” Bucharest, Romania)
Purpose: The aim of this paper is to present the results of a retro-
spective study regarding particular aspects of epilepsy in children born
preterm.
Method: The study included all children with epilepsy admitted in
our hospital from 1 January 2000 to 30 December 2005. From these
patients we selected the cases with a personal history of preterm birth.
The children were evaluated in the clinic and paraclinically. We noted
the age of seizure onset, seizure type, epileptic syndrome, neurologic
and neuroimagistic features, outcome, antiepileptic treatment.
Results: of the 1255 children with epilepsy admitted in our hospi-
tal over this period, 80 children had a preterm birth: 49 boys, 31 girls.
In 50 children, seizure onset was in the first 3 years of life. The most
frequent type of seizure was focal (41 cases), and the most frequent
type of epileptic syndrome was focal symptomatic epilepsy with partial
secondary generalised seizures (27 children). Forty-three children pre-
sented a neurologic syndrome. The most frequent neuroimagistic feature
was leukomalacia, which was present in 23 cases. In all symptomatic
epilepsy more than one antiepileptic drug was necessary, with poor
outcome.
Conclusion: In our study, preterm birth was associated with epilepsy
in a small number of cases. In children with abnormal neurologic and
neuroimagistic features, the seizure onset was early, with focal seizures
and poor outcome, with more than one antiepileptic drug being necessary
for seizure control. The relationship between preterm birth and seizures
with late onset or occasional/rare seizures in normal children will be
discussed.
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EEG-VIDEOTELEMETRY OF PAEDIATRIC ONSET EPILEPSY
PATIENTS IN SLOVENIA IN 2004 AND 2005
M. Krzˇan, N. Krajnc, and I. Ravnik (Department of Child Neurology,
Children’s Hospital, Ljubljana, Slovenia
Purpose: EEG-videotelemetry (VTM) was used in differential diag-
nosis of paroxysmal disorders, classification of seizures and localisation
of the epileptic focus. In Slovenia VTM was inaugurated in paediatrics
in 1996, but has been in continuous use just the last 1.5 years.
Method: Retrospective analysis of recordings performed in 47 pa-
tients in 2004 and 2005 using the Grass-Telefactor Millennium system.
Results: VTM was used 127 recording days (from 2 to 166 h; mean
48 h/patient; 82 full 24 h cycles). Seizures were recorded in 30 patients
(64%). In 8 patients therapy was changed during VTM. Three peaks of
maximum seizure frequency were identified: 5 a.m., 1 to 3 p.m. and 8
to 11 p.m. In 35 (74%) patients VTM showed relevant new information
regarding diagnosis and treatment. Paroxysmal disorder differentiation
was done in 12 patients (epilepsy confirmed in 3), seizure type evaluation
in 21 (seizures recorded in 15) and in 15 possible surgery candidates
(seizures recorded in 12). We identified 12 surgery candidates for further
evaluation. In 11 patients neuropsychological evaluation was done in
parallel with VTM recordings.
Conclusion: Only one-third of recorded seizures occurred during reg-
ular office hours (8 a.m. to 4 p.m.) allotted for intensive monitoring. The
rest (2/3) were recorded with the help of accompanying parents or rel-
atives, since the continuous presence of dedicated personnel is not cov-
ered by health insurance. Professional monitoring during nonoffice hours
and weekends would significantly increase diagnostic yield. Equipment
proved to be stable, needing only modest maintenance: 1× camera fail-
ure, 2× DVD-writer problems not compromising the recording goals.
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CLINICAL AND NEUROINSTRUMENTAL CORRELATION OF
SYMPTOMATIC EPILEPTIC SEIZURES IN CHILDREN
1L. Kirillova, 2V. Rogozhyn, 1A. Perphilov, 2Z. Rozhkova, 2L. Miro-
niak, 1M. Vasilenko, 1L. Silaeva, 1L. Tkachuk, and 1N. Shiyanenko
(1Institute of Paediatrics, Obstetrics and Gynaecology AMS of Ukraine,
Kiev, Ukraine, 2Radiology Centre AMS of Ukraine, Kiev, Ukraine)
Purpose: The work is aimed at a rectification of the role of impair-
ments of main cerebral metabolites in a locally selected region of the
brain in children with symptomatic epileptic seizures.
Method: Ninety-eight children from 2 months to 9 years of age with
different forms of epilepsy underwent the following investigations: clin-
ical monitoring, neurosonography, EEG, MRI and MRS of the brain.
Neurochemical processes of the main metabolites in the brain were
studied by using a noninvasive method of magnetic resonance spec-
troscopy (H1MRS).
Results: A comparative analysis of the clinical picture, EEG and MRI
and MRS of the brain made it possible to diagnose symptomatic epilepsy
in 83.7% of children involved in the study (in 57.1% of such children,
structural changes in the brain were detected by MRI). Epileptic foci
were detected by EEG and in such locally selected regions, impairments
of neurochemical processes involving main cerebral metabolites were
found in 72.4% of the studied children by using MRS. An increase in Cho
concentration (p < 0.01) and in Cho/Cr ratio (p < 0.01) and reduction of
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NAA in the studied regions of the brain suggested metabolic impairments
in such regions showing no structural changes.
Conclusion: Monitoring study of the concentration of main cerebral
metabolites in the brain of children with symptomatic epilepsy has been
employed by us for the purposes of an objective evaluation of the efficacy
of different anticonvulsant therapies.
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OUTCOME OF VAGUS NERVE STIMULATION (VNS) FOR DIF-
FICULT TO TREAT EPILEPSY IN CHILDHOOD 5–10 YEARS
AFTER IMPLANTATION
1,2K. Lascelles, 2R. Selway, and 1,2E. Hughes (1Evelina Children’s Hos-
pital, St Thomas’ Hospital, London UK, 2Kings College Hospital, Den-
mark Hill, London UK)
Purpose: To determine the long-term outcome for seizure frequency
and patient/parent satisfaction following implantation of a vagus nerve
stimulator.
Method: Twenty-three children were identified from theatre records,
implanted between 1995 and 2000. A retrospective case-note review was
carried out followed by a parent/patient telephone interview in November
2005, using a structured proforma. Average number of seizures per month
for the year prior to VNS implantation was calculated and compared with
current seizure records.
Results: Mean age at implantation was 11.9 years. Information was
available for 21/23 patients, with mean duration of follow-up of 8.4
years. All children had refractory epilepsy. 10 had a symptomatic or
probably symptomatic epilepsy. Six patients were considered to have
Lennox-Gastaut syndrome, 2 Dravet’s syndrome and 3, a symptomatic
partial epilepsy. The majority (18/21), had moderate to severe learning
difficulties and 8 reported significant problems with behaviour preim-
plantation. Nine patients (43%) reported a greater than 50% reduction
in seizures. Syndrome classification did not predict response. Seven pa-
tients reported significant benefit for behaviour. In no child did behaviour
worsen following implantation. Sustained benefit is supported by the re-
tention rates with 9/21 having their battery replaced and a further 3/21
awaiting replacement. Nine have had the device switched off because of
inefficacy. There were no significant side effects.
Conclusion: This is the first paediatric VNS study demonstrating
long term and sustained benefit for over 40% of children with medically
refractory epilepsy. The response is highly favourable when compared
to medical treatments in this group of patients.
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FEBRILE CONVULSIONS: PARENTS ATTITUDE AND
BEHAVIOUR
Mucic–B. Pucic, N. Barisic, M. Jurin, and A. Basnec (Universitiy Hos-
pital Rebro, Pediatrics, Neuropediatrics Ward, Croatia)
Purpose: Febrile convulsions (FK) are a clinical entity known for over
2000 years, but parents still panic and think that their child is dying.
Method: There were 200 patients over a period of 12 months. We col-
lected data by means of a questionnaire, filled in by parents. The sample
was divided into two groups: 1) children with first febrile convulsions
(FK I), and 2) children with recurrent convulsions (FK II).
Results: First FK the age 1–2 yrs. (41.67%), recurrent FK at the age
of 3–4 yrs (40.91%). Most often occur in male children in 1) and 2) FK
(54.55%). Occur most frequently in winter and autumn. One parent was
present for 37.5% episodes, both parents for 50%, some other member
of the family for 12.5%, or in 2) FK 18.19%.
50% of the parents reacted with panic, 13.04% gave the antipyretic
or diazepam microclysm. 18.19% of the parents gave antipyretic and
microclysm. 52.17% of the parents thought that the child was dying and
there was a small difference between the two groups.
Conclusion: Mothers are the most frightened. More than half of the
parents panic, thinking that the child is dying. Parents are not sufficiently
prepared and are insecure about the procedure when the next episode of
FK occurs. Actions should be taken to educate parents; composure and
knowledge should take place of fear and shock.
This work was not sponsored by anybody; it was done solely by the
doctors, themselves, working at the ward.
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SYNDROMIC CLASSIFICATION IN CHILDHOOD-ONSET
EPILEPSY
E. Szczepanik (Clinic of Neurology, Epileptology and Sleep Disorders
in Children and Adolescents, Institute of Mother and Child, Warsaw,
Poland)
Purpose: The response of seizure types to antiepileptic treatment and
prognosis for remission differs among epileptic syndromes. Their precise
classification is essential to both patient care and the scientific studies.
Most of the known epileptic syndromes occur in children and adoles-
cents. The purpose of our study was to estimate: 1) the possibilities of
syndromic classification of epilepsy by means of mostly conventional
methods of diagnosis, 2) the distribution of epileptic syndrome types in
a group of patients with childhood-onset epilepsy.
Method: Data from 600 (318 male, 282 female) patients with epilepsy
onset at age 2 months to 15 years (mean 3.3 years) were analysed ret-
rospectively. They were examined at the in- and outclinic between 1987
and 2000, and were followed-up for mean 4.5 years (range 1–14). The
schemes of diagnostic criteria (inclusion to an epileptic syndrome and
criteria of exclusion from one) were worked up according to ILAE (1989)
and Proposed Diagnostic Scheme for People with Epileptic Seizures and
with Epilepsy (2001), and other published data.
Results: Thirty-four epileptic syndromes were recognised. Syndromic
classification was possible in 476 (79%) patients. Among them classifi-
cation according to ILAE (1989) was made in 451 (74%) children, and
in 25 (4%) according to the new diagnostic proposal of ILAE (2001).
Generalised epilepsies were recognised in 234 (39%), partial ones in 346
(57.7%) patients, and underdetermined epilepsies in 20 (3.3%) children.
According to aetiologic classification idiopathic epilepsies were recog-
nised in 225 (37.5%), cryptogenic in 189 (31.5%), and symptomatic in
186 (31%).
Conclusion: 1) Most childhood epilepsies could be classify by means
of conventional methods of diagnosis; 2) long follow-up period is often
useful for syndromic recognition; 3) in some cases accurate syndrome
classification is not possible due to lack of universally accepted diagnos-
tic criteria.
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REFERRALS ABROAD FOR EPILEPSY SURGERY: EXPERI-
ENCE IN NEUROPSYCHOLOGICAL ASSESSMENT GATH-
ERED BY THE CENTER FOR CHILD & ADOLESCENT
EPILEPSY AT THE CHILDREN’S UNIVERSITY HOSPITAL IN
LJUBLJANA
V. Tretnjak, I. Ravnik, N. Krajnc, and D. Gosar (Children’s University
Hospital In Ljubljana, Ljubljana, Slovenia)
Purpose: When considering paediatric patients with intractable
epilepsy for epilepsy surgery, neuropsychological assessment con-
tributes vital information on the developmental level of a child pre-and
postsurgery. Data collected for these purposes was examined in the cur-
rent retrospective study to examine the neuropsychological outcome of
patients with intractable epilepsy who underwent surgery at epilepsy
centres abroad.
Method: The children, adolescents and young adults included in the
study had frontal lobe (n = 7), as well as left (n = 5) and right temporal
lobe epilepsy (n = 5). Their median age at the time of surgery was 14
(range 6–25), with a median confirmed age at epilepsy onset of 3.8 years.
Presurgical neuropsychological assessment was conducted six months
prior to surgery. In investigating the neuropsychological outcome we
included data gathered at the last completed neuropsychological assess-
ment, which was on average 24 months after surgery (range 12–128
months).
Results: At the last neuropsychological follow-up patients who un-
derwent surgery showed no significant reduction in neuropsychological
scores, even showing a trend towards improvement in performance IQ
as measured by the Wechsler intelligence scales (p = 0.051). The effect
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was of medium size (Cohen d = 0.61). Of possible factors influencing
neuropsychological outcome only preoperative global (r = 0.40) and
performance IQ (r = 0.42) approached significance, higher presurgical
scores being associated with better neuropsychological outcome.
Conclusion: Although the neuropsychological data presented show
no signs of a cognitive decline, neuropsychological assessment at various
points after surgery proved to be of great value for patients in their
postsurgical adjustment to the school and work environment.
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PREVALENCE OF ANTIPHOSPHOLIPID AND ANTINUCLEAR
ANTIBODIES IN CHILDREN WITH EPILEPSY
1T. Constantin, 1T. Ka´lovics, 1L. Szabo´, 2G. Pe´ter, 2K. Sallai, 1I.
Moldova´nyi, 1B. Ba´nsa´gi, 3K. Danko´, 1A. Ponyi, 1T. Bense, 1G. Fekete,
and 1R. Ka´lma´nchey (12nd Department of Pediatrics, Semmelweis Uni-
versity, Budapest, Hungary, 2Central Laboratory of Immunology, Sem-
melweis University, Budapest, Hungary, 3Division of Clinical Immunol-
ogy, 3rd Department of Internal Medicine, Medical and Health Science
Center, University of Debrecen, Debrecen, Hungary)
Purpose: An increased prevalence of antiphospholipid autoantibodies
(aPL) has been described in clinical studies among patients with epilepsy.
On the other hand seizures are also reported causing immunological
alterations, even drug induced lupus.
Method: The presence of antinuclear, antiphospholipid antibodies,
serum levels of immunoglobulins and complement factors were also
investigated in 65 randomly selected children with epilepsy. We anal-
ysed the following clinical data: time of follow-up; type and duration of
epilepsy; frequency of seizures; time from last seizure; results of neu-
roimaging and EEG data; antiepileptic medication.
Results: The mean duration of disease was 4.8 years. The mean
time between the last convulsion and the laboratory analysis was 1.9
years. Most patients achieved good disease control and have 1–2 con-
vulsion(s)/year. Partial immunoglobulin deficiency was detected in 14/65
patients. Hypocomplementaemia was detected in 4 children. One of them
showed concurrent ANA and lupus anticoagulant (LA) positivity. Al-
though the diagnostic criteria for SLE are not fulfilled, the patient is
being regularly followed up. Twenty-eight of our patients were ANA
positive. Anti-C1q antibody was positive in 2 cases; none of them have
renal manifestation of lupus. Only 1 child had anticardiolipin (aCL)
antibody, while 6/39 patients were LA positive. Anti-β2-glycoprotein-
I-antibody positivity was not observed. None of the patients have aDNA
antibodies.
Conclusion: In our study lower total prevalence of aPLs was observed
in children with epilepsy than in previous reports (20–30%). The cause
of it can be a higher percentage of well controlled epilepsy patients in
our cohort.
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NEUROCOGNITIVE FUNCTIONING IN CHILDREN WITH
COMPLICATIONS, NEUROINFECTIONS AND CONVULSIVE
SYNDROME
G. Rakhimbaeva, and G. Ishankhojaeva (Tashkent Medical Academy,
Tashkent , Uzbekistan)
Purpose: Hard neuroinfections in children may lead to a convulsive
syndrome that increases a level of invalidisation of them. The aim of
the research was to study cognitive functions in children with sequelae
following meningoencephalitis and convulsive syndrome.
Method: Thirty children, after an acute neuroinfection with convul-
sive syndrome, have been examined. All the patients underwent EEG and
dopplerography. We set out to determine a level of indices of cognitive
disorders in children with sequelae of neuroinfection with convulsive
syndrome. The test of Wexler for children was used to diagnose the in-
tellectual development of patients and test Simernitskaya 
Luria-90
was used to evaluate attention, memory and thinking functions.
Results: Before treatment, EEG revealed diffuse changes in bioelec-
tric activity of the cerebral cortex with a presence of nidal or paroxysmal
convulsive activity in all patients. Transcranial dopplerography of the
cerebral blood stream in the examined children found a hyperconstric-
tory reaction of cerebral vessels: mean linear velocity (MLV) in the mean
cerebral artery (MCA) was reducing to 30% from an initial one. Results
of Wexler and Simernitskaya tests 
Luria-90 exhibited a decrease
of the aural-verbal and visual memory, reduction of operative thinking
activity and intellectual activity in children.
Conclusion: Thus, results confirmed that children with sequelae of
neuroinfection and convulsive syndrome have expressed cognitive dis-
orders, demanding necessary treatment.
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PROGNOSTIC VALUE OF CRANIAL ULTRASOUND AND EEG
IN NEWBORNS WITH PERINATAL ASPHYXIA
N. Cerovac (Department for Neurology and Psychiatry for Children and
Youth, Medical School, Belgrade, Sebia and Montenegro)
Purpose: Improvements in perinatal and neonatal care over the last
decades have resulted in increased survival of newborn infants with peri-
natal asphyxia. Neurological disabilities are among the most severe con-
sequences occurring in these infants.
Method: The group of 115 high-risk newborns was examined neu-
rologically, by ultrasound scanning of the brain and EEG during the
neonatal period. They were followed up with detailed neurological ex-
aminations at three month intervals until one year of age, and thereafter
at 18 months and two, three, four and five years of age. According to their
neurological outcome, infants were classified into two groups: normal
and abnormal.
Results: Normal neurological outcome was found in 44 (100%) of
44 infants with normal neonatal neurological status, in 45 (97.8%) of
46 with normal neonatal ultrasound findings and in 102 (100%) of 102
with normal neonatal EEG findings. Abnormal neurological outcome
was found in 9 (12.7%) of 71 infants with abnormal neonatal neurologi-
cal status, in 8 (11.6%) of 69 infants with abnormal neonatal ultrasound
findings and in 9 (69.3%) of 13 infants with abnormal neonatal EEG find-
ings. Specificity and sensitivity of EEG was higher (100% and 69.2%)
than of ultrasound imaging of the infant’s brain (97.8% and 11.6%) and
neurological assessment (100% and 12.6%).
Conclusion: Neonatal neurological assessment, ultrasound and EEG
have some prognostic value in newborns with perinatal asphyxia. An
integrative approach with the combined use of clinical evaluation and
additional diagnostic methods is needed.
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CORTICOSTEROIDS FOR THE TREATMENT OF LANDAU-
KLEFFNER
C. Triki, F. Kammoun, A. Chaabene, I. Hsairi, and C. Mhiri (Department
of neurology, CHU HBourguiba 3029 SFxa Tunisia)
Purpose: The Landau-Kleffner syndrome (LKS) is defined as an
acquired disorder of language comprehension arising in a child with
centrotemporal epilepsy with either clinical seizures or subclinical
epilepsy particularly enhanced by slow-wave sleep. Our aim is to present
the clinical, electroencephalographic characteristic of 4 patients with
LKS and the language and epilepsy outcome with corticosteroid treat-
ment.
Method: Four children (2 boys and 2 girls) were admitted for LKS.
These patients have benefited from complete clinical investigation,
awake end sleep EEG and cerebral MRI. All of them had valproic acid
as initial therapy and corticosteroids in second intention in 2 patients.
Results: Age of onset ranged from 2 to 6 years (mean 4 years) and
epilepsy was the first symptom for all patients. Language regression
occurred progressively with an inability to understand spoken words.
Awake EEG showed spikes in the temporal cortex and 2 patients had
patterns of continuous spike and wave discharges during sleep. MRI
was normal in all patients. Valproic acid was used as initial treatment
in all patients with seizure control but not language regression. Two
patients were treated with hydrocortisone with improvement in language
and behaviour. One patient was treated only by VPA with favourable
evolution, epilepsy disappeared and he recovered language 10 years after.
Conclusion: Corticosteroids are a safe and effective treatment for
patients with Landau-Kleffner syndrome and should be considered as a
treatment option for children with Landau-Kleffner syndrome.
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ICTAL AND INTERICTAL EEG ABNORMALITIES IN
ADHD CHILDREN RECORDED OVERNIGHT BY VIDEO-
POLYSOMNOGRAPHY
1R. Silvestri, 2A. Gagliano, 2T. Calarese, 1I. Arico`, 1R. Condurso, and
2E. Germano` (1Sleep Medicine Center, Messina Medical School, Italy,
2Pediatric Neurology and Psychiatry, Messina Medical School, Italy)
Purpose: To look at the prevalence of IEDs in ADHD children during
all night video-PSG (vPSG), exploring the possibility of cotreating sleep
disorders (SD) and IEDs to improve behaviour and cognition.
Method: Thirty-two children, diagnosed according to DSMIV IC
were administered standardised questionnaires and scales: Wechsler In-
telligence Scale; attention and short-term memory tests; ADHD-RS,
Conners’ Teachers (CTRS), Parents (CPRS), SNAP IV RS, and pae-
diatric sleep questionnaire. Standard vPSG also included 18 leads EEG.
Sleep and EEG variables were held against cognitive/behavioural scores
with Pearson coefficient test.
Results: Most children/parents reported SD confirmed by vPSG (72%
SRMD, 37% DOA, 19% SRBD). None of the children showed an in-
tellectual deficit, 6% had a tic disorder, 12% language disorders and
44% learning disorders. No seizure history was reported, but 19%
had an abnormal EEG and 53% IEDs on vPSG. Nocturnal seizures
were recorded in 2. There was a significant presence of high lev-
els of impulsivity/hyperactivity scoring with RLS. Language disorder
was positively related to the presence of rolandic or frontal foci, tic
with a temporal occipital focus and RLS, seizures with short-term vi-
sual spatial memory deficit. LEV (500–1000 mg) was offered to chil-
dren with seizures and/or IEDs and with RLS. Seven patients agreed
to this regimen. After 6 months, they improved behaviour and social
adaptation and nocturnal sleep with cessation of RLS and DOA. No
seizures and reduction of IEDs were recorded. A nonparametric anal-
ysis between independent variables run by Wilcoxon Test showed sta-
tistical significance for improved scoring at CTRS, CPRS, ADHDRS,
SNAP IV.
Conclusion: Our study supports data reporting a high prevalence of
IEDs in ADHD children and the role of sleep recordings to improve diag-
nosis of EEG abnormalities and SD in such children, both contributing
to the detected cognitive and behavioural abnormalities. LEV holds a
promising role as a safe therapeutic tool for EEG and SD in ADHD
children.
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OUTCOME AND PRESURGICAL RESOURCES IN EPILEPSY
SURGERY ON CHILDREN WITH IQ/DQ ABOVE AND BELOW
70
1H. Nielsen and 2P. Uldall (1Danish Pilepsy Center, Copenhagen, Den-
mark, 2Rigshospitalet, Copenhagen, Denmark)
Purpose: Operations on mentally retarded children are expected to
have a poor outcome. We studied whether outcome and resources used
for evaluation differed between children with IQ/DQ > 70 (group A)
and < 70 IQ/DQ (group B).
Method: Results from a retrospective study of Danish children (n =
38) operated between 1996 and 2004 were evaluated. The mean age at
operation in group A (n = 15) was 13 years 1 month and for group
B (n = 23) 8 years and 1 month. Nine of group A and 5 of group B
were operated in Denmark, the remaining abroad, mainly at Cleveland
Clinic. Multiple resection or hemispherectomies were performed in 3
from group A (21%) and 14 (61%) from group B.
Results: Seizure free outcome was found in 66% (group A) and 65%
(group B) at one year follow-up. In group A 25% had a decrease and
17% an increase of > 10 IQ/DQ compared to 28% and 14% in group
B. Presurgical admittance in Denmark for ictal video EEG and neu-
ropsychological evaluation required 19.9 days (group A) and 15.4 days
(group B). 20% had an ictal SPECT (group A) and 39% group B. PET
was performed on 46% of group A and 30% of group B.
Conclusion: Seizure and development outcome after epilepsy surgery
were the same in children with IQ/DQ above and below 70. Resources
in the two groups were comparable.
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PREVALENCE OF SLEEP DISORDERS IN CHILDREN AND
ADOLESCENTS WITH EPILEPSY: A PILOT STUDY
M. Zarowski, J. Mlodzikowska-Albrecht, and B. Steinborn (Chair and
Department of Developmental Neurology, Poznan University of Medical
Sciences, Poznan, Poland.)
Purpose: The pilot study was conducted to examine the sleep habits
and the prevalence of sleep disorders in children and adolescents with
epilepsy.
Method: From May to September 2005, 65 children and adolescents
with epilepsy were investigated via our own questionnaires in the De-
partment of Developmental Neurology, Poznan University of Medical
Sciences. The children were admitted to the department to diagnose or
treat epilepsy. We created 4 categories dependent on age: preschool (2–6
years old) – 8, grammar school (7–12) – 20, middle school (13–15) –
19, and secondary school (15–18) – 19.
Results: The average of total sleep duration was 9.7 h (ranged from
11.1 h in preschool group to 8.8 h in secondary school group). The mean
time of falling asleep in the whole group was 27.0 minutes (ranged from
1 min. to 180 min.). In the investigation, 18 (27.7%) children slept with
somebody in the bed, and 48 (73.8%) slept in a common room with
family. Awakening during the night sleep were observed in 47.7% and it
was more frequent in the preschooler group, 87.5%, than in the middle
school group, 31.6%. The presence of different symptoms connected
with sleeping disorders were noticed by 87.7% parents. The frequency
of sleep disorders reported as parasomnia symptoms like sleep talking
41.6%, bruxism 27.7%, enuresis 26.2%, leg movement 24.6%, night-
mares 20.0%, sleep terror 16.9% and sleep breathing disorder symptoms
like snoring 47.7% and breathing pauses 13.8%.
Conclusion: Childhood sleep disorders are very common in groups
of children with epilepsy. Additional research with a control group is
needed to find a correlation between epilepsy and sleep disorders.
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A POPULATION-BASED STUDY OF EPILEPSY IN CHILDREN
K. Larsson and O. Eeg-Olofsson (Department of Women’s and Chil-
dren’s Health, Uppsala University, Uppsala, Sweden)
Purpose: To establish the rate of incidence and prevalence, age dis-
tribution, inheritance, seizure types, epilepsy syndromes and treatment
strategies in the county of Uppsala, Sweden.
Method: A population-based study was performed to select children
aged from 1 month to 16 years with the diagnoses ‘convulsions’ or
‘epilepsy.’ The children were recognised between 1 January 1996 and
31 December 2000, and only those with active epilepsy were included.
Results: 205 children met the study criteria on the prevalence day
31 December 2000. The total prevalence rate was 3.4/1000 with a peak
prevalence in the age group 8–11 years. The incidence year 2000 was
40/100000. A majority of patients, 54.0%, had focal or focal plus sec-
ondarily generalised seizures. A real syndrome could be diagnosed in
90.7%. The most common syndrome was rolandic epilepsy pure, found
in 17%. Different diseases associated with epilepsy were found in 31.7%.
Conclusion: The prevalence and incidence rate in this strictly delin-
eated study are lower than those found in other epidemiological studies in
the Western population. The ILAE classification of epileptic syndromes
has been used, and the majority of the patients could be classified ac-
cordingly. In spite of this well adjusted classification, there are many di-
vergences between reported studies concerning frequencies of different
items. This apparently is partly dependent on design, e.g. difference in
age groups included, inclusion criteria used, and methodology.
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EFFECTS OF LEVETIRACETAM ON EPILEPTIFORM DIS-
CHARGES IN SYMPTOMATIC EPILEPSY IN CHILDREN
A. Trabacca, M. Massimo, M. Costanza, and M. De Rinaldis (Depart-
ment of Neurorehabilitation I – Developmental Neurology and Func-
tional Rehabilitation, Scientific Institute I.R.C.C.S. “Eugenio Medea”–
Association “La Nostra Famiglia” Ostuni, Brindisi, Italy)
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Purpose: To determine the effect of levetiracetam (LEV) as add-on
therapy on epileptiform discharges in children with refractory symp-
tomatic epilepsy.
Method: Patients aged 4–15 years suffering from refractory symp-
tomatic epilepsy with partial and generalised partial seizures, and already
treated with at least one antiepileptic drug (AED) were included in this
retrospective study. LEV was commenced (starting dose 10 mg/kg/day)
and up-titrated every 2 days to a maximum dose of 50 mg/kg/day. Con-
comitant AED doses were not modified. Patients were evaluated by
EEG (sleeping and awake) before commencing LEV treatment, and after
3 months.
Results: Thirteen children aged 4–15 (mean 7.6 ± 3.3) years were
enrolled. All children completed the titration phase. LEV signifi-
cantly decreased seizure frequency by ≥50% in 9/13 (69%) patients
(p = 0.0003). LEV was significantly effective in improving EEG ac-
tivity, with reduction in frequency of epileptiform discharges in 10/13
(77%) children (p = 0.0014). LEV was well tolerated without AEs re-
ported.
Conclusion: LEV is effective in consistently reducing frequency of
interictal epileptic activity. Reduction of epileptiform discharges addi-
tionally supports a clinically relevant antiepileptic effect. Randomised
clinical studies on a larger population are needed to confirm these pre-
liminary results.
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PRENATAL CHEMICAL INSULTS INDUCE BRAIN EDEMA
AND CHANGES IN EXPRESSION OF AQUAPORINS
1K. Hallene, 4N. Marchi, 1S. Santaguida, 1,2S. Bassanini, 3M. Cipolla,
2G. Battaglia, and 1D. Janigro (1Cleveland Clinic Foundation, Cleve-
land, USA, 2Istituto Carlo Besta, Milano, Italy, 3University of Ver-
mont, Burlington, USA, 4Cleveland Clinic Department of Neurological
Surgery, USA
Purpose: Chemical ablation of precursor cells appears to be involved
in the genesis of cortical dysplasia (CD) in human brain and animal mod-
els. Prenatal exposure to the toxin methylazoxymethanol acetate (MAM)
causes cortical dysplasia in rats that partially overlaps with the effects of
the angiogenesis inhibitor thalidomide; both vascular and parenchymal
factors are thus involved. We wished to investigate the effects of MAM
on vascular permeability and cortical development at short intervals after
exposure.
Method: MAM (15 mg/kg) was given at E15 and sections processed
at E16. Standard immunocytochemical and histological techniques were
used.
Results: MAM-treated foetuses exhibited widespread neuronal cell
death paradoxically accompanied by increased cortical thickness (308.2
micron ±5.5 vs 181.9 micron ±4.6; p < 0.05, n = 3 animals). Brain
edema was indirectly quantified by measuring tissue optical density (ex-
pressed in arbitrary units). MAM treated cortices had a cortical tissue
density of 40 ± 0.8 compared to 43 ± 1.1 in control animals. Water
channels AQP1 and AQP4 were respectively increased and decreased
suggesting a rearrangement of water transport. AQP1 expression was
greatly increased in parenchymal cells, while the opposite was observed
for AQP4. Both transporters were strongly expressed in association to
the cerebral vasculature regardless of treatment.
Conclusion: Brain edema was presumably due to altered water per-
meability in the glia and blood–brain barrier. Endothelium is an early
consequence of chemical induction of cortical dysplasia. Our results
suggest that an increase in AQP1 causes cellular edema while A AQP4
decreases may promote greater extracellular or vasogenic edema.
This work was supported by NIH HL51614, NS43284, NS38195, and
NS149514 to DJ.
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NEUROCOGNITIVE DIFFERENCES BETWEEN FRONTAL
AND TEMPORAL SEIZURES IN PAEDIATRIC EPILEPSY
E. Escobar, E. Barraga´n, J. Hernandez, M. Hernandez, and S. Garza
(Hospital Infantil De Me´xico Federico Go´mez, Mexico)
Purpose: The purpose of this clinical trial was to differentiate the
neurocognitive performance between frontal and temporal seizures in
paediatric epilepsy. This is an important issue related to measuring the
impact of different types of seizure in the neurodevelopment of infants
with epilepsy.
Method: We analysed patients with partial epilepsy between 6 and 12
years old, both genders, in the neurology department of the Hospital In-
fantil de Me´xico. After dividing into frontal and temporal epilepsies, we
applied a neurocognitive test, evaluating IQ, attention, working memory,
executive functions and visuospatial performance. Besides, these infants
had an EEG, neuroimaging, social evaluation and physical examination.
Results: Thirty-seven patients, both genders (22 males, 15 females)
with partial frontal epilepsy (17) and temporal epilepsy (20) were evalu-
ated. The principal neurocognitive differences between these two types
of epilepsy were the IQ (mean 82 in frontal epilepsy and 97 in temporal
epilepsy), with more impact in the working memory and visuospatial
performance in infants with frontal epilepsy. The patients with temporal
epilepsy had more problems in executing attention and long memory
tests.
Conclusion: The patients with frontal epilepsy, which started as paedi-
atric epilepsy, had more impact in developmental neurocognitive skills,
and we think this is a very important issue to start early support with
therapeutic approaches in this group of epilepsy, trying to reverse the
impact of seizures over academic and social capacities. Further studies
are needed to find whether this impact over neurocognitive skills can be
reverted with early therapeutic support.
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FOLLOW-UP AFTER SINGLE UNPROVOKED SEIZURE
G. Dizdarer, A. Kanik, E. Toprak, and N. Aksu (SB Tepecik Teaching
Hospital -Izmir- Turkey)
Purpose: Most studies have shown that approximately one third of
the patients with a single seizure will experience a second one; but there
is not any information for the recurrence risk. Therefore, we aimed to
evaluate the risk factors for the recurrence of seizures following a single
unprovoked idiopathic seizure.
Method: The study comprised 88 patients (mean age 7.9 ± 3.7 years,
range 5 months to 13 years, 46 M, 42 F), who were admitted to our
paediatric neurology unit with a history of a single episode seizure;
and followed for at least 3 years. Patients were divided into 2 groups
according to the recurrence of the seizure during the 3 year period;
and risk factors such as age, gender, type of seizure, EEG findings,
neuroimaging, family history of seizures in first degree relatives and
consanguinity were evaluated.
Results: of the 88 patients, 26 (29.5%) had a recurrence within the
5.3 ± 7.3 months (range 4 days to 36 months) after the first seizure. No
significant difference was found in terms of age (7.6 ± 3.6 vs 7.1 ± 3.4
years), gender (46.7% vs 50%), seizure type, EEG abnormality (37% vs
34%), neuroimaging abnormalities (3% vs 11.5%), family history (8%
vs 23%) and consanguinity (8% vs 15.3%) between the groups (p > 0.05
for all parameters).
Conclusion: There is still a dilemma whether a single unprovoked
seizure should be treated or not. We tried to find out risk factors for
seizure recurrence but we couldn’t establish a statistically significant
one.
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STARTLE DISEASE, AN UNCOMMON NONEPILEPTIC DIS-
ORDER: CASE REPORT
1O. Bag, 2G. Dizdarer, 1T. Tuncel, 1N. Harputluoglu, and 1H. Aydin-
lioglu (1Tepecik Teaching Hospital, Department of Pediatrics, Turkey,
2Tepecik Teaching Hospital, Pediatric Neurology Section, Department
of Pediatrics, Turkey)
Startle disease is an uncommon and relatively benign nonepileptic
neurological entity often confused with epilepsy. Early diagnosis and
prompt treatment is important to avoid clinical complications leading to
death. We report two cases presenting with hypertonia and exaggerated
startle response in neonatal period, diagnosed as startle disease.
Epilepsia, Vol. 47, S3, 2006
204 7TH EUROPEAN CONGRESS ON EPILEPTOLOGY
p797
RETROSPECTIVE STUDY OF EFFICACY AND TOLERABIL-
ITY OF LEVETIRACETAM IN CHILDREN WITH REFRAC-
TORY EPILEPSY
P. Rasmini and D. Besana (Child Neuropsychiatric Unit–Child Epilepsy
Centre, Italy)
Purpose: The aim of this retrospective open label add-on study is to
assess the efficacy and safety of levetiracetam in refractory partial or
generalised epilepsy in children and young adults.
Method: We have retrospectively evaluated 24 patients, 14 males
and 10 females, aged between 4 and 18 years, selected from our data
base concerning epilepsy patients, according to the following criteria:
subjects affected by refractory focal or generalised epilepsy with no
more than two baseline AEDs at the moment of LEV add-on and at least
six months of follow up. Data included neurological status, cognitive
function and neuroimaging; epilepsy type and seizure frequency, and
concomitant AEDs treatment. Efficacy was evaluated as seizure freedom,
reduction >50% (responders), reduction <50%, unchanged or worsened
(non responders). Absent or transient side effects were considered a
favourable index of good tolerability.
Results: 24 children or young adults aged between 4 and 19 years
were exposed to LEV as add on therapy at doses ranging from 20 to
60 mg/kg/die. 2 patients discontinued treatment before reaching a dose
considered effective owing to side effects. Follow up is extended over 3
years in some cases and always longer than 6 months. 4 patients reached
complete seizures control, 9 had a >50% seizure reduction, 11 obtained a
mild seizure reduction or were unchanged. None deteriorated. Tiredness
and somnolence were the most common side effects and in 2 patients
lead to drug discontinuation.
Conclusion: Confirming literature data, our study indicates that LEV
is quite effective in childhood refractory epilepsies and effectiveness
on different types of seizures suggests a broad therapeutic spectrum.
Tolerability is also favourable in most cases.
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SEIZURE REDUCTION AND QUALITY OF LIFE IN COGNI-
TIVELY CHALLENGED PATIENTS TREATED WITH VAGUS
NERVE STIMULATION (VNS) THERAPY
M. Trimble (Institute of Neurology, London, UK)
Purpose: Intractable seizures are common in patients with learning
disability (LD), and the seizures may contribute to the LD. Control of
seizures in LD represents a clinical challenge, but vagus nerve stimula-
tion (VNS) is one option.
Method: Data from 396 cognitively challenged patients i.e., institu-
tionalised, with LD or developmental delay treated with (VNS) therapy
in addition to their regular medication were analysed from the VNS Ther-
apy Patient Outcome Registry at 3, 12, and 24 months. Data on seizure
reduction and quality of life (QoL) were analysed at 3, 12 and 24 months
after implant.
Results: of 396 patients, 153 (38.6%) were < 18 years, with 80 pa-
tients (20.2%) < 12 years of age. Mean age was 24.5 years (range, 2–63).
There was a median seizure reduction of 41% after 3 months, 54% at
12 months and 54% at 24 months. Seizure reduction ≥ 50% was re-
ported in 47%, 55% and 55% of the patients after 3, 12 and 24 months,
respectively. Seizure reduction ≥ 75% occurred in 26%, 33% and 37%
of patients after 3, 12 and 24 months, respectively. Seizure reduction ≥
90% was observed in 13%, 17% and 23% of patients after 3, 12 and 24
months, respectively. Regarding QoL, the percentage classified as “bet-
ter” or “much better” were: alertness, 62%, 68% and 66%; mood, 41%,
48% and 45%; and achievements, 24%, 34% and 29%.
Conclusion: VNS Therapy is associated with seizure and QoL im-
provements in this population of cognitively challenged patients.
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AUTISTIC SPECTRUM DISORDER (ASD), ATTENTION
DEFICIT AND/OR HYPERACTIVITY DISORDER (AD/HD)
AND LEARNING DISABILITY IN CHILDHOOD EPILEPSY
SURGERY CANDIDATES AND CANDIDATES FOR VAGUS
NERVE STIMULATION (VNS)
1S. Danielsson, 2T. Ahlse´n, 2C. Gillberg, 1I. Hagberg, 2U. Johansson,
3B. Rydenhag, 1P. Uvebrant, 1G. Viggedal, and 1I. Olsson (1Sahlgrenska
University Hospital, Department of Pediatrics, Go¨teborg, Sweden,
2Sahlgrenska University Hospital, Department of Child and Adolescent
Psychiatry, Go¨teborg, Sweden, 3Sahlgrenska University Hospital, De-
partment of Neurosurgery, Go¨teborg, Sweden)
Purpose: Children with medically intractable epilepsy are at an in-
creased risk of neuropsychiatric disorders. Since 2002 all children in
the Epilepsy Surgery Programme at Sahlgrenska University Hospital in
Go¨teborg, Sweden are referred for neuropsychiatric assessment before
and two years after surgery. We present the results from neuropsychi-
atric preoperative assessment in candidates for resective surgery and in
candidates for VNS.
Method: Children (n = 41) consecutively referred for evaluation be-
fore resective surgery or VNS were studied 2002–2005. All children
had a clinical neuropsychiatric assessment, including parental question-
naires, and a neuropsychological evaluation. Cases with symptoms and
signs on the autistic spectrum were assessed with The Diagnostic Inter-
view for Social and Communication Disorders (DISCO) and the Autism
Diagnostic Observation Schedule (ADOS).
Results: In 21 who had resective surgery 24% had ASD, 29% AD/HD
and 33% had an IQ level ≤ 70. In 20 who were candidates for VNS
treatment 65% had ASD, 50% AD/HD and 90% had an IQ level ≤ 70.
The median age of epilepsy onset in the two groups was 4 years and 2.2
years, respectively.
Conclusion: ASD and/or AD/HD are common in children with medi-
cally intractable epilepsy being referred for presurgical evaluation. These
children are severely impaired with special needs both at home and at
school. Behavioural problems and cognitive impairment were more com-
mon in the VNS group than in children accepted for resective surgery.
Neuropsychiatric assessment is an important part of the epilepsy surgery
programme in children, and makes it possible to determine outcome in
more aspects than seizure control.
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VAGAL NERVE STIMULATION IN DRUG RESISTANT
EPILEPSY: EXPERIENCE WITH 7 CASES
1Z. Gokcil, 2R. Akin, 3N. Bulakbasi, 4F. Acar, and 4E. Erdogan
(1Department of Neurology, Gulhane Military Medical School, Turkey,
2Department of Pediatric Neurology, Gulhane Military Medical School,
Turkey, 3Department of Radiology, Gulhane Military Medical School,
Turkey, 4Department of Neurosurgery, Gulhane Military Medical
School, Turkey)
Purpose: In cases of drug resistant epilepsy with no diagnosed fo-
cus in clinical evaluation, vagal nerve stimulation (VNS) is a choice of
treatment to decrease the seizure frequency or seizure control in 1–2%
of cases. This treatment choice was introduced to clinical application in
1998.
Method: VNS was administered to 7 cases of drug resistant therapy
by the epilepsy surgery group between 2001 and 2004 at Gulhane Mili-
tary Medical Academy. Under the authorisation of the epilepsy council,
electrodes were placed surgically to the left vagus nerve in the carotid
sheath. Electrode cables were directed to the left pectoral region sub-
cutaneously and connected to the pulse generator. Mean surgery time
varied between 30 and 60 minutes.
Results: Complications such as infection, vagal nerve injury and vas-
cular injury were not exposed in any of the cases. There was a 27.8%
(10–50%) decrease in seizure frequency. There were no cases with total
seizure control. VNS application is not intended for total seizure control.
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Conclusion: This application can be expected as an adjuvant ther-
apy. In cases with aura, self induction of a pulse generator effectively
decreases seizure frequency.
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VAGAL NERVE STIMULATION IN CATASTROPHIC
EPILEPSY OF INFANCY: EFFECTS ON SEIZURES AND
QUALITY OF LIFE
L. Corpaci, N. Zamponi, E. Cesaroni, T. Capriotti, and C. Cardinali
(Pediatric Neuropsychiatric Department-Ospedali Riuniti Presidio Os-
pedaliero Di Alta Specializzazione G. Salesi-Ancona, Italy)
Purpose: To assess the efficacy of treating catastrophic epilepsy of
infancy with vagal nerve stimulation (VNS) and its effects on quality of
life (QOL) and behavioural adjustment.
Method: Sixteen patients with Lennox-Gastaut and severe partial
epilepsy (pseudo-Lennox-Gastaut) between the ages of 4 and 17 years
(mean age: 9 years and 3 months) were implanted and followed-up after
18 months of treatment. Medication and VNS parameters were adjusted
for optimal seizure control. Vineland Adaptive Behaviour Scales (VABS)
and analogical scale were used to assess postimplantation QOL and be-
havioural adjustment.
Results: Five out of 16 patients had >90% reduction in seizures,
4 had between 80% and 50%, 4 had <50% and 3 had no change.
Pseudo-Lennox-Gastaut (PLG) patients had higher seizure reduction
(mean seizure reduction 71%) than Lennox-Gastaut (LG) patients (mean
seizure reduction 43%). VABS scores showed no statistical significant
improvement. Socialisation subscale showed a trend of decrease in 50%
of children, while 50% stayed permanent or slightly improved. Daily liv-
ing skills and communication subscales showed more permanent and im-
proved scores (respectively 59% and 52%) than decreased scores. No rel-
evant differences were observed between LG and PLG patients. Analog-
ical scale showed significant decrease (p < 0.05) in anxiety (especially in
PLG) and significant improvement (p < 0.01) in attention/concentration
skills in both groups.
Conclusion: VNS appear to be an emerging option for treatment of
medically intractable catastrophic epilepsy. Its effects appear not to be
only restricted to seizure control but also to behavioural skills and to
mood and attention/concentration disorders related to epilepsy.
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VAGUS NERVE STIMULATION (VNS) THERAPY FOR PA-
TIENTS WITH REFRACTORY SEIZURES ASSOCIATED WITH
TUBEROUS SCLEROSIS COMPLEX
D. Parain (Service Neurophysiologie, Rouen, France)
Purpose: Data from pts with tuberous sclerosis complex (TSC) treated
with adjunctive VNS for refractory epilepsy was analysed from the VNS
Therapy Patient Outcome Registry, including data on seizure reduction
and quality of life (QoL) at 3 and 12 months after implant.
Method: 38 pts (19 M, 19 F) were evaluated. Mean age: 21.58 y
(±12.26), mean age at onset: 2.39 y (±4.16); mean duration of epilepsy:
18.99 y (±11.97); 18 pts (47.4%) were < 18 y. Localisation-related
epilepsy: 23 pts (60.5%); Lennox-Gastaut syndrome: 7 (18.4%); gener-
alised epilepsy: 5 (13.2%); other: 3 (7.4%).
Results: Median seizure reduction: 52% after 3 months and 46% after
12 months. Seizure reduction ≥50% occurred in 50% and 47% of pts
after 3 and 12 months, respectively. The percentage of pts classified as
“better” or “much better” was: alertness, 50% and 58%; post-ictal, 61%
and 47%; clusters, 55% and 50%; verbal skills, 34% and 32%; mood,
34% and 37%; achievements, 21% and 26%; and memory, 26% and 29%
at 3 and 12 months, respectively.
Conclusion: VNS Therapy was associated with seizure reduction
(52% and 46% at 3 and 12 months, respectively) and QoL improve-
ments (≥ 50% for alertness and clusters at 3 and 12 months, and
for post-ictal period at 3 months) in pts with TSC and refractory
epilepsy.
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A REVIEW OF OUTCOMES FOLLOWING FIRST 25 VA-
GAL NERVE STIMULATOR (VNS) IMPLANTATIONS FOR
EPILEPSY
P. Tidswell and L. North (Lancashire Teaching Hospitals Trust, Preston,
England, U.K.)
Purpose: We undertook this review to assess the outcomes of patients
in our Neurosciences Unit who underwent VNS for the management of
intractable epilepsy.
Method: Case notes were reviewed for the 25 patients who had vagal
nerve stimulators inserted between 1998 and November 2005. VNS was
chosen when reasonable drug options were exhausted and resective brain
surgery was not appropriate or declined (2 patients).
Results: of 15 male and 10 female patients, 4 had learning disabilities.
Ages ranged from 14y to 58y at implantation. The duration of epilepsy
ranged from 11–38y (mean 23y). 19 patients had focal epilepsies, 4
primary generalised and 2 Lennox-Gastaut syndrome. 3 patients had un-
dergone previous surgery: 1 callosotomy, 2 hemispherectomy. Patients
were taking a mean of 3 antiepilepsy drugs (range 1–5). 20 patients im-
proved post VNS, including all 4 with primary generalised epilepsy; 5
were unchanged and none worsened. Improvements recorded included
reduced seizure frequency (up to 50–75%), more seizure free days, re-
duced seizure severity (including cessation of tonic–clonic seizures) and
improved alertness. No patient became seizure free. Medication was
reduced in 1 patient. Many patients experienced side effects with the
original VNS settings, but these were easily managed by altering the
stimulus parameters.
Conclusion: VNS offers worthwhile palliative benefits to patients
with intractable epilepsy, and is well tolerated. Our results are consis-
tent with the published literature, and suggest that VNS can usefully be
offered in epilepsy clinics which do not support a full epilepsy surgery
programme. .
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VAGUS NERVE STIMULATION FOR REFRACTORY
EPILEPSY: POOLED RESULTS FROM EPILEPSY CENTRES
IN BELGIUM
1V. De Herdt, 1K. Vonck, 1H. Verschelde, 2B. Legros, 3H. Hauman,
4K. Van Rijckevorsel, 5B. Ceulemans, 6L. Lagae, 6W. Van Paesschen,
7B. Sadzot, and 1P. Boon (1Reference Centre for Refractory Epilepsy,
Ghent University Hospital, 2Hoˆpital Universitaire Erasme, Brussels,
Belgium, 3CEPOS, Duffel, Belgium, 4Universite´ Catholique Louvain,
Hoˆpital Saint-Luc, Brussels, Belgium, 5Centre for Revalidation, Pul-
derbos, Belgium, 6University Hospital Gasthuisberg, Leuven, Belgium,
7Centre Hoˆpital Universitaire Lie`ge, Belgium)
Purpose: This study evaluates the long-term outcome for patients
treated with vagus nerve stimulation (VNS) for refractory epilepsy in
seven different epilepsy centres in Belgium.
Method: Since 1995, 223 patients were treated with VNS in Belgium.
We retrospectively assessed seizure frequency reduction, antiepileptic
drug (AED) treatment and stimulation parameters in patients with a
follow-up of at least one year.
Results: 168 patients (82M/86F) had a mean age of 30 years at time
of implantation and a mean postimplantation follow-up of 37 months
(range: 12–119). Mean number of AEDs before implantation was 3
(range 1–5). 140/168 patients had complex partial epilepsy, 11 patients
had generalised epilepsy and 17 patients were diagnosed with an epilepsy
syndrome e.g. Lennox-Gastaut. At maximum follow-up, mean stimula-
tion output current was 1.75 mA (range 0–3.25). In 12 patients (7%),
output current was programmed 0 mA due to lack of efficacy. 15 pa-
tients were on rapid cycling stimulation. Mean number of AEDs at max-
imum follow-up remained unchanged. 63 patients (37.5%) were non-
responders with a reduction in seizure frequency of <30%. 87 patients
(52%) had a >50% reduction in seizure frequency. 13 patients have been
seizure-free for at least 12 months.
Conclusion: The long-term experience with VNS in Belgium con-
firms that VNS is an efficacious adjunctive antiepileptic treatment for
patients with refractory epilepsy.
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VISUAL FIELD DEFECT AFTER SELECTIVE AMYGDALO-
HIPPOCAMPECTOMY IN MESIAL TEMPORAL SCLEROSIS
1O. Uyanik, 1N. Yeni, 1C. Ozkara, 1N. Karaagac, 2M. Uzan, and 2E.
Ozyurt (1Istanbul University Cerrahpasa School of Medicine Depart-
ment of Neurology, 2 Isanbul University Cerrahpasa School of Medicine
Department of Neurosurgery, Turkey)
Purpose: Visual field defects (VFD) after temporal lobe resection in
temporal lobe epilepsy patients are reported to be frequent (50–52%).
The aim of this study was to detect the frequency of VFD after selec-
tive amygdalohippocampectomy in patients with medically refractory
complex partial seizures due to mesial temporal sclerosis.
Method: Twenty patients (13 men, 7 women; age range 12–57 years)
underwent selective amygdalohippocampectomy (14 right, 6 left) and
were analysed. Mean seizure onset age was 11.5 ± 6 (range 3–25 years).
VFD was examined preoperatively by a neurologist (n = 10) or by stan-
dard Goldmann perimetry (n = 10) and postoperatively by standard
Goldmann perimetry within 1 to 19 months.
Results: Visual field examination was normal in all patients preoper-
atively. Postoperative perimetry measurement revealed upper quadran-
tanopia in 7 patients (35%) although none of them were aware of it. In
one year follow-up 16 patients were in class I, 3 patients were in class II,
and 1 patient was in class IV according to Engel’s outcome classification.
Conclusion: To our knowledge VFD after selective amygdalohip-
pocampectomy has not been reported before. It has been suggested that
there is a relation between the extent of resection in the anterior part of
the superior temporal gyrus and VFD. A limited resection after selective
amygdalohippocampectomy may still cause VFD.
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ANTERIOR TEMPORAL LOBECTOMY/AMYGDALOHIPPO-
CAMPECTOMY FOR MEDICALLY INTRACTABLE COM-
PLEX PARTIAL SEIZURES
P. Sioutos, P. Panaretos, S. Giannakodimos, E. Antoniou, A. Mitropu-
los, M. Koutourousiou, S. Lafazanos, E. Kehagias, G. Orfanides, and A.
Seretis (Neurosurgery and Neurology Services, Athens General Hospi-
tal, Athens, Greece)
Purpose: The results and complications of anterior temporal lobec-
tomy/amygdalohippocampectomy (ATL/AH) in patients with medically
intractable mesial temporal lobe epilepsy are presented.
Method: Fifteen patients (8 males, 7 females) underwent noninvasive
preoperative evaluation (video/scalp EEG, brain MRI, neuropsychologi-
cal evaluation). Twelve patients were submitted to amytal testing as well.
Mesial temporal sclerosis was diagnosed in 12 patients. Two patients had
a hippocampal-amygdala tumour (oligodendroglioma: n = 1, astrocy-
toma grade II: n = 1) and 1 patient had a fusiform/parahippocampal
gyrus astrocytoma grade II. The seizure history ranged from 5 to 40
(mean: 21.3) years. The preoperative seizure frequency ranged from 1
to 100 (mean: 18.6) seizures per month. The patients’ ages at oper-
ation ranged from 20–58 (mean: 32.5) years. All patients underwent
an ATL/AH (right: n = 9, left: n = 6) and lesionectomy as indicated
(n = 3), with or without intraoperative electrocorticography. The hospi-
tal stay ranged from 4 to 21 (mean: 7) days. The follow-up ranged from
1 to 48 (mean: 23) months.
Results: At the latest follow-up visit 9 patients were seizure-free
(60%), 5 were significantly improved (33.3%), and 1 was unchanged
(6.6%). According to the ILAE criteria, 9 patients were Engel class I
(60%), 4 were Engel class II (26.6%), 1 was Engel class III (6.6.%), and
1 was Engel class IV (6.6%). Postoperatively one patient developed a
surgical wound infection (complication rate of 6.6%).
Conclusion: The beneficial ATL/AH outcome (seizure-free and sig-
nificant improvement) is highly dependent on the accuracy of methods
available for patient selection.
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HIGH FREQUENCY DEEP BRAIN STIMULATION OF THE
HIPPOCAMPUS IN A RAT MODEL FOR TEMPORAL LOBE
EPILEPSY
1T. Wyckhuys, 1P. Claeys, 1R. Raedt, 1T. De Smedt, 1L. Waterschoot,
1C. Van den Broecke, 1C. Mabilde, 1L. Leybaert, 2W. Wadman, and
1P. Boon (1Ghent University Hospital, Ghent, Belgium, 2 University of
Amsterdam, Amsterdam, The Netherlands)
Purpose: This experimental animal study evaluates the effect of high
frequency deep brain stimulation (HFS) on seizures in the Alternate Day
Rapid Kindling (ADRK) model, a model for temporal lobe epilepsy
(TLE). The target for HFS is the hippocampus, as it is often the seizure
focus in human TLE.
Method: Following implantation of recording and stimulation elec-
trodes, all rats (n = 12) were fully kindled in the hippocampus accord-
ing the ADRK-protocol (Lothman et al., Epilepsy Res 1993;14:209–20).
After this, all rats received 10 kindling stimuli every other day for 3
days. Then, the rats were divided into two groups: a treated group (n =
7) received 130 Hz-HFS for 1 week, while the control group (n = 5)
received no stimulation. After this week, HFS was stopped and both
groups were retested with 10 kindling stimuli every other day for 3 days.
One week of wash-out was allowed, before continuously stimulating the
HFS-group again for 1 week. During this week of HFS, 10 additional
kindling stimuli every alternate day for 3 days were given. The control
group only received the kindling stimuli. For each rat, the afterdischarge
duration (ADD), the afterdischarge threshold (ADT) and the afterdis-
charge latency (ADL) were compared before, during and after HFS.
Results: HFS significantly reduced the ADD when comparing before
HFS with during HFS (p < 0.001) and after HFS (p < 0.05). Also the
ADL was significantly increased in the HFS-treated group comparing
before HFS with during HFS (p < 0.001) and after HFS (p < 0.001). This
was also found for the ADT. The control groups showed no significant
difference in ADD, ADT and ADL.
Conclusion: Long-term high frequency stimulation of the hippocam-
pus in epileptic rats shortens the afterdischarge duration and increases
the afterdischarge threshold.
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NEURONAVIGATION ASSISTED SUBDURAL STRIP ELEC-
TRODE POSITIONING: A SIMPLE METHOD TO INCREASE
THE ACCURACY OF STRIP LOCALISATION IN EPILESY
SURGERY
1E. Lorand, 2B. Attila, 3P. Halasz, 2J. Vera, 1F. Imre, and 1B. At-
tila (1National Institute of Neurosurgery, Hungary, 2Szt.Istvan Hospital
Budapest, Hungary, 3 National Institute of Psychiatry and Neurology,
Hungary)
Purpose: When localising the epileptogenic zone in cases of clini-
cal focal epilepsies, imaging and different electrophysiological methods
are in use. In some cases intracranial electrodes are used. The proper
positioning of subdural electrodes is always challenging for the neu-
rosurgeon. CT and MR techniques are the gold standard by which to
localise the real postoperative position of the electrode contacts over the
gyri. However, the exact localisation of the electrodes on the patient’s
brain remains uncertain for the surgeon during insertion. Intraoperative
visualisation of the electrodes during positioning through a burr hole
with the combination of navigation systems and fluoroscopy was not
found in the literature.
We introduce the real time parallel use of intraoperative neuronav-
igation and x-ray for colocalising subdural strips and the cortical gyri
during an operation to increase the accuracy of subdural strip electrode
placement.
Method: For describing the proper electroclinical seizure pattern and
localising the epileptogenic zone of patients with drug resistant epilepsy,
subdural strip electrodes were implanted before long-term video EEG
monitoring. We demonstrate our method with 3 cases of focal drug re-
sistant epilepsies.
Brain Lab Vector Vision neuronavigation system was used in the oper-
ating room (OR) to select our entry point and visualise our region of in-
terest and target point on the cortical surface. The radiopaque navigation
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probe was placed on the skin, over the target point under the control of
C-arm (Siemens, Siremobil 2000). The stainless steel, radiopaque strips
(DIXI Medical) were introduced through the burr hole to the target point.
The intracranial target point was visualised on the skin surface by the
radiopaque navigation probe that was kept in place during strip insertion.
Results: We were able to visualise the target point, which was the
region of interest on the convolutions of the patient’s cortex with neu-
ronavigation and localise the strips during insertion with the C-arm. With
the help of the nonradiolucent neuronavigation probe the two modalities
could be fused during the procedure. We controlled our accuracy intra-
operatively with the navigation system and postoperative MR (1,5T GE)
and less then 1 mm registration error was found.
Conclusion: Combining neuronavigation and intraoperative X-ray is
a simple and feasible method to get precise intraoperative localisation
of subdural strips used for long term video EEG monitoring of patients
with drug resistant epilepsy.
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OUTCOMES OF SURGICAL TREATMENT OF SYMP-
TOMATIC EPILEPSY FOR CHILDREN WITH BRAIN
TUMOURS
L. Marushchenko, and Y. Orlov (Institute of Neurosurgery, Kiev,
Ukraine)
Purpose: To determine the factors influencing results of surgical treat-
ment of symptomatic epilepsy for children with brain tumours.
Method: The results of surgical treatment of 58 children with symp-
tomatic epilepsy caused by intracerebral tumours were analysed. The age
of children was from 3–16 years. Duration of a symptomatic epilepsy
before operation was from 1–14 years. A postoperative catamnesis was
from 1–5 years.
Results: 43 (74.1%) patients became seizure free after operation
(Engel I), 6 (10.3%) patients had no more than two seizures per year
(Engel II), and for 9 (15.5%) patients the frequency of seizures decreased
(Engel III).
Conclusion: The best results of surgical treatment were for patients
with a smaller interval from the beginning of seizures to operations. The
best results were for patients with tumours of medial parts of a temporal
area when in volume of a resection the amygdalohippocampal complex
was included. The treatment of symptomatic epilepsy was more effective
in patients with tumours in a temporal area when focal epileptic activity
was recorded in ipsilateral frontal and parietal areas. Conservation of
a zone of epilepsy activity after the resection of tumours is a principal
cause of decrease of efficiency of treatment of seizures. Use in such
cases of corticography can specify the centre of irritation and raise the
efficiency of surgical treatment of symptomatic epilepsy.
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ANTIEPILEPTIC DRUG TREATMENT IN LONG-TERM
FOLLOW-UP AFTER EPILEPSY SURGERY IN PATIENTS
WITH OCCIPITAL LOBE EPILEPSY
1A. Poepel, 1C. Hoppe, 2H. Clusmann, and 1C. Elger (1Department of
Epileptology, University of Bonn, Germany, 2 Department of Neuro-
surgery, University of Bonn, Germany)
Purpose: To evaluate the long-term antiepileptic drug (AED) regime
with regard to medication reduction/discontinuation trials after epilepsy
surgery in patients with occipital lobe epilepsy (OLE).
Method: Out of the total Bonn surgical sample (1988–2002), we were
able to identify 37 patients with surgery for therapy refractory OLE and
obtained postsurgical follow-up data for 36 patients (18 women). Addi-
tionally, patients were surveyed via a standardised telephone interview
which addressed medication reduction/discontinuation trials.
Results: Overall postoperative outcome according to Engel classifi-
cation I A and B is 58%. The average number of AED in postoperative
treatment was reduced for all patients. Two initially seizure-free patients
lost seizure freedom in the first two postoperative years following mod-
erate dosage reduction. One of these patients could be reevaluated and
reoperated. One patient had one isolated generalised tonic–clonic seizure
four years after operation due to alcohol, sleep deprivation and noncom-
pliance. After reestablishing continuous medication he was seizure-free
for another 5 years. All 8 patients who reduced medication stayed com-
pletely seizure free for an average follow-up duration of 8.5 years. Two
initially nonseizure-free patients became seizure-free in the first two
postoperative years (five/eight years follow up) after changing medica-
tion.
Conclusion: If medication could be partially withdrawn without
seizure recurrence complete withdrawal of AED did not change long-
term surgical outcome. In postoperative non seizure-free patients, chang-
ing AED treatment can ultimately lead to long-term seizure freedom.
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INTRACRANIAL VIDEO-EEG MONITORING AT GHENT UNI-
VERSITY HOSPITAL
I. Dewaele, A. Van Dycke, V. De Herdt, K. Vonck, L. Goossens, E.
Achten, E. Thiery, G. Vingerhoets, D. Van Roost, and P. Boon (Reference
Centre for Refractory Epilepsy, Ghent University Hospital, Belgium)
Purpose: To evaluate the outcome of patients with refractory epilepsy
who underwent invasive video-EEG monitoring at Ghent University
Hospital.
Method: We retrospectively analysed seizure frequency, treatment
with antiepileptic drug (AED) treatment and other types of subsequent
intervention in patients who underwent invasive video-EEG monitoring
with subdural grids and strips and/or depth electrodes.
Results: Between October 1990 and January 2006, 800 patients were
admitted at the video-EEG monitoring unit for presurgical evaluation.
From January 1992 until January 2006, 66 of these patients were se-
lected for invasive recording due to incongruent findings during non-
invasive presurgical evaluation. 12/66 patients were lost in follow-up.
Mean follow-up of 54/66 patients was 51 months (range 3–141). 26/54
patients underwent resective surgery (RS) of whom 21 (81%) became
seizure-free; in 3/26 patients AEDs were completely stopped. 12/54 pa-
tients underwent deep brain stimulation of whom 1 became seizure-free
and in 6/12 AEDs could be tapered, but not stopped. The remaining
16/54 patients received ongoing AED treatment (6/16), multiple subpial
transections (MST) (2/16), combination of MST and RS (1/16) or vagus
nerve stimulation (VNS) (7/16, of which 2 are being scheduled). In those
16 patients, seizure-freedom was obtained in 1 patient with AEDs, in 1
patient with MST and in 1 patient with VNS. Tapering of the AEDs in
those patients was not possible.
Conclusion: In the group of 66 patients who underwent invasive
video-EEG monitoring, different treatment options were possible de-
pending on the results of the monitoring. Seizure-freedom and the taper-
ing of AEDs were most likely in patients who underwent RS.
p812
VALUE OF FDG-PET IN SCREENING FOR TEMPORAL LOBE
EPILEPSY SURGERY
1S. Uijl, 1F. Leijten, 2J. Arends, 3J. Parra, 1A. van Huffelen, and 4K.
Moons 1Department Clinical Neurophysiology, University Medical Cen-
ter Utrecht, The Netherlands, 2Epilepsy Center Kempenhaeghe, Heeze,
The Netherlands, 3Department Clinical Neurophysiology, SEIN, Heem-
stede, The Netherlands, 4Julius Center for Health Sciences And Primary
Care, University Medical Center Utrecht, The Netherlands)
Purpose: The decision-making process for temporal lobe epilepsy
(TLE) surgery includes a number of diagnostic tests, starting with patient
history, MRI, and video-EEG monitoring. When the decision for TLE
surgery cannot be reached with these tests, ancillary tests are performed,
usually PET and intracranial EEG monitoring. We studied the value of
FDG-PET and the implications on intracranial EEG monitoring.
Method: This nationwide, retrospective diagnostic study included all
consecutive patients referred for screening for TLE surgery. The impact
of FDG-PET results on the decision-making process for TLE surgery
was assessed. Furthermore, we assessed the influence of the FDG-PET
on the need to perform intracranial EEG monitoring.
Results: of 803 included patients, 186 (23%) had indecisive results
after MRI and video-EEG monitoring and underwent a FDG-PET. In
111 patients (60%), a decision could be reached after the FDG-PET:
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68% were eligible and 32% ineligible for TLE surgery. The 75 patients
for whom FDG-PET also showed indecisive results consecutively under-
went intracranial EEG monitoring. After intracranial monitoring, 71%
were considered eligible and 29% ineligible for TLE surgery. The out-
come after surgery of our study population was comparable to that re-
ported in the literature: 58% Engel Score 1A one year after surgery.
Conclusion: FDG-PET can set the decision for TLE surgery in the
majority of patients with indecisive results after MRI and video-EEG
monitoring. Performing a FDG-PET in these patients can avoid intracra-
nial EEG monitoring, which is an invasive and burdening test.
p813
ELECTROCORTICOGRAPHIC-HISTOPATHOLOGIC COR-
RELATIONS IN TEMPORAL LOBE EPILEPSY DUE TO
CORTICAL MALFORMATIONS, HIPPOCAMPAL SCLEROSIS
AND DUAL PATHOLOGY
A. Rysz, B. Majkowska-Zwolin˜ska, A. Marchel, and E. Matyja (Depart-
ment of Neurosurgery, Medical University of Warsaw, Poland)
Purpose: To correlate intraoperative electrocorticographic (ECoG)
recordings with histopathologic findings in patients with temporal focal
cortical dysplasia (CD), hippocampal sclerosis (HS) and dual pathology
(DP).
Method: Twenty-nine (16 F, 13 M) patients with drug-resistant tem-
poral lobe epilepsy due to pathologically confirmed CD (5), HS (13) and
DP (11) who underwent intraoperative ECoG recordings with electrodes
placed over the anterolateral surface of the temporal lobe, were included.
The analysis of spike activity of the most active fragments ECoG 10 to
15 minutes recording was performed and compared in three histopatho-
logically different groups. In all patients a tailored anterior temporal lobe
resection was performed.
Results: All 13 patients with SH, had ECoG recordings with frequent
burst of spikes with periods of voltage depression. In all patients spikes
and polyspikes were generalised over almost all temporal electrodes.
Most patients with DP (7 of 11) showed ECoG recordings with gener-
alised bursts of spikes with periods of depression. On the other hand 4 of
11 patients had focal rhythmic discharges of spikes and sharp waves. In
5 patients with pure focal cortical dysplasia, 3 recordings showed bursts
of generalised spikes or polyspikes with periods of depression. Only 2
had focal temporal rhythmic or semirhytmic discharges of spikes and
sharp waves.
Conclusion: Hippocampal sclerosis correlated with ECoG gener-
alised bursts of spikes with periods of voltage depression. Dual pathology
and focal cortical dysplasia also correlated with similar activity; how-
ever, a small group of cases with the focal rhythmic discharges without
generalisation was disclosed.
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EARLY LESIONECTOMY IN A CASE OF OHTAHARA SYN-
DROME WITH A LEFT TEMPOROPARIETAL CORTICAL
DYSPLASIA (POLYMICROGYRIA)
1S. Voutoufianakis, 1V. Amanatidou, 2P. Vorgia, 1T. Tsekoura, and
1A. Tsilimigaki (1Pediatric Department, Venizelio General Hospital,
Heraklion, Crete, Greece, 2 Consultant, Paediatric Department, Uni-
versity Hospital, Heraklion, Crete, Greece)
Purpose: Epileptic seizures are rare in the neonatal and early infan-
tile period. Two epileptic encephalopathies characterised by frequent
seizures have been described in this period of life: early myoclonic en-
cephalopathy (EME) and early infantile epileptic encephalopathy with
suppression-bursts (EIEE), or Ohtahara syndrome (OS). There is no ef-
fective pharmaceutical treatment for either of them.
Method: We report a surgically treated case of Ohtahara syndrome
associated with polymicrogyria.
Results: Clusters of brief, repetitive tonic spasms of the upper limbs,
with clonic jerks of the eyelids, head-eye deviation to the left and munch-
ing movements, first occurred at the age of 40 days. Interictal elec-
troencephalogram repeatedly demonstrated a suppression-burst pattern
throughout awake and sleep states. Magnetic Resonance Imaging re-
vealed focal cortical dysplasia (polymicrogyria) in the left temporopari-
etal lobe. Medical treatment with combinations of anticonvulsive drugs
and steroid therapy was only mildly effective. The patient underwent le-
sionectomy at the age of 5 months. Five months postoperatively, during
follow up, the infant showed a decrease of seizures to only one brief
cluster of eyelid jerks every 8–9 days, mild hypertonia of the right upper
limb and a graduate psychomotor development.
Conclusion: This report provides further evidence that early surgical
intervention can be safe and promising in selected cases of Ohtahara syn-
drome with focal cortical dysplasia. We present our acknowledgements
to Dr Alexis Arzimanoglou (Robert-Debre Hospital-Paris) for presenting
this case to the French paediatric epilepsy surgery multidisciplinary net-
work and the surgeon Pr Christian Sainte-Rose (Necker Hospital Enfants
Malades-Paris) for realising the surgical treatment.
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“EPILEPSY SURGERY CENTRE” OF ATHENS UNIVERSITY:
RESULTS OF SURGICAL MANAGEMENT
1S. Gatzonis, 2N. Georgaculias, 1A. Siatouni, 1S. Koskinas, 1S. Kor-
fias, 1T. Mpouras, 1M. Stefanatou, 1A. Kougialis, 1N. Maratheftis, 1E.
Sigounas, 3E. Aggelopoulos, 4M. Papathanassiou, 1M. Remoundou, 5I.
Zalonis, 1C. Baltogiannis, 6K. ˆEonstadinidis, 7I. ˆEaskarellis, 8A. Hatzi-
ioannou, 9E. Patsouris, and 1D. Sakas (1Surgical Unit for Epilepsy,
Department of Neurosurgery, Athens Medical School, “Evangelismos”
Hospital., 2Neurosurgical Clinic, Athens General Public Hospital “G.
Genimatas”, 3Department of Psychiatry Athens Medical School, “Egi-
nition”Hospital., 42nd Radiology Laboratory of Athens University, “At-
tikon” Hospital., 5Department of Neurology, Athens Medical School,
“Eginition”Hospital, 6Cormed Company, 7Department of Radiology,
“Evangelismos” Hospital, 81st Radiology Laboratory of Athens Medical
School, “Areteion” Hospital, 9Pathology Laboratory of Athens Medical
School, Greece.)
Purpose: Surgical therapy for epilepsy is nowadays an established
therapy for drug resistant partial epilepsy. We present the protocol of the
presurgical evaluation and the results of surgical treatment of epilepsy
in our Epilepsy Surgical Centre.
Method: Presurgical evaluation protocol and surgical procedures.
Results: Outcomes for 35 patients, aged 12–47 years old, 19 men
and 16 women, who underwent surgical treatment for their refractory
epilepsy, are presented.
Conclusion: About 80% of patients with drug-resistant epilepsy of
the mesial temporal lobe are seizure-free after surgical treatment. The
percentage of patients with other types of drug-resistant epilepsy who
were treated surgically and remain seizure-free is 55%.
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RESULTS OF SURGERY IN DRUG-RESISTANT, SLEEP-
RELATED FRONTAL LOBE EPILEPSY
R. Mai, L. Tassi, L. Castana, I. Sartori, M. Cossu, F. Cardinale, L. Nobili,
S. Francione, L. Giorgio (Ospedale Niguarda, Centro “C. Munari” per
la Chirurgia Dell’Epilessia, Italy)
Purpose: To retrospectively evaluate the anatomo-electroclinical fea-
tures, histological substrate and outcome on seizures of 21 surgically
treated patients with drug-resistant, sleep-related frontal lobe epilepsy
(4% out of 522 operated on cases).
Method: There were 11 males and 10 females; mean age at seizure
onset was 6.2 years and mean age at surgery was 23.8 years. Seizure
frequency was high in most cases. Magnetic resonance imaging (MRI)
disclosed a focal anatomical lesion in one frontal lobe in 11 cases and
it was unrevealing in 10. Scalp video-EEG monitoring was performed
in all cases. Three patients were operated on after non-invasive inves-
tigations. In the remaining 18 patients a stereo-EEG investigation was
performed for a better definition of the epileptogenic zone. In all cases
the presurgical investigations indicated a frontal lobe origin of seizures.
Surgery consisted of cortical resection in 10 patients, in a lesionectomy
with cortical resection in 9 and in a lesionectomy in 2. Two patients were
operated on twice for poor results on seizures of first surgery.
Results: Histology revealed a Taylor’s focal cortical dysplasia (FCD)
in 16 patients, an architectural FCD in 4 and was negative in 1 case.
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Outcome on seizures (mean follow-up 42.5 months) according to Engel
was: 16 patients (76%) in class Ia, 3 in class II, 2 in class III. All the
patients in class Ia had a Taylor FCD.
Conclusion: Surgery in frontal lobe sleep-related epilepsy provides
better results on seizures than in frontal lobe epilepsy in general. Taylor’s
FCD may represent a histological substrate which supports the occur-
rence of seizures during sleep.
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HUMANISTIC IMPACT SEVERITY AS A DETERMINANT
OF HIGHER COSTS IN PATIENTS WITH REFRACTORY
EPILEPSY: A SPANISH PERSPECTIVE
1G. Palacios, 2J. Sancho, 3M. Rufo, 4P. Pen˜a, 5S. Martı´nez, 5X. Mas-
ramon, and 6J. Rejas (1Department of Neuroscience, Medical Unit,
Pfizer Spain, 2Department of Neurology, General University Hospi-
tal, Valencia, Spain, 3Department of Pediatric Neurology, University,
4Department of Neurology, University Hospital, 5European Biometrics
Institute, Barcelona, Spain, 6Health Outcomes Research Department,
Medical Unit, Pfizer Espan˜a, Madrid, Spain.)
Purpose: To explore the association between humanistic impact (qual-
ity of life, depression, anxiety and health status) and costs in adult patients
with refractory epilepsy in Spain.
Method: Secondary analysis of a cross-sectional study carried out to
determine humanistic impact and cost of refractory epilepsy. Consecutive
male and female adult patients (over 18 years) fulfilling criteria for re-
fractory epilepsy were analysed. Health-related quality of life (HRQoL),
anxiety and depression were assessed by QoLIE-10 and HAD scales, and
health status by a 0–100 mm visual analogue scale. Costs were estimated
from health care and non health care resources used.
Results: A total of 762 consecutive patients [728 valuables, (95.5%);
50.8% males, 40.5 (13.5) years, 24.3 (13.4) years of evolution] were
analysed. Total yearly costs were associated with poorer HRQoL scor-
ing according to patients segmentation in QOLIE-10 deciles; from a
mean yearly total cost of €11,494 (€11,668) to €809 (€2,904), first
and ten deciles respectively, p < 0.001. Severe levels of anxiety and
depression were both associated with higher costs. Anxiety (from nor-
mal to severe): €6,192 (€7,546) and €9,959 (€9,950), respectively,
p < 0.01. Depression (from normal to severe): €5,968 (€6,704) and
€12,691 (€11,746), respectively, p < 0.001. Subjects with health status
below 50 showed higher costs [€9,828 (€10,709)] than those above 50
[€5,897 (€6,749)], p < 0.001.
Conclusion: Costs of refractory epilepsy were associated with higher
negative humanistic disease impact: the higher the negative impact the
higher the costs. Health decision makers and clinicians should be aware
when making health decision. This study has been financed by Pfizer
Spain.
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INTRACAROTID PROPOFOL TEST FOR SPEECH AND MEM-
ORY DOMINANCE IN PRESURGERY EPILEPSY STUDY
J. Rodriguez Uranga, G. Moreno Castro, M. Oliver Romero, I. Trujillo
Pozo, F. Federero, J. Montero Elena, A. Gonzalez Garcı´a, and F. Villalo-
bos Chaves (Surgery Epilepsy Program, Seville, Spain)
Purpose: Since 2000 amobarbital has not been available in Spain and
scarcely in other countries. To evaluate the usefulness of propofol as an
alternative drug to amobarbital for the Wada test, we analysed 11 cases
with refractory epilepsy who were candidates for neurosurgical therapy
and thus underwent the Wada test as a preoperative evaluation.
Method: The authors analysed the recovery time of muscle power to
manual muscle testing (MMT) Grade 3 (T3/5) and Grade 5 (T5/5), onset
time of the first verbal response and nonverbal response. These times
were similar to amobarbital results in the bibliography. Analysis of EEG
background activity during the Wada test was performed. The median
dosage was 10 mg for 5 seconds.
Results: T0/5 was presented to 3–17 seconds. T5/5 was presented in
2–6.20 minutes. Lateralities of language were identified in all patients
and memory lateralities in 7 of 11 patients. A case presented transi-
tory ipsilateral eye pain; no other complications with direct intracarotid
injection were observed.
Conclusion: With direct intracarotid propofol injection, the Wada test
was satisfactorily performed in all 11 patients without any complications.
The times of first response and the recovery were similar to the times
described with amobarbital.
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AN EPILEPSY CENTRE’S ROLE IN EPILEPSY SURGERY IN
CHILDREN OF LOW IQ
R. Newton and D. Taylor (The David Lewis Centre, UK)
Purpose: The Children’s Assessment Service provides new solutions
to old and intractable problems. Surgical treatment is not always consid-
ered for children with complex epilepsy including learning difficulties.
This study, a natural development of clinical audit, describes the oppor-
tunities for and the effects of, epilepsy surgery among children referred
to us.
Method: 287 children had a period of residential assessment. We
got to know them and their parents well. We had a part in assessing
7 patients for surgery (group 1; 3 had hemispherectomy, 3 temporal
lobectomy and 1 had a frontal lobe lesion resected) and played a part in
the rehabilitation of 7 patients (group 2) operated elsewhere (4 resections,
and 3 procedures likely to provide only moderate improvement). We
contacted the parents of as many of the children from both groups as
we could, seeking information about current seizures, drug treatment,
behaviour, living situation and their views about the surgery. The longest
follow-up study was 12 years.
Results: Six of 7 children in group 1 had good results by internation-
ally agreed standards. 5 of 7 were seizure free. 1 was living independently.
All parents who replied were grateful their child had surgery. One child
in group 2 had deteriorated cognitively and behaviourally and continued
to have seizures. The effect of surgery on 6 out of 7 in group 2 was
neutral.
Conclusion: Children with learning disability can benefit from
epilepsy surgery programmes.
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EARLY RESULTS OF MEDICALLY RESISTANT FO-
CAL EPILEPSY SURGERY WITH NEURONAVIGATION
ASSISTANCE
A. Ribenis, I. Aksiks, R. Sverzickis (Neurosurgery Clinic, Pauls Stradins
Clinical University Hospital, Riga, Latvia)
Purpose: Our aim was to evaluate the use of neuronavigation (NN)
in focal epilepsy surgery and early clinical outcome.
Method: The study period was from 2000 until 2005. NN by Zeiss
SMN system, Medtronic Stealth Station Treon. In all cases lesionectomy
was performed. Patients who were totally operated numbered 41 (male:
female 23:18). Age range was 4–68 (mean 35). Epilepsy anamnesis: 29
(70.8%) 1–3 months; 7 (17%) 2 years; 2 (4.9%) 10–15 years; 3 (7.3%)
more than 15 years; mean 16 months. Preoperative EEG: 29 (70.3%)
epileptic focus found; 9 (22%) abnormal, no focus; 3 (7.7%) normal,
close to normal. Antiepileptic medication was administered preopera-
tively to 25 (61%) patients. Operated lesions: 29 (70%) cerebral tumour;
4 (9.8%) arteriovenous malformation; 4 (9.8%) gliosis; 4 (10.4%) other.
Size of lesion from 0.8 to 7.5 cm. Lesion topography (lobes): 15 (36.5%)
frontal; 16 (39%) temporal; 8 (19.5%) parietal; 2 (5%) occipital. In 5
cases more than 1 lesion was operated simultaneously. The size of le-
sions were from 0.8 to 7.5 cm (mean 4.3 cm).
Results: Postoperative follow-up period was 3 months. EEG control
8–10 weeks after operation. Clinically: 35 (85%) no epileptic seizures;
6 (15%) less frequent. EEG results: 11 (26.8%) epileptic focus seen; 23
(56%) abnormal, no focus; 7 (17.2%) normal, close to normal. Patients
on antiepileptic medication: 13 (31.7%).
Conclusion: Neuronavigation is useful in focal minimally invasive
epilepsy surgery and in extirpation of more than one cerebral lesion
simultaneously. So far we have achieved good results, but must still
continue long-term evaluation.
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THE LONG-TERM OUTCOME OF EPILEPSY SURGERY:
HOW MANY PATIENTS DISCONTINUE ANTIEPILEPTIC
MEDICATION?
J. De Tisi, A. McEvoy, J. Sander, J. Duncan, and W. Harkness (Institute
of Neurology, London, UK)
Purpose: Epilepsy can be regarded as cured by surgery if the individ-
ual remains seizure-free having discontinued antiepileptic drugs (AEDs).
We determined how common this optimal outcome is over long-term
follow-up, and identified factors associated with successful discontinu-
ation of AEDs.
Method: 473 patients who had epilepsy surgery at the National Hos-
pital for Neurology and Neurosurgery in 1990–2003 were followed for
2–15 years, analysed in 5 year cohorts. Seizure outcome was classified
according to the 6-point ILAE Epilepsy Surgery Commission scale, at
the latest follow-up available and it was noted whether they remained on
AEDs. Data are so far based on a cohort of 144 patients for whom there
are complete follow-up data.
Results: 69% were seizure-free (Group 1) and 31% continued to have
seizures, including auras (groups 2–6). The former comprised 19% off
AEDs and 50% on AEDs. Gender did not influence the rate of seizure
freedom. However, 14% of seizure-free men were off AEDs and 55%
on AEDs; whilst 23% of women were off AEDs and 46% on AEDs.
The seizure freedom rate was lower in the 1990–1994 cohorts (55%),
possibly reflecting improving methodology with time, and that longer
follow-up increases the risk of relapse.
Conclusion: The greater proportion of seizure-free women who dis-
continued AEDs probably reflects concerns about teratogenesis and the
higher percentage of men who continue on AEDs may be due to concerns
about driving. With current criteria, only 19% could be said to be cured
of epilepsy by surgery; a further 50% are seizure free but continue on
AEDs.
p822
USE OF A DECISION SUPPORT SYSTEM (DESSA) FOR THE
SURGICAL TREATMENT OF EPILEPSY
1C. Baltogiannis, 2V. Kimonides, 2D. Konstantinos, and 2D.
Lymberopoulos (1TYPET-Neurological Department-Athens Greece,
2Wire Communications Lab. University of Patras- Greece)
Purpose: The validation of a newly developed decision support
tool for the early identification of candidates for surgical treatment in
epilepsy.
Method: The DESSA tool is the result of a close collaboration be-
tween engineers, medical doctors, and market analysts. Its architecture
provides the user with an integrated electronic working domain handling
diverse types of information and medical records. DESSA enables the
doctor-user to make a decision based on the identification of critical
interaction factors amongst predefined data categories through a cor-
relations model on the integrated clinical picture of the patient in real
time. The term integrated clinical picture refers to the ability of the sys-
tem to record, describe, and classify in time the epileptic events on the
basis of their type, frequency of occurrence, duration of symptoms, and
correlation with respective pharmacological treatment and period of its
application as well as respective specialised EEG and vEEG pictures.
For the validation of the new tool 24 drug-resistant epilepsy patients
were entered in the database and their presurgical assessment has been
analysed.
Results: At this first stage of implementation, the DESSA tool seems
to provide a holistic view on the patient’s assessment and enables the
easier identification of candidate patients for surgical treatment.
Conclusion: The current phase of development of the tool is a good
platform for the development of markers regarding the cross-reactivity
of treatments as well as at a later stage postsurgical scenarios.
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SURGICAL MANAGEMENT OF PATIENTS WITH PAEDI-
ATRIC ONSET EPILEPSIES IN SLOVENIA
1N. Krajnc, 2D. Gosar, V2. Glavic Tretnjak, 1N. Zupancic, 3M. Krzan,
and 3I. Ravnik (1University Children’s Hospital, Department of Child
Neurology, Ljubljana, Slovenia, 2University Children’s Hospital, Lab-
oratory For Neuropsychology; Ljubljana, Slovenia, 3University Chil-
dren’s Hospital, Center For Epilepsy; Ljubljana, Slovenia)
Purpose: Slovenia’s population is too small for an epilepsy surgery
programme. Following noninvasive presurgical assessment, patients are
referred abroad for further evaluation and surgery. To assess outcome,
data for patients referred from the Center for Epilepsy (Child and Ado-
lescent) to foreign surgery centers were evaluated.
Method: Retrospective data analysis of 40 referrals from 1985 to
2005.
Results: Epilepsy surgery was performed on 22 patients (55% of re-
ferrals), 15 were declined (37.5%), while 3 were waiting phase II as-
sessment. Positive trends in the number of referrals and in shortening
the duration of epilepsy before surgery (from 16.5 to 7.5 years) were ob-
served. The majority had procedures in frontal lobes (13/22), followed
by temporal (5/22) or parietal lobe surgery (1/22), while 3 had calloso-
tomy. Seizure outcome in 12 of 19 patients was Engel I in the first year
and 8/19 after follow-up (mean 4.5 years; 3 missing). One of 2 patients
starting as Engel III switched to Engel IV. Perioperative complications
were transient (7 of 18; 4 missing). The use of AEDs and quality of life
parameters were followed after surgery.
Conclusion: Referrals for epilepsy surgery abroad offers benefits re-
lated to type of pathology and age of the patient but also carries lo-
gistic problems in planning strategies and communication. The high
proportion of patients declined reflects specific pathology of severe
paediatric epilepsy. Further shortening the duration of epilepsy before
surgery by earlier referrals is a desired and possible goal. Specific and
tailored rehabilitation after surgery may reduce problems with social
integration.
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CHARACTERISTICS AND OUTCOME OF OCCIPITAL LOBE
EPILEPSY SURGERY GUIDED BY MONITORING WITH SUB-
DURAL ELECTRODES
1A. G. Caicoya, 2J. Macarro´n, 3J. Albı´sua, and 1J. Serratosa (1Epilepsy
Unit, Fundacio´n Jime´nez Dı´az, Madrid, Spain, 2Department of Neu-
rology, Hospital General De Burgos, Burgos, Spain, 3Department of
Neurosurgery And Epilepsy Unit, Fundacio´n Jime´nez Dı´az, Madrid,
Spain)
Purpose: Occipital lobe epilepsy is uncommon in epilepsy surgery
series and difficult to assess due to rapid propagation and misleading
seizure semiology. Ictal recordings with surface electrodes may not prop-
erly define the seizure onset zone, and intracranial recordings are often
indicated. In this study we present our experience with individually tai-
lored resections of occipital lobe epileptic foci guided by monitoring
with subdural electrodes.
Method: Clinical characteristics, interictal/ictal surface and intracra-
nial recordings, neuroimaging, type of resection, pathology and outcome
of 7 patients are presented.
Results: The most common seizure was complex partial with tempo-
ral lobe semiology; 5 patients reported visual auras. Two patients had
semiology of the supplementary motor area seizures and 1 patient had
temporal and frontal seizure propagation. Neuroimaging showed lesions
in 6/7 patients. Pathological studies revealed cortical dysplasia and tu-
mours as most common causes. Intracranial recordings (6/7 patients)
revealed focal onset in 2 patients, regional onset in 2, and diffuse on-
set in 2. Resections were performed according to intracranial recordings
restricting resections in cases with focal seizure onset (even in large dys-
plastic lesions) and performing wider resections in patients with regional
or diffuse onset. Five of 7 patients are seizure free after 12–55 months
(mean 24.3). The 2 remaining patients may be classified as Engel 2b and
3a.
Conclusion: This series of occipital lobe epilepsy surgery shows that
even in patients with cortical dysplasias restricted resections may have
a good outcome and that intracranial monitoring is usually necessary in
order to design an individually tailored resection.
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PRIMARY TEMPORAL LOBE TUMOURS PRESENTED WITH
SEIZURES
1A. Gunduz, 1O. Uyanik, 2M. Uzan, 1N. Yeni, 1N. Karaagac, 2E. Ozyurt,
and 1C. Ozkara (1Istanbul University, Carrahpasa Medical School, De-
partment of Neurology, Turkey, 2Istanbul University, Carrahpasa Medi-
cal School, Department of Neurosurgery, Turkey)
Purpose: Seizures are observed in 20–45% of primary brain tumour
patients (PBT) depending on tumour type and location. Temporal lobe
tumours (TLT) are common in patients with temporal lobe epilepsy re-
quiring surgery. The aim of this study was to analyse the association
between primary TLT and seizures in terms of localisation, age at onset,
type and outcome after surgery.
Method: Clinical, pathological features, MRI and EEG results and
outcome data of 89 patients with PBT were analysed; 43 patients (21
women/22men, age range: 2–46 years) with TLT who presented with
seizures and underwent surgerybetween 1992 and 2005 were studied
separately.
Results: Mean age at seizure onset 14.0 ± 9.1 years, mean interval
between seizure onset and surgery 7.9 ± 8.3 years. Tumours were lo-
calised on the right in half of the patients. Mesial in 22 (52.4%), lateral
15 (35.7%), mesiolateral 6. The histological investigation revealed gan-
glioglioma in 18, dysembryoplastic neuroepithelial tumour (DNET) 12,
oligodendroglioma 5, others in 8 patients. Gangliogliomas were signifi-
cantly more common under the age of 18 (p < .05). Mean follow-up was
4.4 ± 3.2 years. EEG showed focal epileptiform activity or slow waves
in the majority of patients. Seizure-freedom was achieved in 52.4% of all
patients and 64.3% of patients had no postoperative residual tumour (p <
.05). Postoperatively, 56.3% of DNET and 45.5% of ganglioglioma pa-
tients were seizure free. No significant statistical association was found
among localisation, EEG, onset, pathology and outcome of the tumours.
Conclusion: This study indicates that the majority of primary TLT pre-
sented with seizures are low grade glioneuronal tumours and long-term
good seizure control may be influenced by the presence of postoperative
residual tumour.
p826
ANTIEPILEPTIC DRUG REGIMEN STATUS BEFORE AND
AFTER CORTICOAMYGADALO HIPPOCAMPECTOMY
IN PATIENTS WITH UNILATERAL MESIAL TEMPORAL
SCLEROSIS
1,2C. Baldauf, 1,2A. Cukiert, 1,2J. Burattini, 1,2P. Mariani, 1,2R. Camara,
1,2L. Seda, 1,2M. Argentoni-Baldochi, 1,2C. Baise-Zung, 1,2C. Forster,
and 1,2V. Mello (1Epilepsy Surgery Program, Hospital Brigadeiro, Sa˜o
Paulo, Brazil, 2Clinica De Epilepsia De Sa˜o Paulo, Sa˜o Paulo, Brazil)
Purpose: The surgical outcome after temporal lobe resections regard-
ing seizure frequency has been extensively reported over the last decades.
On the other hand, the status of the antiepileptic drug (AED) regimen
of these patients has been poorly studied, especially over long follow-
up periods. We describe the status of the AED regimen in a series of
patients with mesial temporal sclerosis submitted to corticoamygdalo-
hippocampectomy.
Method: Forty-one patients with refractory unilateral temporal lobe
epilepsy were studied. Mean postoperative follow-up time was 4.3 ± 1.1
years. MRI disclosed unilateral mesial temporal sclerosis (MTS) in all
patients. All patients had interictal EEG recordings. All patients were
submitted to corticoamygdalohippocampectomy at the side determined
by MRI. The AED regimen status was recorded before and at the last
follow-up visit.
Results: Thirty-nine patients (95, 1%) were classified as Engel’s Class
I (70.6% Engel I-A) and two (4.9%) as Engel’s Class II, postoperatively.
Eleven patients (26.8%) were not taking any AED. Mean pre- and postop-
erative doses (mg) for the different AED were as follows: carbamazepine
= 1059/608; phenobarbital = 113.6/96.4; phenytoin = 280/200; oxcar-
bazepine = 900/0; valproic acid = 733.3/1000; clonazepam = 2/4; lam-
otrigine = 125/0; clobazam = 20/20; topiramate = 150/0 and gabapentin
1200/0.
Conclusion: One quarter of the patients were taking no AED at late
follow-up. The majority of the others were taking much lower dosages
of AED. Valproic acid was the only AED more extensively used post-
operatively in this series; it is currently used in the treatment of post-
operative hypomania seen in some of these patients.
p827
SPIKES ON POSTOPERATIVE SCALP EEG DO NOT COR-
RELATE WITH SEIZURE OUTCOME AFTER SELECTIVE
AMYGDALOHIPPOCAMPECTOMY
1N. Yeni, 1U. Uygunoglu, 1A. Kutlu, 1N. Karaagac, 1C. Ozkara, 1G.
Erkol, 2M. Uzan, and 2E. Ozyurt (1Istanbul University Cerrahpasa
School of Medicine Department of Neurology, Turkey)
Purpose: Patients with mesial temporal lobe epilepsy-hippocampal
sclerosis (MTLE-HS) have a favourable prognosis after surgery. How-
ever, up to 20–30% still may not benefit form standardised surgical ap-
proaches. A tailored surgery resecting residual spikes is expected to have
an impact on outcome. After standard surgery, residual spikes on scalp
EEG may be a predictor for the outcome. The aim was to understand the
role of postoperative scalp EEG to make future projections about seizure
outcome in patients with MTLE-HS.
Method: Forty-five patients who underwent selective amygdalohip-
pocampectomy were enrolled in the study. EEG recordings of 30 minutes
in duration with double longitudinal montage were performed in three
consecutive stages: early stage (1–3 months), median stage (6-9 months),
and late stage (12–18 months). The frequency of spike activities but not
their spatial distribution were taken into consideration and they were
classified as more than 5 in one minute (I), 1–5 per minute (II), less
than 1 per minute (III), random (IV) and none (V). Seizure outcome was
classified according to Engel’s seizure outcome classification.
Results: One hundred and one EEG recordings of 45 patients were
evaluated. Mean age was 28.6 years (12–52). The mean follow up period
after the surgery was 49.29 (12–120) months. Spike activities on early
EEG recordings were compared to the following EEG’s and revealed
no change in spike frequencies in time, or statistically. Spike activi-
ties on three consecutive postoperative scalp EEG recordings were not
statistically significant with final seizure outcomes (p = 0.6, 0.4, 0.9,
respectively).
Conclusion: Routine scalp EEG is not a good predictor for seizure
outcome in patients with MTLE-HS after surgery.
p828
FEBRILE SEIZURES ARE NOT A RELEVANT PREDIS-
POSING OR PROGNOSTIC FACTOR IN A HOMOGE-
NEOUS SERIES OF PATIENTS WITH UNILATERAL
MESIAL TEMPORAL SCLEROSIS SUBMITTED TO
CORTICOAMYGDALOHIPPOCAMPECTOMY
1,2J. Burattini, 1,2C. Baldauf, 1L. Seda, 1R. Camara, 1,2P. Mariani, 1,2A.
Cukiert, 1,2M. Argentoni-Baldochi, 1,2C. Baise-Zung, 1,2C. Forster, and
1V. Mello (1Epilepsy Surgery Program, Hospital Brigadeiro, Sa˜o Paulo,
Brazil, 2Clinica de Epilepsia de Sa˜o Paulo, Sa˜o Paulo, Brazil)
Purpose: The occurrence of febrile seizures in patients who would
later develop refractory temporal lobe epilepsy has often been noted.
Although the causal relationship of these events to the development of
refractory epilepsy has been extensively discussed, no consensus has
been reached. We studied the prevalence of febrile seizures and its re-
lation to the surgical outcome in a homogeneous series of patients with
unilateral mesial temporal sclerosis submitted to surgery.
Method: Forty-one patients with refractory unilateral temporal lobe
epilepsy were studied. The presence or not of early febrile seizures was
documented in all of them. MRI disclosed unilateral mesial temporal
sclerosis (MTS) in all patients. All patients were submitted to cortico-
amygdalo-hippocampectomy at the side determined by MRI.
Results: Febrile seizures occurred in 10 patients (24.39%). Non-
febrile seizures started 7.61 ± 9.25 years afterwards in these patients.
There was no statistically significant relationship between the presence of
febrile seizures and the age of onset of nonfebrile seizures. Additionally,
there was no statistical difference regarding neurophysiologic or surgi-
cal outcome findings in patients with or without febrile seizures. Over-
all, interictal EEG showed unilateral epileptiform discharges compatible
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with MRI findings in 37 patients; in 4 out of the 41 patients, bilat-
eral discharges were found. Mean follow-up time was 4.3 ± 1.1 years.
Thirty-nine patients (95.1%) were classified as Engel’s Class I (70.6%
Engel I-A). Two patients (4.9%) were rated as Engel’s Class II. All pa-
tients in whom bilateral discharges were found were in Engel’s Class
I. Pathological examination showed mesial temporal sclerosis in all
patients.
Conclusion: Although frequently recognised during the initial clinical
work-up of patients with refractory temporal lobe epilepsy, the presence
of febrile seizures does not seem to be an important predisposing or
prognostic issue in patients with mesial temporal sclerosis.
p829
CASE REPORT OF A PATIENT WITH REFRACTORY
EPILEPSY DUE TO EXTENSIVE MULTIFOCI EPILEPTO-
GENIC ZONE TREATED WITH COMBINED SURGICAL
PROCEDURE
1D. Sakas, 2N. Gergaculias, 1A. Siatouni, 1S. Korfias, 1N. Martheftis,
3E. Angelopoulos, 1M. Remoundou, 4K. Konstantidis, 5M. Papthana-
siou, 6E. Parskevoulakos, 6A. Syrigou-Papavasiliou, 7E. Patsouris, 1E.
Singounas, and 1S. Gatzonis (1Surgical Unit for Epilepsy, Department
of Neurosurgery, Athens Medical School, “Evangelismos” Hospital.,
Greece 2Neurosurgical Clinic, Athens General Public Hospital “G. Gen-
imatas,” Greece, 3Department of Psychiatry, Athens Medical School,
“Eginition” Hospital, Greece, 4“Cormed” Company, Greece, 52nd Ra-
diology Laboratory of Athens University, “Attikon” Hospital, Greece,
6Department of Neurology, “Penteli” Children’s Hospital, 7Pathology
Laboratory of Athens University, Greece)
Purpose: We report the case of a patient with symptomatic refractory
epilepsy due to a wide epileptogenic zone, who was successfully treated
by a surgical approach.
Method: A 15-year-old boy suffered from complex partial seizures
with frequent secondary generalisation for the last 9 years. Despite the
antiepileptic regimen, seizures were not controlled. Brain MRI revealed
a lesion in the right temporal lobe, with poorly defined margin. The
presurgical evaluation demonstrated the lateralisation of the epilepto-
genic zone, but not the exact localisation. Invasive recording was needed.
An epidural grid and depth electrodes were put on the right frontal-
temporal-occipital region, followed by a prolonged video-ECG moni-
toring in order to find the epileptogenic zone.
Results: The electrocorticography revealed a multifocal wide epilep-
togenic zone from the right occipital lobe to mesial temporal lobe. A
right amygdalohippocampectomy with a tailored removal of the tumour
and the surrounding tissue, and multiple subpial transections modified
by Morrell in the temporal-occipital region were performed. The patient
has experienced no seizures since then (already 16 months).
Conclusion: Combined video-ECG tailored surgical procedures could
be a significant and irreplaceable method for surgical treatment of epilep-
sies with wide epileptogenic zone.
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Neurocognitive functioning in children with epilepsy
NEUROLOGICAL AND DEVELOPMENTAL OUTCOME
OF CHILDREN WITH EPILEPSY; EPIDEMIOLOGICAL
PERSPECTIVE
M. Kerr (Cardiff University, Wales, UK)
Epilepsy is common in childhood with annual incidence rates range
between 50–80 per 100,000 children and prevalence ranges around 0.5%.
The outcomes of these epilpesies are varied. Adult population studies
identify people with epilepsy as having decreased life expectancy, poor
quality of life, increased levels of mental illness, decreased educational
achievement, social isolation and a high prevalence of intellectual im-
pairment. The question for pediatric care is of course how these apparent
epilepsy related outcome can be predicted and whether they can be mod-
ulated.
This presentation will explore the epidemiology of epilepsy in child-
hood in terms of prevalence, incidence, seizure type and syndrome and
associated comorbidity.
Epilepsy parameters include the likelihood of remission off drug and
seizure related mortality.
Other outcomes include the potential associations with developmen-
tal disabilities and educational achievement these will be explored and
where available information on prediction of outcome presented.
Workshop attendees will be expected to attain an understanding of
the neurodevelopment outcomes of epilepsy from an epidemiological
perspective.
COGNITIVE FUNCTIONING IN CHILDREN WITH SYMP-
TOMATIC EPILEPSY
A. Kolk (University of Tartu, Department of Paediatrics, Estonia)
Seizure disorders in childhood may adversely influence the maturation
and maintenance of normal brain function. Intense seizure activity in
early life can be functionally as damaging as status epilepticus in mature
tissue.
We investigated the children with symtomatic epilepsies what are the
heterogenous group of epilepsies with some common characteristics,
including uncertain prognoses, frequent resistance to antiepileptic treat-
ment, localized origin of seizures and frequent associations with neuro-
logical/mental abnormalities. These children need neuropsychological
examination to predict the prospective cognitive development and edu-
cational need in each individual case.
We present resent data in the field of cognitive development, including
profiles of mildly retarded children, also gender differences, and findings
of humour development in epileptic children.
1. Visual-perceptual and visuo-constructive development testing
(TVPS-R and Rey tests) in 36 children with symptomatic epilepsy (18
boys and 18 girls) and 36 healthy controls revealed that the children
with epilepsy were delayed about 12 months on visuospatial perception.
Localized impairment in the parietal lobe or central parts had the most
negative effect on the visuospatial abilities. Co morbidity with speech
disorder was associated with main deficit in visual sequential memory.
The boys outperform girls in visuospatial tasks.
2. A study of 12 hemiparetic children with epilepsy and 10 children
with newly diagnosed epilepsy revealed a higher incidence of cogni-
tive impairment in symptomatic epilepsy cases, especially in immediate
memory and logical learning. Children with left hemisphere lesions were
impaired not only in language and reading abilities, but also in attention.
Boys were more affected. Children with temporal lobe epilepsy often
demonstrate material specific memory deficits.
3. Examination of 10 boys and 10 girls with epilepsy and mild intellec-
tual disability demonstrated low scores in attention, executive, language
and sensorimotor functions. In case of duration of epilepsy >5 years
dysfunctions were noted in all 6 cognitive domains without gender dif-
ferences.
4. The study of humour understanding in 17 epileptic children (7 boys,
10 girls) showed that they appreciated clear and easily understandable
jokes as funnier; and did not appreciate jokes with aggressive/scary tone.
COGNITIVE FUNCTIONING IN CHILDREN WITH NON-
SYMPTOMATIC EPILEPSY
K. Eriksson (Pediatric Research Centre, Medical School, University of
Tampere and Department of Pediatric Neurology, Tampere University
Hospital, Finland)
Nonsymptomatic childhood epilepsies, i.e., idiopathic focal or gen-
eralized epilepsy syndromes and ‘cryptogenic’ epilepsies account for
70–80% of all childhood onset cases. The risk for impairment of cogni-
tive functioning and neurological development are significant hazards for
children with epilepsy. The prevalence of cognitive dysfunctioning (up
to mental retardation) in children with epilepsy, as a group, is increased
and specific neurocognitive difficulties have been described also in the
children with ‘epilepsy only’ i.e., without any evident other neurolog-
ical or cognitive problems. A significant proportion of neurologically
otherwise normal children with epilepsy also need special educational
services.
The cause for specific cognitive dysfunction in children with non-
symptomatic, uncomplicated epilepsy is related to unrecognized etio-
logical factors (e.g., genetic traits), various epilepsy related factors (e.g.,
age at onset, ictal and interictal EEG abnormalities, type of epilepsy syn-
drome, seizure type/localization/frequency and antiepileptic drug treat-
ment) as well as to many psychosocial and socioeconomic factors. Most
cognitive problems have a multifactorial origin and these factors com-
bined are responsible for the specific features of cognitive functioning
in individual cases.
In children with benign and/or idiopathic focal (BCECTS, COE) or
generalised (CAE, JME) epilepsies the most often reported specific
neurocognitive dysfunctioning include problems in language, attention,
memory, phonological processing, visuospatial skills and verbal fluency
but the test results have not always been consistent. Some of these prob-
lems seem to exist already before seizures emerge and the direct causal
link to epilepsy is not always evident.
It should be remembered that child’s prediagnostic learning and be-
havioral histories and contextual variables (e.g., psychosocial, parenting
habits) jointly with epilepsy related variables are important for under-
standing the cognitive and behavioral problems in children with epilepsy
only. Parents’ guidance and neuropsychological as well as educational
multidisciplinary interventions to support neurological development of
children with epilepsy should therefore be emphasized.
THE EFFECTS OF ANTIEPILEPTIC DRUGS ON COGNITIVE
FUNCTIONING IN PEDIATRIC PATIENTS WITH EPILEPSY
A. Aldenkamp (Maastricht University Hospital, Department of Neurol-
ogy, The Netherlands)
Although the causes of cognitive impairment in patients with epilepsy
have not been completely elucidated, three factors are clearly involved:
the underlying etiology of epilepsy, the effects of seizures themselves,
and the central nervous system effects of antiepileptic drugs (AEDs).
All commonly used AEDS have some effect on cognitive function and
behaviour, and the effect may be substantial when crucial functions are
involved, such as learning in children or driving ability in adults, or when
already vulnerable functions are involved, such as memory in elderly
patients. This will be illustrated using a metanalysis for all commonly
used AEDs: valproate, carabamazepine, phenytoin and phenobarbitone.
The available evidence is insufficient to support definite conclusions
about the cognitive effects of three of the newer AEDs, tiagabine,
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gabapentin, and levetiracetam. Better evidence is available for lamotrig-
ine, topiramate, and, to a lesser degree, oxcarbazepine. Oxcarbazepine
appears not to affect cognitive function in healthy volunteers or adults
with newly diagnosed epilepsy, but its cognitive effects in children and
adolescents have not been systematically studied. A relatively large num-
ber of studies are available for lamotrigine, which has demonstrated a
favorable cognitive profile overall, both in volunteers and in patients
with epilepsy. Although dose and titration speed may be confounding
factors in some of the studies of topiramate, there is clear evidence that
this agent does affect cognitive function, with specific effects on atten-
tion and verbal function. For lamotrigine, attempts have been made to
correlate cognitive effects with what is known of the drug’s mechanism
of action; this is an area of research that deserves further exploration
with regard to other AEDs, especially topiramate, as well.
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Epilepsy and genetics
A GENETICIST’S VIEW
O. Steinlein (Institute of Human Genetics, University of Munich,
Germany)
The term epilepsy describes a heterogeneous group of disorders, with
a lifetime cumulative incidence of 3%. In the majority of epilepsies genes
are a minor if not even the only etiological factor. There is a large sub-
group of epilepsies that are suspected or proofed to be mainly genetic in
origin. This group of epilepsies has been named idiopathic, and during
the last decade several genes have already been identified for various
idiopathic epilepsies. On the other hand there is a large group of epilep-
sies and disorders with epilepsy that have been termed “symptomatic”
because they are due to known metabolic, neurodegenerative or struc-
tural brain damage. Many of these disorders have by now shown to be
caused by clearly defined genetic factors. Seizures and myoclonus are
common to many neurodegenerative and metabolic disorders, but are
also a major feature in patients with structural chromosomal arrange-
ments or neuronal migration disorders. In this talk exemplary members
of both groups will be discussed to illustrate principal etiological cate-
gories of the disorder “epilepsy” and trace the various genetic pathways
to epileptogenesis.
A CLINICIAN’S VIEW
J. Serratosa (Fundacio´n Jime´nez Dı´az, Unidad De Epilepsia, Servicio
De Neurologı´a, Madrid, Spain)
No abstract received.
GENETICS IN FOCAL EPILEPSIES
E. Brodtkorb (Department of Neurology and Clinical Neurophysiology,
Trondheim University Hospital, Norway)
Clinical Genetics in Focal Epilepsies
Idiopathic focal epilepsies are considered to be exclusively caused by
genetic factors, but only in a few a monogenetic origin has been proven.
Autosomal dominant frontal lobe epilepsy (ADNFLE) causes char-
acteristic hyperkinetic nocturnal seizures in the form of episodes of
complex motor activity during light sleep, ranging from subtle parox-
ysmal awakenings to violent jerks and posturing. Seizures are usually
numerous and occur in clusters. They are assumed to represent dis-
inhibition phenomena from subcortical structures. Mutations in genes
coding for subunits of the nicotinic acetylcholine receptor have been
identified. Penetrance is incomplete and the course may be variable.
Some patients demonstrate pharmacoresistence. Curiously, nicotine con-
sumption appears to modulate the symptomatology in a number of pa-
tients, and transdermal nicotine has been reported to be effective against
seizures.
Autosomal dominant lateral temporal lobe epilepsy (ADLTE) has re-
cently been found to be associated with mutations in the leucine-rich,
glioma inactivated 1 (LGI1) gene, previously considered a candidate
tumour suppression gene for glioma. It is not encoding an ion channel,
but may regulate axonal guidance and cell migration. Acoustic auras are
common, but a range of other ictal phenomena from the lateral temporal
lobe have been reported, among them aphasia. Another peculiar feature
is its reflex character. In a number of patients, seizures can be triggered
by auditory stimuli. Clinical, EEG as well as evoked response studies
predominantly indicate left-sided brain abnormalities and a role of the
LGI1 gene in the functional development of the dominant hemisphere
has been hypothesized.
The progress in the field of genetics now contributes enormously to
the development of epileptology. The current discoveries suggest new
neurobiological mechanisms for familial epilepsy, which may elucidate
the pathophysiology of the epilepsies in general.
GENETICS AND PATHOPHYSIOLOGICAL CONCEPTS OF
GENERALISED EPILEPSIES
H. Lerche (University of Ulm, Neurological Clinic and Department of
Applied Physiology, Germany)
Idiopathic epilepsies are genetically determined syndromes not asso-
ciated with structural brain lesions and featuring characteristic epileptic
seizures and EEG abnormalities. In recent years, an increasing num-
ber of mutations cosegregating with the disease status in families with
idiopathic epilepsies has been identified in genes encoding subunits of
voltage- or ligand-gated ion channels which play a fundamental role
in brain excitability. Namely axonal conduction of action potentials is
mediated by voltage-gated channels and signal transduction from cell
to cell (synaptic transmission) by ligand-gated channels. Thus from a
pathophysiological point of view, it is plausible that mutation-induced
channel dysfunction can induce neuronal hyperexcitability and epilep-
tic seizures. The mutations can affect ion channels which on one hand
have been known since several decades to be crucial for neuronal func-
tion, such as the voltage-gated sodium channel or the GABAA receptor,
or on the other hand were newly identified within the last decade as
KCNQ potassium channels or the ClC-2 chloride channel. Functional
studies characterizing the molecular defects of the mutant channels point
to an important role of GABAergic synaptic inhibition in the patho-
physiology of IGE. Furthermore, newly discovered genes may be suit-
able as novel targets for pharmacotherapy such as KCNQ channels for
the anticonvulsant drug retigabine. Altogether, these genetic and patho-
physiological investigations will enhance our knowledge about the un-
derstanding of epileptogenesis and can help to improve anticonvulsive
therapy.
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Nonconvulsive status epilepticus – clinical definitions
and biological framework
REVIEW OF BASIC MECHANISM IN STATUS EPILEPTICUS
J. Epsztein (INMED-INSERM U29, France)
Ongoing epileptiform activity without seizures in the postischemic
hippocampus: a permanent shift of the excitatory-inhibitory synaptic
balance in resistant pyramidal neurons
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Ischemic stroke are often associated to late-onset epilepsy but the un-
derlying mechanisms are poorly understood. In the hippocampus, that is
one of the regions most sensitive to ischemic challenge, global ischemia
induces a specific neuronal loss of CA1 pyramidal neurons while the
resistant CA3 pyramidal neurons display a long-term hyperexcitabil-
ity several months after the insult. The mechanisms of this long-term
hyperexcitability remain unknown despite their clinical implications.
The aim of the present report was to analyze the long-term morpho-
functional consequences of global ischemia on glutamatergic and
GABAergic systems in the CA3 area of the hippocampus that could ac-
count for the hyperexcitability of resistant CA3 pyramidal cells. Using
chronic in vivo EEG recordings and in vitro field recordings in slices, we
report spontaneous interictal epileptiform discharges (IEDs) in the CA3
area of the hippocampus from post ischemic rats several months after the
insult. However, none of the recorded postischemic rats showed behav-
ioral or electrographic seizures in the hippocampus during the recording
period. Whole cell recordings from CA3 pyramidal neurons revealed
a permanent reduction in the frequency of spontaneous and miniature
GABAergic inhibitory postsynaptic currents (IPSCs) and a parallel in-
crease in the frequency of spontaneous and miniature glutamatergic ex-
citatory postsynaptic currents (EPSCs). Global ischemia also induced a
dramatic loss of GABAergic interneurons and terminals together with
an increase in glutamatergic terminals in the CA3 area of the hippocam-
pus. Altogether our results show a morpho-functional reorganization in
the CA3 network several months after global ischemia resulting in a
net shift in the excitatory-inhibitory balance towards excitation that may
constitute a substrate for the generation of epileptiform discharges in the
post-ischemic hippocampus.
SIMPLE AND PARTIAL COMPLEX STATUS EPILEPTICUS
H. Meierkord (Charite´ – Universita¨tsmedizin Berlin, Germany)
Focal forms of nonconvulsive status epilepticus may or may not in-
clude altered contact with the environment. In simple partial status
epilepticus (SPSE) consciousness is not compromised. In contrast, in
complex partial status epilepticus (CPSE) changes in behaviour or men-
tal state are associated with impairment or loss of consciousness. This
classification is not entirely satisfactorily since impairment of conscious-
ness may be difficult to prove or to rule out. In this presentation the
various subtypes of SPSE such as somatosensory, psychic, autonomic
and aphasic SPSE will be discussed. The clinical phenomenology and
EEG changes and aetiologies, treatment and prognosis will be presented.
Propagation of epileptic activity is an important neurobiological phe-
nomenon well suited to explain various clinical and EEG features that
may be encountered in status epilepticus. All types of SPSE may evolve
into CPSE but a reversal of such an evolution is rare if not impossible.
CPSE for many years was thought to be a rare condition. In an epidemio-
logical study by DeLorenzo et al. (1996), CPSE was reported to account
for only 3% of all cases of status epilepticus. Only recently European
population-based studies revealed that the proportion of CPSE of all
cases ranges from 16 to 43% (Vignatelli et al. 2003, Knake et al. 2001).
CPSE poses greater diagnostic and therapeutic challenges compared to
SPSE. Typically, the condition evolves gradually and is fluctuating with
waxing and waning symptoms including restlessness, fearful and/or agi-
tated behaviour and automatisms. CPSE most often arises from temporal
or frontal lobe regions and the spectrum of aetiologies causing CPSE
is wide. Regarding prognosis available human data indicate that NCSE
itself seems to be a rather benign condition regarding morbidity and mor-
tality. Poor outcome in most cases results from the underlying aetiology
and associated complications.
NONCONVULSIVE STATUS EPILEPTIC AND COMA
G. Bauer (University Hospital for Neurology Innsbruck, Austria)
Coma is a state of unarousable psychologic unresponsiveness in which
the subjects lie with eyes closed (Plum, F, Posner, JB: The Diagno-
sis of Stupor and Coma. 3rd ed. F.A. Davis Company, Philadelphia,
1980). In coma, the diagnosis of an enduring epileptic condition rests
on epileptiform EEG abnormalities. EEG changes with coma are multi-
faceted and exhibit continuous epileptiform patterns in advanced cases
(Bauer, G: Coma and Brain death. In: Niedermeyer, E, Lopes da Silva,
F: Electroencephalography, Basic Principles, Clinical Applications and
Related Fields, 5th ed. Lippincott Williams & Wilkins, Philadelphia
2005, p 471–487). A second criterion for an epileptic condition would
be a beneficial effect of antiepileptic drug (AED) treatment on EEG
and the clinical state. Several papers deal with the question, how ag-
gressive the AED treatment should be and if it is beneficial or even
harmful. The outcome does not depend on treatment but on etiology
and is bleak in most cases. Therefore, the differential diagnosis-NCSE
or deep coma with epiphenomenal spikes-remains undecided. In most
cases, coma with NCSE designates an acute and serious cerebral in-
sult. NCSE in the form of coma rarely if ever occurs in pre-existing
chronic epilepsies.
Several generalized and lateralized EEG patterns prompted the classi-
fication of deep coma states as NCSE: continuous spikes, periodic epilep-
tiform complexes, several types of burst suppression pattern, triphasic
waves, periodic lateralized epileptiform discharges (PLEDs), bilateral
independent PLEDs (BI-PLEDs) and unilateral suppression burst pat-
tern. All these abnormalities are unspecific with regard to etiology and
the relation to NCSE, but reflect the depth of coma. With generalized pat-
terns, the most frequently observed etiologies are cerebral anoxia, toxic
and metabolic encephalopathies, CNS infections and space occupying
lesions with irreversible tentorial herniation. Lateralized EEG abnormal-
ities occur with acute hemispheric lesions. The relation of EEG changes
to epileptic cellular mechanisms is controversially discussed. Generally,
coma accompanied by continuous epileptiform EEG pattern has a dismal
prognosis. A few exceptions exist. Intoxications with triphasic waves or
suppression burst pattern recover after the elimination of the toxic sub-
stance. In these cases, the treatment with sedative AEDs clearly would be
counterproductive. Remote symptomatic epilepsies following a cerebral
vascular infarct frequently exhibit PLEDs in the postictal unconscious
state. Most of these patients recover promptly without immediate i.v.
AED treatment.
ABSENCE STATUS EPILEPTICUS THROUGHOUT THE LIFE
CIRCLE
P. Thomas (Service de Neurologie, Unite Fonctionnelle EEG-
Epileptologie, Hopital Pasteur, Nice, France)
Absence status (AS) is a polymorphic condition that can complicate
many epileptic syndromes, and can occur at any age. Diagnosis is dif-
ficult on the basis of clinical semiology alone, and requires emergency
EEG. On a nosographic point of view, literature indicates that 4 types
of AS may be recognized. Typical AS occurs as part of an idiopathic
generalised epilepsy most often characterized by absences. Isolated im-
pairment of consciousness, at times with subtle jerks of the eyelids, is
the essential symptomatology. The EEG correlates with repetitive ab-
sence seizures and shows symmetric and bilateral synchronous SW or
PSW complexes faster than 2.5/3 Hz. The immediate prognosis is ex-
cellent. Atypical AS occurs in patients with symptomatic or cryptogenic
generalized epilepsies and is characterized by a fluctuating confusional
state with more prominent tonic and/or myoclonic and/or lateralized ic-
tal manifestations than occur in typical AS. The EEG shows continuous
or intermittent diffuse irregular slow SW or PSW complexes. The im-
mediate prognosis is guarded, as these episodes tend to recur and to
be resistant to medication. “De novo” absence status of late onset is
characterized by toxic or metabolic precipitating factors in middle-aged
or elderly subjects with no previous history of epilepsy. Patients often
have a history of psychiatric illness with multiple psychotropic drug in-
take. The electroclinical characteristics and the immediate prognosis are
variable. These episodes of AS generally represent acute symptomatic
seizures and may not recur if the triggering factors can be controlled
or corrected. Long-term antiepileptic drugs may thus not be needed.
Absence status with focal characteristics occur in subjects with a preex-
isting or newly developing partial epilepsy, most often of extratemporal
origin. The EEG shows bilateral but often asymmetric ictal discharges.
The immediate prognosis is variable. Some of these cases are difficult
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to distinguish from complex partial status epilepticus of frontal lobe
origin.
Sunday July 2, 2006
9:30 – 11:30
Hall 1
Discussion Group Session
Clinical neuropathology of epilepsy associated cortical
malformations
RECENT DEVELOPMENTS IN THE CLASSIFICATION OF
CORTICAL MALFORMATIONS
A. Palmini (UZ Gasthuisberg, Leuven, Belgium and Porto Alegre
Epilepsy Surgery Program, Porto Alegre, Brazil)
Furthering the knowledge about focal epilepsies will depend on a de-
tailed understanding of the determinants of epileptogenicity, other func-
tional properties, clinical and electrographic presentations, and imaging
features of specific types of lesions. A crucial step in this direction is to
precisely define the histopathological features of epileptogenic lesions.
Interestingly, high resolution MRI has led to a puzzling scenario in
which lesions are often identified and described in global, categorical
terminology, distracting the attention to differences between specific
types of lesions that present ‘roughly’ with the same imaging picture.
This situation has been witnessed in relation to the identification and
treatment of cortical malformations associated with epilepsy, particularly
the focal dysplastic lesions.
Therefore, an effort was made to develop a histopathological classifi-
cation system for focal dysplastic lesions that could be correlated with
imaging, clinical, neurophysiological, functional, surgical, and prog-
nostic aspects. This classification proposes the clustering of minimal
histopathological abnormalities that do not disrupt cortical architecture
(such as small clusters of heterotopic neurons in the white matter) in a
specific category, thus abandoning the terminology “microdysgenesis.”
In addition, the classification distributes focal dysplastic lesions in which
cortical dyslamination is a major feature along a continuum of histologi-
cal abnormalities which in one end is represented by dyslamination only,
and proceeds to more complex histopathological patterns characterized
progressively by immature yet ‘nondysplastic’ cellular elements, dys-
plastic neurons, and, finally, in the opposite end, by lesions harboring
dysplastic neurons and balloon cells.
Several clinical studies incorporating this classification system have
appeared in recent years, and have confirmed that specific histopatho-
logical types of focal dysplastic lesions are indeed associated with more
or less specific imaging, neurophysiological, functional and prognostic
features. Some of these studies will be presented in the symposium.
IMAGING, CLINICS, AND HISTOPATHOLOGY OF FOCAL
CORTICAL DYSPLASIAS
R. Spreafico (Istituto Nazionale Neurologico “C. Besta,” Milano, Italy)
Since the original observation of Taylor et al. (1971) the focal corti-
cal dysplasia (FCD) are increasingly revealed by high resolution MRI
and most of the patients with this type of malformation are affected by
drug resistant epilepsy and thus candidate for epilepsy surgery. How-
ever it should be noticed that despite the technological improvements,
MRI is still failing in detecting some of the cortical malformations in
about 10–20% of the cases recognized by neuropathological studies af-
ter surgery. While some forms of MCD are clearly defined, FCD are
variously grouped using disparate terminology and numerous attempts
have been made in the last ten years to classify the FCD. Recently the
classification proposed by Tassi et al. (2002) subsequently refined by
Palmini et al (2004) are recognising four main distinct morphological
subtypes: type IA architectural dysplasia (AD), Type IB cytoarchitec-
tural dysplasia (CD),Type II A Taylor’s type dysplasia (TFCD) without
balloon cells and Type II B Taylor’s type dysplasia (TFCD) with balloon
cells. This classification based on easily recognized histopathological
characteristics, avoiding complicated terminology, were confirmed not
only by more sophisticated immunocytochemical procedures but also
by electroclinical data, MRI characteristics and localization and by the
surgical outcome of the operated patients. These data indicate that the
recognized subgroups of FCD define clinically homogeneous groups and
that a presumptive diagnosis and prognosis could be possible based on
electroclinical and imaging data.
DIFFERENTIAL EXPRESSION OF CYTOKINES AND NEU-
ROTROPHIN RECEPTORS IN MALFORMATIONS OF CORTI-
CAL DEVELOPMENT
E. Aronica (Department of (Neuro)Pathology, Academic Medical Cen-
ter, University of Amsterdam, The Netherlands)
Malformations of cortical development (MCD) are recognized causes
of epilepsy in children and young adults. Although genes that are respon-
sible for selected MCD have been identified, the histogenesis of several
MCD (such as focal cortical dysplasia, FCD and glioneuronal tumors,
GNTs) is not completely understood and it is still unclear whether differ-
ent MCD share common pathogenetic and epileptogenic pathways. An
increasing number of observations suggest an important and complex
role for both neurotrophins and inflammatory cytokines in epilepsy-
associated pathologies.
We have analyzed the expression of both high (trkA, trkB, trkC) and
low affinity (p75) neurotrophin receptors (NTRs) in FCD and GNTs
specimens from patients with medically intractable epilepsy. All three
trk receptors were encountered in high levels in the neuronal compo-
nent of these developmental lesions. Strong trkA, trkB and trkC IR was
found in neurons of different size, including dysmorphic neurons and
balloon cells in FCD cases. Astrocytes showed predominantly IR for
trkA. In addition P75NTR IR was observed in a population of cells of the
microglial/macrophage lineage. These data indicate that the neuronal
and the glial components of both neoplastic and malformative devel-
opmental lesions can be controlled by neurotrophin influences through
specific receptors, potentially influencing both the development and the
epileptogenicity of these lesions.
The presence of NTRs on glial cells suggests a role for neurotrophins
in the regulation of several aspects of glial cell activation and function.
Interestingly, not only astrocytes, but also microglial cells are highly
represented within MCD specimens and may contribute to epilepto-
genesis through production of inflammatory cytokines, such as IL-1β.
IL-1β may also exert neuroprotective effects via production of neu-
rotrophins. The specific cellular distribution of IL-1β and its func-
tional receptor (IL-1RI) and the possible involvement of the IL-1β sys-
tem in the complex functional network of MCD will be presented and
discussed.
ARCHITECTURAL MALFORMATIONS OF CORTICAL DE-
VELOPMENT: NEUROPATHOLOGICAL APPROACHES TO
AN ENIGMA
I. Blu¨mcke (Department of Neuropathology, University of Erlangen,
Germany)
Neurosurgical treatment modalities in epilepsy patients with cortical
dysplasia offer the intriguing opportunity to microscopically confirm the
structural correlate of epileptogenic brain lesions. However, the spec-
trum of neuropathological alterations is large ranging from prominent
to only minute changes and there is yet no international classification
system available to reliable predict postsurgical outcome. Histopatho-
logical lesions associated with Focal Cortical Dysplasia (FCD) type I
include architectural disturbance of cortical lamination as well as ec-
topic neurons in white matter. However, two major subgroups of pa-
tients can be identified. Almost 30% of patients with hippocampal
sclerosis present with type I FCD within the ipsilateral temporopolar
region and neurosurgical resection associates with successful seizure
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control. On the other hand, young children with catastrophic epilep-
sies often show neuroradiological features of FCD, a hypoplastic neo-
cortex within the affected hemisphere and microcolumar arrangements
of cortical layers as histopathological hallmark. Neurosurgical resec-
tion do not always sufficiently control seizure activity in these young
patients. Whether similar pathomechanisms operate in both patient
groups remain to be determined and the common diagnosis of FCD
type I may not reliably clarify different clinicopathological histories and
outcome.
FCD type II present with gross histopathological changes includ-
ing dysplastic neurons (FCD type IIA) and/or balloon cells (FCD type
IIB). These lesions can be readily observed in MRI (transmantle sign)
and histopathological examination of surgical specimens usually cor-
roborates the diagnostic subtype. However, there may be additional
clinico-pathological variants hidden and our recent molecular-biological
approach targeting the insulin–growth factor receptor cascade indicate
that FCD type IIA and IIB are distinct. The latter appears to share patho-
genetic similarities with cortical tubers, although most patients fail to
present with additional stigmata of TSC.
Neuropathological examination of surgical specimens is mandatory
to classify variants of cortical dysplasias and to allow for subsequent
molecular-genetic and/or –biological studies. This neuropathological ap-
proach will help to establish a comprehensive classification system as
prerequisite to support the design of clinical outcome studies and targeted
search for new antiepileptic drugs.
MOLECULAR GENETICS OF FOCAL CORTICAL DYS-
PLASIAS WITH AND WITHOUT TAYLOR TYPE BALLOON
CELL
A. Becker (Department of Neuropathology, University of Bonn Medical
Center, Germany)
Focal cortical dysplasias (FCD) constitute glioneuronal lesions, which
predispose individuals to recurrent pharmacoresistant seizures. In FCD,
a broad spectrum of structural changes can be observed, that is related
to changes in migration and differentiation of neural precursors in corti-
cal development. A frequent variant of FCD is composed of dysplastic
cytomegalic neurons and “Taylor”-type balloon cells (FCDIIb), distin-
guished from FCDIIa that lack balloon cells. Those resemble cells, which
are found in cortical tubers in the autosomal dominant inherited disor-
der tuberous sclerosis (TSC). This phacomatosis is caused by mutations
in the TSC1 or TSC2 genes. Recent data have indicated a pathogenetic
role of TSC1 also in FCDIIb. TSC1 represents a key factor in the phos-
phatidylinositol 3-kinase (PI3K) pathway. In order to further understand
the molecular pathology of FCDIIb, we have analyzed additional major
components of the PI3K-cascade in FCDIIb, i.e., PTEN and Akt, which
operate upstream of TSC1.
Mutational screening of PTEN was performed by single-strand con-
formation polymorphism analysis (SSCP) in 37 FCDIIb. Immunohisto-
chemistry with antibodies against phospho-Akt (Ser473) was carried out
in FCDIIb (n = 33).
SSCP in combination with laser assisted microdissection revealed a
silent polymorphism of PTEN in exon 2 (n = 2/37 vs. 1/100 controls)
and another polymorphism in exon 8 (n = 1/37 vs. 0/100 controls).
An FCDIIb showed a mutation, i.e. amino-acid exchange at nucleotide
position 834 (PTEN cDNA, GenBank AH007803.1) in exon 8 with re-
placement of phenylalanine by leucine (F278L). Intriguingly, increased
immunoreactivity for phospho-Akt was observed in balloon cells and
dysplastic neurons but not in adjacent normal CNS.
Increase of phosphorylated Akt is in line with altered PI3K pathway
signaling in FCDIib. The present findings constitute an important pre-
requisite in order to functionally address epileptogenesis of glioneuronal
lesions.
Supported by DFG SFB TR3, BMBF and BONFOR.
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Seizures, hippocampus, and memory
FUNCTIONAL APPROACH TO MEMORY DEFICITS ON HIP-
POCAMPAL DAMAGE
H. Markowitsch (Physiological Psychology, University of Bielefeld,
Bielefeld, Germany)
Memory deficits belong to the most frequent concomitants of epilepsy-
related hippocampal degeneration. Nevertheless, present-day neuro-
science requires a refined determination of structure-function relations
between areas within the hippocampal formation and different memory
systems. For one, hemispheric-specificity has to be taken into account:
the left hemisphere is seen as primarily engaged in verbal and the right
one in nonverbal memory functions. Secondly, within the hippocampal
formation there is an unequal sensitivity towards epilepsy-related dam-
age (e.g., the special vulnerability of the CA1 region within the hip-
pocampus proper). And thirdly, neuropsychological and neuroscientific
evidence strongly emphasises the existence of process-specific mem-
ory functions (‘implicit memory,’ ‘explicit memory’) and of different
subsystems of memory.
It is distinguished between five basic long-term memory systems:
procedural memory, priming, perceptual, semantic, and episodic mem-
ory systems. Different neuroanatomical networks are proposed to be
active during encoding, storage, and retrieval of information belonging
to each of these systems. Especially the hierachically highest memory
systems (semantic and episodic memory) are strongly dependent on a
well-functioning hippocampal system.
Aside from manifest tissue damage, the high number of glucocorticoid
receptors in the hippocampal region makes this structure vulnerable to
environmental stress and may lead to mnestic block syndromes.
Epilepsy-related memory deficits as well as other causes of hip-
pocampal damage/dysfunction-related memory deficits will be discussed
both from structural-anatomical and from functional-behavioural view-
points.
MEMORY PERFORMANCE IN EPILEPSIES IS GENETICALLY
INFLUENCED?
A. Gambardella (Universita` Magna Graecia, Cattedra di Neurologia,
Catanzaro, Italy)
No abstract received.
SPECIFIC LONG-TERM EFFECTS ON MEMORY AFTER
SURGERY
W. Alpherts (Epilepsy Institute of the Netherlands (SEIN))
Resections in the left temporal lobe (LTL) that include hippocampus,
amygdala and lateral neocortex are generally accompanied by a decline
in verbal memory. There are only a few publications with a follow-up
of one year or two years after surgery. The effect of surgery on memory
in the long-term is not fully known. The one study with a comparison
of early (one year post-op) and late (at least 9 years post-op) cognitive
changes showed a long-term decline of verbal memory in LTL.
We assessed verbal memory performance as measured by a verbal
learning test before surgery, and at three specific times after temporal
lobe surgery: six months, two years and six years in 85 patients. An
amygdalo-hippocampectomy and a neocortical temporal resection be-
tween 2.5 and 8 cm were carried out in all patients. LTL patients showed
an ongoing memory decline for consolidation and acquisition of verbal
material (both 2/3 SDs) for up to two years after surgery. RTL patients at
first showed a gain in both memory acquisition and consolidation, which
vanished in the long-term. Breaking the group up into a mesiotempo-
ral (MTS) group and a non-MTS group showed clear differences. The
group with pure MTS showed an overall lower verbal memory perfor-
mance than the group without MTS, in the LTL group more pronounced
than in the RTL group. After surgery, both pathology groups showed
an ongoing decline up to two years post-op, but the degree of decline
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was greater for the LTL patients with MTS compared with the non-MTS
group.
Becoming and remaining seizure free after surgery does not result in
a better performance in the long-term. Predictors of postoperative verbal
memory performance at 6 years after surgery were: side of surgery, pre-
operative memory score and age.
HIPPOCAMPAL STIMULATION INDUCES MEMORY
CHANGES?
G. Alarco´n (King’s College Hospital, London, UK)
We investigated the role of medial temporal structures (MT) on recog-
nition memory by studying the effects of unilateral and bilateral electrical
stimulation of MT with single pulses during encoding and recognition
of a yes-no recognition memory test in patients with epilepsy implanted
with bilateral electrodes in MT structures. One millisecond electrical
pulse was time-locked to item presentation during encoding and recog-
nition. Four material types were presented (words, objects, geometrical
figures and faces). It was assumed that each electrical pulse disrupts
normal function during approximately 400 ms (the duration of the early
response). All 18 patients studied carried out a baseline memory test
(with no stimulation), a memory test with stimulation of right MT and a
memory test with stimulation of left MT. Six of the 18 patient carried out
an additional memory test with bilateral stimulation of MT. Performance
during baseline was compared with performance during unilateral and
bilateral stimulation. No differences were found in memory performance
between baseline and unilateral stimulation, either in the total score or
in material-specific deficits. In contrast, a pronounced decrease (50%)
in total memory scores was seen when bilateral stimulation was applied
(p<0.05). Decrements in performance with bilateral stimulation com-
pared to baseline were seen for all materials, and the difference was
significant for words and faces (p<0.05). The findings confirm that lo-
calised 1-ms electrical pulses can disrupt cognitive function and that MT
are involved in processing recognition memory. The presence of mem-
ory deficits only with bilateral stimulation suggest that memory is stored
in both hippocampi and processed independently by both hippocampi.
This technique could be used to predict memory deficits of unilateral
hippocampal resections.
ANTIEPILEPTIC DRUG TREATMENTS AND MEMORY
CHANGES
R. Ka¨lvia¨inen (Kuopio Epilepsy Center, Department of Neurology, Kuo-
pio University Hospital, Finland)
Slowing of mental or motor speed and attentional deficits are well
known adverse effects of the many antiepileptic drugs (AEDs). It is
generally assumed that AEDs do not specifically impair memory and
that patients’ memory complaints are secondary to the changes in their
attentional level or mental processing speed induced by AEDs. How-
ever, underlying pathologies in the mesial temporal structures and their
associated neocortices, epileptic discharges, and untoward effects of
AEDs alone or together may disturb memory formation, retention, or
retrieval.
There are several lines of evidence suggesting an independent po-
tential for AEDs to induce or exacerbate memory impairment. Patients
treated with monotherapy show fewer cognitive effects, including mem-
ory deficits, than those treated with polytherapy, particularly at higher
doses. In animal studies on spatial working memory in nonepileptic
rats, the largest disruptive effects on working memory, as measured by
percentage of correct responses, are produced by the benzodiazepines,
phenobarbital and ethosuximide. More modest but significant disruption
is produced by carbamazepine and topiramate, whereas tiagabine, val-
proate, gabapentin, phenytoin, lamotrigine, and levetiracetam are with-
out significant effects on spatial working memory. Studies in healthy
volunteer adults and patients with epilepsy have demonstrated that sev-
eral AEDs can impair memory and that there appear to be differential
effects across AEDs. Most significant changes have been demonstrated
with benzodiazepines and phenobarbital, whereas newer drugs seem to
produce fewer problems. Elderly patients and children appear to be at
the greatest risk. Unfortunately, evaluation of memory impairment has
been limited in most studies.
In conclusion, although the memory impairments in epilepsy are mul-
tifactorial in nature, AEDs can clearly reduce memory performance. At
the moment, however, there are inadequate data to delineate completely
the independent effects of AEDs on memory and to determine the inter-
action of AEDs with seizures, interictal discharges, and underlying brain
disease.
Sunday July 2, 2006
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Discussion Group Session
Ictal and interictal autonomic dysfunction: symptoms,
signs, and potential consequences
AUTONOMIC SEIZURES: AN OVERVIEW OF SEMIOLOGY
AND ANATOMICAL SUBSTRATE
C. Baumgartner (Department of Neurology, Medical University of
Vienna, Austria)
Autonomic symptoms during epileptic seizures can either represent
the sole or predominant seizure manifestation as in simple autonomic
seizures or accompany complex partial or generalized seizures. Auto-
nomic symptoms consist of cardiovascular changes, respiratory manifes-
tations, gastrointestinal symptoms, cutaneous manifestations, pupillary
symptoms, genital and sexual manifestations as well as urinary symp-
toms. Autonomic symptoms are mediated by an activation of the central
autonomic network which comprises (1) the insular and medial pre-
frontal cortex, (2) the central nucleus of the amygdala and the bed nu-
cleus of the stria terminalis, the preoptic region and the hypothalamus,
(4) the midbrain periaqueductal gray matter, (5) the pontine parabrachial
Ko¨lliker-Fuse region, (6) the nucleus of the solitary tract and (7) the in-
termediate reticular zone of the medulla. Inputs to the CAN are multiple,
including viscerosensory inputs relayed on the nucleus of the tractus soli-
tarius and humoral inputs relayed through the circumventricular organs.
The CAN in turn controls preganglionic sympathetic and parasympa-
thetic, neuroendocrine, respiratory and sphincter motor neurons. Due
to a hemispheric specific representation of the CAN certain autonomic
symptoms provide lateralizing and sometimes localizing information on
the seizure onset zone. Autonomic symptoms indicating a seizure on-
set in the non-dominant hemisphere include ictal vomiting and retching,
spitting automatisms and ictal urinary urge. Autonomic symptoms range
from subtle seizure manifestations which become apparent only during
meticulous seizure analysis to severe, sometimes life-threatening events.
Cardiovascular and respiratory autonomic symptoms are discussed as the
mechanisms underlying sudden unexpected death in epilepsy (SUDEP).
When autonomic symptoms represent the sole seizure manifestation,
they can pose problems in the differential diagnosis against various non-
epileptic conditions. Finally, autonomic seizure symptoms open a unique
window on the functional organization of the central autonomic network
and on brain function in general.
ICTAL CARDIAC ARRHYTHMIA
C. Elger (University of Bonn, Department of Epileptology, Germany)
Heart rate alteration in relation to epileptic seizures has been a well-
known phenomenon for over 50 years. A number of publications exist
which deal particularly with TLE. The aim of this presentation is to
provide a brief summary of the published data and to add the results we
obtained from the presurgical evaluation.
When studying ictal cardiac arrhythmia (ICA), two opposing views
are of interest: the first concerns the consequences of ICA; the second, its
causes. For a few patients, the consequences may result in dramatic risks
when extreme tachy-/bradycardia or cardiac arrest are involved and this
may be one of the reasons SUDEP is assumed. Inversely, searching for
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the causes of ICA may contribute to the differential diagnosis or classi-
fication and, hypothetically, even to the individual focus localization. In
this field, the standard reference is still Blumhardt’s work. He documents
a high incidence of tachycardia (91%) for TLE patients and a 57% HR
increase prior to seizure onset.
We performed a retrospective data analysis of 82 consecutive pa-
tients who were examined during the presurgical evaluation. Inclu-
sion criteria were: final diagnosis and a successful operation for either
frontal or temporal lobe epilepsy. A total of 700 seizures were analyzed,
the majority of which were done via intracranial (hippocampal depth,
temporal strip, orbitofrontal grid) electrodes. From R-R intervals, ic-
tal heart rate courses were automatically calculated and parameterized.
Our results for the TL seizures generally confirm those of Blumhardt
(tachycardia > 90%). Compared to TL seizures, tachycardia exceeding
160 bpm occurred significantly more often in FL seizures (23%). The
most exciting aspect reported in this study was finding that the mi-
croanalysis of the HR course in correlation with intracranial registra-
tions can directly reflect the waxing and waning involvement of cerebral
structures.
METHODS TO ASSESS CARDIOVASCULAR REGULATION IN
EPILEPSY
H. Ansakorpi (University of Oulu, department of Neurology, Finland)
It is well known that the heart is one of the most delicate organs reflect-
ing cardiovascular autonomic regulatory function. The heart rate (HR)
during normal sinus rhythm is not uniform but the interval between the
two R spikes in the electrocardiographic (ECG) recordings fluctuates.
Respiration, neurohumoral factors and cardiovascular regulation are the
main effectors on the RR interval. HR variation reflects the competence
of this regulatory system, diminished HR variation being a sign of dys-
function of the autonomic nervous system.
Cardiovascular autonomic reflexes in humans are essential for the
maintenance of arterial blood pressure (BP) during the orthostatic stress
adopting a standing posture and for preventing wide fluctuations of ar-
terial BP in response to adaptive responses. To examine cardiovascu-
lar reflexes, a standardised laboratory test pattern, in which HR and
BP responses at rest and to certain stimuli are measured, is often
used. The method is easy to perform and it has an established role
as the most used method assessing autonomic functions. The test pat-
tern includes the measurement of HR and BP during normal and deep
breathing, the Valsalva maneuver, the tilt test and the isometric work
test.
HR variability can also easily be analysed from 24-hour ECG record-
ings. Information about tonic autonomic effects on the heart can be ob-
tained by the traditional time and frequency domain measures based
on linear fluctuations of HR. Since the genesis of HR variability also
involves nonlinear mechanisms, several newer methods have been de-
veloped to quantify the complex HR dynamics. Whereas the magnitude
of the variability is assessed by the traditional HR variability measures,
methods of analysis derived from the nonlinear system theory provide
information on the quality, scaling and correlation properties of the HR
signal.
HEART RATE VARIABILITY IN EPILEPSY: POSSIBLE RELE-
VANCE FOR SUDEP
T. Tomson (Department of Clinical Neuroscience, Karolinska Institutet,
Sweden)
Impairment of cardiovascular regulation has been discussed as a pos-
sible contributing mechanism for SUDEP. Autonomic cardiac control
can be assessed clinically by analysis of heart rate variability (HRV)
based on ECG recordings. HRV is of special interest in the context of
SUDEP since a reduced HRV has been shown to predict sudden death
in other conditions than epilepsy. Several studied have assessed HRV
in patients with epilepsy to explore whether there are any indications
of an impairment of the autonomic cardiac control and in particular if
HRV is reduced in populations with a particularly high risk of SUDEP.
Most cross-sectional studies suggest a decreased HRV, and thus an im-
paired autonomic cardiac regulation, in patients with chronic temporal
lobe epilepsy. This decrease might be more pronounced during night
than at daytime. The reason for the reduced HRV is probably multifacto-
rial and possibly related to the epilepsy, the underlying etiology, as well
as the antiepileptic drugs. Epilepsy surgery candidates are considered
to be at particularly high risk of SUDEP. Patients rendered seizure free
after epilepsy surgery, seem to have a lower risk whereas the incidence is
high among surgery failures. Impaired HRV has been reported in studies
of epilepsy surgery candidates. Interestingly, preoperative HRV was de-
creased among surgery failures and significantly lower than in patients
seizure free after temporal lobe surgery. Data on the effects of epilepsy
surgery on HRV are more conflicting. Nevertheless, the available infor-
mation confirms that patients with epilepsy have a reduced HRV and
suggest that this decrease is more pronounced among those with a high
SUDEP risk. This indicates that a decreased HRV might be a marker
for an increased risk of SUDEP in line with recent preliminary observa-
tions of lower HRV in patients who later died in SUDEP compared with
epilepsy and nonepilepsy controls.
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9:30 – 11:30
Hall 5C
Discussion Group Session
Neonatal seizures
AETIOLOGY AND OUTCOME OF NEONATAL SEIZURES
M. Levene (University of Leeds, UK)
Neonatal convulsions are common and can manifest themselves in
many ways. There is a very varied aetiology but are due in full-term
infants most commonly to hypoxic-ischaemic injury. Other important
causes include hypoglycaemia, inborn errors of metabolism, intracranial
haemorrhage, cerebral artery infarction and infection.
The prognosis depends to a relatively large degree on the cause of the
convulsions. Moderate HIE has a 25% risk of disability and severe HIE
has almost 90% risk of death or disability. It is difficult to disentangle
the effect of the convulsions from their cause.
Recent animal studies have mimicked the relatively short-lived but fre-
quent seizures seen in the newborn. These studies have shown that short
convulsions in the neonatal period do not increase the rate of neuronal
necrosis/apoptosis but affect the brain functioning later in adolescent life
of the animal. In addition it is thought that later exposure to convulsions
have a worse outcome when the animal has had sensitizing neonatal
convulsions.
This recent data has shifted the pendulum more towards effective and
safe anticonvulsant management of neonatal seizures.
DIAGNOSING NEONATAL SEIZURES: THE ROLE OF THE
EEG
R. Pressler (Department of Clinical Neurophysiology, National Hospital
for Neurology, UK)
The EEG is an important investigation in the diagnosis and treatment
of neonatal seizures. Electrophysiological seizures consist of rhythmic
activity with a sudden and distinct beginning and end lasting >10 sec
(>5 sec if background activity is abnormal). They may consist of sharp
waves or spikes, monomorphous delta or theta waves, sequence of alpha
or beta frequencies or transient suppression. Neonatal seizures are nearly
always partial, but secondary generalisation is not uncommon.
Seizures are not usually sustained, with 97% lasting less than 9 min-
utes. In preterm infants seizure duration is shorter than at term. Multi-
focal seizures (simultaneous independent focal electrographic seizures)
are common in severe encephalopathies and are more often associated
with neurological sequelae than unifocal seizure discharges. A charac-
teristic feature of neonatal seizures is the phenomenon of electroclinical
dissociation: seizures can be electroclinical, electrographic (subclinical)
or clinical only. Treatment with antiepileptic drugs increases electroclin-
ical dissociation and electrographic seizures may persist without clinical
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correlate. Subtle seizures are the most common seizure type in term and
preterm infants and may manifest as ocular, oral or autonomic phenom-
ena, or fragmentary body movements. Prolonged video-EEG has shown
that the majority of infants with subtle seizures will exhibit rhythmic
epileptiform activity at least during some seizures. The absence of ic-
tal EEG discharges, however, does not necessarily rule out seizures.
Neonatal status is currently defined as a total seizure time occupying
50% of a 30 minutes recording. Discharges of less than 10 s duration
have been termed BIRDs (Brief Interictal Rhythmic Discharges or Brief
Ictal Rhythmic Discharges) and are of uncertain significance. However,
BIRDs have been associated with seizures in the same or subsequent
EEG and with poor neurodevelopmental outcome.
THE ROLE OF AMPLITUDE INTEGRATED EEG (aEEG)
L. de Vries (Wilhelmina Children’s Hospital, Utrecht, Netherlands)
Immediate access to aEEG monitoring in full-term infants with neona-
tal encephalopathy (NE), often admitted at night or during the weekend is
one of many advantages of the amplitude integrated EEG (aEEG), which
is easy to learn by senior and junior doctors as well as the nursing staff.
aEEG will provide immediate information about the background activity
and presence of seizures within hours after birth. This information will be
required as soon as possible after birth for selection of patients for neuro-
protective intervention, and for early prediction of neurodevelopmental
outcome.
A rapid rise of both the lower and the upper margins of the aEEG
tracing is suggestive of an ictal discharge. Seizures can be recognised as
single seizures, repetitive seizures and as a status epilepticus. The latter
usually looks like a “saw-tooth” pattern. Correct interpretation is greatly
improved by simultaneous raw EEG recording available on the different
digital devices, which are now mostly used. Since the increased use of
continuous monitoring, it has become apparent that subclinical seizures
are common and tend to be seen following administration of the first
antiepileptic drug. Using a single channel or even using two channels
will not allow detection of all seizures. Due to the nature of the technique
it is clear that very brief seizure activity as well as focal seizure activity
will be missed.
The long duration of the aEEG registration however appears to out-
weigh the limitations of obtaining detailed information during a much
shorter, 30 minutes standard EEG registration, which is usually available
in the neonatal care setting.
NEONATAL SEIZURE DETECTION: OTHER PHYSIOLOGI-
CAL MODALITIES
G. Boylan (Department of Paediatrics & Child Health, University Col-
lege Cork, Ireland)
Seizures in the newborn are notoriously difficult to diagnose and clin-
ical signs may be very subtle or completely absent. In addition, there is
considerable mismatch between clinical and electrographic diagnosis of
neonatal seizure. Diagnosis becomes even more problematic following
antiepileptic treatment, when clinical suppression of seizure activity is
common.
Multichannel video-EEG monitoring is the only reliable method avail-
able for the detection of all neonatal seizures. Video-EEG does require
special expertise for acquisition and interpretation and this expertise is
not always available to many neonatal intensive care units (NICU), par-
ticularly on a 24-hour basis. Many clinicians rely instead on simpler
systems that provide the compressed and filtered amplitude integrated
EEG (aEEG) signal. These systems have proven very useful for mon-
itoring background EEG activity but have some limitations for seizure
detection in the hands of nonexperts (Rennie JM, Chorley G, Boylan
GB, Pressler R, Nguyen Y, Hooper R. Non-expert use of the cerebral
function monitor for neonatal seizure detection. Arch Dis Child Fetal
Neonatal Ed 2004;89(1):F37–F40).
It is not surprising therefore that there have been many attempts to
automatically detect seizures in neonates using the EEG. To date, none
of these methods have proven suitable for clinical use (Faul S, Boylan
GB, Connolly S, Marnane WP, Lightbody G. An Evaluation of Auto-
mated Neonatal Seizure Detection Methods. Clinical Neurophysiology,
2005;116(7):1533–1541). Automated neonatal seizure detection is how-
ever important work, and is a rapidly developing field. Newly emerging
signal processing methods are constantly being applied to the problem
of seizure detection using EEG.
The aims of this presentation are to:
• Examine the EEG characteristics of neonatal seizures
• Review current automated neonatal seizure detection tech-
niques
• Discuss changes that occur in other physiological signals such
as heart rate, respiration and cerebral blood flow during neonatal
seizures
• Explore the possibility of combining information from many
physiological sources to increase neonatal seizure detection relia-
bility in the NICU.
TREATMENT OF NEONATAL SEIZURES
J. Rennie (University College Hospital, London, UK)
The first line treatment for neonatal seizures (phenobarbitone) has not
changed for over thirty years. Phenobarbitone is effective in controlling
seizures in about a third to a half of babies, and is more likely to work if
the seizure burden is low and the background EEG is normal (Boyland
GB, Rennie JM, Pressler RM, et al. Archives of Disease in Childhood,
2002;86:485–489). These cases have a better prognosis than those whose
seizures are resistant to treatment and whose seizure burden is large.
Phenobarbitone has theoretical disadvantages but there is considerable
experience with it, and in our view it should remain the drug of first
choice. There is no evidence that giving a dose of more than 40 mg/kg
is of benefit.
Babies whose seizures are resistant to treatment with phenobarbitone
are a high risk group. Many different AEDs have been tried as sec-
ond line, although few have been evaluated using EEG assessment of
the response. Amongst the AEDs which have been evaluated with EEG
quantification of the seizure burden, phenytoin and has been shown to
be of some benefit (Painter MJ, Scher MS, Stein AD, et al. N Engl J
Med, 1999;341:485–489), and others report good experiences with lig-
nocaine (Hellstrom-Westas L, Westgren U, Rosen I, Svenningsen NW,
Acta Paediatrica Scandinavica, 1988;77:79–84). Experience with mida-
zolam is variable; there is one report of 100% control after a bolus of
150 microg/kg followed by an infusion rate starting at 60 microg/kg/min
and escalating to a very high dose of 1080 microg/kg/hr (Castro Conde
JR, Borges AAH, Martinez ED et al. Neurology, 2005;64:876–879). In
contrast, we did not find a midazolam loading dose of 60 microg/kg fol-
lowed by an infusion rate of 150 microg/kg/hr to be of benefit (Boylan
G, Rennie JM, Chorley G, et al. Neurology, 2004;62:486–488).
Much work remains to be done in this important area. Advances in
the study of neonatal seizures at a cellular level, using animal models,
suggest that drugs such as levetiracetam (Keppra) would prove more
effective than existing agents.
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Lessons learned from local epidemiological studies
EPIDEMIOLOGY OF EPILEPSY IN ESTONIA
A. ˜Oun (Department of Neurology and Neurosurgery, University of
Tartu, Estonia)
Epidemiological data about epilepsy from central and eastern Europe
is controversial. A modern study on prevalence and incidence of epilepsy
in Estonia has been carried out on children–prevalence of active epilepsy
was 3.6/1,000, and incidence 45/100,000 person-years being essentially
similar to those in developed countries. In an adult populaton review of
all databases and lists related to epilepsy in Tartu supplemented by re-
examination of patients to identify all persons with active epilepsy aged
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≥20 years on January 1, 1997. Special attention was paid to extensive
adoption of definitions and criteria proposed by Guidelines for epidemi-
ologic studies. The incidence rate was 35/100,000 person-years. The
age-specific rates tended to increase with advancing age. The prevalence
rate was 5.3/1,000. The largest syndromic categories were localization-
related symptomatic and cryptogenic epilepsies, which are very likely
due to the age-distribution of the study. The risk factors for epilepsy were
identified in 39.6% cases of the prevalent cases. Of the subjects 19% did
not take an entiepileptic drug on the prevalence day, 83% of them were
taking a single drug. The most common agent was carbamazepine (68%),
followed by barbiturates. Epidemiologic rates in the adult, as well as in
the total population of Tartu was comparable to those reported from the
developed countries. The large percentage of medication-free epileptics,
notably small figures for polytherapy, and the associating low aggre-
gate antiepileptic drug sales in Estonia, indicate a tendency for moderate
medication in the epileptic population.
EPIDEMIOLOGY OF EPILEPSY IN SCANDINAVIAN
COUNTRIES
L. Forsgren (Department of Neurology, Umea˚ University Hospital,
Umea˚, Sweden)
Purpose: To give an overview of results from epidemiological studies
on epilepsy in the Scandinavian countries. Studies from Iceland are also
included.
Methods: Survey of epidemiological studies from Denmark, Iceland,
Norway and Sweden published during the last 30 years. Focus on results
from population-based studies.
Results: Prevalence and incidence studies confirm or have later been
confirmed by results from studies in other high income countries in the
world. The prevalence of active epilepsy is around 5–6 per 1000 and
slightly more common in males than females in most studies. Around
40% of patients in epilepsy populations have been seizure free for at
least one year, and 10–20% have one or more seizures per week.
The annual incidence of epilepsy is 35–45 per 100,000 and 45–60
when single unprovoked seizures are included. Young children and in
the elderly have the highest age-specific incidence. Stroke is the most
common identified cause of epilepsy, followed by cerebral tumors, early
brain damage and dementing diseases.
Patients with remote symptomatic causes of epilepsy have signifi-
cantly higher recurrence rate for seizures compared with patients with
unknown cause. The effect of treatment during the first year is a signifi-
cant predictor for long-term prognosis.
Mortality is increased in patients with remote symptomatic etiology,
particularly during the first years following diagnosis.
Learning disability/mental retardation (MR) occurs in 20–25% of
adults and 40% of children with active epilepsy. In a MR-population
around 20% have active epilepsy. The epilepsy in this group is often
poorly controlled with at least 10% having daily seizures. Mortality is
increased.
Conclusions: Epidemiological studies from Scandinavia and Iceland
have provided important contributions to our knowledge on causes, mag-
nitude and prognosis of epilepsy.
EPIDEMIOLOGY OF EPILEPSY IN FINLAND
T. Kera¨nen (University Hospital of Tampere, Finland)
No abstract received.
EPIDEMIOLOGY OF EPILEPSY IN RUSSIA
A. Guekht (Russian State Medical University, Russia)
Rationale: The epidemiological study of epilepsy in people over 14
years old has been performed in 12 regions in European and Siberian
parts of Russia. The total population of the studied regions was 517642.
In each region studied population was representative and sufficient (for
instance, 109436 in Moscow, 28609 in Irkutsk).
Methods: All established or suspected cases were identified from
available medical information sources. Possible epilepsy cases were then
evaluated by the neurologists or epileptologist. Majority of patients un-
derwent EEG, and a part–neuroradiologic investigations or both.
Results: The crude prevalence rate of active epilepsy was 3.39 per
1000, age-adjusted rate was 3.41 per 1000. Men had higher prevalence
rate than women (4.53 vs 2.49; age adjusted −4.49 vs. 2.51, p < 0.0001).
The highest age-specific prevalence was found in patients 50–59 years
old (4.21 per 1000). The prevalence of epilepsy in the Eastern (Siberian)
regions was significantly higher then in the Western (European) regions
(4.11 vs. 2.82 per 1000, p < 0.0001). Partial seizures with or with-
out secondary generalization were more common (78%) than general-
ized seizures. Localization-related symptomatic or cryptogenic epilep-
sies were the largest syndromic category. No cause of epilepsy was iden-
tified in 40% of patients. The most important etiologic factors of epilepsy
in all regions were brain trauma, stroke, tumor, perinatal pathology and
infections.
Significant proportion of patients, especially in Siberian regions, re-
ceived suboptimal treatment. That explained the high level of disability.
It was significantly higher in Siberian regions (66.2%) compared to Eu-
ropean (39.6%, p < 0.0001).
Conclusions: Epidemiological data on epilepsy in European part of
Russia suggest a lower prevalence than in Siberian part. Special attention
to improvement of epilepsy care is required.
Acknowledgement: The author thank Professors W. Hauser and
E. Gusev for the most valuable recommendations during the study, and
Drs. Balhanova, Golovanova, Kabakov, Kotov, Milchakova, Pisova, Sh-
prakh, Spirin, Volkova for their contribution.
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Plastic modifications during the transition between a
normal brain and an epileptic one
THE ROLE OF NEUROGENESIS FOR THE DEVELOPMENT
OF AN EPILEPTIC FOCUS IN A MOUSE MODEL OF TEMPO-
RAL LOBE EPILEPSY
J. Fritschy (University of Zurich, Institute of Pharmacology and Toxi-
cology, Switzerland)
Adult hippocampal neurogenesis is enhanced in response to acute
seizures. However, the significance of neurogenesis in temporal lobe
epilepsy (TLE) remains disputed. Unilateral intrahippocampal injection
of kainate (KA) in adult mice models morphological features (e.g., neu-
ronal loss, granule cell dispersion) and occurrence of chronic recurrent
seizures observed in human TLE. In this model, KA injection transiently
increased cell proliferation bilaterally in the subgranular zone (SGZ). As
a result, neurogenesis was stimulated in the contralateral dentate gyrus.
In contrast, the epileptic hippocampus exhibited strongly reduced neuro-
genic potential, even after onset of recurrent seizures. Therefore, neuro-
genesis does not contribute towards the formation of the epileptic focus
and may be affected when granule cell dispersion occurs. To investi-
gate further the relationship between epileptogenesis and neurogenesis,
we compared the differentiation of cells born shortly before and after
KA injection. Immunohistochemical staining for doublecortin and PSA-
NCAM, two markers of young neurons, revealed rapid down-regulation
of both markers ipsilaterally, whereas they were increased transiently
on the contralateral side. To determine whether KA treatment directly
affects SGZ neural progenitors, dividing cells were prelabeled with 5’-
bromo-2’deoxyuridine (BrdU) treatment before unilateral injection of
KA. Double staining with the proliferation marker PCNA showed that
prelabeled BrdU cells survived KA exposure and proliferated bilaterally.
Unexpectedly, the neuronal differentiation of these cells, as assessed af-
ter two weeks with doublecortin and NeuN triple staining, occurred to
the same extent as in control. Therefore, SGZ progenitor cells that were
committed to a neuronal phenotype before KA treatment completed their
differentiation despite the rapid down-regulation of doublecortin and
PSA-NCAM. These findings suggest impaired fate commitment of pro-
liferating cells in the lesioned dentate gyrus. Loss of neurogenesis in this
TLE model likely reflects an irreversible alteration of the SGZ germinal
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niche during development of the epileptic focus and may therefore be
relevant for human TLE.
ACCUMULATION OF BDNF IN THE DENDRITES: A LINK
WITH EPILEPTOGENESIS?
M. Simonato (Department of Clinical and Experimental Medicine, Sec-
tion of Pharmacology, University of Ferrara, Italy)
Targeting of mRNA into dendrites, followed by a local, extrasomatic,
protein synthesis is a mechanism that enables neurons to synthesize pro-
teins in close proximity to the postsynaptic site of stimulated synapses.
Here, we demonstrate that epileptogenic stimuli induce a dramatic accu-
mulation of BDNF mRNA and protein in the dendrites of hippocampal
neurons in vivo. BDNF mRNA and protein accumulate in dendrites in
all hippocampal subfields after pilocarpine seizures, and in selected sub-
fields after other epileptogenic stimuli (kainate and kindling). BDNF ac-
cumulates selectively in discrete dendritic laminae, suggesting targeting
to synapses that are active during seizures. Dendritic targeting of BDNF
mRNA occurs during the time when the cellular changes that underlie
epilepsy are occurring, and is not seen after intense stimuli that are non-
epileptogenic including electroconvulsive seizures and high frequency
stimulation. MK801, an NMDA receptor antagonist that can prevent
epileptogenesis but not acute seizures, prevents the dendritic accumula-
tion of BDNF mRNA, indicating that dendritic targeting is mediated via
NMDA receptor activation.
We have also investigated the molecular determinants of BDNF
mRNA trafficking. BDNF is encoded by multiple, alternatively spliced,
transcripts whose function is still unknown. We have analyzed the traf-
ficking of five rat BDNF mRNA splice variants in hippocampal neurons
following kainate or pilocarpine injection. Both kainate and pilocarpine
seizures induce a dramatic accumulation of isoforms IIa, IIb and IV in
the dendrites of hippocampal neurons, while exon I and III transcripts
remain in the soma.
These results suggest that dendritic accumulation of BDNF mRNA and
protein play a critical role in the cellular changes leading to epilepsy. Ex-
periments are ongoing to challenge this hypothesis by means of siRNAs
specifically directed against the different BDNF mRNA splice variants.
h-CHANNEL PLASTICITY DURING EXPERIMENTAL
EPILEPTOGENESIS
M. Shah (University College London, UK)
The hyperpolarization-activated cation channel (h-channel) has been
suggested to be involved in the changes in neuronal excitability in many
different types of epilepsy. During chronic temporal lobe epilepsy (TLE),
the expression of the hyperpolarization-activated cation non-selective
(HCN) subunit (molecular correlate of h-channels) was found to be al-
tered in hippocampal CA1 pyramidal neurons (Brewster et al., J Neu-
rosci, 2002;22:4591–9; Bender et al. J Neurosci, 2003;23:6826–36),
leading to a shift in the activation curve for the resultant h-current, Ih
(Chen et al. Nat Med, 2001;7:331–7). Ih is also modified in entorhinal
cortical (EC) layer III neurons during the process of epileptogenesis as
my colleagues and I have recently demonstrated (Shah et al. Neuron,
2004;44:495–508). Interestingly, in these neurons Ih is downregulated
within 24 hr of experimentally induced seizures and remains substan-
tially reduced for at least 1 week following their termination (Shah
et al. Neuron, 2004;44:495–508). The decrease in Ih occurred promi-
nently in the dendrites. As a consequence, excitatory synaptic potential
(EPSP) integration was reduced, resulting in a higher propensity for ac-
tion potentials to occur. Thus, the excitability of individual EC layer
III neurons was considerably enhanced and can be predicted to cause
enhanced network activity of the EC. Indeed, electroencephalographic
(EEG) recordings showed interictal spikes in the EC during this time
period, suggesting that EC neuronal network excitability was increased
in vivo. Alterations in EC neuronal network activity are particularly sig-
nificant since EC layer III neurons provide the predominant excitatory
drive to hippocampal CA1 neurons during chronic TLE. Hence, Ih plas-
ticity in EC neurons may be an important factor in the development of
chronic TLE, and upregulation of Ih may be therapeutically beneficial
in the treatment of the disorder.
PLASTICITY OF LOW-THRESHOLD CURRENTS IN
EPILEPSY
H. Beck (University of Bonn Medical Center, Department of Epileptol-
ogy, Germany)
Seizures potently modify the expression of voltage-gated ion chan-
nels in neurons, leading to changes in intrinsic firing properties. Recent
data indicate that changes in the expression and modulation of voltage-
gated currents active in the subthreshold potential range may be par-
ticularly important. This presentation will therefore focus on epilepsy-
related changes in low-threshold ion channels, such as T-type Ca2+
currents, persistent Na+ currents, and different types of K+ currents.
The molecular mechanisms underlying changes in these current types
will be discussed, as well as how changes in these currents shape dis-
charge behavior of hippocampal neurons in the chronically epileptic
brain.
REORGANISATION OF GLUTAMATERGIC AND GABAergic
PATHWAYS DURING EPILEPTOGENESIS
M. Esclapez INSERM U751, Falculte´ de Me´decine de la Timoˆne, Mar-
seille, France
Temporal Lobe Epilepsy (TLE), one of the most common forms of
partial epilepsy in adult is characterized by the occurrence of sponta-
neous recurrent seizures associated to the excessive and synchronous
discharges of pyramidal cells (PC) which may result from imbalance
between excitation and inhibition (E-I). We address this issue in the
pilocarpine model of TLE by studying the morpho-functional reorgani-
zation of the glutamatergic and GABAergic hippocampal networks and
consequences on the E-I balance in CA1 PCs at the different stages of
development of the epilepsy. Our data demonstrated cell death of GABA
neurons in the stratum oriens of CA1 and in the hilus of the dentate
gyrus (DG) that occurred after the status epilepticus (SE). Remaining
GABA neurons showed already from the latent period on, a marked
up-regulation of the vesicular GABA transporter and synthesizing en-
zymes of GABA at the gene and protein levels reflecting the hyperactiv-
ity of these interneurons. Glutamatergic hilar mossy cells degenerated
during the latent period as revealed by the loss of VGLUT1 mRNA-
containing hilar neurons and VGLUT1-containing terminals in the inner
one-third of the DG molecular layer. Plasticity of glutamatergic neu-
rons, characterized by axonal sprouting of glutamatergic principal cells,
was not evident before the end the latent period. Recovery of VGLUT1-
immunolabeling in the inner molecular layer started at the end of the
latent period and increased massively at the chronic stage due to the pro-
gressive development of mossy fibers sprouting. An increased labeling
of VGLUT1-containing axon terminals in the CA1-CA3 regions was
not detected before the chronic stage. These overall reorganizations and
the measures of GABAergic and glutamatergic drives received by CA1
PCs demonstrated that E-I imbalance is an early outcome of SE that
evolves dynamically during epileptogenesis in a cell domain dependent
manner. Epilepsy may occur when critical E-I imbalance threshold is
reached.
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The role of opioids in epilepsy
OPIOID RECEPTORS: WHAT, WHERE AND HOW?
I. Kitchen (University of Surrey, UK)
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There are four opioid receptors, three sensitive to the opioid antago-
nist naloxone (MOP, DOP and KOP) and a related receptor (NOP) that
mediates the effect of the endogenous peptide, nociceptin. Three other
families of endogenous peptides, (including -endorphin, dynorphins
and the enkephalins) act on the MOP, DOP and KOP receptors. All the
receptors are seven transmembrane structures and are G-protein coupled.
There are receptor agonists and antagonists available, though not all are
sufficiently selective or in vivo active. The characterisation of the recep-
tors and their ligands has been greatly helped by gene knockout mice,
created for all four receptors and their peptide families. MOP receptors
are widely distributed throughout fore, mid and hindbrain regions, and
quantitatively the MOP receptor is the most highly expressed. The DOP
receptor shows a more prominent expression in forebrain, whilst the KOP
receptor, although widely distributed, is expressed at a much lower level
in most rodent species. The NOP receptor also exhibits dense rostral to
caudal labeling but with distinct expression patterns compared to MOP,
DOP and KOP receptors. The presence of all of the opioid receptors
in key motor, limbic, reward, endocrine and sensory structures suggest
broad roles for these receptors in many biological functions. Whether
there are receptor subtypes is still a contentious issue, and evidence for
alternative splicing of the MOP gene might suggest this plays a role
in receptor variants. However, some of the evidence that has suggested
subtypes of the KOP receptor can be dismissed as misinterpretation of
data with nonselective ligands. There is certainly evidence for recep-
tor cross-talk and heterodimerisation of the KOP and DOP receptor has
been demonstrated in cell systems. Finally evidence from peptide gene
knockouts shows that the ligands act and regulate more than one receptor
subtype and that this regulation is region specific.
OPIOID PEPTIDES IN EPILEPSY
G. Sperk (Department of Pharmacology, Medical University Innsbruck,
Austria)
The prodynorphin gene is one of three opioid peptide genes. Prodynor-
phin is processed to various peptides, dynorphin A and B and α– and β-
neoendorphin, all of which are C-terminal extensions of Leu-enkephalin.
These peptides are of different length, however have similar pharmaco-
logical properties. Within the brain, prodynorphin-derived peptides (here
termed as dynorphin) are contained mainly in limbic areas such as the
hippocampus, amygdala, entorhinal and cingulated cortex. Changes in
prodynorphin mRNA and dynorphin-immunoreactivity were extensively
investigated in the hippocampus by several groups. In summary, in most
models of TLE dynorphin levels decrease in the hippocampus during an
initial status epilepticus due to release of the peptide. At the same time,
prodynorphin mRNA levels increase in the granule cell layer of the den-
tate gyrus and in other brain areas indicating its augmented resynthesis.
This increase in prodynorphin mRNA is transient and subsides in most
models after 24 to 48 hrs. Also the subsequent increases in dynorphin
levels are only transient, indicating that the upreguation of dynorphin is
dependent on acute seizure activity. In the hippocampus of TLE patients,
also pronounced upregulation of dynorphin mRNA is seen in dentate
granule cells and dynorphin-immunoreactivity is contained at high con-
centrations in mossy fibers. It is used as immunohistochemical marker
of mossy fibers and depicts aberrant mossy fiber projections to the inner
dentate molecular layer in the TLE hippocampus. In contrast the faint
dynorphin-immunoreactivity in the outer molecular layer of the dentate
gyrus presumably contained in afferent perforant path fibers is reduced
in TLE. Dynorphin primarily acts through κ-opiate receptors. In contrast
to stimulation of μ-opiate receptors, infusion of dynorphin or of dynor-
phin agonists like U-54494A exert anticonvulsive actions. Dynorphin
thus may act as an endogenous anticonvulsant and its κ-opiate receptors
may be a drug target for anticonvulsant treatment.
EVIDENCE FROM GENETIC STUDIES: THE PDYN PRO-
MOTER POLYMORPHISM
F. Zimprich (Department of Neurology, Medical University of Vienna,
Austria)
Opioid peptides play an important role in modulating the excitability of
many different neuronal networks. There is particularly strong evidence
that opioids regulate hippocampal circuits, thus setting the threshold for
seizures originating in the temporal lobe.
A key component in the opioid system is the prodynorphin gene
(PDYN) which codes for dynorphins, opioid peptides with an inhibitory
function in the hippocampus. Recently, a polymorphism in the regulatory
region of this gene was identified that features a 64 bp long element
tandemly repeated one to four times with each repeat containing a tran-
scription factor binding site. Interestingly, this polymorphism was shown
to be functional by influencing the activity of the PDYN promoter.
The relevance of this promoter polymorphism has recently been fur-
ther strengthened by evolutionary genetic studies. A comparison of the
sequence of this polymorphism between primates and different human
population groups has shown that it has undergone sweeps of strong pos-
itive selection during human evolution. Although the exact significance
of these findings is still unknown a role of this promoter polymorphism
in epilepsies appears likely given the results of several association stud-
ies. A meta-analysis of all published studies suggests that alleles with
a low-promoter activity predispose patients with a familial background
for seizures to temporal lobe epilepsy.
EVIDENCE FROM HUMAN PET STUDIES
M. Koepp (Institute of Neurology, UCL, London, UK)
Background: Opioid peptides act as mediators of use-dependent
synaptic activity and as cotransmitters to modulate the actions of the pri-
mary transmitter, glutamate. There is a large, sophisticated and at times
controversial body of animal data showing endogenous opioid release
may occur following induced and spontaneous seizures. There is con-
sensus that endogenous opioids released following seizures contribute
to a raised seizure threshold. Previous interictal PET studies in temporal
lobe epilepsy (TLE) have shown increased binding in the lateral temporal
neocortex with the μ-receptor specific ligand [11C]carfentanyl as well
as with the δ-receptor specific ligand [11C]methyl-naltrindole, but no
side-to-side differences of [11C]diprenorphine (DPN) binding, which is
a partial δ and κ agonist, but antagonist at μ-subtypes. Only dynamic
studies, looking at receptor binding in the same subject over time, can
prove the role of a given receptor / ligand system in some event. PET stud-
ies have shown a dynamic decrease in specific binding of [11C]DPN in
association cortices during hyperventilation-induced absences and lower
binding in reading-associated areas during reading-induced seizures in
reading epilepsy compared to baseline scans.
Rationale: To measure changes in opioid receptor availability follow-
ing spontaneous seizures in patients with TLE by means of a two-scan
paradigm.
Methods: We performed [11C]DPN PET scans as soon as possible
after a spontaneous seizure; a second scan aquired after as long a seizure
free period as achievable in a given patient served as an intrasubject
control. In addition, healthy control subjects were scanned twice in the
same manner to establish normal fluctuation of receptor availability.
Results: Large increases of opioid receptor availability were observed
specifically in the temporal pole which mediates temporal lobe seizures.
These changes correlated with time since the last seizure, but could not
be explained by a number of behavioural variables measured.
Conclusion: We were able to show a regionally specific upregulation
of opioid receptor availability in the temporal pole and fusiform gyrus
on the side of the seizure focus following seizures. This provides di-
rect evidence for opioid receptor plasticity over a time course of hours
following neural events.
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New insights in temporal lobe epilepsy
MICROARRAYS HAVE IDENTIFIED NEW GENES, PATHWAYS
AND PROCESSES IN THE NEUROPATHOLOGY OF TEMPO-
RAL LOBE EPILEPSY
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1K. van Gassen, 1M. de Wit, 2F. Holstege, 3P. van Rijen, 4D. Lind-
hout, and 1P. de Graan (1Rudolf Magnus Institute of Neuroscience,
Department of Pharmacology and Anatomy, University Medical Cen-
ter Utrecht, Utrecht, The Netherlands, 2Department for Physiological
Chemistry, University Medical Center Utrecht, Utrecht, The Nether-
lands, 3Department of Neurosurgery, University Medical Center Utrecht,
Utrecht, The Netherlands, 4Department of Medical Genetics, University
Medical Center Utrecht, Utrecht, The Netherlands)
Purpose: Temporal lobe epilepsy (TLE) is a severe type of epilepsy
with serious clinical symptoms. The aetiology remains elusive but ap-
pears to be multifaceted, with genetic, environmental and developmental
factors all implicated. In terms of pathophysiology, the hippocampus ap-
pears to be the predominant substrate in this disorder. Therefore, we
have investigated genome wide gene expression in the hippocampus of
epilepsy patients and normal autopsy controls.
Method: Oligonucleotide microarrays (21,521 genes) were used to
compare gene expression of hippocampal resections from hippocam-
pal sclerosis (HS) and nonhippocampal sclerosis (non-HS) TLE patients
and autopsy controls using a common reference design. Data were nor-
malised using the Lowess algorithm. Statistical analysis was performed
by Statistical Analysis of Microarrays (SAM) and Gene Ontology clas-
sification was performed with Panther Software (www.pantherdb.org).
Results: Comparing expression in autopsy controls with HS and non-
HS patients, 566 and 642 (q < 0.002) genes and comparing HS with
non-HS patients, 218 (q < 0.005) genes were differentially regulated.
Several genes were validated by qPCR. Pathway analysis identified down
regulation of glutamatergic pathways in non-HS and more severely in
HS patients. Gene ontology analysis implicated immunity and defense
genes in HS patients (p < 0.002) and to a lesser extent also in non-HS
patients.
Conclusion: The use of pathway and gene ontology analysis on our
data set from clinically well defined TLE patients provides a unique, un-
biased insight in the neuropathology of the human epileptic hippocam-
pus. Next to obvious differences, striking similarities were found be-
tween HS and non-HS epileptic hippocampi.
INNATE AND ADAPTIVE IMMUNE MECHANISMS DURING
EPILEPTOGENESIS AND SPONTANEOUS SEIZURES: EVI-
DENCE FROM EXPERIMENTAL MODELS AND HUMAN TEM-
PORAL LOBE EPILEPSY
1B. Gagliardi, 1F. Noe`, 1T. Ravizza, 2K. Boer, 1N. Marchi, 2E. Aron-
ica, and 1A. Vezzani (1Mario Negri Inst for Pharm Res, Milano, Italy,
2Academic Medical Centre, Univ of Amsterdam, The Netherlands)
Purpose: The rodent brain shows a rapid and lasting innate inflamma-
tory response to seizures involving glial and neuronal production of in-
flammatory mediators. Inflammatory processes decrease seizure thresh-
old and promote neurodegeneration. We explored the relative contribu-
tion of innate and adaptive immunity in perpetuating brain inflammation
during epileptogenesis and in the chronic phase of spontaneous seizures
(SS).
Method: The immunohistochemical pattern of microglia (CD-11b/c,
HLA-DR), T-(CD3, CD4, CD8) and B-lymphocytes (CD45RA), mono-
cytes/macrophages (ED-1, CD68), NK (NKR-P1A) and granulocytes
(HIS48) was assessed in rats 4-36h and 3-7d after the onset of
pilocarpine-induced status epilepticus (SE) and during SS, and in hip-
pocampal specimens from medically intractable TLE with or without
hippocampal sclerosis (HS).
Results: Activated IL-1beta-expressing microglia was observed
within 4h after SE in rat forebrain while abundant parenchymal
macrophages were found from 36h onwards. Both cell populations per-
sist in rats with SS. Granulocytes appeared between 36h-3d only. Scarce
B and T-lymphocytes and NK cells (≥3d) were found associated with mi-
crovessels. No changes occurred in pilocarpine+phenobarbital treated
rats. In human TLE with HS, IL-1beta-expressing microglia and clusters
of perivascular monocytes/macrophages occurred in the hippocampus;
CD3- and CD8-positive cells were scarce and B cells were lacking.
Conclusion: Microglia activation sustains the early phases of inflam-
mation after SE and, together with macrophages, contributes to its per-
sistence both in rat and human epileptic tissue. Granulocytes are tran-
siently recruited during epileptogenesis while B-, T-, NK-cells are scarce
or absent. These findings together with functional studies in experi-
mental models strongly suggest that innate, but not adaptive, immunity
significantly contributes to epileptogenesis. Supported by Fondazione
Mariani Onlus (A.V.) and National Epilepsy Fund (E.A., K.B.).
BRAIN MATURATION AND THE EVOLUTION OF DIFFERENT
AXES OF TEMPORAL LOBE SEIZURE SEMIOLOGY
1,2,4A. Fogarasi, 2,3J. Janszky, 4G. Rasonyi, 4P. Halasz, and 2I. Tuxhorn
(1Bethesda Children’s Hospital, Budapest, Hungary, 2Epilepsy Center
Bethel, Bielefeld, Germany, 3University of Pecs, Hungary, 4National
Institute of Psychiatry and Neurology, Budapest, Hungary)
Purpose: To examine objectively the effects of age on different aspects
of temporal lobe (TL) seizure semiology.
Method: We performed a video analysis of 605 archived seizures
from 155 consecutive patients (85 males; 95 with hippocampal scle-
rosis (HS); age 10 months to 49 [mean 17.1 ± 12.6] years) selected
by post temporal lobectomy seizure-free outcome. Beside semiological
seizure classification (Epilepsia 1998;39:1006–13.), we assessed age-
dependency of four axes of seizure semiology: (i) number of different
lateralising signs (Brain 2001;124:1683–1700.), occurrence of ictal (ii)
emotional and (iii) vegetative signs, as well as (iv) the ratio of motor
seizure components (Epilepsia 2002;43:638–43.).
Results: One-hundred patients were <12 and 29 of them <6 years
of age. From the 155 patients, 39 had ictal emotional and 51 had vege-
tative signs at least once during their seizures. Altogether 369 (median:
2/patient) different lateralising signs were recorded. Univariate analysis
of variance (ANOVA) revealed that age of patients, controlled for the
presence of HS, showed an association with the number of different lat-
eralising signs (p < 0.001) and an inverse correlation with the ratio of
motor seizure components (p < 0.001). The occurrences of emotional
and vegetative signs were independent of age.
Conclusions: Our findings support that brain maturation significantly
influences the evolution of some important aspects (motor seizures, later-
alising signs) of TL seizure semiology. Conversely, other aspects (emo-
tional and vegetative signs) are independent of the maturation process.
According to our knowledge, this is the first age-dependent assessment
of TL epilepsy comprehensively analysing different axes of seizure semi-
ology.
LIMBIC ENCEPHALITIS—A FREQUENT CAUSE OF ADULT-
ONSET MEDIOTEMPORAL LOBE EPILEPSY
1B. Soeder, 2H. Urbach, 3A. Becker, 1U. Gleissner, 4J. Schramm,
1C. Elger, and 1C. Bien (1Department of Epileptology, University of
Bonn, Germany, 2Department of Radiology, University of Bonn, Ger-
many, 3Department of Neuropathology, University of Bonn, Germany,
4Department of Neurosurgery, University of Bonn, Germany)
Purpose: Mediotemporal lobe (MTL) epilepsy (MTLE) accounts for
the majority of human localisation-related epilepsies. In the majority of
cases, the morphological substrate of the epileptogenic area is Ammon’s
horn sclerosis (AHS). In these cases, epilepsy usually starts in childhood.
For adult-onset MTLE, the aetiology, disease course, and therapeutic
outcome are unknown.
Method: From the database of the Department of Epileptology, we
collected all patients between 1 January 1999 and 30 September 2005
fulfilling the following criteria: (1) Manifestation of epilepsy at the age of
>20 years. (2) Time between disease manifestation and presentation <6
years. (3) History, brain MRI and neuropsychological testing available.
(4) MTL lesion on brain MRI. Patients were diagnostically classified
by histopathology, autoantibodies, brain MRI, brain PET, neuropsychol-
ogy, and clinical parameters. Outcome was assessed based on seizure
frequency and neuropsychological performance.
Results: The causes for the 84 cases were: limbic encephalitis 25%
(11% definite, 14% probable), tumours 21% (14% WHO I◦/II◦, 7%
WHO III◦/IV◦), AHS 21%, amygdala sclerosis 12%, posttraumatic 6%,
other 15%. After surgical treatment, 6/9 AHS and 9/12 tumour patients
(WHO I◦-IV◦) with follow-up assessment were seizure-free. 11/13 LE
cases improved on immunotherapy.
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Conclusion: Quite unexpectedly, the most frequent cause of adult-
onset MTLE in this sample of early-on diagnosed patients from a tertiary
epilepsy referral centre is limbic encephalitis. Thus, immune-mediated
epilepsy plays the most important role for adult-onset MTLE. The out-
come of adult-onset MTLE is generally favourable, especially for the
AHS and tumour patients if surgical treatment is possible, and for limbic
encephalitis if (early) immunotherapy is provided.
MAGNETIC RESONANCE SPECTROSCOPY OF THE THA-
LAMUS IN PATIENTS WITH MESIAL TEMPORAL LOBE
EPILEPSY AND HIPPOCAMPAL SCLEROSIS
1D. Fojtikova´, 1M. Bra´zdil, 2J. Horky´, 1M. Mikl, 3P. Krupa, and 1I.
Rektor (1Brno Epilepsy Centre, Department of Neurology, St. Anne´s
University Hospital, Brno, Czech Republic., 2Department of Nuclear
Magnetic Resonance, Institute of Scientific Instruments Academy of
Sciences, Brno, Czech Republic., 3Department of Neuroimaging, St.
Anne´s University Hospital, Brno, Czech Republic)
Purpose: To investigate possible neuronal dysfunction of the thalamus
in patients suffering from mesial temporal lobe epilepsy with hippocam-
pal sclerosis (MTLE/HS).
Method: We examined 10 epilepsy patients with MTLE/HS (7 fe-
males, 3 males) and 11 healthy volunteers (8 females, 3 males). The
mean age in the patient group was 40.64 ± 8.96 years (from 21 to 55
years; median 42 years); the mean age in the control group was 40.40 ±
7.53 years (from 28 to 51 years; median 40.50 years). We performed 1H
MR spectroscopic imaging of the right and left thalamus in all patients
and controls. In addition both hippocampi in a patient group were inves-
tigated by MRS-single voxel technique. MR examinations were carried
out on a 1.5 T Siemens scanner. A t-test was performed to compare
the distribution of NAA concentration within thalamic and hippocampal
structures.
Results: Statistical analysis of compared data in both groups demon-
strated that the thalamic NAA/Cr + Cho ratio was significantly decreased
in patients with MTLE as compared to healthy controls. Comparison of
right and left thalami separately, between patients and healthy controls,
also showed statistically significant reduction of NAA/Cr + Cho ratio.
A significant correlation between the patients’ thalamic NAA/Cr + Cho
values and the duration of the epilepsy and their age was revealed. When
comparing MRS data of thalamus ipsilateral to diseased hippocampus
no significant decrease in NAA/Cr + Cho ratio was observed, however
the significant reduction of these values was present in the contralateral
thalamus.
Conclusion: Our results suggest widespread metabolic dysfunction
and possible involvement of bilateral subcortical structures in patients
with MTLE/HS.
IMPACT OF INTERICTAL DISCHARGES ON RESTING STATE
BRAIN ACTIVITY
1,2,3H. Laufs, 1,2K. Hamandi, 1,2A. Salek-Haddadi, 3,4A. Kleinschmidt,
1,2J. Duncan, and 1,2L. Lemieux (1Department of Clinical and Exper-
imental Epilepsy, Institute of Neurology, University College London,
UK, 2MRI Unit, National Society for Epilepsy, Chalfont St Peter, UK,
3Department of Neurology and Brain Imaging Center, Johann Wolfgang
Goethe University, Frankfurt Am Main, Germany, 4INSERM U562, Ser-
vice Hospitalier Fre´de´ric Joliot CEA, Orsay, France)
Purpose: A brain network comprising precuneus, medial frontal and
temporoparietal cortices is overall more active during conscious rest
than during goal-directed behaviour but also than during states of re-
duced consciousness. These areas have been proposed to underpin a
“default mode” of brain function. We have previously shown their ac-
tivity to decrease during generalised spike and wave discharges (GSW)
in absence epilepsy, with associated thalamic activity increase. We in-
vestigated whether there is a common association between interictal dis-
charges (ID) and deactivation of “default mode” brain regions in focal
epilepsy.
Method: Using continuous electroencephalography-correlated func-
tional magnetic resonance echo planar imaging (EEG-fMRI) during re-
laxed wakefulness we investigated the blood oxygen level-dependent
correlates of ID in 19 consecutively recruited patients with focal epilepsy
who had 1-20 ID/minute.
Results: We found significant ID-related deactivations in the named
“default mode” brain regions in the 9 patients with temporal lobe epilepsy
(TLE) at the group level. Significant activations were seen in the ipsi-
lateral medial temporal lobe. No significant deactivations were found in
the 10 patients with extra-TLE.
Conclusion: TLE and extra−TLE seem to be distinct with respect
to their perturbation of resting state brain activity. Deactivation of brain
areas that are active during conscious rest by temporal IDs suggests a
widespread disruption of normal brain function and may contribute to
cognitive dysfunction. In the propagation of ID in TLE, the hippocampus
may have an analogous role to that of the thalamus in GSW, both resulting
in deactivation of “default mode” brain regions.
CLOSING REMARKS: MESIAL TEMPORAL LOBE EPILEPSY:
WHAT HAVE WE LEARNED?
J. Engel Jr. (UCLA, Los Angeles, CA, USA)
Mesial temporal lobe epilepsy (MTLE) is arguably the most common
epilepsy condition, and among the most pharmacoresistant. Research to
elucidate the fundamental neuronal mechanisms leading to the devel-
opment of mesial temporal lobe epilepsy and to the initiation of limbic
seizures has been greatly facilitated due to opportunities for invasive
basic research on patients with MTLE in the epilepsy surgery setting,
and a number of excellent animal models of this condition. Results of
this research will not only provide insights into novel targets for treat-
ment, but ideally they will lead to effective approaches for the prevention
and cure of MTLE. The papers in this symposium represent the appli-
cation of diverse, cutting-edge, research technologies in both patients
with MTLE and animal models. Microarray analysis of gene expression
and investigation of inflammatory processes are revealing the molecu-
lar basis of epileptogenesis, while functional magnetic resonance imag-
ing and magnetic resonance spectroscopy provide crucial evidence for
widespread neuronal networks that are involved in the manifestation of
limbic seizures. Both the molecular and systems approach also must take
into account the fact that the maturational state of the brain influences
epileptogenesis and epileptogenicity. Studies like these are ongoing at
hundreds of laboratories throughout the world, and form the basis of
the transitional research necessary for realizing our goals of improved
treatment, prevention, and cure for temporal lobe epilepsy.
Sunday July 2, 2006
12:00–14:00
Hall 5B
Neurobiology Symposium
In vivo imaging of neurobiology of epileptogenesis
MRI AND MRS AS NONINVASIVE TOOLS TO INVESTIGATE
EXPERIMENTAL MODELS OF EPILEPSY
D. Gadian (UCL Institute of Child Health, UK)
Magnetic resonance imaging (MRI) and spectroscopy (MRS) tech-
niques have found widespread application in the investigation of patients
with epilepsy. Applications in animal models of epilepsy are perhaps less
well established, but they provide important opportunities for probing
pathophysiological changes that may be difficult to characterise in hu-
mans. A key feature of animal studies is that they enable us to carry
out longitudinal examinations, from prior to the onset of seizures on-
wards. Comparisons of data obtained before, during and after seizures
can greatly facilitate the detection of brain abnormalities that may be
functionally important and yet cause only subtle changes in magnetic res-
onance characteristics. Moreover, the longitudinal magnetic resonance
data can be correlated with end-point histopathology.
This presentation will report on our ongoing clinical and experimen-
tal magnetic resonance studies of status epilepticus. Convulsive status
epilepticus (CSE) is the most common medical neurological emergency
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in childhood, and is associated with significant morbidity and mortal-
ity. Although many patients will have no obvious sequelae, possible
outcomes from childhood CSE include epilepsy as well as permanent
neurological or cognitive deficits. However, much remains to be learned
about the pathophysiology associated with CSE and about the relation-
ship between CSE and subsequent epilepsy. Modern magnetic resonance
methods, applied both in patients and in experimental models, provide
an opportunity to understand in more detail the temporal evolution of
brain abnormalities associated with CSE. This may in due course lead
to the development of new therapeutic approaches.
TRACT TRACING OF CIRCUITRY REORGANISATION DUR-
ING EPILEPTOGENESIS WITH MRI
O. Gro¨hn (A.I.Virtanen Institute for Molecular Sciences, University of
Kuopio, Finland)
Mossy fibers are granule cell axons that can loose their normal postsy-
naptic cellular targets due to neurodegeneration caused by epileptogenic
brain insults. As a consequence, mossy fibers sprout and innervate ab-
normal targets. Even though it is still under dispute whether mossy fiber
sprouting is a critical factor for seizure generation, it has been shown to be
present both in mouse, rat, and human brain with symptomatic epilepsy.
The presence of aberrant sprouting before spontaneous seizures provides
a rationale for its use as a surrogate marker for epileptogenesis.
Mn2+-enhanced magnetic resonance imaging (MEMRI) has poten-
tial to reveal functional, structural and connectional alterations in high
spatial resolution. We injected Mn to entorhinal cortex of rats to char-
acterize activity-dependent plasticity in the mossy fiber pathway after
kainic acid induced status epilepticus in rats. High-resolution 3D T1-wt
MRI at 4.7T and volume-rendered 3D reconstruction allowed for visual-
ization of the lamellar organization of the mossy fibers in vivo. Increased
accumulation of Mn into to dentate gyrus and CA3 of rat hippocampus
was correlated with histologically determined mossy fiber sprouting. Our
preliminary results show that also systemically administered Mn accu-
mulates in the same hippocampal subregions and may provide a robust
MEMRI approach for detection of mossy fiber sprouting, in vivo.
The present study demonstrates that MRI can detect plasticity changes
in axons. This is expected to be of great value as axonal plasticity is a
part of several pathologic processes, including epileptogenesis.
IMAGING EPILEPTOGENESIS INDUCED BY FEBRILE
SEIZURES
T. Baram (University of California at Irvine, USA)
Finding biomarkers for the epileptogenic process is important, be-
cause it will allow to monitor this process, to determine the mecha-
nisms involved, and eventually, to intervene and abort the development
of Epilepsy. Signal changes on magnetic resonance imaging (MRI) may
provide early markers for changes in neuronal integrity that may pro-
mote epileptogenesis. In addition, this tool is helpful, because it is non-
invasive and can be used repeatedly. We have previously established that
prolonged experimental febrile seizures (FS) provoke an epileptogenic
process that results in frank Epilepsy in ∼35% of seizure-experiencing
immature rats (Dube et al., Brain, 2006). Here we discuss the use of serial
MRIs, obtained before and at several time-points following the seizures,
(Dube et al., Ann Neurol, 2004) as a biomarker of the epileptogenic
process.
A 7 Tesla magnet provided detailed anatomy of brain regions, in-
cluding the hippocampus and limbic cortices (piriform and entorhinal),
that are involved in FS and in its putative consequence in humans,
temporal lobe epilepsy (TLE). Experimental FS evoked both visually
apparent changes as well as deviations from normal T2 values, deter-
mined using ‘absolute’ T2 maps. To understand the meaning of these
changes in T2, that were found 1,8 and 30 days after the seizures, we
studied the presence of neuronal injury and death (damage). The sig-
nal changes in hippocampus, amygdala and piriform/ entorhinal cortex
were not accompanied by evidence of neuronal injury or death in these
regions, as assessed using the Fluoro-Jade method. In addition, the T2
signal changes were correlated with water content as determined in tis-
sue samples from imaged rats. In summary, experimental prolonged FS
provoke epileptogenesis, and to abnormal MRI signal in temporal lobe
structures, that may denote pathological cellular processes that promote
epileptogenesis.
THE USE OF IMAGING TECHNIQUES TO UNDERSTAND
EPILEPTOGENESIS IN AN ANIMAL MODEL OF TEMPORAL
LOBE EPILEPSY
A. Nehlig (INSERM U 666, Faculty of Medicine, Strasbourg, France)
In patients with temporal lobe epilepsy (TLE), hippocampal sclerosis
and lesions of the temporal lobe, amygdala and thalamus are frequently
observed. Their respective role in epileptogenesis is unclear. To identify
the structures critical in the epileptogenic process, we used the lithium-
pilocarpine model of epilepsy which reproduces most clinical and neu-
ropathological features of TLE. While all adult rats subjected to status
epilepticus (SE) become epileptic, only a subset of 21-day-old (PN21)
rats develop epilepsy. The use of T2-weighted MRI (4.7 T) revealed that,
in adult rats and PN21 rats that became epileptic, entorhinal and piri-
form cortices were the initial structures exhibiting a significant signal
change (as soon as 6 h after SE onset) reflecting rapid and massive neu-
ronal injury and death. In the subset of PN21 rats that did not become
epileptic, the absence of signal in the piriform and entorhinal cortices
confirmed their critical role in the early establishment of epileptic net-
works. In contrast, MRI signal change in the hippocampus appeared
only 36–48 h after SE onset and progressively worsened to sclerosis.
The use of 13C NMR spectroscopy showed that the flux through the
glutamate-glutamine cycle was decreased in temporal cortices but not
in hippocampus while astrocytic metabolism was unchanged in both re-
gions. Moreover, metabolic levels measured in the hilus of the dentate
gyrus of adult and PN21 epileptic rats by 14C-2-deoxyglucose autora-
diography was normal during the latent and chronic phases although
neuronal loss reached 60–75%. This relative hypermetabolism reflects
the involvement of the hilus during circuit reorganization and epilepsy.
In conclusion, these data demonstrate the usefulness of imaging tech-
niques in the identification of the key structures at various steps of the
epileptogenic process.
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Coping with the side effects of antiepileptic drugs
(AEDs)
ASSESSMENT OF ADVERSE EFFECTS: METHODOLOGICAL
ISSUES
E. Perucca (Institute of Neurology, IRCCS C. Mondino Foundation,
and Clinical Pharmacology Unit, Department of Internal Medicine and
Therapeutics, University of Pavia, Italy)
Because antiepileptic drugs (AEDs) have a narrow therapeutic index,
adverse effects (AEs) represent a major determinant of health-related
quality of life in persons with epilepsy. Optimizing the assessment of
AEs is essential not only in differentiating risk/benefit ratios of AEDs in
formal studies, but also in ensuring best care in clinical practice. There
is no simple methodological approach that can be recommended in all
settings, and complementary information can be obtained with differ-
ent methods. Selection and assessment bias are best minimized with
double-blind controlled trials, but enrolment criteria and dosing regi-
mens in these trials may be poorly representative of routine practice, and
sample size and trial duration are usually inadequate to identify rare or
delayed AEs. Relying on spontaneous reports for detection of AEs leads
to underestimation of AEs, whereas use of checklists leads to overes-
timation, and neither approach is free from bias. Specialized tests and
testing protocols may be required to assess certain categories of AEs,
such as cognitive dysfunction or metabolic effects. Elusive AEs include
those which are rare, those which only occur in special patients’ groups
(for example, young children), and those which mimic the manifesta-
tions of underlying pathology or reproduce disorders which have a high
incidence of spontaneous occurrence. Further work is needed to opti-
mize assessment protocols to be used in routine clinical practice. Recent
work suggests that use of standardized self-administered questionnaires
can be valuable in identifying AEs in individual patients, and sensitizing
physicians to the need of reducing the AEs burden.
PREVENTING AND MANAGING SIDE EFFECTS AT ONSET OF
TREATMENT
E. Ben-Menachem (Institution for Clinical Neuroscience and Physiol-
ogy, Sahlgrenska University Hospital, Go¨teborg, Sweden)
When clinical trials are performed especially for approval of drugs
for epilepsy, only ideal patients are included that fit inclusion criteria
and no exclusion criteria. When a drug is then marketed, it is used in
patients who have many risk factors, many concomitant medications
and comorbidities. These patients are those who will be most prone to
experience side effects not even seen in the clinical trials when starting
treatment. The recommendations for adequate dose level and titration
rates are usually based on rigid protocols in the clinical trials. These in
turn are built on hypotheses about the adequate dose most effective and
tolerated by patients which, in turn, are usually founded on animal studies
and phase I normal control trials in healthy people not on concomitant
antiepileptic drugs.
Because the results of clinical trials determine that the majority of
the included patients tolerate a certain titration rate and dose level, these
become the recommended doses and methods for starting the drug in all
patients after approval of the drug. Many examples, however, are now
in the literature about how these recommendations can be inadequate,
causing side effects in unsuspecting patients.
The side effects most often seen are somnolence and other sleep dis-
turbances, headache, dizziness, ataxia, rash and other allergic reactions,
depression and cognitive and behavioral changes.
Side effects at initiation can be prevented using two procedures: slow
titration along with titration of dose to the effective level where the
patient has least amount of seizures with least amount of side effects.
That way the patient may be maintained at dose levels far below that
recommended by the pharmaceutical company. This, however, is not
accomplished quickly and can even take several months. Of course it
is desirable to initiate an effective treatment all at once at an effective
level, but that is exactly how acute side effects appear. Patients with
refractory epilepsy with a chronic seizure condition are usually in no
hurry. However, the situation may be different in specific cases and in
patients with new onset epilepsy. Still, even in the naı¨ve patient just
starting an AED, slow titration can improve compliance, minimize side
effects and increase the trust of the patient in the doctor and the treatment
itself.
With slow titration to effective dose, with the patient keeping a record
of seizure frequency and side effects, then if acute side effects occur the
dose can be down titrated to the level below where no side effects had
appeared previously. Often waiting at that lower level for an extended
period enables the increase in dose later on, enhancing the ability of the
patient to remain on the drug.
The term: “start low-go slow” applies for the initiation of most AEDs
and is the most advantageous way to prevent and manage side effects at
onset of treatment.
RECOGNISING AND MANAGING SIDE EFFECTS EMERGING
DURING LONG-TERM TREATMENT
P. Genton (Centre Saint-Paul-HHG, France)
While severe idiosyncratic side effects (SE) of antiepileptic drugs
(AED), and acute, often transient SE at initiation of therapy are the main
concerns of epileptologists, patients will often complain about the long-
term, daily, “benign” SE, especially when they emerge progressively,
or may exhibit the long-term, hidden but dangerous consequences of
long-term therapy. Most of these used to be of little concern to doctors,
and were considered “a price to pay,” but modern attitudes stress the
importance of quality of life: a longlasting problems like epilepsy should
be controlled with minimal somatic and social impairment. Most of such
SE are fairly common, but patients exhibit specific sensitivities that may
be related to genetic factors: this sector of epileptology is a potentially
fertile ground for pharmacogenetic research. Beneficial SE may also be
noted, e.g., as some AED are efficient mood regulators and painkillers.
Long-term deleterious effects are often interrelated, usually multifac-
torial, occur insidiously, and recent concerns have focused on:
- cosmetic SE, with mainly weight changes (gain with valproate, vi-
gabatrin, gabapentin and pregagalin, and to a lesser extent with car-
bamazepine, or loss with topiramate, felbamate and zonisamide),
but also acnea, hirsutism, gum hyperplasia and coarse facies
(phenytoin).
- cognitive SE, with variable iimpact of AEDs, the highest risks
occurring with topiramate.
- effects on mood and behaviour, which may be superimposed on
disease-related anxiety, depression, or psychotic traits.
- effects on bone mineral balance, with a clear increase in severity
of age-related osteomalacia due to enzyme-inducing AEDs that
interfere with vitamin D metabolism,
- effects on reproductive and sexual functions.
The right attitude is to inform patients about potential risks, putting
them into perspective in terms of incidence and severity, and to re-
view treatment whenever a specific side effect is present or very likely
in a given patient. The relationship between doctor and patient with
epilepsy is necessarily a long-term one, and should be based on trust and
clarity.
RECOGNISING AND COPING WITH SIDE EFFECTS FROM
AED INTERACTIONS
G. Kra¨mer (Schweiz Epilepsie-Zentrum, Zurich, Switzerland)
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Interactions of antiepileptic drugs (AEDs) are a common problem
in clinical practice. As long as drugs are prescribed by the same physi-
cian (e.g., neurologist or neuropediatrician) dosage adjustments are more
common and prevent increased side effects. However, patients are treated
by several physicians simultaneously or my have acute comorbidities re-
quiring additional drugs.
In women AEDs may influenec endogenous as well as exogenous hor-
mones and vice versa. AEDs that induce hepatic microsomal enzymes
interact with hormonal contraception by increasing the metabolisation
of estrogen metabolism and the protein binding of progesterone’s and
decreasing concentrations of both hormones. Thus they are reducing the
efficacy of oral contraceptives (OC) and incraesing the isk of unplanned
pregnancies. Recently it was discovered that at least one AED (lamotrig-
ine) is signifantly influenced by hormones (OC as well as pregnancy).
In elderly people with epilepsy, drug interactions are of sepcial impor-
tance. In principle, they are not different from those in younger patients,
but they are more common and their effects are often stronger. The al-
most always present polytherapy in elderly patients is the cause of an
increased incidence of interactions which, in turn, can result in intox-
ications or losses of activity or the antiepileptic drugs as well as other
undesired drug reactions. The few investigations performed on this topic
have found a prevalence for potential interactions of 2–17% of all drug
prescriptions in 6–42% of all elderly patients.
Another example are patients with brain tumors. In these patients
drug interactions can cause insufficient tumor or seizure control or
lead to unforeseen toxicity. The interactions between AEDs, chemother-
apeutic drugs, and corticosteroids are of special importance. Con-
versely, chemotherapy may lower serum concentrations of AEDs and
corticosteroids.
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To treat or not to treat the EEG in paediatric epilepsy
syndromes
THE AMBIGUITY OF INTERICTAL SPIKES AND SUBCLINI-
CAL SEIZURES
U. Brandl (Friedrich-Schiller-Universita¨t, Jena, Germany)
No abstract received.
SUPPRESSION OF INTERICTAL EPILEPTIFORM DIS-
CHARGES IMPROVES BEHAVIOUR IN CHILDREN WITH
EPILEPSY
R. Pressler (Department of Clinical Neurophysiology, National Hospital
for Neurology, UK)
Treatment of interictal discharges can improve behaviour in children
with epilepsy
Increased behavioural problems in children with epilepsy are a conse-
quence of various factors including underlying brain lesion, age of onset,
antiepileptic drugs, psychosocial issues, seizure type and frequency, and
interictal EEG abnormalities. Suppression of discharges will improve
behaviour in children with nonconvulsive status epilepticus presenting
as pseudo-dementia or more subtle behavioural changes, and in chil-
dren with prolonged nocturnal discharges such as ESES. The effect of
intermittent interictal EEG discharges on behaviour and cognition is
still controversial. Whether cognitive and behavioural problems can be
directly caused by discharges or are a coexisting phenomenon can be
determining through improvement of cognition and behaviour, if EEG
discharges are suppressed.
In children with drug resistant epilepsy and learning difficulties sup-
pression of discharges was associated with improvement in global rating
of psychosocial function. In children showing interictal discharges but
without epilepsy, suppression of discharges showed no definite effect. In
children with well-controlled or mild epilepsy, improved behaviour was
only observed in children who showed a reduction of discharges during
active treatment, but not in patients without a change in discharge rate.
The issue of ‘treating the EEG’ remains controversial. The question
is not whether to treat the EEG, but whether seizures, so subtle as to be
recognisable only by EEG and behavioural monitoring, produce disabil-
ity sufficient to justify treatment.
LESSONS FROM CHILDREN WITH BENIGN IDIOPATHIC FO-
CAL EPILEPSIES
T. Deonna (Neuropaediatric Unit, CHUV, Lausanne, Switzerland)
There is a consensus that most children with benign partial epilepsies
(rolandic epilepsy) do not need prophylactic antiepileptic drug therapy to
prevent recurrence of seizures. These are usually short, harmless, of low
frequency and occur mainly during sleep. There is no morbidity associ-
ated with the seizure, despite the sometime alarming symptoms (sylvian
seizures with pharyngeal contractions). A different problem is the issue
of trying to suppress EEG discharges which are now suspected to be the
potential cause of various cognitive/behavioural problems, increasingly
reported in these children, despite normal intelligence. Recent longitudi-
nal studies have shown that these difficulties sometime arise and regress
in direct relationship with the activity of the epileptic disease as shown
by the epileptic EEG activity during the waking and sleep state. Knowing
also that prolonged acquired oromotor, speech and language problems
can develop in the course of initially typical BEPRS, there is now some
basis to think that even some more minor cognitive/behavioural problems
could also be of direct epileptic origin.
When a child is diagnosed as having BEPRS and has some behav-
ior/cognitive problems it is usually uncertain whether it could be is the
direct consequence of the paroxysmal EEG epileptic activity present at
the time, because there may be many other possible explanations. The
same is true in those children who had already been recognized and
treated beforehand for a developmental disorder, a learning disability
or a behaviour problem. When the problems are clearly of recent on-
set or that a cognitive stagnation, regression or marked fluctuations of
the symptoms can be documented, an antiepileptic drug trial aiming at
suppressing the EEG discharges is justified. If in doubt, a documenta-
tion of the present cognitive status and school achievements with close
clinical and EEG follow-up every few months may be proposed before
a decision is made. Some EEG features, in addition to the typical FSW
have been found to predict a higher risk of future cognitive problems. At
the present time, no single antiepileptic drug or controlled group study
has definitively proven the benefit of this approach, but there are several
suggestive ongoing trials clearly justifying an open, individually based
attitude.
LESSONS FROM CHILDREN WITH EPILEPTOGENIC
LESIONS
H. Holthausen (Behandlungszentrum Vogtareuth, Germany)
Background: There is increasing data that in children with benign id-
iopathic focal epilepsies (BIFEC) or just benign focal idiopathic epilep-
tiform discharges of childhood (BIFEDC) a complete suppression of
the epileptiform discharges in addition to seizure control may have a
favourable impact on their cognition and / or behaviour. Whether this
is also the case in children with epileptogenic lesions is even less well
documented.
Patients and methods: Patient groups have been selected from the
Vogtareuth epilepsy-surgery-database because of the meticulous docu-
mentation of seizures, ictal EEG, interictal EEG, cognition and behaviour
and of the situation on follow-up investigations.
3 Groups were selected:
Group 1: patients with one type of etiology at one localization–chosen
were patients with frontal Type II-FCD.
Group 2: Patients with marked cognitive problems, who have been
operated on despite control of clinical seizures, because it was hypoth-
esized that their cognitive deficits were the result of subclinical seizure
spread / secondary bilateral synchrony as documented during presurgical
evaluation.
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Group 3: Patients with BIFEDC in addition to their symptomatic focal
epilepsies in whom their BIFEDCs were successfully suppressed by
change of medication.
Results:
Group 1: A clear tendency was noticed that it is the combination of
1) early onset of epilepsy plus 2) spread of epileptiform activity to the
contralateral hemisphere which puts children at a very high risk for a
mental retardation.
Group 2: On follow-up investigations all patients showed a better
developmental pace; best results were achieved in patients with a relative
late onset and a short duration of the epilepsy.
Group 3: In 50% of the patients of this subgroup a marked improve-
ment in their cognition and / or behaviour was noticed.
Conclusions: With respect to mental development and / or behaviour,
there are subgroups of patients with symptomatic focal epilepsies for
which suppression of “interictal” sharp waves or subclinical seizures
may be as equally important as is the control of clinical seizures.
Monday July 3, 2006
7:30–9:00
Hall 5C
Teaching Session
Diagnostic methods in presurgical workup—what’s
new?
MODELLING AND VISUALISATION OF BRAIN ELECTRIC
ACTIVITY IN EPILEPSY
M. Scherg (University Hospital Heidelberg, Germany)
No abstract received.
ADVANCED STRUCTURAL AND FUNCTIONAL MRI TECH-
NIQUES IN EPILEPSY
L. Lemieux (Institute of Neurology, University College London, UK)
The principal aims of developments in MRI applied to epilepsy are
the detection and visualisation of ever more subtle abnormalities and
networks that sustain epileptic activity, with a view of improving patient
management. Furthermore, advanced MRI can provide quantitative mor-
phological, connectivity and perfusion data which are essential to study
the mechanisms that underlie epileptogenicity, its consequences and the
effects of treatment. Recent developments from our lab in the follow-
ing areas will be reviewed and illustrated with data acquired in patients:
structural MR acquisition sequences (diffusion tensor imaging, T1 and
T2 mapping and magnetisation transfer ratio); morphological and con-
nectivity image analysis (tractography, segmentation and quantification
of change in serial data); functional MRI (language pathway mapping
and EEG-correlated fMRI; BOLD and perfusion).
THE NEW AND THE VERY NEW PET TRACERS IN EPILEPSY
M. Koepp (Institute of Neurology, UCL, London, UK)
Studies using positron-emission-tomography (PET) have advanced
our pathophysiological and biochemical understanding of focal and
generalised epilepsies. Neurotransmitters are directly responsible for
modulating synaptic activity and PET allows quantification of specific
ligand-receptor relationships which are important for epileptogenesis
and spread of epileptic activity. The following neurotransmitter systems
have recently been examined: (1) GABAergic neurotransmission using
[11C]flumazenil, which images the benzodiazepine/GABAA-receptor
complex; (2) serotonergic neurotransmission using alpha[11C]methyl-
tryptophan, which reflects the uptake of tryptophan into the brain and
in physiological conditions it is thought to relate to the synthesis of
serotonin, using either [18F]MPPF, [18F]FCWAY or [11C]WAY-100635
reflecting 5-HT1A receptor binding, (3) glutamatergic neurotransmission
using [11C]ketamine or [11C]CNS5161 as potential PET tracers for open
NMDA receptor associated ion channels; (4) opioid neurotransmission
using the μ-receptor specific ligand [11C]carfentanyl, the δ-receptor spe-
cific ligand [11C]methylnaltrindole and [11C]diprenorphine, which is a
partial δ and κ agonist, but antagonist at μ-subtypes; (5) dopaminergic
neurotransmission using [18F]fluoro-L-Dopa and the D2-receptor antag-
onist [18F]Fallypride. In this review, we aim to define the potential of
the new PET tracers in clinical and experimental epileptology.
MAGNETOENCEPHALOGRAPHY IN PATIENTS WITH
EPILEPSY—AN UNDERUSED TOOL
H. Stefan (University Erlangen-Neurber, Neurological Clinic, Epilepsy
Centre, Germany)
No abstract received.
Monday July 3, 2006
9:30–11:30
Hall 1
Chairmans Symposium
Promoting European collaboration in epilepsy
research
EUROPEAN COLLABORATIVE INITIATIVES IN BASIC SCI-
ENCE, EXAMPLES FROM EPILEPSY RESEARCH
G. Avanzini (Istituto Nazionale Neurologico C.Besta, Milano, Italy)
As many as 6 million people in Europe currently have active epilepsy
that has major implications not only for health but also for independent
living. The synergy between experimental and clinical research led to
significant advances in identifying new etiological factors (e.g., cortical
dysplasia, epilepsy genes) pathogenetic mechanisms (e.g., channel dys-
function) and rational therapeutic strategies (e.g., molecules targeted to
specific epileptogenic mechanisms, new surgical approaches). However
Several important problems are still open.
Although the European epileptological community has an important
tradition of scientific research contributing by one third to the world-
wide scientific production in the field (see the European White Paper on
Epilepsy, 2001), the great potential of collaborative research has been so
far underexploited because of a lack coordination.
In 2005 The EPICURE multisciplinary integrated project has been
developed aimed at mobilizing the potential synergies of 30 research
groups from 14 European countries.
The project will last 4 years and will include:
• identification of epilepsy genes and characterization of the
functional alteration affecting the encoded proteins, in relation to
their epileptogenic function
• identification of acquired channelopathies and network re-
organisation in human temporal lobe epilepsy and clinically rele-
vant animal models, with the aim of identifying protective strate-
gies and new therapeutic targets
• identification of mechanisms controlling age related epilepto-
genesis in children suffering from brains maldevelopment
• development and testing of new strategies for prevention and
treatment of epilepsies and identifications of mechanisms which
account for pharmacoresistance
The expected results will advance European epilepsy research and
bring about novel therapeutic benefits to patients.
EURAP: A REGISTRY OF ANTIEPILEPTIC DRUGS AND
PREGNANCY AND AN EXAMPLE OF A EUROPEAN COLLAB-
ORATIVE INITIATIVE
T. Tomson ((Karolinska Institutet, Sweden)
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The treatment of epilepsy during pregnancy and the potential terato-
genic effects of antiepileptic drugs (AEDs) and other fetal and maternal
risks associated epilepsy during pregnancy is one of the most important
health issues for women with epilepsy. Yet we are short of data necessary
for a rational approach to the management of women with epilepsy that
are of childbearing potential, because we lack conclusive comparative
data on the teratogenic potential of different AEDs.
This is mainly due to the difficulties to enroll sufficient numbers of
pregnancies. Collaborative efforts are necessary to overcome this prob-
lem and assessment of the comparative teratogenicity of AEDs is there-
fore particularly suitable for an international collaboration.
Based on these considerations, research groups in Europe agreed on
a common protocol and in 1999 launched EURAP in the first two coun-
tries. EURAP has since then been extended to 40 countries in Europe
and other regions. EURAP is a prospective registry aimed at assessing
the comparative risk of malformations following intake of AEDs during
pregnancy. EURAP is organized through networks of reporting physi-
cians, national coordinators and a central registry based in Milan, Italy.
Women taking antiepileptic drugs at conception are enrolled in early
pregnancy Baseline information and follow-up data are collected on-
line and immediate feedback between the central registry and reporting
physicians allows collection of missing data. By March 2006, more than
8,000 pregnancies have been enrolled and approximately 3,500 have
completed one-year follow-up after birth. EURAP is an example of a
European research collaboration, who’s success depends on voluntary
work of more than 700 physicians dedicated to a common cause and on
the development of on-line interaction between collaborators at different
levels, which serves to strengthen this extensive network.
FONDE : FOLLOWING OUTCOMES IN NEWLY DIAGNOSED
EPILEPSY—A MAJOR NEW RESEARCH INITIATIVE
M. Brodie (Epilepsy Unit, University of Glasgow, Glasgow, Scotland
on behalf of the EUCARE Management Group, UK)
EUCARE (European Concerted Action and Research in Epilepsy) is
a joint initiative of the International League against Epilepsy (ILAE) and
the International Bureau for Epilepsy (IBE), sponsored by an unrestricted
educational grant from UCB. The major plank of its research activities
is FONDE (Following Outcomes in Newly Diagnosed Epilepsy), which
is a prospective observational study of the pharmacological and lifestyle
consequences of newly diagnosed epilepsy in the different countries
of Europe. The objective is to assess clinical and social outcomes for
people with newly diagnosed epilepsy from the age of 2 years upwards
in relation to a variety of prognostic factors, including age at onset,
seizure and syndrome classifications, pharmacological treatment, and
socioeconomic background. Data will be collected on an electronic case
record form (CRF). FONDE investigators will be invited to enter the
clinical details of 10 or more patients each year in whom they have
made a diagnosis of epilepsy (see www.eucare.org for information and
application form). Each patient will be followed up prospectively for
a minimum of 3 years. The primary outcome variable is the proportion
seizure free for at least 1 year. Secondary outcome variables include time
to reach 1, 2 and 3 years remission, proportion of patients discontinuing
each drug due to inefficacy or side effects, lifestyles/social parameters
and morbidity and mortality. This study will provide prospective data
in assessing outcomes and responses to treatment, insights into the lives
of people with epilepsy and levers to implement political change in
improving epilepsy services across Europe.
AEDs TRIALS ACROSS EUROPE: OPTIMISING THE RE-
SOURCES AND INCREASING THE POTENTIAL
M. Baulac (Service de Neurologie, Hopital Pitie-Salpetriere, Paris,
France)
No abstract received.
HOW CAN ILAE AND THE COMMISSION ON EURO-
PEAN AFFAIRS (CEA) FACILITATE EUROPEAN RESEARCH
COLLABORATION?
P. Wolf (National Hospital Copenhagen and Danish Epilepsy Centre
Dianalund, Denmark)
To encourage and facilitate research is one of the primary objectives
of the ILAE. The traditional ways comprise the publication of Epilep-
sia and the organization of international congresses. Much attention has
successfully been paid to continuously improve the quality of both con-
gresses and journal. Epilepsy research increasingly needs large databases
(e.g. to study the genetics of epilepsy syndromes with polygenic inheri-
tance or teratogenic effects of antiepileptic drugs), or addresses relatively
rare conditions where as many cases as possible need to be collected.
Therefore, epilepsy research often ideally is collaborative research of
multinational groups. These can develop spontaneously from the initia-
tive of few people, but they may also be facilitated by appropriate means.
Various mechanisms have been installed and others are envisaged.
In 1996, the European Epilepsy Academy (EUREPA) was founded as
an initiative of the CEA, and one of its objectives is to facilitate transna-
tional research. Since EURAP, the Registry of Antiepileptic Drugs and
Pregnancy was implemented, EUREPA provides logistics for its finan-
cial management. EUREPA also has access to an informal network of
European researchers which has been able within days to organize an
expression of interest with multinational, multicentre European partici-
pation in response to a research announcement. These possibilities are
still little known but can be activated for new projects at any moment.
Advanced courses and summer schools, of which the CEA will soon
be offering 2–3 per annum, are fora for young investigators to meet and
establish connections between each others and with seniors who may act
as tutors for collaborative research.
The ILAE is starting to invest funds into the development of educa-
tion, structure of epilepsy care and translational research, and research
scholarships, bursaries and mentorship programmes are being consid-
ered which all should contribute to the expansion of research networks.
Monday July 3, 2006
15:00–17:00
Hall 1
Finnish Epileptology Symposium
Unverricht-Lundborg disease in Finland and else-
where
THE CHANGING CLINICAL PICTURE OF UNVERRICHT-
LUNDBORG DISEASE
P. Genton (Centre Saint-Paul-HHG, France)
Unverricht-Lundborg disease (ULD) was reported under multiple
names, mainly from the Baltic and Mediterranean areas, as a severe,
invalidating condition with limited life expectancy, much as other pro-
gressive myoclonus epilepsies (PME). Recent years have witnessed dra-
matic changes in the overall picture, which occurred in several phases:
1. The disease was unified as ULD on clinical grounds, and this
process was validated by the a single genetic cause, i.e., muta-
tions (dodecamer repeats in most) in the cystatin B (stefin) gene
on chromosome 21. However, this unification has been chal-
lenged recently by the possibility of other loci, which might be
associated with slight clinical variations.
2. The avoidance of aggravating drugs, e.g., phenytoin, and the
use of efficient and adapted anticonvulsant and antimyoclonic
agents (in historical order, phenobarbital and primidone, ben-
zodiazepines and valproate) helped many paitents gain control
of myoclonus and seizures and enjoy a much better qualitiy of
life.
3. The emergence of new, very active agents like piracetam, zon-
isamide, topiramate and levetiracetam brought further progress.
Nowadays, ULD appears as a comparatively mild form of PME, with-
out shortened life expectancy, and in recent long-term studies indeed the
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disease tends to level off in adulthood. Its present clinical picture can
thus be summarized in the following way:
- onset in late childhood or early adolescence with GTCS and action
myoclonus,
- coexistence of very benign and very severe cases, even within
sibships,
- absence of associated dementia or sensory deficits,
- GTCS and clonic seizures that tend to remit after 8–10 years,
- EEG changes, including photosensitivity, that also tend to disap-
pear,
- myoclonus progressing over 2–8 years then stabilizing at a given
level.
ULD thus appears to have limited progression. The overall prognosis,
which is highly variable, can be acurately made within 2–3 years of
onset.
MOLECULAR BASIS OF UNVERRICHT-LUNDBORG DIS-
EASE: WHERE ARE WE TODAY?
A. Lehesjoki (Folkha¨lsan Institute of Genetics and Neuroscience Center,
University of Helsinki, Finland)
The gene underlying progressive myoclonus epilepsy of Unverricht-
Lundborg type (Unverricht-Lundborg disease, EPM1) was identified ten
years ago as the one coding for cystatin B (CSTB), a ubiquitously ex-
pressed inhibitor of several lysosomal cysteine proteases, cathepsins.
Since then, significant advances have been made in understanding the
molecular genetic basis of EPM1. An unstable dodecamer repeat expan-
sion in the regulatory promoter region of the CSTB gene accounts for 90%
of disease alleles worldwide, the majority of the patients being homozy-
gous for this mutation. Seven rare mutations that, with one exception,
occur in compound heterozygous form with the expansion mutation have
also been reported. Molecular diagnostics for EPM1 is currently readily
available and used on a routine basis in clinical work. In a number of
patients only one copy of the minisatellite expansion mutation have been
identified, the other abnormal allele remaining undetected. Moreover, a
number of patients with clinical features compatible with EPM1 do not
have mutations in the CSTB gene, suggesting the presence of other genes
in the genome accounting for the same phenotype. A locus for one such,
EPM1B, has been localized to chromosome 12q. Cstb-deficient mice that
have been produced by targeted disruption of the mouse Cstb gene de-
velop progressive ataxia and myoclonic seizures resembling the human
phenotype and can thus be used to model the human disease. These mice
show apoptotic death in cerebellar granule cells, less marked neuronal
apoptosis in the hippocampal formation and entorhinal cortex, neuronal
atrophy and gliosis. Findings in the mouse model suggest differential
neuronal sensitivity to CSTB deficiency. Even if advances have been
made in functional analyses of cellular and animal models for EPM1 the
molecular mechanisms underlying the development of EPM1 remain,
however, still largely unknown.
NEUROPHYSIOLOGY OF UNVERRICHT-LUNDBORG
DISEASE
S. Franceschetti (National Neurological Institute C. Besta, Italy)
Progressive myoclonus epilepsies (PME) share some clinical aspects,
including action myoclonus, epileptic seizures (Marseille Consensus
group), and neurophysiological features reflecting a hyperexcitable con-
dition of the cerebral cortex. However, PME result from heterogeneous
genetic disorders with different pathogeneses that result in uneven phys-
iopathological mechanisms of excitability. We summarize here the elec-
trophysiological characteristics found in a population of patients with
Unverricht-Lundborg disease (ULD).
Most ULD patients submitted to neurophysiological evaluation
showed mildly enlarged “early” (P25-N33) components of somatosen-
sory evoked potentials and consistently enhanced long-loop “cortical
reflexes.” Moreover, coherence analysis of EEG-EMG relationship in-
variably showed the presence of pathological cortical rhythms driving
recurrent myoclonic burst with a time-transfer consistent with a corti-
cospinal conduction in all patients.
“Paired-pulse” stimulation protocols performed by means of tran-
scranial magnetic stimulation indicated a short-term increased excitabil-
ity/decreased inhibition of motor cortex.
Postmovement EEG synchronization in beta-band, considered as a
marker of cortical inhibition, was weak or lacking in ULD patient, and the
degree of its impairment correlated with the severity of action myoclonus.
All the neurophysiological findings indicated a homogenous neuro-
physiological profile in ULD due to the hyperexcitability of a consistent
circuitry, prominently involving the motor cortex and resulting in a short-
term increased excitation/decreased inhibition. These findings appeared
to be suitable to describe the ULD phenotype, to differentiate it from
other forms of PMEs, to assess the severity of neurological impairment
at the time of patient observation and to give measurable parameters
during the follow-up.
The persistence of a precise dysfunctional profile in patients rationally
treated with antiepileptic and antimyoclonic drugs (usually capable of
controlling epileptic seizures and photosensitivity) well matches with
the poor sensitivity of action myoclonus to pharmacological treatments.
This could also suggest a prominent susceptibility of specific cerebral
structures to the damage due to cystatin B deficiency characterizing ULD.
PROSPECTS FOR ANTIEPILEPTIC TREATMENT IN
UNVERRICHT-LUNDBORG DISEASE
G. de Haan (SEIN, Heemstede, Netherlands)
Treatment of Unverricht-Lundborg disease (ULD) and other progres-
sive myoclonic epilepsies (PME) should encompass seizures and my-
oclonus, and treatment of the underlying neurological disease.
The objective of the presentation is to give an overview of the current
state of anticonvulsant treatment. In the first years after onset of ULD
the seizures and myoclonus may be responsive to medication, but af-
ter a few years myoclonus may become refractory. Valproate has been
widely accepted as drug of first choice, often with adjunctive treatment
for the myoclonus. A number of new drugs may be interesting, due to
reported effectiveness in the treatment of myoclonus. Other drugs, such
as carbamazepine, phenytoine, and lamotrigine may be ineffective and
even may increase myoclonus. Phenytoin may have a detrimental effect
on the course of ULD, and should therefore be avoided.
Progression of ULD is particularly pronounced in the first years after
onset. Causal treatments may be developed now the causative molecular
mechanisms are being unraveled. Such treatment should start as early
as possible in the course of the disease, in order to prevent irreparable
damage to the nervous system.
After this presentation the listener should be informed about current
treatment options for ULD, and we hope a discussion will be encouraged
about the importance of early diagnosis and possibility of measures slow-
ing down progression.
Monday July 3, 2006
15:00–17:00
Hall 5A
Discussion Group Session
Role of electrocorticography, stereo-EEG, subdural
grids, ictal SPECT and magnetoencephalography in
the preoperative evaluation of patients with focal dys-
plastic lesions
ROLE OF ELECTROCORTICOGRAPHY IN THE PRE-
OPERATIVE EVALUATION OF PATIENTS WITH FOCAL DYS-
PLASTIC LESIONS
A. Palmini (UZ Gasthuisberg, Leuven, Belgium and Porto Alegre
Epilepsy Surgery Program, Porto Alegre, Brazil)
Acute electrocorticography (ECoG) is a time-honoured procedure to
delineate the distribution of interictal spikes in the cortical area exposed
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by the craniotomy, and which has been previously demonstrated to (hope-
fully) contain the epileptogenic zone (EZ). Although the precise rele-
vance of these acutely recorded interictal spikes to the final localization
of the EZ is still unclear, significant advances in this regard have been
made in patients with refractory epilepsies due to focal dysplastic lesions.
These dysplastic lesions have at least two important features which can
be fruitfully explored by ECoG electrodes, particularly individualized,
carbon-ball electrodes: (i) microscopic dysplastic abnormalities are often
found surrounding the MRI-visible lesion, and these can often be iden-
tified (or at least suspected) by specific patterns of ECoG spikes, and
(ii) focal dysplastic lesions commonly extend to the depths of sulci, and
completeness of resection may be helped by the identification of spikes
in these deeper regions, not easily probed by purely surface electrodes.
Nevertheless, a major caveat of this procedure is the virtual impossibility
to record seizures in the short duration of the recording.
It is with these assets and caveats in mind that one should conceptual-
ize the role of acute ECoG in the resection planning of patients with focal
dysplastic lesions. Should independent, ‘non-neurophysiological’ surro-
gates of the ictal onset zone be accepted in patients with focal dysplastic
lesions, acute ECoG may often obviate the need for chronic recordings
with intracranial electrodes. More specifically, when the lesion is visible
and concordant with focal ictal hyperperfusion (as probed by SISCOM),
acute ECoG spikes may help the final tailoring of resection. Long-term
results of a large surgical series obtained with the help of acute ECoG
and without resorting to chronic intracranial recordings will be presented
to feed the discussion on the role of ECoG for these patients.
ROLE OF STEREO-EEG IN THE PREOPERATIVE EVALUA-
TION OF PATIENTS WITH FOCAL DYSPLASTIC LESIONS
F. Chassoux (Department of Neurosurgery, Centre Hospitalier Sainte-
Anne, Paris, France)
Focal cortical dysplasias (FCDs) are associated with severe partial
epilepsy that can be cured by surgery if complete resection can be per-
formed. High resolution MRI can detect the dysplastic tissue but limits
of the lesion are often difficult to determine on imaging. Moreover, MRI
can be normal in 20 to 30% of cases. Stereo-EEG recordings have been
proved to be useful to delineating the extent of dysplastic tissue. The main
electrophysiological criteria corresponding to FCDs consist of: 1) inter-
ictal subcontinuous rhythmic spiking activity persisting after diazepam
injection; 2) lack of background activity; 3) site of ictal discharge onset
after brief speeding of rhythmic spikes; 4) site of elicited seizures either
by low or high frequency electrical stimulation; 5) early reappearance of
rhythmic spikes after ictal discharges.
Using these criteria, 24 patients (11 females) aged from 7 to 40 years
(mean 22.6) have been operated during the 5 last years with favourable
outcome (class I) in 23 cases. In these patients, MRI was considered as
normal in 11 cases. Focal resections have been performed in eloquent
areas (central, pre-or postcentral areas) in 13 cases without permanent
motor deficit. Others resections were performed in the frontal lobe (8
cases), the parietal lobe (2 cases) and the occipital lobe (1 case). FDG-
PET was performed in all patients, demonstrating a good concordance
between the extent of hypometabolic areas and the epileptogenic zone
determined by stereo-EEG. Taking into account these data, eight others
patients with frontal (6 cases) or central FCDs were recently successfully
operated without invasive procedure.
Stereo-EEG has allowed to greatly improving surgical strategy and
outcome in FCDs. In our experience, it remains useful in cases of FCDs
with normal MRI (“cryptogenic cases”) and some poorly delineated
FCDs located in functional areas.
ROLE OF SUBDURAL GRIDS IN THE PREOPERATIVE EVAL-
UATION OF PATIENTS WITH FOCAL DYSPLASTIC LESIONS
I. Najm (Cleveland Clinic, USA)
Subdural electrodes (stainless steel or MR-compatible platinum) elec-
trodes are embedded in strips or sheets of polyurethane or other synthetic
material and are implanted subdurally over the suspected epileptogenic
and/or functional dysplastic regions. Subdural grids are inserted through
either open craniotomy or burr-hole openings and registered stereotac-
tically for extraoperative mapping. The cortical covering may extend
beyond the visualized cortical area, as grids may be slid beyond the
edges of the craniotomy to cover adjacent areas for the purpose of bet-
ter electrocorticographic (EcoG) and/or functional sampling. Beside the
EcoG recordings and direct electrical stimulation studies, grids can be
used to record somatosensory evoked potentials after stimulation of the
trigeminal (lip) or median nerves for central sulcus localization.
Advantages of chronic, extraoperative subdural recordings include the
ability to record cortical ictal events and to determine the functionality
of the underlying cortex. Additionally, direct cortical recordings are per-
formed in the well-controlled environment of the epilepsy monitoring
unit on a relaxed, cooperative patient without the time constraints of the
operating room environment.
As this procedure involves the insertion of foreign bodies into the cra-
nial vault, the surgical risks include wound infection, flap osteomyelitis,
acute meningitis, cerebral edema, and hemorrhage. Concerns about in-
creased intracranial pressure may limit the maximal number of electrodes
that can be inserted and therefore may result in limited epileptic mapping
from large cortical areas. Other limitations may include the anatomic lo-
cation of the proposed area of sampling (e.g., mesial orbitofrontal) and
“redo” surgeries with cortical adhesions. In areas of difficult surgical
access, like the mesial surface of the hemispheres or in deep regions
of the brain, stereotactic placement of depths electrodes (stereo-EEG),
alone or combined with subdural grids, are good options, promoting an
adequate coverage and precise targeting of the desired areas.
General indications for invasive electrode implantation in the evalua-
tion of patients with epilepsy:
When noninvasive studies remain nonconcordant or inconclusive re-
garding the localization and the extent of the seizure onset zone and/or
the eloquent cortex, invasive studies using subdural grids and/or depth
electrodes may be needed. Jayakar proposed the following relative indi-
cations for the evaluation with subdural grids: normal structural imag-
ing, extratemporal location, divergent noninvasive data, encroachment
on eloquent cortex, tuberous sclerosis, and cortical dysplasia. Rosenow
and Lu¨ders recommended the use of subdural electrodes only in patients
with focal epilepsy (single focus) in whom there is a clear hypothesis re-
garding the location of the epileptogenic zone (derived from non invasive
studies),
In patients with focal CD, the two main indications for the use of ex-
traoperative invasive electrode recordings are: 1) definition of the epilep-
togenic region and 2) mapping of the eloquent areas.
1. Definition of the epileptogenic zone in patients with focal CD
The epileptogenic zone is the area of the cortex that is indispensable
for the generation of epileptic seizures and whose resection or complete
disconnection leads to seizure control. In most cases of focal CD, the data
generated from noninvasive EEG recordings and other electrophysiolog-
ical/neuroimaging techniques are sufficient to define the approximate
location of the epileptogenic zone.
Various studies using direct electrocorticographic recordings showed
that focal CD lesions are intrinsically epileptogenic. The need for inva-
sive monitoring to define the location and extent of epileptogenicity in
focal CD is warranted by the fact that the epileptogenic area in patients
with CD is frequently larger than the visually identified CD. Moreover, in
CD lesions with severe FLAIR signal increase (balloon cell-containing
dysplastic lesions) epileptogenicity mainly arises from the surrounding
dysplastic cortex that is devoid of balloon cells.
2. Localization of the functional (“eloquent”) cortical regions in
focal CD.
As most CD lesions are often localized in the frontal lobe (therefore in
potentially “eloquent” cortex), an understanding of the functional status
of the involved region(s) and of its anatomical and pathological corre-
lates is of prime importance. We recently assessed the functional status
(as identified by direct cortical electrical stimulation) of focal CD and
its relationship with imaging, and in situ electrocorticographic (ECoG)
characteristics in patients who underwent focal neocortical resection for
the treatment of medically intractable epilepsy. Our results showed that
some focal CD lesions that are typically characterized by significant
FLAIR signal increase on MR imaging and are located in anatomically
functional areas (primary motor, Broca area, etc) are not functional upon
direct electrical stimulation, the same lesions did not show evidence of
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intrinsic epileptogenicity as assessed through the mapping of the ictal
onset zones. On the other hand, CD lesions with mild or no FLAIR sig-
nal increase were functional and at times epileptogenic. These results are
in agreement with previous reports that showed the persistence of elo-
quent function in CD that are devoid of balloon cells. Similar EcoG pat-
terns were reported in patients with low-grade glial tumors (e.g dysem-
bryoplastic neuroepithelial tumor; DNET and ganglioglioma) whereas
dysplastic and epileptic cortical areas were found in the immediate sur-
roundings of these lesions. Moreover, these results show that functional
cortex may be displaced within the same hemisphere and therefore may
have direct implications on the options for epilepsy surgery.
Proposed indications for use of subdural grids in patients with focal
CD: As the limited success after surgical resection in epileptic patients
with CD is likely related to a lack of an accurate definition of the “true
margins” of the epileptogenic lesion, direct electrocorticographic record-
ings using subdural grids are needed.
We believe that subdural electrodes should be used in the evalua-
tion of epileptic patients with suspected focal CD after the diagnosis of
focal epilepsy is confirmed through the careful analysis of the seizure
semiology, noninvasive scalp EEG recordings and other anatomic and
functional neuroimaging techniques. The goals from the invasive eval-
uation should be clear (mapping of epileptogenicity and function) with
the understanding of the limitations and risks of the evaluation
The continuous improvement in current functional imaging techniques
(such as EEG triggered functional MRI) and the future development
of micro imaging techniques that would potentially map the molecular
markers of epileptogenicity will obviate the need for invasive recordings.
ROLE OF ICTAL SPECT AND SISCOM IN THE PRE-
OPERATIVE EVALUATION OF PATIENTS WITH FOCAL DYS-
PLASTIC LESIONS
W. Van Paesschen (UZ Gasthuisberg, Neurology, Leuven, Belgium)
Background: Invasive EEG studies are often considered necessary
to localize the epileptogenic zone in partial epilepsies associated with
focal dysplastic lesions (FDL). Our aim was to evaluate the relationships
between SISCOM hyperperfusion clusters and MRI-visible FDL, and to
establish a preliminary algorithm for a noninvasive presurgical evaluation
protocol for MRI-visible FDLs in patients with refractory epilepsy.
Methods: Fifteen consecutive patients with refractory partial epilepsy
and a single MRI-visible FDL underwent a noninvasive presurgical eval-
uation including SISCOM. Each hyperperfusion cluster was visually
analyzed, automatically quantitated, and its distance form the lesion as
outlined on the MRI was measured. In patients who underwent surgery,
the volumes of resected brain tissue containing the FDL, the SISCOM
hyperperfusion cluster, and surrounding regions were assessed on post-
operative MRI and correlated with surgical outcome.
Results: Fourteen of the 15 patients (93%) showed SISCOM hyper-
perfusion overlapping with the FDL. The FDL was detected only after
re-evaluation of the MRI guided by the ictal SPECT in 7 of the 15 pa-
tients (47%). Four distinct hyperperfusion patterns were observed, rep-
resenting different degrees of seizure propagation. Nine patients have
been operated. Five have been seizure free since surgery and one since
a reoperation. The degree of resection of the MR-visible FDL was the
major determinant of surgical outcome. Full resection of the SISCOM
hyperperfusion cluster was not required to render a patient seizure free.
Conclusion: Detailed analysis of SISCOM hyperperfusion patterns
is a promising tool to detect subtle FDL on MRI and to establish the
epileptic nature of these lesions non-invasively. Overlap between the
SISCOM hyperperfusion cluster and MR-visible FDL in a non-invasive
presurgical evaluation with concordant data may suffice to proceed to
epilepsy surgery aimed at removing the MR-visible FDL and the part
of the hyperperfusion cluster within and immediately surrounding the
FDL.
ROLE OF MAGNETOENCEPHALOGRAPHY IN THE PRE-
OPERATIVE EVALUATION OF PATIENTS WITH FOCAL DYS-
PLASTIC LESIONS
T. Bast (Department of Pediatric Neurology, University Hospital Hei-
delberg, Germany)
Rational: Magnetoencephalography (MEG) simultaneous to EEG is a
non-invasive diagnostic tool with high temporal resolution. Localization
accuracy of inverse source analysis is satisfactory presenting some ad-
vantages of MEG over EEG, i.e., lower influence of volume conduction.
The subject matter consists in the role of MEG in the diagnostic workup
of patients with focal dysplasias.
MEG in focal dysplastic lesions: Several MEG/EEG studies have con-
firmed the concept of intrinsic epileptogenicity of dysplasias (i.e., focal
cortical dysplasia, polymicrogyria), since sources modeling interictal
epileptiform activity were mostly localized within the lesion as defined
from MRI, invasive recordings and resection outcome. However, MEG
provides information exclusively regarding the interictal irritative zone,
as seizures generated by the epileptogenic cortex are rarely recorded.
Only 3 out of 20 patients with FCD investigated by our group had a
seizure during MEG acquisition. Source analysis of ictal MEG patterns
in these cases localized the dipole within the dysplasia. None of the
methods of inverse analysis in MEG or EEG can provide an accurate
estimation of the extent of an activated cortical area. Although MEG
source analysis may identify the maximum center of an irritative or
even epileptogenic zone, other methods are required to tailor a resection
(mainly MRI, eventually PET/SPECT). However, MEG may be helpful
even in clear, MRI-defined cases, because identified maxima of irritative
or epileptogenic zones should be covered by the resection or at least by
invasive electrodes. A special role of MEG can be presumed in cases
of cryptogenic focal epilepsies. Since MEG sources usually localize
within the FCD in “clear” lesions, the same can be assumed for crypto-
genic cases, in many of which a FCD is revealed through histopathology.
To our experience, MEG source analysis was crucial for later epilepsy
surgery in a series of 6 patients with cryptogenic frontal lobe epilepsies
caused by FCD.
Conclusion: MEG with simultaneous EEG analysis is a non-invasive
and helpful tool in the process of presurgical epilepsy evaluation in pa-
tients with focal dysplastic lesions.
Monday July 3, 2006
15:00–17:00
Hall 5B
Discussion Group Session
From functional brain anatomy to clinical seizure
semiology
THE MOTOR SYSTEM AND SEIZURE SEMIOLOGY
C. Baumgartner (Department of Neurology, Medical University of Vi-
enna, Austria)
Motor manifestations during epileptic seizures include focal clonic
motor seizures, seizures with asymmetrical tonic posturing and seizures
with hypermotor automatisms. Focal clonic motor seizures are generated
by epileptic activity in the primary motor cortex and consist of unilateral,
jerky, usually rhythmic movements, frequently also tonic components
like tonic postural signs and tonic face contractions can be observed.
Most frequently they start in the face or hand due to their large repre-
sentation in primary motor cortex and due to a lower seizure threshold
of these cortical regions. Asymmetric tonic seizures or supplementary
motor area (SMA) seizures are mediated by epileptic activity in the sup-
plementary sensorimotor area or the premotor cortex, but can also be
generated by epileptic activity in other frontal lobe regions. Because
frequently somatosensory auras like feelings of pulling, pulsing, heav-
iness, numbness or tingling which can occur ipsi-, contra- or bilater-
ally occur the term “supplementary sensorimotor seizures” has been
introduced. Asymmetric tonic seizures are characterized by bilateral,
asymmetric, tonic or dystonic posturing of the extremities and facial gri-
macing resulting in tonic posturing. Vocalizations frequently occurring
during asymmetrical tonic seizures can be a reactive phenomenon, can
be caused by a tonic contraction of the diaphragm and laryngeal muscles
and finally can be a consequence of an activation of Broca’s area or SMA.
While hyperkinetic or ‘hypermotor’ automatisms are not associated with
a seizure onset in any specific region within the frontal lobes. They are
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characterized by prominent and complex, coordinated, purposeless or
semipurposefull movements (trembling, waving, rotating, stepping, cy-
cling, rocking, hopping etc.) with an agitated or frenetic appearance. Vo-
calizations often are explosive and pronounced which seems to be unique
for frontal lobe seizures with hypermotor automatisms. Seizures with hy-
permotor automatisms usually are associated with a loss of conscious-
ness and therefore also are referred to as frontal lobe complex partial
seizures.
THE CENTRAL AUTONOMIC NETWORK AND SEIZURE
SEMIOLOGY
J. Janszky (University of Pecs, Hungary)
No abstract received.
CONSCIOUSNESS AND SEIZURE SEMIOLOGY
A. Ebner (Department Presurgical Evaluation, Epilepsy Center Bethel,
Bielefeld, Germany)
Semiology of epileptic seizures depends on what part and how much
of the brain is involved by pathologic ictal activation. One among many
observable clinical ictal signs is alteration or even loss of consciousness,
pragmatically defined as loss of contact, inability to respond to external
stimuli, and loss of memory of what occurred during the seizure. These
alterations can take place gradually in the course of a focal seizure, for
example, beginning with the perception of an aura, an initial ability to
respond to the environment, but then followed by a more or less complete
loss of responsiveness. The initial auras may be remembered or not, the
latter probably being a sign of a more rapid spread of seizure activity to
the contralateral hemisphere (Schulz et al. Epilepsy Res 2001;43:201–
10). Automatisms in complex partial seizures (automotor seizures) of
temporal lobe origin are usually associated with loss of consciousness
and occur at the time of spread to the contralateral temporal lobe. How-
ever, in temporal lobe seizures arising in the non-dominant hemisphere
showing no spread, impairment of consciousness may be very mild or
absent even in the presence of vivid distal oral and/or manual automa-
tisms (Ebner et al. Neurology 1995; 45: 61–4). Loss of consciousness
can also set in immediately at the beginning of a complex partial seizure,
probably indicating rapid spreading of the seizure activity to the con-
tralateral temporal lobe, which is also associated with bitemporal dis-
ease and amnesia for auras (Schulz et al. Neurology 1995;45:231–5).
Hypermotor seizures characterized by proximally accentuated and often
violent automatisms can also be accompanied by preserved or impaired
consciousness and memory, partially depending on the duration of the
seizure.
Pathophysiologically, there is evidence that impairment of conscious-
ness has a strong association with secondary hyperperfusion in the tha-
lamic/upper brainstem region as revealed by an ictal SPECT study (Lee
et al. Neurology 2002;59:841–6). These authors suggest that the spread
of epileptic discharges or a trans-synaptic activation (diaschisis) of these
structures is an important mechanism in the alteration of consciousness
during seizures of focal origin.
In focal seizures a gradual impairment of consciousness can often be
observed with disturbance of only some of the constituents representing
“consciousness” such as memory, language, etc.
In absence seizures loss of consciousness is the hallmark of seizure
semiology although sometimes occurring together with motor symp-
toms that are usually mild. Loss of consciousness occurs abruptly and
is indispensably associated with generalized spike wave activity in the
EEG. Several pathophysiological hypotheses exist to explain this sud-
den interruption of the stream of consciousness and emphasize either
the leading role of cortical or subcortical (thalamic or reticular systems)
mechanisms. The new theory of a ”cortical focus” for generalized ab-
sence epilepsy bridges cortical and thalamic theories (Meeren H et al.
Arch Neurol 2005;62:371–6. From this focus, seizure activity general-
izes rapidly over the cortex. During the first cycles of the seizure the
cortex drives the thalamus, while thereafter cortex and thalamus drive
each other, thus amplifying and maintaining the rhythmic discharge.
EMOTION AND SEIZURE SEMIOLOGY
A. Gil-Nagel (Hospital Ruber Internacional, Madrid, Spain)
Affective states are regulated by different brain structures and change
in relation to internal and external situations, creating a range of emo-
tions. Numerous studies have demonstrated abnormal emotional re-
sponses in relation to focal lesions of the central nervous system, mostly
those involving the prefrontal cortex, the cingulate gyrus and the amyg-
dala, however these studies also suggest that many other areas in the
frontal and temporal lobes, the hypothalamus and beyond are also in-
volved in the physiology of emotional responses and the changes in
the autonomic nervous system that often are associated with the mani-
festation of emotions. Clinical research suggests that the generation of
mirth and laughter requires integrity of right hemisphere structures, while
gloom and cry are more related to the left hemisphere. Several studies
have also evaluated the ictal semiology of emotions and its clinical im-
plications. These studies analyze emotional behavior during seizure or at
the time of electrical stimulation during epilepsy surgery. Most of these
studies agree with other anatomical analysis and tend to show a pre-
dominance of ictal emotions in patients with focal epilepsies involving
the temporal and frontal lobes. In a series of 134 seizures analyzed with
ictal video-EEG recordings 34 seizures (25%) showed ictal emotions,
the most common were anxiety and fear; other emotions were laugh-
ter, crying, kissing and restlessness. 74% of seizures showing emotional
features had a temporal lobe origin and 12% were frontal, there were
no significant differences between left and right hemispheres. Laugh-
ter is a usual manifestation of hypothalamic hamartomas, and is related
to activation of the hamartoma. In addition, weeping and crying are
more often observed in psychogenic seizures than in epileptic seizures.
Therefore, the analysis of emotions may have practical value in the eval-
uation of epilepsy, however, larger studies with multimodal diagnostic
analysis are necessary in order to provide guidelines about its clinical
significance.
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Nosology and pathophysiology of the epilepsies in the
first three years of life
ARE THERE RECOGNISABLE EPILEPSY SYNDROMES IN
NEWBORNS?
P. Plouin (Hopital Necker Enfants Malades Paris, France)
Since the last classification of epilepsies and epileptic syndromes,
which was adopted in 1989, 4 epilepsy syndromes appear in neonates.
Two of them are considered as benign: Benign Familial Neonatal
Seizures (BFNS), and Benign Idiopathic Neonatal Seizures (BINS). The
first one is quite rare but easy to recognize as there is a constant family
history, a normal clinical examination, seizures are stereotyped, focal,
brief and never lead to a status epilepticus. It was the first syndrome with a
genetic background assessed from 1989. On the other hand, BINS are no
more frequent among neonates, as it was when described in the seventies.
In this condition, the diagnosis remains one by exclusion, facing a long
lasting status of seizures (around 2 days).
The 2 other syndromes can be associated as “Neonatal Epileptic
Encephalopathies with Suppression Burts.” In Early Myoclonic En-
cephalopathy the main seizure type is myoclonia, erratic or generalized,
as in Ohtahara syndrome, epileptic spasms and focal seizures are predom-
inant. It is not always easy to discriminate the 2 conditions and this may
be important considering etiology ant treatment. Ictal electro-clinical and
interictal EEG patterns may help a lot in this purpose. Some etiologies
as glycine encephalopathy on one hand or hemimegalencephaly on the
other hand are quite easily recognizable.
Since 1989, new syndromes have been reported, among them Migrat-
ing Partial Seizures in Infancy (MPSI). In this syndrome seizures may
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start from birth, and the multifocal character of the seizures as well as
the “subnormal” interictal EEG are a good orientation to the diagnosis.
Still nearly 30% of cases of neonatal seizures do not get any syndromic
nor etiological classification, and the outcome is very difficult to assess
in these conditions.
Definition of epilepsy syndromes among neonates remains an impor-
tant challenge considering treatment and prognosis.
IDIOPATHIC SYNDROMES IN INFANTS: THE GENETIC
BACKGROUND
f C. (Neurogenetics Laboratory, Department of Child Neurology and
Psychiatry, IRCCS Fondazione Stella Maris, Italy)
Seizures occurring in the first 3 years life might be associated with
serious underlying structural brain disease or metabolic abnormalities.
However, there are several idiopathic syndromes beginning in the first
few days of life or in infancy with a genetic aetiology. Benign familial
neonatal seizures (BFNS) begin around day 3 and are caused by mu-
tations in the potassium channel genes KCNQ2 and KCNQ3. Benign
familial infantile seizures (BFIS) begin around 6 months of age and may
be associated with paroxysmal dyskinesias in later childhood. Linkages
to chromosomes 19 and 16 were reported but gene defects have not
yet been identified. A mutation in the ATP1A2 gene was reported in
one family in which there was partial cosegregation of familial hemi-
plegic migraine and infantile seizures. Families with an intermediate
variant–benign familial neonatal-infantile seizures (BFNIS)–have also
been described carrying missense mutations in the gene coding for the
α2 subunit voltage-gated sodium channel (SCN2A).
Febrile seizures are the most common type of seizures in children
occurring between age 6 months to 6 years. The mode of inheritance
has been hypothesised to be autosomal dominant in some families and
polygenic in others. Several loci have been published but no genes have
yet been identified. The variant of febrile seizures plus (FS+) in which
febrile seizures extend past the age 6 years and/or afebrile seizures occur
at any age, is part of the generalized epilepsy with febrile seizures plus
spectrum (GEFS+). Mutations in the genes coding for the α1 and β1
subunits of the voltage-gated sodium channel (SCN1A and SCN1B) and
the γ 2 subunit of the GABAA (GABRG2) have been identified in few
families. Severe myoclonic epilepsy of infancy (SMEI) has also been
described in few families with GEFS+. De novo mutations of SCN1A
are present in about 70% of SMEI patients.
SYMPTOMATIC SYNDROMES IN INFANTS: ETIOLOGY AND
ELECTROCLINICAL PATTERNS
R. Guerrini (Department of Child Neurology and Psychiatry, University
of Pisa, Italy)
A concept that challenges our ability to understand the relationships
between brain structure and function is that of epileptic encephalopa-
thy (EE), often occurring in symptomatic early onset epilepsies. EEs
occur when seizures, epileptiform EEG abnormalities, or both, result in
impaired neurological and cognitive development and functioning. EEs
represent about 40% of all epilepsies occurring in the first three years of
life. Some children (for example those suffering from Dravet syndrome)
have no detectable lesions, in which case most of the entire clinical
picture is usually attributed to epilepsy, as suggested by the temporal
relationship between the onset of seizures and evidence of developmen-
tal impairment. When a brain lesion is present, however, the concept of
epileptic encephalopathy is not easily delineated, since an evaluation of
the extent to which epilepsy is likely to interfere with residual develop-
mental potential could be arbitrary. There is no doubt, however, that the
area of dysfunction that originates from a lesion may spread to anatom-
ically intact areas and circuits that are distant from the primary lesion
and drag them into a dysfunctional network.
Vigorous early pharmacological or surgical treatment is often advo-
cated on the assumption that epileptic activity would cause or worsen the
encephalopathy per se. However, for many of these conditions there are
no established endpoints of treatment and drug adjustments are very em-
pirically established. Complete seizure control should not be presented
as a fundamental target to the child and parents. The main goal should
be minimizing seizure frequency to an extent that seizures, per se, do
not represent an impossible obstacle to social integration. This target can
be reached by trying to find the right balance between side effects and
seizures. For those syndromes, in which a definite structural abnormal-
ity underlying epileptogenesis is recognized, and drug treatment fails,
surgical treatment can be very successful and can prevent or ‘cure’ the
epileptic encephalopathy.
EARLY EPILEPSY AS AN EXPRESSION OF INBORN
METABOLIC DISORDERS IN NEWBORNS AND INFANTS
R. Surtees (UCL Institute of Child Health, London, UK)
Early-onset, treatable metabolic epileptic encephalopathies
Seizures are a common symptom in many metabolic diseases. How-
ever, few present with epilepsy; yet some of these are treatable. Here
I will review the clinical features and treatment of early onset, treat-
able, metabolic epileptic encephalopathies. These naturally divide into
two groups: vitamin-responsive epileptic encephalopathies; and, some
other metabolic epileptic encephalopathies. Vitamin responsive epilep-
sies comprise: pyridoxine dependant epilepsy; folinic acid responsive
epilepsy; pyridoxal phosphate oxidase deficiency and biotinidase de-
ficiency. Other, potentially treatable metabolic epilepsies are glucose
transporter 1 deficiency, creatine deficiency syndromes and serine defi-
ciency syndromes.
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Cognitive dysfunction in children with temporal lobe
epilepsy
NEUROPSYCHOLOGICAL DEFICITS IN CHILDREN WITH
TEMPORAL LOBE EPILEPSY: ARE THEY SPECIFIC?
F. Vargha-Khadem (Institute of Child Health, Development Cognitive
Neuroscience Unit, London, UK)
No abstract received.
INPUT OF FUNCTIONAL AND STRUCTURAL NEUROIMAG-
ING TECHNIQUES WHEN STUDYING COGNITION IN CHIL-
DREN WITH TLE
M. Seeck (University Hospital of Geneva, Switzerland)
Temporal lobe epilepsy (TLE) in children is less frequently diag-
nosed than extratemporal lobe epilepsy as compared to adult patients;
however, TLE in adults is often traced back to childhood. TLE in chil-
dren varies greatly with respect to etiology, severity or age of onset.
While clinical observations find similar deficits as in adult TLE, the
seizure disorder may be more severe and thus comes earlier to medical
attention. Earlier onset, higher seizure frequency and longer exposure
to chronic seizure disorder are associated to a poorer cognitive status,
which may counterbalance “brain plasticity.” The vast majority of imag-
ing studies are devoted to the identification of the epileptogenic focus,
and imaging studies on cognitive functioning in pediatric epilepsy are
rare. Several studies correlated cognitive dysfunction with hippocampal
or global brain atrophy, using 3D-MRI and volumetry. In recent years,
knowledge on physiological changes in the aging brain could be obtained
in subjects starting as early as 7 years. MR-spectroscopy may be another
tool, and some data on MRS-components and cognitive function could be
obtained in children. Pediatric PET-or SPECT studies in TLE-children
are hampered by the fact that control exams in non-epileptic children
cannot be obtained for ethical reasons. A large body of fMRI studies
explored language-related networks and their reorganization; however,
the imaging of memory functions in pediatric TLE-patients has not yet
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been addressed. Multichannel scalp EEG, examining frequency changes
or cognitive evoked potential changes related to specific cognitive tasks,
might provide another avenue of research, given that it is non-invasive,
allow measuring control subjects of all ages, and is less critical for motion
artifacts.
COGNITIVE AND MOOD EFFECTS OF ANTIEPILEPTIC
DRUGS
G. Baker (Division of Neurosciences University of Liverpool, UK)
Purpose: Understanding the impact of antiepileptic drugs on the psy-
chological and neuropsychological well being of children with epilepsy
is of critical importance in the management of their condition. Previ-
ous studies have identified that the older antiepileptic drugs may have a
deleterious impact on learning and memory and subsequently influence
performance and behaviour at home and in the school. Little however is
known about the newer antiepileptic drugs.
Methods: The author has searched the Cochrane Epilepsy Group trial
register, the cochrane central register of controlled trials and Psychoinfo
and cross references from identified publications. In addition a hand
search of relevant journals was undertaken.
Results: There are very few studies that have carefully examined
the effects of newer antiepileptic drugs on cognitive and behavioural
functioning. Those studies that have been published often fail to meet
the rigorous scientific standards required to meet the criterion for level
A scientific evidence. This review will present the available knowl-
edge on the impact of AEDs on neuropsychological and psychological
functioning.
Discussion: There is a need for well designed studies to establish
the impact of AED treatment but also to determine what is the most
beneficial strategy to ameliorate the effects for children’s day-to-day
functioning
COGNITIVE DYSFUNCTION AND TLE IN CHILDREN: DO
WE DISPOSE OF SUFFICIENT DATA TO PRAISE EARLY
SURGERY?
A. Arzimanoglou, Agathe Laurent, Monica Zilbovicius, Scania de Scho-
nen, and the French Network for Epilepsy Surgery in Children (Service
de Neurologie Pe´diatrique et des Maladies Me´taboliques, Hoˆpital Robert
Debre´ (AP-HP), Paris, France)
Traditionally paediatricians, including many child neurologists, con-
sider epilepsy surgery the last treatment option for patients with fo-
cal nonidiopathic epilepsy. The average duration of surgically treatable
epilepsy among young and middle-aged adults referred for epilepsy
surgery is about 20 years. The main arguments usually advanced for
such an approach are: the availability of a great number of drugs to be
tried; the potential cognitive and behavioural affects on a child when
operated on early; the fact that little is known about the natural history,
particularly the time course of development, of refractory epilepsy; and
the risks of surgery. As a consequence a number of available studies
mainly aim to early identification of factors suggesting intractability to
drugs, which then can be used as one of the main criteria to suggest early
surgery.
Another approach would be to take under consideration: available ro-
bust data on the effectiveness and safety of surgery for patients with some
types of epilepsy (temporal lobe epilepsy, epilepsy related to some de-
fects of migration or to the presence of a well circumscribed lesion, etc.);
available data on quality of life, education and professional achievements
in patients that became seizure free following surgery, even late surgery;
available data on cognitive and behavioural affects on children with drug
resistant versus drug sensitive epilepsies; available data suggesting that
alternation between remission and relapse is one of the inherent features
of a number of focal epilepsies, probably depending on aetiology. Lack
of robust data, on the behavioural and neuropsychological outcome of
children with focal non-idiopathic epilepsies operated on early or con-
trolled by AEDs, must also be taken into account. On the basis of all
the above, clinical trials of early surgical intervention including children
and adolescents can be designed. The sine qua non condition for such
studies to provide the medical community with solid data favouring (or
not) early surgery, is to change today’s clinical practice and to refer all
patients that fail two drugs for a presurgical evaluation in centres that
dispose of all available means for a global and comprehensive approach,
as recently suggested by the ILAE subcommission on paediatric epilepsy
surgery.
Focusing on temporal lobe epilepsy and on the basis of available data,
from the literature and from our studies on influence of seizures on
auditory and visual perceptual processing, we will highlight the limits
of drug treatment, the successes and risks of epilepsy surgery and the
need for early implementation of educational interventions. We will insist
on the limits and methodological issues for prospective research projects
assessing the neuropsychological profile of these children. A step further
would be a better understanding of the ways to evaluate the installation
process, and the underlying mechanisms, of such dysfunctions.
We dispose of sufficient data on the results of surgery on seizures.
What remains to be done are prospective follow-up studies on global
development and social integration of children operated-on early in the
course of their disease. But how much early is “early”?
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Programmed cell death pathways in seizure-induced
neuronal injury and epileptogenesis: human and ani-
mal data
INHIBITOR OF APOPTOSIS PROTEINS IN SEIZURE-
INDUCED BRAIN INJURY
D. Lindholm (Uppsala University, Department of Neuroscience,
Sweden)
No abstract received.
CASPASES IN EPILEPTOGENESIS: ANIMAL AND HUMAN
DATA
S. Narkilahti (A.I.Virtanen Institute for Molecular Sciences, University
of Kuopio and Regea Institute for Regenerative Medicine, University of
Tampere, Finland)
Caspases form a group of proteolytic enzymes that are activated dur-
ing programmed cell death. These enzymes are responsible both for
initiating the death signaling and for cleaving of cellular substrates re-
sulting ultimately in cell death. Since caspases are typically inactivated
in normal cells, inhibition of their activity prior or during neurodegener-
ative events might result in reduced cell death and in a better functional
outcome.
To model human TLE, several animal models of TLE have been de-
veloped in which an initial brain insult, that is, status epilepticus (SE),
causes epileptogenesis and epilepsy. In these models, both pathological
and electrophysiological features of human TLE can be mimicked. Im-
portantly, in the experimental models brain samples can be collected in
every phase of the epileptic process, while from human patients’ tissue
samples are only available after epilepsy surgery in the chronic phase of
the disease.
The main aim was to investigate the detailed temporal and spatial
expression and activation patterns of caspases acutely after SE, during
epileptogenesis and epilepsy in a rat model of TLE. Further, the effect of
pharmacological inhibition of caspases after SE on neurodegeneration
and development of epilepsy was evaluated. In addition, presence of
caspases in the hippocampal specimens derived from patients operated
on for drug refractory TLE was assessed.
The main findings were: 1) in addition to acute phase after SE, cas-
pases are enzymatically activated during the epileptogenesis. 2) Individ-
ual caspases have differential cellular and subcellular expression patterns
during the course of epilepsy. 3) Caspase 3 inhibition reduces neuronal
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damage after SE but it does not prevent epilepsy. 4) In TLE patients,
caspase 2 localizes to the remaining neurons of the hippocampus.
In summary, these results provide new data about the role of caspases
in epileptogenic processes both in rats and humans.
DEATH RECEPTORS AND BCL-2 PATHWAYS IN EPILEPSY:
EXPERIMENTAL AND HUMAN DATA
D. Henshall (Royal College of Surgeons in Ireland)
Prolonged seizures (status epilepticus) and repetitive seizures over
time may cause damage to temporal lobe structures such as the hip-
pocampus. Evolving experimental data have demonstrated programmed
cell death (apoptotic) signaling pathways are triggered by seizures and
may contribute to acute injury as well as participate in network remod-
eling during epileptogenesis. Classically, such cell death cascades are
engaged following dysfunction of intracellular organelles such as mito-
chondria (intrinsic pathway) or via activation of surface-expressed death
receptors of the tumor necrosis factor receptor (TNFR) family. Initiation
or progression of these pathways may involve recruitment and activation
of pro-apoptotic members of the Bcl-2 gene family, which function up-
and downstream of the caspase family of cell death proteases which effect
cell death. Since seizures trigger intracellular calcium overload, it has
been presumed that the intrinsic cell death pathway mediated by mito-
chondrial dysfunction would instigate neuronal death following seizures.
However, our work suggests that the extrinsic cell death pathway is also
engaged and may precede or initiate the damage program.
Focally-evoked status epilepticus in rats or mice induced hippocampal
neuronal death, assembly of TNFR1 signaling complexes and activation
of caspase-8. Bcl-2 family member Bid was activated downstream, with
subsequent processing of executioner caspases 3/7. The functional sig-
nificance of this pathway was supported by the neuroprotective efficacy
of pharmacologic inhibition of caspase-8. Examination of resected tem-
poral lobe material from refractory epilepsy patients reveals TNFR1
signaling complexes and their components are also upregulated. How-
ever, such presumably pro-apoptotic responses may be partially kept
in check via concurrent modulation of anti-apoptotic Bcl-2 proteins or
downregulation of pro-cell death genes.
These data highlight unexpected roles for death receptors in seizure-
induced neuronal death and the ongoing neuronal stress and injury re-
sponses in patients with refractory seizures which may have significant
implications for approaches to neuroprotection after damaging seizures
and anti-epileptogenesis.
Monday July 3, 2006
15:00–17:00
Ballroom 1
Discussion Group Session
Blood–brain barrier and epilepsy
STRUCTURE AND FUNCTIONAL PROPERTIES OF THE
BLOOD–BRAIN BARRIER
I. Blasig (FMP, Berlin-Buch, Germany)
No abstract received.
INFLAMMATION AND THE FUNCTION OF THE BLOOD–
BRAIN BARRIER
D. Janigro (Cleveland Clinic Foundation, USA)
One of the most commonly used animal model of status epilepticus
(SE) is based on the intra peritoneal injection of the cholinergic agonist
pilocarpine. While in vivo administration leads to acute SE in approxi-
mately the 70% of the cases, in vitro electrophysiological studies have
shown that pilocarpine causes epileptogenic activity preferentially when
co-applied with other proconvulsants. Moreover, radioactive tracer ex-
periments suggested low brain accumulation of pilocarpine. We mea-
sured the potency of pilocarpine when directly applied to hippocampal
slices and we compared the in vitro pilocarpine ED50 with the levels
measured in the brain after i.p. injection of 350 mg/Kg before (Stage 4)
and at SE. Staging of pilocarpine effects were performed by video EEG
monitoring. At concentrations up to 500 M, synchronized epilepti-
form activity in vitro was never seen. Similar in vitro potency was ob-
served when using a guinea pig whole brain preparation. In contrast,
kainic acid induced dramatic electrographic seizures when applied at
4 M. Surprisingly, pilocarpine brain levels measured after i.p. injec-
tion never exceed 60 M and were on average around 5% of serum
levels. We measured blood-brain barrier permeability by 14C-Sucrose,
3H-Diazepam and FITC-albumin to determine if altered BBB function
may affect pilocarpine penetration. Before SE, only modest modifica-
tions of BBB permeability to FITC-albumin or radiotracers was ob-
served. Pilocarpine permeability was compared to the permeability of
sucrose and diazepam to reveal significantly lower permeation than pre-
dicted by its lipophilicity. Beside CNS cholinergic effects, significant
pro-inflammatory changes (increased serum levels of IL-1 and changes
in the CD4:CD8 T-Cells) were observed after pilocarpine injection and
before Stage 4 or SE. Our results show a discrepancy between the in vivo
and in vitro pilocarpine proepileptogenic effects and reveal, in vivo, the
occurrence of an early peripheral inflammatory event that may cooperate
to the establishment of SE.
THE BLOOD–BRAIN BARRIER AS A SOURCE OF DC POTEN-
TIAL GENERATION
J. Voipio (Department of Biological and Environmental Sciences, Uni-
versity of Helsinki, Finland)
Slow shifts in the human EEG have been generally assumed to result
from changes in the level of tonic excitation of cortical pyramidal neu-
rons. However, prolonged large-amplitude shifts can be readily induced
without an evident change in cortical gross excitation. For instance, vol-
untary hyperventilation by healthy adult subjects results in a prompt
negative shift with amplitudes rising up to −2 mV within 3 min at the
vertex (Cz) (Voipio et al., J Neurophysiol 2003;89:2208–14). Such re-
sponses have an extremely steep dependence (up to 100 μV/mmHg) on
end-tidal PCO2, and blocking hypocapnia with 5% CO2 in air during
a similar breathing pattern blocks the negative DC shift. Hypoventila-
tion or breathing 5% CO2 in air at the normal respiratory rate induces
a positive shift. On the other hand, shifts up to 250 μV can be evoked
by manoeuvres that alter intracranial brain hemodynamics with little
effect on breathing pattern or cortical excitation (jugular vein compres-
sion, head-up/down tilt, Valsalva and Mueller manoeuvres; Vanhatalo
et al., Clin Neurophysiol 2003;114:1744–54). The large amplitude of
such responses is not consistent with a neuronal origin.
The potential difference that prevails across the blood–brain barrier
(VBBB) is capable of generating extracortical volume currents and sta-
tionary potential gradients on the scalp, which together with the known
pH/PCO2 sensitivity of VBBB readily accounts for the hyperventilation-
induced responses. Moreover, hemodynamic changes detected using
near-infrared spectroscopy correlate with slow EEG shifts. Although the
role of neuronal activity and other factors in affecting VBBB are poorly
understood, the blood–brain barrier should be considered as a factor con-
tributing to infra-slow EEG activity (Vanhatalo et al., In: Niedermeyer
and Lopes da Silva (eds.), Electroencephalography: Basic Principles,
Clinical Applications, and Related Fields, 5th edition, pp. 489–493.
Lippincott Williams & Wilkins, 2005).
MECHANISMS UNDERLYING EPILEPTOGENESIS UNDER
BLOOD–BRAIN BARRIER DISRUPTION
A. Friedman (Ben-Gurion University, Beer-Sheva, Israel)
No abstract received.
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7:30–9:00
Hall 1
Orphan Drug Symposium
THE CONCEPT OF RARE OR ORPHAN DISEASES IN
EPILEPSY
M. Baulac (Service de Neurologie, Hopital Pitie-Salpetriere, Paris,
France)
Although epilepsy is one of the commonest neurological disorders,
certain epileptic syndromes or diseases are nonetheless fulfilling all the
criteria, in terms of epidemiology and severity, for being qualified as
rare diseases. These epileptic conditions indeed are distinct entities, af-
fecting no more than 5 in 10,000 persons in Europe, carrying a risk of
chronic impairment, severe debilitation, and mortality, and there is a
lack of specific treatments with durable effects on the seizures and the
neuropsychological disorders.
Most of the epileptic encephalopathies can be qualified as rare dis-
eases. They include Ohtahara syndrome / early myoclonic encephalopa-
thy, migrating partial seizures in infancy, West syndrome, Dravet syn-
drome or severe myoclonic epilepsy in Infancy (1/30,000), Lennox-
Gastaut syndrome (2/10,000), Landau-Kleffner syndrome, continuous
spike-wave during sleep, etc. . . In these specific conditions, the intense
ictal and interictal epileptic activity contributes to the progressive dis-
turbance in brain function. These epileptic encephalopathies can them-
selves be caused by rare mutations or other rare diseases, for instance
tuberous sclerosis in West syndrome. Orphan drugs, which are still in de-
velopment, have been designated by the EMEA for the Dravet syndrome
(stiripentol) and for the Lennox-Gastaut syndrome (rufinamide).
In other situations, epilepsy is the predominant clinical expression of a
disease of genetic, metabolic or inflammatory origin, which is responsi-
ble for progressive brain damage. Progressive myoclonic epilepsies (less
than 1/20,000) for which brivaracetam was recently designated, and Ras-
mussen encephalopathy (approximately 1 case per big center per year)
are good examples.
It is very important for our patients and their families to ensure that
these conditions are well acknowledged as rare diseases, and that they
can benefit from the various governmental and EU incentives dedicated
to specific research and Orphan drugs development.
ORPHAN DRUGS: REVIEW OF THE EU PROGRAM
S. Del Signore (European Medicines Agency EMEA)
The EU Orphan Regulation was adopted in December 1999. It defines
the criteria for designation as orphan medicinal products and offers in-
centives to assist sponsors in the development of medicinal products for
patients affected by rare diseases. This is with a view to ultimately pro-
vide medicinal products to patients in the shortest possible time-frame.
The Regulation incentives include a 10-year period of market exclu-
sivity once authorised throughout the EU, protocol assistance from the
European Medicines Agency (EMEA), eligibility for Community and
Member State initiatives which support research and development of
orphan medicinal products, access to the centralised procedure and the
possibility to request fee reductions.
The EMEA is responsible for opinions on designation through its
Committee for Orphan Medicinal Products (COMP), which is comprised
of health professionals representing each of the Member States, three
patient representatives, and three representatives recommended by the
EMEA. The European Commission takes the administrative decision.
A medicinal product is designated as an orphan medicinal product
in the EU based on the following criteria: (a) rarity of the condition
(no more than 5 in 10,000 patients in the EU), or lack of sufficient
return on investment, (b) a serious or life-threatening condition and (c)
absence of satisfactory method(s) of diagnosis, prevention or treatment
of the condition in question, or if methods exist, significant benefit to
those affected by the condition. In this context, ‘significant benefit’ has
been defined in legislation as a clinically relevant advantage or a major
contribution to patient care.
In April 2006, the COMP adopted its 385th positive opinion recom-
mending orphan designation.
Twenty-six designated orphan medicinal products have gone on to
receive marketing authorization in the EU. As a consequence, up to
approximately 1 million patients suffering from these orphan diseases in
the Community stand to benefit from availability of these new treatments.
OVERVIEW OF BRIVARACETAM FOR PROGRESSIVE MY-
OCLONIC EPILEPSIES (UCB)
P. von Rosenstiel (Clinical Program Director, Therapeutic Area Neurol-
ogy/Psychiatry, UCB, Belgium)
Introduction: Orphan drug legislation offers the possibility to phar-
maceutical industry to develop innovative treatment options in rare dis-
eases with a high medical need.
Brivaracetam orphan drug program: Brivaracetam is a novel SV2A
ligand with sodium-channel inhibiting properties and a clearly distinct
pharmacological profile from levetiracetam. It has shown at least ten-fold
higher potency in animal models of epilepsy and posthypoxic myoclonus,
as well as more complete seizure suppression in several of these models.
First clinical data in a photoparoxysmal response study have confirmed
these preclinical data, with significant effects throughout the tested dose
range. Clinical development programs are currently ongoing in partial
onset epilepsy and other indications.
Recently, brivaracetam has been granted orphan drug status for the
treatment of symptomatic myoclonus in the US and progressive my-
oclonic epilepsies (PMEs) in Europe. UCB is currently in the prepara-
tory phase for a clinical development program in Unverricht-Lundborg
disease (ULD, EPM1).
The program, which will be run in Europe and North America, will
consist of two studies as well as an open-label extension study. The pro-
gram will combine dose-finding, confirmation of efficacy, and proof of
long-term safety, tolerability and maintenance of efficacy. Additional
significant benefit with regard to currently used treatments is to be
demonstrated by an adequate trial design. While patients in Europe are
discretely distributed in certain geographical regions and treated in a
limited number of specialised centers, patients suffering from ULD are
widely dispersed in the US. This makes novel approaches to find and
recruit patients for clinical trials necessary. Among others, the cooper-
ation with research centers and patient organizations is crucial in this
endeavor.
If the clinical development program is successful, it will make a new
treatment option available for patients suffering from a severely disabling
disease, while at the same time allowing the sponsor to demonstrate
efficacy in an extremely difficult to treat indication.
Conclusion: UCB’s development program in ULD is a good example
of the positive effects of orphan drug legislation on the development of
new pharmaceuticals:
• It allows industry to perform controlled clinical trials, which
would be difficult to fund from public sources, advancing our
knowledge of these rare diseases
• It makes new treatment options for patients suffering from rare
and unsatisfactorily treated disorders available, ideally leading to
an improved quality of life for patients and a reduced burden of
these diseases for society.
OVERVIEW OF STIRIPENTOL FOR SMEI (DRAVET SYN-
DROME) (BICODEX)
C. Chiron (Service de Neurologie et Metabolisme, Hopital Necker, Paris,
France)
Stiripentol (STP) is a new antiepileptic compound made by
Biocodex (France). It is structurally unrelated to all currently marketed
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antiepileptic products. It recently proved to increase the GABAergic
transmission using patch-clamp techniques in the hippocampus of im-
mature rats. STP increases both the release of GABA and the duration
of the activation of GABA-A receptors through a barbiturate-like effect.
Clinical studies were based on the fact that STP also inhibits cy-
tochromes P450 (CYP3A4, CYP1A2, and CYP2C19) in vivo in epilep-
tic patients, leading to increase plasma concentrations of concomitant
antiepileptic drugs and to potentiate their antiepileptic efficacy. When it
is associated with clobazam (CLB), STP inhibits the hydroxylation of the
active metabolite of CLB, nor-clobazam through a mechanism mediated
by CYP2C19. The adjunction of STP to clobazam and valproate proved
to be superior to placebo (p < 0.002) in severe myoclonic epilepsy in in-
fancy (SMEI, Dravet syndrome), a highly refractory, but homogeneous
epilepsy in infancy, and a limited number of patients was enough to
show similar results in two independent randomized controlled trials in
France and Italy. Efficacy was maintained in about half the patients at
long term follow-up. Adverse events were reported in about half of the
patients, including drowsiness, hyperexcitability, loss of appetite, and
loss of weight, but they could be minimized by optimizing the dose of
clobazam and valproate. The protracted experience in compassionate use
in France now provides tolerability data available on 400 patient–years.
It confirms the loss of appetit as the first side effect reported, provided
the interactions of STP are carefully taken into account by adjusting
the doses of the combined AEDs. Based on these results, STP is go-
ing to grant orphan drug status for the treatment of Dravet syndrome
and about to become the first orphan antiepileptic drug for children in
Europe.
Tuesday July 4, 2006
9:30–11:30
Hall 1
Main Session
Brain imaging from molecules to networks
IMAGING BRAIN STRUCTURE AND THE NETWORK OF
BLOOD FLOW AND METABOLIC CHANGES
W. Van Paesschen (UZ Gasthuisberg, Neurology, Leuven, Belgium)
High resolution MRI is the method of choice to study the brain struc-
ture in epilepsy. The MRI-identified lesion is important for the progno-
sis to render a patient seizure free with antiepileptic drugs and epilepsy
surgery. Quantitative MRI is useful for research purposes, may facilitate
the detection of focal dysplastic lesions, and has been shown to correlate
with cognitive morbidity. 3 T MRI can improve the presurgical evalua-
tion of patients with partial epilepsy when compared to 1.5 T studies.
Ictal hyperperfusion may localize the seizure onset zone and seizure
propagation pathways accurately. Seizure propagation is characterized
by “hour-glass” patterns. Postictal and interictal SPECT studies are less
useful to localize the ictal onset zone. Subtraction ictal SPECT co-
registered with MRI (SISCOM) improves the localization of the area of
hyperperfusion. Detailed analysis of SISCOM hyperperfusion patterns
is a promising tool to detect subtle focal dysplastic lesions in around
15% of “MR-negative” partial epilepsies and to establish the epileptic
nature of these lesions noninvasively.
Statistical parametric mapping (SPM) analysis of groups of selected
ictal-interictal difference images has the potential to demonstrate the evo-
lution of cortical, subcortical and cerebellar perfusion changes during a
particular seizure type, and to provide new insights into the pathophysi-
ology of seizures. In a comparative study of ictal SPECT during complex
partial seizures (CPS) and interictal FDG-PET in mesial temporal lobe
epilepsy with hippocampal sclerosis (mTLE-HS), hypometabolism was
greatest in the ipsilateral frontal lobe, and represented a seizure-related
dynamic process in view of further ictal decreases. Crossed cerebellar
diaschisis suggested that there was a strong ipsilateral frontal lobe inhi-
bition during CPS. This surround inhibition in the frontal lobe may be
a dynamic defense mechanism against seizure propagation, and may be
responsible for functional deficits observed in mTLE-HS.
VISUALISING THE CHEMISTRY OF THE BRAIN
M. Guye (INSERM U 751 & CNRS UMR 6612, Faculte de Medecine
de Marseille, France)
Proton magnetic resonance spectroscopic imaging (1H-MRSI) is a
metabolic imaging technique providing non-invasive quantification of
several brain metabolites. This method has always been considered as
particularly interesting to assess in vivo the biochemical alterations un-
derlying human epilepsy. However, its clinical use has been limited be-
cause of: 1) technical difficulties (i.e., low signal to noise ratio, high
susceptibility to magnetic field, difficulties for absolute quantification,
overlap of signals coming from different metabolites. . .) and 2) the lack
of knowledge concerning the interpretations of metabolites alterations.
Indeed, since the first use of 1H-MRSI in the early nineties, studies had
identified more or less reproducible modifications of metabolites con-
centrations: mainly N-acetyl-aspartate (NAA), Creatine (Cr) and Choline
(Cho). However, the significance of such alterations has only been clar-
ified recently. This was due to: 1) technical improvement overcoming
several methodological pitfalls, 2) studies investigating not only histo-
logical but also functional and electrophysiological correlates of such
metabolites alterations. An overview of recent advances and findings
of chemical shift imaging technique will be presented. MRS studies of
amino-acids such as GABA and Gutamine-Glutamate (Glx) and their
usefulness in the in vivo assessment of human epilepsy will also be
discussed.
IMAGING NEUROTRANSMISSION
E. Kumlien (Department of Neuroscience, Neurology, University Hop-
sital, Uppsala, Sweden)
Epilepsy research imaging neurotransmission with positron emis-
sion tomography (PET) has been used to elucidate the pathophysio-
logical mechanisms underlying both focal and generalised epilepsies.
The most important clinical contribution of PET has been in the pre-
surgical evaluation of patients with medically refractory partial epilepsy.
-Aminobutyric acid (GABA) is the major inhibitory transmitter in
the brain. 11C-flumazenil is a useful marker of the central GABA-
benzodiazepine receptor complex. The binding of the tracer is reduced in
mesial temporal lobe epilepsy reflecting localized neuronal and synap-
tic loss in the epileptogenic region. In extratemporal lesions the binding
pattern is less distinct and decreased as well as increased uptake may
be seen. Interictal studies of the opiate receptor system have shown
increased binding of the -agonist 11C-carfentanil in lateral temporal
cortex in temporal lobe epilepsy (TLE) indicating an antiepileptic and
inhibitory role of the endogenous opiod system.
Eexperimental models have suggested a potential role for serotonergic
transmission in epilepsy, and interest in this research has been increased
by the development of ligands specific for 5-hydroxytryptamine (5-HT)
receptors and serotonin synthesis. 5-HT1A-binding measured with 11C-
WAY or 18F-FCWAY is reduced in TLE. In children with tuberous scle-
rosis 11C-methyl-L-tryptophan (AMT) can help to identify epilepto-
genic tubers. Glutamate is powerful excitatory neurotransmitter mediat-
ing its effect through glutamate and NMDA receptors. NMDA receptor
dysfunction may underlie epilepsy, ischemia and neurodegenerative dis-
orders. Attempts to visualize the NMDA receptor with ligands such as
11C-S-ketamine have yielded ambiguous results. In addition the choliner-
gic and dopaminergic transmitter systems have been subjected to human
PET-studies.
IMAGING NORMAL AND ABNORMAL CEREBRAL
ACTIVATION
F. Woermann (MRI Unit, Bethel Epilepsy Center, Bielefeld, Germany)
To avoid postsurgical morbidity, the lateralization/localization of pri-
mary motor cortex, of language and of memory have to be known prior
to epilepsy surgery.
Functional MRI (fMRI) is a timely method to visualize cerebral activa-
tion with the aim to delineate areas of eloquent cortex from epileptogenic
lesions. Compared to other methods (Wada test, subdural grids, depth
electrodes), fMRI is noninvasive, free from ionizing radiation, widely
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available, and relatively inexpensive. The method “fMRI” is in the pro-
cess to demonstrate that it can be used in the majority of epilepsy patients
(incl. children); that fMRI acquisition and assessment are easy and re-
producible; and that fMRI provides typical and atypical results in large
number of individual cases in concordance with a gold standard (e.g.
postsurgical outcome etc.).
FMRI visualizes functional networks and shows either even bilat-
eral or unilaterally scattered activations which can be displayed as very
circumscript areas—ultimately as a result of statistical thresholding.
Whether these activation areas of statistical significance are of clini-
cal relevance and carry essential parts of cognitive and motor functions,
can be investigated by correlating fMRI results with deactivating meth-
ods or with outcome: e.g., in patients with congenital hemiparesis and
in the presence of bilateral fMRI activity, transcranial magnetic stimu-
lation identified ipsilateral fMRI activation controlling the paretic hand
(Staudt, 2004); fMRI predicted the absence of essential language areas
compared to intraoperative stimulation (Rutten, 2002); greater left hip-
pocampal activity in memory fMRI predicted a greater postoperative
decline in memory (Richardson, 2006).
While motor and cognitive fMRI seem to approach a certain level of
clinical relevance, the technically challenging, but scientifically certainly
promising combination of EEG and fMRI (to image abnormal epileptic
activity) is at an earlier stage of development and has no current role in
the presurgical evaluation of patients with epilepsy.
VISUALISING THE NETWORKS OF THE BRAIN
R. Powell (Institute of Neurology, UK)
The relationship between brain structure and function is fundamen-
tal to understanding both cognitive neuroscience and clinical neurology.
There is good reason to expect a strong correspondence between re-
gional brain function and the underlying architecture, however studying
this relationship is complicated by the intricacy of the brain’s connec-
tions, and the lack of techniques for exploring structural connectivity
in vivo. Recent advances in neuroimaging now allow brain connections
to be studied noninvasively. Tractography, a derivative of diffusion tensor
imaging allows the mapping of white matter tracts and the exploration of
the anatomical connectivity of regions involved in particular functions.
Tractography has a number of roles in the evaluation of patients with
epilepsy. An important clinical role will be in the presurgical evaluation
of epilepsy patients, and in particular in the prediction of visual and
language deficits. This potential as a presurgical tool can be illustrated
by the mapping of the optic radiations preoperatively, and how this in-
formation can be used to predict, and minimize the risk of, visual field
defects following anterior temporal lobe resection.
Tractography can also demonstrate subtle structural changes in
epilepsy patients, for example the structural connections underlying
functionally defined language regions. The structural connectivity of
language areas in left and right TLE are different from controls, with
a decrease in connections ipsilateral to the focus and a contralateral in-
crease, providing an insight into the basis of functional plasticity.
A further evolving role of tractography is to potentially demonstrate
networks involved in seizure propagation, such as the connections of the
medial temporal lobe.
Tuesday July 4, 2006
9:30–11:30
Hall 5A
Main Session
Epileptogenesis, seizures, and epilepsy
INTRINSIC NEURONAL PLASTICITY: ROLE IN HYPEREX-
CITABILITY AND PHARMACORESISTANCE
H. Beck (University of Bonn Medical Center, Department of Epileptol-
ogy, Germany)
The input-output relationship of neuronal networks depends both
on their synaptic connectivity and on the intrinsic properties of their
neuronal elements. Long-term changes in this relationship can thus be
achieved by changes in synaptic and/or intrinsic neuronal properties.
Recent data clearly demonstrate that seizures can modulate the func-
tional and molecular characteristics of voltage-gated ion channels, lead-
ing to persistent changes in neuronal discharge behavior. We suggest that
this intrinsic plasticity is a potent mechanism that, in conjunction with
synaptic plasticity, can fundamentally alter the input-output properties
of neuronal networks in the mammalian brain. Furthermore, changes in
voltage-gated ion channels that constitute targets for antiepileptic drugs
can cause them to become unresponsive to these agents, thus constituting
one potential molecular cause for drug-resistance.
MOLECULAR BASIS OF EPILEPTOGENESIS IN
CHANNELOPATHIES
S. Baulac (INSERM U679, France)
Epileptic syndromes have very diverse etiologies involving genetic
factors and/or brain insults and injuries. While human epilepsies with
a mendelian inheritance are not common, numerous genes have been
identified over the last decade. Until recently, genes linked to idiopathic
epilepsies with monogenic inheritance were all thought to encode sub-
units of ion channels or transmitter receptors. Thus, potassium channel
mutations cause benign familial neonatal convulsions; sodium channel
mutations are linked to generalized epilepsy with febrile seizures plus and
severe myoclonic epilepsy of infancy; GABAA receptors to generalized
epilepsy with febrile seizures plus and autosomal dominant (AD) juve-
nile myoclonic epilepsy; nicotinic receptors to AD nocturnal frontal lobe
epilepsy, and chloride channels mutations cause idiopathic generalized
epilepsy. However the identification of idiopathic epilepsies as chan-
nelopathies, which alter synaptic transmission or neuronal excitability,
has been challenged by two recent reports describing mutations in hu-
man idiopathic epilepsy that affect unknown proteins, EFHCI and LGI1.
Gaining knowledge on the physiological role of new proteins within the
central nervous system may throw light to normal brain function and to
new mechanisms of epileptogenesis.
IMAGING PROGRESSIVE CHANGES IN EPILEPSY
L. Lemieux (Institute of Neurology, University College London, UK)
Serial MR imaging has increased our understanding of the way struc-
tural changes evolve in epilepsy. Applications include identifying the
structural consequences of status epilepticus or repeated brief seizures
on the brain and the monitoring of lesion size e.g. tumours over time.
This presentation focuses on the secondary effects of seizures.
Various imaging techniques show selective sensitivity to different
stages of the acute postictal period. Methodological considerations are
divided into those MR imaging modalities used to (1) detect acute hip-
pocampal changes in the immediate postictal period, and (2) those used
in identifying subtle volumetric change over a more prolonged period.
Our results and that of others, have demonstrated increases in the
T2-weighted signal, possibly reflectings eizure-induced alterations in
haemodynamic and cell membrane permeability as the result of seizures,
fluctuations in the apparent diffusion coefficient on diffusion-weighted
imaging and metabolite changes detectable using proton and phosphorus
MRS.
Volumetric changes following status epilepticus and repetitive seizures
are best studied using serial volumetry incorporating coregistration to im-
prove sensitivity to change. Manual hippocampal volumetry remains the
most common quantitative measure used in imaging progressive changes
in epilepsy although automated techniques may play a greater role in the
future. Region- and voxel-based tools for detecting cerebellar and neo-
cortical change have also been used. Methodological aspects of serial
imaging are discussed, along with examples of their application. ”Our
results in a population-based study support the concept of early volume
loss resulting from an initial insult followed by age-related volume loss
within the normal range.”
Serial imaging provides valuable information on the timing and patho-
genesis of structural changes in epilepsy, and the findings could have
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important implications in devising timely and targeted neuroprotective
strategies.
EPILEPTOGENESIS AND DISEASE MODIFICATION—ARE
THEY REALISTIC NOVEL TREATMENT INDICATIONS?
A. Pitka¨nen (University of Kuopio, A.I.Virtanen Institute for Molecular
Studies, Finland)
Epileptogenesis refers to abnormal neuronal reorganization occurring
over a long period of time following a cerebral insult (e.g., traumatic
brain injury, stroke) leading to the occurrence of spontaneous seizures.
To prevent epileptogenesis or modify the disease process in such a way
that developing epilepsy is milder and easier to treat will require (i)
clinically relevant animal models for studies on basic mechanisms of
epileptogenesis as well as for preclinical testing of novel treatments, (ii)
molecular targets for development of novel therapies, (iii) compounds
that affect the targets without compromizing the normal brain function
or the recovery process that occurs in parallel with epileptogenesis, and
(iv) surrogate or biomarkers that can be used to identify individuals at
risk of epilepsy after brain damaging insult as well as to follow the
effects of treatments in preclinical and clinical trials. This presentation
will review the developments in these fields over the recent years. As the
data show there have been major progress in epileptogenesis research
providing novel ideas how to proceed in the design of studies aiming
at preventing or modifying the disease process that eventually leads to
acquired symptomatic epilepsies.
Tuesday July 4, 2006
15:00–17:00
Hall 1
Discussion Group Session
Neurostimulation for epilepsy
DEEP BRAIN STIMULATION IN EPILEPTIC PATIENTS IN
2006, WHAT IS THE EVIDENCE?
P. Boon (Laboratory for Clinical and Experimental Neurophysiology
(LCEN) and Department of Neuology, Ghent University Hospital, Bel-
gium)
Acute deep brain stimulation (DBS) in various thalamic nuclei and
medial temporal lobe structures has recently been shown to be effica-
cious in small pilot studies of patients with medically refractory epilepsy.
Only limited data on chronic thalamic and amygdalohippocampal stim-
ulation are available. Chronic DBS in these structures requires resolving
many conceptual and technical issues. There is little evidence based
information on rational targets and stimulation parameters. Currently
available depth EEG recording electrodes are unsuitable for chronic use.
Inversely, the use of DBS electrodes for intracranial EEG recording and
localization of the ictal onset zone prior to stimulation has only been
reported by a few groups. Results from feasibility and pilot studies in
the most recent literature will be presented. The experience with DBS
in temporal lobe epilepsy using quadripolar DBS electrodes bilaterally
implanted in the amygdalohippocampal region to identify and subse-
quently stimulate the ictal onset zone will be described. This work has
yielded a significant decrease of seizure counts and interictal EEG abnor-
malities during long-term follow-up. Various hypotheses on the possible
mechanism(s) of action of DBS for epilepsy using EEG, cerebral blood
flow and metabolic measures including results from animal experiments
have recently been developed. Data from open pilot studies suggests
that chronic DBS for epilepsy may be a feasible, effective and safe pro-
cedure that reduces interictal EEG abnormalities and seizures. Further
trials with larger patient populations, controlled and randomised designs
should be initiated.
BASIC MECHANISM OF DEEP BRAIN STIMULATION, WHAT
IS REALLY KNOWN?
W. Wadman (SILS Center for Neuroscience, University of Amsterdam,
Netherlands)
Deep brain stimulation (DBS) is one of the therapeutic alternatives un-
der development for pharmacoresistant patients in particularly for those
for which surgical resection of the epileptic focus is not an option. The
major advantages for such a treatment are its reversibility e.g., when
new drugs become available and its controllability, eventually allowing
“on-demand” stimulation. Most current treatments for epilepsy aim at
seizure suppression, but DBS could also play a role by interfering with
epileptogenesis. Fortunately DBS technology exists and the technique
has been proven quite successful in patients that suffer from Parkinson’s
disease.
There are at least four distinct mechanisms by which DBS could work:
1) the release of endogenous substances (as most likely occurs in Vagal
Nerve Stimulation) 2) the acute manipulation of the neuronal membrane
voltage by an external electrical field 3) the manipulation of synaptic
coupling by mechanisms that induce Long Term Potentiation or Long
Term Depression and 4) the manipulation of mechanisms involved in
the intrinsic scaling of excitability. For all four mechanisms proofs of
principle exist, but none of them has already been employed in a fully
successful protocol against epileptic seizures.
In particularly for the human situation many questions need to be
resolved: 1) what is (are) the best region(s) to stimulate, 2) which are the
optimal parameters (frequency, intensity, duration, specific patterns) of
the stimulation protocol, 3) are continuous, intermittent or “on demand”
stimulations possible and preferable, and 4) who are the best patients to
treat. For the latter question it is clear that trials will start with patients
that are pharmacoresistant, but if DBS would counteract epileptogenesis
the patient selection will enter a new phase.
RESPONSIVE (CLOSED-LOOP) STIMULATION, IS IT REALLY
FEASIBLE?
F. Mormann (Department of Epileptology, University of Bonn, Germany)
Deep brain stimulation is a promising new technology for the treatment
of medically intractable seizures. Apart from the question where in the
brain the stimulation should take place (e.g., cerebellum, thalamus, basal
ganglia, or direct stimulation of the epileptic focus) there are different
possibilities of how to stimulate.
In principle, neural stimulation can be carried out either in an open-
loop, duty-cycle design, e.g., in the form of continuous or periodic stim-
ulation, or in a closed-loop, responsive design in which the patient’s
electroencephalogram is used to trigger on-demand stimulation. This
type of responsive stimulation can be based, e.g., on seizure detection
algorithms or on seizure prediction algorithms.
Controlled clinical trials are currently being carried out both for
duty-cycle stimulation and for responsive stimulation based on seizure
detection algorithms. The results reported to date must be regarded as
preliminary and do not allow a conclusive comparison of these two stim-
ulation techniques.
Deep brain stimulation based on seizure prediction algorithms does
not appear to be justified at this stage as it is not clear whether prospec-
tive prediction algorithms can indeed perform significantly better than a
random prediction.
VAGUS NERVE STIMULATION IN 2006, WHAT IS THE
EVIDENCE?
K. Vonck (Ghent University Hospital, Reference Centre for Refractory
Epilepsy, Department of Neurology, Ghent, Belgium)
Vagus nerve stimulation, a state-of-the-art
Introduction: Electrical stimulation of the vagus nerve (vagus nerve
stimulation, VNS) is one treatment modality for refractory epilepsy. Clin-
ical efficacy of VNS has been established in randomized controlled stud-
ies. Important issues that still need to be cleared up are mode of action,
optimum stimulation parameters, long-term efficacy and side effects,
cost-efficacy and potential other treatment indications.
Recent literature on the use of VNS in refractory has looked at effi-
cacy in terms of changes of seizure frequency and concommittant AED
treatment in different types of epilepsy. Side effects and cost-efficacy
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analysis in terms of decreases in hospital admission days, clinic visits
and laboratory investigations were also assessed. Mechanism of action
was studied by positron emission tomomgraphy (PET) and single pho-
ton emission tomography (SPECT) studies performed immediately after
initial stimulation to evaluate VNS induced changes in regional cerebral
bloodflow (rCBF) and serial SPECT measurements during follow-up in
these patients to assess temporal evolution of rCBF changes and correlate
findings to clinical efficacy.
Clinical efficacy of VNS in long-term observational studies is in ac-
cordance with the results of the initial controlled studies. In one third of
the patients a more than 50% reduction in seizure frequency is found.
Up to 10% of patients become seizure free for a period of 12 months or
longer. A trend towards improved seizure control with longer use of VNS
was observed. Response during the first 3 months of treatment seemed
predictive of long-term response. VNS is mostly studied in patients with
refractory partial epilepsy but appears to be equally efficacious in pa-
tients with different forms of generalized epilepsies.
Side effects are mostly related to peripheral stimulation effects on the
laryngeus recurrens nerve and other branches of the vagus nerve includ-
ing hoarseness, throath pain or discomfort and coughing and appeared
to decrease with longer treatment. Despite early reports on cardiac arry-
thmias occurring at the time of first stimulation during the implantation
procedure, no serious life-threatening adverse events have been reported.
VNS has a promising cost-efficacy profile. Epilepsy related direct medi-
cal costs were reduced significantly after treatment with VNS, the reduc-
tion in hospital admission days being the most important factor. Cost-
efficacy analysis suggests that the cost of VNS is saved within 2.5 years
following implantation. VNS induces rCBF changes immediately after
initial stimulation that can be studied with SPECT and PET. Ipsilateral
thalamic hypoperfusion was the most significant finding. VNS-induced
changes in the thalamus may play an important role in suppression of
seizures.
Conclusions: VNS is an efficacious, safe and cost-effective treatment
for patients with refractory epilepsy, who are not candidates for resective
surgery. Further studies are needed to elucidate the anti-seizure mecha-
nism of action of VNS.
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The spectrum of temporal “plus” epilepsy
FAILURES OF TEMPORAL LOBE SURGERY
D. Schmidt (Epilepsy Research Group, Berlin, Germany)
Temporal lobe surgery is the nonpharmacological treatment of choice
for carefully selected patients with drug resistant temporal lobe epilepsy.
On average, two of three patients undergoing surgery will become seizure
free or nearly seizure free after surgery with continued antiepileptic drug
(AED) treatment. We limit our discussion to failure to achieve long term
surgical seizure control which can occur in three groups of patients. One,
surgery fails with respect to seizure control with continued AEDs in one
of three cases who never become seizure free after surgery. Two, a small
subgroup of patients who were seizure free after surgery on AEDs will
not remain seizure free in the long run. This is another group of patients in
whom surgery may be considered to have failed. When AEDs are stopped
in patients who have been seizure free after temporal lobe surgery for
several years, one in three patients has a seizure recurrence. This is a
third subgroup of patients in whom surgery has failed, particularly in
a small group in whom reinstitution of AEDs after seizure recurrence
fails to regain seizure freedom. Despite all these instances of failure,
temporal lobe surgery is a very useful procedure and the only one which
achieves seizure freedom in 50% of patients with drug resistant temporal
lobe epilepsy, approximately in 20% of patients with AEDs and in 30%
without AEDs.
TEMPOROORBITAL EPILEPSY
F. Dubeau (Montreal Neurological Hospital and Institute, McGill Uni-
versity, Canada)
There is a subset of epileptic patients with temporal lobe (TL) seizures
where the definition of limbic or neocortical TL epilepsy does not seem
to apply: a TL syndrome can be produced by extratemporal physiologi-
cal or structural abnormalities. The concept of temporal “plus” epilepsy
was introduced to define this group of patients with TL semiology and
electrophysiological characteristics, but poor results after standard TL
resections. These patients are believed to have multilobar epilepsy, or
widespread epileptogenicity, which includes TL and extra-TL structures;
the later likely functionally linked to the mesial or neocortical TL, ex-
plaining the main temporal electroclinical features. Kahane and Ryvlin
(Curr Opin Neurol 2005;18:125–127) proposed to divide patients with
temporal “plus” epilepsy in temporoorbital (orbitofrontal, or OF), peri-
sylvian (opercular and insular) and posterior temporal (parietooccipito-
temporal) epilepsy.
The definition of frontal lobe (FL) semiology is relatively clear, but the
interpretation of FL epileptic semiology remains difficult particularly if
epileptic activity shows poor localizing value or, even more, if no lesion
can be detected. The clinical presentation for OF epilepsy is variable,
and OF seizure discharges may be associated sometimes with typical FL
semiology, but often can be silent until they propagate to other structures
such as the adjacent TL. The OF cortex has extensive connections with
other parts of the brain, including virtually all limbic structures, the
amygdala, hippocampal formation, entorhinal area and insula, and the
anterior temporal cortex. A few cases of OF epilepsy have been described
and often they felt into a broader category of regional epilepsy. On the
other hand, mesial TL epileptic discharges preferentially spread to the
mesial FL, especially to the OF cortex, an important route for the clinical
expression of TL seizures.
To address the issue if the existence of temporoorbital epilepsy ex-
plains some of the surgical failure in patients with a diagnosis of TLE,
we reviewed a series of patients investigated between 1995 and 2005,
in our institution, with intracranial SEEG recordings exploring simul-
taneously the TL and FL structures. The data were compared with our
current knowledge on the electrophysiopathology of OF and temporo-
orbital epilepsy.
TEMPOROSYLVIAN EPILEPSY
P. Kahane (Epilepsy Unit, Neurology Department, Grenoble University
Hospital, France)
The term of temporosylvian epilepsy (TSE) has been proposed 25
years ago (Munari et al. 1980) to describe specific forms of multilobar
epilepsies characterized by a complex epileptogenic network including
the temporal lobe (TL), the frontal and parietal operculum, and the in-
sula. There are, however, only few published data on this topic (Kahane
et al. 2001, Isnard et al. 2004) and, because of this, the identification
of this form of epilepsy has remained largerly ignored. Yet, some pa-
tients submitted to TL surgery who continue to experience seizures
postoperatively might suffer from TSE, and identifying those patients
using invasive recordings might lead to perform a more extensive and
more effective cortectomy, according to the surgical possibilities and
limits (Munari et al. 1995). For instance Kahane et al. (2001) showed
that 6 of the 7 patients studied by intracerebral electrodes and in whom
seizures arose from temporal and suprasylvian opercular cortices were
totally seizure-free after surgery when an adequate TS resection could
be achieved. By contrast, TL surgery alone was unsuccessful in the 2
temporoinsular cases of Isnard et al. (2004) since it allowed to suppress
the seizures of TL origin but not those which arose from the insula. Thus,
though limited, these examples emphasize the interest to better delineate
the spectrum of TSE, in as much as patients suffering from this form of
epilepsy might be at higher risk of sudden death than those suffering from
pure TLE (Persson et al. 2005). Therefore, whether the diagnosis
of TSS can be suspected non invasively remains an important issue and
particular attention must be paid, in the context of TLE, to the presence
of early ictal signs suggesting the involvement of the perisylvian region
(somatosensory, gustatory, vestibular and auditory auras, hypersaliva-
tion, laryngeal constriction, hemifacial motor signs). Also, the presence
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of bilateral or precentral interictal EEG abnormalities might be sugges-
tive of an epileptogenic zone extending outside the anatomical boudaries
of the TL (Barba et al. In preparation). In such cases, invasive recordings
should be considered, even when MRI shows a hippocampal sclerosis.
POSTERIOR TEMPORAL EPILEPSY
S. Francione (“Claudio Munari” Epilepsy Surgery Centre, Ospedale Ni-
guarda Ca’ Granda, Milano, Italy)
Extending a temporal lobe resection to the neighbouring occipital or
parietal cortex can be a useful surgical therapeutic option in selected
cases. In order to analyse the clinical characteristics of this type of
“temporal-plus” epilepsies we selected—from a population of 91 pa-
tients with drug-resistant partial epilepsy operated on in the posterior
part of the brain presented elsewhere (Francione et al, this Congress)—
25 patients in which a temporooccipital (22) or temporo-parietal (3)
resection was performed. Selection criteria followed both anatomical
(localization of surgical resection) and clinical (semiological features
resembling temporal lobe seizure) parameters.
Studied patients are 15 males and 10 females, age at surgery: 3–54
years (28 ± 11.9; 2 patients operated on before the age of 16 years), mean
age at seizures onset: 7.9 ± 4.8 (birth-16 years), mean epilepsy duration:
19.9 ± 11.7 (3–46 years). Seizures were monthly in 3 patients(12%),
weekly in 19(76%) and daily in 3(12%).
Five patients have a familiarity for epilepsy, none presented febrile
convulsions in his personal history.
Preoperatory MR was negative in 7 cases(28%), showed a localised
lesion in 17(68%) and a bilateral double cortex in 1. All the patients but
1 were studied by Video-EEG, and in 21 cases (84%) the extension of
the resection was defined on the basis of an intracerebral stereo-EEG
study. Surgery was right-sided in 17(68%) and left-sided in 8(32%).
After a mean follow-up of 46 months surgical outcome following Engel’s
classification is: 18 patients: Class I(72%), 5 patients: Class II (20%), 2
patients: Class IV(8%).
Histological examination accounted for: 11 MCD (44%), 9 neoplastic
lesions(36%), 4 cryptogenic (16%) and 1 scar. In conclusion, poste-
rior temporal resections, mainly defined by invasive recordings, seem to
represent an effective surgical option; further analysis, especially con-
cerning ictal electroclinical features, will be presented with the aim of
characterising a possible “syndromic” entity.
SURGERY FOR TEMPORAL PLUS EPILEPSY
P. Ryvlin (Hospices Civils de Lyon, France)
Introduction: Temporal-plus (T+) epilepsy is defined by an epilep-
togenic zone (EZ) primarily encompassing temporal lobe structures,
but extending to neighboured areas beyond the boundaries of anterior
temporal lobectomy (ATL), such as the insula, the frontal and parietal op-
erculum, the orbitofrontal cortex and the temporoparietooccipital (TPO)
junction. In this study, we compared the surgical outcome in T+ epilepsy
versus pure temporal lobe epilepsy (TLE).
Methods: We included 283 consecutive patients who underwent an
epilepsy surgery procedure in our institutions that affected at least part
of the temporal lobe. The distinction between pure TLE and temporal
plus epilepsy was made according to the final conclusion of the pre-
surgical assessment which has prompted surgery. The diagnosis of tem-
poral plus epilepsy was always based on invasive stereo-EEG (SEEG)
data, whereas that of pure TLE could be made on non invasive data only.
The completness of removal of the epileptogenic zone was evaluated on
post-operative MRI.
Results: Among the 283 patients, 183 who underwent a stereo-EEG
(65%), and 59 proved to suffer from T+ epilepsy (21%). Surgery was
considered as resulting in a complete resection of the EZ in 97% of “pure”
TLE patients and 69% of T+ epilepsies. Incomplete resection was related
to hippocampal remnant in pure TLE (3%), and to the decision to perform
an ATL or a suboptimal cortectomy in T+ epilepsy due to the presence of
eloquent cortex within the EZ. A regressive tree analysis demonstrated
that the main factor that significantly affected seizure outcome was the
completness of removal of the epileptogenic zone (p < 0,0001), followed
by the type of epilepsy (TLE versus T+: p < 0,001). In patients who
benefited from a complete removal, a class I outcome was achieved in
92% of pure TLE and in 76% of T+ epilepsy.
Conclusion: Fair surgical results can be obtained in T+ epilepsy,
provided an appropriate identification and complete resection of the EZ.
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Mesial temporal epilepsy is an extrahippocampal
disease
EXTRAHIPPOCAMPAL NEUROPATHOLOGICAL CHANGES
IN MESIAL TLE
I. Blu¨mcke (Department of Neuropathology, University of Erlangen,
Germany)
Hippocampal sclerosis comprises the most frequent histopathologi-
cal alteration in mesial TLE. However, there are some extrahippocam-
pal areas severely compromized in many TLE patients, i.e., the amyg-
dala, entorhinal cortex, subiculum and temporal neocortex (pole region).
A major issue to be discussed is whether these lesions arise from an
independent pathogenesis, i.e., as dual pathology, or underlie rather
HS-associated pathomechanisms.
Amygdala sclerosis represent with severe neuronal cell loss in at least
two subnuclei of the human amygdala, mainly from the basolateral com-
plex. A major obstacle for histopathological examination is the com-
pound anatomical organization, which is often not well preserved in
surgical specimens. However, our analysis of 20 en bloc samples of
the human amygdala identifies neuronal cell loss and astrogliosis in the
majority of cases. Ultrastructural analysis further characterize synap-
tic circuitries of local interneurons as well as projection neurons to be
severely affected (i.e., loss of perisomatic inhibitory synapses). These
data point to altered networks between the amygdala and hippocampus,
which is likely to contribute to mesial epileptogenesis in chronic mTLE
patients. Furthermore, amygdala related pathology can be observed in
various TLE animal models, including kindling or kainite-induced status
epilepticus.
Architectural dysplasia of the temporal neocortex is another hallmark
of mTLE. However, there are some concerns with respect to classification
issues. Disturbance of cortical lamination as well as abundant ectopic
neurons in white matter are frequent microscopical features of compro-
mized areas. Whereas some authors consider these lesions as FCD type
I and dual pathology, respectively, other labs regard these patterns as HS
associated pathology. Nonetheless, epileptogenicity appear with these
temporal lobe regions and surgical removal is benefical for the majority
of patients to control seizure activity.
The knowledge of extrahippocampal pathologies is mandatory to bet-
ter characterize the etiology and pathogenesis of chronic seizure in mTLE
patients and to further improve surgical as well as pharmacological treat-
ment strategies.
EXTRAHIPPOCAMPAL VOLUMETRIC CHANGES IN MESIAL
TLE
N. Bernasconi (Mc Connell Brain Imaging Centre/Montreal Neurologi-
cal Institute, Canada)
For many years, temporal lobe epilepsy (TLE) was considered to be
mainly related to hippocampal pathology.
In the last decade, volumetric MRI has been used to evaluate the
structural integrity of mesial temporal lobe structures in TLE. The
entorhinal cortex and the hippocampus are the most atrophic struc-
tures within the mesial temporal lobe, whereas the perirhinal and pos-
terior parahippocampal region are less commonly affected. This pat-
tern of preferential damage is possibly consequence of a disruption of
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entorhinal-hippocampal connections as a result of privileged dialogue
between these two structures. Whole-brain voxel-based morphometry
has revealed that GM and WM pathology in TLE extends beyond the
hippocampus involving other limbic areas such as the cingulum and
the thalamus, as well as extralimbic areas, particularly the frontal lobe.
This is suggestive of disconnection involving preferentially frontolimbic
pathways in TLE.
It is now generally recognized that epilepsy is not a static disorder and
that important structural brain changes may take place over time. Volu-
metric MRI has shown that progressive volume loss of mesial temporal
lobe structures in relation to duration of epilepsy is not restricted to the
hippocampus and also affects the amygdala and the entorhinal cortex. On
the other hand, entorhinal and hippocampal volumes seem to be already
low at the time of onset of recurrent seizures, indicating that the effect
of TLE may be present before the clinically obvious onset of seizures.
Although, the cause of the disease is still unknown, it seems too sim-
plistic to consider that evaluation of the hippocampus alone is sufficient
to fully understand TLE. Indeed, MRI studies have allowed us to view
TLE not as a disease of single structure disease, but as one involving
many structures interconnected through a network.
EVIDENCE FOR EXTRAHIPPOCAMPAL SEIZURE ONSET
WITH INVASIVE RECORDINGS IN MESIAL TLE
F. Bartolomei (INSERM U751 and Clinical Neurophysiology Depart-
ment Timone Hospital, Marseille, France)
The role of extrahippocampal mesial temporal lobe structures in the
genesis of mesial temporal lobe seizures (MTLs) is unclear. In particular,
the role of the rhinal region (entorhinal cortex, EC) in MTLs gene-
sis has been proposed, mainly based on indirect MRI evidence. We will
summarize several studies conducted in patients having depth electrodes-
SEEG recordings in whom we recorded both hippocampus and extrahip-
pocampal areas. The main finding of these studies is to show that the
ictal onset zone in MTLs is made of several structures forming a network
instead of a simple “hippocampal” focus.
The respective role of hippocampal and non hippocampal structures
in these networks will be discussed in the light of S-EEG signal analysis.
EXTRAHIPPOCAMPAL INVOLVEMENT IN MESIAL TLE US-
ING FUNCTIONAL IMAGING METHODS
W. Serles (Universita¨tsklinik fuer Neurologie Wien, Abteilung fu¨r Klin-
ische Epilepsieforschung, Austria)
Structural brain abnormalities are widespread in drug resistant mesial
temporal lobe epilepsy (mTLE). There is compelling evidence that
extrahippocampal volume loss occurs in patients with mTLE which
is more pronounced ipsilateral to hippocampal sclerosis. Specifically,
involvement of the amygdala, the rhinal cortices, the temporal pole, the
lateral regions of the temporal lobe, but also contralateral temporal lobe
areas and extratemporal brain regions have been found. However, besides
neuronal loss, extrahippocampal abnormalities are also seen in functional
imaging methods measuring different aspects of neuronal dysfunction.
Diffusion tensor imaging (DTI) provides evidence for extrahippocam-
pal network abnormalities as do interictal PET methods and proton MR
spectroscopy.
Diffusion abnormalities have been reported to extend to lateral tempo-
ral structures, to the contralateral mesial structures and remote extratem-
poral regions. In FDG-PET, various patterns in temporal and extratem-
poral areas including the insula have been described. Finally, mTLE is
associated with extrahippocampal and extratemporal spectroscopic ab-
normalities. The pathophysiological implications of these findings for
understanding epileptogenesis and neural networks in mTLE are dis-
cussed.
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Pharmacokinetics of concern for women with epilepsy
of childbearing potential
CONTRACEPTIVES AND AEDS, INTERACTIONS IN TWO
DIRECTIONS
M. Bialer (Department of Pharmaceutics, School of Pharmacy, Faculty
of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel)
Antiepilpetic drugs (AEDs) can be categorized into three groups
based on their potential to cause induction-drug interactions (DDI)
with combined oral contraceptives (OC). The old AEDs such as phe-
nobarbital, phenytoin and carbamazepine (CBZ) induce CYP-mediated
metabolic pathways as well as glucuronide conjugation. Consequently,
these enzyme-inducing AEDs reduce OC levels during concomitant
administration and may cause contraceptive failure. A second group
of AEDs includes topiramate (TPM), felbamate and oxcarbazepine
(through its active monohydroxy metabolite or entity - licarbazepine),
which are less potent inducers of CYP isozymes, but have been shown
to alter OC plasma concentrations. A third group of AEDs includes val-
proic acid, gabapentin, lamotrigine (LTG), levetiracetam and tiagabine,
which do not alter OC pharmacokinetics. A recent study evaluated the
TPM-OC interaction in comparison to CBZ. Coadministration of TPM at
daily doses of 50, 100, 200 mg did not have a statistical significant effect
on the mean exposure or area under the curve AUC of ethinyl estradiol
(−12%, +5% and −11%, respectively). A similar nonsignificant differ-
ence was observed with the norethindrone AUC and plasma levels (p >
0.05). In contrast to TPM, CBZ significantly decreased AUC values of
norethindrone and ethinyl estradiol by 58% and 42%, respectively, and
increased their respective oral clearance (CL/F) by 69% and 127% (p <
0.05). These results show that in the above OC-DDI classification TPM
should be categorized by the dose used. At daily doses below 200 mg,
TPM belongs to the third group rather than the second one. Given the
significant effect that CBZ coadministration (600 mg/day) had on the
reduction of plasma levels and AUC values of norethindrone and ethinyl
estradiol, it is clear that TPM does not cause a similar effect.Sabres et al.
2001 & 2003, showed that OC treatment reduces LTG plasma levels by
more than 50%, which may require LTG dose adjustment. Withdrawal of
OC may double LTG plasma levels. Reimers et al. 2005, demonstrated
that it was the ethinyl estradiol component of the combined OC that in-
teracted with LTG by inducing its metabolic glucuronide conjugation.
Such an interaction might be expected with other AEDs that are metab-
olized primarily by glucuronidation mediated by the same glucuronide
isozymes as LTG (e.g. UGT 1A4). In conclusion, DDI between AEDs
and OC should indeed be looked at from both directions. On one side,
both the estrogen and progestin complements of combined OC are very
susceptible (sensitive) to enzyme inducation even by mild inducers such
as OXC or TPM (>200 mg/day). On the other side, ethinyl estardiol
as the estrogen component of combined OC may induce AEDs that are
metabolized primarily by glucuronidation.
ALTERATIONS IN AED KINETICS IN PREGNANCY, DO THEY
MATTER?
T. Tomson (Department of Clinical Neuroscience, Karolinska Institutet,
Sweden)
The pharmacokinetics of many antiepileptic drugs (AEDs) undergo
changes during pregnancy due to a combination of several factors. Such
alterations are of particular importance because they may be relevant not
only for seizure control and adverse effects in the pregnant women with
epilepsy, but also for the extent of exposure of the fetus to potentially
teratogenic drugs. The clinical consequences of the frequently observed
decline in serum concentrations during pregnancy will depend on the
mechanisms behind the alterations. A decreased binding of a drug to
plasma proteins will result in a fall in total serum concentrations but
essentially unchanged unbound serum concentrations. It is the unbound
concentration that exerts the drug’s pharmacological effects and it also
reflects the fetal drug exposure. A reduced plasma protein binding will
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thus not alter the effect of the drug treatment but measuring total drug
concentrations may underestimate the effects under such circumstances.
Such changes can be seen during gestation with valproic acid and pheny-
toin. Increased metabolic or renal elimination will on the other hand lead
to decline in total as well as unbound drug concentrations and can thus
be expected to result in reduced efficacy of the treatment. This mecha-
nism is also relevant for phenytoin but has been reported for other AEDs
such as phenobarbital and carbamazepine. A particularly pronounced de-
cline in serum concentrations due to enhanced metabolism is seen with
lamotrigine and probably also with oxcarbazepine, drugs eliminated by
glucuronidation. For these AEDs plasma levels may fall in late gestation
to 30% of prepregnancy levels, which clearly must be clinically relevant.
Very little is known about the other new generation AEDs in this respect.
The gestational effects on the kinetics thus differ between drugs but
also display marked interindividual variability. Therapeutic drug moni-
toring could be particularly useful in pregnancy because of this unpre-
dictability.
FETAL AND NEONATAL DISPOSITION OF AEDs
P. Patsalos (Institute of Neurology, UK)
Because it is a common therapeutic strategy to continue antiepileptic
drug (AED) treatment during pregnancy in women with active epilepsy,
AEDs can pass from the maternal blood supply via the umbilical cord to
the fetus and via breast milk to the nursed neonate. This passage forms
the basis of fetal and neonatal AED disposition which is dependent in
part on maternal blood concentrations, extent of transfer to breast milk
and the amount of milk intake by the neonate. Additionally, neonatal
disposition is dependent on gastrointestinal absorption, AED distribu-
tion and metabolic elimination, processes that are immature compared
to adults. In order to determine fetal disposition cord blood is used and
cord/maternal blood concentration ratios are close to 1 for most of the
first generation AEDs, with valproate being slightly higher. Ratios close
to unity are also observed for the new AEDs, lamotrigine, topiramate,
levetiracetam, oxcarbazepine and zonisamide. For gabapentin a ratio
of 1.7 has been reported indicating fetal accumulation which may be
the consequence of active transport. Milk/plasma ratios vary from 0.04
−0.19 (phenytoin, valproate, vigabatrin), through to 0.6–0.86 (lamot-
rigine, gabapentin, topiramate), and to 0.93–1.0 (ethosuximide, leve-
tiracetam, zonisamide) indicating respectively minimal, substantial and
considerable breast milk transfer. At birth, processes involving hepatic
cytochrome P450 metabolism are immature and consequently AEDs that
are cleared in this manner are eliminated from the neonate slowly. Fur-
thermore, UGT activity is absent, with adult levels being reached by
3–4 years, and consequently the neonate is unable to eliminate lamotrig-
ine, which is exclusively metabolized by UGT. Finally, in neonates, and
particularly premature neonates, where kidney function is low, elimina-
tion of AEDs that are excreted exclusively renaly is slow (gabapentin,
pregabalin, vigabatrin).
BREAST-FEEDING AND AEDS, WHAT DO WE KNOW AND
WHAT DOES IT MEAN?
S. Johannessen (The National Center for Epilepsy, Sandvika, Norway)
The common strategy to continue AED treatment during pregnancy
in most women with active epilepsy may have implications also for the
perinatal period and for the question whether breast-feeding is advis-
able. Most drugs can pass from maternal serum to breast milk and thus
be transferred to the nursed infant. The amount that the infant will be
exposed to through breast-feeding depends on maternal serum concen-
tration, extent of transfer to the breast milk, and amount of milk intake
by the infant. Drug exposure is also dependent on the infant’s absorption,
distribution, metabolism, and elimination. In particular, metabolism and
excretion may be different in the newborn compared to in children and
adults and also vary with the drug in question.
Phenobarbital can accumulate in the suckling infant and sedation has
been reported. Similar sedation may occur due to exposure to benzo-
diazepines if taken chronically by the nursing mother. However, such
adverse effects do not occur in all nursed infants. Infant serum concen-
trations of ethosuximide and lamotrigine may occationally reach levels
at which pharmacological effects could be seen. There is no clear support
for the occurrence of adverse effects in the nursed infants. For phenytoin,
carbamazepine, and valproate only small to moderate amounts are trans-
ferred. For oxcarbazepine, topiramate, levetiracetam, and gabapentin ex-
cretion into breast milk is considerable, but serum levels in the suckling
infants are generally so low that pharmacological effects are unlikely to
occur.
For several of the newer AEDs (vigabatrin, zonisamide, and tiagabine)
data on breast-feeding are scarce or lacking and warrants further studies.
The potential adverse or unknown effects must be weighed against the
unquestionable medical development, social and economic benefits of
breast-feeding. Women with epilepsy should in general, be encouraged
to nurse their infants. The risk of adverse effects due to exposure through
breast milk is in most cases negligible.
Women who nurse while taking AEDs that might affect the suckling
infant should be advised to monitor their infant for side effects such as
sedation or poor suckling, rather than being discouraged from breast-
feeding. Monitoring maternal and infant AED serum levels is advisable.
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Psychogenic pseudoepileptic seizures; a critical review
of etiological factors, diagnostic procedures, and treat-
ment outcomes
PSYCHOGENIC ETIOLOGICAL FACTORS ASSOCIATED
WITH DEVELOPMENT OF PSYCHOGENIC PSEUDOEPILEP-
TIC SEIZURES
B. Schmitz (Department of Neurology, Campus Virchow-Klinikum,
Charite´, Berlin, Germany)
The diagnosis of dissociative seizures is not difficult in the major-
ity of cases. The prognosis is however much poorer than the prognosis
of epileptic seizures and treatment strategies have not been systemati-
cally evaluated. Surprisingly little research has focused on psychological
mechanisms underlying the development of pseudoseizures.
The lecture will summarise the existing literature on psychological
etiological factors including traumatic events and childhood abuse as
well as gender aspects in patients with exclusive pseudoseizures and in
patients with epilepsy plus pseudoseizures.
DIAGNOSTIC PROCEDURES IN THE DIFFERENTIAL DI-
AGNOSIS OF EPILEPTIC VERSUS PSEUDOEPILEPTIC
SEIZURES
J. Alving (Danish Epilepsy Center, Dianalund, Denmark)
Differentiating between epileptic seizures (ES) and psychogenic non-
pileptic seizures (PNES) often is a challenge. In specialized centers,
10–30% of patients referred for intractable epilepsy have PNES, alone
or in combination with ES.
Video-EEG is considered the most important procedure, but it is re-
source demanding and quite often a good preliminary diagnosis can be
made from qualified clinical observation including video recordings.
In comparative studies, rather few out of many clinical features studies
are of high discriminative value. These are e.g., variability in seizure
duration, eyes and mouth closed versus open, facial myoclonias, ictal
stuttering, occurrence out of sleep. Reported seizure occurrence during
night-time, however, is not discriminative.
Of paraclinical investigations, ictal EEG demonstrating pseudo-
epileptiform artifacts during motor episodes or normal alpha in apparent
unconsciousness are very powerful indicators of nonepilepsy, but it must
be remembered that not all epileptic seizures give rise to scalp EEG ab-
normalities.
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Biochemical markers (mostly prolactin and neuronal specific enolase)
have by and large been disappointing, as there is a considerable overlap
in prolactin rise between ES and PNES.
In differentiating between generalized tonic–clonic seizures and “con-
vulsive” PNES, monitoring of oxygen desaturation may be of some help;
however, according to a study in our center, the sensitivity of pulse oxime-
try was only 34% in detecting generalized tonic–clonic seizures.
It is important that the diagnosis of PNES versus ES is based on a
whole set of data including seizure response to antiepileptic medication
and its withdrawal. No single observation can stand alone.
TREATMENT OUTCOMES OF PSYCHOGENIC PSEU-
DOEPILEPTIC SEIZURES; A COCHRANE REVIEW
J. Brooks (Walton Centre for Neurology & Neurosurgery, UK)
Purpose: Nonepileptic seizures (NES) have the outward appearance
of epilepsy in the absence of physiological or electroencephalographic
correlates. There is a growing literature on the treatment of NES which
includes psychological and nonpsychological therapies such as cognitive
behavioural therapy (CBT), hypnotherapy and paradoxical therapy. The
purpose of this Cochrane Review of the current literature was to establish
the evidence base for the treatment of NES.
Methods: The authors searched the Cochrane Epilepsy Group trial
register (7/9/05), the Cochrane Central Register of Controlled Trials
(9/9/05) and PsychInfo (12/9/05) and cross references from identi-
fied publications. A hand search was conducted in Seizure, Epilepsy
& Behaviour, Epilepsia, and Epilepsy Research between 20/09/05 and
29/9/05. Reference lists of retrieved studies were checked for additional
reports of relevant studies.
Results: Only three small studies met the inclusion criteria. Method-
ological quality was considered poor. These studies were not comparable
due to their different designs. Two of the studies used hypnosis and one
used paradoxical therapy. There were no detailed reports of improved
seizure frequency or quality of life, although reduction in seizure fre-
quency was mentioned. All three studies concluded that the intervention
used was beneficial in the treatment of NES.
Conclusions: Despite the existence of many journal articles suggest-
ing efficacy of various treatment methodologies for NES, there have to
date been no well designed randomized controlled trials of any ther-
apeutic intervention. There is currently therefore no reliable evidence
available on the optimum treatment for NES.
PSYCHOGENIC PSEUDOEPILEPTIC SEIZURES; ASPECTS
OF CARE
N. Bodde (Epilepsiecentrum Kempenhaeghe, Heeze, Netherlands)
Psychogenic nonepileptic seizures (PNS) are a relatively frequently
reported symptom. For example, 7–10% of the patients referred to a
specialized epilepsy centre in The Netherlands have PNS. We will discuss
a review on possible psychogenic factors that underlie the development
of PPS.
One of the crucial factors in clinical practice is that Information on the
long-term effects of psychogenic nonepileptic seizures (PNS), is limited.
We therefore report on a study in which we reassessed patients, 4–6 years
after the initial diagnosis of PNS. Patients with epilepsy and PNS as a
comorbid symptom were not included. Reassessments were aimed at
possible psychogenic factors.
Seizure frequency showed a statistically significant reduction from
baseline to endpoint. At time of diagnosis none of the patients were
seizure free or had only yearly seizures, whereas at endpoint about 30%
of the patients were completely in remission and 10% had only occasional
seizures. The number of patients with daily seizures dropped from 25%
to 8%. It is not fully clarified which factors caused this improvement,
but the common denominator is that a definitive expert diagnosis in a
tertiary centre was made and all possible efforts were made to inform
the patient in a respectful manner about this diagnosis. On the other
hand, the fact that there is a more than seven year delay between seizure
onset and time of diagnosis (7.2 years) also opens the possibility that
other factors have influenced the outcome; in addition to the seizure
reduction, there is an improvement on a wide range of personality traits,
showing a reduction of psychological stress an increase of selfcontrol,
a more active attitude towards social contact, a reduction of dissociative
features, such as amnesia and a reduction of feelings of dissatisfaction
and passive avoidant behaviour. These changes may have preceded the
improvement of seizure control.
The consequences for treatment strategies will be discussed
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Large scale mRNA and protein expression profiling in
epilepsy—where we are and where we are going
MOLECULAR PROFILING OF TEMPORAL LOBE EPILEPSY
M. Majores (Department of Neuropathology, University of Bonn Medi-
cal Center, Germany)
Microarray analysis of temporal lobe epilepsy in surgical tissue spec-
imens and experimental animal models.
Ammon’s horn sclerosis (AHS) is a frequent observation in human
temporal lobe epilepsy (TLE). In AHS hippocampi neuronal loss occurs
in CA1 and CA4, whereas dentate gyrus (DG) granule and CA2 pyrami-
dal cells are more resistant. Molecular pathways involved in stage and
subfield specific hippocampal epileptogenesis have yet to be determined.
Since many patients with pharmacoresistant TLE undergo surgical treat-
ment with removal of hippocampi, we have the unique opportunity to
analyze pathogenetic mechanisms in human brain tissue. In addition,
animal models of TLE with induction of an episode of status epilepticus
(SE) by application of pilocarpine to rats allow the generation of gene
expression profiles during epileptogenesis, i.e., the seizure free latency
interval between SE and onset of chronic recurrent seizures.
We have used oligonucleotide microarrays to carry out expression
profiling as a valuable approach to determine transcript patterns in both
human and experimental TLE. In rats, the transcriptional response to
SE revealed early upregulation of genes linked to stress and cell dam-
age associated signaling cascades. It was followed by upregulation of
transcription factors, neurotransmitter receptors and calcium-signaling
or structure related molecules in the initiation of chronic seizures. In
human tissue, expression patterns from hippocampi with the pattern of
AHS were compared to profiles of “epileptic controls,” i.e., hippocampi
of pharmacoresistant TLE patients with extrahippocampal lesions. In
these patients the hippocampus does not show the pattern of AHS but is
to be resected for seizure control.
Expression profiling allows to determine transcript patterns in anatom-
ically heterogeneous structures such as the brain and to monitor genomic
responses in complex diseases such as TLE. The identification of ge-
nomic networks and pathways specifically involved in key aspects of
human epileptogenesis opens the perspective to develop new therapeu-
tical strategies in order to target the stage of epileptogenesis and prevent
the onset of recurrent chronic epileptic seizures.
Supported by DFG (SFB TR3), Bundesministerium fu¨r Bildung und
Forschung, Deutsche Krebshilfe, BONFOR.
LARGE SCALE mRNA AND PROTEIN EXPRESSION PROFIL-
ING IN EPILEPSY
H. Potschka (University of Veterinary Medicine, Department of Phar-
macology, Toxicology, and Pharmacy, Germany)
Research taught us a lot about seizure- and epileptogenesis-associated
changes in brain structure and function. However, still a complete de-
scription of the factors determining seizure susceptibility and epilepto-
genesis remains elusive.
Available methods for expression analysis allow to perform large scale
or even genome-wide expression profiling, providing insight into the
whole ensemble of molecular events taking place in epileptic tissue. Us-
ing tissue obtained from experimental epilepsy models or obtained from
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surgical resection in epileptic patients, expression profiling has delivered
a large amount of data which can teach us about the pathophysiological
mechanisms of ictogenesis, epileptogenesis, and pharmacoresistance. In
addition, a variety of studies have been designed to identify new target
sites, and to learn about interactions of antiepileptic drugs with gene
expression. In order to gain information from expression data, this needs
to be amended by a thorough bioinformatical analysis considering avail-
able knowledge about biological pathways. Furthermore, selected data
must be validated by more traditional methods focusing on expression
of one gene or protein, and by a functional analysis, e.g., using RNA
interference mediated knockdown or mouse mutants.
Genes which proved to be regulated during epileptic processes belong
to a variety of functional classes, e.g., including those involved in tran-
scriptional regulation, protein synthesis, protein degradation, synaptoge-
nesis, ion channels, cytoskeleton, cation transport, calcium homeostasis.
When gene lists are compared between different studies, there is rela-
tively little overlap. This must be attributed to variations in study design,
including differences in time points and differences in methodological
aspects.
Despite of some drawbacks, simultaneous profiling of thousands of
genes or proteins is a valuable tool to learn more about coregulated
molecules that function in concert, to identify common traits in epilep-
togenesis, and to identify surprising and unexpected changes which can
lead to new targets for antiepileptic drug development.
MOLECULAR PROFILING OF THE EPILEPTIC BASOLAT-
ERAL AMYGDALA
K. Majak (A.I. Virtanen Institute for Molecular Sciences, University of
Kuopio, Finland)
Lateral and basal nuclei of the amygdala play critical role in the emo-
tional learning. During development of temporal lobe epilepsy (epilepto-
genesis) the lateral and basal nuclei of the amygdala are damaged. So the
aim of the study was to reveal the differences in gene expression pattern
during emotional learning in rats undergoing epileptogenesis. Electri-
cal stimulation of the left lateral nucleus induced status epilepticus (SE)
which triggers epileptogenesis. Five days after SE, habituation to the
fear conditioning apparatus started (it continued for 3 days). During the
whole experiment video-EEG monitoring was performed to make sure
that animals do not have spontaneous seizures. 8 days after SE control
and epileptic animals received training session composed of two presen-
tation of either paired or unpaired tone and footshock. 3h after training
animals were sacrificed. Then the lateral and basal nuclei of the amygdala
were microdissected using Leica AS LMD Laser System. 30 ng of total
cellular RNA underwent 2 rounds of amplification. Then aRNAs ani-
mals in 4 experimental groups: epileptic paired (EP), epileptic unpaired
(EU), control paired (CP) and control unpaired (CU) were pooled (2 ani-
mals per group) and hybridized to GeneChip Rat Genome 230 2.0 Array
(Affymetrix). Comparisons of genes expressed in basolateral amygdala
between experimental groups revealed that different genes change their
expression level during Pavlovian fear conditioning in rats undergoing
epileptogenesis comparing to controls, that is epileptogenesis substan-
tially affects molecular processes underlying emotional learning in the
basolateral amygdala. Many genes were up- or down-regulated in the
rats undergoing epileptogenesis and they are much more numerous than
genes involved in emotional learning, which indicates the complexity of
the epileptogenic process.
Acgnowledgements: Array experiments were conducted in Center for
Biotechnology, University of Turku, Finland. The study was financially
supported by Finnish Academy of Science, Medical Council.
MICROARRAY DATA FOR ANALYSIS OF GENE REGULA-
TORY SEQUENCES
M. Dabrowski (Nencki Institute, Poland)
Knowledge of genomic sequence of several vertebrate species
permits—by their comparison—identification of putative regulatory re-
gions of genes on the scale of whole genomes. Analysis of these se-
quences together with data on gene expression permits identification of
cis-regulatory features that are associated with particular patterns of ex-
pression. This task can be simplified by first decomposing (by singular
value decomposition–SVD) the expression profiles into sums of modes,
analogous to the modes of a vibrating violin string, followed by anal-
ysis of regulation separately for of each mode. We applied SVD to the
published time-series dataset (J Mol Neurosci 2005;25:285–98) from
expression profiling of rat hippocampus following injection of kainate
or saline. I will focus on analysis of regulation of mode 3, which is the
most important kainate-specific mode. Mode 3 represents a component
of an increase in expression at the early time-points (1h, 6h) following
the injection of kainate. Distribution of loadings of mode 3 shows a group
of about 20 genes with very high loadings of this mode, separating them
from the rest of the population. This group overlaps heavily with the
group of genes listed in a review (Neurochem Int 2001;38:485–501) as
the genes up-regulated in all hippocampal subfields following the injec-
tion of kainate. In the putative cis-regulatory regions of the 20 genes with
highest contribution of this mode, identified by rat-human comparison,
we identified a statistical overrepresentation (corrected p-values 10−4–
10−3) of sequences containing the motif CRE known to bind CREB/ATF
and two other motifs sharing the same consensus sequence. Of the 13
genes in this group that contain the motif CRE, 7 were recently identi-
fied (personal communication, G. Schutz) as affected in CREB/CREM
knockout, thus validating our in silico prediction of a regulatory role of
the CREB-binding motifs for this group of genes.
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Is epileptic activity during sleep an ignored cause of
neuropsychological disorders in children?
EPILEPTIC ACTIVITY AND COGNITIVE IMPAIRMENT
D. Kasteleijn-Nolst Trenite´ (University La Sapienza (Rome), Italy and
University of Utrecht, Netherlands)
Epileptic activity can disturb cognition even when no clinical signs or
symptoms are present. These short-lasting discharges of 10 seconds or
less are called subclinical EEG-discharges and can occur during sleep
or wakefulness. Not only are these discharges an expression of under-
lying brain dysfunction, but also they have themselves a negative effect
on performance of tasks. Since 1939 research has been undertaken to
unravel the impact of these subclinical discharges, either isolated and
focal or long-lasting and generalised. It is by far easier to determine the
direct impact of short lasting epileptiform discharges on cognition when
the patient is awake than when asleep and most studies were performed
even during evoked epileptiform discharges using hyperventilation or
photic stimulation. The more complex the task, the more disturbance
can be found. Individual differences are important and interaction be-
tween performance of the task and occurrence of epileptiform discharges
complicates matters further.
Much more recently long-term follow-up studies have been under-
taken in patients with rolandic and occipital epilepsy and those with
epileptic activity during sleep to determine their cognitive evolution.
Mainly transient deficits were found and these appeared to be correlated
in time with worsening of the EEG in the active phase
Besides scientific purposes, insight into the various factors involved
in cognitive impairment in patients with subclinical EEG-discharges is
of practical importance.
Grant: European Cie–Marie Curie Actions.
CSWS AND LKS—THE EXTREME OF A SPECTRUM?
C. Tassinari (University of Bologna, Department of Neurological Sci-
ences - Bellaria Hospital, Italy)
No abstract receceived.
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EPILEPTIC ACTIVITY DURING SLEEP IN CHILDREN WITH-
OUT SEIZURES BUT WITH COMMON DISORDERS OF BE-
HAVIOUR AND LEARNING—THE OTHER EXTREME?
J. Wilson (The National Centre for Epilepsy, Norway)
Children without a seizure history, but with interictal spike-wave ac-
tivity, enhanced or exclusively during sleep, share the spectre of cog-
nitive and behavioural disorders that can afflict children with Rolandic
Epilepsy.
105 children were recruited to perform a 24 hr EEG recording, in
the time span of 2 years, by encouraging referrals of children with
Attention Deficit and /or Hyperactivity Disorder, and/or other mod-
erate cognitive disorders, but no seizure history and no known brain
lesion.
46 of these children had abundant focal spike-wave activity, mainly
or exclusively during slow sleep. Spike-wave morphography and topog-
raphy was in most cases indistinguishable from that found in rolandic
epilepsy. Most cases had a single focus in one or the other perisylvian
region, a few had either an occipital, frontal or lateral temporal focus,
a few had bilateral independent foci, and a few had propagation from
one perisylvian area to the other. Spike-wave indexes during slow sleep
ranged from 25 to over 90% of slow sleep time. There was a slight
clustering of right-sided focus in children with interactional problems
and temper tantrums, and left-sided focus in children with language or
speech deficits.
The findings are not population based, thus a reliable assessment of
the prevalence of interictal focal spike wave activity during sleep in
children with moderate disorders of behaviour and cognition can not
be made, and the children may have been atypical and subject to re-
ferral bias. Nonetheless, nearly half of the referred children had sub-
stantial, sometimes abundant, epileptic activity during sleep, indicating
that epileptic pathology can be a grossly underdiagnosed cause of cogni-
tive and behavioural disorders in children that do not have overt seizure
history.
Some of the empirical and neurophysiological evidence as to the clin-
ical relevance of interictal epileptic activity, especially during sleep, is
discussed; as well as some comments on therapeutical implications.
CSWS AND LKS SYNDROME: FROM CHILDHOOD TO
ADULTHOOD
T. Deonna (Neuropaediatric Unit, CHUV, Lausanne, Switzerland)
Childhood partial epilepsy syndromes with major effects on cogni-
tive functions, acquired epileptic aphasia (Landau-Kleffner syndrome)
and epilepsy with continuous spike-waves during sleep (CSWS) con-
stitute a special neurophysiological situation with rarely studied long
term consequences. Although these syndromes share a marked activa-
tion of the epileptic EEG abnormalities during sleep (CSWS), Landau-
Kleffner syndrome is defined by its cognitive consequences (auditory
agnosia) whereas epilepsy with CSWS is the name given for those chil-
dren whose epileptic cognitive dysfunction is not predominantly in the
language domain, and in fact encompasses all other cognitive and behav-
ioral problems directly linked to the epilepsy. Importantly, children with
LKS almost never have an identifiable focal cortical lesion, whereas one
increasingly finds out that the other children with CSWS have recogniz-
able lesions, either cortical or in the thalamus. In the idiopathic cases,
the deficits observed in adulthood is the result of whatever epilepsy did
to the affected part of the developing brain during the active period of
the disease. Such conclusions are possible only if the early deficit and its
direct relationship to epilepsy has been demonstrated from the onset and
that evolution has been monitored for a long period, and more precisely
in the affected domain. Personal long-term studies of children followed
to adulthood will be presented as well as other recently published cases.
These cases were not diagnosed and studied as early and treated as ef-
fectively as occurs nowadays. Disappearance of CSWS (an age-related
phenomenon) does not mean that epilepsy has necessarily remitted. Per-
sistent deficits in very specific domains (i.e., phonologic decoding) are
seen in LKS whereas executive deficits and special behavioural syn-
dromes can be seen in those with CSWS and frontal epilepsy. As there
is a great variability in age at onset, severity, duration and reversibility
(medical control) of the epileptic disease, prolonged follow-up of all
cases, and not only of the most severe ones, is necessary to find out
which variables are the most important for prognosis and also to find out
for how long there is potential for late recovery. This seems greater than
initially anticipated.
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Epileptic syndromes: from childhood to adulthood
IDIOPATHIC PARTIAL EPILEPSIES IN ADULTHOOD
B. Dalla Bernardina (Clin. Ped. Universita`-Borgo Roma, Verona, Italy)
No abstract received.
WEST SYNDROME IN ADULTHOOD
V. Koma´rek (Epilepsy Centre Motol, Prague, Czech Republic)
The first description of infantile spasms was published in Lancet
(1941) by West (British pediatrician) in his own son. In 1952, Gibbs
and Gibbs identified the “interictal” hypsarrhytmia pattern associ-
ated with infantile spasms. West syndrome is related to the combina-
tion of infantile spasms and hypsarrhytmia, with or without cognitive
impairment.
The epidemiological studies show differences (from 1:1900 to 1:4000)
in incidence among ethnic and national groups. There is no doubt about
the age-dependent nature of the syndrome: it begins exclusively during
the first year of life, with maximum frequency between 3 and 7 months.
The semiology of spasms consist of sudden intensive flexion of the head,
trunk and limbs (“jack knife,” “salaam” convulsions). The essential char-
acteristics of spasms is their occurence in series (cluster). The etiolog-
ical factors of symptomatic forms are multiple: predominantly brain
malformation, cortical dysgenesis, tuberous sclerosis complex, perina-
tal anoxia-ischemia, and different form of brain infections.
From the therapeutic point of view early treatment with steroids
(ACTH) or vigabatrine improved unfavourable prognosis of children
suffered from IS. However there are unsufficient data about long-term
outcome when the patients are adults.
We analysed published studies of adults with history of infantile
spasms as well as our own data obtained from patients with cerebral
palsy, tuberous sclerosis and autism. The most relevant informations
about IS long-term outcome were published by Riikonen (1981, 1996,
2001, 2004). In 214 Finnish patients followed up for 20–35 years or un-
till death, one third of patient died (the most of them in first decade), one
third of survivors were seizure-free, twenty percent patients with daily
seizures were on the oposite endpoint of the outcome spectrum.
The most important positive prognostic factors are: early identification
and intervention as well as prompt therapeutic response (cessation of
spasms and hypsarrythmia). The mental/cognitive and social outcome
correlates with severity of underlying etiology, however the quality of
medical care and social services play crucial role for definitive quality
of life of patients with IS history.
Supported in part by IGA MZ NR 8287.
THE LENNOX-GASTAUT SYNDROME IN ADULTHOOD
G. Bauer (University Hospital for Neurology, Medical University
Innsbruck, Austria)
The definition of the Lennox-Gastaut syndrome (LGS) still is contro-
versial. A descriptive definition encompasses the following main criteria:
(a) polymorphous epileptic seizures (atypical absence, tonic and atonic
seizures); (b) EEG patterns consisting of slow spikes and waves and runs
of rapid spikes; and (c) cognitive and emotional disturbances (Genton P,
Dravet C. Lennox-Gastaut syndrome and other childhood epileptic en-
cephalopathies. In: Engel J, Pedley TA (eds.): Epilepsy:A Comprehensive
Textbook. Lippincott-Raven, Philadelphia 1997, pp 2355–66). The LGS
represents an age-dependant condition with onset before 8 years, with a
peak between 3 and 5 years. Several papers reported epilepsies with all
features of LGS except age at onset (Oller-Daurella L. Un type spe´ciale de
crises observe´es dans le syndrome de Lennox-Gastaut d´apparition tar-
dive. Rev Neurol 1970;122:459–62; Lipinski CG. Epilepsies with astatis
seizures of late onset. Epilepsia 1977;18:13–20; Stenzel E, Panteli C.
Lennox-Gastaut-Syndro des 2. Lebensjahrzehntes. Jahrestag. Dt. Sek-
tion Int. Liga gegen Epilepsie, Marburg 1981; Bauer G, Aichner F,
Saltuari L. Epilepsies with diffuse slow spikes and waves of late
onset. Eur Neurol 1983;22:344–50; Roger J, Remy C, Bureau M,
Oller-Daurella L, Beaumanoir A, Favel P, Dravet C. Le syndrome de
Lennox-Gastaut de l´adulte. Rev Neurol 1987;143:401–5).
LGS patients can maintain the complete syndromic profile into adult-
hood. Frequently, the severity of the seizure disorder and neurological
disturbances decreased. In many cases the profound cognitive decline
and behavioral abnormalities represent the major problem compared
to seizures. 27 out of 68 LGS patients with persistent seizures trans-
formed into severe focal or multifocal epilepsies (Othahara S, Ohtsuka
Y, Kobayashi K. The Lennox-Gastaut syndrome: A new vista. Psychia-
try Clin Neurosci 1995;49:179–183). The development of focal aspects
might be confined to EEG without a significant change in the generalized
seizure semiology.
A second group of late onset LGS compromise patients starting with
an idiopathic generalized epilepsy syndrome (IGE) turning into a full
blown LGS. As a cause of this “Lennoxisation” overdosage with AEDs or
abrupt withdrawal and consecutive status epilepticus has been identified
in some cases. The malignisation of the IGE can be transient, but there
are patients with enduring LGS-like features.
In rare cases the LGS starts in the second or even third decade of life.
These patients had a normal neurological and mental status before the
start of seizures, an uncharacteristic seizure disorder until all features
of LGS emerged, no identifiable etiology and a somewhat better social
status compared with the other forms of late LGS. This group seems
to represent the old end of the Gaussian age distribution of cryptogenic
LGS.
LONG-TERM OUTCOME OF SEVERE MYOCLONIC
EPILEPSY IN INFANCY (DRAVET SYNDROME)
1C. Dravet, 2G. Daquin, 2N. Villeneuve, 2D. Viallat, 2P. Genton, 2D.
Broglin, and 1A. Ferrari (1IRCCS Fondazione Stella Maris, Pisa, Italy,
2Centre Saint-Paul-Hoˆpital Henri Gastaut, Marseille, France)
Among more than one hundred patients examined at the Centre Saint-
Paul with a diagnosis of severe myoclonic epilepsy in infancy (SMEI),
forty are now 15 years old or more (up to 40 years). For thirty patients
enough information was obtained either because they were regularly
followed or by letters and telephone calls. Their age was between 15
and 19 years for ten, and between 20 and 40 years for twenty. Four
died after the age of 15. In all the others, epileptic seizures have per-
sisted in spite of treatment but their frequency and their severity have
decreased. All patients had a cognitive deficit, of variable degree, but the
behavioral disturbances had a tendency to improve. None could have a
normal job and the majority was institutionalized or remained at home.
Seizure type and frequency, electroencephalographic features, neuro-
logical signs, psychological evaluation, response to treatment, social
situation of these patients will be presented.
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Pharmacogenomics: possibilities, realities, and diffi-
culties
THE PROMISE OF PHARMACOGENOMICS
S. Sisodiya (UCL Institute of Neurology, UK)
Whilst drug resistance in epilepsy is difficult to define, there are clearly
patients for whom no antiepileptic drug brings about seizure control,
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whilst other patients, with the same types of epilepsy, may be rendered
seizure-free with currently available antiepileptic drugs. Even for the
majority of patients who do obtain response, and seizure freedom, from
current antiepileptic drugs, the choice of drug remains empirical for
an individual patient. Antiepileptic drugs also have potential for gen-
erating harm, with adverse effects that may or may not be reversible,
and that can be life-threatening. Currently, there are no rigorous, useful
predictors of responsiveness in general, or of responsiveness to spe-
cific antiepileptic drugs, or of harm that may ensue from antiepileptic
drug treatments. Syndrome-specific trials of particular drugs may pro-
vide such information, especially if individual cases within trials can
be more precisely described—the trials could then be conceptualised
as disease-specific trials, for example in genetically-defined conditions.
Even syndrome-specific trials are rare, and it is unlikely that appropri-
ate, sizeable studies will be undertaken for already-licensed agents. On
the other hand, significant advances in theoretical and practical aspects
of genetics offer the possibility of more closely linking particular ther-
apeutic options to individual patients. Early progress will be reviewed.
Whilst significant challenges remain, and it is possible that no clinically
useful benefit will derive from studies in epilepsy pharmacogenetics, ex-
isting knowledge of drug transport, metabolism and activity on the one
hand, and variation in the genes encoding the relevant proteins on the
other suggest further benefit is likely to accrue. Formal assessment of the
cost-effectiveness of treatment-related genotyping will be necessary. In
combination with other investigations, including formalised assessment
of pharmacometabonomics, pharmacogenetics holds at least theoretical
promise for improving treatment decisions in patients with epilepsy.
THE CHALLENGE OF PHARMACOGENOMICS
D. Goldstein (Duke Institute for Genome Sciences & Policy, USA)
Pharmacogenetics–lessons from antiepileptic drugs
Many clinical challenges remain in the treatment of epilepsy, including
the optimization of dosing, the control of adverse reactions, and perhaps
most importantly the significant minority of patients who do not respond
well to pharmacological treatment.
The potential modes of action of most antiepileptic drugs are known,
permitting detailed candidate gene and candidate pathway screens for
gene variants that may influence response. Such variants would be of
potential relevance in the treatment of epilepsy and other in other in-
dications that make use of antiepileptic drugs. Here I report the results
of a search for genetic determinants of predisposition to epilepsy and
response to anti epileptic drugs in a data set of 3000 SNPs drawn from
300 candidate genes related to the action of anti epileptic drugs.
PHARMACOKINETIC PHARMACOGENOMICS AS APPLIED
TO EPILEPSY
M. Johnson (Imperial College London, Charing Cross Hospital, UK)
Pharmacokinetic variability in antiepileptic drug (AED) response is
under considerable clinical as well as genetic control, including age, sex,
weight, nutritional status, pregnancy, drug formulation, comorbidity and
comedication influences. Genetic influences can be considered to act at
peripheral (Phase I and II metabolism) and central (transport proteins
regulating the flux of drugs across the blood brain barrier) mechanisms.
With respect to peripheral mechanisms, genotyping to determine drug
metabolism alone probably has a limited role in epilepsy for two main
reasons (1) for many AEDs, there is not a clear relationship between
plasma concentration and efficacy/adverse events; (2) AEDs are suc-
cessfully titrated up slowly and concomitant clinical and blood level
monitoring usually gives an accurate idea if patients are slow or fast me-
tabolizers. To date, pharmacogenetic analysis of pharmacokinetic factors
influencing drug response in epilepsy has focused on a single central
pharmacokinetic mechanism P-glycoprotein, the product of the ABCB1
gene. Case control association studies of a single variant C3435T and a 3
SNP haplotype containing C3435T have produced discordant findings,
which reflect the complexities and pitfalls of pharmacogenetic analysis.
Potential statistical explanations for the discordant findings have been
well rehearsed, but less well considered are the potential biases of the
retrospective case control design or problems of non-standardized defi-
nitions of outcome when assessing the genetic basis of AED response.
PHARMACODYNAMIC PHARMACOGENOMICS AS APPLIED
TO EPILEPSY
C. Depondt (Universite´ Libre de Bruxelles, Belgium)
Pharmacodynamics is the interaction of a drug with its target(s) at the
cellular level, e.g., binding to a receptor or inhibition of an enzyme. The
aim of pharmacodynamic pharmacogenomics in epilepsy is to identify
polymorphisms in genes encoding antiepileptic drug (AED) targets that
affect response to AEDs. These polymorphisms may have an influence
on AED efficacy and/or adverse drug reactions. They may also play a
role in the pathogenesis of drug refractory epilepsy.
Except for levetiracetam, which acts on synaptic vesicle protein SV2A,
all currently licensed AEDs of which the mechanism of action is known,
act through one or several of the following three mechanisms: modulation
of voltage-dependent ion channels, enhancement of GABA-mediated
inhibitory neurotransmission, and attenuation of excitatory (particularly
glutamate-mediated) transmission. This knowledge allows drafting of a
list of candidate genes for pharmacodynamic pharmacogenomics. Other
candidate genes besides the genes encoding the actual AED target are
those encoding effector proteins downstream in the pathway of AED
action and target.
Only a handful of genetic associations relating to pharmacodynamics
have been reported in epilepsy to date. These will be discussed, with spe-
cial emphasis on the association of a putative functional polymorphism
in the SCN1A gene with clinical use of phenytoin and carbamazepine.
Many other candidate genes remain to be examined. Major advances
in the field of genetics have significantly facilitated large-scale candi-
date gene studies, and even whole genome scans. Therefore it is likely
that further genetic associations in epilepsy pharmacodynamics will
emerge in the near future. It is hoped that this knowledge will ulti-
mately lead to a more efficacious and less harmful drug treatment of pa-
tients with epilepsy, as well as to the development of new, more efficient
AEDs.
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Imaging language and memory
IMAGING LANGUAGE FUNCTIONS USING fMRI
F. Woermann (MRI Unit, Bethel Epilepsy Center, Bielefeld, Germany)
Cognitive functional MRI (fMRI) is noninvasive, but often produces
maps with bilateral activations.
There is a large variety of literature describing fMRI results of lan-
guage functions in normal subjects. These interesting group studies are
designed to describe the normal pattern of cortical representations of
speech, reading and auditory language. Aiming to reveal regions respon-
sible for specific cognitive components, very similar tasks are contrasted,
which do not necessarily reveal all essential language areas and might
have only insufficient power to produce activations in individuals.
This approach differs substantially from what is needed in the presur-
gical evaluation of individual patients with epilepsy (simple tasks; con-
trasted with a baseline condition which allows to visualize the entire
network; statistics aiming to reduce false negatives; individual concor-
dance with a gold standard). Studies in patients with epilepsy show a high
concordance between language fMRI and Wada test (Woermann, 2003).
FMRI predicted the absence of essential language areas when compared
with intraoperative electrocortical stimulation (Rutten, 2002). Use of
preoperative fMRI predicted language deficits from epilepsy surgery
(Sabsevitz, 2003).
FMRI studies of language in patients with epilepsy contribute to the
discussion on reorganization of cognitive functions. A longitudinal fMRI
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study of language pre- and postseizures demonstrated false lateralization
of language cortex after a cluster of seizures and subsequent recovery
(Jayakar, 2002). A crossectional study on language fMRI in patients
with left sided hippocampal sclerosis showed EEG spiking frequency
associated with atypical language lateralization (Janszky, 2006). A lon-
gitudinal fMRI study of reading skills after left anterior temporal lobe
resection used operated patients as human lesion model and described
mechanisms maintaining function postoperatively (Noppeney, 2005).
Atypical language lateralization is more frequent in patients with
epilepsy and associated with left sided (extra)temporal epilepsy, left-
handedness, younger age at epilepsy onset and at early precipitating
injury.
IMAGING MEMORY FUNCTIONS USING fMRI
M. Richardson (King’s College London Institute of Psychiatry, UK)
In determining the site and extent of surgical resection, the anatomical
location of the epileptogenic zone needs to be established. Additionally,
the functional capacity of regions affected by resection needs to be taken
into account. Mesial temporal structures, especially hippocampus, play
a crucial role in long-term memory function. Mesial temporal resection
can impair memory function; preoperative assessment of memory func-
tion and evaluation of the risk of postoperative memory impairment is
routine in presurgical investigation. It has been established that patients
with a relatively larger hippocampus, or with relatively well-preserved
preoperative memory function, are at greatest risk of significant postop-
erative memory decline. Furthermore, the intracarotid amobarbital test
(IAT, ‘Wada test’) may provide information about the risk of an amnesic
syndrome. However, none of these tests has a strong predictive value for
postoperative memory outcome. The suboptimal value of these tests mo-
tivates a search for an improved means to examine preoperative memory
function using functional MRI (fMRI). A number of techniques have
been applied to epilepsy patients to examine memory function using
fMRI. These include; comparison of the brain activity during viewing
of visual scenes versus viewing ‘scrambled’ pictures; comparison of the
activity during covert recall of a familiar route versus a rest state; and
comparison of the activity during presentation of items subsequently re-
membered at a postscan recognition test versus items not remembered.
These approaches have different advantegs and disadvantages, and acti-
vate somwhat different brain regions. Initial attempts have been made to
optimise the way in which fMRI data from patients is examined, and to
compare the predictive value of fMRI with existing tools. In this session,
current fMRI techniques to assess memory function in epilepsy patients
will be reviewed, and important problems and pitfalls discussed. An at-
tempt will be made to suggest directions for further work in this area.
IMAGING STRUCTURAL AND FUNCTIONAL CONNECTIV-
ITY OF MEMORY AND LANGUAGE USING TRACTOGRAPHY
R. Powell (Institute of Neurology, UK)
Understanding the relationship between brain structure and function
would be enhanced by a detailed knowledge of the anatomical connec-
tions of the white matter fibres linking functional regions. The combina-
tion of functional magnetic resonance imaging (fMRI) to identify cortical
regions involved in specific functions and MR-tractography to visualise
pathways connecting these regions offers an opportunity to increase our
understanding of brain functioning.
A number of fMRI studies have demonstrated a reorganisation of lan-
guage function in patients with left temporal lobe epilepsy (TLE) with
greater involvement of the nondominant hemisphere however the struc-
tural brain connections supporting this atypical language dominance
have not previously been identified. Preliminary findings using trac-
tography have demonstrated a structural reorganisation of white matter
pathways that reflects the reorganisation of language function seen in
TLE patients. Correlations were shown between structure and function,
with subjects with more lateralised functional activation having more
highly lateralised connecting pathways. This combination of fMRI and
tractography offers a promising research and clinical tool to supersede
the Wada test for studying language function in many neurological con-
ditions and may prove useful in predicting language deficits following
temporal lobe surgery.
The connections of the medial temporal lobe are important for seizure
propagation and memory function in TLE patients. In vivo visualisation
of these pathways using tractography has shown a pattern of connections
in keeping with information from histological tract-tracing studies in
animals. Tractography may prove a useful presurgical investigation for
predicting postoperative memory outcome, as well as providing insights
into the networks involved in memory function and seizure spread.
GAMMA OSCILLATIONS DURING MEMORY AND
LANGUAGE TASKS
J. Lachaux (INSERM, Lyon, France)
While functional neuroimaging studies have helped elucidate major
regions associated with reading, the dynamics of activation within those
regions and the actual neural phenomena underlying reading within that
network are still virtually unknown. We used intracranial EEG record-
ings in ten epileptic patients to measure directly the neural activity oc-
curring in the temporal and frontal lobes during reading. The patients
were presented with visual letters strings and performed a classic hier-
archical reading paradigm contrasting semantic processes (an animacy
decision task with words), phonological processes (a rhyme decision
task with pseudowords) and visual processes (a visual analysis of con-
sonant strings). We found that reading was associated with transient
and local neural synchronization in the gamma frequency range, in dis-
tributed brain regions including the fusiform gyrus, the anterior and
middle superior temporal gyrus, the inferior frontal gyrus, and the dorsal
prefrontal cortex. Reproducible gamma band deactivations were also ob-
served in the ventral lateral prefrontal cortex. Further, we observed that
those effects were amplified by attention. The reproducibility in timing
and task-sensitivity of those gamma band responses made it possible
to reach robust conclusions regarding the dynamics of neural activation
within the reading network and regarding the function of each of its
components.
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New concepts in pharmacotherapy
CIRCUMVENTING MULTIDRUG RESISTANCE MEDIATED
BY EFFLUX PROTEINS
H. Potschka (University of Veterinary Medicine, Department of Phar-
macology, Toxicology and Pharmacy, Hannover, Germany)
Local limitation of antiepileptic drug brain access by overexpression
of efflux-transporters at the blood–brain barrier has been substantiated
as a mechanism of multidrug resistance of epilepsy by numerous studies.
Awareness of this mechanism now renders a basis for the development
of new therapeutic strategies aimed to overcome efflux-transporter me-
diated pharmacoresistance. Modulation of transporter function by coad-
ministration of inhibitors proved to be efficacious in experimental set
ups including a model of pharmacoresistant epilepsy. First clinical data
also indicate that inhibition of efflux transporter function may be one
means to improve therapeutic success. Alternatively, efflux-transporter
expression can be downregulated by RNA interference. Both strategies
have the potential to reduce efflux function at the blood–brain barrier,
thereby enhancing brain permeability of transporter substrates including
antiepileptic drugs. However, these concepts must take into considera-
tion the putative complications of such modulation in view of the general
protective role of efflux-transporters.
Thus, by-passing of efflux-transporters seems to be a more elegant
strategy to overcome transporter mediated drug resistance. This may
imply the use of immunoliposome-based drug delivery systems targeted
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to the blood–brain barrier or modes of administration which are suitable
to circumvent the blood–brain barrier.
Instead of dealing with the problem of overexpressed transporters in
multi-drug resistant individuals, it is a promising approach to prevent
seizure-induced upregulation of efflux-transporters. In this context, we
currently study the cascades which are involved in seizure-induced up-
regulation in order to identify targets for resistance prophylaxis.
In summary, knowledge about a correlation between efflux-transporter
expression and multidrug resistance renders a basis for new therapeu-
tic concepts, which need further thorough validation with regard to ef-
fectiveness and tolerability. When heading to clinical studies it will be
important to select appropriate patients, taking into consideration that
drug resistance per se must be considered a complex phenomenon that
is likely to involve many mechanisms.
EXPANDING MECHANISTIC DIVERSITY OF ANTIEPILEP-
TIC DRUGS
G. Sills (University of Glasgow, Scotland, UK)
The last two decades have witnessed an unprecedented development of
novel antiepileptic drugs (AEDs) and a quantum leap forward in our un-
derstanding of how these agents work at the cellular level. From a handful
of compounds with unknown pharmacology discovered by serendipitous
means, we now possess an extensive and well-characterised pharma-
copoeia with which to treat seizure disorders. Despite these significant
advances, current evidence suggests that the majority of established and
modern antiepileptic agents exert their effects by one or more of just three
principal mechanisms of action; blockade of voltage-gated cation chan-
nels (sodium, calcium), potentiation of the inhibitory effects of the neuro-
transmitter γ -aminobutyric acid (GABA) and inhibition of the excitatory
effects of the neurotransmitter glutamate. This relatively narrow phar-
macological spectrum is most likely symptomatic of a drug development
process that continues to rely on experimental models first employed in
the identification of phenytoin in the 1930s. It may also be indicative of
a chemical and mechanistic “me-too” philosophy that is aimed at min-
imising risk, at the potential expense of therapeutic advantage, in the
identification of novel compounds. It is reasonable to speculate that for
some epilepsy types, or some individuals, this pharmacological spectrum
is inadequate and that new AEDs with innovative mechanisms of action
are required to address the important clinical issue of non-response to
medication. In this regard, the recent introduction into clinical practice
of compounds with novel cellular effects, such as α2δ-subunit selective
calcium channel blockade and SV2A protein inhibition, may be a useful
indicator of whether expanding mechanistic diversity is a worthwhile
pursuit in AED development and one which can genuinely improve the
outcome of treated epilepsy.
DELIVERING DRUGS DIRECTLY TO THE BRAIN VIA VEC-
TORS OR DEPOTS
P. Boon (Laboratory for Clinical and Experimental Neurophysiology
(LCEN) and Department of Neurology, Ghent University Hospital,
Belgium)
The inability of currently available antiepileptic drug treatment to
provide seizure freedom in about 30% of patients and the limitations of
resective, disconnective or stimulation-based surgical techniques provide
a strong impetus for developing new treatment strategies. In this context
delivering agents with antiepileptic properties directly to the brain tissue
seems an attractive avenue. Two major strategies are conceivable. The
first one is to locally administer antiepileptic drugs in various technical
ways (via catheters, implanted polymeric wafers,); the other is to graft
tissue or cells that locally produce antiepileptic agents.
The majority of epileptic patients are taking antiepileptic drugs orally
on a bid or tid basis. In developing innovative antiepileptic drugs, in-
creasing the bioavailability is a key issue. The drawbacks of systemic
delivery are well recognized and the potential benefits of local delivery
can be easily anticipated. Key difficulties for local delivery are associated
with bringing in and keeping antiepileptic drugs in the brain, by tem-
porarily breaking, circumventing or “cheating” the blood brain barrier.
Moreover, there is a need for safe and minimally invasive drug delivery
systems that can locally release drugs from a large enough reservoir in
a controlled fashion. Finally, locally delivered antiepileptic agents may
have to be pharmacologically quite different from the antiepileptic drugs
that are currently used and much attention should be focused on develop-
ing such new molecules. Once appropriate agents and delivery systems
are available these could be used in a closed loop system provided a
reliable seizure detection or anticipation algorithm is also available.
Local grafting of cholinergic, GABAergic, noradrenergic or seroton-
ergic cells or cells engineered to secrete adenosine or neuropeptides such
as galanin are alternative strategies that may result in a direct and potent
antiepileptic effect locally but also in an alteration of the epileptic net-
work beyond the immediate area of transplantation. Key issues are the
long-term survival of transplanted cells and the control of cell growth
and release of antiepileptic agents. Intensive animal experiments are in
progress to address these issues before any human experiment can be
undertaken.
EXPLOITING PHARMACOGENOMICS TO INDIVIDUALISE
PRESCRIBING
N. Delanty (Epilepsy Programme, Beaumont Hospital, Royal College of
Surgeons in Ireland, Dublin, Ireland)
Pharmacogenomics may be defined as the use of genomic data from an
individual’s genotytpe to help predict drug efficacy and adverse effects
of drug therapy. Pharmacogneomics also has the potential to advance our
understanding of the biology of disease. Pharmacogenomics (or phar-
macogenetics) is still at its infancy as a clinical science, and overall has
so far failed to deliver on its promise to revolutionise therapeutics and
allow for individualised prescribing. However, pharmacogenomics of-
fers huge potential to significantly improve therapy in many areas of
medicine and obviate the “controlled trial and error” approach to ther-
apeutics. These areas include psychiatry (depression, schizophrenia),
cardiology (hypertension), oncology, and neurology (epilepsy, multiple
sclerosis, Parkinson’s disease). The epilepsies are particularly amenable
to pharmacogenomic study because of heterogeneity of disease, the sig-
nificant proportion of patients with refractory epilepsy, and the clinical
problem of antiepileptic drug adverse effects.
To date, pharmacogenomic association studies in epilepsy have been
hampered by conflicting results in cohorts of small size. No pharma-
cogenomic study has yet to significantly change the way patients with
epilepsy are treated in the clinic. It is now appreciated that such studies
need to be completed in large cohorts and positive associations with spe-
cific phenotypes should be confirmed in another collaborative cohort to
attempt to avoid the publication of misleading false positive association.
The numbers required for study depend on the individual phenotypic
question but overall are significantly greater (thousands) than the co-
hort sizes studied to date (hundreds). Therefore, there is now increased
awareness of the importance of collaboration in epilepsy pharmacoge-
nomics, and the fruits of such collaboration will be eagerly awaited over
the coming years.
Thus far, pharmacogenomics has yielded important but clinically lim-
ited information in the areas of pharmacokinetics (related to cytochrome
P450 2C9/2C19 metabolism of phenytoin), pharmacodynamics (related
to dosing requirements of phenytoin and carbamazepine and a polymor-
phism of the SCN1A gene), and idiosyncratic adverse effects of AEDs
(carbamazepine hypersensitivity). Studies on the importance in variation
in multi-drug transporter genes as a mechanism of refractory epilepsy
has yielded conflicting results. We have recently explored the pharma-
cogenomics of vigabatrin retinopathy, in an effort to resurrect this drug
as an important AED. Currently we are also examining associations in
a multigene, multi-SNP collaborative project using an Illumina-based
platform.
Despite the promise of individualised prescribing enabled by pharma-
cogenomic data, we are some way off exploiting genomic data in ev-
eryday clinical practice. Significant obstacles remain in the way before
we can routinely prescribe by genotype. These include poor understand-
ing of the biology of disease and the molecular basis of important side
effects of therapy, the need for large-scale well-phenotyped collaborative
pharmacogenomic research consortia, challenges in bioinformatics and
statistical analysis, and cost of both research and clinical genotyping.
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We may be at the dawn of a new age of genomic therapeutics, but the
sun is barely rising.
Wednesday July 5, 2006
9:30–11:30
Hall 5A
Main Session
Brain maturation in epilepsy evolution
DEVELOPMENTAL PLASTICITY OF THE SENSORIMOTOR
NETWORKS
R. Khazipov (INSERM U29/INMED, France)
Early in development, cortical activity is characterized by particular
patterns of activity that disappear upon maturation. Using extracellular
and patch-clamp recordings from somatosensory (S1) cortex of neonatal
rat in vivo we have shown that the principal cortical pattern of activity
is spindle-burst. S1 spindle bursts were tightly correlated with charac-
teristic motor activity in the neonatal rat myoclonic twitches. S1 spindle
bursts were reliably triggered in a somatotopic manner by myoclonic
twitches of hindlimbs, forelimbs and whiskers. Direct sensory stimula-
tion of various parts of the body also evoked S1 delta brushes in somato-
topic manner. Sensory deafferentation by spinal cord transaction reduced
the frequency of delta brushes, but did not completely suppress them.
These results suggest that spindle bursts are generated by circuits intrin-
sic to immature brain but can be triggered by sensory feedback resulting
from spontaneous movements. Study in the preterm human neonates
revealed that similar scenario also operates in human, in which homol-
ogous pattern of delta brushes was tightly correlated with the neonate
spontaneous myoclonic jerks and could be evoked by sensory stimula-
tion in a somatotopic manner. These results suggest that basic functional
properties of immature cortical networks are conserved through mam-
malian evolution making the neonatal rodent an excellent model to study
early cortical activity and associated plasticity during the developmental
period corresponding to the fetal stage in human.
IMAGING PLASTICITY OF LANGUAGE IN CHILDREN WITH
EPILEPSY
L. Hertz-Pannier (Pediatric Radiology and INSERM U663, Necker-
Enfants Malades Hospital, Paris, and SHFJ, CEA, Orsay, France)
Despite methodological difficulties, brain functional MRI (fMRI) is
a unique tool to study the development of language functions in healthy
children, as well as to assess functional reorganization following early
brain lesions and/or epilepsy, with the possibility of multi-tasks and
longitudinal studies.
The early left lateralisation of language networks during perceptive
tasks was demonstrated in infants, with fMRI activation patterns com-
parable to those of adults despite obvious differences in linguistic skills.
Subsequently, the hemispheric language specialisation progresses with
age, until at least the end of adolescence. This functional profile is par-
alleled by structural asymmetric focal changes of both grey and white
matter.
It is well known that language development and/or recovery following
left lesions is largely better in children than in adults. The organization
of language networks in right perisylvian regions, homotopic of those
usually observed in the left hemisphere, seems to be the modality of
choice of brain plasticity in cases of destructive or large brain lesions,
or in early refractory epilepsy. Contrarily to adults, children with focal
epilepsy restricted to the left temporal lobe do not exhibit a higher risk
of atypical dominance. This suggests a role for a “chronic plasticity”
related to duration and/or intensity of the epileptic activity. However,
the respective contribution of various factors such as age at onset, dura-
tion of epilepsy, type and location of lesion, etc. is still highly debated.
The recovery of efficient language, along with right-sided shift of lan-
guage networks can occur after left hemispherotomy performed as late as
10 years of age.
At a clinical level, the assessment of possible reorganization of lan-
guage networks is critical in the presurgical work-up of intractable focal
epilepsies. High quality multitask fMRI can advantageously replace the
Wada test in cases of clear left dominance, but mixed representations
may still benefit from invasive techniques.
BRAIN MATURATION AND THE EVOLUTION OF EPILEPSY
SYNDROMES
R. Guerrini (Epilepsy, Neurophysiology and Neurogenetics Unit,
Unicversity of Pisa and IRCCS Stella Maris Foundation, Pisa, Italy)
A main achievement is the definition of age related epilepsy syn-
dromes, for which after onset in a given period of life, course and out-
come will be relatively predictable. However, assessment of children
with age related epilepsy must be very careful as slight deviations from
the “typical” clinical picture may result in atypical cases with entirely
different course. Seizure onset outside the usual age range for a spe-
cific syndrome may be accompanied by a different than expected course
and outcome. There are several other factors that may be related in the
typical or atypical evolution of epilepsy syndromes during infancy, child-
hood and adolescence. However, in human epilepsy such factors can be
inferred from clinical observation and neurophysiological analysis but
cannot be proven. A fundamental difference resides in the idiopathic or
symptomatic nature of epilepsy. Symptomatic epilepsies, in turn, have
a different propensity to undergo age related changes according to the
type of structural abnormality. For example, focal cortical dysplasia only
cuases focal epilepsy and, in some cases, asymmetric infantile spasms,
but always has a focal expression and never changes to other forms of
epileptogenesis. Polymicrogyria, on the other hand, often starts as focal
epilepsy and then translates into ESES (or CSWS) during school age to
reverse to focal epilepsy after a variable time. This evolution demon-
strates that even a fixed lesion can undergo age related influences that
modify epileptogenesis and outcome. Another main factor influencing
epileptogenesis is the age related area specific cortical hyperexcitability
often observed in idiopathic epilepsies. Early onset occipital idiopathic
epilepsy, rolandic epilepsy and the photosensitive epilepsies are typical
examples and there may be overlap of these forms in the same patient.
Although our knowledge about phenomenolology of clinical and elec-
trographic changes related to age is greatly increased, our understanding
of pathophysiology of age related epileptogenesis is very poor.
BRAIN MATURATION AND SURGICAL STRATEGIES IN
CHILDREN
H. Holthausen (Behandlungszentrum Vogtareuth, Germany)
Developmental aspects always play a major role, when it comes to the
discussion, if, when and how a child with drug-resistant seizures should
be operated on. “When” usually means “timing.”
The most often comment with respect to “timing” is “the earlier, the
better.” But this is an oversimplistic attitude towards a complex issue.
There is no doubt that children with onset of epilepsy within the first
2 years of life and drug-resitant focal seizures are in general at great
risk for a permanent mental retardation and that a surgical intervention
should be discussed earlier. But today we are able to identify better those,
who are at a great risk and those where this risk is much lower.
Timing of surgery is also a major issue in children with epileptogenic
lesions bordering or overlapping language-areas.
Plasticity of the sensorimotor system is very limited beyond the first
year of life—therefore to rush for a better sensorimotor outcome is sel-
dom justified.
And there is also no pressure for a rush towards surgery with respect
to visual outcome, because there is no or almost no “plasticity” as far as
the visual cortex is concerned.
At centers specialized in epilepsy surgery for children in more than
half of the patients etiology of the drug-resistant seizures is focal cortical
dysplasia (FCD).
In FCD-type I the limits of the lesion is extremely difficult to visualize
at all ages.
To get an idea about the exact extend of this peculiar type of pathology
before completion of myelination is one of the most challenging tasks
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during the presurgical evaluation. It is not rare that one has to decide,
whether surgery should be carried out soon for reasons of a better mental
outcome of whether the surgical internention should be done somewhat
later, after the repetition of the MRI with the hope that the delineation
of the extend of the resection would then be somewhat easier.
Considerations about “brain maturation and surgical strategies in chil-
dren are not limited to the very young age-group.
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Translational research in design and development of
new antiepileptic drugs (AEDs): from academia to
commercialisation and clinical utilisation
ACADEMIC INITIATIVES AND IDEAS FOR DEVELOPMENT
OF NEW AEDs
M. Bialer (Department of Pharmaceutics, School of Pharmacy, Faculty
of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel)
Currently the following three approaches are the major strategies for
the development of new antiepileptic drugs (AEDs): 1) The animal model
approach that utilizes screening of new compounds in various anticon-
vulsant animal (rodent) models; 2) The second-generation approach that
designs follow-up compounds or second-generation AEDs by modifying
the structure of existing AEDs and 3) The mechanism-based approach
that designs new drugs by targeting them to specific physiological sub-
strates or macromolecules. Academia can contribute ideas and initiatives
to any one of these strategies.
In the last decade ten new AEDs have been introduced that offer appre-
ciable advantages in terms of their favorable pharmacokinetics, improved
tolerability and lower potential for drug interactions. However, in spite
of the large therapeutic range of old and new AEDs about 30% of pa-
tients with epilepsy are still not seizure-free and consequently, there is a
substantial need to develop new AEDs. The new AEDs currently in de-
velopment can be divided into two categories: a) Drugs with completely
new chemical structures such as lacosamide, retigabine, rufinamide and
talampanel. Most of these drugs were developed utilizing the animal
model strategy with some involvement of the mechanism-based approach
in two fo the AEDs. b) Drugs that are derivatives or analogues of existing
AEDs that can be regarded as second-generation to established AEDs.
The second-generation compounds are: eslicarzepine acetate or BIA 2–
093 and 10-hydroxy carbazepine (MHD) (carbamazepine derivatives);
valrocemide and NPS 1776 (valproic acid (VPA) derivatives); XP13512
(a gabapentin derivative); brivaracetam (ucb 34714) and seletracetam
(ucb 44212) (levetiracetam derivatives); and flurofelbamate (a felba-
mate derivative). In addition, some lead compounds of a series of VPA
derivatives currently in preclinical stage have a promising potential to
become new antiepileptics and CNS drugs. For these follow-up com-
pounds to become successful second-generations to an existing AED,
they must be more potent, safer and possess favorable pharmacokinetics
(PK) including low potential for PK and pharmacodynamic (PD) drug
interactions.
The design and development of new AEDs by any strategy should
incorporate PK-based design considerations to minimize the failures in
clinical trials due to PK shortcomings or drawbacks. The PK of new
drugs can be better predicted from in vitro or animal data than PD.
By implementing PK considerations in early stages of development, it is
possible to design molecules based not only on their intrinsic PD activity
(intrinsic potency and lack of toxicity), but also based on their PK profile
and predesign metabolic and elimination pathways.
Although the development of second-generation AEDs based on PK-
and/or PD-based design can complement existing strategies in drug
development, other needs must also be addressed. Consequently, new
AEDs that are currently being developed, should also have a potential
in nonepileptic CNS disorders such neuropathic pain, migraine prophy-
laxis and bipolar disorder. This can triple the market potential of any
new AED and will make its costly development worthwhile despite the
ten new AEDs that have entered the market in the last decade.
Second-generation AEDs are likely to work in a mechanism of action
similar to that of their parent compounds and thus may, not provide the
incentive of a new mechanism of action. However, this disadvantage
might be outweighed by the advantage of having extensive information
about PK, toxicological and PD problems associated with the parent drug
and by relying on the vast array of anticonvulsant animal models that
have proven reputation and predication capabilities since the discovery of
phenytoin in 1938. In addition, the design of second-generation AEDs
is less risky economically for the industry than the development of a
completely new chemical entity that possesses a new mechanism of
action. Thus, it is not too speculative to predict that eslicarbazepine
acetate is more likely to become a second generation to CBZ than a CBZ
derivative with a new mechanism of action like ADCI.
In the holy scripture it is written: “If there is not flour there is no
Torah.” This has meaning for academia and industry as well. To achieve
commercialization, academic initiatives must present an incentive to the
pharmaceutical industry. If the current clinical trial of arundic acid or
ONO-2506 in neurodegenerative diseases and of VPA in cancer patients
is successful, it may serve as a model and incentive for future research
leading possibly to the utilization of AEDs or other VPA derivatives in the
treatment of Parkinson’s and Alzheimer’s diseases. Thus, the design and
development of broad spectrum AEDs will be more attractive to industry
as their utilization in epilepsy may open doors for subsequent therapeutic
use (following regulatory approval) in other nonepileptic CNS disorders.
UNCONTROLLED STUDIES: SOME THOUGHTS
S. Schwabe (Novartis Pharmaceuticals, USA)
The pharmaceutical industry, like many others, is adapting to a rapidly
changing environment. This will necessitate the rethinking of many top-
ics long considered to have been definitively dealt with, including the
quality and type of data generated by development programs and used
to obtain health authority approvals.
This presentation will look at some of the ways in which the data
traditionally collected in drug development programs does, and does
not, tie in with clinical reality when these drugs are used in real patients.
Long held beliefs will be discussed. These include issues around the
use of highly complex and sometimes artificial trial designs to generate
data on populations, whereas physicians have to use this data on indi-
vidual patients.
Difficulties that can arise when scientific data is used as guidance for
an art, such as medicine, will also be touched upon.
COLLABORATION WITH A LARGE PHARMA COMPANY AS
A WAY FORWARD IN THE DEVELOPMENT OF NOVEL AEDs
R. Hill (Licensing and External Research, Europe, MSD Research,
Harlow, UK)
Research on novel antiepileptic drugs has been most productive in the
last 20 years and many new agents and mechanisms are at various stages
of evaluation from early discovery research through to clinical trials.
This is also a field where academic laboratories have been very active.
There is therefore no shortage of opportunities for members of the phar-
maceutical industry if they wish to set up a collaboration or to license an
early stage project from workers in an academic laboratory. It is therefore
necessary for academic scientists seeking a collaboration to make sure
that they differentiate their project from the offerings of others so that
the merits and advantages of their drug or strategy are clearly perceived
as attractive by the licensing and scientific team from industry. A clear
and concise, nonconfidential summary, making ownership of IP and the
exact stage of the project evident, is essential to generate interest as most
large companies review thousands of such proposals from academic lab-
oratories each year and reject most of them. Broad spectrum agents with
activity (or predicted activity) against, for example, bipolar disease and /
or neuropathic pain will be more attractive than agents which are solely
antiepileptic. Also, the more advanced a compound is in development the
more attractive it will be with clinical proof of concept data conveying a
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real advantage over projects where only preclinical data is available. The
pharmaceutical industry needs the inspiration and inventiveness of the
academic world to make sure that it stays at the cutting edge of research
into diseases where there is a real medical need such as epilepsy. In turn,
the experience and ability of industry to effectively perform late stage
development and commercialization can provide an academic partner
with the capacity to turn their novel science into a prescribed medicine.
A REGULATORY APPROACH TO ACADEMIA–INDUSTRY
PARTNERSHIPS IN DEVELOPING NEW AEDs
R. Katz (FDA-Center For Drug Evaluation & Research, Neuropharma-
cology Division, USA)
No abstract received.
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Magnetoencephalography: its contribution for de-
tection of epileptogenicity and functional important
cortex
FAST (RIPPLE) ACTIVITY: A MARKER OF REGIONAL
EPILEPTOGENICITY
S. Rampp (Epilepsycenter (ZEE)–Department of Neurology, University
Erlangen-Nuremberg, Germany)
The detection of epileptiform discharges in electroencephalography
recordings (EEG) is a crucial part in diagnosing epilepsy. Thorough
electrophysiologic evaluation yields information that allows for tailored
surgical therapy in many cases, and thus improves treatment outcome. In
recent years, the existence of oscillations in frequency bands >60–80 Hz
(ripple activity) has been demonstrated in the animal and human brain. It
was shown that these high frequency oscillations are highly significant
for epileptic network function. Analysis of high frequency activity might
provide valuable information for localization of epileptic networks and
understanding of their dynamics. While initial research concentrated
on the investigation of these basic mechanisms, clinical applications,
especially the diagnostic value beyond the information yielded by well-
known patterns such as epileptic transients, are increasingly coming into
focus.
While investigations regarding pathological high frequency activity
have mostly been performed using intracerebral depth electrodes and
subdural EEG, magnetoencephalography (MEG) and surface EEG might
offer noninvasive alternatives. However, small and highly localized sig-
nal generating neuronal populations and consequently very low signal-
to-noise ratios pose difficult problems for these modalities. Nevertheless,
new methods for the analysis of oscillations, such as beamformer algo-
rithms, are becoming available and might offer solutions.
An overview concering recent findings on high frequency activ-
ity and clinical applications is given. The use of MEG for noninva-
sive detection and analysis of high-frequency activity in patients with
epilepsy is discussed, including methods, challenges and preliminary
results.
ORGANISATION OF LANGUAGE SPECIFIC CORTEX
E. Pataraia (Medical University of Vienna, Department of Neurology,
Austria)
Objective: Advanced knowledge of the language-specific zones
can facilitate surgical planning and reduce the morbidity associated
with resection of eloquent cortex, especially in cases of epilepsy
surgery. In the present study the noninvasive neurophysiological method–
magnetoencephalography (MEG) was used to examine brain activation
profiles associated with receptive language in patients with left temporal
lobe epilepsy (TLE) before and after an anterior temporal lobectomy as
well as in patients suffering from focal lesions or mesial TLE in the left
hemisphere. We evaluated which patients were most likely to show a
change in the lateralization and localization of the mechanisms support-
ing receptive language.
Methods: Event related fields (ERFs) time-locked to abstract word
stimuli were recorded in the context of a continuous word recognition
task. The anatomical location of magnetic activity sources was deter-
mined by coregistering MEG coordinates onto the patients’ structural
MRI scans.
Results: The incidence of atypical lateralization of language-specific
activity was higher among MTLE patients compared with lesional pa-
tients (43% vs. 13%, p < 0.02). The majority (78%) of patients with onset
of seizures before the age of 5 years had atypical lateralization of lan-
guage. The incidence of atypical localization of the receptive language-
specific cortex in left-hemisphere dominant patients was higher in the
lesional than in the MTLE group (30% vs. 14%, p = 0.023). Patients
with atypical language lateralization on the Wada test were signifi-
cantly more likely to show a shift in language representation toward
greater right hemispheric activity after surgery. Patients with left hemi-
spheric dominance preoperatively were more likely to show intrahemi-
spheric changes involving a slight inferior shift of the putative location of
Wernicke’s area.
Conclusion: There is an increased risk of partial or total shift of
language-specific brain functions to the right hemisphere in patients
with MTLE. Focal lesions in the left temporal lobe typically result in an
aberrant location of the language-specific cortex within the left hemi-
sphere. Variables such as type and lesion location did not appear to
play a role in the type of reorganization of receptive language functions.
MEG can contribute significantly not only to the precise localization of
Wernicke’s area for presurgical planning, but is also an important tool
for documenting postoperative language reorganization.
EPILEPTOGENICITY OF THE SYLVIAN REGION
R. Paetau (Hospital for Children and Adolescents, University of Helsinki,
Finland)
Unilateral perisylvian spikes are common during childhood, and of-
ten give neither ictal nor developmental symptoms, while bilateral
epileptic dysfunction of the sylvian region can cause serious perma-
nent regression of the receptive and/or expressive language, and some-
times, a wider regression of communication skills. Bilateral perisylvian
epileptogenesis is either due to bilateral independent foci or to bilateral
synchrony secondary to a unilateral epileptogenic focus. Only the lat-
ter group may benefit from surgery. Simulateously recorded EEG and
MEG may help to separate the two groups with diffferent treatment
options.
Methods: We used MEG to record intrasylvian fissural cortex and
simultaneous EEG to record the perisylvian convexity spike-waves under
natural sleep or light thiopental anaesthesia, and determined small time
lags between left and right sylvian sources, and between fissural and
convexial sources to identify a pacemaker area, if present.
Results: One-third (32%) of CSWS patients showed a unilateral pace-
maker allowing for surgical treatment with successful outcome. In occa-
sional patients, separately recorded MEG and EEG suggested different
hemispheres for surgery.
Conclusion: Simultaneous MEG and EEG recordings are crucial and
very effective in determining, whether a patient with bilateral spike-
waves and language regression is suitable to surgical treatment
FUNCTIONAL CORTEX, PATHWAYS AND EPILEPSY
SURGERY
M. Buchfelder (Department of Neurosurgery, University of Erlangen-
Nuremberg, Germany)
Current operative therapy of pharmacoresistant focal epilepsies is
based on thorough preoperative diagnostic evaluation. To estimate the
area of epileptogenic brain tissue precise morphological and functional
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examination is necessary. Given that the anatomical localization of the
suspected epilepsy focus and the topographic representation of various
functional qualities are defined, the neurosurgical resection of epilepto-
genic brain tissue becomes possible.
Relatively recently presurgical diagnostic methods and new intra-
operative techniques were developed allowing to diagnose and treat
patients who were unsuitable candidates for epilepsy surgery several
years before. Preoperatively collected structural and functional data
are provided by advanced magnetic resonance imaging (MRI) and
spectroscopy, functional MRI, MRI volumetry and tractography, nu-
clear medical imaging, magnetic source imaging (MSI) and magne-
toencephalography (MEG). Pathological findings are matched with nor-
mal cerebral function in eloquent brain regions, e.g., the speech areas
and the motor pathways. During surgery this information is integrated
into the operative work flow allowing the resection of putative epilepto-
genic foci in the close vicinity of functionally significant eloquent brain
areas.
Intraoperative imaging with a high-field MRI scanner offers the op-
portunity to evaluate the volume of resected tissue during surgery, the
combination with a neuronavigation system allows to precisely approach
epileptogenic foci and to spare functionally eloquent structures. Our ex-
perience with 86 patients operated on temporal or extratemporal focal
epilepsy with intraoperative MR imaging and functional neuronavigation
is promising, the combined use with intraoperative electrocorticography
(ECoG) helps to add certainty to the definition of the suspected epilep-
togenic area.
The combination of intraoperative high-field MRI, electrocorticogra-
phy and integration of functional data into a neuronavigation system is
a novel approach to optimize the tailoring of epilepsy surgery close to
eloquent cortical areas. Especially patients harboring lesional patholo-
gies or suffering from critical neuropsychological backgrounds are good
candidates to profit from this technological progress.
EPILEPTOGENICITY: DEPTH AND MEG RECORDINGS,
PROS AND CONS
P. Chauvel (Hopital Timone Adultes, INSERM EMI 9926, Marseille,
France)
No abstract received.
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Is low IQ a contraindication for resective epilepsy
surgery?
COGNITIVE AND SEIZURE OUTCOME AFTER RESECTIVE
EPILEPSY SURGERY IN CHILDREN WITH LOW IQ
H. Bjørnæs (The National Centre for Epilepsy, Norway)
There are relatively few studies regarding outcome following resec-
tive surgery for refractory focal epilepsy in children with low IQ. The
obvious reason for this is that few of these children have been considered
for surgery. As mental retardation is often associated with multifocality
or diffuse lesions, the prognosis for becoming seizure free has not been
considered good. There has also been a concern whether cognitive abil-
ities in these children would be particularly vulnerable to surgery due to
insufficient cognitive reserve capacity.
Outcome with respect to seizures seems indeed to be poorer in these
children than in nonretarded children, although there are exceptions to
these findings. Nevertheless, between 1/3 and 2/3 of surgically treated
children with low IQ are reported to become seizure free, and a substan-
tial additional proportion has significantly improved seizure frequency,
results that may be considered good enough from a risk-benefit point of
view. Predictors for success are not well known, but will probably show
up to be the same as in nonretarded children.
Cognitive outcome has been reported in a few studies. Seemingly,
cognitive levels do not change significantly in most patients, although
the probability of an improved development is greater than for a cognitive
decline. Predictors are largely unknown with the exception of duration
of epilepsy: Early surgery is clearly enhancing the probability of an
improvement, while late intervention is associated with a decline. The
relation to seizure outcome is unclear.
We report on a small group of children with IQ ≤ 70 who were treated
with epilepsy surgery. Seven out of eight patients (88%) became seizure
free. On a group level, there were no significant changes in cognition,
although many children improved their performance with more than one
standard deviation compared to baseline on several test measures, and
only a few declined.
COGNITIVE AND SEIZURE OUTCOME AFTER RESECTIVE
EPILEPSY SURGERY IN ADULTS WITH LOW IQ
U. Gleissner (University of Bonn, Department of Epileptology,
Germany)
Intellectual disability (ID, pragmatically defined as a measured IQ
of more than 2 SD below the mean IQ ≤ 70) is more frequent in pa-
tients with medically intractable epilepsy than in the normal population
(∼35% for those patients with an early onset of epilepsy versus 2%–
3% in the normal population). Patients with epilepsy and ID are often
difficult to treat and drug resistance is frequent. On the other hand, bilat-
eral or diffuse morphological brain damage is frequent thus increasing
the probability of a multifocal epilepsy or diffuse epileptogenic regions.
Therefore, a surgical treatment is often not considered as a possibility
for patients with ID. Behavioral problems can further complicate the
presurgical examination and the postoperative cognitive outcome could
be unfavourable, since compensation of surgically induced deficits also
depends on the integrity of the whole brain. My talk will give a sur-
vey of recent studies regarding the cognitive and seizure outcome after
resective epilepsy surgery in adults with ID and I will present current
data from our department. The available data allow the conclusion, that
IQ alone is not a good predictor of the postoperative outcome. As with
patients of normal intelligence, the decision to operate on patients with a
low level of intelligence should depend on the results of the presurgical
workup. However, all available studies are post hoc studies on the group
of operated patients. Some information, necessary to estimate the per-
centage of good surgical candidates with ID, remains unclear (f.i., how
many patients are a priori excluded from a presurgical workup because
of ID; in how many patients with ID a presurgical workup indicated a
multifocal epilepsy). Therefore, further research will be necessary.
IS THERE A RELATION BETWEEN IQ AND SEIZURE
OUTCOME AFTER TEMPORAL LOBE RESECTIONS FOR
EPILEPSY?
K. Malmgren (Institute of Neuroscience and Physiology, Epilepsy Re-
search Group, Sahlgrenska Academy at Go¨teborg University, Sweden)
Temporal lobe resection (TLR) is the most common epilepsy surgery
procedure. It has been assumed that low IQ indicates diffuse brain dam-
age and hence less probability of good seizure outcome. Few investi-
gations have, however, focused on the results of TLR in patients with
IQ < 70.
Chelune et al. (1998) studied TLR outcome in relation to preoperative
IQ in 1034 adults. In the highest IQ category (110+) 83% of patients
became seizure free versus 76% in the middle (76–109) and 67% in the
lowest IQ category (50–75) (p < 0.037). The conclusion was, that IQ
scores alone should not be used to exclude patients from surgery, but
are useful for counseling. Interestingly, only 2.3% of the patients in this
study had IQ < 70.
To further study seizure outcome after TLR in relation to IQ, data
from the population-based Swedish National Epilepsy Surgery Reg-
ister 1990–99 were analysed. Outcome data at the two-year follow-
up were related to preoperative IQ. Of 448 resective procedures 73%
(N = 325) were TLR, 250 adults and 75 children. 8% of the adults and
27% of the children had IQ < 70. 65% of those with IQ > 70 became
seizure-free compared to 42% of those with IQ 50–69 and only 13% of
those with IQ < 50 (p < 0.001), but a substantial proportion of low-IQ
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patients obtained >75% reduction of seizure frequency (29% versus
38%).
Hence, there is a clear relation between IQ and seizure outcome after
TLR with worse outcome in low-IQ patients. However, many patients
with low IQ benefit from TLR, either by becoming seizure free or by
obtaining a substantial reduction in seizure frequency. It may well be that
TLR is an underutilised treatment for low IQ patients. Low IQ should not
per se be an exclusion criterion for TLR in patients otherwise suitable
for surgical treatment of their epilepsy.
ARE THERE LESSONS TO LEARN FROM THE PATHO-
ANATOMICAL DIAGNOSES IN PATIENTS WITH LOW VER-
SUS NORMAL IQ?
B. Rydenhag (Institute of Neuroscience and Physiology, Epilepsy Re-
search Group, Sweden)
Epilepsy surgery has been questioned for patients with low IQ. There
are few studies of the underlying pathologies in these patients. Gleissner
(1998) reported 16 patients with IQ < 85, 6 with lesions and 5 with
mesial sclerosis. 14 of the patients had a one-year follow up, 64% were
seizure-free. In a recent study by Gleissner et al. (2006) three IQ groups
(IQ < 70, N = 21; IQ 70–85, N = 24 and IQ > 85, N = 21) were
matched according to clinical and etiological criteria. 79% had mesial
sclerosis, low-grade tumours or cortical malformations. Seizure outcome
was shown not to depend on IQ level. Bjo¨rna¨s (2004) reported on 35
patients with IQ < 70: 8 posttraumatic, 1 tumour, 1 migration disorder,
4 other and 17 cryptogenic. In 52% of the temporal and 35% of the
extratemporal resections the low-IQ patients became seizure free.
Data from The Swedish National Epilepsy Surgery Register 1990–99
were analysed with respect to resective epilepsy surgery, IQ and patho-
anatomical diagnoses. In patients with IQ > 70 27% had a lesion (low-
grade tumours and cavernomas), 14% had cortical malformations and
48% had gliosis. In patients with IQ < 70 the corresponding proportions
were 8%, 20% and 51%.
Patients with IQ>70 became seizure free in 80% if the etiology
was a lesion, in 62% if they had cortical malformations and in 53%
when the diagnosis was gliosis. Corresponding proportions for IQ < 70
were 67%, 27% and 31%. The seizure outcome thus correlated to the
patho-anatomical diagnosis in both IQ groups, but with better outcome
in the patients with IQ>70.
These data support the notion that epilepsy surgery in patients with
epileptogenic lesions is successful irrespective of IQ level. In the Swedish
series there were remarkably few lesions in patients with IQ<70, and one
reason for this might be that low-IQ patients seldom get the opportunity
to be evaluated for epilepsy surgery.
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Epilepsy and the emotional brain
NEURAL SYSTEMS MEDIATING HUMAN EMOTIONS
A. Papanicolaou (The University of Texas Medical School, USA)
Affective valence–specific spatiotemporal brain activation profiles:
an MEG study
Regions of the brain involved in the generation of affect in response
to picture sets rated as extremely unpleasant(disgusting and/or fearful),
pleasant(sexually arousing), and affectively neutral, as well as the or-
der of activation of each region, were investigated using magnetoen-
cephalography (MEG) in a group of sixteen young normal adult male
volunteers. We found spatiotemporal maps consisting of two basic com-
ponents: An early one involving activation in the occipital and basal
aspects of the temporal cortex, related to the perception of the stimuli
was common to all three affect conditions. The second, later compo-
nent, involving activation of the cingulate gyrus, the prefrontal cortex
and the temporal lobes, differentiated the pleasant and unpleasant con-
ditions, featuring more activity over right hemisphere structures during
the unpleasant condition. These activation patterns are consistent with
the notion of hemispheric specialization for affective valence and they
demonstrate the utility of the MEG method in exploring both the struc-
tures involved in the generation of affective responses and the temporal
order of their activation.
EMOTIONAL EXPRESSION AND BEHAVIOUR DURING
EPILEPTIC SEIZURES
E. Gardella (Department of Neurosciences, Bellaria Hospital–University
of Bologna, Italy)
Introduction: the extension of the emotional network and its rela-
tionships with neocortical frontotemporal structures suggest its probable
significant contribute to frontotemporal ictal semiology. Steaming from
this consideration, we aimed to analyze the spectrum of ictal emotional
behaviors.
Methods: we reviewed video-EEG recordings of 477 seizures of 84
candidates to epilepsy surgery (45 temporal/39 frontal lobe), 51 studied
with SEEG (epilepsy surgery centre “C. Munari,” Milan). The clinical in-
terpretation of emotion—including facial expression of emotion (FEE),
motor and/or verbal behavior and coherent emotional experience—has
been validated by psychological studies (F.A.C.S., spectrograms, body
movements rating). We compared prevalence and features of the six basic
emotions (fear, happiness, disgust, rage, sadness and surprise).
Results: in 66% of seizures we observed emotional manifestations,
ranging from isolated FEE to complex motor/acoustic behaviors (21%
of seizures); only in 13% of seizures the experience of emotion was
referred. All the six basic emotions were represented; about 25% of FEE
were morphed.
FEEs had similar prevalence in frontal and temporal lobe seizures and
in both genders, but female more frequently shoved also an emotional be-
havior and/or referred an emotional feeling. Fear, disgust, rage, sadness
were related with right ictal discharge. Fear and disgust were associated
with oro-alimentary automatisms. The same patient expressed 1–3 types
of ictal emotions (mean 1,6) and up to three different emotion could
emerge in one single seizure (mean 1,3). Only 35% of patients presented
the same type of emotion in all seizure, with variable latency.
Conclusions: Ictal emotional manifestations consisted in a spectrum
of events, from isolated mimic modifications to complex motor/acoustic
behaviors, that showed inter and intraindividual heterogeneity. The as-
sociation of ictal display of emotions and complex eupraxic behavior
support the hypothesis of the involvement of a wide physiological net-
work including prefrontal, frontomesial and temporal limbic structures;
the right prevalence of the ictal discharge confirm the hemispheric right
specialization for emotions. Study of behavioral psychology have docu-
mented a prevalence of rage expression in males and happiness/sadness
in females. This difference, as well as the female prevalence in report-
ing emotions, has been justified by the competitive social role of males
and the nursing attitude of females. The sexual dimorphism in express-
ing ictal emotions suggest the involvement of “universal” cross-cultural
mechanisms.
RECOGNITION AND MEMORY OF EMOTIONS IN EPILEPSY
PATIENTS
E. Lehner-Baumgartner (Department of Neurology, Medical University
of Vienna, Austria)
Mesial temporal lobe epilepsy (MTLE) affects key brain structures
mediating emotions, namely the amygdala and the hippocampus. There-
fore MTLE represents a unique model disease to study human emotions.
Indeed, more than 50% of patients with MTLE suffer from serious emo-
tional disturbances including depression and anxiety disorders. More-
over, MTLE offers the unique opportunity to assess the effect of se-
lective removal of these brain structures in patients undergoing elec-
tive epilepsy surgery for medically refractory seizures. Recognition and
memory for emotional faces offers a validated neuropsychological tool
to study disturbances of emotion processing in patients with MTLE.
Possible factors affecting the performance on emotion recognition and
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memory tasks include (1) the lateralization and location of the epilep-
togenic zone, (2) epilepsy specific variables like age at seizure onset,
disease duration and seizure frequency, (3) volumetric measurements of
amygdala and hippocampus, (4) a comprehensive neuropsychological
examination, (5) personality traits and psychopathological abnormali-
ties, and (6) the lateralization and site of surgical resection. Concerning
emotion recognition in right versus left temporal lobe epilepsy patients,
most authors found an impairment of emotional recognition in patients
with right TLE or after right temporal lobectomy, while one study re-
ported an impaired emotional recognition in left TLE patients. No con-
sistent findings were reported on emotion memory in right versus left
TLE patients. Some authors proposed that reduced emotion recognition
explained at least in part a reduced emotion memory. Study of emotion
recognition and memory for emotional faces should provide new in-
sights into the basis of human emotions and should open new therapeu-
tic strategies for emotional disturbances in patients with temporal lobe
epilepsy.
CLINICAL fMRI OF THE AMYGDALA IN PATIENTS WITH
TEMPORAL LOBE EPILEPSY
H. Jokeit (Swiss Epilepsy Center Zurich, Switzerland)
Rationale: Amygdalar and hippocampal sclerosis usually occur to-
gether in mesial temporal lobe epilepsy (MTLE), but the sclerosis may
also be solely restricted to the hippocampus or amygdala. The surgical
treatment of MTLE involves both structures. The amygdala is one of
the key structures involved in emotional processing and social percep-
tion. Bilateral, and to some degree also unilateral, amygdala damage
may lead to impairments in these functions. Current fMRI studies of
MTLE exclusively focus on memory-related MTL structures. Our aim
was to investigate whether fMRI of the amygdala could contribute to
the presurgical evaluation of MTL structures in patients with refractory
MTLE.
Methods: A fearful face fMRI paradigm using video sequences was
developed and subsequently investigated in 17 patients with epilepsy (12
had MTLE [6 right- and 6 left-sided]) and 17 healthy control subjects. Re-
producibility was demonstrated by reimaging 12 of the control subjects.
In addition, parahippocampal activation was measured using Roland’s
Hometown Walking Task within the same session in all patients and in
nine of the control subjects.
Results: A fearful face paradigm led to significant amygdala acti-
vation (p < 0.001) in all subjects. Amygdala activation was bilateral
in control subjects and clearly lateralized in patients with MTLE. Dis-
sociated amygdala and parahippocampal activation was found in three
MTLE patients. A combination of results from both fMRI paradigms
improved the identification of the laterality of seizure onset in patients
with MTLE.
Conclusions: fMRI activation of the amygdala evoked by a fearful
face video paradigm is strong, reproducible, and specific in individual
subjects. The combination of the fearful face paradigm and Roland’s
Hometown Walking Task provides a more reliable presurgical mapping
of mesial temporal lobe structures. First results on the relation between
amygdalar fMRI activation and performance in tests of advanced social
cognition will be presented.
THE AMYGDALA AND PSYCHOPATHOLOGY IN EPILEPSIES
M. Trimble (Institute of Neurology, London, UK)
No abstract received.
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Brain inflammation in temporal lobe epilepsy
THE CONTRIBUTION OF BRAIN INFLAMMATION TO
INJURY AND RECOVERY IN EXPERIMENTAL MODELS OF
TEMPORAL LOBE EPILEPSY
A. Vezzani (Department of Neuroscience, Mario Negri Inst for Pharma-
col Res, Milano, Italy)
Innate inflammatory responses are triggered by experimentally-
induced seizures in microglia, astrocytes and neurons. Interleukin (IL)-
1 is an early marker of brain inflammation which decreases seizure
threshold, prolongs seizure duration and exacerbates neurodegeneration.
In the acute phases (4–18h) of status epilepticus (SE), during the latency
phase (3–7 days after SE) preceding the onset of spontaneous seizures,
and in the chronic phase of spontaneous seizures (8 months after SE),
IL-1β and its signaling receptor, IL-1R1, are both increased in glia in rat
neocortical and limbic areas. Damaged Fluoro-Jade-positive neurons are
observed 18h-7days after SE in the same brain regions where IL-1β was
up-regulated. Blood–brain barrier (BBB) damage is evident 18-48h af-
ter SE concomitantly with IL-1β up-regulation and neurodegeneration.
Monocytes (macrophages invade brain parenchyma from 18h after SE
until spontaneous seizures occur while granulocytes appear transiently
(18h-3 days) in areas of IL-1β over-expression. Markers of adaptive
immunity such as B-, T-, NK-cells are scarse or absent during acute
seizures, epileptogenesis and in chronic epileptic tissue.
In organotypic hippocampal slice cultures and primary cultures of hip-
pocampal neurons IL-1β dose-dependently enhances NMDA-dependent
Ca2+ influx and excitotoxic damage. These actions of IL-1β, together
with effects on BBB permeability and immune cell brain infiltration, may
promote hyperexcitability and excitotoxicity. However, IL-1β intrinsi-
cally contributes to the generation of the seizures in a rodent model of
febrile seizures where seizures evoke epileptogenesis but not cell death.
Thus, in this model the proepileptogenic actions of IL-1β may be disso-
ciated from excitotoxicity. Finally, IL-1β and IL-1R1 can be expressed
by surviving neurons and surrounding astrocytes in chronic epileptic tis-
sue suggesting autocrine/paracrine neurotrophic actions. IL-1β actions
on hyperexcitability, neuronal survival and epileptogenesis may involve
different signaling cascades (direct actions on ion channels and neu-
rotransmitter receptors or transcription-dependent enduring alterations
in gene expression programs) and may significantly contribute to the
pathophysiology of epilepsy.
INFLAMMATORY REACTIONS IN HUMAN TEMPORAL
LOBE EPILEPSY WITH HIPPOCAMPAL SCLEROSIS
A. Crespel (CHU Gui De Chauliac, Montpellier, France)
Temporal lobe epilepsy (TLE) associated with hippocampal sclerosis
has a well defined course: first, a complicated febrile seizure in early
childhood and, several years later, occurrence of typical TLE seizures.
Our knowledge about the events occuring during this silent period in
Human is purely speculated on the basis of experimental models of
TLE: neuronal loss, release of proinflammatory cytokines, microgliosis,
astrogliosis, increased neurogenesis and synaptogenesis. All these pro-
cesses participate in an intense tissue remodelling, which is assumed to
support hyperexcitability and hypersynchronization.
Epilepsy surgery, a treatment proposed in refractory (TLE) allows
the possibility to analyse directly the epilepsy focus. Looking for these
changes in human chronic focus (analyzed after several years of refrac-
tory epilepsy), confirmed that most of TLE patients presented a hip-
pocampal sclerosis (HS) and a dispersion of the dentate gyrus.
In these tissues, we reported that reactive astrocytes, few surviving
pyramidal neurons of the injuried areas and numerous dentate gran-
ule cells over-expressed NFkappaB-p65, a transcription factor which
up-regulates genes related to the inflammatory and immunological
responses. The overexpression of this marker in all foci of TLE with HS
suggests either a chronic inflammatory state or frequent acute reactions
to recurrent seizures. Many target genes activated by NFkappaB partici-
pate in secondary epileptogenesis by worsening excitability or neuronal
death (IL-1beta, TNFalpha). Moreover, proliferative cytokines (M-CSF,
GM-CSF) and adhesion molecules (VCAM, ICAM), also upregulated
by NF?B, may play a pivotal role in neurogenesis and tissue remodeling.
In connection with this, we described in human TLE with HS
large quantitites of neural progenitors in the subgranular layer and the
peri-ventricular zone (both known neurogenic areas) as well as in the
fissura hippocampi. The quantity of progenitors seems to be related to
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the extent of lesions. However, this abundant population shows a phe-
notype of immature astrocytes which never differentiate in mature neu-
rons. More, in the zones of dentate gyrus dispersion, progenitor cells
resemble to radial glia, building a scaffold for granule cell migration.
We hypothesize that the excessive proliferation of progenitors and their
differentiation in glial cells is due to inflammatory conditions.
Finally, we recently brought evidence for of vascular reorganization in
TLE foci, showing the presence of endothelial progenitors and immature
microvessels in neurogenic areas. This putative angiogenesis is probably
related to the strong and persistent expression of VEGF by neurons and
glia. VEGF is a pleiotropic factor, able to increase inflammation by
stimulating progenitor proliferation and by disrupting the blood brain
barrier.
It seems therefore that, in the focus of human TLE, inflammatory
reactions are chronically active and involve a vicious circle of redundant
neuro-glio-vascular interactions.
FROM FEBRILE SEIZURES TO TEMPORAL LOBE
EPILEPSY—THE PUTATIVE ROLE OF INTERLEUKINS
J. Peltola (Tampere University Hospital, Department of Neurology,
Tampere, Finland)
No abstract received.
IMMUNOGETICS OF TEMPORAL LOBE EPILEPSY
C. Ozkara (Univesity of Istanbul, Cerrapasa Medical School, Istanbul,
Turkey)
Immunological mechanisms have been implicated in the pathogenesis
of epilepsy although their role still remains hypothetical despite some
evidence obtained from animal and human studies. Several proinflam-
matory signals are found to be induced during a seizure. In brain tissue of
patients who undergone to epilepsy surgery, an overexpression of such
molecules in neurons and glia was demonstrated. These inflammatory
responses are regulated by different genetic programs especially, the
homozygosity in allele variants of the IL-1 ß gene promotes enhanced
cytokine production. Recent genetic studies shown that a polymorphism
in the promotor region at position −511 of the IL-1 ß gene is associated
in temporal lobe epilepsy (TLE) and hipocampal sclerosis (HS) and in
children with febrile seizures (FS). However, this Japanese study was not
confirmed with other studies from different countries which may raise
the issue of ethnicity. The preliminary results of ongoing study which
investigate the association between the gene polymorphisms of different
cytokines (IL-10, IL-6, TNF-α, TGF-β1b, IFN-γ ) in Turkish popula-
tion showed a slight difference in TGF- β 1b expression the patients and
control group.
Human leukocyte antigens (HLA) located on chromosome 6p is ge-
netically controlled part of immune system. Several studies in differ-
ent epilepsy syndromes such as juvenile myoclonic epilepsy, Lennox-
Gastout syndrome demonstrated some correlation with various HLA
subgroups. Class II antigens namely DQ2–DR4 and DR7 were found
to be more frequent in patients with TLE-HS in one study which may
implicate a possible impact on epileptogenesis. An association between
HLA system and FS was also investigated but results were usually failed
to show any relationship. However, in one study an increased frequency
of HLA-B5 was demonstrated in Egyptian children with FS where in
another study HLA-A11 was significantly increased in children with
previous cytomegalovirus infection and FS.
In conclusion, current evidence related to the role of immunogetics
in epilepsy is yet inadequate to establish definite correlations which
necessitates further studies.
Wednesday July 5, 2006
15:00–17:00
Ballroom 1
Discussion Group Session
The occipital lobe and how to see it
DEVELOPMENT AND PATHOPHYSIOLOGY OF THE VISUAL
PATHWAY
S. Seri (Birmingham Children’s Hospital, Birmingham, UK)
No abstract received.
ELECTROENCEPHALOGRAPHIC MANIFESTATIONS
G. Rubboli (Department of Neurosciences, Bellaria Hospital, Bologna,
Italy)
Several epileptic conditions affecting occipital lobe can display pho-
tosensitivity. Photosensitivity is an abnormal sensitivity to visual stimuli,
that can be investigated in the EEG laboratory with different techniques.
The most common procedure is intermittent photic stimulation (IPS).
Although IPS is a widespread and routinely used procedure in the EEG
laboratories, only recently standardized protocols (including character-
istics of photostimulators, protocol of investigation) have been proposed
(Kasteleijn-Nolst Trenite´ et al., 1999; Rubboli et al., 2004). IPS can elicit
several types of EEG responses, with different clinical significance. A
recent classification (Kasteleijn-Nolst Trenite´ et al., 2001) has identified
the following types: a) photic following: a normal response that ends
with termination of the stimulus train; b) orbitofrontal photomyoclonus,
represented by an essentially electromyographic (although a frontal cor-
tical component has been hypothesized) response at the flash frequency,
terminating at the end of stimulation; c) posterior stimulus-dependent
response, that is a particular type of EEG reaction that can be observed
in neuronal ceroid lipofuscinosis or after suppression of IPS-induced
generalized epileptiform activity because of medication; d) posterior
stimulus-independent response, that is characterized by a theta-delta ac-
tivity and overt epileptiform patterns, not related to the flash frequency
or its harmonics; this type of response can stop at the end of stimulation
or outlast it, in this latter case evolving eventually in an overt seizure; e)
generalized photoparoxysmal response (PPR), represented by multiple
spikes or by spike-wave complexes, apparently generalized, with ante-
rior predominance. This response can be related to the stimulus train
or be self sustaining, continuing after the end of stimulation. This lat-
ter type of response has been demonstrated to be related to epilepsy
and visually induced seizures; f) activation of preexisting epileptogenic
areas is the triggering, rarely occurring, of a spontaneously, posteri-
orly located, epileptogenic cortex; its relationships with PPR is still
unclear.
CLINICAL VARIABILITY AND IMPACT ON GENETIC
RESEARCH
D. Kasteleijn-Nolst Trenite´ (University La Sapienza (Rome), Italy and
University of Utrecht, The Netherlands)
Occipital seizures are by definition seizures, that start in the occipi-
tal cortex. Patterns of spreading of the epileptiform discharges to other
brain areas as well as the velocity of spreading determine the eventual
clinical picture. Therefore a rather broad variability in semiology can be
found ranging from subjective complaints like visual auras to objective
signs like loss of consciousness and a generalised tonic clonic seizure.
Most typical are the seizures without loss of consciousness in which the
epileptiform discharges last for about a minute and remain limited to
the occipital lobe with a visual aura as the only clinical manifestation.
Differentiation with migraine might be difficult since both have visual
aura and headache as symptoms and sometimes even a combination of
the two occurs in the same patient or family. The occipital seizures can
be spontaneous or evoked by visual stimuli. Sometimes a anatomical
lesion is found, in most cases however no underlying cause can be de-
tected. Patients with these seizures can thus be found among those with
an symptomatic, idiopathic or cryptogenic epilepsy. More precise phe-
notyping helps genetic research. Examples of seizure typing and genetic
research will be given.
Conclusion: Information about the variety of symptomatology of oc-
cipital seizures within the various syndromes will be given and its im-
portance for genetic research explained.
Grant: European Cie–Marie Curie Actions
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PSYCHOLOGICAL MANIFESTATIONS
K. Eriksson (Pediatric Research Centre, Medical School, University of
Tampere and Department of Pediatric Neurology, Tampere University
Hospital, Finland)
There is more known about the occipital lobes than any other region of
the brain, probably because of the importance of vision for humans and
the interest in how the brain processes visual information. Case studies
reported in the literature have demonstrated the clinical symptomatology
related to dysfunctioning of occipital lobes which include distinct syn-
dromes of visual disturbance, dissociation between vision for guiding
movements and recognizing objects.
One of the main dysfunction of occipital lobes is visual agnosia, i.e.,
inability to recognize objects without impairment of visual acuity or gen-
eral intelligence. Agnosias are classified in object agnosias and other ag-
nosias. Object agnosias can be either apperceptive or associative whereas
other agnosias include prosopagnosia (i.e., inability to recognise famil-
iar, even own, faces), alexia (inability to read) and visuospatial agnosia
(disorder of spatial perception and orientation). The most commonly
involved anatomical region related to visual agnosias is the occipito-
temporal boarder, a part of the ventral visual system.
The occipital epilepsy syndromes (idiopathic photosensitive occipital
lobe epilepsy, Landau syndrome, Panayiotopoulos syndrome) manifest
as seizures related to elementary visual hallucinations, ictal blindness or
severe blurring of vision, epigastric discomfort, emesis/vomiting, tonic
deviation of the eyes, eyelid fluttering or repetitive eye closures, and un-
responsiveness with hemiconvulsions or generalized convulsions. How-
ever, relatively little is know about those structural and neuropsycholog-
ical abnormalities which relate to electrophysiological abnormalities of
occipital lobes in persons without observable seizures.
Single case report of long-term follow-up of neuropsychological
functions in a patient diagnosed with occipitotemporal continuous
epileptiform activity during sleep (CSWS) and severe visual agnosia
(ventral simultanagnosia) has been published. This follow-up study sug-
gests that the general intellectual measurement (IQ) is not enough and
more precise assessment of neuropsychological functioning and descrip-
tion of academic skills are needed in patients with CSWS–even after the
disappearance of the electrophysiological phenomena.
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Thursday July 6, 2006
7:30–9:00
Hall 5A
Teaching Session
Epilepsy surgery in infancy and childhood
PRESURGICAL EVALUATION OF EPILEPSY
I. Tuxhorn (Epilepsy Center Bethel, Germany)
Epilepsy surgery is no longer a treatment of last resort for children
with drug resistant focal epilepsy. It should be considered early to reduce
the negative impact of epilepsy on developmental and social outcome.
The spectrum of surgically remediable epilepsy syndromes of child-
hood has expanded in recent years to include 1) patients with tuber-
ous sclerosis who have a leading resectable focus, 2) infantile spasms
or Lennox-Gastaut syndrome (or other age specific epileptic en-
cephalopathies) secondary to a resectable epileptogenic zone and
3) formerly “cryptogenic” cases with very subtle cortical dysplasias.
The goal of the presurgical evaluation is to identify patients who have
surgically treatable epilepsy by assessing the risk benefit scenario of
surgical intervention.
The accepted standards of evaluation include seizure analysis with
video monitoring and scalp recording of the interictal and ictal EEG, high
resolution MRI, neuropsychology, WADA test for assessing laterality
of mnestic and language functions. Functional imaging including PET,
ictal SPECT, postprocessing MRI techniques and fMRI are important
techniques to evaluate difficult extratemporal cases.
The role of invasive neurophysiology with subdural, epidural and in-
tracerebral recordings is changing since the advent of functional imaging
of the epileptogenic region e.g., EEG triggered MRI and methods out-
lined above.
Patients with a focal electroclinical syndrome and a congruent MRI
lesion are excellent candidates for selection and the seizure outcome
prognosis may be considered high if the epileptogenic zone is completely
resectable.
In pediatric epilepsy early patient referral for presurgical evaluation
should be considered in specific syndromes—catastrophic focal epilepsy,
hemispheric syndromes, Sturge Weber syndrome, and well localized
symptomatic epilepsies.
SURGICAL PROCEDURES AND COMPLICATIONS
W. Harkness (UK)
No abstract received.
RESULTS OF EPILEPSY SURGERY
H. Cross (Great Ormond Street Hosp. NHS Trust, UK)
Advances in presurgical evaluation and neurosurgical techniques have
resulted in an increased number of children being selected for epilepsy
surgery. Data now accumulating on outcome show considerable benefits.
Seizure outcome is clearly important but other aspects such as psychoso-
cial, functional and cognitive outcome are also significant determinants
of surgical success.
Seizure outcome depends on underlying causative pathology as well as
the degree of resection based on electrical or structural studies. This will
also be determined by surgical procedure but limited series suggest it is
not influenced by age of surgery. Data on children undergoing temporal
lobe resection suggest less chance of seizure freedom in children with
associated comorbidities, but is not predicted by IQ. Despite the emphasis
on reduction in AEDs postoperatively, there is little data to guide in whom
this will be possible.
The rate of cognitive dysfunction in those coming to surgery is high.
Although many consider that seizure control will lead to improved de-
velopmental progress, this is difficult to evaluate objectively and longi-
tudinal studies are required. There is also a high rate of psychopathology
in children coming to epilepsy surgery, but it is difficult to predict those
in whom this is likely to improve and this should be incorporated into
preoperative counselling.
It remains important to assess each individual with regard to all com-
ponents of likely outcome preoperatively, and to discuss this at length
with the family. Primary outcome aims may differ between patients; this
should be documented and reviewed postoperatively.
EFFECTS OF EPILEPSY SURGERY ON COGNITION AND
BEHAVIOUR
M. Korkman (Psychology, A◦ bo Akademi University, Finland)
Effects of pediatric epilepsy surgery on cognitive development
Most studies on cognitive effects of pediatric epilepsy surgery have
concerned temporal lobe resections. In general, no postsurgical decline
in general intelligence has been reported. Some studies have reported
a decline of verbal memory after left temporal resection whereas other
studies have not found effects. Visual memory seems to be relatively
robust.
Few studies have been undertaken on cognitive development after
extratemporal resections. This group of patients is very heterogeneous
and the results of follow-up studies have been varied. Children who un-
dergo hemispherotomy usually have a compromised cognitive capacity
presurgically. In general, the surgery has not added to the impairment.
Factors that may influence postsurgical cognitive development other
than site and size of surgery include gender, age at surgery, medication,
and seizure control. The results are relatively contradictory. Taken to-
gether, the results concerning the cognitive effects of pediatric epilepsy
surgery are varied and individual variation is great.
Another factor that increases the variability in cognitive findings is
variation in methods. Not many studies have applied comprehensive
neuropsychological assessments. On an individual level problems with
attention and executive functions as well as language and learning disor-
ders are common in children with epilepsy. Manual and constructional
functions, visuospatial perception, and different types of memory and
learning may be affected as well. It would be important to follow the
development in these domains after surgery.
Comprehensive neuropsychological assessments are recommended
both for studies and in individual patients. Individual assessments are
best carried out using comprehensive, standardized sets of tests; stud-
ies may alternatively employ control groups. Tests should cover a broad
age range to permit follow-up over several years and assessment of chil-
dren of various ages and cognitive levels. Ideally, base rates or norms
concerning developmental changes and repeated assessments should be
collected.
Thursday July 6, 2006
9:15–11:00
Hall 1
European Epileptology Award Symposium
Bridging basic with clinical epileptology
PROGRESSIVE MYOCLONUS EPILEPSY EPM1: A MODEL
FOR GENETICALLY DETERMINED SUSCEPTIBILITY TO
SEIZURE-INDUCED NEURODEGENERATION
A. Lehesjoki (Folkha¨lsan Institute of Genetics and Neuroscience Center,
University of Helsinki, Finland)
Progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1)
is characterized by the age of onset at 5–16 years, stimulus-sensitive
myoclonus, tonic–clonic seizures and progressive ataxia. Mutations in
the gene encoding cystatin B (CSTB), an inhibitor of lysosomal cys-
teine proteases, cathepsins, underlie EPM1. The majority of patients are
homozygous for a dodecamer repeat expansion in the CSTB promoter.
In cells of the patients significantly reduced cystatin inhibitory activity
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correlates with significantly increased cathepsin activity suggesting that
cathepsins contribute to the EPM1 pathogenesis. CSTB is a multicom-
partment protein being mainly lysosomal and nuclear in dividing cells
and mainly cytoplasmic in differentiated cells. Missense mutant proteins
representing patient mutations fail to associate with lysosomes, imply-
ing a critical lysosome-associated physiological function for CSTB. A
mouse model for EPM1 has been created by targeted disruption of the
mouse Cstb gene. The Cstb−/− mice show progressive ataxia and my-
oclonic seizures. Loss of cerebellar granule cells by apoptosis and less
marked neuronal apoptosis, neuronal atrophy and gliosis in the cerebrum
are characteristic neuropathological findings in the mice. The uneven dis-
tribution of neuropathological changes in the mice suggests differential
neuronal sensitivity to CSTB deficiency. The changes are similar in both
seizure-prone and seizure-resistant genetic backgrounds indicating that
CSTB deficiency causes neuronal degeneration independent of seizure
events. However, initial data suggest that kainate-induced seizures evoke
greater hippocampal neuronal damage in Cstb−/− than control mice im-
plying that neurodegeneration in EPM1 can be enhanced by recurrent
seizures or myoclonic jerks. Studies of mice double mutant for the Cstb
and Cathepsin B genes show that cathepsin B contributes to cerebel-
lar phenotype, but not to the abnormal EEG or to ataxia phenotypes
suggesting that CSTB has other functions than preventing cell death.
Despite these advances, the molecular pathogenesis of EPM1 and the
physiological function of CSTB remain to be elucidated.
PATHOPHYSIOLOGICAL MECHANISMS OF ABSENCE
SEIZURES
V. Crunelli (School of Biosciences, Cardiff University, UK)
Typical absence seizures of idiopathic generalized epilepsies are char-
acterized by brief loss of consciousness and the appearance of 3Hz spike-
and-waves discharges (SWDs) in the EEG, that involve paroxysmal firing
in thalamic and cortical networks. Whereas molecular-genetic analyses
of affected individuals and families have led to important breakthroughs
in the identification of candidate genes for the simple mendelian types
of idiopathic generalized epilepsies, the genetics and pathophysiological
mechanisms of typical absence seizures are still not fully understood.
During my presentation, I will critically review data from the last ten
years of experimental work in thalamus and cortex, and highlight how
the use of inappropriate models has often led to unsatisfactory views on
the intrinsic and network mechanisms of SWD generation. In addition, I
will present some of our recent data showing abnormalities both in pha-
sic and tonic GABAergic inhibition in a well established genetic model
of typical absence seizures, the Genetic Epilepsy Rats from Strasbourg
(GAERS). The phasic GABAergic abnormalities include a 40% faster
decay of the IPSCs, a reduced GABAB autoreceptor sensitivity (58%
with 1mM baclofen) and a 45% smaller paired-pulse depression, com-
pared to Non-Epileptic Control (NEC) rats: all these differences are area-
selective, being present in neurons of the thalamic reticular nucleus but
absent in thalamocortical and cortical neurones. Tonic GABAergic inhi-
bition is stronger in thalamocortical neurones of GAERS, and is likely
to represent the mechanism underlying the tonic hyperpolarization that
is present in these neurones during spontaneous SWDs.
UPDATE ON BASIC MECHANISMS OF TEMPORAL LOBE
EPILEPSY
J. Engel Jr (UCLA, USA)
Because mesial temporal lobe epilepsy with hippocampal sclerosis
(MTLE with HS) can be successfully treated surgically, it is often the
subject of invasive research into basic mechanisms. In vivo studies can
be carried out during intracranial EEG evaluations, and in vitro stud-
ies can be performed on resected tissue. Consequently, more is known
about the fundamental neuronal disturbances underlying epileptogenesis
in MTLE with HS than about any other form of human epilepsy. Basic
research on MTLE with HS is augmented by numerous excellent animal
models of this condition induced with excitotoxic agents such as kainic
acid and pilocarpine, or prolonged hippocampal stimulation. Reiterative
parallel investigations using patients and animals indicate that epilep-
togenesis in HS is initiated by specific types of cell loss and neuronal
reorganization, which results not only in enhanced excitation, but also
enhanced inhibition, predisposing to hypersynchronization. Even within
this single, well-studied epileptic disorder, however, there is evidence
for more than one type of ictal onset, and multiple mechanisms respon-
sible for ictal propagation and termination, as well as enduring interictal
disturbances. The most common ictal onset pattern consists of hypersyn-
chronous discharges, which are usually associated with the aura, or no
clinical signs or symptoms. Transition to a low-voltage fast ictal pattern
results in contralateral propagation and the behavioral complex partial
seizure. Some seizures, however, begin with low-voltage fast activity.
Novel high frequency (200–500 Hz) oscillations, termed Fast Ripples
(FR), characterize the primary epileptogenic region, and may reflect the
principal epileptogenic dysfunction. FR-generating neurons are not ho-
mogeneously distributed throughout mesial temporal structures, but are
located within small neuronal clusters. An increase in the size of, and syn-
chronization among these clusters could be mechanisms of seizure ini-
tiation. Fundamental neuronal mechanisms underlying these abnormal
high-frequency oscillations, and factors that modulate their temporospa-
tial relationships, could elucidate important substrates of epileptogenesis
and epileptogenicity.
WHAT CAN WE LEARN FROM HUMAN TISSUE STUDIES ON
MECHANISMS OF PHARMACORESISTANCE?
U. Heinemann (Institute Neurophysiology, Charite´ Universita¨tsmedizin
Berlin, Humboldt Universita¨t, Germany)
We have used surgical specimen from patients with TLE to study
mechanism of pharmacoresistance. Two hypotheses try to explain this
feature. The transporter hypothesis suggests that drug resistance is due
to upregulation of multidrug transporters in the blood brain barrier and
in the tissue preventing sufficient drug levels in the tissue. The target
hypothesis contends that tissue alterations account for drug resistance.
We were able to induce different forms of epileptiform activity in the
human hippocampus by elevating extracellular potassium concentration.
In most specimen from pharmacoresistant patients the evoked activity
was insensitive to carbamazepine and valproate. By contrast, in slices
from patients suffering from tumours the evoked activity was suppressed
by carbamazepine or valproate. Application of inhibitors of drug trans-
porters (probenecide combined with verapamil) had usually no beneficial
effect. However. in a minority of specimen inhibition of drug transporters
was able to suppress epileptiform activity. The findings suggest that drug
resistance can only in a minority of patients be explained by upregula-
tion of multi drug transporters. It is likely due to alterations in tissue
properties on a cellular and or on a network level.
Thursday July 6, 2006
11:30–13:30
Hall 1
Discussion Group Session
Chronic epilepsy: a development retarding or progres-
sively dementing disease?
EVIDENCE FROM LONGITUDINAL EVALUATION OF CHIL-
DREN VERSUS ADULTS WITH CHRONIC EPILEPSY
H. Bjørnæs (The National Centre for Epilepsy, Norway)
Several longitudinal studies have revealed a cognitive/intellectual de-
cline in children with refractory seizures, whereas cognitive functioning
in adults seems to be more resistant. Whether this may be due to more
severe or progressive epilepsy on part of the selected children compared
to the adults is not clear, as no direct comparisons of the seizure condition
in the respective groups have previously been performed.
In the present study, we wanted to assess longitudinally the effects of
refractory seizures on intelligence in children and adults, taking seizure
severity and possible changes in the condition into consideration.
Seventeen children and 17 adults were tested twice with the age-
appropriate version of Wechsler’s Intelligence Scales. Mean test-retest
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interval in the two groups was 3.5 and 6.0 years, respectively. There
were no statistically significant differences between the groups with
respect to severity of the epilepsy at Test 1, as indicated by retrospective
assessments of seizure severity, interictal EEG pathology, and number
of antiepileptic drugs received per patient. Assessments of changes in
these variables during the test-retest interval did not indicate different
courses of the disease in the two groups. Despite these similarities, a
statistically significant difference was found between the children and
the adults regarding changes in intellectual functioning. In the children,
there was a decline in mean IQ scores during the test-retest interval,
while the IQ scores increased in the adult group. As an explanation of
these differences we proposed a development retarding model, as none
of the children actually regressed in sum of raw scores. The gain in IQ
scores in the adults might have been caused by improved AED treatment
with respect to side effects.
Results in 15 children who were re-tested on average 11 years later as
adults paralleled the findings in the former group of children.
EVIDENCE FROM CROSS-SECTIONAL AND LONGITUDINAL
QUANTITATIVE MRI ANALYSIS
R. Liu (UCL Institute of Neurology, UK)
Chronic epilepsy: a development retarding or progressively dementing
disease?
Chronic epilepsy is associated with widespread structural change and
functional cognitive deficits. This presentation focuses on MRI evidence
for seizure-related damage and whether a greater understanding of the
timing and pathogenesis of these changes can contribute towards a model
of how cognitive impairment develops in chronic epilepsy.
Cross-sectional and longitudinal quantitative MRI studies focus pri-
marily on the hippocampus in patients with recent-onset and chronic
temporal lobe epilepsy (TLE). Hippocampal volumes are easily and re-
producibly quantified and the correlation between hippocampal atro-
phy and pathological hippocampal sclerosis is well-recognised. Besides
the hippocampal changes in chronic TLE, cross-sectional studies re-
port widespread extrahippocampal changes which may correlate with
epilepsy duration. Literature on the cross-sectional relationship between
seizures, epilepsy duration and hippocampal atrophy in TLE is reviewed.
Inherent limitations of cross-sectional studies have led to the develop-
ment of longitudinal quantitative MRI studies. These MRI studies focus
primarily on the evolution and progression of hippocampal atrophy in
TLE. Single case studies and small patient series suggest that hippocam-
pal atrophy may develop over years or even months following recurrent
seizures or an episode of status epilepticus, although larger patient se-
ries have produced disparate findings possibly relating to methodologi-
cal differences.Our results in a large population-based longitudinal MRI
study show that hippocampal atrophy develops in some patients but is
not common and that seizure-induced damage is likely to be influenced
by individual susceptibility factors. Our findings are consistent with the
concept that hippocampal and neocortical atrophy in chronic epilepsy is
primarily the result of normal aging processes superimposed on a brain
primed by preexisting damage.
EVIDENCE FROM ANIMAL MODELS
A. Nehlig (INSERM U 666, Faculty of Medicine, Strasbourg, France)
The lesions and plasticity phenomena induced by pilocarpine or
kainate status epilepticus (SE) and leading to circuit reorganization and
epileptogenesis induce behavioral and cognitive deficits in rodents. The
nature and severity of the long-term consequences of SE depends on
the nature of the structures undergoing neuronal loss during SE and
also on the age of the animals at the time of SE. Adult rats undergo-
ing SE develop behavioral impairment, mainly in spatial memory tasks,
visuo-spatial learning and memory retention, reflecting mainly the dis-
ruption of the hippocampal-entorhinal cortex pathway. Disturbances
in emotional behavior, reduced anxiety, hyperactivity and disinhibi-
tion were also reported. The disruption of hippocampal/entorhinal cor-
tex/amygdala circuits occurring after SE might lead to misevaluation of
threatening situations and hence enhanced activity and decreased anx-
iety. Conversely, when rats are subjected to SE earlier around PN10–
PN14, most often there is only limited long-term impairment in spatial
memory and sometimes enhanced anxiety and fear. Likewise, the repe-
tition of seizures in very young animals (PN0–PN5 or PN7–PN9) leads
to learning impairment, impaired visuospatial learning and decreased
activity levels when rats are tested as adults. Full kindling in adult rats
which does not lead to marked damage but rather to plastic changes
also induces disrupted memory retention and increases anxiety. Finally,
in genetic absence epilepsy models in which there are no lesions, the
rats perform better than controls. Thus, it appears that the pattern of be-
havioral impairment corresponds to the distribution of lesions but also to
plastic molecular changes. However, since the panel of testing paradigms
is quite limited in rodents and since there are no available studies that
performed temporal follow-up of the behavioral disturbances in animals
rendered epileptic, the available experimental evidence does not allow to
conclude whether epilepsy is developmentally retarding or progressively
dementing.
EVIDENCE FROM LONGITUDINAL DATA FROM CHILDREN
WITH IDIOPATHIC OR CRYPTOGENIC EPILEPSY
K. Oostrom (University Medical Center Utrecht, Wilhelmina Chil-
dren’s Hospital, Departments of Neuropsychology and Child Neurology,
Utrecht, The Netherlands)
Background: We examined the course of early instability in cogni-
tive and behavioural functioning of children with ‘epilepsy only’ (EO)
and evaluated the importance of illness-related and contextual variables
during the first few years after diagnosis.
Methods: We used a multicenter, prospective, controlled, initially
one-year follow-up study of cognition and behaviour in 69 outpatient
schoolchildren with newly diagnosed idiopathic or cryptogenic epilepsy.
Using a call-back procedure to which 42 children with EO and 30 con-
trols responded favourably, the follow-up was extended to 3.5 years after
diagnosis. Three sources of information were used: 1) comprehensive
neuropsychological assessments covering major domains of cognition,
mental and motor speed and academic language skills, 2) behavioural
checklists completed by parents and teachers, 3) semi-structured inter-
views of patients’ parents inventorying contextual adversity. Contextual
and illness data (aetiological classification, AED-use, seizure remission)
were used as between subject factors in general linear model repeated
measures analyses of variance with neuropsychological and behavioural
scores as outcome measures. School delay was controlled for and taken
into consideration in the study.
Results: 1) Group-wise, cognitive and behavioural differences be-
tween children with EO and healthy classmates existed but did not
change. 2) Instability in performances was characteristic of children
with EO. 3) ‘Persistent’ cognitive deficits, over-represented in children
with EO (19 vs 3% in controls) concerned children with contextual
adversity.
Conclusion: In the first three to four years after diagnosis EO cannot
be considered to cause cognitive or behavioural deterioration. Individual
deficits pertained to instability of performance, i.e., processing aspects
that could be best understood by contextual adversity (difficulties in
adjustment to the diagnosis by parents and by the children themselves,
and—even prior family problems).
EVIDENCE FROM CROSS-SECTIONAL AND LONGITUDI-
NAL EVALUATION OF PATIENTS WITH TEMPORAL LOBE
EPILEPSY
C. Helmstaedter (University Clinic of Epileptology Bonn, Germany)
Recent studies on the impact of chronic epilepsy on brain and brain-
function give rise to propose a model which takes into consideration the
age at which epilepsy hits the brain, where epilepsy hits the brain, and
whether damage and dysfunction are transient or persistent. Seizures, in-
terictual epileptic dysfunction, as well as unwanted negative side effects
of medical or surgical treatment can add to cognitive impairment. Thus,
lesions and more or less controllable and reversible epileptic dysfunction
may interfere with brain and cognitive development. Accumulation of
damage in the course of epilepsy appears an individual rather than a sys-
tematic aspect of chronic epilepsy. Finally, accelerated mental decline
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can be assumed as a consequence of the interaction of physiological or
pathological mental aging with preexisting damage. This proposition of
a model of cognitive development in chronic epilepsy will be outlined
on the basis of recent cross sectional and longitudinal studies in patients
with temporal lobe epilepsy in particular.
Thursday July 6, 2006
11:30–13:30
Hall 5A
Discussion Group Session
What future for radiosurgery in epilepsy surgery?
WHAT HAVE WE LEARNED FROM EXPERIMENTAL
STUDIES?
A. Gil-Nagel (Hospital Ruber Internacional, Madrid, Spain)
The goal of stereotactic radiosurgery is the precise delivery of a single
high dose of radiation to an area of pathological tissue of the brain with
minimal effect on normal tissue. Tolerance of normal tissues to radia-
tion depends on total dose, time of exposure, volume radiated, radiation
quality, and adjunctive treatments. Mathematical models have been de-
vised to predict a 5% to 50% probability of injury at 5 years (T-D 5/5);
according to these models, 50 ± 10 Gy is the T-D 5/5 for the whole
brain, and 60 ± 10 Gy is the T-D 5/5 for a limited volume of the brain.
The effect of radiation in non-neoplastic brain tissue has been analyzed
in the rat frontal lobe model. These studies have demonstrated that ra-
diosurgery produces predictable histological changes: edema within the
treatment volume at 14 days, circumscribed cerebral necrosis at 21 days,
and complete destruction within the treatment volume later in time. In-
formation on the mechanism of action of radiosurgery in non-neoplastic
brain tissue in humans is less abundant. Series on gamma-knife therapy
in the treatment of epilepsy have demonstrated some relevant aspects:
(1) delayed onset of its effect is probably related to the time mitotic cy-
cles occur in susceptible tissues, such as the endothelium of small vessels
and capillaries, and astrocytes; (2) occurrence of an increased frequency
of brief simple partial seizures is common at the time of tissue changes
seen in brain MRI, and this is probably related to earlier involvement
of white matter pathways, those that participate in seizure propagation;
(3) differences in individual susceptibility to radiation may explain fail-
ure of treatment in some patients, and indicate the existence of a higher
risk of radiation necrosis in some individuals. Assays have been de-
vised to quantify individual susceptibility to radiation; however, infor-
mation on their predictive value is still inconclusive and their use in
the analysis of patients with lower sensitivity to radiation has not been
explored.
RATIONALE FOR RADIOSURGERY IN MESIAL TEMPORAL
LOBE EPILEPSY
F. Brunnhuber (King’s College Hospital, UK)
The fundamental reason and logical basis for resective epilepsy
surgery is rooted in Lueder’s concept that the removal or resection of
the epileptogenic zone leads to partial or complete seizure control with
minimal or at least acceptable risks and side effects. Resective surgery in
Mesial temporal lobe epilepsy (MTLE), which is one of the best-studied
epileptic conditions, yields very favourable results and thus makes it the
treatment of first choice if intractability has been demonstrated (1).
Whereas radiosurgery complies with Lueders concept of the epilepto-
genic zone as treatment target, it does not aim at its removal or destruc-
tion but rather its irradiation, thus leading to partial or complete seizure
control with minimal or at least acceptable risks and side effects.
Three strands of rationale provide justification for its clinical use and
development:
Firstly, irradiation has been shown to have antiseizure properties and
can lead to seizure control in humans (2, 3, 4, 6).
Secondly, animal models with hippocampal epilepsy have demon-
strated that seizure control can be achieved with nondestructive radiation
doses. These experiments have also found a dose response relationship
and proved the anatomical accuracy of the radiosurgical procedure. One
study has reported clear seizure control with no neuropsychological or
behavioural deterioration (5, 7, 8, 9, 10, 11). Thirdly, clinical studies
have shown that the noninvasive radiosurgical approach can yield sim-
ilar results as a well-established resective approach, the selective amy-
gadalohippocampectomy in MTLE. (12, 14)
However, in order to secure a place in the treatment arena of intractable
MTLE, radiosurgery will have to demonstrate superiority or a potential
advantage over the established treatment in at least one of the following
clinical or public health outcomes: patient selection, peri-operative risks,
side effects, seizure outcome or socioeconomic benefit.
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RESULTS OF THE U.S. PROSPECTIVE TRIAL
N. Barbaro (University of California, San Francisco Medical Center, San
Francisco, CA, USA)
Patients with pharmacoresistant temporal lobe epilepsy are frequently
referred for possible surgical management, and approximately half of
them are found to be candidates for surgical resection of their seizure
focus. The most common type of surgery performed is anterior temporal
lobectomy. Data from contemporary surgical series indicate that for pa-
tients with well-defined medial temporal foci, that the seizure-free rate
following surgical treatment is approximately 80%. The most common
pathologic finding in tissue removed during these procedures is mesial
temporal sclerosis. We are in the process of completing a multicenter pi-
lot clinical trial investigating the effectiveness of radiosurgical treatment
of temporal lobe epilepsy. A recently completed European multicenter
trial showed that approximately 65% of patients became seizure-free
following Gamma Knife radiosurgery to the medial temporal lobe. We
randomly assigned patients into two dosage groups (20 Gy and 24 Gy)
Preliminary data indicate that there is a significant reduction of seizures
in these patients with approximately 80% of the patients in the 24 Gy
group becoming seizure-free. Approximately 60% of patients in the 20
Gy group are seizure-free. One patient in the high-dose group required
surgical treatment for radiation-induced brain swelling with the neu-
ropathological findings consistent with radiation necrosis. No patients
in the European trial required surgery for acute radiation changes. Thus
preliminary data indicate that radiosurgical treatment has a clear biolog-
ical effect on seizures and that seizure-free rates are comparable with
open temporal lobectomy.
Patients who undergo open temporal resections for epilepsy in the
dominant hemisphere show measurable changes in language approxi-
mately 30% of the time and may have significant problems with psy-
chosocial adjustment following their operations (irrespective of seizure
outcomes). Patients treated for dominant hemisphere seizures seem not
to develop significant reductions in verbal memory at the time of maxi-
mal radiation change (one year), and two-year data confirm this lack of
deficits. Likewise, patients treated with radiosurgery seem not to develop
significant depression or other reductions in quality of life measures seen
soon after temporal lobe surgery. Thus, there may be an advantage of
radiosurgery over temporal lobectomy in this select patient population.
When all outcome aspects are considered, there is equipoise that jus-
tifies a direct comparison between these two forms of treatment for
patients with refractory seizures. A prospective, multicenter U.S. Trial
is being planned to compare temporal lobectomy with radiosurgery for
well-defined temporal lobe epilepsy patients.
LONG-TERM CLINICAL RESULTS OF RADIOSURGERY IN
MTLE AND NEUROPSYCHOLOGICAL OUTCOME
J. Re´gis, M. Tamura, F. Bartolomei, and P. Chauvel (Hoˆpital D’adulte
De La Timone, Marseille, France)
Radiosurgery in mesial temporal lobe epilepsy: long-term outcome
Objective: The short-term safety efficacy of Gamma knife surgery
(GKS), using 24 Gy, in patients presenting with mesial temporal lobe
epilepsies (MTLE) have been demonstrated by several teams. However,
till now no long-term follow-up was available.
Methods: Since march 1993, 53 patients presenting with MTLE
have been operated in Marseille University Timone Hospital. A total of
38 patients with unilateral MTLE have been operated more than 4 years
ago. Among these patients a follow up longer thant 4 years is available
for 17 patients operated by GKS at the state of the art including 9 females
for 8 males. The marginal dose at the 50% was 24 Gy. The target was
essentially including the anterior parahippocampal cortex the ventral part
of the amygdaloid nucleus and hippocampus (head and body).
Results: The median age was 34 years (mean 35, min 22, max 46) and
the median age at the onset of the epilepsy was 10,5 years (mean 8,5,
min 1 & max 27). The MTLE was on the dominant side in 9 cases (53%).
The median follow up is 8 years (mean 7,7, min 4, max 10). At the last
follow up 12 were still seizure free (70,5%) one have been operated on
due to a failure. Seizures have stopped with a median delay of 14 months
(mean 13, min 1 and max 19). A visual field have revealed a deficit in
8 patients (47%). Neuropsychological testing have failed to identify any
deficit and specially no verbal memory deficit when the MTLE was on
the dominant side.
Conclusion: Long term results of GKS in MTLE are confirming the
very good safety efficacy observed on the short term. Memory sparing
on the long term seems to be a major advantage over microsurgical
resection.
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Focal drug and gene delivery for refractory epilepsy:
fantasy or clinical reality?
SCIENTIFIC RATIONALE: OVERVIEW OF FOCAL DRUG
DELIVERY STUDIES IN VITRO AND IN VIVO
H. Cock (St Georges, University of London, UK)
Refractory epilepsy remains a significant clinical problem, on which
the availability of new antiepileptic drugs has had little impact. For the
large number of patients for whom resective surgery is not an option,
novel treatment approaches are urgently required. Systemic drug deliv-
ery is inevitably limited by the potential for unwanted side effects, due to
actions both outside the CNS and in nonepileptic brain regions. There is
now a considerable body of work in which a range of established and pu-
tative antiepileptic agents applied directly to the brain (most commonly
the seizure focus) have proven efficacy in reducing/aborting seizure ac-
tivity both in brain slices, and in vivo. The commonest approach has
been to infuse or apply GABAergic agents such as diazepam direct to
the seizure focus, although other agents including glutamate antagonists
and sodium channel blockers have also been used. Other sites, such as
the substantia nigra, potentially important in seizure propagation, have
also been used, with some benefits at least in terms of reducing seizure
severity, but usually with unacceptable side effects, even in the short
term. Until recently most studies have been in acute seizure provocation
models (rather than epilepsy), and in models known to be essentially
drug sensitive. However in a model of cortical epilepsy which has been
well characterized, including frequent spontaneous seizures and which
is known to be refractory to systemic AEDs, it has recently been demon-
strated that a focal drug delivery approach offers clear benefits in terms
of efficacy and tolerability, at least in the short term. A focal approach
also offers the potential for using novel agents that would be considered
too toxic systemically (e.g., gap junction blockers). If longer term bene-
fits can be established, this offers a real hope for patients with refractory
cortical epilepsy who are not suitable for surgery.
VIRAL VECTORS AND GENE THERAPY IN EPILEPSY
A. Vezzani (Department of Neuroscience, Mario Negri Inst for Pharma-
col Res, Milano, Italy)
Gene therapy techniques may provide a realistic therapeutic approach
for intractable focal epilepsies not responding to conventional antiepilep-
tic drugs. These techniques involve the transfer and expression of a
“therapeutic” gene into the ictogenic brain area(s), thus permitting long-
term CNS expression of molecules with potential anticonvulsive and
antiepileptogenic properties. The success of a gene therapy approach
is largely dependent on the selection of the “therapeutic” gene and the
methods of gene delivery. There are mainly two approaches to deliver
genes to CNS: ex vivo—gene transfer is performed in cultured cells
which are subsequently transplanted; in vivo—the gene is delivered to
the subject to transduce target cells directly. The in vivo gene deliv-
ery approach includes nonviral (naked DNA, liposomes, polymers) and
viral (retrovirus, HSV, AAV, lentivirus) approaches. Neurotropic AAV
represent the most often used tool for gene delivery in experimental
models of epilepsy. Therapeutic strategies have been focused mainly on
modulating signaling mediated by excitatory neurotransmitters (NMDA
receptors), or enhancing the release of neuroactive peptides (galanin,
neuropeptide Y). Enzyme replacement has also been addressed, i.e., in
a model of Canavan Disease. Gene therapy studies have been carried
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out using experimental models of focally induced acute seizures, with
or without secondarily generalization, and in some instances models of
primary generalized, genetically determined seizures. Preclinical studies
are now focusing on the efficacy of gene therapy in rats with spontaneous
recurrent seizures. Thus, chronic epileptic tissue is often characterized
by neuropathological features which may affect the targets of the ther-
apeutic genes and impair their efficacy. Regulation of gene expression
and possible host tissue reactions to these transgenes or side effects are
under evaluation in experimental models since they are instrumental for
establishing a proof-of-principle of the applicability of gene transfer
technologies in epilepsy.
IN VIVO EXPERIENCE WITH ADENOSINE IN EPILEPSY:
POLYMERS VERSUS NEURONAL GRAFTING
D. Boison (R.S. Dow Neurobiology Laboratories, Legacy Research,
Portland, Oregon, USA)
Adenosine is a neuromodulator with antiepileptic and neuroprotective
properties. The adult brain is normally kept under tonic adenosinergic
control by low levels of adenosine kinase (ADK), the key enzyme of
adenosine metabolism, which, in most brain regions, is restricted to ex-
pression in astrocytes. Recently, dysfunction of the adenosine system,
in particular upregulation of ADK as a consequence of astrogliosis, was
shown to contribute to epileptogenesis and to cause seizures. Therefore,
restoration of adenosinergic neuromodulation is a rational treatment ap-
proach for epilepsy. Although pharmacological activation of the adeno-
sine system prevents pharmacoresistant seizures, systemic application of
such agents is precluded by cardiovascular and sedative side effects. We
therefore explored three strategies for focal adenosine delivery in the rat
hippocampal kindling model: (i) Intraventricular implants of synthetic
polymers releasing adenosine provided transient seizure protection, thus
demonstrating that a local source of adenosine is sufficient to suppress
seizures. (ii) A more long-term solution was achieved by engineering
fibroblasts and myoblasts to release adenosine based on a disruption
of their Adk genes. To study selectively paracrine effects, these cells
were encapsulated into semipermeable polymer membranes. Intraven-
tricular release of adenosine from encapsulated cells provided seizure
protection for up to 8 weeks, without sedative side effects. (iii) To as-
sess a combination of paracrine adenosine release and network effects
on epileptogenesis, embryonic stem cells were engineered to lack both
alleles of ADK and differentiated into neural precursors and adenosine
releasing neurons. ADK deficient neural precursors were transplanted
into hippocampi of rats one week before initiation of kindling. Rats with
ADK deficient implants were characterized by a significant delay in
kindling acquisition and failed to develop generalized seizures during
48 stimulations. In contrast, wild-type implant or sham treated animals
consistently developed generalized seizures after 40 stimulations. Thus,
focal cell mediated adenosine release might have an antiepileptogenic
potential.
PRECLINICAL AND CLINICAL EXPERIENCE OF FOCAL
DRUG DELIVERY FROM NEUROONCOLOGY AND NEU-
RODEGENERATION: PROSPECTS AND PITFALLS
J. Benoit (INSERM U 646, France)
Drug delivery to the central nervous system remains a challenging
area of investigation for both basic and clinical neuroscientists. Numer-
ous drugs are generally excluded from blood to brain transfer due to
the negligible permeability of the brain capillary endothelial wall, which
makes up the blood brain barrier in vivo. For several years, we have
explored the potential applications of the microencapsulation of ther-
apeutic agents to provide local controlled drug release in the central
nervous system. Due to their size, these microparticles can be easily
implanted by stereotaxy in discreet, precise and functional areas of the
brain without damaging the surrounding tissue. This type of implanta-
tion avoids the inconvenient insertion of large implants by open surgery
and can be repeated if necessary. We have established the compatibility
of poly(lactide-co-glycolide) microspheres with brain tissues. Presently,
the most developed applications concern Neurology and Neurooncology,
with local delivery of neurotrophic factors and antimitotic drugs into
neurodegenerative lesions and brain tumours, respectively. The drugs
that had been encapsulated by our group included nerve growth factor
(NGF), glial-cell derived neurotrophic factor (GDNF), 5-fluorouracil
(5-FU) and BCNU. Preclinical studies have been performed with each
drug. Studies with NGF and GDNF are reported as examples. A phase
IIb clinical trial has been carried out in patients with newly diagnosed
glioblastomas to assess the potentialities of 5-FU-loaded microspheres
when intracranially implanted.
Menei P, Capelle L, Guyotat J, Fuentes S, assaker R, Bataille B,
Francois P, Dorwling-Carter D, Paquis P, Bauchet L, Parker F, Sabatier
J, Faisant N, Benoit JP
Local and sustained delivery of 5-fluorouracil from biodegradable mi-
crospheres for the radiosensitization of malignant glioma: a randomized
phase II trial
Neurosurgery, 2005, 56, 2, 1–6.
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Non–age-related familial focal epilepsies: genotype-
phenotype correlations
AUTOSOMAL DOMINANT NOCTURNAL FRONTAL LOBE
EPILEPSY: GENOTYPE-PHENOTYPE CORRELATIONS
A. Gambardella (Universita` Magna Graecia, Italy)
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is
a recently identified partial epilepsy, which is characterized by brief
frontal-lobe motor seizures occurring mostly during light sleep. The age
of onset is usually infancy and adolescence, although seizures may start in
adult life. Inheritance is autosomal dominant with 70% penetrance. The
clinical picture of ADNFLE is relatively homogeneous, even if a broad
range of severity has been observed even among affected members of the
same pedigree. The interictal EEG is usually normal but ictal recordings
show that these events are epileptic and appear to arise from the frontal
lobes. Misdiagnosis as nightmares, night terrors, other parasomnias or
even hysteria is common if clinicians are unaware of ADNFLE.
So far, ADNFLE has been associated with mutations affecting two
genes coding for alfa4 and beta2 subunits of the neuronal nicotinic acetyl-
choline receptor (nAChR), which are located on chromosome 20q and
chromosome 1 respectively. Moreover, although the gene has not yet
been identified, another ADNFLE locus has been mapped to chromo-
some 15q24. More recently, there has been evidence that variations in
the promoter of the corticotropic-releasing hormone gene may be also
associated with ADNFLE. Nonetheless, the underlying gene has not yet
been found in most ADNFLE families. Overall, these data support the
pathogenic role of the cholinergic system in ADNFLE, even if its etiol-
ogy appears to be the result of a variety of molecular defects despite the
relative homogeneity of the clinical manifestations.
FAMILIAL MESIAL TEMPORAL LOBE EPILEPSIES: THE
CLINICAL SPECTRUM AND GENETICS IMPLICATIONS
F. Picard (Department of Neurology, University Hospital of Geneva,
Switzerland)
Familial mesial temporal lobe epilepsy (FMTLE) corresponds to an
heterogeneous entity with syndromes of different severity.
FMTLE was first described as a benign autosomal dominant syndrome
with onset in early adulthood, no temporal lobe or hippocampal abnor-
malities on MRI and no association with febrile seizures. Simple partial
seizures comprise psychic (especially de´ja` vu) or autonomic symptoms,
or special sensory components. Interictal EEG abnormalities are rare. A
genetic locus has just been identified in a family with a classical form
of FMTLE (with no hippocampal sclerosis) on chromosome 4q, but no
gene has been identified yet.
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Subsequently, families with more severe syndromes were described,
especially FMTLE with frequent hippocampal sclerosis and a variable
association with febrile seizures. Epilepsy begins in the first to third
decade of life. Interictal EEGs show frequent temporal discharges. Pa-
tients are often pharmacoresistant. In these more severe forms, there is
accumulating evidence for a genetic predisposition for the development
of hippocampal sclerosis, but no linkages or genes have been identified
yet.
Finally, a few families with individuals with both febrile seizures and
temporal lobe seizures, but without hippocampal abnormalities on MRI,
have also been reported. A common genetic susceptibility to both types
of seizures is likely in these families.
AUTOSOMAL DOMINANT LATERAL TEMPORAL LOBE
EPILEPSY AND THE SPORADIC FORM WITH AUDITORY
FEATURES
R. Michelucci (Department of Neurosciences, Bellaria Hospital,
Bologna, Italy)
Autosomal dominant lateral temporal epilepsy (ADLTE) otherwise
reported as autosomal dominant partial epilepsy with auditory features
(ADPEAF) is a recently recognised epileptic condition characterized
by autosomal dominant transmission, non-age related onset, focal and
secondary generalized tonic–clonic seizures with typical auditory auras
and/or symptoms suggesting a lateral temporal onset, absence of neu-
rological or mental impairment, mild and inconstant temporal EEG ab-
normalities, normal MRI findings, and benign evolution with rare and
drug-responsive seizures. Since the first description by Ottman et al.
in 1995, this condition was found to be linked to a locus on chromo-
some 10q24. Recently, the disease-causing gene for ADLTE has been
identified: it is the leucine-rich, glioma inactivated 1 (LGI1) gene, now
also named Epitempin, whose mutations often introduce premature stop
codons, thus preventing the production of the full-length protein from
the affected allele. The predicted protein structure of LGI1 consists, in
the N-terminal portion, of three leucine-rich repeats (LRRs) flanked by
typical cysteine-rich repeat sequences and, in the C-terminal portion,
of seven newly identified repeats of about 50 aminoacids. LRRs are
widespread among different classes of intra- and extracellular proteins
and may be involved in ligand binding or protein-protein interaction. Al-
though the function of Lgi1 is largely unknown, recent proteomic anal-
ysis data suggest that Lgi1 is tightly associated with Kv1.1-containing
channel complexes and may promote epileptic activity by changes in
inactivation gating of presynaptic A-type K channels.
Up to now it is clear that less than 50% of ADLTE families carry
the LGI1 mutations; phenotypically, no differences may be observed be-
tween mutated and non-mutated families. Studies aimed to identify other
putative loci or genes, including the structurally similar genes LGI2,
LGI3 and LGI4, have not produced positive results.
The relevance of this gene has been also investigated in sporadic,
“idiopathic” cases exhibiting a phenotype similar to ADLTE. One out of
100 patients has been shown to bear a de novo LGI1 mutation, suggesting
that this gene plays a minor role in non familial cases.
OTHER FAMILIAL FOCAL EPILEPSIES AND THE FUTURE
STRATEGIES OF CLINICAL AND GENETIC RESEARCH
O. Steinlein (Institute of Human Genetics, University of Munich,
Germany)
Genetic factors play a major role not only in generalized epilepsy but
also in partial epilepsies. During the last decade most known epilepsy
genes were first located within the genome by linkage analysis and than
finally cloned either by looking for the most promising candidate genes
in the region of interest or by systematically sequencing every gene in
this particular region. This approaches led to the successful cloning of
several genes for generalized but also for some focal epilepsies, some
of the latter have already been discussed in the previous talks of this
session. However, the linkage approach requires large families or sam-
ples of many smaller families that are often difficult and time consuming
to collect. Furthermore, it is of limited usefulness in epilepsies with an
oligogenic rather than monogenic mode of inheritance. Thus, in the fu-
ture other strategies will have to be used for the successful cloning of
epilepsy genes. Examples for such strategies will be discussed in this pre-
sentation, like the identification of new candidate genes by phylogenetic
and functional motif analysis of known epilepsy genes, the search for
genes involved in epileptogenetic pathways by siRNA and morpholino
knock down experiments as well as the introduction of animal models
for epilepsy.
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Further understanding of the pathophysiological
mechanisms involved in Landau-Kleffener and related
syndromes
THE CLINICAL SPECTRUM
U. Stefani (Klinik fur Neuropadiatrie Der Universitat Kiel, Germany)
No abstract received.
FROM ANATOMICAL TO FUNCTIONAL NEUROIMAGING
P. Van Bogaert (Universite´ Libre de Bruxelles, Hoˆpital Erasme, Belgium)
The pathophysiological mechanisms underlying the EEG phe-
nomenon of continuous spike-waves during sleep (CSWS) and related
cognitive and behavioral deficits remain poorly understood. It is now
admitted that diffusion of the epileptiform discharges during NREM
sleep is related to a mechanism of secondary bilateral synchrony from
a focal cortical onset. It is probable that thalamic nuclei play an im-
portant role in this phenomenon, presumably through a development
of the physiological slow-sleep oscillation into diffuse slow waves be-
cause of the lack of inhibitory constraint. This hypothesis is supported
by experimental CSWS-like pattern obtained in cats following unilat-
eral thalamic ablation. The role of the thalamus in the generation of
the CSWS phenomenon was recently emphasized by reports of patients
showing thalamic clastic lesions on MRI. Studies performed using PET
with 18F-fluorodeoxyglucose (FDG) by our group and by others in chil-
dren with CSWS and normal MRI have failed to show consistent thalamic
abnormalities, but data analysis is complicated by the fact that physio-
logical metabolic changes occur in the thalamus during brain develop-
ment. Indeed, the metabolic activity of the thalamus adjusted for global
metabolism increases significantly during childhood. On the other hand,
numerous studies have shown that cortical metabolic abnormalities are
frequently found in epileptic children with CSWS. The latter consist in
either focal hypermetabolism or focal hypometabolism. The analysis of
our FDG-PET data led to the following conclusions: (1) The hyperme-
tabolic zone is the ictal onset zone; (2) Hypermetabolic areas are usually
associated with distinct cortical hypometabolic areas, probably as a re-
sult of either loss of functional connectivity or inhibition mechanism;
(3) Both hypermetabolic and hypometabolic areas tend to decrease or
even disappear at the recovery phase of CSWS; and (4) Similar types of
metabolic patterns and evolution may be seen in children with CSWS
associated with polymicrogyric-like lesions.
WHAT DO WE LEARN FROM RECENT ADVANCES IN NEURO-
PHYSIOLOGY?
E. Hirsch (Department of Neurology, Strasbourg, France)
In 1992, Landau hopes that medical community achieved collective
agreement about Landau-Kleffner syndrome (LKS), diagnosis criteria,
etiology, pathophysiology, rational therapy. Since 1992, neurophysio-
logical recording (High resolution EEG, MEG, depths) correlated to
neuroimaging studies and long term follow up studies, lead to the view
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that LKS is an acquired aphasia, secondary to an epileptic disturbance
affecting a cortical area involved in verbal processing. This view fits
with the hypothesis of a “functional ablation” caused by epileptic activ-
ity “interictal spike-waves.” Epileptic aphasia would then be a subgroup
of the CSWS syndrome in which epileptic discharges arise from tempo-
ral cortex. Genetic predisposition could be derive from hyperexcitability
and synchronization of interneurons within perisylvian cortices who are
responsible for spike-waves generation. Major spike-waves activation
during NREM sleep, following thalamocortical uncoupling, lead to an
alteration of blood brain barrier who provokes an autoimmune system re-
action. Interneurons hyperactivity might have an antiepileptic protective
effect, associated with an inhibition of specific function. Long-term con-
sequence of spike-waves might be associated with focal atrophy. This
morphological defect might explain the poor verbal outcome in some
cases of LKS.
FROM RATIONALE FOR EXISTING TREATMENT TO
CONTROL STUDY?
E. Roulet Perez (CHUV, Lausanne, Switzerland)
No abstract received.
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Glutamate and epilepsy: from molecules to molecular
imaging
PHYSIOLOGY AND PHARMACOLOGY OF GLUTAMATE
NEUROTRANSMISSION
N. Bowery (PsyCEDD, GSK Medicines Research Centre, Verona, Italy)
Glutamate plays a fundamental role in the mammalian CNS as an
excitatory neurotransmitter. It can be synthesised in nerve terminals from
α-ketoglutarate or glutamine and is accumulated in synaptic vesicles.
Depolarisation of the nerve terminal releases the amino acid into the
synaptic cleft from where it activates membrane receptors. It is removed
to a large extent from the extracellular space by transport into glial cells
where it is converted to glutamine. This is then transported back into
the nerve terminal where it is reconverted to glutamate to replenish the
neurotransmitter levels.
Glutamate can activate both ionotropic and metabotropic receptors
which are located primarily at postsynaptic sites but they are also
present, particularly metabotropic receptors, on presynaptic terminals.
The ionotropic receptors have been classified broadly on the basis of
selective agonists, namely NMDA, AMPA and Kainate. NMDA and
AMPA receptors are widely distributed in the brain and coexist at the
same synapses. Kainate receptors have a much more restricted distri-
bution. AMPA and NMDA receptors exist as tetramers (GLU1-4) and
(NR1+NR2[A-D]+NR3A+NR3B) respectively. Both of these recep-
tors are permeable to Na+ but NMDA also has a high Ca2+ permeability.
Kainate receptors have a tetrameric structure comprising a combination
of subunits from GLU5-7, KA1 and KA2. Multiple binding sites for
coligands are present on NMDA receptors and the channel associated
with this receptor is blocked at resting membrane potentials by mag-
nesium ions. Occupation of the coligand site with glycine plus mem-
brane depolarisation (by e.g. AMPA) is obligatory to obtain a response
to NMDA activation. Metabotropic receptors for glutamate, of which
there are eight, all belong to group 3 GPCRs. The eight mGluRs can
be separated into 3 groups, Gp I (mGluR1&5), Gp II (mGluR2&3) and
Gp III (mGluR4,7,&8) with Gp I signalling being mediated via inositol
phospholipid breakdown and Gps II and III via modulation of adeny-
lyl cyclase. All mGluRs are widely distributed throughout the brain at
postsynaptic sites and on nerve terminals where they modify transmitter
release.
IMAGING GLUTAMATE SIGNALLING AT THE SYNAPTIC
LEVEL
D. Rusakov (Institute of Neurology, University College London, UK)
Information processing in the brain relies in large part on rapid activa-
tion of postsynaptic receptors by the excitatory neurotransmitter gluta-
mate. In parallel, modulation of axonal excitability and neurotransmitter
release by presynaptic glutamate receptors impinges on the susceptibil-
ity of cortical networks to seizures. The latter phenomenon is classically
associated with the hippocampal mossy fibre system where presynaptic
kainate receptors have long been implicated in the initiation and mainte-
nance of epileptiform activity. Do these receptors change in number, do
they redistribute or do they exert a ‘pathologically’ altered action after
status epilepticus? To approach these questions, experimental probing of
presynaptic receptor function at the level of single synapses is required.
We therefore combine single-cell electrophysiology with two-photon
microscopy to investigate the role of kainate receptors in modulating
presynaptic Ca2+ signalling at individual mossy fibre synapses in the
hippocampus. Our pilot results indicate that presynaptic kainate recep-
tors (a) may act as autoreceptors activated by a single glutamate discharge
from a single giant mossy fibre bouton, (b) enhance the action poten-
tial evoked presynaptic Ca2+ transient, in a use-dependent manner, by
involving Ca2+ release from presynaptic Ca2+ stores, and (c) are func-
tionally expressed in a cell-target dependent manner. These data shed
light on the principles of synapse-specific actions regulating neurotrans-
mitter release through presynaptic glutamatergic signalling. Whether
these actions undergo significant modifications associated with epilepsy
is currently under study.
IMAGING GLUTAMATE USING MAGNETIC RESONANCE
SPECTROSCOPY
M. Guye (INSERM U 751 & CNRS UMR 6612, Faculte de Medecine
de Marseille, France)
Proton magnetic resonance spectroscopic imaging (1H-MRSI) is a
metabolic imaging technique providing totally noninvasive in vivo quan-
tification of brain metabolites. Using acquisition sequences with short
echo time, this technique may identify in the resulting spectra, a sig-
nal at the resonance frequency of 2.29 ppm corresponding to glutamate
(Glu) and/or its degradation product glutamine (Gln). Differentiation
between these two metabolites is difficult at 1.5T; therefore, the term
glutamine-glutamate (Glx) concentration is usually used. Identification
of Glx concentrations changes in brain areas in partial epilepsies and
idiopathic generalized epilepsies have provided not only new insight,
but also new questions about the biochemical alterations associated to
these different forms of epilepsy, at a macroscopic scale. Technical is-
sues and interpretation of findings will be discussed. Use of high fields
scanners (>3T) and new techniques such as 13C-MRS allowing better
Glu quantification will also be presented.
IMAGING GLUTAMATE NEUROTRANSMISSION USING PET
AND SPECT
A. Hammers (Imperial College London, UK)
Glutamate is the most important neurotransmitter, and its role in
epilepsy is well recognized. Imaging glutamatergic neurotransmission
has long been an elusive goal. While basic science has progressed enor-
mously over the past decade, imaging has so far been lagging behind,
with no successful PET/SPECT ligands for excitatory amino acids avail-
able.
Substituted methylguanidines are a comparatively new group of un-
competitive NMDA channel blockers. Three candidates from this group
are currently being evaluated; [11C]GMOM and [11C]CNS 5161 as PET
tracers and [123I]CNS 1261 as a SPECT tracer. I will discuss the results
so far and the difficulties in evaluating tracers for biological systems that
are difficult to fully block in vivo.
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Preventing epilepsy—a realistic goal?
PREVENTABLE CAUSES OF EPILEPSY
L. Forsgren (Professor of Neurology, Department of Neurology, Umea˚
University Hospital, Umea˚, Sweden)
Purpose: To give an overview of the most common causes of epilepsy,
with special emphasis on causes that are potentially preventable.
Methods: Survey of population-based epidemiological studies of
epilepsy from high- and low-income countries.
Results: In population-based studies of epilepsy, presumed causes
are identified in a minority–between 30 and 50%. The most common
potentially preventable causes are infectious (e.g., neurocysticercosis,
meningitis/encephalitis), stroke, head trauma, and perinatal/early brain
damage events. Neurocysticercosis is caused by ingestion of eggs dis-
charged from humans with intestinal infection of the adult worm. The
disease is common in many low-income countries. The proportion of
epilepsy caused by neurocysticercosis is unknown. However, if 10% of
epilepsies in endemic countries are assumed to be due to neurocysticer-
cosis, this would account for around three million people. The proportion
of epilepsies caused by meningitis/encephalitis is difficult to estimate due
to variability of the causative microbial agents by time and place. It is
likely that more than 100,000 people worldwide develop post-infectious
epilepsy annually.
Studies show that 3–4 % of a stroke population develops epilepsy.
Based on a stroke incidence of 250 per 100,000 in ages 25 years and
above, and a 30% one-month mortality, it can be estimated that around
200,000 new cases with epilepsy are seen annually. In most studies,
stroke is the most commonly identified cause of epilepsy, and it is
estimated that 4–9 million people worldwide suffer from post-stroke
epilepsy.
Traumatic Brain Injury (TBI)–both moderate and severe–accounts for
3–5% of all epilepsies, i.e., 1.5–2.5 million patients globally.
Conclusions: Reduction of poverty, improved sanitation, mass vacci-
nation, treatment of hypertension and proper use of intoxicating agents
would prevent many from developing epilepsy.
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PREVENTING EPILEPTOGENESIS–EXPERIMENTAL EVI-
DENCE AND CANDIDATE TARGETS
A. Pitka¨nen (A.I.Virtanen Institute for Molecular Sciences, University
of Kuopio, Kuopio, Finland)
Epileptogenesis refers to abnormal neuronal reorganisation occurring
over a long period of time following a specific cerebral insult leading
to the occurrence of spontaneous seizures. Attempts to prevent epilep-
togenesis in experimental models have used status epilepticus (SE) as
an epileptogenic brain insult and antiepileptic drugs (AEDs) as candi-
date antiepileptogenic compounds. So far, there is no hard evidence that
any of these compounds is antiepileptogenic. Some positive effects that
have been found have been difficult to distinguish from the suppress-
ing effects of AEDs on the severity of SE itself (Pitka¨nen A, Kubova
H. Antiepileptic drugs in neuroprotection. Expert Opin Pharmacother
2004;5(4):777–98). There are several recent developments in the field
of epileptogenesis that will undoubtedly advance future research. These
include enlargement of the armamentarium of animal models from SE-
induced epileptogenesis to epilepsy that is triggered by traumatic brain
injury (TBI) or stroke (Karhunen H, Jolkkonen J, Sivenius J, Pitka¨nen A.
Epileptogenesis after experimental focal cerebral ischemia. Neurochem
Res 2005;30(12):1529–42); (Pitka¨nen A, McIntosh TK. Animal models
of post-traumatic epilepsy. J Neurotrauma 2006;23(2):241–61). Mouse
models under development will provide tools to investigate the contri-
bution of risk genes to epileptogenesis. Availability of long-term video-
EEG monitoring and magnetic resonance imaging will advance the se-
lection and follow-up of animals in a clinically relevant manner so as to
minimise the possibility of false negative or positive findings in preclin-
ical studies. Recently, experimental studies provided proof-of-principle
evidence that epileptogenesis can be modified by pharmacological treat-
ment. It was shown that chronic administration of the proconvulsant α2-
adrenergic antagonist, atipamezole, started one week after SE did not
prevent the development of epilepsy but had a clear disease-modifying
effect, i.e., seizure frequency was substantially lower than in the vehicle
group (Pitka¨nen A, Narkilahti S, Bezvenyuk Z, et al. Atipamezole, an
α2-adrenoceptor antagonist, has disease modifying effects on epilepto-
genesis in rats. Epilepsy Res 2004;61:119–40). Recent molecular stud-
ies have elucidated the mechanisms that regulate various components
of circuitry reorganisation including cell death, axonal and dendritic
plasticity, neurogenesis, gliosis, angiogenesis, reorganisation of the ex-
tracellular matrix, and alterations in cellular membranes that eventu-
ally lead to change in network excitability and seizure generation [5].
Bioinformatic analysis has suggested that there are some similarities in
the expression patterns of different functional gene groups after various
epileptogenic brain insults such as SE, TBI and stroke, including genes
contributing to inflammatory reactions. It remains to be explored if mod-
ification of inflammatory cascades will affect the risk of epileptogenesis
in various aetiologies (Lukasiuk K, Dabrowski M, Adach A, Pitka¨nen A.
Epileptogenesis-related genes revisited. Prog Brain Res 2006; in press).
Future studies will determine whether treatments enhancing somatosen-
sory or cognitive recovery after TBI or stroke will also improve epilepsy
outcome.
PREVENTION OF EPILEPSY–TRANSLATING EXPERIMEN-
TAL EVIDENCE TO CLINICAL TRIALS
G. Holmes (Professor of Neurology & Pediatrics, Neuroscience Center
at Dartmouth, Dartmouth Medical School, Lebanon, New Hampshire,
USA)
While there has been a multitude of pharmacological agents reported
to have antiepileptogenic properties in preclinical studies, results from
animal models have yet to be validated by clinical research. To date, no
drug has been shown to have disease-modifying properties in epilepsy.
Although kindling has been widely considered to be a model of epilepto-
genesis, agents that reduce kindling rate in animals have not been demon-
strated to alter epileptogenesis in humans. The ideal antiepileptogenic
agent is likely to be one that prevents the development of spontaneous
seizures in rats with either acquired lesions or genetic abnormalities. Fur-
ther studies in animals exploring the processes resulting from an insult
to the brain to spontaneous seizures are needed. Determining which of
the many biological changes that occur in the brain following an in-
sult that should be a target for intervention remains a major challenge.
In addition to not having validated animal models, clinical investiga-
tions may fail because of inappropriate study populations, inadequate
outcome measures, or insufficient power. Proper studies of antiepilep-
togenic agents in patients are lengthy and costly, and surrogate markers
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of epileptogenesis are urgently needed. Studies have indicated that both
MRI and electroencephalographic features have potential as surrogate
markers. Studies of MRI changes following prolonged febrile seizures
as a predictor of epilepsy are ongoing and there is considerable inter-
est in determining whether high-frequency oscillations following brain
insults contribute to epileptogenesis. Before becoming clinically rele-
vant, surrogate markers will require validation in human epilepsy. Trial
methodology that bridges the gap from the experimental drug candidate
to the clinical arena requires a novel approach to study design combining
scientific rigour with economic practicalities. Despite our current failure
in finding a drug or device that prevents epilepsy, increasing knowledge
of the pathophysiological basis of epilepsy offers considerable hope that
novel targets can be developed.
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An age-old challenge—epilepsy in the elderly
OLDER BUT ANY WISER? ARE WE MEETING THE CHAL-
LENGE OF EPILEPSY IN OLDER PEOPLE?
R. Tallis (Emeritus Professor of Geriatric Medicine, University of
Manchester, Manchester, UK)
Older adults are now the largest group of individuals presenting
with epilepsy (Wallace H, Shorvon S, Tallis R. Age-specific incidence
and prevalence rates of treated epilepsy in an unselected population
of 2,052,922 and age-specific fertility rates of women with epilepsy.
Lancet 1998;352:1970–3) which affects over 1% of people over 65
years of age (Purcell B, Gaitatzis A, Sander JW, Majeed A. Epilepsy
prevalence and prescribing patterns in England and Wales, Office
of National Statistics. Health Statistics Quarterly 2002;15:23–30).
The impact of seizures, their misdiagnosis, or their mismanagement,
on an elderly person cannot be exaggerated. It is a matter of the
greatest concern, therefore, that seizures in old age are comparatively
neglected both in the scientific literature and in clinical practice (Tallis
RC. ‘Epilepsy’. In: Tallis RC, Fillit H (eds) Textbook of Geriatric
Medicine and Gerontology. 6th ed. Edinburgh: (Churchill Livingstone,
2003;549–572). A recent survey in the United Kingdom showed a
lack of training in the diagnosis and management of epilepsy by
geriatricians (Epilepsy Action: Survey of Geriatricians in the United
Kingdom, 2005 [http://www.epilepsy.org.uk/press/releases/2005/
epilepsyaction pr epilepsyweek2005 medical.pdf]).
There are many challenges facing a physician who wishes to provide
good care for people with late-onset seizures: diagnosis; education and
support to minimise the psycho-social impact of seizures; rational deci-
sions about the use of antiepileptic drugs; the management of co-morbid
conditions; and long-term monitoring of seizure control and the effects
of medication.
Diagnosis often presents the most difficult challenge (Rowan AJ.
‘Paroxysmal disturbances resembling seizures in the elderly’. In Kaplan
PW, Fisher RS (eds) Imitators of Epilepsy. New York: Demos, 2005;111–
119). The range of differential diagnoses is extensive and accurate diag-
nosis is often made more difficult by the lack of a detailed history. The
most important differential diagnosis is syncope and physicians dealing
with ‘blackouts’ in older people should provide, or have ready access to,
a service for diagnosing and managing this very common condition. Di-
agnosis should include identification of the underlying cause. The close
relationship between elderly-onset seizures and cerebrovascular disease
is now more fully understood (Cleary P, Shorvon S, Tallis R. Late-onset
seizures as a predictor of subsequent stroke. Lancet 2004;363:1184–6)
and detection and treatment of cardiovascular risk factors should be a
routine part of the service.
At present, we are a long way off meeting the challenge of epilepsy
in older adults.
DOUBLE TROUBLE! THE IMPACT OF COMORBIDITY ON
TREATMENT STRATEGIES
A. Kanner (Professor of Neurological Sciences & Psychiatry, Rush Med-
ical College, Director, Laboratory of EEG and Video-EEG-Telemetry,
Rush University Medical Center, Chicago, Illinois, USA)
Today, the choice of antiepileptic drug (AED) for the treatment of
epilepsy is not only based on the type of epileptic syndrome and/or
seizure, but on the presence of comorbid disorders and concomitant
medications. Implementation of this principle is especially relevant in
elderly people with epilepsy (EPWE), as they are more likely to suffer
from a variety of comorbid neurological, psychiatric, cognitive and med-
ical disorders than younger patients (Rowan AJ, Ramsay RE, Collins JF,
et al. New onset geriatric epilepsy: a randomized study of gabapentin,
lamotrigine, and carbamazepine. Neurology 2005;64(11):1868–74). Fur-
thermore, EPWE living in a nursing home have been found to be taking
an average of five concomitant medications in addition to their AED
(Lackner TE, Cloyd JC, Thomas LW, Leppik IE. Antiepileptic drug use
in nursing home residents: effect of age, gender, and comedication on
patterns of use. Epilepsia 1998;39:1083–7).
For example, in the selection of an AED to treat a seizure disorder
caused by stroke, clinicians must factor-in: (i) a potential negative im-
pact on the course of likely comorbid disorders such as dyslipidaemia,
hypertension, large and small vessel disease of the brain, coronary artery
disease and diabetes; (ii) the AED’s potential pharmacokinetic and phar-
macodynamic interaction with the concomitant medications used for the
treatment of these conditions; (iii) a 30 to 50% risk of post-stroke depres-
sion that is often associated with comorbid generalized anxiety disorder,
both of which are likely to limit the recovery of neurological deficits (in-
cluding activities of daily living) and increase mortality risk (Beekman
AT, de Beurs E, van Balkom AJ, et al. Anxiety and depression in later
life: Co-occurrence and communality of risk factors. Am J Psychiatry
2000;157:89–95; Robinson RG. Poststroke depression: prevalence, diag-
nosis, treatment, and disease progression. Biol Psychiatry 2003;54:376–
87).
The most frequently prescribed AEDs in most countries are enzyme-
inducing AEDs (i.e., carbamazepine, phenytoin and phenobarbital).
These drugs have a potentially negative impact on these comorbid dis-
orders for the following reasons: (i) they may potentially worsen the
course of the concomitant cerebrovascular disease and dementing disor-
ders since they are associated with an increase of serum homocysteine
concentrations (Apeland T, Mansoor MA, Strandjord RE, Kristensen
O. Homocysteine concentrations and methionine loading in patients on
antiepileptic drugs. Acta Neurol Scand 2000,101:217–23); and (ii) they
limit the efficacy of concomitant medications by increasing their clear-
ance (Ucar M, Neuvonen M, Luurila H et al. Carbamazepine markedly
reduces serum concentrations of simvastatin and simvastatin acid. Eur
J Clin Pharmacol 2004;59:879–82; (Faught E. Pharmacokinetic con-
siderations in prescribing antiepileptic drugs. Epilepsia 2001;42(Suppl
4):19–23). This presentation will review practical strategies in the selec-
tion of AEDs for the treatment of EPWE taking into consideration some
of the frequent comorbid medical and psychiatric disorders.
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INTO A NEW AGE—CLINICAL TRIALS OF AEDS IN THE
ELDERLY
E. Perucca (Clinical Pharmacology Unit, University of Pavia and Insti-
tute of Neurology IRCCS C. Mondino Foundation, University of Pavia,
Pavia, Italy)
The incidence of epilepsy peaks in old age, and the number of per-
sons with epilepsy in the over 65 age group is increasing exponentially
due to improved life expectancy and higher rates of survival following
epileptogenic insults such as cerebrovascular accidents. This epidemi-
ological dimension contrasts with the paucity of well-conducted com-
parative trials of antiepileptic drug (AED) treatment in old age. This is
regrettable since treatment outcome data in younger age groups cannot
be readily extrapolated to the elderly, due to age-related differences in
pharmacokinetics and pharmacodynamics. A few randomised trials have
been completed in recent years, but interpretation of results is made dif-
ficult by methodological shortcomings in some of the studies. These
include relatively small sample sizes; suboptimal inclusion criteria; rel-
atively short duration of follow-up; and suboptimal dose titration rates,
target dosages or dosing schedules. In most trials, carbamazepine was
found to have inferior tolerability compared with some newer genera-
tion AEDs, particularly lamotrigine, but use of suboptimal (immediate-
release) formulations and dosing schedules may have contributed to the
differences in outcome between treatment groups. More studies with
improved methodology are necessary before a fully evidence-based ap-
proach can be applied to the treatment of epilepsy with onset in old
age.
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Management of epilepsy across the ages
IDIOPATHIC GENERALISED EPILEPSIES IN CHILDREN:
TREATMENT AND CARE
A. Arzimanoglou (University Hospital Robert Debre´, Paris, France)
Idiopathic Generalised Epilepsies (IGE) account for nearly one third
of all epilepsies and the majority of cases have an onset in childhood
or adolescence. When treated with the appropriate AEDs the majority
of IGE patients will become seizure-free and will benefit from fully
normal schooling and societal life. Consequently, individual tolerance
of the chosen drug is of primary importance. Age-related and gender
issues must also be taken into consideration. Whenever possible, drugs
with an eventual impact on learning and language abilities or behaviour
should be avoided. Drugs like carbamazepine, oxcarbazepine, vigabatrin,
gabapentine and pregabalin must be avoided as they can aggravate, or
sometimes even induce, myoclonic seizures and cannot control absence
seizures.
Some of the IGE syndromes, like childhood absence epilepsy, will
definitely resolve by adolescence, resulting in AED discontinuation. For
patients with photosensitive epilepsies, treatment with AEDs is not al-
ways necessary as measures to avoid environmental stimuli may be suf-
ficient. Juvenile myoclonic epilepsy is one of the most AED-dependent
syndromes since discontinuation of all AEDs usually leads to recurrence
of seizures.
Valproate is the only AED available that has the potential to control
all three types of seizures encountered in the category of idiopathic gen-
eralized epilepsies (typical absences, myoclonias and generalized tonic–
clonic seizures). Ethosuximide can be active for the control of typical
absences and sometimes myoclonias. From the newer AEDs only leve-
tiracetam, topiramate and lamotrigine can be used. Combination of two
drugs may prove to be very useful in intractable cases or when a smaller
dose is needed to avoid an undesirable effect.
MANAGING EPILEPSY IN WOMEN OF CHILD-BEARING PO-
TENTIAL: HOW CAN WE BALANCE THE RISK-BENEFIT
RATIO?
T. Tomson (Karolinska Institutet, Stockholm, Sweden)
The majority of women with epilepsy who become pregnant will have
uncomplicated pregnancies and give birth to perfectly normal children.
Nevertheless, the risk that seizures and antiepileptic drugs (AEDs) may
harm the unborn child is a major concern. Potential adverse effects of
AEDs need to be weighed against the fetal and maternal risks associ-
ated with uncontrolled seizures during pregnancy. The general strategy in
pregnant women has been to use monotherapy with an AED suited to the
type of epilepsy, at the lowest effective dose to maintain seizure control.
In some recent studies the use of valproate has been associated with a
particularly high risk of congenital malformations and a lower verbal IQ
in the offspring. These potential adverse effects appear to be dose-related
with higher risks at doses above 800–1000 mg/day. Whether lower doses
of valproate are associated with higher risks than with other AEDs is un-
clear. Although further studies are needed, a conservative approach to the
use of valproate in women of child-bearing potential is recommended.
Thus, alternative AEDs should be proposed to those planning pregnan-
cies wherever satisfactory seizure control can thereby be maintained.
The importance of seizure control during pregnancy should not be ne-
glected and any major treatment changes should be completed before
conception. In cases where valproate is used during pregnancy, either
because the pregnancy was unplanned or because alternative treatment
options of equivalent efficacy are unavailable, appropriate counselling,
precautionary measures and monitoring should be provided.
SPECIFIC ASPECTS OF ANTIEPILEPTIC DRUG TOXIC-
ITY IN THE ELDERLY: PREVENTION, DETECTION, AND
MANAGEMENT
A. Aldenkamp (Epilepsy Centre Kempenhaeghe, Heeze & Department
of Neurology, Maastricht University Hospital, The Netherlands)
Epilepsy affects around 1% of elderly people. Several studies have
shown a linear increase in the incidence of epilepsy for each decade af-
ter the age of 60 years. The aetiology and manifestations of epilepsies
in the elderly are complex due to comorbidities and other common un-
derlying risk factors such as concomitant cerebrovascular, neurodegen-
erative, or neoplasic diseases. Elderly people are generally more suscep-
tible than younger adults to antiepileptic drugs (AEDs) adverse effects
such as sedation, cognitive side effects, and osteoporosis. For these rea-
sons, elderly people should be treated with low starting doses of AEDs
that should be titrated slowly according to clinical response. Drug-drug
interactions should be given special consideration. The pharmacokinet-
ics of all AEDs are altered in the elderly; the most significant change
common to all AEDs is a moderate reduction in renal and metabolic
clearance. Predicting pharmacokinetic changes in the individual, how-
ever, can be very difficult because multiple factors contribute to a high
inter-patient variability. Moreover elderly patients are often taking other
drugs which can influence pharmacodynamics. Seizures can sometimes
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be severely disabling in an elderly person, though in many cases appro-
priate management can avoid this. The nature of the disease is poorly
understood and minor seizures are often overlooked. An increase in the
frequency of seizures may severely affect quality of life, particularly with
regard to the resultant loss of independence. Elderly patients may become
more isolated and reclusive. The psychosocial impact of the diagnosis
of epilepsy in the elderly can cause anxiety due to memories of a remote
past in which seizures were poorly controlled, as well as fear of social
stigma.
A REAPPRAISAL OF THE PLACE OF VALPROATE TODAY IN
THE TREATMENT OF EPILEPSY ACROSS THE AGES
G. Kra¨mer (Zu¨rich, Switzerland)
Although a lack of data prevents a comparison of the relative effi-
cacies of traditional and ‘new generation’ antiepileptic drugs, 40 years
of clinical experience have provided substantial evidence (level II & III
ILAE) supporting the use of valproate in the treatment of many epilepsy
syndromes across the ages. The clinical experience of drugs such as lam-
otrigine, levetiracetam and zonisamide is much less extensive. Valproate
monotherapy has proven effectiveness in the treatment of focal epilepsy,
generalised tonic–clonic seizures and partial onset seizures. For the same
reason valproate may be prescribed to newly diagnosed patients in whom,
pending identification of the specific epilepsy type, a conservative treat-
ment option is recommended. Findings from open, uncontrolled studies
also support a role for valproate in the treatment of idiopathic generalised
epilepsies with multiple seizure types. Unlike other antiepileptic drugs
(AEDs) that may aggravate seizures, valproate has been successfully
used in clinical series to treat juvenile myoclonic epilepsy. In addition,
other studies have concluded that valproate may be effective as an ‘add
on’ treatment, acting synergistically when used in conjunction with lam-
otrigine. Insufficient evidence prevents the evaluation of valproate rela-
tive to other drugs such as lamotrigine, levetiracetam and topiramate in
the treatment of absence epilepsies. With a proven track-record in safety
and effectiveness, valproate is today a first-line treatment of choice for
a broad spectrum of epilepsy syndromes in patients of all ages.
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What’s around the corner: AEDs in late development
LACOSAMIDE—EFFICACY AND TOLERABILITY
E. Ben-Menachem (Neurologkliniken, Sahlgrenska Univer-
sitetssjukhuset, Goteberg, Sweden)
Lacosamide is in Phase 3 of clinical development for the adjunc-
tive treatment of epilepsy and neuropathic pain. Currently the mode of
action (MOA) is under investigation since it has been previously demon-
strated that lacosamide does not share a MOA with other currently mar-
keted antiepileptic drugs (AEDs). The drug can be administered orally
or intravenously. Results from pharmacokinetic studies suggest that la-
cosamide has a low potential for drug-drug interactions, and it appears
that lacosamide has a minimal risk for affecting the pharmacokinetics of
commonly prescribed concomitant AEDs for the treatment of epilepsy.
In a double-blind, randomized, placebo-controlled, multicenter trial
for the treatment of partial seizures (SP667), lacosamide was adminis-
tered orally in doses of 200 mg, 400 mg and 600 mg divided in 2 daily
doses. In this trial, lacosamide demonstrated a statistically significant
reduction in seizure frequency over placebo. Moreover, the 50% respon-
der rate (defined as patients with at least a 50% reduction in seizure
frequency) was statistically significant.
A further trial (SP616) investigated the safety, tolerability and phar-
macokinetics of IV lacosamide as replacement for oral lacosamide in
patients with partial-onset seizures. The nature of AEs reported follow-
ing 60- and 30 minute infusions of lacosamide was consistent with AEs
reported following oral administration of lacosamide.
Dose-related adverse events include dizziness, nausea, fatigue, ataxia,
vision abnormal, diplopia, and nystagmus.
The currently available results justify the further development of la-
cosamide for the treatment of epilepsy.
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